PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	EKSTRAND, AJ; LONGO, N; HAMID, ML; OLSON, JJ; COLLINS, VP; JAMES, CD; LIU, L				EKSTRAND, AJ; LONGO, N; HAMID, ML; OLSON, JJ; COLLINS, VP; JAMES, CD; LIU, L			FUNCTIONAL-CHARACTERIZATION OF AN EGF RECEPTOR WITH A TRUNCATED EXTRACELLULAR DOMAIN EXPRESSED IN GLIOBLASTOMAS WITH EGFR GENE AMPLIFICATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMAS; HUMAN-BRAIN TUMORS; ENHANCED EXPRESSION; HUMAN GLIOMAS; FACTOR-ALPHA; LINES; OVEREXPRESSION; IDENTIFICATION; PROTEIN	The most common type of alteration of the epidermal growth factor receptor gene (EGFR) in human glioblastomas results in the synthesis of an aberrant mRNA lacking 801 bases that encode amino acids 6-273 of the receptor's extracellular domain. To study the effects of this mutation on receptor function, we have developed chinese hamster ovary cell transfectants which express the mutant EGF receptor. Comparison of wildtype and mutant receptor properties in this cell host indicates that the truncated receptor does not bind EGF or TGF-alpha and, consequently, DNA synthesis is not stimulated in cultures of mutant transfectants by either grown factor. However, levels of DNA synthesis determined for mutant transfectants in serum-free media are several-fold higher than those determined for corresponding cultures of wild-type transfectants. Western blot analysis with anti-phosphotyrosine antibody indicates that the mutant receptor is constitutively phosphorylated in CHO cells, and the same analysis applied to lysates of glioblastoma biopsies reveals the altered receptor is readily detectable as a phosphotyrosine protein in tumors for which there is evidence of corresponding EGFR gene and transcript alterations. In total, these results indicate that the aberrant EGF receptor synthesized in glioblastomas, and which lacks a portion of the extracellular domain necessary for ligand binding, is an activated tyrosine kinase.	EMORY UNIV,SCH MED,DEPT NEUROSURG,MOLEC NEUROONCOL LAB,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA 30322; KAROLINSKA HOSP,LUDWIG INST CANC RES,S-17671 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,S-17671 STOCKHOLM,SWEDEN	Emory University; Emory University; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska University Hospital			James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NCI NIH HHS [CA55728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGNER SH, 1990, CANCER RES, V50, P8017; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAFFANET M, 1992, EUR J CANCER, V28A, P11, DOI 10.1016/0959-8049(92)90374-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V131, P207, DOI 10.1016/0006-291X(85)91790-5; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HALEY J, 1987, ONCOGENE RES, V1, P375; HALEY JD, 1989, ONCOGENE, V4, P273; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JAMES CD, 1988, CANCER RES, V48, P5546; LEONARD JH, 1991, INT J CANCER, V48, P511, DOI 10.1002/ijc.2910480406; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LONGO N, 1992, J BIOL CHEM, V267, P12416; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALDEN LT, 1988, CANCER RES, V48, P2711; MASUI H, 1991, CANCER RES, V51, P6170; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; NISTER M, 1988, CANCER RES, V48, P3910; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1048; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	32	224	232	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2313	2320						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036013				2022-12-17	WOS:A1994NX62900024
J	Zhao, J; Du, PZ; Cui, P; Qin, YY; Hu, CE; Wu, J; Zhou, ZW; Zhang, WH; Qin, LX; Huang, GJ				Zhao, Jing; Du, Peizhun; Cui, Peng; Qin, Yunyun; Hu, Cheng'en; Wu, Jing; Zhou, Zhongwen; Zhang, Wenhong; Qin, Lunxiu; Huang, Guangjian			LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer	ONCOGENE			English	Article							NONCODING RNA PVT1; ENDOTHELIAL GROWTH-FACTOR; PHASE-III; TUMORIGENICITY; PROLIFERATION; BEVACIZUMAB; METASTASIS; EXPRESSION; CISPLATIN; CELLS	Angiogenesis can aggravate gastric cancer progression. LncRNAs exert important roles in regulating various cancer behaviors. However, the functions and mechanisms of lncRNAs in angiogenesis remain largely unknown. Here we demonstrated that lncRNA PVT1 was upregulated and significantly associated with high-microvessel density and poor prognosis in gastric cancer. Through gain-and loss-of PVT1 expression, we found PVT1 could obviously induce angiogenesis within tumors, in addition to promoting tumor growth in vitro and in vivo. Mechanistically, PVT1 directly interacted with the signal transducer activator phospho-STAT3 in the nucleus, and increased its protein stability by protecting it from poly-ubiquitination and proteasome-dependent degradation. The binding of PVT1 activated the STAT3 signalling pathway, and successively elevated VEGFA expression to stimulate angiogenesis. The positive correlation of PVT1 and VEGFA expression was also verified in gastric cancer specimens, and high levels of PVT1 and VEGFA in combination frequently predicted shorter survival time. Moreover, we revealed that PVT1 was a STAT3-responsive lncRNA, as STAT3 could occupy the PVT1 promoter to facilitate its transcription. The positive feed-back loop of PVT1 and STAT3 continuously enhanced the oncogenic effects. Collectively, our study first elucidates the mechanism of PVT1-mediated angiogenesis via evoking the STAT3/VEGFA signalling axis, which provides promising target for developing new therapeutic strategy in gastric cancer.	[Zhao, Jing; Du, Peizhun; Qin, Yunyun; Hu, Cheng'en; Qin, Lunxiu; Huang, Guangjian] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China; [Zhao, Jing; Qin, Lunxiu] Fudan Univ, Canc Metastasis Inst, Shanghai 200040, Peoples R China; [Du, Peizhun; Wu, Jing; Zhang, Wenhong] Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai 200040, Peoples R China; [Zhou, Zhongwen] Fudan Univ, Huashan Hosp, Dept Pathol, Shanghai 200040, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Qin, LX; Huang, GJ (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China.; Qin, LX (corresponding author), Fudan Univ, Canc Metastasis Inst, Shanghai 200040, Peoples R China.; Zhang, WH (corresponding author), Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai 200040, Peoples R China.	zhangwenhong@fudan.edu.cn; qinlx@fudan.edu.cn; gjhuang@fudan.edu.cn	Wu, Jing/GQI-1843-2022; 高, 雨莉/HGU-8187-2022	Wu, Jing/0000-0002-1224-0912	Natural Science Foundation of China [81672378, 81201521, 81071994, 81672820, 81400007]; Foundation from Science and Technology Commission of Shanghai [09XD1400800]; National Major Scientific Instruments and Equipment Development Project of China [2013YQ15082909, 2012ZX10002012]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation from Science and Technology Commission of Shanghai; National Major Scientific Instruments and Equipment Development Project of China	This study was supported by the Natural Science Foundation of China (81672378, 81201521, 81071994, 81672820, and 81400007), the Foundation from Science and Technology Commission of Shanghai (09XD1400800), and the National Major Scientific Instruments and Equipment Development Project of China (2013YQ15082909, 2012ZX10002012).	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Carramusa L, 2007, J CELL PHYSIOL, V213, P511, DOI 10.1002/jcp.21133; Chen ZZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12598; Colombo T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/304208; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882; Guo XB, 2016, ONCOTARGET, V7, P30276, DOI 10.18632/oncotarget.7217; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hegde PS, 2013, CLIN CANCER RES, V19, P929, DOI 10.1158/1078-0432.CCR-12-2535; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jariwala N, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.27; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Liu YJ, 2015, PROCEEDINGS OF 2015 INTERNATIONAL CONFERENCE ON FLUID POWER AND MECHATRONICS - FPM 2015, P1, DOI 10.1109/FPM.2015.7337074; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Shah MA, 2006, J CLIN ONCOL, V24, P5201, DOI 10.1200/JCO.2006.08.0887; Shen L, 2015, GASTRIC CANCER, V18, P168, DOI 10.1007/s10120-014-0351-5; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Xu Z, 2017, ONCOGENE, V36, P1965, DOI 10.1038/onc.2016.356; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan CL, 2016, NEOPLASMA, V63, P442, DOI 10.4149/314_150825N45; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zhao J, 2015, CELL CYCLE, V14, P3112, DOI 10.1080/15384101.2015.1078034; Zhu Y, 2016, ONCOTARGET, V7, P14429, DOI 10.18632/oncotarget.7418	34	223	233	5	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4094	4109		10.1038/s41388-018-0250-z	http://dx.doi.org/10.1038/s41388-018-0250-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706652				2022-12-17	WOS:000439847000004
J	Giovino, GA				Giovino, GA			Epidemiology of tobacco use in the United States	ONCOGENE			English	Review						epidemiology; tobacco use; cigarette smoking	CIGARETTE-SMOKING; TEENAGE SMOKING; INDUSTRY; YOUTH; CARCINOMA; PREVALENCE; CESSATION; CAMPAIGN; HEALTH; IMPACT	Efforts to understand trends in and patterns of lung cancer are well served by studies of trends in and patterns of tobacco use. In the United States, the manufactured cigarette emerged as the tobacco product of choice shortly after the turn of the twentieth century. Lung cancer emerged after years of inhalation of cigarette smoke, first among men and then among women. The massive public health education campaign that began after scientists recognized the dangers of cigarette smoking has contributed to large reductions in cigarette use and subsequent smoking-attributable morbidity and mortality. Since 1965, the prevalence of cigarette smoking among US adults has declined by almost half, with positive trends observed among persons in almost all sociodemographic groups and efforts to reduce disparities recognized as an important goal in public health. An epidemiologic approach to understanding and controlling patterns of tobacco use is proposed. The model focuses on the agent (tobacco products), host (consumer or potential consumer), vector (tobacco companies and other users), and environment (with influences from families, social sources, culture, history, politics, law, and media). Accelerating progress in reducing tobacco use will accelerate reductions in tobacco-attributable morbidity and mortality.	Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Giovino, GA (corresponding author), Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Elm & Carlton St, Buffalo, NY 14263 USA.	Gary.Giovino@RoswellPark.org			NCI NIH HHS [P30 CA16056-26] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos A, 2000, TOB CONTROL, V9, P3, DOI 10.1136/tc.9.1.3; Anda RF, 1999, JAMA-J AM MED ASSOC, V282, P1652, DOI 10.1001/jama.282.17.1652; BACHMAN J, 1993, MONITORING FUTURE QU; Bachman J. G., 1980, MONITORING FUTURE QU; Bachman JG., 2001, MONITORING FUTURE QU; Bachman JG, 1981, MONITORING FUTURE QU; Balbach ED, 1995, AM J PUBLIC HEALTH, V85, P1650, DOI 10.2105/AJPH.85.12.1650; BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; Bondurant, 2001, CLEARING SMOKE ASSES; Burns D. M., 1997, SMOKING TOBACCO CONT, P13; Burton S L, 2000, MMWR Morb Mortal Wkly Rep, V49, P665; *CAL ENV PROT AG, 1997, HLTH EFF EXP ENV TOB; Caraballo RS, 2001, AM J EPIDEMIOL, V153, P807, DOI 10.1093/aje/153.8.807; *CDCP, 1999, BEST PRACT COMP TOB; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P300; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P409; *CDCP, 2001, MMWR SS, V50, P4; Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P342; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P986; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1101; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P925; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P869; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1107; Chaloupka FJ, 2002, TOB CONTROL, V11, pI62, DOI 10.1136/tc.11.suppl_1.i62; Chapman S, 1999, AM J PUBLIC HEALTH, V89, P1018, DOI 10.2105/AJPH.89.7.1018; Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142; Cummings KM, 2002, TOB CONTROL, V11, pI5, DOI 10.1136/tc.11.suppl_1.i5; CUMMINGS KM, 2002, TOB CONTROL S1, V11, pI220; CUMMINGS KM, 2002, ONCOGENE REV; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; EVERETTJONES S, 2002, TOB CONTROL, V11, P20; Fant RV, 1999, TOB CONTROL, V8, P387, DOI 10.1136/tc.8.4.387; Farrelly MC, 2002, AM J PUBLIC HEALTH, V92, P901, DOI 10.2105/AJPH.92.6.901; FIORE MC, 2000, TREATING TOBACCO USE; *FTC, 2001, CIG REP 1999; Gfroerer J, 1997, DRUG ALCOHOL DEPEN, V47, P19, DOI 10.1016/S0376-8716(97)00063-X; GIOBINO GA, 1994, MMWR SURV SUM, V43, P31; Giovino G, 2000, PREVALENCE SELECTED; Giovino G A, 1999, Nicotine Tob Res, V1 Suppl 1, pS31, DOI 10.1080/14622299050011571; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; Glantz S.A., 1996, CIGARETTE PAPERS; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P1176, DOI 10.1001/jama.272.15.1176; HARRIS JE, 1983, JNCI-J NATL CANCER I, V71, P473; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HAZAN AR, 1995, AM J PUBLIC HEALTH, V85, P116, DOI 10.2105/AJPH.85.1.116; Hurt RD, 1998, JAMA-J AM MED ASSOC, V280, P1173, DOI 10.1001/jama.280.13.1173; Jacobson PD., 2001, REGULATING TOBACCO, P207; JAMIESON KH, 1998, TAX SPEND LITTLE KID; Johnston L. D., 1997, MONITORING FUTURE QU; JOHNSTON LD, 1986, MONITORING FUTURE QU; KENDRICK JS, 1995, AM J PUBLIC HEALTH, V85, P217, DOI 10.2105/AJPH.85.2.217; Kluger R, 1996, ASHES ASHES AMERICAS; KOZLOWSKI L, 2002, NICOTINE PUBLIC HLTH, V11, pI40; KOZLOWSKI LT, 2000, NICOTINE PUBLIC HLTH; Lantz PM, 2000, TOB CONTROL, V9, P47, DOI 10.1136/tc.9.1.47; Last JM., 2001, DICT EPIDEMIOLOGY, V4th; Lopez AD, 1994, TOB CONTROL, V3, P242, DOI [DOI 10.1136/TC.3.3.242, 10.1136/tc.3.3.242]; McMahon R J, 1999, Nicotine Tob Res, V1 Suppl 2, pS45; MILLER L, 1954, READERS DIGEST   JUL, P1; MILMORE B K, 1956, Public Health Monogr, V45, P107; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; MURRAY CJL, 1996, INVESTING RES DEV; *NAT CANC POL BOAR, 2000, STAT PROGR RED TOB U; *NCI, 1997, CIGARS HLTH EFFECTS, V9; *NCI, 2000, TOBACCO RES IMPLEMEN; *NCI, 2001, NIH PUBLICATION, V14; *NCI, 2001, RISKS ASSOCIATED SMO, V13; Nelson DE, 1996, PREV MED, V25, P91, DOI 10.1006/pmed.1996.9999; Noland MP, 1996, ADDICT BEHAV, V21, P349; Norr Roy, 1952, READERS DIG, P738; NOVOTNY TE, 1998, CHRONIC DIS EPIDEMIO, P117; Orleans CT, 1993, NICOTINE ADDICTION P, pix; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; Pauly JL, 2002, TOB CONTROL, V11, pI51, DOI 10.1136/tc.11.suppl_1.i51; Pollay RW, 2000, TOB CONTROL, V9, P136, DOI 10.1136/tc.9.2.136; Pollay RW, 2002, TOB CONTROL, V11, pI18, DOI 10.1136/tc.11.suppl_1.i18; POMERLEAU OF, 1993, J CONSULT CLIN PSYCH, V61, P723, DOI 10.1037/0022-006X.61.5.723; Rabin R. L., 2001, REGULATING TOBACCO; Ries LA, 2002, SEER CANC STAT REV 1; RIGOTTI NA, 2001, REGULATING TOBACCO, P143; Saloojee Y, 2000, B WORLD HEALTH ORGAN, V78, P902; SAMET JM, 1999, ENV TOXICANTS HUMAN; SHOPLAND DR, 1995, LUNG CANCER, P1; SILLETT RW, 1978, BRIT MED J, V2, P1185, DOI 10.1136/bmj.2.6146.1185; SLADE J, 1989, J PSYCHOACTIVE DRUGS, V21, P281, DOI 10.1080/02791072.1989.10472169; SLADE J, 1993, NICOTINE ADDICTION P, P3; SLADE J, 2001, REGULATING TOBACCO, P72; Slovic P., 2001, SMOKING RISK PERCEPT, DOI 10.4135/9781452232652; Smith SS, 1999, PRIMARY CARE, V26, P433, DOI 10.1016/S0095-4543(05)70112-3; *SUBS AB MENT HLTH, 2001, SUMM FIND 2000 NHSDA; Swedrock TL, 1999, TOB CONTROL, V8, P111, DOI 10.1136/tc.8.1.111; Teti TS, 1998, TOB CONTROL, V7, P441, DOI 10.1136/tc.7.4.441; *TOB I, 1991, TIMN01644224424 TOB; TOLLEY HD, 1991, NIH PUBL, P75; TURNER C, 1992, DHHS PUBLICATION; Tyas SL, 1998, TOB CONTROL, V7, P409, DOI 10.1136/tc.7.4.409; *US DEP LAB, 2002, CONS PRIC IND ALL UR; *US FOOD DRUG ADM, 1996, FED REGISTER, V61, P44395; *USDA, 1994, TOB SIT OUTL REP; *USDA, 1989, DHHS PUBLICATION; *USDA, 1988, HLTH CONS SMOK NIC A; *USDA, 1987, TOB SIT OUTL REP; *USDA, 2002, TOB OUTL; *USDA, 1999, TOB SIT; *USDHHS, 1994, PREV TOB US AM YOUNG; *USDHHS, 2001, WOM TOB REP SURG GEN; *USDHHS, 1990, DHHS PUBLICATION; *USDHHS, 1998, TOB US AM US RAC ETH; *USPHS, 1964, PHS PUBLICATION, V1103; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23; VONGERNET A, 2000, NICOTINE PUBLIC HLTH; Wakefield M, 2000, TOB CONTROL, V9, P177, DOI 10.1136/tc.9.2.177; Wakefield MA, 2000, BRIT MED J, V321, P333, DOI 10.1136/bmj.321.7257.333; WALLACE JM, 2002, IN PRESS PUB HLTH RE; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; WARNER KE, 1985, HEALTH EDUC QUART, V12, P115, DOI 10.1177/109019818501200111; Wayne GF, 2002, TOB CONTROL, V11, pI32, DOI 10.1136/tc.11.suppl_1.i32; Weinstein ND, 1998, ANN BEHAV MED, V20, P135, DOI 10.1007/BF02884459; World Bank, 1999, CURB EP GOV EC TOB C; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; YEE SL, 2001, SURVEILLANCE EVALUAT; 1953, CONSUMER REPORTS, V18, P58; 1954, CONSUMER REPORTS, V19, P54	124	223	224	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7326	7340		10.1038/sj.onc.1205808	http://dx.doi.org/10.1038/sj.onc.1205808			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379876				2022-12-17	WOS:000178618000006
J	Thomas, M; Banks, L				Thomas, M; Banks, L			Inhibition of Bak-induced apoptosis by HPV-18 E6	ONCOGENE			English	Article						HPV; apoptosis; Bak; ubiquitin	HUMAN PAPILLOMAVIRUS TYPE-16; PROGRAMMED CELL-DEATH; P53 DNA-BINDING; UBIQUITIN-PROTEIN LIGASE; IN-VIVO; MEDIATED DEGRADATION; TRANSFORMED-CELLS; ANGELMAN SYNDROME; OLIGOMERIC STATE; BCL-2 HOMOLOG	Human papillomavirus (HPV) E6 proteins inhibit apoptosis in both p53-dependent and p53-independent manners. A key point in apoptosis is the regulation provided by the Bcl-2 family; and in differentiating keratinocytes, in which HPV replicates, the Bak protein is highly expressed. We show that HPV-18 E6 will inhibit Bak-induced apoptosis and this is mediated by an interaction between the E6 and Bak proteins resulting in degradation of the Bak protein in vivo. We also show that Bak protein interacts with the ubiquitin ligase, E6AP, and that a mutant of Bak defective in E6AP binding is overexpressed in comparison with wild type. These studies suggest that Bak is probably the first naturally occurring target of E6AP to be identified.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; FADOK VA, 1992, J IMMUNOL, V148, P2207; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GARDIOL D, 1998, IN PRESS J GEN VIROL; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KANDA T, 1991, VIROLOGY, V185, P536, DOI 10.1016/0042-6822(91)90523-E; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Krajewski S, 1996, CANCER RES, V56, P2849; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Steller MA, 1996, CANCER RES, V56, P5087; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; Thomas M, 1996, ONCOGENE, V13, P471; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	55	223	235	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					2943	2954		10.1038/sj.onc.1202223	http://dx.doi.org/10.1038/sj.onc.1202223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881696				2022-12-17	WOS:000077427800001
J	Panagopoulos, I; Hoglund, M; Mertens, F; Mandahl, N; Mitelman, F; Aman, P				Panagopoulos, I; Hoglund, M; Mertens, F; Mandahl, N; Mitelman, F; Aman, P			Fusion of the EWS and CHOP genes in myxoid liposarcoma	ONCOGENE			English	Article						myxoid liposarcoma; translocation; EWS gene; CHOP gene; PCR; fusion gene	TRANSLOCATION; TUMORS	The translocation t(12;16)(q13;pll), which cytogenetically characterizes myxoid liposarcomas (MLS), results in a fusion of the CHOP gene in 12q13 and the I;US gene in 16p11, creating a chimeric FUS/CHOP gene. We have identified two cases of MLS with translocations giving rise to recombination between 12q13 and 22q12. The result was a fusion of the N-terminal part of the EWS gene in 22q12, involved in a number of mesenchymal tumor types, with the CHOP gene and the creation of an EWS/CHOP chimeric gene. The presence of the EWS/CHOP chimeric gene in MLS Shows that (i) the N-terminal part of FUS may be replaced by the N-terminal part of EWS in a CHOP fusion oncoprotein (ii) the two N-terminal parts, when fused to certain transcription factors, have a common or very similar oncogenic potential and (iii) the tumorigenic process in MLS and the morphogenetically distinctly different EWS-associated tumor types may be related.			Panagopoulos, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Panagopoulos, Ioannis/0000-0003-2159-5341; Aman, Pierre/0000-0002-1482-8875; Hoglund, Mattias/0000-0001-9283-4421; Mitelman, Felix/0000-0002-3757-7212; Mertens, Fredrik/0000-0002-6278-5232				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; LADANYI M, 1994, CANCER RES, V54, P2837; MANDAHL N, 1988, HUM GENET, V79, P203, DOI 10.1007/BF00366238; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; 1991, GUIDELINES CANCER CY	19	223	233	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					489	494						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637704				2022-12-17	WOS:A1996TV59700004
J	DOUGALL, WC; QIAN, XL; PETERSON, NC; MILLER, MJ; SAMANTA, A; GREENE, MI				DOUGALL, WC; QIAN, XL; PETERSON, NC; MILLER, MJ; SAMANTA, A; GREENE, MI			THE NEU-ONCOGENE - SIGNAL-TRANSDUCTION PATHWAYS, TRANSFORMATION MECHANISMS AND EVOLVING THERAPIES	ONCOGENE			English	Review							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; BREAST-CARCINOMA CELLS; FACTOR RECEPTOR MUTANTS; PHOSPHOLIPASE-C-GAMMA; TUMOR EFFECTS INVIVO; NIH 3T3 CELLS; EGF-RECEPTOR; MONOCLONAL-ANTIBODIES; POINT MUTATION		UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania	DOUGALL, WC (corresponding author), UNIV PENN,SCH MED,CTR RECEPTOR BIOL,DIV IMMUNOL,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AASLAND R, 1988, BRIT J CANCER, V57, P358, DOI 10.1038/bjc.1988.82; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ALPER O, 1990, CELL GROWTH DIFFER, V1, P591; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; CAO HN, 1992, J BIOL CHEM, V267, P20489; CHAZIN VR, 1992, ONCOGENE, V7, P1859; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; COHEN JA, 1989, ONCOGENE, V4, P81; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; DREBIN JA, 1982, B T CELL TUMORS, P221; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FLANAGAN JG, 1988, P NATL ACAD SCI USA, V85, P8057, DOI 10.1073/pnas.85.21.8057; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1992, J BIOL CHEM, V267, P13851; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HOPKINS N, 1981, P NATL ACAD SCI-BIOL, V78, P7555, DOI 10.1073/pnas.78.12.7555; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUDZIAK RM, 1991, J BIOL CHEM, V266, P24109; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KATZEN AL, 1991, DEV BIOL, V145, P287, DOI 10.1016/0012-1606(91)90127-O; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KOSKINEN P, 1990, ONCOGENE, V5, P615; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANGTON BC, 1991, CANCER RES, V51, P2593; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHTOLA L, 1991, J CELL BIOCHEM, V45, P69, DOI 10.1002/jcb.240450114; LEITZEL K, 1992, J CLIN ONCOL, V10, P1436, DOI 10.1200/JCO.1992.10.9.1436; LEVEA CM, 1993, RECEPTOR, V3, P293; LIN YZJ, 1991, ONCOGENE, V6, P639; LIN YZJ, 1992, J CELL BIOCHEM, V49, P290, DOI 10.1002/jcb.240490312; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MAIER LA, 1991, CANCER RES, V51, P5361; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MORI S, 1990, JPN J CANCER RES, V81, P489, DOI 10.1111/j.1349-7006.1990.tb02596.x; MORI S, 1987, VIRCHOWS ARCH B, V54, P8, DOI 10.1007/BF02899192; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MYERS JN, 1992, RECEPTOR, V2, P1; NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRESS MF, 1990, ONCOGENE, V5, P953; PUPA SM, 1993, ONCOGENE, V8, P2917; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; QUIRKE P, 1989, BRIT J CANCER, V60, P64, DOI 10.1038/bjc.1989.221; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, IMMUNOMETHODS, V1, P1; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SEGATTO O, 1992, ONCOGENE, V7, P1339; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WADA T, 1989, ONCOGENE, V4, P489; WANG DP, 1993, CANCER, V72, P2628, DOI 10.1002/1097-0142(19931101)72:9<2628::AID-CNCR2820720918>3.0.CO;2-R; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1994, J CELL BIOCHEM, V18, P221; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	163	223	241	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2109	2123						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913542				2022-12-17	WOS:A1994NX62900001
J	Hernandez, C; Huebener, P; Schwabe, RF				Hernandez, C.; Huebener, P.; Schwabe, R. F.			Damage-associated molecular patterns in cancer: a double-edged sword	ONCOGENE			English	Review							MOBILITY GROUP BOX-1; REGULATORY T-CELLS; URIC-ACID PROMOTES; FIND-ME SIGNAL; IMMUNE-SYSTEM; TUMOR-GROWTH; ANTICANCER CHEMOTHERAPY; CALRETICULIN EXPOSURE; DIFFERENTIAL EXPRESSION; INFLAMMATORY RESPONSE	Damage-associated molecular patterns (DAMPs) are released in response to cell death and stress, and are potent triggers of sterile inflammation. Recent evidence suggests that DAMPs may also have a key role in the development of cancer, as well as in the host response to cytotoxic anti-tumor therapy. As such, DAMPs may exert protective functions by alerting the immune system to the presence of dying tumor cells, thereby triggering immunogenic tumor cell death. On the other hand, cell death and release of DAMPs may also trigger chronic inflammation and, thereby promote the development or progression of tumors. Here, we will review the contribution of candidate DAMPs and their receptors, and discuss the evidence for DAMPs as tumor-promoting and anti-tumor effectors, as well as unsolved questions such as DAMP release from non-tumor cells as well as the existence of tumorspecific DAMPs.	[Hernandez, C.; Huebener, P.; Schwabe, R. F.] Columbia Univ, Coll Phys & Surg, Dept Med, Russ Berrie Pavil,Room 415,1150 St Nicholas Ave, New York, NY 10032 USA; [Huebener, P.] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 1, Hamburg, Germany; [Schwabe, R. F.] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	Columbia University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Columbia University	Schwabe, RF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Russ Berrie Pavil,Room 415,1150 St Nicholas Ave, New York, NY 10032 USA.	rfs2102@cumc.columbia.edu	Huebener, Peter/AAF-2593-2020; Schwabe, Robert/AAY-6506-2021	Huebener, Peter/0000-0001-7558-7625	NCI NIH HHS [R01 CA200597, R01 CA190844] Funding Source: Medline; NIAAA NIH HHS [U01 AA021912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA200597, R01CA190844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA021912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adinolfi E, 2015, CANCER RES, V75, P635, DOI 10.1158/0008-5472.CAN-14-1259; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Beavis PA, 2013, P NATL ACAD SCI USA, V110, P14711, DOI 10.1073/pnas.1308209110; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bettum IJ, 2014, CANCER LETT, V344, P28, DOI 10.1016/j.canlet.2013.10.036; Bianchi G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.109; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje; Chaiswing L, 2010, ANTIOXID REDOX SIGN, V13, P449, DOI 10.1089/ars.2009.3020; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Cheng BQ, 2008, DIGEST LIVER DIS, V40, P446, DOI 10.1016/j.dld.2007.11.024; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Chiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376; Choi YR, 2003, CANCER RES, V63, P2188; Chung HW, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-38; Ciampricotti M, 2012, NAT MED, V18, P344, DOI 10.1038/nm.2652; Daniele S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.487; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Draganov D, 2015, SCI REP-UK, V5, DOI 10.1038/srep16222; Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Fettelschoss A, 2011, P NATL ACAD SCI USA, V108, P18055, DOI 10.1073/pnas.1109176108; Fini MA, 2012, CLIN TRANSL MED, V1, DOI 10.1186/2001-1326-1-16; Fini MA, 2008, J CELL BIOCHEM, V105, P1008, DOI 10.1002/jcb.21901; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Garg AD, 2015, ONCOTARGET, V6, P26841, DOI 10.18632/oncotarget.4754; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guo ZS, 2005, CANCER RES, V65, P9991, DOI 10.1158/0008-5472.CAN-05-1630; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haybaeck J, 2009, CANCER CELL, V16, P295, DOI 10.1016/j.ccr.2009.08.021; He Y, 2013, CANCER RES, V73, P629, DOI 10.1158/0008-5472.CAN-12-2704; Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hockel A, 2005, CANCER RES, V65, P2997; Hofman P, 2015, CANCER RES, V75, P835, DOI 10.1158/0008-5472.CAN-14-1778; Hong C, 2010, J IMMUNOL, V185, P4561, DOI 10.4049/jimmunol.1000536; Hu DE, 2004, CANCER RES, V64, P5059, DOI 10.1158/0008-5472.CAN-04-1586; Huebener P, 2015, J CLIN INVEST, V125, P539, DOI 10.1172/JCI76887; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jovanovic IP, 2014, INT J CANCER, V134, P1669, DOI 10.1002/ijc.28481; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Kono H, 2010, J CLIN INVEST, V120, P1939, DOI 10.1172/JCI40124; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Ladoire S, 2015, AUTOPHAGY, V11, P1878, DOI 10.1080/15548627.2015.1082022; Policastro LL, 2013, ANTIOXID REDOX SIGN, V19, P854, DOI 10.1089/ars.2011.4367; Liu XJ, 2014, BIOCHEM BIOPH RES CO, V453, P486, DOI 10.1016/j.bbrc.2014.09.106; Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009; Loi S, 2013, P NATL ACAD SCI USA, V110, P11091, DOI 10.1073/pnas.1222251110; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; Luo Y, 2013, EUR J CANCER, V49, P741, DOI 10.1016/j.ejca.2012.09.016; Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75; Maywald RL, 2015, P NATL ACAD SCI USA, V112, pE2487, DOI 10.1073/pnas.1422445112; Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307; Meyer A, 2008, LEUKEMIA LYMPHOMA, V49, P1184, DOI 10.1080/10428190802064909; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ohta A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00190; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Pawaria S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1524; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Pusterla T, 2013, HEPATOLOGY, V58, P363, DOI 10.1002/hep.26395; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ran S, 2015, CANCER RES, V75, P2405, DOI 10.1158/0008-5472.CAN-14-3525; Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967; Rider P, 2013, SEMIN IMMUNOL, V25, P430, DOI 10.1016/j.smim.2013.10.005; Romio M, 2011, AM J PHYSIOL-CELL PH, V301, pC530, DOI 10.1152/ajpcell.00385.2010; Ryzhov S, 2011, J IMMUNOL, V187, P6120, DOI 10.4049/jimmunol.1101225; Sack U, 2011, JNCI-J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Schlueter C, 2005, AM J PATHOL, V166, P1259, DOI 10.1016/S0002-9440(10)62344-9; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666; Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; Vacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779; Vanlangenakker N, 2012, CELL DEATH DIFFER, V19, P75, DOI 10.1038/cdd.2011.164; Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189; Vernon PJ, 2013, J IMMUNOL, V190, P1372, DOI 10.4049/jimmunol.1201151; Villarreal DO, 2014, CURR OPIN IMMUNOL, V28, P102, DOI 10.1016/j.coi.2014.03.004; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wang L, 2011, J CLIN INVEST, V121, P2371, DOI 10.1172/JCI45559; Wild CA, 2012, ORAL ONCOL, V48, P409, DOI 10.1016/j.oraloncology.2011.12.009; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xu J, 2014, CELL DEATH DIFFER, V21, P1229, DOI 10.1038/cdd.2014.40; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Zeng G, 2006, J IMMUNOL, V177, P3582, DOI 10.4049/jimmunol.177.6.3582; Zhou JM, 2015, SCI REP-UK, V5, DOI 10.1038/srep15085; Zhu XR, 2015, J CLIN INVEST, V125, P1098, DOI 10.1172/JCI76344; Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014	130	222	233	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5931	5941		10.1038/onc.2016.104	http://dx.doi.org/10.1038/onc.2016.104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27086930	Green Accepted			2022-12-17	WOS:000388509400001
J	Wei, JS; Song, YK; Durinck, S; Chen, QR; Cheuk, ATC; Tsang, P; Zhang, Q; Thiele, CJ; Slack, A; Shohet, J; Khan, J				Wei, J. S.; Song, Y. K.; Durinck, S.; Chen, Q-R; Cheuk, A. T. C.; Tsang, P.; Zhang, Q.; Thiele, C. J.; Slack, A.; Shohet, J.; Khan, J.			The MYCN oncogene is a direct target of miR-34a	ONCOGENE			English	Article						microRNA; miR-34a; MYCN; 1p36 LOH; neuroblastoma; translation regulation	TUMOR-SUPPRESSOR GENE; HUMAN NEUROBLASTOMA-CELLS; N-MYC; EXPRESSION PROFILES; FREQUENT DELETIONS; CONSENSUS REGION; TRANSGENIC MICE; NERVOUS-SYSTEM; CHROMOSOME 1P; APOPTOSIS	Loss of 1p36 heterozygosity commonly occurs with MYCN amplification in neuroblastoma tumors, and both are associated with an aggressive phenotype. Database searches identified five microRNAs that map to the commonly deleted region of 1p36 and we hypothesized that the loss of one or more of these microRNAs contributes to the malignant phenotype of MYCN-amplified tumors. By bioinformatic analysis, we identified that three out of the five microRNAs target MYCN and of these miR-34a caused the most significant suppression of cell growth through increased apoptosis and decreased DNA synthesis in neuroblastoma cell lines with MYCN amplification. Quantitative RT-PCR showed that neuroblastoma tumors with 1p36 loss expressed lower level of miR-34a than those with normal copies of 1p36. Furthermore, we demonstrated that MYCN is a direct target of miR-34a. Finally, using a series of mRNA expression pro. ling experiments, we identified other potential direct targets of miR-34a, and pathway analysis demonstrated that miR- 34a suppresses cell-cycle genes and induces several neural-related genes. This study demonstrates one important regulatory role of miR-34a in cell growth and MYCN suppression in neuroblastoma.	[Wei, J. S.; Song, Y. K.; Durinck, S.; Chen, Q-R; Cheuk, A. T. C.; Tsang, P.; Zhang, Q.; Khan, J.] Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Adv Technol Ctr, Gaithersburg, MD 20892 USA; [Chen, Q-R] NCI, Adv Biomed Comp Ctr, SAIC Frederick Inc, Frederick, MD 21701 USA; [Thiele, C. J.] Natl Canc Inst, Cell & Mol Biol Sect, Pediat Oncol Branch, Bethesda, MD USA; [Slack, A.; Shohet, J.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Khan, J (corresponding author), Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Adv Technol Ctr, Room 134E,8717 Grovemont Circle, Gaithersburg, MD 20892 USA.	khanjav@mail.nih.gov	Khan, Javed/P-9157-2014		Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [Z01BC010788, ZIASC010366, ZIABC011001, ZIABC011002] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Joon-Yong Chung and Xinyu Wen, MS for their excellent technical support. We also thank Dr John Maris, Dr Wendy London (Children's Oncology Group, Philadelphia, PA, USA) and Dr Steven Qualman (Cooperative Human Tissue Network, Columbus, OH, USA) for the NB tumor samples, and for invaluable discussion of this study with Dr John Maris and his group. This study is supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US government.	Abel F, 2004, INT J ONCOL, V25, P1297; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bieche I, 1998, ONCOL REP, V5, P267; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Cheung TH, 2005, GYNECOL ONCOL, V96, P510, DOI 10.1016/j.ygyno.2004.10.035; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Eggert A, 2002, EUR J CANCER, V38, P92, DOI 10.1016/S0959-8049(01)00347-1; Ejeskar K, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-161; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; HASHIMOTO N, 1995, GENE CHROMOSOME CANC, V14, P295, DOI 10.1002/gcc.2870140408; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kang JH, 2006, BIOCHEM BIOPH RES CO, V351, P192, DOI 10.1016/j.bbrc.2006.10.020; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Kong Xiao-Tang, 1999, Neoplasia (New York), V1, P80, DOI 10.1038/sj.neo.7900010; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Mathysen D, 2004, EUR J CANCER, V40, P1255, DOI 10.1016/j.ejca.2004.01.013; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; Nara K, 2007, INT J ONCOL, V30, P1189; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ozaki T, 2005, CANCER LETT, V228, P29, DOI 10.1016/j.canlet.2004.12.050; Poetsch M, 1998, CANCER GENET CYTOGEN, V104, P146, DOI 10.1016/S0165-4608(97)00471-8; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Valentijn LJ, 2005, CANCER RES, V65, P3136, DOI 10.1158/0008-5472.CAN-04-2469; VOGAN K, 1993, CANCER RES, V53, P5269; Wei J.S., 2002, DNA MICROARRAYS MOL, P110; Wei JS, 2005, ONCOGENE, V24, P7976, DOI 10.1038/sj.onc.1208947; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; WOO CM, 2007, PEDIAT BLOOD CANC, V50, P208; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; Zindy F, 2006, P NATL ACAD SCI USA, V103, P11579, DOI 10.1073/pnas.0604727103	66	222	231	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	39					5204	5213		10.1038/onc.2008.154	http://dx.doi.org/10.1038/onc.2008.154			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18504438	Green Accepted			2022-12-17	WOS:000258915100004
J	Garofalo, M; Quintavalle, C; Di Leva, G; Zanca, C; Romano, G; Taccioli, C; Liu, CG; Croce, CM; Condorelli, G				Garofalo, M.; Quintavalle, C.; Di Leva, G.; Zanca, C.; Romano, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.; Condorelli, G.			MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer	ONCOGENE			English	Article						microRNA; non-small cell lung cancer; apoptosis	CHRONIC LYMPHOCYTIC-LEUKEMIA; KINASE INHIBITOR P27(KIP1); PROTEIN EXPRESSION; INDUCED APOPTOSIS; KIT RECEPTOR; IN-VIVO; DEATH; GROWTH; P27; DIFFERENTIATION	To de. ne novel pathways that regulate susceptibility to tumor necrosis factor ( TNF)-related apoptosis-inducing ligand ( TRAIL) in non-small cell lung cancer (NSCLC), we have performed genome-wide expression pro. ling of microRNAs (miRs). We show that in TRAIL- resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222. We demonstrate that these miRs impair TRAIL- dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3'- UTR of Kit and p27(kip1) mRNAs, but interfere with TRAIL signaling mainly through p27kip1. In conclusion, we showthat high expression levels of miR-221 and -222 are needed to maintain the TRAIL- resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC.	[Garofalo, M.; Quintavalle, C.; Zanca, C.; Romano, G.; Condorelli, G.] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Garofalo, M.; Quintavalle, C.; Zanca, C.; Romano, G.; Condorelli, G.] IEOS, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy; [Garofalo, M.; Di Leva, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; [Condorelli, G.] Univ Naples Federico 2, Fac Sci Biotecnol, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Naples Federico II	Condorelli, G (corresponding author), Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	gecondor@unina.it	Taccioli, Cristian/F-8801-2010; Taccioli, Cristian/ABC-3379-2020; Young, Richard A/F-6495-2012; Condorelli, Gerolama/AAC-3472-2022	Taccioli, Cristian/0000-0003-2995-5612; Taccioli, Cristian/0000-0003-2995-5612; Young, Richard A/0000-0001-8855-8647; Condorelli, Gerolama/0000-0003-0177-8829; Di Leva, Gianpiero/0000-0001-6759-8682	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fulda S, 2000, CANCER RES, V60, P3947; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garofalo M, 2007, INT J CANCER, V120, P1215, DOI 10.1002/ijc.22495; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Katayose Y, 1997, CANCER RES, V57, P5441; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smirnova L, 2005, EUR J NEUROSCI, V21, P1469, DOI 10.1111/j.1460-9568.2005.03978.x; StCroix B, 1996, NAT MED, V2, P1204; Tamborini E, 2004, CLIN CANCER RES, V10, P8214, DOI 10.1158/1078-0432.CCR-04-1013; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010	39	222	260	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3845	3855		10.1038/onc.2008.6	http://dx.doi.org/10.1038/onc.2008.6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246122	Green Published			2022-12-17	WOS:000256904700008
J	Hayward, NK				Hayward, NK			Genetics of melanoma predisposition	ONCOGENE			English	Article						CDKN2A; CDK4; ARF; MC1R; pigmentation; penetrance	CDKN2A GERMLINE MUTATIONS; CUTANEOUS MALIGNANT-MELANOMA; S-TRANSFERASE M1; PRONE FAMILIES; NERVOUS-SYSTEM; PANCREATIC ADENOCARCINOMA; RECEPTOR POLYMORPHISMS; MULTIPLE MELANOMAS; HAPLOTYPE ANALYSIS; DYSPLASTIC NEVI	Predisposition to melanoma is genetically heterogeneous. Two high penetrance susceptibility genes, CDKN2A and CDK4, have so far been identified and mapping is ongoing to localize and identify others. With the advent of a catalogue of millions of potential DNA polymorphisms, attention is now also being focused on identification of genes that confer a more modest contribution to melanoma risk, such as those encoding proteins involved in pigmentation, DNA repair, cell growth and differentiation or detoxification of metabolites. One such pigmentation gene, MC1R, has not only been found to be a low penetrance melanoma gene but has also been shown to act as a genetic modifier of melanoma risk in individuals carrying CDKN2A mutations. Most recently, an environmental agent, ultraviolet radiation, has also been established as a modifier of melanoma risk in CDKN2A mutation carriers. Hence, melanoma is turning out to be an excellent paradigm for studying gene-gene and gene-environment interactions.	Queensland Inst Med Res, Herston, Qld 4029, Australia	QIMR Berghofer Medical Research Institute	Hayward, NK (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4029, Australia.	nickH@qimr.edu.au	hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	hayward, nicholas k/0000-0003-4760-1033; 				*AIHW AICR, 1999, AIHW CANC SER; Aitken J, 1999, JNCI-J NATL CANCER I, V91, P446, DOI 10.1093/jnci/91.5.446; Armstrong BK, 1996, CANC EPIDEMIOLOGY PR, P1282; Auroy S, 2001, GENE CHROMOSOME CANC, V32, P195, DOI 10.1002/gcc.1183; AZIZI E, 1995, CANCER, V76, P1571, DOI 10.1002/1097-0142(19951101)76:9<1571::AID-CNCR2820760912>3.0.CO;2-6; Bahuau M, 1998, CANCER RES, V58, P2298; Bahuau M, 1997, ANN GENET-PARIS, V40, P78; Bastiaens M, 2001, HUM MOL GENET, V10, P1701, DOI 10.1093/hmg/10.16.1701; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; BLISS JM, 1995, INT J CANCER, V62, P367, DOI 10.1002/ijc.2910620402; Borg A, 2000, J NATL CANCER I, V92, P1260, DOI 10.1093/jnci/92.15.1260; Borg A, 1996, CANCER RES, V56, P2497; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; CHENEVIXTRENCH G, 1995, CARCINOGENESIS, V16, P1655, DOI 10.1093/carcin/16.7.1655; Ciotti P, 1996, NEW ENGL J MED, V334, P469; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; Della Torre G, 2001, BRIT J CANCER, V85, P836; DOLZAN V, 1995, CARCINOGENESIS, V16, P2675, DOI 10.1093/carcin/16.11.2675; Easton DF, 1997, AM J HUM GENET, V61, P120, DOI 10.1086/513891; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Ghiorzo P, 1999, INT J CANCER, V83, P441, DOI 10.1002/(SICI)1097-0215(19991112)83:4<441::AID-IJC2>3.0.CO;2-R; Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Goldstein AM, 2001, BRIT J CANCER, V85, P527, DOI 10.1054/bjoc.2001.1944; Grammatico P, 2001, MELANOMA RES, V11, P447, DOI 10.1097/00008390-200110000-00002; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Harding RM, 2000, AM J HUM GENET, V66, P1351, DOI 10.1086/302863; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; Hashemi J, 2000, CANCER RES, V60, P6864; Hayward N, 2000, Curr Oncol Rep, V2, P300, DOI 10.1007/s11912-000-0022-z; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hutchinson PE, 2000, CLIN CANCER RES, V6, P498; Ichii-Jones F, 1998, J INVEST DERMATOL, V111, P218, DOI 10.1046/j.1523-1747.1998.00287.x; Iscovich J, 2002, INT J CANCER, V98, P42, DOI 10.1002/ijc.10155; Kanetsky PA, 2002, AM J HUM GENET, V70, P770, DOI 10.1086/339076; Kanetsky PA, 2001, CANCER EPIDEM BIOMAR, V10, P509; KAUFMAN DK, 1993, NEUROLOGY, V43, P1728, DOI 10.1212/WNL.43.9.1728; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kumar R, 2001, INT J CANCER, V95, P388, DOI 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6; LAFUENTE A, 1995, BRIT J CANCER, V72, P324, DOI 10.1038/bjc.1995.332; Lal G, 2000, GENE CHROMOSOME CANC, V27, P358, DOI 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O; Lal G, 2000, CANCER RES, V60, P409; LIU L, 1995, ONCOGENE, V11, P405; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; MacKie RM, 1998, J INVEST DERMATOL, V111, P269, DOI 10.1046/j.1523-1747.1998.00267.x; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; Metzelaar-Blok JAW, 2001, INVEST OPHTH VIS SCI, V42, P1951; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Moskaluk C A, 1998, Hum Mutat, V12, P70; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2002, CANCER RES, V62, P875; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; PETTY EM, 1993, AM J HUM GENET, V53, P96; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Ries LA, 2002, SEER CANC STAT REV 1; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sauroja I, 2000, GENE CHROMOSOME CANC, V28, P404, DOI 10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P; Shahbazi M, 2002, LANCET, V359, P397, DOI 10.1016/S0140-6736(02)07600-6; SHANLEY SM, 1995, CARCINOGENESIS, V16, P2003, DOI 10.1093/carcin/16.8.2003; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sinilnikova OM, 1999, INT J CANCER, V82, P325; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Strange RC, 1999, PHARMACOGENETICS, V9, P269, DOI 10.1097/00008571-199906000-00001; Sturm RA, 1998, BIOESSAYS, V20, P712, DOI 10.1002/(SICI)1521-1878(199809)20:9<712::AID-BIES4>3.0.CO;2-I; Sturm RA, 2001, GENE, V277, P49, DOI 10.1016/S0378-1119(01)00694-1; Sun S, 1997, INT J CANCER, V73, P531, DOI 10.1002/(SICI)1097-0215(19971114)73:4<531::AID-IJC13>3.0.CO;2-C; Tsao H, 2000, ARCH DERMATOL, V136, P1118, DOI 10.1001/archderm.136.9.1118; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; Whiteman DC, 1997, J NATL CANCER I, V89, P1460, DOI 10.1093/jnci/89.19.1460; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; Yakobson E, 2000, EUR J HUM GENET, V8, P590, DOI 10.1038/sj.ejhg.5200505; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Youl P, 2002, INT J CANCER, V98, P92, DOI 10.1002/ijc.10117; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97; 1992, CANC INCIDENCE 5 CON, P871	91	222	229	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3053	3062		10.1038/sj.onc.1206445	http://dx.doi.org/10.1038/sj.onc.1206445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789280				2022-12-17	WOS:000183096600005
J	Wykoff, CC; Pugh, CW; Maxwell, PH; Harris, AL; Ratcliffe, PJ				Wykoff, CC; Pugh, CW; Maxwell, PH; Harris, AL; Ratcliffe, PJ			Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling	ONCOGENE			English	Article						VHL; hypoxia; HIF-1 alpha	RECEPTOR-RELATED PROTEIN; RENAL-CELL CARCINOMA; TISSUE TRANSGLUTAMINASE; INDUCIBLE GENES; DOWN-REGULATION; CYCLIN G2; C-FOS; ENDOTHELIN-1; ANGIOGENESIS; HIF-1-ALPHA	The von Hippel-Lindau tumour suppressor gene (VHL) targets hypoxia inducible factor (HIF)-alpha subunits for ubiquitin dependent proteolysis, To better understand the role of this and other putative pathways of gene regulation in VHL function we subjected mRNA from VHL defective renal carcinoma cells and transfectants re-expressing a wild type VHL allele to differential expression profiling, and analysed VHL target genes for oxygen regulated expression, Among a group of newly identified VHL target genes the majority but not all were regulated by oxygen, indicating that whilst dysregulation of the HIF system makes a dominant contribution to alterations in transcription, VHL has other influences on patterns of gene expression. Genes newly defined as targets of the VHL/hypoxia pathway (conditionally downregulated by VHL in normoxic cells) include aminopeptidase A, collagen type V, alpha 1, cyclin G2, DEC1/Stra13, endothelin 1, low density lipoprotein receptor-related protein 1, MIC2/CD99, and transglutaminase 2. These genes have a variety of functions relevant to tumour biology. However, not all are connected with the promotion of tumour growth, some being pro-apoptotic or growth inhibitory. We postulate that co-ordinate regulation as part of the HIF pathway may explain this paradox, and that evolution of anti; apoptotic pathways may be required for tumour growth under VHL-dysregulation, Our results indicate that it will be necessary to consider the effects of abnormal activity in integral regulatory pathways, as well as the effects of individual genes to understand the role of abnormal patterns of gene expression in cancer.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Ratcliffe, PJ (corresponding author), Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.		Maxwell, Patrick H/C-5557-2008; Harris, Adrian L/ABA-3343-2020	Maxwell, Patrick H/0000-0002-0338-2679; Harris, Adrian L/0000-0003-1376-8409; Pugh, Chris/0000-0002-5170-1662; Ratcliffe, Peter/0000-0002-2853-806X				Bates S, 1996, ONCOGENE, V13, P1103; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chazaud B, 2000, EXP CELL RES, V258, P237, DOI 10.1006/excr.2000.4934; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Fujimura H, 2000, ONCOLOGY-BASEL, V58, P342, DOI 10.1159/000012122; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hahn JH, 1997, J IMMUNOL, V159, P2250; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HIEDA HS, 1990, LIFE SCI, V47, P247, DOI 10.1016/0024-3205(90)90327-N; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Koong AC, 2000, CANCER RES, V60, P883; Kozawa O, 2000, CELL SIGNAL, V12, P375, DOI 10.1016/S0898-6568(00)00061-9; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Okuda Y, 1998, LIFE SCI, V63, P477, DOI 10.1016/S0024-3205(98)00296-3; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Pasqualini R, 2000, CANCER RES, V60, P722; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soslow RA, 1997, HUM PATHOL, V28, P1158, DOI 10.1016/S0046-8177(97)90254-9; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; YIN J, 1992, MOL BRAIN RES, V14, P213, DOI 10.1016/0169-328X(92)90176-C; Zhang PJ, 2000, MODERN PATHOL, V13, P452, DOI 10.1038/modpathol.3880077; ZOUBEK A, 1995, KLIN PADIATR, V207, P242, DOI 10.1055/s-2008-1046548	47	222	233	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6297	6305		10.1038/sj.onc.1204012	http://dx.doi.org/10.1038/sj.onc.1204012			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175344				2022-12-17	WOS:000166210500013
J	TORNALETTI, S; PFEIFER, GP				TORNALETTI, S; PFEIFER, GP			COMPLETE AND TISSUE-INDEPENDENT METHYLATION OF CPG SITES IN THE P53 GENE - IMPLICATIONS FOR MUTATIONS IN HUMAN CANCERS	ONCOGENE			English	Article						METHYLATION; P53; MUTATION	TUMOR SUPPRESSOR GENE; LIGATION-MEDIATED PCR; UV PHOTOPRODUCTS; DNA METHYLATION; SKIN-CANCER; CELLS; MUTAGENESIS; PROTEIN	CpG dinucleotides are the target of about one third of transition mutations found in human genetic diseases and tumors. Methylation at these sites is thought to be the cause of these genetic changes through spontaneous deamination of 5-methylcytosine. In order to define the contribution of 5-methylcytosine to the spectrum of p53 mutations in human cancers, we have determined the complete DNA methylation pattern along exons 5-8 of the human p53 gene by ligation-mediated polymerase chain reaction genomic sequencing. The study was conducted with nine different types of normal human tissue and cell lines, including skin fibroblasts, keratinocytes, lung epithelial cells, mammary epithelial cells and colonic mucosa cells. We found that the p53 sequences along exons 5-8 are completely methylated at every CpG site, including 46 different sites on both DNA strands. This methylation pattern is tissue-independent suggesting that tissue-specific methylation does not contribute to the differential mutation patterns seen in tumors, The occurrence of mutational hotspots at specific CpG sites is not related to selective methylation of only a subset of CpGs but may rather depend on a selection bias for particular amino acid changes. Our results are not inconsistent with theories that mutations in tumors with high CpG mutation rates, like colon cancer, are caused by spontaneous deamination of 5-methylcytosine and mutations in tumors with a lack of CpG involvement reflect superimposed fingerprints from exogenous carcinogens. However, given the lack of tissue specificity of methylation, alternative explanations (eg targeting of methylated CpG sites by tissue-selective carcinogens) should be considered to explain the high percentage of CPG mutations in some tumor types.	BECKMAN RES INST CITY HOPE,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BENTIVEGNA SS, 1994, CANCER RES, V54, P327; BIGGS PJ, 1993, MUTAGENESIS, V4, P275; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KETTERLING RP, 1994, AM J HUM GENET, V54, P831; KOCHANEK S, 1991, P NATL ACAD SCI USA, V88, P5759, DOI 10.1073/pnas.88.13.5759; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; ORY K, 1994, EMBO J, V15, P3496; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUGGERI B, 1993, P NATL ACAD SCI USA, V88, P10657; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SPRUCK CH, 1993, DNA METHYLATION MOL, P487; TORMANEN VT, 1992, ONCOGENE, V7, P1729; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wiebauer K., 1993, DNA METHYLATION MOL, P510; WIEBAUER K, 1989, NATURE, V399, P234; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	42	222	231	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1493	1499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731703				2022-12-17	WOS:A1995QU68100004
J	MAESTRO, R; DOLCETTI, R; GASPAROTTO, D; DOGLIONI, C; PELUCCHI, S; BARZAN, L; GRANDI, E; BOIOCCHI, M				MAESTRO, R; DOLCETTI, R; GASPAROTTO, D; DOGLIONI, C; PELUCCHI, S; BARZAN, L; GRANDI, E; BOIOCCHI, M			HIGH-FREQUENCY OF P53-GENE ALTERATIONS ASSOCIATED WITH PROTEIN OVEREXPRESSION IN HUMAN SQUAMOUS-CELL CARCINOMA OF THE LARYNX	ONCOGENE			English	Article							HUMAN P53 GENE; LUNG-CANCER; BREAST-CANCER; BLAST CRISIS; ALLELE LOSS; MUTANT P53; EXPRESSION; MUTATIONS; ONCOGENE; REARRANGEMENT	A series of 58 primary human squamous cell carcinomas of the larynx (LSCCs) was examined for the expression of the p53 tumor-suppressor gene by a combined immunohistochemical and molecular approach. About 60% of the cases displayed nuclear p53 overexpression as revealed by immunostaining with PAb1801, PAb122 and PAb240 monoclonal antibodies. This phenomenon was associated with the presence of structural and/or transcriptional alterations of the p53 gene. Our results provide evidence that p53 abnormalities constitute the most frequent genetic alteration identified so far in LSCC and indicate that the abnormal accumulation of the protein correlates with the presence of p53-mutated versions. These findings, taken together with the peculiar biochemical properties of p53, support the hypothesis of a possible pathogenetic relationship between smoke carcinogen exposure and p53 inactivation in the development of this tumor type.	CTR RIFERIMENTO ONCOL,DIV EXPTL ONCOL 1,VIA PEDEMONTANA OCCIDENTALE,I-33081 AVIANO,ITALY; OSPED FELTRE,DIV PATHOL,FELTRE,ITALY; UNIV FERRARA,DEPT OTORHINOLARYNGOL,I-44100 FERRARA,ITALY; OSPED CIVILE,DIV OTORHINOLARYNGOL,PORDENONE,ITALY; UNIV FERRARA,DEPT PATHOL,I-44100 FERRARA,ITALY	IRCCS Aviano (CRO); ULSS 1 Dolomiti; Ospedale di Feltre; University of Ferrara; University of Ferrara			Maestro, Roberta/M-1846-2015; Dolcetti, Riccardo/O-3832-2015; Maestro, Roberta/P-9748-2019; Gasparotto, Daniela/Y-2351-2019	Maestro, Roberta/0000-0002-6642-5592; Dolcetti, Riccardo/0000-0003-1625-9853; Maestro, Roberta/0000-0002-6642-5592; Gasparotto, Daniela/0000-0003-0914-1654; DOGLIONI, Claudio/0000-0002-4969-5216				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BENDAVID Y, 1988, ONCOGENE, V3, P179; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN YM, 1991, ONCOGENE, V6, P1799; CHIBA I, 1990, ONCOGENE, V5, P1603; DOLCETTI R, 1988, EUR J CANCER CLIN ON, V24, P1321, DOI 10.1016/0277-5379(88)90223-4; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLANDERS WD, 1982, AM J EPIDEMIOL, V115, P371, DOI 10.1093/oxfordjournals.aje.a113315; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KELMAN Z, 1989, BLOOD, V74, P2318; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; Kriek E, 1984, Biochim Biophys Acta, V738, P181; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACKAY J, 1988, LANCET, V2, P1384; Maniatis T, 1989, DECONTAMINATION DILU; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASHAL R, 1990, BLOOD, V75, P180; MASHARANI U, 1988, NUCLEIC ACIDS RES, V16, P7757, DOI 10.1093/nar/16.15.7757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEIER R, 1988, NUCLEIC ACIDS RES, V16, P2340, DOI 10.1093/nar/16.5.2340; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STELL PM, 1972, LANCET, V1, P617; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TUYNS AJ, 1982, INT J CANCER, V30, P9, DOI 10.1002/ijc.2910300103; VERONESI U, 1979, TUMORI TESTA COLLO; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; WOLF D, 1984, CELL, V38, P453; 1986, MONOGRAPHS EVALUATIO, V38	57	222	226	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1159	1166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594246				2022-12-17	WOS:A1992HU64200013
J	BORG, A; BALDETORP, B; FERNO, M; KILLANDER, D; OLSSON, H; SIGURDSSON, H				BORG, A; BALDETORP, B; FERNO, M; KILLANDER, D; OLSSON, H; SIGURDSSON, H			ERBB2 AMPLIFICATION IN BREAST-CANCER WITH A HIGH-RATE OF PROLIFERATION	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; HER-2 NEU ONCOGENE; TYROSINE PHOSPHORYLATION; BIOPSY SAMPLES; CARCINOMA; PROTEIN; GENE; DNA; EXPRESSION; SURVIVAL	The ERBB2 proto-oncogene was studied in 539 invasive primary breast tumors and was found amplified (2- > 30 copies) in 19%. Amplification was correlated to most known risk factors, including; large tumor size, lymph node positivity and many tumor involved nodes, advanced stage, low patient age (< 40 years), non-diploidy and hypertetraploidy, and most significantly (P < 0.00001) to the absence of steroid receptors and to a high rate of proliferation (flow cytometric determined S phase fraction). ERBB2 amplification was strongly associated (P < 0.0001) with early recurrence and death in breast cancer among node-positive patients. This connection did not, however, remain in multivariate analyses. No correlations to clinical outcome were seen among node-negative patients. Similarly, non-diploid, but not diploid, amplified tumors were particularly aggressive. Furthermore, ERBB2 amplification was associated with a high rate of proliferation and poor prognosis in steroid receptor positive, but not receptor negative tumors. In progesterone receptor positive breast cancer, amplification was an independent and with node status equally powerful (P < 0.0001) predictor of poor survival. It is concluded that ERBB2 activity is related to an increased tumor growth rate but not directly to metastasizing ability. Its clinical relevance as a prognostic factor may be in selecting a high risk subgroup of breast cancer, in general considered as being of good prognosis.			BORG, A (corresponding author), UNIV LUND HOSP, DEPT ONCOL, S-22185 LUND, SWEDEN.		Baldetorp, Bo/HDM-9924-2022	Olsson, Hakan/0000-0002-8794-9635				ALLRED D, 1990, P ASCO, V9, P23; BAISCH H, 1975, RADIAT ENVIRON BIOPH, V12, P31, DOI 10.1007/BF02339807; BALDETORP B, 1989, CYTOMETRY, V10, P695, DOI 10.1002/cyto.990100605; BERGER MS, 1988, CANCER RES, V48, P1238; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; BRESLOW NE, 1975, INT STAT REV, V43, P45, DOI 10.2307/1402659; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; COX DR, 1972, J R STAT SOC B, V34, P187; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FERNO M, 1989, ACTA ONCOL, V28, P19, DOI 10.3109/02841868909111175; FERNO M, 1986, ACTA ONCOL, V25, P171, DOI 10.3109/02841868609136398; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE GM, 1984, ANAL BIOCHEM, V137, P221, DOI 10.1016/0003-2697(84)90374-9; LIPPMAN ME, 1990, P ASCO, V9, P24; MANGEL WF, 1988, J STEROID BIOCHEM, V30, P79, DOI 10.1016/0022-4731(88)90079-9; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARX D, 1990, J CANCER RES CLIN, V116, P15, DOI 10.1007/BF01612634; NORGREN A, 1982, ANTICANCER RES, V2, P315; NOWELL PC, 1986, CANCER RES, V46, P2203; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; ROCHEFORT H, 1988, BIOCHIMIE, V70, P943, DOI 10.1016/0300-9084(88)90236-2; SAINSBURY JRC, 1987, LANCET, V1, P1398; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SIGURDSSON H, 1990, BRIT J CANCER, V62, P786, DOI 10.1038/bjc.1990.380; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THORNTHWAITE JT, 1980, CYTOMETRY, V1, P229, DOI 10.1002/cyto.990010309; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VOGELSTEIN B, 1989, CC MOL BIOL, P73; WRIGHT C, 1989, CANCER RES, V49, P2087; ZEILLINGER R, 1989, ONCOGENE, V4, P109	47	222	226	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					137	143						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1671531				2022-12-17	WOS:A1991EY03900019
J	Carroll, PE; Okuda, M; Horn, HF; Biddinger, P; Stambrook, PJ; Gleich, LL; Li, YQ; Tarapore, P; Fukasawa, K				Carroll, PE; Okuda, M; Horn, HF; Biddinger, P; Stambrook, PJ; Gleich, LL; Li, YQ; Tarapore, P; Fukasawa, K			Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression	ONCOGENE			English	Article						chromosome instability; p53; Mdm2; human cancer; centrosome hyperamplification	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; GENOMIC INSTABILITY; P53-DEFICIENT MICE; GAMMA-TUBULIN; BARRETTS-ESOPHAGUS; BREAST-CANCER; PROTEIN; AMPLIFICATION; CELLS	We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability, Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification, Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types, Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, me observed centrosome hyperamplification in tumors that retained wild-type p53, These tumors contained high levels of Mdm2, Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification, We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Okuda, Masaru/0000-0003-4690-8244; Horn, Henning/0000-0002-5885-8996				BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BLOUNT PL, 1994, CANCER RES, V54, P2292; Bornens Michel, 1992, P1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CAHILLYSYNDER L, 1987, GENET, V13, P234; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG KC, 1993, ADV CANCER RES, V60, P121; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; EYFJORD JE, 1995, CANCER RES, V55, P646; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAPANY M, 1993, CANCER DETECT PREV, V17, P379; Gleich LL, 1996, LARYNGOSCOPE, V106, P1378, DOI 10.1097/00005537-199611000-00013; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSHIMURA M, 1986, ENVIRON MUTAGEN, V8, P129, DOI 10.1002/em.2860080112; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVELIC ZP, 1994, ANTICANCER RES, V14, P2259; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; PURDIE CA, 1994, ONCOGENE, V9, P603; RaybaudDiogene H, 1996, ORAL ONCOL, V32B, P143; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; VISSING H, 1987, NUCLEIC ACIDS RES, V15, P1363, DOI 10.1093/nar/15.4.1363; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	58	221	229	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1935	1944		10.1038/sj.onc.1202515	http://dx.doi.org/10.1038/sj.onc.1202515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208415				2022-12-17	WOS:000079191300003
J	Savatier, P; Lapillonne, H; vanGrunsven, LA; Rudkin, B; Samarut, J				Savatier, P; Lapillonne, H; vanGrunsven, LA; Rudkin, B; Samarut, J			Withdrawal of differentiation inhibitory activity leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells	ONCOGENE			English	Article						mouse embryonic stem cells; mouse embryo; cell cycle; G1-cyclins; cyclin-dependent kinase inhibitors; gastrulation; DIA/LIF	AUTORADIOGRAPHIC ANALYSIS; MESODERM FORMATION; DIFFERENT REGIONS; GENE-EXPRESSION; CARCINOMA-CELLS; RETINOIC ACID; T-GENE; FIBROBLASTS; PROTEIN; G(1)	The expression of E and D-type cyclins, Cyclin-Dependent Kinase (CDK) 2 and 4, as web as CDK inhibitors p21(Cip1) and p27(Kip1) were examined during in vitro differentiation of mouse embryonic stem (ES) cells. ES cells cultured in presence of Differentiation Inhibitory Activity/Leukemia Inhibitory Factor (DIA/LIF) express very low levels of cylin E/CDK2 complexes, p21(Cip1) and p27(Kip1) CDK inhibitors, while cylin D/CDK4-associated kinase activity is undetectable. Withdrawal of DIA/LIF, which induces differentiation, results in the progressive up-regulation of all. Up-regulation of D cyclins occurs through an increase in the steady-state levels of mRNA, concomitantly with the activation of Brachyury and Goosecoid, two early markers of mesoderm differentiation. Similarly, cells from the epiblast of the early postimplantation mouse embryo do not express any cyclin D/CDK4 complexes, These are progressively up-regulated at gastrulation and early organogenesis, DIA/LIF-stimulated ES cells are not growth-arrested by overexpression of p16(Ink4a), a specific inhibitor of CDK4 and CDK6. We propose that the G1/S transition may be regulated by a minimal mechanism in mouse embryonic stem cells. Induction of differentiation triggers the establishment of a more sophisticated mechanism involving both cyclin D/CDK4- and CDK inhibitor-associated control of G1-phase progression.			Savatier, P (corresponding author), ECOLE NORMALE SUPER LYON,LA INRA,UMR 49 CNRS,LAB BIOL MOLEC & CELLULAIRE,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Samarut, Jacques/AAD-2587-2019; van Grunsven, Leo/E-5839-2010; SAVATIER, Pierre/J-4663-2014	van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1983, J EMBRYOL EXP MORPH, V75, P189; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAMJANOV I, 1971, ROUX ARCH DEV BIOL, V167, P288; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIWAN SB, 1976, J NATL CANCER I, V57, P937, DOI 10.1093/jnci/57.4.937; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS M, 1981, J REPROD FERTIL, V62, P625; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; JIANG W, 1993, ONCOGENE, V8, P3447; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, ONCOGENE, V10, P87; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUKAS J, 1995, MOL CELL BIOL, V15, P2660; MARTIN GR, 1980, SCIENCE, V209, P676; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCAULEY A, 1993, DEVELOPMENT, V117, P873; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3462; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROBERTSON EJ, 1986, EXPT APPROACHES MAMM, P475; ROGERS MB, 1991, DEVELOPMENT, V113, P815; ROSS ME, 1994, J NEUROSCI, V14, P6384; SAVATIER P, 1994, ONCOGENE, V9, P809; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOLTER D, 1980, INT J CANCER, V25, P341, DOI 10.1002/ijc.2910250306; SOLTER D, 1973, EXPERIENTIA, V29, P701, DOI 10.1007/BF01944785; TAM SW, 1994, ONCOGENE, V9, P2663; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	81	221	232	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					309	322						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570208				2022-12-17	WOS:A1996TR53800010
J	VIGLIETTO, G; CHIAPPETTA, G; MARTINEZTELLO, FJ; FUKUNAGA, FH; TALLINI, G; RIGOPOULOU, D; VISCONTI, R; MASTRO, A; SANTORO, M; FUSCO, A				VIGLIETTO, G; CHIAPPETTA, G; MARTINEZTELLO, FJ; FUKUNAGA, FH; TALLINI, G; RIGOPOULOU, D; VISCONTI, R; MASTRO, A; SANTORO, M; FUSCO, A			RET/PTC ONCOGENE ACTIVATION IS AN EARLY EVENT IN THYROID CARCINOGENESIS	ONCOGENE			English	Note						RET PROTOONCOGENE; RET/PTC ONCOGENE; THYROID; OCCULT CARCINOMAS; RT-PCR	RET TYROSINE KINASE; PAPILLARY CARCINOMAS; PROTOONCOGENE	RET/PTC oncogene activation occurs in about 20% of human thyroid papillary carcinomas, However, it is not known yet whether it is an early or late event in the process of thyroid carcinogenesis, Here we demonstrate, by using a combined immunohistochemical and reverse-transcriptase-polymerase chain reaction based approach, that RET/PTC activation is present in 11 out of 26 occult thyroid papillary carcinomas analysed. Therefore, we conclude that it represents an early event in the process of thyroid cell transformation.	IST NAZL TUMORI,FDN SENATORE PASCALE,I-80131 NAPLES,ITALY; UNIV COMPLUTENSE MADRID,HOSP UNIV 12 OCTUBRE,DEPT PATHOL,E-28041 MADRID,SPAIN; KUAKINI MED CTR,HONOLULU,HI 96817; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; UNIV COMPLUTENSE MADRID,HOSP UNIV 12 OCTUBRE,SERV ENDOCRINOL,E-28041 MADRID,SPAIN; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	IRCCS Fondazione Pascale; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Yale University; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria			Visconti, Roberta/C-5299-2009; Tallini, Giovanni/F-7850-2013; Viglietto, Giuseppe/AAC-2852-2019	Tallini, Giovanni/0000-0003-0113-6682; Viglietto, Giuseppe/0000-0003-2327-7515; Visconti, Roberta/0000-0001-7613-3801; Fusco, Alfredo/0000-0003-3332-5197				BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUKUNAGA FH, 1975, CANCER-AM CANCER SOC, V36, P1095, DOI 10.1002/1097-0142(197509)36:3<1095::AID-CNCR2820360338>3.0.CO;2-9; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; JACKSON DP, 1989, LANCET, V1, P1391; LANZI C, 1992, ONCOGENE, V7, P2189; MARTINEZTELLO FJ, 1993, CANCER-AM CANCER SOC, V71, P4022, DOI 10.1002/1097-0142(19930615)71:12<4022::AID-CNCR2820711236>3.0.CO;2-O; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509	16	221	233	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1207	1210						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566982				2022-12-17	WOS:A1995RX18000025
J	RHYU, MG; PARK, WS; MELTZER, SJ				RHYU, MG; PARK, WS; MELTZER, SJ			MICROSATELLITE INSTABILITY OCCURS FREQUENTLY IN HUMAN GASTRIC-CARCINOMA	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; APC GENE; COLORECTAL TUMORIGENESIS; MUTATIONS OCCUR; CANCER; DELETIONS; REPEAT	Microsatellites are short repeated oligonucleotide sequences found throughout the human genome. Microsatellite instability has been reported in hereditary and sporadic colorectal carcinomas. Since gastric carcinoma shares numerous molecular abnormalities with colon cancer, we evaluated 52 gastric adenocarcinomas and adjacent dysplastic tissues for microsatellite instability at five chromosomal loci. Instability at one or more loci was observed in 16 (31%) of the 52 tumors, but in only two dysplastic tissues adjacent to their respective tumors. These results demonstrate that microsatellite instability is not limited to colorectal carcinoma, but also occurs frequently in another cancer, that of the stomach. It is probably a late event, developing only rarely in premalignant dysplastic lesions.	DEPT VET AFFAIRS,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; UNIV MARYLAND HOSP,BALTIMORE,MD 21201; CATHOLIC UNIV SEOUL,COLL MED,DEPT PATHOL,SEOUL,SOUTH KOREA	University System of Maryland; University of Maryland Baltimore; Catholic University of Korea								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, CANCER RES, V50, P7717; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; GUSELLA JF, 1993, NEW ENGL J MED, V329, P571, DOI 10.1056/NEJM199308193290811; HORII A, 1992, CANCER RES, V52, P3231; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAERVI O, 1951, ACTA PATHOL MIC SC, V29, P26; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEISTER I, 1990, CANCER RES, V50, P7232; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MELTZER SJ, 1990, CANCER RES, V50, P3627; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RENAULT B, 1993, CANCER RES, V53, P2614; SANO T, 1991, CANCER RES, V51, P2926; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1989, AM J HUM GENET, V44, P388	23	221	227	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					29	32						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302591				2022-12-17	WOS:A1994MW24700004
J	Gan, Y; Shi, C; Inge, L; Hibner, M; Balducci, J; Huang, Y				Gan, Y.; Shi, C.; Inge, L.; Hibner, M.; Balducci, J.; Huang, Y.			Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells	ONCOGENE			English	Article						EGFR; ERK; Akt; phosphorylation; signaling; cell migration	GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; FOCAL ADHESION PROTEIN; E-CADHERIN EXPRESSION; DOWN-REGULATION; TUMOR PROGRESSION; ERBB RECEPTORS; BETA-CATENIN; C-CBL	Upregulation of epidermal growth factor receptor (EGFR) and subsequent increases in extracellular-regulated kinase (ERK) and Akt signaling are implicated in prostate cancer progression. Impaired endocytic downregulation of EGFR also contributes to oncogenic phenotypes such as metastasis. Thus, understanding the roles of divergent signaling pathways in the regulation of EGFR trafficking and EGFR-driven invasive migration may enable the development of more effective therapies. In this study, we use the human prostate cancer cell lines, DU145 and PC3, to investigate the effects of both the ERK and Akt pathways on epidermal growth factor (EGF)-mediated EGFR signaling, trafficking and cell motility. We show that DU145 and PC3 cells overexpress EGFR and migrate in a ligand (EGF)dependent manner. Next, we show that pharmacological inhibition of ERK (but not Akt) signaling enhances EGF-induced EGFR activation, ubiquitination and downregulation, and may lead to enhanced receptor turnover. These findings negatively correlate with ERK-mediated threonine phosphorylation of EGFR, implicating it as a possible mechanism. Further, we uncover that EGF promotes disassembly of cell-cell junctions, downregulation of E-cadherin and upregulation of the transcriptional repressor, Snail, typical characteristics of epithelial-mesenchymal transition (EMT). These effects are dependent on activation of Akt, as inhibition of Akt signaling abolishes EGF/EGFR-driven cell migration and EMT. Knockdown of endogenous Snail also prevents EGFR-mediated downregulation of E-cadherin, EMT and cell migration. Surprisingly, inhibition of the ERK pathway augments EGFR-dependent motility, occurring concomitantly with elevation of EGF-induced Akt activity. Collectively, our results suggest that EGF-triggered ERK activation has profound feedback on EGFR signaling and trafficking by EGFR threonine phosphorylation, and Akt has a pivotal role in EGFR-mediated cell migration by activating EMT. More important, our results also suggest that therapeutic targeting of ERK signaling may have undesirable outcomes (for example, augmenting EGFR-driven motility). Oncogene (2010) 29, 4947-4958; doi: 10.1038/onc.2010.240; published online 21 June 2010	[Gan, Y.; Shi, C.; Hibner, M.; Balducci, J.; Huang, Y.] St Josephs Hosp, Dept Obstet & Gynecol, Phoenix, AZ 85004 USA; [Inge, L.] St Josephs Hosp, Heart & Lung Inst, Phoenix, AZ 85004 USA; [Shi, C.] Huazhong Univ Sci & Technol, Dept Pathogen Biol, Tongji Med Coll, Wuhan 430074, Peoples R China	St. Joseph's Hospital and Medical Center; St. Joseph's Hospital and Medical Center; Huazhong University of Science & Technology	Huang, Y (corresponding author), St Josephs Hosp, Dept Obstet & Gynecol, 445 N 5th St,Suite 110, Phoenix, AZ 85004 USA.	yhuang@chw.edu	高, 雨莉/HGU-8187-2022		St Joseph's Foundation	St Joseph's Foundation	We thank Prof. Michael Croft for generously providing retroviral expression vector for constitutively active (myristoylated) Akt. This work was supported by a St Joseph's Foundation Startup Fund (to YH). Part of this work was presented at the 91st Endocrine Society Annual Meeting in Washington DC, USA, 2009.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Davies MA, 2002, CLIN CANCER RES, V8, P1904; Deng L, 2007, MOL ENDOCRINOL, V21, P1537, DOI 10.1210/me.2007-0138; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hipp S, 2009, J CELL MOL MED, V13, P3858, DOI 10.1111/j.1582-4934.2008.00526.x; Huang Y, 2006, ONCOGENE, V25, P7565, DOI 10.1038/sj.onc.1209740; Huang Y, 2004, ENDOCRINOLOGY, V145, P3297, DOI 10.1210/en.2003-1658; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kambhampati S, 2005, FRONT BIOSCI-LANDMRK, V10, P1355, DOI 10.2741/1625; Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Ma FX, 2009, GENES CELLS, V14, P281, DOI 10.1111/j.1365-2443.2008.01267.x; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Schlessinger K, 2004, NAT CELL BIOL, V6, P913, DOI 10.1038/ncb1004-913; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Traish AM, 2009, BRIT J CANCER, V101, P1949, DOI 10.1038/sj.bjc.6605376; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; UMBAS R, 1994, CANCER RES, V54, P3929; UMBAS R, 1992, CANCER RES, V52, P5104; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yang CC, 2009, CANCER CELL, V15, P355, DOI 10.1016/j.ccr.2009.04.003; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	48	220	228	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4947	4958		10.1038/onc.2010.240	http://dx.doi.org/10.1038/onc.2010.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562913				2022-12-17	WOS:000281578700009
J	Deisenroth, C; Zhang, Y				Deisenroth, C.; Zhang, Y.			Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway	ONCOGENE			English	Review						ribosome biogenesis; ribosomal protein; Mdm2; p53; nucleolar stress	POLYMERASE-III TRANSCRIPTION; DIAMOND-BLACKFAN ANEMIA; NUCLEOLAR PROTEIN BOP1; RNA-SYNTHESIS; P53-DEPENDENT CHECKPOINT; CELL-PROLIFERATION; SACCHAROMYCES-CEREVISIAE; I TRANSCRIPTION; P53 ACTIVATION; DNA-DAMAGE	The dynamic processes of cell growth and cell division remain under constant surveillance. As one of the primary 'gatekeepers' of the cell, p53 has a major role in sensing a variety of stressors to maintain cellular homeostasis. Growth is driven by new protein synthesis, a process that requires robust manufacture of ribosomes in the nucleolus. Ribosome biogenesis is a complex process comprising transcription, modification, and processing of ribosomal RNA, production of ribosomal proteins (RPs) and auxiliary factors, and coordinated assembly of ribonucleoprotein particles to produce mature ribosomes. As the major function of the nucleolus, ribosome biogenesis demands a considerable amount of resources and must be maintained in a coordinated manner to ensure fidelity of the process. Perturbations to many aspects of ribosome biogenesis are thought to contribute to 'nucleolar stress' and trigger a RP-Mdm2-p53 stress response pathway. In this review, we will clarify how disruption to three major components of ribosome biogenesis can trigger nucleolar stress and activate p53, thereby lending support to a RP-Mdm2-p53 ribosome biogenesis surveillance pathway. Oncogene (2010) 29, 4253-4260; doi: 10.1038/onc.2010.189; published online 24 May 2010	[Deisenroth, C.; Zhang, Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27514 USA; [Deisenroth, C.; Zhang, Y.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27514 USA; [Zhang, Y.] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27514 USA; [Deisenroth, C.; Zhang, Y.] Univ N Carolina, Dept Radiat Oncol, Sch Med, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Box 7512,101 Manning Dr, Chapel Hill, NC 27514 USA.	ypzhang@med.unc.edu		Zhang, Yi/0000-0002-2789-0811	NCI NIH HHS [R01 CA127770, R01 CA100302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100302, R01CA127770] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Ayrault O, 2006, ONCOGENE, V25, P7577, DOI 10.1038/sj.onc.1209743; Azuma M, 2006, J BIOL CHEM, V281, P13309, DOI 10.1074/jbc.M601892200; Barkic M, 2009, MOL CELL BIOL, V29, P2489, DOI 10.1128/MCB.01588-08; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chakraborty A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004152; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Ellis SR, 2008, CURR TOP DEV BIOL, V82, P217, DOI 10.1016/S0070-2153(07)00008-7; Fujii K, 2009, GENE DEV, V23, P963, DOI 10.1101/gad.1775609; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Holzel M, 2005, J CELL BIOL, V170, P367, DOI 10.1083/jcb.200501141; Huang M, 2008, LEUKEMIA RES, V32, P131, DOI 10.1016/j.leukres.2007.03.025; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lai K, 2009, DEV DYNAM, V238, P76, DOI 10.1002/dvdy.21815; Lempiainen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Lindstrom MS, 2008, J BIOL CHEM, V283, P15568, DOI 10.1074/jbc.M801151200; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Liu JJ, 2006, J CELL PHYSIOL, V207, P287, DOI 10.1002/jcp.20589; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Luft F, 2010, J MOL MED-JMM, V88, P1, DOI 10.1007/s00109-009-0570-0; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARIA FC, 2008, HUM MUTAT, V29, P911; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Meek DW, 2003, MOL CANCER RES, V1, P1017; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Oliver ER, 2004, DEVELOPMENT, V131, P3907, DOI 10.1242/dev.01268; Panic L, 2006, MOL CELL BIOL, V26, P8880, DOI 10.1128/MCB.00751-06; Parlato R, 2008, J NEUROSCI, V28, P12759, DOI 10.1523/JNEUROSCI.2439-08.2008; PERRY RP, 1963, EXP CELL RES, V29, P400, DOI 10.1016/S0014-4827(63)80003-8; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Skarie JM, 2008, HUM MOL GENET, V17, P2474, DOI 10.1093/hmg/ddn147; SOBELL HM, 1971, NATURE-NEW BIOL, V231, P200, DOI 10.1038/newbio231200a0; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.biochem.55.1.801; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Szymanski M, 2003, BIOCHEM J, V371, P641, DOI 10.1042/BJ20020872; Tang Q, 1999, DEV BIOL, V207, P239, DOI 10.1006/dbio.1998.9142; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang C, 2005, MOL CELL BIOL, V25, P6899, DOI 10.1128/MCB.25.16.6899-6911.2005; Zhang J, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-115; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	77	220	222	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4253	4260		10.1038/onc.2010.189	http://dx.doi.org/10.1038/onc.2010.189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498634				2022-12-17	WOS:000280547900002
J	Kremsdorf, D; Soussan, P; Paterlini-Brechot, P; Brechot, C				Kremsdorf, D.; Soussan, P.; Paterlini-Brechot, P.; Brechot, C.			Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis B virus; viral integration; HBx; HBSP	X PROTEIN HBX; CORE PROMOTER MUTATIONS; TRANSGENIC MOUSE MODEL; T-CELL EPITOPES; PRE-S MUTANT; SURFACE-ANTIGEN; IN-VIVO; INSERTIONAL MUTAGENESIS; GENE-EXPRESSION; LIVER-TUMORS	As discussed in detail in other chapters of this review, chronic hepatitis B (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). Most HCCs complicate the evolution of an active or inactive cirrhosis. However, some tumors occur on livers with minimal histological changes; the prevalence of such cases varies from one geographical region to the other, being much higher in the southern half of Africa (around 40% of HCCs) than in Asia, America and Europe, where at least 90% of HCCs are associated with the cirrhosis. This heterogeneity is probably a reflection of different environmental and genetic factors. This review will summarize the current knowledge on the mechanisms involved in HBV-related liver carcinogenesis. It will show in particular how viruses can be viewed as tools to discover and dissect new cellular pathways involved in cancer development and emphasize the potential synergistic effects between HBV and hepatitis C virus, as well as between viral infections and other environmental factors, such as alcohol.	INSERM, U812, Paris, France; Univ Paris 05, Fac Med, CHU Necker, Paris, France; Inst Pasteur, Paris, France; INSERM, U807, Paris, France; INSERM, U785, Villejuif, France; Univ Paris 11, Fac Med, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Brechot, C (corresponding author), Univ Paris 11, INSERM, U785, Liver Hepatobiliary Ctr,Paul Brousse Hosp, F-94800 Villejuif, France.	brechot@vjf.inserm.fr	Kremsdorf, Dina/O-9797-2017; soussan, patrick/O-9801-2017	soussan, patrick/0000-0003-2706-7371; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Ahn JY, 2002, J GEN VIROL, V83, P2765, DOI 10.1099/0022-1317-83-11-2765; Andrisani OM, 1999, INT J ONCOL, V15, P373; Anthony PP, 2001, HISTOPATHOLOGY, V39, P109, DOI 10.1046/j.1365-2559.2001.01188.x; Aoki H, 1996, P NATL ACAD SCI USA, V93, P7300, DOI 10.1073/pnas.93.14.7300; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BANNASCH P, 1989, FALK SYMP, V51, P55; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bergametti F, 2002, J VIROL, V76, P6495, DOI 10.1128/JVI.76.13.6495-6501.2002; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Bouchard MJ, 2003, J VIROL, V77, P7713, DOI 10.1128/JVI.77.14.7713-7719.2003; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRECHOT C, 1998, VIRAL HEPATITIS LIVE, P490; Bruni R, 2004, VIROLOGY, V329, P1, DOI 10.1016/j.virol.2004.08.008; Bruni R, 1999, VIROLOGY, V257, P483, DOI 10.1006/viro.1999.9678; BUENDIA MA, 1994, PRIMARY LIVER CANC E, P211; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Chan HLY, 2004, GUT, V53, P1494, DOI 10.1136/gut.2003.033324; CHEN C, 1986, BR J EXP PATHOL, V67, P1868; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Chen GG, 2005, J CLIN VIROL, V34, P7, DOI 10.1016/j.jcv.2005.01.006; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chen YY, 2005, INT IMMUNOPHARMACOL, V5, P1839, DOI 10.1016/j.intimp.2005.06.004; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2; Choi YW, 2005, VIROLOGY, V332, P454, DOI 10.1016/j.virol.2004.11.019; Chun E, 2003, J IMMUNOL, V170, P1183, DOI 10.4049/jimmunol.170.3.1183; Chung MK, 1999, J IMMUNOTHER, V22, P279, DOI 10.1097/00002371-199907000-00001; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; CLEMENTI M, 1993, RES VIROLOGY, V144, P297, DOI 10.1016/S0923-2516(06)80044-0; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cui F, 2006, PROTEOMICS, V6, P498, DOI 10.1002/pmic.200500218; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Fan YF, 2000, J GASTROEN HEPATOL, V15, P519, DOI 10.1046/j.1440-1746.2000.02187.x; Fan YF, 2001, HEPATOLOGY, V33, P277, DOI 10.1053/jhep.2001.21163; FARZA H, 1994, MOL CARCINOGEN, V9, P185, DOI 10.1002/mc.2940090402; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEITELSON MA, 2005, CANC LETT        SEP; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; GERIN JL, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P556; Gong SS, 1996, J VIROL, V70, P2000, DOI 10.1128/JVI.70.3.2000-2007.1996; Guidotti LG, 2000, VIROLOGY, V273, P221, DOI 10.1006/viro.2000.0442; Guidotti LG, 1999, J EXP MED, V189, P1555, DOI 10.1084/jem.189.10.1555; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Gunther S, 1997, VIROLOGY, V238, P363, DOI 10.1006/viro.1997.8863; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; HAN KH, 1993, HEPATOLOGY, V18, P1032; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; HESS J, 1988, MED MICROBIOL IMMUN, V177, P195, DOI 10.1007/BF00211219; Hessein M, 2005, TUMORI J, V91, P241, DOI 10.1177/030089160509100306; Hind O, 2002, J GASTROENTEROL, V37, P883, DOI 10.1007/s005350200149; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Hsieh YH, 2004, CARCINOGENESIS, V25, P2023, DOI 10.1093/carcin/bgh207; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Hui AY, 2005, CURR OPIN INFECT DIS, V18, P400, DOI 10.1097/01.qco.0000180163.84271.5e; Hung L, 2004, FEBS LETT, V560, P210, DOI 10.1016/S0014-5793(04)00113-9; Huy TTT, 2003, J CLIN MICROBIOL, V41, P5449, DOI 10.1128/JCM.41.12.5449-5455.2003; Hwang GY, 2003, J CLIN MICROBIOL, V41, P5598, DOI 10.1128/JCM.41.12.5598-5603.2003; Hwang YK, 2002, VACCINE, V20, P3770, DOI 10.1016/S0264-410X(02)00297-9; Iavarone M, 2003, J HEPATOL, V39, P253, DOI 10.1016/S0168-8278(03)00217-4; Kanai Y, 1997, INT J CANCER, V71, P355; Kao JH, 2003, GASTROENTEROLOGY, V124, P327, DOI 10.1053/gast.2003.50053; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; KIM DG, 2005, METHOD MOL BIOL, V317, P141; Kim JH, 2003, J VIROL, V77, P7166, DOI 10.1128/JVI.77.13.7166-7173.2003; Kim KH, 2003, EMBO J, V22, P2104, DOI 10.1093/emboj/cdg210; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Kojiro M, 2005, SEMIN LIVER DIS, V25, P133, DOI 10.1055/s-2005-871193; Koo JS, 2005, INTERVIROLOGY, V48, P16, DOI 10.1159/000082090; KORBA BE, 1989, HEPATOLOGY, V9, P461, DOI 10.1002/hep.1840090321; Koziel MJ, 1999, SEMIN LIVER DIS, V19, P157, DOI 10.1055/s-2007-1007107; Kuang SY, 2004, P NATL ACAD SCI USA, V101, P3575, DOI 10.1073/pnas.0308232100; Kwun HJ, 2004, NUCLEIC ACIDS RES, V32, P2202, DOI 10.1093/nar/gkh553; Lakhtakia R, 2003, J GASTROEN HEPATOL, V18, P80, DOI 10.1046/j.1440-1746.2003.02902.x; Larkin J, 1999, NAT MED, V5, P907, DOI 10.1038/11347; Lee ATC, 2005, J BIOL CHEM, V280, P33525, DOI 10.1074/jbc.M506628200; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Lee MO, 2002, J HEPATOL, V37, P380, DOI 10.1016/S0168-8278(02)00181-2; Lee SW, 2000, BIOCHEM BIOPH RES CO, V268, P456, DOI 10.1006/bbrc.2000.2093; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; Leon B, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-60; Leupin O, 2005, J VIROL, V79, P4238, DOI 10.1128/JVI.79.7.4238-4245.2005; Leupin O, 2003, J VIROL, V77, P6274, DOI 10.1128/JVI.77.11.6274-6283.2003; LEVRERO M, 1991, HEPATOLOGY, V13, P143, DOI 10.1002/hep.1840130121; Li Donghua, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P383; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Lin X, 2005, WORLD J GASTROENTERO, V11, P4703, DOI 10.3748/wjg.v11.i30.4703; Lin Y, 1997, CANCER RES, V57, P5137; LONCAREVIC IF, 1990, VIROLOGY, V174, P158, DOI 10.1016/0042-6822(90)90064-X; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; Malmassari S, 2005, MICROBES INFECT, V7, P626, DOI 10.1016/j.micinf.2004.12.022; Mathonnet G, 2004, MUTAT RES-FUND MOL M, V554, P305, DOI 10.1016/j.mrfmmm.2004.05.010; McMahon BJ, 2005, SEMIN LIVER DIS, V25, P3, DOI 10.1055/s-2005-915644; Melegari M, 2005, J VIROL, V79, P9810, DOI 10.1128/JVI.79.15.9810-9820.2005; MIAO J, 2005, CANC LETT       0628; Minami M, 1996, GASTROENTEROLOGY, V111, P691, DOI 10.1053/gast.1996.v111.pm8780574; Minami M, 2005, ONCOGENE, V24, P4340, DOI 10.1038/sj.onc.1208628; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002; MORGAN D, 1990, J VIROL, V64, P969, DOI 10.1128/JVI.64.3.969-976.1990; Murakami Y, 2005, GUT, V54, P1162, DOI 10.1136/gut.2004.054452; Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Oon CJ, 2002, J GASTROEN HEPATOL, V17, pS491; Orito E, 2001, HEPATOLOGY, V33, P218, DOI 10.1053/jhep.2001.20532; Orito E, 2003, INTERVIROLOGY, V46, P408, DOI 10.1159/000075000; PANG R, 2005, CANC LETT       1017; Paradis V, 1998, HEPATOLOGY, V28, P953, DOI 10.1002/hep.510280409; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Peng ZH, 2005, INT J ONCOL, V26, P467; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; PONTISSO P, 1984, BRIT MED J, V288, P1563, DOI 10.1136/bmj.288.6430.1563; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Pujol FH, 2005, J CLIN GASTROENTEROL, V39, P611, DOI 10.1097/01.mcg.0000170770.49394.92; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; Reifenberg K, 2002, J GEN VIROL, V83, P991, DOI 10.1099/0022-1317-83-5-991; Robek MD, 2002, J VIROL, V76, P3570, DOI 10.1128/JVI.76.7.3570-3574.2002; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Romero R, 1996, HEPATOLOGY, V23, P17, DOI 10.1053/jhep.1996.v23.pm0008550037; ROSMORDUC O, 1995, HEPATOLOGY, V22, P10, DOI 10.1016/0270-9139(95)90346-1; Rosmorduc O, 1999, J GEN VIROL, V80, P1253, DOI 10.1099/0022-1317-80-5-1253; Sanchez-Prieto R, 1999, NAT MED, V5, P1076, DOI 10.1038/12516; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SELL S, 1993, INT J DEV BIOL, V37, P189; Shin EC, 1999, INT J CANCER, V82, P587, DOI 10.1002/(SICI)1097-0215(19990812)82:4<587::AID-IJC19>3.0.CO;2-9; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; Soussan P, 2000, J CLIN INVEST, V105, P55, DOI 10.1172/JCI8098; Soussan P, 2003, J HEPATOL, V38, P343, DOI 10.1016/S0168-8278(02)00422-1; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Tamori A, 2005, CLIN CANCER RES, V11, P5821, DOI 10.1158/1078-0432.CCR-04-2055; Tamori A, 1999, HEPATOLOGY, V29, P1429, DOI 10.1002/hep.510290520; Tanaka Y, 2004, BIOCHEM BIOPH RES CO, V318, P461, DOI 10.1016/j.bbrc.2004.04.046; Tang H, 2005, J VIROL, V79, P5548, DOI 10.1128/JVI.79.9.5548-5556.2005; Tennant BC, 2004, GASTROENTEROLOGY, V127, pS283, DOI 10.1053/j.gastro.2004.09.043; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TERRE S, 1991, J VIROL, V65, P5539; TOSHKOV I, 1994, HEPATOLOGY, V20, P1162, DOI 10.1002/hep.1840200510; Tralhao JG, 2002, P NATL ACAD SCI USA, V99, P6991, DOI 10.1073/pnas.092657699; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; Tu H, 2001, CANCER RES, V61, P7803; Wang HC, 2005, HEPATOLOGY, V41, P761, DOI 10.1002/hep.20615; WANG WL, 1991, CANCER RES, V51, P4971; Wang Y, 2004, ONCOGENE, V23, P142, DOI 10.1038/sj.onc.1206889; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Xu ZM, 2002, J VIROL, V76, P2579, DOI 10.1128/JVI.76.5.2579-2584.2002; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Yoo YG, 2004, J BIOL CHEM, V279, P36242, DOI 10.1074/jbc.M401290200; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yotsuyanagi H, 2002, J HEPATOL, V37, P355, DOI 10.1016/S0168-8278(02)00180-0; Yu FL, 2005, J HEPATOL, V42, P520, DOI 10.1016/j.jhep.2004.11.031; Zhang JL, 2005, ARCH VIROL, V150, P721, DOI 10.1007/s00705-004-0446-0; Zhang SM, 2005, ARCH VIROL, V150, P1579, DOI 10.1007/s00705-005-0521-1; Zhang ZS, 2004, J VIROL, V78, P4566, DOI 10.1128/JVI.78.9.4566-4572.2004; Zhu HZ, 2004, EXP MOL PATHOL, V76, P44, DOI 10.1016/j.yexmp.2003.09.001; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	173	220	229	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3823	3833		10.1038/sj.onc.1209559	http://dx.doi.org/10.1038/sj.onc.1209559			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799624				2022-12-17	WOS:000238559600010
J	Sutherland, BW; Kucab, J; Wu, J; Lee, C; Cheang, MCU; Yorida, E; Turbin, D; Dedhar, S; Nelson, C; Pollak, M; Grimes, HL; Miller, K; Badve, S; Huntsman, D; Blake-Gilks, C; Chen, M; Pallen, CJ; Dunn, SE				Sutherland, BW; Kucab, J; Wu, J; Lee, C; Cheang, MCU; Yorida, E; Turbin, D; Dedhar, S; Nelson, C; Pollak, M; Grimes, HL; Miller, K; Badve, S; Huntsman, D; Blake-Gilks, C; Chen, M; Pallen, CJ; Dunn, SE			Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells	ONCOGENE			English	Article						breast cancer; Akt; YB-1; phosphorylation; cold shock domain; signal transduction	PROTEIN-KINASE B/AKT; TRANSCRIPTION FACTOR YB-1; DOMINANT-NEGATIVE MUTANT; GLYCOGEN-SYNTHASE KINASE; INTEGRIN-LINKED KINASE; BINDING-PROTEIN; NUCLEAR EXPRESSION; P-GLYCOPROTEIN; GENE; PROGRESSION	Akt/PKBis a serine/threonine kinase that promotes tumor cell growth by phosphorylating transcription factors and cell cycle proteins. There is particular interest in finding tumor-specific substrates for Akt to understand how this protein functions in cancer and to provide new avenues for therapeutic targeting. Our laboratory sought to identify novel Akt substrates that are expressed in breast cancer. In this study, we determined that activated Akt is positively correlated with the protein expression of the transcription/translation factor Y-box binding protein-1 (YB-1) in primary breast cancer by screening tumor tissue microarrays. We therefore questioned whether Akt and YB-1 might be functionally linked. Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102. We then addressed the functional significance of disrupting Ser102 by mutating it to Ala102. Following the stable expression of Flag: YB-1 and Flag: YB-1 ( Ala102) in MCF-7 cells, we observed that disruption of the Akt phosphorylation site on YB-1 suppressed tumor cell growth in soft agar and in monolayer. This correlated with an inhibition of nuclear translocation by the YB-1( Ala102) mutant. In conclusion, YB-1 is a new Akt substrate and disruption of this specific site inhibits tumor cell growth.	Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Lab Oncogenom Res, Vancouver, BC V5Z 4H4, Canada; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Vancouver Hosp & Hlth Sci Ctr, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Vancouver Gen Hosp, Jack Bell Res Labs, Prostate Ctr, Vancouver, BC, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Inst Cellular Therapeut, Louisville, KY USA; Indiana Univ, Dept Med, Bloomington, IN USA; Indiana Univ, Dept Pathol, Bloomington, IN USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Cell Phosphosignaling Lab, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; Fred Hutchinson Cancer Center; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; McGill University; McGill University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of British Columbia	Dunn, SE (corresponding author), Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Lab Oncogenom Res, 950 W 28th Ave,Room 3083, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca	Huntsman, David/ABE-6082-2020; Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604; Grimes, H. Leighton/0000-0001-8162-6758; Cheang, Maggie Chon U/0000-0001-5718-2501; Badve, Sunil/0000-0001-8861-9980; Dedhar, Shoukat/0000-0003-4355-1657; Pallen, Catherine/0000-0002-3576-5295				Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 2001, CANCER RES, V61, P1367; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kloks CPAM, 2002, J MOL BIOL, V316, P317, DOI 10.1006/jmbi.2001.5334; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lasham A, 2003, J BIOL CHEM, V278, P35516, DOI 10.1074/jbc.M303920200; Makretsov NA, 2004, CLIN CANCER RES, V10, P6143, DOI 10.1158/1078-0432.CCR-04-0429; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rubinstein DB, 2002, CANCER RES, V62, P4985; Shibao K, 1999, INT J CANCER, V83, P732; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Yahata H, 2002, J CANCER RES CLIN, V128, P621, DOI 10.1007/s00432-002-0386-6; Zhou BP, 2001, NAT CELL BIOL, V3, P438	39	220	230	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4281	4292		10.1038/sj.onc.1208590	http://dx.doi.org/10.1038/sj.onc.1208590			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806160				2022-12-17	WOS:000229815300011
J	Rotman, G; Shiloh, Y				Rotman, G; Shiloh, Y			ATM: A mediator of multiple responses to genotoxic stress	ONCOGENE			English	Review						ATM; ataxia-telangiectasia; DNA damage; ionizing radiation; genotoxic stress	NF-KAPPA-B; REPLICATION PROTEIN-A; ATAXIA-TELANGIECTASIA CELLS; DOUBLE-STRAND BREAKS; RADIATION-INDUCED PHOSPHORYLATION; ABL TYROSINE KINASE; DNA-DAMAGING AGENTS; S-PHASE CHECKPOINT; IONIZING-RADIATION; CYCLE CHECKPOINTS	The ATM protein kinase is the product of the gene responsible for the pleiotropic recessive disorder ataxia-telangiectasia. ATM-deficient cells show enhanced sensitivity and greatly reduced responses to genotoxic agents that generate DNA double strand breaks (DSBs), such as ionizing radiation and radiomimetic chemicals, but exhibit normal responses to DNA adducts and base modifications induced by other agents. Therefore, DSBs are most likely the predominant signal for the activation of ATM-mediated pathways. Identification of the ATM gene triggered extensive research aimed at elucidating the numerous functions of its large multifaceted protein product. While ATM has both nuclear and cytoplasmic functions, this review will focus on its roles in the nucleus where it plays a central role in the very early stages of damage detection and serves as a master controller of cellular responses to DSBs. By activating key regulators of multiple signal transduction pathways, ATM mediates the efficient induction of a signaling network responsible for repair of the damage, and for cellular recovery and survival.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Rotman, G (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel.							Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ARTUSO M, 1995, ONCOGENE, V11, P1427; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1998, DEVELOPMENT, V125, P4007; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bentley NJ, 1997, BIOL CHEM, V378, P1267; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown JM, 1997, CANCER RES, V57, P2313; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Bryant PE, 1997, INT J RADIAT BIOL, V71, P675, DOI 10.1080/095530097143680; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHATURVEDI P, 1999, IN PRESS ONCOGENE; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Crawford T O, 1998, Semin Pediatr Neurol, V5, P287, DOI 10.1016/S1071-9091(98)80007-7; DANNA JA, 1997, RADIAT RES, V138, P260; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fang Z. H., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P142; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOLBROOK NJ, 1996, STRESS INDUCIBLE CEL, P273; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; Huang LC, 1996, CANCER RES, V56, P2940; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Jin SF, 1997, CANCER SURV, V29, P221; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Jung M, 1997, Radiat Oncol Investig, V5, P265, DOI 10.1002/(SICI)1520-6823(1997)5:6<265::AID-ROI1>3.0.CO;2-W; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KYSELA BP, 1995, RADIAT RES, V144, P276, DOI 10.2307/3578946; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; LIU Y, 1996, DNA DAMAGE REPAIR, V2, P263; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Lohrer HD, 1996, EXPERIENTIA, V52, P316, DOI 10.1007/BF01919534; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mayo LD, 1997, CANCER RES, V57, P5013; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, CANCER RES, V57, P3386; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; PANDITA TK, 1995, INT J CANCER, V61, P738, DOI 10.1002/ijc.2910610524; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PAULES RS, 1995, CANCER RES, V55, P1763; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Piette J, 1997, BIOL CHEM, V378, P1237; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rathmell WK, 1997, CANCER RES, V57, P68; Rhind N, 1998, GENETICS, V149, P1729; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; RHYS CMJ, 1996, STRESS INDUCIBLE CEL, P289; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1998, CANCER RES, V58, P4375; Schwartz JL, 1998, RADIAT RES, V149, P319, DOI 10.2307/3579692; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SMILENOV LB, 1999, IN PRESS MOL CELL BI; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAYLOR YC, 1991, INT J RADIAT BIOL, V59, P359, DOI 10.1080/09553009114550331; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JF, 1998, ADV MATER, V10, P230, DOI 10.1002/(SICI)1521-4095(199802)10:3<230::AID-ADMA230>3.0.CO;2-Y; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	157	220	227	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6135	6144		10.1038/sj.onc.1203124	http://dx.doi.org/10.1038/sj.onc.1203124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557105				2022-12-17	WOS:000083447100008
J	Kerkhoff, E; Rapp, UR				Kerkhoff, E; Rapp, UR			Cell cycle targets of Ras/Raf signalling	ONCOGENE			English	Review						Ras; Raf; cell cycle	NIH 3T3 CELLS; PC12 PHEOCHROMOCYTOMA CELLS; C-MYC; PROTEIN-KINASE; DEPENDENT KINASES; BIOCHEMICAL-PROPERTIES; COOPERATING ONCOGENES; INDUCED PROLIFERATION; RAPID INDUCTION; GENE-EXPRESSION	The regulation of cell proliferation in multicellular organisms is a complex process, which is primarily regulated by external growth factors provided by surrounding cells. Once induced to proliferate, the passage through the mitotic cell cycle is directed by the components of the so called cell cycle machinery. Over the last years research on growth factor signal-transduction and the components of the cell cycle system has lead to a detailed knowledge of the mechanisms by which growth factors transmit their signals and of the relationship between the components of the cell cycle machinery. The remaining question how the growth factor mediated signal-transduction cascades couple with the cell cycle regulators has recently been a focus of interest.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, USZ, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, USZ, Versbacher Str 5, D-97078 Wurzburg, Germany.							AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Cleveland J L, 1988, Oncogene Res, V3, P357; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cooper G.M., 1995, ONCOGENES; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Draetta G.F., 1997, CURR BIOL, V7, P50; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILMUS J, 1994, ONCOGENE, V9, P3627; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERBER B, 1994, ONCOGENE, V9, P1295; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENN LJ, 1990, EMBO J, P1113; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1994, ONCOGENE, V9, P3493; RAPP UR, 1994, FOS JUN FAMILIES TRA, P221; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WATERS CM, 1991, ONCOGENE, V6, P797; Winston JT, 1996, ONCOGENE, V12, P127; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	78	220	221	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1457	1462		10.1038/sj.onc.1202185	http://dx.doi.org/10.1038/sj.onc.1202185			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779991				2022-12-17	WOS:000076161900012
J	MuellerPillasch, F; Lacher, U; Wallrapp, C; Micha, A; Zimmerhackl, F; Hameister, H; Varga, G; Friess, H; Buchler, M; Beger, HG; Vila, MR; Adler, G; Gress, TM				MuellerPillasch, F; Lacher, U; Wallrapp, C; Micha, A; Zimmerhackl, F; Hameister, H; Varga, G; Friess, H; Buchler, M; Beger, HG; Vila, MR; Adler, G; Gress, TM			Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein	ONCOGENE			English	Article						pancreatic cancer; KH-domain; RNA-binding; overexpression	RNA-BINDING PROTEINS; IN-VITRO; IDENTIFICATION; STABILITY; PANCREAS; COMPLEX	In a previous large scale screen for differentially expressed genes in pancreatic cancer, we identified a gene highly overexpressed in cancer encoding a novel protein with four K-homologous (KH) domains, KH-domains are found in a subset of RNA-binding proteins, including pre-mRNA-binding (hnRNP)K protein and the fragile X mental retardation gene product (FMR1). By fluorescence in situ hybridization (FISH) the identified gene named koc (KH domain containing protein overexpressed in cancer) was assigned to chromosome 7p11.5, Two pseudogenes were localised on chromosome 6 and 11, The cloned koc cDNA has a 250 bp 5'-UTR, a 1740 bp ORF and a 2168 bp 3'-UTR, The AU-rich 3'-untranslated region of koc contains eight AUUUA and four AUUUUUA reiterated motifs, The deduced koc protein with 580 amino-acids has a relative molecular mass (M-r) of approximately 65 000 (65 K), The koc transcript is highly overexpressed in pancreatic cancer cell lines and in pancreatic cancer tissue as compared to both, normal pancreas and chronic pancreatitis tissue, High levels of expression were as well found in tissue samples of other human tumours, As the KH domain has been shown to be involved in the regulation of RNA synthesis and metabolism, we speculate that koc may assume a role in the regulation of tumour cell proliferation by interfering with transcriptional and or posttranscriptional processes, However, the precise role of koc in human tumour cells is unknown and remains to be elucidated.	UNIV ULM,DEPT MED GENET,ULM,GERMANY; HUNGARIAN ACAD SCI,INST EXPT MED,BUDAPEST,HUNGARY; UNIV BERN,INSELSPITAL,DEPT VISZERAL & TRANSPLANTAT SURG,CH-3010 BERN,SWITZERLAND; UNIV ULM,DEPT SURG,ULM,GERMANY; UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,E-08193 BARCELONA,SPAIN	Ulm University; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Bern; University Hospital of Bern; Ulm University; Autonomous University of Barcelona	MuellerPillasch, F (corresponding author), UNIV ULM,DEPT INTERNAL MED 1,ROBERT KOCH STR 8,D-89081 ULM,GERMANY.		Varga, Gábor/O-8858-2017	Varga, Gabor/0000-0002-5506-8198; Gress, Thomas/0000-0002-9333-5461				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Gordis Leon, 1993, P837; Gress TM, 1996, ONCOGENE, V13, P1819; GRESS TM, 1994, EUR J CANCER, V30A, P1391, DOI 10.1016/0959-8049(94)90191-0; HAHM K, 1993, NUCLEIC ACIDS RES, V21, P3894, DOI 10.1093/nar/21.16.3894; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; SCHUSSLER MH, 1992, AM J PATHOL, V140, P559; SIMOI H, 1994, CELL, V77, P33; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VILA MR, 1994, LAB INVEST, V71, P423; WANG XM, 1995, MOL CELL BIOL, V15, P1769	21	220	243	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2729	2733		10.1038/sj.onc.1201110	http://dx.doi.org/10.1038/sj.onc.1201110			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178771				2022-12-17	WOS:A1997XB97800012
J	Gum, R; Wang, H; Lengyel, E; Juarez, J; Boyd, D				Gum, R; Wang, H; Lengyel, E; Juarez, J; Boyd, D			Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades	ONCOGENE			English	Article						MMP-9; type IV collagenase; JNK; ERK; AP-1	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; C-JUN; MAP KINASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; TRANSDUCTION PATHWAYS; 92-KDA GELATINASE	The 92 kDa type IV collagenase (MMP-9), which degrades type IV collagen, has been implicated in tissue remodeling. The purpose of the current study was to determine the role of Jun amino-terminal kinase (JNK)- and extracellular signal-regulated kinase- (ERK)-dependent signaling cascades in the regulation of MMP-9 expression. Towards this end, we first determined the transcriptional requirements for MMP-9 promoter activity in a cell line (UM-SCC-1) which is an avid secretor of this collagenase. Transfection of these cells with a CAT reporter driven by progressive 5' deleted fragments of the MMP-9 promoter indicated the requirement of a region spanning -144 to -73 for optimal promoter activity. DNase I footprinting revealed a protected region of the promoter spanning nucleotides -91 to -68 and containing a consensus AP-1 motif at -79. Mutation of this AP-1 motif practically abolished the activity of the MMP-9 promoter-driven CAT reporter. Mobility shift assays indicated c-Fos and Jun-D bound to this motif and transfection of the cells with a mutated c-Jun, which quenches the function of endogenous Jun and Fos proteins, decreased MMP-9 promoter activity by 80%. UM-SCC-1 cells contained a constitutively activated JNK and the expression of a kinase-deficient JNK1 reduced the activity of a CAT reporter driven either by the MMP-9 promoter or by three tandem AP-1 repeats upstream of a thymidine kinase minimal promoter. Conditioned medium collected from UM-SCC-1 cells transfected with the dominant negative JNK1 expression vector diminished 92 kDa gelatinolysis. Similarly, interfering with MEKK, which lies upstream of JNK1, using a dominant negative expression vector reduced MMP-9 promoter activity over the same concentration range which repressed the AP-l-thymidine kinase CAT reporter construct. UM-SCC-1 cells also contained a constitutively activated ERK1. MMP-9 expression, as determined by CAT assays and by zymography, was reduced by the co-expression of a kinase-deficient ERK1. Interfering with MEK1, which is an upstream activator of ERK1, either with PD 098059, which prevents the activation of MEK1, or with a dominant negative expression construct, reduced 92 kDa gelatinolysis and MMP-9 promoter activity respectively. c-Raf-l is an upstream activator of MEK1 and a kinase-deficient c-Raf-l expression construct decreased the activity of a promoter driven by either the MMP-9 promoter or three tandem AP-1 repeats. Conversely, treatment of UM-SCC-1 cells with PMA, which activates c-Raf-l, increased 92 kDa gelatinolysis. These data suggest that MMP-9 expression in UM-SCC-1 cells, is regulated by JNK- and ERK-dependent signaling pathways.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG TUMOR BIOL,HOUSTON,TX 77030; TECH UNIV MUNICH,DEPT OBSTET & GYNECOL,D-8000 MUNICH,GERMANY	University of Texas System; UTMD Anderson Cancer Center; Technical University of Munich			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADLER V, 1994, J BIOL CHEM, V269, P11186; AGARWAL S, 1995, ONCOGENE, V11, P427; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson IC, 1996, CANCER RES, V56, P715; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cha HJ, 1996, CANCER RES, V56, P2281; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DECLERCK YA, 1992, CANCER RES, V52, P701; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIDMAN R, 1995, CANCER RES, V55, P2548; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HURWITZ A, 1993, ENDOCRINOLOGY, V132, P2709, DOI 10.1210/en.132.6.2709; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENGYEL E, 1995, CANCER RES, V55, P963; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKAJIMA M, 1993, CANCER RES, V53, P5802; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1992, CANCER RES, V52, P1336; RAO JS, 1993, CANCER RES, V53, P2208; RAO VN, 1993, CANCER RES, V53, P3449; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SOZERI O, 1992, ONCOGENE, V7, P2259; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	73	220	231	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1481	1493		10.1038/sj.onc.1200973	http://dx.doi.org/10.1038/sj.onc.1200973			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136992				2022-12-17	WOS:A1997WT58400011
J	LEONE, A; SEEGER, RC; HONG, CM; HU, YY; ARBOLEDA, MJ; BRODEUR, GM; STRAM, D; SLAMON, DJ; STEEG, PS				LEONE, A; SEEGER, RC; HONG, CM; HU, YY; ARBOLEDA, MJ; BRODEUR, GM; STRAM, D; SLAMON, DJ; STEEG, PS			EVIDENCE FOR NM23 RNA OVEREXPRESSION, DNA AMPLIFICATION AND MUTATION IN AGGRESSIVE CHILDHOOD NEUROBLASTOMAS	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; DUCTAL BREAST CARCINOMAS; TUMOR-METASTASIS; N-MYC; DROSOPHILA DEVELOPMENT; PROTEIN-KINASE; GENE; EXPRESSION; ASSOCIATION; CANCER	Reduced expression of nm23 RNAs/proteins has been associated previously with high tumor metastatic potential. In contrast, we report that regional (state III) and metastatic (stage IV) childhood neuroblastomas exhibit elevated nm23 RNA levels as compared with localized tumors. Elevated neuroblastoma nm23 RNA levels were associated with significant reductions in patient survival in the overall (n = 75) and N-myc non-amplified (n = 61) portion of the cohort. Amplification of the chromosomal nm23-H1 gene was observed in 6/18 stage III and IV tumors; amplification of nm23-H2 was not demonstrated. Genomic amplification of nm23-H1 was associated with increased tumor nm23 RNA expression and reduced patient survival. Single-strand conformational polymorphism (SSCP) analysis was performed on seven neuroblastomas. Minor subpopulations of cDNAs exhibiting altered mobility were apparent in both nm23-H1 and nm23-H2 translated regions of stage III and IV tumors, suggestive.of mutations. Confirmation of the SSCP data was provided by direct sequencing of nm23-H2 in a stage IV tumor, revealing a leucine to valine mutation at position 48. The data indicate that molecular alterations to nm23 other than its reduced expression can be associated with tumor aggressiveness, and provide the first evidence for nm23 mutation in a human cancer.	NCI, PATHOL LAB, BLDG 10, ROOM 2A33, BETHESDA, MD 20892 USA; CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA; CHILDRENS CANC GRP, ARCADIA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90027 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL)			Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 	NCI NIH HHS [CA 02649, CA49712, CA22794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022794, P01CA049712, U10CA002649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE P, 1971, STATISTICAL METHODS; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BUCKMAN VL, 1988, GENE, V70, P245; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; COX DR, 1972, J R STAT SOC B, V34, P187; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GANSLER T, 1986, CANCER, V58, P2453, DOI 10.1002/1097-0142(19861201)58:11<2453::AID-CNCR2820581117>3.0.CO;2-I; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, ONCOGENES TUMOR SUPP; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1259; HOSSAIN A, 1991, CLIN EXP METASTAS, V9, P500; KANEKO Y, 1987, CANCER RES, V47, P311; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LANDSCHULTZ WH, 1988, SCIENCE, V240, P1750; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; MATSUNAGA T, 1991, CANCER RES, V51, P3148; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STAHL JA, 1991, CANCER RES, V48, P6550; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; SUZUKI T, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P210; TANAKA T, 1988, CANCER RES, V48, P1030; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; YAGUE J, 1991, NUCLEIC ACIDS RES, V19, P6663, DOI 10.1093/nar/19.23.6663	43	220	223	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					855	865						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384356				2022-12-17	WOS:A1993KT22000006
J	GEBERT, JF; MOGHAL, N; FRANGIONI, JV; SUGARBAKER, DJ; NEEL, BG				GEBERT, JF; MOGHAL, N; FRANGIONI, JV; SUGARBAKER, DJ; NEEL, BG			HIGH-FREQUENCY OF RETINOIC ACID RECEPTOR BETA ABNORMALITIES IN HUMAN LUNG-CANCER	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN HEPATOCELLULAR-CARCINOMA; TRACHEAL EPITHELIAL-CELLS; SQUAMOUS DIFFERENTIATION; T(15-17) TRANSLOCATION; RESPONSIVE ELEMENT; MESSENGER-RNAS; GENE; EXPRESSION; GAMMA	One of the three human retinoic acid receptors, RAR-beta, maps to a region on the short arm of chromosome 3 frequently deleted in lung cancer. Because retinoic acid is required for normal epithelial cell growth and regulation, and loss of a retinoic acid receptor might be expected to contribute to oncogenesis, we examined RAR-beta RNA and DNA in normal lung, 33 lung cancer cell lines and nine primary lung tumors. Normally, RAR-beta is expressed as two transcripts, of sizes 3.1 kb and 2.8 kb, which are strongly induced by retinoic acid. At least 50% of the cell lines and 30% of the tumor samples show altered RAR-beta expression and/or inducibility, including examples of absence or specific loss of one of the RAR-beta transcripts. Abnormalities in the expression patterns of RAR-alpha and RAR-gamma also are found, but at a lower frequency than RAR-beta abnormalities. Southern analysis reveals alteration of the RAR-beta gene in three of the cell lines. Our data suggest that abnormalities in structure and expression of the RAR-beta gene may be involved in the pathogenesis of lung cancer.	BETH ISRAEL HOSP,MOLEC MED UNIT,330 BROOKLINE AVE,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DIV THORAC SURG,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 49152-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; IBSON JM, 1987, J CELL BIOCHEM, V33, P267, DOI 10.1002/jcb.240330405; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1985, RETINOIDS DIFFERENTI, P61; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1989, CANCER RES, V49, P651; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LECHNER JF, 1981, CANCER RES, V41, P2294; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REARICK JI, 1987, J CELL PHYSIOL, V133, P573, DOI 10.1002/jcp.1041330320; ROBERTS AB, 1984, RETINOIDS, V2, P209; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1988, NATURE, V333, P15; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; WU R, 1982, IN VITRO CELL DEV B, V18, P800; WU R, 1986, IN VITRO MODELS RESP, P1; YOKOTA J, 1989, CANCER RES, V49, P3598; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; [No title captured]	60	220	224	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1859	1868						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1717924				2022-12-17	WOS:A1991GX11800019
J	Dai, J; Peng, L; Fan, K; Wang, H; Wei, R; Ji, G; Cai, J; Lu, B; Li, B; Zhang, D; Kang, Y; Tan, M; Qian, W; Guo, Y				Dai, J.; Peng, L.; Fan, K.; Wang, H.; Wei, R.; Ji, G.; Cai, J.; Lu, B.; Li, B.; Zhang, D.; Kang, Y.; Tan, M.; Qian, W.; Guo, Y.			Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells	ONCOGENE			English	Article						osteopontin; angiogenesis; HUVEC; VEGF; signal pathway	BREAST-CANCER CELLS; NF-KAPPA-B; GROWTH-FACTOR; TUMOR PROGRESSION; SURVIVAL FACTOR; PERMEABILITY; MECHANISMS; APOPTOSIS; MIGRATION; KINASE	Angiogenesis is a key step in tumor growth and metastasis. The mechanism by which osteopontin (OPN) induces the angiogenesis of endothelial cells remains unclear. Here, we show that OPN confers cytoprotection through the activation of the PI3K/Akt pathway with subsequent upregulation of Bcl-xL and activation of nuclear factor-kappa B. OPN enhances the expression of vascular endothelial growth factor (VEGF) through the phosphorylation of AKT and extracellular signal-regulated kinase (ERK). In turn, OPN-induced VEGF activates PI3K/AKT and the ERK1/2 pathway as a positive feedback signal. Blocking the feedback signal by anti-VEGF antibody, PI3-kinase inhibitor or ERK inhibitor can partially inhibit the OPN-induced human umbilical vein endothelial cell (HUVEC) motility, proliferation and tube formation, while blocking the signal by anti-OPN or anti-alpha v beta 3 antibody completely abrogates the biological effects of OPN on HUVECs. In addition, blood vessel formation is also investigated in vivo. The antiangiogenesis efficacy of anti-OPN antibody in vivo is more effective than that of anti-VEGF antibody, which only blocks the feedback signals. These data show that OPN enhances angiogenesis directly through PI3K/AKT and ERK-mediated pathways with VEGF acting as a positive feedback signal. The results suggest that OPN might be a valuable target for developing novel antiangiogenesis therapy for treatment of cancer. Oncogene (2009) 28, 3412-3422; doi: 10.1038/onc.2009.189; published online 13 July 2009	[Dai, J.; Peng, L.; Fan, K.; Wang, H.; Ji, G.; Lu, B.; Li, B.; Zhang, D.; Kang, Y.; Tan, M.; Qian, W.; Guo, Y.] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China; [Dai, J.; Peng, L.; Fan, K.; Wang, H.; Ji, G.; Lu, B.; Li, B.; Zhang, D.; Kang, Y.; Tan, M.; Qian, W.; Guo, Y.] Second Mil Med Univ, Gen Hosp 301, Ctr Canc, Shanghai 200433, Peoples R China; [Zhang, D.; Tan, M.; Qian, W.; Guo, Y.] Shanghai Jiao Tong Univ, Coll Pharm, Natl Engn Res Ctr Antibody Med, Shanghai 200030, Peoples R China; [Zhang, D.; Tan, M.; Qian, W.; Guo, Y.] Shanghai Jiao Tong Univ, Coll Pharm, Shanghai Key Lab Cell Engn, Shanghai 200030, Peoples R China; [Wei, R.; Cai, J.] Shanghai Changzheng Hosp, Dept Ophthalmol, Shanghai, Peoples R China	Naval Medical University; Naval Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Naval Medical University	Guo, Y (corresponding author), Second Mil Med Univ, Int Joint Canc Inst, Adm Bldg 10th 11th Floor,800 Xiang Yin Rd, Shanghai 200433, Peoples R China.	yjguo@smmu.edu.cn		Ji, Guanghui/0000-0003-3763-2311	National Natural Science Foundation of China; Shanghai Commission of Science and Technology; Ministry of Science and Technology of China; Shanghai Commission of Education; Shanghai Pudong Bureau of Science and Technology of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Commission of Science and Technology(Shanghai Science & Technology Committee); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Shanghai Commission of Education; Shanghai Pudong Bureau of Science and Technology of China	This study was supported in part by the grants from the National Natural Science Foundation of China, Shanghai Commission of Science and Technology, Ministry of Science and Technology of China (973 and 863 projects), Shanghai Commission of Education as well as a special grant from Shanghai Pudong Bureau of Science and Technology of China. JX Dai is a recipient of 'Pujiang' Research Scholarship from Shanghai Commission of Education.	ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ASANO M, 1995, CANCER RES, V55, P5296; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Brady H, 2002, CANCER RES, V62, P1439; Cao ZG, 2008, MOL IMMUNOL, V45, P3683, DOI 10.1016/j.molimm.2008.06.008; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DENHARDT DT, 1994, J CELL BIOCHEM, V56, P48, DOI 10.1002/jcb.240560109; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Jain S, 2006, CANCER RES, V66, P6638, DOI 10.1158/0008-5472.CAN-06-0661; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; L'Hote CGM, 2005, EXP CELL RES, V304, P417, DOI 10.1016/j.yexcr.2004.11.012; Nishiyama K, 2005, CIRCULATION, V112, P2840, DOI 10.1161/CIRCULATIONAHA.104.516898; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Senger DR, 1996, AM J PATHOL, V149, P293; Shijubo N, 2003, MICROSC RES TECHNIQ, V60, P186, DOI 10.1002/jemt.10257; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Solorzano CC, 2001, CANCER RES, V61, P7048; Standal T, 2004, EXP ONCOL, V26, P179; TOSHIFUMI S, 2003, J BIOL CHEM, V278, P5001; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038; WU LW, 2000, J BIOL CHEM, V18; Xu GW, 2005, J CLIN INVEST, V115, P1060	33	219	231	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3412	3422		10.1038/onc.2009.189	http://dx.doi.org/10.1038/onc.2009.189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597469				2022-12-17	WOS:000270103300008
J	Jazirehi, AR; Bonavida, B				Jazirehi, AR; Bonavida, B			Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention	ONCOGENE			English	Review						non-Hodgkin's lymphoma; rituximab; chemosensitization; signaling; apoptosis; RKIP	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; RETROVIRUS-INDUCED IMMUNODEFICIENCY; MONOCLONAL-ANTIBODY THERAPY; STAGE-SPECIFIC EXPRESSION; CD20 ANTIGEN-EXPRESSION; BCL-X-L; IN-VITRO; MEDIATED APOPTOSIS	The clinical application of rituximab ( chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has signicantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL). The exact in vivo mechanisms of action of rituximab are not fully understood, although antibody-dependent cell-mediated cytotoxicity ( ADCC), complement-dependent cytotoxicity (CDC), and apoptosis have been suggested. We have proposed that modi. cations of the cellular signaling pathways by rituximab may be crucial for its clinical response. The B-cell restricted cell surface phosphoprotein CD20 is involved in many cellular signaling events including proliferation, activation, differentiation, and apoptosis upon crosslinking. Monomeric rituximab chemosensitizes drug-resistant NHL cells via selective downregulation of antiapoptotic factors through the type II mitochondrial apoptotic pathway. Several signaling pathways are affected by rituximab which are implicated in the underlying molecular mechanisms of chemosensitization. ARL ( acquired immunodeficiency syndrome (AIDS)-related lymphoma) and non-ARL cell lines have been examined as in vitro model systems. In ARL, rituximab diminishes the activity of the p38MAPK signaling pathway resulting in inhibition of the interleukin (IL)-10/IL-10R autocrine/paracrine cytokine autoregulatory loop leading to the inhibition of constitutive STAT-3 activity and subsequent downregulation of Bcl-2 expression leading to chemosensitization. Rituximab upregulates Raf-1 kinase inhibitor protein (RKIP) expression in non-ARL cells. Through physical association with Raf-1 and nuclear factor kappa B (NF-kappa B)-inducing kinase (NIK), RKIP negatively regulates two major survival pathways, namely, the extracellular signal-regulated kinase1/2 (ERK1/2) and the NF-kappa B pathways, respectively. Downmodulation of the ERK1/2 and NF-kappa B pathways inhibits the transcriptional activity of AP-1 and NF-kappa B transcription factors, respectively, both of which lead to the downregulation of Bcl-(xL) (Bcl-2 related gene (long alternatively spliced variant of Bcl-x gene)) transcription and expression and sensitization to drug-induced apoptosis. Bcl-(xL)-overexpressing cells corroborated the pivotal role of Bcl-(xL) in chemosensitization. The specificity of rituximab-mediated signaling and functional effects were corroborated by the use of specific pharmacological inhibitors. Many patients do not respond and/or relapse and the mechanisms of unresponsiveness are unknown. Rituximab-resistant B-NHL clones were generated to investigate the acquired resistance to rituximab-mediated signaling, and chemosensitization. Resistant clones display different phenotypic, genetic and functional properties compared to wildtype cells. This review summarizes the data highlighting a novel role of rituximab as a signal-inducing antibody and as a chemosensitizing agent through negative regulation of major survival pathways. Studies presented herein also reveal several intracellular targets modified by rituximab, which can be exploited for therapeutic and prognostic purposes in the treatment of patients with rituximab- and drug-refractory NHL.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, 10833 Le Conte Ave,A2-060, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu						ACKER B, 1983, J CLIN ONCOL, V1, P11, DOI 10.1200/JCO.1983.1.1.11; ADRA CN, 1994, GENOMICS, V24, P188, DOI 10.1006/geno.1994.1601; Alas S, 2000, ANTICANCER RES, V20, P2961; Alas S, 2001, CANCER RES, V61, P5137; Alas S, 2001, CLIN CANCER RES, V7, P709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alvaro-Naranjo T, 2003, ANN HEMATOL, V82, P585, DOI 10.1007/s00277-003-0694-1; Amundson SA, 2000, CANCER RES, V60, P6101; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Ariga A, 2002, J BIOL CHEM, V277, P24625, DOI 10.1074/jbc.M112063200; Avivi I, 2003, BRIT J CANCER, V89, P1389, DOI 10.1038/sj.bjc.6601187; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Bannerji R, 2003, J CLIN ONCOL, V21, P1466, DOI 10.1200/JCO.2003.06.012; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bellosillo B, 2001, BLOOD, V98, P2771, DOI 10.1182/blood.V98.9.2771; BENJAMIN D, 1994, LEUKEMIA LYMPHOMA, V12, P205, DOI 10.3109/10428199409059591; Bieker R, 2003, ONCOL REP, V10, P1915; BLAY JY, 1993, BLOOD, V82, P2169; Blum KA, 2003, SEMIN ONCOL, V30, P448, DOI 10.1016/S0093-7754(03)00251-3; BOURGET I, 1993, EUR J IMMUNOL, V23, P768, DOI 10.1002/eji.1830230330; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Cardarelli PM, 2002, CANCER IMMUNOL IMMUN, V51, P15, DOI 10.1007/s00262-001-0247; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CERNY A, 1991, EUR J IMMUNOL, V21, P1747, DOI 10.1002/eji.1830210724; Chan HTC, 2003, CANCER RES, V63, P5480; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chow KU, 2002, HAEMATOLOGICA, V87, P33; CLARK EA, 1987, J IMMUNOL, V138, P720; Coffey J, 2003, EUR J NUCL MED MOL I, V30, pS28, DOI 10.1007/s00259-003-1157-6; Cohen SBA, 1997, IMMUNOLOGY, V92, P1, DOI 10.1046/j.1365-2567.1997.00348.x; Cohen Y, 2003, HAEMATOLOGICA, V88, P811; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier Bertrand, 2003, Curr Hematol Rep, V2, P23; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; Dai Y, 2001, CANCER RES, V61, P5106; DANCESCU M, 1992, J IMMUNOL, V148, P2411; Davis TA, 1999, CLIN CANCER RES, V5, P611; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; DEARON M, 1997, INT REV IMMUNOL, V16, P1; DEMIDEM A, 1995, FASEB J, V9, pA206; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dent P, 2001, CLIN CANCER RES, V7, P775; Dillman RO, 2003, SEMIN ONCOL, V30, P434, DOI 10.1016/S0093-7754(03)00235-5; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Filipits M, 2000, CLIN CANCER RES, V6, P3417; Fisher RI, 2003, LEUKEMIA, V17, P1948, DOI 10.1038/sj.leu.2403096; Fisher RI, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.23797; Foran JM, 2001, BRIT J HAEMATOL, V114, P881, DOI 10.1046/j.1365-2141.2001.03019.x; Friedberg JW, 2002, BRIT J HAEMATOL, V117, P828, DOI 10.1046/j.1365-2141.2002.03535.x; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Galandrini R, 1999, J IMMUNOL, V162, P3148; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; GENESTIER L, 1995, INT IMMUNOL, V7, P533, DOI 10.1093/intimm/7.4.533; GENOT E, 1991, J IMMUNOL, V146, P870; GERGELY J, 1990, FASEB J, V4, P3275, DOI 10.1096/fasebj.4.15.2253843; Ghetie MA, 1997, P NATL ACAD SCI USA, V94, P7509, DOI 10.1073/pnas.94.14.7509; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Ghobrial IM, 2003, LANCET ONCOL, V4, P679, DOI 10.1016/S1470-2045(03)01246-4; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Golay J, 2000, BLOOD, V95, P3900; Golay J, 2002, BRIT J HAEMATOL, V119, P923, DOI 10.1046/j.1365-2141.2002.03935.x; Goy A, 2004, CLIN LYMPHOMA, V4, P230, DOI 10.3816/CLM.2004.n.003; GRAG A, 2002, LEUKEMIA, V16, P1053; Grillo-Lopez AJ, 2002, INT J HEMATOL, V76, P385, DOI 10.1007/BF02982803; Hagenbeek A, 2002, ANTI-CANCER DRUG, V13, pS11, DOI 10.1097/00001813-200211002-00003; Haidar JH, 2003, EUR J HAEMATOL, V70, P330, DOI 10.1034/j.1600-0609.2003.00007.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harjunpaa A, 2000, SCAND J IMMUNOL, V51, P634; Hauke RJ, 2000, CURR OPIN ONCOL, V12, P412, DOI 10.1097/00001622-200009000-00005; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hennessy BT, 2004, LANCET ONCOL, V5, P341, DOI 10.1016/S1470-2045(04)01490-1; Hewitt SM, 1997, ANTICANCER RES, V17, P3211; Hiddemann W, 1995, EUR J CANCER, V31A, P2141, DOI 10.1016/0959-8049(95)00367-3; Hiddemann W, 2003, SEMIN ONCOL, V30, P16, DOI 10.1053/sonc.2003.50024; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hofmeister JK, 2000, BLOOD CELL MOL DIS, V26, P133, DOI 10.1006/bcmd.2000.0287; HOLDER M, 1995, EUR J IMMUNOL, V25, P3160, DOI 10.1002/eji.1830251126; HOOIJBERG E, 1995, CANCER RES, V55, P2627; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; Horning SJ, 2001, BLOOD, V97, P404, DOI 10.1182/blood.V97.2.404; Hulett MD, 2001, BIOCHEM BIOPH RES CO, V280, P374, DOI 10.1006/bbrc.2000.4088; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Idusogie EE, 2001, J IMMUNOL, V166, P2571, DOI 10.4049/jimmunol.166.4.2571; Jazirehi AR, 2004, BLOOD, V104, p930A, DOI 10.1182/blood.V104.11.3410.3410; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2004, MOL CANCER THER, V3, P71; Jazirehi AR, 2002, BLOOD, V100, p817A; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Jilani I, 2003, BLOOD, V102, P3514, DOI 10.1182/blood-2003-01-0055; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson P, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50025; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Keating MJ, 2002, SEMIN ONCOL, V29, P70, DOI 10.1053/sonc.2002.30142; KEHRL JH, 1994, IMMUNOL TODAY, V15, P432, DOI 10.1016/0167-5699(94)90273-9; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; Kikuchi E, 2003, CANCER RES, V63, P107; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Kobayashi H, 2001, Hum Cell, V14, P172; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kunala S, 2001, INT J CANCER, V96, P178, DOI 10.1002/ijc.1018; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; LIDA M, 1999, LEUKEMIA, V13, P585; Lin TS, 2003, SEMIN ONCOL, V30, P483, DOI 10.1016/S0093-7754(03)00239-2; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Maldonado V, 1997, MUTAT RES-FUND MOL M, V381, P67, DOI 10.1016/S0027-5107(97)00150-4; Maloney David G, 2003, Curr Hematol Rep, V2, P13; Manches O, 2003, BLOOD, V101, P949, DOI 10.1182/blood-2002-02-0469; Manna SK, 2000, J INTERF CYTOK RES, V20, P725, DOI 10.1089/10799900050116435; Manshouri T, 2003, BLOOD, V101, P2507, DOI 10.1182/blood-2002-06-1639; Marcus R, 2003, LEUKEMIA LYMPHOMA, V44, pS15, DOI 10.1080/10428190310001616926; Mathas S, 2000, CANCER RES, V60, P7170; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Miki H, 1999, ANTICANCER RES, V19, P5283; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Montserrat E, 2003, SEMIN ONCOL, V30, P34, DOI 10.1053/sonc.2003.50033; MORGAN A, 1995, IMMUNOLOGY, V86, P319; Mori N, 1997, EUR J HAEMATOL, V59, P162; Murayama Y, 1996, MICROBIOL IMMUNOL, V40, P467, DOI 10.1111/j.1348-0421.1996.tb01096.x; NEWMAN R, 1992, BIO-TECHNOL, V10, P1455, DOI 10.1038/nbt1192-1455; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Ng CP, 2002, ADV CANCER RES, V85, P145, DOI 10.1016/S0065-230X(02)85005-9; NG VL, 1994, BLOOD, V83, P1067; Nooter K, 1996, PATHOL RES PRACT, V192, P768, DOI 10.1016/S0344-0338(96)80099-9; O'Keefe TL, 1998, IMMUNOGENETICS, V48, P125, DOI 10.1007/s002510050412; Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pan LF, 2003, CHINESE MED J-PEKING, V116, P487; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Pels H, 2003, ONKOLOGIE, V26, P351, DOI 10.1159/000072095; Pickartz T, 2001, EXP HEMATOL, V29, P1410, DOI 10.1016/S0301-472X(01)00753-6; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Polito I, 2004, LEUKEMIA, V18, P1215, DOI 10.1038/sj.leu.2403378; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; PRESS OW, 1987, BLOOD, V69, P584; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Reams D, 2003, CHEST, V124, P1242, DOI 10.1378/chest.124.4.1242; Reed JC, 1995, TOXICOL LETT, V82-3, P155, DOI 10.1016/0378-4274(95)03551-6; REFF ME, 1994, BLOOD, V83, P435; RIECKMANN P, 1991, J IMMUNOL, V147, P3994; Riksen NP, 2003, NETH J MED, V61, P262; Rose AL, 2002, BLOOD, V100, P1765, DOI 10.1182/blood.V100.5.1765.h81702001765_1765_1773; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SanchezGarcia I, 1997, J MOL BIOL, V267, P225, DOI 10.1006/jmbi.1996.0779; Sandor V, 1997, LEUKEMIA LYMPHOMA, V28, P23, DOI 10.3109/10428199709058327; Sarris AH, 1999, ANN ONCOL, V10, P433, DOI 10.1023/A:1008301602785; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; Semac I, 2003, CANCER RES, V63, P534; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shan D, 2001, CLIN CANCER RES, V7, P2490; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Sivaraman S, 2000, CYTOKINES CELL MOL T, V6, P81, DOI 10.1080/13684730050515804; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SMELAND EB, 1987, EXP CELL RES, V172, P101, DOI 10.1016/0014-4827(87)90097-8; Smith MR, 1996, CURR PROB CANCER, V20, P6, DOI 10.1016/S0147-0272(96)80303-5; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Swerdlow AJ, 2003, EUR J NUCL MED MOL I, V30, pS3, DOI 10.1007/s00259-003-1154-9; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; Tan B R, 2000, Expert Opin Pharmacother, V1, P451, DOI 10.1517/14656566.1.3.451; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; TEDDER TF, 1989, J IMMUNOL, V142, P2560; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1988, J BIOL CHEM, V263, P10009; TEDDER TF, 1988, MOL IMMUNOL, V25, P1321, DOI 10.1016/0161-5890(88)90047-8; TEDDER TF, 1988, J IMMUNOL, V141, P4388; TEDDER TF, 1989, J IMMUNOL, V142, P2555; Theodossiou C, 2002, CLIN OBSTET GYNECOL, V45, P820, DOI 10.1097/00003081-200209000-00029; THEVENIN C, 1993, J BIOL CHEM, V268, P5949; Thommesen JE, 2000, MOL IMMUNOL, V37, P995, DOI 10.1016/S0161-5890(01)00010-4; Treon SP, 2001, J IMMUNOTHER, V24, P263, DOI 10.1097/00002371-200105000-00011; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Uchida J, 2004, INT IMMUNOL, V16, P119, DOI 10.1093/intimm/dxh009; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; VALENTINE MA, 1987, P NATL ACAD SCI USA, V84, P8085, DOI 10.1073/pnas.84.22.8085; van der Kolk LE, 2002, LEUKEMIA, V16, P693, DOI 10.1038/sj.leu.2402424; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Venugopal P, 2000, LEUKEMIA RES, V24, P411, DOI 10.1016/S0145-2126(99)00206-4; Voorzanger N, 1996, CANCER RES, V56, P5499; Vose Julie M., 1999, Seminars in Hematology, V36, P15; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; Warren TL, 2002, SEMIN ONCOL, V29, P93, DOI 10.1053/sonc.2002.30147; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WeberNordt RM, 1996, BLOOD, V88, P2549, DOI 10.1182/blood.V88.7.2549.bloodjournal8872549; Weichert G, 2003, J CUTAN MED SURG, V7, P460, DOI 10.1007/s10227-003-0153-6; Weinstein-Oppenheimer CR, 2001, CLIN CANCER RES, V7, P2898; Weng WK, 2001, BLOOD, V98, P1352, DOI 10.1182/blood.V98.5.1352; White CA, 2001, ANNU REV MED, V52, P125, DOI 10.1146/annurev.med.52.1.125; WHITE MW, 1991, J IMMUNOL, V146, P846; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; ZELENTEZ A, 1999, INT C MAL LYMPH LUG; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	249	219	236	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2121	2143		10.1038/sj.onc.1208349	http://dx.doi.org/10.1038/sj.onc.1208349			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15789036				2022-12-17	WOS:000227857900001
J	Kremenevskaja, N; von Wasielewski, R; Rao, AS; Schofl, C; Andersson, T; Brabant, G				Kremenevskaja, N; von Wasielewski, R; Rao, AS; Schofl, C; Andersson, T; Brabant, G			Wnt-5a has tumor suppressor activity in thyroid carcinoma	ONCOGENE			English	Article						Wnt; beta-catenin; thyroid cancer; tumor suppression	BETA-CATENIN GENE; SIGNALING PATHWAY; ECTOPIC EXPRESSION; OVARIAN CARCINOMAS; FRIZZLED HOMOLOGS; SOMATIC MUTATIONS; EXON 3; PROTEIN; CANCER; CELLS	Stabilization of beta-catenin by inhibition of its phosphorylation is characteristic of an activation of the canonical Wnt/beta-catenin signaling pathway and is associated with various human carcinomas. It contrasts to an as yet incompletely characterized action of an alternative noncanonical Wnt signaling pathway on neoplastic transformation. The aim of the present study was to test the effects of a member of the noncanonical Wnt signaling pathway, Wnt-5a, in primary thyroid carcinomas and in thyroid carcinoma cell lines. Compared to normal tissue Wnt-5a mRNA expression was clearly increased in thyroid carcinomas. Immunohistochemically, a bell-shaped response was observed with low to undetectable levels in normal tissue and in anaplastic tumors whereas differentiated thyroid carcinomas showed strong positive immunostaining for Wnt-5a. Transfection of Wnt-5a in a thyroid tumor cell line FTC-133 was able to reduce proliferation, migration, invasiveness and clonogenicity in these cells. These effects of Wnt-5a are associated with membranous b-catenin translocation and c-myc oncogene suppression and are mediated through an increase in intracellular Ca2+ release, which via CaMKII pathways promotes beta-catenin phosphorylation. Specific inhibition of beta-catenin phosphorylation by W-7, a calmodulin inhibitor, or by KN-93, a CaMKII inhibitor, supports these. findings whereas PKC inhibitors were without effect. This interaction occurs downstream of GSK-3 beta as no Wnt-5a effect was seen on the Ser(9) phosphorylation of GSK-3 beta. Our data are compatible with the hypothesis that Wnt-5a serves as an antagonist to the canonical Wnt- signaling pathway with tumor suppressor activity in differentiated thyroid carcinomas.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Pathol, Hannover, Germany; Malmo Univ Hosp, Malmo, Sweden	Hannover Medical School; Hannover Medical School; Lund University; Skane University Hospital	Brabant, G (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	brabant.georg@mh-hannover.de		Annavarapu, Srinivas/0000-0002-0340-935X; Andersson, Tommy/0000-0003-4032-5769				Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bui TD, 1997, BIOCHEM BIOPH RES CO, V239, P911, DOI 10.1006/bbrc.1997.7530; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Fukuchi T, 1998, CANCER RES, V58, P3526; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; IOZZO RV, 1995, CANCER RES, V55, P3495; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jeng YM, 2000, CANCER LETT, V152, P45, DOI 10.1016/S0304-3835(99)00433-4; Jonsson M, 2002, CANCER RES, V62, P409; Kitaeva MN, 1997, CANCER RES, V57, P4478; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Koch A, 1999, CANCER RES, V59, P269; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meng QH, 2000, BREAST CANCER RES TR, V63, P147, DOI 10.1023/A:1006495824158; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Miyoshi Y, 1998, CANCER RES, V58, P2524; Olson DJ, 1998, TUMOR BIOL, V19, P244, DOI 10.1159/000030014; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; Palacios J, 1998, CANCER RES, V58, P1344; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Park WS, 1999, CANCER RES, V59, P4257; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Yamada T, 2000, CANCER RES, V60, P4761; Zhang T, 2001, CANCER RES, V61, P8664	42	219	244	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2144	2154		10.1038/sj.onc.1208370	http://dx.doi.org/10.1038/sj.onc.1208370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735754				2022-12-17	WOS:000227857900002
J	Karpf, AR; Jones, DA				Karpf, AR; Jones, DA			Reactivating the expression of methylation silenced genes in human cancer	ONCOGENE			English	Article						DNA methylation; cancer; 5-aza-2 '-deoxycytidine; DNA methyltransferase	DNA METHYLATION; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSOR; DRUG-RESISTANCE; MAMMALIAN-CELLS; GENOMIC DNA; METHYLTRANSFERASE; BINDING; DEMETHYLATION; PROTEINS	DNA methylation alterations are now widely recognized as a contributing factor in human tumorigenesis. A significant number of tumor suppressor genes are transcriptionally silenced by promoter hypermethylation, and recent research implicates alterations in chromatin structure as the mechanistic basis for this repression. The enzymes responsible for catalyzing DNA-cytosine methylation, as well as the proteins involved in interpreting the DNA methylation signal, have now been elucidated. Technological advances, including gene expression microarrays and genome scanning techniques, have allowed the comprehensive measurement of DNA methylation changes in human cancers. An important distinction between DNA methylation (epigenetic) and mutation or deletion (genetic) tumor suppressor gene inactivation is that epigenetic inactivation can be abrogated by small molecules, including DNA methyltransferase and histone deacetylase inhibitors. Further, strategies have been developed that combine treatments with drugs that reactivate silenced gene expression with secondary agents that target the re-expressed genes and/or reconstituted signal transduction pathways. In this review, we will discuss in detail the mechanisms of gene silencing by DNA methylation, the techniques used to decipher the complement of methylation-inactivated genes in human cancers, and current and future strategies for reactivating the expression of methylation-silenced genes.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Karpf, AR (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	adam.karpf@hci.utah.edu; david.jones@hci.utah.edu		Karpf, Adam/0000-0002-0866-0666	NCI NIH HHS [P01-CA73992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Albanesi T, 1999, MUTAT RES-FUND MOL M, V429, P239, DOI 10.1016/S0027-5107(99)00112-8; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bender CM, 1998, PHARM RES-DORDR, V15, P175, DOI 10.1023/A:1011946030404; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Esteller M, 2001, CANCER RES, V61, P3225; Fang JY, 1996, J GASTROEN HEPATOL, V11, P1079, DOI 10.1111/j.1440-1746.1996.tb00040.x; FEINBERG AP, 1988, CANCER RES, V48, P1159; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; GASTON K, 1995, NUCLEIC ACIDS RES, V23, P901, DOI 10.1093/nar/23.6.901; Gillespie AM, 1999, CANCER TREAT REV, V25, P219, DOI 10.1053/ctrv.1999.0126; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jones DA, 2001, CLIN CANCER RES, V7, p3827S; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LESHIN M, 1985, P NATL ACAD SCI USA, V82, P3005, DOI 10.1073/pnas.82.9.3005; Liang G, 2002, CANCER RES, V62, P961; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Neidhart M, 2000, ARTHRITIS RHEUM-US, V43, P2634, DOI 10.1002/1529-0131(200012)43:12<2634::AID-ANR3>3.0.CO;2-1; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plumb JA, 2000, CANCER RES, V60, P6039; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wang R, 1998, CHINESE MED J-PEKING, V111, P339; WEBER J, 1994, CANCER RES, V54, P1766; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Yan PS, 2001, CANCER RES, V61, P8375; Yan PS, 2000, CLIN CANCER RES, V6, P1432	66	219	249	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5496	5503		10.1038/sj.onc.1205602	http://dx.doi.org/10.1038/sj.onc.1205602			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154410				2022-12-17	WOS:000177197700014
J	Jhiang, SM				Jhiang, SM			The RET proto-oncogene in human cancers	ONCOGENE			English	Review						RET; papillary thyroid carcinomas; MEN 2; signal transduction	RECEPTOR TYROSINE KINASE; PAPILLARY THYROID CARCINOMAS; NEOPLASIA TYPE 2A; RET/PTC1 ONCOGENE; CELL LINE; TRANSGENIC MICE; HIGH PREVALENCE; TRANSFORMING ACTIVITY; TARGETED EXPRESSION; SIGNAL-TRANSDUCTION	The activation of the RET proto-oncogene contributes to the development of human cancers in two different ways. Somatic rearrangements of RET with a variety of activating genes, which contribute to unscheduled expression and constitutive dimerization of the chimeric RET/PTC oncoproteins in thyroid follicular cells, are frequently found in radiation-induced papillary thyroid carcinomas. Germ-line mutations, mainly point mutations, that lead to constitutive activation of RET tyrosine kinase activity are responsible for the development of the inherited cancer syndrome, multiple endocrine neoplasia type 2, There appears to be a correlation between specific types of RET mutation and clinical phenotypes of the cancers involved. The biological effects and the signaling pathways induced by different forms of RET activation have been investigated in a variety of cultured cells as well as in genetically engineered animal models. The identification of RET mutations in most MEN 2 families (95%) has translated into improved care for MEN 2 patients. However, further investigation of the signaling pathways contributing to tumorigenesis in relevant tissues will eventually help us to develop no, el strategies to prevent or to treat human papillary thyroid carcinomas, MEN 2 disease, as well as the sporadic cancers relevant to MEN 2 disease.	Ohio State Univ, Dept Cell Biol & Physiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Cell Biol & Physiol, 302 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NCI NIH HHS [CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060074, R29CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Asai N, 1999, BIOCHEM BIOPH RES CO, V255, P587, DOI 10.1006/bbrc.1999.0237; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bartsch DK, 2000, EXP CLIN ENDOCR DIAB, V108, P128, DOI 10.1055/s-2000-5806; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BOND JA, 1994, ONCOGENE, V9, P281; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Cho JY, 1999, ONCOGENE, V18, P3659, DOI 10.1038/sj.onc.1202709; Cinti R, 2000, CYTOGENET CELL GENET, V88, P56, DOI 10.1159/000015485; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Fischer AH, 1998, AM J PATHOL, V153, P1443, DOI 10.1016/S0002-9440(10)65731-8; Giannini R, 2000, INT J ONCOL, V16, P485; GRIECO D, 1995, ONCOGENE, V11, P113; Ito S, 1997, CANCER RES, V57, P2870; ITOH F, 1989, Tumor Research, V24, P1; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; JHIANG SM, 1992, ONCOGENE, V7, P1331; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRIJGER RR, 2000, J PATHOL, V191, P264; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Powell DJ, 1998, CANCER RES, V58, P5523; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; ROMANO A, 1994, ONCOGENE, V9, P2923; Sagartz JE, 1997, LAB INVEST, V76, P307; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro M, 1999, BIOCHIMIE, V81, P397, DOI 10.1016/S0300-9084(99)80087-X; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.0.CO;2-L; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Soares P, 1998, J PATHOL, V185, P71; Tallini G, 1998, CLIN CANCER RES, V4, P287; Tessitore A, 1999, J CLIN ENDOCR METAB, V84, P3522, DOI 10.1210/jc.84.10.3522; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; TSUZUKI T, 1995, ONCOGENE, V10, P191; Uchino S, 1999, JPN J CANCER RES, V90, P1231, DOI 10.1111/j.1349-7006.1999.tb00701.x; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512	71	219	249	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5590	5597		10.1038/sj.onc.1203857	http://dx.doi.org/10.1038/sj.onc.1203857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114739				2022-12-17	WOS:000165659300006
J	DAMICO, D; CARBONE, D; MITSUDOMI, T; NAU, M; FEDORKO, J; RUSSELL, E; JOHNSON, B; BUCHHAGEN, D; BODNER, S; PHELPS, R; GAZDAR, A; MINNA, JD				DAMICO, D; CARBONE, D; MITSUDOMI, T; NAU, M; FEDORKO, J; RUSSELL, E; JOHNSON, B; BUCHHAGEN, D; BODNER, S; PHELPS, R; GAZDAR, A; MINNA, JD			HIGH-FREQUENCY OF SOMATICALLY ACQUIRED P53 MUTATIONS IN SMALL-CELL LUNG-CANCER CELL-LINES AND TUMORS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; POINT MUTATIONS; T-ANTIGEN; SHORT ARM; WILD-TYPE; GENE; CHROMOSOME-17; EXPRESSION; IDENTIFICATION; LOCALIZATION	We analysed the p53 open reading frame (ORF) in 16 small-cell lung cancer (SCLC) cell lines by direct sequencing of cDNA/PCR products and in 20 SCLC tumors by chemical cleavage and single-strand conformation polymorphism analyses of genomic DNA/PCR products. Abnormalities of p53 were found in 16/16 cell lines (100%) and in 16/20 tumors (80%). In the SCLC cell lines, mutations (59% missense, 18% nonsense and 23% splicing) changing the coding sequence were dispersed between amino acids 68 and 342. In the tumor samples, while the mutations occurred predominantly in exons 5-8, other mutations were located outside these regions. G to T transversions were common, occurring in 32% of the cases. We found no p53 mutations in the corresponding normal tissue from 19 patients whose tumors had p53 lesions, indicating that the mutations were all somatically acquired. In analysing the clinical data of the patients we found no correlation between tumor response to therapy or survival and the location or type of mutations. We conclude from these data that: (1) p53 mutations are found in SCLC with high frequency; (2) p53 mutations in a significant fraction of cases generate cDNAs with nonsense or splicing mutations; and (3) to date, these mutations have all been somatically acquired events.	NATL NAVAL MED CTR, NCI, NAVY MED ONCOL BRANCH, BETHESDA, MD 20814 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA	DAMICO, D (corresponding author), UNIV TEXAS, SW MED CTR DALLAS, SIMMONS CANC CTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				ADDISON C, 1990, ONCOGENE, V5, P423; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; Battey, 1986, BASIC METHODS MOL BI; BODNER S, 1991, IN PRESS ONCOGENE; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CAPORASO NE, 1990, J NATL CANCER I, V82, P1264, DOI 10.1093/jnci/82.15.1264; CARNEY DN, 1985, CANCER RES, V45, P2913; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CURIEL DT, 1990, AM J RESP CELL MOL, V3, P405, DOI 10.1165/ajrcmb/3.5.405; DOHERTY PJ, 1989, ANAL BIOCHEM, V177, P7, DOI 10.1016/0003-2697(89)90003-1; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUJIMORI M, 1991, CANCER RES, V51, P89; HEIGHWAY J, 1986, BRIT J CANCER, V53, P453, DOI 10.1038/bjc.1986.72; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; LYNCH H, 1986, CANCER, V57, P640; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHAL R, 1990, BLOOD, V75, P180; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MITSUDOMI T, 1991, IN PRESS ONCOGENE; MORI N, 1989, CANCER RES, V49, P5130; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OOI WL, 1986, J NATL CANCER I, V76, P217; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLAGLE BL, 1991, CANCER RES, V51, P49; SOUSSI T, 1990, J VIROL, V64, P967; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	58	219	221	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					339	346						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312696				2022-12-17	WOS:A1992HG98200020
J	Aga, M; Bentz, GL; Raffa, S; Torrisi, MR; Kondo, S; Wakisaka, N; Yoshizaki, T; Pagano, JS; Shackelford, J				Aga, M.; Bentz, G. L.; Raffa, S.; Torrisi, M. R.; Kondo, S.; Wakisaka, N.; Yoshizaki, T.; Pagano, J. S.; Shackelford, J.			Exosomal HIF1 alpha supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes	ONCOGENE			English	Article							INDUCIBLE FACTOR 1-ALPHA; MULTIVESICULAR BODIES; MESSENGER-RNAS; HYPOXIA; MICROVESICLES; MECHANISM; RELEASE; CELLS; PALMITOYLATION; INHIBITION	It has emerged recently that exosomes are potential carriers of pro-tumorigenic factors that participate in oncogenesis. However, whether oncogenic transcription factors are transduced by exosomes is unknown. Hypoxia-inducible factor-1 alpha (HIF1 alpha) transcriptionally regulates numerous key aspects of tumor development and progression by promoting a more aggressive tumor phenotype, characterized by increased proliferation and invasiveness coupled with neoangiogenesis. It has been shown that the principal oncoprotein of Epstein-Barr virus (EBV), latent membrane protein 1 (LMP1), drives oncogenic processes and tumor progression of the highly invasive EBV malignancy, nasopharyngeal carcinoma (NPC). We now demonstrate that endogenous HIF1 alpha is detectable in exosomes and that LMP1 significantly increases levels of HIF1 alpha in exosomes. HIF1 recovered from exosomes retains DNA-binding activity and is transcriptionally active in recipient cells after exosome uptake. We also show that treatment of EBV-negative cells with LMP1-exosomes increases migration and invasiveness of NP cell lines in functional assays, which correlates with the phenotype associated with epithelial-mesenchymal transition (EMT). In addition, we provide evidence that HIF1 alpha itself participates in exosome-mediated pro-metastatic effects in recipient cells, as exosome-mediated delivery of active and inactive forms of HIF1 alpha results in reciprocal changes in the expression of E- and N-cadherins associated with EMT. Further, immunohistochemical analysis of NPC tumor tissues revealed direct correlation between protein levels of LMP1 and of the endosome/exosome marker tetraspanin, CD63, which suggests an increase in exosome formation in this EBV-positive malignancy. We hypothesize that exosome-mediated transfer of functional pro-metastatic factors by LMP1-positive NPC cells to surrounding tumor cells promotes cancer progression.	[Aga, M.; Bentz, G. L.; Pagano, J. S.; Shackelford, J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Aga, M.; Kondo, S.; Wakisaka, N.; Yoshizaki, T.] Kanazawa Univ, Grad Sch Med, Div Otolaryngol, Kanazawa, Ishikawa, Japan; [Raffa, S.; Torrisi, M. R.] Univ Roma La Sapienza, Dipartimento Med Clin & Mol, I-00185 Rome, Italy; [Shackelford, J.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Kanazawa University; Sapienza University Rome; University of North Carolina; University of North Carolina Chapel Hill	Pagano, JS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	joseph_pagano@med.unc.edu	Raffa, Salvatore/GPX-5723-2022; Raffa, Salvatore/AAW-7060-2020; RAFFA, SALVATORE/AAL-5514-2020	Raffa, Salvatore/0000-0001-9501-7638; 	National Cancer Institute [2P01-CA19014-26]; International Training Program of Cancer Research Institute of Kanazawa University; Grants-in-Aid for Scientific Research [25670713] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); International Training Program of Cancer Research Institute of Kanazawa University; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Meckes DG Jr. and Raab-Traub N (University of North Carolina, Chapel Hill, NC, USA) for providing helpful advice on the further experimental strategies and Richard DE (Centre de Recherche en Cancerologie de l'Universite Laval, Quebec, QC, Canada) for the HA-DN HIF1a plasmid. This work was supported by a grant from the National Cancer Institute 2P01-CA19014-26 and International Training Program of Cancer Research Institute of Kanazawa University.	Ceccarelli S, 2007, INT J CANCER, V121, P1494, DOI 10.1002/ijc.22844; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Corrado C, 2013, INT J MOL SCI, V14, P5338, DOI 10.3390/ijms14035338; Daker M, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-34; Denzer K, 2000, J CELL SCI, V113, P3365; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Gourzones C, 2012, SEMIN CANCER BIOL, V22, P127, DOI 10.1016/j.semcancer.2012.01.002; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hendrix A, 2011, INT J DEV BIOL, V55, P879, DOI 10.1387/ijdb.113391ah; Hong BS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-556; Houali K, 2007, CLIN CANCER RES, V13, P4993, DOI 10.1158/1078-0432.CCR-06-2945; Johnstone RM, 2006, BLOOD CELL MOL DIS, V36, P315, DOI 10.1016/j.bcmd.2005.12.001; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008-5472.CAN-06-1679; Kovalenko OV, 2004, BIOCHEM J, V377, P407, DOI 10.1042/BJ20031037; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11; Meckes DG, 2010, P NATL ACAD SCI USA, V107, P20370, DOI 10.1073/pnas.1014194107; Meckes Jr DG, P NATL ACAD IN PRESS, V110, pE2925; Pant S, 2012, BIOCHEM PHARMACOL, V83, P1484, DOI 10.1016/j.bcp.2011.12.037; Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084; Raab-Traub N, 2012, CURR OPIN VIROL, V2, P453, DOI 10.1016/j.coviro.2012.07.001; Rana S, 2011, BIOCHEM SOC T, V39, P559, DOI 10.1042/BST0390559; Richard DE, 2000, J BIOL CHEM, V275, P26765; Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079636; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Staubach S, 2009, PROTEOMICS, V9, P2820, DOI 10.1002/pmic.200800793; Sund M, 2009, CANCER METAST REV, V28, P177, DOI 10.1007/s10555-008-9175-2; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004; Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yoshizaki T, 2005, EPSTEIN-BARR VIRUS, P171; Yoshizaki T, 2013, CANCER LETT, V337, P1, DOI 10.1016/j.canlet.2013.05.018; Yu X, 2012, J MOL CELL CARDIOL, V53, P848, DOI 10.1016/j.yjmcc.2012.10.002	43	218	239	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4613	4622		10.1038/onc.2014.66	http://dx.doi.org/10.1038/onc.2014.66			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24662828	hybrid, Green Submitted, Green Published, Green Accepted			2022-12-17	WOS:000342004800008
J	Yen, KE; Bittinger, MA; Su, SM; Fantin, VR				Yen, K. E.; Bittinger, M. A.; Su, S. M.; Fantin, V. R.			Cancer-associated IDH mutations: biomarker and therapeutic opportunities	ONCOGENE			English	Review						IDH; mutations; cancer	ACUTE MYELOID-LEUKEMIA; DEPENDENT ISOCITRATE DEHYDROGENASE; INTEGRATED GENOMIC ANALYSIS; CODON 132 MUTATION; MYELOPROLIFERATIVE NEOPLASMS; L-2-HYDROXYGLUTARIC ACIDURIA; BETA-OXIDATION; FATTY-ACIDS; GLIOMAS; TUMORS	The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-wide mutational analysis in glioblastoma represents a milestone event in cancer biology. The nature of the heterozygous, point mutations mapping to arginine residues involved in the substrate binding inspired several research teams to investigate their impact on the biochemical activity of these enzymes. Soon, it became clear that the mutations identified impaired the ability of IDH1 and IDH2 to catalyze the conversion of isocitrate to alpha-ketoglutarate (alpha KG), whereas conferring a gain of a novel enzymatic activity leading to the reduction of alpha KG to the metabolite D2-hydroxyglutarate (D-2HG). Across glioma as well as several hematologic malignancies, mutations in IDH1 and IDH2 have shown prognostic value. Several hypotheses implicating the elevated levels of D-2HG and tumorigenesis, and the therapeutic potential of targeting mutant IDH enzymes will be discussed. Oncogene (2010) 29, 6409-6417; doi:10.1038/onc.2010.444; published online 25 October 2010	[Yen, K. E.; Bittinger, M. A.; Su, S. M.; Fantin, V. R.] Agios Pharmaceut, Mol Oncol, Cambridge, MA 02139 USA	Agios Pharmaceuticals	Fantin, VR (corresponding author), Agios Pharmaceut, Mol Oncol, 2nd Floor,38 Sidney St, Cambridge, MA 02139 USA.	valeria.fantin@agios.com						Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878; Abdel-Wahab O, 2010, CANCER RES, V70, P447, DOI 10.1158/0008-5472.CAN-09-3783; Aydin K, 2003, PEDIATR RADIOL, V33, P872, DOI 10.1007/s00247-003-1029-z; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; Chalmers R A, 1980, J Inherit Metab Dis, V3, P11, DOI 10.1007/BF02312516; Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Frezza C, 2010, CANCER CELL, V17, P7, DOI 10.1016/j.ccr.2009.12.031; Gaal J, 2010, J CLIN ENDOCR METAB, V95, P1274, DOI 10.1210/jc.2009-2170; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; Gillies RJ, 2007, CANCER METAST REV, V26, P311, DOI 10.1007/s10555-007-9065-z; Green A, 2010, NEW ENGL J MED, V362, P369, DOI 10.1056/NEJMc0910063; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hayden JT, 2009, CELL CYCLE, V8, P1806, DOI 10.4161/cc.8.11.8594; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Ho PA, 2010, LEUKEMIA, V24, P909, DOI 10.1038/leu.2010.56; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaelin WG, 2009, CANCER CELL, V16, P180, DOI 10.1016/j.ccr.2009.08.013; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; KAUFMAN EE, 1988, J NEUROCHEM, V51, P1079, DOI 10.1111/j.1471-4159.1988.tb03071.x; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Kolker S, 2002, EUR J NEUROSCI, V16, P21, DOI 10.1046/j.1460-9568.2002.02055.x; Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lalisang RI, 1997, J CLIN ONCOL, V15, P1367, DOI 10.1200/JCO.1997.15.4.1367; LINDAHL G, 1967, ARCH BIOCHEM BIOPHYS, V119, P347, DOI 10.1016/0003-9861(67)90463-8; Loenarz C, 2008, NAT CHEM BIOL, V4, P152, DOI 10.1038/nchembio0308-152; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Murugan AK, 2010, BIOCHEM BIOPH RES CO, V393, P555, DOI 10.1016/j.bbrc.2010.02.095; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Pardanani A, 2010, LEUKEMIA, V24, P1370, DOI 10.1038/leu.2010.98; Pardanani A, 2010, LEUKEMIA, V24, P1146, DOI 10.1038/leu.2010.77; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Rzem R, 2007, J INHERIT METAB DIS, V30, P681, DOI 10.1007/s10545-007-0487-0; Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sener RN, 2003, J COMPUT ASSIST TOMO, V27, P38, DOI 10.1097/00004728-200301000-00008; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; THOL F, 2010, HAEMATOLOGICA, DOI DOI 10.3324/HAEMAT0L.2010.025494; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Voelzke WR, 2008, CURR TREAT OPTION ON, V9, P23, DOI 10.1007/s11864-008-0053-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yoshihara T, 2001, J HISTOCHEM CYTOCHEM, V49, P1123, DOI 10.1177/002215540104900906; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	62	218	226	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6409	6417		10.1038/onc.2010.444	http://dx.doi.org/10.1038/onc.2010.444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20972461				2022-12-17	WOS:000285138900001
J	Mori, S; Chang, JT; Andrechek, ER; Matsumura, N; Baba, T; Yao, G; Kim, JW; Gatza, M; Murphy, S; Nevins, JR				Mori, S.; Chang, J. T.; Andrechek, E. R.; Matsumura, N.; Baba, T.; Yao, G.; Kim, J. W.; Gatza, M.; Murphy, S.; Nevins, J. R.			Anchorage-independent cell growth signature identifies tumors with metastatic potential	ONCOGENE			English	Article						anchorage-independent cell growth; phenotype; expression signature; metastatic potential; heterogeneity	WIDE EXPRESSION PROFILES; BREAST-CANCER CELLS; SUBCELLULAR-LOCALIZATION; GENES; CARCINOMA; METABOLISM; LINES; TRANSCRIPTION; ENRICHMENT; INCREASES	The oncogenic phenotype is complex, resulting from the accumulation of multiple somatic mutations that lead to the deregulation of growth regulatory and cell fate controlling activities and pathways. The ability to dissect this complexity, so as to reveal discrete aspects of the biology underlying the oncogenic phenotype, is critical to understanding the various mechanisms of disease as well as to reveal opportunities for novel therapeutic strategies. Previous work has characterized the process of anchorage-independent growth of cancer cells in vitro as a key aspect of the tumor phenotype, particularly with respect to metastatic potential. Nevertheless, it remains a major challenge to translate these cell biology findings into the context of human tumors. We previously used DNA microarray assays to develop expression signatures, which have the capacity to identify subtle distinctions in biological states and can be used to connect in vitro and in vivo states. Here we describe the development of a signature of anchorage-independent growth, show that the signature exhibits characteristics of deregulated mitochondrial function and then demonstrate that the signature identifies human tumors with the potential for metastasis. Oncogene ( 2009) 28, 2796-2805; doi:10.1038/onc.2009.139; published online 1 June 2009	[Mori, S.; Chang, J. T.; Andrechek, E. R.; Matsumura, N.; Baba, T.; Yao, G.; Kim, J. W.; Gatza, M.; Murphy, S.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA; [Matsumura, N.; Baba, T.; Murphy, S.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27708 USA; [Matsumura, N.; Baba, T.] Kyoto Univ, Dept Gynecol & Obstet, Kyoto, Japan	Duke University; Duke University; Kyoto University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, 2123 CIEMAS, Durham, NC 27708 USA.	j.nevins@duke.edu	Murphy, Susan/R-3903-2019	Murphy, Susan/0000-0001-8298-7272; Andrechek, Eran/0000-0002-8680-3423; BABA, Tsukasa/0000-0003-0066-3747; Gatza, Michael/0000-0001-6796-7791; , Guang/0000-0003-0167-777X; Matsumura, Noriomi/0000-0002-4512-7975	NIH/NCI [5U54CA-112952-05]; Uehara Memorial Foundation; NATIONAL CANCER INSTITUTE [U54CA112952] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Uehara Memorial Foundation(Uehara Memorial Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Drs J-T Chi, T Hallstrom, L Kong, R Rempel, J Freedman, M Gatza, Dr B Balakumaran, H Dressman, Y Yokota, S Akiyama, T Inoue, M Oshimura, M Araki, H Saya, Aburatani, A Niida, K Araki, Y Taya and Y Ito for helpful discussions; A Bild, T Kitamura, M Eilers and H Hanafusa for providing materials; L Jakoi for help with experiments; and T Henry and K Culler for assistance with the preparation of the article. This work was supported by a grant (5U54CA-112952-05) from the NIH/NCI to JRN. SM was a research fellow of the Uehara Memorial Foundation	Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Edelman E, 2006, BIOINFORMATICS, V22, pE108, DOI 10.1093/bioinformatics/btl231; Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Guda C, 2005, BIOINFORMATICS, V21, P3963, DOI 10.1093/bioinformatics/bti650; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JOHNS ME, 1983, CANCER, V52, P1401, DOI 10.1002/1097-0142(19831015)52:8<1401::AID-CNCR2820520811>3.0.CO;2-7; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; MATTOX DE, 1980, AM J SURG, V140, P527, DOI 10.1016/0002-9610(80)90205-6; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137; NICOLSON GL, 1988, CANCER RES, V48, P399; NOMURA Y, 1989, CANCER RES, V49, P5288; PRICE JE, 1986, J NATL CANCER I, V77, P529; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Scott MS, 2004, GENOME RES, V14, P1957, DOI 10.1101/gr.2650004; SHAFIE SM, 1980, CANCER LETT, V11, P81, DOI 10.1016/0304-3835(80)90097-X; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUTHERLAND CM, 1983, SURGERY, V94, P370; Telang S, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-77; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; VANSLOOTEN HJ, 1995, BRIT J CANCER, V72, P22, DOI 10.1038/bjc.1995.271; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WARBURG O, 1956, SCIENCE, V124, P269; Weinberg RA, 2007, BIOL CANC; Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100; ZHANG RD, 1991, INVAS METAST, V11, P204; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	43	218	221	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2796	2805		10.1038/onc.2009.139	http://dx.doi.org/10.1038/onc.2009.139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19483725	Green Accepted			2022-12-17	WOS:000268684400003
J	Heath-Engel, HM; Chang, NC; Shore, GC				Heath-Engel, H. M.; Chang, N. C.; Shore, G. C.			The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family	ONCOGENE			English	Review						BH3; ER stress; calcium; mitochondria; Beclin-1	STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; CELL-DEATH PROGRAM; OUTER-MEMBRANE PERMEABILIZATION; THAPSIGARGIN-INDUCED APOPTOSIS; INOSITOL TRISPHOSPHATE RECEPTOR; DEPLETION-INDUCED APOPTOSIS; ER STRESS; PHOSPHATASE 2A	Apoptosis is essential for normal development and maintenance of homeostasis, and disruption of apoptotic pathways is associated with multiple disease states, including cancer. Although initially identified as central regulators of apoptosis at the level of mitochondria, an important role for BCL-2 proteins at the endoplasmic reticulum is now well established. Signaling pathways emanating from the endoplasmic reticulum ( ER) are involved in apoptosis initiated by stimuli as diverse as ER stress, oncogene expression, death receptor (DR) ligation and oxidative stress, and the BCL-2 family is almost invariably implicated in the regulation of these pathways. This also includes Ca2(+)-mediated cross talk between ER and mitochondria during apoptosis, which contributes to the mitochondrial dynamics that support the core mitochondrial apoptosis pathway. In addition to the regulation of apoptosis, BCL-2 proteins at the ER also regulate autophagy, a survival pathway that limits metabolic stress, genomic instability and tumorigenesis. In cases where apoptosis is inhibited, however, prolonged autophagy can lead to cell death. This review provides an overview of ER-associated apoptotic and autophagic signaling pathways, with particular emphasis on the BCL-2 family proteins.	[Heath-Engel, H. M.; Chang, N. C.; Shore, G. C.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Room 906B,3655 Promenade Si, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca		Chang, Natasha C./0000-0003-0589-9660	Canadian Institutes of Health Research Canada Graduate Scholarships Doctoral award	Canadian Institutes of Health Research Canada Graduate Scholarships Doctoral award(Canadian Institutes of Health Research (CIHR))	NCC is a recipient of the Canadian Institutes of Health Research Canada Graduate Scholarships Doctoral award.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Armstrong JL, 2007, APOPTOSIS, V12, P613, DOI 10.1007/s10495-006-0020-1; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baltzis D, 2007, J BIOL CHEM, V282, P31675, DOI 10.1074/jbc.M704491200; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Bhatt K, 2008, AM J PHYSIOL-RENAL, V294, pF499, DOI 10.1152/ajprenal.00415.2007; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brewster JL, 2006, MOL CELL NEUROSCI, V32, P242, DOI 10.1016/j.mcn.2006.04.006; Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Cheung HH, 2006, EXP CELL RES, V312, P2347, DOI 10.1016/j.yexcr.2006.03.027; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Christen V, 2007, HEPATOLOGY, V46, P558, DOI 10.1002/hep.21611; Cipolat S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Distelhorst CW, 2004, ONCOGENE, V23, P2875, DOI 10.1038/sj.onc.1207519; Dong Z, 2006, ANNU REV PATHOL-MECH, V1, P405, DOI 10.1146/annurev.pathol.1.110304.100218; Dremina ES, 2006, BIOCHEMISTRY-US, V45, P175, DOI 10.1021/bi050800s; Dremina ES, 2004, BIOCHEM J, V383, P361, DOI 10.1042/BJ20040187; Elyaman W, 2002, MOL BRAIN RES, V109, P233, DOI 10.1016/S0169-328X(02)00582-X; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gao ZH, 2005, J BIOL CHEM, V280, P38271, DOI 10.1074/jbc.M506488200; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gonzalvez F, 2007, APOPTOSIS, V12, P877, DOI 10.1007/s10495-007-0718-8; Groenendyk J, 2004, MOL CELLS, V17, P383; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; HANSON CJ, 2008, CELL CALCIUM; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Heath-Engel HM, 2006, BBA-MOL CELL RES, V1763, P549, DOI 10.1016/j.bbamcr.2006.02.006; Hetz C, 2007, CELL DEATH DIFFER, V14, P1386, DOI 10.1038/sj.cdd.4402166; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003; Hetz CA, 2007, ANTIOXID REDOX SIGN, V9, P2345, DOI 10.1089/ars.2007.1793; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hitomi J, 2004, NEUROSCI LETT, V357, P127, DOI 10.1016/j.neulet.2003.12.080; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Iizaka Toru, 2007, Toxicology, V241, P146, DOI 10.1016/j.tox.2007.08.095; Imai T, 2007, NEUROSCIENCE, V147, P639, DOI 10.1016/j.neuroscience.2007.04.057; Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karki P, 2007, BIOCHEM BIOPH RES CO, V356, P1056, DOI 10.1016/j.bbrc.2007.03.102; Kieran D, 2007, P NATL ACAD SCI USA, V104, P20606, DOI 10.1073/pnas.0707906105; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200; Kinnally KW, 2007, APOPTOSIS, V12, P857, DOI 10.1007/s10495-007-0722-z; Kitamura Y, 2003, J PHARMACOL SCI, V92, P228; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Li XD, 2005, VIROLOGY, V333, P180, DOI 10.1016/j.virol.2005.01.002; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liao PC, 2008, J CELL BIOCHEM, V104, P1509, DOI 10.1002/jcb.21730; Lin CF, 2007, J CELL SCI, V120, P2935, DOI 10.1242/jcs.03473; Lin SS, 2006, J BIOL CHEM, V281, P23003, DOI 10.1074/jbc.M602648200; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Liu N, 2006, VIROLOGY, V348, P398, DOI 10.1016/j.virol.2006.01.002; Lopez-Anton N, 2006, J BIOL CHEM, V281, P33078, DOI 10.1074/jbc.M607904200; Luo X, 2005, CELL DEATH DIFFER, V12, P1310, DOI 10.1038/sj.cdd.4401659; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Masud A, 2007, J BIOL CHEM, V282, P14132, DOI 10.1074/jbc.M700077200; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Murakami Y, 2007, J BIOCHEM, V141, P401, DOI 10.1093/jb/mvm044; Muscarella DE, 2008, TOXICOL APPL PHARM, V228, P93, DOI 10.1016/j.taap.2007.11.032; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Nickson P, 2007, CARDIOVASC RES, V73, P48, DOI 10.1016/j.cardiores.2006.10.001; Nieto-Miguel T, 2007, CANCER RES, V67, P10368, DOI 10.1158/0008-5472.CAN-07-0278; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oda T, 2008, NEUROSCI RES, V60, P29, DOI 10.1016/j.neures.2007.09.005; Oh SH, 2004, BIOCHEM PHARMACOL, V68, P1845, DOI 10.1016/j.bcp.2004.06.021; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516; Ott M, 2007, CELL DEATH DIFFER, V14, P1243, DOI 10.1038/sj.cdd.4402135; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pellegrini L, 2007, CELL DEATH DIFFER, V14, P1275, DOI 10.1038/sj.cdd.4402145; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pizzo P, 2007, TRENDS CELL BIOL, V17, P511, DOI 10.1016/j.tcb.2007.07.011; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rahmani M, 2007, MOL CELL BIOL, V27, P5499, DOI 10.1128/MCB.01080-06; Rao RV, 2006, CELL DEATH DIFFER, V13, P415, DOI 10.1038/sj.cdd.4401761; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852; Roy S, 2008, P NATL ACAD SCI USA, V105, P4133, DOI 10.1073/pnas.0706658105; Rudner J, 2001, J CELL SCI, V114, P4161; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shi J, 2005, CELL DEATH DIFFER, V12, P1601, DOI 10.1038/sj.cdd.4401676; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Simizu S, 2004, CANCER SCI, V95, P266, DOI 10.1111/j.1349-7006.2004.tb02214.x; Smith MI, 2007, CELL DEATH DIFFER, V14, P1011, DOI 10.1038/sj.cdd.4402089; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Srinivasan S, 2005, DIABETES, V54, P968, DOI 10.2337/diabetes.54.4.968; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; SZEGEZDI EHK, 2008, J CELL MOL MED; Takadera T, 2007, NEUROCHEM RES, V32, P1336, DOI 10.1007/s11064-007-9310-4; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Upton JP, 2008, MOL CELL BIOL, V28, P3943, DOI 10.1128/MCB.00013-08; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Walter L, 2005, J BIOENERG BIOMEMBR, V37, P191, DOI 10.1007/s10863-005-6600-x; Wang B, 2008, CELL, V133, P1080, DOI 10.1016/j.cell.2008.04.042; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wasiak S, 2007, J CELL BIOL, V177, P439, DOI 10.1083/jcb.200610042; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Wlodkowic D, 2007, LEUKEMIA RES, V31, P1687, DOI 10.1016/j.leukres.2007.03.008; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu LP, 2007, MOL CELL BIOCHEM, V295, P153, DOI 10.1007/s11010-006-9285-5; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Yukioka F, 2008, NEUROCHEM INT, V52, P683, DOI 10.1016/j.neuint.2007.08.017; Zalk R, 2007, ANNU REV BIOCHEM, V76, P367, DOI 10.1146/annurev.biochem.76.053105.094237; Zhang D, 2007, CELL DEATH DIFFER, V14, P703, DOI 10.1038/sj.cdd.4402072; Zhang DW, 2008, J BIOL CHEM, V283, P3476, DOI 10.1074/jbc.M707528200; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zhong F, 2006, J CELL BIOL, V172, P127, DOI 10.1083/jcb.200506189; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	206	218	229	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6419	6433		10.1038/onc.2008.309	http://dx.doi.org/10.1038/onc.2008.309			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955970				2022-12-17	WOS:000260501600003
J	Slee, EA; O'Connor, DJ; Lu, X				Slee, EA; O'Connor, DJ; Lu, X			To die or not to die: how does p53 decide?	ONCOGENE			English	Review						p53; apoptosis; transactivation; transrepression	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; TATA-BINDING PROTEIN; CELL-CYCLE ARREST; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; MUTANT P53; IN-VIVO; TRANSCRIPTIONAL REPRESSION; P53-INDUCED APOPTOSIS	p53 is frequently mutated in cancer and as a result is one of the most intensely studied tumour suppressors. Analysis of the primitive forms of p53 found in Caenorhabditis elegans and Drosophila, alongside studies using transgenic mouse models, indicate that the induction of apoptosis is both the most conserved function of p53 and vital for tumour suppression. p53-mediated apoptosis occurs through a combination of mechanisms which include pathways that are both dependent and independent of alterations in gene expression. In response to genotoxic insult, these pathways probably act together, thereby amplifying the apoptotic signal. However, the picture is complicated because the p53 activity is determined by stress type and individual cellular characteristics. The numerous p53 responsive genes that have been identified also provide further means of controlling the actions of p53. The recent discoveries of proteins that interact with p53 and specifically regulate the ability of p53 to trigger apoptosis have provided further mechanistic insights into the role of p53 in inducing cell death. Understanding the molecular basis of the proapoptotic action of p53 can assist in our quest to reintroduce or reactivate p53 in human tumours.	Imperial Coll Sch Med St Marys, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Imperial Coll Sch Med St Marys, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.	x.lu@imperial.ac.uk		Lu, Xin/0000-0002-6587-1152				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fei PW, 2002, CANCER RES, V62, P7316; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALDAR S, 1994, CANCER RES, V54, P2095; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Knudson CM, 2001, CANCER RES, V61, P659; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Le Bras M, 2003, ONCOGENE, V22, P5082, DOI 10.1038/sj.onc.1206424; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Lossos IS, 2002, LEUKEMIA LYMPHOMA, V43, P2309, DOI 10.1080/1042819021000040017; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsuda K, 2002, CANCER RES, V62, P2883; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	110	218	235	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2809	2818		10.1038/sj.onc.1207516	http://dx.doi.org/10.1038/sj.onc.1207516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077144				2022-12-17	WOS:000220799600008
J	Burger, M; Glodek, A; Hartmann, T; Schmitt-Graff, A; Silberstein, LE; Fujii, N; Kipps, TJ; Burger, JA				Burger, M; Glodek, A; Hartmann, T; Schmitt-Graff, A; Silberstein, LE; Fujii, N; Kipps, TJ; Burger, JA			Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells	ONCOGENE			English	Article						chemokine receptor; lung cancer; signal transduction; integrin activation; adhesion; migration	CHEMOKINE RECEPTOR CXCR4; LEUKEMIA B-CELLS; BONE-MARROW; TRANSENDOTHELIAL MIGRATION; HEMATOPOIETIC PROGENITORS; SIGNAL-TRANSDUCTION; CD34(+) CELLS; STEM-CELLS; VLA-4; FIBRONECTIN	Small-cell lung cancer (SCLC) is an aggressive, rapidly metastasizing neoplasm. The chemokine stromal cell-derived factor-1 (SDF-1/CXCL12) is constitutively secreted by marrow stromal cells and plays a key role for homing of hematopoietic cells to the marrow. Here, we report that tumor cells from patients with SCLC express high levels of functional CXCR4 receptors for the chemokine CXCL12. Reverse transcriptase-polymerase chain reaction and flow cytometry demonstrated CXCR4 mRNA and CXCR4 surface expression in SCLC cell lines. Immunohistochemistry of primary tumor samples from SCLC patients revealed high expression of CXCR4. CXCL12 elicited CXCR4 receptor endocytosis, actin polymerization, and a robust activation of phospho-p44/42 mitogen-activated protein kinase in SCLC cells. Furthermore, CXCL12 induced SCLC cell invasion into extracellular matrix and firm adhesion to marrow stromal cells. Stromal cell adhesion of SCLC cells was significantly inhibited by the specific CXCR4 antagonist T140, pertussis toxin, antivascular cell adhesion molecule-1(VCAM-1) antibodies, and CS-1 peptide, demonstrating the importance of CXCR4 chemokine receptor activation and alpha4beta1 integrin binding, respectively. In addition, CXCL12 enhanced the adhesion of SCLC cells to immobilized VCAM-1, demonstrating that CXCR4 chemokine receptors can induce integrin activation on SCLC cells. As SCLC has a high propensity for bone marrow involvement, our findings suggest that CXCR4 chemokine receptors and alpha4beta1 integrins play a critical role in the interaction of SCLC cells with stromal cells in the tumor microenvironment.	Freiburg Univ Hosp, Dept Internal Med, Freiburg, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Freiburg Univ Hosp, Dept Pathol, Freiburg, Germany; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto, Japan; Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA	University of Freiburg; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Freiburg; Kyoto University; University of California System; University of California San Diego	Burger, JA (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burger@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/C-9345-2017; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; Boyle DL, 2000, CELL IMMUNOL, V200, P1, DOI 10.1006/cimm.2000.1610; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Burger JA, 2001, J CLIN INVEST, V107, P305, DOI 10.1172/JCI11092; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; IHDE D, 1993, CANC PRINCIPLES PRAC, P591; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; Imai K, 1999, BLOOD, V93, P149, DOI 10.1182/blood.V93.1.149.401a02_149_156; Kijima T, 2002, CANCER RES, V62, P6304; Kristensen CA, 1996, CRIT REV ONCOL HEMAT, V22, P27, DOI 10.1016/1040-8428(94)00170-7; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; MASN DY, 2001, TISSUE ANTIGENS, V58, P425; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Nagasawa T, 1998, SEMIN IMMUNOL, V10, P179, DOI 10.1006/smim.1998.0128; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SIMMONS PJ, 1992, BLOOD, V80, P388; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	44	218	229	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8093	8101		10.1038/sj.onc.1207097	http://dx.doi.org/10.1038/sj.onc.1207097			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603250				2022-12-17	WOS:000186403400004
J	Yang, W; Shen, J; Wu, M; Arsura, M; FitzGerald, M; Suldan, Z; Kim, DW; Hofmann, CS; Pianetti, S; Romieu-Mourez, R; Freedman, LP; Sonenshein, GE				Yang, W; Shen, J; Wu, M; Arsura, M; FitzGerald, M; Suldan, Z; Kim, DW; Hofmann, CS; Pianetti, S; Romieu-Mourez, R; Freedman, LP; Sonenshein, GE			Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc	ONCOGENE			English	Article						c-Myc; Max; p27(Kip1); WEHI 231 cells; smooth muscle cells; breast cancer	RECEPTOR-MEDIATED APOPTOSIS; GROWTH-FACTOR-BETA; B-CELL LYMPHOMAS; PRIMARY BREAST-CANCER; CD40 LIGAND RESCUE; FACTOR-KAPPA-B/REL; PROGNOSTIC-SIGNIFICANCE; CONTACT INHIBITION; MESSENGER-RNA; CDK INHIBITOR	Upon engagement of the B Cell Receptor (BCR) of WEHI 231 immature B cells, a drop in c-Myc expression is followed by activation of the cyclin-dependent kinase inhibitor (CKI) p27(kip1), which induces growth arrest and apoptosis, Here, we report inverse patterns of p27 and c-Myc protein expression follow BCR engagement, We present evidence demonstrating, for the first time, that the p27(Kip1) gene is a target of transcriptional repression by c-Myc, Specifically, the changes in p27 protein levels correlated with changes in p27 mRNA levels, and gene transcription, Induction of p27 promoter activity followed BCR engagement of WEHI 231 cells, and this induction could be repressed upon co-transfection of a c-Myc expression vector. Inhibition of the TATA-less p27 promoter by c-Myr was also observed in Jurkat T cells, vascular smooth muscle, and Hs578T breast canter cells, extending the observation beyond immune cells, Consistent with putative Inr element CC (A) under bar GACC (where +1 is underlined) at the start site of transcription in the p27 promoter, deletion of Myc homology box II reduced the extent of repression, Furthermore, enhanced repression was observed upon transfection of the c-Myc 'super-repressor', with mutation of Phe115 to Leu, The sequences mediating transcriptional activity and c-Myc repression were mapped to bp -20 to +20 of the p27 gene, Finally, binding of Max was shown to facilitate c-Myc binding and repression of p27 promoter activity, Overall, these studies identify the p27 CKI gene as a new target whereby c-Myc can control cell proliferation, survival and neoplastic transformation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Boston University; Memorial Sloan Kettering Cancer Center	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.				NCI NIH HHS [CA 82742, CA 36355, CA64070] Funding Source: Medline; NHLBI NIH HHS [HL07429, HL13262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA064070, R01CA082742, R01CA036355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Arsura M, 2000, BLOOD, V96, P1013, DOI 10.1182/blood.V96.3.1013.015k06_1013_1020; ARSURA M, 2001, TRANSCRIPTION FACTOR, P521; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BERNS EMJJ, 1992, CANCER RES, V52, P1107; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BOYD AW, 1981, J IMMUNOL, V126, P2466; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; CLARK HM, 1994, CANCER RES, V54, P3383; Dang CV, 1999, MOL CELL BIOL, V19, P1; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FitzGerald MJ, 1999, ONCOGENE, V18, P2489, DOI 10.1038/sj.onc.1202611; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Kamesaki H, 1998, J IMMUNOL, V160, P770; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lee CCR, 1999, CARCINOGENESIS, V20, P1697, DOI 10.1093/carcin/20.9.1697; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; NORVELL A, 1995, J IMMUNOL, V154, P4404; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Runge D, 1997, BIOL CHEM, V378, P873, DOI 10.1515/bchm.1997.378.8.873; Schauer SL, 1998, J IMMUNOL, V160, P4398; Schauer SL, 1996, J IMMUNOL, V157, P81; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; Steiner P, 1996, Prog Cell Cycle Res, V2, P73; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsuchiya A, 1999, J SURG ONCOL, V70, P230, DOI 10.1002/(SICI)1096-9098(199904)70:4<230::AID-JSO6>3.0.CO;2-I; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang W, 1999, J IMMUNOL, V162, P314; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wu M, 1999, J IMMUNOL, V163, P6530; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yanagisawa K, 1999, J BIOCHEM-TOKYO, V125, P36, DOI 10.1093/oxfordjournals.jbchem.a022265; YANO T, 1993, ONCOGENE, V8, P2741; Yi AK, 1996, J IMMUNOL, V157, P4918	93	218	230	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1688	1702		10.1038/sj.onc.1204245	http://dx.doi.org/10.1038/sj.onc.1204245			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313917				2022-12-17	WOS:000167750900003
J	Kleeff, J; Ishiwata, T; Maruyama, H; Friess, H; Truong, P; Buchler, MW; Falb, D; Korc, M				Kleeff, J; Ishiwata, T; Maruyama, H; Friess, H; Truong, P; Buchler, MW; Falb, D; Korc, M			The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer	ONCOGENE			English	Article						Smad7; TGF-beta; pancreas; cancer	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; MAD-RELATED PROTEIN; II RECEPTOR GENE; CYCLIN D1; CELL-LINE; PLASMINOGEN-ACTIVATOR; CARCINOMA CELLS; EXPRESSION	Transforming growth factor-beta (TGF-beta) signaling is dependent on the heterodimerization of the type II TGF-beta receptor (T beta RII) with the type I TGF-beta receptor (T beta RI), Activated T beta RI then mediates TGF-beta signals by inducing the phosphorylation of Smad2 and/or Smad3, which separately hetetorodimerize with Smad4 and translocate to the nucleus. Phosphorylation of Smad2/Smad3 by activated T beta RI is inhibited by two newly discovered members of the Smad family, Smad6 and Smad7. We now report that Smad7 mRNA levels are increased in human pancreatic cancer by comparison with the normal pancreas, and that by in situ hybridization, Smad7 is over-expressed in the cancer cells within the tumor mass, Stable transfection of COLO-357 human pancreatic cancer cells with a full-length Smad7 construct leads to complete loss of the growth inhibitory response to TGF-beta 1, without altering TGF-beta 1-mediated induction of PAI-I. Furthermore, Smad7 transfected COLO-357 cells display enhanced anchorage-independent growth and accelerated growth in nude mice. These findings point to a previously unrecognized mechanism for selective suppression of TGF-beta-mediated growth inhibition in cancer cells that allows for continued activation of the PAI-I promoter by TGF-beta 1, which may act to enhance the tumorigenicity of certain cancer cells.	Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Bern, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Millennium Pharmaceut, Cambridge, MA 02139 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Bern; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Korc, M (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA.		Ishiwata, Toshiyuki/H-1151-2014; Kleeff, Jorg/B-2124-2009	Ishiwata, Toshiyuki/0000-0002-4180-0069; Kleeff, Jorg/0000-0003-3432-6669	NATIONAL CANCER INSTITUTE [R01CA075059] Funding Source: NIH RePORTER; NCI NIH HHS [CA75059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; BERGMANN U, 1995, CANCER RES, V55, P2007; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Gansauge S, 1997, CANCER RES, V57, P1634; Goggins M, 1998, CANCER RES, V58, P5329; Grau AM, 1997, CANCER RES, V57, P3929; GrondahlHansen J, 1997, BREAST CANCER RES TR, V43, P153, DOI 10.1023/A:1005744914124; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hofmann R, 1996, CANCER, V78, P487; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim IY, 1996, CANCER RES, V56, P44; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kore M, 1992, J CLIN INVEST, V90, P1352; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kornmann M, 1998, ONCOLOGY-BASEL, V55, P363, DOI 10.1159/000011879; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maesawa C, 1997, JPN J CANCER RES, V88, P340, DOI 10.1111/j.1349-7006.1997.tb00386.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; Reiss M, 1997, ONCOL RES, V9, P447; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Riggins GJ, 1997, CANCER RES, V57, P2578; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; Schutte M, 1996, CANCER RES, V56, P2527; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253	55	218	242	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5363	5372		10.1038/sj.onc.1202909	http://dx.doi.org/10.1038/sj.onc.1202909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498890				2022-12-17	WOS:000082718600001
J	Brenner, AJ; Stampfer, MR; Aldaz, CM				Brenner, AJ; Stampfer, MR; Aldaz, CM			Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation	ONCOGENE			English	Article						p16(INK4a); p21(WAF1); immortal; extended life; breast	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN FIBROBLASTS; BREAST-CANCER; IMMORTALIZATION; CULTURE; METHYLATION; GENE; P16(INK4A); CODELETION; P16/CDKN2	Aberrations affecting the tumor suppressor gene p16(INK4a) have been described for a variety of tumors. In breast cancer, approximately 50% of tumors show low or lack p16 expression. While evidence provided by some studies has implicated a possible role for p16 in normal replicative senescence, other studies have suggested that the Rb, pathway through which p16 functions, may not be involved in senescence control. Previously we observed that all immortal lines derived from normal mammary epithelium which were analysed for p16 displayed inactivation of this gene through distinct mechanisms, supporting p16 inactivation as a possible necessary event in escape from senescence. To further clarify this issue, we have analysed p16 expression in a panel of normal finite lifespan human mammary epithelial cells (HMEC) from initial propagation through growth arrest, using media which confer different replicative capacity. Approximately 10-25-fold increase in pld expression was observed for all normal HMEC with initial onset of a senescence phenotype following 15-25 population doublings in culture. These cells also displayed expression of the senescence associated beta-galactosidase, Interestingly, HMEC with additional long term replicative capacity (approximately 80 population doublings) arose from these growth arrested cultures, showing lack of pld expression. This extended growth capacity appears to be associated with a methylation phenomenon since treatment of these cells with the methylation inhibitor 5-aza-2-deoxycytidine resulted in growth arrest concurrent with reacquisition of p16 expression and senescence associated beta-galactosidase. Analysis of p21waf1 expression revealed no change in expression during growth in vitro. These results support p16(INK4a) as the 9p senescence gene and suggest a role for p16 loss in the escape from initial onset of senescence and in acquisition of an extended life span of human mammary epithelial cells.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Aldaz, CM (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Res, Smithville, TX 78957 USA.		Aldaz, C. Marcelo/E-7868-2011	Aldaz, C. Marcelo/0000-0002-2453-2939	NATIONAL CANCER INSTITUTE [R01CA024844, R37CA024844] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; BRENNER AJ, 1995, CANCER RES, V55, P2892; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYLING MH, 1995, CANCER RES, V55, P984; Foster SA, 1996, ONCOGENE, V12, P1773; GERADTS J, 1995, CANCER RES, V55, P6006; Gollahon LS, 1996, ONCOGENE, V12, P715; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HERMAN JG, 1995, CANCER RES, V55, P4525; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPFER M, 1994, CANC SURVEYS, V18, P7; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; XIAO S, 1995, ONCOGENE, V11, P511; XIAO S, 1995, CANCER RES, V55, P2968; YANG LQ, 1995, EXP CELL RES, V221, P126, DOI 10.1006/excr.1995.1359	30	218	224	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					199	205		10.1038/sj.onc.1201919	http://dx.doi.org/10.1038/sj.onc.1201919			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674704				2022-12-17	WOS:000074706700008
J	Mashima, T; Naito, M; Noguchi, K; Miller, DK; Nicholson, DW; Tsuruo, T				Mashima, T; Naito, M; Noguchi, K; Miller, DK; Nicholson, DW; Tsuruo, T			Actin cleavage by CPP-32/apopain during the development of apoptosis	ONCOGENE			English	Article						CPP-32/apopain; ICE; actin; apoptosis	PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; ICE/CED-3 PROTEASE; GENE CED-3; CRMA GENE; ENCODES; TRANSFORMATION; PRODUCT; ICE	Interleukin-1 beta-converting enzyme (ICE)/ced-3 family proteases play key roles in apoptosis, However, cellular substrates for ICE family proteases involved in apoptosis are not well understood, We previously showed that actin is cleaved in vitro by an ICE family protease, distinct from ICE itself, which is activated during VP-16-induced apoptosis, In this report, we demonstrate that the actin-cleaving ICE-family protease in the apoptotic cell extract is the activated CPP-32/apopain. CPP-32 effectively cleaves actin protein to 15 kDa and 31 kDa fragments, Studies with an antibody raised against Gly-Gln-Val-Ile-Thr peptide, the N-terminal sequence of the cleaved 15 kDa actin fragment, showed that actin is also cleaved in vivo during the development of apoptosis, Moreover, Benzyloxycarbonyl-Glu-Val-Asp-CH2OC(O)-2,6,-dichlorobenzene (Z-EVD-CH2-DCB), a selective inhibitor of CPP-32(-like) protease, efficiently inhibited the cleavage of actin and the apoptosis of VP-16-treated U937 cells, Our present results indicate that actin is the substrate of CPP-32/apopain(-like) protease both in vitro and in vivo and suggest the role of actin in the control of cell growth and apoptosis.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BIOMED RES LAB, TOKYO 113, JAPAN; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, INFLAMMAT RES, RAHWAY, NJ 07065 USA; MERCK FROSST CTR THERAPEUT RES, QUEBEC CITY, PQ H9R 4P8, CANADA; JAPANESE FDN CANC RES, CTR CANC CHEMOTHERAPY, TOKYO 170, JAPAN	University of Tokyo; Merck & Company; Merck & Company; Japanese Foundation for Cancer Research								ANTECOL MH, 1986, CANCER RES, V46, P1867; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KAKUNAGA T, 1984, FED PROC, V43, P2275; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Noguchi K, 1996, ONCOGENE, V13, P39; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDEKERCKHOVE J, 1980, CELL, V22, P893, DOI 10.1016/0092-8674(80)90566-8; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	218	223	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1007	1012		10.1038/sj.onc.1200919	http://dx.doi.org/10.1038/sj.onc.1200919			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070648				2022-12-17	WOS:A1997WM07000001
J	PATWARDHAN, S; GASHLER, A; SIEGEL, MG; CHANG, LC; JOSEPH, LJ; SHOWS, TB; LEBEAU, MM				PATWARDHAN, S; GASHLER, A; SIEGEL, MG; CHANG, LC; JOSEPH, LJ; SHOWS, TB; LEBEAU, MM			EGR3, A NOVEL MEMBER OF THE EGR FAMILY OF GENES ENCODING IMMEDIATE-EARLY TRANSCRIPTION FACTORS	ONCOGENE			English	Article							GROWTH-FACTORS ENCODES; ZINC-FINGER GENE; C-FOS; G0/G1 TRANSITION; MOLECULAR-CLONING; CULTURED-CELLS; BINDING-SITES; MESSENGER-RNA; HUMAN GENOME; EXPRESSION	We have previously described two cellular immediate-early genes, Egr-1 (mouse) and EGR2 (human) that encode zinc finger proteins. Here we report the characterization of a new member of the Egr family referred to as EGR3 (human). This cDNA clone was isolated using low stringency hybridization with the zinc finger domain of Egr-1. The EGR3 cDNA sequence predicts a 387 amino acid (a.a.) protein containing three Cys2-His2 zinc fingers nearly identical to those of Egr-1 and EGR2. This similarity has a functional consequence: EGR3 can activate transcription of a CAT gene linked to the sequence CGCCCCCGC, a cis element which is a target for Egr-1 and EGR2. We show that EGR3 is an immediate-early growth response gene induced by mitogenic stimulation of rodent and human fibroblasts and a monkey kidney epithelial cell line. The EGR3 gene has a single intron and maps to chromosome 8 at bands p21-23.	UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, HEMATOL ONCOL SECT, CHICAGO, IL 60637 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; Roswell Park Cancer Institute	LEBEAU, MM (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Groh, Margaret/0000-0002-7473-597X	NCI NIH HHS [CA40046] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA040046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; Curran T, 1988, ONCOGENE HDB, P307; DOOLITTLE RF, 1986, URFS ORFS; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARTHA S, 1987, AM J PHYSIOL, V252, pF1175, DOI 10.1152/ajprenal.1987.252.6.F1175; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAYLOR SL, 1983, J EXP MED, V157, P1020, DOI 10.1084/jem.157.3.1020; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TSUI LC, 1989, CYTOGENET CELL GENET, V51, P166, DOI 10.1159/000132791; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	56	218	225	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					917	928						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906159				2022-12-17	WOS:A1991GU62200005
J	STRATTON, MR; MOSS, S; WARREN, W; PATTERSON, H; CLARK, J; FISHER, C; FLETCHER, CDM; BALL, A; THOMAS, M; GUSTERSON, BA; COOPER, CS				STRATTON, MR; MOSS, S; WARREN, W; PATTERSON, H; CLARK, J; FISHER, C; FLETCHER, CDM; BALL, A; THOMAS, M; GUSTERSON, BA; COOPER, CS			MUTATION OF THE P53 GENE IN HUMAN SOFT-TISSUE SARCOMAS - ASSOCIATION WITH ABNORMALITIES OF THE RB1 GENE	ONCOGENE			English	Article									INST CANC RES,CHEM CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; ST THOMAS HOSP,DEPT HISTOPATHOL,LONDON SE1,ENGLAND; ROYAL MARSDEN HOSP,LONDON SW3 6JJ,ENGLAND	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust			gusterson, barry a/D-3752-2009					AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, CANCER RES, V44, P1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARVIN AJ, 1986, AM J PATHOL, V125, P208; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACKAY J, 1988, LANCET, V2, P1384; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MUNROE DG, 1988, ONCOGENE, V2, P621; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1987, ONCOGENE, V1, P71; STEFFEN D, 1978, CELL, V15, P1003, DOI 10.1016/0092-8674(78)90284-2; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	37	218	220	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1297	1301						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216456				2022-12-17	WOS:A1990EC24100004
J	Luthra, R; Singh, RR; Luthra, MG; Li, YX; Hannah, C; Romans, AM; Barkoh, BA; Chen, SS; Ensor, J; Maru, DM; Broaddus, RR; Rashid, A; Albarracin, CT				Luthra, R.; Singh, R. R.; Luthra, M. G.; Li, Y. X.; Hannah, C.; Romans, A. M.; Barkoh, B. A.; Chen, S. S.; Ensor, J.; Maru, D. M.; Broaddus, R. R.; Rashid, A.; Albarracin, C. T.			MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers	ONCOGENE			English	Article						annexin A1; miR-196a; esophageal cancer; breast cancer; endometrial cancer	ACUTE MYELOID-LEUKEMIA; MICROARRAY ANALYSIS; PROSTATE-CANCER; MESSENGER-RNAS; EXPRESSION; CELLS; ESOPHAGEAL; APOPTOSIS; PROTEIN; CARCINOMA	Suppression of annexin A1 (ANXA1), a mediator of apoptosis and inhibitor of cell proliferation, is well documented in various cancers but the underlying mechanism remains unknown. We investigated whether decreased ANXA1 expression was mediated by microRNAs (miRNAs), which are small, non-coding RNAs that negatively regulate gene expression. Using Sanger miR-Base, we identified miR-584, miR-196a and miR-196b as potential miRNAs targeting ANXA1. Only miRNA-196a showed significant inverse correlation with ANXA1 mRNA levels in 12 cancer cell lines of esophageal, breast and endometrial origin (Pearson's correlation -0.66, P=0.019), identifying this as the candidate miRNA targeting ANXA1. Inverse correlation was also observed in 10 esophageal adenocarcinomas (Pearson's correlation -0.64, P=0.047). Analysis of paired normal/tumor tissues from additional 10 patients revealed an increase in miR-196a in the cancers (P=0.003), accompanied by a decrease in ANXA1 mRNA (P=0.004). Increasing miR-196a levels in cells by miR-196a mimics resulted in decreased ANXA1 mRNA and protein. In addition, miR-196a mimics inhibited luciferase expression in luciferase plasmid reporter that included predicted miR-196a recognition sequence from ANXA1 3'-untranslated region conforming that miR-196a directly targets ANXA1. miR-196a promoted cell proliferation, anchorage-independent growth and suppressed apoptosis, suggesting its oncogenic potential. This study demonstrated a novel mechanism of post-transcriptional regulation of ANXA1 expression and identified miR-196a as a marker of esophageal cancer.	[Luthra, R.] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Hematopathol, Houston, TX 77054 USA; [Luthra, M. G.; Li, Y. X.; Maru, D. M.; Broaddus, R. R.; Rashid, A.; Albarracin, C. T.] Univ Texas MD Anderson Canc Ctr, Dept Anat Pathol, Houston, TX 77054 USA; [Chen, S. S.] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77054 USA; [Ensor, J.] Univ Texas MD Anderson Canc Ctr, Dept Quantitat Sci, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Luthra, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Hematopathol, 8515 Fannin St,NAO1-091, Houston, TX 77054 USA.	rluthra@mdanderson.org		Ensor, Joe/0000-0003-3533-4388	Goodwin Fund for Target Molecular Diagnosis; Institutional Research; NIH [1P50CA098258-01]; NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER	Goodwin Fund for Target Molecular Diagnosis; Institutional Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dawn Chalaire for critical editing of the manuscript and James M Gilbert and Kim-Anh Vu for assistance with preparation of the manuscript and illustrations. We also thank Drs Raju, Izzo and Liu of MD Anderson Cancer Center for providing the cell lines used in the study. This study was supported by Goodwin Fund for Target Molecular Diagnosis and Institutional Research Grant (CT Albarracin), NIH 1P50CA098258-01, SPORE in Uterine Cancer (RR Broaddus).	Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bai XF, 2004, WORLD J GASTROENTERO, V10, P1466; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Debernardi S, 2007, LEUKEMIA, V21, P912, DOI 10.1038/sj.leu.2404605; Debret R, 2003, FEBS LETT, V546, P195, DOI 10.1016/S0014-5793(03)00570-2; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Hsiang CH, 2006, PROSTATE, V66, P1413, DOI 10.1002/pros.20457; Hu N, 2004, CLIN CANCER RES, V10, P6013, DOI 10.1158/1078-0432.CCR-04-0317; JOHNSON MD, 1989, HUM PATHOL, V20, P772, DOI 10.1016/0046-8177(89)90071-3; Kang JS, 2002, CLIN CANCER RES, V8, P117; Kimchi ET, 2005, CANCER RES, V65, P3146, DOI 10.1158/0008-5472.CAN-04-2490; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Luthra R, 2006, J CLIN ONCOL, V24, P259, DOI 10.1200/JCO.2005.03.3688; Masaki T, 1996, HEPATOLOGY, V24, P72, DOI 10.1002/hep.510240114; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Paweletz CP, 2000, CANCER RES, V60, P6293; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Sakamoto T, 1996, BIOCHEM BIOPH RES CO, V220, P643, DOI 10.1006/bbrc.1996.0457; Shen DJ, 2006, HUM PATHOL, V37, P1583, DOI 10.1016/j.humpath.2006.06.001; Sinha P, 1998, J BIOCHEM BIOPH METH, V37, P105, DOI 10.1016/S0165-022X(98)00020-7; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Vishwanatha JK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-8; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	30	217	226	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	52					6667	6678		10.1038/onc.2008.256	http://dx.doi.org/10.1038/onc.2008.256			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18663355				2022-12-17	WOS:000260638800005
J	Vaquero, A; Sternglanz, R; Reinberg, D				Vaquero, A.; Sternglanz, R.; Reinberg, D.			NAD(+)-dependent deacetylation of H4 lysine 16 by class IIIHDACs	ONCOGENE			English	Review						H4K16Ac; SIRT1; SIRT2; SIRT3; HDAC; chromatin	NAD-DEPENDENT DEACETYLASE; YEAST HISTONE H4; REPLICATIVE LIFE-SPAN; ACETYL-COA SYNTHETASE; SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; SIR2 HOMOLOG; CELL-CYCLE; METHYLTRANSFERASE ACTIVITY	Histone deacetylases ( HDACs) catalyse the removal of acetyl groups from the N-terminal tails of histones. All known HDACs can be categorized into one of four classes (I-IV). The class III HDAC or silencing information regulator 2 ( Sir2) family exhibits characteristics consistent with a distinctive role in regulation of chromatin structure. Accumulating data suggest that these deacetylases acquired new roles as genomic complexity increased, including deacetylation of non-histone proteins and functional diversification in mammals. However, the intrinsic regulation of chromatin structure in species as diverse as yeast and humans, underscores the pressure to conserve core functions of class III HDACs, which are also known as Sirtuins. One of the key factors that might have contributed to this preservation is the intimate relationship between some members of this group of proteins ( SirT1, SirT2 and SirT3) and deacetylation of a specific residue in histone H4, lysine 16 ( H4K16). Evidence accumulated over the years has uncovered a unique role for H4K16 in chromatin structure throughout eukaryotes. Here, we review the recent findings about the functional relationship between H4K16 and the Sir2 class of deacetylases and how that relationship might impact aging and diseases including cancerand diabetes.	NYU, Sch Med, Dept Biochem, Howard Hughes Med Inst,Smilow Res Ctr, New York, NY 10016 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; ICREA, Barcelona, Spain; CSIC, IBMB, Barcelona, Spain	Howard Hughes Medical Institute; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; ICREA; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Reinberg, D (corresponding author), NYU, Sch Med, Dept Biochem, Howard Hughes Med Inst,Smilow Res Ctr, 522 1st Ave,2nd Floor,Room 211, New York, NY 10016 USA.	reinbd01@med.nyu.edu	Vaquero, Alejandro/I-9845-2014; Vaquero, Alejandro/ABG-8634-2020	Vaquero, Alejandro/0000-0002-8735-4156; Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM028220, R01GM064844, R01GM028220] Funding Source: NIH RePORTER; ICREA Funding Source: Custom; NIGMS NIH HHS [GM28220, GM64844] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ICREA(ICREA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agricola E, 2006, MOL MICROBIOL, V62, P1433, DOI 10.1111/j.1365-2958.2006.05451.x; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bell E, 2002, NAT REV IMMUNOL, V2, P148, DOI 10.1038/nri752; Belyaev ND, 1997, CHROMOSOMA, V106, P193, DOI 10.1007/s004120050239; Benson LJ, 2006, J BIOL CHEM, V281, P9287, DOI 10.1074/jbc.M512956200; Bernander R, 2003, MOL MICROBIOL, V48, P599, DOI 10.1046/j.1365-2958.2003.03414.x; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calestagne-Morelli A, 2006, BIOCHEM CELL BIOL, V84, P518, DOI 10.1139/O06-067; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chiani F, 2006, NUCLEIC ACIDS RES, V34, P5426, DOI 10.1093/nar/gkl678; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Clapier CR, 2002, NUCLEIC ACIDS RES, V30, P649, DOI 10.1093/nar/30.3.649; CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Furuyama T, 2004, CURR BIOL, V14, P1812, DOI 10.1016/j.cub.2004.09.060; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Glowczewski L, 2004, MOL CELL BIOL, V24, P10180, DOI 10.1128/MCB.24.23.10180-10192.2004; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guarente L, 2005, MECH AGEING DEV, V126, P923, DOI 10.1016/j.mad.2005.03.013; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Halme A, 2004, CELL, V116, P405, DOI 10.1016/S0092-8674(04)00118-7; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Henikoff S, 2005, P NATL ACAD SCI USA, V102, P5308, DOI 10.1073/pnas.0501853102; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jasencakova Z, 2000, PLANT CELL, V12, P2087, DOI 10.1105/tpc.12.11.2087; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kume S, 2007, J BIOL CHEM, V282, P151, DOI 10.1074/jbc.M605904200; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lavender JS, 1994, CHROMOSOME RES, V2, P398, DOI 10.1007/BF01552799; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Marmorstein R, 2004, BIOCHEM SOC T, V32, P904, DOI 10.1042/BST0320904; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; Millar CB, 2006, COLD SPRING HARB SYM, V69, P193; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; O'Neill LP, 2006, NAT GENET, V38, P835, DOI 10.1038/ng1820; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S; Polevoda B, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-5-reviews0006; Polo SE, 2006, CURR OPIN GENET DEV, V16, P104, DOI 10.1016/j.gde.2006.02.011; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rose G, 2003, EXP GERONTOL, V38, P1065, DOI 10.1016/S0531-5565(03)00209-2; Rosenberg MI, 2002, CELL, V109, P447, DOI 10.1016/S0092-8674(02)00732-8; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004; Sakurada K, 1996, J BACTERIOL, V178, P5781, DOI 10.1128/jb.178.19.5781-5786.1996; Sandmeier JJ, 2002, GENETICS, V160, P877; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Shia WJ, 2006, GENE DEV, V20, P2507, DOI 10.1101/gad.1439206; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith CM, 2003, ANAL BIOCHEM, V316, P23, DOI 10.1016/S0003-2697(03)00032-0; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; Tsuchiya M, 2006, AGING CELL, V5, P505, DOI 10.1111/j.1474-9726.2006.00240.x; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; van Leeuwen F, 2002, CURR OPIN CELL BIOL, V14, P756, DOI 10.1016/S0955-0674(02)00393-9; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; VAQUERO A, UNPUB; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaquero Alejandro, 2006, P23; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wilson JM, 2006, EMBO REP, V7, P1247, DOI 10.1038/sj.embor.7400829; Xie JX, 1999, EMBO J, V18, P6448, DOI 10.1093/emboj/18.22.6448; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu YC, 2005, P NATL ACAD SCI USA, V102, P8650, DOI 10.1073/pnas.0501458102; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057	167	217	227	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5505	5520		10.1038/sj.onc.1210617	http://dx.doi.org/10.1038/sj.onc.1210617			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694090				2022-12-17	WOS:000248674300017
J	Chen, A; Xu, J; Johnson, AC				Chen, A; Xu, J; Johnson, AC			Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1	ONCOGENE			English	Article						colon cancer; receptors; phyto-chemical; gene expression; chemo-prevention	NF-KAPPA-B; SERUM RESPONSE ELEMENTS; TERNARY COMPLEX FACTORS; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION; MALIGNANCIES; CONTRIBUTES; INDUCTION; APOPTOSIS	High expression of epidermal growth factor receptor (EGFR) is found in a variety of solid tumors, including colorectal cancer. EGFR has been identified as a rational target for anticancer therapy. Curcumin, the yellow pigment of turmeric in curry, has received attention as a promising dietary supplement for cancer prevention and treatment. We recently reported that curcumin inhibited the growth of human colon cancer-derived Moser cells by suppressing gene expression of cyclinD1 and EGFR. The aim of the present study was to explore the molecular mechanisms underlying curcumin inhibition of gene expression of EGFR in colon cancer cells. The generality of the inhibitory effect of curcumin on gene expression of EGFR was verified in other human colon cancer-derived cell lines, including Caco-2 and HT-29 cells. Promoter deletion assays and site-directed mutageneses identified a binding site for the transcription factor early growth response-1 (Egr-1) in egfr promoter as a putative curcumin response element in regulating the promoter activity of the gene in Moser cells. Electrophoretic mobility shift assays demonstrated that curcumin significantly reduced the DNA-binding activity of the transcription factor Egr-1 to the curcumin response element. In addition, curcumin reduced the trans-activation activity of Egr-1 by suppressing egr-1 gene expression, which required interruption of the ERK signal pathway and reduction of the level of phosphorylation of Elk-1 and its activity. Taken together, our results demonstrated that curcumin inhibited human colon cancer cell growth by suppressing gene expression of EGFR through reducing the trans-activation activity of Egr-1. These results provided novel insights into the mechanisms of curcumin inhibition of colon cancer cell growth and potential therapeutic strategies for treatment of colon cancer.	Louisiana State Univ, HSC, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA USA; NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chen, A (corresponding author), Louisiana State Univ, HSC, Dept Pathol, BRI F8-20,1501 Kings Hwy, Shreveport, LA 71130 USA.	achen@lsuhsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047995] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47995] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Andrade AA, 2004, BIOCHEM J, V381, P437, DOI 10.1042/BJ20031375; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Baselga J, 2000, ANN ONCOL, V11, P187, DOI 10.1023/A:1011144502974; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chauhan DP, 2002, CURR PHARM DESIGN, V8, P1695, DOI 10.2174/1381612023394016; Chen AP, 2002, BIOCHEM J, V368, P695, DOI 10.1042/BJ20020894; Chen AP, 2005, AM J PHYSIOL-GASTR L, V288, pG447, DOI 10.1152/ajpgi.00209.2004; Chen AP, 2002, AM J PHYSIOL-GASTR L, V283, pG864, DOI 10.1152/ajpgi.00524.2001; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Chen CC, 2004, J CELL BIOCHEM, V93, P1063, DOI 10.1002/jcb.20257; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Giri RK, 2004, J NEUROCHEM, V91, P1199, DOI 10.1111/j.1471-4159.2004.02800.x; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Harja E, 2004, CIRC RES, V94, P333, DOI 10.1161/01.RES.0000112405.61577.95; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jobin C, 1999, J IMMUNOL, V163, P3474; Kamimura M, 2004, HYPERTENSION, V44, P944, DOI 10.1161/01.HYP.0000146908.75091.99; LEVINE AE, 1985, CANCER RES, V45, P2248; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Mohandas K M, 1999, Indian J Gastroenterol, V18, P118; Nishi H, 2002, CANCER RES, V62, P827; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; Pendurthi UR, 2000, THROMB RES, V97, P179, DOI 10.1016/S0049-3848(99)00148-6; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rowinsky E, 2000, DRUGS, V60, P41; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schaefer A, 2004, CELL SIGNAL, V16, P223, DOI 10.1016/j.cellsig.2003.07.001; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Xu JY, 2003, AM J PHYSIOL-GASTR L, V285, pG20, DOI 10.1152/ajpgi.00474.2002; Zheng Liduan, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P55	48	217	231	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					278	287		10.1038/sj.onc.1209019	http://dx.doi.org/10.1038/sj.onc.1209019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170359				2022-12-17	WOS:000234583600012
J	Reynolds, AB; Roczniak-Ferguson, A				Reynolds, AB; Roczniak-Ferguson, A			Emerging roles for p120-catenin in cell adhesion and cancer	ONCOGENE			English	Review						cell adhesion; p120 catenin; cadherin; Rho; Rac; tumor suppressor	PROTEIN-KINASE-C; E-CADHERIN; P120 CATENIN; TYROSINE-KINASE; BETA-CATENIN; GROWTH-FACTOR; BINDING-PROTEIN; ALPHA-CATENIN; PARTNER KAISO; SMALL GTPASES	Although originally identified as a Src substrate, p120-catenin (p120) is now known to regulate cell-cell adhesion through its interaction with the cytoplasmic tail of classical and type II cadherins. New evidence indicates that p120 regulates cadherin turnover at the cell surface, thereby controlling the amount of cadherin available for cell-cell adhesion. This function is necessary but not sufficient to promote strong adhesion, which is further controlled by signals acting on the amino-terminal p120 regulatory domain. p120 also modulates the activities of RhoA, Rac, and Cdc42, suggesting that along with other Src substrates, p120 regulates actin dynamics. Thus, p120 is a master regulator of cadherin abundance and activity, and likely participates in regulating the balance between adhesive and motile cellular phenotypes. This review summarizes recent progress in understanding mechanisms of p120 action, and discusses new implications with respect to roles for p120 in disease and cancer.	Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University	Reynolds, AB (corresponding author), Vanderbilt Univ, Dept Canc Biol, 771PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	al.reynolds@vanderbilt.edu						Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; DOWNING JR, 1991, ONCOGENE, V6, P607; Fang X, 2004, J CELL BIOL, V165, P87, DOI 10.1083/jcb.200307109; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grosheva I, 2001, J CELL SCI, V114, P695; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kallakury BVS, 2001, HUM PATHOL, V32, P849, DOI 10.1053/hupa.2001.26463; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Karayiannakis AJ, 1998, J PATHOL, V185, P413; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KIM L, 1995, MOL CELL BIOL, V15, P4553; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Konstantoulaki M, 2003, AM J PHYSIOL-LUNG C, V285, pL434, DOI 10.1152/ajplung.00075.2003; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Magie Craig R., 2002, Development (Cambridge), V129, P3771; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nieman MT, 1999, J CELL SCI, V112, P1621; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pettitt J, 2003, J CELL BIOL, V162, P15, DOI 10.1083/jcb.200212136; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Ratcliffe MJ, 1997, J BIOL CHEM, V272, P31894, DOI 10.1074/jbc.272.50.31894; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Roczniak-Ferguson A, 2003, J CELL SCI, V116, P4201, DOI 10.1242/jcs.00724; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Troxell ML, 1999, AM J PHYSIOL-CELL PH, V276, pC404, DOI 10.1152/ajpcell.1999.276.2.C404; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wong EYM, 2000, BIOCHEM J, V346, P209, DOI 10.1042/0264-6021:3460209; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Xu G, 2004, J CELL SCI, V117, P3207, DOI 10.1242/jcs.01174; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zhu AJ, 1996, J CELL SCI, V109, P3013; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	84	217	231	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7947	7956		10.1038/sj.onc.1208161	http://dx.doi.org/10.1038/sj.onc.1208161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489912				2022-12-17	WOS:000224558300005
J	D'Assoro, AB; Lingle, WL; Salisbury, JL				D'Assoro, AB; Lingle, WL; Salisbury, JL			Centrosome amplification and the development of cancer	ONCOGENE			English	Review						aneuploidy; cell cycle; centriole; chromosomal instability	HUMAN-PAPILLOMAVIRUS TYPE-16; CELL-CYCLE PROGRESSION; HUMAN PROTEIN-KINASE; GENOMIC INSTABILITY; GENETIC INSTABILITY; CHROMOSOMAL INSTABILITY; SUBCELLULAR-LOCALIZATION; MICROTUBULE DYNAMICS; P53; ABNORMALITIES		Mayo Clin, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Salisbury, JL (corresponding author), Mayo Clin, Tumor Biol Program, Rochester, MN 55905 USA.	salisbury@mayo.edu		Salisbury, Jeffrey/0000-0001-9257-4578				Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; DASSORO AB, 2002, IN PRESS BREAST CANC; DEBEC A, 1992, BIOL CELL, V75, P121, DOI 10.1016/0248-4900(92)90131-J; Deng CX, 2000, BIOESSAYS, V22, P728; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; DONCHOWER LA, 1992, NATURE, V356, P215; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; DUENSING S, 2002, IN PRESS ONCOGENE; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Duesberg P, 1999, SCIENCE, V284, P2091; Dutcher SK, 2001, CURR BIOL, V11, pR419, DOI 10.1016/S0960-9822(01)00250-0; Dutcher SK, 2001, CURR OPIN CELL BIOL, V13, P49, DOI 10.1016/S0955-0674(00)00173-3; DUTERTRE, 2002, IN PRESS ONCOGENE; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; FRIEDLANDER M, 1982, J SUBMICR CYTOL PATH, V14, P401; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 2000, J CELL SCI, V113, P1973; Fry AM, 2000, CURR TOP DEV BIOL, V49, P291; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Gustafson LM, 2000, LARYNGOSCOPE, V110, P1798; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Helps NR, 1998, J CELL SCI, V111, P1331; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HINCHCLIFFE EH, 2002, IN PRESS ONCOGENE; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 2002, IN PRESS ONCOGENE; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; KANEKO H, 1980, ACTA PATHOL JAPON, V30, P651; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Keezer SM, 2002, EXP CELL RES, V273, P54, DOI 10.1006/excr.2001.5421; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; Keryer G, 1999, EXP CELL RES, V249, P131, DOI 10.1006/excr.1999.4447; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.040529797; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Meraldi P, 2001, J CELL SCI, V114, P3749; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MITELMAN F, 1994, CA-CANCER J CLIN, V44, P133, DOI 10.3322/canjclin.44.3.133; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OKUDA M, 2002, IN PRESS ONCOGENE; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Passalacqua M, 1999, BIOCHEM J, V337, P113, DOI 10.1042/0264-6021:3370113; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; RAO PN, 1989, J CELL SCI, V93, P63; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; Roghi C, 1998, J CELL SCI, V111, P557; Salisbury JL, 1999, J HISTOCHEM CYTOCHEM, V47, P1265, DOI 10.1177/002215549904701006; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schatten H, 2000, BIOL CELL, V92, P331, DOI 10.1016/S0248-4900(00)01079-0; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; SEIFERT HW, 1978, ARCH DERMATOL RES, V263, P159, DOI 10.1007/BF00446437; SHARP GA, 1981, J CELL SCI, V47, P1; SHARP GA, 1982, EUR J CELL BIOL, V29, P97; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Skyldberg B, 2001, MODERN PATHOL, V14, P279, DOI 10.1038/modpathol.3880303; Sluder G, 1998, CELL BIOL INT, V22, P3, DOI 10.1006/cbir.1997.0249; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; TARAPORE P, 2002, IN PRESS ONCOGENE; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; VANDRE DD, 1989, J CELL SCI, V94, P245; Vandre DD, 2000, MICROSC RES TECHNIQ, V49, P458; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; Whitehead CM, 1998, J CELL SCI, V111, P2551; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wu L, 1998, J CELL BIOL, V141, P1575, DOI 10.1083/jcb.141.7.1575; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	136	217	229	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6146	6153		10.1038/sj.onc.1205772	http://dx.doi.org/10.1038/sj.onc.1205772			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214243				2022-12-17	WOS:000177840500002
J	Holcik, M; Yeh, C; Korneluk, RG; Chow, T				Holcik, M; Yeh, C; Korneluk, RG; Chow, T			Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death	ONCOGENE			English	Article						IAP; radiation induced cell death; IRES; translation	CANCER; SURVIVIN; GENE; THERAPY	Inhibitory regulators of apoptosis play a critical role in the responsiveness of tumour cells to cytotoxic agents. The X-linked inhibitor of apoptosis protein (XIAP) is a member of a novel family of Inhibitor of Apoptosis (IAP) proteins. Here we show that acute lon dose ionizing irradiation results in the translational upregulation of XIAP that correlates with an increased resistance to radiation in non-small cell lung carcinoma. This upregulation is mediated by an internal ribosome binding mechanism, ia an IRES element located within a XIAP 5' UTR. Transient overexpression of XIAP rendered human carcinoma cells resistant to low dose gamma-irradiation. By contrast, the antisense targeting of XIAP resulted in increased cell death following irradiation advocating a distinct role for XIAP in radiation resistant phenotype of human cancers.	Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON K1H 8L1, Canada; Apoptogen Inc, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1A4, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; McGill University	Korneluk, RG (corresponding author), Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Holcik, Martin/A-9768-2008; Holcik, Martin/AAC-6660-2019; Holcik, Martin/E-5372-2011	Holcik, Martin/0000-0002-1922-5299; 				Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bold RJ, 1997, SURG ONCOL, V6, P133, DOI 10.1016/S0960-7404(97)00015-7; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu CD, 1998, CANCER RES, V58, P1808; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Withers HR, 1999, CANCER RES, V59, p1676S; Yount GL, 1998, CANCER RES, V58, P3819; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	20	217	233	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4174	4177		10.1038/sj.onc.1203765	http://dx.doi.org/10.1038/sj.onc.1203765			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962579				2022-12-17	WOS:000088955100012
J	COLLINS, N; MCMANUS, R; WOOSTER, R; MANGION, J; SEAL, S; LAKHANI, SR; ORMISTON, W; DALY, PA; FORD, D; EASTON, DF; STRATTON, MR				COLLINS, N; MCMANUS, R; WOOSTER, R; MANGION, J; SEAL, S; LAKHANI, SR; ORMISTON, W; DALY, PA; FORD, D; EASTON, DF; STRATTON, MR			CONSISTENT LOSS OF THE WILD-TYPE ALLELE IN BREAST CANCERS FROM A FAMILY LINKED TO THE BRCA2 GENE ON CHROMOSOME 13Q12-13	ONCOGENE			English	Note						BREAST CANCER; GENETICS; LOSS OF HETEROZYGOSITY	RETINOBLASTOMA; HETEROZYGOSITY; CARCINOMA; REGION	A small proportion of breast cancer is attributable to the inheritance of dominant, high penetrance susceptibility genes. One of these genes, BRCA2, has recently been localised by genetic linkage analysis to chromosome 13q12-13, This is a region known to exhibit loss of heterozygosity in 20-40% sporadic breast cancers, In this study, we have examined cancers from a family showing strong evidence of linkage to BRCA2. LOH was seen in seven out of eight informative cancers, In all cases the allele lost was the wild type allele that does not segregate with the disease in the family. The data suggest that both alleles of BRCA2 are inactivated in cancers, the pattern expected of a recessive oncogene or tumour suppressor gene.	ROYAL MARSDEN HOSP,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; ROYAL MARSDEN HOSP,INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND; UNIV IRELAND TRINITY COLL,ST JAMES HOSP,SCH MED,DEPT MED,DUBLIN 8,IRELAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Trinity College Dublin; Trinity College Dublin			McManus, Ross/AAE-9236-2020; Lakhani, Sunil/I-1970-2018	McManus, Ross/0000-0002-0529-9617; Lakhani, Sunil/0000-0003-4067-2760				CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; GERSDORFSTEICHE.E, 1994, AM J HUM GENET, V55, P870; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; STRATTON MR, 1995, IN PRESS J PATHOL; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	14	217	219	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1673	1675						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731724				2022-12-17	WOS:A1995QU68100026
J	BOLEN, JB				BOLEN, JB			NONRECEPTOR TYROSINE PROTEIN-KINASES	ONCOGENE			English	Review							CELL ANTIGEN RECEPTOR; EXPRESS HIGH-LEVELS; C-ABL; SRC-FAMILY; SIGNAL TRANSDUCTION; TRANSFORMING PROTEIN; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; CATALYTIC DOMAINS; MOLECULAR-CLONING				BOLEN, JB (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA.							APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWE C, 1993, IN PRESS P NATL ACAD; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MATHEYPREVOT B, 1982, CELL, V28, P897, DOI 10.1016/0092-8674(82)90069-1; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1990, ONCOGENE, V5, P1437; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEFTON BM, 1991, ONCOGENE, V6, P683; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TOSHIHIKO T, 1992, BLOOD, V80, P617; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	101	217	378	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2025	2031						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336932				2022-12-17	WOS:A1993LP17100001
J	MASHIYAMA, S; MURAKAMI, Y; YOSHIMOTO, T; SEKIYA, T; HAYASHI, K				MASHIYAMA, S; MURAKAMI, Y; YOSHIMOTO, T; SEKIYA, T; HAYASHI, K			DETECTION OF P53 GENE-MUTATIONS IN HUMAN BRAIN-TUMORS BY SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS OF POLYMERASE CHAIN-REACTION PRODUCTS	ONCOGENE			English	Article							POINT MUTATIONS; HUMAN GLIOMA; LUNG-CANCER; TRANSFORMATION; DNA; ONCOGENE; NEUROFIBROMATOSIS; RAS; ABNORMALITIES; AMPLIFICATION	Single-strand conformation polymorphism analysis of polymerase chain reaction products (PCR-SSCP analysis) was used for detection of mutations of the p53 gene in surgical specimens of human brain tumors. Six of 45 brain tumors showed mobility shifts in the analyses. These six tumors also showed loss of a normal allele. The samples were examined further by direct sequencing. Results showed that four of them had single-base substitutions and the other two had deletions of one and eight base pairs. Five of the six mutations detected were clustered in highly conserved regions of the p53 gene. The frequency of p53 gene mutations in primary brain tumors examined was 9.8%. We also found two new polymorphic markers in the p53 gene, one in intron 7 and the other in an Alu repeat in exon 11. Both markers could be detected by SSCP analysis. Using these two markers, we found two cases of loss of heterozygosity in other brain tumor specimens. Results suggested that aberrations of the p53 gene were not correlated with the malignancy of some types of brain tumors such as anaplastic astrocytoma and glioblastoma, contrary to previous observations on colorectal cancers.	NATL CANC CTR,RES INST,DIV ONCOGENE,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; TOHOKU UNIV,SCH MED,INST BRAIN DIS,DIV NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	National Cancer Center - Japan; Tohoku University								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGNER SH, 1988, CANCER RES, V48, P405; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HENN W, 1986, HUM GENET, V74, P104; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUMPHREY PA, 1988, CANCER RES, V48, P2231; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; MACKAY J, 1988, LANCET, V2, P1384; MASHIYAMA S, 1990, Technique (Philadelphia), V2, P304; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNROE DG, 1988, ONCOGENE, V2, P621; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROHRINGER M, 1989, J NEUROSURG, V71, P665, DOI 10.3171/jns.1989.71.5.0665; RUSSELL DS, 1977, PATHOLOGY TUMORS NER; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SOUSSI T, 1990, ONCOGENE, V5, P945; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	41	217	219	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1313	1318						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886708				2022-12-17	WOS:A1991GX27200003
J	Dong, P; Karaayvaz, M; Jia, N; Kaneuchi, M; Hamada, J; Watari, H; Sudo, S; Ju, J; Sakuragi, N				Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N.			Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis	ONCOGENE			English	Article						EMT; cancer; gain-of-function; miRNA; p53 mutation	ENDOMETRIAL CANCER-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SUPPRESSES METASTASIS; MICRORNA EXPRESSION; DNA-BINDING; PROMOTES; ZEB1; CONTRIBUTES; REPRESSION	The tumor suppressor gene p53 has been implicated in the regulation of epithelial-mesenchymal transition (EMT) and tumor metastasis by regulating microRNA (miRNA) expression. Here, we report that mutant p53 exerts oncogenic functions and promotes EMT in endometrial cancer (EC) by directly binding to the promoter of miR-130b (a negative regulator of ZEB1) and inhibiting its transcription. We transduced p53 mutants into p53- null EC cells, profiled the miRNA expression by miRNA microarray and identified miR-130b as a potential target of mutant p53. Ectopic expression of p53 mutants repressed the expression of miR-130b and triggered ZEB1-dependent EMT and cancer cell invasion. Loss of an endogenous p53 mutation increased the expression of miR-130b, which resulted in reduced ZEB1 expression and attenuation of the EMT phenotype. Furthermore, re-expression of miR-130b suppressed mutant p53- induced EMT and ZEB1 expression. Importantly, the expression of miR-130 was significantly reduced in EC tissues, and patients with higher expression levels of miR-130b survived longer. These data provide a novel understanding of the roles of p53 gain-of-function mutations in accelerating tumor progression and metastasis through modulation of the miR-130b-ZEB1 axis.	[Dong, P.; Kaneuchi, M.; Watari, H.; Sudo, S.; Sakuragi, N.] Hokkaido Univ, Sch Med, Dept Gynecol, Sapporo, Hokkaido 0608638, Japan; [Karaayvaz, M.; Ju, J.] SUNY Stony Brook, Dept Pathol, Med Ctr, Stony Brook, NY 11794 USA; [Jia, N.] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China; [Hamada, J.] Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Shanghai Jiao Tong University; Hokkaido University	Dong, P (corresponding author), Hokkaido Univ, Sch Med, Dept Gynecol, Sapporo, Hokkaido 0608638, Japan.	dongpeix@yahoo.co.jp; Jingfang.Ju@stonybrookmedicine.edu	Dong, Peixin/M-5592-2015	Dong, Peixin/0000-0002-2335-1394; Ju, Jingfang/0000-0002-4821-7458	Women's Health Educational System; Ministry of Health, Labour and Welfare of Japan; Shanghai Municipal Natural Science Foundation [11ZR1430500]; Stony Brook University Translational Research Laboratory Start-up fund [R01CA155019, R33CA147966]; NATIONAL CANCER INSTITUTE [R33CA147966] Funding Source: NIH RePORTER	Women's Health Educational System; Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Shanghai Municipal Natural Science Foundation; Stony Brook University Translational Research Laboratory Start-up fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the critical review by Ms Sonya R Lorrain. This work was funded by a grant from Women's Health Educational System, a Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan, Shanghai Municipal Natural Science Foundation (11ZR1430500) and by Stony Brook University Translational Research Laboratory Start-up fund (J Ju), R01CA155019 (J Ju) and R33CA147966 (J Ju). We thank Dr Zhujie Xu for his technical assistance.	Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Forrest ARR, 2010, LEUKEMIA, V24, P460, DOI 10.1038/leu.2009.246; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Fujisawa T, 2003, Hum Cell, V16, P47, DOI 10.1111/j.1749-0774.2003.tb00128.x; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Kogan-Sakin I, 2011, CELL DEATH DIFFER, V18, P271, DOI 10.1038/cdd.2010.94; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Navon R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008003; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh M, 2008, MODERN PATHOL, V21, P912, DOI 10.1038/modpathol.2008.82; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xi YG, 2006, BIOMARK INSIGHTS, V1, P113; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Yang C, 2012, GYNECOL ONCOL, V124, P325, DOI 10.1016/j.ygyno.2011.10.013; Yip L, 2011, ANN SURG ONCOL, V18, P2035, DOI 10.1245/s10434-011-1733-0; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; ZHANG W, 1993, ONCOGENE, V8, P2555	49	216	227	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3286	3295		10.1038/onc.2012.334	http://dx.doi.org/10.1038/onc.2012.334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22847613	Green Published, hybrid			2022-12-17	WOS:000321301600008
J	Wolf, I; Levanon-Cohen, S; Bose, S; Ligumsky, H; Sredni, B; Kanety, H; Kuro-o, M; Karlan, B; Kaufman, B; Koeffler, HP; Rubinek, T				Wolf, I.; Levanon-Cohen, S.; Bose, S.; Ligumsky, H.; Sredni, B.; Kanety, H.; Kuro-o, M.; Karlan, B.; Kaufman, B.; Koeffler, H. P.; Rubinek, T.			Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer	ONCOGENE			English	Article						breast cancer; klotho; insulin; insulin growth factor-1; tumor suppressor	GROWTH-FACTOR CONFERS; ADIPOCYTE DIFFERENTIATION; MOLECULAR-CLONING; TRPV5 CHANNEL; C/EBP-BETA; CELLS; PROTEIN; MOUSE; ACTIVATION; INHIBITION	Klotho is an anti-aging gene, which has been shown to inhibit the insulin and insulin-like growth factor 1 (IGF-1) pathways in mice hepatocytes and myocytes. As IGF-1 and insulin regulate proliferation, survival and metastasis of breast cancer, we studied klotho expression and activities in human breast cancer. Immunohistochemistry analysis of klotho expression in breast tissue arrays revealed high klotho expression in normal breast samples, but very low expression in breast cancer. In cancer samples, high klotho expression was associated with smaller tumor size and reduced KI67 staining. Forced expression of klotho reduced proliferation of MCF-7 and MDA-MB-231 breast cancer cells, whereas klotho silencing in MCF-7 cells, which normally express klotho, enhanced proliferation. Moreover, forced expression of klotho in these cells, or treatment with soluble klotho, inhibited the activation of IGF-1 and insulin pathways, and induced upregulation of the transcription factor CCAAT/enhancer-binding protein beta, a breast cancer growth inhibitor that is negatively regulated by the IGF-1-AKT axis. Co-immunoprecipitation revealed an interaction between klotho and the IGF-1 receptor. Klotho is also a known modulator of the fibroblast growth factor (FGF) pathway, a pathway that inhibits proliferation of breast cancer cells. Studies in breast cancer cells revealed increased activation of the FGF pathway by basic FGF following klotho overexpression. Klotho did not affect activation of the epidermal growth factor pathway in breast cancer cells. These data suggest klotho as a potential tumor suppressor and identify it as an inhibitor of the IGF-1 pathway and activator of the FGF pathway in human breast cancer.	[Wolf, I.; Levanon-Cohen, S.; Ligumsky, H.; Kaufman, B.; Rubinek, T.] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel; [Wolf, I.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Levanon-Cohen, S.; Sredni, B.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Safdie Inst AIDS & Immunol Res, Ramat Gan, Israel; [Bose, S.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Anat Pathol, Los Angeles, CA 90048 USA; [Kanety, H.] Chaim Sheba Med Ctr, Inst Endocrinol, Ramat Gan, Israel; [Kuro-o, M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Karlan, B.] Womens Canc Res Inst, Dept Obstet & Gynecol, Los Angeles, CA USA; [Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Bar Ilan University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chaim Sheba Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wolf, I (corresponding author), Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel.	wolf-i@inter.net.il			United States-Israel Binational Science Foundation (BSF) Jerusalem, Israel; Koschitzky Family Foundation; Israel Cancer Association; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel; The Talpiot Medical Leadership Program, Sheba Medical Center; Inger Fund; Rountree Trust; Mary Barry Foundation; Women's Cancer Research Institute; Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center	United States-Israel Binational Science Foundation (BSF) Jerusalem, Israel(US-Israel Binational Science Foundation); Koschitzky Family Foundation; Israel Cancer Association; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel; The Talpiot Medical Leadership Program, Sheba Medical Center; Inger Fund; Rountree Trust; Mary Barry Foundation; Women's Cancer Research Institute; Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center	This research was supported in part by grants from the United States-Israel Binational Science Foundation (BSF), Jerusalem, Israel; Koschitzky Family Foundation; the Israel Cancer Association; the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel; The Talpiot Medical Leadership Program, Sheba Medical Center; the Inger Fund, Rountree Trust and the Mary Barry Foundation and by grants from the Women's Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. HPK is a member of the Molecular Biology Institute and Jonsson Comprehensive Cancer Center at UCLA and holds the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine. IW is the Mary Barry Medical Bridges Foundation Fellow.	Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Bartucci M, 2001, CANCER RES, V61, P6747; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Chihara Y, 2006, ENDOCRINOLOGY, V147, P3835, DOI 10.1210/en.2005-1529; de Oliveira RM, 2006, FEBS LETT, V580, P5753, DOI 10.1016/j.febslet.2006.09.036; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Fenig E, 2002, ONCOL REP, V9, P875; Fenig E, 1997, CLIN CANCER RES, V3, P135; GEIER A, 1995, CANCER INVEST, V13, P480, DOI 10.3109/07357909509024911; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Haimsohn M, 2002, ENDOCRINOLOGY, V143, P837, DOI 10.1210/en.143.3.837; Haluska P, 2006, CANCER RES, V66, P362, DOI 10.1158/0008-5472.CAN-05-1107; Hsiung R, 2002, CANCER J, V8, P303, DOI 10.1097/00130404-200207000-00006; Ikushima M, 2006, BIOCHEM BIOPH RES CO, V339, P827, DOI 10.1016/j.bbrc.2005.11.094; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Imura A, 2007, SCIENCE, V316, P1615, DOI 10.1126/science.1135901; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kim Y, 2006, NEUROSCI LETT, V407, P189, DOI 10.1016/j.neulet.2006.08.039; Korah RM, 2000, CANCER RES, V60, P733; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Li X, 2007, P NATL ACAD SCI USA, V104, P11597, DOI 10.1073/pnas.0703771104; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Ohyama Y, 1998, BIOCHEM BIOPH RES CO, V251, P920, DOI 10.1006/bbrc.1998.9576; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; URAKAWA I, 2006, SCIENCE, V444, P770; Utsugi T, 2000, METABOLISM, V49, P1118, DOI 10.1053/meta.2000.8606; Vandermoere F, 2005, ONCOGENE, V24, P5482, DOI 10.1038/sj.onc.1208713; Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Wolf I, 2006, EUR J CANCER, V42, P1077, DOI 10.1016/j.ejca.2006.01.027; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Zarrabeitia MT, 2007, CALCIFIED TISSUE INT, V80, P10, DOI 10.1007/s00223-006-0233-x	41	216	229	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7094	7105		10.1038/onc.2008.292	http://dx.doi.org/10.1038/onc.2008.292			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18762812				2022-12-17	WOS:000261195900004
J	Lavin, MF				Lavin, M. F.			ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks	ONCOGENE			English	Review						ATM; Mre11 complex; DNA double strand breaks; signal transduction; functional consequences	DEPENDENT NUCLEAR-DYNAMICS; IONIZING-RADIATION; REQUIRES ATM; DAMAGE RESPONSE; PROTEIN-KINASE; MRN COMPLEX; IN-VITRO; ACTIVATION; REPAIR; PHOSPHORYLATION	The recognition and repair of DNA double-strand breaks (DSBs) is a complex process that draws upon a multitude of proteins. This is not surprising since this is a lethal lesion if left unrepaired and also contributes to genome instability and the consequential risk of cancer and other pathologies. Some of the key proteins that recognize these breaks in DNA are mutated in distinct genetic disorders that predispose to agent sensitivity, genome instability, cancer predisposition and/or neurodegeneration. These include members of the Mre11 complex (Mre11/Rad50/Nbs1) and ataxia-telangiectasia (A-T) mutated (ATM), mutated in the human genetic disorder A-T. The mre11 (MRN) complex appears to be the major sensor of the breaks and subsequently recruits ATM where it is activated to phosphorylate in turn members of that complex and a variety of other proteins involved in cell-cycle control and DNA repair. The MRN complex is also upstream of ATM and ATR (A-T-mutated and rad3-related) protein in responding to agents that block DNA replication. To date, more than 30 ATM-dependent substrates have been identified in multiple pathways that maintain genome stability and reduce the risk of disease. We focus here on the relationship between ATM and the MRN complex in recognizing and responding to DNA DSBs.	Queensland Inst Med Res, Radiat Biol & Oncol Lab, Brisbane, Qld 4029, Australia; Univ Queensland, Fac Hlth Sci, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, Radiat Biol & Oncol Lab, Brisbane, Qld 4029, Australia.	martin.lavin@qimr.edu.au	Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Agarwal S, 2006, DNA REPAIR, V5, P1075, DOI 10.1016/j.dnarep.2006.05.029; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cerosaletti K, 2004, J BIOL CHEM, V279, P38813, DOI 10.1074/jbc.M404294200; Cerosaletti K, 2006, MOL CELL BIOL, V26, P1691, DOI 10.1128/MCB.26.5.1691-1699.2006; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Difilippantonio S, 2007, J EXP MED, V204, P1003, DOI 10.1084/jem.20070319; Digweed M, 1999, BIOESSAYS, V21, P649, DOI 10.1002/(SICI)1521-1878(199908)21:8<649::AID-BIES4>3.0.CO;2-O; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2000, CANCER RES, V60, P4881; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Hamer G, 2004, BIOL REPROD, V70, P1206, DOI 10.1095/biolreprod.103.024950; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Krause DR, 2003, ONCOGENE, V22, P5927, DOI 10.1038/sj.onc.1206691; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Lisby M, 2004, CURR BIOL, V14, pR994, DOI 10.1016/j.cub.2004.11.020; Livak F, 2004, IMMUNOL REV, V200, P23, DOI 10.1111/j.0105-2896.2004.00170.x; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lukas J, 2006, DNA REPAIR, V5, P591, DOI 10.1016/j.dnarep.2006.01.006; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McManus KJ, 2005, METHODS, V36, P351, DOI 10.1016/j.ymeth.2005.03.010; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nelms K, 1998, ADV EXP MED BIOL, V452, P37; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Powers JT, 2004, MOL CANCER RES, V2, P203; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Schroff KC, 2004, ADDICT BIOL, V9, P265, DOI 10.1080/13556210412331292596; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Stracker TH, 2007, NATURE, V447, P218, DOI 10.1038/nature05740; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Usui T, 2006, EXP CELL RES, V312, P2694, DOI 10.1016/j.yexcr.2006.06.013; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yuan SSF, 2002, TOXICOLOGY, V177, P123, DOI 10.1016/S0300-483X(02)00220-2; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	77	216	225	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7749	7758		10.1038/sj.onc.1210880	http://dx.doi.org/10.1038/sj.onc.1210880			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066087	Bronze			2022-12-17	WOS:000251537900005
J	Lin, X; Morgan-Lappe, S; Huang, X; Li, L; Zakula, DM; Vernetti, LA; Fesik, SW; Shen, Y				Lin, X.; Morgan-Lappe, S.; Huang, X.; Li, L.; Zakula, D. M.; Vernetti, L. A.; Fesik, S. W.; Shen, Y.			'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X-L inhibitor ABT-737	ONCOGENE			English	Article						siRNA; off-target; seed; Mcl-1; ABT-737; Bcl-X-L	RNA; EXPRESSION; PROTEINS; CELLS	ABT-737 is a subnanomolar inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w. Although ABT-737 triggers extensive cell death in many small-cell lung carcinoma ( SCLC) cell lines, some of the SCLC cell lines and the majority of the cancer cell lines derived from other solid tumors were found to be resistant to ABT-737. To better understand the mechanism of resistance to ABT-737, we screened a short interfering RNA library consisting of short interfering RNA against 4000 'druggable' targets in an SCLC-derived cell line, NCI-H196. By comparing the knockdowns with phenotypes, all of the three top 'hits' from the screen were found to result from off-target gene silencing. Interestingly, the three off-target siRNAs were found to knock down an antiapoptotic Bcl-2 family protein Mcl-1 owing to the complementation between their seed regions with the 30 untranslated region ( 30 UTR) of Mcl-1. Furthermore, reducing the level of Mcl-1 using siRNAs or the small-molecule compounds Bay43-9006 and Seliciclib was sufficient to overcome the resistance to ABT-737 in the resistant SCLC cell line and cancer cell lines derived from other solid tumors. These results provide further evidence that Mcl-1 is the major factor that causes resistance to ABT-737 in cancer cells derived from diverse solid tumors, and the combination of Mcl-1 downregulating agents with ABT-737 could be potent therapeutic regimens for patient with ABT-737 resistant SCLC and many other types of solid tumors.	Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Shen, Y (corresponding author), Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, AP10,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	yu.shen@abbott.com		Vernetti, Lawrence/0000-0003-4861-3167				Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Kitada S, 2000, BLOOD, V96, P393; Lin XY, 2005, NUCLEIC ACIDS RES, V33, P4527, DOI 10.1093/nar/gki762; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood-2003-03-0970; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	14	216	229	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3972	3979		10.1038/sj.onc.1210166	http://dx.doi.org/10.1038/sj.onc.1210166			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173063				2022-12-17	WOS:000247144500007
J	Benali-Furet, NL; Chami, M; Houel, L; De Giorgi, F; Vernejoul, F; Lagorce, D; Buscail, L; Bartenschlager, R; Ichas, F; Rizzuto, R; Paterlini-Brechot, P				Benali-Furet, NL; Chami, M; Houel, L; De Giorgi, F; Vernejoul, F; Lagorce, D; Buscail, L; Bartenschlager, R; Ichas, F; Rizzuto, R; Paterlini-Brechot, P			Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion	ONCOGENE			English	Article						apoptosis; calcium signalling; ER stress; HCV core; liver cancer	ENDOPLASMIC-RETICULUM STRESS; HEPATOCELLULAR-CARCINOMA; NITRIC-OXIDE; PROTEIN; ACTIVATION; CA2+; LOCALIZATION; MITOCHONDRIA; BAX; TRANSLOCATION	Hepatitis C virus (HCV) core, known to be involved in liver carcinogenesis, is processed in the endoplasmic reticulum (ER). We thus investigated the impact of three HCV core isolates on ER stress, ER calcium signalling and apoptosis. We show that HCV core constructs trigger hyperexpression of Grp78/BiP, Grp 94, calreticulin and sarco/endoplasmic reticulum calcium ATPase, inducing ER stress. By using the ER-targeted aequorin calcium probe, we found that ER calcium depletion follows ER stress in core-expressing cells. HCV core induces apoptosis through overexpression of the CHOP/GADD153 proapoptotic factor, Bax translocation to mitochondria, mitochondrial membrane depolarization, cytochrome c release, caspase-3 and PARP cleavage. Furthermore, reversion of HCV core-induced ER calcium depletion (by transfection of SERCA2) completely abolished mitochondrial membrane depolarization, suggesting that both ER stress (through CHOP overexpression) and calcium signalling play a major role in the HCV core-mediated control of apoptosis. ER stress and apoptosis were also found in a proportion of HCV-full-length replicon-expressing cells and in the liver of HCV core transgenic mice. In conclusion, our data demonstrate that HCV core deregulates the control of apoptosis by inducing ER stress and ER calcium depletion providing new elements to understand the mechanisms involved in HCV-related liver chronic diseases.	Inst Pasteur, INSERM, U370, Dept Liver Canc & Mol Virol, F-75015 Paris, France; Univ Paris 05, CHU Necker, F-75005 Paris, France; Univ Ferrara, Dept Expt Med, I-44100 Ferrara, Italy; INSERM, E347, Inst Europeen Chim & Biol, F-33600 Pessac, France; Inst Louis Bugnard, INSERM, U531, F-31059 Toulouse, France; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Ferrara; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg	Paterlini-Brechot, P (corresponding author), Fac Necker Enfants Malad, INSERM, U370 Pasteur, 156 Rue Vaugirard, F-75730 Paris, France.	paterlini@necker.fr	HOUEL, Ludivine J/E-4151-2016; Rizzuto, Rosario/B-6312-2008; Ichas, François/ABD-8277-2020; Chami, Mounia/S-6471-2019; Bartenschlager, Ralf/L-2582-2015	HOUEL, Ludivine J/0000-0003-0218-1418; Ichas, François/0000-0001-8184-5248; Chami, Mounia/0000-0003-1498-7187; Bartenschlager, Ralf/0000-0001-5601-9307; Paterlini- Brechot, Patrizia/0000-0001-7981-6325; De Giorgi, Francesca/0000-0003-4850-3582; Rizzuto, Rosario/0000-0001-7044-5097				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bergqvist A, 2003, J BIOL CHEM, V278, P18877, DOI 10.1074/jbc.M300185200; Bianchi K, 2004, BBA-MOL CELL RES, V1742, P119, DOI 10.1016/j.bbamcr.2004.09.015; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Colombo M, 2003, ANTIVIR RES, V60, P145, DOI 10.1016/j.antiviral.2003.08.010; de Lucas S, 2003, ANTIVIR RES, V60, P117, DOI 10.1016/j.antiviral.2003.08.006; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Doutheil J, 2000, CELL CALCIUM, V27, P107, DOI 10.1054/ceca.1999.0099; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Martire G, 2001, VIROLOGY, V280, P176, DOI 10.1006/viro.2000.0733; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Minczuk M, 2002, NUCLEIC ACIDS RES, V30, P5074, DOI 10.1093/nar/gkf647; Moorman JP, 2003, VIROLOGY, V312, P320, DOI 10.1016/S0042-6822(03)00208-3; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Pawlotsky JM, 2004, TRENDS MICROBIOL, V12, P96, DOI 10.1016/j.tim.2003.12.005; Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Realdon S, 2004, J HEPATOL, V40, P77, DOI 10.1016/j.jhep.2003.09.017; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rodrigues CMP, 2000, J VIRAL HEPATITIS, V7, P175; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Vernejoul F, 2002, CANCER RES, V62, P6124; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	52	216	227	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4921	4933		10.1038/sj.onc.1208673	http://dx.doi.org/10.1038/sj.onc.1208673			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897896				2022-12-17	WOS:000230646500005
J	Nagy, R; Sweet, K; Eng, C				Nagy, R; Sweet, K; Eng, C			Highly penetrant hereditary cancer syndromes	ONCOGENE			English	Review						inherited cancer susceptibility; familial cancer syndromes; breast cancer; colon cancer; endocrine neoplasia	NONPOLYPOSIS COLORECTAL-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; ENDOCRINE NEOPLASIA TYPE-1; GERM-LINE MUTATIONS; MEDULLARY-THYROID CARCINOMA; VONHIPPEL-LINDAU DISEASE; PEUTZ-JEGHERS-SYNDROME; GENOTYPE-PHENOTYPE CORRELATIONS; CELL-CYCLE ARREST	The past two decades have brought many important advances in our understanding of the hereditary susceptibility to cancer. Approximately 5-10% of all cancers are inherited, the majority in an autosomal dominant manner with incomplete penetrance. While this is a small fraction of the overall cancer burden worldwide, the molecular genetic discoveries that have resulted from the study of families with heritable cancer have not only changed the way these families are counselled and managed, but have shed light on molecular regulatory pathways important in sporadic tumour development as well. In this review, we consider 10 of the more highly penetrant cancer syndromes, with emphasis on those predisposing to breast, colon, and/or endocrine neoplasia. We discuss the prevalence, penetrance, and tumour spectrum associated with these syndromes, as well as their underlying genetic defects.	Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43221 USA; Ohio State Univ, Human Genet Program, Ctr Comprehens Canc, Div Human Genet,Dept Internal Med, Columbus, OH 43221 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Nagy, R (corresponding author), Ohio State Univ, Clin Canc Genet Program, 2050 Kenny Rd,8th Floor Tower, Columbus, OH 43221 USA.	nagy-1@medctr.osu.edu	Sweet, Kevin/E-4172-2011; Nagy, Rebecca Shrigley/E-4088-2011; Pinheiro, Maísa/E-7424-2012	Eng, Charis/0000-0002-3693-5145				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; AALTONEN LA, 2000, PATHOLOGY GENETICS T, P74; Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L; Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Anderson TI, 1996, AM J HUM GENET, V59, P486; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Avizienyte E, 1998, CANCER RES, V58, P2087; BALLARD HS, 1964, MEDICINE, V43, P481, DOI 10.1097/00005792-196407000-00003; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BARDRAM L, 1985, SCAND J GASTROENTERO, V20, P233; BENSON L, 1987, AM J MED, V82, P731, DOI 10.1016/0002-9343(87)90008-8; Bertario L, 2001, INT J CANCER, V95, P102, DOI 10.1002/1097-0215(20010320)95:2<102::AID-IJC1018>3.0.CO;2-8; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bevan S, 1999, GUT, V45, P406, DOI 10.1136/gut.45.3.406; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; BIRCH JM, 1994, CANCER RES, V54, P1298; Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621; Bisgaard ML, 2002, HUM MUTAT, V20, P20, DOI 10.1002/humu.10083; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Borrello MG, 1995, ONCOGENE, V11, P2419; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BORRESEN AL, 1992, CANCER RES, V52, P3234; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253; Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658; BRANDI ML, 1987, ENDOCR REV, V8, P391, DOI 10.1210/edrv-8-4-391; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; BULOW S, 1995, INT J COLORECTAL DIS, V10, P43, DOI 10.1007/BF00337586; Burgess JR, 1996, ARCH SURG-CHICAGO, V131, P699; BURN J, 1991, J MED GENET, V28, P289, DOI 10.1136/jmg.28.5.289; BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655; Bussey H, 1975, FAMILIAL POLYPOSIS C; CANTU JM, 1980, CANCER, V46, P223, DOI 10.1002/1097-0142(19800701)46:1<223::AID-CNCR2820460137>3.0.CO;2-8; Carlomagno F, 1997, CANCER RES, V57, P391; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Carty SE, 1998, SURGERY, V124, P1106, DOI 10.1067/msy.1998.93107; Cetta F, 2000, J CLIN ENDOCR METAB, V85, P286, DOI 10.1210/jc.85.1.286; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Chan TL, 2001, ONCOGENE, V20, P2976, DOI 10.1038/sj.onc.1204376; Chandrasekharappa SC, 2001, FRONT HORM RES, V28, P50; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chrousos GP, 1998, J INTERN MED, V243, P573; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; COBURN MC, 1995, ANN SURG ONCOL, V2, P386, DOI 10.1007/BF02306370; Corbetta S, 1997, CLIN ENDOCRINOL, V47, P507, DOI 10.1046/j.1365-2265.1997.3311122.x; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; Dackiw APB, 1999, SURGERY, V126, P1097, DOI 10.1067/msy.2099.101376; Darling TN, 1997, ARCH DERMATOL, V133, P853, DOI 10.1001/archderm.133.7.853; DECKER RA, 1995, SURGERY, V118, P257, DOI 10.1016/S0039-6060(05)80332-0; Desai DC, 1998, J MED GENET, V35, P476, DOI 10.1136/jmg.35.6.476; DESAI DC, 1995, BRIT J SURG, V82, P14, DOI 10.1002/bjs.1800820106; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EASTON DF, 1989, AM J HUM GENET, V44, P208; EASTON DF, 1993, AM J HUM GENET, V52, P678; Eeles RA, 1995, CANCER SURV, V25, P101; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; Eng C, 2000, Rev Endocr Metab Disord, V1, P283, DOI 10.1023/A:1026514301172; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Eng C, 2001, NAT GENET, V28, P105, DOI 10.1038/88802; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; ENG C, 2001, MOL GENETICS CANC, P171; Enholm S, 2003, AM J PATHOL, V163, P827, DOI 10.1016/S0002-9440(10)63443-8; Entius MM, 2001, J CLIN PATHOL, V54, P126, DOI 10.1136/jcp.54.2.126; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Evans DGR, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.012104; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; FELIX CA, 1995, MED PEDIATR ONCOL, V25, P431, DOI 10.1002/mpo.2950250603; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FORD D, 1995, AM J HUM GENET, V57, P1457; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Foulkes WD, 2002, AM J HUM GENET, V71, P1395, DOI 10.1086/345075; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Friedl W, 1996, HUM GENET, V97, P579; Friedl W, 2002, HUM GENET, V111, P108, DOI 10.1007/s00439-002-0748-9; Friedl W, 2001, GUT, V48, P515, DOI 10.1136/gut.48.4.515; Furnari FB, 1998, CANCER RES, V58, P5002; Gao Q, 1997, AM J HUM GENET, V60, P1233; GARBER JE, 1991, CANCER RES, V51, P6094; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; Gayther SA, 1997, AM J HUM GENET, V60, P1239; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Giardiello FM, 1996, GUT, V39, P867, DOI 10.1136/gut.39.6.867; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; Gille JJP, 2002, BRIT J CANCER, V87, P892, DOI 10.1038/sj.bjc.6600565; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gimm O, 2001, FRONT HORM RES, V28, P103; Giraud S, 1998, AM J HUM GENET, V63, P455, DOI 10.1086/301953; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GORLIN RJ, 1968, CANCER, V22, P293, DOI 10.1002/1097-0142(196808)22:2<293::AID-CNCR2820220206>3.0.CO;2-R; Gorski B, 2000, AM J HUM GENET, V66, P1963, DOI 10.1086/302922; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gruber SB, 1998, CANCER RES, V58, P5267; Guillem JG, 1999, CURR PROB SURG, V36, P222; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Halford SER, 2003, AM J PATHOL, V162, P1545, DOI 10.1016/S0002-9440(10)64288-5; HARTLEY AL, 1993, CANCER GENET CYTOGEN, V67, P133, DOI 10.1016/0165-4608(93)90166-J; He LS, 1998, CANCER RES, V58, P4238; Heiskanen I, 1999, ENDOSCOPY, V31, P412; HELWIG EB, 1946, AM J DIS CHILD, V72, P289; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Hisada M, 1998, JNCI-J NATL CANCER I, V90, P606, DOI 10.1093/jnci/90.8.606; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; HORRILLENO EG, 1957, CANCER, V10, P1210, DOI 10.1002/1097-0142(195711/12)10:6<1210::AID-CNCR2820100619>3.0.CO;2-2; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hutter P, 1996, J MED GENET, V33, P636, DOI 10.1136/jmg.33.8.636; Hwang SJ, 2003, AM J HUM GENET, V72, P975, DOI 10.1086/374567; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Ito S, 1997, CANCER RES, V57, P2870; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; JARVINEN HJ, 1992, GUT, V33, P357, DOI 10.1136/gut.33.3.357; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; JASS JR, 1988, HISTOPATHOLOGY, V13, P619; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johannsson O, 1996, AM J HUM GENET, V58, P441; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Kadmon M, 2001, INT J COLORECTAL DIS, V16, P63, DOI 10.1007/s003840100290; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kolodner RD, 1999, CANCER RES, V59, P5068; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42; Kuismanen SA, 2002, AM J PATHOL, V160, P1953, DOI 10.1016/S0002-9440(10)61144-3; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lalloo F, 2003, LANCET, V361, P1101, DOI 10.1016/S0140-6736(03)12856-5; LAMIELL JM, 1989, MEDICINE, V68, P1; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li DM, 1997, CANCER RES, V57, P2124; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1988, CANCER RES, V51, P6094; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li YJ, 1995, INT J CANCER, V64, P383, DOI 10.1002/ijc.2910640606; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liede A, 2000, BRIT J CANCER, V82, P705; Lipton L, 2003, CANCER RES, V63, P7595; Longy M, 1996, ANN GENET-PARIS, V39, P35; Lynch HT, 1996, GASTROENTEROLOGY, V110, P943, DOI 10.1053/gast.1996.v110.agast960943; Lynch HT, 2004, JAMA-J AM MED ASSOC, V291, P718, DOI 10.1001/jama.291.6.718; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; LYNCH HT, 1988, GASTROENTEROL CLIN N, V17, P679; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; LYNCH HT, 1971, CANCER, V27, P1505, DOI 10.1002/1097-0142(197106)27:6<1505::AID-CNCR2820270635>3.0.CO;2-L; Maddock IR, 1996, J MED GENET, V33, P120, DOI 10.1136/jmg.33.2.120; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marra G, 2003, NEW ENGL J MED, V348, P845, DOI 10.1056/NEJMe030002; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Marx SJ, 2002, GENETIC BASIS HUMAN, P475; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MCCOLL I, 1964, P ROY SOC MED, V57, P896; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; MEGERIAN CA, 1995, LARYNGOSCOPE, V105, P801, DOI 10.1288/00005537-199508000-00006; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meijers-Heijboer H, 2003, AM J HUM GENET, V72, P1308, DOI 10.1086/375121; Miedlich S, 2001, EUR J ENDOCRINOL, V145, P155, DOI 10.1530/eje.0.1450155; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Millar AL, 1999, HUM MOL GENET, V8, P823, DOI 10.1093/hmg/8.5.823; Miyaki M, 2000, CANCER RES, V60, P6311; Miyauchi A, 1999, JPN J CANCER RES, V90, P1; Moisio AL, 2002, GUT, V50, P845, DOI 10.1136/gut.50.6.845; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Murphy GP, 1995, AM CANC SOC TXB CLIN; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakagawa H, 2002, CANCER RES, V62, P4579; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83; Nilsson O, 1999, JAMA-J AM MED ASSOC, V281, P1587, DOI 10.1001/jama.281.17.1587; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Norton JA, 1999, NEW ENGL J MED, V341, P635, DOI 10.1056/NEJM199908263410902; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Olivier M, 2003, CANCER RES, V63, P6643; Olschwang S, 1998, J MED GENET, V35, P42, DOI 10.1136/jmg.35.1.42; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pannett AAJ, 2003, CLIN ENDOCRINOL, V58, P639, DOI 10.1046/j.1365-2265.2003.01765.x; Parc Y, 2003, J MED GENET, V40, P208, DOI 10.1136/jmg.40.3.208; Park YJ, 2000, CLIN CANCER RES, V6, P2994; PASINI B, 1995, ONCOGENE, V11, P1737; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; Piao Z, 2000, CANCER RES, V60, P4701; PIPELEERSMARICHAL M, 1990, NEW ENGL J MED, V322, P723, DOI 10.1056/NEJM199003153221103; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; PONDER BAJ, 1988, LANCET, V1, P397; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; ROTH SI, 1963, CANCER, V16, P468, DOI 10.1002/1097-0142(196304)16:4<468::AID-CNCR2820160408>3.0.CO;2-F; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Roy PK, 2000, MEDICINE, V79, P379, DOI 10.1097/00005792-200011000-00004; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Sampson JR, 2003, LANCET, V362, P39, DOI 10.1016/S0140-6736(03)13805-6; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sayed MG, 2002, ANN SURG ONCOL, V9, P901, DOI 10.1007/BF02557528; SCHEITHAUER BW, 1987, SEMIN DIAGN PATHOL, V4, P205; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schuffenecker I, 1998, J CLIN ENDOCR METAB, V83, P487, DOI 10.1210/jc.83.2.487; Schuffenecker I, 1997, AM J HUM GENET, V60, P233; Schutte M, 2003, AM J HUM GENET, V72, P1023, DOI 10.1086/373965; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHANNON KE, 1999, J ENDOCR GENET, V1, P39; SHEPHERD NA, 1987, AM J SURG PATHOL, V11, P743, DOI 10.1097/00000478-198710000-00001; SIDRANSKY D, 1992, CANCER RES, V52, P2984; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SKOGSEID B, 1994, ENDOCRIN METAB CLIN, V23, P1; SKOGSEID B, 1992, J CLIN ENDOCR METAB, V75, P76, DOI 10.1210/jc.75.1.76; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Sodha N, 2002, HUM MUTAT, V20, P460, DOI 10.1002/humu.10136; SOLOMAN C, GENEREVIEWS GENE TES; Somasundaram K, 2003, J CELL BIOCHEM, V88, P1084, DOI 10.1002/jcb.10469; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Soravia C, 1998, AM J HUM GENET, V62, P1290, DOI 10.1086/301883; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Syngal S, 2000, J MED GENET, V37, P641, DOI 10.1136/jmg.37.9.641; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Teh BT, 1998, ANN SURG, V228, P99, DOI 10.1097/00000658-199807000-00015; Thakker RV, 1995, ENDOCRINOLOGY; Thompson D, 2002, CANCER EPIDEM BIOMAR, V11, P329; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TOCCALIN.H, 1973, ACTA PAEDIATR SCAND, V62, P337, DOI 10.1111/j.1651-2227.1973.tb08117.x; TOMLINSON MJ, 1987, BRIT J RADIOL, V60, P89, DOI 10.1259/0007-1285-60-709-89; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Tonin PN, 1999, CLIN GENET, V55, P318, DOI 10.1034/j.1399-0004.1999.550504.x; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trump D, 1996, QJM-INT J MED, V89, P653; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; Uchino S, 2000, CANCER RES, V60, P5553; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; VANDERLUIJT RB, 1995, HUM GENET, V96, P705, DOI 10.1007/BF00210303; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Varley JM, 2003, HUM MUTAT, V21, P313, DOI 10.1002/humu.10185; Varley JM, 1997, CANCER RES, V57, P3245; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Vasen HFA, 2001, J CLIN ONCOL, V19, P4074, DOI 10.1200/JCO.2001.19.20.4074; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; VERALDI S, 1991, J AM ACAD DERMATOL, V25, P632, DOI 10.1016/0190-9622(91)70244-V; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wagner A, 2003, AM J HUM GENET, V72, P1088, DOI 10.1086/373963; Wagner A, 2002, GENE CHROMOSOME CANC, V35, P49, DOI 10.1002/gcc.10094; Wagner A, 2001, J MED GENET, V38, P318, DOI 10.1136/jmg.38.5.318; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wallis YL, 1999, J MED GENET, V36, P14; Walon C, 1997, HUM GENET, V100, P601, DOI 10.1007/s004390050560; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Warthin AS, 1931, ANN INTERN MED, V4, P681, DOI 10.7326/0003-4819-4-7-681; Watson P, 1998, CANCER, V83, P259, DOI 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L; Wautot V, 2002, HUM MUTAT, V20, P35, DOI 10.1002/humu.10092; WEBER HC, 1995, GASTROENTEROLOGY, V108, P1637, DOI 10.1016/0016-5085(95)90124-8; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wiench M, 2001, J CLIN ONCOL, V19, P1374, DOI 10.1200/JCO.2001.19.5.1374; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Wohllk N, 1996, J CLIN ENDOCR METAB, V81, P3740, DOI 10.1210/jc.81.10.3740; Woodford-Richens K, 2000, CANCER RES, V60, P2477; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wynford-Thomas D, 1999, J PATHOL, V187, P100; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	354	216	221	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6445	6470		10.1038/sj.onc.1207714	http://dx.doi.org/10.1038/sj.onc.1207714			26	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322516				2022-12-17	WOS:000223468800010
J	Grassme, H; Cremesti, A; Kolesnick, R; Gulbins, E				Grassme, H; Cremesti, A; Kolesnick, R; Gulbins, E			Ceramide-mediated clustering is required for CD95-DISC formation	ONCOGENE			English	Article						receptor aggregation; ceramide; acid sphingomyelinase; CD95; apoptosis	FAS-INDUCED APOPTOSIS; RICH MEMBRANE RAFTS; ACID SPHINGOMYELINASE; T-LYMPHOCYTES; CELL-DEATH; SIGNALING PATHWAY; CD95; ACTIVATION; RECEPTOR; FADD	Early events required for induction of apoptosis by CD95 are preassociation of CD95, the formation of the death-inducing signaling complex (DISC) and clustering of CD95 in distinct membrane domains. Here, we identify the molecular ordering of these events and show that the acid sphingomyelinase (ASM) functions upstream of the DISC to mediate CD95 clustering in ceramide-enriched membrane platforms, an event that is required for DISC formation. Experiments in ASM-deficient cells revealed that CD95 ligation, in the absence of ceramide generation, triggers <1% of full caspase 8 activation at the receptor. This event, however, is both necessary and sufficient to trigger translocation of ASM onto the outer leaflet of the plasma membrane, ASM activation and ceramide release, but insufficient for apoptosis induction. Ceramide-mediated CD95 clustering then amplifies the primary CD95 signaling and drives the second step of CD95 signaling, that is, formation of the DISC yielding 100% caspase activity and apoptosis. These studies suggest that the most parsimonious interpretation of the molecular ordering of the earliest events in CD95 signaling, at least in some cells, is: CD95 ligation&RARR;1% of maximum caspase 8 activation&RARR;ASM translocation&RARR;ceramide generation&RARR;CD95 clustering&RARR;DISC formation&RARR;100% of maximum caspase 8 activation&RARR;apoptosis.	Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University of Duisburg Essen; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.		Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342	NCI NIH HHS [CA 21765, CA 85704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085704, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Altman A, 1994, Semin Immunol, V6, P9, DOI 10.1006/smim.1994.1003; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; FANZO JC, 2003, UNPUB MCB; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudner J, 2001, J CELL SCI, V114, P4161; Sakata K, 1998, EUR J IMMUNOL, V28, P2648, DOI 10.1002/(SICI)1521-4141(199809)28:09<2648::AID-IMMU2648>3.0.CO;2-M; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; Sawada M, 2002, EXP CELL RES, V273, P157, DOI 10.1006/excr.2001.5437; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267	45	216	224	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5457	5470		10.1038/sj.onc.1206540	http://dx.doi.org/10.1038/sj.onc.1206540			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934106				2022-12-17	WOS:000184735000011
J	Everett, RD				Everett, RD			DNA viruses and viral proteins that interact with PML nuclear bodies	ONCOGENE			English	Article						PML nuclear bodies; SUMO-1; DNA viruses; ICP0; ubiquitin-proteasome pathway	HERPES-SIMPLEX-VIRUS; EPSTEIN-BARR-VIRUS; PROTEASOME-DEPENDENT DEGRADATION; UBIQUITIN-SPECIFIC PROTEASE; HUMAN CYTOMEGALOVIRUS; REPLICATION COMPARTMENTS; GENE-EXPRESSION; DOMAIN 10; ALPHAHERPESVIRUS PROTEINS; CAPSID PROTEIN	Connections between PML nuclear bodies (PML NBs) and DNA virus replication have been investigated from the earliest days of the molecular characterization of PML and associated proteins. It appears to be a general feature of nuclear-replicating DNA viruses that their parental genomes preferentially become associated with PML NBs, and that their initial sites of transcription and development of DNA replication centres are frequently juxtaposed to these domains or their remnants. In addition, regulatory proteins encoded by several DNA viruses associate with and sometimes cause catastrophic changes to PML NBs by a variety of mechanisms. These events can be correlated with the efficiency of viral infection and the functions of viral regulatory proteins, but the underlying molecular connections between PML NB function and viral infection remain poorly understood. This article reviews the latest developments in the interactions between PML NBs and herpesviruses, adenoviruses and papovaviruses.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland		Everett, RD (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.							Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1999, J VIROL, V73, P10458, DOI 10.1128/JVI.73.12.10458-10471.1999; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Bastien N, 2000, VIROLOGY, V270, P124, DOI 10.1006/viro.2000.0265; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; Burkham J, 2001, J VIROL, V75, P2353, DOI 10.1128/JVI.75.5.2353-2367.2001; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1999, TRENDS BIOCHEM SCI, V24, P293, DOI 10.1016/S0968-0004(99)01433-4; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1998, EMBO J, V17, P7161, DOI 10.1093/emboj/17.24.7161; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1999, J CELL SCI, V112, P4581; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; EVERETT RD, 1991, CONTROL HERPES SIMPL; Fabunmi RP, 2001, J CELL SCI, V114, P29; Fields BN., 1996, VIROLOGY; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Halford WP, 2001, J VIROL, V75, P3240, DOI 10.1128/JVI.75.7.3240-3249.2001; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; Hobbs WE, 2001, J VIROL, V75, P3391, DOI 10.1128/JVI.75.7.3391-3403.2001; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Hsu WL, 2001, J VIROL, V75, P3819, DOI 10.1128/JVI.75.8.3819-3831.2001; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Ishov AM, 1997, J CELL BIOL, V138, P5, DOI 10.1083/jcb.138.1.5; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jiang WQ, 1996, EXP CELL RES, V229, P289, DOI 10.1006/excr.1996.0374; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; LALLEMANDBREITE.V, 2001, EXPT MED, V193, P1361; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Lomonte P, 2001, J BIOL CHEM, V276, P5829, DOI 10.1074/jbc.M008547200; Lukonis CJ, 1997, J VIROL, V71, P2390, DOI 10.1128/JVI.71.3.2390-2399.1997; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Mocarski ES, 1996, P NATL ACAD SCI USA, V93, P11321, DOI 10.1073/pnas.93.21.11321; Mossman KL, 2000, J VIROL, V74, P2052, DOI 10.1128/JVI.74.4.2052-2056.2000; Muller S, 1999, J VIROL, V73, P5137; Parkinson J, 2000, J VIROL, V74, P10006, DOI 10.1128/JVI.74.21.10006-10017.2000; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Parkinson J, 2001, J VIROL, V75, P5357, DOI 10.1128/JVI.75.11.5357-5362.2001; Plehn-Dujowich D, 2000, CHROMOSOMA, V109, P266, DOI 10.1007/s004120000073; Preston CM, 2000, J GEN VIROL, V81, P1; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Tang QY, 2000, J VIROL, V74, P9694, DOI 10.1128/JVI.74.20.9694-9700.2000; Taylor JL, 2000, J INTERF CYTOK RES, V20, P805, DOI 10.1089/10799900050151076; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Wilkinson GWG, 1998, J GEN VIROL, V79, P1233, DOI 10.1099/0022-1317-79-5-1233; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001; Wu H, 2000, EMBO REP, V1, P140, DOI 10.1093/embo-reports/kvd026	79	216	217	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7266	7273		10.1038/sj.onc.1204759	http://dx.doi.org/10.1038/sj.onc.1204759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704855				2022-12-17	WOS:000171891900015
J	Sanchez-Perez, I; Murguia, JR; Perona, R				Sanchez-Perez, I; Murguia, JR; Perona, R			Cisplatin induces a persistent activation of JNK that is related to cell death	ONCOGENE			English	Article						cisplatin; JNK1; phosphatases; DNA damage	TERNARY COMPLEX-FORMATION; C-JUN; PROTEIN-KINASE; PLATINUM(II) COMPOUNDS; OXIDATIVE STRESS; GAMMA-RADIATION; MAP-KINASES; DNA; PHOSPHORYLATION; APOPTOSIS	Genotoxic stress triggers signalling pathways that either mediate cell killing or protection of affected cells. While induction of p53 is observed for most of the genotoxins, activation of MAPK/SAPK cascades is not a general response. The role of MAPK/SAPK activation on cell fate, seems to be dependent, in some systems, on the balanced response among both cascades. We have here examined the effect of cis and trans-DDP on the activation of ERK and JNK activities. While no significant induction of ERK was observed with the compounds, both of them are able to strongly activate JNK. Trans-DDP response is rapid and transient while the cis-DDP one is slow and persistent. In contrast with the observed nuclear translocation of JNK in response to U.V. light, none of the platinum compounds induces translocation, on the contrary, activation of JNK occurs in both the nuclear and cytoplasmic compartments, Inhibition of tyrosine phosphatases by orthovanadate pretreatment prolongs the time of JNK induction in response to both platinum compounds, The positive modulation of JNK activation correlates with an increase in toxicity that, for cis-DDP corresponds to a tenfold decrease in the IC50. A strong increase in MKP-1 levels was observed only in response to trans-DDP suggesting the involvement of this activity in the downregulation of JNK activity in response to this compound, Altogether the results suggest that the prolonged activation of JNK in response to cis-DDP contributes to cell death induction.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Perona, R (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Murguia, Jose R./H-4419-2015; Sánchez-Pérez, Isabel/R-4107-2016	Murguia, Jose R./0000-0001-9364-4603; Sánchez-Pérez, Isabel/0000-0002-4829-201X				ALAZARD R, 1982, MUTAT RES, V93, P327, DOI 10.1016/0027-5107(82)90148-8; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P6058; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KASTAN MB, 1991, CANCER RES, V51, P6304; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PASCOE JM, 1974, BIOCHEM PHARMACOL, V23, P1345, DOI 10.1016/0006-2952(74)90354-2; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; WANG HG, 1994, ONCOGENE, V9, P2751; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	52	216	222	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					533	540		10.1038/sj.onc.1201578	http://dx.doi.org/10.1038/sj.onc.1201578			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484843				2022-12-17	WOS:000071739400012
J	Plaumann, B; Fritsche, M; Rimpler, H; Brandner, G; Hess, RD				Plaumann, B; Fritsche, M; Rimpler, H; Brandner, G; Hess, RD			Flavonoids activate wild-type p53	ONCOGENE			English	Article						flavonoids; p53; cell cycle; G2M; apoptosis; DNA damage	CELL-CYCLE CHECKPOINTS; DNA-DAMAGE; LIPID-PEROXIDATION; INDUCED APOPTOSIS; GROWTH ARREST; QUERCETIN; EXPRESSION; PROTEIN; DIFFERENTIATION; ACCUMULATION	Flavonoids are diphenyl propanoids widely distributed in edible plants. They play a dual role in mutagenesis and carcinogenesis. Some of them act as anticarcinogens or inhibit the growth of tumour cells, whereas others act as cocarcinogens, are mutagenic or able to induce DNA damage. To further elucidate this dual role, we investigated the influence of apigenin, luteolin and quercetin on the tumour suppressor protein p53, regarding p53 accumulation, cell cycle arrest, apoptosis, and biological activity. We found that incubation of the non-tumour cell line C3H10T1/2CL8 with these flavonoids resulted in induction of p53 accumulation and apoptosis. Apoptosis occurred out of the G(2)/M phase of the cell cycle, The G(2)/M arrest seems to be p53-dependent as it did not occur in p53 knockout fibroblasts which further supports the recent finding that p53 is involved in the G(2)/M checkpoint control. Differences between the flavonoids tested concerned p53 accumulation kinetics as well as the biological activity of accumulated p53 and might be due to different modes of flavonoid action. These data suggest that both aspects of flavonoid effects, i.e. inhibition of tumour growth through cell cycle arrest and induction of apoptosis, are functionally related to p53.	UNIV FREIBURG, INST MED MIKROBIOL & HYG, ABT VIROL, D-79104 FREIBURG, GERMANY; INST EXPT KREBSFORSCH, KLIN TUMORBIOL, D-79106 FREIBURG, GERMANY; UNIV FREIBURG, INST PHARMAZEUT BIOL, D-79104 FREIBURG, GERMANY	University of Freiburg; University of Freiburg								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AHMAD MS, 1992, CARCINOGENESIS, V13, P605, DOI 10.1093/carcin/13.4.605; AHMED MS, 1994, CARCINOGENESIS, V15, P1627, DOI 10.1093/carcin/15.8.1627; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUSTIN CA, 1992, BIOCHEM J, V282, P883, DOI 10.1042/bj2820883; BABICH H, 1987, TOXICOL IN VITRO, V1, P3, DOI 10.1016/0887-2333(87)90031-2; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BORENFREUND E, 1988, TOXICOL IN VITRO, V2, P1, DOI 10.1016/0887-2333(88)90030-6; CANADA AT, 1990, FREE RADICAL BIO MED, V9, P441, DOI 10.1016/0891-5849(90)90022-B; CARIA H, 1995, MUTAT RES-GENET TOX, V343, P85, DOI 10.1016/0165-1218(95)90075-6; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FIALA ES, 1985, ANNU REV NUTR, V5, P295, DOI [10.1146/annurev.nu.05.070185.001455, 10.1146/annurev.nutr.5.1.295]; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HENDERSON D, 1995, NAT MED, V1, P525, DOI 10.1038/nm0695-525; HOTZ MA, 1994, CYTOMETRY, V15, P237, DOI 10.1002/cyto.990150309; JUVEN T, 1993, ONCOGENE, V8, P3411; KANTENGWA S, 1991, BIOCHEM BIOPH RES CO, V180, P308, DOI 10.1016/S0006-291X(05)81293-8; KINOSHITA T, 1985, CHEM PHARM BULL, V33, P4109; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANACH C, 1995, J NUTR, V125, P1911, DOI 10.1093/jn/125.7.1911; MARKAVERICH BM, 1983, J BIOL CHEM, V258, P1663; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MCGREGOR JT, 1986, GENETIC TOXICOLOGY D, P33; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; OCHIAI M, 1984, MUTAT RES, V129, P19, DOI 10.1016/0027-5107(84)90118-0; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; RAHMAN A, 1989, CARCINOGENESIS, V10, P1833, DOI 10.1093/carcin/10.10.1833; RENZING J, 1995, ONCOGENE, V10, P1865; SAHU SC, 1994, CANCER LETT, V85, P159, DOI 10.1016/0304-3835(94)90269-0; SATO F, 1994, BIOCHEM BIOPH RES CO, V204, P578, DOI 10.1006/bbrc.1994.2498; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHIMOI K, 1994, CARCINOGENESIS, V15, P2669, DOI 10.1093/carcin/15.11.2669; SIEGEL J, 1995, ONCOGENE, V11, P1363; STEWART N, 1995, ONCOGENE, V10, P109; THOMPSON RS, 1972, J CHEM SOC PERK T 1, P1387, DOI 10.1039/p19720001387; TOREL J, 1994, PHYTOCHEMISTRY, V26, P2489; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEI YQ, 1994, CANCER RES, V54, P4952; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG W, 1993, ONCOGENE, V8, P2555	54	216	224	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1605	1614						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895505				2022-12-17	WOS:A1996VM88700004
J	AHOMADEGBE, JC; BARROIS, M; FOGEL, S; LEBIHAN, ML; DOUCRASY, S; DUVILLARD, P; ARMAND, JP; RIOU, G				AHOMADEGBE, JC; BARROIS, M; FOGEL, S; LEBIHAN, ML; DOUCRASY, S; DUVILLARD, P; ARMAND, JP; RIOU, G			HIGH-INCIDENCE OF P53 ALTERATIONS (MUTATION, DELETION, OVEREXPRESSION) IN HEAD AND NECK PRIMARY TUMORS AND METASTASES - ABSENCE OF CORRELATION WITH CLINICAL OUTCOME - FREQUENT PROTEIN OVEREXPRESSION IN NORMAL EPITHELIUM AND IN EARLY NONINVASIVE LESIONS	ONCOGENE			English	Article						P53 ALTERATIONS; HEAD AND NECK METASTASES; PROGNOSIS	SQUAMOUS-CELL CARCINOMA; SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; OVER-EXPRESSION; CANCER PATIENTS; POOR-PROGNOSIS; BREAST-CANCER; TP53 GENE; ACCUMULATION; CARCINOGENESIS	We have analysed 78 head and neck carcinomas (50 node metastases and 28 primary tumors including 13 matched specimens) in 65 patients for p53 alterations. Mutations were found in 54 (69%) tumors. Of the 53 mutations within exons, 40 (76%) were missense, five (9%) nonsense and eight (15%) microdeletions or microinsertions. Twenty-five (47%) mutations were transitions mostly G-->A (40%) and 20 (38%) were transversions, mostly G-->T (25%), thus confirming the role of tobacco carcinogens in the induction of these mutations. The incidence of mutations was not different in primary tumors (68%) and node metastases (70%) indicating that this gene alteration was not related to the metastatic dissemination, For eight patients, mutations were observed in matched primary tumors and metastases, indicating clonal dissemination of tumor cells in most of these carcinomas. There was a good correlation between mutation and protein overexpression (Fisher's exact test P < 10(-4)). Immunostaining was also observed in basal cells from normal epithelium and in early lesions adjacent to the primary tumor in 11/15 (73%) specimens irrespective of the presence of mutation in the corresponding tumors. These data confirm that p53 overexpression is an early event in the multistep process of epithelial cell carcinogenesis. Loss of heterozygosity for the TP53 locus was detected in 54% of tumors but no association was found with mutation (Fisher's exact test P = 0.14). No mdm-2 amplification was detected in any tumors. No correlation was found between mutation and clinical parameters, the 5-year survival rates were not different (log rank test P = 0.39) in patients with and without mutation. In conclusion, we have shown that p53 gene mutations and deletions and protein overexpression are frequent in the most aggressive head and neck carcinomas but are not associated with disease progression. The presence of protein in normal mucosa and in non-invasive lesions may constitute a biomarker for early stages of carcinogenesis.	INST GUSTAVE ROUSSY,PHARMACOL CLIN & MOLEC LAB,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT ANATOMOPATHOL,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94800 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy								ADAMSON R, 1994, ONCOGENE, V9, P2077; ANWAR K, 1993, INT J CANCER, V53, P952; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BENNETT WP, 1992, CANCER RES, V52, P6092; BENNETT WP, 1993, CANCER RES, V53, P4817; BOURHIS J, 1994, INT J CANCER, V57, P458, DOI 10.1002/ijc.2910570403; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1993, CANCER RES, V53, P3667; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHUNG KY, 1993, CANCER RES, V53, P1676; CORDONCARDO C, 1994, CANCER RES, V54, P794; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DENG G, 1994, CANCER RES, V54, P499; DOLCETTI R, 1992, INT J CANCER, V52, P178, DOI 10.1002/ijc.2910520204; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO;2-3; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HELLAND A, 1993, J PATHOL, V171, P105, DOI 10.1002/path.1711710207; Hill C., 1993, EVOLUTION MORTALITE; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEES M, 1993, CANCER RES, V53, P4189; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PUISIEUX A, 1991, CANCER RES, V51, P6185; RICHARD JM, 1987, LARYNGOSCOPE, V97, P97; RIOU G, 1993, J NATL CANCER I, V85, P1765, DOI 10.1093/jnci/85.21.1765; RIOU G, 1995, IN PRESS MOL CARCINO; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SHENG ZM, 1990, BRIT J CANCER, V62, P398, DOI 10.1038/bjc.1990.306; SHIN DM, 1994, CANCER RES, V54, P321; SLOOTWEG PJ, 1994, ORAL ONCOL, V30B, P138; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG LD, 1993, CANCER RES, V53, P1783; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	57	216	219	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1217	1227						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700647				2022-12-17	WOS:A1995QN35300024
J	Testa, JR; Tsichlis, PN				Testa, JR; Tsichlis, PN			AKT signaling in normal and malignant cells	ONCOGENE			English	Article						AKT/ PKB pathway; tumor suppressor genes	MOLECULAR-CLONING; PROTEIN-KINASE; ONCOGENE	AKT/protein kinase B (PKB) is a cardinal node in diverse signaling cascades important in both normal cellular physiology and various disease states. AKT signaling regulates cell proliferation and survival, cell growth ( size), glucose metabolism, cell motility and angiogenesis. Aberrant regulation of these processes result in cellular perturbations considered hallmarks of cancer, and numerous studies testify to the frequent hyperactivation of AKT signaling in many human cancers. Various oncoproteins and tumor suppressors intersect the AKT signal transduction pathway and are activated or inactivated, respectively, in cancer. This issue of Oncogene Reviews includes a collection of perspectives on the normal cellular functions of various components of the AKT pathway, as well as biological consequences of alterations of these proteins as related to tumorigenesis. Two reviews focus on AKT regulation, one of which addresses various aspects of phosphoinositide metabolism, while the other emphasizes the role of AKT-interacting proteins in AKT activation. Several reviews highlight the role of major AKT substrates involved in cellular metabolism, transcription and translation; another focuses on the role of AKT signaling in epithelial-mesenchymal transition. Also included are articles on the involvement of AKT pathway deregulation in human cancer and certain hereditary cancer syndromes, as well as in murine models of cancer based on AKT pathway activation. Additional articles discuss current approaches to identify selective inhibitors of the AKT pathway.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Fox Chase Cancer Center; Tufts Medical Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu			NATIONAL CANCER INSTITUTE [R01CA077429, P50CA083638, R01CA057436, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA83638, CA06927, CA57436, CA77429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHENG JQ, ONCOGENE REV, V24, P7482; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065	10	215	226	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7391	7393		10.1038/sj.onc.1209100	http://dx.doi.org/10.1038/sj.onc.1209100			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288285				2022-12-17	WOS:000233201900001
J	Snijders, AM; Schmidt, BL; Fridlyand, J; Dekker, N; Pinkel, D; Jordan, RCK; Albertson, DG				Snijders, AM; Schmidt, BL; Fridlyand, J; Dekker, N; Pinkel, D; Jordan, RCK; Albertson, DG			Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma	ONCOGENE			English	Article						array CGH; hedgehog; notch; oral SCC; amplicon	COMPARATIVE GENOMIC HYBRIDIZATION; HEDGEHOG-BINDING PROTEIN; NECK-CANCER; TUMOR-SUPPRESSOR; HEAD; GENE; EXPRESSION; PROGRESSION; GROWTH; NOTCH	Genomes of solid tumors are characterized by gains and losses of regions, which may contribute to tumorigenesis by altering gene expression. Often the aberrations are extensive, encompassing whole chromosome arms, which makes identification of candidate genes in these regions difficult. Here, we focused on narrow regions of gene amplification to facilitate identification of genetic pathways important in oral squamous cell carcinoma (SCC) development. We used array comparative genomic hybridization ( array CGH) to define minimum common amplified regions and then used expression analysis to identify candidate driver genes in amplicons that spanned <3 Mb. We found genes involved in integrin signaling (TLN1), survival ( YAP1, BIRC2), and adhesion and migration ( TLN1, LAMA3, MMP7), as well as members of the hedgehog (GLI2) and notch (JAG1, RBPSUH, FJX1) pathways to be amplified and overexpressed. Deregulation of these and other members of the hedgehog and notch pathways (HHIP, SMO, DLL1, NOTCH4) implicates deregulation of developmental and differentiation pathways, cell fate misspecification, in oral SCC development.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu		Schmidt, Brian/0000-0002-2409-8984	NCI NIH HHS [CA92531, CA90421, CA94407] Funding Source: Medline; NIDCR NIH HHS [K12 DE14609, DE19604] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA094407, R01CA090421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F31DE019604, K12DE014609] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Aho S, 2004, J CELL BIOCHEM, V92, P1271, DOI 10.1002/jcb.20125; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buckles GR, 2001, DEVELOPMENT, V128, P3533; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Fridlyand J, 2004, J MULTIVARIATE ANAL, V90, P132, DOI 10.1016/j.jmva.2004.02.008; Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367; Ha PK, 2003, CLIN CANCER RES, V9, P3058; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; HUME WJ, 1979, J ORAL PATHOL MED, V8, P3, DOI 10.1111/j.1600-0714.1979.tb01618.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kim MM, 2004, INT J CANCER, V112, P545, DOI 10.1002/ijc.20379; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Lefort K, 2004, SEMIN CANCER BIOL, V14, P374, DOI 10.1016/j.semcancer.2004.04.017; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Macabeo-Ong M, 2003, ORAL ONCOL, V39, P638, DOI 10.1016/S1368-8375(03)00034-4; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; MIELE M, 1989, MUTAT RES, V219, P171, DOI 10.1016/0921-8734(89)90012-X; Mineta H, 1997, ORAL ONCOL, V33B, P42, DOI 10.1016/S0964-1955(96)00039-5; Moore L, 2000, BIOTECHNIQUES, V28, P986, DOI 10.2144/00285rr04; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nishimaki H, 2004, BIOCHEM BIOPH RES CO, V314, P313, DOI 10.1016/j.bbrc.2003.12.097; Ohki K, 2004, INT J ORAL MAX SURG, V33, P584, DOI 10.1016/j.ijom.2004.01.013; Parkhurst HB, 1999, J CREATIVE BEHAV, V33, P1, DOI 10.1002/j.2162-6057.1999.tb01035.x; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Redon R, 2002, CANCER RES, V62, P6211; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Roth JR, 2004, RES MICROBIOL, V155, P342, DOI 10.1016/j.resmic.2004.01.016; Shimizu N, 2005, EXP CELL RES, V302, P233, DOI 10.1016/j.yexcr.2004.09.001; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watkins DN, 2004, BIOCHEM PHARMACOL, V68, P1055, DOI 10.1016/j.bcp.2004.04.025; Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004; Westfall P.H., 1993, RESAMPLING BASED MUL; Wolff E, 1998, ORAL ONCOL, V34, P186, DOI 10.1016/S1368-8375(97)00079-1; Zeidler MP, 1999, CURR BIOL, V9, P1363, DOI 10.1016/S0960-9822(00)80081-0	48	215	229	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4232	4242		10.1038/sj.onc.1208601	http://dx.doi.org/10.1038/sj.onc.1208601			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824737				2022-12-17	WOS:000229815300007
J	Hartmann, TN; Burger, JA; Glodek, A; Fujii, N; Burger, M				Hartmann, TN; Burger, JA; Glodek, A; Fujii, N; Burger, M			CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells	ONCOGENE			English	Article						chemokine receptor; CXCR4; CXCR4; antagonists; integrins; lung cancer	DRUG-RESISTANCE; TYROSINE PHOSPHORYLATION; SPONTANEOUS MIGRATION; FACTOR-1-ALPHA; EXPRESSION; ACTIVATION; PROTEIN; ARREST; KINASE; TRANSDUCTION	Small cell lung cancer (SCLC) is an aggressive, rapidly metastazising neoplasm with a high propensity for marrow involvement. SCLC cells express high levels of functional CXCR4 receptors for the chemokine stromal-cell-derived factor-1 (SDF-1/CXCL12). Adhesion of SCLC cells to extracellular matrix or accessory cells within the tumor microenvironment confers resistance to chemotherapy via integrin signaling and thus may be responsible for residual disease and relapses commonly seen in SCLC. We examined the signaling mechanisms that regulate CXCL12-induced adhesion of SCLC cells to fibronectin, collagen, and stromal cells and the effects on SCLC cell chemoresistance. We found that CXCL12-induced integrin activation which resulted in an increased adhesion of SCLC cells to fibronectin and collagen. This was mediated by alpha 2, alpha 4, alpha 5, and beta 1 integrins along with CXCR4 activation, which could be inhibited by CXCR4 antagonists. Stromal cells protected SCLC cells from chemotherapy-induced apoptosis, and this protection could also be antagonized by CXCR4 inhibitors. We conclude that activation of integrins and CXCR4 chemokine receptors co-operate in mediating adhesion and survival signals from the tumor microenvironment to SCLC cells. Therefore, CXCR4 antagonists in combination with cytotoxic drugs should be explored in SCLC to overcome CXCL12-mediated adhesion and survival signals in the tumor microenvironment.	Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, D-79106 Freiburg, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto, Japan	University of Freiburg; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyoto University	Burger, M (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burgerm@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/C-9345-2017; Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301				Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Burger JA, 2003, BRIT J HAEMATOL, V122, P579, DOI 10.1046/j.1365-2141.2003.04466.x; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Fujii N, 2003, EXPERT OPIN INV DRUG, V12, P185, DOI 10.1517/13543784.12.2.185; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; Kijima T, 2002, CANCER RES, V62, P6304; Kraus AC, 2002, ONCOGENE, V21, P8683, DOI 10.1038/sj.onc.1205939; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wright N, 2002, J IMMUNOL, V168, P5268, DOI 10.4049/jimmunol.168.10.5268; ZIPORI D, 1985, BLOOD, V66, P447	39	215	235	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4462	4471		10.1038/sj.onc.1208621	http://dx.doi.org/10.1038/sj.onc.1208621			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806155				2022-12-17	WOS:000229976900015
J	Levanon, D; Groner, Y				Levanon, D; Groner, Y			Structure and regulated expression of mammalian RUNX genes	ONCOGENE			English	Review						gene structure; promoter analysis; translation control; signaling pathways; tissue-specific expression	ACUTE MYELOID-LEUKEMIA; BONE MORPHOGENETIC PROTEIN-2; T-CELL DEVELOPMENT; GROWTH-FACTOR-BETA; OSTEOSARCOMA ROS17/2.8 CELLS; HEMATOPOIETIC STEM-CELLS; HUMAN CBFA1 GENE; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; CHONDROCYTE DIFFERENTIATION	The RUNX are key regulators of lineage-specific gene expression in major developmental pathways. The expression of RUNX genes is tightly regulated, leading to a highly specific spatio/temporal expression pattern and to distinct phenotypes of gene knockouts. This review highlights the extensive structural similarities between the three mammalian RUNX genes and delineates how regulation of their expression at the levels of transcription and translation are orchestrated into the unique RUNX expression pattern.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Groner, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	yoram.groner@weizmann.ac.il						Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; AVRAHAM KB, 1995, GENOMICS, V25, P603, DOI 10.1016/0888-7543(95)80073-U; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bae SC, 2000, GENE, V241, P255, DOI 10.1016/S0378-1119(99)00488-6; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Ben Aziz-Aloya R, 1998, CELL DEATH DIFFER, V5, P765, DOI 10.1038/sj.cdd.4400415; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; CALABI F, 1995, GENOMICS, V26, P607, DOI 10.1016/0888-7543(95)80184-N; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Choi KY, 2002, EXP MOL MED, V34, P426, DOI 10.1038/emm.2002.60; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Eggers JH, 2002, GENE, V291, P159, DOI 10.1016/S0378-1119(02)00592-9; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; Enomoto-Iwamoto M, 2001, OSTEOARTHR CARTILAGE, V9, pS76, DOI 10.1053/joca.2001.0448; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fossett N, 2001, DIFFERENTIATION, V69, P83, DOI 10.1046/j.1432-0436.2001.690202.x; Fujiwara M, 1999, BBA-GENE STRUCT EXPR, V1446, P265, DOI 10.1016/S0167-4781(99)00113-X; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hayashi K, 2001, J IMMUNOL, V167, P4957, DOI 10.4049/jimmunol.167.9.4957; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kanzler B, 1998, DEVELOPMENT, V125, P2587; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2003, BLOOD CELL MOL DIS, V30, P161, DOI 10.1016/S1079-9796(03)00023-8; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2003, J CELL PHYSIOL, V196, P301, DOI 10.1002/jcp.10316; Liu B, 2003, BLOOD, V101, P124, DOI 10.1182/blood-2002-02-0398; LORSBACH RB, 2003, IN PRESS BLOOD; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Nibu K, 2000, BIOCHEM BIOPH RES CO, V279, P172, DOI 10.1006/bbrc.2000.3899; North T, 1999, DEVELOPMENT, V126, P2563; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Rennert J, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-4; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shi MJ, 1998, J IMMUNOL, V161, P6751; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Spender LC, 2002, J VIROL, V76, P4919, DOI 10.1128/JVI.76.10.4919-4927.2002; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stricker S, 2003, DEV COMP IMMUNOL, V27, P673, DOI 10.1016/S0145-305X(03)00037-5; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033; Sun LX, 2001, CANCER RES, V61, P4994; Takamoto M, 2003, J ENDOCRINOL, V177, P413, DOI 10.1677/joe.0.1770413; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303-7207(01)00594-9; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Tsuji K, 2001, J BONE MINER METAB, V19, P213, DOI 10.1007/s007740170023; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Yamashiro T, 2002, MECH DEVELOP, V119, pS107, DOI 10.1016/S0925-4773(03)00101-1; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Yousfi M, 2002, BIOCHEM BIOPH RES CO, V297, P641, DOI 10.1016/S0006-291X(02)02260-X; Zambotti A, 2002, J BIOL CHEM, V277, P41497, DOI 10.1074/jbc.M204271200; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133; Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001	123	215	221	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4211	4219		10.1038/sj.onc.1207670	http://dx.doi.org/10.1038/sj.onc.1207670			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156175				2022-12-17	WOS:000221586000004
J	Sullivan, A; Syed, N; Gasco, M; Bergamaschi, D; Trigiante, G; Attard, M; Hiller, L; Farrell, PJ; Smith, P; Lu, X; Crook, T				Sullivan, A; Syed, N; Gasco, M; Bergamaschi, D; Trigiante, G; Attard, M; Hiller, L; Farrell, PJ; Smith, P; Lu, X; Crook, T			Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo	ONCOGENE			English	Article						carcinoma; p53; SNP; apoptosis; clinical outcome	COLORECTAL-CANCER CELLS; P53-DEPENDENT APOPTOSIS; PUMA; VARIANTS; MEDIATOR; AGENTS; NOXA	A single-nucleotide polymorphism (SNP) in exon 4 results in expression of either arginine (72R) or proline (72P) at codon 72 of p53. We demonstrate that the in vitro response of cells exposed to anticancer agents is strongly influenced by this SNP in wild-type p53. In inducible systems and in cells expressing the endogenous protein, expression of 72P wild-type p53 results in a predominant G1 arrest, with only a minor apoptosis, at drug concentrations causing extensive apoptosis in cells expressing the 72R wild-type variant. The superior apoptosis-inducing activity of the 72R form correlates with more efficient induction of specific apoptosis-associated genes, and is maximal in the presence of serine 46 (S46). In vivo, the outcome of chemo-radiotherapy of squamous carcinomas is more favourable in cancers retaining a wild-type 72R allele, such cases having higher response rates and longer survival than those with wild-type 72P. Together, these results reveal that this SNP is an important determinant of response to anticancer agents in cells expressing wild-type p53. Analysis of complete p53 genotype (mutation and SNP) merits detailed investigation as a simple means for prediction of treatment response and survival in clinical oncology.	St Marys Hosp, Imperial Coll Fac Med, Ludwig Inst Canc Res, London W1, England; S Croce & Carle Hosp, Dept Med Oncol, I-12100 Cuneo, Italy; Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England	Imperial College London; Ludwig Institute for Cancer Research; Cancer Research UK; University of Birmingham	Crook, T (corresponding author), St Marys Hosp, Imperial Coll Fac Med, Ludwig Inst Canc Res, Norfolk Pl, London W1, England.	t.crook@ic.ac.uk		Farrell, Paul/0000-0002-6754-9351; Bergamaschi, Daniele/0000-0002-3955-1091; Lu, Xin/0000-0002-6587-1152				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; SJALANDER A, 1995, HUM HERED, V45, P144, DOI 10.1159/000154275; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	26	215	235	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3328	3337		10.1038/sj.onc.1207428	http://dx.doi.org/10.1038/sj.onc.1207428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077186				2022-12-17	WOS:000220975000007
J	Machado, JC; Oliveira, C; Carvalho, R; Soares, P; Berx, G; Caldas, C; Seruca, R; Carneiro, F; Sobrinho-Simoes, M				Machado, JC; Oliveira, C; Carvalho, R; Soares, P; Berx, G; Caldas, C; Seruca, R; Carneiro, F; Sobrinho-Simoes, M			E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma	ONCOGENE			English	Article						E-cadherin; mutation; methylation; gastric cancer; stomach; diffuse cancer	LOBULAR BREAST CANCERS; MUTATIONS PROVIDE; EXPRESSION; HYPERMETHYLATION; CELLS; PROGRESSION; PATTERNS; ADHESION; ISLAND	In diffuse gastric carcinoma, despite common E-cadherin gene (CDH1) mutations, tumors show absence of CDH1 loss of heterozigosity (LOH) in most cases. This observation challenges the classical two-hit model of tumor suppresser gene inactivation. In order to investigate whether or not CDH1 promoter methylation may function as the second hit we analysed a series of 23 sporadic gastric carcinomas for the presence of CDH1 mutations, CDH1 promoter methylation, LOH and E-cadherin expression. CDH1 mutations were detected in nine of the 16 (56.3%) diffuse gastric carcinomas and in none of the seven intestinal gastric carcinomas. In diffuse gastric carcinomas harboring CDH1 mutations, LOH was observed in a single case. Loss of plasma membrane E-cadherin expression was consistently found in all nine cases with CDH1 mutation, suggesting that tumors inactivated the remaining CDH1 allele via a different mechanism. CDH1 promoter methylation was observed in nine of the 16 (56.3%) diffuse-type gastric carcinoma cases, including six of the nine cases (66.7%) harboring CDH1 mutations. CDH1 promoter methylation was also seen in two (28.6%) intestinal-type cases. Our results show that CDH1 promoter methylation is the second hit in more than half of the sporadic diffuse gastric carcinoma cases harboring CDH1 mutations.	IPATIMUP, P-4200 Oporto, Portugal; Univ Cambridge, Dept Oncol, Cambridge CB2 2XY, England; VIB Ghent Univ, KL, Dept Mol Biol, B-9000 Ghent, Belgium; Univ Porto, Fac Med, P-4200 Oporto, Portugal	University of Cambridge; Flanders Institute for Biotechnology (VIB); Ghent University; Universidade do Porto	Machado, JC (corresponding author), IPATIMUP, Rua Roberto Frias S-N, P-4200 Oporto, Portugal.		Soares, Paula/B-6054-2008; Caldas, Carlos/U-7250-2019; Carneiro, Fatima/J-6432-2013; Caldas, Carlos/A-7543-2008; Oliveira, Carla/F-8188-2011; Carneiro, Fatima/AAV-8677-2021; Machado, Jose Carlos/C-5907-2009; seruca, raquel/F-8187-2011; Sobrinho-Simões, Manuel/J-8290-2013	Soares, Paula/0000-0001-9607-6998; Caldas, Carlos/0000-0003-3547-1489; Carneiro, Fatima/0000-0002-1964-1006; Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; Machado, Jose Carlos/0000-0003-4741-8415; Seruca, Raquel/0000-0002-8851-4166; Berx, Geert/0000-0001-5770-2458; Sobrinho-Simoes, Manuel/0000-0003-1613-1235				BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Gayther SA, 1998, CANCER RES, V58, P4086; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Lee YY, 1997, CANCER, V80, P1889, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1889::AID-CNCR3>3.0.CO;2-J; Leung SY, 1999, CANCER RES, V59, P159; Luber B, 2000, CELL ADHES COMMUN, V7, P391, DOI 10.3109/15419060009109021; Machado JC, 1998, INT J SURG PATHOL, V6, P135, DOI 10.1177/106689699800600302; Machado JC, 1999, LAB INVEST, V79, P459; Shin JY, 2000, CANCER RES, V60, P262; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569	23	215	234	0	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1525	1528		10.1038/sj.onc.1204234	http://dx.doi.org/10.1038/sj.onc.1204234			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313896				2022-12-17	WOS:000167595200013
J	Herrington, J; Smit, LS; Schwartz, J; Carter-Su, C				Herrington, J; Smit, LS; Schwartz, J; Carter-Su, C			The role of STAT proteins in growth hormone signaling	ONCOGENE			English	Review						growth hormone (GH); STAT proteins; tyrosines	ACUTE-PHASE RESPONSE; PROMOTED TYROSYL PHOSPHORYLATION; COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; ACID-LABILE SUBUNIT; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; MESSENGER-RIBONUCLEIC-ACID; MAMMARY-GLAND DEVELOPMENT; DEPENDENT NUCLEAR IMPORT; I GENE-TRANSCRIPTION	Growth hormone (GH) has long been known to be the body's primary regulator of body growth and a regulator of metabolism, yet the mechanisms by which GH regulates the transcription of specific genes required for these processes are just now being delineated. GH binding to its receptor recruits and activates the receptor-associated JAK2 that in turn phosphorylates tyrosines within itself and the GH receptor. These tyrosines form binding sites for a number of signaling proteins, including members of the family of signal transducers and activators of transcription (STAT), Among the known signaling molecules for GH, STAT proteins play a particularly prominent role in the regulation of gene transcription. This paper will review what is currently understood about which STAT proteins are regulated by GH, how they are regulated by GH, the GH-dependent genes they regulate, and discuss current theories about how GH-activated STAT signaling is regulated, Particular attention will be given to the novel role that STAT5 plays in sexually dimorphic gene expression in the liver as determined by the secretory pattern of GH and the role of STAT5 in body growth.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [R01-DK54222, R01 DK034171, R01 DK046072, R01 DK054222, R01-DK34171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054222, R01DK034171, R01DK046072] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASPLIN CM, 1989, J CLIN ENDOCR METAB, V69, P239, DOI 10.1210/jcem-69-2-239; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Benbassat C, 1999, ENDOCRINOLOGY, V140, P3073, DOI 10.1210/en.140.7.3073; Bergad PL, 2000, J BIOL CHEM, V275, P8114, DOI 10.1074/jbc.275.11.8114; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; BILLESTRUP N, 1985, ENDOCRINOLOGY, V116, P1175, DOI 10.1210/endo-116-3-1175; Boisclair YR, 1996, P NATL ACAD SCI USA, V93, P10028, DOI 10.1073/pnas.93.19.10028; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; DAI J, 1994, ENDOCRINOLOGY, V135, P1066, DOI 10.1210/en.135.3.1066; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Davey HW, 1999, J BIOL CHEM, V274, P35331, DOI 10.1074/jbc.274.50.35331; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EDEN S, 1982, ENDOCRINOLOGY, V111, P1505, DOI 10.1210/endo-111-5-1505; EILERS A, 1995, MOL CELL BIOL, V15, P3579; ENBERG B, 1994, J MOL ENDOCRINOL, V12, P39, DOI 10.1677/jme.0.0120039; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fain JN, 1999, BIOCHEM BIOPH RES CO, V263, P201, DOI 10.1006/bbrc.1999.1302; Favre H, 1999, FEBS LETT, V453, P63, DOI 10.1016/S0014-5793(99)00681-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fernandez L, 1998, ENDOCRINOLOGY, V139, P1815, DOI 10.1210/en.139.4.1815; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; Freeth JS, 1998, ENDOCRINOLOGY, V139, P20, DOI 10.1210/en.139.1.20; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; HERRINGTON J, 2000, IN PRESS J BIOL CHEM; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ISGAARD J, 1988, ENDOCRINOLOGY, V122, P1515, DOI 10.1210/endo-122-4-1515; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; JOHNSON RJ, 1988, J ENDOCRINOL, V119, P101, DOI 10.1677/joe.0.1190101; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Le Stunff C, 1998, ENDOCRINOLOGY, V139, P859, DOI 10.1210/en.139.3.859; LECAM A, 1994, J BIOL CHEM, V269, P21532; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meton I, 1999, FEBS LETT, V444, P155, DOI 10.1016/S0014-5793(99)00064-2; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; PETER MA, 1993, ENDOCRINOLOGY, V133, P2624, DOI 10.1210/en.133.6.2624; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; RAZ R, 1994, J BIOL CHEM, V269, P24391; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; Simar-Blanchet AE, 1998, MOL ENDOCRINOL, V12, P391, DOI 10.1210/me.12.3.391; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; SMIT LS, 1999, HDB PHYSL, V5, P445; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOTIROPOULOS A, 1995, FEBS LETT, V369, P169, DOI 10.1016/0014-5793(95)00734-Q; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; STOFEGA MR, 2000, UNPUB J BIOL CHEM; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; TOURKINE N, 1995, J BIOL CHEM, V270, P20952, DOI 10.1074/jbc.270.36.20952; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XY, 1993, J BIOL CHEM, V268, P3573; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WINER LM, 1990, J CLIN ENDOCR METAB, V70, P1678, DOI 10.1210/jcem-70-6-1678; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; YOON JB, 1987, J BIOL CHEM, V262, P4284; YOON JB, 1990, J BIOL CHEM, V265, P19947; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	166	215	225	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2585	2597		10.1038/sj.onc.1203526	http://dx.doi.org/10.1038/sj.onc.1203526			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851057	Green Published			2022-12-17	WOS:000087459400014
J	Suzuki, A; Ito, T; Kawano, H; Hayashida, M; Hayasaki, Y; Tsutomi, Y; Akahane, K; Nakano, T; Miura, M; Shiraki, K				Suzuki, A; Ito, T; Kawano, H; Hayashida, M; Hayasaki, Y; Tsutomi, Y; Akahane, K; Nakano, T; Miura, M; Shiraki, K			Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death	ONCOGENE			English	Article						Survivin; Cdk4; procaspase 3/p21 complex; Fas-mediated cell death; cell survival	ANTI-APOPTOSIS GENE; RETINOBLASTOMA PROTEIN; ICE/CED-3 PROTEASE; ICE CASCADE; GRANZYME-B; CYCLE; ACTIVATION; INVOLVEMENT; EXPRESSION; CASPASE-3	Caspase 3 is ran essential death factor for the Fas-mediated cell death, and its inactivation in cells is initiated by an interaction with p21 on mitochondria or with PAP family member ILP, Survivin is also a member of HAP family and is specifically expressed during embryogenesis and in tumor cells and suppresses cell death signaling, In our current study, we demonstrated that Survivin translocation into the nucleus is dependent on Fas stimulation and cell proliferation. Survivin also interacts with the cell cycle regulator Cdk4, leading to Cdk2/Cyclin E activation and Rb phosphorylation, As a result of Survivin/Cdk4 complex formation, p21 is released from its complex with Cdk4 and interacts with mitochondrial procaspase 3 to suppress Fas-mediated cell death, Here, we propose that Survivin supports procaspase 3/p21 complex formation as a result of interaction with Cdk4 resulting in suppression of cell death signaling.	Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, Basic Technol Res Lab, Project Cell Death Res,Edogawa Ku, Tokyo 1348630, Japan; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, Drug Safety Res Lab, Edogawa Ku, Tokyo 1348630, Japan; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, New Prod Res Lab 4, Edogawa Ku, Tokyo 1348630, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Suita, Osaka 565, Japan	Daiichi Sankyo Company Limited; Mie University; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Osaka University	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, Basic Technol Res Lab, Project Cell Death Res,Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.							Adida C, 1998, AM J PATHOL, V152, P43; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fleischer S, 1974, Methods Enzymol, V31, P6; Hasegawa J, 1996, CANCER RES, V56, P1713; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu S, 1996, ONCOGENE, V12, P2251; SMITH PK, 1985, ANAL BIOCHEM, V170, P203; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1997, EXP CELL RES, V234, P507, DOI 10.1006/excr.1997.3639; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	39	215	379	2	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1346	1353		10.1038/sj.onc.1203429	http://dx.doi.org/10.1038/sj.onc.1203429			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713676				2022-12-17	WOS:000085743800011
J	Sciacca, L; Costantino, A; Pandini, G; Mineo, R; Frasca, F; Scalia, P; Sbraccia, P; Goldfine, ID; Vigneri, R; Belfiore, A				Sciacca, L; Costantino, A; Pandini, G; Mineo, R; Frasca, F; Scalia, P; Sbraccia, P; Goldfine, ID; Vigneri, R; Belfiore, A			Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism	ONCOGENE			English	Article						insulin receptor; IGF-I receptor; IGF-I; IGF-II; breast cancer	HAMSTER OVARY CELLS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; TRANSFORMED PHENOTYPE; OVEREXPRESSION; EXPRESSION; INHIBITION; BINDING; CDNA	IGF-II, produced by breast cancer epithelial and stromal cells, enhances tumor growth by activating the IGF-I receptor (IGF-I-R) via autocrine and paracrine mechanisms. Previously we found that the insulin receptor (IR), which is related to the IGF-I-R, is overexpressed in breast cancer cells. Herein, we find that, in breast cancer the IR is activated by IGF-II, In eight human breast cancer cell lines studied there,vas high affinity ICF-II binding to the IR, with subsequent IR activation, In these lints, IGF-II had a potency up to 63% that of insulin. In contrast, in non malignant human breast cells, IGF-II was less than 1% potent as insulin. Via activation of the IR tyrosine kinase IGF-II stimulated breast cancer cell growth. However, IGF-II also activated the IR in breast cancer tissue specimens; IGF-II was 10-100% as potent as insulin. The IR occurs in two isoforms generated by alternative splicing of exon 11; these isoforms are IR-A (Ex11-) and IR-B (Ex11+). IR-A was predominantly expressed in breast cancer cells and specimens and the potency of IGF-II was correlated to the expression of this isoform (P<0.0001). These data indicate, therefore, that the IR-A, which binds IGF-II with high affinity, is predominantly expressed in breast cancer cells and represents a new autocrine/paracrine loop involved in tumor biology.	Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy; Univ La Sapienza, Policlin Umberto I, Cattedra Endocrinol 1, I-00161 Rome, Italy; Univ Calif San Francisco, Div Diabet & Endocrine Res, San Francisco, CA 94115 USA	University of Catania; Sapienza University Rome; University Hospital Sapienza Rome; University of California System; University of California San Francisco	Belfiore, A (corresponding author), Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy.		Pandini, Giuseppe/AAB-9650-2019; SCIACCA, Laura/AAS-2896-2020; Scalia, Pierluigi/AAH-8443-2019; Belfiore, Antonino/B-4652-2011; Sciacca, Laura/B-9368-2014; Frasca, Francesco/J-1332-2018; Vigneri, Riccardo/M-3968-2017	Pandini, Giuseppe/0000-0003-3747-7649; SCIACCA, Laura/0000-0002-3258-7200; Scalia, Pierluigi/0000-0002-5911-1640; Belfiore, Antonino/0000-0002-6181-4193; Sciacca, Laura/0000-0002-3258-7200; Frasca, Francesco/0000-0002-5556-3201; Vigneri, Riccardo/0000-0002-4401-3140				ARTEAGA CL, 1989, CANCER RES, V49, P6237; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; CARMICHAEL J, 1987, CANCER RES, V47, P943; CULLEN K, 1997, ASSIST TECHN RES SER, V2, P1; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ENJOH T, 1993, J CLIN ENDOCR METAB, V77, P510, DOI 10.1210/jc.77.2.510; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; FRASCA F, 1999, IN PRESS MOL CELL BI, V19; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; JONAS HA, 1990, ENDOCRINOLOGY, V127, P1301, DOI 10.1210/endo-127-3-1301; JONAS HA, 1989, BIOCHEM J, V257, P101, DOI 10.1042/bj2570101; JONAS HA, 1992, BIOCHEM J, V266, P737; KULL FC, 1983, J BIOL CHEM, V258, P6561; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Mathieu MC, 1997, P ASSOC AM PHYSICIAN, V109, P565; MILAZZO G, 1992, CANCER RES, V52, P3924; MILAZZO G, 1992, J CLIN INVEST, V89, P899, DOI 10.1172/JCI115670; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Papa V, 1996, J ENDOCRINOL INVEST, V19, P324, DOI 10.1007/BF03347871; PODSKALNY JM, 1986, J BIOL CHEM, V261, P14076; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Steller MA, 1996, CANCER RES, V56, P1761; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058	31	215	224	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2471	2479		10.1038/sj.onc.1202600	http://dx.doi.org/10.1038/sj.onc.1202600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229198				2022-12-17	WOS:000079703300007
J	Ladanyi, A; Mukherjee, A; Kenny, HA; Johnson, A; Mitra, AK; Sundaresan, S; Nieman, KM; Pascual, G; Benitah, SA; Montag, A; Yamada, SD; Abumrad, NA; Lengyel, E				Ladanyi, Andras; Mukherjee, Abir; Kenny, Hilary A.; Johnson, Alyssa; Mitra, Anirban K.; Sundaresan, Sinju; Nieman, Kristin M.; Pascual, Gloria; Aznar Benitah, Salvador; Montag, Anthony; Yamada, S. Diane; Abumrad, Nada A.; Lengyel, Ernst			Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis	ONCOGENE			English	Article							FATTY-ACID UPTAKE; MONOCYTE-DERIVED MACROPHAGES; B SCAVENGER RECEPTOR; MESOTHELIAL CELLS; TRANSPORT; MEMBRANE; ACTIVATION; OXIDATION; PROTEINS; ADHESION	Ovarian cancer (OvCa) is characterized by widespread and rapid metastasis in the peritoneal cavity. Visceral adipocytes promote this process by providing fatty acids (FAs) for tumour growth. However, the exact mechanism of FA transfer from adipocytes to cancer cells remains unknown. This study shows that OvCa cells co-cultured with primary human omental adipocytes express high levels of the FA receptor, CD36, in the plasma membrane, thereby facilitating exogenous FA uptake. Depriving OvCa cells of adipocyte-derived FAs using CD36 inhibitors and short hairpin RNA knockdown prevented development of the adipocyte-induced malignant phenotype. Specifically, inhibition of CD36 attenuated adipocyte-induced cholesterol and lipid droplet accumulation and reduced intracellular reactive oxygen species (ROS) content. Metabolic analysis suggested that CD36 plays an essential role in the bioenergetic adaptation of OvCa cells in the adipocyte-rich microenvironment and governs their metabolic plasticity. Furthermore, the absence of CD36 affected cellular processes that play a causal role in peritoneal dissemination, including adhesion, invasion, migration and anchorage independent growth. Intraperitoneal injection of CD36-deficient cells or treatment with an anti-CD36 monoclonal antibody reduced tumour burden in mouse xenografts. Moreover, a matched cohort of primary and metastatic human ovarian tumours showed upregulation of CD36 in the metastatic tissues, a finding confirmed in three public gene expression data sets. These results suggest that omental adipocytes reprogram tumour metabolism through the upregulation of CD36 in OvCa cells. Targeting the stromal-tumour metabolic interface via CD36 inhibition may prove to be an effective treatment strategy against OvCa metastasis.	[Ladanyi, Andras; Mukherjee, Abir; Kenny, Hilary A.; Johnson, Alyssa; Mitra, Anirban K.; Nieman, Kristin M.; Yamada, S. Diane; Lengyel, Ernst] Univ Chicago, Dept Obstet, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Ladanyi, Andras; Mukherjee, Abir; Kenny, Hilary A.; Johnson, Alyssa; Mitra, Anirban K.; Nieman, Kristin M.; Yamada, S. Diane; Lengyel, Ernst] Univ Chicago, Dept Gynecol, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Ladanyi, Andras] Univ Illinois, Dept Obstet, Gynecol Oncol Sect, Chicago, IL USA; [Ladanyi, Andras] Univ Illinois, Dept Gynecol, Gynecol Oncol Sect, Chicago, IL USA; [Sundaresan, Sinju; Abumrad, Nada A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Sundaresan, Sinju; Abumrad, Nada A.] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; [Pascual, Gloria; Aznar Benitah, Salvador] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain; [Aznar Benitah, Salvador] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain; [Montag, Anthony] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Washington University (WUSTL); Washington University (WUSTL); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; University of Chicago	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet, Gynecol Oncol Sect, Chicago, IL 60637 USA.; Lengyel, E (corresponding author), Univ Chicago, Dept Gynecol, Gynecol Oncol Sect, Chicago, IL 60637 USA.	elengyel@uchicago.edu	Aznar-Benitah, Salvador/F-4761-2016; Angulo, Gloria Pascual/AAA-7668-2019; Lengyel, Ernst/D-9220-2014	Aznar-Benitah, Salvador/0000-0002-9059-5049; Angulo, Gloria Pascual/0000-0003-3810-6647; Lengyel, Ernst/0000-0001-8624-1507; Nieman, Kristin/0000-0001-7529-0872	Bears Care, the charitable beneficiary of the Chicago Bears Football Club; National Cancer Institute [DK033301]; Foundation for Women's Cancer, Amgen Ovarian Cancer Research Grant;  [CA 169604]; NATIONAL CANCER INSTITUTE [R01CA111882, R01CA211916, R01CA169604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK060022, R01DK111175, R01DK033301] Funding Source: NIH RePORTER	Bears Care, the charitable beneficiary of the Chicago Bears Football Club; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Foundation for Women's Cancer, Amgen Ovarian Cancer Research Grant; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a grant from Bears Care, the charitable beneficiary of the Chicago Bears Football Club (SD Yamada and E Lengyel) by National Cancer Institute grant DK033301 (NA Abumrad) and by CA 169604 (E Lengyel) and the Foundation for Women's Cancer, Amgen Ovarian Cancer Research Grant (A Ladanyi). We thank Chunling Zhang and the Center for Research Informatics at the University of Chicago for their bioinformatics support on the microarray data. We are grateful to Gail Isenberg for editing this manuscript.	Abumrad N A, 2000, Curr Opin Clin Nutr Metab Care, V3, P255, DOI 10.1097/00075197-200007000-00003; Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999; Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Agrawal S, 2007, CIRCULATION, V115, P2939, DOI 10.1161/CIRCULATIONAHA.107.696922; Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Baranova IN, 2010, J BIOL CHEM, V285, P8492, DOI 10.1074/jbc.M109.007526; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Cheng JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep21808; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Coscia F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12645; de Gonzalo-Calvo D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1469-5; Dobrzyn P, 2008, AM J PHYSIOL-ENDOC M, V294, pE357, DOI 10.1152/ajpendo.00471.2007; Eckert MA, 2016, CANCER DISCOV, V6, P1342, DOI 10.1158/2159-8290.CD-16-0607; Ehehalt R, 2006, MOL CELL BIOCHEM, V284, P135, DOI 10.1007/s11010-005-9034-1; Guillaumond F, 2015, P NATL ACAD SCI USA, V112, P2473, DOI 10.1073/pnas.1421601112; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Janabi M, 2001, BIOCHEM BIOPH RES CO, V283, P26, DOI 10.1006/bbrc.2001.4718; Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kazantzis M, 2012, BBA-MOL CELL BIOL L, V1821, P852, DOI 10.1016/j.bbalip.2011.09.010; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Kenny HA, 2011, CLIN CANCER RES, V17, P459, DOI 10.1158/1078-0432.CCR-10-2258; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lee SH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7364; Li W, 2010, J CLIN INVEST, V120, P3996, DOI 10.1172/JCI42823; Liu YY, 2015, CANCER RES, V75, P5046, DOI 10.1158/0008-5472.CAN-15-0706; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Mwaikambo BR, 2009, J BIOL CHEM, V284, P26695, DOI 10.1074/jbc.M109.033480; Nath A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14752; Naville D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030686; Nergiz-Unal R., 2011, Cardiovascular & Hematological Agents in Medicinal Chemistry, V9, P42, DOI 10.2174/187152511794182855; Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Parrales A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122074; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pepino MY, 2014, ANNU REV NUTR, V34, P281, DOI 10.1146/annurev-nutr-071812-161220; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; RANDLE PJ, 1963, LANCET, V1, P785; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rodrigue-Way A, 2014, FASEB J, V28, P1910, DOI 10.1096/fj.13-240168; Romero IL, 2015, CLIN CANCER RES, V21, P680, DOI 10.1158/1078-0432.CCR-14-2198; Samovski D, 2015, DIABETES, V64, P353, DOI 10.2337/db14-0582; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Sehouli J, 2009, J SURG ONCOL, V99, P424, DOI 10.1002/jso.21288; Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3; Su X, 2009, TRENDS ENDOCRIN MET, V20, P72, DOI 10.1016/j.tem.2008.11.001; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; TANDON NN, 1989, J BIOL CHEM, V264, P7570; Thompson BR, 2010, MOL CELL ENDOCRINOL, V318, P24, DOI 10.1016/j.mce.2009.08.015; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Witz CA, 2001, J SOC GYNECOL INVEST, V8, P299, DOI 10.1016/S1071-5576(01)00122-8	58	214	223	7	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2285	2301		10.1038/s41388-017-0093-z	http://dx.doi.org/10.1038/s41388-017-0093-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29398710	Green Accepted			2022-12-17	WOS:000431100200006
J	Yu, T; Li, J; Yan, M; Liu, L; Lin, H; Zhao, F; Sun, L; Zhang, Y; Cui, Y; Zhang, F; Li, J; He, X; Yao, M				Yu, T.; Li, J.; Yan, M.; Liu, L.; Lin, H.; Zhao, F.; Sun, L.; Zhang, Y.; Cui, Y.; Zhang, F.; Li, J.; He, X.; Yao, M.			MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway	ONCOGENE			English	Article						NSCLC; miR-193a-3p; miR-193a-5p; target genes; metastasis	COLORECTAL-CANCER; EXPRESSION; GENE; INVASION; GROWTH; PROLIFERATION; INHIBITION; MICRORNAS; MIGRATION; MIR-193A	The metastatic cascade is a complex and multistep process with many potential barriers. Recent evidence has shown that microRNAs (miRNAs) are involved in carcinogenesis and tumor progression in non-small-cell lung cancer (NSCLC). In this study, by comparing the miRNA expression profiles of SPC-A-1sci (high metastatic) and SPC-A-1 (weakly metastatic) cells, we demonstrated that the downregulation and function of miR-193a-3p and miR-193a-5p in NSCLC metastasis and the expression of these miRNAs was suppressed in NSCLC compared with corresponding non-tumorous tissues. Decreased miR-193a-3p/5p expression was significantly associated with tumor node metastasis (TNM) and lymph node metastasis. Furthermore, functional assays showed that the overexpression of miR-193a-3p/5p inhibited NSCLC cell migration, invasion and epithelial-mesenchymal transition (EMT) in vitro and lung metastasis formation in vivo. In addition, we discovered that ERBB4 and S6K2 were the direct targets of miR-193a-3p and that PIK3R3 and mTOR were the direct targets of miR-193a-5p in NSCLC. We also observed that miR-193a-3p/5p could inactivate the AKT/mTOR signaling pathway. Thus, miR-193a-3p/5p functions as a tumor suppressor and has an important role in NSCLC metastasis through ERBB signaling pathway.	[Yu, T.; Li, J.; Yan, M.; Liu, L.; Lin, H.; Zhao, F.; Sun, L.; Zhang, Y.; Cui, Y.; Zhang, F.; Li, J.; He, X.; Yao, M.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University	Yao, M (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, 25-2200 Xietu Rd, Shanghai 200032, Peoples R China.	myao@shsci.org	Zhang, Fang/HHN-2153-2022; He, Xianghuo/I-1497-2014; Yu, Tao/GLN-8283-2022	He, Xianghuo/0000-0001-8872-668X; Yu, Tao/0000-0001-5330-2086	Shanghai Science and Technology Developing Program [12140901500, 13140900502]	Shanghai Science and Technology Developing Program	This work was supported by Shanghai Science and Technology Developing Program (12140901500, 13140900502). We thank Deshui Jia and QiangTan for the kind suggestions and technical assistance.	Almeida MI, 2012, GASTROENTEROLOGY, V142, P886, DOI 10.1053/j.gastro.2011.12.047; Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Feng B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043452; Goldberger N, 2013, CANCER RES, V73, P2671, DOI 10.1158/0008-5472.CAN-12-3513; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Hegde GV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004438; Heist Rebecca S, 2012, Cancer Cell, V21, DOI 10.1016/j.ccr.2012.03.007; Heller G, 2012, CLIN CANCER RES, V18, P1619, DOI 10.1158/1078-0432.CCR-11-2450; Hu HJ, 2012, ACTA BIOCH BIOPH SIN, V44, P424, DOI [10.1093/abbs/gms018, 10.1093/abbs/gms018.]; Iliopoulos D, 2011, CANCER RES, V71, P5144, DOI 10.1158/0008-5472.CAN-11-0425; Imbert AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043752; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jia DS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-364; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li YH, 2013, BLOOD, V121, P499, DOI 10.1182/blood-2012-07-444729; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Lin HC, 2013, J PROTEOME RES, V12, P3423, DOI 10.1021/pr400273z; Mendoza-Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343; Meng W, 2013, CLIN CANCER RES, V19, P5423, DOI 10.1158/1078-0432.CCR-13-0320; Minami A, 2013, J BIOL CHEM, V288, P11845, DOI 10.1074/jbc.M112.405993; Muraoka-Cook RS, 2008, MOL ENDOCRINOL, V22, P2307, DOI 10.1210/me.2008-0055; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Sasaki H, 2007, CLIN LUNG CANCER, V8, P429, DOI 10.3816/CLC.2007.n.027; Sharieff W, 2013, CLIN ONCOL-UK, V25, P697, DOI 10.1016/j.clon.2013.07.011; Sridharan S, 2011, CANCER RES, V71, P2590, DOI 10.1158/0008-5472.CAN-10-3253; Starr A, 2006, INT J CANCER, V119, P269, DOI 10.1002/ijc.21818; Tao ZH, 2013, J EXP MED, V210, P789, DOI 10.1084/jem.20120153; Tomizawa Kenji, 2010, J Thorac Oncol, V5, P1859, DOI 10.1097/JTO.0b013e3181f1c433; Trask MC, 2012, DEV BIOL, V368, P273, DOI 10.1016/j.ydbio.2012.05.031; Uhlmann S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.100; Wander SA, 2013, BREAST CANCER RES TR, V138, P369, DOI 10.1007/s10549-012-2389-6; Wu X, 2014, ONCOGENE, V33, P1506, DOI 10.1038/onc.2013.108; Xu L, 2013, MOL BIOL CELL, V24, P42, DOI 10.1091/mbc.E12-07-0519; Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315; Yang X, 2013, CANCER LETT, V341, P265, DOI 10.1016/j.canlet.2013.08.020; Yang Y, 2013, ONCOGENE, V32, P3432, DOI 10.1038/onc.2012.360; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	44	214	222	3	59	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					413	423		10.1038/onc.2013.574	http://dx.doi.org/10.1038/onc.2013.574			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469061				2022-12-17	WOS:000348451300002
J	Liu, LL; Xie, N; Sun, S; Plymate, S; Mostaghel, E; Dong, X				Liu, L. L.; Xie, N.; Sun, S.; Plymate, S.; Mostaghel, E.; Dong, X.			Mechanisms of the androgen receptor splicing in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen deprivation therapy; RNA splice variant; alternative splicing	GENE-EXPRESSION; TRANSCRIPTION; PROGRESSION; VARIANTS; RESISTANCE; RECRUITMENT; THERAPIES; RESOURCE; PSF	Prostate tumors develop resistance to androgen deprivation therapy (ADT) by multiple mechanisms, one of which is to express constitutively active androgen receptor (AR) splice variants lacking the ligand-binding domain. AR splice variant 7 (AR-V7, also termed AR3) is the most abundantly expressed variant that drives prostate tumor progression under ADT conditions. However, the molecular mechanism by which AR-V7 is generated remains unclear. In this manuscript, we demonstrated that RNA splicing of AR-V7 in response to ADT was closely associated with AR gene transcription initiation and elongation rates. Enhanced AR gene transcription by ADT provides a prerequisite condition that further increases the interactions between AR pre-mRNA and splicing factors. Under ADT conditions, recruitment of several RNA splicing factors to the 3' splicing site for AR-V7 was increased. We identified two RNA splicing enhancers and their binding proteins (U2AF65 and ASF/SF2) that had critical roles in splicing AR pre-mRNA into AR-V7. These data indicate that ADT-induced AR gene transcription rate and splicing factor recruitment to AR pre-mRNA contribute to the enhanced AR-V7 levels in prostate cancer cells.	[Liu, L. L.; Xie, N.; Dong, X.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada; [Sun, S.; Plymate, S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA; [Sun, S.; Plymate, S.] VAPSHCS GRECC, Seattle, WA 98104 USA; [Mostaghel, E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Dong, X.] Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada	University of British Columbia; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; Fred Hutchinson Cancer Center; University of Toronto	Plymate, S (corresponding author), Univ Washington, Sch Med, Dept Med, Box 359625,325 9th Ave, Seattle, WA 98104 USA.	splymate@u.washington.edu; xdong@prostatecentre.com	Dong, Xuesen/AGF-9228-2022		Pacific Northwest Prostate Cancer SPORE, National Cancer Institute [P50CA097186]; Prostate Cancer Canada [RS2013-58]; Canadian Institute of Health Research [MOP-97934]; Department of Defence plus Veterans Administration Grants; Prostate Cancer Foundation; NIH [P01 CA163227]; NATIONAL CANCER INSTITUTE [P50CA097186, P01CA163227] Funding Source: NIH RePORTER	Pacific Northwest Prostate Cancer SPORE, National Cancer Institute; Prostate Cancer Canada; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Department of Defence plus Veterans Administration Grants; Prostate Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Pacific Northwest Prostate Cancer SPORE, National Cancer Institute (P50CA097186; XD and SRP); Prostate Cancer Canada (RS2013-58; to XD) and Canadian Institute of Health Research (MOP-97934; XD); Department of Defence plus Veterans Administration Grants (SRP), NIH P01 CA163227 (SRP) and Prostate Cancer Foundation (SRP).	Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3; Cheng H, 2006, CANCER RES, V66, P10613, DOI 10.1158/0008-5472.CAN-06-0028; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dong XS, 2007, MOL CELL BIOL, V27, P4863, DOI 10.1128/MCB.02144-06; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Heemers HV, 2010, PROSTATE, V70, P959, DOI 10.1002/pros.21130; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kornblihtt AR, 2007, ADV EXP MED BIOL, V623, P175, DOI 10.1007/978-0-387-77374-2_11; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Moore MJ, 2009, CELL, V136, P688, DOI 10.1016/j.cell.2009.02.001; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; Olshavsky NA, 2010, CANCER RES, V70, P3975, DOI 10.1158/0008-5472.CAN-09-3468; Paronetto MP, 2007, J CELL BIOL, V176, P929, DOI 10.1083/jcb.200701005; Rokhlin OW, 2006, MOL CANCER RES, V4, P113, DOI 10.1158/1541-7786.MCR-05-0085; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053; Stamm S, 2006, NUCLEIC ACIDS RES, V34, pD46, DOI 10.1093/nar/gkj031; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Xie N, 2012, MOL ENDOCRINOL, V26, P1370, DOI 10.1210/me.2012-1088; Yang X, 2011, J BIOL CHEM, V286, P36152, DOI 10.1074/jbc.M111.265124; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970	48	214	223	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3140	3150		10.1038/onc.2013.284	http://dx.doi.org/10.1038/onc.2013.284			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851510	Green Accepted			2022-12-17	WOS:000338410000007
J	Li, B; Antonyak, MA; Zhang, J; Cerione, RA				Li, B.; Antonyak, M. A.; Zhang, J.; Cerione, R. A.			RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells	ONCOGENE			English	Article						microvesicles; oncosomes; RhoA; ROCK; LIMK; tissue transglutaminase	LIM-KINASE; PROSTATE-CANCER; TISSUE TRANSGLUTAMINASE; IN-VIVO; ROCK; METASTASIS; EXOSOMES; PHOSPHORYLATION; MEDIATORS; INVASION	Vesicular structures called microvesicles (MVs) that are shed from the surfaces of cancer cells are capable of transferring oncogenic cargo to recipient cancer cells, as well as to normal cells, sending mitogenic signals that greatly enhance tumor growth. Because MVs are stable in the circulation, they also may have a key role in secondary colonization and metastasis. Thus, understanding how MVs are generated could have important consequences for interfering with cancer progression. Here we report that the small GTPase RhoA triggers a specific signaling pathway essential for MV biogenesis in various human cancer cells. Inhibiting the activity of different proteins comprising this pathway blocks MV biogenesis in the donor cancer cells and prevents oncogenic transformation in cell culture as well as tumor growth in mice. Although RhoA has often been implicated in human cancer, these findings now highlight a previously unappreciated role for this GTPase in malignant transformation, and demonstrate that blocking MV biogenesis may offer novel approaches for interfering with malignant transformation.	[Li, B.; Antonyak, M. A.; Zhang, J.; Cerione, R. A.] Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; [Li, B.; Cerione, R. A.] Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu	Li, Bo/O-7127-2019; Li, Bo/M-2192-2013; Li, Bo/Y-2835-2019; Li, Bo/M-2192-2013	Li, Bo/0000-0002-7979-8339; Li, Bo/0000-0002-7979-8339; Li, Bo/0000-0001-8256-5045	NIH; Komen Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Cindy Westmiller for her secretarial assistance and the NIH and the Komen Foundation for funding.	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Antonyak MA, 2011, P NATL ACAD SCI USA, V108, P4852, DOI 10.1073/pnas.1017667108; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Catellana D, 2009, CANCER RES, V69, P785; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Di Vizio D, 2009, CANCER RES, V69, P5601, DOI 10.1158/0008-5472.CAN-08-3860; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Hao S., 2006, Experimental Oncology, V28, P126; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Li B, 2010, P NATL ACAD SCI USA, V107, P1408, DOI 10.1073/pnas.0907907107; Loirand G, 2006, CIRC RES, V98, P322, DOI 10.1161/01.RES.0000201960.04223.3c; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Micuda S, 2010, CURR CANCER DRUG TAR, V10, P127, DOI 10.2174/156800910791054202; Muralidharan-Chari V, 2009, CURR BIOL, V19, P1875, DOI 10.1016/j.cub.2009.09.059; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Teis D, 2009, CELL, V137, DOI 10.1016/j.cell.2009.03.027; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048	35	214	216	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4740	4749		10.1038/onc.2011.636	http://dx.doi.org/10.1038/onc.2011.636			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266864	Green Accepted			2022-12-17	WOS:000311033000002
J	Keklikoglou, I; Koerner, C; Schmidt, C; Zhang, JD; Heckmann, D; Shavinskaya, A; Allgayer, H; Guckel, B; Fehm, T; Schneeweiss, A; Sahin, O; Wiemann, S; Tschulena, U				Keklikoglou, I.; Koerner, C.; Schmidt, C.; Zhang, J. D.; Heckmann, D.; Shavinskaya, A.; Allgayer, H.; Gueckel, B.; Fehm, T.; Schneeweiss, A.; Sahin, Oe; Wiemann, S.; Tschulena, U.			MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappa B and TGF-beta signaling pathways	ONCOGENE			English	Article						NF-kappaB; TGF-beta; miR-373; miR-520c; breast cancer; ER-negative	EMBRYONIC STEM-CELLS; GROWTH-FACTOR; BONE METASTASIS; UP-REGULATION; INVASION; EXPRESSION; ACTIVATION; MICRORNAS; PROLIFERATION; ANGIOGENESIS	MicroRNAs (miRNAs) as modulators of gene expression have been described to display both tumor-promoting and tumor-suppressive functions. Although their role has been studied in different tumor types, little is known about how they regulate nuclear factor kappa B (NF-kappa B) signaling in breast cancer. Here, we performed an unbiased whole genome miRNA (miRome) screen to identify novel modulators of NF-kappa B pathway in breast cancer. The screen identified 13 miRNA families whose members induced consistent effects on NF-kappa B activity. Among those, the miR-520/373 family inhibited NF-kappa B signaling through direct targeting of RELA and thus strongly reduced expression and secretion of the pro-inflammatory cytokines interleukin (IL)-6 and IL-8. With a combination of in vitro and in vivo approaches, we propose a metastasis-suppressive role of miR-520/373 family. miR-520c and miR-373 abrogated both in vitro cell invasion and in vivo intravasation of highly invasive MDA-MB-231 cells. However, knockdown of RELA did not affect their metastatic ability. mRNA profiling of MDA-MB-231 cells on overexpression of miR-520/373 members revealed a strong downregulation of transforming growth factor-beta (TGF-beta) signaling. Mechanistically, the metastasis-suppressive role of miR-520/373 can be attributed to direct suppression of TGFBR2, as the silencing of TGFBR2 phenocopied the effects of miR-520/373 overexpression on suppression of Smad-dependent expression of the metastasis-promoting genes parathyroid hormone-related protein, plasminogen activator inhibitor-1 and angiopoietin-like 4 as well as tumor cell invasion, in vitro and in vivo. A negative correlation between miR-520c and TGFBR2 expression was observed in estrogen receptor negative (ER-) breast cancer patients but not in the ER positive (ER+) subtype. Remarkably, decreased expression of miR-520c correlated with lymph node metastasis specifically in ER- tumors. Taken together, our findings reveal that miR-520/373 family has a tumor-suppressive role in ER- breast cancer by acting as a link between the NF-kappa B and TGF-beta pathways and may thus contribute to the interplay of tumor progression, metastasis and inflammation. Oncogene (2012) 31, 4150-4163; doi:10.1038/onc.2011.571; published online 12 December 2011	[Keklikoglou, I.; Koerner, C.; Schmidt, C.; Zhang, J. D.; Sahin, Oe; Wiemann, S.; Tschulena, U.] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Germany; [Heckmann, D.; Shavinskaya, A.; Allgayer, H.] German Canc Res Ctr, Clin Cooperat Unit Mol Oncol Solid Tumors, D-69120 Heidelberg, Germany; [Gueckel, B.; Fehm, T.] Univ Tubingen, Womens Hosp, Dept Gynecol & Obstet, Tubingen, Germany; [Schneeweiss, A.] Univ Heidelberg Hosp, Dept Gynecol & Obstet, Natl Ctr Tumor Dis, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Keklikoglou, I (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	i.keklikoglou@dkfz-heidelberg.de; s.wiemann@dkfz-heidelberg.de	Wiemann, Stefan/E-4424-2013; Sahin, Özgür/F-4403-2014	Wiemann, Stefan/0000-0003-4683-3174; Sahin, Özgür/0000-0002-8033-7089; Schmidt, Christian/0000-0002-9605-5959; Koerner, Cindy/0000-0003-1150-9462; Fehm, Tanja/0000-0002-4926-0108; Keklikoglou, Ioanna/0000-0003-1219-6912	National Genome Research Network of the German Federal Ministry of Education and Research (BMBF) [01GS0816, 01GS0864]; DKFZ International PhD Program	National Genome Research Network of the German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); DKFZ International PhD Program	We thank Dr Wolfgang Koestler for critical reading of the paper and discussion. We also thank Professor Dr George Mosialos for kindly providing us with the 3xKBL vector, Jennifer Lee for providing us with the pcDNA3.1-TGFBR2 vector, Johanna Sonntag, Dr Frank Goetschel and Dr Ulrike Korf for providing us with antibodies. We thank Serafeim Perdikis for data analysis and Aoife Ward, Angelika Worner, Ute Ernst, Heike Wilhelm, Ewald Munstermann for excellent technical assistance. This work was supported by the National Genome Research Network (Contracts No. 01GS0816 and 01GS0864) of the German Federal Ministry of Education and Research (BMBF). CK and JDZ were supported by the DKFZ International PhD Program.	Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Biswas DK, 2003, CANCER RES, V63, P290; Buck MB, 2004, CLIN CANCER RES, V10, P491, DOI 10.1158/1078-0432.CCR-0320-03; Camp JT, 2011, MOL CANCER RES, V9, P3, DOI 10.1158/1541-7786.MCR-10-0372; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen YP, 2010, ADV APPL MATH MECH, V2, P56, DOI 10.4208/aamm.09-m0931; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Ganapathy V, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-122; Gu S, 2009, NAT STRUCT MOL BIOL, V16, P144, DOI 10.1038/nsmb.1552; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang S, 2000, CANCER RES, V60, P5334; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Laurent LC, 2008, J CELL MOL MED, V12, P2181, DOI 10.1111/j.1582-4934.2008.00513.x; Lee KH, 2009, EXP CELL RES, V315, P2529, DOI 10.1016/j.yexcr.2009.06.001; Leek RD, 1996, CANCER RES, V56, P4625; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu ZX, 2011, EMBO J, V30, P57, DOI 10.1038/emboj.2010.296; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ren JQ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-20; Schultz Nikolaus, 2011, Silence, V2, P3, DOI 10.1186/1758-907X-2-3; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sorlie Therese, 2007, Methods Mol Biol, V360, P91; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; van der Horst EH, 2004, BIOTECHNIQUES, V37, P940, DOI 10.2144/04376ST02; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Walter M, 2009, ONCOGENE, V28, P2745, DOI 10.1038/onc.2009.130; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Wu N., 2011, FEBS J; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhou ZG, 2007, CELL SIGNAL, V19, P1238, DOI 10.1016/j.cellsig.2006.12.013; Zijlstra A, 2002, CANCER RES, V62, P7083	58	214	223	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	37					4150	4163		10.1038/onc.2011.571	http://dx.doi.org/10.1038/onc.2011.571			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158050	hybrid			2022-12-17	WOS:000308688900007
J	Mullan, PB; Quinn, JE; Harkin, DP				Mullan, P. B.; Quinn, J. E.; Harkin, D. P.			The role of BRCA1 in transcriptional regulation and cell cycle control	ONCOGENE			English	Review						BRCA1; transcription; cell cycle	RNA-POLYMERASE-II; ESTROGEN-RECEPTOR ACTIVITY; SUSCEPTIBILITY GENE BRCA1; ZINC-FINGER PROTEIN; DIRECTED DNA-REPAIR; C-TERMINAL REGION; INTERACT IN-VIVO; BREAST-CANCER; S-PHASE; IONIZING IRRADIATION	The exact functions of BRCA1 have not been fully described but it now seems apparent that it has roles in DNA damage repair, transcriptional regulation, cell cycle control and most recently in ubiquitylation. These functions of BRCA1 are most likely interdependent but this review will focus on the role of BRCA1 in relation to transcriptional regulation and in particular how this impacts upon cell cycle control. We will (i) describe the structure of BRCA1 and how it may contribute to its transcription function; (ii) describe the interaction of BRCA1 with the core transcriptional machinery ( RNA polII); (iii) describe how BRCA1 may regulate transcription at an epigenetic level through chromatin modi. cation; (iv) discuss the role of BRCA1 in modulating transcription through its association with sequence-specific transcription factors. Finally, we will discuss the possible effects of BRCA1 transcriptional regulation on downstream targets with known roles in cell cycle control.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Harkin, DP (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk			MRC [G0200103] Funding Source: UKRI; Medical Research Council [G0200103] Funding Source: Medline; Breast Cancer Now [2003:596] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now		Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bernabei P, 2003, BLOOD, V102, P2933, DOI 10.1182/blood-2003-01-0100; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cabart P, 2004, ONCOGENE, V23, P5316, DOI 10.1038/sj.onc.1207684; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Chen GC, 2001, BIOCHEM BIOPH RES CO, V284, P507, DOI 10.1006/bbrc.2001.5003; Chen YM, 1996, CANCER RES, V56, P3168; Chiba N, 2002, CANCER RES, V62, P4222; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; Gilmore PM, 2004, CANCER RES, V64, P4148, DOI 10.1158/0008-5472.CAN-03-4080; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hulka BS, 2001, MATURITAS, V38, P103, DOI 10.1016/S0378-5122(00)00196-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Ikeda T, 2002, J LEUKOCYTE BIOL, V72, P1198; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moisan A, 2004, MOL CELL BIOL, V24, P6947, DOI 10.1128/MCB.24.16.6947-6956.2004; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Mullan PB, 2005, ONCOGENE, V24, P5492, DOI 10.1038/sj.onc.1208698; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200; Ongusaha PP, 2003, ONCOGENE, V22, P3749, DOI 10.1038/sj.onc.1206439; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Quinn JE, 2003, CANCER RES, V63, P6221; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Tan W, 2004, J BIOL CHEM, V279, P55153, DOI 10.1074/jbc.M410926200; Tan W, 2004, J BIOL CHEM, V279, P6576, DOI 10.1074/jbc.M312270200; Wada O, 2004, ONCOGENE, V23, P6000, DOI 10.1038/sj.onc.1207786; Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yun JH, 2003, MOL CELL BIOL, V23, P7305, DOI 10.1128/MCB.23.20.7305-7314.2003; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200	88	214	218	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2006	25	43					5854	5863		10.1038/sj.onc.1209872	http://dx.doi.org/10.1038/sj.onc.1209872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998500				2022-12-17	WOS:000240765900006
J	Nakamura, T; Furukawa, Y; Nakagawa, H; Tsunoda, T; Ohigashi, H; Murata, K; Ishikawa, O; Ohgaki, K; Kashimura, N; Miyamoto, M; Hirano, S; Kondo, S; Katoh, H; Nakamura, Y; Katagiri, T				Nakamura, T; Furukawa, Y; Nakagawa, H; Tsunoda, T; Ohigashi, H; Murata, K; Ishikawa, O; Ohgaki, K; Kashimura, N; Miyamoto, M; Hirano, S; Kondo, S; Katoh, H; Nakamura, Y; Katagiri, T			Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection	ONCOGENE			English	Article						pancreatic cancer; laser microbeam microdissection; cDNA microarray; gene expression profiles	HEPATOCELLULAR-CARCINOMA; COLORECTAL CARCINOMAS; MONOCLONAL-ANTIBODY; IDENTIFICATION; ADENOCARCINOMA; KINASE; CARCINOGENESIS; INHIBITORS; APOPTOSIS; DISCOVERY	To characterize molecular mechanism involved in pancreatic carcinogenesis, we analysed gene-expression profiles of 18 pancreatic tumors using a cDNA microarray representing 23 040 genes. As pancreatic ductal adenocarcinomas usually contain a low proportion of cancer cells in the tumor mass, we prepared 95% pure populations of pancreatic cancer cells by means of laser microbeam microdissection, and compared their expression profiles to those of similarly purified, normal pancreatic ductal cells. We identified 260 genes that were commonly upregulated and 346 genes that were downregulated in pancreatic cancer cells. Because of the high degree of purity in the cell populations, a large proportion of genes that we detected as upregulated or downregulated in pancreatic cancers were different from those reported in previous studies. Comparison of clinicopathological parameters with the expression profiles indicated that altered expression of 76 genes was associated with lymph-node metastasis and that of 168 genes with liver metastasis. In addition, expression levels of 30 genes were related to the recurrence of disease. These genome-wide expression profiles should provide useful information for finding candidate genes whose products might serve as specific tumor markers and/or as molecular targets for treatment of patients with pancreatic cancer.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Hokkaido Univ, Grad Sch Med, Div Canc Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; RIKEN, Inst Phys & Chem Res,SNP Res Ctr, Lab Med Informat, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Higashinari Ku, Osaka 5378511, Japan; Kyoto Police Hosp, Dept Surg, Kita Ku, Kyoto 6038142, Japan; Teine Keijinkai Hosp, Dept Surg, Teine Ku, Sapporo, Hokkaido 0068555, Japan	University of Tokyo; Hokkaido University; RIKEN; Osaka Medical Center for Cancer & Cardiovascular Diseases; Teine Keijinkai Hospital	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Nakamura, toru/F-6901-2012; Kondo, Satoshi/B-1114-2008; Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Chambers SK, 1997, CLIN CANCER RES, V3, P999; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gianni L, 2002, ONCOLOGY-BASEL, V63, P47, DOI 10.1159/000066197; Gjerdrum LM, 2001, J MOL DIAGN, V3, P105, DOI 10.1016/S1525-1578(10)60659-9; Goggins M, 2000, AM J PATHOL, V156, P1767, DOI 10.1016/S0002-9440(10)65047-X; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Guo HM, 2000, CANCER RES, V60, P888; Han HY, 2002, CANCER RES, V62, P2890; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Ishiguro H, 2002, ONCOGENE, V21, P6387, DOI 10.1038/sj.onc.1205751; Ishiguro H, 2001, ONCOGENE, V20, P5062, DOI 10.1038/sj.onc.1204603; Kitahara O, 2001, CANCER RES, V61, P3544; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Laheru D, 2001, CANCER J, V7, P324; Logsdon CD, 2003, CANCER RES, V63, P2649; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Ng IOL, 2000, CANCER RES, V60, P6581; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ono K, 2000, CANCER RES, V60, P5007; Rehwald U, 2003, BLOOD, V101, P420, DOI 10.1182/blood.V101.2.420; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Rozenblum E, 1997, CANCER RES, V57, P1731; Saito-Hisaminato A, 2002, DNA RES, V9, P35, DOI 10.1093/dnares/9.2.35; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Scanlan MJ, 2002, CANCER RES, V62, P4041; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Violette S, 2003, INT J CANCER, V103, P185, DOI 10.1002/ijc.10788; Yagyu R, 2002, INT J ONCOL, V20, P1173; Yuan BZ, 1998, CANCER RES, V58, P2196	39	214	235	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2385	2400		10.1038/sj.onc.1207392	http://dx.doi.org/10.1038/sj.onc.1207392			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14767473				2022-12-17	WOS:000220427700013
J	Willis, A; Jung, EJ; Wakefield, T; Chen, XB				Willis, A; Jung, EJ; Wakefield, T; Chen, XB			Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes	ONCOGENE			English	Article						p53; mutant p53; cell cycle arrest; transcription	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR P53; GAIN-OF-FUNCTION; FUNCTION MUTATIONS; TERMINAL DOMAIN; HUMAN CANCER; DNA-BINDING; APOPTOSIS; PROTEIN; ACTIVATION	Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. A majority of these mutations are missense mutations in the DNA-binding domain. As a result, the mutated p53 gene encodes a full-length protein incapable of transactivating its target genes. In addition to this loss of function, mutant p53 can have a dominant negative effect over wild-type p53 and/or gain of function activity independently of the wild-type protein. To better understand the nature of the tumorigenic activity of mutant p53, we have investigated the mechanism by which mutant p53 can exert a dominant negative effect. We have established several stable cell lines capable of inducibly expressing a p53 mutant alone, wild-type p53 alone, or both proteins concurrently. In this context, we have used chromatin immunoprecipitation to determine the ability of wild-type p53 to bind to its endogenous target genes in the presence of various p53 mutants. We have found that p53 missense mutants markedly reduce the binding of wild-type p53 to the p53 responsive element in the target genes of p21, MDM2, and PIG3. These findings correlate with the reduced ability of wild-type p53 in inducing these and other endogenous target genes and growth suppression in the presence of mutant p53. We also showed that mutant p53 suppresses the ability of wild-type p53 in inducing cell cycle arrest. This highlights the sensitivity and utility of the dual inducible expression system because in previous studies, p53-mediated cell cycle arrest is not affected by transiently overexpressed p53 mutants. Together, our data showed that mutant p53 exerts its dominant negative activity by abrogating the DNA binding, and subsequently the growth suppression, functions of wild-type p53.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		Amara, Amy/0000-0003-0762-9656	NCI NIH HHS [2 R01 CA076069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atema A, 2002, CANCER LETT, V185, P103, DOI 10.1016/S0304-3835(02)00318-X; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN XB, 1995, CANCER RES, V55, P4257; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; Hussain SP, 1998, CANCER RES, V58, P4023; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1995, ONCOGENE, V10, P2387; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marutani M, 1999, CANCER RES, V59, P4765; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Prives C, 1999, J PATHOL, V187, P112; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; ROLLEY N, 1995, ONCOGENE, V11, P763; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Willis AC, 2003, ONCOGENE, V22, P5481, DOI 10.1038/sj.onc.1206505; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhu JH, 1998, CANCER RES, V58, P5061	55	214	221	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2330	2338		10.1038/sj.onc.1207396	http://dx.doi.org/10.1038/sj.onc.1207396			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743206				2022-12-17	WOS:000220427700007
J	Schafer, B; Gschwind, A; Ullrich, A				Schafer, B; Gschwind, A; Ullrich, A			Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion	ONCOGENE			English	Article						EGFR; GPCR; transactivation; LPA; invasion; metalloprotemase	CELL-CARCINOMA-CELLS; EGF RECEPTOR; HB-EGF; TRANSFORMING GROWTH; AUTOCRINE GROWTH; BLADDER-CANCER; FACTOR-ALPHA; TRANSACTIVATION; CLEAVAGE; EXPRESSION	Signalling through G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTK) is involved in the regulation of essential cellular processes and its deregulation is associated with tumorigenesis in vitro and in vivo. We investigated pathophysiological processes that are regulated by GPCR pathways in human kidney and bladder cancer cell lines. Our results show that GPCR ligands induce tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as well as downstream signalling events such as recruitment of the adapter protein Shc and activation of the mitogen-activated protein kinases (MAPK) ERK1/2, JNK and p38. Moreover, we report that the EGFR transactivation signal involves the EGFR ligands amphiregulin, HB-EGF and TGFalpha as well as the metalloproteinases ADAM 10, 15 and 17, depending on the cellular system. Finally, we demonstrate that EGFR transactivation is part of a regulatory system that modulates the migratory and invasive behaviour of kidney and bladder cancer cells. In conclusion, our findings demonstrate that metalloproteinase-mediated transactivation of the EGFR is a key mechanism of the cellular signalling network that promotes MAPK activation as well as tumour cell migration and invasion in response to a variety of physiologically relevant GPCR ligands, and therefore represents a novel target for cancer intervention strategies.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de						Bue P, 1998, INT J CANCER, V76, P189, DOI 10.1002/(SICI)1097-0215(19980413)76:2<189::AID-IJC4>3.0.CO;2-T; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DeBoer WI, 1997, INT J CANCER, V71, P284, DOI 10.1002/(SICI)1097-0215(19970410)71:2<284::AID-IJC25>3.0.CO;2-G; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; Ghanem MA, 2001, CANCER-AM CANCER SOC, V92, P3120, DOI 10.1002/1097-0142(20011215)92:12<3120::AID-CNCR10173>3.0.CO;2-2; Gildea JJ, 2002, CANCER RES, V62, P982; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; Gschwind A, 2002, CANCER RES, V62, P6329; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; ISHIKAWA J, 1989, INT J CANCER, V44, P1000, DOI 10.1002/ijc.2910440610; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Levine JS, 1997, AM J PHYSIOL-RENAL, V273, pF575, DOI 10.1152/ajprenal.1997.273.4.F575; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Ruck A, 1997, ANTICANCER RES, V17, P1925; Ruck A, 1998, ANTICANCER RES, V18, P1447; Sieuwerts AM, 1997, CLIN EXP METASTAS, V15, P53; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; Van Brussel JP, 1999, BJU INT, V83, P902; Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	34	214	220	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					991	999		10.1038/sj.onc.1207278	http://dx.doi.org/10.1038/sj.onc.1207278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647423				2022-12-17	WOS:000188486600015
J	Sidhu, SS; Mengistab, AT; Tauscher, AN; LaVail, J; Basbaum, C				Sidhu, SS; Mengistab, AT; Tauscher, AN; LaVail, J; Basbaum, C			The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions	ONCOGENE			English	Article						EMMPRIN; MMP; microvesicle	MATRIX METALLOPROTEINASE INDUCER; BREAST-CARCINOMA CELLS; MEMBRANE-VESICLES; IMMUNOGLOBULIN SUPERFAMILY; MEDIATED RELEASE; MOUSE BASIGIN; MEMBER; RECEPTOR; SURFACE; EXPRESSION	EMMPRIN is a transmembrane glycoprotein expressed at high levels by tumor cells. It has been identified as a tumor-derived factor that can stimulate matrix metalloproteinase expression in fibroblasts and hence facilitate tumor invasion and metastasis. Recent studies have shown that full-length EMMPRIN is released by tumor cells, but the mechanism of release remains unclear. Here, we show that EMMPRIN is released from the surface of NCI-H460 cells via microvesicle shedding. However, these vesicles are unstable and rapidly break down to release bioactive EMMPRIN. Although microvesicle shedding has been considered a constitutive process in tumor cells, our data show that it can be amplified upon cell exposure to PMA, elucidating at least one signalling cascade responsible for EMMPRIN release. This pathway is dependent on protein kinase C, calcium mobilization and mitogen-activated protein kinase kinase (MEK 1/2). Thus, the results outline a novel form of tumor-stromal interaction in which extracellular matrix degradation by fibroblasts is controlled through the microvesicular release of EMMPRIN from tumor cells.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Biomol Sci Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Neurosci Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	cbas@itsa.ucsf.edu		Sidhu, Sukhvinder/0000-0002-2999-4358	NHLBI NIH HHS [R0-1 HL 43762, P0-1 HL24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043762, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albanese J, 1998, BLOOD, V91, P3862; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Beer S, 1999, J CELL SCI, V112, P2667; BISWAS C, 1995, CANCER RES, V55, P434; Black P H, 1980, Adv Cancer Res, V32, P75, DOI 10.1016/S0065-230X(08)60361-9; Cassara D, 1998, J SUBMICR CYTOL PATH, V30, P45; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; DAINIAK N, 1991, BLOOD, V78, P264; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Dolo V, 1998, CANCER RES, V58, P4468; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173; Dolo V, 1999, CLIN EXP METASTAS, V17, P131, DOI 10.1023/A:1006500406240; DOLO V, 1995, J SUBMICR CYTOL PATH, V27, P535; ELLIS SM, 1989, CANCER RES, V49, P3385; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; Ginestra A, 1999, ANTICANCER RES, V19, P3439; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Guo HM, 1997, J BIOL CHEM, V272, P24; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KANEKURA T, 1991, CELL STRUCT FUNCT, V16, P23, DOI 10.1247/csf.16.23; KASINRERK W, 1992, J IMMUNOL, V149, P847; Kim CW, 2002, CANCER RES, V62, P6312; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045; MIYAUCHI T, 1995, J BIOCHEM-TOKYO, V118, P717, DOI 10.1093/oxfordjournals.jbchem.a124971; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Salzer U, 2002, BLOOD, V99, P2569, DOI 10.1182/blood.V99.7.2569; SATTA N, 1994, J IMMUNOL, V153, P3245; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Taylor D D, 1986, Dev Biol (N Y 1985), V3, P33; Taylor PM, 2002, ONCOGENE, V21, P5765, DOI 10.1038/sj.onc.1205702; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thorns C, 2002, ANTICANCER RES, V22, P1983; Vincent JP, 2002, TRENDS CELL BIOL, V12, P57, DOI 10.1016/S0962-8924(01)02227-9; Wang W, 2002, J CELL BIOL, V157, P1061, DOI 10.1083/jcb.200203014; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	53	214	229	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					956	963		10.1038/sj.onc.1207070	http://dx.doi.org/10.1038/sj.onc.1207070			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749763				2022-12-17	WOS:000188486600011
J	Polager, S; Kalma, Y; Berkovich, E; Ginsberg, D				Polager, S; Kalma, Y; Berkovich, E; Ginsberg, D			E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis	ONCOGENE			English	Article						E2F; cell cycle; mitosis; DNA replication; DNA repair; DNA microarrays	TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; CELL-CYCLE; PROTEIN; INDUCTION; PROMOTER; BINDING; MICE; SAK; NUCLEAR	The E2F family of transcription factors plays a pivotal role in the regulation of cell proliferation in higher eukaryotes. We used DNA microarrays and cell lines containing either inducible E2F-1 or inducible E2F-3 to identify novel E2F target genes. Our data indicate that E2F up-regulates the expression of genes not previously described as E2F target genes. A number of these E2F-regulated genes are involved in DNA replication, DNA repair and mitosis. These results suggest that E2F affects cell cycle progression both at S phase and during mitosis. Furthermore, our findings indicate that E2F-dependent gene activation may contribute to the cellular response to DNA damage.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hudson JW, 2000, GENE, V241, P65, DOI 10.1016/S0378-1119(99)00467-9; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lavia P, 1999, BIOESSAYS, V21, P221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Scherer SJ, 1996, HUM GENET, V97, P114; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOMPAYRAC L, 1994, VIROLOGY, V200, P849, DOI 10.1006/viro.1994.1255; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WALSH MJ, 1995, J BIOL CHEM, V270, P5289, DOI 10.1074/jbc.270.10.5289; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	45	214	217	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					437	446		10.1038/sj.onc.1205102	http://dx.doi.org/10.1038/sj.onc.1205102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821956				2022-12-17	WOS:000173311200012
J	Zebedee, Z; Hara, E				Zebedee, Z; Hara, E			Id proteins in cell cycle control and cellular senescence	ONCOGENE			English	Review						Id; cell cycle; senescence; Ets; CDKs; P16(INK4a)	LOOP-HELIX PROTEIN; RETINOBLASTOMA GENE FAMILY; DNA-BINDING PROTEIN; REPLICATIVE SENESCENCE; IMMUNOGLOBULIN ENHANCER; TRANSCRIPTION FACTOR; PREMATURE SENESCENCE; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; G(1) PROGRESSION	The Id family of hefix-loop-helix (HLH) proteins are thought to affect the balance between cell growth and differentiation by negatively regulating the function of basic -helix -loop -helix (bHLH) transcription factors. Although it has been suggested for some time that Id is involved in cell cycle regulation, little is known about the molecular mechanism of this control. Recent studies, however, have revealed that Id binds to important cell cycle regulatory proteins other than bHLH proteins. Two such proteins, pRB (retinoblastoma tumour suppressor protein) family proteins and Ets-family transcription factors are known to play key roles in cell cycle regulation, transformation and tumour suppression. Through the characterization of these pathways we will begin to understand the mechanisms by which Id controls normal and abnormal cell cycle progression.	Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC Cell Cycle Grp, Manchester M20 4BX, Lancs, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Hara, E (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC Cell Cycle Grp, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Ehara@picr.man.ac.uk						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; CAMPISI J, 1996, HDB BIOL AGING, V4, P121; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Chu C, 2001, J BIOL CHEM, V276, P8524, DOI 10.1074/jbc.M008371200; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Humbert PO, 2000, GENE DEV, V14, P690; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Inoue T, 2000, GENES CELLS, V5, P699, DOI 10.1046/j.1365-2443.2000.00362.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEJOSSIC C, 1994, CANCER RES, V54, P6065; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; Loughran O, 1996, ONCOGENE, V13, P561; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Reznikoff CA, 1996, CANCER RES, V56, P2886; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; SKERJANC IS, 1996, J BIOL CHEM, V270, P24818; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Vooijs M, 1999, ONCOGENE, V18, P5293, DOI 10.1038/sj.onc.1202999; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	113	214	229	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8317	8325		10.1038/sj.onc.1205092	http://dx.doi.org/10.1038/sj.onc.1205092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840324				2022-12-17	WOS:000173319500005
J	Wang, WL; Healy, ME; Sattler, M; Verma, S; Lin, J; Maulik, G; Stiles, CD; Griffin, JD; Johnson, BE; Salgia, R				Wang, WL; Healy, ME; Sattler, M; Verma, S; Lin, J; Maulik, G; Stiles, CD; Griffin, JD; Johnson, BE; Salgia, R			Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571	ONCOGENE			English	Article						small cell lung cancer; c-Kit and stem cell factor; STI 571; signal transduction in lung cancer; cell motility	C-KIT; BCR-ABL; EXPRESSION; COEXPRESSION; PAXILLIN	Small cell lung cancer (SCLC) is an aggressive cancer characterized by several autocrine growth mechanisms including stem cell factor and its receptor c-Kit, In order to arrive at potentially new and novel therapy for SCLC, we have investigated the effects of the tyrosine kinase inhibitor, STI 571, on SCLC cell lines. It has been previously reported that STI 571 does not only inhibit cellular Abl tyrosine kinase activity but also the PDGF receptor and c-Kit tyrosine kinases at similar concentrations (approximately 0.1 mu M). There is no expression of the PDGF-receptor, and the Abl kinase is not activated by SCLC, but over 70% of SCLC contain the c-Kit receptor. Utilizing this preliminary data, we have determined that three (NCI-H69, NCI-H146 and NCI-H209) of five (including NCI-H82 and NCI-H249) SCLC cell lines had detectable c-Kit receptors and were inhibited in growth and viability at concentrations 1-5 mu M of STI 571 after 48 h of treatment. The SCLC cell lines, NCI-H69, NCI-H146 and NCI-H209, showed a dose-response (tested between 0.1-10 mu M) inhibition of tyrosine phosphorylation of c-git as well as in vitro kinase activity (at 5 mu M) of c-Kit in response to STI 571, STI 571 inhibited cell motility, as assessed by time-lapsed video microscopy, within 6 h of STI 571 treatment (5 mu M). STI 571 also decreased intracellular levels of reactive oxygen species (ROS) by at least 60%, at a concentration (5 mu M) that also inhibited cell growth. Cell cycle analysis of STI 571 responsive cells showed that cells were generally slowed in G2/M phase, but there was no arrest at G1/S, A downstream phosphorylation target of c-Kit, Akt, was not phosphorylated in response to stem cell factor in the presence of STI 571, These data imply that STI 571 inhibits growth of SCLC cells through a mechanism that involves inactivation of the tyrosine kinase c-Kit, The effectiveness of STI 571 in this study suggests this drug may be useful in a clinical trial, for patients with SCLC.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Salgia, R (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Dana 530C,44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R29CA075348] Funding Source: NIH RePORTER; NCI NIH HHS [CA75348-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buchdunger E, 1996, CANCER RES, V56, P100; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; Chute JP, 1999, J CLIN ONCOL, V17, P1794, DOI 10.1200/JCO.1999.17.6.1794; DiPaola RS, 1997, CANCER GENE THER, V4, P176; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Druker BJ, 1999, BLOOD, V94, p368A; FERRY D, 2000, P AN M AM SOC CLIN, V19, pA3; HIBI K, 1991, ONCOGENE, V6, P2291; JOHNSON BE, 1995, LUNG CANCER-J IASLC, V12, pS5, DOI 10.1016/S0169-5002(10)80014-5; Krystal GW, 1996, CANCER RES, V56, P370; PLUMMER H, 1993, CANCER RES, V53, P4337; Salgia R, 1998, BLOOD, V92, p487A; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1999, BLOOD, V94, P4233; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 1999, BLOOD, V93, P2928; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 1999, CANCER J SCI AM, V5, P63	23	214	230	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3521	3528		10.1038/sj.onc.1203698	http://dx.doi.org/10.1038/sj.onc.1203698			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918610				2022-12-17	WOS:000088346500008
J	OTTERSON, GA; KHLEIF, SN; CHEN, WD; COXON, AB; KAYE, FJ				OTTERSON, GA; KHLEIF, SN; CHEN, WD; COXON, AB; KAYE, FJ			CDKN2 GENE SILENCING IN LUNG-CANCER BY DNA HYPERMETHYLATION AND KINETICS OF P16(INK4) PROTEIN INDUCTION BY 5-AZA 2'DEOXYCYTIDINE	ONCOGENE			English	Article						P16(INK4); CDKN2; METHYLATION; 5-AZA 2'DEOXYCYTIDINE; LUNG CANCER	RETINOBLASTOMA GENE; MUTATION	Absent expression of the cyclin dependent kinase-inhibitor, p16(INK4), is observed in a wide range of primary human cancers. Although homozygous deletions and point mutations have been reported in a subset of these tumors, the molecular basis for absent p16(INK4) in other samples is unknown. We have examined 33 tumor cell lines and have shown that hypermethylation of a G:C-rich region within exon 1 of the CDKN2 gene was present in 100% of samples with wildtype RE expression and no detectable CDKN2 mutations. Treatment for at least 4 hours with the demethylating agent 5-aza 2'deoxycytidine, but not 5-azacytidine or 6-azacytidine, induces the prolonged expression of p16(INK4) protein each of these samples following a discrete 24-48 hour lag period, Consistent with the hypothesis that hypermethylation of the CDKN2 gene is a tumor-specific mechanism for gene inactivation, we observed hypomethylation at the exon 1 site exclusively in tumor lines that expressed p16(INK4) or that had sustained inactivating point mutations within the CDKN2 open reading frame, These findings demonstrate a link between DNA methylation and the p16(INK4):RB tumor suppressor pathway.	NCI,USN HOSP,ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA			CHEN, WEI-DONG/F-4521-2014; kaye, frederic/E-2437-2011	CHEN, WEI-DONG/0000-0003-2264-5515; 				FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAIRD PW, 1994, HUM MOL GENET, P1487; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; NAKAGAWA K, 1995, IN PRESS ONCOGENE; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Rideout W M 3rd, 1991, Princess Takamatsu Symp, V22, P207; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU E, 1994, ONCOGENE, V9, P2441; TAM SW, 1994, CANCER RES, V54, P5816; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	28	214	233	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1211	1216						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566983				2022-12-17	WOS:A1995RX18000026
J	BURKS, RT; KESSIS, TD; CHO, KR; HEDRICK, L				BURKS, RT; KESSIS, TD; CHO, KR; HEDRICK, L			MICROSATELLITE INSTABILITY IN ENDOMETRIAL CARCINOMA	ONCOGENE			English	Article							GENE-MUTATIONS; P53	Microsatellite instability (MI), detected as electrophoretic shifts in allele sizes of microsatellite DNA sequences, has been identified in some colorectal carcinomas. Investigators have previously attributed such microsatellite instability to replication errors (RER). The colorectal carcinomas with RER have been found to arise either sporadically or in association with the hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Because endometrial carcinoma is also commonly associated with HNPCC, we studied 30 cases of endometrial carcinoma to characterize the presence of MI in these neoplasms. Seven cases (23%) showed MI. Four cases showed both Type I (large shifts) and Type II (small shifts) mutation patterns and the remaining three cases showed Type I mutations only. We conclude that MI frequently occurs in endometrial cancers and that this type of genetic alteration may be an important pathogenetic feature of this tumor type.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University				Cho, Kathleen/0000-0003-0500-9998				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; ENOMOTO T, 1990, CANCER RES, V50, P6139; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; IGNARTROWBRIDGE D, 1992, AM J OBSTET GYNECOL, V167, P227, DOI 10.1016/S0002-9378(11)91663-9; IMAMURA T, 1992, INT J CANCER, V51, P47, DOI 10.1002/ijc.2910510110; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; OKAMOTO A, 1991, CANCER RES, V51, P5632; PELOYPELTOMAKI P, 1993, SCIENCE, V260, P810; RISINGER JI, 1992, MOL CARCINOGEN, V5, P250, DOI 10.1002/mc.2940050403; Rousseau Francois, 1992, Human Mutation, V1, P91, DOI 10.1002/humu.1380010202; SASAKI H, 1993, CANCER RES, V53, P1906; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122	19	214	219	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1163	1166						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134118				2022-12-17	WOS:A1994NC04800019
J	TAKAHASHI, T; TAKAHASHI, T; SUZUKI, H; HIDA, T; SEKIDO, Y; ARIYOSHI, Y; UEDA, R				TAKAHASHI, T; TAKAHASHI, T; SUZUKI, H; HIDA, T; SEKIDO, Y; ARIYOSHI, Y; UEDA, R			THE P53 GENE IS VERY FREQUENTLY MUTATED IN SMALL-CELL LUNG-CANCER WITH A DISTINCT NUCLEOTIDE SUBSTITUTION PATTERN	ONCOGENE			English	Article							MUTATIONS; EXPRESSION	The p53 gene has been implicated as a tumor-suppressor gene whose disruption is involved in the pathogenesis of common human cancers. The results of extensive analysis of p53 mutations in non-small cell lung cancers (NSCLCs) have revealed that p53 is mutated in 45% of NSCLC with base changes different from those of colon cancer. In this study, we examined 17 SCLC tumor samples taken directly from 15 patients as well as the corresponding nine tumor cell lines. Mutations changing the p53 coding sequence were found in 11 of 15 patients (73.3%) and showed a similar but distinct nucleotide substitution pattern compared with NSCLC, suggesting that a different mutagenic process is involved. In addition, a strong correlation was seen between the presence of p53 mutations in tumors and the successful establishment of the corresponding cell lines, suggesting that p53 mutations can confer a selective growth advantage in vitro (and probably also in vivo).	AICHI CANC CTR,DEPT INTERNAL MED,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	TAKAHASHI, T (corresponding author), AICHI CANC CTR,CHEMOTHERAPY LAB,NAGOYA,AICHI 464,JAPAN.		Sekido, Yoshitaka/P-9756-2015; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Sekido, Yoshitaka/0000-0002-2428-3848				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, 1990, SCIENCE, V249, P1912; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LAWLEY P, 1990, N NITROSO COMPOUNDS, V1, P409; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Minna JD, 1989, CANCER PRINCIPLES PR, P591; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SINGER B, 1982, ANNU REV BIOCHEM, V52, P655; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WATANABE S, 1987, JPN J CANCER RES, V78, P460; 1990, VITAL STATISTICS 198, V1, P252	23	214	215	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1775	1778						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656362				2022-12-17	WOS:A1991GX11800008
J	SOUSSI, T; DEFROMENTEL, CC; MECHALI, M; MAY, P; KRESS, M				SOUSSI, T; DEFROMENTEL, CC; MECHALI, M; MAY, P; KRESS, M			CLONING AND CHARACTERIZATION OF A CDNA FROM XENOPUS-LAEVIS CODING FOR A PROTEIN HOMOLOGOUS TO HUMAN AND MURINE P53	ONCOGENE			English	Article									INST J MONOD,UNITE EMBRYOL MOLEC,F-75221 PARIS 05,FRANCE		SOUSSI, T (corresponding author), INST RECH SCI CANC,UNITE ONCOL MOLEC,BP 8,F-94802 VILLEJUIF,FRANCE.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; soussi, thierry/0000-0001-8184-3293				BENCHIMOL S, 1984, CANCER CELL, V2, P383; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DEFROMETAL CC, 1987, IN PRESS INT J CANCE; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANIATIS T, 1982, MOL CLONING LABORATO; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MESSING J, 1983, METHOD ENZYMOL, V101, P21; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; OREN M, 1983, P NATL ACAD SCI-BIOL, V80, P56, DOI 10.1073/pnas.80.1.56; OREN M, 1983, EMBO J, V2, P1533; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P4765, DOI 10.1093/nar/10.15.4765; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SANGER F, 1977, P NATL ACAD SCI USA, V80, P3963; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; TAYLOR HV, 1986, EMBO J, V5, P3563; TYMOWSKA J, 1973, CHROMOSOMA, V44, P335, DOI 10.1007/BF00291027; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	52	214	216	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1987	1	1					71	78						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	2830576				2022-12-17	WOS:A1987J635100008
J	Cheng, MS; Sheng, L; Gao, Q; Xiong, QC; Zhang, HJ; Wu, MQ; Liang, Y; Zhu, FY; Zhang, YY; Zhang, XH; Yuan, Q; Li, Y				Cheng, Maosheng; Sheng, Lu; Gao, Qian; Xiong, Qiuchan; Zhang, Haojie; Wu, Mingqing; Liang, Yu; Zhu, Fengyu; Zhang, Yingyin; Zhang, Xiuhong; Yuan, Quan; Li, Yang			The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappa B/MYC signaling network	ONCOGENE			English	Article							MYC INHIBITOR KSI-3716; MESSENGER-RNA; C-MYC; ELONGATION COMPLEX; ANTITUMOR-ACTIVITY; NUCLEAR-RNA; N-6-METHYLADENOSINE; METHYLATION; TRANSLATION; N6-METHYLADENOSINE	N-6-methyladenosine (m6A) is the most abundant modification in eukaryotic messenger RNAs (mRNAs), and plays important roles in many bioprocesses. However, its functions in bladder cancer (BCa) remain elusive. Here, we discovered that methyltransferase-like 3 (METTL3), a major RNA N-6-adenosine methyltransferase, was significantly up-regulated in human BCa. Knockdown of METTL3 drastically reduced BCa cell proliferation, invasion, and survival in vitro and tumorigenicity in vivo. On the other hand, overexpression of METTL3 significantly promoted BCa cell growth and invasion. Through transcriptome sequencing, m(6)A sequencing and m(6)A methylated RNA immuno-precipitation quantitative reverse-transcription polymerase chain reaction, we revealed the profile of METTL3-mediated m(6)A modification in BCa cells for the first time. AF4/FMR2 family member 4 (AFF4), two key regulators of NF-kappa B pathway (IKBKB and RELA) and MYC were further identified as direct targets of METTL3-mediated m(6)A modification. In addition, we showed that besides NF-kappa B, AFF4 binds to the promoter of MYC and promotes its expression, implying a novel multilevel regulatory network downstream of METTL3. Our results uncovered an AFF4/NF-kappa B/MYC signaling network operated by METTL3-mediated m6A modification and provided insight into the mechanisms of BCa progression.	[Cheng, Maosheng; Gao, Qian; Wu, Mingqing; Liang, Yu; Zhu, Fengyu; Zhang, Yingyin; Zhang, Xiuhong; Li, Yang] Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China; [Sheng, Lu; Zhang, Haojie] Fudan Univ, Huadong Hosp, Dept Urol, Shanghai 200040, Peoples R China; [Xiong, Qiuchan; Yuan, Quan] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; [Xiong, Qiuchan; Yuan, Quan] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Sichuan, Peoples R China	Anhui Medical University; Fudan University; Sichuan University; Sichuan University	Li, Y (corresponding author), Anhui Med Univ, Sch Life Sci, Dept Genet, Hefei 230031, Anhui, Peoples R China.	liyang@ahmu.edu.cn	yuan, quan/GZM-5597-2022	Yuan, Quan/0000-0002-2836-1081	National Natural Science Foundation of China [81872313, 81672776, 81802391, 31501838]; Anhui Provincial Natural Science Foundation [1808085QH266]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Anhui Provincial Natural Science Foundation(Natural Science Foundation of Anhui Province)	This work was supported by the National Natural Science Foundation of China (81872313 and 81672776 to YL, 81802391 to QG, 31501838 to XH Z), and Anhui Provincial Natural Science Foundation (1808085QH266 to QG)	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; BOKAR JA, 1994, J BIOL CHEM, V269, P17697; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Cao GC, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160003; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Choe J, 2018, NATURE, V561, P556, DOI 10.1038/s41586-018-0538-8; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Deng P, 2018, CARCINOGENESIS, V39, P937, DOI 10.1093/carcin/bgy046; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P3971, DOI 10.1073/pnas.71.10.3971; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; El-Sheikh A, 2010, PEDIATR BLOOD CANCER, V55, P35, DOI 10.1002/pbc.22465; Felsenstein KM, 2018, NAT REV UROL, V15, P92, DOI 10.1038/nrurol.2017.179; Gabay M, 2014, COLD SPRING HARBOR P, V4; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Jeong KC, 2014, J UROLOGY, V191, P510, DOI 10.1016/j.juro.2013.07.019; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Kamat AM, 2009, CANCER RES, V69, P8958, DOI 10.1158/0008-5472.CAN-09-2045; Li Y, 2015, ONCOTARGET, V6, P10195, DOI 10.18632/oncotarget.3555; Li Y, 2013, BIOMED REP, V1, P918, DOI 10.3892/br.2013.157; Li YF, 2013, CELL TISSUE RES, V354, P533, DOI 10.1007/s00441-013-1715-6; Liang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29479; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Luo ZJ, 2012, MOL CELL BIOL, V32, P2608, DOI 10.1128/MCB.00182-12; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Mahe M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708163; Merkurjev D, 2018, NAT NEUROSCI, V21, P1004, DOI 10.1038/s41593-018-0173-6; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Meyer KD, 2014, NAT REV MOL CELL BIO, V15, P313, DOI 10.1038/nrm3785; Mukherjee N, 2015, CARCINOGENESIS, V36, P299, DOI 10.1093/carcin/bgu321; Niu Yamei, 2013, Genomics Proteomics & Bioinformatics, V11, P8, DOI 10.1016/j.gpb.2012.12.002; Oing C, 2016, J UROLOGY, V195, P254, DOI 10.1016/j.juro.2015.06.115; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Ribas A, 2014, CLIN CANCER RES, V20, P4982, DOI 10.1158/1078-0432.CCR-14-0933; Seo HK, 2014, ONCOTARGET, V5, P326, DOI 10.18632/oncotarget.1545; Shi HL, 2018, NATURE, V563, P249, DOI 10.1038/s41586-018-0666-1; Shiina H, 2002, J UROLOGY, V168, P2220, DOI 10.1016/S0022-5347(05)64359-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tabach Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014632; Taketo K, 2018, INT J ONCOL, V52, P621, DOI 10.3892/ijo.2017.4219; Tong JY, 2018, CELL RES, V28, P253, DOI 10.1038/cr.2018.7; van Kessel KEM, 2015, NAT REV UROL, V12, P681, DOI 10.1038/nrurol.2015.231; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902; Watters AD, 2002, BRIT J CANCER, V87, P654, DOI 10.1038/sj.bjc.6600531; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Weng YL, 2018, NEURON, V97, P313, DOI 10.1016/j.neuron.2017.12.036; Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06898-4; Wu YS, 2018, CURR STEM CELL RES T, V13, P31, DOI 10.2174/1574888X12666170621125457; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015; Zheng J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3401-7; Zheng QL, 2017, NAT IMMUNOL, V18, P1094, DOI 10.1038/ni.3830; Zhu FY, 2017, STEM CELL REP, V9, P429, DOI 10.1016/j.stemcr.2017.07.004; Zhu JL, 2017, NEOPLASIA, V19, P672, DOI 10.1016/j.neo.2017.06.002	66	213	220	6	84	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3667	3680		10.1038/s41388-019-0683-z	http://dx.doi.org/10.1038/s41388-019-0683-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30659266				2022-12-17	WOS:000467379600008
J	Dufraine, J; Funahashi, Y; Kitajewski, J				Dufraine, J.; Funahashi, Y.; Kitajewski, J.			Notch signaling regulates tumor angiogenesis by diverse mechanisms	ONCOGENE			English	Review						angiogenesis; Notch; Jagged1; Dll4; sprout; VEGFR-2	HUMAN BREAST-CANCER; ENDOTHELIAL-CELLS; ARTERIOVENOUS-MALFORMATIONS; DELTA-LIKE-4 EXPRESSION; VASCULAR MORPHOGENESIS; EMBRYONIC LETHALITY; LIGAND JAGGED1; UP-REGULATION; ARTERIES; GROWTH	The Notch signaling pathway is fundamental to proper cardiovascular development and is now recognized as an important player in tumor angiogenesis. Two key Notch ligands have been implicated in tumor angiogenesis, Delta-like 4 and Jagged1. We introduce the proteins and how they work in normal developing vasculature and then discuss differing models describing the action of these Notch ligands in tumor angiogenesis. Endothelial Dll4 expression activates Notch resulting in restriction of new sprout development; for instance, in growing retinal vessels. In agreement with this activity, inhibit ion of Dll4-mediated Notch signaling in tumors results in hypersprouting of nonfunctional vasculature. This Dll4 inhibition may paradoxically lead to increased angiogenesis but poor tumor growth because the newly growing vessels are not functional. In contrast, Jagged1 has been described as a Notch ligand expressed in tumor cells that can have a positive influence on tumor angiogenesis, possibly by activating Notch on tumor endothelium. A novel Notch inhibitor, the Notch1 decoy, which blocks both Dll4 and Jagged1 has been recently shown to restrict tumor vessel growth. We discuss these models and speculate on therapeutic approaches.	[Kitajewski, J.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Funahashi, Y.] Eisai & Co Ltd, Tsukuba Res Labs, Ibaraki, Japan; [Dufraine, J.; Kitajewski, J.] Columbia Univ, Med Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA; [Dufraine, J.; Kitajewski, J.] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA	Columbia University; Eisai Co Ltd; Columbia University; Columbia University	Kitajewski, J (corresponding author), Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, 1130 St Nicholas Ave, New York, NY 10032 USA.	jkk9@columbia.edu			NHLBI NIH HHS [R01 HL062454] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alva JA, 2004, CURR OPIN HEMATOL, V11, P278, DOI 10.1097/01.moh.0000130309.44976.ad; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Carlson TR, 2005, P NATL ACAD SCI USA, V102, P9884, DOI 10.1073/pnas.0504391102; Claxton S, 2004, GENE EXPR PATTERNS, V5, P123, DOI 10.1016/j.modgep.2004.05.004; Funahashi Y, 2008, CANCER RES, V68, P4727, DOI 10.1158/0008-5472.CAN-07-6499; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; High FA, 2008, P NATL ACAD SCI USA, V105, P1955, DOI 10.1073/pnas.0709663105; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; Iso T, 2006, BIOCHEM BIOPH RES CO, V341, P708, DOI 10.1016/j.bbrc.2006.01.020; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Krebs LT, 2000, GENE DEV, V14, P1343; Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lawson ND, 2002, NAT REV GENET, V3, P674, DOI 10.1038/nrg888; Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Patel NS, 2006, CLIN CANCER RES, V12, P4836, DOI 10.1158/1078-0432.CCR-06-0285; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; REEDIJK M, 2007, BREAST CANC RES TREA; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749-6632.2003.tb03219.x; Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104; Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	41	213	230	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	38					5132	5137		10.1038/onc.2008.227	http://dx.doi.org/10.1038/onc.2008.227			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758482	Green Accepted			2022-12-17	WOS:000258914900007
J	Mahadevan, D; Cooke, L; Riley, C; Swart, R; Simons, B; Della Croce, K; Wisner, L; Iorio, M; Shakalya, K; Garewal, H; Nagle, R; Bearss, D				Mahadevan, D.; Cooke, L.; Riley, C.; Swart, R.; Simons, B.; Della Croce, K.; Wisner, L.; Iorio, M.; Shakalya, K.; Garewal, H.; Nagle, R.; Bearss, D.			A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors	ONCOGENE			English	Article						tyrosine kinases; morphological change; Kit mutations; GIST	CELL-ADHESION MOLECULE; C-KIT; CRYSTAL-STRUCTURE; GROWTH; MICROENVIRONMENT; IDENTIFICATION; INHIBITOR; MUTATIONS; INVASION; BIOLOGY	KIT or alpha-platelet-derived growth factor receptor (alpha-PDGFR) activating mutations are the pathogenic mechanisms that characterize gastrointestinal stromal tumors (GIST). Despite excellent responses to imatinib mesylate (IM), patients are relapsing. We developed an IM-resistant GIST cell line (GIST-R) from the IM-sensitive GIST882 cell line (GIST-S) by growing these cells in IM. Gene expression pro. ling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance. Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor tyrosine kinase-AXL-in a kinase switch'. Further, the two IM resistant GIST patients express AXL and not c-Kit, seen by immunohistochemistry (IHC). Real time reverse transcriptase-polymerase chain reaction and Western blotting of the GIST-S and GIST-R cells confirmed the switch from Kit to AXL. In GIST-R, AXL is tyrosine phosphorylated and its ligand growth-arrest-specific gene 6 is overexpressed implying autocrine activation. The kinase switch is associated with a morphological change from spindle to epithelioid. Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470, a novel c-Kit/ AXL kinase inhibitor. MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; Supergen Pharmaceut, Salt Lake City, UT USA	Arizona Center Cancer Care; University of Arizona; Radboud University Nijmegen	Mahadevan, D (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave,POB 245024, Tucson, AZ 85724 USA.	dmahadevan@azcc.arizona.edu	Bearss, David/Q-9141-2019	Riley, Christopher/0000-0001-7930-1495; Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NCI NIH HHS [CA23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; BAUER S, 2005, ASCO9034, V23, pS824; Buchholz M, 2003, CANCER RES, V63, P4945; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Chen Lei L, 2005, Curr Oncol Rep, V7, P293, DOI 10.1007/s11912-005-0053-6; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; DeMatteo RP, 2002, HUM PATHOL, V33, P466, DOI 10.1053/hupa.2002.124122; Duffaud F, 2003, ONCOLOGY-BASEL, V65, P187, DOI 10.1159/000074470; Haldar S, 1997, CANCER RES, V57, P229; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kitamura Y, 2004, CELL MOL LIFE SCI, V61, P2924, DOI 10.1007/s00018-004-4273-y; Kristiansen G, 2004, J MOL HISTOL, V35, P255; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahadevan D, 2005, MOL CANCER THER, V4, P1867, DOI 10.1158/1535-7163.MCT-05-0146; MAHADEVAN D, 2005, 96 ANN M APR 16 20 2; McLean SR, 2005, MOL CANCER THER, V4, P2008, DOI 10.1158/1535-7163.MCT-05-0070; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; PEREZATAYDE AR, 1993, AM J SURG PATHOL, V17, P706, DOI 10.1097/00000478-199307000-00008; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Theou N, 2005, CLIN CANCER RES, V11, P7593, DOI 10.1158/1078-0432.CCR-05-0710; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989	38	213	238	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3909	3919		10.1038/sj.onc.1210173	http://dx.doi.org/10.1038/sj.onc.1210173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17325667				2022-12-17	WOS:000247144500001
J	Sun, JZ; Blaskovich, MA; Jove, R; Livingston, SK; Coppola, D; Sebti, SDM				Sun, JZ; Blaskovich, MA; Jove, R; Livingston, SK; Coppola, D; Sebti, SDM			Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity	ONCOGENE			English	Article						STAT3; apoptosis; antitumor activity; cucurbitacins; JAK2	SIGNALING INDUCES APOPTOSIS; BREAST-CARCINOMA CELLS; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; SRC ONCOPROTEIN; MYELOMA CELLS; CANCER-CELLS; EXPRESSION; TRANSDUCER; GROWTH	Constitutive activation of the JAK/STAT3 pathway is a major contributor to oncogenesis. In the present study, structure-activity relationship (SAR) studies with five cucurbitacin (Cuc) analogs, A, B, E, I, and Q, led to the discovery of Cuc Q, which inhibits the activation of STAT3 but not JAK2; Cuc A which inhibits JAK2 but not STAT3 activation; and Cuc B, E, and I, which inhibit the activation of both. Further more, these SAR studies demonstrated that conversion of the C3 carbonyl of the cucurbitacins to a hydroxyl results in loss of anti-JAK2 activity, whereas addition of a hydroxyl group to C11 of the cucurbitacins results in loss of anti-STAT3 activity. Cuc Q inhibits selectively the activation of STAT3 and induces apoptosis without inhibition of JAK2, Src, Akt, Erk, or JNK activation. Furthermore, Cuc Q induces apoptosis more potently in human and murine tumors that contain constitutively activated STAT3 (i.e., A549, MDA-MB-435, and v-Src/NIH 3T3) as compared to those that do not (i.e., H-Ras/NIH 3T3, MDA-MB-453, and NIH 3T3 cells). Finally, in a nude mouse tumor xenograft model, Cuc Q, but not Cuc A, suppresses tumor growth indicating that JAK2 inhibition is not sufficient to inhibit tumor growth and suggesting that the ability of Cuc Q to inhibit tumor growth is related to its anti-STAT3 activity. These studies further validate STAT3 as a drug discovery target and provide evidence that pharmacological agents that can selectively reduce the P-STAT3 levels in human cancer cells result in tumor apoptosis and growth inhibition.	Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Sebti, SDM (corresponding author), Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, MRC DRDIS, 12902 Magnolia Dr, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu			NCI NIH HHS [CA 78038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bowman, 1999, Cancer Control, V6, P615; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Lefebvre DC, 2003, BBA-PROTEINS PROTEOM, V1650, P40, DOI 10.1016/S1570-9639(03)00190-0; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Mora LB, 2002, CANCER RES, V62, P6659; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Paner GP, 2003, ANTICANCER RES, V23, P2253; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shuai K, 1996, ONCOGENE, V13, P247; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang T, 2003, BIOCHEM J, V376, P457, DOI 10.1042/BJ20030668	38	213	233	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3236	3245		10.1038/sj.onc.1208470	http://dx.doi.org/10.1038/sj.onc.1208470			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735720				2022-12-17	WOS:000228881800002
J	You, L; He, B; Xu, ZD; Uematsu, K; Mazieres, J; Mikami, I; Reguart, N; Moody, TW; Kitajewski, J; McCormick, F; Jablons, DM				You, L; He, B; Xu, ZD; Uematsu, K; Mazieres, J; Mikami, I; Reguart, N; Moody, TW; Kitajewski, J; McCormick, F; Jablons, DM			Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells	ONCOGENE			English	Article						Wnt signaling; apoptosis; lung cancer	HUMAN COLORECTAL-CANCER; BETA-CATENIN; SURVIVIN EXPRESSION; INDUCED APOPTOSIS; COLON-CARCINOMA; UP-REGULATION; C-MYC; PATHWAY; WNT-2; GENE	In this report, we have demonstrated that Wnt-2 protein is overexpressed in freshly resected human non-small-cell lung cancer (NSCLC) tissues. We have also developed a monoclonal antibody against the N-terminus of human Wnt-2 protein. This monoclonal antibody induces apoptosis in human NSCLC cell lines that overexpress Wnt-2 protein. Incubation of this antibody with normal human airway cells lacking Wnt-2 expression does not induce apoptosis. Wnt-2 signaling blockade by the anti-Wnt-2 antibody is confirmed by downregulation of cytosolic beta-catenin and reduction in TCF-dependent transcriptional activity (TOPFLASH assay). In addition, Wnt-2-specific small interfering RNA (siRNA) treatment in the NSCLC cell line A549 also downregulated cytosolic beta-catenin and induced apoptosis. Moreover, downregulation of an inhibitor of apoptosis family protein, Survivin, was noticed both in the Wnt-2 antibody- and siRNA-treated NSCLC cells, suggesting that inhibition of Wnt-2-mediated signaling induces apoptosis through inactivating Survinin.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94115 USA; NCI, Off Director, Ctr Canc Res, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Obstet & Gynecol, New York, NY 10032 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University	Jablons, DM (corresponding author), Ctr Canc, Dept Surg, 1600 Divisadero St,C322C,Box 1674, San Francisco, CA 94115 USA.	jablonsd@surgery.ucsf.edu	MAZIERES, JULIEN/M-3986-2014	MAZIERES, JULIEN/0000-0002-5921-7613	NATIONAL CANCER INSTITUTE [R01CA093708] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093708, R01 CA093708-01A3] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BLASBAND A, 1992, ONCOGENE, V7, P153; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dale TC, 1996, CANCER RES, V56, P4320; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; HUGUET EL, 1994, CANCER RES, V54, P2615; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Katoh M, 2001, INT J ONCOL, V19, P1003; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Olie RA, 2000, CANCER RES, V60, P2805; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shih IM, 2000, CANCER RES, V60, P1671; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uematsu K, 2003, CANCER RES, V63, P4547; Uthoff SMS, 2001, MOL CARCINOGEN, V31, P56, DOI 10.1002/mc.1039; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vider BZ, 1996, ONCOGENE, V12, P153; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang T, 2001, CANCER RES, V61, P8664	38	213	234	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6170	6174		10.1038/sj.onc.1207844	http://dx.doi.org/10.1038/sj.onc.1207844			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208662				2022-12-17	WOS:000223261000017
J	Cande, C; Vahsen, N; Kouranti, I; Schmitt, E; Daugas, E; Spahr, C; Luban, J; Kroemer, RT; Giordanetto, F; Garrido, C; Penninger, JM; Kroemer, G				Cande, C; Vahsen, N; Kouranti, I; Schmitt, E; Daugas, E; Spahr, C; Luban, J; Kroemer, RT; Giordanetto, F; Garrido, C; Penninger, JM; Kroemer, G			AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis	ONCOGENE			English	Article						mitochondria; Bcl-2	CELL-DEATH; GLYCOPROTEIN COMPLEX; ISOMERASE ACTIVITY; DNA-DEGRADATION; ENDONUCLEASE-G; INHIBITOR; BINDING; MITOCHONDRIA; QUANTITATION; REFINEMENT	Cyclophilin A (CypA) was determined to interact with apoptosis-inducing factor (AIF) by mass spectroscopy, coimmunoprecipitation, pull-down assays, and molecular modeling. During the initial, caspase-independent stage of chromatin condensation that accompanies apoptosis, AIF and CypA were found to coimmunolocalize in the nucleus. Recombinant AIF and CypA proteins synergized in vitro in the degradation of plasmid DNA, as well as in the capacity to induce DNA loss in purified nuclei. The apoptogenic cooperation between AIF and CypA did not rely on the CypA peptidyl-prolyl cis-trans isomerase activity. In Cyp-expressing cells, AIF overexpression augmented apoptotic chromatinolysis. The AIF-dependent large-scale DNA fragmentation was less pronounced in CypA knockout cells as compared to controls. AIF mutants lacking the CypA-binding domain were inefficient apoptosis sensitizers in transfection experiments. Moreover, AIF failed to sensitize CypA knockout cells to apoptosis induction, and this defect in the AIF response was reversed by reintroduction of the CypA gene into CypA-deficient cells. In summary, AIF and CypA collaborate in chromatinolysis.	Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France; Fac Med & Pharm, INSERM, U517, F-21033 Dijon, France; Amgen Inc, Amgen Ctr, Prot Sci, Thousand Oaks, CA 91320 USA; Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Med, New York, NY 10032 USA; Pharmacia, Mol Modeling & Design, I-20014 Nerviano, MI, Italy; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Amgen; Columbia University; Columbia University; Pfizer; University of Cambridge; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Giordanetto, Fabrizio/E-2811-2012; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Garrido, carmen/G-1633-2018; Penninger, Josef M/I-6860-2013; Garrido, Carolina/GWM-5557-2022	KROEMER, Guido/0000-0002-9334-4405; Garrido, carmen/0000-0003-1368-1493; Penninger, Josef M/0000-0002-8194-3777; Luban, Jeremy/0000-0001-5650-4054; DAUGAS, Eric/0000-0001-7256-7979	NIAID NIH HHS [R01 AI036199, AI 36199] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036199] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aloy P, 1998, PROTEINS, V33, P535, DOI 10.1002/(SICI)1097-0134(19981201)33:4<535::AID-PROT6>3.3.CO;2-4; Ansari H, 2002, MOL CELL BIOL, V22, P6993, DOI 10.1128/MCB.22.20.6993-7003.2002; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; Bergsmedh A, 2002, CANCER RES, V62, P575; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Colgan J, 2000, GENOMICS, V68, P167, DOI 10.1006/geno.2000.6295; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; de la Taille A, 1999, CANCER RES, V59, P5461; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lorenzo HK, 2000, METHOD ENZYMOL, V322, P198; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHMITT E, 2003, IN PRESS CANC RES; Spahr CS, 2000, ELECTROPHORESIS, V21, P1635, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1635::AID-ELPS1635>3.0.CO;2-1; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Wyllie AH, 2001, P NATL ACAD SCI USA, V98, P11, DOI 10.1073/pnas.98.1.11; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	50	213	224	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1514	1521		10.1038/sj.onc.1207279	http://dx.doi.org/10.1038/sj.onc.1207279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716299				2022-12-17	WOS:000189219500004
J	Takahashi, M; Tsunoda, T; Seiki, M; Nakamura, Y; Furukawa, Y				Takahashi, M; Tsunoda, T; Seiki, M; Nakamura, Y; Furukawa, Y			Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers	ONCOGENE			English	Article						beta-catenin; Wnt/wingless signaling pathway; MT1-MMP; colon cancer	MESSENGER-RNA EXPRESSION; COLON-CARCINOMA CELLS; BETA-CATENIN; GELATINASE-A; HEPATOCELLULAR CARCINOMAS; CLINICAL-SIGNIFICANCE; INTERGLOBULAR DOMAIN; PROMOTES ACTIVATION; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY	Genetic alterations of APC and CTNNB1 (beta-catenin) have been identified in a number of human cancers including tumors arising in the colon and liver. Mutations in these genes lead to abnormal accumulation of beta-catenin and constitutive activation of target genes in the Wnt signaling pathway. To clarify the precise role of accumulated beta-catenin in colorectal carcinogenesis, we searched for genes involved in the beta-catenin/Tcf signaling pathway by cDNA microarray. MT1 - MMP (membrane-type matrix metalloproteinase) was among 84 genes that were down-regulated after beta-catenin had been depleted by transduction of wild-type APC in SW480 cells. Expression of MT1 - MMP was elevated in 22 of 24 colon carcinomas we examined. Reporter assays and an electromobility-shift assay revealed a DNA fragment between - 1169 bp and - 1163 bp in the 5' flanking region of this gene to be a target of the beta-catenin/Tcf4 complex. Our results indicate that MT1 - MMP is a direct down-stream target in the Wnt signaling pathway, and that one of the ways accumulated beta-catenin contributes to colorectal carcinogenesis is by transactivating this gene.	Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Lab Med Informat, SNP Res Ctr,Minato Ku, Tokyo, Japan; Univ Tokyo, Dept Canc Cell Res, Inst Med Sci, Minato Ku, Tokyo, Japan	University of Tokyo; RIKEN; University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015; Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Takahashi, Meiko/0000-0002-8344-5472				Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; Fujita M, 2001, CANCER RES, V61, P7722; Ha HY, 2001, CANCER RES, V61, P984; Harada T, 1998, J HEPATOL, V28, P231, DOI 10.1016/0168-8278(88)80010-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hlubek F, 2001, CANCER RES, V61, P8089; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Imanishi Y, 2000, HUM PATHOL, V31, P895, DOI 10.1053/hupa.2000.9756; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kikuchi A, 2001, BRIT J CANCER, V85, P741, DOI 10.1054/bjoc.2001.1973; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lin YM, 2001, CANCER RES, V61, P6345; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Maekawa R, 2000, CLIN EXP METASTAS, V18, P61, DOI 10.1023/A:1026553414492; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mimori K, 2001, ONCOL REP, V8, P401; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsunezuka Y, 1996, CANCER RES, V56, P5678; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YOSHIMOTO M, 1993, INT J CANCER, V54, P614, DOI 10.1002/ijc.2910540415	52	213	230	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5861	5867		10.1038/sj.onc.1205755	http://dx.doi.org/10.1038/sj.onc.1205755			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185585				2022-12-17	WOS:000177520900005
J	Fulda, S; Debatin, KM				Fulda, S; Debatin, KM			IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway	ONCOGENE			English	Article						caspase-8; apoptosis; interferon; drugs; resistance	DRUG-INDUCED APOPTOSIS; CD95 APO-1/FAS SYSTEM; INTERFERON-GAMMA; DEATH; ACTIVATION; CELLS; METHYLATION; RECEPTORS; PROTEINS; PROMOTER	Resistance of tumors to cytotoxic therapy may be due to disrupted apoptosis programs and remains a major obstacle in cancer treatment. Here, we report that IFNgamma sensitizes resistant tumor cells with absent or low caspase-8 expression for apoptosis induced by death-inducing ligands or cytotoxic drugs by upregulating caspase-8 through a Stat1/IRF1 dependent pathway. Combined treatment using IFNgamma with TRAIL, APO1 TNFalpha or cytotoxic drugs cooperated to trigger apoptosis in various resistant tumor cell lines derived from Ewing tumor, neuroblastoma or medulloblastoma, while single agents exerted only a minimal effect. Importantly, IFN- induced caspase-8 expression also in cells with inactivation of the caspase-8 gene by hypermethylation, although no direct effect of IFNgamma on the methylation status of regulatory sequences of the caspase-8 gene was found. IFNgamma-mediated facilitation of apoptosis was inhibited by the caspase-8 specific inhibitor zIETD.fmk or in caspase8 mutant Jurkat cells implying a prominent role of caspase-8 in mediating sensitization by IFNgamma. Upregulation of caspase-8 and sensitization for apoptosis by IFNgamma was blocked by overexpression of dominant-negative mutants of Stat1 or in Stat1-deficient U3A cells, while complementation of Statl-deficient U3A cells with wildtype Stat1 restored the IFNgamma effect. Moreover, ectopic expression of IRFI induced caspase-8 expression thereby sensitizing cells for TRAIL-, APO1- or doxorubicin-induced apoptosis. These findings provide evidence that the Stat1/IRF1 pathway is involved in induction of caspase-8 expression and apoptosis initiated by IFN- and indicate that IFNgamma might be an effective strategy to sensitize various resistant tumor cells with deficient caspase-8 expression for chemotherapy- or death receptor-induced apoptosis.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MONTALDO PG, 1994, J NATL CANCER I, V86, P1694, DOI 10.1093/jnci/86.22.1694; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VANVALEN F, 1999, EWINGS SARCOMA FAMIL, P55; WADLER S, 1990, CANCER RES, V50, P3473	44	213	223	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2295	2308		10.1038/sj.onc.1205255	http://dx.doi.org/10.1038/sj.onc.1205255			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948413				2022-12-17	WOS:000174635600002
J	Iwata, N; Yamamoto, H; Sasaki, S; Itoh, F; Suzuki, H; Kikuchi, T; Kaneto, H; Iku, S; Ozeki, I; Karino, Y; Satoh, T; Toyota, J; Satoh, M; Endo, T; Imai, K				Iwata, N; Yamamoto, H; Sasaki, S; Itoh, F; Suzuki, H; Kikuchi, T; Kaneto, H; Iku, S; Ozeki, I; Karino, Y; Satoh, T; Toyota, J; Satoh, M; Endo, T; Imai, K			Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma	ONCOGENE			English	Article						cell cycle; G2 arrest; 14-3-3 sigma; hypermethylation; hepatocarcinogenesis	STRAND CONFORMATION POLYMORPHISM; DNA METHYLATION; CELL-CYCLE; CANCER; P16(INK4A); PROGRESSION; PROMOTER; PROTEIN; CLONING; LINES	The 14-3-3 sigma gene has been implicated in G2/M cell cycle arrest by p53, Frequent inactivation of the 14-3-3 sigma gene by hypermethylation of CpG islands has recently been reported in human breast carcinoma. The aim of this study was to examine the methylation status of CpG islands of the 14-3-3 sigma gene in hepatocellular carcinoma (HCC), The methylation status of the 14-3-3 sigma gene was evaluated in four normal liver tissues and 19 paired specimens of carcinoma and adjacent non-tumorous liver tissues using bisulfite-single strand conformation polymorphism (bisulfite-SSCP), a combination of sodium bisulfite modification and fluorescence-based polymerase chain reaction (PCR)-SSCP, The 14-3-3 sigma protein expression was examined by immunohistochemical staining. Hypermethylation of CpG islands of the 14-3-3 sigma gene was detected in 89% (17/19) of the HCC tissues but not in any of the four normal liver tissues. All of the 14 methylation-positive HCC samples analysed by immunohistochemistry showed loss of 14-3-3 sigma expression, while both of the methylation-negative HCC samples retained the expression, and a significant correlation was found between methylation and loss of expression. Lower levels of methylation were detected in adjacent non-tumorous liver tissues (6/16 in cirrhotic tissues and 1/3 in chronic hepatitis tissues), but the 14-3-3 sigma expression was retained in all of these tissues. In a methylation-positive HCC cell line, HLE, 5-aza-2'-deoxycytidine (5-aza-dC)-induced demethylation of CpG islands led to reactivation of gene expression, indicating that hypermethylation plays a causal role in inactivation of the 14-3-3 sigma gene in HCC, Hypermethylation and the resulting loss of expression of the 14-3-3 sigma gene corresponds to one of the most common abnormalities reported to date in HCC, suggesting their crucial role in the development and/or progression of HCC.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Kosei Gen Hosp, Dept Gastroenterol 3, Sapporo, Hokkaido 0600033, Japan; Sapporo Kosei Gen Hosp, Dept Clin Pathol, Sapporo, Hokkaido 0600033, Japan; Sapporo Med Univ, Dept Clin Pathol, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University; Sapporo Kosei General Hospital; Sapporo Kosei General Hospital; Sapporo Medical University	Sasaki, S (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Burri N, 1999, BIOTECHNIQUES, V26, P232, DOI 10.2144/99262bm10; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; DELLAMBRA E, 1995, J CELL SCI, V108, P3569; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1999, GASTROENTEROLOGY, V116, P483, DOI 10.1016/S0016-5085(99)70146-0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hsieh CJ, 1998, CANCER RES, V58, P3942; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JONES PA, 1999, NAT GENET, V11, P136; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kanai Y, 2000, CANCER LETT, V148, P73, DOI 10.1016/S0304-3835(99)00316-X; Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Maekawa M, 1999, BIOCHEM BIOPH RES CO, V262, P671, DOI 10.1006/bbrc.1999.1230; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Melis R, 1999, ELECTROPHORESIS, V20, P1055, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1055::AID-ELPS1055>3.0.CO;2-O; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; Ostergaard M, 1997, CANCER RES, V57, P4111; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Suzuki H, 2000, ELECTROPHORESIS, V21, P904, DOI 10.1002/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.3.CO;2-W; Tajima M, 1998, JPN J CANCER RES, V89, P262, DOI 10.1111/j.1349-7006.1998.tb00557.x; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Wilentz RE, 1998, CANCER RES, V58, P4740; Wong IHN, 1999, CANCER RES, V59, P71; Yamamoto H, 1999, CANCER RES, V59, P3313	37	213	227	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5298	5302		10.1038/sj.onc.1203898	http://dx.doi.org/10.1038/sj.onc.1203898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077447				2022-12-17	WOS:000165059700011
J	Peterziel, H; Mink, S; Schonert, A; Becker, M; Klocker, H; Cato, ACB				Peterziel, H; Mink, S; Schonert, A; Becker, M; Klocker, H; Cato, ACB			Rapid signalling by androgen receptor in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; anti-androgens; growth factors; MAP kinase; rapid response	PROTEIN-KINASE CASCADE; MAMMARY-TUMOR VIRUS; DNA-BINDING DOMAIN; INTRACELLULAR CALCIUM; WITHDRAWAL SYNDROME; MAP KINASE; ACTIVATION; TRANSCRIPTION; GROWTH; MOUSE	Androgens are important growth regulators in prostate cancer. Their known mode of action in target cells requires binding to a cytoplasmic androgen receptor followed by a nuclear translocation event and modulation of the expression of specific genes. Here, we report another mode of action of this receptor. Treatment of androgen responsive prostate cancer cells with dihydrotestosterone leads to a rapid and reversible activation of mitogen-activated protein kinases MAPKs (also called extracellular signal-regulated kinases or Erks). Transient transfection assays demonstrated that the androgen receptor-mediated activation of MAP kinase results in enhanced activity of the transcription factor Elk-1. This action of the androgen receptor differs from its known transcriptional activity since it is rapid and insensitive to androgen antagonists such as hydroxyflutamide or casodex. Biochemical studies as well as analyses with dominant negative mutants showed the involvement of kinases such as MAPK/Erk kinase, phosphatidyl-inositol 3-kinase and protein kinase C in the androgen receptor-mediated activation of MAP kinase. These results demonstrate a novel regulatory action of the androgen receptor and prove that in addition to its known transcriptional effects, it also uses non-conventional means to modulate several cellular signalling processes.	Forschungszentrum Karlsruhe, Inst Genet & Toxikol, D-76021 Karlsruhe, Germany; Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria	Helmholtz Association; Karlsruhe Institute of Technology; University of Innsbruck	Cato, ACB (corresponding author), Forschungszentrum Karlsruhe, Inst Genet & Toxikol, Postfach 3640, D-76021 Karlsruhe, Germany.		Klocker, Helmut/AAI-7130-2020; Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834				AHN NG, 1991, J BIOL CHEM, V266, P4220; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERREVOETS CA, 1993, J STEROID BIOCHEM, V46, P731, DOI 10.1016/0960-0760(93)90313-L; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DiDomenico M, 1996, CANCER RES, V56, P4516; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FABBRO D, 1986, BIOCHEM BIOPH RES CO, V135, P65, DOI 10.1016/0006-291X(86)90943-5; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kamano H, 1995, ONCOGENE, V11, P2575; KLOCKER H, 1992, AM J HUM GENET, V50, P1318; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; Marcinkowska E, 1997, BIOCHEM BIOPH RES CO, V241, P419, DOI 10.1006/bbrc.1997.7832; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Moul J W, 1995, Semin Urol, V13, P157; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SMALL EJ, 1994, UROLOGY, V43, P408, DOI 10.1016/0090-4295(94)90092-2; STEINSAPIR J, 1991, BIOCHEM BIOPH RES CO, V179, P90, DOI 10.1016/0006-291X(91)91338-D; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang J, 1997, PROSTATE, V30, P117	46	213	220	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6322	6329		10.1038/sj.onc.1203032	http://dx.doi.org/10.1038/sj.onc.1203032			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597231				2022-12-17	WOS:000083934100016
J	Zhang, YK; Fujita, N; Tsuruo, T				Zhang, YK; Fujita, N; Tsuruo, T			Caspase-mediated cleavage of p21(Wafl)/(Cip1) converts cancer cells from growth arrest to undergoing apoptosis	ONCOGENE			English	Article						p21; apoptosis; caspases; DNA damage; p53	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; DNA-REPLICATION; P53-INDUCED APOPTOSIS; PROTEASE ACTIVATION; NUCLEAR ANTIGEN; CYTOCHROME-C; IN-VIVO; INHIBITION; P21	The cyclin-dependent kinase inhibitor p21(Waf1/Cip1) is a downstream effector of the p53-dependent cell growth arrest. We report herein that p21 was cleaved by caspase-3/CPP32 at the site of (DHVDL)-L-112 down arrow during the DNA damage-induced apoptosis of cancer cells. The cleaved p21 fragment could no more arrest the cells in G(1) phase nor suppress the cells undergoing apoptosis because it failed to bind to the proliferating cell nuclear antigen (PCNA) and lost its capability to localize in the nucleus. Thus, caspase-3-mediated cleavage and inactivation of p21 protein may convert cancer cells from growth arrest to undergoing apoptosis, leading to the acceleration of chemotherapy-induced apoptotic process in cancer cells.	Univ Tokyo, Lab Biomed Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Lab Biomed Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Lee SH, 1996, ONCOGENE, V13, P2131; LEHMAN TA, 1991, CANCER RES, V51, P4090; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOMIDA A, 1996, ONCOGENE, V13, P299; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	51	213	222	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1131	1138		10.1038/sj.onc.1202426	http://dx.doi.org/10.1038/sj.onc.1202426			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022118				2022-12-17	WOS:000078510700001
J	Akiri, G; Nahari, D; Finkelstein, Y; Le, SY; Elroy-Stein, O; Levi, BZ				Akiri, G; Nahari, D; Finkelstein, Y; Le, SY; Elroy-Stein, O; Levi, BZ			Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription	ONCOGENE			English	Article						vascular endothelial growth factor (VEGF); internal ribosome entry site (IRES); 5 ' untranslated region; translational regulation; angiogenesis	FACTOR MESSENGER-RNA; SMOOTH-MUSCLE CELLS; FACTOR GENE; PERMEABILITY FACTOR; EPITHELIAL-CELLS; IN-VIVO; HYPOXIA; PROTEIN; ANGIOGENESIS; SEQUENCES	Vascular Endothelial Growth Factor (VEGF) is very potent angiogenic agent that has a central role in normal physiological angiogenesis as well as in tumor angiogenesis, VEGF expression is induced by hypoxia and hypoglycemia, and thus was suggested to promote neovascularization during tumor outgrowth, Yet, the molecular mechanism that governs VEGF expression is not fully characterized, VEGF induction is attributed in part to increased levels of transcription and RNA stability, Previously, we demonstrated that the 5' Untranslated Region (5' UTR) of VEGF has an important regulatory role in its expression. VEGF has an exceptionally long 5' UTR (1038 bp) which is highly rich in G+C nucleotides, This suggests that secondary structures in the 5' UTR might be essential for VEGF expression through transcriptional and post-transcriptional control mechanisms, as demonstrated for other growth factors, In this communication, we provide evidence that a computer predicted Internal Ribosome Entry Site (IRES) structure is biologically active and is located at the 3' end of the UTR, In addition, the results demonstrate that an alternative transcriptional initiation site for VEGF exists in the 5' UTR of VEGF, This alternative initiation site is 633 bp downstream of the main transcription start site and the resulting 5' UTR includes mainly the IRES structure. Therefore, our results suggest that VEGF is subjected to regulation at either translational level through a mechanism of ribosome internal initiation and/or transcriptional level through alternative initiation.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; NCI, Lab Expt & Computat Biol, DBS, NIH, Frederick, MD 21702 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Technion Israel Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tel Aviv University	Levi, BZ (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.			Elroy-Stein, Orna/0000-0002-3716-1540				ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P2815, DOI 10.1093/nar/23.15.2815; DOLECKI GJ, 1991, BIOCHEM BIOPH RES CO, V180, P572, DOI 10.1016/S0006-291X(05)81103-9; FEN Z, 1991, ONCOGENE, V6, P953; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Furbass R, 1997, ENDOCRINOLOGY, V138, P2813, DOI 10.1210/en.138.7.2813; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Guerrin M, 1997, ONCOGENE, V14, P463, DOI 10.1038/sj.onc.1200846; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; Joukov V, 1996, EMBO J, V15, P290; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAGGERUD SM, 1995, ANTICANCER RES, V15, P683; LE SY, 1993, NUCLEIC ACIDS RES, V21, P2173, DOI 10.1093/nar/21.9.2173; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAGLIONE D, 1993, GROWTH FACTORS, V8, P141, DOI 10.3109/08977199309046934; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MINCHENKO A, 1994, LAB INVEST, V71, P374; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Townson S, 1996, BIOCHEM BIOPH RES CO, V220, P922, DOI 10.1006/bbrc.1996.0507; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WEISZ A, 1992, J BIOL CHEM, V267, P25589; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	52	213	227	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					227	236		10.1038/sj.onc.1202019	http://dx.doi.org/10.1038/sj.onc.1202019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674707				2022-12-17	WOS:000074706700011
J	Wang, Y; Yu, Y; Tsuyada, A; Ren, X; Wu, X; Stubblefield, K; Rankin-Gee, EK; Wang, SE				Wang, Y.; Yu, Y.; Tsuyada, A.; Ren, X.; Wu, X.; Stubblefield, K.; Rankin-Gee, E. K.; Wang, S. E.			Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM	ONCOGENE			English	Article						TGF-beta; cancer stem cells; microRNA; ATM; CHK2	TGF-BETA; SOLID TUMORS; MICRORNA EXPRESSION; P53; HETEROGENEITY; PATHWAYS; LEUKEMIA; DELETION	Recent studies indicate that a subset of cancer cells possessing stem cell properties, referred to as cancer-initiating or cancer stem cells (CSCs), have crucial roles in tumor initiation, metastasis and resistance to anticancer therapies. Transforming growth factor (TGF)-beta and their family members have been implicated in both normal (embryonic and somatic) stem cells and CSCs. In this study, we observed that exposure to TGF-beta increased the population of breast cancer (BC) cells that can form mammospheres in suspension, a feature endowed by stem cells. This was mediated by the micro (mi) RNA family miR-181, which was upregulated by TGF-beta at the post-transcriptional level. Levels of the miR-181 family members were elevated in mammospheres grown in undifferentiating conditions, compared with cells grown in two-dimensional conditions. Ataxia telangiectasia mutated (ATM), a target gene of miR-181, exhibited reduced expression in mammospheres and upon TGF-b treatment. Overexpression of miR-181a/b, or depletion of ATM or its substrate CHK2, was sufficient to induce sphere formation in BC cells. Finally, knockdown of ATM enhanced in vivo tumorigenesis of the MDA361 BC cells. Our results elucidate a novel mechanism through which the TGF-b pathway regulates the CSC property by interfering with the tumor suppressor ATM, providing insights into the cellular and environmental factors regulating CSCs, which may guide future studies on therapeutic strategies targeting these cells. Oncogene (2011) 30, 1470-1480; doi:10.1038/onc.2010.531; published online 22 November 2010	[Wang, Y.; Yu, Y.; Tsuyada, A.; Stubblefield, K.; Rankin-Gee, E. K.; Wang, S. E.] Beckman Res Inst City Hope, Div Tumor Cell Biol, Duarte, CA 91010 USA; [Yu, Y.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Head & Neck Tumor, Tianjin, Peoples R China; [Ren, X.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol & Biotherapy, Tianjin, Peoples R China; [Wu, X.] City Hope Comprehens Canc Ctr, Bioinformat Core Facil, Duarte, CA USA; [Wang, S. E.] City Hope Comprehens Canc Ctr, Canc Biol Program, Duarte, CA USA	City of Hope; Beckman Research Institute of City of Hope; Tianjin Medical University; Tianjin Medical University; City of Hope; City of Hope	Wang, SE (corresponding author), Beckman Res Inst City Hope, Div Tumor Cell Biol, 1500 E Duarte Rd,KCRB Room 2007, Duarte, CA 91010 USA.	ewang@coh.org	Rankin-Gee, Elyse/B-2776-2013	Rankin-Gee, Elyse/0000-0002-0675-6955; Wang, Shizhen Emily/0000-0002-5036-8175	NCI [R00 CA125892]; CBCRP [16IB-0081]; NATIONAL CANCER INSTITUTE [R00CA125892, K99CA125892] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CBCRP; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI R00 CA125892 (SEW) and CBCRP 16IB-0081 (SEW). We thank Dr John J Rossi for kindly providing reagents, Dr Shiuan Chen and Dr Susan Kane for valuable comments, the Bioinformatics Core for professional service and colleagues in the Division of Tumor Cell Biology for enthusiastic support and discussion. Financial Support: NCI R00 CA125892 (SEW); CBCRP 16IB-0081 (SEW).	Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Austen B, 2007, J CLIN ONCOL, V25, P5448, DOI 10.1200/JCO.2007.11.2649; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dontu G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2130; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Haidar MA, 2000, CANCER-AM CANCER SOC, V88, P1057, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Ren YS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-111; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Tribius S, 2001, INT J RADIAT ONCOL, V50, P511, DOI 10.1016/S0360-3016(01)01489-4; Vallier L, 2009, STEM CELLS, V27, P2655, DOI 10.1002/stem.199; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang SZE, 2007, J BIOL CHEM, V282, P5661, DOI 10.1074/jbc.M608499200; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323	32	212	228	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1470	1480		10.1038/onc.2010.531	http://dx.doi.org/10.1038/onc.2010.531			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102523	Green Accepted, Bronze, Green Published			2022-12-17	WOS:000288743800009
J	Zhang, H; OzakiZ, I; Mizuta, T; Hamajima, H; Yasutake, T; Eguchi, Y; Ideguchi, H; Yamamoto, K; Matsuhashi, S				Zhang, H.; Ozaki, I.; Mizuta, T.; Hamajima, H.; Yasutake, T.; Eguchi, Y.; Ideguchi, H.; Yamamoto, K.; Matsuhashi, S.			Involvement of programmed cell death 4 in transforming growth factor-beta 1-induced apoptosis in human hepatocellular carcinoma	ONCOGENE			English	Article						PDCD4 gene; TGF-beta 1; HCC; Smad; tumor suppressor	GROWTH-FACTOR-BETA; PROGRAMMED CELL-DEATH; INITIATION-FACTOR 4A; HUMAN HEPATOMA-CELLS; CHICKEN PDCD4 GENE; NF-KAPPA-B; TGF-BETA; TRANSFORMATION SUPPRESSOR; AP-1 TRANSACTIVATION; BINDING-PROTEIN	The programmed cell death 4 (PDCD4) gene was originally identified as a tumor-related gene in humans and acts as a tumor-suppressor in mouse epidermal carcinoma cells. However, its function and regulatory mechanisms of expression in human cancer remain to be elucidated. We therefore investigated the expression of PDCD4 in human hepatocellular carcinoma (HCC) and the role of PDCD4 in human HCC cells. Downregulation of PDCD4 protein was observed in all HCC tissues tested compared with corresponding noncancerous liver, as revealed by Western blotting or immunohistochemical staining. Human HCC cell line, Huh7, transfected with PDCD4 cDNA showed nuclear fragmentation and DNA laddering characteristic of apoptotic cells associated with mitochondrial changes and caspase activation. Transforming growth factor-beta 1 (TGF-beta 1) treatment of Huh7 cells resulted in increased PDCD4 expression and occurrence of apoptosis, also concomitant with mitochondrial events and caspase activation. Transfection of Smad7, a known antagonist to TGF-beta 1 signaling, protected cells from TGF-beta 1-mediated apoptosis and suppressed TGF-beta 1-induced PDCD4 expression. Moreover, antisense PDCD4 transfectants were resistant to apoptosis induced by TGF-beta 1. In conclusion, these data suggest that PDCD4 is a proapoptotic molecule involved in TGF-beta 1-induced apoptosis in human HCC cells, and a possible tumor suppressor in hepatocarcinogenesis.	Saga Univ, Saga Med Sch, Hlth Adm Ctr, Saga 8498501, Japan; Saga Univ, Saga Med Sch, Dept Internal Med, Div Hepatol & Metab, Saga 840, Japan; China Med Univ, Affiliated Hosp 1, Dept Surg 2, Shenyang, Peoples R China; Saga Univ, Saga Med Sch, Dept Pathol, Saga 840, Japan; Towha Univ, Fac Engn, Fukuoka, Japan	Saga University; Saga University; China Medical University; Saga University	OzakiZ, I (corresponding author), Saga Univ, Saga Med Sch, Hlth Adm Ctr, 5-1-1 Nabeshima, Saga 8498501, Japan.	ozaki@cc.saga-u.ac.jp		Zhang, Hao/0000-0002-9938-8433				Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; AKAO Y, 1994, CANCER RES, V54, P2468; Aravind L, 2000, GENOME RES, V10, P1172, DOI 10.1101/gr.10.8.1172; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horowitz J, 1999, CURR OPIN MOL THER, V1, P500; Huang JZ, 2003, WORLD J GASTROENTERO, V9, P84, DOI 10.3748/wjg.v9.i1.84; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; KITAJIMA Y, 1991, J BIOCHEM-TOKYO, V109, P544, DOI 10.1093/oxfordjournals.jbchem.a123417; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; Matsuzaki K, 2000, CANCER RES, V60, P1394; Musch A, 2005, DIGESTION, V71, P78, DOI 10.1159/000084523; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; Ozaki I, 2000, CANCER RES, V60, P6519; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Paik SY, 2003, MODERN PATHOL, V16, P86, DOI 10.1097/01.MP.0000047308.03300.9C; Rider MA, 2002, INT J ONCOL, V20, P235; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Simmons HM, 2005, GENE, V347, P137, DOI 10.1016/j.gene.2004.12.027; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wong SF, 2001, PATHOLOGY, V33, P85; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zhang H, 2004, CANCER SCI, V95, P878, DOI 10.1111/j.1349-7006.2004.tb02197.x	49	212	237	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2006	25	45					6101	6112		10.1038/sj.onc.1209634	http://dx.doi.org/10.1038/sj.onc.1209634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16682950				2022-12-17	WOS:000241101200007
J	Zhang, HG; Wang, JH; Yang, XW; Hsu, HC; Mountz, JD				Zhang, HG; Wang, JH; Yang, XW; Hsu, HC; Mountz, JD			Regulation of apoptosis proteins in cancer cells by ubiquitin	ONCOGENE			English	Review						cancer; apoptosis; ubiquitin proteasome inhibitor; TRAIL; BAX; NF-kappa B; p53; Mdm2	NF-KAPPA-B; PROTEASOME PATHWAY; LIGASE ACTIVITY; MEDIATED DEGRADATION; CASPASE ACTIVITY; FLIP PROTEIN; IN-VITRO; C-FLIP; P53; TRAIL	Ubiquitin inhibitors act at many levels to enhance apoptosis signaling. For TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis signaling, there are at least five mechanisms by which apoptosis are regulated by the ubiquitin - proteasome pathway. First, proteasome inhibitors can decrease Fas-like inhibitor protein ( FLIP) protein levels in tumors, resulting in increased apoptosis signaling due to increased caspase-8 activation. This appears to involve the ubiquitin ligase TNF receptor activation factor-2 (TRAF2) and acts indirectly by causing cell-cycle arrest at a stage where there is high degradation of the FLIP - TRAF2 complex. Second, the regulation of the proapoptotic Bcl-2 family member BAX occurs indirectly. Apoptosis signaling and caspase activation results in a confirmation change in the normally monomeric BAX, which exposes the BH3 domain of BAX, leading to dimerization and resistance to ubiquitin degradation. BAX then translocates into the mitochondria, resulting in the release of proapoptotic mitochondrial factors such as cytochrome c and second mitochondria-derived activator of caspase ( SMAC). This results in the activation of caspase-9 and formation of the apoptosome and efficient apoptosis signaling. A third mechanism of the regulation of TRAIL signaling in the ubiquitin - proteasome pathway is mediated by the inhibitor of apoptosis proteins (IAP) E3 ligases. These IAPs can directly bind to caspases but also can act as ubiquitin ligases for caspases, resulting in the degradation of these caspases. IAP binding to caspases can be inhibited by SMAC, which exhibits a caspase-9 homology domain. The fourth mechanism for apoptosis activation by proteasome inhibitors is through the stabilization of the inhibitor of the kappaB (IkappaB)/NF-kappaB complex and prevention of nuclear translocation of the antiapoptosis transcription factor NFkappaB. During TRAIL-DR4, DR5 signaling, this pathway is activated by interactions of activated Fas-associated death domain with activated receptor-interacting protein ( RIP), which in turn activates NF-kappaB-inducing kinase and phosphorylates IkappaB. Therefore, the inhibition of IkappaB degradation blocks this RIP-mediated antiapoptosis signaling event. Last, p53 protein levels, and susceptibility to apoptosis, can be deregulated by the human homolog Hdm2 (Mdm2) E3 ligase. This process is inhibited by p53 phosphorylation and by sequestration of Mdm2 by ARF. Better mechanisms to inhibit the ubiquitin - proteasome pathway targeted at the ubiquitin - proteasome degradation process itself, or more specifically at the E3 ligases known to modulate and downregulate proapoptosis pathways will lead to the enhancement of TRAIL apoptosis signaling and better cancer therapeutic outcomes act through this pathway.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mountz, JD (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 701 S 19th St,LHRB 473, Birmingham, AL 35294 USA.	john.mountz@ccc.uab.edu			NCI NIH HHS [CA 20408] Funding Source: Medline; NIAID NIH HHS [R01 AI 42900] Funding Source: Medline; NIA NIH HHS [R01 AG 11653] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011653] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Argentini M, 2000, ONCOGENE, V19, P3849, DOI 10.1038/sj.onc.1203737; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Basu A, 2002, INT J ONCOL, V21, P597; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Gottifredi V, 2001, SCIENCE, V292, P1851, DOI 10.1126/science.1062238; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang HK, 2000, J BIOL CHEM, V275, P26661; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Martinou I, 1998, NEUROREPORT, V9, P15, DOI 10.1097/00001756-199801050-00004; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Park SJ, 2001, BIOCHEM BIOPH RES CO, V289, P1205, DOI 10.1006/bbrc.2001.6086; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Rossi D, 2003, HAEMATOLOGICA, V88, P212; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; Silke J, 2000, CELL DEATH DIFFER, V7, P1275, DOI 10.1038/sj.cdd.4400790; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; WANG Q, 2003, J BIOL CHEM; Wesierska-Gadek J, 2002, INT J CANCER, V101, P128, DOI 10.1002/ijc.10580; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zhou T, 2002, IMMUNOL RES, V26, P323, DOI 10.1385/IR:26:1-3:323	57	212	227	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2009	2015		10.1038/sj.onc.1207373	http://dx.doi.org/10.1038/sj.onc.1207373			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021888				2022-12-17	WOS:000220213400005
J	Morali, OG; Delmas, V; Moore, R; Jeanney, C; Thiery, JP; Larue, L				Morali, OG; Delmas, V; Moore, R; Jeanney, C; Thiery, JP; Larue, L			IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition	ONCOGENE			English	Article						cadherin; catenin; insulin-like growth factor; epithelium to mesenchyme transition	MOUSE EMBRYONIC-DEVELOPMENT; EPIDERMAL GROWTH-FACTOR; CELL-CELL-ADHESION; PROTEIN-KINASE-B; E-CADHERIN; TRANSCRIPTIONAL ACTIVITY; CYTOPLASMIC DOMAIN; DROSOPHILA HOMOLOG; FACTOR RECEPTOR; INSULIN	The epithelium to mesenchyme transition is thought to play a fundamental role during embryonic development and tumor progression. Loss of cell-cell adhesion and modification of both cell morphology and gene expression are the main events associated with this transition. There is a large amount of evidence suggesting that growth factors can initiate these events. Yet, the connection from growth factor induction to changes in cell adhesion and morphology is largely unknown. To elucidate this connection, we have investigated the action of IGF-II on E-eadherin/beta -catenin complex-mediated cell-cell adhesion and on beta -catenin/TCF-3 mediated gene expression. We can show that (1) IGF-II induces a rapid epithelium to mesenchymal transition; (2) IGF1R, the receptor for IGF-II, belongs to the same membrane complex as E-cadherin and beta -catenin; (3) IGF-II induces a redistribution of beta -catenin from the plasma membrane to the nucleus and an intracellular sequestration and degradation of E-cadherin; (4) IGF-II induces the transcription of beta -catenin/TCF-3 target genes. Based on the given case of IGF-II and E-eadherin/beta -catenin complex, this study reveals the backbone of a cascade connecting growth factor signaling with cell-cell adhesion during EMT.	Inst Curie, UMR 146 CNRS, F-91405 Orsay, France; Inst Curie, UMR 144 CNRS, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Larue, L (corresponding author), Inst Curie, UMR 146 CNRS, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Delmas, veronique/0000-0001-7368-3664				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 1999, J CELL BIOCHEM, P68; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Birchmeier C, 1996, ACTA ANAT, V156, P217; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLAKESLEY VA, 1999, CONT ENDOCRINOLOGY I, V7, P143; BOYER B, 1992, EXP CELL RES, V201, P347, DOI 10.1016/0014-4827(92)90283-E; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Butz S, 1995, CELL ADHES COMMUN, V3, P337, DOI 10.3109/15419069509081018; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delmas V, 1999, DEV BIOL, V216, P491, DOI 10.1006/dbio.1999.9517; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; Greaves S, 1999, GENETICS, V153, P1753; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Larue L, 1996, DEVELOPMENT, V122, P3185; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yagi T, 2000, GENE DEV, V14, P1169	48	212	218	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4942	4950		10.1038/sj.onc.1204660	http://dx.doi.org/10.1038/sj.onc.1204660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526479				2022-12-17	WOS:000170439800004
J	Yu, DH; Liu, BL; Tan, M; Li, JZ; Wang, SS; Hung, MC				Yu, DH; Liu, BL; Tan, M; Li, JZ; Wang, SS; Hung, MC			Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms	ONCOGENE			English	Article						c-erbB-2/HER-2; oncogene; breast cancer; drug resistance; Taxol	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; PHASE-II TRIAL; NEU ONCOGENE; PROTO-ONCOGENE; MULTIDRUG RESISTANCE; MEDICAL PROGRESS; P-GLYCOPROTEIN; OVARIAN-CANCER; DNA-REPAIR	It has been reported that breast tumors that overexpress c-erbB-2/neu are less responsive to certain adjuvant chemotherapy regimens than those that express a normal amount of the gene product, To investigate whether overexpression of the c-erbB-2/neu-encoded p185 can indeed lead to increased chemoresistance in breast cancers, we introduced the human c-erbB-2/neu gene into the very low p185-expressing MDA-MB-435 human breast cancer cells and examined Taxol sensitivities among the parental MDA-MB-435 cells and stable transfectants which express increased levels of p185. The p185-overexpressing MDA-MB-435 transfectants were more resistant to Taxol than the parental cells. The increased Taxol resistance was not accompanied by changes in doubling time and S-phase fraction. The increased Taxol resistance was independent from oncogenic transformation since it was observed only in c-erbB-2/neu-transformed cells and not ras-transformed cells when oncogene-transformed NIH3T3 cells were examined. To study whether p185 induced Taxol resistance through the mdr-1 pathway, we examined the mdr-1-encoded p170 levels in these transfectants. The MDA-MB-435 cells expressed very low levels of p170 and there was no increase of p170 expression in the p185-overexpressing MDA-MB-435 transfectants. Furthermore, these transfectants were not sensitized to Taxol treatment by mdr-1 blocker thioradazine. These data demonstrated that overexpression of c-erbB-2/neu can lead to intrinsic Taxol resistance independent from mdr-1 mechanisms.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BAS RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, DH (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,BOX 107,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Tan, Ming/ABD-5847-2021; Hung, Mien-Chie/ABD-5911-2021	Tan, Ming/0000-0003-2007-9898; Hung, Mien-Chie/0000-0003-4317-4740; Liu, Bolin/0000-0003-0150-8650; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA060488, R29CA060488, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA60488, CA60856, CA58880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CHEVALLIER B, 1995, J CLIN ONCOL, V13, P314, DOI 10.1200/JCO.1995.13.2.314; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CREE IA, 1995, ANTI-CANCER DRUG, V6, P398, DOI 10.1097/00001813-199506000-00006; EFFERTH T, 1993, CANCER LETT, V70, P197, DOI 10.1016/0304-3835(93)90231-W; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LACROIX H, 1989, ONCOGENE, V4, P145; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; *PROM, 1991, TECHN B PROM CORP, V169; SCHNEIDER J, 1994, J NATL CANCER I, V86, P850, DOI 10.1093/jnci/86.11.850; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tsai CM, 1996, CANCER RES, V56, P206; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; TSAI CM, 1995, J NATL CANCER I, V87, P685; WALL ME, 1995, CANCER RES, V55, P753; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	37	212	223	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1359	1365						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808711				2022-12-17	WOS:A1996VJ20200028
J	Wu, XP; Rubin, M; Fan, Z; DeBlasio, T; Soos, T; Koff, A; Mendelsohn, J				Wu, XP; Rubin, M; Fan, Z; DeBlasio, T; Soos, T; Koff, A; Mendelsohn, J			Involvement of p27(KIP1) in G(1) arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody	ONCOGENE			English	Article						EGF receptor; mAb; p27(KIP1); cyclins; CDKs; cell cycle arrest	PROTEIN-KINASE; BREAST-CANCER; FACTOR-ALPHA; CELLS; CARCINOMA; CYCLIN	Activation of the cyclin dependent kinases (CDK4/CDK6 and CDK2) is required for G(1) phase progression and entry into S-phase. The activation of these kinases is regulated by checkpoints that monitor environmental and intracellular conditions. Progression into S-phase is controlled, in part, by the availability of growth factors, and we have investigated the relationship between growth factor availability and the activation of the CDK kinases. Blocking activation of epidermal growth factor (EGF) receptor tyrosine kinase with anti-EGF receptor monoclonal antibody (mAb) 225 induces G(1) phase cell cycle arrest in DiFi human colon adenocarcinoma cells. When DiFi cells are treated with mAb 225 for 24 h, eve observe marked decreases in the activities of CDK2 kinase and cyclin E-associated CDK kinase which are not accompanied by reduced levels of cyclin E and CDK2 proteins. However, the amount of cyclin/CDK kinase inhibitor p27(KIP1) increases in the mAb-treated cells and p27(KIP1) is bound to CDK2 in increasing amounts. Immunodepletion of p27(KIP1) removes an inhibitory activity from lysates of mAb-treated cells: the immuno-depleted and heated lysates lose the capacity to inhibit cyclin E/CDK2 activity in an in vitro assay. The results suggest that G(1) arrest in the cell cycle induced by EGF receptor blockade involves p27(KIP1).	MEM SLOAN KETTERING CANC CTR,LAB RECEPTOR BIOL,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University				Rubin, Mark/0000-0002-8321-9950	NCI NIH HHS [CA42060, CA 37641] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042060, U01CA037641, U19CA037641, R37CA042060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; FAN Z, 1995, FJ CELL BIOL, V131, P235; GILL GN, 1984, J BIOL CHEM, V259, P7755; GRANA X, 1995, ONCOGENE, V11, P211; GROSS ME, 1991, CANCER RES, V51, P1452; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARRIS AL, 1989, CANCER CEL, V7, P353; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1995, PROGR CELL CYCLE RES, P141; MASUI H, 1984, CANCER RES, V44, P1002; MASUI H, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P394; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; NEAL DE, 1985, LANCET, V1, P366; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SAINSBURY JRC, 1985, J CLIN PATHOL, V38, P1225, DOI 10.1136/jcp.38.11.1225; Sato J D, 1983, Mol Biol Med, V1, P511; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871	37	212	225	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1397	1403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622855				2022-12-17	WOS:A1996UF07600003
J	MCINTOSH, GG; ANDERSON, JJ; MILTON, I; STEWARD, M; PARR, AH; THOMAS, MD; HENRY, JA; ANGUS, B; LENNARD, TWJ; HORNE, CHW				MCINTOSH, GG; ANDERSON, JJ; MILTON, I; STEWARD, M; PARR, AH; THOMAS, MD; HENRY, JA; ANGUS, B; LENNARD, TWJ; HORNE, CHW			DETERMINATION OF THE PROGNOSTIC VALUE OF CYCLIN D1 OVEREXPRESSION IN BREAST-CANCER	ONCOGENE			English	Article						CYCLIN D1; MONOCLONAL ANTIBODY; IMMUNOHISTOCHEMISTRY; BREAST CANCER; PROGNOSIS	CELL-CYCLE; GENE AMPLIFICATION; DNA-REPLICATION; EXPRESSION; ONCOGENE; RETINOBLASTOMA; PROGRESSION; CARCINOMAS; SURVIVAL; C-ERBB-2	Cyclin D1 plays a critical role in the timing of the initiation of DNA synthesis in the normal cell cycle of mammalian cells, Deregulated expression of this protein has been seen in a variety of tumours either as a result of gene amplification or chromosomal translocation, in breast cancer and B cell malignancies respectively. In order to determine the role this putative oncoprotein plays in breast cancer, we have applied a new monoclonal antibody, recently produced in our laboratory, in an imnunohistochemical study of 93 primary breast carcinomas. We show that approximately 28% of the cases displayed enhanced expression of the cyclin D1 protein. Furthermore, either cyclin D1, cyclin D3, or both, were expressed in 69% of cases, suggesting that overexpression of any one member of this family may relieve cancer cells of their mitogenic stimulatory requirement. In addition, we show that those patients whose breast cancers co-express cyclin D1 with either epidermal growth factor receptor (EGFR) or the retinoblastoma protein (pRB) have a significantly poorer prognosis in comparison to those expressing cyclin D1 alone. Our observations indicate that, in a subset of breast cancers, aberrant cyclin D1 expression is a contributory factor to tumorigenesis and in association with EGFR or pRB expression, identify those tumours which may require more aggressive therapy.	NOVOCASTRA LABS, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT SURG, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK	MCINTOSH, GG (corresponding author), UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, DEPT PATHOL, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.		Angus, Brian/L-9246-2019	Angus, Brian/0000-0003-3598-7784				ADNANE J, 1989, ONCOGENE, V4, P1389; AJCHENBAUM F, 1992, J CELL BIOL, V268, P4113; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CARTER MJ, 1993, NUCLEIC ACIDS RES, V21, P1044, DOI 10.1093/nar/21.4.1044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; HARPER JW, 1993, CELL, V75, P805; HASTRICH D, 1992, J PATHOL S, V167, pA143; HENRY JA, 1993, INT J CANCER, V53, P774, DOI 10.1002/ijc.2910530512; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KCOH KS, 1994, BIOCHEM BIOPH RES CO, V204, P91; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LAMMIE GA, 1991, ONCOGENE, V6, P439; LI Y, 1994, ONCOGENE, V9, P2261; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; Maniatis T, 1989, MOL CLONING; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCINTOSH EM, 1993, MUTAT RES, V289, P61, DOI 10.1016/0027-5107(93)90131-X; MORGAN JM, 1994, J PATHOL, V174, P301, DOI 10.1002/path.1711740410; MORISAKI T, 1994, CANCER RES, V54, P1113; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NANXIN L, 1994, ONCOGENE, V9, P3457; PALMERO I, 1993, ONCOGENE, V8, P1049; PEPPER DS, 1994, BIOCHIM BIOPHYS ACTA, V1198, P215; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SURMACZ E, 1992, CANCER RES, V52, P4522; TAM SW, 1994, ONCOGENE, V9, P2663; THEILLET C, 1989, ONCOGENE, V4, P915; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; WRIGHT C, 1989, CANCER RES, V49, P2087; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHANG SY, 1994, AM J CLIN PATHOL, V102, P695, DOI 10.1093/ajcp/102.5.695	52	212	215	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					885	891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675447				2022-12-17	WOS:A1995RU79800009
J	BROWN, PH; CHEN, TK; BIRRER, MJ				BROWN, PH; CHEN, TK; BIRRER, MJ			MECHANISM OF ACTION OF A DOMINANT-NEGATIVE MUTANT OF C-JUN	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; MAMMALIAN-CELLS; PROTO-ONCOGENE; LEUCINE ZIPPER; FOS; PROTEINS; AP-1; TRANSFORMATION; DOMAIN; ONCOPROTEIN	The AP-1 transcriptional activating complex, made up of Jun and Fos proteins, is involved in controlling many cellular processes such as cell proliferation, differentiation and transformation. We have previously characterized a dominant-negative mutant of c-Jun called TAM-67 which forms dimers with c-Jun and c-Fos, and binds DNA as a homodimer or heterodimer with c-Jun or c-Fos. This dominant-negative mutant is a potent inhibitor of AP-1 mediated transactivation, as well as c-jun/ras and TPA/ras-induced transformation. The present report describes experiments designed to elucidate the exact molecular mechanism of this dominant-negative inhibitor. The DNA binding kinetics of both TAM-67:TAM-67 homodimers as well as TAM-67:Fos heterodimers were studied and compared to those of c-Jun and other transactivation-deficient mutants of c-Jun. These studies demonstrated that the TAM-67 proteins have similar DNA binding kinetics to c-Jun and other Jun mutant proteins. Thus, the deletion of the amino-terminal end of the Jun protein does not significantly alter the protein's affinity for DNA. In addition, to determine whether TAM-67 functions through the formation of homodimers, or through interactions with endogenous c-Jun or c-Fos, we constructed a pair of chimeric proteins made by replacing the leucine zipper of TAM-67 with the leucine zippers of GCN4 and c-Fos. These chimeric proteins, termed TAM/GCN4 and TAM/Fos, were then tested for their ability to bind DNA, inhibit c-Jun-induced transactivation, and inhibit TPA/ras-mediated transformation. The results of these studies show that while both chimeric proteins bind equally well to DNA, only the TAM/Fos protein, and not the TAM/GCN4 protein, inhibits AP-1-induced transactivation and TPA/ras-induced transformation. When compared to the TAM-67 protein, the TAM/Fos protein is an equally potent inhibitor of transactivation and transformation. These results suggest that TAM-67 inhibits AP-1-mediated processes through a 'quenching' mechanism by inhibiting the function of endogenous Jun and/or Fos proteins. The implications of these mechanistic findings on the development of potent inhibitors of signal transduction pathways are discussed.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, ROCKVILLE, MD 20850 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA				Brown, Powel/0000-0002-3398-163X				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BROWN PH, 1993, ONCOGENE, V8, P877; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HIRAI SI, 1990, ONCOGENE, V5, P39; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN IM, 1992, ONCOGENE, V7, P1119; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	30	212	217	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					791	799						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108121				2022-12-17	WOS:A1994MW55100014
J	SAVATIER, P; HUANG, S; SZEKELY, L; WIMAN, KG; SAMARUT, J				SAVATIER, P; HUANG, S; SZEKELY, L; WIMAN, KG; SAMARUT, J			CONTRASTING PATTERNS OF RETINOBLASTOMA PROTEIN EXPRESSION IN MOUSE EMBRYONIC STEM-CELLS AND EMBRYONIC FIBROBLASTS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; MOLECULAR-CLONING; RB GENE; E1A-LIKE ACTIVITY; CARCINOMA-CELLS; BINDING PROTEIN; CELLULAR GENES	The expression of the retinoblastoma susceptibility (RB-1) gene was investigated in highly proliferating mouse embryonic stem (ES) cells and in slowly proliferating mouse embryonic fibroblasts. The RIB protein was expressed at the same level in these two cell types. Mainly hyperphosphorylated RB was detected in exponentially-growing ES cells. Embryonic fibroblasts and embryonic stem cells were synchronized by colcemid block followed by mitotic shake-off. In embryonic fibroblasts, DNA replication started 10-15 h after exit from mitosis and RB was transiently dephosphorylated during the G1 phase as previously described. In ES cells, DNA replication started 2h after release from the colcemid block but virtually no hypophosphorylated RB was observed after the release. Instead, there was a dramatic decrease in the total RB protein level between exit from mitosis and entry into S phase, These observations were made by using two different monoclonal antibodies, both in immunoblotting and immunoprecipitation experiments. Absence of hypophosphorylated RB and cell cycle-dependent change in total RB protein level may be relevant to the high proliferation rate and to the tumorigenic nature of mouse embryonic stem tells.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet	SAVATIER, P (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021; SAVATIER, Pierre/J-4663-2014; Samarut, Jacques/AAD-2587-2019	Wiman, Klas/0000-0002-7113-524X; 				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BEDDINGTON RSP, 1983, J EMBRYOL EXP MORPH, V75, P189; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DAMJANOV I, 1971, ROUX ARCH DEV BIOL, V167, P288, DOI 10.1007/BF00584254; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLINGSWORTH RE, 1993, CURRENT OPINION CELL, V5, P1194; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCCORMICK PJ, 1990, EXP CELL RES, V189, P183, DOI 10.1016/0014-4827(90)90234-2; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MURRAY EJ, 1991, MOL CELL BIOL, V11, P5534, DOI 10.1128/MCB.11.11.5534; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLACK RS, 1993, ONCOGENE, V8, P1585; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; STOKKE T, 1993, EXP CELL RES, V204, P147, DOI 10.1006/excr.1993.1019; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	63	212	215	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					809	818						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108123				2022-12-17	WOS:A1994MW55100016
J	LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			NUCLEOTIDE-SEQUENCE AND EXPRESSION OF A CDNA-ENCODING MYD88, A NOVEL MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE INDUCED BY IL6	ONCOGENE			English	Note									UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007152] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005415] Funding Source: NIH RePORTER; NCI NIH HHS [IROICA43618-01] Funding Source: Medline; NCRR NIH HHS [SO7-RR-05415-28] Funding Source: Medline; NICHD NIH HHS [5T32HD07152] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		FORANCE AJ, 1989, MOL CELL BIOL, V9, P4196; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE F, 1989, ANN NY ACAD SCI, V5576, P215; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD K, 1989, IN PRESS ONCOGENE; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHABO Y, 1988, BLOOD, V72, P1543; VARNUM BC, 1989, ONCOGENE, V4, P119	11	212	233	0	17	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1095	1097						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2374694				2022-12-17	WOS:A1990DP41500024
J	Etienne-Manneville, S				Etienne-Manneville, S.			Polarity proteins in migration and invasion	ONCOGENE			English	Review						Par proteins; epithelial mesenchymal transition (EMT); Rho GTPases; Wnt; Scribble	TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; SIGNAL-TRANSDUCTION PATHWAYS; ADENOMATOUS POLYPOSIS-COLI; CELL-SHAPE CHANGE; KINASE-C-ZETA; TIGHT JUNCTION; DISCS-LARGE; NEURONAL POLARITY; E-CADHERIN	Cancer is the result of the deregulation of cell proliferation and cell migration. In advanced tumors, cells invade the surrounding tissue and eventually form metastases. This is particularly evident in carcinomas in which epithelial cells have undergone epithelial-mesenchymal transition. Increased cell migration often correlates with a weakening of intercellular interactions. Junctions between neighboring epithelial cells are required to establish and maintain baso-apical polarity, suggesting that not only loss of cell-cell adhesion but also alteration of cell polarity is involved during invasion. Accordingly, perturbation of cell polarity is an important hallmark of advanced invasive tumors. Cell polarity is also essential for cell migration. Indeed, a front-rear polarity axis has first to be generated to allow a cell to migrate. Because cells migrate during invasion, cell polarity is not completely lost. Instead, polarity is modified. From a nonmigrating baso-apically polarized epithelial phenotype, cells acquire a polarized migrating mesenchymal phenotype. The aim of this review is to highlight the molecular relationship between the control of cell polarity and the regulation of cell motility during oncogenesis.	[Etienne-Manneville, S.] Inst Pasteur, Cell Polar & Migrat Grp, F-74724 Paris 15, France; [Etienne-Manneville, S.] CNRS, URA 2582, F-74724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Etienne-Manneville, S (corresponding author), Inst Pasteur, Cell Polar & Migrat Grp, 25 Rue Dr Roux, F-74724 Paris 15, France.	sandrine.etienne-manneville@pasteur.fr	Etienne-Manneville, Sandrine/C-5879-2015	Etienne-Manneville, Sandrine/0000-0001-6651-3675	l'Agence Nationale pour la Recherche; la Fondation de France; La Ligue contre le Cancer et l'Association pour la Recherche sur le Cancer; la Fondation Schlumberger pour l'Enseignement et la Recherche; EMBO Young Investigator Program	l'Agence Nationale pour la Recherche(French National Research Agency (ANR)); la Fondation de France(Fondation de France); La Ligue contre le Cancer et l'Association pour la Recherche sur le Cancer; la Fondation Schlumberger pour l'Enseignement et la Recherche; EMBO Young Investigator Program(European Molecular Biology Organization (EMBO))	We apologize for those authors whose work was not cited directly owing to space limitation. This work was supported by grants from the l'Agence Nationale pour la Recherche, la Fondation de France, La Ligue contre le Cancer et l'Association pour la Recherche sur le Cancer, la Fondation Schlumberger pour l'Enseignement et la Recherche, the EMBO Young Investigator Program.	Abdelilah-Seyfried S, 2003, DEVELOPMENT, V130, P1927, DOI 10.1242/dev.00420; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Arquier N, 2001, DEVELOPMENT, V128, P2209; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; Barth AIM, 2008, SEMIN CELL DEV BIOL, V19, P245, DOI 10.1016/j.semcdb.2008.02.003; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Charest PG, 2007, BIOCHEM J, V401, P377, DOI 10.1042/BJ20061432; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; DOW L, 2008, ONCOGENE; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Helfrich I, 2007, J INVEST DERMATOL, V127, P782, DOI 10.1038/sj.jid.5700621; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johansson AS, 2000, J CELL SCI, V113, P3267; Kaelin WG, 2005, COLD SH Q B, V70, P159, DOI 10.1101/sqb.2005.70.001; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kikuchi A, 2008, CANCER SCI, V99, P202, DOI 10.1111/j.1349-7006.2007.00675.x; KNUST E, 1993, DEVELOPMENT, P261; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Kuribayashi K, 2007, J CELL BIOL, V176, P1049, DOI 10.1083/jcb.200607019; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Mehenni H, 2005, HUM MOL GENET, V14, P2209, DOI 10.1093/hmg/ddi225; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Mertens AEE, 2006, TRENDS CELL BIOL, V16, P308, DOI 10.1016/j.tcb.2006.04.001; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Ossipova O, 2005, DEV CELL, V8, P829, DOI 10.1016/j.devcel.2005.04.011; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pinheiro EM, 2004, DEVELOPMENT, V131, P5243, DOI 10.1242/dev.01412; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Schlessinger K, 2007, J CELL BIOL, V178, P355, DOI 10.1083/jcb.200701083; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shelly M, 2007, CELL, V129, P565, DOI 10.1016/j.cell.2007.04.012; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009; Shin K, 2007, EMBO REP, V8, P158, DOI 10.1038/sj.embor.7400890; Siegrist SE, 2007, GENE DEV, V21, P483, DOI 10.1101/gad.1511207; Stern CD, 2006, CURR OPIN GENET DEV, V16, P413, DOI 10.1016/j.gde.2006.06.005; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tapon N, 2003, CANCER CELL, V4, P333, DOI 10.1016/S1535-6108(03)00279-4; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Thiery JP, 2005, DEV CELL, V8, P456, DOI 10.1016/j.devcel.2005.03.002; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang Q, 2007, KIDNEY INT, V72, P1448, DOI 10.1038/sj.ki.5002579; Wang Q, 2004, J BIOL CHEM, V279, P30715, DOI 10.1074/jbc.M401930200; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; Zhang X, 2007, NAT CELL BIOL, V9, P743, DOI 10.1038/ncb1603	120	211	216	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2008	27	55					6970	6980		10.1038/onc.2008.347	http://dx.doi.org/10.1038/onc.2008.347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029938				2022-12-17	WOS:000261108200009
J	Cheng, N; Bhowmick, NA; Chytil, A; Gorksa, AE; Brown, KA; Muraoka, R; Arteaga, CL; Neilson, EG; Hayward, SW; Moses, HL				Cheng, N; Bhowmick, NA; Chytil, A; Gorksa, AE; Brown, KA; Muraoka, R; Arteaga, CL; Neilson, EG; Hayward, SW; Moses, HL			Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks	ONCOGENE			English	Article						TGF-beta; TGF-beta receptor type II; mammary gland; tumor-stromal interactions; tumor progression; subrenal grafting	MACROPHAGE-STIMULATING PROTEIN; TUMOR-STROMAL INTERACTIONS; HUMAN PROSTATE-CANCER; HUMAN BREAST-CANCER; EPITHELIAL INTERACTIONS; FACTOR/SCATTER FACTOR; EXTRACELLULAR-MATRIX; GLAND DEVELOPMENT; TYROSINE KINASE; REACTIVE STROMA	Stromal fibroblasts regulate epithelial cell behavior through direct and indirect cell-cell interactions. To clarify the role of TGF-beta signaling in stromal. broblasts during mammary development and tumorigenesis, we conditionally knocked out the TGF-beta type II receptor gene in mouse mammary. broblasts (Tgfbr2(fspKO)). Tgfbr2(fspKO) mice exhibit defective mammary ductal development, characterized in part by increased ductal epithelial cell turnover associated with an increase in stromal. fibroblast abundance. Tgfbr2(fspKO) mammary. broblasts transplanted with mammary carcinoma cells promote growth and invasion, which is associated with increased activating phosphorylation of the receptors: erbB1, erbB2, RON, and c- Met. Furthermore, the increased receptor phosphorylation correlates with increased secretion of the cognate ligands by Tgfbr2(fspKO). broblasts. Treatment of tumor cells with. fibroblast-conditioned medium leads to increased tumor cell proliferation and motility, which are blocked by addition of pharmacologic inhibitors of TGF-alpha signaling or neutralizing antibodies to macrophage-stimulating protein (MSP), HGF, or c- Met. These studies characterize a significant role for stromal TGF-beta signaling in mammary tissue homeostasis and mammary tumor progression via regulation of TGF-alpha, MSP, and HGF signaling pathways.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Urol Surg, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, 691 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	Hal.Moses@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019; Thomson, Axel/A-7893-2013	Bhowmick, Neil/0000-0001-8747-5989; Hayward, Simon/0000-0002-6059-6550	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA085492, R01CA102162, T32CA009592, R01CA108646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085492, R01 CA108646-01, P30 CA068485, R01 CA102162, CA102162, P30 CA68485, CA85492, R01 CA108646, T32 CA009592] Funding Source: Medline; NIAMS NIH HHS [AR41943, P30 AR041943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bitzer M, 2000, GENE DEV, V14, P187; Bottinger EP, 1997, CANCER RES, V57, P5564; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Cardiff RD, 2001, VET PATHOL, V38, P357, DOI 10.1354/vp.38-4-357; Cardiff RD, 2001, MICROSC RES TECHNIQ, V52, P224, DOI 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.3.CO;2-1; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; CUNHA G, 2000, METHODS MAMMARY GLAN; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; Daniel CW, 2001, ADV EXP MED BIOL, V501, P61; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hagedorn HG, 2001, INT J ONCOL, V18, P669; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Hayward SW, 1998, DIFFERENTIATION, V63, P131, DOI 10.1046/j.1432-0436.1998.6330131.x; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Joseph H, 1999, MOL BIOL CELL, V10, P1221, DOI 10.1091/mbc.10.4.1221; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; Leonard E J, 1979, Adv Exp Med Biol, V121B, P181; LEONARD JE, 1987, CANCER RES, V47, P2899; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Maglione JE, 2001, CANCER RES, V61, P8298; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Moinfar F, 2000, CANCER RES, V60, P2562; Moulder SL, 2001, CANCER RES, V61, P8887; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949; SAKAKURA T, 1981, J NATL CANCER I, V66, P953; SCHOR AM, 1994, INT J CANCER, V59, P25, DOI 10.1002/ijc.2910590107; Shekhar MPV, 2001, CANCER RES, V61, P1320; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Simian M, 2001, DEVELOPMENT, V128, P3117; SKEEL A, 1994, J IMMUNOL, V152, P4618; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Sun LZ, 2004, FRONT BIOSCI, V9, P1925, DOI 10.2741/1382; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tolstonog GV, 2001, DNA CELL BIOL, V20, P509, DOI 10.1089/104454901317094945; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Wakeling AE, 2002, CANCER RES, V62, P5749; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2002, SCAND J IMMUNOL, V56, P545, DOI 10.1046/j.1365-3083.2002.01177.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Zangani D, 1999, EXP CELL RES, V247, P399, DOI 10.1006/excr.1998.4373; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	66	211	220	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5053	5068		10.1038/sj.onc.1208685	http://dx.doi.org/10.1038/sj.onc.1208685			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856015	Green Accepted			2022-12-17	WOS:000230816900005
J	Cromer, A; Carles, A; Millon, R; Ganguli, G; Chalmel, F; Lemaire, F; Young, J; Dembele, D; Thibault, C; Muller, D; Poch, O; Abecassis, J; Wasylyk, B				Cromer, A; Carles, A; Millon, R; Ganguli, G; Chalmel, F; Lemaire, F; Young, J; Dembele, D; Thibault, C; Muller, D; Poch, O; Abecassis, J; Wasylyk, B			Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis	ONCOGENE			English	Article						HNSCC; chromosomal location; prognosis; gene amplification	SQUAMOUS-CELL CARCINOMAS; LASER CAPTURE MICRODISSECTION; MOLECULAR CLASSIFICATION; EXPRESSION PROFILES; COPY NUMBER; BONE-MARROW; NECK; HEAD; AUTOTAXIN; AMPLIFICATION	Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer among men in the developed world. There is a need, for both clinical and scientific reasons, to find markers to identify patients with aggressive disease as early as possible, and to understand the events leading to malignant transformation and susceptibility to metastasis. We report the first large-scale gene expression analysis of a unique HNSCC location, the hypopharynx. Four normal and 34 tumour samples were analysed with 12 600 gene microarrays. Clusters of differentially expressed genes were identified in the chromosomal regions 3q27.3, 17q21.2-q21.31, 7q11.22-q22.1 and 11q13.1-q13.3, which, interestingly, have already been identified by comparative genomic hybridization (CGH) as major regions of gene amplification. We showed that six overexpressed genes (EIF4G1, DVL3, EPHB4, MCM7, BRMS1 and SART1) located in these regions are indeed amplified. We report 119 genes that are highly differentially expressed between 'early' tumours and normal samples. Of these, we validated by quantitative PCR six novel poorly characterized genes. These genes are potential new markers of HNSCC. Comparing patients with relatively nonaggressive and aggressive tumours (without or with clinical evidence of metastasis 3 years after surgery), we identified 164 differentially expressed genes potentially involved in the acquisition of metastatic potential. This study contributes to the understanding of HNSCC, staging patients into prognostic groups and identifying high-risk patients who may benefit from more aggressive treatment.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Ctr Paul Strauss, UPRES EA 34 30, F-67085 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Chalmel, Frederic/M-1297-2016; Dembélé, Doulaye/O-6513-2017; Young, Julia/A-7219-2013; Chalmel, Frédéric/L-5360-2018; Chalmel, Frédéric/AAM-1079-2021; Indra, Gitali/G-2963-2016; Wasylyk, Bohdan/ABG-6778-2020	Dembélé, Doulaye/0000-0003-3879-6940; Chalmel, Frédéric/0000-0002-0535-3628; Chalmel, Frédéric/0000-0002-0535-3628; Wasylyk, Bohdan/0000-0002-1718-1237; Young, Julia/0000-0001-7219-7824; Thibault-Carpentier, Christelle/0000-0003-1562-1451				Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Belbin TJ, 2002, CANCER RES, V62, P1184; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Crawley JJ, 2002, GENOME BIOL, V3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Naggar AK, 2002, ONCOGENE, V21, P8206, DOI 10.1038/sj.onc.1206021; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Genden EM, 2003, ORAL ONCOL, V39, P207, DOI 10.1016/S1368-8375(02)00049-0; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; Hyman E, 2002, CANCER RES, V62, P6240; Kano M, 2003, PHYSIOL GENOMICS, V13, P31, DOI 10.1152/physiolgenomics.00116.2002; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kol S, 1997, J CLIN INVEST, V99, P2274, DOI 10.1172/JCI119403; LaTulippe E, 2002, CANCER RES, V62, P4499; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Lemaire F, 2003, BRIT J CANCER, V89, P1940, DOI 10.1038/sj.bjc.6601373; Li AH, 2001, CLIN CANCER RES, V7, P3298; Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Muller D, 1997, EUR J CANCER, V33, P2203, DOI 10.1016/S0959-8049(97)00198-6; Murakami T, 2002, CANCER RES, V62, P7328; Nam SW, 2001, CANCER RES, V61, P6938; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Phillips JL, 2001, CANCER RES, V61, P8143; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Quon H, 2001, HEAD NECK-J SCI SPEC, V23, P147, DOI 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#; Redon R, 2001, CANCER RES, V61, P4122; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Taichman RS, 2002, CANCER RES, V62, P1832; Tao M, 2000, CYTOKINE, V12, P699, DOI 10.1006/cyto.2000.0666; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Watanabe H, 2002, ORAL ONCOL, V38, P670, DOI 10.1016/S1368-8375(02)00006-4; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	49	211	232	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2484	2498		10.1038/sj.onc.1207345	http://dx.doi.org/10.1038/sj.onc.1207345			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676830				2022-12-17	WOS:000220558000006
J	Courtois, S; Verhaegh, G; North, S; Luciani, MG; Lassus, P; Hibner, U; Oren, M; Hainaut, P				Courtois, S; Verhaegh, G; North, S; Luciani, MG; Lassus, P; Hibner, U; Oren, M; Hainaut, P			Delta N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53	ONCOGENE			English	Article						p53; Delta N-p53; p53 isoforms; N-terminal domain; cell cycle	PROTEOLYTIC CLEAVAGE; FUNCTIONAL DOMAIN; DNA-BINDING; IN-VITRO; PROTEIN; TRANSLATION; INITIATION; MDM2; P63; IDENTIFICATION	The tumor suppressor protein p53 is ubiquitously expressed as a major isoform of 53 kD, but several forms of lower molecular weight have been observed. Here, we describe a new isoform, DeltaN-p53, produced by internal initiation of translation at codon 40 and lacking the N-terminal first transactivation domain. This isoform has impaired transcriptional activation capacity, and does not complex with the p53 regulatory protein Mdm2. Furthermore, DeltaN-p53 oligomerizes with full-length p53 (FL-p53) and negatively regulates its transcriptional and growth-suppressive activities. Consistent with the lack of Mdm2 binding, DeltaN-p53 does not accumulate in response to DNA-damage, suggesting that this isoform is not involved in the response to genotoxic stress. However, in serum-starved cells expressing wild-type p53, DeltaN-p53 becomes the predominant p53 form during the synchronous progression into S phase after serum stimulation. These results suggest that DeltaN-p53 may play a role as a transient, negative regulator of p53 during cell cycle progression.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France; CNRS, UMR5535, Inst Genet Mol, F-34293 Montpellier 5, France; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	World Health Organization; International Agency for Research on Cancer (IARC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Weizmann Institute of Science	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Verhaegh, Gerald/L-4708-2015; Hainaut, Pierre/B-6018-2012	Verhaegh, Gerald/0000-0003-0227-2280; Hainaut, Pierre/0000-0002-1303-1610; Lassus, Patrice/0000-0002-2785-7843; Hibner, Urszula/0000-0002-5520-7311; Oren, Moshe/0000-0003-4311-7172				Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Barraille P, 1999, BIOCHEM BIOPH RES CO, V257, P84, DOI 10.1006/bbrc.1999.0334; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Hainaut P, 2000, ADV CANCER RES, V77, P81; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; Levrero M, 2000, J CELL SCI, V113, P1661; LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; Molinari M, 1996, ONCOGENE, V13, P2077; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Okorokov AL, 1997, ONCOL RES, V9, P267; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Veldhoen N, 1999, ONCOGENE, V18, P7026, DOI 10.1038/sj.onc.1203182; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	38	211	217	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6722	6728		10.1038/sj.onc.1205874	http://dx.doi.org/10.1038/sj.onc.1205874			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360399				2022-12-17	WOS:000178315800002
J	ALVES, F; VOGEL, W; MOSSIE, K; MILLAUER, B; HOFLER, H; ULLRICH, A				ALVES, F; VOGEL, W; MOSSIE, K; MILLAUER, B; HOFLER, H; ULLRICH, A			DISTINCT STRUCTURAL CHARACTERISTICS OF DISCOIDIN-I SUBFAMILY RECEPTOR TYROSINE KINASES AND COMPLEMENTARY EXPRESSION IN HUMAN CANCER	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCTION; DISCOIDIN I MOTIF; SH3 BINDING SITE; TUMOR INVASION	GROWTH-FACTOR RECEPTOR; BINDING; DOMAIN; IDENTIFICATION; MOLECULE; FAMILY; SIGNAL; CELLS; ACID	Mammary carcinoma kinase 10 (MCK-10) and colon carcinoma kinase 2 (CCK-2) constitute a subclass of receptor tyrosine kinases characterized by a discoidin I motif in the extracellular domain and a large cytoplasmic juxtamembrane (JM) region. While the ectodomain structure suggests a common role in cell aggregation, the JM domains of MCK-10 and CCK-2 are structurally most divergent and display features that suggest an involvement in signal generation and definition. MCK-10 occurs in at least three isoforms, which contain alternatively spliced consensus sequences for internalization and SH3 domain interaction. The presence of the 37 amino acid insert affects receptor autophosphorylation and changes ectodomain glycosylation. Proteolytic cleavage within the extracellular domain of MCK-10 generates a membrane-anchored kinase domain and releases a soluble ectodomain fragment including the discoidin I homology domain. CCK-2 and MCK-10 expression was found in connective and epithelial tissues, respectively, which in cancers of epithelial origin results in mutually exclusive expression in stroma and tumor cells, indicating a possible involvement of this class of RTKs in tumor invasion.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY; SUGEN INC, DEPT MOLEC BIOL, REDWOOD CITY, CA 94063 USA; TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, INST ALLGEMEINE & PATHOL ANAT, D-81675 MUNICH, GERMANY	Max Planck Society; Technical University of Munich								ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENDLY BM, 1990, CANCER RES, V50, P1550; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KARN T, 1993, ONCOGENE, V8, P3433; LAI C, 1994, ONCOGENE, V9, P877; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEREZ JL, 1994, ONCOGENE, V9, P211; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZERLIN M, 1993, ONCOGENE, V8, P2731; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	211	219	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					609	618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845687				2022-12-17	WOS:A1995QF64800023
J	KALTHOFF, H; SCHMIEGEL, W; ROEDER, C; KASCHE, D; SCHMIDT, A; LAUER, G; THIELE, HG; HONOLD, G; PANTEL, K; RIETHMULLER, G; SCHERER, E; MAURER, J; MAACKE, H; DEPPERT, W				KALTHOFF, H; SCHMIEGEL, W; ROEDER, C; KASCHE, D; SCHMIDT, A; LAUER, G; THIELE, HG; HONOLD, G; PANTEL, K; RIETHMULLER, G; SCHERER, E; MAURER, J; MAACKE, H; DEPPERT, W			P53 AND K-RAS ALTERATIONS IN PANCREATIC EPITHELIAL-CELL LESIONS	ONCOGENE			English	Article							GROWTH FACTOR-ALPHA; LARGE T-ANTIGEN; MONOCLONAL-ANTIBODIES; COLORECTAL TUMORIGENESIS; ADENOCARCINOMA CELLS; EXOCRINE PANCREAS; SIMIAN VIRUS-40; TUMOR-ANTIGEN; GENE; MUTATIONS	We have analysed the expression of p53 at the mRNA level, and extensively at the protein level by immunostaining, Western blotting, and ELISA measurements revealing a p53 increase in 8 out of 14 cell lines established from human pancreatic carcinomas. The mRNA levels closely paralleled the protein levels in most of the cell lines. Overexpression of p53 in tumor cells correlated with mutations in the p53 gene. Immunocytochemistry was also performed with tissue cryosections showing a nuclear p53 staining in 8 out of 12 exocrine, and 2 out of 2 endocrine tumors. In addition, nonmalignant peri-tumoral tissue specimens and cells derived from pancreatic juice of acute pancreatic patients were also positively stained. These findings may suggest functions of p53 in stress situations induced by acute inflammation or tissue regeneration. Genomic mutations in the tumor suppressor gene were associated with point mutations in either codon 12, 13 or 61 in the c-K-RAS oncogene in about two-thirds of cell lines. The frequent activations of a RAS oncogene in combination with mutations of a tumor suppressor gene are likely to contribute to the malignant phenotype of pancreatic adenocarcinomas.	UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH 2,GERMANY; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; FU BERLIN,KLINIKUM STEGLITZ,INNERE MED ABT,W-1000 BERLIN 45,GERMANY; HEINRICH PETTE INST,TUMORVIROL ABT,HAMBURG,GERMANY	University of Munich; Netherlands Cancer Institute; Free University of Berlin; Heinrich Pette Institute	KALTHOFF, H (corresponding author), UNIV HAMBURG,MED KLIN,IMMUNOL ABT,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Kalthoff, Holger/B-1618-2010; Lauer, Georg/J-1467-2018	Lauer, Georg/0000-0002-9792-4271				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1992, IN PRESS J CELL SCI; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, NATO ASI SERIES H, V34, P399; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERNANDEZPOL JA, 1989, J CELL BIOCHEM, V41, P159, DOI 10.1002/jcb.240410306; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KAKU M, 1980, GANN, V71, P596; KALTHOFF H, 1991, ONCOGENE, V6, P1015; KALTHOFF H, 1992, IN PRESS INT S CLIN; KLOPPEL G, 1988, PANCREAS CONNECTION, P122; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; LEMOINE NR, 1991, J PATHOL, V165, P7; LEMOINE NR, 1991, GASTROENTEROLOGY, V101, P1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; METZGAR RS, 1982, CANCER RES, V42, P601; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1987, ONCOGENE, V1, P453; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHMURA E, 1990, CANCER RES, V50, P103; OKABE T, 1983, CANCER, V51, P662, DOI 10.1002/1097-0142(19830215)51:4<662::AID-CNCR2820510419>3.0.CO;2-X; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SHIBATA D, 1990, BAILLIERE CLIN GASTR, V4, P151, DOI 10.1016/0950-3528(90)90044-H; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; VANKRANEN HJ, 1991, CARCINOGENESIS, V12, P1477, DOI 10.1093/carcin/12.8.1477; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERRAHN J, 1992, ONCOGENE, V7, P1371	54	211	213	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					289	298						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426738				2022-12-17	WOS:A1993KN00600007
J	PROSSER, J; THOMPSON, AM; CRANSTON, G; EVANS, HJ				PROSSER, J; THOMPSON, AM; CRANSTON, G; EVANS, HJ			EVIDENCE THAT P53 BEHAVES AS A TUMOR SUPPRESSOR GENE IN SPORADIC BREAST-TUMORS	ONCOGENE			English	Article									ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	PROSSER, J (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; ATKIN NB, 1989, CANCER GENET CYTOGEN, V37, P229, DOI 10.1016/0165-4608(89)90053-8; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BHATTACHARYYA A, 1989, J MOL BIOL, V209, P583, DOI 10.1016/0022-2836(89)90596-2; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHUNG R, 1989, American Journal of Human Genetics, V45, pA17; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEVILEE P, 1989, LANCET, V1, P154; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GENDLER SJ, 1989, P INT ASS BREAST CAN; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOYHEIM B, 1989, NUCLEIC ACIDS RES, V17, P8898, DOI 10.1093/nar/17.21.8898; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JONG P, 1988, P NATL ACAD SCI USA, V85, P3499; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE J H, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P442; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SASAKI M, 1989, CANCER RES, V49, P4402; SOUSSI T, 1987, ONCOGENE, V1, P71; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; TSAI YC, 1990, CANCER RES, V50, P44; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; YANO T, 1989, J NATL CANCER I, V81, P518, DOI 10.1093/jnci/81.7.518; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	82	211	216	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1573	1579						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250913				2022-12-17	WOS:A1990EK50200018
J	BERENSON, JR; YANG, J; MICKEL, RA				BERENSON, JR; YANG, J; MICKEL, RA			FREQUENT AMPLIFICATION OF THE BCL-1 LOCUS IN HEAD AND NECK SQUAMOUS-CELL CARCINOMAS	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES, SCH MED, DIV HEAD & NECK SURG, LOS ANGELES, CA 90024 USA; VET ADM WADSWORTH MED CTR, LOS ANGELES, CA 90073 USA; JONSSON CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center	BERENSON, JR (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, 11-266 FACTOR BLDG, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ANTONARAKIS SE, 1982, P NATL ACAD SCI-BIOL, V79, P137, DOI 10.1073/pnas.79.1.137; BERENSON J, 1989, LEUKEMIA, V3, P133; BERENSON J, 1987, BLOOD, V70, P1550; BERGER MS, 1988, CANCER RES, V48, P1238; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; CALLAHAN R, 1989, J CELL BIOCH B, V13, P6; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; EISBRUCH A, 1987, CANCER RES, V47, P3603; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FIELD JK, 1986, ANTICANCER RES, V6, P595; HATADA I, 1988, ONCOGENE, V3, P537; INCE C, 1988, LEUKEMIA, V2, P343; KAOSHAN CS, 1987, CANCER RES, V47, P6278; KRAUSE CJ, 1981, ARCH OTOLARYNGOL, V107, P703; LESTER EP, 1988, P AM ASSOC CANC RES, V29, P28; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOORE C, 1971, J AMER MED ASSOC, V218, P553, DOI 10.1001/jama.218.4.553; MULERIS M, 1987, INT J CANCER, V39, P595, DOI 10.1002/ijc.2910390509; PULCIANI S, 1982, J CELL BIOCHEM, V20, P51, DOI 10.1002/jcb.240200106; RABBITTS PH, 1988, ONCOGENE, V3, P99; RECHAVI G, 1989, LEUKEMIA, V3, P57; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SELVANAYAGAM P, 1987, P AM ASSOC CANC RES, V28, P19; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VANDENBERGHE H, 1984, CANCER GENET CYTOGEN, V11, P381, DOI 10.1016/0165-4608(84)90017-7; VARLEY JM, 1988, ONCOGENE, V3, P87; WONG DTW, 1987, ONCOGENE, V2, P67; WUU KD, 1986, CANCER GENET CYTOGEN, V20, P279, DOI 10.1016/0165-4608(86)90084-1; YAMAMOTO T, 1986, CANCER RES, V46, P414; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOKOTA J, 1986, LANCET, V1, P765; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZHOU DJ, 1987, CANCER RES, V47, P6123; ZHOU DJ, 1988, ONCOGENE, V2, P279	48	211	212	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1989	4	9					1111	1116						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2476705				2022-12-17	WOS:A1989AM53100009
J	Sun, L; Yao, Y; Liu, B; Lin, Z; Lin, L; Yang, M; Zhang, W; Chen, W; Pan, C; Liu, Q; Song, E; Li, J				Sun, L.; Yao, Y.; Liu, B.; Lin, Z.; Lin, L.; Yang, M.; Zhang, W.; Chen, W.; Pan, C.; Liu, Q.; Song, E.; Li, J.			MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1	ONCOGENE			English	Article						chemotherapy resistance; EMT; microRNA; BMI1; tongue squamous cell carcinoma	BREAST-CANCER; TAMOXIFEN RESISTANCE; MULTIDRUG-RESISTANCE; SELF-RENEWAL; EXPRESSION; MICRORNAS; APOPTOSIS; CHEMORESISTANCE; TUMORIGENICITY; OVEREXPRESSION	Chemotherapy has been reported to induce epithelial-mesenchymal transition (EMT) in tumor cells, which is a critical step in the process of metastasis leading to cancer spreading and treatment failure. However, the underlying mechanisms of chemotherapy-induced EMT remain unclear, and the involvement of microRNAs (miRNA) in this process is poorly understood. To address these questions, we established stable chemotherapy-resistant tongue squamous cell carcinoma (TSCC) cell lines CAL27-res and SCC25-res by exposing the parental CAL27 and SCC25 lines to escalating concentrations of cisplatin for 6 months. CAL27-res and SCC25-res cells displayed mesenchymal features with enhanced invasiveness and motility. MiRNA microarray illustrated that miR-200b and miR-15b were the most significantly downregulated microRNAs in CAL27-res cells. Ectopic expression of miR-200b and miR-15b with miRNA mimics effectively reversed the phenotype of EMT in CAL27-res and SCC25-res cells, and sensitized them to chemotherapy, but inhibition of miR-200b and miR-15b in the sensitive lines with anti-sense oligonucleotides induced EMT and conferred chemoresistance. Retrieving the expression of B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a target for miR-200b and miR-15b, in the presence of the miRNA mimics by transfecting CAL27-res cells with pcDNA3.1-BMI1-carrying mutated seed sequences of miR-200b or miR-15b at its 3'-UTR recapitulated chemotherapy-induced EMT. In vivo, enforced miR-200b or miR-15b expression suppressed metastasis of TSCC xenografts established by CAL27-res cells. Clinically, reduced miR-200b or miR-15b expression was associated with chemotherapeutic resistance in TSCCs and poor patient survival. Our data suggest that reduced expression of miR-200b and miR-15b underscores the mechanisms of chemotherapy-induced EMT in TSCC, and may serve as therapeutic targets to reverse chemotherapy resistance in tongue cancers. Oncogene (2012) 31, 432-445; doi: 10.1038/onc.2011.263; published online 4 July 2011	[Sun, L.; Yao, Y.; Liu, B.; Lin, L.; Yang, M.; Song, E.] Sun Yat Sen Univ, Dept Breast Tumor Ctr, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China; [Lin, Z.; Zhang, W.; Chen, W.; Pan, C.; Li, J.] Sun Yat Sen Univ, Dept Oral & Maxillofacial Surg, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China; [Liu, Q.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Song, E.] Sun Yat Sen Univ, Key Lab Gene Engn, Minist Educ, State Key Lab Biocontrol,Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Sun Yat Sen University	Song, E (corresponding author), Sun Yat Sen Univ, Breast Tumor Ctr, Sun Yat Sen Mem Hosp, 107 Yanjiang W Rd, Gz 510120, Peoples R China.	songerwei02@yahoo.com.cn; lijinsong1967@163.com	Liu, Bodu/G-5222-2016; Liu, Bodu/AAR-9402-2021	Liu, Bodu/0000-0003-2097-725X; Liu, Bodu/0000-0003-2097-725X; Liu, Qiang/0000-0002-5451-4862; Sun, Lijuan/0000-0003-0080-7886	National Natural Science Foundation of China [81072225, 30921140312, 30831160515, 30830110, 81072177]; Natural Science Foundation of Guangdong Province [10251008901000022, 9151008901000201, 8251008901000011]; Guangzhou Science and Technology Bureau [2008Z1-E201]; Ministry of Science and Technology of China [2010CB912800, 2011CB504203, 2009CB521706]; Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University [KLB09001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Bureau; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University	This work was supported by Grants to JL from National Natural Science Foundation of China (81072225), Natural Science Foundation of Guangdong Province (10251008901000022, 9151008901000201) and Guangzhou Science and Technology Bureau (2008Z1-E201); and to ES from '973' Program Projects (2010CB912800, 2011CB504203, 2009CB521706) from Ministry of Science and Technology of China, National Natural Science Foundation of China (30921140312, 30831160515, 30830110), and Natural Science Foundation of Guangdong Province (8251008901000011), Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University (KLB09001), and to LL from National Natural Science Foundation of China (81072177).	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Chua KN, 2008, DRUG DISCOV TODAY, V4, P261; Crea F, 2011, INT J CANCER, V128, P1946, DOI 10.1002/ijc.25522; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Gibson MK, 2005, J CLIN ONCOL, V23, P3562, DOI 10.1200/JCO.2005.01.057; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Gosepath EM, 2008, INT J CANCER, V123, P2013, DOI 10.1002/ijc.23721; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Jeyaseelan K, 2007, EXPERT OPIN THER TAR, V11, P1119, DOI 10.1517/14728222.11.8.1119; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Li JH, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-36; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Mihic-Probst D, 2007, INT J CANCER, V121, P1764, DOI 10.1002/ijc.22891; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Seve P, 2005, CLIN CANCER RES, V11, P5481, DOI 10.1158/1078-0432.CCR-05-0285; Shida T, 2006, CANCER BIOL THER, V5, P1530, DOI 10.4161/cbt.5.11.3458; Song E, 2001, BRIT J CANCER, V85, P1047, DOI 10.1038/sj.bjc.6692042; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toner M, 2009, HEAD NECK PATHOL, V3, P249, DOI 10.1007/s12105-009-0137-y; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Yamauchi K, 2008, CANCER RES, V68, P516, DOI 10.1158/0008-5472.CAN-07-3063; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	43	210	223	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					432	445		10.1038/onc.2011.263	http://dx.doi.org/10.1038/onc.2011.263			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21725369				2022-12-17	WOS:000300219300003
J	Li, DD; Wang, L; Deng, R; Tang, J; Shen, Y; Guo, JF; Wang, Y; Xia, LP; Feng, GK; Liu, QQ; Huang, WL; Zeng, YX; Zhu, XF				Li, D-D; Wang, L-L; Deng, R.; Tang, J.; Shen, Y.; Guo, J-F; Wang, Y.; Xia, L-P; Feng, G-K; Liu, Q. Q.; Huang, W-L; Zeng, Y-X; Zhu, X-F			The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells	ONCOGENE			English	Article						c-Jun NH2-terminal kinase (JNK); autophagy; ceramide; Beclin 1	PROTEIN-KINASE; CERAMIDE; DEATH; MACROAUTOPHAGY; PATHWAY; INHIBITION; SURVIVAL; DEGRADATION; MECHANISMS; INDUCTION	The c-Jun NH2-terminal kinase (JNK) pathway represents one subgroup of MAP kinases that are activated primarily by cytokines and exposure to environmental stress. Autophagy is a protein-degradation system characterized by the formation of double-membrane vacuoles termed autophagosomes. Autophagy-related gene beclin 1 plays a key role in autophagosome formation. However, the relationships between activation of JNK pathway, autophagy induction and Beclin 1 expression remain elusive. In this study, we used human cancer cell lines CNE2 and Hep3B to investigate the role of JNK-mediated Beclin 1 expression in ceramide-induced autophagic cell death. Ceramide-treated cells exhibited the characteristics of autophagy (that is, acidic vesicular organelle formation and the LC3-II generation). JNK was activated in these two cell lines exposed to ceramide and the phosphorylation of c-Jun also increased. In the meantime, we found that ceramide upregulated Beclin 1 expression in cancer cells. The upregulation of Beclin 1 expression could be blocked by SP600125 (a specific inhibitor of JNK) or a small interfering RNA (siRNA) directed against JNK1/2 or c-Jun. Chromatin immunoprecipitation and luciferase reporter analysis revealed that c-Jun was involved in the regulation of beclin 1 transcription in response to ceramide treatment. In addition, inhibition of JNK activity by SP600125 could inhibit autophagy induction by ceramide. Furthermore, Beclin 1 knockdown by siRNA also inhibited ceramide-mediated autophagic cell death. JNK-mediated Beclin 1 expression was also observed in topotecan-induced autophagy. These data suggest that activation of JNK pathway can mediate Beclin 1 expression, which plays a key role in autophagic cell death in cancer cells.	[Li, D-D; Wang, L-L; Deng, R.; Tang, J.; Shen, Y.; Guo, J-F; Wang, Y.; Xia, L-P; Feng, G-K; Liu, Q. Q.; Huang, W-L; Zeng, Y-X; Zhu, X-F] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	zhuxfeng@mail.sysu.edu.cn	huang, wen/GXW-0661-2022		National Nature Science Foundation of China [30572363, 30873085]; 863 programme [2006AA02A404]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); 863 programme(National High Technology Research and Development Program of China)	This study was supported by grants from the National Nature Science Foundation of China (30572363, 30873085) and 863 programme (2006AA02A404).	Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280; Bergamini E, 2003, BIOMED PHARMACOTHER, V57, P203, DOI 10.1016/S0753-3322(03)00048-9; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Cao Q, 2008, INT J BIOCHEM CELL B, V40, P272, DOI 10.1016/j.biocel.2007.07.020; Chu CT, 2007, AUTOPHAGY, V3, P663, DOI 10.4161/auto.4625; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Deng R, 2006, ONCOGENE, V25, P7070, DOI 10.1038/sj.onc.1209686; Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gewies A, 2000, LAB INVEST, V80, P671, DOI 10.1038/labinvest.3780070; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hamdi M, 2005, ONCOGENE, V24, P7135, DOI 10.1038/sj.onc.1208875; Huwiler A, 2004, BBA-MOL CELL BIOL L, V1636, P159, DOI 10.1016/j.bbalip.2003.08.010; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; KIM MY, 1991, J BIOL CHEM, V266, P484; Kim WH, 2005, NEUROCHEM RES, V30, P969, DOI 10.1007/s11064-005-6223-y; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Liu JN, 2007, LEUKEMIA, V21, P1300, DOI 10.1038/sj.leu.2404652; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mengubas K, 1999, ONCOGENE, V18, P2499, DOI 10.1038/sj.onc.1202622; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mochizuki T, 2002, J BIOL CHEM, V277, P2790, DOI 10.1074/jbc.M106361200; Nishino Ichizo, 2003, Curr Neurol Neurosci Rep, V3, P64, DOI 10.1007/s11910-003-0040-y; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang ZH, 2007, GYNECOL ONCOL, V107, P107, DOI 10.1016/j.ygyno.2007.05.034; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5; Zheng W, 2006, BBA-BIOMEMBRANES, V1758, P1864, DOI 10.1016/j.bbamem.2006.08.009; Zhou JM, 2006, ONCOGENE, V25, P503, DOI 10.1038/sj.onc.1209067; Zhu XF, 2005, MOL PHARMACOL, V67, P1444, DOI 10.1124/mol.104.009894	58	210	220	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					886	898		10.1038/onc.2008.441	http://dx.doi.org/10.1038/onc.2008.441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060920				2022-12-17	WOS:000263320000011
J	Avvakumov, N; Cote, J				Avvakumov, N.; Cote, J.			The MYST family of histone acetyltransferases and their intimate links to cancer	ONCOGENE			English	Review						MYST; histone acetyltransferase (HAT); chromatin modification; cancer	ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; UV-INDUCED APOPTOSIS; ZINC-FINGER PROTEIN; MONOCYTIC LEUKEMIA; METASTASIS SUPPRESSOR-1; RECEPTOR COACTIVATOR; DEACETYLASE COMPLEX; ANDROGEN RECEPTOR	The histone acetyltransferases ( HATs) of the MYST family are highly conserved in eukaryotes and carry out a significant proportion of all nuclear acetylation. These enzymes function exclusively in multisubunit protein complexes whose composition is also evolutionarily conserved. MYST HATs are involved in a number of key nuclear processes and play critical roles in genespecific transcription regulation, DNA damage response and repair, as well as DNA replication. This suggests that anomalous activity of these HATs or their associated complexes can easily lead to severe cellular malfunction, resulting in cell death or uncontrolled growth and malignancy. Indeed, the MYST family HATs have been implicated in several forms of human cancer. This review summarizes the current understanding of these enzymes and their normal function, as well as their established and putative links to oncogenesis.	Univ Laval, Canc Res Ctr, Hotel Dieu, CHUQ, Quebec City, PQ G1R 2J6, Canada	Laval University	Cote, J (corresponding author), Univ Laval, Canc Res Ctr, Hotel Dieu, CHUQ, 9 McMahon St, Quebec City, PQ G1R 2J6, Canada.	Jacques.Cote@crhdq.ulaval.ca	Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bertram MJ, 2001, GENE, V266, P111, DOI 10.1016/S0378-1119(01)00372-9; Bewersdorf J, 2006, P NATL ACAD SCI USA, V103, P18137, DOI 10.1073/pnas.0608709103; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chamberlin HM, 2000, DEVELOPMENT, V127, P713; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chang S, 2003, GENE DEV, V17, P2123, DOI 10.1101/gad.1117903; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Collins HM, 2006, J BIOL CHEM, V281, P17124, DOI 10.1074/jbc.M602633200; Contzler R, 2006, BIOCHEM BIOPH RES CO, V350, P208, DOI 10.1016/j.bbrc.2006.09.030; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Grienenberger A, 2002, CURR BIOL, V12, P762, DOI 10.1016/S0960-9822(02)00814-X; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hobbs CA, 2006, CANCER RES, V66, P8116, DOI 10.1158/0008-5472.CAN-06-0359; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Knoops L, 2004, GROWTH FACTORS, V22, P207, DOI 10.1080/08977190410001720879; Kojima K, 2003, BRIT J HAEMATOL, V120, P271, DOI 10.1046/j.1365-2141.2003.04059.x; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; LAFON N, 2007, IN PRESS ONCOGENE; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06; Lleonart ME, 2006, ONCOL REP, V16, P603; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Meehan WJ, 2003, CLIN EXP METASTAS, V20, P45, DOI 10.1023/A:1022542519586; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485; Miotto B, 2006, GENE DEV, V20, P101, DOI 10.1101/gad.359506; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; Moore SDP, 2004, CANCER RES, V64, P5570, DOI 10.1158/0008-5472.CAN-04-0050; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; O'Connell S, 2001, J BIOL CHEM, V276, P43065, DOI 10.1074/jbc.M104294200; OHTA K, 2006, BIOCHEM J, V3, P3; Panagopoulos I, 2002, GENE CHROMOSOME CANC, V35, P372, DOI 10.1002/gcc.10131; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park JH, 2006, MOL CELL BIOL, V26, P4006, DOI 10.1128/MCB.02185-05; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; PHILLIPS DM, 1963, BIOCHEM J, V87, P258, DOI 10.1042/bj0870258; Radhakrishnan SK, 2006, BBA-REV CANCER, V1766, P53, DOI 10.1016/j.bbcan.2006.02.001; Raho G, 2007, ONCOGENE, V26, P5247, DOI 10.1038/sj.onc.1210335; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rozman M, 2004, GENE CHROMOSOME CANC, V40, P140, DOI 10.1002/gcc.20022; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Scott M, 2001, J CELL SCI, V114, P3455; Selleck W, 2005, MOL CELL BIOL, V25, P5535, DOI 10.1128/MCB.25.13.5535-5542.2005; Severinsen JE, 2006, MOL PSYCHIATR, V11, P1126, DOI 10.1038/sj.mp.4001885; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Shiseki M, 2003, CANCER RES, V63, P2373; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Stedman W, 2004, J VIROL, V78, P12566, DOI 10.1128/JVI.78.22.12566-12575.2004; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Thomas T, 2000, DEVELOPMENT, V127, P2537; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Unoki M, 2006, J BIOL CHEM, V281, P34677, DOI 10.1074/jbc.M606296200; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; VAQUERO A, 2006, SCI AGING KNOWLEDGE, P20; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhang ZH, 2006, CLIN CANCER RES, V12, P6410, DOI 10.1158/1078-0432.CCR-06-1347; Zhou MI, 2005, P NATL ACAD SCI USA, V102, P11035, DOI 10.1073/pnas.0500757102	137	210	223	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5395	5407		10.1038/sj.onc.1210608	http://dx.doi.org/10.1038/sj.onc.1210608			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694081				2022-12-17	WOS:000248674300008
J	Dhanasekaran, DN; Kashef, K; Lee, CM; Xu, H; Reddy, EP				Dhanasekaran, D. N.; Kashef, K.; Lee, C. M.; Xu, H.; Reddy, E. P.			Scaffold proteins of MAP-kinase modules	ONCOGENE			English	Review						scaffold proteins; ERK; JNK; p38MAPK; JLP; JIP	N-TERMINAL KINASE; CYTOKINE-INDUCED APOPTOSIS; SACCHAROMYCES-CEREVISIAE REQUIRES; AMYLOID PRECURSOR PROTEIN; INSULIN-SECRETING CELLS; FOCAL ADHESION KINASE; KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-JUN; GROWTH-FACTOR	Mitogen-activated protein kinases (MAPKs) regulate critical signaling pathways involved in cell proliferation, differentiation and apoptosis. Recent studies have shown that a novel class of scaffold proteins mediates the structural and functional organization of the three-tier MAPK module. By linking the MAP3K, MAP2K and MAPK into a multienzyme complex, these MAPK-specific scaffold proteins provide an insulated physical conduit through which signals from the respective MAPK can be transmitted to the appropriate spatiotemporal cellular loci. Scaffold proteins play a determinant role in modulating the signaling strength of their cognate MAPK module by regulating the signal amplitude and duration. The scaffold proteins themselves are finely regulated resulting in dynamic intra- and inter-molecular interactions that can modulate the signaling outputs of MAPK modules. This review focuses on de. ning the diverse mechanisms by which these scaffold proteins interact with their respective MAPK modules and the role of such interactions in the spatiotemporal organization as well as context-specific signaling of the different MAPK modules.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@temple.edu	Reddy, E. Premkumar/F-6233-2011; Lee, Clement M./E-7104-2012	Lee, Clement M./0000-0003-3486-8492	NIA NIH HHS [AG22022] Funding Source: Medline; NIGMS NIH HHS [GM49897] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG022022] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barr AJ, 2002, BIOCHEM BIOPH RES CO, V293, P647, DOI 10.1016/S0006-291X(02)00259-0; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Bogoyevitch MA, 2004, CELL SIGNAL, V16, P1345, DOI 10.1016/j.cellsig.2004.05.004; Bogoyevitch MA, 2006, BIOESSAYS, V28, P923, DOI 10.1002/bies.20458; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; BRADY ST, 1995, TRENDS CELL BIOL, V5, P159, DOI 10.1016/S0962-8924(00)88980-1; Bridges D., 2005, SCI STKE, V296, pre10, DOI DOI 10.1126/STKE.2962005RE10; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Channavajhala PL, 2003, J BIOL CHEM, V278, P47089, DOI 10.1074/jbc.M306002200; CHOI KY, 1994, CELL, V78, P499; COULOMBE P, 2006, BIOCH BIOPHYS ACTA; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Elion EA, 2001, J CELL SCI, V114, P3967; Elion EA, 2005, SCIENCE, V307, P687, DOI 10.1126/science.1109500; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feng JW, 1998, IEEE SIGNAL PROC LET, V5, P11, DOI 10.1109/97.654867; FERRELL JE, 2000, SCI STKE; Ferrer I, 2004, NEUROTOX RES, V6, P469, DOI 10.1007/BF03033283; Flatauer LJ, 2005, MOL CELL BIOL, V25, P1793, DOI 10.1128/MCB.25.5.1793-1803.2005; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Ha HY, 2005, DEV BIOL, V277, P184, DOI 10.1016/j.ydbio.2004.09.019; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Ito M, 1999, MOL CELL BIOL, V19, P7539; Ito M, 2000, GENE, V255, P229, DOI 10.1016/S0378-1119(00)00335-8; Jagadish N, 2005, J REPROD IMMUNOL, V67, P69, DOI 10.1016/j.jri.2005.06.004; Jagadish N, 2005, BIOCHEM J, V389, P73, DOI 10.1042/BJ20041577; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Kang JS, 1998, J CELL BIOL, V143, P403, DOI 10.1083/jcb.143.2.403; Karandikar M, 1999, CELL CALCIUM, V26, P219, DOI 10.1054/ceca.1999.0074; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kashef K, 2005, BIOCHEMISTRY-US, V44, P14090, DOI 10.1021/bi050604l; Kashef K, 2006, J CELL BIOCHEM, V98, P715, DOI 10.1002/jcb.20930; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Krauss RS, 2005, J CELL SCI, V118, P2355, DOI 10.1242/jcs.02397; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Ling ZD, 2003, DIABETES, V52, P2497, DOI 10.2337/diabetes.52.10.2497; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Matheny SA, 2006, METHOD ENZYMOL, V407, P237, DOI 10.1016/S0076-6879(05)07020-5; Matsuda S, 2001, J NEUROSCI, V21, P6597; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Nakamura K, 2006, MOL CELL BIOL, V26, P2065, DOI 10.1128/MCB.26.6.2065-2079.2006; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Nguyen Q, 2005, J BIOL CHEM, V280, P30185, DOI 10.1074/jbc.M505499200; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Nikulina MA, 2003, CYTOKINE, V24, P13, DOI 10.1016/S1043-4666(03)00242-4; Ohmachi M, 2002, CURR BIOL, V12, P427, DOI 10.1016/S0960-9822(02)00690-5; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; PRINTEN JA, 1994, GENETICS, V138, P609; Ptashne M, 2003, SCIENCE, V299, P1025, DOI 10.1126/science.1081519; Pullikuth A, 2005, MOL CELL BIOL, V25, P5119, DOI 10.1128/MCB.25.12.5119-5133.2005; Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470; Raabe T, 2003, CURR BIOL, V13, pR635, DOI 10.1016/S0960-9822(03)00568-2; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Robidoux J, 2005, MOL CELL BIOL, V25, P5466, DOI 10.1128/MCB.25.13.5466-5479.2005; Roemer T, 1998, J CELL SCI, V111, P479; Roy F, 2002, CURR BIOL, V12, pR325, DOI 10.1016/S0960-9822(02)00831-X; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Roy M, 2005, MOL CELL BIOL, V25, P7940, DOI 10.1128/MCB.25.18.7940-7952.2005; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schermanz K, 2002, CATALY SCI, V2, P1, DOI 10.1142/9781860949654_0001; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Shankar S, 2004, MOL REPROD DEV, V69, P186, DOI 10.1002/mrd.20164; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Takaesu G, 2006, J CELL BIOL, V175, P383, DOI 10.1083/jcb.200608031; Takekawa M, 2005, MOL CELL, V18, P295, DOI 10.1016/j.molcel.2005.04.001; Takino T, 2005, J BIOL CHEM, V280, P37772, DOI 10.1074/jbc.M505241200; Takino T, 2002, ONCOGENE, V21, P6488, DOI 10.1038/sj.onc.1205840; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Tatebayashi K, 2003, EMBO J, V22, P3624, DOI 10.1093/emboj/cdg353; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Uhlik MT, 2004, BIOCHEM CELL BIOL, V82, P658, DOI 10.1139/O04-114; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Vomastek T, 2004, P NATL ACAD SCI USA, V101, P6981, DOI 10.1073/pnas.0305894101; Whitmarsh AJ, 2006, BIOCHEM SOC T, V34, P828, DOI 10.1042/BST0340828; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; WHITMARSH AJ, 1999, SCI STKE, pPE1, DOI DOI 10.1126/STKE.1999.1.PE1; Willoughby EA, 2005, J BIOL CHEM, V280, P25651, DOI 10.1074/jbc.M501926200; Willoughby EA, 2003, J BIOL CHEM, V278, P10731, DOI 10.1074/jbc.M207324200; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Xia Y, 2007, MOL CELL BIOL, V27, P510, DOI 10.1128/MCB.01355-06; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	162	210	219	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3185	3202		10.1038/sj.onc.1210411	http://dx.doi.org/10.1038/sj.onc.1210411			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496915				2022-12-17	WOS:000246603600008
J	Yang, XJ				Yang, XJ			Multisite protein modi. cation and intramolecular signaling	ONCOGENE			English	Review						multisite; phosphorylation; histone acetylation; lysine methylation; arginine methylation; ubiquitination	RNA-POLYMERASE-II; TRANSCRIPTION FACTOR SP3; CARBOXY-TERMINAL DOMAIN; PROLYL ISOMERASE PIN1; STRUCTURAL BASIS; HISTONE H3; SUMO MODIFICATION; POSTTRANSLATIONAL MODIFICATIONS; DEPENDENT ACETYLATION; CDC2 PHOSPHORYLATION	Post-translational modi. cation is a major mechanism by which protein function is regulated in eukaryotes. Instead of single-site action, many proteins such as histones, p53, RNA polymerase II, tubulin, Cdc25C and tyrosine kinases are modified at multiple sites by modi. cations like phosphorylation, acetylation, methylation, ubiquitination, sumoylation and citrullination. Multisite modi. cation on a protein constitutes a complex regulatory program that resembles a dynamic 'molecular barcode' and transduces molecular information to and from signaling pathways. This program imparts effects through 'loss-of-function' and 'gain-of-function' mechanisms. Among the latter, covalent modi. cations specifically recruit a diverse array of modules, including the SH2 domain, 14-3-3, WW domain, Polo box, BRCT repeat, bromodomain, chromodomain, Tudor domain and motifs binding to ubiquitin and other protein modifiers. Such recruitments are often modulated by modi. cations occurred at neighboring and distant sites. Multisite modi. cation thus coordinates intermolecular and intramolecular signaling for the qualitative and quantitative control of protein function in vivo.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Yang, XJ (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mol Oncol Grp, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca						Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Hunter Tony, 2004, Cell, VS116, pS35, DOI 10.1016/S0092-8674(04)00049-2; Hutchins JRA, 2004, CELL CYCLE, V3, P41; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li YH, 2003, P NATL ACAD SCI USA, V100, P259, DOI 10.1073/pnas.0235361100; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Margolis SS, 2003, EMBO J, V22, P5734, DOI 10.1093/emboj/cdg545; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Narang MA, 2004, HUM MOL GENET, V13, P15, DOI 10.1093/hmg/ddh006; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reinehr R, 2004, J BIOL CHEM, V279, P10364, DOI 10.1074/jbc.M311997200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Slawson C, 2003, CURR OPIN STRUC BIOL, V13, P631, DOI 10.1016/j.sbi.2003.08.003; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	115	210	240	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1653	1662		10.1038/sj.onc.1208173	http://dx.doi.org/10.1038/sj.onc.1208173			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15744326				2022-12-17	WOS:000227345100001
J	Frattini, M; Ferrario, C; Bressan, P; Balestra, D; De Cecco, L; Mondellini, P; Bongarzone, I; Collini, P; Gariboldi, M; Pilotti, S; Pierotti, MA; Greco, A				Frattini, M; Ferrario, C; Bressan, P; Balestra, D; De Cecco, L; Mondellini, P; Bongarzone, I; Collini, P; Gariboldi, M; Pilotti, S; Pierotti, MA; Greco, A			Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer	ONCOGENE			English	Article						papillary thyroid cancer; BRAF mutation; RET and TRK rearrangement	HIGH PREVALENCE; MICROARRAY DATA; CARCINOMAS; TUMORS; ACTIVATION	Papillary thyroid carcinoma (PTC) is associated with RET and NTRK1 rearrangements and BRAF mutations. A series of 60 PTCs collected in a single center from Italian patients were histologically re-examined and subclassified as well differentiated or tall cell variant. The sample collection was analysed for the presence of all the reported PTC-associated genetic alterations through DNA or cDNA amplification, followed by automated sequencing. The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant. Oncogenic rearrangements of RET and NTRK1 receptors were found in 33 and 5% of cases, respectively. No Ras mutations were detected. Overall, genetic alterations were detected in two-thirds of samples, and in no single case more than one mutational event was found simultaneously. Gene expression pro. ling of a subset of 31 tumors performed using cDNA microarray chips showed no strong differences in global gene expression among the different cases. However, a supervised analysis of the obtained data identified a subset of genes differentially expressed in tumors carrying BRAF mutation or RTK rearrangement.	Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol Expt Mol Pathol, I-20133 Milan, Italy; IFOM Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; angela.greco@istitutotumori.mi.it	Collini, Paola/K-7354-2016; Greco, Angela/C-1953-2017; Bongarzone, Italia/B-9544-2017; De Cecco, Loris/K-7036-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Gariboldi, Manuela/K-4744-2016	Collini, Paola/0000-0002-6158-210X; Greco, Angela/0000-0003-2994-0349; Bongarzone, Italia/0000-0003-2530-9170; De Cecco, Loris/0000-0002-7066-473X; Pierotti, Marco Alessandro/0000-0002-7431-8332; Gariboldi, Manuela/0000-0001-8406-165X				Bunone G, 2000, CANCER RES, V60, P2845; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DECECCO L, 2004, IN PRESS ONCOGENE; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Kimura ET, 2003, CANCER RES, V63, P1454; Klugbauer S, 1995, ONCOGENE, V11, P2459; Knauf JA, 2002, J CLIN ENDOCR METAB, V87, P2150, DOI 10.1210/jc.87.5.2150; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PILOTTI S, 1995, SEMIN DIAGN PATHOL, V12, P249; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Xu XL, 2003, CANCER RES, V63, P4561; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	22	210	225	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7436	7440		10.1038/sj.onc.1207980	http://dx.doi.org/10.1038/sj.onc.1207980			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15273715				2022-12-17	WOS:000224021400014
J	Izzi, L; Attisano, L				Izzi, L; Attisano, L			Regulation of the TGF beta signalling pathway by ubiquitin-mediated degradation	ONCOGENE			English	Review						smad; smurf; ubiquitination	ANAPHASE-PROMOTING COMPLEX; PROTEASOMAL DEGRADATION; DEPENDENT DEGRADATION; NUCLEAR EXPORT; PROTEIN; LIGASE; RECEPTOR; SMURF1; SMAD2; FAMILY	The transforming growth factor-beta (TGFbeta) superfamily controls a plethora of biological responses, and alterations in its signalling pathway are associated with a range of human diseases, including cancer. TGFbeta superfamily ligands signal through a heteromeric complex of Ser/ Thr kinase receptors that propagate the signal to the Smad family of intracellular proteins. The ubiquitin-mediated proteasomal degradation pathway is an evolutionary conserved cascade that tightly regulates TGFbeta superfamily signalling. Both the size of the Smad pool in unstimulated cells and Smad protein levels subsequent to the activation of the pathway are controlled by ubiquitination. E3 ligases are components of the ubiquitin-degradation complex that specifically recognize targeted proteins and the E3 ligases, Smad ubiquitination-related factor 1 (Smurf1), Smurf2 and SCF/Roc1 have been implicated in Smad degradation. The Smurfs are of particular importance to TGFbeta signalling, as Smads also function as adapters that recruit the Smurfs to various pathway components including the TGFbeta receptor complex and the transcriptional repressor, SnoN, and thereby regulate the degradation of these Smad-associating proteins. Thus, by controlling the level of Smads as well as positive and negative regulators of the pathway, Smurfs provide for complex and. ne control of signalling output. Finally, growing evidence demonstrates that ubiquitination and proteasomal degradation is also implicated in the turnover of tumor-derived Smad mutants and may thus contribute to disease progression.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Attisano, L (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg,Room 6336, Toronto, ON M5S 1A8, Canada.	liliana.attisano@utoronto.ca	高, 雨莉/HGU-8187-2022					ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dumont E, 2003, J BIOL CHEM, V278, P24881, DOI 10.1074/jbc.M212496200; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ehrlich M, 2001, J CELL SCI, V114, P1777; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fukuchi M, 2002, CANCER RES, V62, P7162; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gruendler C, 2001, J BIOL CHEM, V276, P46533, DOI 10.1074/jbc.M105500200; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moren A, 2003, J BIOL CHEM, V278, P33571, DOI 10.1074/jbc.M300159200; Moustakas A, 2001, J CELL SCI, V114, P4359; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Stroschein SL, 2001, GENE DEV, V15, P2822; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	61	210	232	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2071	2078		10.1038/sj.onc.1207412	http://dx.doi.org/10.1038/sj.onc.1207412			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021894				2022-12-17	WOS:000220213400011
J	Tsou, JA; Hagen, JA; Carpenter, CL; Laird-Offringa, IA				Tsou, JA; Hagen, JA; Carpenter, CL; Laird-Offringa, IA			DNA methylation analysis: a powerful new tool for lung cancer diagnosis	ONCOGENE			English	Article						lung cancer; methylation; CpG island; diagnosis; hypermethylation	TUMOR-SUPPRESSOR GENE; ABERRANT PROMOTER METHYLATION; CPG-ISLAND METHYLATION; CELL-LINES; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; EPIGENETIC INACTIVATION; ADVANCED-STAGE; EARLY EVENT; DAP-KINASE; HYPERMETHYLATION	Carcinoma of the lung is the most common cause of cancer death worldwide. The estimated 5-year survival ranges from 6-16%, depending on the cell type. The best opportunity for improving survival of lung cancer patients is through early detection, when curative surgical resection is possible. Although the subjects at increased risk for developing carcinoma of the lung (long-term smokers) can be identified, only 10-20% of this group will ultimately develop the disease. Screening tests of long-term smokers employed to date (radiography and sputum cytology) have not been successful in reducing lung cancer mortality. The application of molecular markers specific for lung cancer offers new possibilities for early detection. Hypermethylation of CpG islands in the promoter regions of genes is a common phenomenon in lung cancer, as demonstrated by the analysis of the methylation status of over 40 genes from lung cancer tumors, cell lines, patient sputum and/or serum. Determination of the methylation patterns of multiple genes to obtain complex DNA methylation signatures promises to provide a highly sensitive and specific tool for lung cancer diagnosis. When combined with the development of non-invasive methods to detect such signatures, this may provide a viable method to screen subjects at risk for lung cancer.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Laird-Offringa, IA (corresponding author), Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem, NOR 6420,1441 Eastlake Ave, Los Angeles, CA 90089 USA.	ilaird@hsc.usc.edu	Offringa, Ite/R-4101-2019; Carpenter, Catherine L/E-5834-2015	Carpenter, Catherine L/0000-0001-8334-4084				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; [Anonymous], 1999, CANC INCIDENCE SURVI; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Belinsky SA, 1998, EXP LUNG RES, V24, P463, DOI 10.3109/01902149809087381; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BLACK WC, 1999, CANC SCREENING THEOR, P327; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eguchi K, 1997, CANCER RES, V57, P4913; Elias AD, 1997, CHEST, V112, pS251, DOI 10.1378/chest.112.4_Supplement.251S; Ellis JRC, 2001, BRIT J RADIOL, V74, P478, DOI 10.1259/bjr.74.882.740478; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; Feng G, 2001, CANCER RES, V61, P7999; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; FLATAU E, 1983, CANCER RES, V43, P4901; Fleiss JL, 1981, STAT METHODS RATES P; GAMOU S, 1988, JPN J CANCER RES, V79, P989, DOI 10.1111/j.1349-7006.1988.tb00065.x; GANDERTON RH, 1995, EUR J CANCER, V31A, P1697, DOI 10.1016/0959-8049(95)00351-I; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Herman JG, 1996, CANCER RES, V56, P722; Hou M, 1999, INT J CANCER, V84, P609, DOI 10.1002/(SICI)1097-0215(19991222)84:6<609::AID-IJC12>3.0.CO;2-Q; Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Issa JPJ, 1996, CANCER RES, V56, P3655; Jang SJ, 2001, CANCER RES, V61, P7959; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kashiwabara K, 1998, INT J CANCER, V79, P215, DOI 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LEON SA, 1977, CANCER RES, V37, P646; Marcus PM, 2001, J CLIN ONCOL, V19, p83S; Markl IDC, 2001, CANCER RES, V61, P5875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nagatake M, 1996, CANCER RES, V56, P1886; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Ng CSH, 2002, J SURG ONCOL, V79, P101, DOI 10.1002/jso.10046; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Osada H, 2001, CANCER RES, V61, P8331; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Palmisano WA, 2000, CANCER RES, V60, P5954; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; ROBERTSON KD, 2001, ONCOGENE, V30, P3189; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sanchez-Cespedes M, 2001, CANCER RES, V61, P2092; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Seike M, 2000, CLIN CANCER RES, V6, P4307; SIEGMUND KD, 2002, IN PRESS METHODS; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Stirzaker C, 1997, CANCER RES, V57, P2229; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Tanaka H, 1998, INT J CANCER, V79, P111, DOI 10.1002/(SICI)1097-0215(19980417)79:2<111::AID-IJC2>3.0.CO;2-W; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, MOL CANCER THER, V1, P61; TRAVIS WD, 1996, LUNG CANC PRINCIPLES, P361; Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268; Usadel H, 2002, CANCER RES, V62, P371; VACHTENHEIM J, 1994, CANCER RES, V54, P1145; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wain J C, 1986, Curr Surg, V43, P489; Ward AM, 2001, ANN CLIN BIOCHEM, V38, P633, DOI 10.1258/0004563011901055; *WHO, 1982, WORLD HLTH ORG; Williams M D, 2001, Cancer Treat Res, V105, P31; Wolf P, 2001, CANCER RES, V61, P8113; Woodson K, 2001, CANCER EPIDEM BIOMAR, V10, P69; Xu XL, 2001, CANCER RES, V61, P7943; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	100	210	224	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5450	5461		10.1038/sj.onc.1205605	http://dx.doi.org/10.1038/sj.onc.1205605			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154407				2022-12-17	WOS:000177197700011
J	Lee, SH; Shin, MS; Park, WS; Kim, SY; Kim, HS; Han, JY; Park, GS; Dong, SM; Pi, JH; Kim, CS; Kim, SH; Lee, JY; Yoo, NJ				Lee, SH; Shin, MS; Park, WS; Kim, SY; Kim, HS; Han, JY; Park, GS; Dong, SM; Pi, JH; Kim, CS; Kim, SH; Lee, JY; Yoo, NJ			Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer	ONCOGENE			English	Article						lung cancer; apoptosis; Fas; mutation; loss of heterozygosity	TUMOR-NECROSIS-FACTOR; LYMPHOPROLIFERATIVE SYNDROME; MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS; PTEN/MMAC1 GENE; EXPRESS FAS; MUTATIONS; FAS/APO-1; LIGAND; RECEPTOR	Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. The key role of the Fas system in negative growth regulation has been studied mostly within the immune system, and somatic mutations of Fas gene in cancer patients have been described solely in lymphoid-lineage malignancies. However, many nonlymphoid tumor cells have been found to be resistant to Fas-mediated apoptosis, which suggests that Fas mutations, one of the possible mechanisms for Fas-resistance, may be involved in the pathogenesis of non-lymphoid malignancies as well. In this study, we have analysed the entire coding region and all splice sites of the Fns gene for the detection of the gene mutations in 65 human nonsmall cell lung cancers by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing. Overall, five tumors (7.7%) were found to have the I;as mutations, which were all missense mutations. Four of the five mutations identified were located in the cytoplasmic region (death domain) known to be involved in the transduction of an apoptotic signal and one mutation was located in the transmembrane domain. This is the first report on the I;ns gene mutations in non-lymphoid malignancies, and the data presented here suggests that alterations of the Fns gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some human lung cancers.	Catholic Univ, Coll Med, Dept Pathol, Socho Gu, Seoul 137701, South Korea; Catholic Univ, Coll Med, Dept Biochem, Socho Gu, Seoul 137701, South Korea; Catholic Univ, Coll Med, Dept Internal Med, Seoul 137701, South Korea; Catholic Univ, Canc Res Inst, Catholic Res Inst Med Sci, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Yoo, NJ (corresponding author), Catholic Univ, Coll Med, Dept Pathol, Socho Gu, 505 Banpo Dong, Seoul 137701, South Korea.		Yoo, Nam Jin/GNM-9060-2022					Beltinger C, 1998, BLOOD, V91, P3943; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bettinardi A, 1997, BLOOD, V89, P902, DOI 10.1182/blood.V89.3.902; Davidson WF, 1998, J EXP MED, V187, P1825, DOI 10.1084/jem.187.11.1825; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; FIUCCI G, 1994, IMMUNOGENETICS, V39, P437; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Gronbaek K, 1998, BLOOD, V92, P3018; Huang QR, 1997, MOL IMMUNOL, V34, P577, DOI 10.1016/S0161-5890(97)00081-3; Hughes SJ, 1997, CANCER RES, V57, P5571; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1998, LAB INVEST, V78, P453; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; NATOLI G, 1995, ONCOGENE, V11, P1157; Niehans GA, 1997, CANCER RES, V57, P1007; Okami K, 1998, CANCER RES, V58, P509; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tamiya S, 1998, BLOOD, V91, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Ungefroren H, 1998, CANCER RES, V58, P1741; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZORNIG M, 1995, ONCOGENE, V10, P2397	39	210	213	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3754	3760		10.1038/sj.onc.1202769	http://dx.doi.org/10.1038/sj.onc.1202769			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391683				2022-12-17	WOS:000081140200009
J	SALCINI, AE; MCGLADE, J; PELICCI, G; NICOLETTI, I; PAWSON, T; PELICCI, PG				SALCINI, AE; MCGLADE, J; PELICCI, G; NICOLETTI, I; PAWSON, T; PELICCI, PG			FORMATION OF SHC-GRB2 COMPLEXES IS NECESSARY TO INDUCE NEOPLASTIC TRANSFORMATION BY OVEREXPRESSION OF SHC PROTEINS	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; EGF RECEPTOR; RAS; DOMAINS; ACTIVATION; SEVENLESS	The mammalian SHC gene encodes three overlapping proteins which all contain a carboxy-terminal SH2 domain. Shc proteins are phosphorylated on tyrosine by a variety of receptor and cytoplasmic tyrosine kinases. Phosphorylated Shc proteins form a complex with the SH2-SH3 containing Grb2 protein which is implicated in the regulation of Ras, suggesting that Shc is involved in the intracellular transmission of growth signals from activated tyrosine kinases to Ras. Overexpression of Shc proteins in cultured fibroblasts induces a transformed phenotype. We now report that, in vitro, the high affinity binding of Grb2 to Shc proteins requires phosphorylation of Shc at Tyr317, which lies within the high affinity binding motif for the Grb2 SH2 domain, pYVNV, where Asn at the +2 position is crucial for complex formation. In vivo, Tyr317 is the major, but not the only, site for Shc phosphorylation, and is the sole Shc high affinity binding site for Grb2. Mutant Shc proteins with substitution of the Tyr317 by Phe lose the capacity to be highly phosphorylated on tyrosine upon growth factor receptor activation, to bind Grb2 and to induce neoplastic transformation. In contrast, Shc proteins that have an extensive aminoterminal deletion, but retain the Tyr317 site and the SH2 domain conserve the capacity to be phosphorylated, to bind to Grb2 and to induce cell transformation. These data indicate that the formation of the Shc-Grb2 complex is a crucial event in the transformation induced by overexpression of Shc and support the notion that Shc proteins can deliver activation signals to RAS.	UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Perugia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013; Salcini, Anna Elisabetta/G-4472-2017; Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Salcini, Anna Elisabetta/0000-0001-5828-2512				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWMAN S, 1990, TECHNIQUE, V5, P254; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAMEN JE, 1993, BLOOD, V82, P2296; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	210	215	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2827	2836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084588				2022-12-17	WOS:A1994PG82200008
J	BENNETT, WP; HOLLSTEIN, MC; HE, A; ZHU, SM; RESAU, JH; TRUMP, BF; METCALF, RA; WELSH, JA; MIDGLEY, C; LANE, DP; HARRIS, CC				BENNETT, WP; HOLLSTEIN, MC; HE, A; ZHU, SM; RESAU, JH; TRUMP, BF; METCALF, RA; WELSH, JA; MIDGLEY, C; LANE, DP; HARRIS, CC			ARCHIVAL ANALYSIS OF P53 GENETIC AND PROTEIN ALTERATIONS IN CHINESE ESOPHAGEAL CANCER	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; TRANSFORMED-CELLS; BREAST-CANCER; SV40-TRANSFORMED CELLS; MATE DRINKING; LUNG-CANCER; WILD-TYPE; KI-RAS; MUTATIONS; EXPRESSION	A strategy and methods for archival analysis of genetic and protein alterations in the p53 tumor-suppressor gene are presented. The tumor series includes 43 paraffin-embedded esophageal carcinomas from two high-incidence regions in the People's Republic of China. More than half contained elevated p53 protein levels which were detected by a high-titer polyclonal antiserum and a sensitive immunohistochemical method. To estimate the frequency of underlying mutations, DNA was isolated from conventional paraffin sections, amplified by the polymerase chain reaction, and examined by dideoxy termination sequencing. Analysis of exons 5-8 in a subset of 10 tumors revealed mis-sense point mutations in 4 out of 5 immunostain-positive tumors and a mutation encoding a stop codon in 1 of 5 immunostain-negative tumors. In this report of archival material, we conclude that detectable levels of p53 protein correlate closely with the occurrence of mis-sense mutations. Furthermore, these methods render large repositories of paraffin-embedded tumor and non-tumor tissues accesible to analysis. Immunohistochemical screening for elevated protein levels followed by sequence analysis represents an efficient strategy for the evaluation of the p53 mutational spectrum.	NCI, HUMAN CARCINOGENESIS LAB, BLDG 37, ROOM 2C05, BETHESDA, MD 20892 USA; CHINA MED UNIV, CANC RES INST, SHENYANG, PEOPLES R CHINA; SUN YAT-SAN UNIV MED SCI, GUANGZHOU, PEOPLES R CHINA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; UNIV DUNDEE, INST MED SCI, CANC RES CAMPAIGN LAB, DUNDEE DD1 4HN, SCOTLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); China Medical University; Sun Yat Sen University; University System of Maryland; University of Maryland Baltimore; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARRA S, 1990, INT J CANCER, V46, P1017, DOI 10.1002/ijc.2910460612; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BONHAM K, 1989, MOL CARCINOGEN, V2, P34, DOI 10.1002/mc.2940020106; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CHIBA I, 1990, ONCOGENE, V5, P1603; DESTEFANI E, 1990, CANCER RES, V50, P426; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVI F, 1990, INT J CANCER, V45, P852, DOI 10.1002/ijc.2910450511; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEB LA, 1989, CANCER RES, V49, P5489; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VICTORA CG, 1990, CANCER RES, V50, P7112; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; [No title captured]	54	210	211	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1779	1784						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923503				2022-12-17	WOS:A1991GX11800009
J	Pradere, JP; Dapito, DH; Schwabe, RF				Pradere, J-P; Dapito, D. H.; Schwabe, R. F.			The Yin and Yang of Toll-like receptors in cancer	ONCOGENE			English	Review						MyD88; interleukin 6; tumor necrosis factor; NF-kappa B; Coley's toxin; imiquimod	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DENDRITIC CELLS; CPG DNA; COMPENSATORY PROLIFERATION; PANCREATIC CARCINOGENESIS; HEPATOCELLULAR-CARCINOMA; LIVER-REGENERATION; GENE POLYMORPHISMS; TOPICAL IMIQUIMOD	Recognition of non-self molecular patterns by pattern recognition receptors is a cornerstone of innate immunity. Toll-like receptors (TLRs) exert a key role in recognizing pathogen-associated molecular patterns (PAMPs) but have also been implicated in the recognition of damage-associated molecular patterns (DAMPs). As such, TLRs regulate a wide range of biological responses including inflammatory and immune responses during carcinogenesis. The high expression of TLRs by antigen-presenting cells, including dendritic cells, and their ability to induce antitumor mediators such as type I interferon has led to efforts to utilize TLR agonists in tumor therapy in order to convert the often tolerant immune response toward antitumor responses. However, TLRs are also increasingly recognized as regulators of tumor-promoting inflammation and promoters of tumor survival signals. Here, we will review in detail the dichotomous role of TLRs in tumor biology, focusing on relevant TLR-dependent pro-and antitumor pathways, and discuss clinical applications of TLR-targeted therapies for tumor prevention and treatment.	[Pradere, J-P; Dapito, D. H.; Schwabe, R. F.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Dapito, D. H.; Schwabe, R. F.] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	Columbia University; Columbia University	Schwabe, RF (corresponding author), Columbia Univ, Dept Med, Russ Berrie Pavil,1150 St Nicholas Ave,Room 415, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021	Pradere, Jean-Philippe/0000-0003-1734-1429	NIH [U54CA163111, R01DK076920, R01AA020211, F31DK091980]; NATIONAL CANCER INSTITUTE [U54CA163111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076920, F31DK091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020211] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by NIH grants U54CA163111, R01DK076920 and R01AA020211 (to RFS). Dianne H Dapito was supported by NIH grant F31DK091980.	Adams S, 2012, CLIN CANCER RES, V18, P6748, DOI 10.1158/1078-0432.CCR-12-1149; Ahmed A, 2013, ANN SURG ONCOL, V20, pS389, DOI 10.1245/s10434-012-2595-9; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Apte RN, 2008, IMMUNOL REV, V222, P222, DOI 10.1111/j.1600-065X.2008.00615.x; Arslan F, 2012, CIRC-CARDIOVASC INTE, V5, P279, DOI 10.1161/CIRCINTERVENTIONS.111.967596; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Babjuk M, 2011, EUR UROL, V59, P997, DOI 10.1016/j.eururo.2011.03.017; Baines J, 2003, CLIN CANCER RES, V9, P2693; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bass NM, 2010, NEW ENGL J MED, V362, P1071, DOI 10.1056/NEJMoa0907893; Bauer AK, 2005, J NATL CANCER I, V97, P1778, DOI 10.1093/jnci/dji403; BEKIERKUNST A, 1971, SCIENCE, V174, P1240, DOI 10.1126/science.174.4015.1240; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Bong AB, 2002, DERMATOLOGY, V205, P135, DOI 10.1159/000063904; Bourquin C, 2009, J IMMUNOL, V183, P6078, DOI 10.4049/jimmunol.0901594; Brignole C, 2010, CANCER RES, V70, P9816, DOI 10.1158/0008-5472.CAN-10-1251; BRUNS P, 1887, BEITR KLIN CHIR, V3, P443; Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986; Busch W., 1868, BERL KLIN WOCHENSCHR, V5, P137; Cai ZY, 2011, CANCER RES, V71, P2466, DOI 10.1158/0008-5472.CAN-10-1993; Campbell JS, 2006, J IMMUNOL, V176, P2522, DOI 10.4049/jimmunol.176.4.2522; Carpentier AF, 1999, CANCER RES, V59, P5429; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Cherfils-Vicini J, 2010, J CLIN INVEST, V120, P1285, DOI 10.1172/JCI36551; Chew V, 2012, JNCI-J NATL CANCER I, V104, P1796, DOI 10.1093/jnci/djs436; Chin AI, 2010, CANCER RES, V70, P2595, DOI 10.1158/0008-5472.CAN-09-1162; Coley W, 1894, T AM SURG ASS, V12, P183; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Couturier-Maillard A, 2013, J CLIN INVEST, V123, P700, DOI 10.1172/JCI62236; Csak T, 2011, AM J PHYSIOL-GASTR L, V300, pG433, DOI 10.1152/ajpgi.00163.2009; Cubillos-Ruiz JR, 2009, J CLIN INVEST, V119, P2231, DOI 10.1172/JCI37716; Damiano V, 2009, CLIN CANCER RES, V15, P6921, DOI 10.1158/1078-0432.CCR-09-1599; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; de Oliveira JG, 2013, DIGEST DIS SCI, V58, P978, DOI 10.1007/s10620-012-2460-5; De Palma M, 2008, CANCER CELL, V14, P299, DOI 10.1016/j.ccr.2008.09.004; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; Drobits B, 2012, J CLIN INVEST, V122, P575, DOI 10.1172/JCI61034; Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ebihara T, 2010, J EXP MED, V207, P2675, DOI 10.1084/jem.20091573; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fort MM, 2005, J IMMUNOL, V174, P6416, DOI 10.4049/jimmunol.174.10.6416; Forte G, 2012, J IMMUNOL, V188, P5357, DOI 10.4049/jimmunol.1103811; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; Fukata M, 2009, INFLAMM BOWEL DIS, V15, P997, DOI 10.1002/ibd.20880; Galluzzi L, 2012, ONCOIMMUNOLOGY, V1, P699, DOI 10.4161/onci.20696; Garaude J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002868; Geisse J, 2004, J AM ACAD DERMATOL, V50, P722, DOI 10.1016/j.jaad.2003.11.066; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Goldszmid RS, 2012, NAT IMMUNOL, V13, P932, DOI 10.1038/ni.2422; Goutagny N, 2012, TARGET ONCOL, V7, P29, DOI 10.1007/s11523-012-0213-1; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Guha M, 2012, NAT REV DRUG DISCOV, V11, P503, DOI 10.1038/nrd3775; Hall MC, 2007, J UROLOGY, V178, P2314, DOI 10.1016/j.juro.2007.09.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hasan UA, 2007, P NATL ACAD SCI USA, V104, P8047, DOI 10.1073/pnas.0700664104; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huebener P, 2013, BBA-MOL BASIS DIS, V1832, P1005, DOI 10.1016/j.bbadis.2012.11.017; Isayama F, 2006, AM J PHYSIOL-GASTR L, V290, pG1318, DOI 10.1152/ajpgi.00405.2005; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kadowaki N, 2001, J IMMUNOL, V166, P2291, DOI 10.4049/jimmunol.166.4.2291; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kirkwood JM, 2012, CA-CANCER J CLIN, V62, P309, DOI 10.3322/caac.20132; Kolida S, 2011, ANNU REV FOOD SCI T, V2, P373, DOI 10.1146/annurev-food-022510-133739; Kortylewski M, 2009, NAT BIOTECHNOL, V27, P925, DOI 10.1038/nbt.1564; Krieg AM, 2008, ONCOGENE, V27, P161, DOI 10.1038/sj.onc.1210911; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kroemer G, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23687; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Kurt-Jones EA, 2004, J ENDOTOXIN RES, V10, P419, DOI 10.1179/096805104225006516; Kutikhin AG, 2011, HUM IMMUNOL, V72, P193, DOI 10.1016/j.humimm.2010.11.003; Lan T, 2007, P NATL ACAD SCI USA, V104, P13750, DOI 10.1073/pnas.0706059104; Le Leu RK, 2010, CARCINOGENESIS, V31, P246, DOI 10.1093/carcin/bgp197; Lee J, 2012, CELL, V151, P547, DOI 10.1016/j.cell.2012.09.034; Li Y, 2014, ONCOGENE, V33, P369, DOI 10.1038/onc.2012.581; Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137; Lin H, 2013, HEPATOLOGY, V57, P171, DOI 10.1002/hep.25991; Lofgren JL, 2011, GASTROENTEROLOGY, V140, P210, DOI 10.1053/j.gastro.2010.09.048; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; Love WE, 2009, ARCH DERMATOL, V145, P1431, DOI 10.1001/archdermatol.2009.291; Lowe EL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013027; Macedo L, 2007, AM J PATHOL, V171, P1774, DOI 10.2353/ajpath.2007.061048; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mantovani A, 2008, LANCET, V371, P771, DOI 10.1016/S0140-6736(08)60241-X; Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007; Minmin Shi, 2011, PLoS One, V6, pe19466, DOI 10.1371/journal.pone.0019466; Mittal D, 2010, EMBO J, V29, P2242, DOI 10.1038/emboj.2010.94; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367; Naseemuddin M, 2012, INT J CANCER, V130, P765, DOI 10.1002/ijc.26100; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Newton K., 2012, COLD SPRING HARB PER, V4; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nierkens S, 2011, CANCER RES, V71, P6428, DOI 10.1158/0008-5472.CAN-11-2154; Ochi A, 2012, J CLIN INVEST, V122, P4118, DOI 10.1172/JCI63606; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Otte JM, 2003, GASTROENTEROLOGY, V124, P1866, DOI 10.1016/S0016-5085(03)00403-7; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Paik YH, 2003, HEPATOLOGY, V37, P1043, DOI 10.1053/jhep.2003.50182; Paik YH, 2006, LAB INVEST, V86, P676, DOI 10.1038/labinvest.3700422; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Pandey S, 2009, GYNECOL ONCOL, V114, P501, DOI 10.1016/j.ygyno.2009.05.032; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Pfeffer LM, 1997, SEMIN ONCOL, V24, P963; Pierer M, 2004, J IMMUNOL, V172, P1256, DOI 10.4049/jimmunol.172.2.1256; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rajpar SF, 2006, BRIT J DERMATOL, V155, P653, DOI 10.1111/j.1365-2133.2006.07476.x; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; REDDY BS, 1974, CANCER RES, V34, P2368; REDDY BS, 1978, J NATL CANCER I, V61, P1269, DOI 10.1093/jnci/61.5.1269; Ren T, 2007, CANCER BIOL THER, V6, P1704, DOI 10.4161/cbt.6.11.4826; Ren T, 2009, PATHOL ONCOL RES, V15, P623, DOI 10.1007/s12253-009-9162-0; Rhee SH, 2008, GASTROENTEROLOGY, V135, P518, DOI 10.1053/j.gastro.2008.04.022; Rigoli L, 2010, ANTICANCER RES, V30, P513; Rossignol DP, 2002, J ENDOTOXIN RES, V8, P483, DOI 10.1179/096805102125001127; Rowland IR, 1998, CARCINOGENESIS, V19, P281, DOI 10.1093/carcin/19.2.281; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Schon MP, 2008, ONCOGENE, V27, P190, DOI 10.1038/sj.onc.1210913; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Seki E, 2005, HEPATOLOGY, V41, P443, DOI 10.1002/hep.20603; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Sfondrini L, 2006, J IMMUNOL, V176, P6624, DOI 10.4049/jimmunol.176.11.6624; Sha T, 2007, EUR J PHARMACOL, V571, P231, DOI 10.1016/j.ejphar.2007.06.027; Shime H, 2012, P NATL ACAD SCI USA, V109, P2066, DOI 10.1073/pnas.1113099109; SIDKY YA, 1987, CANCER RES, V47, P5155; SIDKY YA, 1992, CANCER RES, V52, P3528; SJOGREN HO, 1969, NATURE, V221, P863, DOI 10.1038/221863a0; Smits ELJM, 2008, ONCOLOGIST, V13, P859, DOI 10.1634/theoncologist.2008-0097; Smyth EC, 2011, J CLIN ONCOL, V29, pE809, DOI 10.1200/JCO.2011.36.8829; So EY, 2010, INT J BIOL SCI, V6, P675; Srivastava K, 2010, LIVER INT, V30, P1067, DOI 10.1111/j.1478-3231.2010.02268.x; STARNES CO, 1992, NATURE, V357, P11, DOI 10.1038/357011a0; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; TRINCHIERI G, 1978, J EXP MED, V147, P1314, DOI 10.1084/jem.147.5.1314; Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Vacchelli E, 2012, ONCOIMMUNOLOGY, V1, P894, DOI 10.4161/onci.20931; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZY, 2013, HEPATOLOGY, V57, P1869, DOI 10.1002/hep.26234; Watanabe A, 2007, HEPATOLOGY, V46, P1509, DOI 10.1002/hep.21867; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421; Wolf G, 2006, J AM SOC NEPHROL, V17, P1585, DOI 10.1681/ASN.2005070699; Wolf IH, 2003, ARCH DERMATOL, V139, P273, DOI 10.1001/archderm.139.3.273; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012; Yu LX, 2010, HEPATOLOGY, V52, P1322, DOI 10.1002/hep.23845; Yu P, 2012, IMMUNITY, V37, P867, DOI 10.1016/j.immuni.2012.07.018; Yusuf N, 2008, CANCER RES, V68, P615, DOI 10.1158/0008-5472.CAN-07-5219; ZBAR B, 1970, SCIENCE, V170, P1217, DOI 10.1126/science.170.3963.1217; ZBAR B, 1971, SCIENCE, V172, P271, DOI 10.1126/science.172.3980.271; Zhang HL, 2012, J HEPATOL, V57, P803, DOI 10.1016/j.jhep.2012.06.011	187	209	216	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3485	3495		10.1038/onc.2013.302	http://dx.doi.org/10.1038/onc.2013.302			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934186	Green Accepted			2022-12-17	WOS:000338941100001
J	Kumar, M; Lu, Z; Takwi, AAL; Chen, W; Callander, NS; Ramos, KS; Young, KH; Li, Y				Kumar, M.; Lu, Z.; Takwi, A. A. L.; Chen, W.; Callander, N. S.; Ramos, K. S.; Young, K. H.; Li, Y.			Negative regulation of the tumor suppressor p53 gene by microRNAs	ONCOGENE			English	Article						microRNA; p53; senescence; apoptosis; cell cycle arrest; multiple myeloma	MIR-34A; TARGET; IDENTIFICATION; RESTORATION; ACTIVATION; APOPTOSIS; PATHWAY; ARREST; TP53	The tumor suppressor p53, encoded by the TP53 gene, is recognized as the guardian of the human genome because it regulates many downstream genes to exercise its function in cell cycle and cell death. Recent studies have revealed that several microRNAs (miRNAs) are important components of the p53 tumor suppressor network with miR-125b and miR-504 directly targeting TP53. In this study, we use a screening method to identify that two miRNAs (miR-25 and miR-30d) directly target the 3'UTR of TP53 to downregulate p53 protein levels and reduce the expression of genes that are transcriptionally activated by p53. Correspondingly, both miR-25 and miR-30d adversely affect apoptotic cell death, cell cycle arrest and cellular senescence. Inhibition of either miR-25 or miR-30d expression increases endogenous p53 expression and elevates cellular apoptosis in several cell lines, including one from multiple myeloma that has little TP53 mutations. Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d. Oncogene (2011) 30, 843-853; doi:10.1038/onc.2010.457; published online 11 October 2010	[Kumar, M.; Lu, Z.; Takwi, A. A. L.; Chen, W.; Ramos, K. S.; Li, Y.] Univ Louisville, Sch Med, Ctr Genet & Mol Med, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; [Callander, N. S.; Young, K. H.] Univ Wisconsin, Sch Med & Publ Hlth, Paul P Carbone Comprehens Canc Ctr, Dept Pathol & Lab Med Oncol, Madison, WI USA	University of Louisville; University of Wisconsin System; University of Wisconsin Madison	Li, Y (corresponding author), Univ Louisville, Sch Med, Ctr Genet & Mol Med, Dept Biochem & Mol Biol, 319 Abraham Flexner Way,Room 513-A Bldg, Louisville, KY 40202 USA.	yong.li@louisville.edu	Kumar, Munish/Z-4106-2019; Xie, Huangming/B-2260-2012	Callander, Natalie/0000-0002-6975-1086	NIEHS/NIH [P30ES014443]; NCI/NIH [R01CA138688, P20CA103697, 1RC1CA146299]; NCRR/NIH [P20 RR024489]; University of Wisconsin Paul Carbone Comprehensive Cancer Center; Gundersen Medical Foundation; University of Wisconsin; NATIONAL CANCER INSTITUTE [RC1CA146299, R01CA138688, P20CA103697] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES014443] Funding Source: NIH RePORTER	NIEHS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); University of Wisconsin Paul Carbone Comprehensive Cancer Center; Gundersen Medical Foundation; University of Wisconsin; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Y L is supported by the Director's Biomarker Award from the Center for Environmental Genomics and Integrative Biology, funded by NIEHS/NIH (P30ES014443), Kentucky Lung Cancer Research Program, NCI/NIH (R01CA138688) and NCRR/NIH (P20 RR024489). K H Y is supported by the University of Wisconsin Paul Carbone Comprehensive Cancer Center Award, the Gundersen Medical Foundation Award, the University of Wisconsin Pathology R & D Fund and by NCI/NIH (P20CA103697 and 1RC1CA146299). We are grateful to the critical reviews from Drs Korise E Rasmusson and Nancy C Martin.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chng WJ, 2007, LEUKEMIA, V21, P582, DOI 10.1038/sj.leu.2404524; Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Prendergast NJ, 1996, J UROLOGY, V155, P1685, DOI 10.1016/S0022-5347(01)66165-2; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; VOELLER HJ, 1994, J UROLOGY, V151, P492; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Xiong W, 2008, BLOOD, V112, P4235, DOI 10.1182/blood-2007-10-119123; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	39	209	219	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					843	853		10.1038/onc.2010.457	http://dx.doi.org/10.1038/onc.2010.457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20935678	Green Accepted			2022-12-17	WOS:000287444600008
J	Li, Y; Ye, X; Tan, C; Hongo, JA; Zha, J; Liu, J; Kallop, D; Ludlam, MJC; Pei, L				Li, Y.; Ye, X.; Tan, C.; Hongo, J-A; Zha, J.; Liu, J.; Kallop, D.; Ludlam, M. J. C.; Pei, L.			Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis	ONCOGENE			English	Article						RTK; tumorigenesis; metastasis; angiogenesis; RNAi; therapeutic antibodies	RECEPTOR TYROSINE KINASE; ENDOTHELIAL-CELLS; MYELOID-LEUKEMIA; BREAST-CANCER; TAM RECEPTORS; GAS6; EXPRESSION; FAMILY; MICE; ACTIVATION	Dysregulation of Axl and its ligand growth arrest-specific 6 is implicated in the pathogenesis of several human cancers. In this study, we have used RNAi and monoclonal antibodies to assess further the oncogenic potential of Axl. Here we show that Axl knockdown reduces growth of lung and breast cancer xenograft tumors. Inhibition of Axl expression attenuates breast cancer cell migration and inhibits metastasis to the lung in an orthotopic model, providing the first in vivo evidence that links Axl directly to cancer metastasis. Axl knockdown in endothelial cells impaired tube formation and this effect was additive with anti-vascular endothelial growth factor (VEGF). Further analysis demonstrated that Axl regulates endothelial cell functions by modulation of signaling through angiopoietin/Tie2 and Dickkopf (DKK3) pathways. We have developed and characterized Axl monoclonal antibodies that attenuate non-small cell lung carcinoma xenograft growth by downregulation of receptor expression, reducing tumor cell proliferation and inducing apoptosis. Our data demonstrate that Axl plays multiple roles in tumorigenesis and that therapeutic antibodies against Axl may block Axl functions not only in malignant tumor cells but also in the tumor stroma. The additive effect of Axl inhibition with anti-VEGF suggests that blocking Axl function could be an effective approach for enhancing antiangiogenic therapy. Oncogene (2009) 28, 3442-3455; doi: 10.1038/onc.2009.212; published online 27 July 2009	[Li, Y.; Ye, X.; Pei, L.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Tan, C.; Hongo, J-A] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA; [Zha, J.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Liu, J.] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; [Kallop, D.] Genentech Inc, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA; [Ludlam, M. J. C.] Genentech Inc, Dept Cell Regulat, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Pei, L (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	lpei@gene.com		Liu, Jinfeng/0000-0002-0343-8222				Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Angelillo-Scherrer A, 2008, J CLIN INVEST, V118, P583, DOI 10.1172/JCI30375; Berclaz G, 2001, ANN ONCOL, V12, P819, DOI 10.1023/A:1011126330233; Budagian V, 2005, EMBO J, V24, P4260, DOI 10.1038/sj.emboj.7600874; Budagian V, 2005, MOL CELL BIOL, V25, P9324, DOI 10.1128/MCB.25.21.9324-9339.2005; Cao WM, 2001, ARTERIOSCL THROM VAS, V21, P1592, DOI 10.1161/hq1001.097062; Caraux A, 2006, NAT IMMUNOL, V7, P747, DOI 10.1038/ni1353; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; D'Arcangelo D, 2006, CARDIOVASC RES, V71, P754, DOI 10.1016/j.cardiores.2006.06.002; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Gould WR, 2005, J THROMB HAEMOST, V3, P733, DOI 10.1111/j.1538-7836.2005.01186.x; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hasanbasic I, 2005, J THROMB HAEMOST, V3, P2790, DOI 10.1111/j.1538-7836.2005.01662.x; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Katagiri M, 2001, J BIOL CHEM, V276, P7376, DOI 10.1074/jbc.M007393200; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Korshunov VA, 2006, CIRC RES, V98, P1446, DOI 10.1161/01.RES.0000223322.16149.9a; Korshunov VA, 2007, HYPERTENSION, V50, P1057, DOI 10.1161/HYPERTENSIONAHA.107.096289; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Melaragno MG, 1999, TRENDS CARDIOVAS MED, V9, P250, DOI 10.1016/S1050-1738(00)00027-X; Meric F, 2002, CLIN CANCER RES, V8, P361; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Prasad D, 2006, MOL CELL NEUROSCI, V33, P96, DOI 10.1016/j.mcn.2006.06.011; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sasaki T, 2006, EMBO J, V25, P80, DOI 10.1038/sj.emboj.7600912; Shankar SL, 2006, J NEUROSCI, V26, P5638, DOI 10.1523/JNEUROSCI.5063-05.2006; Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Untergasser G, 2008, INT J CANCER, V122, P1539, DOI 10.1002/ijc.23255; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	52	209	256	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3442	3455		10.1038/onc.2009.212	http://dx.doi.org/10.1038/onc.2009.212			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19633687				2022-12-17	WOS:000270478300002
J	Matsumoto, S; Iwakawa, R; Takahashi, K; Kohno, T; Nakanishi, Y; Matsuno, Y; Suzuki, K; Nakamoto, M; Shimizu, E; Minna, JD; Yokota, J				Matsumoto, S.; Iwakawa, R.; Takahashi, K.; Kohno, T.; Nakanishi, Y.; Matsuno, Y.; Suzuki, K.; Nakamoto, M.; Shimizu, E.; Minna, J. D.; Yokota, J.			Prevalence and specificity of LKB1 genetic alterations in lung cancers	ONCOGENE			English	Article						LKB1; lung cancer mutation; deletion; smoking; poor differentiation	PEUTZ-JEGHERS-SYNDROME; FREQUENT EGFR MUTATIONS; SOMATIC MUTATIONS; TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; LKB1/STK11; STK11/LKB1; CARCINOMA; INDUCTION; DELETIONS	Germline LKB1 mutations cause Peutz-Jeghers syndrome, a hereditary disorder that predisposes to gastrointestinal hamartomatous polyposis and several types of malignant tumors. Somatic LKB1 alterations are rare in sporadic cancers, however, a few reports showed the presence of somatic alterations in a considerable fraction of lung cancers. To determine the prevalence and the specificity of LKB1 alterations in lung cancers, we examined a large number of lung cancer cell lines and lung adenocarcinoma ( AdC) specimens for the alterations. LKB1 genetic alterations were frequently detected in the cell lines ( 21/70, 30%), especially in non-small cell lung cancers ( NSCLCs) ( 20/51, 39%), and were significantly more frequent in cell lines with KRAS mutations. Point mutations were detected only in AdCs and large cell carcinomas, whereas homozygous deletions were detected in all histological types of lung cancer. Among lung AdC specimens, LKB1 mutations were found in seven ( 8%) of 91 male smokers but in none of 64 females and/or nonsmokers, and were significantly more frequent in poorly differentiated tumors. The difference in the frequency of LKB1 alterations between cell lines and tumor specimens was likely to be owing to masking of deletions by the contamination of noncancerous cells in the tumor specimens. These results indicate that somatic LKB1 genetic alterations preferentially occur in a subset of poorly differentiated lung AdCs that appear to correlate with smoking males.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 1040045, Japan; Natl Canc Ctr, Diagnost Pathol Div, Tokyo, Japan; Natl Canc Ctr, Thorac Surg Div, Tokyo, Japan; Tottori Univ, Fac Med, Div Med Oncol & Mol Respirol, Tottori 680, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp			NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA070907, P50 CA 70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Bignell GR, 1998, CANCER RES, V58, P1384; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Fujita T, 1999, INT J ONCOL, V15, P927; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; GUDLBERG P, 1999, ONCOGENE, V18, P1777; Hearle NCM, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-38; Hearle NCM, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.036830; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kishimoto M, 2005, CLIN CANCER RES, V11, P512; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Matsumoto S, 2006, INT J CANCER, V118, P2498, DOI 10.1002/ijc.21670; Matsumoto S, 2006, INT J CANCER, V119, P1491, DOI 10.1002/ijc.21940; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Upadhyay S, 2006, CANCER RES, V66, P7870, DOI 10.1158/0008-5472.CAN-05-2902; Volikos E, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039875; Westerman AM, 1999, LANCET, V353, P1211, DOI 10.1016/S0140-6736(98)08018-0; Zhong DS, 2006, LUNG CANCER, V53, P285, DOI 10.1016/j.lungcan.2006.05.018	31	209	225	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5911	5918		10.1038/sj.onc.1210418	http://dx.doi.org/10.1038/sj.onc.1210418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384680	Green Accepted			2022-12-17	WOS:000249123100008
J	Ji, H; Houghton, AM; Mariani, TJ; Perera, S; Kim, CB; Padera, R; Tonon, G; McNamara, K; Marconcini, LA; Hezel, A; El-Bardeesy, N; Bronson, RT; Sugarbaker, D; Maser, RS; Shapiro, SD; Wong, KK				Ji, H; Houghton, AM; Mariani, TJ; Perera, S; Kim, CB; Padera, R; Tonon, G; McNamara, K; Marconcini, LA; Hezel, A; El-Bardeesy, N; Bronson, RT; Sugarbaker, D; Maser, RS; Shapiro, SD; Wong, KK			K-ras activation generates an inflammatory response in lung tumors	ONCOGENE			English	Article						K-ras; inflammation; lung cancer; macrophages; neutrophils	PEPTIDE ENA-78; CANCER; INTERLEUKIN-8; EXPRESSION; CELL; IDENTIFICATION; TUMORIGENESIS; ANGIOGENESIS; INDUCTION; GROWTH	Activating mutations in K-ras are one of the most common genetic alterations in human lung cancer. To dissect the role of K-ras activation in bronchial epithelial cells during lung tumorigenesis, we created a model of lung adenocarcinoma by generating a conditional mutant mouse with both Clara cell secretory protein (CC10)-Cre recombinase and the Lox-Stop-Lox K-ras(G12D) alleles. The activation of K-ras mutant allele in CC10 positive cells resulted in a progressive phenotype characterized by cellular atypia, adenoma and ultimately adenocarcinoma. Surprisingly, K-ras activation in the bronchiolar epithelium is associated with a robust inflammatory response characterized by an abundant infiltration of alveolar macrophages and neutrophils. These mice displayed early mortality in the setting of this pulmonary inflammatory response with a median survival of 8 weeks. Bronchoalveolar lavage fluid from these mutant mice contained the MIP-2, KC, MCP-1 and LIX chemokines that increased significantly with age. Cell lines derived from these tumors directly produced MIP-2, LIX and KC. This model demonstrates that K-ras activation in the lung induces the elaboration of inflammatory chemokines and provides an excellent means to further study the complex interactions between inflammatory cells, chemokines and tumor progression.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Wong, KK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, 44 Binney St,M413, Boston, MA 02115 USA.	kwong1@partners.org	Tonon, Giovanni/J-9804-2018; Maser, Richard/B-2970-2012	Tonon, Giovanni/0000-0003-2973-5038; 	NHLBI NIH HHS [R01 HL70321] Funding Source: Medline; NIA NIH HHS [K08AG 2400401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BAGGIOLINI M, 1994, CHEST, V105, pS95, DOI 10.1378/chest.105.3_Supplement.95S; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Doll RJ, 2004, CURR OPIN DRUG DISC, V7, P478; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karin M, 2005, NAT MED, V11, P20, DOI 10.1038/nm0105-20; Karp JE, 2001, CURR OPIN ONCOL, V13, P470, DOI 10.1097/00001622-200111000-00009; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Linnoila RI, 2000, ANN NY ACAD SCI, V923, P249; LUKACS NW, 1995, AM J PHYSIOL-LUNG C, V268, pL856, DOI 10.1152/ajplung.1995.268.5.L856; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Ono M, 1999, CANCER CHEMOTH PHARM, V43, pS69, DOI 10.1007/s002800051101; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Poznansky MC, 2002, J CLIN INVEST, V109, P1101, DOI 10.1172/JCI200213853; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WATNICK RS, 2003, CANCER CELL, V6, P447	34	209	213	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2105	2112		10.1038/sj.onc.1209237	http://dx.doi.org/10.1038/sj.onc.1209237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288213				2022-12-17	WOS:000236359700013
J	Kim, SO; Kundu, JK; Shin, YK; Park, JH; Cho, MH; Kim, TY; Surh, YJ				Kim, SO; Kundu, JK; Shin, YK; Park, JH; Cho, MH; Kim, TY; Surh, YJ			[6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappa B in phorbol ester-stimulated mouse skin	ONCOGENE			English	Article						chemoprevention; cyclooxygenase-2; [6]-gingerol; p38 MAPK; NF-kappa B; mouse skin	SIGNAL-TRANSDUCTION PATHWAYS; NITRIC-OXIDE-SYNTHASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-MECHANISMS; CELL-TRANSFORMATION; BINDING PROTEIN; P65 SUBUNIT	[6]-Gingerol, a pungent ingredient of ginger (Zingiber officinale Roscoe, Zingiberaceae), has a wide array of pharmacologic effects. The present study was aimed at unraveling the molecular mechanisms underlying previously reported antitumor promoting effects of [6]- gingerol in mouse skin in vivo. One of the well-recognized molecular targets for chemoprevention is cyclooxygenase-2 (COX-2) that is abnormally upregulated in many premalignant and malignant tissues and cells. In our present study, topical application of [6]- gingerol inhibited COX-2 expression in mouse skin stimulated with a prototype tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Since the transcription factor nuclear factor-kappaB (NF-KB) is known to regulate COX-2 induction, we attempted to determine the effect of [6]- gingerol on TPA-induced activation of NF-KB. Pretreatment with [6]-gingerol resulted in a decrease in both TPA-induced DNA binding and transcriptional activities of NF-KB through suppression of IKB alpha degradation and p65 nuclear translocation. Phosphorylation of both IKB alpha and p65 was substantially blocked by [6]-gingerol. In addition, [6]-gingerol inhibited TPA-stimulated interaction of phospho-p65-(Ser-536) with cAMP response element binding protein-binding protein, a transcriptional coactivator of NF-KB. Moreover, [6]-gingerol prevented TPA-induced phosphorylation and catalytic activity of p38 mitogen-activated protein ( MAP) kinase that regulates COX-2 expression in mouse skin. The p38 MAP kinase inhibitor SB203580 attenuated NF-KB activation and subsequent COX-2 induction in TPA-treated mouse skin. Taken together, our data suggest that [6]-gingerol inhibits TPA-induced COX-2 expression in mouse skin in vivo by blocking the p38 MAP kinase-NF-KB signaling pathway.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; Catholic Univ Korea, Coll Med, Seoul 150010, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Catholic University of Korea	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr	Shin, Young Kee/C-8929-2011; Kundu, Joydeb/E-6004-2010	Shin, Young Kee/0000-0003-0896-718X; 				Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Asano TK, 2004, DIS COLON RECTUM, V47, P665, DOI 10.1007/s10350-003-0111-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bode A M, 2000, Lancet Oncol, V1, P181, DOI 10.1016/S1470-2045(00)00029-2; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; Bode AM, 2001, CANCER RES, V61, P850; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chen NY, 2001, CANCER RES, V61, P3908; Chun KS, 2004, CARCINOGENESIS, V25, P713, DOI 10.1093/carcin/bgh076; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Chun KS, 2003, CARCINOGENESIS, V24, P1515, DOI 10.1093/carcin/bgg107; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grab LT, 2004, BBA-MOL CELL BIOL L, V1636, P29, DOI 10.1016/j.bbalip.2003.12.002; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gupta S, 2004, CANCER RES, V64, P3334, DOI 10.1158/0008-5472.CAN-03-2422; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kismet K, 2004, CANCER DETECT PREV, V28, P127, DOI 10.1016/j.cdp.2003.12.005; Kundu JK, 2003, J NUTR, V133, p3805S, DOI 10.1093/jn/133.11.3805S; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee MW, 2000, BIOL PHARM BULL, V23, P517, DOI 10.1248/bpb.23.517; Liao CH, 2004, MOL CARCINOGEN, V41, P140, DOI 10.1002/mc.20050; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mohan S, 2003, ORAL ONCOL, V39, P537, DOI 10.1016/S1368-8375(03)00035-6; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; NEWALL CA, 1996, HERBAL MED GUIDE HLT, V4, P296; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Park KK, 1998, CANCER LETT, V129, P139, DOI 10.1016/S0304-3835(98)00081-0; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Surh YJ, 2002, FOOD CHEM TOXICOL, V40, P1091, DOI 10.1016/S0278-6915(02)00037-6; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Surh YJ, 1999, MUTAT RES-FUND MOL M, V428, P305, DOI 10.1016/S1383-5742(99)00057-5; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Tiano HF, 2002, CANCER RES, V62, P3395; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	60	209	225	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2558	2567		10.1038/sj.onc.1208446	http://dx.doi.org/10.1038/sj.onc.1208446			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735738				2022-12-17	WOS:000228180600013
J	Verissimo, F; Jordan, P				Verissimo, F; Jordan, P			WNK kinases, a novel protein kinase subfamily in multi-cellular organisms	ONCOGENE			English	Article						protein kinases; catalytic domain; MAP kinases; chromosome 12; gene cloning; alternative splicing	CATALYTIC SUBUNIT; ORGANIZATION	We have cloned and characterized a novel human serine/ threonine protein kinase gene from chromosome 12p13.3 encoding 2382 amino acids. Remarkably, the catalytic domain sequence contains a cysteine in place of a lysine residue conserved in subdomain II of most kinases. The same amino acid alteration was recently described for rat WNK1 (with no K=lysine) in which another nearby lysine residue was shown to confer kinase activity to the protein. Rat WNK1 is 85% identical to a splice variant lacking exons 11 and 12 of the described human kinase which we have called human WNK1. The WNK1 catalytic domain has closest homology with human PAK2, MEKK3, and Raf-1. Three additional, partial human protein kinase sequences, WNK2, WNK3 and WNK4, are also reported here with catalytic domains that are 95% homologous to WNK1. These genes differ both in chromosomal location and tissue-specific expression. Moreover, we have identified in the database a total of 18 WNK-related genes, all exclusively from multicellular organisms, which share a WNK kinase sequence signature within subdomains I and II of the catalytic domain. We suggest that they constitute a novel subfamily of protein kinases that evolved together with cell adhesion and tissue-formation.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, P-1649016 Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, Ave Padre Cruz, P-1649016 Lisbon, Portugal.		Jordan, Peter/G-9335-2012	Jordan, Peter/0000-0002-1425-9211				BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dhanasekaran N, 1998, ONCOGENE, V17, P1329, DOI 10.1038/sj.onc.1202170; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jordan P, 2000, BIOCHEM BIOPH RES CO, V279, P741, DOI 10.1006/bbrc.2000.3901; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795	17	209	222	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5562	5569		10.1038/sj.onc.1204726	http://dx.doi.org/10.1038/sj.onc.1204726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571656				2022-12-17	WOS:000170781100019
J	Gutkind, JS				Gutkind, JS			Cell growth control by G protein-coupled receptors: from signal transduction to signal integration	ONCOGENE			English	Review						g proteins; g protein-coupled receptors; Ras; MAP kinases; Rho; cell growth	BETA-GAMMA-SUBUNITS; TERNARY COMPLEX FACTORS; SMOOTH-MUSCLE CELLS; MAP KINASE CASCADE; FACTOR RAS-GRF; CONSTITUTIVELY ACTIVATING MUTATION; INDUCED TYROSINE PHOSPHORYLATION; VAV PROTOONCOGENE PRODUCT; HETEROTRIMERIC G-PROTEIN; SERUM RESPONSE ELEMENT		NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				Aaronson S A, 1985, Carcinog Compr Surv, V10, P35; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Akada R, 1996, GENETICS, V143, P103; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Charlesworth A, 1997, ONCOGENE, V14, P2323, DOI 10.1038/sj.onc.1201075; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; CHEN J, 1995, BIOCHEM SOC T, V23, P129, DOI 10.1042/bst0230129; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Coso OA, 1996, J BIOL CHEM, V271, P3963; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gaits F, 1996, J BIOL CHEM, V271, P20151; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HOOSEIN NM, 1988, CANCER RES, V48, P7179; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUS MH, 1988, ANN NY ACAD SCI, V551, P320, DOI 10.1111/j.1749-6632.1988.tb22358.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGDON S, 1992, CANCER RES, V52, P4554; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOODY TW, 1993, LIFE SCI, V52, P1161, DOI 10.1016/0024-3205(93)90098-N; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; POUYSSEGUR J, 1988, PHILOS T ROY SOC B, V320, P427, DOI 10.1098/rstb.1988.0086; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHULLER HM, 1991, EXP LUNG RES, V17, P837, DOI 10.3109/01902149109064321; SCHULLER HM, 1991, CANCER CELL-MON REV, V3, P496; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAHARA E, 1990, J CANCER RES CLIN, V116, P121, DOI 10.1007/BF01612665; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Teramoto H, 1997, J BIOL CHEM, V272, P10751; THOMAS F, 1992, CANCER RES, V52, P4872; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRONICK SR, 1988, ADV SEC MESS PHOSPH, V21, P201; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; UI M, 1990, ADV SEC MESS PHOSPH, V24, P63; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626	163	209	213	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1331	1342		10.1038/sj.onc.1202186	http://dx.doi.org/10.1038/sj.onc.1202186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779981				2022-12-17	WOS:000076161900002
J	SHAULSKY, G; BENZEEV, A; ROTTER, V				SHAULSKY, G; BENZEEV, A; ROTTER, V			SUBCELLULAR-DISTRIBUTION OF THE P53 PROTEIN DURING THE CELL-CYCLE OF BALB/C 3T3 CELLS	ONCOGENE			English	Article									WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	SHAULSKY, G (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.			Shaulsky, Gad/0000-0002-0532-0551; ben-ze'ev, avri/0000-0001-6113-3921				ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAER JS, 1989, SCIENCE, V244, P217; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; DANG CV, 1989, J BIOL CHEM, V264, P18019; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KELMAN Z, 1989, BLOOD, V74, P2318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROTTER V, 1985, P NATL ACAD SCI USA, V82, P790; SHOHAT O, 1987, ONCOGENE, V1, P277; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WYNFORDTHOMAS D, 1985, EXP CELL RES, V159, P191, DOI 10.1016/S0014-4827(85)80048-3; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	41	209	211	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1707	1711						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267137				2022-12-17	WOS:A1990EL40100014
J	Ogiwara, H; Ui, A; Otsuka, A; Satoh, H; Yokomi, I; Nakajima, S; Yasui, A; Yokota, J; Kohno, T				Ogiwara, H.; Ui, A.; Otsuka, A.; Satoh, H.; Yokomi, I.; Nakajima, S.; Yasui, A.; Yokota, J.; Kohno, T.			Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors	ONCOGENE			English	Article						non-homologous end joining; DNA double-strand break; DNA repair; chromatin; histone acetyltransferase	DNA-DAMAGE; HUMAN-CELLS; HOMOLOGOUS RECOMBINATION; DISTINCT ROLES; TUMOR-CELLS; REPAIR; PROTEIN; ACETYLTRANSFERASE; CANCER; GAMMA-H2AX	Non-homologous end joining (NHEJ) is a major repair pathway for DNA double-strand breaks (DSBs) generated by ionizing radiation (IR) and anti-cancer drugs. Therefore, inhibiting the activity of proteins involved in this pathway is a promising way of sensitizing cancer cells to both radiotherapy and chemotherapy. In this study, we developed an assay for evaluating NHEJ activity against DSBs in chromosomal DNA in human cells to identify the chromatin modification/remodeling proteins involved in NHEJ. We showed that ablating the activity of the homologous histone acetyltransferases, CBP and p300, using inhibitors or small interfering RNAs-suppressed NHEJ. Ablation of CBP or p300 impaired IR-induced DSB repair and sensitized lung cancer cells to IR and the anti-cancer drug, etoposide, which induces DSBs that are repaired by NHEJ. The CBP/p300 proteins were recruited to sites of DSBs and their ablation suppressed acetylation of lysine 18 within histone H3, and lysines 5, 8, 12, and 16 within histone H4, at the DSB sites. This then suppressed the recruitment of KU70 and KU80, both key proteins for NHEJ, to the DSB sites. Ablation of CBP/p300 also impaired the recruitment of BRM, a catalytic subunit of the SWI/SNF complex involved in chromatin remodeling at DSB sites. These results indicate that CBP and p300 function as histone H3 and H4 acetyltransferases at DSB sites in NHEJ and facilitate chromatin relaxation. Therefore, inhibition CBP and p300 activity may sensitize cancer cells to radiotherapy and chemotherapy. Oncogene (2011) 30, 2135-2146; doi:10.1038/onc.2010.592; published online 10 January 2011	[Ogiwara, H.; Ui, A.; Otsuka, A.; Kohno, T.] Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, Tokyo 1040045, Japan; [Ui, A.; Otsuka, A.; Yokota, J.] Natl Canc Ctr, Res Inst, Div Multistep Carcinogenesis, Tokyo 1040045, Japan; [Ui, A.; Nakajima, S.; Yasui, A.] Tohoku Univ, Div Dynam Proteome Aging & Canc, Dept Mol Genet, Inst Dev, Sendai, Miyagi, Japan; [Satoh, H.; Yokomi, I.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Tumor Cell Biol, Tokyo, Japan; [Yokomi, I.] St Marianna Univ, Sch Med, Dept Pharmacol, Kanagawa, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tohoku University; University of Tokyo; Saint Marianna University	Kohno, T (corresponding author), Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tkkohno@ncc.go.jp	Ui, Ayako/GON-4666-2022	Ui, Ayako/0000-0001-6698-7168; Ogiwara, Hideaki/0000-0003-0860-1807	Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; National Institute of Biomedical Innovation (NiBio)	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); National Institute of Biomedical Innovation (NiBio)(National Institute of Biomedical Innovation)	We thank Dr Maria Jasin of the Memorial Sloan-Kettering Cancer Center, USA, for the pCBASce plasmid, Dr Marc Tini of the University of Western Ontario for the yellow fluorescent protein-Cbp plasmid and Dr Kazunori Aoki of the National Cancer Center Research Institute for the pAD-TK plasmid. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas; from the Ministry of Health, Labor and Welfare of Japan for the 3rd-term Comprehensive 10-year Strategy for Cancer Control and for Cancer Research (19-9); and from the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio).	Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Downs JA, 2007, ONCOGENE, V26, P7765, DOI 10.1038/sj.onc.1210874; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hong ZH, 2008, NUCLEIC ACIDS RES, V36, P2939, DOI 10.1093/nar/gkn146; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Javvadi P, 2008, MOL PHARMACOL, V73, P1491, DOI 10.1124/mol.107.043554; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Karamouzis MV, 2007, CELL RES, V17, P324, DOI 10.1038/cr.2007.10; Khafif A, 2005, OTOLARYNG HEAD NECK, V132, P317, DOI 10.1016/j.otohns.2004.09.006; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Park EJ, 2003, NUCLEIC ACIDS RES, V31, P6819, DOI 10.1093/nar/gkg921; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Sun YL, 2006, FEBS LETT, V580, P4353, DOI 10.1016/j.febslet.2006.06.092; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; Yoshida S, 2001, CYTOGENET CELL GENET, V94, P88, DOI 10.1159/000048791; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275	44	208	216	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	18					2135	2146		10.1038/onc.2010.592	http://dx.doi.org/10.1038/onc.2010.592			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217779				2022-12-17	WOS:000290249600005
J	Olmeda, D; Jorda, M; Peinado, H; Fabra, A; Cano, A				Olmeda, D.; Jorda, M.; Peinado, H.; Fabra, A.; Cano, A.			Snail silencing effectively suppresses tumour growth and invasiveness	ONCOGENE			English	Article						snail; E-cadherin; EMT; MET; tumorigenicity; invasion	TRANSCRIPTION FACTOR SNAIL; EPITHELIAL-MESENCHYMAL TRANSITIONS; CELL-ADHESION MOLECULE; E-CADHERIN EXPRESSION; GENE-EXPRESSION; REPRESSOR SNAIL; SUPERFAMILY; PROGRESSION; JUNCTIONS; INVASION	The transcription factor Snail has been recently proposed as an important mediator of tumour invasion because of its role in downregulation of E-cadherin and induction of epithelial-mesenchymal transitions (EMT). This behaviour has led to the consideration of Snail as a potential therapeutic target to block tumour progression. In this report, we provide evidence for this hypothesis. We show that silencing of Snail by stable RNA interference in MDCK-Snail cells induces a complete mesenchymal to epithelial transition (MET), associated to the upregulation of E-cadherin, downregulation of mesenchymal markers and inhibition of invasion. More importantly, stable interference of endogenous Snail in two independent carcinoma cell lines leads to a dramatic reduction of in vivo tumour growth, accompanied by increased tumour differentiation and a significant decrease in the expression of MMP-9 and angiogenic markers and invasiveness. These results indicate that use of RNA interference can be an effective tool for blocking Snail function, opening the way for its application in new antiinvasive therapies.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, Madrid 28029, Spain; IDIBELL, Inst Invest Bellvitge, Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Cano, A (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, C Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Peinado, Hector/A-6417-2013; Jordà, Mireia/Z-4519-2019; Olmeda, David/L-4270-2017	Peinado, Hector/0000-0002-4256-3413; Olmeda, David/0000-0001-5513-5621; Jorda, Mireia/0000-0003-3709-1850				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1992, Semin Cell Biol, V3, P169; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Llorens A, 1998, LAB INVEST, V78, P1131; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Sefton M, 1998, DEVELOPMENT, V125, P3111; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	37	208	220	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1862	1874		10.1038/sj.onc.1209997	http://dx.doi.org/10.1038/sj.onc.1209997			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043660				2022-12-17	WOS:000245117700004
J	Sharma, GG; Gupta, A; Wang, H; Scherthan, H; Dhar, S; Gandhi, V; Iliakis, G; Shay, JW; Young, CSH; Pandita, TK				Sharma, GG; Gupta, A; Wang, H; Scherthan, H; Dhar, S; Gandhi, V; Iliakis, G; Shay, JW; Young, CSH; Pandita, TK			HTERT associates with human telomeres and enhances genomic stability and DNA repair	ONCOGENE			English	Article						hTERT; telomeres; transcription; DNA repair; ionizing radiation	ATAXIA-TELANGIECTASIA CELLS; EXTENDED-LIFE-SPAN; IONIZING-RADIATION; HUMAN FIBROBLASTS; RNA COMPONENT; IMMUNOHISTOCHEMICAL DETECTION; SACCHAROMYCES-CEREVISIAE; CHROMOSOME INSTABILITY; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT	Ectopic expression of telomerase in telomerase-silent cells is sufficient to overcome senescence and to extend cellular lifespan. We show here that the catalytic subunit of human telomerase (hTERT) crosslinks telomeres. This interaction is blocked by the telomere repeat binding factor 1, but not by a dominant negative form of this protein. It is also abolished by destruction of the RNA component of telomerase as well as by mutations in the hTERT protein. Ectopic expression of hTERT leads to transcriptional alterations of a subset of genes and changes in the interaction of the telomeres with the nuclear matrix. This is associated with reduction of spontaneous chromosome damage in G, cells, enhancement of the kinetics of DNA repair and an increase in NTP levels. The effect on DNA repair is likely indirect as TERT does not directly affect DNA end rejoining in vitro or meiotic recombination in vivo. The observed effects of hTERT occurred rapidly before any significant lengthening of telomeres was observed. Our findings establish an intimate relationship between hTERT-telomere interactions and alteration in transcription of a subset of genes that may lead to increased genomic stability and enhanced repair of genetic damage. These novel functions of telomerase are distinct from its known effect on telomere length and have potentially important biological consequences.	Washington Univ, Sch Med, Radiat & Canc Biol Div, St Louis, MO 63108 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Texas, MDACC, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	Washington University (WUSTL); Columbia University; Jefferson University; Max Planck Society; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pandita, TK (corresponding author), 4511 Forest Pk,Suite 411, St Louis, MO 63108 USA.		Pandita, Tej K/AAM-9188-2020; Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA13696, CN-15015] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Fan ZH, 2000, CANCER GENE THER, V7, P1307, DOI 10.1038/sj.cgt.0243; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Iliakis G, 1999, METH MOL B, V113, P543; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; Kawakami Y, 2000, ONCOGENE, V19, P3888, DOI 10.1038/sj.onc.1203733; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Ng P, 2000, BIOTECHNIQUES, V29, P524, DOI 10.2144/00293st04; NISHIKAWA K, 1992, CANCER RES, V52, P4758; OLOVNIKOV AM, 1992, IZV AN SSSR BIOL+, P641; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; PLUNKETT W, 1980, CANCER RES, V40, P588; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6406, DOI 10.1021/bi00344a014; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; ROBERTS JJ, 1978, ADV RADIAT BIOL, V7, P211; Rodriguez CO, 2000, J CHROMATOGR B, V745, P421, DOI 10.1016/S0378-4347(00)00303-0; RUDD GN, 1995, CANCER CHEMOTH PHARM, V35, P323, DOI 10.1007/BF00689452; Sawant SG, 1999, FASEB J, V13, P1047, DOI 10.1096/fasebj.13.9.1047; Scherthan H, 2000, MOL CELL BIOL, V20, P7773, DOI 10.1128/MCB.20.20.7773-7783.2000; Scherthan H, 2001, NAT REV MOL CELL BIO, V2, P621, DOI 10.1038/35085086; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	67	208	224	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					131	146		10.1038/sj.onc.1206063	http://dx.doi.org/10.1038/sj.onc.1206063			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527915				2022-12-17	WOS:000180166900014
J	Baserga, R				Baserga, R			The contradictions of the insulin-like growth factor 1 receptor	ONCOGENE			English	Review						insulin-like growth factor 1 receptor; differentiation; cell size; cytoskeleton; transformation	GROWTH-FACTOR-I; FOCAL ADHESION KINASE; DOMINANT-NEGATIVE MUTANT; PROSTATE-CANCER CELLS; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSFORMING ACTIVITIES; SIGNALING PATHWAYS; ANTISENSE RNA; CONSTITUTIVE EXPRESSION	In recent years, the type I insulin-like growth factor receptor (IGF-IR) has emerged as a receptor that plays a very important role in the growth of cells, both in vivo and in vitro. The ability of the IGF-IR to induce mitogenesis and to promote survival of cells against a variety of apoptotic agents is well documented. Somewhat less known are other functions of the ICF-IR, like its ability to induce differentiation, to regulate cell size and to affect the organization of the cytoskeleton of cells. This review will focus on these lesser known functions of the IGF-IR, At the same time, we will emphasize how the IGF-IR can send contradictory signals, which depend on different domains of the receptor and the availability of downstream transducing molecules.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA 56309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Baserga R, 1999, CONT ENDOCRINOL, V17, P329; BASERGA R, 1985, BIOL CELL REPRODUCTI, P251; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Brown G, 1999, EXP CELL RES, V253, P511, DOI 10.1006/excr.1999.4660; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Carson JP, 1999, CANCER RES, V59, P1449; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; Comai L, 2000, CELL GROWTH DIFFER, V11, P63; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DAmbrosio C, 1996, CANCER RES, V56, P4013; Davies MA, 1999, CANCER RES, V59, P2551; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; Hongo A, 1996, ONCOGENE, V12, P1231; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lee CT, 1996, CANCER RES, V56, P3038; Leventhal PS, 1999, CONT ENDOCRINOL, V17, P425; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Liu Q, 1998, J IMMUNOL, V160, P1393; Liu XD, 1998, CANCER RES, V58, P5432; LONG L, 1995, CANCER RES, V55, P1006; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Navarro M, 1997, ENDOCRINOLOGY, V138, P5210, DOI 10.1210/en.138.12.5210; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; ROGALSKY V, 1993, BIOCHEM BIOPH RES CO, V192, P1139, DOI 10.1006/bbrc.1993.1535; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Soon L, 1999, MOL CELL BIOL, V19, P3816; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Steller MA, 1996, CANCER RES, V56, P5087; Stewart CEH, 1996, J CELL PHYSIOL, V169, P23, DOI 10.1002/(SICI)1097-4652(199610)169:1<23::AID-JCP3>3.0.CO;2-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; SURMACZ E, 1987, MOL CELL BIOL, V7, P657, DOI 10.1128/MCB.7.2.657; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VALENTINIS B, 2000, IN PRESS J BIOL CHEM; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Werner H, 1999, CONT ENDOCRINOL, V17, P63; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	109	208	225	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5574	5581		10.1038/sj.onc.1203854	http://dx.doi.org/10.1038/sj.onc.1203854			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114737				2022-12-17	WOS:000165659300004
J	Weyemi, U; Lagente-Chevallier, O; Boufraqech, M; Prenois, F; Courtin, F; Caillou, B; Talbot, M; Dardalhon, M; Al Ghuzlan, A; Bidart, JM; Schlumberger, M; Dupuy, C				Weyemi, U.; Lagente-Chevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Caillou, B.; Talbot, M.; Dardalhon, M.; Al Ghuzlan, A.; Bidart, J-M; Schlumberger, M.; Dupuy, C.			ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence	ONCOGENE			English	Article						oncogenic H-RasV12; ROS; NADPH oxidase NOX4; DNA damage; senescence	SMOOTH-MUSCLE-CELLS; REACTIVE OXYGEN; PREMATURE SENESCENCE; GENOMIC INSTABILITY; CELLULAR SENESCENCE; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MAMMALIAN-CELLS; NAD(P)H OXIDASE; TUMORIGENESIS	Activated Ras oncogene induces DNA-damage response by triggering reactive oxygen species (ROS) production and this is critical for oncogene-induced senescence. Until now, little connections between oncogene expression, ROS-generating NADPH oxidases and DNA-damage response have emerged from different studies. Here we report that H-RasV12 positively regulates the NADPH oxidase system NOX4-p22(phox) that produces H2O2. Knocking down the NADPH oxidase with small interference RNA decreases H-RasV12-induced DNA-damage response detected by gamma-H2A.X foci analysis. Using HyPer, a specific probe for H2O2, we detected an increase in H2O2 in the nucleus correlated with NOX4-p22(phox) perinuclear localization. DNA damage response can be caused not only by H-RasV12-driven accumulation of ROS but also by a replicative stress due to a sustained oncogenic signal. Interestingly, NOX4 downregulation by siRNA abrogated H-RasV12 regulation of CDC6 expression, an essential regulator of DNA replication. Moreover, senescence markers, such as senescence-associated heterochromatin foci, PML bodies, HP1 beta foci and p21 expression, induced under H-RasV12 activation were decreased with NOX4 inactivation. Taken together, our data indicate that NADPH oxidase NOX4 is a critical mediator in oncogenic H-RasV12-induced DNA-damage response and subsequent senescence. Oncogene (2012) 31, 1117-1129; doi:10.1038/onc.2011.327; published online 15 August 2011	[Weyemi, U.; Lagente-Chevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Bidart, J-M; Schlumberger, M.; Dupuy, C.] CNRS, Inst Gustave Roussy, UMR8200, F-94805 Villejuif, France; [Weyemi, U.; Lagente-Chevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Talbot, M.; Al Ghuzlan, A.; Bidart, J-M; Schlumberger, M.; Dupuy, C.] Univ Paris 11, Orsay, France; [Dardalhon, M.] CNRS, Inst Curie, Sect Rech, UMR 3348, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Dupuy, C (corresponding author), CNRS, Inst Gustave Roussy, UMR8200, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	dupuy@igr.fr	Weyemi, Urbain/E-2083-2016; Boufraqech, Myriem/E-4823-2016		Electricite de France (EDF); Association pour la Recherche sur le Cancer (ARC); Ligue Contre le Cancer (comite du Val-de Marne); Agence Nationale de la Recherche (ANR)	Electricite de France (EDF)(Electricite de France (EDF)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Ligue Contre le Cancer (comite du Val-de Marne); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR))	Urbain Weyemi is the recipient of a grant from the Fondation pour la Recherche Medicale (FRM). We are indebted to Didier Methivier from Unite U848 INSERM, Villejuif, F-94805, France for his assistance in flow cytometry. This work was supported by grants from Electricite de France (EDF), Association pour la Recherche sur le Cancer (ARC), Ligue Contre le Cancer (comite du Val-de Marne) and Agence Nationale de la Recherche (ANR).	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Anilkumar N, 2008, ARTERIOSCL THROM VAS, V28, P1347, DOI 10.1161/ATVBAHA.108.164277; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866; Boucher D, 2006, RADIAT ENVIRON BIOPH, V45, P267, DOI 10.1007/s00411-006-0070-3; Chiera F, 2008, FREE RADICAL BIO MED, V44, P332, DOI 10.1016/j.freeradbiomed.2007.09.018; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hemann MT, 2007, GENE DEV, V21, P1, DOI 10.1101/gad.1514207; Hilenski LL, 2004, ARTERIOSCL THROM VAS, V24, P677, DOI 10.1161/01.ATV.0000112024.13727.2c; Johnson DG, 2006, CURR MOL MED, V6, P731; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Kuroda J, 2005, GENES CELLS, V10, P1139, DOI 10.1111/j.1365-2443.2005.00907.x; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Lener B, 2009, BIOCHEM J, V423, P363, DOI 10.1042/BJ20090666; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Lyle AN, 2009, CIRC RES, V105, P249, DOI 10.1161/CIRCRESAHA.109.193722; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schilder YDC, 2009, FREE RADICAL BIO MED, V46, P1598, DOI 10.1016/j.freeradbiomed.2009.03.013; Serrander L, 2007, BIOCHEM J, V406, P105, DOI 10.1042/BJ20061903; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Weyemi U, 2010, ENDOCR-RELAT CANCER, V17, P27, DOI 10.1677/ERC-09-0175; Zhang L, 2008, FREE RADICAL BIO MED, V45, P679, DOI 10.1016/j.freeradbiomed.2008.05.019; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	47	207	211	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1117	1129		10.1038/onc.2011.327	http://dx.doi.org/10.1038/onc.2011.327			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21841825	Green Published, hybrid			2022-12-17	WOS:000300945900005
J	Peng, S; Maihle, NJ; Huang, Y				Peng, S.; Maihle, N. J.; Huang, Y.			Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer	ONCOGENE			English	Article						Lin28; Oct4; ovarian cancer; cancer stem cell; gene therapy; molecular diagnostics	MESSENGER-RNA; LIN-28; EXPRESSION; BIOGENESIS; SUPPRESSES; PROMOTES; MARKER	Lin28 and Oct4 are highly expressed in human embryonic stem (ES) cells and, along with two other stem cell marker proteins (Nanog and Sox2), together can convert human somatic cells to pluripotency. As an RNA-binding protein, Lin28 acts to stimulate the translation of a specific subset of mRNAs, and to inhibit the biogenesis of a group of microRNAs. Oct4 is a transcription factor essential for the maintenance of pluripotency and survival of ES cells. In this study, we report that a sub-population of epithelial ovarian cancer (EOC) cells co-expresses Lin28 and Oct4 as demonstrated in the analyses of both cell lines and patient tumor samples. We also observe that the combined expression of these proteins in tumor samples is correlated with advanced tumor grade. Intriguingly, when the expression of these two proteins is repressed in the same cells using RNA interference, there is significant reduction in cell growth and survival. We thus propose that Lin28 and Oct4 may have important roles in the initiation and/or progression of EOC, and consequently may serve as important molecular diagnostics and/or therapeutic targets for the development of novel treatment strategies in EOC patients. Oncogene (2010) 29, 2153-2159; doi: 10.1038/onc.2009.500; published online 25 January 2010	[Peng, S.; Maihle, N. J.; Huang, Y.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06510 USA; [Maihle, N. J.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Maihle, N. J.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Huang, Y (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, 310 Cedar St,LSOG 205C, New Haven, CT 06510 USA.	yingqun.huang@yale.edu			Fannie E Rippel Foundation; CT Stem Cell Grant [09SCAYALE14]; Yale School of Medicine 'Senior Women in Medicine' Professorship; NIH [CA 79808]; NATIONAL CANCER INSTITUTE [R01CA079808] Funding Source: NIH RePORTER	Fannie E Rippel Foundation; CT Stem Cell Grant; Yale School of Medicine 'Senior Women in Medicine' Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jianyu Jin for technical assistance, Jill Reiter for extracts from ovarian cancer cells and insightful scientific discussions, Philip Low and Gil Mor for cell lines and Jason Wilken for critical discussions and reading of this paper. This study was supported by the Fannie E Rippel Foundation and a CT Stem Cell Grant 09SCAYALE14 to YH, and a Yale School of Medicine 'Senior Women in Medicine' Professorship, and NIH CA 79808 to NJM.	Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Assou S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-10; BENARD J, 1985, CANCER RES, V45, P4970; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270; Cheng L, 2007, J PATHOL, V211, P1, DOI 10.1002/path.2105; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Darr H, 2009, STEM CELLS, V27, P352, DOI 10.1634/stemcells.2008-0720; Fodde R, 2009, CANCER CELL, V15, P87, DOI 10.1016/j.ccr.2009.01.011; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Jinawath N, 2009, ONCOGENE, V28, P1941, DOI 10.1038/onc.2009.37; Jordan CT, 2009, CELL STEM CELL, V4, P203, DOI 10.1016/j.stem.2009.02.003; Lu LG, 2009, EUR J CANCER, V45, P2212, DOI 10.1016/j.ejca.2009.05.003; Mlarotta LLC, 2009, CURR OPIN GENET DEV, V19, P44, DOI 10.1016/j.gde.2008.12.003; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Pei DQ, 2009, J BIOL CHEM, V284, P3365, DOI 10.1074/jbc.R800063200; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Trabucchi M, 2009, NATURE, V459, P1010, DOI 10.1038/nature08025; Vasey PA, 2008, ANN ONCOL, V19, P61, DOI 10.1093/annonc/mdn479; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Xu BS, 2009, NUCLEIC ACIDS RES, V37, P4256, DOI 10.1093/nar/gkp372; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Yang DH, 2003, GENE EXPR PATTERNS, V3, P719, DOI 10.1016/S1567-133X(03)00140-6; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang KX, 2008, RNA, V14, P577, DOI 10.1261/rna.739308; Zhang M, 2007, PLACENTA, V28, P779, DOI 10.1016/j.placenta.2007.01.012	34	207	219	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2153	2159		10.1038/onc.2009.500	http://dx.doi.org/10.1038/onc.2009.500			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101213				2022-12-17	WOS:000276402800013
J	Bailey, JM; Mohr, AM; Hollingsworth, MA				Bailey, J. M.; Mohr, A. M.; Hollingsworth, M. A.			Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; sonic hedgehog; lymphangiogenesis; metastasis	PRIMARY CILIA; N-CADHERIN; EXPRESSION; CELLS; PATHWAY; GROWTH; SHH	Sonic hedgehog (SHH) expression is tightly regulated throughout development. In the adult, aberrant expression of SHH is associated with the onset and progression of pancreatic cancer, as evidenced by increased levels of expression in premalignant and malignant lesions of the pancreas. We investigated the hypothesis that SHH, secreted from pancreatic tumors, functions in a paracrine manner to influence the biological condition of mesenchymal and endothelial cells. Orthotopic implantation of a pancreatic tumor cell line expressing SHH (Capan-2) and a transformed primary cell line that overexpresses SHH (T-HPNE.SHH) were used to show that overexpression of SHH increased primary tumor size and metastasis. Treatment with a neutralizing antibody, 5E1, decreased primary tumor volume and inhibited metastasis. Lyve-1+ vessels and stromal fibroblasts in tumors expressed primary cilium and showed localization of the receptor Smoothened to the primary cilium, providing evidence of active SHH signaling through this pathway. Although primary cilia are present on normal ductal cells of the pancreas, we did not observe primary cilium on the ductal tumor cells, suggesting decreased autocrine signaling through pathways mediated by the primary cilium in pancreatic cancer. These data support the hypothesis that SHH, secreted from pancreatic epithelia, is critical in establishing and regulating the tumor microenvironment and thereby contributes to progression of pancreatic cancer. Oncogene (2009) 28, 3513-3525; doi: 10.1038/onc.2009.220; published online 27 July 2009	[Bailey, J. M.; Mohr, A. M.; Hollingsworth, M. A.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Hollingsworth, MA (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 985950 Nebraska Med Ctr, Omaha, NE 68198 USA.	mahollin@unmc.edu		Bailey-Lundberg, Jennifer/0000-0002-4750-106X	National Institutes of Health [R01CA57362, P30CA36727, U01CA111294]; University of Nebraska [CA09476]; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA057362, T32CA009476, U01CA111294] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Nebraska; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kim McDermott for insight, comments and suggestions. We also thank Dr Rick Tempero and Dr Phil Kelley for the gift of HMVEC cells and suggestions related to their use. This work was supported by grants from the National Institutes of Health (R01CA57362, P30CA36727, U01CA111294), training grant awards to JMB and AMM (CA09476) and assistantship awards from the University of Nebraska (JMB).	Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Bailey JM, 2008, CLIN CANCER RES, V14, P5995, DOI 10.1158/1078-0432.CCR-08-0291; Cano DA, 2004, DEVELOPMENT, V131, P3457, DOI 10.1242/dev.01189; Cano DA, 2006, GASTROENTEROLOGY, V131, P1856, DOI 10.1053/j.gastro.2006.10.050; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; HEESCHEN C, 2008, J CLIN INVEST; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Hwang JM, 2008, MOL CELL BIOCHEM, V311, P179, DOI 10.1007/s11010-008-9708-6; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kawahira H, 2005, DEV BIOL, V280, P111, DOI 10.1016/j.ydbio.2005.01.008; Kayed H, 2006, PANCREAS, V32, P119, DOI 10.1097/01.mpa.0000202937.55460.0c; Lee KM, 2003, BIOCHEM BIOPH RES CO, V301, P1038, DOI 10.1016/S0006-291X(03)00086-X; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Lipinski RJ, 2006, EXP CELL RES, V312, P1925, DOI 10.1016/j.yexcr.2006.02.019; Liu MS, 2007, PANCREAS, V34, P340, DOI 10.1097/mpa.0b013e3180333ab5; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nagai S, 2008, CANCER SCI, V99, P1377, DOI 10.1111/j.1349-7006.2008.00822.x; Nagase T, 2008, ANGIOGENESIS, V11, P71, DOI 10.1007/s10456-008-9105-5; Nielsen SK, 2008, DEV DYNAM, V237, P2039, DOI 10.1002/dvdy.21610; Odent S, 1999, HUM MOL GENET, V8, P1683, DOI 10.1093/hmg/8.9.1683; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; SOLER AP, 1995, HUM PATHOL, V26, P1363, DOI 10.1016/0046-8177(95)90302-X; Straface G, 2009, J CELL MOL MED, V13, P2424, DOI 10.1111/j.1582-4934.2008.00440.x; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Tsutsumida H, 2006, CLIN CANCER RES, V12, P2976, DOI 10.1158/1078-0432.CCR-05-1197; Velcheti Vamsidhar, 2007, Med Hypotheses, V69, P948, DOI 10.1016/j.mehy.2007.02.021; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Zhang QH, 2005, LAB INVEST, V85, P45, DOI 10.1038/labinvest.3700207	40	207	230	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3513	3525		10.1038/onc.2009.220	http://dx.doi.org/10.1038/onc.2009.220			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19633682	Green Accepted			2022-12-17	WOS:000270851700001
J	Ploner, C; Kofler, R; Villunger, A				Ploner, C.; Kofler, R.; Villunger, A.			Noxa: at the tip of the balance between life and death	ONCOGENE			English	Review						apoptosis; BH3-only proteins; p53	BCL-2 FAMILY-MEMBERS; ACUTE LYMPHOBLASTIC-LEUKEMIA; BH3-ONLY PROTEIN NOXA; CELL-DEATH; PROTEASOME INHIBITION; TRIGGERS APOPTOSIS; UP-REGULATION; T-CELLS; PUMA; MCL-1	Among all Bcl2 homology domain 3 (BH3)-only proteins known to date, APR/PMAIP1/Noxa, albeit showing weak proapoptotic potential on its own, appears to be crucial in fine-tuning cell death decisions by targeting the prosurvival molecule Mcl1 for proteasomal degradation. This event appears critical for cell death induction along the mitochondrial Bcl2-regulated apoptosis pathway in response to factor deprivation or DNA damage, presumably by sensitizing the cell toward the action of additional BH3-only protein family members. This review aims to summarize the function of Noxa in normal physiology, stress-induced cell death and tumorigenesis. Oncogene (2009) 27, S84-S92; doi: 10.1038/onc.2009.46	[Villunger, A.] Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria; [Ploner, C.; Kofler, R.] Innsbruck Med Univ, Div Mol Pathophysiol, Bioctr, A-6020 Innsbruck, Austria; [Kofler, R.] Tyrolean Canc Res Inst, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at		Ploner, Christian/0000-0002-0313-2960	Austrian Science Fund (FWF) [Y212-B13 START]; Doctoral College MCBO [SFB021, P18747, P18571]; Association for International Cancer Research (AICR) [EU-FP7]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Doctoral College MCBO(Austrian Science Fund (FWF)); Association for International Cancer Research (AICR)	The work in our laboratories was supported by fellowships and grants from the Austrian Science Fund (FWF): Y212-B13 START, the Doctoral College MCBO, the SFB021, projects P18747 and P18571, the Association for International Cancer Research (AICR), EU-FP7 (ApopTrain) and the Tyrolean Science Fund (TWF). We apologize to the many scientists in this field whose excellent research was not cited but was only referred to indirectly through reviews.	Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Bauer A, 2006, P NATL ACAD SCI USA, V103, P10979, DOI 10.1073/pnas.0603625103; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Coultas L, 2002, CELL DEATH DIFFER, V9, P1163, DOI 10.1038/sj.cdd.4401096; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fei PW, 2002, CANCER RES, V62, P7316; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hallaert DYH, 2007, CELL DEATH DIFFER, V14, P1958, DOI 10.1038/sj.cdd.4402211; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Huntington ND, 2007, NAT IMMUNOL, V8, P856, DOI 10.1038/ni1487; Inoue S, 2007, LEUKEMIA, V21, P1773, DOI 10.1038/sj.leu.2404760; Jansson AK, 2003, ONCOGENE, V22, P4675, DOI 10.1038/sj.onc.1206655; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919; Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Lee SH, 2003, APMIS, V111, P599, DOI 10.1034/j.1600-0463.2003.1110602.x; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Mackus WJM, 2005, LEUKEMIA, V19, P427, DOI 10.1038/sj.leu.2403623; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; MICHALAK EM, 2009, CELL DEATH DIFFER; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; Naik E, 2007, J CELL BIOL, V176, P415, DOI 10.1083/jcb.200608070; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olejniczak ET, 2007, MOL CANCER RES, V5, P331, DOI 10.1158/1541-7786.MCR-06-0367; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang Z, 2008, ANTICANCER RES, V28, P1667; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	56	207	214	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S84	S92		10.1038/onc.2009.46	http://dx.doi.org/10.1038/onc.2009.46			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641509	Green Accepted			2022-12-17	WOS:000268566800007
J	Dotto, GP				Dotto, G. P.			Notch tumor suppressor function	ONCOGENE			English	Review						cancer stem cells; p53; p63; Rho signaling; epigenetics; keratinocytes	NF-KAPPA-B; CERVICAL-CANCER CELLS; NEGATIVE TRANSCRIPTIONAL REGULATOR; KERATINOCYTE STEM-CELLS; RBP-J-KAPPA; SIGNALING PATHWAYS; BETA-CATENIN; GROWTH ARREST; HAIR FOLLICLE; P53 HOMOLOG	Cancer development results from deregulated control of stem cell populations and alterations in their surrounding environment. Notch signaling is an important form of direct cell-cell communication involved in cell fate determination, stem cell potential and lineage commitment. The biological function of this pathway is critically context dependent. Here we review the pro-differentiation role and tumor suppressing function of this pathway, as revealed by loss-of-function in keratinocytes and skin, downstream of p53 and in cross-connection with other determinants of stem cell potential and/or tumor formation, such as p63 and Rho/CDC42 effectors. The possibility that Notch signaling elicits a duality of signals, involved in growth/differentiation control and cell survival will be discussed, in the context of novel approaches for cancer therapy.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; [Dotto, G. P.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA	University of Lausanne; Harvard University; Massachusetts General Hospital	Dotto, GP (corresponding author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	gian-paolo.dotto@unil.ch			NIH [AR39190, AR054856]; Swiss National Foundation; European Union [LSHB-CT-2005-019067]; NATIONAL CANCER INSTITUTE [R01CA073796, P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054856, R01AR039190] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	I thank Dr Cathrin Brisken for careful reading of the paper. This study was supported by NIH Grants AR39190, AR054856, the Swiss National Foundation, a grant from the European Union (Epistem, Sixth Framework Program, LSHB-CT-2005-019067).	Alimirah F, 2007, NEOPLASIA, V9, P427, DOI 10.1593/neo.07211; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; D'Errico M, 2007, MUTAT RES-FUND MOL M, V614, P37, DOI 10.1016/j.mrfmmm.2006.06.009; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Dotto GP, 2005, SCIENCE, V309, P890, DOI 10.1126/science.1117192; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Estrach S, 2008, J INVEST DERMATOL, V128, P825, DOI 10.1038/sj.jid.5701113; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hofmann M, 2004, GENE DEV, V18, P2712, DOI 10.1101/gad.1248604; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Jehn BM, 1999, J IMMUNOL, V162, P635; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kim JW, 2005, P NATL ACAD SCI USA, V102, P14308, DOI 10.1073/pnas.0501600102; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; KOLEV V, 2008, NATURE CELL BIOL; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Kunnimalaiyaan M, 2006, J BIOL CHEM, V281, P39819, DOI 10.1074/jbc.M603578200; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Laws AM, 2004, EUR J IMMUNOL, V34, P726, DOI 10.1002/eji.200324772; Lee J, 2007, DEVELOPMENT, V134, P2795, DOI 10.1242/dev.02868; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Li T, 2007, J BIOL CHEM, V282, P32264, DOI 10.1074/jbc.M703649200; Lin MH, 2000, DEVELOPMENT, V127, P2421; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MacKenzie F, 2004, J BIOL CHEM, V279, P11657, DOI 10.1074/jbc.M312102200; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Miele L, 2006, CURR CANCER DRUG TAR, V6, P313, DOI 10.2174/156800906777441771; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Moriyama M, 2008, DEV CELL, V14, P594, DOI 10.1016/j.devcel.2008.01.017; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Niimi H, 2007, J CELL BIOL, V176, P695, DOI 10.1083/jcb.200612129; Oishi K, 2004, DEV BIOL, V276, P172, DOI 10.1016/j.ydbio.2004.08.039; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Perera RJ, 2006, J CELL BIOCHEM, V98, P394, DOI 10.1002/jcb.20785; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; Sriuranpong V, 2002, MOL CELL BIOL, V22, P3129, DOI 10.1128/MCB.22.9.3129-3139.2002; Sriuranpong V, 2001, CANCER RES, V61, P3200; Talora C, 2005, EXP CELL RES, V305, P343, DOI 10.1016/j.yexcr.2005.01.015; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vauclair S, 2007, DEV CELL, V13, P242, DOI 10.1016/j.devcel.2007.06.012; Wang L, 2007, INT J GYNECOL CANCER, V17, P1283, DOI 10.1111/j.1525-1438.2007.00927.x; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinberg WC, 1999, CANCER RES, V59, P2050; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Xu XW, 2003, AM J PATHOL, V163, P969, DOI 10.1016/S0002-9440(10)63456-6; Yamamoto N, 2003, CURR BIOL, V13, P333, DOI 10.1016/S0960-9822(03)00081-2; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014; Yao J, 2007, INT J GYNECOL CANCER, V17, P502, DOI 10.1111/j.1525-1438.2007.00872.x; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; YUSPA SH, 1991, CUTANEOUS CARCINOGEN; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700; Zheng QJ, 2007, ONCOL REP, V17, P847; Zhu AJ, 1999, DEVELOPMENT, V126, P2285; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	117	207	220	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5115	5123		10.1038/onc.2008.225	http://dx.doi.org/10.1038/onc.2008.225			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758480	Green Accepted, Green Submitted			2022-12-17	WOS:000258914900005
J	De Bosscher, K; Vanden Berghe, W; Haegeman, G				De Bosscher, K.; Vanden Berghe, W.; Haegeman, G.			Cross-talk between nuclear receptors and nuclear factor kappa B	ONCOGENE			English	Review						NF-kappaB; hormone; nuclear receptor; glucocorticoid receptor; estrogen receptor; PPAR	TUMOR-NECROSIS-FACTOR; INTERLEUKIN-6 GENE-EXPRESSION; LIGAND-BINDING DOMAIN; HUMAN PROSTATE-CANCER; HISTONE ACETYLTRANSFERASE ACTIVITY; SMOOTH-MUSCLE-CELLS; RNA-POLYMERASE-II; GLUCOCORTICOID-RECEPTOR; ESTROGEN-RECEPTOR; ANDROGEN-RECEPTOR	A variety of studies have shown that some activated nuclear receptors (NRs), especially the glucorticoid receptor, the estrogen receptor and peroxisome proliferator-activated receptor, can inhibit the activity of the transcription factor nuclear factor kappa B (NF-kappa B), which plays a key role in the control of genes involved in inflammation, cell proliferation and apoptosis. This review describes the molecular mechanisms of cross-talk between NRs and NF-kappa B and the biological relevance of this crosstalk. The importance and mechanistic aspects of selective NR modulation are discussed. Also included are future research prospects, which will lead to a new era in the field of NR research with the aim of specifically inhibiting NF-kappa B-driven gene expression for anti-inflammatory, anti-tumor and immune-modulatory purposes.	Univ Ghent, Dept Biol Mol, LEGEST, B-9000 Ghent, Belgium	Ghent University	De Bosscher, K (corresponding author), Univ Ghent, Dept Biol Mol, LEGEST, B-9000 Ghent, Belgium.	karolien.debosscher@ugent.be	Berghe, Wim Vanden/S-6425-2018; Vanden Berghe, Wim/HGE-4696-2022	Berghe, Wim Vanden/0000-0003-0161-7355; De Bosscher, Karolien/0000-0001-5059-9718				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Adcock IM, 1997, BIOCHEM SOC T, V25, pS154, DOI 10.1042/bst025154s; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baek SH, 2004, BIOCHEM BIOPH RES CO, V319, P707, DOI 10.1016/j.bbrc.2004.04.169; Barnes PJ, 2006, EUR J PHARMACOL, V533, P2, DOI 10.1016/j.ejphar.2005.12.052; Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x; Bellentani S, 2005, EUR J GASTROEN HEPAT, V17, P137, DOI 10.1097/00042737-200502000-00001; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Belvisi MG, 2001, PULM PHARMACOL THER, V14, P221, DOI 10.1006/pupt.2001.0284; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Bird A, 2003, NAT IMMUNOL, V4, P208, DOI 10.1038/ni0303-208; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x; Bosisio D, 2006, EMBO J, V25, P798, DOI 10.1038/sj.emboj.7600977; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Burkhart BA, 2005, J BIOL CHEM, V280, P6349, DOI 10.1074/jbc.M411147200; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Chakalova L, 2005, NAT REV GENET, V6, P669, DOI 10.1038/nrg1673; Chandran UR, 1999, BEHAV BRAIN RES, V105, P29, DOI 10.1016/S0166-4328(99)00080-7; Chaudhary LR, 1996, J BIOL CHEM, V271, P16591, DOI 10.1074/jbc.271.28.16591; Chen JG, 2006, MOL ENDOCRINOL, V20, P1, DOI 10.1210/me.2005-0192; Cheung E, 2003, EMBO J, V22, P600, DOI 10.1093/emboj/cdg037; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; Condon JC, 2006, MOL ENDOCRINOL, V20, P764, DOI 10.1210/me.2005-0242; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; Cutolo M, 2004, AUTOIMMUN REV, V3, P193, DOI 10.1016/j.autrev.2003.08.003; Cutolo M, 2003, CLIN EXP RHEUMATOL, V21, P687; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Davie JR, 1999, J CELL BIOCHEM, P141; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; De Bosscher K, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P221; De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102; De Bosscher K, 2001, MOL ENDOCRINOL, V15, P219, DOI 10.1210/me.15.2.219; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DeFranco DB, 2000, CRIT REV EUKAR GENE, V10, P39; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; Delerive P, 2002, MOL ENDOCRINOL, V16, P1029, DOI 10.1210/me.16.5.1029; Delfino FJ, 2003, MOL CELL ENDOCRINOL, V201, P1, DOI 10.1016/S0303-7207(03)00005-4; Dijsselbloem N, 2004, BIOCHEM PHARMACOL, V68, P1171, DOI 10.1016/j.bcp.2004.05.036; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; Dutnall RN, 2003, MOL CELL, V12, P3, DOI 10.1016/S1097-2765(03)00282-X; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Eissenberg JC, 2006, CURR OPIN GENET DEV, V16, P184, DOI 10.1016/j.gde.2006.02.004; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Eun CS, 2006, DIGEST DIS SCI, V51, P693, DOI 10.1007/s10620-006-3193-0; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Fujita N, 2004, MOL ENDOCRINOL, V18, P2937, DOI 10.1210/me.2004-0258; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Glass CK, 2000, GENE DEV, V14, P121; Glyn J, 1998, J ROY SOC MED, V91, P513, DOI 10.1177/014107689809101004; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Haffner SM, 2006, J CARDIOVASC PHARM, V47, P469; Hager GL, 2000, BIOCHEM SOC T, V28, P405, DOI 10.1042/0300-5127:0280405; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Hofmann TG, 2002, BIOL CHEM, V383, P1947, DOI 10.1515/BC.2002.219; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2003, CURR OPIN PHARMACOL, V3, P192, DOI 10.1016/S1471-4892(03)00009-2; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; KIAN TM, 2004, MOL BIOL CELL, V15, P1262; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Kong EH, 2005, P NATL ACAD SCI USA, V102, P3593, DOI 10.1073/pnas.0407189102; Kwon HJ, 2004, MOL CELL BIOL, V24, P9317, DOI 10.1128/MCB.24.21.9317-9326.2004; Lanz RB, 2003, MOL CELL BIOL, V23, P7163, DOI 10.1128/MCB.23.20.7163-7176.2003; Lanz RB, 2002, P NATL ACAD SCI USA, V99, P16081, DOI 10.1073/pnas.192571399; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Leclercq G, 2006, CURR CANCER DRUG TAR, V6, P39, DOI 10.2174/156800906775471716; Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Lewis BA, 2003, J CELL SCI, V116, P3667, DOI 10.1242/jcs.00734; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Liden J, 2000, BIOCHEM BIOPH RES CO, V273, P1008, DOI 10.1006/bbrc.2000.3079; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551; Maret A, 1999, ENDOCRINOLOGY, V140, P2876, DOI 10.1210/en.140.6.2876; MARKHAM A, 1995, DRUGS, V50, P317, DOI 10.2165/00003495-199550020-00008; Martens C, 2005, MOL ENDOCRINOL, V19, P885, DOI 10.1210/me.2004-0333; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/en.143.7.2461; Meaney Michael J, 2005, Dialogues Clin Neurosci, V7, P103; Mendelson CR, 2005, J STEROID BIOCHEM, V93, P113, DOI 10.1016/j.jsbmb.2004.12.027; Metivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Miao F, 2006, MOL ENDOCRINOL, V20, P1562, DOI 10.1210/me.2005-0365; Miner JN, 2002, BIOCHEM PHARMACOL, V64, P355, DOI 10.1016/S0006-2952(02)01121-8; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miura T, 2001, J BIOL CHEM, V276, P47371, DOI 10.1074/jbc.M107098200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012; Nakajima Y, 1996, PROSTATE, V29, P296; Natoli G, 2006, CELL DEATH DIFFER, V13, P693, DOI 10.1038/sj.cdd.4401880; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Necela BM, 2003, TRENDS PHARMACOL SCI, V24, P58, DOI 10.1016/S0165-6147(02)00046-9; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; Neve BP, 2000, BIOCHEM PHARMACOL, V60, P1245, DOI 10.1016/S0006-2952(00)00430-5; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Olivier S, 2006, MOL PHARMACOL, V69, P1615, DOI 10.1124/mol.105.020479; Pacifici R, 1996, J BONE MINER RES, V11, P1043; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Paumelle R, 2006, CIRC RES, V98, P361, DOI 10.1161/01.RES.0000202706.70992.95; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Ray A, 1995, ANN NY ACAD SCI, V762, P79; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Reichardt HM, 2000, ADV PHARMACOL, V47, P1; Reily MM, 2006, EMBO J, V25, P108, DOI 10.1038/sj.emboj.7600919; Resche-Rigon M, 1998, CURR OPIN CHEM BIOL, V2, P501, DOI 10.1016/S1367-5931(98)80126-9; Robinson-Rechavi M, 2003, J CELL SCI, V116, P585, DOI 10.1242/jcs.00247; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Roux S, 1999, J BIOL CHEM, V274, P10059, DOI 10.1074/jbc.274.15.10059; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schotta Gunnar, 2004, Novartis Found Symp, V259, P22; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Sowers JR, 2003, AM J CARDIOL, V91, p14B; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stewart S, 2000, NATURE, V408, P46, DOI 10.1038/35040690; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Szyf M, 2005, FRONT NEUROENDOCRIN, V26, P139, DOI 10.1016/j.yfrne.2005.10.002; Thomassin H, 2001, EMBO J, V20, P1974, DOI 10.1093/emboj/20.8.1974; TOBLER A, 1992, BLOOD, V79, P45; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; VANDENBERGHE W, 2006, BIOCHEM PHARMACOL, DOI DOI 10.1016/J.BQ.2006.07.012; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vina J, 2005, FEBS LETT, V579, P2541, DOI 10.1016/j.febslet.2005.03.090; Wang JC, 2006, GENE DEV, V20, P689, DOI 10.1101/gad.1400506; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; Widen C, 2003, BIOCHEM J, V373, P211, DOI 10.1042/BJ20030175; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Wissink S, 2001, MOL ENDOCRINOL, V15, P543, DOI 10.1210/me.15.4.543; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu J, 2004, MOL ENDOCRINOL, V18, P53, DOI 10.1210/me.2002-0373; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Wu YL, 2005, MOL CELL, V18, P413, DOI 10.1016/j.molcel.2005.04.014; Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704; Xu W, 2003, METHOD ENZYMOL, V364, P205; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977; Zhou YM, 2005, INT J BIOCHEM CELL B, V37, P1130, DOI 10.1016/j.biocel.2004.09.006; [No title captured], DOI DOI 10.1126/STKE.2882005PE27	252	207	211	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6868	6886		10.1038/sj.onc.1209935	http://dx.doi.org/10.1038/sj.onc.1209935			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072333				2022-12-17	WOS:000241666700013
J	Helguero, LA; Faulds, MH; Gustafsson, JA; Haldosen, LA				Helguero, LA; Faulds, MH; Gustafsson, JA; Haldosen, LA			Estrogen receptors alfa (ER alpha) and beta (ER beta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11	ONCOGENE			English	Article						estrogen receptors; mammary epithelial cells; estradiol; estrogen receptor-selective ligands; proliferation; apoptosis	HUMAN BREAST-CANCER; MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; IN-VIVO; QUANTITATIVE-ANALYSIS; MOLECULAR MECHANISMS; BCL-2; PROTEIN; LIGANDS; PHENOTYPE	The mitogenic effect of 17 beta-estradiol (E2) on the breast is mediated by estrogen receptor alfa (ER alpha), hence ER alpha antagonists are effective in the treatment of breast cancer. The possible use of estrogen receptor beta (ER beta) as a target in treatment of breast cancer is under investigation. The mouse mammary cell line HC11 expresses both ERs and was used to study the role of the two receptors in proliferation. E2 had no effect on proliferation. The ER alpha-selective agonist 4,4',4''-(4- propyl-(1H)- pyrazole- 1,3,5-triyl) trisphenol (PPT) stimulated proliferation. The ER beta-selective agonist 2,3-bis(4-hydroxy-phenyl)- propionitrile (DPN) inhibited cell growth and induced apoptosis. PPT upregulated while DPN downregulated cyclin D1 and proliferating cell nuclear antigen (PCNA). Upon inhibition of ER alpha expression with RNA interference, E2 caused a decrease in cyclin D1 and PCNA, and increased apoptosis. When ER beta expression was blocked, E2 induced proliferation and cells gained the capacity to grow in soft agar. In summary, in HC11 mammary epithelial cells, ER alpha drives proliferation in response to E2 while ER beta is growth inhibitory. The lack of effect of E2 on HC11 cell growth is the result of the combined actions of ER alpha (proliferation) and ER beta (apoptosis). We suggest that use of ER beta agonists will be a useful addition in treatment of breast cancer, which, at present, is only aimed at inhibition of ER alpha.	Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden	Karolinska Institutet	Haldosen, LA (corresponding author), Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden.	lars-arne.haldosen@mednut.ki.se	Helguero, Luisa/B-1221-2013; Cruz e Silva, Odete/AAH-5595-2020	Helguero, Luisa/0000-0001-8237-2390; 				BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bocchinfuso WP, 2000, ENDOCRINOLOGY, V141, P2982, DOI 10.1210/en.141.8.2982; Clarke R, 1996, Cancer Treat Res, V87, P263; Deugnier MA, 1999, J CELL SCI, V112, P1035; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Faulds MH, 2004, MOL ENDOCRINOL, V18, P412, DOI 10.1210/me.2003-0290; Forster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fuqua SAW, 2003, CANCER RES, V63, P2434; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Imamov O, 2004, P NATL ACAD SCI USA, V101, P9375, DOI 10.1073/pnas.0403041101; Iwao K, 2000, CANCER, V89, P1732, DOI 10.1002/1097-0142(20001015)89:8<1732::AID-CNCR13>3.0.CO;2-2; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lamb CA, 2003, BREAST CANCER RES TR, V79, P25, DOI 10.1023/A:1023324827225; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Leygue E, 1998, CANCER RES, V58, P3197; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Margeat E, 2003, J MOL BIOL, V326, P77, DOI 10.1016/S0022-2836(02)01355-4; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; Omoto Y, 2003, ONCOGENE, V22, P5011, DOI 10.1038/sj.onc.1206787; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; SHYAMALA G, 1982, ENDOCRINOLOGY, V110, P1249, DOI 10.1210/endo-110-4-1249; Speirs V, 1999, CANCER RES, V59, P525; Speirs V, 2004, LANCET ONCOL, V5, P174, DOI 10.1016/S1470-2045(04)01413-5; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Vanzulli S, 2002, CARCINOGENESIS, V23, P749, DOI 10.1093/carcin/23.5.749; VisserWisselaar HA, 1997, ENDOCRINOLOGY, V138, P1180, DOI 10.1210/en.138.3.1180; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang WH, 2003, FEBS LETT, V546, P17, DOI 10.1016/S0014-5793(03)00436-8	42	207	217	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6605	6616		10.1038/sj.onc.1208807	http://dx.doi.org/10.1038/sj.onc.1208807			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007178				2022-12-17	WOS:000232367800002
J	Kiyoi, H; Ohno, R; Ueda, R; Saito, H; Naoe, T				Kiyoi, H; Ohno, R; Ueda, R; Saito, H; Naoe, T			Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain	ONCOGENE			English	Article						FLT3; receptor tyrosine kinase; juxtamembrane; internal tandem duplication; leukemia	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; C-KIT RECEPTOR; CELL-LINES; MYELODYSPLASTIC SYNDROME; MOLECULAR CHAPERONES; MYELOGENOUS LEUKEMIA; GENE; MUTATIONS; TRANSFORMATION	Internal tandem duplication (ITD) of the juxtamembrane (JM) domain of FLT3 is the most frequent mutation in human acute myeloid leukemia, and is significantly associated with leukocytosis and a poor prognosis. Previously we reported that FLT3 with ITD (FLT3/ ITD) formed a homodimer and was autophosphorylated on tyrosine residues, while the mechanism remains unclear. In this study, we elucidated the role of the JM domain in FLT3 activation. Mutant FLT3 with not only ITD but also an elongating or shortening JM domain transformed murine IL-3-dependent myeloid progenitor cell line 32D regardless of the tyrosine residues in the JM domain. These mutant FLT3s were constitutively tyrosine phosphorylated and activated signal-transduction molecules such as SHC, MAP kinase and STAT5a. Notably, co-transfection of the truncated FLT3/ITD lacking kinase and C-terminal domains with the wild type (Wt)-FLT3 into 32D cells resulted in the autonomous proliferation. In these cells, truncated FLT3/ITD generated a hetero-complex with Wt-FLT3 and Wt-FLT3 was constitutively tyrosine phosphorylated. These findings indicate that the FLT3 JM domain plays an important role in receptor activation, and that the length-mutated JM domain induces ligand-independent receptor activation but also activates Wt-FLT3 in a trans-manner.	Nagoya Univ, Sch Med, Dept Infect Dis, Showa Ku, Nagoya, Aichi 4668560, Japan; Aichi Canc Ctr Hosp, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Dept Med 2, Nagoya, Aichi 4678601, Japan; Nagoya Natl Hosp, Dept Med, Nagoya, Aichi 4600001, Japan	Nagoya University; Aichi Cancer Center; Nagoya City University	Kiyoi, H (corresponding author), Nagoya Univ, Sch Med, Dept Infect Dis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	kiyoi@med.nagoya-u.ac.jp	Naoe, Tomoki/I-1888-2012					Boissan M, 2000, J LEUKOCYTE BIOL, V67, P135, DOI 10.1002/jlb.67.2.135; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Iwai T, 1999, LEUKEMIA, V13, P38, DOI 10.1038/sj.leu.2401241; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Kiyoi H, 1999, BLOOD, V93, P3074; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Kondo M, 1999, MED PEDIATR ONCOL, V33, P525; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lam LPY, 1999, BIOCHEM J, V338, P131, DOI 10.1042/0264-6021:3380131; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Nakao M, 1996, LEUKEMIA, V10, P1911; Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Tsujimura T, 1996, PATHOL INT, V46, P933, DOI 10.1111/j.1440-1827.1996.tb03571.x; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Xu F, 1999, BRIT J HAEMATOL, V105, P155, DOI 10.1111/j.1365-2141.1999.01284.x; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, J LEUKOCYTE BIOL, V65, P372, DOI 10.1002/jlb.65.3.372; Zhao M, 2000, LEUKEMIA, V14, P374, DOI 10.1038/sj.leu.2401680	34	207	217	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2555	2563		10.1038/sj.onc.1205332	http://dx.doi.org/10.1038/sj.onc.1205332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971190				2022-12-17	WOS:000174918400012
J	Tan, C; Costello, P; Sanghera, J; Dominguez, D; Baulida, J; de Herreros, AG; Dedhar, S				Tan, C; Costello, P; Sanghera, J; Dominguez, D; Baulida, J; de Herreros, AG; Dedhar, S			Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells	ONCOGENE			English	Article						cyclin D1; E-cadherin; GSK-3; colon cancer	GLYCOGEN-SYNTHASE KINASE; CYCLIN D1; ADHESION; ACTIVATION; TARGET; CANCER; B/AKT; GENE	Loss of functional adenomatous polyposis coli (APC) protein results in the stabilization of cytosolic beta -catenin and activation of genes that are responsive to Lef/Tcf family transcription factors. We have recently shown that an independent cell adhesion and integrin linked kinase (ILK)-dependent pathway can also activate beta -catenin/LEF mediated gene transcription and downregulate E-cadherin expression. In addition, ILK activity and expression are elevated in adenomatous polyposis and colon carcinomas. To examine the role of this pathway in the background of APC mutations we inhibited ILK activity in APC-/- human colon carcinoma cell lines. In all cases, inhibition of ILK resulted in substantial inhibition of TCF mediated gene transcription and inhibition of transcription and expression of the TCF regulated gene, cyclin D1, Inhibition of ILK resulted in decreased nuclear beta-catenin expression, and in the inhibition of phosphorylation of GSK-3 and stimulation of its activity, leading to accelerated degradation of beta -catenin. In addition, inhibition of ILK suppressed cell growth in culture as well as growth of human colon carcinoma cells in SCID mice. Strikingly, inhibition of ILK also resulted in the transcriptional stimulation of E-cadherin expression and correlated with the inhibition of gene transcription of snail, a repressor of E-cadherin gene expression. Overexpression of ILK caused a stimulation of expression of snail, but snail expression was found not to be regulated by beta -catenin/ Tcf, These data demonstrate that ILK can regulate beta -catenin/TCF and snail transcription factors by distinct pathways. We propose that inhibition of ILK may be a useful strategy in the control of progression of colon as well as other carcinomas.	British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Kinetek Pharmceut Inc, Vancouver, BC V6P 6P2, Canada; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Pompeu Fabra University	Dedhar, S (corresponding author), British Columbia Canc Agcy, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808; Dominguez-Sola, David/0000-0001-9569-8402; Dedhar, Shoukat/0000-0003-4355-1657				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baulida J, 1999, BIOCHEM J, V344, P565, DOI 10.1042/0264-6021:3440565; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li FG, 1999, J CELL SCI, V112, P4589; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Popov Z, 2000, BRIT J CANCER, V83, P209; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	27	207	229	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					133	140		10.1038/sj.onc.1204052	http://dx.doi.org/10.1038/sj.onc.1204052			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244511				2022-12-17	WOS:000166361400015
J	Hart, KC; Robertson, SC; Kanemitsu, MY; Meyer, AN; Tynan, JA; Donoghue, DJ				Hart, KC; Robertson, SC; Kanemitsu, MY; Meyer, AN; Tynan, JA; Donoghue, DJ			Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4	ONCOGENE			English	Article						FGFR; transformation; Stats; signal transduction	FIBROBLAST-GROWTH-FACTOR; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; MYELOPROLIFERATIVE DISORDER FUSES; LIGAND-INDEPENDENT ACTIVATION; LETHAL SKELETAL DYSPLASIA; FACTOR RECEPTOR-3 GENE; THANATOPHORIC DYSPLASIA; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION	The fibroblast growth factor receptor (FC;FR) family members mediate a number of important cellular processes, and are mutated or overexpressed in several forms of human cancer. Mutation of Lys650 --> Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas. This mutation leads to constitutive activation of FGFR3, To compare the signaling activity of FGFR family members, this activating mutation aas generated in FGFR1, FGFR3, and FGFR I. We show that the kinase domains of FGFR1, FGFR3, and FGFR3 containing the activation loop mutation, when targeted to the plasma membrane by a myristylation signal, can transform NIH3T3 cells and induce neurite outgrowth in PC12 cells. Phosphorylation of Shp2, PLC-gamma, and MAPK was also stimulated by all three 'TDII-like' FGFR derivatives. Additionally, activation of Stat1 and Stat3 mas observed in cells expressing the activated FGFR deriVatives. Finally, we demonstrate that FGFR1, FGFR3, and FGFR4 derivatives can stimulate PI-3 kinase activity. Our comparison of these activated receptor derivatives reveals a significant overlap in the panel of effector proteins used to mediate downstream signals. This also represents the first demonstration that activation of FGFR3, in addition to FGFR1 and FGFR3, can induce cellular transformation. Moreover, our results suggest that Stat activation by FGFRs is important in their ability to act as oncogenes.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NIDCR NIH HHS [R01 DE12581] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012581] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Galvin BD, 1996, P NATL ACAD SCI USA, V93, P7894, DOI 10.1073/pnas.93.15.7894; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hart KC, 1997, ONCOGENE, V14, P945, DOI 10.1038/sj.onc.1200908; HATTORI Y, 1992, CANCER RES, V52, P3367; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOUHARA H, 1995, ONCOGENE, V10, P2315; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lin HY, 1996, J NEUROSCI, V16, P4579; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Olson DC, 1998, CELL GROWTH DIFFER, V9, P557; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; STARK KL, 1991, DEVELOPMENT, V113, P641; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEBSTER MK, 1998, GENE THER MOL BIOL, V1, P365; WILKIE AOM, 1995, CURR BIOL, V5, P500; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yoshimura N, 1998, CLIN IMMUNOL IMMUNOP, V89, P28, DOI 10.1006/clin.1998.4551; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	78	207	214	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3309	3320		10.1038/sj.onc.1203650	http://dx.doi.org/10.1038/sj.onc.1203650			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918587				2022-12-17	WOS:000088019300009
J	Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM				Sun, JZ; Qian, YM; Hamilton, AD; Sebti, SM			Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts	ONCOGENE			English	Article						Ras; farnesyltransferase; geranylgeranyltransferase; prenylation and antitumor efficacy	FARNESYL-PROTEIN TRANSFERASE; PEPTIDOMIMETIC INHIBITORS; MEMBRANE ASSOCIATION; SELECTIVE-INHIBITION; WHOLE CELLS; TRANSFORMATION; CANCER; CAAX; BLOCKS; GERANYLGERANYLATION	The ability of Ras oncoproteins to cause malignant transformation requires their post-translational modifications by prenyl groups, Because K-Ras can be both farnesylated and geranylgeranylated it is not known whether both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for suppressing human tumor growth in whole animals, In this paper we report that oncogenic Ras processing. MAP kinase activation and growth in nude mice are inhibited by the farnesyltransferase inhibitor FTI-276 in H- and N-Ras transformed NIH3T3 cells; whereas in K-B-Ras transformed NIH3T3 cells both FTI-276 and the geranylgeranyltransferase I inhibitor GGTI-297 are required for inhibition, Furthermore, human lung A-549 and Calu-1 carcinoma cell lines were found to co-express H-, N- and K-Ras, In Calu-1 cells, the processing of H- and N-Ras is inhibited greatly by FTI-276 but only partially by GGTI-297 whereas K-Ras processing inhibition requires both FTI-276 and GGTI-297, In contrast, in A-549 cells the processing of H- and N-Ras is inhibited only by FTI-276 and K-Ras processing is resistant to co-treatment with FTI-276 and GGTI-297, Yet, the growth in nude mice of A-549 and Calu-1 xenografts, both of which express K-Ras mutations, is inhibited by FTI-276 (80% inhibition) and GGTI-297 (60%). Furthermore, FTI-276 inhibits tumor growth of NIH3T3 cells transformed by a form of oncogenic H-Ras that is exclusively geranylgeranylated and whose processing is resistant to this inhibitor, Taken together, the results demonstrate that both FTase and GGTase I inhibitors are required for inhibition of K-Ras processing but that each alone is sufficient to suppress human tumor growth in nude mice.	Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ Pittsburgh, Sch Arts & Sci, Dept Chem, Pittsburgh, PA 15261 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Program, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BOS JL, 1989, CANCER RES, V49, P4682; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; Hamilton A., 1995, DRUG NEWS PERSPECT, V8, P138; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; LEBOWITZ PF, 1997, IN PRESS J BIOL CHEM; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Miquel K, 1997, CANCER RES, V57, P1846; NAGASU T, 1995, CANCER RES, V55, P5310; NIGAM M, 1993, J BIOL CHEM, V268, P20695; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIAN Y, 1994, BIOL CHEM, V269, P12410; QIAN YM, 1994, BIOORG MED CHEM LETT, V4, P2579, DOI 10.1016/S0960-894X(01)80287-0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SATLER I, 1996, REGULATION RAS SIGNA, P95; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SUN JZ, 1995, CANCER RES, V55, P4243; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	45	207	217	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1467	1473		10.1038/sj.onc.1201656	http://dx.doi.org/10.1038/sj.onc.1201656			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525745				2022-12-17	WOS:000072572400010
J	Santoro, M; Chiappetta, G; Cerrato, A; Salvatore, D; Zhang, L; Manzo, G; Picone, A; Portella, G; Santelli, G; Vecchio, G; Fusco, A				Santoro, M; Chiappetta, G; Cerrato, A; Salvatore, D; Zhang, L; Manzo, G; Picone, A; Portella, G; Santelli, G; Vecchio, G; Fusco, A			Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice	ONCOGENE			English	Article						thyroid; oncogene; tyrosine-kinase; mice	RET TYROSINE KINASE; PROTO-ONCOGENE; PROTOONCOGENE; TUMORIGENESIS; MUTATIONS; NEOPLASIA; FUSION; INVIVO; GENE; LINE	Gene rearrangements activating the RET proto-oncogene are frequently associated with human thyroid carcinomas belonging to the papillary subtype, These rearrangements cause the fusion of the tyrosine-kinase domain of RET to the 5-terminal region of different genes creating the RET/PTC chimeric oncogenes. Here we report the generation of transgenic mice lines expressing the RET/PTC1 oncogene under the control of the thyroid-specific rat thyroglobulin promoter. RET/PTC1-transgenic mice developed thyroid tumors displaying the histological aspect of papillary carcinomas. These tumors were slowly progressive and did not cause premature death of the animals. Two additional mice developed areas of thyroid hyperplasia. Immunohistochemical and reverse-transcriptase polymerase chain reaction analyses confirmed the thyroid-specific expression of the transgene. Given the frequency of activating rearrangements of RET in human papillary thyroid carcinomas we conclude that this animal system could be a good model for studying the neoplastic progression of thyroid carcinomas.	FDN SENATORE PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Santoro, M (corresponding author), UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY.		Portella, Giuseppe/AFU-6826-2022; Salvatore, Domenico/D-4881-2013; Cerrato, Aniello/AAY-1484-2020	Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769; SALVATORE, DOMENICO/0000-0002-4556-7620				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BIANCIFIORI C, 1979, 23 IARC, V2, P451; BOND JA, 1994, ONCOGENE, V9, P281; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FAGIN JA, 1992, J CLIN ENDOCR METAB, V75, P1398, DOI 10.1210/jc.75.6.1398; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hogan B., 1986, MANIPULATING MOUSE E; IWAMOTO T, 1990, ONCOGENE, V5, P535; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; LANZI C, 1992, ONCOGENE, V7, P2189; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MONACO C, 1995, INT J CANCER, V63, P757, DOI 10.1002/ijc.2910630525; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; PORTELLA G, 1989, ONCOGENE, V4, P181; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTELLI G, 1993, CANCER RES, V53, P1; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WILLIAMS DW, 1989, THYROID TUMORS MOL B; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; [No title captured]	39	207	218	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1821	1826						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622903				2022-12-17	WOS:A1996UG45800025
J	KONDO, M; SUZUKI, H; UEDA, R; OSADA, H; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T				KONDO, M; SUZUKI, H; UEDA, R; OSADA, H; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T			FREQUENT LOSS OF IMPRINTING OF THE H19 GENE IS OFTEN ASSOCIATED WITH ITS OVEREXPRESSION IN HUMAN LUNG CANCERS	ONCOGENE			English	Article						GENOMIC IMPRINTING; H19; IGF2; SNRPN; LUNG CANCER	SPORADIC WILMS-TUMOR; GROWTH FACTOR-II; DNA METHYLATION; EXPRESSION; RELAXATION; H19-GENE; ALLELES; RNA	Accumulating evidence suggests that deregulation of the insulin-like growth factor II (IGF2) and H19 genes at 11p15, due to loss of imprinting (LOI), plays a role in the oncogenesis of Wilms' tumors, We previously reported LOI of IGF2 in carcinomas of the lung, a common cancer of adults, We show here that LOI of H19 is also a frequent event in lung cancer development, and correlated with hypomethylation of the promoter region, Furthermore, the present study also revealed that overexpression of H19 is often associated with LOI of H19 in lung cancers retaining both parental alleles, showing a contrast to LOI in Wilms' tumors, Interestingly, in contrast to frequent LOI of the imprinted genes at 11p15, LOI was not observed for the remaining gene known to be imprinted in man, SNRPN at 15q12.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; 				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; JONES PA, 1986, CANCER RES, V46, P461; KONDO M, 1994, ONCOGENE, V9, P3063; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OWEN RD, 1993, CELL GROWTH DIFFER, V4, P1013; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAL N, 1990, ONCOGENE, V5, P1665; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TYCKO B, 1994, AM J PATHOL, V144, P431; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	32	207	211	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1193	1198						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700644				2022-12-17	WOS:A1995QN35300021
J	PULVERER, BJ; FISHER, C; VOUSDEN, K; LITTLEWOOD, T; EVAN, G; WOODGETT, JR				PULVERER, BJ; FISHER, C; VOUSDEN, K; LITTLEWOOD, T; EVAN, G; WOODGETT, JR			SITE-SPECIFIC MODULATION OF C-MYC COTRANSFORMATION BY RESIDUES PHOSPHORYLATED IN-VIVO	ONCOGENE			English	Article							CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3-BETA; HUMAN NEUROBLASTOMA-CELLS; CELLULAR GENE-EXPRESSION; DNA-BINDING ACTIVITY; PROTEIN-KINASE; ACTIVATES TRANSCRIPTION; NUCLEAR-LOCALIZATION; NUCLEOTIDE-SEQUENCE; RAPID INDUCTION	c-Myc is a nuclear phosphoprotein which binds DNA as a heterodimer with Max. We have identified two in vivo phosphorylation sites, Thr58 and Ser62, within a domain highly conserved among all Myc family members. Thr58 is mutated in several viral forms of the protein and constitutes a mutational hot-spot in Burkitt's lymphoma. Members of the GSK-3 and MAP kinase families, but not CKII, specifically phosphorylated these sites in vitro. The effect of these phosphorylation sites on Myc function was assessed by cotransformation of primary rat embryo fibroblasts with Pas. Mutagenesis of Thr58 to alanine potentiated focus formation, whereas substitution of Ser62 severely inhibited transformation. Mutation of both residues restored wild-type activity. These data suggest acute, post-translational modulation of Myc via phosphorylation of a conserved region previously implicated in transactivation, transformation and autorepression.	ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Imperial College London; Ludwig Institute for Cancer Research; Cancer Research UK			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BISTER K, 1980, J VIROL, V36, P617, DOI 10.1128/JVI.36.2.617-621.1980; BISTER K, 1987, ONCOGENE, V1, P97; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CROUCH DH, 1990, ONCOGENE, V5, P683; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOODE N, 1992, J BIOL CHEM, V267, P16878; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAMANN U, 1991, ONCOGENE, V6, P1745; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUO K, 1990, ONCOGENE, V5, P921; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MEEK DW, 1992, BIOCHEM J, V287, P1; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOORE JP, 1987, ONCOGENE RES, V2, P65; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAMAKRISHNA S, 1989, BIOCHEMISTRY-US, V28, P856, DOI 10.1021/bi00428a067; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SAKSELA K, 1992, ONCOGENE, V7, P347; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; SETH A, 1991, J BIOL CHEM, V266, P23521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; WATERS CM, 1991, ONCOGENE, V6, P797; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WOODGETT JR, 1989, ANAL BIOCHEM, V180, P237, DOI 10.1016/0003-2697(89)90423-5; WOODGETT JR, 1992, NEURONAL CELL LINES, P133; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	83	207	210	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					59	70						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302604				2022-12-17	WOS:A1994MW24700008
J	BARBOSA, MS; SCHLEGEL, R				BARBOSA, MS; SCHLEGEL, R			THE E6 AND E7 GENES OF HPV-18 ARE SUFFICIENT FOR INDUCING 2-STAGE INVITRO TRANSFORMATION OF HUMAN KERATINOCYTES	ONCOGENE			English	Note									NCI, TUMOR VIRUS BIOL, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BARBOSA, MS (corresponding author), NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA.				NCI NIH HHS [5T32CA09030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BARBOSA MS, 1987, J VIROL, V61, P2938, DOI 10.1128/JVI.61.9.2938-2942.1987; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DURST M, 1987, ONCOGENE, V1, P251; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HAUSEN HZ, 1987, PAPOVAVIRIDAE, V2, P245; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; LE JY, 1988, J VIROL, V62, P4420, DOI 10.1128/JVI.62.11.4420-4426.1988; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YUTSUDO M, 1988, VIROLOGY, V166, P594, DOI 10.1016/0042-6822(88)90532-6	26	207	211	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1529	1532						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2556677				2022-12-17	WOS:A1989CB65900018
J	DIPAOLO, JA; WOODWORTH, CD; POPESCU, NC; NOTARIO, V; DONIGER, J				DIPAOLO, JA; WOODWORTH, CD; POPESCU, NC; NOTARIO, V; DONIGER, J			INDUCTION OF HUMAN CERVICAL SQUAMOUS-CELL CARCINOMA BY SEQUENTIAL TRANSFECTION WITH HUMAN PAPILLOMAVIRUS-16 DNA AND VIRAL HARVEY RAS	ONCOGENE			English	Article											DIPAOLO, JA (corresponding author), NCI,DIV CANC ETIOL,BIOL LAB,BETHESDA,MD 20892, USA.		/AAB-6461-2022; /AFP-0764-2022					ADAM E, 1974, PREV MED, V3, P122, DOI 10.1016/0091-7435(74)90068-1; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ATKIN NB, 1982, CANCER GENET CYTOGEN, V7, P209, DOI 10.1016/0165-4608(82)90068-1; BANGLE R, 1963, CANCER, V16, P1151, DOI 10.1002/1097-0142(196309)16:9<1151::AID-CNCR2820160909>3.0.CO;2-D; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BRINTON LA, 1986, JAMA-J AM MED ASSOC, V255, P3265, DOI 10.1001/jama.255.23.3265; CHANG EH, 1980, J VIROL, V35, P76, DOI 10.1128/JVI.35.1.76-92.1980; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1987, ONCOGENE, V1, P251; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GISSMANN L, 1984, J INVEST DERMATOL, V83, P26; HAUSEN HZ, 1982, LANCET, V2, P1370; HAUSEN HZ, 1977, CURR TOP MICROBIOL I, V78, P1; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; KAUR K, 1988, J VIROL, V62, P1917; KAZUMITSU U, 1987, P NATL ACAD SCI USA, V84, P3004; KING JFW, 1980, NY STATE J MED, V1, P1253; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEVINE RU, 1984, OBSTET GYNECOL, V64, P16; MARTINEZ I, 1969, CANCER, V24, P777, DOI 10.1002/1097-0142(196910)24:4<777::AID-CNCR2820240418>3.0.CO;2-C; ORIEL JD, 1971, BRIT J VENER DIS, V47, P1; PETO R, 1986, BRADBURY REPORT, V21; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PRIDAN H, 1971, ISRAEL J MED SCI, V7, P1465; REEVES WC, 1987, INT J CANCER, V40, P450, DOI 10.1002/ijc.2910400403; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RIOU G, 1988, ONCOGENE, V3, P329; RIOU G, 1985, PAPILLOMAVIRUSES MOL, P47; ROTKIN ID, 1973, CANCER RES, V33, P1353; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SANDBERG AA, 1980, CHROMOSOMES HUMAN CA; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHIRASAWA H, 1987, J GEN VIROL, V68, P583, DOI 10.1099/0022-1317-68-2-583; SINGER A, 1976, AM J OBSTET GYNECOL, V126, P110, DOI 10.1016/0002-9378(76)90474-9; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VOUSDEN KH, 1988, ONCOGENE RES, V3, P1; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WOODWORTH CD, 1988, CANCER RES, V48, P4620; YUNIS JJ, 1987, SOMAT CELL MOLEC GEN, V13, P397, DOI 10.1007/BF01534938	43	207	212	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					395	399						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2541388				2022-12-17	WOS:A1989U567700001
J	Arlt, A; Sebens, S; Krebs, S; Geismann, C; Grossmann, M; Kruse, ML; Schreiber, S; Schafer, H				Arlt, A.; Sebens, S.; Krebs, S.; Geismann, C.; Grossmann, M.; Kruse, M-L; Schreiber, S.; Schaefer, H.			Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity	ONCOGENE			English	Article						chemoresistance; oxidative stress; tumorigenesis; pancreas	COMPONENTS CHLOROGENIC ACID; SIGNALING PATHWAY; OXIDATIVE STRESS; DECAFFEINATED COFFEE; ADAPTIVE RESPONSE; CARCINOMA CELLS; KEAP1 MUTATIONS; ACTIVATION; SUBUNIT; CHEMORESISTANCE	Evidence accumulates that the transcription factor nuclear factor E2-related factor 2 (Nrf2) has an essential role in cancer development and chemoresistance, thus pointing to its potential as an anticancer target and undermining its suitability in chemoprevention. Through the induction of cytoprotective and proteasomal genes, Nrf2 confers apoptosis protection in tumor cells, and inhibiting Nrf2 would therefore be an efficient strategy in anticancer therapy. In the present study, pancreatic carcinoma cell lines (Panc1, Colo357 and MiaPaca2) and H6c7 pancreatic duct cells were analyzed for the Nrf2-inhibitory effect of the coffee alkaloid trigonelline (trig), as well as for its impact on Nrf2-dependent proteasome activity and resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and anticancer drug-induced apoptosis. Chemoresistant Panc1 and Colo357 cells exhibit high constitutive Nrf2 activity, whereas chemosensitive MiaPaca2 and H6c7 cells display little basal but strong tert-butylhydroquinone (tBHQ)-inducible Nrf2 activity and drug resistance. Trig efficiently decreased basal and tBHQ-induced Nrf2 activity in all cell lines, an effect relying on a reduced nuclear accumulation of the Nrf2 protein. Along with Nrf2 inhibition, trig blocked the Nrf2-dependent expression of proteasomal genes (for example, s5a/psmd4 and alpha 5/psma5) and reduced proteasome activity in all cell lines tested. These blocking effects were absent after treatment with Nrf2 siRNA, a condition in which proteasomal gene expression and proteasome activity were already decreased, whereas siRNA against the related transcription factor Nrf1 did not affect proteasome activity and the inhibitory effect of trig. Depending on both Nrf2 and proteasomal gene expression, the sensitivity of all cell lines to anticancer drugs and TRAIL-induced apoptosis was enhanced by trig. Moreover, greater antitumor responses toward anticancer drug treatment were observed in tumor-bearing mice when receiving trig. In conclusion, representing an efficient Nrf2 inhibitor capable of blocking Nrf2-dependent proteasome activity and thereby apoptosis protection in pancreatic cancer cells, trig might be beneficial in improving anticancer therapy.	[Arlt, A.; Krebs, S.; Geismann, C.; Grossmann, M.; Kruse, M-L; Schreiber, S.; Schaefer, H.] UKSH, Lab Mol Gastroenterol & Hepatol, Dept Internal Med 1, Kiel, Germany; [Sebens, S.] Inst Expt Med, Inflammatory Carcinogenesis Res Grp, Kiel, Germany; [Schreiber, S.] UKSH, Inst Clin Mol Biol, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Dept Internal Med I, Lab Mol Gastroenterol & Hepatol, Bldg 6,UKSH Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Geismann, Claudia/AAX-8158-2021; Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Geismann, Claudia/0000-0003-0640-9256; Arlt, Alexander/0000-0002-6160-1059; Schafer, Heiner/0000-0001-6936-9090	German Research Society DFG [SCHA 677/9-1]; Sander Foundation [2010.076.1]; German Cluster of Excellence 'Inflammation-at-Interfaces'	German Research Society DFG(German Research Foundation (DFG)); Sander Foundation; German Cluster of Excellence 'Inflammation-at-Interfaces'	Technical assistance by Frauke Grohmann, Dagmar Leisner and Iris Bauer is acknowledged. The project was funded by the German Research Society DFG (SCHA 677/9-1), the Sander Foundation (2010.076.1) and the German Cluster of Excellence 'Inflammation-at-Interfaces'.	Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006; Akhdar H, 2009, EUR J CANCER, V45, P2219, DOI 10.1016/j.ejca.2009.05.017; Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Boettler U, 2011, J NUTR BIOCHEM, V22, P426, DOI 10.1016/j.jnutbio.2010.03.011; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Du ZX, 2011, J CLIN ENDOCR METAB, V96, pE763, DOI 10.1210/jc.2010-2642; Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495; Elangovan M, 2010, BIOCHEM BIOPH RES CO, V396, P425, DOI 10.1016/j.bbrc.2010.04.108; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Geismann C, 2011, INT J ONCOL, V38, P257, DOI 10.3892/ijo_00000846; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hong YB, 2010, PANCREAS, V39, P463, DOI 10.1097/MPA.0b013e3181c31314; Hu XT, 2009, ONCOL REP, V22, P1247, DOI 10.3892/or_00000561; Hu Y, 2012, MOL BIOL REP, V39, P4743, DOI 10.1007/s11033-011-1266-4; Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713; Kannan S, 2006, CANCER RES, V66, P8421, DOI 10.1158/0008-5472.CAN-06-1181; Kapeta S, 2010, J BIOL CHEM, V285, P8171, DOI 10.1074/jbc.M109.031575; Kim J, 2010, MUTAT RES-FUND MOL M, V690, P12, DOI 10.1016/j.mrfmmm.2009.09.007; Kim SK, 2008, FREE RADICAL BIO MED, V45, P537, DOI 10.1016/j.freeradbiomed.2008.05.011; Kim TH, 2011, CANCER RES, V71, P2260, DOI 10.1158/0008-5472.CAN-10-3007; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Kinch L, 2011, CANCER CELL, V20, P418, DOI 10.1016/j.ccr.2011.10.005; Konstantinopoulos PA, 2011, CANCER RES, V71, P5081, DOI 10.1158/0008-5472.CAN-10-4668; Kwak MK, 2006, BIOCHEM BIOPH RES CO, V345, P1350, DOI 10.1016/j.bbrc.2006.05.043; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Niture SK, 2009, J BIOL CHEM, V284, P13856, DOI 10.1074/jbc.M808084200; Olthof MR, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-10; Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006; Radhakrishnan SK, 2010, MOL CELL, V38, P17, DOI 10.1016/j.molcel.2010.02.029; Ren SR, 2000, ONCOGENE, V19, P1419, DOI 10.1038/sj.onc.1203462; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rho JH, 2008, J PROTEOME RES, V7, P2959, DOI 10.1021/pr8000892; Schaedler S, 2010, J BIOL CHEM, V285, P41074, DOI 10.1074/jbc.M110.145862; Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902; Shim GS, 2009, FREE RADICAL BIO MED, V47, P1619, DOI 10.1016/j.freeradbiomed.2009.09.006; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2010, ANTIOXID REDOX SIGN, V13, P1627, DOI 10.1089/ars.2010.3219; Singh S, 2010, FREE RADICAL RES, V44, P1267, DOI 10.3109/10715762.2010.507670; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Steffen J, 2010, MOL CELL, V40, P147, DOI 10.1016/j.molcel.2010.09.012; Taguchi A, 2011, CANCER CELL, V20, P289, DOI 10.1016/j.ccr.2011.08.007; van Dijk AE, 2009, DIABETES CARE, V32, P1023, DOI 10.2337/dc09-0207; Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Wang XJ, 2007, P NATL ACAD SCI USA, V104, P19589, DOI 10.1073/pnas.0709483104; Xie YM, 2010, CANCER METAST REV, V29, P687, DOI 10.1007/s10555-010-9255-y; Zhang DD, 2010, ANTIOXID REDOX SIGN, V13, P1623, DOI 10.1089/ars.2010.3301; Zhou W, 2007, MOL CELL ENDOCRINOL, V278, P52, DOI 10.1016/j.mce.2007.08.011	59	206	211	5	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4825	4835		10.1038/onc.2012.493	http://dx.doi.org/10.1038/onc.2012.493			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23108405				2022-12-17	WOS:000325274700011
J	Dimberg, LY; Anderson, CK; Camidge, R; Behbakht, K; Thorburn, A; Ford, HL				Dimberg, L. Y.; Anderson, C. K.; Camidge, R.; Behbakht, K.; Thorburn, A.; Ford, H. L.			On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics	ONCOGENE			English	Review						TRAIL; pro-apoptotic receptor agonists; apoptosis; TRAIL resistance; clinical trials	APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR; AGONISTIC MONOCLONAL-ANTIBODY; RECOMBINANT HUMAN APO2L/TRAIL; DEATH RECEPTOR 5; MEDIATED APOPTOSIS; CARCINOMA-CELLS; PHASE-I; PROTEASOME INHIBITION; SIX1 OVEREXPRESSION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies against TRAIL death receptors (DR) kill tumor cells while causing virtually no damage to normal cells. Several novel drugs targeting TRAIL receptors are currently in clinical trials. However, TRAIL resistance is a common obstacle in TRAIL-based therapy and limits the efficiency of these drugs. In this review article we discuss different mechanisms of TRAIL resistance, and how they can be predicted and therapeutically circumvented. In addition, we provide a brief overview of all TRAIL-based clinical trials conducted so far. It is apparent that although the effects of TRAIL therapy are disappointingly modest overall, a small subset of patients responds very well to TRAIL. We argue that the true potential of targeting TRAIL DRs in cancer can only be reached when we find efficient ways to select for those patients that are most likely to benefit from the treatment. To achieve this, it is crucial to identify biomarkers that can help us predict TRAIL sensitivity. Oncogene (2013) 32, 1341-1350; doi:10.1038/onc.2012.164; published online 14 May 2012	[Dimberg, L. Y.; Anderson, C. K.; Behbakht, K.; Ford, H. L.] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO 80045 USA; [Camidge, R.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA; [Thorburn, A.; Ford, H. L.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ford, HL (corresponding author), Univ Colorado, Sch Med, Dept Obstet & Gynecol, RC2,Room 3100C,MS8613, Aurora, CO 80045 USA.	heide.ford@ucdenver.edu	Camidge, David Ross/AAG-9144-2019	Behbakht, Kian/0000-0003-4793-9958	NIH [CA124545]; Department of Defense (DOD) [BC093627]; Swedish Research Council [2009-618]; DOD Ovarian Cancer Idea Award [OC06143]; Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals; NATIONAL CANCER INSTITUTE [R01CA124545] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (DOD)(United States Department of Defense); Swedish Research Council(Swedish Research CouncilEuropean Commission); DOD Ovarian Cancer Idea Award; Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to the many investigators whose important works were not cited here owing to space limitations. This work was supported by NIH Grant CA124545 (A Thorburn, K Behbakht and H Ford), Department of Defense (DOD) postdoctoral fellowship BC093627 and Swedish Research Council postdoctoral fellowship 2009-618 (L Dimberg), DOD Ovarian Cancer Idea Award OC06143 (K Behbakht), and Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals (C Anderson).	Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Bevis KS, 2010, GYNECOL ONCOL, V119, P157, DOI 10.1016/j.ygyno.2010.05.034; Bin L, 2007, J BIOL CHEM, V282, P28189, DOI 10.1074/jbc.M704210200; Blay JY, 2008, PHASE 1B OPEN LABEL; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Burns TF, 2001, J BIOL CHEM, V276, P37879; Camidge DR, 2008, EXPERT OPIN BIOL TH, V8, P1167, DOI 10.1517/14712598.8.8.1167 ; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Earel JK, 2006, CANCER RES, V66, P499, DOI 10.1158/0008-5472.CAN-05-3017; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ehrlich S, 2003, CYTOKINE, V24, P244, DOI 10.1016/S1043-4666(03)00094-2; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Fricker N, 2010, J CELL BIOL, V190, P377, DOI 10.1083/jcb.201002060; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ghiotto F, 2010, CYTOM PART A, V77A, P11, DOI 10.1002/cyto.a.20819; Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Greco FA, 2008, LUNG CANCER, V61, P82, DOI 10.1016/j.lungcan.2007.12.011; Halaas O, 2000, SCAND J IMMUNOL, V51, P244; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Herbst RS, 2010, CLIN CANCER RES, V16, P5883, DOI 10.1158/1078-0432.CCR-10-0631; Herbst RS, 2010, J CLIN ONCOL, V28, P2839, DOI 10.1200/JCO.2009.25.1991; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136; Horita H, 2009, J NEURO-ONCOL, V95, P175, DOI 10.1007/s11060-009-9914-4; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kandasamy K, 2003, CANCER RES, V63, P1712; Kanzler S, 2005, ECCO 13 EUR CANC C, P360; Karapetis CS, 2010, ASCO M, V28, P7535; Karikari CA, 2007, MOL CANCER THER, V6, P957, DOI 10.1158/1535-7163.MCT-06-0634; Kim JY, 2008, J CELL BIOCHEM, V105, P1386, DOI 10.1002/jcb.21958; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kindler, 2009, J CLIN ONCOL, V27, P4501; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee TJ, 2009, FREE RADICAL BIO MED, V46, P1639, DOI 10.1016/j.freeradbiomed.2009.03.022; Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; Logan AE, 2010, APOPTOSIS, V15, P1435, DOI 10.1007/s10495-010-0533-5; LoRusso P, 2007, J CLIN ONCOL, V25; Lu JF, 2011, MOL CANCER THER, V10, P902, DOI 10.1158/1535-7163.MCT-10-0864; MacFarlane M, 2005, CELL DEATH DIFFER, V12, P773, DOI 10.1038/sj.cdd.4401649; Makhov P, 2008, CELL DEATH DIFFER, V15, P1745, DOI 10.1038/cdd.2008.106; Martin S, 2005, CANCER RES, V65, P11447, DOI 10.1158/0008-5472.CAN-05-1494; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Mellier G, 2010, MOL ASPECTS MED, V31, P93, DOI 10.1016/j.mam.2009.12.002; Menke C, 2011, CANCER RES, V71, P1883, DOI 10.1158/0008-5472.CAN-10-2252; Menke C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014527; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Mom CH, 2009, CLIN CANCER RES, V15, P5584, DOI 10.1158/1078-0432.CCR-09-0996; Natoni A, 2007, BRIT J HAEMATOL, V139, P568, DOI 10.1111/j.1365-2141.2007.06852.x; Ng CP, 2002, MOL CANCER THER, V1, P1051; Nimmanapalli R, 2001, CANCER RES, V61, P759; Oberst A, 2010, J BIOL CHEM, V285, P16632, DOI 10.1074/jbc.M109.095083; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pacey S, 2005, J CLIN ONCOL, V23, p205S; Paz-Ares L, 2009, J CLIN ONCOL, V27; PEETERS M, 2010, GASTR CANC S ORL FL; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Petak I, 2000, CLIN CANCER RES, V6, P4119; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pop C, 2011, BIOCHEM J, V433, P447, DOI 10.1042/BJ20101738; Psahoulia FH, 2007, MOL CANCER THER, V6, P2591, DOI 10.1158/1535-7163.MCT-07-0001; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Rougier, 2009, J CLIN ONCOL, P4130; Saleh MN, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3537; Saltz, 2009, J CLIN ONCOL, V27, P4079; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Shenoy K, 2009, CANCER RES, V69, P1941, DOI 10.1158/0008-5472.CAN-08-1996; Sikic BI, 2007, J CLIN ONCOL, V25; Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289; Song JH, 2008, J BIOL CHEM, V283, P25003, DOI 10.1074/jbc.M802511200; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Soria JC, 2010, J CLIN ONCOL, V28, P1527, DOI 10.1200/JCO.2009.25.4847; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tolcher AW, 2007, J CLIN ONCOL, V25, P1390, DOI 10.1200/JCO.2006.08.8898; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Von Pawel J, 2010, J CLIN ONCOL, V28; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wakelee HA, 2010, ANN ONCOL, V21, P376, DOI 10.1093/annonc/mdp292; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiezorek J, 2010, CLIN CANCER RES, V16, P1701, DOI 10.1158/1078-0432.CCR-09-1692; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu LP, 2011, MOL CANCER THER, V10, P550, DOI 10.1158/1535-7163.MCT-10-0571; Yang JK, 2008, YONSEI MED J, V49, P19, DOI 10.3349/ymj.2008.49.1.19; Yee L, 2007, J CLIN ONCOL, V25; Yee L, 2009, J CLIN ONCOL, V27; Younes A VJ, 2005, ASH ANN M, P489; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586; Zhang LA, 2010, CLIN CANCER RES, V16, P4478, DOI 10.1158/1078-0432.CCR-10-0859; Zheng SJ, 2004, J IMMUNOL, V173, P5652, DOI 10.4049/jimmunol.173.9.5652	110	206	215	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1341	1350		10.1038/onc.2012.164	http://dx.doi.org/10.1038/onc.2012.164			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22580613	Green Accepted			2022-12-17	WOS:000316455600001
J	Chonghaile, TN; Letai, A				Chonghaile, T. Ni; Letai, A.			Mimicking the BH3 domain to kill cancer cells	ONCOGENE			English	Review						BH3 mimetic; Bcl-2; apoptosis; cancer; drug resistance and ABT-737	OUTER MITOCHONDRIAL-MEMBRANE; CHRONIC LYMPHOCYTIC-LEUKEMIA; SMALL-MOLECULE INHIBITOR; BCL-2 FAMILY PROTEINS; SURVIVAL-PROMOTING PROTEINS; MIMETIC ABT-737; CYTOCHROME-C; X-L; PROAPOPTOTIC ACTIVITY; ANTIAPOPTOTIC BCL-2	Cancer cells show deviant behavior that induces apoptotic signaling. To survive, cancer cells typically acquire changes enabling evasion of death signals. One way they do this is by increasing the expression of anti- apoptotic BCL-2 proteins. Anti-apoptotic BCL-2 family proteins antagonize death signaling by forming heterodimers with pro-death proteins. Heterodimer formation occurs through binding of the pro-apoptotic protein's BH3 domain into the hydrophobic cleft of anti- apoptotic proteins. The BH3 mimetics are small molecule antagonists of the anti- apoptotic BCL-2 members that function as competitive inhibitors by binding to the hydrophobic cleft. Under certain conditions, antagonism of antiapoptotic BCL-2 family proteins can unleash pro-death molecules in cancer cells. Thus, the BH3 mimetics are a new class of cancer drugs that specifically target a mechanism of cancer cell survival to selectively kill cancer cells. Oncogene (2009) 27, S149-S157; doi: 10.1038/onc.2009.52	[Chonghaile, T. Ni; Letai, A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Letai, A (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Dana 530B,44 Binney St, Boston, MA 02115 USA.	anthony_letai@dfci.harvard.edu	Chonghaile, Triona Ni/L-9418-2015	Chonghaile, Triona Ni/0000-0002-3041-4031	NATIONAL CANCER INSTITUTE [R01CA129974] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA129974] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Becattini B, 2004, CHEM BIOL, V11, P389, DOI 10.1016/j.chembiol.2004.02.020; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D, 2007, ONCOGENE, V26, P2374, DOI 10.1038/sj.onc.1210028; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER FE, 1994, ONCOGENE, V9, P3049; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Gibson L, 1996, ONCOGENE, V13, P665; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANADA M, 1993, BLOOD, V82, P1820; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kutuk O, 2008, CANCER RES, V68, P7985, DOI 10.1158/0008-5472.CAN-08-1418; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee EF, 2007, CELL DEATH DIFFER, V14, P1711, DOI 10.1038/sj.cdd.4402178; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MEIJERINK JPP, 1995, LEUKEMIA, V9, P1828; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1993, BLOOD, V81, P151; Mohammad RM, 2007, CLIN CANCER RES, V13, P2226, DOI 10.1158/1078-0432.CCR-06-1574; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nakashima T, 2000, CANCER RES, V60, P1229; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; O'Brien SM, 2005, J CLIN ONCOL, V23, P7697, DOI 10.1200/JCO.2005.02.4364; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OLTVAI ZN, 1993, CELL, V74, P619; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shoemaker AR, 2008, CLIN CANCER RES, V14, P3268, DOI 10.1158/1078-0432.CCR-07-4622; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Takahashi M, 2003, HEPATOL RES, V25, P192, DOI 10.1016/S1386-6346(02)00244-9; Trudel S, 2007, BLOOD, V109, P5430, DOI 10.1182/blood-2006-10-047951; Trudel S, 2007, CLIN CANCER RES, V13, P621, DOI 10.1158/1078-0432.CCR-06-1526; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogler M, 2008, CELL DEATH DIFFER, V15, P820, DOI 10.1038/cdd.2008.25; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang ZW, 2008, INT J CANCER, V123, P958, DOI 10.1002/ijc.23610; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Wilson WH, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8511; Witham J, 2007, CLIN CANCER RES, V13, P7191, DOI 10.1158/1078-0432.CCR-07-0362; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zhang LZ, 2001, AM J PHYSIOL-CELL PH, V281, pC1642, DOI 10.1152/ajpcell.2001.281.5.C1642; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	93	206	216	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S149	S157		10.1038/onc.2009.52	http://dx.doi.org/10.1038/onc.2009.52			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641500	Green Accepted			2022-12-17	WOS:000268566800013
J	Hiscott, J; Nguyen, TLA; Arguello, M; Nakhaei, P; Paz, S				Hiscott, J.; Nguyen, T-L A.; Arguello, M.; Nakhaei, P.; Paz, S.			Manipulation of the nuclear factor-kappa B pathway and the innate immune response by viruses	ONCOGENE			English	Review						NF-kappaB; innate immunity; interferons; viral evasion; Toll-like receptors	CELL LEUKEMIA-VIRUS; VESICULAR-STOMATITIS-VIRUS; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; HTLV-I TAX; INTERFERON REGULATORY FACTOR-3; RESPIRATORY SYNCYTIAL VIRUS; DOMAIN-CONTAINING ADAPTER; LONG TERMINAL REPEAT; IFN-BETA PROMOTER	Viral and microbial constituents contain specific motifs or pathogen-associated molecular patterns (PAMPs) that are recognized by cell surface-and endosome-associated Toll-like receptors (TLRs). In addition, intracellular viral double-stranded RNA is detected by two recently characterized DExD/H box RNA helicases, RIG-I and Mda-5. Both TLR-dependent and -independent pathways engage the I kappa B kinase (IKK) complex and related kinases TBK-1 and IKK epsilon. Activation of the nuclear factor kappa B (NF-kappa B) and interferon regulatory factor (IRF) transcription factor pathways are essential immediate early steps of immune activation; as a result, both pathways represent prime candidates for viral interference. Many viruses have developed strategies to manipulate NF-kappa B signaling through the use of multifunctional viral proteins that target the host innate immune response pathways. This review discusses three rapidly evolving areas of research on viral pathogenesis: the recognition and signaling in response to virus infection through TLR-dependent and -independent mechanisms, the involvement of NF-kappa B in the host innate immune response and the multitude of strategies used by different viruses to short circuit the NF-kappa B pathway.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Med & Oncol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca		Paz, Suzanne/0000-0002-0465-7144				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aizaki H, 2000, J INTERF CYTOK RES, V20, P1111, DOI 10.1089/107999000750053780; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alefantis T, 2005, J BIOMED SCI, V12, P961, DOI 10.1007/s11373-005-9026-x; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Aupperle KR, 2001, CELL IMMUNOL, V214, P54, DOI 10.1006/cimm.2002.1885; Azran I, 2005, ONCOGENE, V24, P4521, DOI 10.1038/sj.onc.1208645; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bex F, 1999, J VIROL, V73, P738, DOI 10.1128/JVI.73.1.738-745.1999; BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bossert B, 2003, J VIROL, V77, P8661, DOI 10.1128/JVI.77.16.8661-8668.2003; Bossert B, 2002, J VIROL, V76, P4287, DOI 10.1128/JVI.76.9.4287-4293.2002; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Brinkmann MM, 2006, J GEN VIROL, V87, P1047, DOI 10.1099/vir.0.81598-0; Brzozka K, 2005, J VIROL, V79, P7673, DOI 10.1128/JVI.79.12.7673-7681.2005; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Cardenas WB, 2006, J VIROL, V80, P5168, DOI 10.1128/JVI.02199-05; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Cesaire R, 2006, ONCOGENE, V25, P349, DOI 10.1038/sj.onc.1209055; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chen-Park FE, 2002, J BIOL CHEM, V277, P24701, DOI 10.1074/jbc.M200007200; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chisari FV, 2005, NATURE, V436, P930, DOI 10.1038/nature04076; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Civas A, 2006, J BIOL CHEM, V281, P4856, DOI 10.1074/jbc.M506812200; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Conzelmann KK, 2005, J VIROL, V79, P5241, DOI 10.1128/JVI.79.9.5241-5248.2005; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Donelan NR, 2004, J VIROL, V78, P11574, DOI 10.1128/JVI.78.21.11574-11582.2004; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Duyao M P, 1992, Curr Top Microbiol Immunol, V182, P421; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; Eshima N, 2003, MATH MED BIOL, V20, P29, DOI 10.1093/imammb/20.1.29; Ferran MC, 1997, J VIROL, V71, P371, DOI 10.1128/JVI.71.1.371-377.1997; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; FOY E, 2005, P NATL ACAD SCI USA, V79, P2689; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Garcia-Sastre A, 2006, EMERG INFECT DIS, V12, P44, DOI 10.3201/eid1201.051186; Garcia-Sastre A, 2004, CURR TOP MICROBIOL, V283, P249; Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P89; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Granja AG, 2006, J IMMUNOL, V176, P451, DOI 10.4049/jimmunol.176.1.451; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Grindstaff P, 2005, SEMIN NEUROL, V25, P315, DOI 10.1055/s-2005-917668; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Guo HG, 2004, J VIROL, V78, P9336, DOI 10.1128/JVI.78.17.9336-9342.2004; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He B, 2002, VIROLOGY, V303, P15, DOI 10.1006/viro.2002.1738; He ZM, 2000, CANCER RES, V60, P1845; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hengel H, 2005, TRENDS IMMUNOL, V26, P396, DOI 10.1016/j.it.2005.05.004; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; HIMES SR, 1993, ONCOGENE, V8, P3189; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hiscott J, 2006, TRENDS MOL MED, V12, P53, DOI 10.1016/j.molmed.2005.12.003; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; HUEN DS, 1995, ONCOGENE, V10, P549; Imaizumi Y, 2001, JPN J CANCER RES, V92, P1284, DOI 10.1111/j.1349-7006.2001.tb02151.x; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004; Kaisho T, 2004, MICROBES INFECT, V6, P1388, DOI 10.1016/j.micinf.2004.08.019; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kashanchi F, 2005, ONCOGENE, V24, P5938, DOI 10.1038/sj.onc.1208973; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Keller SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730; Kfoury Y, 2005, CELL DEATH DIFFER, V12, P871, DOI 10.1038/sj.cdd.4401624; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Krug RM, 2006, SCIENCE, V311, P1562, DOI 10.1126/science.1125998; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; La Rocca SA, 2005, J VIROL, V79, P7239, DOI 10.1128/JVI.79.11.7239-7247.2005; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Latz E, 2004, J ENDOTOXIN RES, V10, P406, DOI 10.1179/096805104225006525; Lee BS, 2002, J VIROL, V76, P12185, DOI 10.1128/JVI.76.23.12185-12199.2002; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; LeMosy EK, 1998, DEVELOPMENT, V125, P4045; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Lye E, 2004, J BIOL CHEM, V279, P40653, DOI 10.1074/jbc.M402666200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mamane Y, 2005, J INTERF CYTOK RES, V25, P43, DOI 10.1089/jir.2005.25.43; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Melen K, 2004, J MED VIROL, V73, P536, DOI 10.1002/jmv.20123; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Meylan E, 2006, MOL CELL, V22, P561, DOI 10.1016/j.molcel.2006.05.012; Miller K, 2004, J INTERF CYTOK RES, V24, P391, DOI 10.1089/1079990041535647; Min JY, 2006, P NATL ACAD SCI USA, V103, P7100, DOI 10.1073/pnas.0602184103; Minakhina S, 2006, ONCOGENE, V25, P6749, DOI 10.1038/sj.onc.1209940; Mink M, 2001, GENOMICS, V74, P234, DOI 10.1006/geno.2001.6548; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; MORI N, 1995, J RHEUMATOL, V22, P2049; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mosialos G, 2001, CYTOKINE GROWTH F R, V12, P259, DOI 10.1016/S1359-6101(00)00035-6; Munshi N, 1999, COLD SPRING HARB SYM, V64, P149, DOI 10.1101/sqb.1999.64.149; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nagai Y, 2004, CURR TOP MICROBIOL, V283, P197; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nicot C, 2000, AIDS RES HUM RETROV, V16, P1629, DOI 10.1089/08892220050193065; Noah DL, 2005, ADV VIRUS RES, V65, P121, DOI 10.1016/S0065-3527(05)65004-X; Nomura F, 2000, GENES CELLS, V5, P191; Nourbakhsh M, 1997, IMMUNOBIOLOGY, V198, P65, DOI 10.1016/S0171-2985(97)80027-7; Nourbakhsh M, 1999, EMBO J, V18, P6415, DOI 10.1093/emboj/18.22.6415; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; Ohno S, 2004, J GEN VIROL, V85, P2991, DOI 10.1099/vir.0.80308-0; Okamoto K, 2006, GENES CELLS, V11, P177, DOI 10.1111/j.1365-2443.2006.00927.x; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Palese P, 2006, IMMUNITY, V24, P121, DOI 10.1016/j.immuni.2006.01.007; Palosaari H, 2003, J VIROL, V77, P7635, DOI 10.1128/JVI.77.13.7635-7644.2003; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; PAZ S, 2006, IN PRESS CELL MOL BI, V52; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Pise-Masison CA, 2005, ARCH IMMUNOL THER EX, V53, P283; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Qin BY, 2005, STRUCTURE, V13, P1269, DOI 10.1016/j.str.2005.06.011; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; Quinto I, 1999, J BIOL CHEM, V274, P17567, DOI 10.1074/jbc.274.25.17567; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rodriguez CI, 2002, J VIROL, V76, P3936, DOI 10.1128/JVI.76.8.3936-3942.2002; Roof P, 2002, VIROLOGY, V296, P77, DOI 10.1006/viro.2001.1397; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schaefer TM, 2005, J IMMUNOL, V174, P992, DOI 10.4049/jimmunol.174.2.992; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schlender J, 2000, J VIROL, V74, P8234, DOI 10.1128/JVI.74.18.8234-8242.2000; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sgarbanti M, 2004, ONCOGENE, V23, P5770, DOI 10.1038/sj.onc.1207707; Shaffer JA, 2003, VIROLOGY, V315, P389, DOI 10.1016/S0042-6822(03)00537-3; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Song J, 1999, J GEN VIROL, V80, P879, DOI 10.1099/0022-1317-80-4-879; Sorokina EM, 2004, J BIOL CHEM, V279, P13469, DOI 10.1074/jbc.M305250200; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tait SWG, 2000, J BIOL CHEM, V275, P34656, DOI 10.1074/jbc.M000320200; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; tenOever BR, 2006, IMMUNITY, V24, P510, DOI 10.1016/j.immuni.2006.05.006; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Thoetkiattikul H, 2005, P NATL ACAD SCI USA, V102, P11426, DOI 10.1073/pnas.0505240102; Thornburg NJ, 2006, ONCOGENE, V25, P288, DOI 10.1038/sj.onc.1209023; Tissari J, 2005, J IMMUNOL, V174, P4289, DOI 10.4049/jimmunol.174.7.4289; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tsujimura H, 2004, J IMMUNOL, V172, P6820, DOI 10.4049/jimmunol.172.11.6820; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; Valarcher JF, 2003, J VIROL, V77, P8426, DOI 10.1128/JVI.77.15.8426-8439.2003; van Opijnen T, 2004, J VIROL, V78, P3675, DOI 10.1128/JVI.78.7.3675-3683.2004; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; Wang S, 1996, CANCER RES, V56, P4610; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Wieland SF, 2005, J VIROL, V79, P9369, DOI 10.1128/JVI.79.15.9369-9380.2005; Wu LM, 2006, J BIOL CHEM, V281, P2162, DOI 10.1074/jbc.M505903200; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; Yang K, 2006, MOL BIOL CELL, V17, P1461, DOI 10.1091/mbc.E05-09-0853; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yasui T, 2004, P NATL ACAD SCI USA, V101, P278, DOI 10.1073/pnas.2237224100; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; YOSHIDA M, 1994, LEUKEMIA, V8, pS51; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	335	206	211	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6844	6867		10.1038/sj.onc.1209941	http://dx.doi.org/10.1038/sj.onc.1209941			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072332	Green Published, Bronze			2022-12-17	WOS:000241666700012
J	Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H				Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H			Inhibition of NF-kappa B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin	ONCOGENE			English	Article						programmed cell death; DNA-damage; transcription factor; chemotherapy; anthracyclin; phyllotoxin	ALPHA-INDUCED APOPTOSIS; TOPOISOMERASE II-ALPHA; TRANSCRIPTION FACTOR; ACTIVATION; EXPRESSION; TNF; P53; RESISTANCE; CHEMOSENSITIVITY; DIFFERENTIATION	The transcription factor NF-kappaB has anti-apoptotic properties and may confer chemoresistance to cancer cells. Here, me describe human pancreatic carcinoma cell lines that differ in the responsiveness to the topoisomerase-2 inhibitors VP16 (20 muM) and doxorubicin (0.3 muM): Highly sensitive BxPC-3 and PT45-P1 cells, and Capan-1 and A818-4 cells that were almost resistant to both anti cancer drugs. VP16, but not doxorubicin, transiently induced NF-kappaB activity in all cell lines, whereas basal NF-kappaB binding was nearly undetectable in BxPc-3 and PT45-P1 cells, but rather high in Capan-1 and A818-4 cells, as demonstrated by gel-shift and luciferase assays. Treatment with various NF-kappaB inhibitors (Gliotoxin, MG132 and Sulfasalazine), or transfection with the I kappaB alpha super-repressor, strongly enhanced the apoptotic effects of VP16 or doxorubicin on resistant Capan-1 and 818-4 cells. Our results indicate that under certain conditions the resistance of pancreatic carcinoma cells to chemotherapy is due to their constitutive NF-kappaB activity rather than the transient induction of NF-kappaB by some anti-cancer drugs. Blockade of basal NF-kappaB activity by well established drugs efficiently reduces chemoresistance of pancreatic cancer cells and offers the potential for improved therapeutic strategies.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24098 Kiel, Germany; Univ Kiel, Dept Gen Surg, Res Unit Mol Oncol, D-24098 Kiel, Germany; Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, D-4630 Bochum, Germany	University of Kiel; University of Kiel; Ruhr University Bochum	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24098 Kiel, Germany.		Kalthoff, Holger/B-1618-2010; Arlt, Alexander/G-7308-2019; Schäfer, Heiner/C-1055-2011	Arlt, Alexander/0000-0002-6160-1059; 				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dingemans AMC, 1999, CLIN CANCER RES, V5, P2048; Egawa N, 1996, VIRCHOWS ARCH, V429, P59, DOI 10.1007/BF00196822; ESTIVAL A, 1992, GASTROENTEROLOGY, V103, P1851, DOI 10.1016/0016-5085(92)91444-9; FRY AM, 1991, CANCER RES, V51, P6592; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lam VT, 1999, LEUKEMIA RES, V23, P871, DOI 10.1016/S0145-2126(99)00102-2; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LONG BH, 1991, CANCER RES, V51, P5275; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; MAZO A, 1991, PANCREAS, V6, P37, DOI 10.1097/00006676-199101000-00006; McDade TP, 1999, J SURG RES, V83, P56, DOI 10.1006/jsre.1998.5560; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Ungefroren H, 1998, CANCER RES, V58, P1741; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	31	206	214	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					859	868		10.1038/sj.onc.1204168	http://dx.doi.org/10.1038/sj.onc.1204168			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314019				2022-12-17	WOS:000166924400009
J	Sternlicht, MD; Bissell, MJ; Werb, Z				Sternlicht, MD; Bissell, MJ; Werb, Z			The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter	ONCOGENE			English	Article						matrix metalloproteinases; stromelysin; TIMP; mammary carcinogenesis; epithelial-to-mesenchymal conversion	HUMAN BREAST-CANCER; ERYTHROID-POTENTIATING ACTIVITY; MESSENGER-RNA EXPRESSION; TIMP-1 TRANSGENIC MICE; TISSUE INHIBITOR; GROWTH-FACTOR; EPITHELIAL-CELLS; IN-VIVO; INTESTINAL TUMORIGENESIS; DISTANT METASTASES	Extracellular matrix-degrading matrix metalloproteinases (MMPs) ape invariably upregulated in epithelial cancers and are key agonists in angiogenesis, invasion and metastasis. Yet most MMPs are secreted not by the cancer cells themselves, but by stromal cells within and around the tumor mass. Because the stromal environment can influence tumor formation, and because MMPs can alter this environment, MMPs may also contribute to the initial stages of cancer development. Several recent studies in MMP-overexpressing and MMP-deficient mice support this possibility, but have required carcinogens or pre-existing oncogenic mutations to initiate tumorigenesis. Here we review the spontaneous development of premalignant and malignant lesions in the mammary glands of transgenic mice that express an autoactivating form of MMP3/stromelysin-1 under the control of the whey acidic protein gene promoter. These changes were absent in nontransgenic littermates and were quenched by co-expression of a human tissue inhibitor of metalloproteinases-1 (TIMP-1) transgene, Thus by altering the cellular microenvironment, stromelysin-l can act res a natural tumor promoter and enhance cancer susceptibility.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Sternlicht, MD (corresponding author), Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,HSW-1301, San Francisco, CA 94143 USA.				NCI NIH HHS [R01 CA057621-07, CA72006, R01 CA057621, P01 CA072006, CA57621, P01 CA072006-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621, P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad A, 1998, AM J PATHOL, V152, P721; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bachman KE, 1999, CANCER RES, V59, P798; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Birchmeier C, 1996, ACTA ANAT, V156, P217; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Codony-Servat J, 1999, CANCER RES, V59, P1196; Cool M, 1999, CANCER RES, V59, P2438; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GACK S, 1994, J BIOL CHEM, V269, P10363; Gilles C, 1996, BREAST JOURNAL, VOL 2, NO 1, JANUARY/FEBRUARY 1996, P83; Goss KJH, 1998, INT J CANCER, V78, P629; Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Imren S, 1996, CANCER RES, V56, P2891; Jacobs TW, 1999, NEW ENGL J MED, V340, P430, DOI 10.1056/NEJM199902113400604; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Jung K, 1997, INT J CANCER, V74, P220, DOI 10.1002/(SICI)1097-0215(19970422)74:2<220::AID-IJC14>3.0.CO;2-H; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kossakowska AE, 1996, BRIT J CANCER, V73, P1401, DOI 10.1038/bjc.1996.266; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Lindsay CK, 1997, HUM PATHOL, V28, P359, DOI 10.1016/S0046-8177(97)90136-2; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; LU XQ, 1991, CANCER RES, V51, P6231; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Lund LR, 1996, DEVELOPMENT, V122, P181; Martin DC, 1999, LAB INVEST, V79, P225; Martin DC, 1996, ONCOGENE, V13, P569; Martorana AM, 1998, CANCER RES, V58, P4970; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P; Mimori K, 1997, BRIT J CANCER, V76, P531, DOI 10.1038/bjc.1997.420; Mitsiades N., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P722; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Nemeth JA, 1996, EXP CELL RES, V224, P110, DOI 10.1006/excr.1996.0117; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Ritland SR, 1997, CANCER RES, V57, P3520; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; Shoji A, 1997, CARCINOGENESIS, V18, P2093, DOI 10.1093/carcin/18.11.2093; Soloway PD, 1996, ONCOGENE, V13, P2307; STASKUS PW, 1991, J BIOL CHEM, V266, P449; Sternlicht M., 1999, GUIDEBOOK EXTRACELLU, P503; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; URIA JA, 1994, CANCER RES, V54, P2091; Vallorosi C. J., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P721; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Willenbucher RF, 1999, AM J PATHOL, V154, P1825, DOI 10.1016/S0002-9440(10)65438-7; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; WRIGHT JH, 1994, MOL CARCINOGEN, V10, P207, DOI 10.1002/mc.2940100405; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; Zeng ZS, 1995, CLIN CANCER RES, V1, P899	98	206	214	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1102	1113		10.1038/sj.onc.1203347	http://dx.doi.org/10.1038/sj.onc.1203347			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713697	Green Submitted, Green Accepted			2022-12-17	WOS:000085796400019
J	Merlino, G; Helman, LJ				Merlino, G; Helman, LJ			Rhabdomyosarcoma - working out the pathways	ONCOGENE			English	Review						rhabdomyosarcoma; myogenesis; cell cycle regulation; terminal differentiation	HEPATOCYTE GROWTH-FACTOR; MUSCLE SATELLITE CELLS; FACTOR SCATTER FACTOR; SOFT-TISSUE SARCOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; DEPENDENT KINASE-ACTIVITY; PAX3-FKHR FUSION PROTEIN; II GENE-EXPRESSION; C-MET RECEPTOR; SKELETAL-MUSCLE	Rhabdomyosarcomas constitute a collection of childhood malignancies thought to arise as a consequence of regulatory disruption of skeletal muscle progenitor cell growth and differentiation. Our understanding of the pathogenesis of this neoplasm has recently benefited from the study of normal and malignant myogenic cells in vitro, facilitating the identification of diagnostic cytogenetic markers and the elucidation of mechanisms by which myogenesis is regulated. It is now appreciated that the delicate balance between proliferation and differentiation, mutually exclusive yet intimately associated processes, is normally controlled in large part through the action of a multitude of growth factors, whose signals are interpreted ba members of the MyoD family of helix - loop - helix proteins, and key regulatory cell cycle factors. The latter have proven to be frequent targets of mutational events that subvert myogenesis and promote the development of rhabdomyosarcoma. Although significant progress has been made in the treatment of rhabdomyosarcoma, patients presenting with metastatic disease or certain high risk features are still faced with a dismal prognosis. Only now are genetically engineered mouse models becoming available that are certain to provide fresh insights into the molecular/genetic pathways ba which rhabdomyosarcomas arise and progress, and to suggest novel avenues of therapeutic opportunity.	NCI, Mol Genet Sect, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Oncol Sect, Pediat Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merlino, G (corresponding author), NCI, Mol Genet Sect, Mol Biol Lab, NIH, Bldg 37,Room 2E24, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC008756, ZIABC008756] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Arnold HH, 1996, INT J DEV BIOL, V40, P345; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BAYANI J, 1995, PEDIATR PATHOL LAB M, V15, P831, DOI 10.3109/15513819509027020; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; Bischoff R, 1994, MYOLOGY, P97; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BrandSaberi B, 1996, DEV BIOL, V179, P303, DOI 10.1006/dbio.1996.0260; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Dagher R, 1999, Oncologist, V4, P34; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1994, CANCER RES, V54, P2869; DECHIARA A, 1993, J NATL CANCER I, V85, P152, DOI 10.1093/jnci/85.2.152; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; Dickman PS, 1997, HUM PATHOL, V28, P200, DOI 10.1016/S0046-8177(97)90107-6; Dietrich S, 1999, DEVELOPMENT, V126, P1621; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Feinberg AP, 1999, CANCER RES, V59, p1743S; FELIX CA, 1992, CANCER RES, V52, P2243; Ferracini R, 1996, ONCOGENE, V12, P1697; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gal-Levi R, 1998, BBA-MOL CELL RES, V1402, P39, DOI 10.1016/S0167-4889(97)00124-9; GALILI N, 1993, NAT GENET, V5, P30; GARSON JA, 1986, LANCET, V1, P1496; Ginsberg JP, 1998, CANCER RES, V58, P3542; GOULDING M, 1994, DEVELOPMENT, V120, P957; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Iolascon A, 1996, GENE CHROMOSOME CANC, V15, P217, DOI 10.1002/(SICI)1098-2264(199604)15:4<217::AID-GCC3>3.3.CO;2-X; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; JOHNSON SE, 1995, EXP CELL RES, V219, P449, DOI 10.1006/excr.1995.1251; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1999, CANCER RES, V59, P2217; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Keleti J, 1996, AM J PATHOL, V149, P143; Khan J, 1998, CANCER RES, V58, P5009; KHATIB ZA, 1993, CANCER RES, V53, P5535; Knudsen ES, 1998, CANCER RES, V58, P2042; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lam PYP, 1999, MOL CELL BIOL, V19, P594; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEACH FS, 1993, CANCER RES, V53, P2231; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LOH SY, 1992, BRIT J CANCER, V66, P1109, DOI 10.1038/bjc.1992.419; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maione R, 1997, BBA-REV CANCER, V1332, pM19, DOI 10.1016/S0304-419X(96)00036-4; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mandell L R, 1993, Oncology (Williston Park), V7, P71; MANDELL LR, 1993, ONCOLOGY HUNTINGT, V7, P89; MANDELL LR, 1993, ONCOLOGY HUNTINGT, V7, P84; Mansouri A, 1998, CRIT REV ONCOGENESIS, V9, P141, DOI 10.1615/CritRevOncog.v9.i2.40; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MAURER HM, 1988, CANCER-AM CANCER SOC, V61, P209, DOI 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L; Meddeb M, 1996, CYTOGENET CELL GENET, V73, P325, DOI 10.1159/000134368; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MITANI K, 1986, JPN J CANCER RES, V77, P1062; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; ROSENTHAL SM, 1991, MOL ENDOCRINOL, V5, P678, DOI 10.1210/mend-5-5-678; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STERN HM, 1995, DEVELOPMENT, V121, P3675; STOUT AP, 1946, ANN SURG, V123, P447, DOI 10.1097/00000658-194603000-00011; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, CANCER RES, V49, P6324; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; TEITZ T, 1993, P NATL ACAD SCI USA, V90, P2910, DOI 10.1073/pnas.90.7.2910; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wang W, 1998, CANCER RES, V58, P4426; Weber CO, 1854, VIRCHOWS ARCH, V7, P115, DOI [DOI 10.1007/BF01936232, 10.1007/BF01936232]; WeberHall SR, 1996, CANCER RES, V56, P3220; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XM, 1996, DEVELOPMENT, V122, P2163; Zhan S, 1998, NAT MED, V4, P559, DOI 10.1038/nm0598-559; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang LJ, 1998, DNA CELL BIOL, V17, P125, DOI 10.1089/dna.1998.17.125; Zhang LJ, 1996, CANCER RES, V56, P1367	136	206	212	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5340	5348		10.1038/sj.onc.1203038	http://dx.doi.org/10.1038/sj.onc.1203038			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498887				2022-12-17	WOS:000082808400013
J	MORRISON, BW; LEDER, P				MORRISON, BW; LEDER, P			NEU AND RAS INITIATE MURINE MAMMARY-TUMORS THAT SHARE GENETIC-MARKERS GENERALLY ABSENT IN C-MYC AND INT-2-INITIATED TUMORS	ONCOGENE			English	Article							TRANSGENIC MICE; BREAST-CANCER; RETINOIC ACID; HA-RAS; MOUSE; ONCOGENE; SEQUENCE; PROTEIN; CELLS; TUMORIGENESIS	We have previously shown that each of four activated oncogenes (c-myc, nea, ras, and int-2) can serve as transgenic initiators of morphologically distinct adenocarcinomas of the murine mammary gland. Since abnormalities of these oncogenes are found frequently in human breast cancers, such differences are of particular interest. Thus, the distinctiveness of each murine tumor type might reflect a relationship between a specific oncogene and a susceptible target cell or might reflect distinctive changes brought about by the idiosyncratic action of each oncogene. We have identified six genes (two of them novel) expressed in tumors initiated by nea, but usually absent from tumors initiated by c-myc. The expression of these genes (kappa-casein, transferrin, cellular retinol binding protein I (CRBPI), WDNM1, and the two novel ones) cannot be induced in c-myc-initiated tumors by the introduction of an activated nea oncogene nor can their expression be inhibited in nea-initiated tumors by the introduction of c-myc. Therefore, these genes appear to represent markers of a cell type preferentially transformed by neu. Further analysis reveals that the six markers are also expressed by ras-initiated mammary tumors, but not by int-2 initiated tumors suggesting that neu/ras-initiated tumors share a common cellular lineage and/or a common signal transduction pathway. Interestingly, one of the novel marker genes (Mat-8) appears to encode a cell-surface chloride channel and the other, a secreted protein with homologies to glycosyl hydrolases, both of which might be useful for the diagnosis and treatment of specific mammary tumors.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute					NCI NIH HHS [K11 CA01578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRES AC, 1994, ONCOGENE, V9, P1461; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1993, CANCER SURV, V16, P97; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; CHEN LH, 1987, J BIOL CHEM, V262, P17247; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAR TN, 1988, CANCER RES, V48, P5203; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAKALA BE, 1993, J BIOL CHEM, V28, P25803; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; MORRISON BW, 1994, HEMATOL ONCOL CLIN N, V8, P15, DOI 10.1016/S0889-8588(18)30185-0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NYIRKOS P, 1990, BIOCHEM J, V268, P265; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; ROSEN PP, 1991, BREAST DISEASES, P245; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMAS P, 1981, P NATL ACAD SCI USA, V77, P5201; THOMPSON MD, 1985, DNA-J MOLEC CELL BIO, V4, P263, DOI 10.1089/dna.1985.4.263; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	50	206	223	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3417	3426						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970700				2022-12-17	WOS:A1994PT39200002
J	Zhang, HY; Deng, T; Ge, SH; Liu, Y; Bai, M; Zhu, KG; Fan, Q; Li, JL; Ning, T; Tian, F; Li, HL; Sun, W; Ying, GG; Ba, Y				Zhang, Haiyang; Deng, Ting; Ge, Shaohua; Liu, Ying; Bai, Ming; Zhu, Kegan; Fan, Qian; Li, Jialu; Ning, Tao; Tian, Fei; Li, Hongli; Sun, Wu; Ying, Guoguang; Ba, Yi			Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7	ONCOGENE			English	Article							CELL-PROLIFERATION; CIRCULAR RNAS; BETA-CATENIN; CANCER; STABILIZATION; BIOGENESIS; DELIVERY; PROTEIN	Hepatocellular carcinoma (HCC), the major form of liver cancer, has shown increasing incidence and poor prognosis. Adipose tissue is known to function in energy storage and metabolism regulation by the secretion of adipokines. Circular RNAs (circRNAs), a novel type of noncoding RNA, have recently been recognized as key factors in tumor development, but the role of exosome circRNAs derived from adipose tissues has not been defined yet. Here, adipose-secreted circRNAs were found to regulate deubiquitination in HCC, thus facilitating cell growth. It was observed that exosome circ-deubiquitination (circ-DB) is upregulated in HCC patients with higher body fat ratios. Moreover, in vitro and in vivo studies showed that exocirc-DB promotes HCC growth and reduces DNA damage via the suppression of miR-34a and the activation of deubiquitination-related USP7. Finally, the results showed that the effects of adipose exosomes on HCC cells can be reversed by knockdown of circ-DB. These results indicate that exosome circRNAs secreted from adipocytes promote tumor growth and reduce DNA damage by suppressing miR-34a and activating the USP7/Cyclin A2 signaling pathway.	[Zhang, Haiyang; Deng, Ting; Ge, Shaohua; Liu, Ying; Bai, Ming; Zhu, Kegan; Fan, Qian; Ning, Tao; Tian, Fei; Li, Hongli; Sun, Wu; Ying, Guoguang; Ba, Yi] Tianjin Med Univ, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Canc Inst & Hosp,Tianjins Clin Res Ctr Canc, Tianjin 300060, Peoples R China; [Li, Jialu] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Shanghai Inst Digest Dis, Sch Med,Renji Hosp, Shanghai 200001, Peoples R China; [Li, Jialu] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, Sch Med,Renji Hosp, Shanghai 200001, Peoples R China	Tianjin Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Ying, GG; Ba, Y (corresponding author), Tianjin Med Univ, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Canc Inst & Hosp,Tianjins Clin Res Ctr Canc, Tianjin 300060, Peoples R China.	yingguoguang163@163.com; bayi@tjmuch.com	li, jia/GVT-7587-2022	ying, guoguang/0000-0002-9563-991X	National Natural Science Foundation of China [81772629, 81772843, 81702431, 81702275, 81702437, 81602158, 81602156]; Individualized Medical Platform of National Clinical Research Center for Cancer [13ZCZCSY20300]; Demonstrative research platform of clinical evaluation technology for new anticancer drugs [2018ZX09206004]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-017, 2017-I2M-BR-13]; Nature Science Foundation of Tianjin City [16PTSYJC00170]; Science& Technology Development fund of Tianjin Education Commission for Higher Education [2018KJ046]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Individualized Medical Platform of National Clinical Research Center for Cancer; Demonstrative research platform of clinical evaluation technology for new anticancer drugs; CAMS Innovation Fund for Medical Sciences (CIFMS); Nature Science Foundation of Tianjin City; Science& Technology Development fund of Tianjin Education Commission for Higher Education	This work was supported by National Natural Science Foundation of China (Nos. 81772629, 81772843, 81702431, 81702275, 81702437, 81602158, and 81602156), Individualized Medical Platform of National Clinical Research Center for Cancer (13ZCZCSY20300) and Demonstrative research platform of clinical evaluation technology for new anticancer drugs (No. 2018ZX09206004). This study was also supported by CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-017 and 2017-I2M-B&R-13), Nature Science Foundation of Tianjin City (16PTSYJC00170) and the Science& Technology Development fund of Tianjin Education Commission for Higher Education (2018KJ046). The funders had no role in study design, collection, analysis, or interpretation of the data, in the writing of the report, or in the decision to submit this article for publication.	Aspichueta P, 2018, GUT, V67, P1376, DOI 10.1136/gutjnl-2018-316047; Axley P, 2018, J CLIN TRANSL HEPATO, V6, P79, DOI 10.14218/JCTH.2017.00067; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Carra G, 2017, ONCOTARGET, V8, P35508, DOI 10.18632/oncotarget.16348; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Colleran A, 2013, P NATL ACAD SCI USA, V110, P618, DOI 10.1073/pnas.1208446110; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Coombs N, 2011, INT J MED MICROBIOL, V301, P213, DOI 10.1016/j.ijmm.2010.09.004; Deng XJ, 2018, EXP THER MED, V15, P3705, DOI 10.3892/etm.2018.5920; Dong L, 2018, ONCOGENE, V37, P2702, DOI 10.1038/s41388-018-0137-z; Farooqi AA, 2018, BIOTECHNOL ADV, V36, P328, DOI 10.1016/j.biotechadv.2017.12.010; Felicetti F, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0811-2; Gan L, 2018, BBA-REV CANCER, V1869, P97, DOI 10.1016/j.bbcan.2017.12.006; Gopinathan L, 2014, CANCER RES, V74, P3870, DOI 10.1158/0008-5472.CAN-13-3440; Hagstrom H, 2018, GUT, V67, P1536, DOI 10.1136/gutjnl-2016-313622; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Ji Q, 2018, ONCOL LETT, V15, P23, DOI 10.3892/ol.2017.7348; Li SS, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0579-3; Lv T, 2018, BIOCHEM CELL BIOL, V96, P663, DOI 10.1139/bcb-2018-0031; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Morra F, 2017, ONCOTARGET, V8, P31815, DOI 10.18632/oncotarget.16463; Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072; Palmer C, 2010, GUT, V59, P397, DOI 10.1136/gut.2008.165316; Petruzziello Arnolfo, 2018, Open Virol J, V12, P26, DOI 10.2174/1874357901812010026; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Schmittgen TD, 2008, METHODS, V44, P31, DOI 10.1016/j.ymeth.2007.09.006; Sun L, 2016, CYTOTHERAPY, V18, P413, DOI 10.1016/j.jcyt.2015.11.018; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang Q, 2016, J CLIN INVEST, V126, P2205, DOI 10.1172/JCI85747; Wei Y, 2016, MOLECULES, V21, DOI 10.3390/molecules21060777; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Yin Y, 2014, CELL RES, V24, P1164, DOI 10.1038/cr.2014.121; Yu B, 2016, SCI REP-UK, V6, DOI 10.1038/srep34562; Zhang C, 2016, INT J BIOCHEM CELL B, V79, P209, DOI 10.1016/j.biocel.2016.08.025; Zhang HY, 2016, CANCER LETT, V375, P331, DOI 10.1016/j.canlet.2016.03.026; Ziogas IA, 2017, WORLD J GASTRO SURG, V9, P233, DOI 10.4240/wjgs.v9.i12.233	39	205	218	11	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2844	2859		10.1038/s41388-018-0619-z	http://dx.doi.org/10.1038/s41388-018-0619-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30546088	Green Published, hybrid			2022-12-17	WOS:000464121600013
J	Pang, MF; Georgoudaki, AM; Lambut, L; Johansson, J; Tabor, V; Hagikura, K; Jin, Y; Jansson, M; Alexander, JS; Nelson, CM; Jakobsson, L; Betsholtz, C; Sunds, M; Karlsson, MCI; Fuxe, J				Pang, M-F; Georgoudaki, A-M; Lambut, L.; Johansson, J.; Tabor, V.; Hagikura, K.; Jin, Y.; Jansson, M.; Alexander, J. S.; Nelson, C. M.; Jakobsson, L.; Betsholtz, C.; Sunds, M.; Karlsson, M. C. I.; Fuxe, J.			TGF-beta 1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CHEMOKINE RECEPTOR 7; NF-KAPPA-B; TGF-BETA; ENDOTHELIAL-CELLS; NODE METASTASIS; VESSEL INVASION; STEM-CELLS; INFLAMMATION; EXPRESSION	Tumor cells frequently disseminate through the lymphatic system during metastatic spread of breast cancer and many other types of cancer. Yet it is not clear how tumor cells make their way into the lymphatic system and how they choose between lymphatic and blood vessels for migration. Here we report that mammary tumor cells undergoing epithelial-mesenchymal transition (EMT) in response to transforming growth factor-beta (TGF-beta 1) become activated for targeted migration through the lymphatic system, similar to dendritic cells (DCs) during inflammation. EMT cells preferentially migrated toward lymphatic vessels compared with blood vessels, both in vivo and in 3D cultures. A mechanism of this targeted migration was traced to the capacity of TGF-beta 1 to promote CCR7/CCL21-mediated crosstalk between tumor cells and lymphatic endothelial cells. On one hand, TGF-beta 1 promoted CCR7 expression in EMT cells through p38 MAP kinase-mediated activation of the JunB transcription factor. Blockade of CCR7, or treatment with a p38 MAP kinase inhibitor, reduced lymphatic dissemination of EMT cells in syngeneic mice. On the other hand, TGF-beta 1 promoted CCL21 expression in lymphatic endothelial cells. CCL21 acted in a paracrine fashion to mediate chemotactic migration of EMT cells toward lymphatic endothelial cells. The results identify TGF-beta 1-induced EMT as a mechanism, which activates tumor cells for targeted, DC-like migration through the lymphatic system. Furthermore, it suggests that p38 MAP kinase inhibition may be a useful strategy to inhibit EMT and lymphogenic spread of tumor cells.	[Pang, M-F; Lambut, L.; Johansson, J.; Tabor, V.; Hagikura, K.; Jin, Y.; Jakobsson, L.; Betsholtz, C.; Fuxe, J.] Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, SE-17177 Stockholm, Sweden; [Pang, M-F; Nelson, C. M.] Princeton Univ, Dept Chem & Biol Engn, Princeton, NJ 08544 USA; [Georgoudaki, A-M; Karlsson, M. C. I.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden; [Hagikura, K.] Nihon Univ, Sch Med, Div Cell Regenerat & Transplantat, Dept Funct Morphol, Tokyo, Japan; [Jansson, M.; Sunds, M.] Umea Univ, Dept Surg & Perioperat Sci Surg, Umea, Sweden; [Alexander, J. S.] Louisiana State Univ, Dept Mol & Cellular Physiol, Hlth Sci Ctr, Shreveport, LA 71105 USA	Karolinska Institutet; Princeton University; Karolinska Institutet; Nihon University; Umea University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Fuxe, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, SE-17177 Stockholm, Sweden.	jonas.fuxe@ki.se	Nelson, Celeste/AAT-7612-2021; Fuxe, Jonas/T-4433-2017; Georgoudaki, Anna-Maria/AAM-9829-2020; Jakobsson, Lars/B-4200-2011	Nelson, Celeste/0000-0001-9973-8870; Fuxe, Jonas/0000-0003-4576-9377; Jakobsson, Lars/0000-0001-7956-587X; Jin, Yi/0000-0001-9704-973X	Swedish Research Council; Swedish Cancer Society; Strategic Cancer Programme at Karolinska Institutet; Nordic Cancer Foundation; Swedish Childhood Cancer Foundation; Stockholm County Council/Karolinska Institutet; Nilsson-Ehle donation; Robert Lundberg foundation; Swedish Society for Medical Research (SSMF); Swedish Medical Society; Magnus Bergvall foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Strategic Cancer Programme at Karolinska Institutet; Nordic Cancer Foundation; Swedish Childhood Cancer Foundation(European Commission); Stockholm County Council/Karolinska Institutet(Stockholm County Council); Nilsson-Ehle donation; Robert Lundberg foundation; Swedish Society for Medical Research (SSMF); Swedish Medical Society; Magnus Bergvall foundation	We thank Drs Carl-Henrik Heldin and Marene Landstrom at the Ludwig Institute for Cancer Research (Uppsala, Sweden) and Dr Lars Holmgren at the Karolinska Institutet (Stockholm, Sweden) for valuable input on the results. We thank Dr Lena Claesson-Welsh at Uppsala University and Dr Jonathan S Alexander (Louisiana State University Health Sciences Center, Shreveport, Louisiana) for providing the lymphatic endothelial cells. We also thank Dr Seonghyang SOHN (Department of Microbiology School of Medicine, Suwon, Korea) for providing the CCL21 construct. JF was supported by project grants from the Swedish Research Council, the Swedish Cancer Society, The Strategic Cancer Programme at Karolinska Institutet, the Nordic Cancer Foundation and the Swedish Childhood Cancer Foundation. M-FP was supported by a PhD fellowship (KID-funding) from Stockholm County Council/Karolinska Institutet, by the Nilsson-Ehle donation, The Robert Lundberg foundation and the Swedish Society for Medical Research (SSMF). MCIK was supported by the Swedish Research Council, the Swedish Cancer Society, the Swedish Medical Society and the Magnus Bergvall foundation. VT was supported by the Swedish Cancer Society.	Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554; Biswas S, 2014, BREAST CANCER RES TR, V143, P265, DOI 10.1007/s10549-013-2811-8; Chladkova B, 2011, J CELL MOL MED, V15, P938, DOI 10.1111/j.1582-4934.2010.01066.x; Chod J, 2008, EUR J GYNAECOL ONCOL, V29, P613; Choi B, 2013, IMMUNOBIOLOGY, V218, P579, DOI 10.1016/j.imbio.2012.07.003; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cote SC, 2009, MOL IMMUNOL, V46, P2682, DOI 10.1016/j.molimm.2008.08.269; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cunningham HD, 2010, TRANSL ONCOL, V3, P354, DOI 10.1593/tlo.10178; DALAL BI, 1993, AM J PATHOL, V143, P381; Davidson B, 2006, GYNECOL ONCOL, V102, P453, DOI 10.1016/j.ygyno.2006.01.034; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Esteva FJ, 2004, CANCER-AM CANCER SOC, V100, P499, DOI 10.1002/cncr.11940; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; Fuxe J, 2012, SEMIN CANCER BIOL, V22, P455, DOI 10.1016/j.semcancer.2012.05.004; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Issa A, 2009, CANCER RES, V69, P349, DOI 10.1158/0008-5472.CAN-08-1875; Johansson J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00003; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lappin MB, 1999, IMMUNOLOGY, V98, P181; LAURIA R, 1995, CANCER-AM CANCER SOC, V76, P1772, DOI 10.1002/1097-0142(19951115)76:10<1772::AID-CNCR2820761014>3.0.CO;2-O; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Mburu YK, 2012, J BIOL CHEM, V287, P3581, DOI 10.1074/jbc.M111.294876; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shields JD, 2007, CANCER CELL, V11, P526, DOI 10.1016/j.ccr.2007.04.020; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Van den Eynden GG, 2006, BRIT J CANCER, V94, P1643, DOI 10.1038/sj.bjc.6603152; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	47	205	211	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					748	760		10.1038/onc.2015.133	http://dx.doi.org/10.1038/onc.2015.133			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961925	hybrid, Green Published			2022-12-17	WOS:000370331300008
J	Lin, T; Ponn, A; Hu, X; Law, BK; Lu, J				Lin, T.; Ponn, A.; Hu, X.; Law, B. K.; Lu, J.			Requirement of the histone demethylase LSD1 in Snail-mediated transcriptional repression during epithelial-mesenchymal transition	ONCOGENE			English	Article						EMT; E-cadherin; Snail; histone modifications; LSD1; bivalent	E-CADHERIN REPRESSION; LYSINE DEMETHYLASES; TUMOR PROGRESSION; GENE-EXPRESSION; CHROMATIN; PROTEIN; DIFFERENTIATION; METHYLATION; DISEASE; COMPLEX	Epithelial-mesenchymal transition (EMT) has pivotal roles during embryonic development and carcinoma progression. Members of the Snai1 family of zinc finger transcription factors are central mediators of EMT and induce EMT in part by directly repressing epithelial markers such as E-cadherin, a gatekeeper of the epithelial phenotype and a suppressor of tumor invasion. However, the molecular mechanism underlying Snai1-mediated transcriptional repression remains incompletely understood. Here we show that Snai1 physically interacts with and recruits the histone demethylase LSD1 (KDM1A) to epithelial gene promoters. LSD1 removes dimethylation of lysine 4 on histone H3 (H3K4m2), a covalent histone modification associated with active chromatin. Importantly, LSD1 is essential for Snai1-mediated transcriptional repression and for maintenance of the silenced state of Snai1 target genes in invasive cancer cells. In the absence of LSD1, Snai1 fails to repress E-cadherin. In cancer cells in which E-cadherin is silenced, depletion of LSD1 results in partial de-repression of epithelial genes and elevated H3K4m2 levels at the E-cadherin promoter. These results underline the critical role of LSD1 in Snai1-dependent transcriptional repression of epithelial markers and suggest that the LSD1 complex could be a potential therapeutic target for prevention of EMT-associated tumor invasion. Oncogene (2010) 29, 4896-4904; doi: 10.1038/onc.2010.234; published online 21 June 2010	[Lin, T.; Ponn, A.; Hu, X.; Lu, J.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Law, B. K.] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Hu, X.] Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Jilin University	Lu, J (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, POB 103633, Gainesville, FL 32610 USA.	jrlu@ufl.edu	Lin, Tong/G-4105-2012; Law, Brian/L-6043-2019; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	Stop! Children's Cancer, Florida Bankhead-Coley Cancer Research Program [09BN-12-23092]; The National Cancer Institute [R01CA137021]; University of Florida, Gainesville, FL, USA; NATIONAL CANCER INSTITUTE [R01CA137021] Funding Source: NIH RePORTER	Stop! Children's Cancer, Florida Bankhead-Coley Cancer Research Program; The National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Florida, Gainesville, FL, USA(University of Florida); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate technical assistance from Linbao Ai and Heiman Wang. We are grateful to Mien-Chie Hung (MD Anderson Cancer Center, Texas, USA), M Angela Nieto (Instituto de Neurociencias CSIC-UMH, Spain), Suming Huang, Yi Qiu and Lizi Wu for kindly providing reagents. We thank Mike Kilberg and Jorg Bungert for critical reading of the paper. This study was supported by grants to JL from Stop! Children's Cancer, Florida Bankhead-Coley Cancer Research Program (09BN-12-23092), The National Cancer Institute (R01CA137021) and to AP from the University Scholars Program at University of Florida, Gainesville, FL, USA.	Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hajra KM, 2002, CANCER RES, V62, P1613; Hay ED, 1995, ACTA ANAT, V154, P8; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	33	205	219	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4896	4904		10.1038/onc.2010.234	http://dx.doi.org/10.1038/onc.2010.234			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562920	Green Accepted			2022-12-17	WOS:000281578700004
J	Menon, SG; Goswami, PC				Menon, S. G.; Goswami, P. C.			A redox cycle within the cell cycle: ring in the old with the new	ONCOGENE			English	Review						redox; antioxidant enzymes; cell cycle; cyclin D1; MnSOD	UBIQUITIN-CONJUGATING ENZYMES; DENSITY-DEPENDENT REGULATION; NORMAL HUMAN FIBROBLASTS; TOPOISOMERASE-II-ALPHA; GROWTH-FACTOR RECEPTOR; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; PROTEIN-KINASE	In recent years, the intracellular oxidation-reduction ( redox) state has gained increasing attention as a critical mediator of cell signaling, gene expression changes and proliferation. This review discusses the evidence for a redox cycle ( i. e., fluctuation in the cellular redox state) regulating the cell cycle. The presence of redox-sensitive motifs ( cysteine residues, metal co-factors in kinases and phosphatases) in several cell cycle regulatory proteins indicate periodic oscillations in intracellular redox state could play a central role in regulating progression from G(0)/G(1) to S to G(2) and M cell cycle phases. Fluctuations in the intracellular redox state during cell cycle progression could represent a fundamental mechanism linking oxidative metabolic processes to cell cycle regulatory processes. Proliferative disorders are central to a variety of human pathophysiological conditions thought to involve oxidative stress. Therefore, a more complete understanding of redox control of the cell cycle could provide a biochemical rationale for manipulating aberrant cell proliferation.	Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Med Labs, Iowa City, IA 52242 USA	University of Iowa	Goswami, PC (corresponding author), Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Med Labs, B180,500 Newton Rd, Iowa City, IA 52242 USA.	prabhat-goswami@uiowa.edu	Menon, Sarita/B-5609-2012	Goswami, Prabhat/0000-0002-5700-2096; Menon, Sarita/0000-0001-9548-149X	NCI NIH HHS [CA 111365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bloomfield G, 2003, J CELL SCI, V116, P3387, DOI 10.1242/jcs.00649; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; Burch PM, 2005, ANTIOXID REDOX SIGN, V7, P741, DOI 10.1089/ars.2005.7.741; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; BURDON RH, 1990, FREE RADICAL RES COM, V11, P65, DOI 10.3109/10715769009109669; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; BURDON RH, 1989, FREE RADICAL RES COM, V7, P149, DOI 10.3109/10715768909087937; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Conour JE, 2004, PHYSIOL GENOMICS, V18, P196, DOI 10.1152/physiolgenomics.00058.2004; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; DeYulia GJ, 2005, P NATL ACAD SCI USA, V102, P5044, DOI 10.1073/pnas.0501154102; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DI MASCIO P, 1991, AM J CLIN NUTR, V53, pS194, DOI 10.1093/ajcn/53.1.194S; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; FOLZ RJ, 1994, GENOMICS, V22, P162, DOI 10.1006/geno.1994.1357; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Goswami PC, 2000, J BIOL CHEM, V275, P38384, DOI 10.1074/jbc.M005298200; GRANA X, 1995, ONCOGENE, V11, P211; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; Havre PA, 2002, CANCER RES, V62, P1443; Humphries KM, 2005, J BIOL CHEM, V280, P2750, DOI 10.1074/jbc.M410242200; Hutter DE, 1997, EXP CELL RES, V232, P435, DOI 10.1006/excr.1997.3527; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JANSSEN YMW, 1995, CANCER RES, V55, P2085; Jonas CR, 2002, FREE RADICAL BIO MED, V33, P1499, DOI 10.1016/S0891-5849(02)01081-X; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; KAWAMURA N, 1960, EXP CELL RES, V20, P127, DOI 10.1016/0014-4827(60)90229-9; Kim KY, 2001, J BIOL CHEM, V276, P40591, DOI 10.1074/jbc.M100975200; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Kyaw M, 2004, J PHARMACOL SCI, V95, P483, DOI 10.1254/jphs.SC0040061; Laurent A, 2005, CANCER RES, V65, P948; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; Liberto M, 2000, CANCER LETT, V154, P151, DOI 10.1016/S0304-3835(00)00378-5; Limoli CL, 2004, P NATL ACAD SCI USA, V101, P16052, DOI 10.1073/pnas.0407065101; Liu M, 1999, CARCINOGENESIS, V20, P1869, DOI 10.1093/carcin/20.9.1869; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAURO F, 1969, BIOPHYS J, V9, P1377, DOI 10.1016/S0006-3495(69)86460-X; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Menendez S, 2003, J BIOL CHEM, V278, P18720, DOI 10.1074/jbc.M211007200; Menon SG, 2005, ANTIOXID REDOX SIGN, V7, P711, DOI 10.1089/ars.2005.7.711; Menon SG, 2003, CANCER RES, V63, P2109; Munoz CM, 2001, CELL MOL LIFE SCI, V58, P990, DOI 10.1007/PL00013204; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; NEVINS JR, 1992, SCIENCE, V258, P424; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; OBERLEY TD, 1990, AM J PATHOL, V137, P199; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Okuyama H, 2001, J BIOL CHEM, V276, P28274, DOI 10.1074/jbc.M102995200; Pan WJ, 2001, CANCER RES, V61, P2885; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rapkine L., 1931, ANN PHYSICOCHIM BIOL, V7, P382; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Sarsour EH, 2005, J BIOL CHEM, V280, P18033, DOI 10.1074/jbc.M501939200; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schrader M, 2004, HISTOCHEM CELL BIOL, V122, P383, DOI 10.1007/s00418-004-0673-1; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; STIRPE F, 1991, EXP CELL RES, V192, P635, DOI 10.1016/0014-4827(91)90086-A; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; Wang HP, 2003, FREE RADICAL RES, V37, P621, DOI 10.1080/1071576031000088283; YAMAMOTO K, 1988, EUR J CELL BIOL, V46, P129; Yamauchi A, 1997, BLOOD, V89, P4092, DOI 10.1182/blood.V89.11.4092; Zangar RC, 2004, TOXICOL APPL PHARM, V199, P316, DOI 10.1016/j.taap.2004.01.018; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	98	205	213	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1101	1109		10.1038/sj.onc.1209895	http://dx.doi.org/10.1038/sj.onc.1209895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924237				2022-12-17	WOS:000244406400001
J	Cummins, JM; Velculescu, VE				Cummins, J. M.; Velculescu, V. E.			Implications of micro-RNA profiling for cancer diagnosis	ONCOGENE			English	Review						microRNAs; expression profiling; miRAGE; cancer; molecular diagnostics; biomarkers	EMBRYONIC STEM-CELLS; HUMAN LUNG CANCERS; DOWN-REGULATION; ADJUVANT CHEMOTHERAPY; EXPRESSION PROFILES; GENES; DIFFERENTIATION; MOUSE; ONCOGENES; GENOMICS	Micro-RNAs (miRNAs) are a large class of small noncoding RNAs that regulate protein expression in eucaryotic cells. Initially believed to be unique to the nematode Caenorhabditis elegans, miRNAs are now recognized to be important gene regulatory elements in multicellular organisms and have been implicated in a variety of disease processes, including cancer. Advances in expression technologies have facilitated the high-throughput analysis of small RNAs, identifying novel miRNAs and showing that these genes may be aberrantly expressed in various human tumors. These studies suggest that miRNA expression pro. ling can be correlated with disease pathogenesis and prognosis, and may ultimately be useful in the management of human cancer.	Johns Hopkins Univ, Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA	Johns Hopkins University	Velculescu, VE (corresponding author), Johns Hopkins Univ, Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.	velculescu@jhmi.edu	Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X				AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Babak T, 2004, RNA, V10, P1813, DOI 10.1261/rna.7119904; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brigden ML, 1999, POSTGRAD MED, V105, P63, DOI 10.3810/pgm.1999.05.1.738; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2006, SEMIN ONCOL, V33, P167, DOI 10.1053/j.seminoncol.2006.01.010; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hall PA, 2005, HEMATOL ONCOL, V23, P49, DOI 10.1002/hon.748; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; HAYASHITA Y, 2005, CANCER RES, V65, P9628, DOI [DOI 10.1158/0008-5472.CAN-05-2352, 10.1158/0008-5472.CAN-05-2352]; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kasashima K, 2004, BIOCHEM BIOPH RES CO, V322, P403, DOI 10.1016/j.bbrc.2004.07.130; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liang RQ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni019; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; MORRIS JP, 2005, SCI STKE, pPE41; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Neely LA, 2006, NAT METHODS, V3, P41, DOI 10.1038/NMETH825; Nelson PT, 2004, NAT METHODS, V1, P155, DOI 10.1038/NMETH717; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Raymond CK, 2005, RNA, V11, P1737, DOI 10.1261/rna.2148705; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040; Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544; Shi R, 2005, BIOTECHNIQUES, V39, P519, DOI 10.2144/000112010; Shingara J, 2005, RNA, V11, P1461, DOI 10.1261/rna.2610405; Slack Frank J, 2006, Future Oncol, V2, P73, DOI 10.2217/14796694.2.1.73; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Varmus H, 2005, COLD SH Q B, V70, P1, DOI 10.1101/sqb.2005.70.039; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	86	205	236	0	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6220	6227		10.1038/sj.onc.1209914	http://dx.doi.org/10.1038/sj.onc.1209914			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028602				2022-12-17	WOS:000241158900011
J	Yin, D; Zhou, H; Kumagai, T; Liu, GT; Ong, JM; Black, KL; Koeffler, HP				Yin, D; Zhou, H; Kumagai, T; Liu, GT; Ong, JM; Black, KL; Koeffler, HP			Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)	ONCOGENE			English	Article						proteasome inhibitor; glioblastoma multiforme; PS-341; apoptosis; NF-kappa B	FACTOR-KAPPA-B; HUMAN GLIOMA-CELLS; MULTIPLE-MYELOMA CELLS; DRUG-RESISTANCE; C-MYC; CANCER; INDUCTION; P53; ANGIOGENESIS; ACTIVATION	The proteasome plays a pivotal role in controlling cell proliferation, apoptosis, and differentiation in a variety of normal and tumor cells. PS-341, a novel boronic acid dipeptide that inhibits 26S proteasome activity, has prominent effects in vitro and in vivo against several solid tumors. We examined its antiproliferation, proapoptotic effects using three human glioblastoma multiforme (GBM) cell lines and five primary GBM explants. PS-341 markedly inhibited proliferation of GBM cell lines and explants in liquid and soft agar culture. These cells developed a G2/M cell cycle arrest with a concomitant decreased percentage of cells in S phase (approximate to2-fold), associated with an increased expression of p21(WAF1), p27(KIP1), as well as cyclin B1 and decreased levels of CDK2, CDK4, and E2F4. About 35-40% of the cells became apoptotic when exposed to PS-341 (10(-7) M, 24-48 h) as shown by Annexin V analysis; in concert with these findings, immunobloting showed a C-terminal 85 kDa apoptotic fragment of poly ADP-ribose polymerase (PARP), and a decreased level of Bcl2 and Bcl-xl. PS-341 downregulated the expression of Bcl-2 and Bcl-xl in protein levels at an early time of treatment. These changes occurred irrespective of the p53 mutational status of the cells. PS-341 activated JNK/c-Jun signaling in GBM cells, and the JNK inhibitor SP600125 blocked the JNK signaling to reverse partially the PS-341 growth inhibition. PS-341 (10(-7) M, 24 h) decreased nuclear NF-kappaB levels as shown by Western blot, and reduced transcriptional activity of NF-kappaB as measured by reporter assays in these transformed cells. Also, PS-341 enhanced TRAIL (TNF-related apoptosis-inducing ligand) and TNFalpha (tumor necrosis factor alpha) induced cell death and apoptosis (two-to-five-fold) in GBM cells. In summary, PS-341 has profound effects on growth and apoptosis of GBM cells, suggesting that PS-341 maybe an effective therapy for patients with gliomas.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, D (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, 8700 Beverly Blvd,Davis Bldg 5022 Room, Los Angeles, CA 90048 USA.	Dong.Yin@cshs.org		Black, Keith/0000-0002-0546-4934				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; An JB, 2003, CLIN CANCER RES, V9, P4537; Cusack JC, 2001, CANCER RES, V61, P3535; Dai Y, 2003, ONCOGENE, V22, P7108, DOI 10.1038/sj.onc.1206863; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; IMAI Y, 1994, MODERN PATHOL, V7, P766; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LeBlanc R, 2002, CANCER RES, V62, P4996; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Ling YH, 2002, MOL CANCER THER, V1, P841; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nawrocki ST, 2002, MOL CANCER THER, V1, P1243; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tani E, 2001, FEBS LETT, V504, P53, DOI 10.1016/S0014-5793(01)02770-3; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349-7006.2004.tb03200.x	33	205	211	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2005	24	3					344	354		10.1038/sj.onc.1208225	http://dx.doi.org/10.1038/sj.onc.1208225			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531918				2022-12-17	WOS:000226279700006
J	Osato, M				Osato, M			Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia	ONCOGENE			English	Article						RUNX; AML1; PEBP2; point mutation; familial leukemia	ACUTE MYELOID-LEUKEMIA; FAMILIAL PLATELET DISORDER; GENOTYPE-PHENOTYPE CORRELATIONS; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR GENE; AML1 GENE; CLEIDOCRANIAL DYSPLASIA; PLECKSTRIN PHOSPHORYLATION; MYELODYSPLASTIC SYNDROME; AML1/PEBP2-ALPHA-B GENE	The RUNX1/AML1 gene is the most frequent target for chromosomal translocation in leukemia. In addition, recent studies have demonstrated point mutations in the RUNX1 gene as another mode of genetic alteration in development of leukemia. Monoallelic germline mutations in RUNX1 result in familial platelet disorder predisposed to acute myelogenous leukemia (FPD/AML). Sporadic point mutations are frequently found in three leukemia entities: AML M0 subtype, MDS-AML, and secondary (therapy-related) MDS/AML. Therapy-related leukemias resulting from anticancer treatments are not uncommon, and the incidence of RUNX1 point mutations appears comparable to the incidence of the t(8; 21) AML M2 subtype and the inv(16) AML M4Eo subtype. Half of the point mutations in M0 cases are biallelic, although the frequencyvaries with ethnicity. Most of the RUNX1 mutations are clustered in the Runt domain and result in defective DNA binding but active beta-subunit binding, which is consistent with three-dimensional structural findings and may explain the dominant inhibitory effects. Unlike the classical tumor suppressor genes requiring biallelic inactivation, haploinsufficient RUNX1 is apparently leukemogenic. However, RUNX1 abnormalities per se are insufficient to cause full-blown leukemia. Intensive investigation of cooperating genetic alterations should elucidate leukemic mechanisms.	Natl Univ Singapore, Oncol Res Inst, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Osato, M (corresponding author), Natl Univ Singapore, Oncol Res Inst, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	motomi@imcb.a-star.edu.sg	Osato, Motomi/N-5056-2014	Osato, Motomi/0000-0003-3982-9054				Antonarakis SE, 1998, HUM MUTAT, V11, P1; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Carnicer MJ, 2002, LEUKEMIA, V16, P2329, DOI 10.1038/sj.leu.2402656; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DOWTON SB, 1985, BLOOD, V65, P557; Ferrari T, 2001, ANN HEMATOL, V80, P72, DOI 10.1007/s002770000238; Gabbeta J, 1996, BLOOD, V87, P1368, DOI 10.1182/blood.V87.4.1368.bloodjournal8741368; GERRARD JM, 1991, BRIT J HAEMATOL, V79, P246, DOI 10.1111/j.1365-2141.1991.tb04529.x; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Matsuno N, 2003, LEUKEMIA, V17, P2492, DOI 10.1038/sj.leu.2403160; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Osato M, 2001, INT J HEMATOL, V74, P245, DOI 10.1007/BF02982056; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; Roumier C, 2003, BLOOD, V101, P1277, DOI 10.1182/blood-2002-05-1474; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sun LS, 2004, BLOOD, V103, P948, DOI 10.1182/blood-2003-07-2299; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(02)02053-6; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; Taketani T, 2002, LEUKEMIA, V16, P1866, DOI 10.1038/sj.leu.2402612; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Walker LC, 2002, BRIT J HAEMATOL, V117, P878, DOI 10.1046/j.1365-2141.2002.03512.x; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yoshida T, 2003, BLOOD CELL MOL DIS, V30, P184, DOI 10.1016/S1079-9796(03)00020-2; Yoshida T, 2002, AM J HUM GENET, V71, P724, DOI 10.1086/342717; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	41	205	208	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4284	4296		10.1038/sj.onc.1207779	http://dx.doi.org/10.1038/sj.onc.1207779			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156185	Bronze			2022-12-17	WOS:000221586000014
J	Zhao, RB; Goldman, ID				Zhao, RB; Goldman, ID			Resistance to antifolates	ONCOGENE			English	Review						antifolates; folates; folic acid; leucovorin; MRP; PGP; BCRP; exporters; polyglutamate; methotrexate; raltitrexed reduced folate carrier; folate receptors; thymidylate synthase; dihydrofolate reductase; folylpolyglutamate synthetase; GAR transforylase; membrane transport	REDUCED FOLATE CARRIER; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHINESE-HAMSTER OVARY; THYMIDYLATE SYNTHASE INHIBITOR; ORGANIC ANION TRANSPORTER; HUMAN DIHYDROFOLATE-REDUCTASE; GAMMA-GLUTAMATE SYNTHETASE; BREAST-CANCER-CELLS; RECEPTOR-TYPE-BETA; CCRF-CEM CELLS	The antifolates were the first class of antimetabolites to enter the clinics more than 50 years ago. Over the following decades, a full understanding of their mechanisms of action and chemotherapeutic potential evolved along with the mechanisms by which cells develop resistance to these drugs. These principals served as a basis for the subsequent exploration and understanding of the mechanisms of resistance to a variety of diverse antineoplastics with different cellular targets. This section describes the bases for intrinsic and acquired antifolate resistance within the context of the current understanding of the mechanisms of actions and cytotoxic determinants of these agents. This encompasses impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells. This chapter also describes how these insights are being utilized to develop gene therapy approaches to protect normal bone marrow progenitor cells as a strategy to improve the efficacy of bone marrow transplantation. Finally, clinical studies are reviewed that correlate the cellular pharmacology of methotrexate with the clinical outcome in children with neoplastic diseases treated with this antifolate.	Yeshiva Univ Albert Einstein Coll Med, Dept Med & Mol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Goldman, ID (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med & Mol, Chanin 2,Room 209,1300 Morris Pk Ave, Bronx, NY 10461 USA.	igoldman@aecom.yu.edu						Abe T, 2001, GASTROENTEROLOGY, V120, P1689, DOI 10.1053/gast.2001.24804; Aghi M, 1999, J NATL CANCER I, V91, P1233, DOI 10.1093/jnci/91.14.1233; Alati T, 1996, CANCER RES, V56, P2331; ALBRECHT AM, 1972, CANCER RES, V32, P1539; ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720; ALLEGRA CJ, 1987, J BIOL CHEM, V262, P13520; Allen JD, 2002, CANCER RES, V62, P2294; Andreassi JL, 2002, BIOCHEMISTRY-US, V41, P226, DOI 10.1021/bi015644d; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ARKIN H, 1989, CANCER RES, V49, P6556; Assaraf YG, 1999, BIOCHEM PHARMACOL, V58, P1321, DOI 10.1016/S0006-2952(99)00227-0; ASSARAF YG, 1989, J NATL CANCER I, V81, P290, DOI 10.1093/jnci/81.4.290; Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BAGGOTT JE, 1986, BIOCHEM J, V236, P193, DOI 10.1042/bj2360193; BALINSKA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P219, DOI 10.1016/0003-9861(91)90287-S; BANERJEE D, 1994, GENE, V139, P269, DOI 10.1016/0378-1119(94)90768-4; Banerjee R, 1999, INDIAN J BIOCHEM BIO, V36, P107; BARAM J, 1987, J CLIN INVEST, V79, P692, DOI 10.1172/JCI112872; BARBOUR KW, 1992, MOL PHARMACOL, V42, P242; Barnes MJ, 1999, CLIN CANCER RES, V5, P2548; BARREDO JC, 1994, BLOOD, V84, P564; BAUGH CM, 1973, BIOCHEM BIOPH RES CO, V52, P27, DOI 10.1016/0006-291X(73)90949-2; Belkov VM, 1999, BLOOD, V93, P1643, DOI 10.1182/blood.V93.5.1643.405k06_1643_1650; BERTINO JR, 1977, SEMIN ONCOL, V4, P203; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Calvert H, 2002, SEMIN ONCOL, V29, P3, DOI 10.1016/S0093-7754(02)70209-1; CAMPBELL IG, 1991, CANCER RES, V51, P5329; Capiaux GM, 2003, HUM GENE THER, V14, P435, DOI 10.1089/104303403321467207; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; Chancy CD, 2000, J BIOL CHEM, V275, P20676, DOI 10.1074/jbc.M002328200; Chango A, 2000, MOL GENET METAB, V70, P310, DOI 10.1006/mgme.2000.3034; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2003, CANCER RES, V63, P4048; Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165; Chu E, 1996, ADV ENZYME REGUL, V36, P143, DOI 10.1016/0065-2571(95)00004-6; CHU E, 1994, MOL CELL BIOL, V14, P207, DOI 10.1128/MCB.14.1.207; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1990, J BIOL CHEM, V265, P8470; CHUNG KN, 1993, J CLIN INVEST, V91, P1289, DOI 10.1172/JCI116327; Cole PD, 2001, CANCER RES, V61, P4599; CONEY LR, 1991, CANCER RES, V51, P6125; COWAN KH, 1984, J BIOL CHEM, V259, P793; CURT GA, 1985, J CLIN INVEST, V76, P1323, DOI 10.1172/JCI112106; CURT GA, 1983, NEW ENGL J MED, V308, P199, DOI 10.1056/NEJM198301273080406; DeGraaf D, 1996, P NATL ACAD SCI USA, V93, P1238, DOI 10.1073/pnas.93.3.1238; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; DICKER AP, 1990, J BIOL CHEM, V265, P8317; Ding BC, 2001, BIOCHEM PHARMACOL, V61, P665; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1992, J BIOL CHEM, V267, P24140; DIXON KH, 1994, J BIOL CHEM, V269, P17; DOLNICK BJ, 1979, J CELL BIOL, V83, P394, DOI 10.1083/jcb.83.2.394; DOMIN BA, 1982, MOL PHARMACOL, V21, P231; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Drake JC, 1996, BIOCHEM PHARMACOL, V51, P1349, DOI 10.1016/0006-2952(96)00057-3; Drori S, 2000, J BIOL CHEM, V275, P30855, DOI 10.1074/jbc.M003988200; Dudeja PK, 1997, AM J PHYSIOL-GASTR L, V272, pG1408, DOI 10.1152/ajpgi.1997.272.6.G1408; Ercikan E, 1993, Adv Exp Med Biol, V338, P537; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; FABRE I, 1984, CANCER RES, V44, P3190; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLASSHOVE M, 1995, LEUKEMIA, V9, pS34; FLASSHOVE M, 1995, BLOOD, V85, P566; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; FREEMANTLE SJ, 1995, BRIT J CANCER, V71, P925, DOI 10.1038/bjc.1995.179; FRY DW, 1982, J BIOL CHEM, V257, P1890; FRY DW, 1983, CANCER RES, V43, P1087; FRY DW, 1982, CANCER RES, V42, P2532; FRY DW, 1980, CANCER RES, V40, P3669; FYFE MJ, 1973, J BIOL CHEM, V248, P5067; Galipeau J, 1997, HUM GENE THER, V8, P1773, DOI 10.1089/hum.1997.8.15-1773; Galivan J, 2000, PHARMACOL THERAPEUT, V85, P207, DOI 10.1016/S0163-7258(99)00063-7; Galpin AJ, 1997, MOL PHARMACOL, V52, P155, DOI 10.1124/mol.52.1.155; Gifford AJ, 1998, INT J CANCER, V78, P176, DOI 10.1002/(SICI)1097-0215(19981005)78:2<176::AID-IJC10>3.3.CO;2-F; Gifford AJ, 2002, LEUKEMIA, V16, P2379, DOI 10.1038/sj.leu.2402655; GOKER E, 1993, LEUKEMIA, V7, P1000; GOLDIE JH, 1980, EUR J CANCER, V16, P1539, DOI 10.1016/0014-2964(80)90026-2; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1974, MOL PHARMACOL, V10, P257; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Guo W, 1999, CLIN CANCER RES, V5, P621; HABECK LL, 1995, MOL PHARMACOL, V48, P326; HAKALA MT, 1965, BIOCHIM BIOPHYS ACTA, V102, P210, DOI 10.1016/0926-6585(65)90214-1; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; HENDERSON GB, 1981, BIOCHEM BIOPH RES CO, V99, P163, DOI 10.1016/0006-291X(81)91727-7; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1990, BIOCHEM PHARMACOL, V39, P2019, DOI 10.1016/0006-2952(90)90624-T; HENDERSON GB, 1982, BIOCHEM BIOPH RES CO, V104, P474, DOI 10.1016/0006-291X(82)90661-1; HENDERSON GB, 1982, BIOCHEM INT, V4, P493; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HILL BT, 1979, CANCER RES, V39, P2440; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Honjo Y, 2001, CANCER RES, V61, P6635; Hooijberg JH, 2003, BIOCHEM PHARMACOL, V65, P765, DOI 10.1016/S0006-2952(02)01615-5; Hooijberg JH, 1999, CANCER RES, V59, P2532; HORNE DW, 1990, BIOCHIM BIOPHYS ACTA, V1023, P47, DOI 10.1016/0005-2736(90)90008-C; Horne DW, 2001, ARCH BIOCHEM BIOPHYS, V394, P39, DOI 10.1006/abbi.2001.2528; HORNS RC, 1984, J CLIN ONCOL, V2, P2, DOI 10.1200/JCO.1984.2.1.2; HOUGHTON PJ, 1992, CANCER RES, V52, P558; HSUEH CT, 1994, BIOCHEM PHARMACOL, V47, P1019, DOI 10.1016/0006-2952(94)90413-8; Huang W, 1997, INVEST OPHTH VIS SCI, V38, P1578; Ito K, 2001, J BIOL CHEM, V276, P38108; JACKMAN AL, 1991, CANCER RES, V51, P5579; Jackman AL, 1997, CLIN CANCER RES, V3, P911; JACKMAN AL, 1995, BRIT J CANCER, V71, P914, DOI 10.1038/bjc.1995.178; JACKSON RC, 1977, ARCH BIOCHEM BIOPHYS, V182, P646, DOI 10.1016/0003-9861(77)90545-8; JACKSON RC, 1976, CANCER RES, V36, P1991; JACKSON RC, 1984, ADV ENZYME REGUL, V22, P187, DOI 10.1016/0065-2571(84)90014-1; JACKSON RC, 1973, ARCH BIOCHEM BIOPHYS, V158, P827, DOI 10.1016/0003-9861(73)90579-1; JANSEN G, 1990, CANCER RES, V50, P7544; JANSEN G, 1989, CANCER RES, V49, P1959; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1999, MOL PHARMACOL, V55, P761; JOHNSON TB, 1988, CANCER RES, V48, P2426; JOLIVET J, 1983, J CLIN INVEST, V72, P773, DOI 10.1172/JCI111048; JOLIVET J, 1982, J CLIN INVEST, V70, P351, DOI 10.1172/JCI110624; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1986, J BIOL CHEM, V261, P44; KATES RE, 1976, BIOCHEM PHARMACOL, V25, P1485, DOI 10.1016/0006-2952(76)90065-4; KAUFMAN RJ, 1979, P NATL ACAD SCI USA, V76, P5669, DOI 10.1073/pnas.76.11.5669; Khokhar NZ, 2001, CLIN CANCER RES, V7, P3199; KIM JS, 1993, J BIOL CHEM, V268, P21680; Kitchens ME, 1999, J BIOL CHEM, V274, P12544, DOI 10.1074/jbc.274.18.12544; Kitchens ME, 1999, MOL PHARMACOL, V56, P1063, DOI 10.1124/mol.56.5.1063; KOIZUMI S, 1985, J CLIN INVEST, V75, P1008, DOI 10.1172/JCI111761; KOIZUMI S, 1990, JPN J CANCER RES, V81, P1162, DOI 10.1111/j.1349-7006.1990.tb02529.x; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kuhnel JM, 2000, J CELL PHYSIOL, V184, P364, DOI 10.1002/1097-4652(200009)184:3<364::AID-JCP11>3.0.CO;2-N; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; KUMAR P, 1989, BIOCHEM PHARMACOL, V38, P541, DOI 10.1016/0006-2952(89)90397-3; Kusuhara H, 1998, AM J PHYSIOL-GASTR L, V275, pG789, DOI 10.1152/ajpgi.1998.275.4.G789; LAINI E, 2003, INT J CANCER, V103, P587; Leamon CP, 2001, DRUG DISCOV TODAY, V6, P44, DOI 10.1016/S1359-6446(00)01594-4; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; LI WW, 1992, CANCER RES, V52, P1434; LI WW, 1992, CANCER RES, V52, P3908; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Liu XY, 2001, BIOCHEM J, V358, P511, DOI 10.1042/0264-6021:3580511; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Longley DB, 2001, CLIN CANCER RES, V7, P3533; Longo GSA, 1997, ONCOL RES, V9, P259; LU K, 1995, BIOCHEM PHARMACOL, V50, P391, DOI 10.1016/0006-2952(95)00135-M; Lu YJ, 2002, ADV DRUG DELIVER REV, V54, P675, DOI 10.1016/S0169-409X(02)00042-X; Mahdavian E, 1999, ARCH BIOCHEM BIOPHYS, V368, P257, DOI 10.1006/abbi.1999.1319; Masson E, 1996, J CLIN INVEST, V97, P73, DOI 10.1172/JCI118409; Masuda M, 1997, CANCER RES, V57, P3506; Masuda S, 1999, MOL PHARMACOL, V55, P743; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MATHERLY LH, 1995, BLOOD, V85, P500; MATHERLY LH, 1986, CANCER RES, V46, P588; MATHERLY LH, 1983, CANCER RES, V43, P2694; MATHERLY LH, 1984, CANCER RES, V44, P2325; MATHERLY LH, 1990, CANCER RES, V50, P3262; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MATHERLY LH, 1990, BIOCHEM PHARMACOL, V39, P2005, DOI 10.1016/0006-2952(90)90622-R; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Mauritz R, 2002, BIOCHEM PHARMACOL, V63, P105, DOI 10.1016/S0006-2952(01)00824-3; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; McGuire JJ, 1998, ONCOL RES, V10, P193; McGuire JJ, 1995, ONCOL RES, V7, P535; MCIVOR RS, 1990, NUCLEIC ACIDS RES, V18, P7025, DOI 10.1093/nar/18.23.7025; MELERA PW, 1984, MOL CELL BIOL, V4, P38, DOI 10.1128/MCB.4.1.38; MELERA PW, 1988, J BIOL CHEM, V263, P1978; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109; MINI E, 1985, CANCER RES, V45, P317; MIOTTI S, 1995, INT J CANCER, V63, P395, DOI 10.1002/ijc.2910630316; MIYACHI H, 1995, CANCER LETT, V88, P93, DOI 10.1016/0304-3835(94)03616-Q; MORAN RG, 1976, J BIOL CHEM, V251, P3569; MOSCOW JA, 1995, CANCER RES, V55, P3790; NIETHAMMER D, 1975, EUR J CANCER, V11, P845, DOI 10.1016/0014-2964(75)90083-3; NIMEC Z, 1983, ARCH BIOCHEM BIOPHYS, V226, P671, DOI 10.1016/0003-9861(83)90337-5; Niyikiza C, 2002, MOL CANCER THER, V1, P545; Norris MD, 1996, INT J CANCER, V65, P613; OCONNOR BM, 1992, CANCER RES, V52, P1137; Pan XQ, 2002, BLOOD, V100, P594, DOI 10.1182/blood.V100.2.594; Pisters KMW, 1996, CLIN CANCER RES, V2, P1819; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1988, CANCER RES, V48, P2149; PIZZORNO G, 1989, CANCER RES, V49, P5275; PIZZORNO G, 1991, MOL PHARMACOL, V39, P85; POSER RG, 1981, CANCER RES, V41, P4441; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRIEST DG, 1989, CANCER RES, V49, P4204; RAGOUSSIS J, 1992, GENOMICS, V14, P423, DOI 10.1016/S0888-7543(05)80236-8; Rajgopal A, 2001, AM J PHYSIOL-CELL PH, V281, pC1579, DOI 10.1152/ajpcell.2001.281.5.C1579; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; Reddy JA, 1999, BLOOD, V93, P3940, DOI 10.1182/blood.V93.11.3940.411k09_3940_3948; Reilly RT, 1997, ARCH BIOCHEM BIOPHYS, V342, P338, DOI 10.1006/abbi.1997.0116; RHEE MS, 1993, CANCER RES, V53, P2227; RHEE MS, 1990, CANCER RES, V50, P3979; Roberts JD, 2000, CANCER CHEMOTH PHARM, V45, P103, DOI 10.1007/s002800050017; ROSENBLATT DS, 1978, MOL PHARMACOL, V14, P210; ROSENBLATT DS, 1978, MOL PHARMACOL, V14, P1143; Rosowsky A, 1998, J MED CHEM, V41, P5310, DOI 10.1021/jm980477+; Rosowsky A, 2000, PHARMACOL THERAPEUT, V85, P191, DOI 10.1016/S0163-7258(99)00055-8; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; Ross JF, 1999, CANCER-AM CANCER SOC, V85, P348, DOI 10.1002/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; Rothem L, 2003, J BIOL CHEM, V278, P8935, DOI 10.1074/jbc.M209578200; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Rots MG, 1999, BLOOD, V94, P3121, DOI 10.1182/blood.V94.9.3121.421k08_3121_3128; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Roy K, 1997, J BIOL CHEM, V272, P6903, DOI 10.1074/jbc.272.11.6903; Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563, DOI 10.1146/annurev.physiol.64.081501.155913; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SAIKAWA Y, 1993, J BIOL CHEM, V268, P5293; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Sanghani SP, 1999, J BIOL CHEM, V274, P27018, DOI 10.1074/jbc.274.38.27018; Sanghani SP, 1997, BIOCHEMISTRY-US, V36, P10506, DOI 10.1021/bi970825u; Sauerbrey A, 1999, HUM GENE THER, V10, P2495, DOI 10.1089/10430349950016834; Saxena M, 1996, BIOCHEM PHARMACOL, V51, P975, DOI 10.1016/0006-2952(96)00051-2; SAXENA M, 1995, J BIOL CHEM, V270, P5312, DOI 10.1074/jbc.270.10.5312; SCHILSKY RL, 1980, P NATL ACAD SCI-BIOL, V77, P2919, DOI 10.1073/pnas.77.5.2919; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCHLEMMER SR, 1995, BIOCHEM PHARMACOL, V49, P1427, DOI 10.1016/0006-2952(95)00069-C; Schmitz JC, 2001, CANCER METAST REV, V20, P33, DOI 10.1023/A:1013100306315; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Schultz RM, 1999, SEMIN ONCOL, V26, P68; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SEITHER RL, 1991, J BIOL CHEM, V266, P4112; SELHUB J, 1983, PHARMACOL THERAPEUT, V20, P397, DOI 10.1016/0163-7258(83)90034-7; Sharif KA, 1998, BIOCHEM PHARMACOL, V55, P1683, DOI 10.1016/S0006-2952(98)00039-2; Sharina IG, 2001, MOL PHARMACOL, V59, P1022, DOI 10.1124/mol.59.5.1022; SHEN F, 1995, BIOCHEMISTRY-US, V34, P5660, DOI 10.1021/bi00016a042; SHEN F, 1994, BIOCHEMISTRY-US, V33, P1209, DOI 10.1021/bi00171a021; Shih C, 1997, CANCER RES, V57, P1116; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; Sierra EE, 1998, BIOCHEM PHARMACOL, V55, P1505, DOI 10.1016/S0006-2952(97)00673-4; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1981, CANCER RES, V41, P3944; SIROTNAK FM, 1981, CANCER RES, V41, P966; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SIROTNAK FM, 1978, CANCER RES, V38, P345; SIROTNAK FM, 1974, CANCER RES, V34, P3332; Sirotnak FM, 2000, CLIN CANCER RES, V6, P3705; SIROTNAK FM, 1968, CANCER RES, V28, P75; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; Sorrentino B P, 1999, Prog Exp Tumor Res, V36, P143; Spencer HT, 1996, LEUKEMIA, V10, P439; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; Stark M, 2003, MOL PHARMACOL, V64, P220, DOI 10.1124/mol.64.2.220; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Sun W, 2001, BIOCHEM BIOPH RES CO, V283, P417, DOI 10.1006/bbrc.2001.4774; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; Takebe N, 2001, MOL THER, V3, P88, DOI 10.1006/mthe.2000.0236; Takebe N, 2000, CANCER GENE THER, V7, P910, DOI 10.1038/sj.cgt.7700199; Theti DS, 2003, CANCER RES, V63, P3612; Tong YZ, 1998, J BIOL CHEM, V273, P11611, DOI 10.1074/jbc.273.19.11611; Tong YZ, 1998, J BIOL CHEM, V273, P31209, DOI 10.1074/jbc.273.47.31209; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; TRENT DF, 1991, J BIOL CHEM, V266, P5445; TRENT JM, 1984, J CLIN ONCOL, V2, P8, DOI 10.1200/JCO.1984.2.1.8; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; van der Wilt CL, 2001, CANCER RES, V61, P3675; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Volk EL, 2000, CANCER RES, V60, P3514; Volk EL, 2002, CANCER RES, V62, P5035; Wang H, 2000, BLOOD, V96, P3529; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; Wang YH, 2003, BIOCHEM PHARMACOL, V65, P1163, DOI 10.1016/S0006-2952(03)00007-8; Wang YH, 2001, BBA-BIOMEMBRANES, V1513, P49, DOI 10.1016/S0005-2736(01)00340-6; Webber S, 1996, CANCER CHEMOTH PHARM, V37, P509, DOI 10.1007/s002800050422; Wedge SR, 1995, CLIN CANCER RES, V1, P1479; WEITMAN SD, 1994, J NEURO-ONCOL, V21, P107, DOI 10.1007/BF01052894; WEITMAN SD, 1992, CANCER RES, V52, P3396; WEITMAN SD, 1992, CANCER RES, V52, P6708; Welsh SJ, 2000, CLIN CANCER RES, V6, P2538; WERKHEISER W, 1961, J BIOL CHEM, V236, P888; WESTERHOF GR, 1991, CANCER RES, V51, P5507; WESTERHOF GR, 1995, MOL PHARMACOL, V48, P459; Whetstine JR, 2001, CLIN CANCER RES, V7, P3416; WHITE JC, 1981, J BIOL CHEM, V256, P5722; WHITE JC, 1976, MOL PHARMACOL, V12, P711; WHITE JC, 1975, MOL PHARMACOL, V11, P287; WHITE JC, 1979, J BIOL CHEM, V254, P889; Whitehead VM, 1998, LEUKEMIA LYMPHOMA, V31, P507, DOI 10.3109/10428199809057610; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WHITEHEAD VM, 1990, BLOOD, V76, P44; Whitehead VM, 1998, CLIN CANCER RES, V4, P183; Whitehead VM, 2001, LEUKEMIA, V15, P1081, DOI 10.1038/sj.leu.2402165; WHITEHEAD VM, 1977, CANCER RES, V37, P408; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Worzalla JF, 1998, ANTICANCER RES, V18, P3235; Wright JE, 2000, BIOCHEM PHARMACOL, V60, P41, DOI 10.1016/S0006-2952(00)00294-X; Wu M, 1997, J MEMBRANE BIOL, V159, P137, DOI 10.1007/s002329900277; Wu M, 1999, CANCER EPIDEM BIOMAR, V8, P775; YALOWICH JC, 1982, CANCER RES, V42, P3648; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; Yang R, 2003, CLIN CANCER RES, V9, P837; YU MH, 1993, CANCER RES, V53, P6031; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 2000, CANCER RES, V60, P4779; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274; Zhang L, 1998, CLIN CANCER RES, V4, P2169; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 2000, CLIN CANCER RES, V6, P3687; Zhao RB, 2000, J BIOL CHEM, V275, P26599, DOI 10.1074/jbc.M002580200; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 2003, BBA-BIOMEMBRANES, V1613, P49, DOI 10.1016/S0005-2736(03)00136-6; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68; Zhao RB, 2000, MOL PHARMACOL, V57, P317; Zhao RB, 2002, AM J PHYSIOL-CELL PH, V282, pC1512, DOI 10.1152/ajpcell.00547.2001; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207; Zhao RB, 2001, BIOCHEM PHARMACOL, V61, P857, DOI 10.1016/S0006-2952(01)00532-9; Zhao RB, 2001, J BIOL CHEM, V276, P1114, DOI 10.1074/jbc.M007919200	345	205	210	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7431	7457		10.1038/sj.onc.1206946	http://dx.doi.org/10.1038/sj.onc.1206946			27	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576850				2022-12-17	WOS:000186112500015
J	Criswell, T; Leskov, K; Miyamoto, S; Luo, GB; Boothman, DA				Criswell, T; Leskov, K; Miyamoto, S; Luo, GB; Boothman, DA			Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation	ONCOGENE			English	Review						DNA damage sensors; ionizing radiation (IR); NF-kappa B; p53; signal transduction; SP1	NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA EXPRESSION; IMMEDIATE-EARLY GENES; TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; C-JUN EXPRESSION; WILD-TYPE; GAMMA-IRRADIATION	Over the past 15 years, a wealth of information has been published on transcripts and proteins 'induced' (requiring new protein synthesis) in mammalian cells after ionizing radiation (IR) exposure. Many of these studies have also attempted to elucidate the transcription factors that are 'activated' (i.e., not requiring de novo synthesis) in specific cells by IR. Unfortunately, all too often this information has been obtained using supralethal doses of IR, with investigators assuming that induction of these proteins, or activation of corresponding transcription factors, can be 'extrapolated' to low-dose IR exposures. This review focuses on what is known at the molecular level about transcription factors induced at clinically relevant (less than or equal to 2 Gy) doses of IR. A review of the literature demonstrates that extrapolation from high doses of IR to low doses of IR is inaccurate for most transcription factors and most IR-inducible transcripts/proteins, and that induction of transactivating proteins at low doses must be empirically derived. The signal transduction pathways stimulated after high versus low doses of IR, which act to transactivate certain transcription factors in the cell, will be discussed. To date, only three transcription factors appear to be responsive (i.e. activated) after physiological doses (doses wherein cells survive or recover) of IR. These are p53, nuclear factor kappa B(NF-kappaB), and the SP1-related retinoblastoma control proteins (RCPs). Clearly, more information on transcription factors and proteins induced in mammalian cells at clinically or environmentally relevant doses of IR is needed to understand the role of these stress responses in cancer susceptibility/resistance and radio-sensitivity/resistance mechanisms.	Case Western Reserve Univ, Dept Radiat Oncol, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Program Mol Basis Dis, Lab Mol Stress Responses, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol & Biochem, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Genet, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Ireland Comprehens Canc Ctr, 10900 Euclid Ave,BRB 326 E, Cleveland, OH 44106 USA.	dab30@po.cwru.edu	Leskov, Konstantin S/J-2339-2017; Boothman, David/Q-7776-2019	Leskov, Konstantin S/0000-0001-6201-5660; 	NCI NIH HHS [R01 CA078530, CA-77474-03, CA-83196-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078530, R01CA077474, R01CA083196] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEYAMA K, 1995, FEBS LETT, V364, P298, DOI 10.1016/0014-5793(95)00412-3; Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Ahn JY, 2000, CANCER RES, V60, P5934; ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Araki R, 1999, CANCER RES, V59, P3543; Ashburner BP, 1999, CANCER RES, V59, P5456; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Bae I, 1996, CANCER RES, V56, P840; BAE IS, 1995, CANCER RES, V55, P2387; Baeuml H, 1997, FREE RADICAL RES, V27, P127, DOI 10.3109/10715769709097846; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Bertagna A, 2001, THROMB HAEMOSTASIS, V85, P837; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; BRACH MA, 1993, J BIOL CHEM, V268, P8466; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Burger H, 1998, INT J RADIAT ONCOL, V41, P415, DOI 10.1016/S0360-3016(98)00065-0; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1992, J BIOL CHEM, V267, P1345; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen XF, 2002, CANCER RES, V62, P1213; Choi EK, 2001, INT J RADIAT ONCOL, V49, P397, DOI 10.1016/S0360-3016(00)01485-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; Davis TW, 1998, CONT CANC RES, P223; Davis TW, 1998, CANCER RES, V58, P767; Didelot C, 2001, INT J RADIAT ONCOL, V51, P1354, DOI 10.1016/S0360-3016(01)02608-6; Durand RE, 2001, METHOD CELL BIOL, V64, P211; Eichholtz-Wirth H, 2000, APOPTOSIS, V5, P255, DOI 10.1023/A:1009656513307; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fei PW, 2002, CANCER RES, V62, P7316; Finch JS, 2002, J CANCER RES CLIN, V128, P3, DOI 10.1007/s00432-001-0298-x; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 2001, CANCER RES, V61, P7369; Fornace AJ, 1999, GENE EXPRESSION, V7, P387; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fornace Albert J Jr, 2002, Mil Med, V167, P13; Gault N, 2002, RADIAT RES, V157, P249, DOI 10.1667/0033-7587(2002)157[0249:PSIITG]2.0.CO;2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; Goldwasser F, 1999, ANTICANCER RES, V19, P3167; Grana TM, 2002, CANCER RES, V62, P4142; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; Hallahan DE, 1998, CANCER RES, V58, P5484; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HALLAHAN DE, 1991, INT J RADIAT ONCOL, V21, P1677, DOI 10.1016/0360-3016(91)90352-5; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; Hallahan DE, 1996, INT J RADIAT ONCOL, V36, P355, DOI 10.1016/S0360-3016(96)00327-6; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HIGO H, 1989, TERATOGEN CARCIN MUT, V9, P191, DOI 10.1002/tcm.1770090402; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda N, 2002, J RADIAT RES, V43, P283, DOI 10.1269/jrr.43.283; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIHARA H, 1993, RADIAT RES, V133, P321, DOI 10.2307/3578216; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; Jackson SP, 1996, CANCER SURV, V28, P261; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin Y, 1996, CARCINOGENESIS, V17, P873, DOI 10.1093/carcin/17.4.873; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kawai H, 1999, CANCER RES, V59, P6038; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KICK G, 1995, CANCER RES, V55, P2373; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; Mayo LD, 1997, CANCER RES, V57, P5013; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Meyer RG, 2002, EUR J BIOCHEM, V269, P337, DOI 10.1046/j.0014-2956.2001.02658.x; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Miyakoshi J, 2000, BRIT J CANCER, V82, P28; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; NEL AE, 1994, J IMMUNOL, V152, P4347; Nenoi M, 2001, CANCER RES, V61, P5885; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Novotny V, 1998, NUCLEIC ACIDS RES, V26, P5480, DOI 10.1093/nar/26.23.5480; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Pajonk F, 2000, INT J RADIAT ONCOL, V47, P1025, DOI 10.1016/S0360-3016(00)00516-2; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; PRASAD AV, 1995, RADIAT RES, V143, P263, DOI 10.2307/3579212; Prives C, 1999, J PATHOL, V187, P112; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Raju U, 2000, INT J RADIAT BIOL, V76, P1045, DOI 10.1080/09553000050111514; Raju U, 1998, INT J RADIAT BIOL, V74, P617, DOI 10.1080/095530098141195; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JS, 2002, CANCER RES, V62, P2318; Russell JS, 2002, MOL BIOL CELL, V13, P3431, DOI 10.1091/mbc.E02-05-0252; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; RYSECK RP, 1991, ONCOGENE, V6, P533; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shao RP, 2001, CANCER RES, V61, P7413; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; Stavridi ES, 2001, CANCER RES, V61, P7030; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Takahashi T, 1997, HUM GENE THER, V8, P827, DOI 10.1089/hum.1997.8.7-827; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; Wang Y, 2000, GENE DEV, V14, P927; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Weichselbaum RR, 2002, LANCET ONCOL, V3, P665, DOI 10.1016/S1470-2045(02)00900-2; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON RE, 1993, ONCOGENE, V8, P3229; WOLOSCHAK GE, 1990, RADIAT RES, V124, P183, DOI 10.2307/3577864; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhao HC, 2000, CANCER RES, V60, P6276; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou DH, 1999, RADIAT RES, V151, P703, DOI 10.2307/3580209; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047; Zhou H, 2000, J BIOL CHEM, V275, P22868, DOI 10.1074/jbc.M909273199	204	205	209	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5813	5827		10.1038/sj.onc.1206680	http://dx.doi.org/10.1038/sj.onc.1206680			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947388				2022-12-17	WOS:000185086100008
J	Ambartsumian, N; Klingelhofer, J; Grigorian, M; Christensen, C; Kriajevska, M; Tulchinsky, E; Georgiev, G; Berezin, V; Bock, E; Rygaard, J; Cao, RH; Cao, YH; Lukanidin, E				Ambartsumian, N; Klingelhofer, J; Grigorian, M; Christensen, C; Kriajevska, M; Tulchinsky, E; Georgiev, G; Berezin, V; Bock, E; Rygaard, J; Cao, RH; Cao, YH; Lukanidin, E			The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor	ONCOGENE			English	Article						angiogenesis; S100A4; stimulation of motility	CALCIUM-BINDING PROTEIN; ENDOTHELIAL GROWTH-FACTOR; NONMUSCLE MYOSIN; MAMMALIAN-CELLS; S100A4 P9KA; TUMOR-CELLS; MTS1 GENE; IN-VIVO; EXPRESSION; MICE	The involvement of Mts1(S100A4), a small Call-binding protein in tumor progression and metastasis had been demonstrated. However, the mechanism by which mts1(S100A4) promoted metastasis had not been identified. Here we demonstrated that Mts1(S100A4) had significant stimulatory effect on the angiogenesis. We detected high incidence of hemangiomas - benign tumors of vascular origin in aged transgenic mice ubiquitously expressing the mts1(S100A4) gene. Furthermore, the serum level of the Mts1(Sl00A4) protein increased with ageing. Tumors developed in Mts1-transgenic mice revealed an enhanced vascular density. We showed that an oligomeric, but not a dimeric form of the Mts1(S100A4) protein was capable of enhancing the endothelial cell motility in vitro and stimulate the corneal neovascularization in vivo. An oligomeric fraction of the protein was detected in the conditioned media as well as in human serum. The data obtained allowed us to conclude that mts1(S100A4) might induce tumor progression via stimulation of angiogenesis.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Copenhagen, Panum Inst, Prot Lab, DK-2200 Copenhagen N, Denmark; Kommune Hosp Copenhagen, Bartholin Inst, DK-1399 Copenhagen K, Denmark; Inst Gene Biol, Moscow, Russia	Danish Cancer Society; Karolinska Institutet; University of Copenhagen; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Ambartsumian, N (corresponding author), Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark.	na@cancer.dk	Tulchinsky, Eugene/ABD-7070-2021; Klingelhöfer, Jörg/C-1676-2013					Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; BOOTH CJ, 1995, LAB ANIM SCI, V45, P497; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Duarte WR, 1999, BIOCHEM BIOPH RES CO, V255, P416, DOI 10.1006/bbrc.1999.0214; Dunn G A, 1983, Agents Actions Suppl, V12, P14; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FORD HL, 1995, ONCOGENE, V10, P1597; FRITH CH, 1982, LAB ANIM SCI, V32, P157; GESZY C, 1996, BIOCHIM BIOPHYS ACTA, V1313, P246; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kumar R, 1998, INT J ONCOL, V12, P749; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; LIOTTA LA, 1974, CANCER RES, V34, P997; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; PETERS RL, 1972, INT J CANCER, V10, P273, DOI 10.1002/ijc.2910100207; Polverini PJ, 1996, EUR J CANCER, V32A, P2430, DOI 10.1016/S0959-8049(96)00386-3; Rudland PS, 2000, CANCER RES, V60, P1595; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SENIN VM, 1983, EKSP ONKOL, V5, P35; SENIN VM, 1984, VESTN AKAD MED NAUK+, P85; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; Walmod PS, 1998, CELL MOTIL CYTOSKEL, V40, P220; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WEIDNER N, 1995, AM J PATHOL, V147, P9; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	54	205	229	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4685	4695		10.1038/sj.onc.1204636	http://dx.doi.org/10.1038/sj.onc.1204636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498791				2022-12-17	WOS:000170208600009
J	Xu, DW; Wang, Q; Gruber, A; Bjorkholm, M; Chen, ZG; Zaid, A; Selivanova, G; Peterson, C; Wiman, KG; Pisa, P				Xu, DW; Wang, Q; Gruber, A; Bjorkholm, M; Chen, ZG; Zaid, A; Selivanova, G; Peterson, C; Wiman, KG; Pisa, P			Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells	ONCOGENE			English	Article						hTERT; p53; Sp1; telomerase	CATALYTIC SUBUNIT HTERT; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; GROWTH ARREST; BREAST-CANCER; DNA-BINDING; MUTANT P53; LIFE-SPAN; C-MYC; PROTEIN	The p53 tumor suppressor protein inhibits the formation of tumors through induction of cell cycle arrest and/or apoptosis, In the present study we demonstrated that p53 is also a powerful inhibitor of human telomerase reverse transcriptase (hTERT), a key component for telomerase, Activation of either exogenous temperature-sensitive (ts) p53 in BL41 Burkitt lymphoma cells or endogenous wild type (wt) p53 at a physiological level in MCF-7 breast carcinoma cells triggered a rapid downregulation of hTERT mRNA expression, independently of the induction of the p53 target gene p21, Co-transfection of an hTERT promoter construct with wt p53 but not mutant p53 in HeLa cells inhibited the hTERT promoter activity. Furthermore, the activation of the hTERT promoter in Drosophila Schneider SL2 cells was completely dependent on the ectopic expression of Sp1 and was abrogated by wt p53, Finally, wt p53 inhibited Sp1 binding to the hTERT proximal promoter by forming a p53-Sp1 complex. Since activation of telomerase, widely observed in human tumor cell lines and primary tumors, is a critical step in tumorigenesis, wt p53-triggered inhibition of hTERT/telomerase expression may reflect yet another mechanism of p53-mediated tumor suppression. Our findings provide new insights into both the biological function of p53 and the regulation of hTERT/telomerase expression.	Karolinska Hosp, Hematol Lab, CMM, Radiumhemmet,Dept Med,Div Hematol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Radiumhemmet, Dept Oncol, SE-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Stockholm Univ, Dept Biochem, SE-10405 Stockholm, Sweden; Linkoping Univ, Fac Hlth Sci, SE-58185 Linkoping, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University; Linkoping University	Xu, DW (corresponding author), Karolinska Hosp, Hematol Lab, CMM, Radiumhemmet,Dept Med,Div Hematol, L8-03, SE-17176 Stockholm, Sweden.		Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Chen, Zhiguo/0000-0003-1508-510X; Zaid, Ahmed/0000-0002-1063-2883; Selivanova, Galina/0000-0002-8698-4332; Xu, Dawei/0000-0003-3141-4524				Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Loveday RL, 1999, INT J CANCER, V84, P516, DOI 10.1002/(SICI)1097-0215(19991022)84:5<516::AID-IJC12>3.0.CO;2-Y; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OKAN I, 1995, ONCOGENE, V11, P1027; PERREM K, 1995, ONCOGENE, V11, P1299; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SOUSSI T, 1990, ONCOGENE, V5, P945; Takakura M, 1999, CANCER RES, V59, P551; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang QJ, 1998, CANCER RES, V58, P5762; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu X, 1999, BRIT J CANCER, V80, P453, DOI 10.1038/sj.bjc.6690378; Xu D, 1996, LEUKEMIA, V10, P1354; XU D, 1999, BRIT J CANCER, V80, P453; Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x	47	205	224	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5123	5133		10.1038/sj.onc.1203890	http://dx.doi.org/10.1038/sj.onc.1203890			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064449				2022-12-17	WOS:000090124100001
J	Meek, DW				Meek, DW			Mechanisms of switching on p53: a role for covalent modification?	ONCOGENE			English	Article						p53 activation; DNA damage; phosphorylation	DEPENDENT PROTEIN-KINASE; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; CELL-CYCLE ARREST; PHOSPHORYLATED IN-VITRO; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; ULTRAVIOLET-RADIATION; V(D)J RECOMBINATION	The p53 protein plays a pivotal role in activating and integrating adaptive cellular responses to a wide range of environmental stresses, Activation of p53 can occur by different molecular routes, depending on the nature of the activating signal. Central to the activation process, by whichever route, is the destabilization of the p53-MDM2 interaction, The molecular mechanisms which activate p53 involve elements of post-translational modification, protein stabilization and protein-protein interaction. Two central themes are emerging from recent work in this area. The first is that there are common events in the p53 activation process among different activating pathways. The second is that activation involves not just a single molecular event such as disruption of the p53-MDM2 interaction, but a series of sequential events the nature of which is governed by the type of activating stimulus. This review summarizes our current knowledge of the p53 activation process in response to two stimuli, DNA damage and activated oncogenes, and considers the contribution made by multisite phosphorylation in determining the nature of the p53 response.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.							Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jongmans W, 1996, ONCOGENE, V13, P1133; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meek DW, 1997, PATHOL BIOL, V45, P804; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; QUELLE DE, 1995, CELL, V83, P993; Rathmell WK, 1997, CANCER RES, V57, P68; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	91	205	207	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	1999	18	53					7666	7675		10.1038/sj.onc.1202951	http://dx.doi.org/10.1038/sj.onc.1202951			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618706				2022-12-17	WOS:000084634500005
J	Li, SY; Labrecque, S; Gauzzi, MC; Cuddihy, AR; Wong, AHT; Pellegrini, S; Matlashewski, GJ; Koromilas, AE				Li, SY; Labrecque, S; Gauzzi, MC; Cuddihy, AR; Wong, AHT; Pellegrini, S; Matlashewski, GJ; Koromilas, AE			The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha	ONCOGENE			English	Article						interferon; human papilloma virus; cell signaling; oncoproteins; protein phosphorylation; DNA-binding	ANOGENITAL HUMAN PAPILLOMAVIRUS; TYROSINE KINASE; GENE-EXPRESSION; IFN-GAMMA; TRANSCRIPTIONAL ACTIVATION; BETA RECEPTOR; PROTEIN; BINDING; SUBUNIT; CELLS	We have examined the effects of human papilloma virus (HPV) E6 proteins on interferon (IFN) signaling. Here we show that expression of the 'malignant' HPV-18 E6 in human HT1080 cells results in inhibition of Jak-STAT activation in response to IFN-alpha but not IFN-gamma. This inhibitory effect is not shared by the 'benign' HPV-11 E6, The DNA-binding and transactivation capacities of the transcription factor ISGF3 are diminished in cells expressing HPV-18 E6 after IFN-alpha treatment as a result of decreased tyrosine phosphorylation of Tyk2, STAT2 and STAT1. However, HPV-18 E6 does not affect the induction of tyrosine phosphorylation and DNA-binding of STAT1 by IFN-gamma. In addition, HPV E6 proteins physically interact,vith Tyk2, This interaction takes place preferably with HPV-18 E6 and to a lesser extent with HPV-11 E6. The E6/Tyk2 interaction requires the JH(6)-JH(7) domains of Tyk2, which are important for Tyk2 binding to the cytoplasmic portion of IFN-alpha receptor 1 (IFNAR1). These findings demonstrate an inhibitory role of HPV-18 E6 in the IFN-alpha-induced Jak-STAT pathway, which may be explained, at least in part, by the ability of E6 to interact with and impair Tyk2 activation.	McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; McGill Univ, Inst Parasitol, Montreal, PQ, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada; Inst Pasteur, INSERM, U276, F-75724 Paris 15, France	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Koromilas, AE (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine St, Montreal, PQ H3T 1E2, Canada.		Pellegrini, Sandra -/G-5546-2015; Gauzzi, Maria Cristina/N-7038-2017; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Gauzzi, Maria Cristina/0000-0002-2996-5231; Pellegrini, Sandra/0000-0001-5837-7589; Cuddihy, Andrew/0000-0002-9898-0443				BLUYSSEN HAR, 1996, CYTOKINE GROWTH F R, V1, P11; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; FUERST TR, 1986, P NATL ACAD SCI USA, V86, P2365; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HAY R, 1994, ATCC CELL LINES HYBR, P70; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; LABRECQUE S, 1995, ONCOGENE, V11, P387; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; ROCKLEY PF, 1995, PHARMACOL THERAPEUT, V65, P265, DOI 10.1016/0163-7258(94)00063-9; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Routes JM, 1996, J IMMUNOL, V156, P1055; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SHAH KV, 1996, FIELDS VIROLOGY, P2077; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; STELLATO G, 1992, SEX TRANSM DIS, V19, P124, DOI 10.1097/00007435-199205000-00002; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TROFATTER KF, 1991, DERMATOL CLIN, V9, P343; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VILCEK J, 1996, FIELDS VIROLOGY, P375; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	49	205	220	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5727	5737		10.1038/sj.onc.1202960	http://dx.doi.org/10.1038/sj.onc.1202960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523853	Bronze			2022-12-17	WOS:000083095100001
J	Saikumar, P; Dong, Z; Weinberg, JM; Venkatachalam, MA				Saikumar, P; Dong, Z; Weinberg, JM; Venkatachalam, MA			Mechanisms of cell death in hypoxia/reoxygenation injury	ONCOGENE			English	Article						apoptosis; necrosis; Bax; Bcl-2; hypoxia; reoxygenation	FOCAL CEREBRAL-ISCHEMIA; CYTOCHROME-C; REPERFUSION INJURY; PROTEASE CASCADE; IN-VITRO; APOPTOSIS; BCL-2; RELEASE; NECROSIS; OXYGEN	Investigation of death pathways during cell injury in vivo caused by ischemia and reperfusion is of clinical importance, but technically difficult. Heterogeneity of cell types, differences between organ systems, diversity of death paradigms and exacerbation of tissue damage caused by inflammation are only some of the variables that need to be taken into account. With respect to the identification of necrosis and apoptosis in affected organs, technical issues related to preparation artifacts, occurrence of internucleosomal DNA cleavage in necrotic as well as apoptotic cells and other overlaps in death pathways bear consideration. In that caspase independent as well as caspase dependent processes cause cell death and that caspase inhibitors can act as anti-inflammatory agents, evaluation of ischemic death mechanisms in parenchymal cells needs to be performed with caution. When the effects of inflammation are removed by appropriate in vitro studies using purified or cultured cells, several mitochondrial factors that lead to cell death can be studied. Substantial evidence exists for the participation of electron transport defects, mitochondrial permeability transitions (MPT) and release of cytochrome c from mitochondria, effected by pro-apoptotic proteins such as Bax. The anti-apoptotic protein Bcl-2 exerts an overriding protective role in this type of injury by preserving mitochondrial structure and function. In contrast, caspase inhibitors cannot offer long-term protection to ischemically injured parenchymal cells regardless of how effectively they can inhibit apoptotic events, if the cells have suffered permanent mitochondrial damage impairing respiration.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health San Antonio; University of Michigan System; University of Michigan	Saikumar, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.							Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borutaite V, 1996, J MOL CELL CARDIOL, V28, P2195, DOI 10.1006/jmcc.1996.0211; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chopp M, 1996, ACT NEUR S, V66, P21; Cotran R.S., 1998, ROBBINS PATHOLOGIC B; Dong Z, 1997, AM J PATHOL, V151, P1205; Dong Z, 1998, AM J PATHOL, V152, P231; Eguchi Y, 1997, CANCER RES, V57, P1835; ENGLER RL, 1989, AM J CARDIOL, V63, P19; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FLITTER WD, 1993, BRIT MED BULL, V49, P545, DOI 10.1093/oxfordjournals.bmb.a072629; Frade JM, 1997, BIOESSAYS, V19, P827, DOI 10.1002/bies.950190913; GONZALEZFLECHA B, 1995, BBA-GEN SUBJECTS, V1243, P361, DOI 10.1016/0304-4165(94)00160-Y; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Johnson K J, 1993, Curr Opin Nephrol Hypertens, V2, P625, DOI 10.1097/00041552-199307000-00014; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kajstura J, 1998, AM J CARDIOL, V82, p30K, DOI 10.1016/S0002-9149(98)00535-9; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; McCarthy NJ, 1998, CURR TOP DEV BIOL, V36, P259; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MURFITT RR, 1978, J MOL CELL CARDIOL, V10, P109, DOI 10.1016/0022-2828(78)90036-6; NARO F, 1993, CARDIOSCIENCE, V4, P177; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Nogae S, 1998, J AM SOC NEPHROL, V9, P620; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PIPER HM, 1994, CARDIOVASC RES, V28, P1, DOI 10.1093/cvr/28.1.1; Piper HM, 1998, CARDIOVASC RES, V38, P291, DOI 10.1016/S0008-6363(98)00033-9; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; SAIKUMAR P, 1998, IN PRESS ONCOGENE; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thiagarajan RR, 1997, THROMB HAEMOSTASIS, V78, P310; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toleikis A, 1980, Adv Myocardiol, V2, P327; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wiegele G, 1998, NEPHROL DIAL TRANSPL, V13, P1158, DOI 10.1093/ndt/13.5.1158; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; ZAGER RA, 1993, CIRC RES, V73, P926, DOI 10.1161/01.RES.73.5.926; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	205	225	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3341	3349		10.1038/sj.onc.1202579	http://dx.doi.org/10.1038/sj.onc.1202579			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916996				2022-12-17	WOS:000078048200015
J	Casey, G; Lopez, ME; Ramos, JC; Plummer, SJ; Arboleda, MJ; Shaughnessy, M; Karlan, B; Slamon, DJ				Casey, G; Lopez, ME; Ramos, JC; Plummer, SJ; Arboleda, MJ; Shaughnessy, M; Karlan, B; Slamon, DJ			DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies	ONCOGENE			English	Article						p53 tumor suppressor gene; breast cancer; ovarian cancer; lung cancer; mutations; immunohistochemical staining	HUMAN BREAST-CANCER; TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; STRAND CONFORMATION POLYMORPHISM; DENATURANT GEL-ELECTROPHORESIS; LI-FRAUMENI-SYNDROME; PROTEIN EXPRESSION; OVARIAN-CANCER; MUTANT P53; PROGNOSTIC-SIGNIFICANCE	p53 mutations are the most common genetic alterations found in human malignancies, However current estimates of p53 alterations in cancers may be inaccurate because there is evidence that current approaches do not detect all p53 alterations, In this study we determine the status of the p53 gene by complete DNA sequencing of exons 2 through 11 as well as immunohistochemical staining in cohorts of primary human breast, ovarian and non small cell lung cancer, Overall, 24 of 93 (26%) breast cancers, 62 of 108 (57%) ovarian cancers and 88 of 154 (57%) non small cell lung cancers contained DNA sequence mutations, whereas positive immunohistochemical staining was detected in 15 of 64 (23%) breast, 35 of 94 (37%) ovarian, and 63 of 137 (46%) lung cancers, Of those tumors that contained mutations, the mutation occurred outside the 'hot-spot' region in 19% of breast, 18% of ovarian and 17% of lung tumors, indicating that a substantial number of mutations remain undetected in studies that are restricted to exons 5 through 9, We observed a high concordance between the presence of p53 missense mutations and positive immunohistochemical staining, but a poor concordance between other types of mutations and staining in all three types of malignancies. We conclude that a combination of DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known alterations in the p53 gene in human malignancies.	UNIV CALIF LOS ANGELES, DEPT MED, DIV HEMATOL & ONCOL, LOS ANGELES, CA 90024 USA; CEDARS SINAI MED CTR, DEPT OBSTET & GYNECOL, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90048 USA	University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Casey, G (corresponding author), CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CASEY G, 1991, ONCOGENE, V6, P1791; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CHIBA I, 1990, ONCOGENE, V5, P1603; CHO KR, 1992, J CELL BIOCHEM, P137; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLES C, 1992, CANCER RES, V52, P5291; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DENG G, 1994, CANCER RES, V54, P499; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EELES RA, 1993, CANCER SURV, V18, P57; EELES RA, 1993, ONCOGENE, V8, P1269; ELLEDGE RM, 1994, CANCER RES, V54, P3752; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL PA, 1993, ONCOGENE, V8, P203; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTMANN A, 1995, J CLIN INVEST, V95, P686, DOI 10.1172/JCI117714; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORAK E, 1991, ONCOGENE, V6, P2277; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LIPPONEN P, 1993, INT J CANCER, V55, P51, DOI 10.1002/ijc.2910550110; LOHMANN D, 1993, DIAGN MOL PATHOL, V2, P36, DOI 10.1097/00019606-199300020-00006; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKS JR, 1991, CANCER RES, V51, P2979; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MILNER BJ, 1993, CANCER RES, V53, P2128; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLES JP, 1993, ONCOGENE, V8, P583; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOYRET C, 1994, ONCOGENE, V9, P1739; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE RJ, 1991, CANCER RES, V51, P6194; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; PENG HQ, 1993, CANCER RES, V53, P3574; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; POLLER DN, 1993, HUM PATHOL, V24, P463, DOI 10.1016/0046-8177(93)90157-C; PROSSER J, 1990, ONCOGENE, V5, P1573; PURDIE CA, 1994, ONCOGENE, V9, P603; REIHSAUS E, 1990, ONCOGENE, V5, P137; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SOMERS KD, 1992, CANCER RES, V52, P5997; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WALKER RA, 1991, J PATHOL, V165, P203, DOI 10.1002/path.1711650303; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	93	205	207	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1971	1981						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934544				2022-12-17	WOS:A1996VR79500017
J	GRECO, A; PIEROTTI, MA; BONGARZONE, I; PAGLIARDINI, S; LANZI, C; DELLAPORTA, G				GRECO, A; PIEROTTI, MA; BONGARZONE, I; PAGLIARDINI, S; LANZI, C; DELLAPORTA, G			TRK-T1 IS A NOVEL ONCOGENE FORMED BY THE FUSION OF TPR AND TRK GENES IN HUMAN PAPILLARY THYROID CARCINOMAS	ONCOGENE			English	Article							TYROSINE KINASE DOMAIN; PROTO-ONCOGENE; BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; PROTOONCOGENE; SEQUENCES; RECOMBINATION; PROTEINS; MECHANISM; DNA	We have recently reported the frequent activation of the TRK oncogene in human papillary thyroid carcinoma. In this paper we describe the isolation and characterization of one of the thyroid TRK oncogenes, designated TRK-T1. A 1746-bp-long cDNA was isolated from a library derived from a primary transformant. The cDNA was able to induce foci in NIH3T3 cells. Sequence analysis revealed that TRK-T1 is created by an intrachromosomal rearrangement that juxtaposes the 5' end of the TPR gene to the TRK tyrosine kinase domain. The resulting hybrid mRNA contains 598 nucleotides of the TPR gene and 1148 nucleotides of the TRK proto-oncogene. TRK-T1 mRNA encodes a protein of 55 kDa reacting with antibodies against the carboxy terminus of the proto-TRK protein. We show also the involvement of TPR in the generation of another TRK-T oncogene.	IST NAZL TUMORI,DIV EXPTL ONCOL B,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	GRECO, A (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		Pierotti, Marco Alessandro/AAC-4728-2022; Lanzi, Cinzia/J-6539-2016; Bongarzone, Italia/B-9544-2017; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Lanzi, Cinzia/0000-0002-4480-9413; Bongarzone, Italia/0000-0003-2530-9170; Greco, Angela/0000-0003-2994-0349				BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CHAN AML, 1987, ONCOGENE, V1, P229; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KING WSH, 1988, ONCOGENE, V2, P617; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIOZZO M, 1990, ONCOGENE, V5, P1411; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MORRIS CM, 1991, ONCOGENE, V6, P1093; NALDINI L, 1991, ONCOGENE, V6, P501; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	31	205	227	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					237	242						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532241				2022-12-17	WOS:A1992HG98200005
J	KAHN, SM; JIANG, W; CULBERTSON, TA; WEINSTEIN, IB; WILLIAMS, GM; TOMITA, N; RONAI, Z				KAHN, SM; JIANG, W; CULBERTSON, TA; WEINSTEIN, IB; WILLIAMS, GM; TOMITA, N; RONAI, Z			RAPID AND SENSITIVE NONRADIOACTIVE DETECTION OF MUTANT K-RAS GENES VIA ENRICHED PCR AMPLIFICATION	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; POINT MUTATIONS; HUMAN CANCER; ONCOGENES; ACTIVATION; DIAGNOSIS; ADENOCARCINOMA; CARCINOGENESIS; TUMORIGENESIS; ANTIONCOGENES	We have developed a rapid and highly sensitive nonradioactive method for the detection of a mutant codon 12 human c-K-ras allele in the presence of as many as 10(4) copies of the wild type codon 12 allele. This sensitivity is achieved by selective polymerase chain reaction (PCR) amplification of mutant K-ras gene sequences employing a two stage procedure. The first stage entails the amplification of both K-ras mutant and wild type codon 12 sequences, followed by a selective restriction enzyme digestion of only wild type sequences. The second stage involves a subsequent amplification of undigested amplified fragments, enriched in mutant codon 12 sequences. These products are subject to restriction length polymorphism analysis for the detection of point mutations at codon 12. This technique is rapid, nonradioactive, and eliminates the need for either oligonucleotide hybridization or DNA sequencing. Variations of this selective amplification procedure may prove promising for the detection of specific point mutations in heterogenous cell populations.	COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032; AMER HLTH FDN,MOLEC CARCINOGENESIS PROGRAM,VALHALLA,NY 10595; AMER HLTH FDN,DIV PATHOL & TOXICOL,VALHALLA,NY 10595	Columbia University; Columbia University; American Health Foundation; American Health Foundation	RONAI, Z (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032, USA.			Jiang, Wei/0000-0002-2309-9571	NATIONAL CANCER INSTITUTE [P01CA021111, P30CA017613, R01CA039545] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39545, CA021111, CA17613] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1988, MUTAT RES, V195, P225; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; JIANG W, 1989, ONCOGENE, V4, P923; KAHN SM, 1990, AMPLIFICATIONS, V4, P22; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUMAR R, 1989, CANCER CEL, V7, P151; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR R, 1988, ONCOGENE, V3, P647; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; MCCORMICK F, 1989, CANCER CELL-MON REV, V1, P56; MIYAOTO S, 1990, MOL CELL BIOL, V19, P1593; NASSAL M, 1990, NUCLEIC ACIDS RES, V18, P3077, DOI 10.1093/nar/18.10.3077; PERUCHO M, 1989, CANCER CEL, V7, P137; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	29	205	223	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1079	1083						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1676837				2022-12-17	WOS:A1991GU62200027
J	Peter, ME				Peter, M. E.			Targeting of mRNAs by multiple miRNAs: the next step	ONCOGENE			English	Review						miRNA; targeting; p21	MICRORNA TARGETS; DIFFERENTIATION; TUMORIGENESIS; PREDICTIONS; FAMILY	Micro(mi)RNAs are small noncoding RNAs that regulate expression of the majority of the genes in the genome at either the messenger RNA (mRNA) level (by degrading mRNA) or the protein level (by blocking translation). miRNAs are thought to be components of vast regulatory networks. Currently, the field is focused primarily on identifying novel targets of individual miRNAs. This focus is about to undergo a dramatic change. In a new paper by Wu et al. (2010) it is experimentally confirmed that multiple miRNAs target the same gene, suggesting that it is the combination of all these activities that determines the expression of miRNA target genes. This study ushers in a new era of miRNA research that focuses on networks more than on individual connections between miRNA and strongly predicted targets. Oncogene (2010) 29, 2161-2164; doi: 10.1038/onc.2010.59;	Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA	University of Chicago	Peter, ME (corresponding author), Univ Chicago, Ben May Dept Canc Res, 924 E 57th St,R112, Chicago, IL 60637 USA.	MPeter@uchicago.edu		Peter, Marcus Ernst/0000-0003-3216-036X				Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hammell M, 2008, NAT METHODS, V5, P813, DOI 10.1038/NMETH.1247; Hobert O, 2007, CELL, V131, P22, DOI 10.1016/j.cell.2007.09.031; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jiang Q, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-194; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Khan AA, 2009, NAT BIOTECHNOL, V27, P549, DOI 10.1038/nbt.1543; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003592; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Ritchie W, 2009, NAT METHODS, V6, P397, DOI 10.1038/nmeth0609-397; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Watanabe Y, 2007, METHOD ENZYMOL, V427, P65, DOI 10.1016/S0076-6879(07)27004-1; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34	23	204	215	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2161	2164		10.1038/onc.2010.59	http://dx.doi.org/10.1038/onc.2010.59			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20190803				2022-12-17	WOS:000276685200001
J	DeYoung, MP; Ellisen, LW				DeYoung, M. P.; Ellisen, L. W.			p63 and p73 in human cancer: defining the network	ONCOGENE			English	Review						p53; p63; p73; apoptosis; tumorigenesis; squamous cell carcinoma (SCC)	SQUAMOUS-CELL CARCINOMA; YES-ASSOCIATED PROTEIN; P53 FAMILY-MEMBERS; KINASE C-ABL; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; REGULATES P73; UP-REGULATION; LUNG-CANCER	The p53-related genes p63 and p73 exhibit signicant structural homology to p53; however, they do not function as classical tumor suppressors and are rarely mutated in human cancers. Both p63 and p73 exhibit tissue-specific roles in normal development and a complex contribution to tumorigenesis that is due to their expression as multiple protein isoforms. The predominant p63/p73 isoforms expressed both in normal development and in many tumors lack the conserved transactivation ( TA) domain; these isoforms instead exhibit a truncated N-terminus (DN) and function at least in part as transcriptional repressors. p63 and p73 isoforms are regulated through both transcriptional and post-translational mechanisms, and they in turn regulate diverse cellular functions including proliferation, survival and differentiation. The net effect of p63/p73 expression in a given context depends on the ratio of TA/DN isoforms expressed, on physical interaction between p63 and p73 isoforms, and on functional interactions with p53 at the promoters of specific downstream target genes. These multifaceted interactions occur in diverse ways in tumor-specific contexts, demonstrating a functional 'p53 family network' in human tumorigenesis. Understanding the regulation and mechanistic contributions of p63 and p73 in human cancers may ultimately provide new therapeutic opportunities for a variety of these diseases.	Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ellisen, LW (corresponding author), Massachusetts Gen Hosp, Ctr Canc, GRJ-904,55 Fruit St, Boston, MA 02114 USA.	ellisen@helix.mgh.harvard.edu	Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910	NIDCR NIH HHS [R01 DE015945, DE-15945] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015945] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agami R, 1999, NATURE, V399, P809; Antonini D, 2006, MOL CELL BIOL, V26, P3308, DOI 10.1128/MCB.26.8.3308-3318.2006; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barbieri CE, 2006, EXP CELL RES, V312, P695, DOI 10.1016/j.yexcr.2005.11.028; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79; Blandino G, 2004, CELL CYCLE, V3, P886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Chi SG, 1999, CANCER RES, V59, P2791; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Choi HR, 2002, HUM PATHOL, V33, P158, DOI 10.1053/hupa.2002.30722; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Corn PG, 1999, CANCER RES, V59, P3352; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Cuadros M, 2006, LEUKEMIA RES, V30, P170, DOI 10.1016/j.leukres.2005.06.024; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Dominguez G, 2001, BREAST CANCER RES TR, V66, P183, DOI 10.1023/A:1010624717311; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Ghioni P, 2005, CELL CYCLE, V4, P183, DOI 10.4161/cc.4.1.1359; Gong JG, 1999, NATURE, V399, P806; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Green H, 2003, P NATL ACAD SCI USA, V100, P15625, DOI 10.1073/pnas.0307226100; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hagiwara K, 1999, CANCER RES, V59, P4165; Hanamoto T, 2005, J BIOL CHEM, V280, P16665, DOI 10.1074/jbc.M414323200; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Jacobs WB, 2005, NEURON, V48, P743, DOI 10.1016/j.neuron.2005.10.027; Jeong MH, 2006, J BIOL CHEM, V281, P8707, DOI 10.1074/jbc.M513853200; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamiya M, 2002, J NEURO-ONCOL, V59, P143, DOI 10.1023/A:1019633910603; Kawano S, 1999, BLOOD, V94, P1113; Keyes WM, 2006, P NATL ACAD SCI USA, V103, P8435, DOI 10.1073/pnas.0602477103; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Koga F, 2003, CLIN CANCER RES, V9, P5501; Koker MM, 2004, AM J SURG PATHOL, V28, P1506, DOI 10.1097/01.pas.0000138183.97366.fd; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leupin N, 2004, LEUKEMIA LYMPHOMA, V45, P1205, DOI 10.1080/10298190310001623829; Li N, 2006, ONCOGENE, V25, P2349, DOI 10.1038/sj.onc.1209270; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu SS, 2006, CLIN CANCER RES, V12, P3922, DOI 10.1158/1078-0432.CCR-05-2573; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Massion PP, 2003, CANCER RES, V63, P7113; Matheny KE, 2003, LARYNGOSCOPE, V113, P936, DOI 10.1097/00005537-200306000-00004; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; Moll UM, 2004, MOL CANCER RES, V2, P371; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peters UR, 1999, CANCER RES, V59, P4233; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ramalho FS, 2006, J GASTROEN HEPATOL, V21, P1276, DOI 10.1111/j.1440-1746.2006.04309.x; Redon R, 2001, CANCER RES, V61, P4122; Reis JS, 2003, CANCER CYTOPATHOL, V99, P172, DOI 10.1002/cncr.11061; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Rizzo MG, 2004, LEUKEMIA, V18, P1804, DOI 10.1038/sj.leu.2403483; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2006, J INVEST DERMATOL, V126, P1469, DOI 10.1038/sj.jid.5700297; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rossi M, 2006, CELL CYCLE, V5, P1816, DOI 10.4161/cc.5.16.2861; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Tannapfel A, 2001, J PATHOL, V195, P163, DOI 10.1002/path.947; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; TROUNG AB, 2006, GENE DEV, V20, P3185; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wager M, 2006, BRIT J CANCER, V95, P1062, DOI 10.1038/sj.bjc.6603410; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Wang TY, 2001, HUM PATHOL, V32, P479, DOI 10.1053/hupa.2001.24324; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Watson IR, 2006, NEOPLASIA, V8, P655, DOI 10.1593/neo.06439; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yamamoto T, 2001, BREEDING SCI, V51, P63, DOI 10.1270/jsbbs.51.63; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zamo A, 2005, MODERN PATHOL, V18, P1448, DOI 10.1038/modpathol.3800440; Zangen R, 2005, CELL CYCLE, V4, P1313, DOI 10.4161/cc.4.10.2066; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	159	204	217	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5169	5183		10.1038/sj.onc.1210337	http://dx.doi.org/10.1038/sj.onc.1210337			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334395				2022-12-17	WOS:000248674200001
J	Salvesen, GS; Abrams, JM				Salvesen, GS; Abrams, JM			Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies	ONCOGENE			English	Review						caspase; IAP; apoptosis; zymogen activation; drosophila	PROGRAMMED CELL-DEATH; STRESS-INDUCED APOPTOSIS; DROSOPHILA CASPASE; CYTOCHROME-C; STRUCTURAL BASIS; CYSTEINE PROTEASE; IMMUNE-RESPONSE; IAP PROTEINS; GRANZYME-B; REAPER	The central components of the execution phase of apoptosis in worms, flies, and humans are members of the caspase protease family. Work in Drosophila and mammalian systems has revealed a web of interactions that govern the activity of these proteases, and two fundamental control points have been identified. These are zymogen activation-the process that converts a latent caspase into its active form, and inhibition of the resulting active protease. In humans, the driving force for caspase activity is activation of the zymogens, but in Drosophila, a major thrust is derepression of caspase inhibitors. In this review, we consider evidence for these two distinct events in terms of the regulation of caspase activity. This sets the scene for therapy to reinstate the normal death mechanisms that have been overcome in a cancer cell's quest for immortality.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92122 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92122 USA.	gsalvesen@burnham.org; john.abrams@utsouthwestern.edu			NCI NIH HHS [CA69381] Funding Source: Medline; NIA NIH HHS [AG15402, AG12466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012466, R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bose K, 2001, BIOCHEMISTRY-US, V40, P14236, DOI 10.1021/bi0110387; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chai JJ, 2003, NAT STRUCT BIOL, V10, P892, DOI 10.1038/nsb989; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Claveria C, 2002, EMBO J, V21, P3327, DOI 10.1093/emboj/cdf354; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HEGDE R, 2001, J BIOL CHEM; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(02)02075-5; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Lisi S, 2000, GENETICS, V154, P669; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Manderson AP, 2001, J EXP MED, V194, P747, DOI 10.1084/jem.194.6.747; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MARTINS LM, 2001, J BIOL CHEM; MCCALL K, 2003, 44 ANN DROS RES C A, V946; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Pop C, 2001, BIOCHEMISTRY-US, V40, P14224, DOI 10.1021/bi011037e; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thress K, 1999, EMBO J, V18, P5486, DOI 10.1093/emboj/18.20.5486; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; VERHAGEN AM, 2001, J BIOL CHEM; Verhagen AM, 2001, GENOME BIOL, V2; Vernooy SY, 2002, CURR BIOL, V12, P1164, DOI 10.1016/S0960-9822(02)00935-1; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2001, MECH DEVELOP, V102, P193, DOI 10.1016/S0925-4773(01)00316-1; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Wu TYH, 2003, CHEM BIOL, V10, P759, DOI 10.1016/S1074-5521(03)00157-1; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Yu SY, 2002, DEVELOPMENT, V129, P3269; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	135	204	208	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2774	2784		10.1038/sj.onc.1207522	http://dx.doi.org/10.1038/sj.onc.1207522			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077141				2022-12-17	WOS:000220799600005
J	Agochiya, M; Brunton, VG; Owens, DW; Parkinson, EK; Paraskeva, C; Keith, WN; Frame, MC				Agochiya, M; Brunton, VG; Owens, DW; Parkinson, EK; Paraskeva, C; Keith, WN; Frame, MC			Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells	ONCOGENE			English	Article						focal adhesion kinase; tyrosine kinase; protein expression; cancer; FAK	PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-SRC; TERMINAL DOMAIN; PP125(FAK); ASSOCIATION; CARCINOMA; PAXILLIN; EXPRESSION; APOPTOSIS	Focal adhesion kinase (pp125(FAK)) is present at sites of cell/extracellular matrix adhesion and has been implicated in the control of cell behaviour. In particular, as a key component of integrin-stimulated signal transduction pathways, pp125(FAK) is involved in cellular processes such as spreading, motility, growth and survival. In addition, a number of reports have indicated that pp125(FAK) may be up-regulated in human tumour cells of diverse origin, and consequently, a role has been proposed for pp125(FAK) in the development of invasive cancers. However, to date the mechanisms that lead to elevated pp125(FAK) expression in tumour cells have not been determined. Here ne used iii situ hybridization to confirm chromosome 8q as the genomic location of the human fak gene and report that elevation of pp125(FAK) protein in cell lines derived from invasive squamous cell carcinomas is accompanied by gains in copy number of the fak gene in all cases examined, In addition,,ve observed increased fak copy number in frozen sections of squamous cell carcinomas. Furthermore, increased dosage of the fak gene was also observed in many cell lines derived from human tumours of lung, breast and colon, including two cell lines Calu3 and HT29, in which fak was amplified. In addition, in an in vitro model for human colon cancer progression there was a copy number gain of the fak gene during conversion from adenoma to carcinoma, which was associated with increased pp125(FAK) protein expression, Thus, ne show for the first time that many cell lines derived from invasive epithelial tumours hare increased dosage of the fak gene, which may contribute to the elevated protein expression commonly observed, Although other genes near the fak locus are coamplified or increased in copy number, including the proto-oncogene c-myc, the biological properties of pp125(FAK) in controlling the growth, survival and invasiveness of tumour cells, suggest that it may contribute to the selection pressure for maintaining increased dosage of the region of chromosome 8q that encodes these genes.	Beatson Inst Canc Res, CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; Univ Glasgow, Dept Med Oncol, CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Bristol; Beatson Institute; University of Glasgow	Frame, MC (corresponding author), Beatson Inst Canc Res, CRC Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FIEDOREK FT, 1995, MAMM GENOME, V6, P123, DOI 10.1007/BF00303256; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MANNING AM, 1991, ONCOGENE, V6, P1471; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; MURPHY LM, 1995, J SYNCHROTRON RADIAT, V2, P64, DOI 10.1107/S0909049594010861; OWENS LV, 1995, CANCER RES, V55, P2752; PARKINSON EK, 1986, INT J RADIAT BIOL, V50, P717, DOI 10.1080/09553008614551111; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; TURNER CE, 1994, J CELL SCI, V107, P1583; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	43	204	213	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5646	5653		10.1038/sj.onc.1202957	http://dx.doi.org/10.1038/sj.onc.1202957			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523844	Bronze			2022-12-17	WOS:000083016500005
J	Balmanno, K; Cook, SJ				Balmanno, K; Cook, SJ			Sustained MAP kinase activation is required for the expression of cyclin D1, p21(Cip1) and a subset of AP-1 proteins in CCL39 cells	ONCOGENE			English	Article						thrombin; Fos; Jun; AP-1; cyclin D1	SIGNAL-REGULATED KINASE; NIH 3T3 CELLS; C-FOS; GROWTH-FACTORS; TRANSCRIPTIONAL ACTIVATION; NEURONAL DIFFERENTIATION; TRANSFORMING ACTIVITY; G0-TO-G1 TRANSITION; THROMBIN-RECEPTOR; MOUSE FIBROBLASTS	In CCL39 cells thrombin is a potent growth factor which requires sustained activation of mitogen activated protein kinases (MAPKs) to promote DNA synthesis. Some of the effects of thrombin can be mimicked by peptides based on the new amino terminus of the cleaved receptor; however, these thrombin receptor peptides (TRPs) fail to induce sustained activation of MAPK or DNA synthesis, We have used thrombin, TRP-7 and other agonists which elicit sustained or transient MAPK activation to identify immediate-early and delayed-early genes which are only expressed under conditions of sustained MAPK activation focusing on cyclin D1, p21(Cip1) and the AP-1 transcription factor, Of the stimuli tested only FBS and thrombin were able to stimulate a sustained activation of MAPK, expression of cyclin D1, p21(Cip1) and cell cycle re-entry, The expression of cyclin D1 was strongly, though not completely, inhibited by the MEK1 inhibitor PD098059. Thrombin stimulated a rapid but transient accumulation of c-Fos whereas the expression of Fra-1, Fra-2, c-Jun and JunB was sustained throughout the G1 phase of the cell cycle. We focussed our analysis on c-Fos (typical of AP-1 genes which are expressed rapidly and transiently) and Fra-1 and JunB (typical of AP-1 genes expressed after a delay but in a sustained manner). The expression of c-Fos, Fra-1 and JunB was dependent upon the activation of MAPK since these responses were inhibited by PD098059, However, a comparison of responses to FBS, thrombin, TRPs, LPA and EGF revealed that Fra-1 and JunB expression required sustained activation of MAPK whereas c-Fos expression was strongly induced even by non-mitogenic stimuli which elicited only transient MAPK activation, The expression of c-Fos (in response to thrombin; TRP or LPA) or Fra-1, JunB and cyclin D1 (thrombin only) was also inhibited by pertussis toxin, This suggests that both early and late AP-1 gene expression is regulated by the same Gi-mediated, MEK-dependent MAPK signalling pathway but that expression of late AP-1 genes and cyclin D1 requires that this pathway be persistently activated. The results suggest that the duration of receptor signalling and therefore MAPK activation is a key determinant of qualitative changes in gene expression during cell cycle re-entry.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Babraham Hall, Cambridge CB2 4AT, England.			Balmanno, Kathryn/0000-0002-6417-3889				AGARWAL S, 1995, ONCOGENE, V11, P427; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen RH, 1996, ONCOGENE, V12, P1493; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; COOK SJ, 1999, IN PRESS MOL CELL BI, V19; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DECESARE D, 1995, ONCOGENE, V11, P365; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRUDA MC, 1994, ONCOGENE, V9, P2537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hawker KL, 1996, ONCOGENE, V13, P283; HERBER B, 1994, ONCOGENE, V9, P1295; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TREINIES I, 1999, IN PRESS MOL CELL BI, V19; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAN GZ, 1995, J NEUROSCI, V15, P6200	69	204	207	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3085	3097		10.1038/sj.onc.1202647	http://dx.doi.org/10.1038/sj.onc.1202647			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340380				2022-12-17	WOS:000080388000004
J	Bosher, JM; Totty, NF; Hsuan, JJ; Williams, T; Hurst, HC				Bosher, JM; Totty, NF; Hsuan, JJ; Williams, T; Hurst, HC			A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma	ONCOGENE			English	Article						c-erbB-2; AP-2; transcription; mammary carcinoma	TRANSCRIPTION FACTOR AP-2; POSITIVE BREAST-CANCER; RNA POLYMERASE-II; NEU ONCOGENE; DNA-BINDING; RECEPTOR; OVEREXPRESSION; ACTIVATION; AMPLIFICATION; EMBRYOGENESIS	The proto-oncogene c-erbB-2 is overexpressed in 25-30% of breast cancers through increased transcription and amplification of the gene, We have previously described a factor, OB2-1 which upregulates c-erbB-2 transcription and which is closely related to the developmentally regulated transcription factor, AP-2. Further analysis of affinity purified OB2-1 has now shown that it is in fact a combination of proteins from three AP-2-related genes, the previously described AP-2 alpha gene and two new human family members, AP-2 beta and AP-2 gamma whose cloning and characterisation are described here. All three AP-2 proteins show a high degree of homology and are capable of binding to the c-erbB-2 promoter as homo- or heterodimers. The three proteins can also activate a c-erbB-2 reporter construct, but AP-2 alpha and AP-2 gamma are 3-4 times more active in this regard than AP-2 beta. In addition both AP-2 alpha and AP-2 gamma are expressed at elevated levels in the majority of c-erbB-2 overexpressing mammary tumour lines examined. Mechanisms which may have led to the increased AP-2 levels in these cells are discussed.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,ONCOL UNIT,GENE TRANSPORTAT LAB,LONDON W12 0NN,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOL BIOL,LONDON WC1E 6BT,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; Yale University			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564	NIGMS NIH HHS [GM46770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DSOUZA B, 1993, ONCOGENE, V8, P1797; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HOLLYWOOD DP, 1995, BRIT J CANCER, V71, P753, DOI 10.1038/bjc.1995.146; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SNAPE AM, 1991, DEVELOPMENT, V113, P283; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9; TOTTY NF, 1972, SCIENCE, V1, P1215; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	34	204	210	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1701	1707						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895516				2022-12-17	WOS:A1996VM88700015
J	VIGLIETTO, G; MAGLIONE, D; RAMBALDI, M; CERUTTI, J; ROMANO, A; TRAPASSO, F; FEDELE, M; IPPOLITO, P; CHIAPPETTA, G; BOTTI, G; FUSCO, A; PERSICO, MG				VIGLIETTO, G; MAGLIONE, D; RAMBALDI, M; CERUTTI, J; ROMANO, A; TRAPASSO, F; FEDELE, M; IPPOLITO, P; CHIAPPETTA, G; BOTTI, G; FUSCO, A; PERSICO, MG			UP-REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) AND DOWN-REGULATION OF PLACENTA GROWTH-FACTOR (PIGF) ASSOCIATED WITH MALIGNANCY IN HUMAN THYROID-TUMORS AND CELL-LINES	ONCOGENE			English	Article						HUMAN THYROID; P1GF; VEGF; TUMOR; ANGIOGENESIS	PERMEABILITY FACTOR; TYROSINE KINASE; DEVELOPMENTAL EXPRESSION; NUCLEOTIDE-SEQUENCE; STROMA GENERATION; ANGIOGENIC FACTOR; RIBONUCLEIC-ACID; MESSENGER-RNA; FACTOR-ALPHA; FACTOR GENE	Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells in vitro, promotes neoangiogenesis in vivo and increases the permeability of the vascular endothelium. VEGF overexpression occurs in several cultured tumor cell lines and in certain human malignancies, Placenta growth factor (PIGF) is a recently identified growth factor for endothelial cells (EC); PIGF strongly potentiates both the proliferative and the permeabilization effects exerted by VEGF on the vascular endothelium, To uncover the molecular mechanisms underlying neoangiogenesis in human thyroid tumors, we have analysed VEGF and PIGF expression in a panel of thyroid carcinoma cell lines with different tumorigenic potential as well as in human primary thyroid tumors, We show that a high tumorigenic potential is associated with an elevated VEGF expression in human thyroid tumor cell lines, Furthermore, VEGF overexpression occurs in 5/5 highly malignant anaplastic carcinomas, Papillary and follicular carcinomas express intermediate levels of VEGF mRNA. In contrast, PIGF expression is severely down regulated in the majority of thyroid tumor cell lines and in tumors, Furthermore, we show that both the VEGF receptors, FLT-1 and flk/KDR, are expressed in endothelial cells that line tumor-embedded microvascular vessels, suggesting that VEGF but not PIGF, contributes to thyroid tumor development.	FAC MED & CHIRURG,CNR,CTR ONCOL SPERIMENTALE,DIPARTIMENTO BIOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	VIGLIETTO, G (corresponding author), IST NAZL TUMORI,FDN SENATORE PASCALE,VIA M SEMMOLA,I-80131 NAPLES,ITALY.		Cerutti, Janete M/E-9121-2014; Viglietto, Giuseppe/AAC-2852-2019; Cerutti, Janete/D-3513-2014; Fedele, Monica/C-1417-2015	Viglietto, Giuseppe/0000-0003-2327-7515; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197; Botti, Gerardo/0000-0002-6287-733X; Cerutti, Janete/0000-0003-0156-8274				BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BROWN LF, 1993, CANCER RES, V53, P4727; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1993, CANCER, V73, P2206; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, P995; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; OLSON TA, 1994, CANCER RES, V54, P276; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISHER E, 1991, J BIOL CHEM, V266, P11974; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILSON JD, 1989, TXB ENDOCRINOLOGY; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZEKI K, 1991, J CLIN ENDOCR METAB, V76, P125	70	204	210	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1569	1579						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478581				2022-12-17	WOS:A1995TC53500015
J	TENHOEVE, J; MORRIS, C; HEISTERKAMP, N; GROFFEN, J				TENHOEVE, J; MORRIS, C; HEISTERKAMP, N; GROFFEN, J			ISOLATION AND CHROMOSOMAL LOCALIZATION OF CRKL, A HUMAN CRK-LIKE GENE	ONCOGENE			English	Article							INTERPHASE CELL-NUCLEI; SH3 DOMAINS; GENOMIC DISTANCE; DNA-SEQUENCES; NCK PROTEIN; PHOSPHORYLATION; RECEPTORS; LEUKEMIA; BCR	We have identified and partially characterized a gene located on chromosome 22, band q11, centromeric of the chronic myelogenous leukemia breakpoint region. A number of overlapping cDNAs were isolated from this locus and the largest of 1.8 kb was sequenced. Its deduced amino acid sequence shows homology to the SH2 domains of protein tyrosine kinases such as FER. and is strikingly similar to the cellular part of the v-crk oncogene product. We identified one SH2 and two SH3 domains within the 303 amino acid open reading frame of this crk-like gene, CRKL. The CRKL gene product is predicted to have a molecular mass of 36 kDa. In addition, we demonstrate that this gene does not represent the human homolog of v-crk but rather a novel gene potentially capable of mediating the transduction of intracellular signals.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAG SECT,4650 SUNSET BLVD,LOS ANGELES,CA 90027; CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND	Children's Hospital Los Angeles; Christchurch Hospital New Zealand			Morris, Christine/G-1690-2011; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 47456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER SR, 1988, IMMUNOGENETICS, V28, P328, DOI 10.1007/BF00364231; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P8045, DOI 10.1093/nar/16.16.8045; HEITER PA, 1981, NATURE, V294, P536; KAPLAN JC, 1987, J MED GENET, V24, P65, DOI 10.1136/jmg.24.2.65; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, AM J HUM GENET, V48, P1; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B	28	204	208	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2469	2474						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361759				2022-12-17	WOS:A1993LT36800018
J	SHAULSKY, G; GOLDFINGER, N; TOSKY, MS; LEVINE, AJ; ROTTER, V				SHAULSKY, G; GOLDFINGER, N; TOSKY, MS; LEVINE, AJ; ROTTER, V			NUCLEAR-LOCALIZATION IS ESSENTIAL FOR THE ACTIVITY OF P53 PROTEIN	ONCOGENE			English	Article							TRANSFORMATION-RELATED PROTEIN; COLI BETA-GALACTOSIDASE; VIRUS-40 TUMOR-ANTIGENS; CELL-CYCLE CONTROL; LARGE-T-ANTIGEN; MONOCLONAL-ANTIBODY; WILD-TYPE; SV40-TRANSFORMED CELLS; SEQUENCE REQUIREMENTS; DNA-REPLICATION	p53 appears to be a growth regulator, the perturbation of which induces changes in normal cell proliferation. Wild-type p53 protein is thought to function as a growth arrest gene, whereas mutant p53, which accumulates in transformed cells, has been shown to enhance malignant transformation. Both wild-type and mutant p53 migrate into the cell nucleus by means of identical nuclear localization signals (NLS) inherent in their primary sequences. Results presented here show that the suppressive activity of wild-type p53 measured as the reduction of transformation of primary rat fibroblasts induced by cotransfection with ras and either E1A or mutant p53, as well as the transformation enhancement of mutant p53 estimated by cooperation with ras in transformation of primary rat fibroblasts, is dependent upon nuclear localization signals in p53 protein. While transfection of unmodified wild-type p53 significantly reduces the number of rat embryonic fibroblast-transformed foci induced by E1A and ras or mutant p53 and ras, the wild-type p53 protein without NLS has completely lost this suppressive activity. Partially defective NLS wild-type p53, with a reduced nuclear accumulation ability, still exhibits some suppressive activity. In addition, we found that plasmids coding for intact mutant p53 protein efficiently cooperate with the ras oncogene, whereas the corresponding plasmids without NLS are totally inert. On this basis we conclude that nuclear localization of both wild-type and mutant p53 is a fundamental feature for manifesting the activities of these proteins. Both the suppressor activity mediated by the wild-type p53 and enhancement of transformation mediated by the mutant p53 require nuclear localization of the proteins to function.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	ROTTER, V (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.			Shaulsky, Gad/0000-0002-0532-0551				ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KELMAN Z, 1989, BLOOD, V74, P2318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINGJUN Z, 1988, CELL, V55, P1005; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; MORIN N, 1989, MOL CELL BIOL, V9, P4372, DOI 10.1128/MCB.9.10.4372; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROTTER V, 1983, J IMMUNOL, V181, P329; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6567; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WYCHOWSKI C, 1986, EMBO J, V5, P2569, DOI 10.1002/j.1460-2075.1986.tb04536.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	63	204	206	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2055	2065						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719467				2022-12-17	WOS:A1991GX11900017
J	STURZBECHER, HW; CHUMAKOV, P; WELCH, WJ; JENKINS, JR				STURZBECHER, HW; CHUMAKOV, P; WELCH, WJ; JENKINS, JR			MUTANT P53 PROTEINS BIND HSP 72/73 CELLULAR HEAT SHOCK-RELATED PROTEINS IN SV40-TRANSFORMED MONKEY CELLS	ONCOGENE			English	Article									ACAD SCI USSR,INST MOLEC BIOL,MOSCOW V-71,USSR; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory	STURZBECHER, HW (corresponding author), MARIE CURIE RES INST,OXTED RH8 0TL,SURREY,ENGLAND.		Chumakov, Peter M/E-7731-2014	Chumakov, Peter/0000-0002-8078-2908				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE DG, 1986, J BIOL CHEM, V261, P2102; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1981, J VIROL, V38, P336, DOI 10.1128/JVI.38.1.336-346.1981; ROTTER V, 1983, J IMMUNOL, V131, P329; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RUSCETTI SK, 1983, J VIROL, V46, P1022, DOI 10.1128/JVI.46.3.1022-1026.1983; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	46	204	206	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					201	211						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2830579				2022-12-17	WOS:A1987J635200013
J	Petrilli, AM; Fernandez-Valle, C				Petrilli, A. M.; Fernandez-Valle, C.			Role of Merlin/NF2 inactivation in tumor biology	ONCOGENE			English	Review							NEUROFIBROMATOSIS TYPE-2 GENE; SUPPRESSOR PROTEIN MERLIN; HISTONE DEACETYLASE INHIBITOR; HUMAN SCHWANNOMA CELLS; MEDIATES CONTACT INHIBITION; HIPPO SIGNALING PATHWAY; CPG ISLAND METHYLATION; ORGAN SIZE CONTROL; NF2 GENE; VESTIBULAR SCHWANNOMAS	Merlin (Moesin-ezrin-radixin-like protein, also known as schwannomin) is a tumor suppressor protein encoded by the neurofibromatosis type 2 gene NF2. Loss of function mutations or deletions in NF2 cause neurofibromatosis type 2 (NF2), a multiple tumor forming disease of the nervous system. NF2 is characterized by the development of bilateral vestibular schwannomas. Patients with NF2 can also develop schwannomas on other cranial and peripheral nerves, as well as meningiomas and ependymomas. The only potential treatment is surgery/radiosurgery, which often results in loss of function of the involved nerve. There is an urgent need for chemotherapies that slow or eliminate tumors and prevent their formation in NF2 patients. Interestingly NF2 mutations and merlin inactivation also occur in spontaneous schwannomas and meningiomas, as well as other types of cancer including mesothelioma, glioma multiforme, breast, colorectal, skin, clear cell renal cell carcinoma, hepatic and prostate cancer. Except for malignant mesotheliomas, the role of NF2 mutation or inactivation has not received much attention in cancer, and NF2 might be relevant for prognosis and future chemotherapeutic approaches. This review discusses the influence of merlin loss of function in NF2-related tumors and common human cancers. We also discuss the NF2 gene status and merlin signaling pathways affected in the different tumor types and the molecular mechanisms that lead to tumorigenesis, progression and pharmacological resistance.	[Petrilli, A. M.; Fernandez-Valle, C.] Univ Cent Florida, Dept Biomed Sci, Coll Med, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Burnett Sch Biomed Sci, Coll Med, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	cfv@ucf.edu			National Institute of Health [5R01DC10189, 5R01NS062825]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010189] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by the National Institute of Health 5R01DC10189 and 5R01NS062825 grants. We thank AB Knott for editorial assistance and Dr C Vivacharawongse for reviewing the manuscript and helpful discussions.	Aboukais R, 2013, ACTA NEUROCHIR, V155, P997, DOI 10.1007/s00701-013-1692-2; Agnihotri S, 2014, J NEUROSURG, V121, P1434, DOI 10.3171/2014.6.JNS131433; Ahmad Z, 2010, OTOL NEUROTOL, V31, P460, DOI 10.1097/MAO.0b013e3181d2777f; Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Allison KH, 2014, ONCOLOGY-NY, V28, P772; Alonso ME, 2004, J NEURO-ONCOL, V67, P159; Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Ammoun S, 2014, ONCOGENE, V33, P336, DOI 10.1038/onc.2012.587; Ammoun S, 2015, MOL ONCOL, V9, P236, DOI 10.1016/j.molonc.2014.08.005; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2012, GLIA, V60, P1721, DOI 10.1002/glia.22391; Ammoun S, 2011, NEURO-ONCOLOGY, V13, P759, DOI 10.1093/neuonc/nor056; Ammoun S, 2010, NEURO-ONCOLOGY, V12, P834, DOI 10.1093/neuonc/noq012; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2; Bai Y, 2007, ONCOGENE, V26, P836, DOI 10.1038/sj.onc.1209849; Barron DA, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-25; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Baylin SB, 1998, ADV CANCER RES, V72, P141; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Bensenor LB, 2010, P NATL ACAD SCI USA, V107, P7311, DOI 10.1073/pnas.0907389107; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Boin A, 2014, NEURO-ONCOLOGY, V16, P1196, DOI 10.1093/neuonc/nou020; Bosco EE, 2010, ONCOGENE, V29, P2540, DOI 10.1038/onc.2010.20; Bourguignon LYW, 2007, J NEUROCHEM, V101, P1002, DOI 10.1111/j.1471-4159.2007.04485.x; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Burns SS, 2013, CANCER RES, V73, P792, DOI 10.1158/0008-5472.CAN-12-1888; Bush ML, 2011, NEURO-ONCOLOGY, V13, P983, DOI 10.1093/neuonc/nor072; Bydon M, 2013, SPINE J, V13, P1379, DOI 10.1016/j.spinee.2013.06.037; Cacev T, 2014, CELL ONCOL, V37, P69, DOI 10.1007/s13402-013-0164-2; Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Cooper J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002314; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Evans DGR, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-16; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Flaiz C, 2008, GLIA, V56, P506, DOI 10.1002/glia.20629; Flaiz C, 2009, BRAIN PATHOL, V19, P27, DOI 10.1111/j.1750-3639.2008.00165.x; Fleury-Feith J, 2003, ONCOGENE, V22, P3799, DOI 10.1038/sj.onc.1206593; Frontzek F, 2014, BIOCHEM CELL BIOL, V92, P530, DOI 10.1139/bcb-2014-0041; Garcia C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097320; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gehlhausen JR, 2015, HUM MOL GENET, V24, P1, DOI 10.1093/hmg/ddu414; Geissler KJ, 2013, P NATL ACAD SCI USA, V110, P20587, DOI 10.1073/pnas.1222078110; Gilbert MR, 2010, CURR NEUROL NEUROSCI, V10, P240, DOI 10.1007/s11910-010-0109-3; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 2014, NEURO-ONCOLOGY, V16, P493, DOI 10.1093/neuonc/not242; Gonzalez-Gomez P, 2003, CLIN CANCER RES, V9, P5601; Goutagny S, 2014, BRAIN PATHOL, V24, P184, DOI 10.1111/bpa.12110; Gronholm M, 1999, J CELL SCI, V112, P895; Guerrero PA, 2015, ONCOGENE, V34, P2621, DOI 10.1038/onc.2014.185; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Hansen JR, 2006, GLIA, V53, P593, DOI 10.1002/glia.20316; Hennigan RF, 2010, MOL CELL BIOL, V30, P54, DOI 10.1128/MCB.00248-09; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Hiemer SE, 2013, BBA-GEN SUBJECTS, V1830, P2323, DOI 10.1016/j.bbagen.2012.07.005; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; Horiguchi A, 2008, PROSTATE, V68, P975, DOI 10.1002/pros.20760; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; Jacob A, 2008, OTOL NEUROTOL, V29, P58, DOI 10.1097/mao.0b013e31816021f7; Jacob A, 2012, LARYNGOSCOPE, V122, P174, DOI 10.1002/lary.22392; James MF, 2012, MOL CANCER RES, V10, P649, DOI 10.1158/1541-7786.MCR-11-0425-T; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Johnson MD, 2002, J NEUROSURG, V97, P668, DOI 10.3171/jns.2002.97.3.0668; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kalamarides M, 2010, J NEURO-ONCOL, V99, P325, DOI 10.1007/s11060-010-0331-5; Kawana Y, 2002, PROSTATE, V53, P60, DOI 10.1002/pros.10131; Khajeh JA, 2014, J MOL BIOL, V426, P2755, DOI 10.1016/j.jmb.2014.05.011; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Kodaka M, 2015, CELL MOL LIFE SCI, V72, P285, DOI 10.1007/s00018-014-1742-9; Koutsimpelas D, 2012, ORL J OTO-RHINO-LARY, V74, P33, DOI 10.1159/000334968; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Larsson J, 2008, CELL STEM CELL, V3, P221, DOI 10.1016/j.stem.2008.06.005; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Laulajainen M, 2011, NEOPLASIA, V13, P643, DOI 10.1593/neo.11356; Lee TX, 2009, EUR J CANCER, V45, P1709, DOI 10.1016/j.ejca.2009.03.013; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Lloyd SKW, 2013, HAND CLINIC, V115, P957, DOI 10.1016/B978-0-444-52902-2.00054-0; Lomas J, 2005, GENE CHROMOSOME CANC, V42, P314, DOI 10.1002/gcc.20141; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Low BC, 2014, FEBS LETT, V588, P2663, DOI 10.1016/j.febslet.2014.04.012; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Malhotra A, 2013, CANCER BIOL THER, V14, P840, DOI 10.4161/cbt.25329; Mawrin C, 2005, CLIN CANCER RES, V11, P4074, DOI 10.1158/1078-0432.CCR-04-2550; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Morales FC, 2010, NEURO-ONCOLOGY, V12, P528, DOI 10.1093/neuonc/nop060; Mori T, 2014, GENES CELLS, V19, P603, DOI 10.1111/gtc.12161; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Mukherjee J, 2009, CANCER RES, V69, P5099, DOI 10.1158/0008-5472.CAN-08-4475; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Muranen T, 2007, HUM MOL GENET, V16, P1742, DOI 10.1093/hmg/ddm122; Murray LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043295; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pass HI, 2004, CURR PROB CANCER, V28, P85; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Petrilli A, 2014, ONCOGENE, V33, P3571, DOI 10.1038/onc.2013.320; Petrilli AM, 2014, AM J TRANSL RES, V6, P471; Petrilli AM, 2013, ONCOTARGET, V4, P2354, DOI 10.18632/oncotarget.1422; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Pineau P, 2003, HEPATOLOGY, V37, P852, DOI 10.1053/jhep.2003.50138; Plotkin SR, 2011, J NEUROSURG-SPINE, V14, P543, DOI 10.3171/2010.11.SPINE10350; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Reinhold WC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101670; Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1; Robinson BS, 2011, CURR BIOL, V21, pR890, DOI 10.1016/j.cub.2011.09.019; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Rustgi AK, 1995, CANCER GENET CYTOGEN, V84, P24, DOI 10.1016/0165-4608(95)00059-3; Sabha N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039412; Sainio M, 1997, J CELL SCI, V110, P2249; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Schroeder MC, 2012, SEMIN CELL DEV BIOL, V23, P803, DOI 10.1016/j.semcdb.2012.06.001; Schulz A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0082-1; Schulz A, 2014, BRAIN, V137, P420, DOI 10.1093/brain/awt327; Schulz A, 2013, NAT NEUROSCI, V16, P426, DOI 10.1038/nn.3348; Scoles DR, 2008, BBA-REV CANCER, V1785, P32, DOI 10.1016/j.bbcan.2007.10.001; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sheikh HA, 2004, AM J SURG PATHOL, V28, P101, DOI 10.1097/00000478-200401000-00012; Sher I, 2012, DEV CELL, V22, P703, DOI 10.1016/j.devcel.2012.03.008; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smole Z, 2014, CANCER RES, V74, P353, DOI 10.1158/0008-5472.CAN-13-1334; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Sperfeld AD, 2002, BRAIN, V125, P996, DOI 10.1093/brain/awf115; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Striedinger K, 2008, NEOPLASIA, V10, P1204, DOI 10.1593/neo.08642; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Thaxton C, 2008, ONCOGENE, V27, P2705, DOI 10.1038/sj.onc.1210923; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; Thurneysen C, 2009, LUNG CANCER, V64, P140, DOI 10.1016/j.lungcan.2008.08.014; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wickremesekera A, 2007, J CLIN NEUROSCI, V14, P1199, DOI 10.1016/j.jocn.2007.05.009; Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; YAEGASHI S, 1995, JPN J CANCER RES, V86, P929, DOI 10.1111/j.1349-7006.1995.tb03003.x; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Ye KQ, 2007, CELL ADHES MIGR, V1, P196, DOI 10.4161/cam.1.4.5192; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yogesha SD, 2011, PROTEIN SCI, V20, P2113, DOI 10.1002/pro.751; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Yoo NJ, 2012, PATHOLOGY, V44, P29, DOI 10.1097/PAT.0b013e32834c3599; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	186	203	209	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					537	548		10.1038/onc.2015.125	http://dx.doi.org/10.1038/onc.2015.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893302	Green Accepted			2022-12-17	WOS:000369548800001
J	Lara, E; Mai, A; Calvanese, V; Altucci, L; Lopez-Nieva, P; Martinez-Chantar, ML; Varela-Rey, M; Rotili, D; Nebbioso, A; Ropero, S; Montoya, G; Oyarzabal, J; Velasco, S; Serrano, M; Witt, M; Villar-Garea, A; Inhof, A; Mato, JM; Esteller, M; Fraga, MF				Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M. L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Inhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F.			Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect	ONCOGENE			English	Article						HDACs inhibitors; Sirtuins; cancer; apoptosis	HISTONE DEACETYLASE INHIBITORS; SMALL-MOLECULE INHIBITOR; DNA-DAMAGE; SIR2; P53; DISCOVERY; IDENTIFICATION; NICOTINAMIDE; MECHANISM; SURVIVAL	Sirtuin 1 (Sirt1) and Sirtuin 2 (Sirt2) belong to the family of NAD+(nicotinamide adenine dinucleotide-positive)dependent class III histone deacetylases and are involved in regulating lifespan. As cancer is a disease of ageing, targeting Sirtuins is emerging as a promising antitumour strategy. Here we present Salermide (N-{3-[(2-hydroxynaphthalen-1-ylmethylene)-amino]-phenyl}-2-phenyl-propionamide), a reverse amide with a strong in vitro inhibitory effect on Sirt1 and Sirt2. Salermide was well tolerated by mice at concentrations up to 100 mu M and prompted tumour-specific cell death in a wide range of human cancer cell lines. The antitumour activity of Salermide was primarily because of a massive induction of apoptosis. This was independent of global tubulin and K16H4 acetylation, which ruled out a putative Sirt2-mediated apoptotic pathway and suggested an in vivo mechanism of action through Sirt1. Consistently with this, RNA interference-mediated knockdown of Sirt1, but not Sirt2, induced apoptosis in cancer cells. Although p53 has been reported to be a target of Sirt1, genetic p53 knockdowns showed that the Sirt1-dependent proapoptotic effect of Salermide is p53-independent. We were finally able to ascribe the apoptotic effect of Salermide to the reactivation of proapoptotic genes epigenetically repressed exclusively in cancer cells by Sirt1. Taken together, our results underline Salermide's promise as an anticancer drug and provide evidence for the molecular mechanism through which Sirt1 is involved in human tumorigenesis.	[Lara, E.; Calvanese, V.; Lopez-Nieva, P.; Ropero, S.; Fraga, M. F.] CNIO, Spanish Natl Canc Res Ctr, Canc Epigenet Lab, E-28029 Madrid, Spain; [Mai, A.; Rotili, D.] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy; [Altucci, L.; Nebbioso, A.] Univ Naples 2, Dipartimento Patol Gen, Naples, Italy; [Martinez-Chantar, M. L.; Varela-Rey, M.; Mato, J. M.] CIC BioGUNE, CIBERehd, Bizkaia, Spain; [Montoya, G.] CNIO, Spanish Natl Canc Res Ctr, Ctr Macromol Crystallog, E-28029 Madrid, Spain; [Oyarzabal, J.] CNIO, Spanish Natl Canc Res Ctr, Computat Chem Grp, E-28029 Madrid, Spain; [Velasco, S.; Serrano, M.] CNIO, Spanish Natl Canc Res Ctr, Tumour Suppress Grp, E-28029 Madrid, Spain; [Witt, M.] Bruker Daltonik GmbH, Bremen, Germany; [Villar-Garea, A.; Inhof, A.] Univ Munich, Histone Modificat Grp, Adolf Butenandt Inst, Munich, Germany; [Esteller, M.] ICO, PEBC, Barcelona, Spain; [Fraga, M. F.] CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Fondazione Cenci Bolognetti; Sapienza University Rome; Universita della Campania Vanvitelli; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; CIC bioGUNE; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Bruker Corporation; Bruker Daltonik GmbH; University of Munich; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Fraga, MF (corresponding author), CNIO, Spanish Natl Canc Ctr, Canc Epigenet Lab, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mesteller@cnio.es; mffraga@cnio.es	Esteller, Manel/L-5956-2014; Calvanese, Vincenzo/E-1145-2016; Serrano, Manuel/H-2634-2015; Rotili, Dante/J-9157-2016; Nieva, Pilar López/R-9516-2019; Varela-Rey, Marta/C-5460-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Fraga, Mario F/H-7824-2017; Chantar, Maria Luz Martinez/F-5190-2011; MATO, JOSE/A-5187-2011; Oyarzabal, Julen/K-7393-2017; Calvanese, Vincenzo/AAO-4311-2020; Altucci, Lucia/S-8031-2019; Mai, Antonello/AAC-2144-2019; NEBBIOSO, Angela/C-3566-2016	Esteller, Manel/0000-0003-4490-6093; Calvanese, Vincenzo/0000-0002-7937-1511; Serrano, Manuel/0000-0001-7177-9312; Nieva, Pilar López/0000-0001-6369-2444; Fraga, Mario F/0000-0001-8450-2603; Chantar, Maria Luz Martinez/0000-0002-6446-9911; MATO, JOSE/0000-0003-1264-3153; Oyarzabal, Julen/0000-0003-1941-7255; Calvanese, Vincenzo/0000-0002-7937-1511; Rotili, Dante/0000-0002-8428-8763; NEBBIOSO, Angela/0000-0001-5374-3527; Villar Garea, Ana/0000-0001-8960-1635; Varela-Rey, Marta/0000-0002-2413-8659; altucci, lucia/0000-0002-7312-5387; Mai, Antonello/0000-0001-9176-2382	European Union [LSHG-CT-2006-037415]; Spanish Ramon & Cajal Programme; Health Department of the Spanish Government [PI061267]; Health and Education and Science Departments of the Spanish Government [FIS01-04, I+D+I MCYT08-03, FU2004-02073/BMC, MEC09-05]; European Grant [TRANSFOG LSHC-CT-2004-503438, EPITRON LSHC-CT2005- 518417, APO-SYS HEALTH-F4-2007-200767]; Spanish Association Against Cancer; FIS Spanish Research Program; FPU Spanish Research Program;  [PRIN2006];  [AICR2007]	European Union(European Commission); Spanish Ramon & Cajal Programme(Spanish Government); Health Department of the Spanish Government; Health and Education and Science Departments of the Spanish Government; European Grant; Spanish Association Against Cancer; FIS Spanish Research Program; FPU Spanish Research Program(Spanish Government); ; 	This work was primarily supported by the European Union (LSHG-CT-2006-037415). MFF is funded by the Spanish Ramon & Cajal Programme and the Health Department of the Spanish Government (PI061267). Thanks are due to PRIN2006 (AM) and AICR2007 (AM) for grants. The Cancer Epigenetics group at the CNIO is supported by the Health (FIS01-04) and Education and Science (I+D+I MCYT08-03, FU2004-02073/BMC and Consolider MEC09-05) Departments of the Spanish Government, the European Grant TRANSFOG LSHC-CT-2004-503438, EPITRON LSHC-CT2005- 518417, APO-SYS HEALTH-F4-2007-200767 and the Spanish Association Against Cancer (AECC). EL is a recipient of a fellowship from the FIS Spanish Research Program. VC is a recipient of a Fellowship from the FPU Spanish Research Program.	Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Clark AM, 2006, J CHEM INF MODEL, V46, P1107, DOI 10.1021/ci050550m; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fraga MF, 2007, ANN NY ACAD SCI, V1100, P60, DOI 10.1196/annals.1395.005; Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Herranz M, 2006, BLOOD, V107, P1174, DOI 10.1182/blood-2005-05-2033; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huhtiniemi T, 2006, J COMPUT AID MOL DES, V20, P589, DOI 10.1007/s10822-006-9084-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kamel C, 2006, AGING CELL, V5, P81, DOI 10.1111/j.1474-9726.2006.00191.x; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mai A, 2005, J MED CHEM, V48, P7789, DOI 10.1021/jm050100l; Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Napper AD, 2005, J MED CHEM, V48, P8045, DOI 10.1021/jm050522v; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Olaharski AJ, 2005, PLOS GENET, V1, P689, DOI 10.1371/journal.pgen.0010077; Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Parks BA, 2007, ANAL CHEM, V79, P7984, DOI 10.1021/ac070553t; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Ropero S, 2004, BREAST CANCER RES TR, V86, P125, DOI 10.1023/B:BREA.0000032981.20384.c6; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Sun YN, 2007, LUNG CANCER, V58, P21, DOI 10.1016/j.lungcan.2007.05.013; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Villar-Garea A, 2008, CURR PROTOC PROTEIN; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620	46	203	207	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					781	791		10.1038/onc.2008.436	http://dx.doi.org/10.1038/onc.2008.436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060927				2022-12-17	WOS:000263320000001
J	Calin, GA; Croce, CM				Calin, G. A.; Croce, C. M.			MicroRNAs and chromosomal abnormalities in cancer cells	ONCOGENE			English	Review						microRNAs; chromosom al aberrations; cancer	CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN LUNG CANCERS; C-MYC; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; CHAIN GENE; EXPRESSION; LOCUS; TRANSLOCATION; 13Q14	Over the past five decades, a plethora of nonrandom chromosomal abnormalities have been consistently reported in malignant cells facilitating the identification of cancer-associated protein coding oncogenes and tumor suppressors. The genetic dissection of hot spots for chromosomal abnormalities in the age of the sequenced human genome resulted in the discovery that microRNA ( miRNA) genes, encoding for a class of small noncoding RNAs, frequently resides in such genomic regions. The combination of nonrandom chromosomal abnormalities and other types of genetic alterations or epigenetic events contribute to downregulation or overexpression of miRNAs. The consequent abnormal expression of miRNAs affect cell cycle, survival and differentiation programs and selective targeting of these noncoding genes could provide novel therapeutic options for killing the malignant cells.	Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Croce, CM (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Wiseman Hall Room 385K,400 12th Ave, Columbus, OH 43210 USA.	Carlo.Croce@osumc.edu	Calin, George/E-9390-2011; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Calin, George/0000-0001-6704-5615				ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Barlund M, 2000, CANCER RES, V60, P5340; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Berezikov E, 2005, HUM MOL GENET, V14, pR183, DOI 10.1093/hmg/ddi271; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bullrich F, 2001, CANCER RES, V61, P6640; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2006, LEUKEMIA RES, V30, P653, DOI 10.1016/j.leukres.2005.10.017; Calin GA, 2006, SEMIN ONCOL, V33, P167, DOI 10.1053/j.seminoncol.2006.01.010; Calin GA, 2005, NEW ENGL J MED, V352, P1667, DOI 10.1056/NEJMoa042280; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; CROCE CM, 1985, BLOOD, V65, P1; CROCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P6922, DOI 10.1073/pnas.80.22.6922; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Czech MP, 2006, NEW ENGL J MED, V354, P1194, DOI 10.1056/NEJMcibr060065; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; di Iasio MG, 1999, ONCOGENE, V18, P1635, DOI 10.1038/sj.onc.1202453; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; ETIEMBLE J, 1989, ONCOGENE, V4, P51; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Harfe BD, 2005, CURR OPIN GENET DEV, V15, P410, DOI 10.1016/j.gde.2005.06.012; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; MORRIS JPI, 2005, SCI STKE, V297, P1; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pekarsky Y, 2005, CURR TOP MICROBIOL, V294, P51, DOI 10.1007/3-540-29933-5_4; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; ROLDO C, 2006, IN PRESS J CLIN ONCO; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Slack Frank J, 2006, Future Oncol, V2, P73, DOI 10.2217/14796694.2.1.73; Sonoki T, 2005, LEUKEMIA, V19, P2009, DOI 10.1038/sj.leu.2403938; Tagawa H, 2005, LEUKEMIA, V19, P2013, DOI 10.1038/sj.leu.2403942; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tam W, 2006, GENE CHROMOSOME CANC, V45, P211, DOI 10.1002/gcc.20282; Tsuchiya E, 2000, JPN J CANCER RES, V91, P589, DOI 10.1111/j.1349-7006.2000.tb00986.x; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhao XT, 2003, CANCER LETT, V190, P221, DOI 10.1016/S0304-3835(02)00622-5	90	203	225	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6202	6210		10.1038/sj.onc.1209910	http://dx.doi.org/10.1038/sj.onc.1209910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028600				2022-12-17	WOS:000241158900009
J	Zeng, Y				Zeng, Y.			Principles of micro-RNA production and maturation	ONCOGENE			English	Review						micro-RNA; micro-RNA processing; Drosha; precursor miRNAs	DOUBLE-STRANDED-RNA; MEDIATES NUCLEAR EXPORT; STRUCTURAL BASIS; HUMAN DICER; BINDING; GENE; IDENTIFICATION; INTERFERENCE; BIOGENESIS; PROTEIN	Micro-RNAs ( miRNAs) are a class of approximately 22-nucleotide non-coding RNAs expressed in multicellular organisms. They are first transcribed in a similar manner to pre-mRNAs. The transcripts then go through a series of processing steps, including endonucleolytic cleavage, nuclear export and a strand selection procedure, to yield the single-stranded mature miRNA products. The transcription and processing of miRNAs determines the abundance and the sequence of mature miRNAs and has important implications for the function of miRNAs.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Zeng, Y (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zengx033@umn.edu						Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Andersson MG, 2005, J VIROL, V79, P9556, DOI 10.1128/JVI.79.15.9556-9565.2005; Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Blow MJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r27; Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Bracht J, 2004, RNA, V10, P1586, DOI 10.1261/rna.7122604; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Eliceiri GL, 1999, CELL MOL LIFE SCI, V56, P22, DOI 10.1007/s000180050003; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Feinbaum R, 1999, DEV BIOL, V210, P87, DOI 10.1006/dbio.1999.9272; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Gwizdek C, 2003, J BIOL CHEM, V278, P5505, DOI 10.1074/jbc.C200668200; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hiraguri A, 2005, PLANT MOL BIOL, V57, P173, DOI 10.1007/s11103-004-6853-5; Houbaviy HB, 2005, RNA, V11, P1245, DOI 10.1261/rna.2890305; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kurihara Y, 2006, RNA, V12, P206, DOI 10.1261/rna.2146906; Kurihara Y, 2004, P NATL ACAD SCI USA, V101, P12753, DOI 10.1073/pnas.0403115101; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li JJ, 2005, CURR BIOL, V15, P1501, DOI 10.1016/j.cub.2005.07.029; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Mallory AC, 2004, EMBO J, V23, P3356, DOI 10.1038/sj.emboj.7600340; Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Papp I, 2003, PLANT PHYSIOL, V132, P1382, DOI 10.1104/pp.103.021980; Park MY, 2005, P NATL ACAD SCI USA, V102, P3691, DOI 10.1073/pnas.0405570102; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shen BZ, 2004, SCIENCE, V306, P997, DOI 10.1126/science.1103521; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Tahbaz N, 2004, EMBO REP, V5, P189, DOI 10.1038/sj.embor.7400070; Tam W, 2001, GENE, V274, P157, DOI 10.1016/S0378-1119(01)00612-6; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2005, EMBO J, V24, P138, DOI 10.1038/sj.emboj.7600491; Zeng Y, 2005, J BIOL CHEM, V280, P27595, DOI 10.1074/jbc.M504714200; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	97	203	248	1	39	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6156	6162		10.1038/sj.onc.1209908	http://dx.doi.org/10.1038/sj.onc.1209908			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028594				2022-12-17	WOS:000241158900003
J	Veeck, J; Niederacher, D; An, H; Klopocki, E; Wiesmann, F; Betz, B; Galm, O; Camara, O; Durst, M; Kristiansen, G; Huszka, C; Knuchel, R; Dahl, E				Veeck, J.; Niederacher, D.; An, H.; Klopocki, E.; Wiesmann, F.; Betz, B.; Galm, O.; Camara, O.; Duerst, M.; Kristiansen, G.; Huszka, C.; Knuechel, R.; Dahl, E.			Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis	ONCOGENE			English	Article						breast cancer; tumour suppressor gene; Wnt pathway; SFRP1; methylation; epigenetics	TUMOR-SUPPRESSOR; BETA-CATENIN; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; BLADDER-CANCER; OVARIAN-CANCER; COMMON EVENT; CYCLIN D1; GENE	The canonical Wnt signalling pathway plays a key role during embryogenesis and defects in this pathway have been implicated in the pathogenesis of various types of tumours, including breast cancer. The gene for secreted frizzled-related protein 1 (SFRP1) encodes a soluble Wnt antagonist and is located in a chromosomal region (8p22-p12) that is often deleted in breast cancer. In colon, lung, bladder and ovarian cancer SFRP1 expression is frequently inactivated by promoter methylation. We have previously shown that loss of SFRP1 protein expression is a common event in breast tumours that is associated with poor overall survival in patients with early breast cancer. To investigate the cause of SFRP1 loss in breast cancer, we performed mutation, methylation and expression analysis in human primary breast tumours and breast cell lines. No SFRP1 gene mutations were detected. However, promoter methylation of SFRP1 was frequently observed in both primary breast cancer (61%, n=130) and cell lines analysed by methylation-specific polymerase chain reaction (MSP). We found a tight correlation (P < 0.001) between methylation and loss of SFRP1 expression in primary breast cancer tissue. SFRP1 expression was restored after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Most interestingly, SFRP1 promoter methylation was an independent factor for adverse patient survival in Kaplan-Meier analysis. Our results indicate that promoter hypermethylation is the predominant mechanism of SFRP1 gene silencing in human breast cancer and that SFRP1 gene inactivation in breast cancer is associated with unfavourable prognosis.	Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Dusseldorf, Dept Obstet & Gynecol, D-4000 Dusseldorf, Germany; Free Univ Berlin, Inst Med Genet, Berlin, Germany; Univ Hosp Aachen, Rhein Westfal TH Aachen, Med Clin 4, D-52074 Aachen, Germany; Univ Jena, Dept Gynecol, D-6900 Jena, Germany; Free Univ Berlin, Inst Pathol, Berlin, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Heinrich Heine University Dusseldorf; Free University of Berlin; RWTH Aachen University; RWTH Aachen University Hospital; Friedrich Schiller University of Jena; Free University of Berlin	Dahl, E (corresponding author), Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Klopocki, Eva/B-6823-2017; Veeck, Jürgen/B-9256-2008	Klopocki, Eva/0000-0003-1438-2081; Veeck, Jürgen/0000-0002-2952-6159; An, Han-Xiang/0000-0002-3453-9149				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2002, J NATL CANCER I, V94, P26; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Klopocki E, 2004, INT J ONCOL, V25, P641; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273; Polakis P, 2000, GENE DEV, V14, P1837; REMMELE W, 1987, PATHOLOGE, V8, P138; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447	40	203	217	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3479	3488		10.1038/sj.onc.1209386	http://dx.doi.org/10.1038/sj.onc.1209386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449975				2022-12-17	WOS:000238448100013
J	Dutertre, S; Descamps, S; Prigent, C				Dutertre, S; Descamps, S; Prigent, C			On the role of aurora-A in centrosome function	ONCOGENE			English	Review						aurora; cancer; centrosome; kinase	CHROMOSOME SEGREGATION REGULATORS; HISTONE H3 PHOSPHORYLATION; BIPOLAR MITOTIC SPINDLE; HUMAN BREAST-TUMORS; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; COLORECTAL CANCERS; DUCTAL CARCINOMA; FLOW-CYTOMETRY	Mammalian aurora-A belongs to a multigenic family of mitotic serine/threonine kinases comprising two other members: aurora-B and aurora-C. In this review we will focus on aurora-A that starts to localize to centrosomes only in S phase as soon as centrioles have been duplicated, the protein is then degraded in early G1. Works in various organisms have revealed that the kinase is involved in centrosome separation, duplication and maturation as well as in bipolar spindle assembly and stability. Aurora kinases are found in all organisms in which their function has been conserved throughout evolution, namely the control of chromosome segregation. In human, aurora-A has focused a lot of attention, since its overexpression has been found to be correlated with the grade of various solid tumours. Ectopic kinase overexpression in any culture cell line leads to polyploidy and centrosome amplification. However, overexpression of aurora-A in particular cell tines such as NIH3T3 is sufficient to induce growth on soft agar. Those transformed cells form tumours when implanted in immunodeficient mice, indicating that the kinase is an oncogene.	Univ Rennes 1, CNRS, UMR 6061 Genet & Dev, Grp Cycle Cellulaire,Fac Med, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1	Prigent, C (corresponding author), Univ Rennes 1, CNRS, UMR 6061 Genet & Dev, Grp Cycle Cellulaire,Fac Med, IFR 97,2 Ave Pr Leon Bernard,CS 34317, F-35043 Rennes, France.							Abad M, 1998, ANAL CELL PATHOL, V16, P223, DOI 10.1155/1998/158243; Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Arlot-Bonnemains Y, 2001, FEBS LETT, V508, P149, DOI 10.1016/S0014-5793(01)03048-4; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Frank-Vaillant M, 2000, J CELL SCI, V113, P1127; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, BIOL CELL, V91, P461, DOI 10.1016/S0248-4900(99)80087-2; Giet R, 1998, EXP CELL RES, V244, P470, DOI 10.1006/excr.1998.4218; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Giet R, 2001, J CELL SCI, V114, P2095; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Gustafson LM, 2000, LARYNGOSCOPE, V110, P1798; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hu HM, 2000, DNA CELL BIOL, V19, P679, DOI 10.1089/10445490050199063; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KLEIN FA, 1982, CANCER, V50, P389, DOI 10.1002/1097-0142(19820801)50:3<389::AID-CNCR2820500302>3.0.CO;2-I; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Magennis DP, 1997, BRIT J BIOMED SCI, V54, P140; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Petersen J, 2001, J CELL SCI, V114, P4371; Pihan GA, 1998, CANCER RES, V58, P3974; Roghi C, 1998, J CELL SCI, V111, P557; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sasaki O, 1999, ANAL QUANT CYTOL, V21, P85; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Sato N, 1999, CLIN CANCER RES, V5, P963; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sturgis CD, 1999, CANCER CYTOPATHOL, V87, P155, DOI 10.1002/(SICI)1097-0142(19990625)87:3<155::AID-CNCR9>3.0.CO;2-#; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tanaka T, 1999, CANCER RES, V59, P2041; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Whitehead CM, 1998, J CELL SCI, V111, P2551; Whitehead CM, 1996, CELL MOTIL CYTOSKEL, V35, P298, DOI 10.1002/(SICI)1097-0169(1996)35:4<298::AID-CM3>3.0.CO;2-3; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	74	203	226	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6175	6183		10.1038/sj.onc.1205775	http://dx.doi.org/10.1038/sj.onc.1205775			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214247				2022-12-17	WOS:000177840500006
J	de Molina, AR; Gutierrez, R; Ramos, MA; Silva, JM; Silva, J; Bonilla, F; Sanchez, JJ; Lacal, JC				de Molina, AR; Gutierrez, R; Ramos, MA; Silva, JM; Silva, J; Bonilla, F; Sanchez, JJ; Lacal, JC			Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy	ONCOGENE			English	Article						choline kinase; breast carcinomas; anticancer drugs; estrogen receptors	CANCER; INHIBITORS; TAMOXIFEN; PROGNOSIS; ANTIBODY; THERAPY; PROTEIN; MARKER	Choline kinase (ChoK) and its product, phosphocholine (PCho), have been implicated in human carcinogenesis. Inhibition of this enzyme has been shown to be an efficient antitumor strategy in viro. The aim of this study was to assess the relationship between the regulation of ChoK and clinical features in patients with breast cancer. To that end, normal and tumoral tissues from 53 patients with breast carcinomas were analysed for ChoK activity and expression, and compared to some clinical parameters. We report a relevant increase in ChoK activity in 38.5% of the tumoral tissues analysed when compared to the normal levels in healthy tissues. Furthermore, some clinical features were found significant versus ChoK status. First, an association of choline enzymatic activity with histological tumor grade was observed (P<0.001). In addition, increased ChoK activity was also associated with ER-negative breast carcinomas (P=0.037). A significant association between ChoK overexpression and both high histologic tumor grade (P=0.017) and ER-negative tumors (P=0.003) was found. Finally, ChoK overexpression was found in 17% of the samples and all corresponded with those that display the highest increase in ChoK activity (P<0.004). Here we provide evidence that ChoK may e related to the development of human breast cancer, suggesting that this finding may constitute the basis for the development of a novel antitumoral strategy for these patients.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, E-28029 Madrid, Spain; Hosp Puerta Hierro, Med Oncol Serv, Madrid, Spain; Univ Autonoma Madrid, Dept Estadist, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				Dominguez G, 2000, BREAST CANCER RES TR, V63, P17, DOI 10.1023/A:1006446709715; Fentiman IS, 2000, EUR J CANCER, V36, P1085, DOI 10.1016/S0959-8049(00)00088-5; Ferlay J, 2001, 5 IARC; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Lacal J C, 2001, IDrugs, V4, P419; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Powles T, 1998, LANCET, V352, P98; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; SALAZAR JM, 2001, REV ONCOLOGIA, V3, P171; Schneider J, 2000, ANTICANCER RES, V20, P4373; SLUYSER M, 1990, Anti-Cancer Drugs, V1, P127, DOI 10.1097/00001813-199012000-00003; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Tripathy D, 1992, Cancer Treat Res, V63, P15; VELASCO FB, 2001, REV ONCOLOGIA, V3, P130	20	203	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4317	4322		10.1038/sj.onc.1205556	http://dx.doi.org/10.1038/sj.onc.1205556			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082619				2022-12-17	WOS:000176174200014
J	Duyster, J; Bai, RY; Morris, SW				Duyster, J; Bai, RY; Morris, SW			Translocations involving anaplastic lymphoma kinase (ALK)	ONCOGENE			English	Review						ALK; NPM-ALK; variant ALK fusions; ALCL; IMT; pleiotrophin	LARGE-CELL LYMPHOMA; GROWTH-FACTOR PLEIOTROPHIN; LEUKOCYTE TYROSINE KINASE; MAJOR NUCLEOLAR PROTEINS; ALK-POSITIVE LYMPHOMA; NON-HODGKINS-LYMPHOMA; NF-KAPPA B; NPM-ALK; KI-1 LYMPHOMA; CLINICOPATHOLOGICAL FEATURES	Anaplastic large-cell lymphoma (ALCL) comprises a group of non-Hodgkin's lymphomas (NHLs) that were first described in 1985 by Stein and co-workers and are characterized by the expression of the CD30/Ki-1 antigen (Stein et al., 1985). Approximately half of these lymphomas are associated with a typical chromosomal translocation, t(2;5)(p23;q35). Much confusion about the exact classification and clinico pathological features of this subgroup of NHL was clarified with the identification of NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) as the oncogene created by the t(2;5) (Morris et al., 1994). With the discovery of NPM-ALK as the specific lymphoma gene mutation, this NHL subtype could be redefined on the molecular level. This achievement was enhanced by the availability of specific antibodies that recognize ALK fusion proteins in paraffin-embedded lymphoma tissues. Several excellent recent reviews have summarized the histo pathological and molecular findings of ALCL and their use in the classification of this lymphoma entity (Anagnostopoulos and Stein, 2000; Benharroch et al., 1998; Drexler et al., 2000, Foss et al., 2000; Gogusev and Nezelof, 1998; Kadin and Morris, 1998; Ladanyi, 1997; Morris et al., 2001; Shiota and Mori, 1996; Skinnider et al., 1999; Stein et al., 2000). This review will focus on the molecular function and signal transduction pathways activated by ALK fusion oncogenes, with recent advances and possible clinical implications to be discussed.	Tech Univ Munich, Lab Leukemogenesis, Dept Internal Med 3, D-81675 Munich, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	Technical University of Munich; University of Munich; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Duyster, J (corresponding author), Tech Univ Munich, Lab Leukemogenesis, Dept Internal Med 3, Ismanigerstr 22, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de; steve.morris@stjude.org			NATIONAL CANCER INSTITUTE [R01CA069129, R01CA076301, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA76301, CA69129, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anagnostopoulos I, 2000, PATHOLOGE, V21, P178, DOI 10.1007/s002920050384; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 1998, BLOOD, V92, p512A; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Beylot-Barry M, 1998, BLOOD, V91, P4668, DOI 10.1182/blood.V91.12.4668.412k20_4668_4676; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRUNEL V, 1995, GENE CHROMOSOME CANC, V14, P307, DOI 10.1002/gcc.2870140410; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; CHAN PK, 1995, BBA-GENE STRUCT EXPR, V1262, P37, DOI 10.1016/0167-4781(95)00044-H; CHAN PK, 1990, BIOCHEM J, V270, P549, DOI 10.1042/bj2700549; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cordell JL, 1999, BLOOD, V93, P632, DOI 10.1182/blood.V93.2.632; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; Falini B, 1999, BLOOD, V93, P2697; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Foss HD, 2000, PATHOLOGE, V21, P124, DOI 10.1007/s002920050380; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Gogusev J, 1998, HEMATOL ONCOL CLIN N, V12, P445, DOI 10.1016/S0889-8588(05)70522-0; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Griffin CA, 1999, CANCER RES, V59, P2776; HARRIS NL, 1994, BLOOD, V84, P1361; Hernandez L, 1999, BLOOD, V94, P3265; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hubinger G, 1999, BLOOD, V94, p598A; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Kadin ME, 1997, CANCER SURV, V30, P77; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kinney MC, 1999, AM J CLIN PATHOL, V111, pS56; Kinney MC, 1996, LAB INVEST, V74, P664; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ladanyi M, 1997, CANCER SURV, V30, P59; Ladanyi M, 1996, DIAGN MOL PATHOL, V5, P154, DOI 10.1097/00019606-199609000-00002; Ladanyi M, 1996, GENE CHROMOSOME CANC, V15, P173, DOI 10.1002/(SICI)1098-2264(199603)15:3<173::AID-GCC5>3.0.CO;2-#; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lamant L, 1999, BLOOD, V93, P3088; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luthra R, 1998, HEMATOPATHOL MOL HEM, V11, P173; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mason DY, 1998, CANCER RES, V58, P1057; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; Miething C, 2000, BLOOD, V96, p93A; Mir SS, 2000, BLOOD, V96, P4307; Mitev L, 1998, LEUKEMIA LYMPHOMA, V28, P613, DOI 10.3109/10428199809058372; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nakamura S, 1997, AM J SURG PATHOL, V21, P1420, DOI 10.1097/00000478-199712000-00004; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NIEBOROWSKASKOR.M, 2000, BLOOD, V96, pA2017; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Park JP, 1997, CANCER GENET CYTOGEN, V96, P118, DOI 10.1016/S0165-4608(96)00281-6; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Pfeifer W, 1999, AM J PATHOL, V155, P1353, DOI 10.1016/S0002-9440(10)65237-6; Pileri SA, 1997, AM J PATHOL, V150, P1207; Pulford K, 2000, BLOOD, V96, P1605, DOI 10.1182/blood.V96.4.1605.h8001605_1605_1607; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Pulford K, 1999, AM J PATHOL, V154, P1657, DOI 10.1016/S0002-9440(10)65421-1; RAULO E, 1994, J BIOL CHEM, V269, P12999; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SANDLUND JT, 1994, BLOOD, V84, P2467, DOI 10.1182/blood.V84.8.2467.bloodjournal8482467; SANDLUND JT, 1994, J CLIN ONCOL, V12, P895, DOI 10.1200/JCO.1994.12.5.895; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; SHIOTA M, 1994, ONCOGENE, V9, P1567; Shiota M, 1996, LEUKEMIA LYMPHOMA, V23, P25, DOI 10.3109/10428199609054798; SHIOTA M, 1994, BLOOD, V84, P3648, DOI 10.1182/blood.V84.11.3648.bloodjournal84113648; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Skinnider BF, 1999, HEMATOL ONCOL, V17, P137, DOI 10.1002/(SICI)1099-1069(199912)17:4<137::AID-HON642>3.3.CO;2-M; Slupianek A, 2001, CANCER RES, V61, P2194; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; STEIN H, 1985, BLOOD, V66, P848; Stein H, 2000, BLOOD, V96, P3681; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; TIAN ZG, 1995, CANCER RES, V55, P5335; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Trumper L, 1998, BRIT J HAEMATOL, V103, P1138; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; Zatsepina OV, 1999, J CELL SCI, V112, P455	122	203	222	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5623	5637		10.1038/sj.onc.1204594	http://dx.doi.org/10.1038/sj.onc.1204594			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607814				2022-12-17	WOS:000170887500005
J	Dilworth, FJ; Chambon, P				Dilworth, FJ; Chambon, P			Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription	ONCOGENE			English	Review						nuclear receptors; histone acetyltransferases; ATP-dependent chromatin remodeling coactivators; in vitro transcription; RAR/RXR heterodimers	THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASE; ACTIVATE TRANSCRIPTION; DEPENDENT ACTIVATION; CRYSTAL-STRUCTURE; DNA-BINDING; IN-VITRO	Recent advances in the field of in vitro chromatin assembly have led to in vitro transcription systems which reproduce in the test tube, in vivo characteristics of ligand-dependent transcriptional activation by nuclear receptors. Dissection of these systems has begun to provide us with information concerning the underlying molecular mechanisms. Through recruitment of coactivator proteins, nuclear receptors act first to remodel chromatin within the promoter region and then to recruit the transcriptional machinery to the promoter region in order to initiate transcription. Here we present a possible sequential mechanism for ligand-dependent transcriptional activation by nuclear receptors and discuss the in vitro and in vivo data that support this model.	Coll France, ULP, INSERM, CNRS,IGBMC, F-67404 Illkirch Graffenstaden, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Coll France, ULP, INSERM, CNRS,IGBMC, BP163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.			Dilworth, F. Jeffrey/0000-0002-6265-8102				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; CLEVER U, 1965, CHROMOSOMA, V17, P309, DOI 10.1007/BF00348790; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dilworth FJ, 1999, P NATL ACAD SCI USA, V96, P1995, DOI 10.1073/pnas.96.5.1995; Driscoll MD, 1996, J STEROID BIOCHEM, V58, P45, DOI 10.1016/0960-0760(96)00015-5; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Giguere V, 1990, Genet Eng (N Y), V12, P183; Glass CK, 2000, GENE DEV, V14, P121; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito T, 2000, GENE DEV, V14, P1899; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kal AJ, 2000, GENE DEV, V14, P1058; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Minucci S, 1998, MOL ENDOCRINOL, V12, P315, DOI 10.1210/me.12.3.315; Morales V, 2000, MOL CELL BIOL, V20, P7230, DOI 10.1128/MCB.20.19.7230-7237.2000; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Savoldi G, 1997, DNA CELL BIOL, V16, P1467, DOI 10.1089/dna.1997.16.1467; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THOMPSON EB, 1966, P NATL ACAD SCI USA, V56, P296, DOI 10.1073/pnas.56.1.296; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108	82	203	205	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3047	3054		10.1038/sj.onc.1204329	http://dx.doi.org/10.1038/sj.onc.1204329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420720				2022-12-17	WOS:000169308500008
J	Fan, SJ; Ma, YX; Wang, CG; Yuan, RQ; Meng, QH; Wang, JA; Erdos, M; Goldberg, ID; Webb, P; Kushner, PJ; Pestell, RG; Rosen, EM				Fan, SJ; Ma, YX; Wang, CG; Yuan, RQ; Meng, QH; Wang, JA; Erdos, M; Goldberg, ID; Webb, P; Kushner, PJ; Pestell, RG; Rosen, EM			Role of direct interaction in BRCA1 inhibition of estrogen receptor activity	ONCOGENE			English	Article						BRCA1; estrogen receptor (ER); breast cancer; activation function-2 (AF-2)	TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; BREAST; MUTATIONS; BINDING	The BRCA1 gene was previously found to inhibit the transcriptional activity of the estrogen receptor [ER-alpha] in human breast and prostate cancer cell Lines. In this study, we found that breast cancer-associated mutations of BRCA1 abolish or reduce its ability to inhibit ER-alpha activity and that domains within the amino- and carboxyl-termini of the BRCA1 protein are required for the inhibition. BRCA1 inhibition of ER-alpha activity was demonstrated under conditions in which a BRCA1 transgene was transiently or stably over-expressed in cell lines with endogenous wild-type BRCA1 and in a breast cancer cell line that lacks endogenous functional BRCA1 (HCC1937), In addition, BRCA1 blocked the expression of two endogenous estrogen-regulated gene products in human breast cancer cells: pS2 and cathepsin D, The BRCA1 protein was found to associate with ER-alpha in vivo and to bind to ER-alpha in vitro, by an estrogen-independent interaction that mapped to the amino-terminal region of BRCA1 (ca, amino acid 1-300) and the conserved carboxyl-terminal activation function [AF-2] domain of ER-alpha, Furthermore, several truncated BRCA1 proteins containing the amino-terminal ER-alpha binding region blocked the ability of the full-length BRCA1 protein to inhibit ER-alpha activity. Our findings suggest that the amino-terminus of BRCA1 interacts with ER-alpha, while the carboxyl-terminus of BRCA1 may function as a transcriptional repression domain.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY 11040 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Duv Human Endocrine Tumor Biol, Bronx, NY 10461 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Univ Calif San Francisco, Sch Med, Metab Res Unit, San Francisco, CA 94143 USA	Northwell Health; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Francisco	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New York, NY 11040 USA.		Meng, Q./GSI-6185-2022		NCI NIH HHS [R01-CA70897] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169 , +] Funding Source: Medline; PHS HHS [R01-82599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chlebowski RT, 2000, NEW ENGL J MED, V343, P191, DOI 10.1056/NEJM200007203430307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tirkkonen M, 1997, CANCER RES, V57, P1222; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Webber MM, 1997, PROSTATE, V30, P58; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	21	203	218	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					77	87		10.1038/sj.onc.1204073	http://dx.doi.org/10.1038/sj.onc.1204073			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244506				2022-12-17	WOS:000166361400009
J	Chi, SJ; Kitanaka, C; Noguchi, K; Mochizuki, T; Nagashima, Y; Shirouzu, M; Fujita, H; Yoshida, M; Chen, WB; Asai, A; Himeno, M; Yokoyama, S; Kuchino, Y				Chi, SJ; Kitanaka, C; Noguchi, K; Mochizuki, T; Nagashima, Y; Shirouzu, M; Fujita, H; Yoshida, M; Chen, WB; Asai, A; Himeno, M; Yokoyama, S; Kuchino, Y			Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells	ONCOGENE			English	Article						Bcl-2; caspase; oncogenic Ras; human glioma	WILD-TYPE P53; S-MYC; MEDIATED APOPTOSIS; GLIOMA-CELLS; GENE; TRANSFORMATION; INDUCTION; PROTEASES; DISEASE; FIBROBLASTS	To prevent neoplasia, cells of multicellular organisms activate cellular disposal programs such as apoptosis in response to deregulated oncogene expression, making the suppression of such programs an essential step for potentially neoplastic cells to become established as clinically relevant tumors. Since the mutation of ras proto-oncogenes, the most frequently mutated protooncogenes in human tumors, is very rare in some tumor types such as glioblastomas and gastric cancers, we hypothesized that mutated ras genes might activate a cell death program that cannot be overcome by these tumor types. Here we show that the expression of oncogenically mutated ras gene induces cellular degeneration accompanied by cytoplasmic vacuoles in human glioma and gastric cancer cell lines. Cells dying as a result of oncogenic Ras expression had relatively well-preserved nuclei that were negative for TUNEL staining. An immunocytochemical analysis demonstrated that the cytoplasmic vacuoles are derived mainly from lysosomes, This oncogenic Ras-induced cell death occurred in the absence of caspase activation, and was not inhibited by the overexpression of anti-apoptotic Bcl-2 protein. These observations suggested that oncogenic Ras-induced cell death is most consistent with a type of programmed cell death designated 'type 2 physiological cell death' or 'autophagic degeneration', and that this cell death is regulated by a molecular mechanism distinct from that of apoptosis, Our findings suggest a possible role for this non-apoptotic cell death in the prevention of neoplasia, and the activation of the non-apoptotic cell death program may become a potential cancer therapy complementing apoptosis-based therapies. In addition, the approach used in this study may be a valuable way to find genetically-regulated cell suicide programs that cannot be overcome by particular tumor types.	Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa 236004, Japan; Inst Phys & Chem Res, RIKEN, Cellular Signaling Lab, Wako, Saitama 3510198, Japan; Kyushu Univ, Fac Pharmaceut Sci, Div Physiol Chem, Higashi Ku, Fukuoka 8120082, Japan; Sasaki Inst, Dept Pathol, Chiyoda Ku, Tokyo 1010062, Japan; Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; Yokohama City University; RIKEN; Kyushu University; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Kitanaka, C (corresponding author), Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fujita, Hideaki/0000-0002-4105-4430				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CLARKE EF, 1990, MUSIC PERCEPT, V7, P213; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOVEC H, 1994, ONCOGENE, V9, P323; MAHER J, 1995, ONCOGENE, V11, P1639; MATTAR R, 1992, ONCOLOGY LIFE SCI AD, V11, P7; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shimizu S, 1996, ONCOGENE, V12, P2045; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	39	203	213	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2281	2290		10.1038/sj.onc.1202538	http://dx.doi.org/10.1038/sj.onc.1202538			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327074	Bronze			2022-12-17	WOS:000079525100012
J	Zhong, WX; Oberley, LW; Oberley, TD; StClair, DK				Zhong, WX; Oberley, LW; Oberley, TD; StClair, DK			Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase	ONCOGENE			English	Article						MnSOD; tumor suppressor gene; gene transfection; glioma; antioxidant enzymes; reactive oxygen species	GLUTATHIONE-PEROXIDASE-ACTIVITY; ANTIOXIDANT ENZYMES; EXPRESSION VECTOR; MAMMALIAN-CELLS; GENE; MELANOMA; DIFFERENTIATION; CHROMOSOME-6; METASTASIS; INDUCTION	Manganese superoxide dismutase (MnSOD) has been previously shown to suppress the malignant phenotype of human melanoma and breast cancer cells, To test the possible role of MnSOD in glioma malignancy, MnSOD was overexpressed in wild type human glioma U118 cells and subcloned U118-9 cells by transfection of human MnSOD cDNA, The MnSOD-transfected cell lines demonstrated expression of exogenous (plasmid) MnSOD mRNA, increase in MnSOD immunoreactive protein, and a three- to eightfold increase in MnSOD enzymatic activity, The MnSOD overexpressing cell lines became less malignant as demonstrated by requiring a higher serum concentration to grow in vitro and much slower tumor growth in nude mice than the parental and neo control cell lines, These findings further support the hypothesis that MnSOD may be a tumor suppressor gene in a aide variety of human tumors.	UNIV IOWA, RADIAT RES LAB, MED LABS 77, IOWA CITY, IA 52242 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, PATHOL SERV, MADISON, WI 53705 USA; UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53705 USA; UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40536 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Kentucky					NATIONAL CANCER INSTITUTE [R29CA049797, R01CA041267, R01CA049797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010758] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [DOI 10.1016/0003-2697(71)90370-8, 10.1016/0003-2697(71)90370-8]; BECKMAN BS, 1989, J CELL PHYSIOL, V139, P370, DOI 10.1002/jcp.1041390220; BULLARD DE, 1981, J NEUROPATH EXP NEUR, V40, P410, DOI 10.1097/00005072-198107000-00005; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Claiborne A., 1985, CRC HDB METHODS OXYG, DOI DOI 10.1016/0531-5565(85)90021-X; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG737, DOI 10.1152/ajpgi.1994.266.4.G737; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LI JJ, 1995, ONCOGENE, V10, P1989; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miele ME, 1995, ANTICANCER RES, V15, P2065; MILLIKIN D, 1991, CANCER RES, V51, P5449; MURAMATSU H, 1995, CANCER RES, V55, P6210; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; Oberley LW, 1986, FREE RADICALS AGING, P352; OBERLEY TD, 1990, AM J PATHOL, V137, P199; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI DOI 10.1074/jbc.RA117.001068; SAFFORD SE, 1994, CANCER RES, V54, P4261; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; SUN Y, 1993, CARCINOGENESIS, V14, P1457, DOI 10.1093/carcin/14.7.1457; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YOSHIZAKI N, 1994, INT J CANCER, V57, P287, DOI 10.1002/ijc.2910570226; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	38	203	217	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	1997	14	4					481	490		10.1038/sj.onc.1200852	http://dx.doi.org/10.1038/sj.onc.1200852			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053845				2022-12-17	WOS:A1997WE36400011
J	LONGATI, P; BARDELLI, A; PONZETTO, C; NALDINI, L; COMOGLIO, PM				LONGATI, P; BARDELLI, A; PONZETTO, C; NALDINI, L; COMOGLIO, PM			TYROSINES(1234-1235) ARE CRITICAL FOR ACTIVATION OF THE TYROSINE KINASE ENCODED BY THE MET PROTOONCOGENE (HGF RECEPTOR)	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; SIGNAL TRANSDUCTION; SCATTER FACTOR; SH2 DOMAINS; CELL-LINE; AUTOPHOSPHORYLATION	The tyrosine kinase encoded by the MET proto-oncogene (p190(MET)) is the receptor for Hepatocyte Growth Factor/Scatter Factor (HGF/SF). Previous work has shown that autophosphorylation of p190(MET) enhances its enzymatic activity and that the major phosphorylation site is Tyr(1235), located in the catalytic domain. This residue is part of a 'three tyrosine' motif, including Tyr(1230), Tyr(1234), and Tyr(1235), conserved in several other receptor kinases. We studied the role of these tyrosines in the positive regulation of the p190(MET) kinase by site-directed mutagenesis. Substitution of either Tyr(1235) Or Tyr(1234) with phenylalanine severely reduced the in vitro kinase activity toward exogenous substrates. Kinetic experiments showed that the residual activity of these mutants could still be enhanced by autophosphorylation. Phosphopeptide mapping indicated that, in the absence of Tyr(1235), Tyr(1234) is phosphorylated. Only the replacement of both Tyr(1234) and Tyr(1235) yielded a mutant which completely lost the ability to be activated by autophosphorylation. In stable transfectants expressing the HGF/SF receptor with single substitution of either Tyr(1234) Or Tyr(1235) the response to HGF/SF was impaired. The ligand did not induce tyrosine phosphorylation of the receptor nor stimulated chemotaxis. These data show that Tyr(1234) and Tyr(1235) are critical for the activation of the HGF/SF receptor kinase both in vitro and in response to the ligand in intact cells.	UNIV TORINO,SCH MED,DEPT BIOMED SCI & OCOL,I-10126 TURIN,ITALY	University of Turin			Naldini, Luigi/E-9083-2012; BARDELLI, Alberto/J-9721-2018	BARDELLI, Alberto/0000-0003-1647-5070				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1992, ONCOGENE, V7, P3; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAYNE DM, EMBO J, V4, P885; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE FM, 1988, J BIOL CHEM, V263, P2629	44	203	206	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					49	57						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302603				2022-12-17	WOS:A1994MW24700007
J	Ward, A; Balwierz, A; Zhang, JD; Kublbeck, M; Pawitan, Y; Hielscher, T; Wiemann, S; Sahin, O				Ward, A.; Balwierz, A.; Zhang, J. D.; Kueblbeck, M.; Pawitan, Y.; Hielscher, T.; Wiemann, S.; Sahin, Oe			Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer	ONCOGENE			English	Article						microRNAs; tamoxifen resistance; epithelial-mesenchymal transition; breast cancer; metadherin	EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; MIR-200 FAMILY; CELL-SURVIVAL; E-CADHERIN; RECEPTOR; TARGETS; PROLIFERATION; 14-3-3-ZETA; METASTASIS	Epithelial-mesenchynnal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of nniRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed nnesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer. Oncogene (2013) 32, 1173-1182; doi:10.1038/onc.2012.128; published online 16 April 2012	[Ward, A.; Balwierz, A.; Zhang, J. D.; Kueblbeck, M.; Wiemann, S.; Sahin, Oe] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Baden Wurttembe, Germany; [Pawitan, Y.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Hielscher, T.] German Canc Res Ctr, Div Biostat, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ)	Sahin, O (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Baden Wurttembe, Germany.	sahinozgur@gmail.com	Sahin, Özgür/F-4403-2014; Wiemann, Stefan/E-4424-2013	Sahin, Özgür/0000-0002-8033-7089; Wiemann, Stefan/0000-0003-4683-3174; Balwierz, Aleksandra/0000-0002-5640-9839; Ward Gahlawat, Aoife/0000-0001-7854-7207	National Genome Research Network [01GS0864]; German Federal Ministry of Education and Research (BMBF); Wilhelm Sanderstiftung [2009.051.1]; DKFZ International PhD Program	National Genome Research Network; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Wilhelm Sanderstiftung; DKFZ International PhD Program	We thank Sara Burmester for excellent technical help as well as Stefan Uhlmann and Sarah Jurmeister for valuable discussions. We also thank Brian Pickering for critical reading of the manuscript. We would also like to thank Doris Mayer for providing the ERE-reporter construct. This work was supported within the National Genome Research Network (grant 01GS0864) of the German Federal Ministry of Education and Research (BMBF) and Wilhelm Sanderstiftung (grant 2009.051.1). JDZ was supported by the DKFZ International PhD Program.	Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Berstein LM, 2004, CLIN CANCER RES, V10, P1530, DOI 10.1158/1078-0432.CCR-0433-03; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Dweep H, 2011, J BIOMED INFORM, P14; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KATZENELLENBOGEN BS, 1985, BREAST CANCER RES TR, V5, P231, DOI 10.1007/BF01806018; Kim MR, 2009, CANCER SCI, V100, P1834, DOI 10.1111/j.1349-7006.2009.01260.x; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Li XA, 2011, CANCER SCI, V102, P1151, DOI 10.1111/j.1349-7006.2011.01919.x; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mazar J, 2011, FEBS LETT, V585, P2467, DOI 10.1016/j.febslet.2011.06.025; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Sahin O, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-1; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193	36	202	215	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2013	32	9					1173	1182		10.1038/onc.2012.128	http://dx.doi.org/10.1038/onc.2012.128			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22508479	hybrid			2022-12-17	WOS:000316428800011
J	Liu, F; Killian, JK; Yang, M; Walker, RL; Hong, JA; Zhang, M; Davis, S; Zhang, Y; Hussain, M; Xi, S; Rao, M; Meltzer, PA; Schrump, DS				Liu, F.; Killian, J. K.; Yang, M.; Walker, R. L.; Hong, J. A.; Zhang, M.; Davis, S.; Zhang, Y.; Hussain, M.; Xi, S.; Rao, M.; Meltzer, P. A.; Schrump, D. S.			Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate	ONCOGENE			English	Article						tobacco smoke; lung cancer; epigenetics; respiratory epithelial cells	CELL LUNG-CANCER; MODIFICATIONS PREDICT PROGNOSIS; IN-VITRO; METHYLTRANSFERASES CONTRIBUTES; MAINSTREAM SMOKE; POOR-PROGNOSIS; UP-REGULATION; MAGE-A; METHYLATION; ACTIVATION	Limited information is available regarding epigenomic events mediating initiation and progression of tobacco-induced lung cancers. In this study, we established an in vitro system to examine epigenomic effects of cigarette smoke in respiratory epithelia. Normal human small airway epithelial cells and cdk-4/hTERT-immortalized human bronchial epithelial cells (HBEC) were cultured in normal media with or without cigarette smoke condensate (CSC) for up to 9 months under potentially relevant exposure conditions. Western blot analysis showed that CSC mediated dose- and time-dependent diminution of H4K16Ac and H4K20Me3, while increasing relative levels of H3K27Me3; these histone alterations coincided with decreased DNA methyltransferase 1 (DNMT1) and increased DNMT3b expression. Pyrosequencing and quantitative RT-PCR experiments revealed time-dependent hypomethylation of D4Z4, NBL2, and LINE-1 repetitive DNA sequences; up-regulation of H19, IGF2, MAGE-A1, and MAGE-A3; activation of Wnt signaling; and hypermethylation of tumor suppressor genes such as RASSF1A and RAR-beta, which are frequently silenced in human lung cancers. Array-based DNA methylation profiling identified additional novel DNA methylation targets in soft-agar clones derived from CSC-exposed HBEC; a CSC gene expression signature was also identified in these cells. Progressive genomic hypomethylation and locoregional DNA hypermethylation induced by CSC coincided with a dramatic increase in soft-agar clonogenicity. Collectively, these data indicate that cigarette smoke induces 'cancer-associated' epigenomic alterations in cultured respiratory epithelia. This in vitro model may prove useful for delineating early epigenetic mechanisms regulating gene expression during pulmonary carcinogenesis. Oncogene ( 2010) 29, 3650-3664; doi: 10.1038/onc.2010.129; published online 3 May 2010	[Liu, F.; Yang, M.; Hong, J. A.; Zhang, M.; Zhang, Y.; Hussain, M.; Xi, S.; Rao, M.; Schrump, D. S.] NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Killian, J. K.; Walker, R. L.; Davis, S.; Meltzer, P. A.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res, 10 Ctr Dr,Bldg 10,Room 4-3940, Bethesda, MD 20892 USA.	David_Schrump@nih.gov	Davis, Sean/AAD-1801-2021	Davis, Sean/0000-0002-8991-6458; Walker, Robert/0000-0001-8235-4686	NATIONAL CANCER INSTITUTE [ZIABC011122, ZICBC011040, ZIABC011091] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC011115-09, ZIA BC011122-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622; Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Cho Hearn J, 2006, Cancer Immun, V6, P12; D'Alessio AC, 2006, BIOCHEM CELL BIOL, V84, P463, DOI 10.1139/O06-090; Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Fields WR, 2005, TOXICOL SCI, V86, P84, DOI 10.1093/toxsci/kfi179; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Ho YS, 2005, TOXICOL APPL PHARM, V205, P133, DOI 10.1016/j.taap.2004.09.019; Hoogeboom D, 2009, BBA-REV CANCER, V1796, P63, DOI 10.1016/j.bbcan.2009.02.002; Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807; Jensen TJ, 2009, TOXICOL APPL PHARM, V235, P39, DOI 10.1016/j.taap.2008.10.013; Jin Q, 2008, CARCINOGENESIS, V29, P1614, DOI 10.1093/carcin/bgm234; Jorgensen ED, 2004, CELL CYCLE, V3, P1154; Kang Y, 2007, ONCOGENE, V26, P4394, DOI 10.1038/sj.onc.1210218; Kaplan R, 2003, CANCER RES, V63, P1475; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Killian JK, 2009, CANCER RES, V69, P758, DOI 10.1158/0008-5472.CAN-08-2984; Kim HJ, 2006, CANCER, V107, P1042, DOI 10.1002/cncr.22087; LE FN, 2005, FASEB J, V19, P144; Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Malusecka E, 2008, ANTICANCER RES, V28, P501; Mathews LA, 2009, DIFFERENTIATION, V78, P1, DOI 10.1016/j.diff.2009.04.002; McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Schrump DS, 2007, CANCER J, V13, P56, DOI 10.1097/PPO.0b013e31803c74cf; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seng TJ, 2008, BRIT J CANCER, V99, P375, DOI 10.1038/sj.bjc.6604452; Sexton K, 2008, PHARMACOGENET GENOM, V18, P853, DOI 10.1097/FPC.0b013e328307bddf; Shin HJ, 2009, FOOD CHEM TOXICOL, V47, P192, DOI 10.1016/j.fct.2008.10.028; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Smith CJ, 2003, FOOD CHEM TOXICOL, V41, P807, DOI 10.1016/S0278-6915(03)00021-8; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Toyooka S, 2006, CANCER RES, V66, P1371, DOI 10.1158/0008-5472.CAN-05-2625; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; Vrzalikova K, 2008, J CANCER RES CLIN, V134, P1037, DOI 10.1007/s00432-008-0361-y; Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Winn RA, 2006, J BIOL CHEM, V281, P26943, DOI 10.1074/jbc.M604145200; Wu JP, 2009, TOXICOL SCI, V107, P385, DOI 10.1093/toxsci/kfn239; Xing J, 2008, BRIT J CANCER, V98, P1716, DOI 10.1038/sj.bjc.6604343; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478; Zhou X, 2009, TOXICOL APPL PHARM, V236, P78, DOI 10.1016/j.taap.2009.01.009	51	202	218	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3650	3664		10.1038/onc.2010.129	http://dx.doi.org/10.1038/onc.2010.129			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440268	Green Accepted			2022-12-17	WOS:000279108600006
J	Zhu, K; Dunner, K; McConkey, DJ				Zhu, K.; Dunner, K., Jr.; McConkey, D. J.			Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells	ONCOGENE			English	Article						bortezomib; NPI-0052; autophagy; unfolded protein response; prostate cancer	ENDOPLASMIC-RETICULUM STRESS; TRANSLATIONAL CONTROL; PROTEIN-DEGRADATION; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; ER STRESS; BORTEZOMIB; PHOSPHORYLATION; THERAPY; KINASE	The ubiquitin-proteasome and lysosome-autophagy pathways are the two major intracellular protein degradation systems that work cooperatively to maintain homeostasis. Proteasome inhibitors (PIs) have clinical activity in hematological tumors, and inhibitors of autophagy are also being evaluated as potential antitumor therapies. In this study, we found that chemical PIs and small interfering RNA-mediated knockdown of the proteasome's enzymatic subunits promoted autophagosome formation, stimulated autophagic flux, and upregulated expression of the autophagy-specific genes (ATGs) (ATG5 and ATG7) in some human prostate cancer cells and immortalized mouse embryonic fibroblasts (MEFs). Upregulation of ATG5 and ATG7 only occurred in cells displaying PI-induced phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2 alpha), an important component of the unfolded protein responses. Furthermore, PIs did not induce autophagy or upregulate ATG5 in MEFs expressing a phosphorylation-deficient mutant form of eIF2 alpha. Combined inhibition of autophagy and the proteasome induced an accumulation of intracellular protein aggregates reminiscent of neuronal inclusion bodies and caused more cancer cell death than blocking either degradation pathway alone. Overall, our data show that proteasome inhibition activates autophagy through a phospho-eIF2 alpha-dependent mechanism to eliminate protein aggregates and alleviate proteotoxic stress. Oncogene (2010) 29, 451-462; doi:10.1038/onc.2009.343; published online 2 November 2009	[Zhu, K.; McConkey, D. J.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Zhu, K.; Dunner, K., Jr.; McConkey, D. J.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McConkey, DJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Urol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	dmcconke@mdanderson.org			Department of Defense Prostate Cancer Research Program [PC050288]; MD Anderson Cancer Center Support Grant [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA127494] Funding Source: NIH RePORTER	Department of Defense Prostate Cancer Research Program(United States Department of Defense); MD Anderson Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the Department of Defense Prostate Cancer Research Program (PC050288). The TEM studies were supported by the MD Anderson Cancer Center Support Grant (CA16672) to the High Resolution Electron Microscopy Facility. We also acknowledge Dr Woonyoung Choi and Maosheng Huang's help with the array data analyses.	Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Anderson Kenneth C, 2004, Curr Hematol Rep, V3, P65; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188; Fels DR, 2008, CANCER RES, V68, P9323, DOI 10.1158/0008-5472.CAN-08-2873; Geng JF, 2008, J CELL BIOL, V182, P129, DOI 10.1083/jcb.200711112; Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Ito H, 2005, INT J ONCOL, V26, P1401; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0070-6879(08)01416-X, 10.1016/S0076-6879(08)01416-X]; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; McConkey DJ, 2008, DRUG RESIST UPDATE, V11, P164, DOI 10.1016/j.drup.2008.08.002; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nelson DA, 2004, GENE DEV, V18, P1223, DOI 10.1101/gad.1212404; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853; Reyes S, 2001, Brain Tumor Pathol, V18, P83, DOI 10.1007/BF02479420; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rubinsztein DC, 2007, NEURON, V54, P854, DOI 10.1016/j.neuron.2007.06.005; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sakaki K, 2008, J BIOL CHEM, V283, P15370, DOI 10.1074/jbc.M710209200; Savarino A, 2006, LANCET ONCOL, V7, P792, DOI 10.1016/S1470-2045(06)70875-0; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Zhou DH, 2008, J BIOL CHEM, V283, P7064, DOI 10.1074/jbc.M708530200; Zhu KY, 2009, CANCER RES, V69, P1836, DOI 10.1158/0008-5472.CAN-08-4103	43	202	211	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					451	462		10.1038/onc.2009.343	http://dx.doi.org/10.1038/onc.2009.343			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO		Green Accepted			2022-12-17	WOS:000273793200014
J	Desnoyers, L; Pai, R; Ferrando, R; Hotzel, K; Le, T; Ross, J; Carano, R; D'Souza, A; Qing, J; Mohtashemi, I; Ashkenazi, A; French, D				Desnoyers, Lr; Pai, R.; Ferrando, Re; Hotzel, K.; Le, T.; Ross, J.; Carano, R.; D'Souza, A.; Qing, J.; Mohtashemi, I.; Ashkenazi, A.; French, Dm			Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models	ONCOGENE			English	Article						fibroblast growth factor; hepatocellular carcinoma; FGF19; colon adenocarcinoma; FGFR4; beta-catenin	FACTOR RECEPTOR-3; HUMAN BREAST; ACTIVATING MUTATIONS; INCREASED EXPRESSION; MULTIPLE-MYELOMA; PROSTATE-CANCER; FIBROBLAST; FGFR4; GENE; TRANSLOCATION	Although fibroblast growth factor 19 (FGF19) can promote liver carcinogenesis in mice its involvement in human cancer is not well characterized. Here we report that FGF19 and its cognate receptor FGF receptor 4 (FGFR4) are coexpressed in primary human liver, lung and colon tumors and in a subset of human colon cancer cell lines. To test the importance of FGF19 for tumor growth, we developed an anti-FGF19 monoclonal antibody that selectively blocks the interaction of FGF19 with FGFR4. This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice. The efficacy of the antibody in these models was linked to inhibition of FGF19-dependent activation of FGFR4, FRS2, ERK and beta-catenin. These findings suggest that the inactivation of FGF19 could be beneficial for the treatment of colon cancer, liver cancer and other malignancies involving interaction of FGF19 and FGFR4.	[Desnoyers, Lr; D'Souza, A.; Qing, J.; Ashkenazi, A.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Pai, R.; Ferrando, Re; Hotzel, K.; French, Dm] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Le, T.; Ross, J.; Carano, R.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA; [Mohtashemi, I.] Genentech Inc, Dept Protein Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	French, D (corresponding author), Genentech Inc, Dept Mol Oncol, MS 72B,1 DNA Way, San Francisco, CA 94080 USA.	dfrench@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				ANTHONY PP, 1979, J TOXICOL ENV HEALTH, V5, P301, DOI 10.1080/15287397909529751; Bange J, 2002, CANCER RES, V62, P840; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gowardhan B, 2005, BRIT J CANCER, V92, P320, DOI 10.1038/sj.bjc.6602274; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Huang Yao Qi, 1993, Anticancer Research, V13, P887; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jang JH, 2000, CANCER RES, V60, P4049; Jang JH, 2001, CANCER RES, V61, P3541; Jeffers Michael, 2002, Expert Opin Ther Targets, V6, P469, DOI 10.1517/14728222.6.4.469; Jubb Adrian M, 2006, Methods Mol Biol, V326, P255; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; Kobayashi M, 2006, CANCER-AM CANCER SOC, V106, P636, DOI 10.1002/cncr.21607; Krejci P, 2001, LEUKEMIA, V15, P228, DOI 10.1038/sj.leu.2402012; Lee FT, 1997, RADIOLOGY, V203, P465, DOI 10.1148/radiology.203.2.9114106; LISCIA DS, 1989, ONCOGENE, V4, P1219; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Mattila MMT, 2001, ONCOGENE, V20, P2791, DOI 10.1038/sj.onc.1204430; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Morimoto Y, 2003, CANCER, V98, P2245, DOI 10.1002/cncr.11778; Nicholes K, 2002, AM J PATHOL, V160, P2295, DOI 10.1016/S0002-9440(10)61177-7; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Qian ZR, 2004, J CLIN ENDOCR METAB, V89, P1904, DOI 10.1210/jc.2003-031489; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Ruohola JK, 2001, CANCER RES, V61, P4229; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Shima K, 2003, IEEE T ENERGY CONVER, V18, P63, DOI 10.1109/TEC.2002.808337; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; Spinola M, 2005, J CLIN ONCOL, V23, P7307, DOI 10.1200/JCO.2005.17.350; Streit S, 2004, INT J CANCER, V111, P213, DOI 10.1002/ijc.20204; Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078-0432.CCR-04-0408; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Yamada SM, 2002, NEUROL RES, V24, P244, DOI 10.1179/016164102101199864; Yu CD, 2005, J BIOL CHEM, V280, P17707, DOI 10.1074/jbc.M411771200; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481	46	202	238	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					85	97		10.1038/sj.onc.1210623	http://dx.doi.org/10.1038/sj.onc.1210623			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599042				2022-12-17	WOS:000252118700009
J	Moll, UM; Marchenko, N; Zhang, XK				Moll, U. M.; Marchenko, N.; Zhang, X-k			p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction	ONCOGENE			English	Review						p53; Nur77/ TR3; mitochondria	ORPHAN NUCLEAR RECEPTOR; RETINOID-X-RECEPTOR; OVARIAN-CARCINOMA CELLS; LUNG-CANCER; STEROID-RECEPTOR; NGFI-B; INDUCED APOPTOSIS; PROSTATE-CANCER; GENE-EXPRESSION; FATTY-ACIDS	The complex apoptotic functions of the p53 tumor suppressor are central to its antineoplastic activity in vivo. Conversely, p53 function is altered or attenuated in one way or another in the majority of human cancers. Besides its well-understood action as a transcriptional regulator of multiple apoptotic genes, p53 also exerts a direct pro-apoptotic role at the mitochondria by engaging in protein-protein interactions with anti- and pro-apoptotic Bcl2 family members, thereby executing the shortest known circuitry of p53 death signaling. Nur77, also known as TR3 or NGFI-B, is a unique transcription factor belonging to the orphan nuclear receptor superfamily. Even more extreme than p53, Nur77 can exert opposing biological activities of survival and death. Its activities are regulated by subcellular distribution, expression levels, protein modi. cation and heterodimerization with retinoid X receptor. In cancer cells, Nur77 functions in the nucleus as an oncogenic survival factor, but becomes a potent killer when certain death stimuli induce its migration to mitochondria, where it binds to Bcl2 and conformationally converts it to a killer that triggers cytochrome c release and apoptosis. This review focuses on their unexpected transcription-independent pro-death programs at mitochondria and highlights the remarkable mechanistic similarities between them. Moreover, an accumulating body of evidence provides ample rationale to further investigate how these mitochondrial p53 and Nur77 pathways could become exploitable targets for new cancer therapeutics.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Burnham Inst Med Res, Ctr Canc, La Jolla, CA USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Sanford Burnham Prebys Medical Discovery Institute	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu						Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Bonafe M, 2004, CELL DEATH DIFFER, V11, P962, DOI 10.1038/sj.cdd.4401415; Bonini P, 2004, J NEUROSCI RES, V75, P83, DOI 10.1002/jnr.10822; Bras A, 2000, CELL DEATH DIFFER, V7, P262, DOI 10.1038/sj.cdd.4400653; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Castro-Obregon S, 2004, J BIOL CHEM, V279, P17543, DOI 10.1074/jbc.M312363200; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; Chen GQ, 2002, INT J CANCER, V99, P171, DOI 10.1002/ijc.10304; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Chinnaiyan P, 2006, INT J CANCER, V118, P1041, DOI 10.1002/ijc.21465; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Dagher PC, 2004, KIDNEY INT, V66, P506, DOI 10.1111/j.1523-1755.2004.761_7.x; Daidone MG, 1999, ENDOCR-RELAT CANCER, V6, P61, DOI 10.1677/erc.0.0060061; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Dawson MI, 2001, CANCER RES, V61, P4723; de Souza-Pinto NC, 2004, ONCOGENE, V23, P6559, DOI 10.1038/sj.onc.1207874; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Fan YY, 2003, CARCINOGENESIS, V24, P1541, DOI 10.1093/carcin/bgg110; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gennari A, 2002, TOXICOL APPL PHARM, V181, P27, DOI 10.1006/taap.2002.9357; Gilman CP, 2003, NEUROMOL MED, V3, P159, DOI 10.1385/NMM:3:3:159; Goldstein JT, 2003, ARCH BIOCHEM BIOPHYS, V420, P185, DOI 10.1016/j.abb.2003.09.034; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAN YH, 2006, ONCOGENE; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2004, J CELL PHYSIOL, V199, P317, DOI 10.1002/jcp.10338; Holmes WF, 2003, ONCOGENE, V22, P6377, DOI 10.1038/sj.onc.1206694; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jacobs CM, 2005, BIOCHEM BIOPH RES CO, V336, P646, DOI 10.1016/j.bbrc.2005.08.143; Jeong JH, 2003, ANN NY ACAD SCI, V1010, P171, DOI 10.1196/annals.1299.029; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kaul SC, 2005, J BIOL CHEM, V280, P39373, DOI 10.1074/jbc.M500022200; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Kochel I, 2005, BIOCHEM BIOPH RES CO, V334, P1102, DOI 10.1016/j.bbrc.2005.07.004; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kolluri SK, 2005, P NATL ACAD SCI USA, V102, P2525, DOI 10.1073/pnas.0409721102; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Le W, 1999, J NEUROCHEM, V73, P2218; Lee JM, 2004, J VIROL, V78, P12694, DOI 10.1128/JVI.78.22.12694-12697.2004; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LIM RW, 1987, ONCOGENE, V1, P263; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin XF, 2004, J CELL SCI, V117, P5609, DOI 10.1242/jcs.01474; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martin B, 2003, BRIT J CANCER, V89, P55, DOI 10.1038/sj.bjc.6601095; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MOLL U, 2000, NEW P53 BASED STRATE; Mu XM, 2003, J BIOL CHEM, V278, P42840, DOI 10.1074/jbc.M305594200; Nemajerova A, 2005, FEBS LETT, V579, P6079, DOI 10.1016/j.febslet.2005.09.074; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; Park KC, 2005, MOL ENDOCRINOL, V19, P12, DOI 10.1210/me.2004-0107; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; PETROS AM, 2004, FEBS LETT, P1; Pfahl M, 2003, ONCOGENE, V22, P9058, DOI 10.1038/sj.onc.1207109; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Shin HJ, 2004, CARCINOGENESIS, V25, P1467, DOI 10.1093/carcin/bgh135; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; SPEIDEL D, 2005, ONCOGENE; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Subramanian T, 2003, J CELL BIOCHEM, V89, P1102, DOI 10.1002/jcb.10573; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wilson AJ, 2003, CANCER RES, V63, P5401; WINGATE AD, 2005, BIOCH J; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG YL, 1995, P NATL ACAD SCI USA, V92, P3051, DOI 10.1073/pnas.92.7.3051; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Yoshida Y, 2003, CANCER RES, V63, P3729; Zeimet AG, 2003, LANCET ONCOL, V4, P415, DOI 10.1016/S1470-2045(03)01139-2; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	164	202	209	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4725	4743		10.1038/sj.onc.1209601	http://dx.doi.org/10.1038/sj.onc.1209601			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892086				2022-12-17	WOS:000239687000010
J	Vieira, HLA; Belzacq, AS; Haouzi, D; Bernassola, F; Cohen, I; Jacotot, E; Ferri, KF; El Hamel, C; Bartle, LM; Melino, G; Brenner, C; Goldmacher, V; Kroemer, G				Vieira, HLA; Belzacq, AS; Haouzi, D; Bernassola, F; Cohen, I; Jacotot, E; Ferri, KF; El Hamel, C; Bartle, LM; Melino, G; Brenner, C; Goldmacher, V; Kroemer, G			The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal	ONCOGENE			English	Article						apoptosis; Bcl-2; (V)MIA; mitochondria; permeability transition	PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; MITOCHONDRIAL ADP/ATP CARRIER; CELL-DEATH; INDUCED APOPTOSIS; CYCLOPHILIN-D; BCL-2; BAX; PROTEINS	Nitric oxide (NO), peroxynitrite, and 4-hydroxynonenal (HNE) may be involved in the pathological demise of cells via apoptosis, Apoptosis induced by these agents is inhibited by Bcl-2, suggesting the involvement of mitochondria in the death pathway. In vitro, NO, peroxynitrite and HNE can cause direct permeabilization of mitochondrial membranes, and this effect is inhibited by cyclosporin A, indicating involvement of the permeability transition pore complex (PTPC) in the permeabilization event. NO, peroxynitrite and HNE also permeabilize proteoliposomes containing the adenine nucleotide translocator (ANT), one of the key components of the PTPC, yet have no or little effects on protein-free control liposomes, ANT-dependent, NO-, peroxynitrite- or HNE-induced permeabilization is at least partially inhibited by recombinant Bcl-2 protein, as well as the antioxidants trolox and butylated hydroxytoluene, In vitro, none of the tested agents (NO, peroxynitrite, FINE, and tert-butylhydroperoxide) causes preferential carbonylation HNE adduction, or nitrotyrosylation of ANT. How ever, all these agents induced ANT to undergo thiol oxidation/derivatization. Peroxynitrite and HNE also caused significant lipid peroxidation, which was antagonized by butylated hydroxytoluene but not by recombinant Bcl-2, Transfection-enforced expression of vMIA, a viral apoptosis inhibitor specifically targeted to ANT, largely reduces the mitochondrial and nuclear signs of apoptosis induced by NO, peroxynitrite and HNE in intact cells. Taken together these data suggest that NO, peroxynitrite, and HNE may directly act on ANT to induce mitochondrial membrane permeabilization and apoptosis.	Inst Gustave Roussy, CNRS, UMR1599, F-94805 Villejuif, France; Univ Technol Compiegne, CNRS, UMR6022, F-60205 Compiegne, France; Univ Roma Tor Vergata, Biochem Lab, I-00133 Rome, Italy; Apoptosis Technol Inc, Cambridge, MA 02139 USA	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; University of Rome Tor Vergata	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Vieira, Helena/AAZ-9562-2021; brenner, catherine/AAE-8632-2020; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; /0000-0002-5301-1569; Vieira, Helena/0000-0001-9415-3742				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Allione A, 1999, J IMMUNOL, V163, P4182; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BouHamdan M, 1998, J BIOL CHEM, V273, P8009, DOI 10.1074/jbc.273.14.8009; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Buege J A, 1978, Methods Enzymol, V52, P302; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dorner A, 1999, BBA-BIOMEMBRANES, V1417, P16, DOI 10.1016/S0005-2736(98)00245-4; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Glockzin S, 1999, J BIOL CHEM, V274, P19581, DOI 10.1074/jbc.274.28.19581; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Hashimoto M, 1999, BIOCHEMISTRY-US, V38, P1050, DOI 10.1021/bi9822978; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kruman I, 1997, J NEUROSCI, V17, P5089; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mossalayi MD, 1999, MOL MED, V5, P812, DOI 10.1007/BF03401994; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	65	202	213	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4305	4316		10.1038/sj.onc.1204575	http://dx.doi.org/10.1038/sj.onc.1204575			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466611				2022-12-17	WOS:000169912600004
J	Fuchs, SY; Adler, V; Buschmann, T; Wu, XW; Ronai, Z				Fuchs, SY; Adler, V; Buschmann, T; Wu, XW; Ronai, Z			Mdm2 association with p53 targets its ubiquitination	ONCOGENE			English	Article						p53; ubiquitination; Mdm2; stability	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; E6 ONCOPROTEIN; IN-VIVO; KINASE; PHOSPHORYLATION; DEGRADATION; CELLS; STABILITY	Key to p53 ability to mediate its multiple cellular functions lies in its stability, In the present study we have elucidated the mechanism by which Mdm2 regulates p53 degradation. Using in vitro and in vivo ubiquitination assays we demonstrate that Mdm2 association with p53 targets p53 ubiquitination, Exposure of cells to UV-irradiation inhibits this targeting. Mdm2 which is deficient in p53 binding failed to target p53 ubiquitination, suggesting that the association is essential for Mdm2 targeting ability. While mdm2-p53 complex is found in non-stressed cells, the amount of p53-bound mdm2 is decreased after UV-irradiation, further pointing to the relationship between mdm2 binding and p53 level. Similar to Swiss 3T3 cells, the dissociation of mdm2-p53 complex was also found in UV-treated Scid cells, lacking functional DNA-PK, suggesting that DNA-PK is not sufficient for dissociating mdm2 from p53, Together our studies point to the role of Mdm2, as one of p53-associated proteins, in targeting p53 ubiquitination.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave Levy Pl Box 1130, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORDONCARDO C, 1994, CANCER RES, V54, P794; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUCHS SY, 1998, UNPUB; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rathmell WK, 1997, CANCER RES, V57, P68; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SICILIANO JD, 1997, GENE DEV, V11, P3471; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	42	202	207	1	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2543	2547		10.1038/sj.onc.1202200	http://dx.doi.org/10.1038/sj.onc.1202200			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824166				2022-12-17	WOS:000076927300015
J	Rice, JC; Massey-Brown, KS; Futscher, BW				Rice, JC; Massey-Brown, KS; Futscher, BW			Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells	ONCOGENE			English	Article						BRCA1; CpG island; 5-methylcytosine; breast cancer; tumor suppressor	CLONAL CHROMOSOME-ABNORMALITIES; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; OVARIAN-CANCER; MESSENGER-RNA; LUNG-CANCER; MGMT GENE; CARCINOMAS; MUTATIONS; SITES	BRCA1 mRNA is reduced in sporadic breast cancer cells despite the lack of mutations. Because a CpG island is found at the 5' end of the BRCA1 gene, we hypothesized that the decreased BRCA1 mRNA in sporadic breast cancer was associated with aberrant cytosine methylation of the CpG island. We examined BRCA1 mRNA expression in normal human mammary epithelial cells (HMECs), peripheral blood lymphocytes (PBLs) and six sporadic breast cancer cell lines using RT-PCR. The normal breast cells expressed high levels of BRCA1 mRNA. The sporadic breast cancer cell lines and PBLs expressed lower levels of BRCA1 mRNA ranging from a 3-16-fold decrease compared to the normal breast cells. We identified a 600 bp region of the BRCA1 CpG island that possessed strong promoter activity (similar to 40-fold above control), and determined the cytosine methylation patterns of the 30 CpG sites within this region by sodium bisulfite genomic sequencing. The HMECs, PBLs and five of the sporadic breast cancer cell lines were largely unmethylated. However, one sporadic breast cancer cell line, UACC3199, was greater than or equal to 60% methylated at all 30 CpG sites (18 sites were 100% methylated) and was associated with an eightfold decrease in BRCA1 mRNA compared to normal breast cells. These findings suggest that aberrant cytosine methylation of the BRCA1 CpG island promoter may be one mechanism of BRCA1 repression in sporadic breast cancer.	Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Arizona Canc Ctr, Tucson, AZ 85724 USA; Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA	University of Arizona; Arizona Center Cancer Care; Arizona Center Cancer Care	Futscher, BW (corresponding author), Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.		Rice, Judd C/B-7806-2009		NATIONAL CANCER INSTITUTE [R01CA065662, R29CA065662, P30CA023074] Funding Source: NIH RePORTER; NCI NIH HHS [CA65662, 3P30 CA23074-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dobrovic A, 1997, CANCER RES, V57, P3347; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1994, HUM GENET, V94, P491; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Pieper RO, 1996, J BIOL CHEM, V271, P13916, DOI 10.1074/jbc.271.23.13916; Qian XLC, 1997, CANCER RES, V57, P3672; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Stirzaker C, 1997, CANCER RES, V57, P2229; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	36	202	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1807	1812		10.1038/sj.onc.1202086	http://dx.doi.org/10.1038/sj.onc.1202086			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778046				2022-12-17	WOS:000076303300006
J	Mirkovic, N; Voehringer, DW; Story, MD; McConkey, DJ; McDonnell, TJ; Meyn, RE				Mirkovic, N; Voehringer, DW; Story, MD; McConkey, DJ; McDonnell, TJ; Meyn, RE			Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols	ONCOGENE			English	Article						apoptosis; lymphoma; Bcl-2; radiation; thiols; antioxidants	DNA FRAGMENTATION; BCL-2 PROTECTION; REDOX REGULATION; LYMPHOMA-CELLS; MURINE TUMORS; DEATH; GLUTATHIONE; OXYGEN; P53; GENE	The mechanism by which Bcl-2 oncogene expression inhibits radiation-induced apoptosis has been investigated in two mouse lymphoma cell lines: line LY-as is radiation sensitive, displays substantial radiaton-induced apoptosis. and expresses low levels of Bcl-2; line LY-ar is radiation-resistant, displays a low apoptosis propensity, and expresses 30-fold higher amount of Bcl-2 protein than does the sensitive line. We observed that upon incubation in cystine/methionine-free (C/M-) medium, radiation-induced apoptosis in the LY-ar cells was restored to levels comparable to that seen in the LY-as cells. Intracellular glutathione (GSH) concentrations in LY-ar cells incubated in C/M- medium plummeted to 50% of control values within 2 h. LY-ar cells treated with diethyl maleate (DEM) or diamide, agents that deplete cellular thiols, had increased susceptibility to radiation-induced apoptosis in a manner similar to C/M- medium. These results are consistent with the general idea that Bcl-2 expression blocks apoptosis through an antioxidant pathway that involves cellular thiols. That Bcl-2-expressing tumor cells can be sensitized by exogeneous agents that modify cellular thiols offers strategies for overcoming such resistance.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPT RADIAT ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NCI NIH HHS [P01-CA-06294, R01-CA-69003, R01-CA-62597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062597, P01CA006294, R01CA069003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFY G, 1993, J BIOL CHEM, V268, P6511; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dynlacht JR, 1996, CYTOMETRY, V24, P348, DOI 10.1002/(SICI)1097-0320(19960801)24:4<348::AID-CYTO6>3.0.CO;2-B; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; FAN SJ, 1994, CANCER RES, V54, P5824; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; Herrmann JL, 1996, BIOCHEM SOC T, V24, P1059, DOI 10.1042/bst0241059; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KROMER G, 1997, IMMUNOL TODAY, V18, P44; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEISTER A, 1994, CANCER RES, V54, pS1969; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MUSCHEL RJ, 1995, CANCER RES, V55, P995; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SATO N, 1995, J IMMUNOL, V154, P3194; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shimizu S, 1996, ONCOGENE, V13, P21; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUZUKAKE K, 1982, BIOCHEM PHARMACOL, V31, P121; Voehringer DW, 1997, INT J RADIAT BIOL, V71, P237, DOI 10.1080/095530097144102; von Sonntag C., 1987, CHEM BASIS RAD BIOL; WALTON MI, 1993, CANCER RES, V53, P1853; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	55	202	205	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1461	1470		10.1038/sj.onc.1201310	http://dx.doi.org/10.1038/sj.onc.1201310			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333022				2022-12-17	WOS:A1997XW41100010
J	Lerner, EC; Zhang, TT; Knowles, DB; Qian, YM; Hamilton, AD; Sebti, SM				Lerner, EC; Zhang, TT; Knowles, DB; Qian, YM; Hamilton, AD; Sebti, SM			Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines	ONCOGENE			English	Article						Ras; prenylation; human tumors; FTase inhibitors	PROTEIN GERANYLGERANYLATION; FARNESYL; GROWTH; BLOCKS	The farnesyltransferase (FTase) inhibitor FTI-277 is highly effective at blocking oncogenic H-Ras but not K-Ras4B processing and signaling. While inhibition of processing and signaling of oncogenic K-Ras4B is more sensitive to the geranylgeranyltransferase I (GGTase I) inhibitor GGTI-286 than it is to FTI-277 in K-Ras4B-transformed NIH3T3 cells, the sensitivity of K-Ras as well as H-and N-Ras to the CAAX peptidomimetics in human tumor cell lines is not known. Here, we report that a panel of five human carcinoma cell lines from pancreatic, pulmonary, and bladder origins all express H-, N-, and K-Ras, and their respective prenylation sensitivities to the FTase and GGTase I inhibitors is variable. In all of the cell lines investigated, the prenylation of N-Ras was highly sensitive to FTI-277, and in two of the cell lines, N-Ras showed slight sensitivity to GGTI-298, an analog of GGTI-286. Although the prenylation of H-Ras was also sensitive to FTI-277, complete inhibition of H-Ras processing even at high concentrations of FTI-277 and/or GGTI-298 was never achieved. The prenylation of K-Ras, on the other hand, was highly resistant to FTI-277 and GGTI-298. Most significantly, treatment of human tumor cell lines with both inhibitors inhibition of K-Ras prenylation. In human lung adenocarcinoma A-549, prenylation of K-Ras was highly resistant even when co-treated with both inhibitors. Furthermore, soft agar experiments demonstrated that in all the human tumor cell lines tested inhibition of K-Ras prenylation was not necessary for inhibition of anchorage-independent growth. In addition, although GGTI-298 had very little effect on soft agar growth, the combination of FTI-277 and GGTI-298 resulted in significant growth inhibition. Therefore, the results demonstrate that while FTI-277 inhibits N-Ras and H-Ras processing in the human tumor cell lines evaluated, inhibition of K-Ras processing requires both an FTase inhibitor as well as a GGTase I inhibitor, and that inhibition of human tumor growth in soft agar does not require inhibition of oncogenic K-Ras processing.	UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [U19-CA67771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NAGASU T, 1995, CANCER RES, V55, P5310; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SATTLER I, 1996, REGULATION RAS SIGNA, P95; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	17	202	214	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1283	1288		10.1038/sj.onc.1201296	http://dx.doi.org/10.1038/sj.onc.1201296			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315095				2022-12-17	WOS:A1997XV84500005
J	HORI, Y; KIKUCHI, A; ISOMURA, M; KATAYAMA, M; MIURA, Y; FUJIOKA, H; KAIBUCHI, K; TAKAI, Y				HORI, Y; KIKUCHI, A; ISOMURA, M; KATAYAMA, M; MIURA, Y; FUJIOKA, H; KAIBUCHI, K; TAKAI, Y			POSTTRANSLATIONAL MODIFICATIONS OF THE C-TERMINAL REGION OF THE RHO-PROTEIN ARE IMPORTANT FOR ITS INTERACTION WITH MEMBRANES AND THE STIMULATORY AND INHIBITORY GDP/GTP EXCHANGE PROTEINS	ONCOGENE			English	Article							GTP-BINDING PROTEIN; BOVINE BRAIN MEMBRANES; BOTULINUM ADP-RIBOSYLTRANSFERASE; GENE-PRODUCT; MOLECULAR-CLONING; CLOSTRIDIUM-BOTULINUM; PARTIAL-PURIFICATION; SUBSEQUENT BINDING; EFFECTOR DOMAIN; TOXIN TYPE-C1	We have recently found, by use of the rhoA p21 purified from bovine aortic smooth muscle, that it is similarly post-translationally processed as described for ras p21s: it is first geranylgeranylated at the cysteine residue in the C-terminal region followed by removal of the three C-terminal amino acids and the subsequent carboxyl methylation of the revealed C-terminal cysteine residue. In the present study, we investigated the function(s) of these post-translational modifications of the C-terminal region of rhoA p21 by use of the rhoA p21s purified from bovine aortic smooth muscle and rhoA p21-overexpressing Escherichia coli since the bacterial protein was not modified with a geranylgeranyl moiety. Bovine rhoA p21 bound to plasma membranes and phosphatidylserine-linked Affigel, but bacterial rhoA p21 did not bind to them. The inhibitory GDP/GTP exchange protein for rhoA p21, named GDP dissociation inhibitor (GDI), made a complex with the GDP-bound form of bovine rhoA p21 and thereby inhibited the dissociation of GDP from and the subsequent binding of GTP to it. However, rho GDI neither made a complex with the GDP-bound form of bacterial rhoA p21 nor affected these reactions of the bacterial protein. The stimulatory GDP/GTP exchange protein for rhoA p21, named GDP dissociation stimulator (GDS), stimulated the dissociation of GDP from bovine rhoA p21, but was inactive for the bacterial protein. In contrast, the GTPase activating protein for rhoA p21 is active not only for bovine rhoA p21 but also for the bacterial protein. These results suggest that the post-translational modifications of the C-terminal region of bovine rhoA p21, most presumably the geranylgeranylation, which are absent in bacterial rhoA p21, play important roles in its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins but not with the GAP.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; ARAKI S, 1991, IN PRESS MOL CELL BI; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIROYOSHI M, 1991, IN PRESS J BIOL CHEM; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1990, IN PRESS ONCOGENE; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, IN PRESS P NATL ACAD; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SSAKI T, 1990, J BIOL CHEM, V263, P2333; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; UEDA T, 1990, J BIOL CHEM, V265, P9373; Weber K, 1972, Methods Enzymol, V26, P3; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	44	202	205	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					515	522						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903193				2022-12-17	WOS:A1991FR93900004
J	Shao, R; Hamel, K; Petersen, L; Cao, QJ; Arenas, RB; Bigelow, C; Bentley, B; Yan, W				Shao, R.; Hamel, K.; Petersen, L.; Cao, Q. J.; Arenas, R. B.; Bigelow, C.; Bentley, B.; Yan, W.			YKL-40, a secreted glycoprotein, promotes tumor angiogenesis	ONCOGENE			English	Article						tumor angiogenesis; vascular endothelial cells; YKL-40 (human cartilage-glycoprotein 39 or Chitinase 3-like 1); signal transduction; heparin-binding protein; breast cancer	HUMAN CARTILAGE GLYCOPROTEIN-39; CHITINASE PROTEIN FAMILY; GROWTH-FACTOR; SERUM YKL-40; INTEGRIN ACTIVITY; CARCINOMA CELLS; SYNOVIAL-CELLS; SHORT SURVIVAL; BREAST-CANCER; IN-VIVO	Tumor angiogenesis is of paramount importance in solid tumor development. Elevated serum levels of YKL-40, which is a secreted heparin-binding glycoprotein, have been associated with a worse prognosis from various advanced human cancers. Yet the role of YKL-40 activity in these cancers is still missing. In this study, we showed that ectopic expression of YKL-40 in MDA-MB-231 breast cancer cells and in HCT-116 colon cancer cells led to larger tumor formation with an extensive angiogenic phenotype than did control cancer cells in mice. Affinity-purified recombinant YKL-40 protein promoted vascular endothelial cell angiogenesis in vitro, the effects of which are similar to the activities observed using MDA-MB-231 and HCT-116 cell-conditioned medium after transfection with YKL-40. Furthermore, YKL-40 was found to induce coordination of membrane-bound receptor syndecan-1 and integrin alpha(v)beta(3) and to activate an intracellular signaling cascade, including focal adhesion kinase and mitogen-activated protein kinase extracellular signal-related kinase1/2 in endothelial cells. Moreover, blockade of YKL-40 using small-interfering RNA gene knockdown suppressed tumor angiogenesis in vitro and in vivo. Immunohistochemical analysis of human breast cancer showed a correlation between YKL-40 expression and blood vessel density. These findings provide novel insights into angiogenic activities and molecular mechanisms of YKL-40 in cancer development. Oncogene (2009) 28, 4456-4468; doi:10.1038/onc.2009.292; published online 21 September 2009	[Shao, R.] Univ Massachusetts Amherst, Pioneer Valley Life Sci Inst, Baystate Med Ctr, Springfield, MA 01199 USA; [Shao, R.; Hamel, K.; Petersen, L.] Univ Massachusetts, Mol & Cellular Biol Program, Morrill Sci Ctr, Amherst, MA 01003 USA; [Shao, R.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; [Cao, Q. J.] Baystate Med Ctr, Dept Pathol, Springfield, MA USA; [Arenas, R. B.] Baystate Med Ctr, Dept Surg, Springfield, MA 01107 USA; [Bigelow, C.] Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	Baystate Medical Center; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center; Baystate Medical Center; University of Massachusetts System; University of Massachusetts Amherst	Shao, R (corresponding author), Univ Massachusetts Amherst, Pioneer Valley Life Sci Inst, Baystate Med Ctr, 3601 Main St, Springfield, MA 01199 USA.	rong.shao@bhs.org			NCI [R01 CA120659]; DOD [W81XWH-06-1-0563]; Collaborative Biomedical Research Program; Baystate Medical Center/University of Massachusetts at Amherst; Rays of Hope, Baystate Medical Center; NATIONAL CANCER INSTITUTE [R01CA120659] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Collaborative Biomedical Research Program; Baystate Medical Center/University of Massachusetts at Amherst; Rays of Hope, Baystate Medical Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs A Schneyer, S Schneider and S Scully for their critical comments. This work was supported by NCI R01 CA120659 and DOD W81XWH-06-1-0563 (RS), Collaborative Biomedical Research Program, Baystate Medical Center/University of Massachusetts at Amherst (RS, QJC and RBA) and Rays of Hope, Baystate Medical Center (QJC and RS).	Albini A, 1996, ONCOGENE, V12, P289; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bergmann OJ, 2005, CLIN CANCER RES, V11, P8644, DOI 10.1158/1078-0432.CCR-05-1317; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brasso K, 2006, PROSTATE, V66, P503, DOI 10.1002/pros.20311; Cintin C, 2002, CANCER-AM CANCER SOC, V95, P267, DOI 10.1002/cncr.10644; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Fusetti F, 2003, J BIOL CHEM, V278, P37753, DOI 10.1074/jbc.M303137200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hogdall EVS, 2003, ONCOL REP, V10, P1535; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hormigo A, 2006, CLIN CANCER RES, V12, P5698, DOI 10.1158/1078-0432.CCR-06-0181; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1; Johansen JS, 2004, LUNG CANCER-J IASLC, V46, P333, DOI 10.1016/j.lungcan.2004.05.010; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Kim H, 2007, J KOREAN ASTRON SOC, V40, P17, DOI 10.5303/JKAS.2007.40.1.017; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lal A, 1999, CANCER RES, V59, P5403; Lau SH, 2006, ONCOGENE, V25, P1242, DOI 10.1038/sj.onc.1209141; MAGLIONE D, 1993, ONCOGENE, V8, P925; McQuade KJ, 2006, J CELL SCI, V119, P2445, DOI 10.1242/jcs.02970; Millauer B, 1996, CANCER RES, V56, P1615; Naruse T, 2006, CARCINOGENESIS, V27, P584, DOI 10.1093/carcin/bgi240; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Pelloski CE, 2005, CLIN CANCER RES, V11, P3326, DOI 10.1158/1078-0432.CCR-04-1765; Polnaszek N, 2003, CANCER RES, V63, P5754; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Roslind A, 2008, BREAST CANCER RES TR, V112, P275, DOI 10.1007/s10549-007-9870-7; Schmidt H, 2006, CANCER-AM CANCER SOC, V106, P1130, DOI 10.1002/cncr.21678; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Sharif M, 2006, RHEUMATOLOGY, V45, P522, DOI 10.1093/rheumatology/kei216; Yan W, 2008, MOL BIOL CELL, V19, P2278, DOI 10.1091/mbc.E07-10-1068; Yan W, 2006, J BIOL CHEM, V281, P19700, DOI 10.1074/jbc.M601856200; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	43	201	217	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	2009	28	50					4456	4468		10.1038/onc.2009.292	http://dx.doi.org/10.1038/onc.2009.292			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19767768	Green Accepted			2022-12-17	WOS:000272876500005
J	Baker, SJ; Rane, SG; Reddy, EP				Baker, S. J.; Rane, S. G.; Reddy, E. P.			Hematopoietic cytokine receptor signaling	ONCOGENE			English	Review						hematopoiesis; cytokine receptors; Src kinases; JAKs; STATs	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; DNA-BINDING ACTIVITY; INTERLEUKIN-5 TRANSDUCE SIGNALS; C-TERMINAL DOMAINS; FACTOR GM-CSF; INTERFERON-ALPHA; ERYTHROPOIETIN RECEPTOR; SH2 DOMAIN; MOLECULAR-CLONING	Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors. Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types. Recent studies conducted over the past 10 - 15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases ( JAKs) and their downstream transcription factors termed STATs ( signal transducers and activators of transcription). Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders. This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK- STAT pathway in both normal cellular development and disease states.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NIDDK, NIH, Diabet Branch, Bethesda, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@temple.edu	Reddy, E. Premkumar/F-6233-2011		NHLBI NIH HHS [5R01HL080666-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080666] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; Durand C, 2005, HAEMATOLOGICA, V90, P100; EDER M, 1994, J BIOL CHEM, V269, P30173; Eilers A, 1996, CELL GROWTH DIFFER, V7, P833; Ema H, 2003, CURR OPIN GENET DEV, V13, P508, DOI 10.1016/j.gde.2003.08.011; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feener EP, 2004, MOL CELL BIOL, V24, P4968, DOI 10.1128/MCB.24.11.4968-4978.2004; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Frank DA, 1996, LEUKEMIA, V10, P1724; Funakoshi-Tago M, 2006, EMBO J, V25, P4763, DOI 10.1038/sj.emboj.7601365; Gartsbein M, 2006, J CELL SCI, V119, P470, DOI 10.1242/jcs.02744; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2006, BIOCHEM PHARMACOL, V72, P1538, DOI 10.1016/j.bcp.2006.04.013; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARPUR AG, 1992, ONCOGENE, V7, P1347; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JUBINSKY PT, 1993, BLOOD, V81, P587; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Khwaja A, 2006, BRIT J HAEMATOL, V134, P366, DOI 10.1111/j.1365-2141.2006.06206.x; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Lu XQ, 2007, MOL CELL BIOL, V27, P2166, DOI 10.1128/MCB.01234-06; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 2001, CANCER RES, V61, P3276; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rakesh K, 2005, BIOCHEM PHARMACOL, V70, P649, DOI 10.1016/j.bcp.2005.04.042; RANE SG, 1994, ONCOGENE, V9, P2415; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schindler C, 2000, ADV PHARMACOL, V47, P113; Seki Y, 2002, P NATL ACAD SCI USA, V99, P13003, DOI 10.1073/pnas.202477099; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Ungureanu D, 2005, BLOOD, V106, P224, DOI 10.1182/blood-2004-11-4514; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Valentino L, 2006, BIOCHEM PHARMACOL, V71, P713, DOI 10.1016/j.bcp.2005.12.017; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Waiboci LW, 2007, J IMMUNOL, V178, P5058, DOI 10.4049/jimmunol.178.8.5058; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamada T, 2002, J BIOL CHEM, V277, P28830, DOI 10.1074/jbc.M201781200; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	130	201	214	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6724	6737		10.1038/sj.onc.1210757	http://dx.doi.org/10.1038/sj.onc.1210757			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934481				2022-12-17	WOS:000250147000005
J	Ozanne, BW; Spence, HJ; McGarry, LC; Hennigan, RF				Ozanne, B. W.; Spence, H. J.; McGarry, L. C.; Hennigan, R. F.			Transcription factors control invasion: AP-1 the first among equals	ONCOGENE			English	Review						invasion; metastasis; AP-1; Fos; Jun; transcription factors	ANCHORAGE-INDEPENDENT GROWTH; CHICKEN-EMBRYO FIBROBLASTS; TUMOR-CELL INVASION; C-FOS GENE; MULTIGENIC INVASION; SIGNAL-TRANSDUCTION; PROTEIN CAUSES; UP-REGULATION; DNA-BINDING; V-FOS	Metastasis, the aggressive spread of a malignant tumor to distant organs, is a major cause of death in cancer patients. Despite this critical role in cancer outcomes, the molecular mechanisms that control this process are just beginning to be understood. Metastasis is largely dependent upon the ability of tumor cells to invade the barrier formed by the basement membrane and to migrate through neighboring tissues. This review will summarize the evidence that tumor cell invasion is the result of oncogene-mediated signal transduction pathways that control the expression of a specific set of genes that together mediate tumor cell invasion. We focus on the role of the transcription factor AP-1 to both induce the expression of genes that function as invasion effectors and repress other genes that function as invasion suppressors. This identies AP-1 as a critical regulator of a complex program of gene expression that de. nes the invasive phenotype.	Univ Cincinnati, Dept Cell Biol, Cincinnati, OH 45267 USA; Beatson Inst Canc Res, Invas & Metastasis Lab, Glasgow G61 1BD, Lanark, Scotland	University System of Ohio; University of Cincinnati; Beatson Institute	Hennigan, RF (corresponding author), Univ Cincinnati, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Robert.Hennigan@uc.edu						ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Andela VB, 2003, CLIN ORTHOP RELAT R, pS75, DOI 10.1097/01.blo.0000093048.96273.aa; Andersen H, 2005, MOL CELL BIOL, V25, P9138, DOI 10.1128/MCB.25.20.9138-9150.2005; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bahassi EM, 2004, CLIN EXP METASTAS, V21, P293, DOI 10.1023/B:CLIN.0000046132.46946.dd; Bailly M, 1998, MICROSC RES TECHNIQ, V43, P433, DOI 10.1002/(SICI)1097-0029(19981201)43:5<433::AID-JEMT9>3.0.CO;2-2; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Black EJ, 2004, ONCOGENE, V23, P2357, DOI 10.1038/sj.onc.1207377; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; CHEN LL, 1993, BIOCHEM BIOPH RES CO, V193, P167, DOI 10.1006/bbrc.1993.1605; Chen RH, 1996, ONCOGENE, V12, P1493; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENHARDT DT, 1987, ONCOGENE, V2, P55; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Foos G, 2000, ONCOGENE, V19, P5507, DOI 10.1038/sj.onc.1203946; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; JOOSS KU, 1995, ONCOGENE, V10, P603; KOVARY K, 1991, NEW BIOL, V3, P870; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; KY M, 1996, ONCOGENE, V12, P221; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE MS, 1993, ONCOGENE, V8, P387; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Lindholm PF, 2001, CLIN EXP METASTAS, V18, P471, DOI 10.1023/A:1011845725394; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Liu S, 2006, EXP MOL PATHOL, V80, P132, DOI 10.1016/j.yexmp.2005.07.005; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mashimo J, 1997, CANCER LETT, V113, P213, DOI 10.1016/S0304-3835(97)04700-9; McGarry LC, 2004, ONCOGENE, V23, P5284, DOI 10.1038/sj.onc.1207687; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Nguyen A, 2005, INT J ONCOL, V27, P949; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; OKUNO H, 1991, ONCOGENE, V6, P1491; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Ordway JM, 2002, CELL GROWTH DIFFER, V13, P149; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; PARTIN AW, 1988, CANCER RES, V48, P6050; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; PRICE CHG, 1972, BRIT J CANCER, V26, P15, DOI 10.1038/bjc.1972.5; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAZ A, 1989, CANCER RES, V49, P3489; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sapi E, 1998, CANCER RES, V58, P1027; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Seth A, 2001, Expert Opin Ther Targets, V5, P87, DOI 10.1517/14728222.5.1.87; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Spence HJ, 2006, MOL CELL BIOL, V26, P1480, DOI 10.1128/MCB.26.4.1480-1495.2006; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stapleton G, 2002, J CELL SCI, V115, P2713; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; TANIGUCHI S, 1989, CANCER RES, V49, P6738; Tkach V, 2003, ONCOGENE, V22, P5045, DOI 10.1038/sj.onc.1206570; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; WANG ZQ, 1995, CANCER RES, V55, P6244; Weissman I, 2005, JAMA-J AM MED ASSOC, V294, P1359, DOI 10.1001/jama.294.11.1359; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	116	201	206	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					1	10		10.1038/sj.onc.1209759	http://dx.doi.org/10.1038/sj.onc.1209759			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799638				2022-12-17	WOS:000243236500001
J	Uren, AG; Kool, J; Berns, A; van Lohuizen, M				Uren, AG; Kool, J; Berns, A; van Lohuizen, M			Retroviral insertional mutagenesis: past, present and future	ONCOGENE			English	Review						retroviral insertional mutagenesis; murine leukemia virus; genetic screens; cancer; common insertion site; lymphoma	MURINE LEUKEMIA-VIRUS; E-MU-MYC; SLEEPING-BEAUTY TRANSPOSON; LONG TERMINAL REPEAT; T-CELL LYMPHOMAS; LARGE-SCALE IDENTIFICATION; IN-VITRO AMPLIFICATION; TARGET SITE SELECTION; ZINC-FINGER PROTEIN; C-MYC	Retroviral insertion mutagenesis screens in mice are powerful tools for efficient identification of oncogenic mutations in an in vivo setting. Many oncogenes identified in these screens have also been shown to play a causal role in the development of human cancers. Sequencing and annotation of the mouse genome, along with recent improvements in insertion site cloning has greatly facilitated identification of oncogenic events in retro-virus-induced tumours. In this review, we discuss the features of retroviral insertion mutagenesis screens, covering the mechanisms by which retroviral insertions mutate cellular genes, the practical aspects of insertion site cloning, the identification and analysis of common insertion sites, and finally we address the potential for use of somatic insertional mutagens in the study of non-haematopoietic and nonmammary tumour types.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl; m.v.lohuizen@nki.nl	Uren, Anthony G/A-5784-2009	Uren, Anthony G/0000-0002-6019-7111				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Arnold C, 1991, PCR Methods Appl, V1, P39; Bahrami S, 2004, J VIROL, V78, P9343, DOI 10.1128/JVI.78.17.9343-9351.2004; Beatty J, 2002, CANCER RES, V62, P7175; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; BEN-DAVID Y, 1990, New Biologist, V2, P1015; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Carlson CM, 2003, GENETICS, V165, P243; Cavazzana-Calvo Marina, 2005, Annu Rev Med, V56, P585, DOI 10.1146/annurev.med.56.090203.104142; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHO BC, 1995, J VIROL, V69, P7138, DOI 10.1128/JVI.69.11.7138-7146.1995; Clark KJ, 2004, GENESIS, V39, P225, DOI 10.1002/gene.20049; CLAUSSE N, 1993, VIROLOGY, V194, P157, DOI 10.1006/viro.1993.1245; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; Cui ZB, 2002, J MOL BIOL, V318, P1221, DOI 10.1016/S0022-2836(02)00237-1; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; CUYPERS HT, 1984, CELL, V37, P141; Dave UP, 2004, SCIENCE, V303, P333, DOI 10.1126/science.1091667; DAVID YB, 1988, ONCOGENE, V3, P179; Davidson AE, 2003, DEV BIOL, V263, P191, DOI 10.1016/j.ydbio.2003.07.013; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; DESGROSEILLERS L, 1984, J VIROL, V52, P945, DOI 10.1128/JVI.52.3.945-952.1984; DESGROSEILLERS L, 1984, J VIROL, V52, P448, DOI 10.1128/JVI.52.2.448-456.1984; DEVON RS, 1995, NUCLEIC ACIDS RES, V23, P1644, DOI 10.1093/nar/23.9.1644; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ding S, 2005, CELL, V122, P473, DOI 10.1016/j.cell.2005.07.013; DOMEN J, 1987, ONCOGENE RES, V1, P103; Dudley JP, 2002, LEUKEMIA, V16, P1086, DOI 10.1038/sj.leu.2402451; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; Ethelberg S, 1997, J VIROL, V71, P7273, DOI 10.1128/JVI.71.10.7273-7280.1997; Ethelberg S, 1997, J VIROL, V71, P1196, DOI 10.1128/JVI.71.2.1196-1206.1997; Feldman BJ, 2000, BLOOD, V96, P1906, DOI 10.1182/blood.V96.5.1906.h8001906_1906_1913; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Geurts AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Grabher C, 2003, GENE, V322, P57, DOI 10.1016/j.gene.2003.09.009; GRAVES BJ, 1985, MOL CELL BIOL, V5, P1948, DOI 10.1128/MCB.5.8.1948; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HALLBERG B, 1991, J VIROL, V65, P4177, DOI 10.1128/JVI.65.8.4177-4181.1991; Hamer L, 2001, CURR OPIN CHEM BIOL, V5, P67, DOI 10.1016/S1367-5931(00)00162-9; Han JS, 2004, NATURE, V429, P314, DOI 10.1038/nature02535; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Hanlon L, 2003, J VIROL, V77, P1059, DOI 10.1128/JVI.77.2.1059-1068.2003; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423; HERMAN SA, 1986, J VIROL, V60, P497, DOI 10.1128/JVI.60.2.497-505.1986; Hirai H, 2001, CANCER CHEMOTH PHARM, V48, pS35, DOI 10.1007/s002800100303; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JAENISCH R, 1980, CELL, V19, P181, DOI 10.1016/0092-8674(80)90399-2; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Joosten M, 2002, ONCOGENE, V21, P7247, DOI 10.1038/sj.onc.1205813; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; Largaespada David A, 2003, Reprod Biol Endocrinol, V1, P80, DOI 10.1186/1477-7827-1-80; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li L, 2000, J VIROL, V74, P10965, DOI 10.1128/JVI.74.23.10965-10974.2000; Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Liu GY, 2005, J MOL BIOL, V346, P161, DOI 10.1016/j.jmb.2004.09.086; Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Ma SL, 2003, VIROLOGY, V313, P638, DOI 10.1016/S0042-6822(03)00379-9; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Marshall E, 2003, SCIENCE, V299, P320, DOI 10.1126/science.299.5605.320; Martin-Hernandez J, 2001, J VIROL, V75, P11907, DOI 10.1128/JVI.75.23.11907-11912.2001; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mikkers H, 2002, ONCOGENE, V21, P6559, DOI 10.1038/sj.onc.1205930; Miskey C, 2003, NUCLEIC ACIDS RES, V31, P6873, DOI 10.1093/nar/gkg910; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nielsen AA, 2005, J VIROL, V79, P67, DOI 10.1128/JVI.79.1.67-78.2005; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; OCHMAN H, 1988, GENETICS, V120, P621; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; REISMAN D, 1990, FEBS LETT, V277, P209, DOI 10.1016/0014-5793(90)80846-B; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Roh M, 2003, CANCER RES, V63, P8079; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; Rosenberg N., 1997, P475; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schmidt M, 2005, BLOOD, V105, P2699, DOI 10.1182/blood-2004-07-2648; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shore SK, 2002, ONCOGENE, V21, P8568, DOI 10.1038/sj.onc.1206084; Sorensen AB, 1996, J VIROL, V70, P4063; SORENSEN AB, 1993, J VIROL, V67, P7118; Sorensen KD, 2004, J VIROL, V78, P13216, DOI 10.1128/JVI.78.23.13216-13231.2004; Starkey CR, 1998, J VIROL, V72, P1078, DOI 10.1128/JVI.72.2.1078-1084.1998; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Suzuki Y, 2004, EMBO J, V23, P4670, DOI 10.1038/sj.emboj.7600452; SWAIN A, 1993, J VIROL, V67, P6265, DOI 10.1128/JVI.67.10.6265-6269.1993; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TSICHLIS PN, 1983, NATURE, V302, P445, DOI 10.1038/302445a0; Uhrbom L, 1998, CANCER RES, V58, P5275; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1982, NUCLEIC ACIDS RES, V10, P577, DOI 10.1093/nar/10.2.577; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Vigdal TJ, 2002, J MOL BIOL, V323, P441, DOI 10.1016/S0022-2836(02)00991-9; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WALKER GT, 1992, P NATL ACAD SCI USA, V89, P392, DOI 10.1073/pnas.89.1.392; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; Wotton S, 2002, CANCER RES, V62, P7181; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yan YX, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng068; Yant SR, 2002, NAT BIOTECHNOL, V20, P999, DOI 10.1038/nbt738; Yant SR, 2004, MOL CELL BIOL, V24, P9239, DOI 10.1128/MCB.24.20.9239-9247.2004; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zayed H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	176	201	209	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7656	7672		10.1038/sj.onc.1209043	http://dx.doi.org/10.1038/sj.onc.1209043			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299527				2022-12-17	WOS:000233372600003
J	Pennarun, G; Granotier, C; Gauthier, LR; Gomez, D; Hoffschir, F; Mandine, E; Riou, JF; Mergny, JL; Mailliet, P; Boussin, FD				Pennarun, G; Granotier, C; Gauthier, LR; Gomez, D; Hoffschir, F; Mandine, E; Riou, JF; Mergny, JL; Mailliet, P; Boussin, FD			Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands	ONCOGENE			English	Article						glioma; anticancer agent; G-quadruplex ligands; apoptosis	S-PHASE CHECKPOINT; LEUKEMIA-CELLS; INHIBITION; ARREST; GROWTH; RETINOBLASTOMA; TELOMESTATIN; PROGRESSION; SENESCENCE; INDUCTION	Telomerase represents a relevant target for cancer therapy. Molecules able to stabilize the G-quadruplex (G4), a structure adopted by the 3'-overhang of telomeres, are thought to inhibit telomerase by blocking its access to telomeres. We investigated the cellular effects of four new 2,6-pyridine-dicarboxamide derivatives displaying strong selectivity for G4 structures and strong inhibition of telomerase in in vitro assays. These compounds inhibited cell proliferation at very low concentrations and then induced a massive apoptosis within a few days in a dose-dependent manner in cultures of three telomerase-positive glioma cell lines, T98G, CB193 and U118-MG. They had also antiproliferative effects in SAOS-2, a cell line in which telomere maintenance involves an alternative lengthening of telomeres (ALT) mechanism. We show that apoptosis was preceded by multiple alterations of the cell cycle: activation of S-phase checkpoints, dramatic increase of metaphase duration and cytokinesis defects. These effects were not associated with telomere shortening, but they were directly related to telomere instability involving telomere end fusion and anaphase bridge formation. Pyridine-based G-quadruplex ligands are therefore promising agents for the treatment of various tumors including malignant gliomas.	CEA, DRR, DSV, Lab Radiopathol, 18 Route Panorama, F-92265 Fontenay Aux Roses, France; Univ Reims, JE 2428, Lab Oncopharmacol, F-51096 Reims, France; Aventis Pharma SA, Ctr Rech Paris, F-94403 Vitry Sur Seine, France; Museum Natl Hist Nat USM 503, Biophys Lab, CNRS, UMR 5153,INSERM,U565, F-75005 Paris, France	CEA; Universite de Reims Champagne-Ardenne; Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Universite Paris Cite	Boussin, FD (corresponding author), CEA, DRR, DSV, Lab Radiopathol, 18 Route Panorama, F-92265 Fontenay Aux Roses, France.	boussin@cea.fr	Mergny, Jean-Louis/E-2860-2013; Gomez Zamorano, Dennis Gomez/AAX-5182-2021; Pennarun, Gaelle/AAX-6579-2021; Gauthier, Laurent/ABC-7614-2021	Mergny, Jean-Louis/0000-0003-3043-8401; Gomez Zamorano, Dennis Gomez/0000-0001-9942-1451; Gauthier, Laurent/0000-0003-4644-7660; riou, jean-francois/0000-0002-0055-6506; Pennarun, Gaelle/0000-0001-9881-9345; GRANOTIER-BECKERS, Christine/0000-0003-1063-1159; Boussin, francois/0000-0003-3778-4403				Alonso M, 2003, MOL CANCER THER, V2, P139; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2003, CANCER RES, V63, P6149; Gomez D, 2002, CANCER RES, V62, P3365; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Kim MY, 2003, J MED CHEM, V46, P571, DOI 10.1021/jm0203377; Lemarteleur T, 2004, BIOCHEM BIOPH RES CO, V323, P802, DOI 10.1016/j.bbrc.2004.08.150; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; MAILLIET P, 2003, 94 AACR M LB28 JUL 1; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Shammas MA, 2003, MOL CANCER THER, V2, P825; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Shi Z, 2001, CANCER RES, V61, P1065; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	45	201	210	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2917	2928		10.1038/sj.onc.1208468	http://dx.doi.org/10.1038/sj.onc.1208468			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735722				2022-12-17	WOS:000228649500001
J	Saleem, M; Afaq, F; Adhami, VM; Mukhtar, H				Saleem, M; Afaq, F; Adhami, VM; Mukhtar, H			Lupeol modulates NF-kappa B and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice	ONCOGENE			English	Article						lupeol; chemoprevention; NF-kappa B; PI3K/Akt; skin cancer	ORNITHINE-DECARBOXYLASE ACTIVITY; SENCAR MOUSE SKIN; GREEN TEA; TUMOR PROMOTION; ANTIINFLAMMATORY TRITERPENOIDS; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-LINE; IN-VITRO; CHEMOPREVENTION	Chemoprevention has become an effective cancer control modality; however, the search for novel agent(s) for the armamentarium of cancer chemoprevention continues. We argue that agents capable for inhibition of promotion stage of tumorigenesis with the ability to intervene at several critical pathways in the tumorigenesis process will have greater advantage over other single-target agents. Lupeol, a triterpene, is the principal constituent of common fruit plants such as olive, mango,. g and medicinal herbs that have been used to treat skin aliments. Lupeol has been reported to possess a wide range of medicinal properties that include strong antioxidant, antimutagenic, anti-inflammatory and antiarthritic effects. In the present study, we show that Lupeol possesses antitumor-promoting effects in a mouse skin tumorigenesis model. We first determined the effect of topical application of Lupeol to CD-1 mouse against 12-O-tetradecanoylphorbol- 13-acetate (TPA)-induced conventional markers and other novel markers of skin tumor promotion. We found that topical application of Lupeol (1 - 2 mg/mouse) 30 min prior to TPA (3.2 nmol/mouse) application onto the skin of CD-1 mice afforded significant inhibition, in a time- and dose-dependent manner, against TPA-mediated increase in (i) skin edema and hyperplasia, (ii) epidermal ornithine decarboxylase (ODC) activity, and (iii) protein expression of ODC, cyclo-oxygenase-2 and nitric oxide synthase. As of the role of nuclear factor kappa B (NF-kappaB) and phosphatidyl inositol 3-kinase (PI3K)/Akt signaling in tumor promotion, we next determined the effect of topical application of Lupeol to mouse skin against these signaling pathways. We found that Lupeol treatment to mouse skin resulted in the inhibition of TPA-induced ( i) activation of PI3K, ( ii) phosphorylation of Akt at Thr(308), ( iii) activation of NF-kappaB and IKKalpha, and (iv) degradation and phosphorylation of IkappaBalpha. The animals pretreated with Lupeol showed significantly reduced tumor incidence, lower tumor body burden and a significant delay in the latency period for tumor appearance. At the termination of the experiment at 28 weeks, 100% of the animals in TPA-treated group exhibited seven to eight tumors/mouse, whereas only 53% of the mice receiving Lupeol prior to TPA treatment exhibited one to three tumors/mouse. These results for the first time provide evidence that Lupeol possesses antiskin tumor-promoting effects in CD-1 mouse and inhibits conventional as well as novel biomarkers of tumor promotion. We suggest that Lupeol is an attractive antitumor-promoting agent that must be evaluated in tumor models other than skin carcinogenesis.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave,B-25, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Saleem, Mohammad/GVS-9221-2022; Adhami, Vaqar/AAY-2837-2020	Saleem, Mohammad/0000-0002-7422-7967; Adhami, Vaqar/0000-0002-2048-4570	NATIONAL CANCER INSTITUTE [R03CA099909, R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809, R03 CA 99909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Ahmad N, 2000, CLIN CANCER RES, V6, P1524; Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; ANJANEYLU V, 1982, Indian Journal of Pharmaceutical Sciences, V44, P58; Auvinen M, 1997, JNCI-J NATL CANCER I, V89, P533, DOI 10.1093/jnci/89.8.533; Badria FA, 2003, Z NATURFORSCH C, V58, P505; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beveridge THJ, 2002, J AGR FOOD CHEM, V50, P744, DOI 10.1021/jf010701v; BHIMANI RS, 1993, CANCER RES, V53, P4528; Bickers D R, 2000, J Dermatol, V27, P691; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Callejas NA, 1999, J CELL SCI, V112, P3147; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chun Kyung-Soo, 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P131; Conney AH, 1997, P SOC EXP BIOL MED, V216, P234, DOI 10.3181/00379727-216-44173; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Fernandez MA, 2001, J PHARM PHARMACOL, V53, P1533, DOI 10.1211/0022357011777909; FOURNET A, 1992, J ETHNOPHARMACOL, V37, P159, DOI 10.1016/0378-8741(92)90074-2; FURSTENBERGER G, 1985, ARACHIDONIC ACID MET, P49; Geetha T, 2001, J ETHNOPHARMACOL, V76, P77, DOI 10.1016/S0378-8741(01)00175-1; Geetha T, 1999, MOL CELL BIOCHEM, V201, P83, DOI 10.1023/A:1007056300503; Guevara AP, 1996, MUTAT RES-ENVIR MUTA, V361, P67, DOI 10.1016/S0165-1161(96)90240-X; Gupta S, 2002, CANCER METAST REV, V21, P363, DOI 10.1023/A:1021275330385; Gupta S, 2001, SKIN PHARMACOL APPL, V14, P373, DOI 10.1159/000056371; Gupta S, 1999, CANCER RES, V59, P2115; Hasmeda M, 1999, PLANTA MED, V65, P14, DOI 10.1055/s-1999-13954; Hata K, 2003, J BIOCHEM, V134, P441, DOI 10.1093/jb/mvg162; Hata K, 2002, J NAT PROD, V65, P645, DOI 10.1021/np0104673; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hodges LD, 2003, MOL CELL BIOCHEM, V252, P97, DOI 10.1023/A:1025569805468; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kakuda R, 2002, PHYTOCHEMISTRY, V59, P791, DOI 10.1016/S0031-9422(02)00021-3; Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117; Katiyar SK, 1996, CANCER RES, V56, P1023; Katiyar SK, 1997, CARCINOGENESIS, V18, P497, DOI 10.1093/carcin/18.3.497; Katiyar SK, 1997, CARCINOGENESIS, V18, P1911, DOI 10.1093/carcin/18.10.1911; Kim DJ, 2003, MUTAT RES-FUND MOL M, V523, P99, DOI 10.1016/S0027-5107(02)00325-1; Liang YC, 2002, NUTR CANCER, V42, P217, DOI 10.1207/S15327914NC422_11; Lin LC, 2001, J NAT PROD, V64, P674, DOI 10.1021/np000569d; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mills GB, 2003, SEMIN ONCOL, V30, P93, DOI 10.1053/j.seminoncol.2003.08.011; Miura K, 2001, PHYTOCHEMISTRY, V58, P1171, DOI 10.1016/S0031-9422(01)00341-7; Mohan RR, 1999, CLIN CANCER RES, V5, P143; Moriarity DM, 1998, PLANTA MED, V64, P370, DOI 10.1055/s-2006-957454; Nagaraj M, 2000, J APPL TOXICOL, V20, P413, DOI 10.1002/1099-1263(200009/10)20:5<413::AID-JAT706>3.0.CO;2-Y; NAKADATE T, 1985, JPN J PHARMACOL, V37, P253, DOI 10.1254/jjp.37.253; Nikiema JB, 2001, PHYTOTHER RES, V15, P131, DOI 10.1002/ptr.700; Osaki M, 2004, J CANCER RES CLIN, V130, P8, DOI 10.1007/s00432-003-0505-z; Pereira AD, 2003, Z NATURFORSCH C, V58, P201; Rajic A, 2000, PLANTA MED, V66, P206, DOI 10.1055/s-2000-8657; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Saeed MA, 2002, FITOTERAPIA, V73, P417, DOI 10.1016/S0367-326X(02)00127-2; Saleem M, 2001, PHARMACOL RES, V43, P127, DOI 10.1006/phrs.2000.0710; Saleem R, 2003, BIOL PHARM BULL, V26, P41, DOI 10.1248/bpb.26.41; Seo HJ, 2002, INT J CANCER, V100, P456, DOI 10.1002/ijc.10489; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SOSA A, 1963, B SOC CHIM BIOL, V45, P117; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Sunitha S, 2001, FITOTERAPIA, V72, P516, DOI 10.1016/S0367-326X(01)00259-3; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Ulubelen A, 1997, J NAT PROD, V60, P1275, DOI 10.1021/np9700681; VERMA AK, 1979, CANCER RES, V39, P419; Vidya L, 2002, PHYTOTHER RES, V16, P514, DOI 10.1002/ptr.940; Wada S, 2001, J NAT PROD, V64, P1545, DOI 10.1021/np010176u; Ziegler HL, 2002, ANTIMICROB AGENTS CH, V46, P1441, DOI 10.1128/AAC.46.5.1441-1446.2002	72	201	212	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5203	5214		10.1038/sj.onc.1207641	http://dx.doi.org/10.1038/sj.onc.1207641			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122342				2022-12-17	WOS:000222382500010
J	Argani, P; Lui, MY; Couturier, J; Bouvier, R; Fournet, JC; Ladanyi, M				Argani, P; Lui, MY; Couturier, J; Bouvier, R; Fournet, JC; Ladanyi, M			A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23)	ONCOGENE			English	Article						chromosome translocation; carcinoma; pediatric; kidney	SOFT PART SARCOMA; CELL CARCINOMA; TFE3 GENE; NUCLEAR-LOCALIZATION; TUBEROUS SCLEROSIS; CLATHRIN; PRCC; ALK; KINASE; IMMUNOREACTIVITY	A distinctive subset of renal carcinomas is associated with Xp11.2 translocations and resulting TFE3 gene fusions (PRCC-TFE3, PSF-TFE3, NONO-TFE3, ASPL-TFE3), encoding related aberrant transcription factors. We report the cloning of a novel clathrin heavy-chain gene (CLTC)-TFE3 gene fusion resulting from a t(X;l7)(p11.2;q23) in a renal carcinoma arising in a 14-year-old boy. The fusion transcript joined the 5' exons of CLTC on chromosome band 17q23 to the 3' exons of TFE3. CLTC encodes a major subunit of clathrin, a multimeric protein on cytoplasmic organelles, and is a known recurrent fusion partner of the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors. The predicted CLTC-TFE3 product retains the nuclear localization and DNA-binding domains of TFE3, but lacks the multimerization domain of CLTC. The present renal tumor demonstrated morphologic and immunohistochemical features of both PRCC-TFE3 and ASPL-TFE3 carcinomas, including strong nuclear immunoreactivity for the TFE3 C-terminal and only minimal expression of epithelial proteins. However, unlike most renal carcinomas, it also focally expressed melanocytic proteins. The present report highlights the promiscuity of certain genes involved in chromosomal translocations. Further analysis of the shared features of CLTC and other TFE3 fusion partners may shed light on the essential biology of TFE3 fusion proteins.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Inst Curie, F-75248 Paris 05, France; Hop Edouard Herriot, F-69437 Lyon 3, France; Hop St Justine, Montreal, PQ H3T 1C5, Canada	Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CHU Lyon; Universite de Montreal	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Room S-801,1275 York Ave, New York, NY 10021 USA.	ladanyim@mskcc.org	Ladanyi, Marc/AAG-8585-2019		NCI NIH HHS [R01CA95785] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095785] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Argani P, 2002, AM J SURG PATHOL, V26, P1553, DOI 10.1097/00000478-200212000-00003; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9; Avery AK, 2000, AM J SURG PATHOL, V24, P203, DOI 10.1097/00000478-200002000-00006; Bjornsson J, 1996, AM J PATHOL, V149, P1201; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Cools J, 2002, GENE CHROMOSOME CANC, V34, P354, DOI 10.1002/gcc.10033; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Heimann P, 2001, CANCER RES, V61, P4130; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Ladanyi M, 2000, AM J PATHOL, V157, P341, DOI 10.1016/S0002-9440(10)64545-2; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Pea M, 1998, AM J SURG PATHOL, V22, P180, DOI 10.1097/00000478-199802000-00005; PEROT C, 2003, IN PRESS CANC GENET; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Smith CJ, 1999, TRENDS CELL BIOL, V9, P335, DOI 10.1016/S0962-8924(99)01631-1; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	28	201	213	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5374	5378		10.1038/sj.onc.1206686	http://dx.doi.org/10.1038/sj.onc.1206686			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917640				2022-12-17	WOS:000184734900018
J	Heppner, C; Bilimoria, KY; Agarwal, SK; Kester, MB; Whitty, LJ; Guru, SC; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL				Heppner, C; Bilimoria, KY; Agarwal, SK; Kester, MB; Whitty, LJ; Guru, SC; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL			The tumor suppressor protein menin interacts with NF-kappa B proteins and inhibits NF-kappa B-mediated transactivation	ONCOGENE			English	Article						MEN1; MEN1 gene; menin; NF-kappa B; transcriptional repression; oncogene; Rel-homology domain	JUND-ACTIVATED TRANSCRIPTION; GENE-MUTATIONS; P65; FAMILY; IDENTIFICATION; EXPRESSION; PRODUCT; SUBUNIT; CANCER; P300	Multiple endocrine neoplasia type I is an autosomal dominant tumor syndrome. Manifestations include neoplasms of the parathyroid glands, entero pancreatic neuroendocrine cells, and the anterior pituitary gland. The MEN1 tumor suppressor gene encodes menin, a 610 amino acid nuclear protein without sequence homology to other proteins. To elucidate menin function, we used immunoprecipitation to identify interacting proteins. The NF-kappaB proteins p50, p52 and p65 were found to interact specifically and directly with menin in vitro and in vivo. The region of NF-kappaB proteins sufficient for binding to menin is the N-terminus. Furthermore, amino acids 305-381 of menin are essential for this binding. Menin represses p65-mediated transcriptional activation on NF-kappaB sites in a dose-dependent and specific manner. Also, PMA (phorbol 12-myristate 13-acetate)-stimulated NF-kappaB activation is suppressed by menin. These observations suggest that menin's ability to interact with NF-kappaB proteins and its modulation of NF-kappaB transactivation contribute to menin's tumor suppressor function.	NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Burns, AL (corresponding author), Univ Klin Koln, Klin & Poliklin Innere Med 2, D-50924 Cologne, Germany.		Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIEDK043009, Z01DK043009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000062] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Goebel SU, 2000, J CLIN ENDOCR METAB, V85, P116, DOI 10.1210/jc.85.1.116; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Marx SJ, 2001, METABOLIC MOL BASES, P943; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Ravi R, 1998, CANCER RES, V58, P4531; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VALLE MA, 2001, IN PRESS CYTOTECHNOL; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	38	201	209	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4917	4925		10.1038/sj.onc.1204529	http://dx.doi.org/10.1038/sj.onc.1204529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526476				2022-12-17	WOS:000170439800001
J	Hall-Jackson, CA; Cross, DAE; Morrice, N; Smythe, C				Hall-Jackson, CA; Cross, DAE; Morrice, N; Smythe, C			ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK	ONCOGENE			English	Article						ATR; checkpoint; protein kinase; DNA damage; caffeine	ATAXIA-TELANGIECTASIA GENE; CELL-CYCLE CHECKPOINTS; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; SCHIZOSACCHAROMYCES-POMBE; INDUCED PHOSPHORYLATION; SIGNALING PATHWAY; MAMMALIAN-CELLS; FISSION YEAST	ATR is a large, >300 kDa protein containing a carboxy-terminus kinase domain related to PI-3 kinase, and is homologous to the ATM gene product in human cells and the rad3/MEC1 proteins in yeast. These proteins, together with the DNA-PK, are part of a new family of PI-3 kinase related proteins. All members of this family play important roles in checkpoints which operate to permit cell survival following many forms of DNA damage. We have expressed ATR protein in HEK293 cells and purified the protein to near-homogeneity. We show that pure ATR is a protein kinase which is activated by circular single-stranded, double-stranded or linear DNA. Thus ATR is a new member of a sub-family of PIK related kinases, founded by the DNA-PK, which are activated in the presence of DNA, Unlike DNA-PK, ATR does not appear to require Ku proteins for its activation by DNA, We show directly that, like ATM and DIVA-PK, ATR phosphorylates the genome surveillance protein p53 on serine 15, a site which is up-regulated in response to DNA damage. In addition, we find that ATR has a substrate specificity similar to, but unique from, the DNA-PK in vitro, suggesting that these proteins have overlapping but distinct functions in vivo. Finally, we find that the kinase activity of ATR in the presence and absence of DNA is suppressed by caffeine, a compound which is known to induce loss of checkpoint control. Our results are consistent with the notion that ATR plays a role in monitoring DIVA structure and phosphorylation of proteins involved in the DNA damage response pathways.	Univ Dundee, Dept Biochem, Prot Phosphorylat Unit, MCR, Dundee DD1 5EH, Scotland	University of Dundee	Smythe, C (corresponding author), Univ Dundee, Dept Biochem, Prot Phosphorylat Unit, MCR, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CROMPTON NEA, 1993, RADIAT RES, V135, P372, DOI 10.2307/3578877; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Morgan SE, 1997, CANCER RES, V57, P3386; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; Osman F, 1998, MOL GEN GENET, V260, P319, DOI 10.1007/s004380050901; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STACK JH, 1994, J BIOL CHEM, V269, P31552; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	54	201	241	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6707	6713		10.1038/sj.onc.1203077	http://dx.doi.org/10.1038/sj.onc.1203077			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597277				2022-12-17	WOS:000083792000011
J	Rousseau, D; Gingras, AC; Pause, A; Sonenberg, N				Rousseau, D; Gingras, AC; Pause, A; Sonenberg, N			The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth	ONCOGENE			English	Article						malignant transformation; cap binding protein; translation inhibitors	CAP-BINDING-PROTEIN; EUKARYOTIC INITIATION FACTOR-4E; RAT EMBRYO FIBROBLASTS; 5' NONCODING REGION; TRANSLATION INITIATION; MALIGNANT TRANSFORMATION; SECONDARY STRUCTURE; ADIPOSE-TISSUE; FACTOR 4E; PHOSPHORYLATION	Initiation in eukaryotes is the rate limiting step of translation. The binding of the mRNA to the 40S ribosomal subunit, which is mediated by the mRNA cap structure, is a key target for control of protein synthesis. The cap binding protein, eIF4E, is the most limiting of all initiation factors and its overexpression in NIH3T3 cells causes malignant transformation. 4E-binding protein 1 (BP1) and 4E-BP2 are small proteins that bind to eIF4E and inhibit translation, Here, 4E-BPs were expressed in cells transformed by eIF4E or by v-src to determine the effect of 4E-BPs on cell growth and tumorigenicity. We show that 4E-BPs cause a significant reversion of the transformed phenotype. Thus, we demonstrate that the eIF4E-binding proteins act as negative regulators of cell growth. We propose that 4E-BPs are members of a class of negative regulators of cell growth acting on the translation machinery of the cell.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University			Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; BELSHAM GJ, 1982, BIOCHEM J, V204, P345, DOI 10.1042/bj2040345; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEGG AE, 1988, CANCER RES, V48, P759; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245	38	201	214	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2415	2420						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957083				2022-12-17	WOS:A1996VX10800014
J	Rao, GN				Rao, GN			Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases	ONCOGENE			English	Article						oxidant; receptor tyrosine kinases; signal transduction; vascular smooth muscle cells	EPIDERMAL GROWTH-FACTOR; OXYGEN FREE-RADICALS; SMOOTH-MUSCLE CELLS; I RECEPTOR; C-JUN; PHOSPHORYLATION; SHC; TRANSDUCTION; INSULIN; MOUSE	Protein tyrosine phosphorylation events play determinant roles in cellular processes such as proliferation and differentiation. We have recently reported that hydrogen peroxide, an active oxygen species and a cellular oxidant, stimulates growth response events in vascular smooth muscle cells (VSMC). To understand the mechanisms by which oxidant stress modulates these growth response events, we have studied the effect of hydrogen peroxide on protein tyrosine phosphorylation events in VSMC. Our findings show that hydrogen peroxide stimulates tyrosine phosphorylation of several proteins including epidermal growth factor receptor (EGFR) in VSMC. Hydrogen peroxide-induced tyrosine phosphorylation of EGFR was found to be time dependent; with a threefold increase at 5 min and a 20-fold increase at 30 min of treatment as compared to control levels. Hydrogen peroxide treatment of VSMC also resulted in a time-dependent increase in tyrosine phosphorylation of SHC proteins. In addition, hydrogen peroxide-induced tyrosine-phosphorylated EGFR formed a complex with SHC-Grb2-SOS. These events were followed by activation of Pas and extracellular signal-regulated protein kinases (ERKs) group of mitogen-activated protein kinases (MAPKs). Together these findings demonstrate for the first time that hydrogen peroxide, a cellular oxidant, possess the ability to activate EGFR-mediated signaling events in VSMC. These EGFR-mediated signaling events may be important in oxidant stress-induced cellular responses			Rao, GN (corresponding author), UNIV TEXAS, MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,RT 1064, 301 UNIV BLVD, GALVESTON, TX 77555 USA.							BASU T, 1994, ONCOGENE, V9, P3483; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COFFER PJ, 1995, ONCOGENE, V11, P561; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; DUQUE I, 1993, J PHARMACOL EXP THER, V267, P612; FANTONE JC, 1982, AM J PATHOL, V107, P397; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; XIE YM, 1995, ONCOGENE, V10, P2409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	201	212	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					713	719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761292				2022-12-17	WOS:A1996VD43300006
J	BARTKOVA, J; LUKAS, J; STRAUSS, M; BARTEK, J				BARTKOVA, J; LUKAS, J; STRAUSS, M; BARTEK, J			CYCLIN D1 ONCOPROTEIN ABERRANTLY ACCUMULATES IN MALIGNANCIES OF DIVERSE HISTOGENESIS	ONCOGENE			English	Note						CELL CYCLE; OVER-EXPRESSION OF CYCLIN D1; HUMAN TUMORS; ONCOGENE	ASSISTED IMAGE-ANALYSIS; BREAST-CANCER; RETINOBLASTOMA PROTEIN; SQUAMOUS-CELL; AMPLIFICATION; GENES; CARCINOMAS; EXPRESSION; ONCOGENE; BCL-1	Cyclin D1 is a cell cycle regulator essential for G1 phase progression and a candidate proto-oncogene whose deregulated expression has been implicated in pathogenesis of several types of cancer. We have examined expression of cyclin D1 in 212 primary tumours of five histogenetically distinct types by immunohistochemistry and found strong aberrant accumulation of the protein in 21%, and a moderate overabundance in further 25% of cases. While the abnormalities were more frequent in carcinomas of the breast, i.e. the cancer type known for cyclin D1 gene amplification, aberrant expression was also seen in significant subsets of colorectal cancers, soft tissue sarcomas, uterine carcinomas and malignant melanomas. Comparison of distinct stages of tumour progression showed concordant cyclin D1 patterns in the in situ vs invasive breast carcinoma components (n=37) and between primary and metastatic lesions (n=51) of several tumour types. The specificity of the immunohistochemical data was supported by immunoblotting analysis of tissue and tumour lysates, and the tumour-specific over-expression was confirmed by computer-assisted image analysis. These observations suggest that alterations of cyclin D1 expression represent a common feature of malignancies of diverse histogenesis and indicate that both the spectrum of tumour types and the frequency of cyclin D1 aberrations significantly exceed previous estimations based on genetic analyses.	DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK; MAX PLANCK GESELL,MAX DELBRUCK HANS,D-13122 BERLIN,GERMANY	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BERENSON JR, 1989, ONCOGENE, V4, P1111; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CZERNIAK B, 1990, J HISTOCHEM CYTOCHEM, V38, P463, DOI 10.1177/38.4.1969431; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GILLETT C, 1994, CANCER RES, V54, P1812; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAM SW, 1994, ONCOGENE, V9, P2663; THEILLET C, 1990, ONCOGENE, V5, P147; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	39	201	203	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					775	778						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862456				2022-12-17	WOS:A1995QH61200019
J	SHIOTA, M; FUJIMOTO, J; SEMBA, T; SATOH, H; YAMAMOTO, T; MORI, S				SHIOTA, M; FUJIMOTO, J; SEMBA, T; SATOH, H; YAMAMOTO, T; MORI, S			HYPERPHOSPHORYLATION OF A NOVEL 80 KDA PROTEIN-TYROSINE KINASE SIMILAR TO LTK IN A HUMAN KI-1 LYMPHOMA CELL-LINE, AMS3	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; C-ERBB-2 ONCOGENE; HODGKINS-DISEASE; BREAST-CANCER; BLADDER-CANCER; GENE-PRODUCT; PHOSPHORYLATION; EXPRESSION; TRANSLOCATION; AMPLIFICATION	Ki-l lymphoma is a subtype of human malignant lymphoma characterized by the expression of CD30 (Ki-1) and a peculiar morphology. It is occasionally accompanied by a unique reciprocal chromosomal translocation t(2;5)(p23;q35). A Ki-l lymphoma cell line, AMS3, was established by maintaining biopsied tumor cells in SCID (severe combined immunodeficiency) mice. To investigate abnormalities of the signal transduction in Ki-l lymphomas, AMS3 lysate was immunoprecipitated with anti-phosphotyrosine monoclonal antibody, 25.2G4, and the immunoprecipitates were subjected to kinase assay and immune-blotting with 25.2G4. A unique phosphotyrosine-containing protein of MW 80 000, designated p80, was found only in AMS3 cells and not in other cell lines or mononuclear cells from healthy donors. Subsequent amino acid sequence analysis of its tryptic digests showed that p80 was a hitherto undescribed tyrosine phosphoprotein similar to Ltk (leukocyte tyrosine kinase). Furthermore, physical interaction of p80 with CD30 was suggested from immunoprecipitation experiments with AMS3 lysates.	APPL BIOSYST JAPAN,URAYASU,CHIBA 279,JAPAN	Thermo Fisher Scientific; Applied Biosystems	SHIOTA, M (corresponding author), UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,4-6-1 SHIROKAMEDAI,TOKYO 108,JAPAN.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EBSTEIN SA, 1990, GENES CHROMOSOME CAN, V2, P27; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2276, DOI 10.1073/pnas.80.8.2276; HASSE VH, 1991, ONCOGENE, V6, P2319; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ITOH T, 1993, CANCER, V72, P2684; KADIN ME, 1986, BLOOD, V68, P1042; KANEKO Y, 1989, BLOOD, V73, P806; KANEKO Y, 1990, Current Opinion in Oncology, V2, P816, DOI 10.1097/00001622-199010000-00003; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARU Y, 1990, ONCOGENE RES, V5, P199; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORIYAMA M, 1991, J UROLOGY, V145, P423, DOI 10.1016/S0022-5347(17)38356-8; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEAL DE, 1985, LANCET, V1, P366; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PENNY RJ, 1991, CANCER, V68, P362, DOI 10.1002/1097-0142(19910715)68:2<362::AID-CNCR2820680226>3.0.CO;2-C; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; SATOH H, 1993, CYTOGENET CELL GENET, V62, P49, DOI 10.1159/000133443; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SLAMON DJ, 1989, SCIENCE, V244, P7047; STEIN H, 1985, BLOOD, V66, P848; TAKAHASHI E, 1993, GENOMICS, V17, P234, DOI 10.1006/geno.1993.1310; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMORI T, 1991, CANCER RES, V51, P5859; YOKOTA J, 1988, ONCOGENE, V2, P283; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	44	201	219	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1567	1574						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183550				2022-12-17	WOS:A1994NL81500006
J	MAZARS, R; PUJOL, P; MAUDELONDE, T; JEANTEUR, P; THEILLET, C				MAZARS, R; PUJOL, P; MAUDELONDE, T; JEANTEUR, P; THEILLET, C			P53 MUTATIONS IN OVARIAN-CANCER - A LATE EVENT	ONCOGENE			English	Article							PROTO-ONCOGENE; HUMAN-BREAST; TUMOR-ANTIGEN; LUNG-CANCER; ALLELE LOSS; MUTANT P53; GENE; TRANSFORMATION; CHROMOSOME-17; CELLS	Using a combination of polymerase chain reaction and single-strand conformation polymorphism techniques we analyzed 34 ovarian cancer samples (30 primary tumors and four matched metastases) for the presence of mutations in exons 5, 6, 7, 8 and 9 of the p53 gene. Mutations in this portion of the gene are known to lead to the loss of the oncosuppressive potential of p53. Thirty-six percent (11/30) of the ovarian carcinomas tested presented a mutated p53 allele. Mutations were clustered in exons 5 and 7 to the exclusion of the other exons screened. Most mutations (10/11) were point mutations, but no preferential pattern of nucleotide substitution could be observed. In three tumors the mutation of one allele was concomitant with the loss of the wild-type counterpart. Another sample presented both alleles independently mutated. These observations are in agreement with the recessive nature of the p53 mutation. However, analysis of tissue sections from two tumors showed that the portion composed of 100% cancer cells could hold both the mutated and the wild-type form. Moreover analysis of serial sections gave evidence of a heterogeneous cellular content in one of these tumors, suggesting that p53 mutations may, in some cases, occur late during ovarian cancer evolution. It is, moreover, noticeable that, in matched sets of primary tumors and metastases, the same mutation was observed in both tumor samples. Therefore, even as a late event, p53 mutation occurs before metastatic spread.	CTR PAUL LAMARQUE,BIOCHIM LAB,CNRS,UA 1191,VAL AURELLE,F-34094 MONTPELLIER 5,FRANCE; CHR MONTPELLIER,BIOL CELLULAIRE LAB,F-34090 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1991, ONCOGENE, V6, P659; ADNANE J, 1989, ONCOGENE, V4, P1389; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BIRD A, 1987, TRENDS GENED, V3, P32; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FILMUS JE, 1985, CANCER RES, V45, P4468; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE JH, 1989, CANCER RES, V49, P1220; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, ONCOGENE, V5, P973; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NANDA RR, 1990, P NATL ACAD SCI USA, V87, P7555; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOUSSI T, 1990, ONCOGENE, V5, P945; STATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	36	201	204	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1685	1690						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923532				2022-12-17	WOS:A1991GX27400026
J	Xu, TP; Liu, XX; Xia, R; Yin, L; Kong, R; Chen, WM; Huang, MD; Shu, YQ				Xu, T-P; Liu, X-X; Xia, R.; Yin, L.; Kong, R.; Chen, W-M; Huang, M-D; Shu, Y-Q			SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SP1; KRUPPEL-LIKE FACTOR-2; POOR-PROGNOSIS; DECREASED EXPRESSION; REPRESSION; INHIBITORS; HALLMARKS; SURVIVAL; NCRNAS; DECAY	The long noncoding RNA TINCR shows aberrant expression in human squamous carcinomas. However, its expression and function in gastric cancer remain unclear. We report that TINCR is strongly upregulated in human gastric carcinoma (GC), where it was found to contribute to oncogenesis and cancer progression. We also revealed that TINCR overexpression is induced by nuclear transcription factor SP1. Silencing TINCR expression inhibited cell proliferation, colony formation, tumorigenicity and apoptosis promotion, whereas TINCR overexpression promoted cell growth, as documented in the SGC7901 and BGC823 cell lines. Mechanistic analyses indicated that TINCR could bind to STAU1 (staufen1) protein, and influence KLF2 mRNA stability and expression, then KLF2 regulated cyclin-dependent kinase genes CDKN1A/P21 and CDKN2B/P15 transcription and expression, thereby affecting the proliferation and apoptosis of GC cells. Together, our findings suggest that TINCR contributes to the oncogenic potential of GC and may constitute a potential therapeutic target in this disease.	[Xu, T-P; Xia, R.; Yin, L.; Chen, W-M; Shu, Y-Q] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China; [Liu, X-X] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Dept Gastrointestinal Surg, Sch Clin Med, Yangzhou 225009, Jiangsu, Peoples R China; [Kong, R.] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Clin Med Examinat Ctr, Sch Clin Med, Yangzhou 225009, Jiangsu, Peoples R China; [Huang, M-D] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Med Oncol, Huaian, Peoples R China	Nanjing Medical University; Yangzhou University; Yangzhou University; Nanjing Medical University	Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	yongqian_shu@163.com	Shu, Yongqian/ABD-5698-2021		National Natural Science Foundation of China [81172140, 81272532]; Jiangsu Province Clinical Science and Technology projects (Clinical Research Center) [BL2012008]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine) [JX10231801]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province Clinical Science and Technology projects (Clinical Research Center); Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine)	We thank Dr Taniguchi (First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan) for the kind gift of KLF2-FLAG expression vector, Dr Wei-liang Xiong (Department of Biochemistry and The Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University) for the help of RNA pull down assay, and Professor Wei De and Dr Ming Sun (Department of Biochemistry and Molecular Biology, Nanjing Medical University) for the help of assay design. This study was supported by the National Natural Science Foundation of China (81172140, 81272532), Jiangsu Province Clinical Science and Technology projects (Clinical Research Center, BL2012008) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine, JX10231801).	Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Cesana M, 2011, CELL, V147, P947, DOI 10.1016/j.cell.2011.10.031; Cho H, 2012, MOL CELL, V46, P495, DOI 10.1016/j.molcel.2012.03.009; Duhagon MA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-324; Fu XQ, 2006, DNA CELL BIOL, V25, P135, DOI 10.1089/dna.2006.25.135; Gong CG, 2011, CELL CYCLE, V10, P1882, DOI 10.4161/cc.10.12.15589; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kim YK, 2005, CELL, V120, P195, DOI 10.1016/j.cell.2004.11.050; Kim YK, 2007, EMBO J, V26, P2670, DOI 10.1038/sj.emboj.7601712; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105; Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088; Okugawa Y, 2014, CARCINOGENESIS; Pibouin L, 2002, CANCER GENET CYTOGEN, V133, P55, DOI 10.1016/S0165-4608(01)00634-3; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Ravasi T, 2006, GENOME RES, V16, P11, DOI 10.1101/gr.4200206; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-319; Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277-013-1142-z; Sun M, 2012, MOL CANCER THER, V11, P842, DOI 10.1158/1535-7163.MCT-11-1015; Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wan DF, 2004, P NATL ACAD SCI USA, V101, P17565, DOI 10.1073/pnas.0408124101; Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zhang SZ, 2005, MOL CANCER THER, V4, P1577, DOI 10.1158/1535-7163.MCT-05-0106; Zhuang M, 2014, BIOCHEM BIOPH RES CO, V448, P315, DOI 10.1016/j.bbrc.2013.12.126	38	200	208	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5648	5661		10.1038/onc.2015.18	http://dx.doi.org/10.1038/onc.2015.18			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25728677				2022-12-17	WOS:000364594300006
J	Akech, J; Wixted, JJ; Bedard, K; van der Deen, M; Hussain, S; Guise, TA; van Wijnen, AJ; Stein, JL; Languino, LR; Altieri, DC; Pratap, J; Keller, E; Stein, GS; Lian, JB				Akech, J.; Wixted, J. J.; Bedard, K.; van der Deen, M.; Hussain, S.; Guise, T. A.; van Wijnen, A. J.; Stein, J. L.; Languino, L. R.; Altieri, D. C.; Pratap, J.; Keller, E.; Stein, G. S.; Lian, J. B.			Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions	ONCOGENE			English	Article						Runx2; bone metastasis; prostate cancer tissue arrays	MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; TUMOR-CELLS; EXPRESSION; DIFFERENTIATION; INTERLEUKIN-8; SIALOPROTEIN; OSTEOCALCIN; ACTIVATION; PROMOTE	Runx2, a bone-specific transcriptional regulator, is abnormally expressed in highly metastatic prostate cancer cells. Here, we identified the functional activities of Runx2 in facilitating tumor growth and osteolysis. Our studies show that negligible Runx2 is found in normal prostate epithelial and non-metastatic LNCaP prostate cancer cells. In the intra-tibial metastasis model, high Runx2 levels are associated with development of large tumors, increased expression of metastasis-related genes (MMP9, MMP13, VEGF, Osteopontin) and secreted bone-resorbing factors (PTHrP, IL8) promoting osteolytic disease. Runx2 siRNA treatment of PC3 cells decreased cell migration and invasion through Matrigel in vitro, and in vivo shRunx2 expression in PC3 cells blocked their ability to survive in the bone microenvironment. Mechanisms of Runx2 function were identified in co-culture studies showing that PC3 cells promote osteoclastogenesis and inhibit osteoblast activity. The clinical significance of these findings is supported by human tissue microarray studies of prostate tumors at stages of cancer progression, in which Runx2 is expressed in both adenocarcinomas and metastatic tumors. Together these findings indicate that Runx2 is a key regulator of events associated with prostate cancer metastatic bone disease. Oncogene (2010) 29, 811-821; doi:10.1038/onc.2009.389; published online 16 November 2009	[Akech, J.; Bedard, K.; van der Deen, M.; Hussain, S.; van Wijnen, A. J.; Stein, J. L.; Pratap, J.; Stein, G. S.; Lian, J. B.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Akech, J.; Wixted, J. J.; Bedard, K.; van der Deen, M.; Hussain, S.; van Wijnen, A. J.; Stein, J. L.; Languino, L. R.; Altieri, D. C.; Pratap, J.; Stein, G. S.; Lian, J. B.] Univ Massachusetts, Sch Med, Ctr Canc, Prostate Canc Discovery & Dev Program, Worcester, MA 01655 USA; [Wixted, J. J.] Univ Massachusetts, Sch Med, Dept Orthoped Surg & Rehabil, Worcester, MA 01655 USA; [Guise, T. A.] Indiana Univ, Sch Med, Dept Internal Med, Indianapolis, IN USA; [Languino, L. R.; Altieri, D. C.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA; [Keller, E.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Indiana University System; Indiana University-Purdue University Indianapolis; University of Massachusetts System; University of Massachusetts Worcester; University of Michigan System; University of Michigan	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019; Keller, Evan T/M-1446-2016	van Wijnen, Andre J./0000-0002-4458-0946; Keller, Evan T/0000-0002-7592-7535; Languino, Lucia/0000-0001-9011-7031	NIH [PO1CA082834, RO1CA89720, RO1CA090917, P01CA093900, SPORE P50CA69568, R01CA069158]; Our Danny Cancer Fund post-doctoral fellowship [ODCF 114357]; NATIONAL CANCER INSTITUTE [R01CA089720, P01CA082834, R01CA090917, R01CA109874, P01CA093900, P50CA069568, R01CA069158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039588, R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Our Danny Cancer Fund post-doctoral fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We acknowledge the following for providing us with prostate cancer cell lines: RWPE, George Barnes (Boston University School of Medicine); PC3-H and C4-2B, Leland Chung (Emory University School of Medicine). This work was supported by NIH Grants PO1CA082834 (GSS); RO1CA89720 (LRL); RO1CA090917 (DCA); P01CA093900 and SPORE P50CA69568 (EK); R01CA069158 (TAG); and Our Danny Cancer Fund post-doctoral fellowship, ODCF 114357 (JA). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303; Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008-5472.CAN-05-2630; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090-4295(00)01122-5; Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006-0346; Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008-5472.CAN-03-1382; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Glinsky GV, 2006, CELL CYCLE, V5, P191, DOI 10.4161/cc.5.2.2320; Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078-0432.CCR-06-1007; Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Li ZG, 2008, ONCOGENE, V27, P596, DOI 10.1038/sj.onc.1210694; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555-006-9033-z; Morgia G, 2005, UROL RES, V33, P44, DOI 10.1007/s00240-004-0440-8; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Pratap J, 2003, CANCER RES, V63, P5357; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Selvamurugan N, 2006, J CELL BIOCHEM, V99, P545, DOI 10.1002/jcb.20878; Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140; THALMANN GN, 1994, CANCER RES, V54, P2577; Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005; Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zaidi SK, 2007, NAT REV CANCER, V7, P454, DOI 10.1038/nrc2149; Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200	44	200	207	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					811	821		10.1038/onc.2009.389	http://dx.doi.org/10.1038/onc.2009.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915614	Green Accepted			2022-12-17	WOS:000274397800004
J	Weniger, MA; Melzner, I; Menz, CK; Wegener, S; Bucur, AJ; Dorsch, K; Mattfeldt, T; Barth, TFE; Moller, P				Weniger, MA; Melzner, I; Menz, CK; Wegener, S; Bucur, AJ; Dorsch, K; Mattfeldt, T; Barth, TFE; Moller, P			Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation	ONCOGENE			English	Article						SOCS-1; Hodgkin lymphoma; primary mediastinal B-cell lymphoma; STAT5	B-CELL LYMPHOMA; EPIGENETIC ACTIVATION; SHP1 HYPERMETHYLATION; NEGATIVE REGULATOR; METHYLATION; REL; DEGRADATION; PROTEINS; GAINS; 2P	The suppressors of cytokine signaling ( SOCS) are critically involved in the regulation of cellular proliferation, survival, and apoptosis via cytokine-induced JAK/STAT signaling. SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-cell neoplasias and carcinomas. Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of primary mediastinal B-cell lymphoma ( PMBL) and in the PMBL line MedB-1, and a biallelic SOCS-1 deletion in PMBL line Karpas1106P. For both cell lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5. Here, we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg ( HRS) cells of classical Hodgkin lymphoma ( cHL). We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin lymphoma ( HL)derived cell lines by sequencing analysis. Moreover, we found a significant association between mutated SOCS-1 of isolated HRS cells and nuclear phospho-STAT5 accumulation in HRS cells of cHL tumor tissue ( P < 0.01). Collectively, these findings support the concept that PMBL and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both lymphomas.	Univ Ulm, Dept Pathol, D-89081 Ulm, Germany	Ulm University	Moller, P (corresponding author), Univ Ulm, Dept Pathol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	peter.moeller@medizin.uni-ulm.de						Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2002, LANCET ONCOL, V3, P229, DOI 10.1016/S1470-2045(02)00714-3; Chen CY, 2003, GENE CHROMOSOME CANC, V37, P300, DOI 10.1002/gcc.10222; Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; Chim CS, 2004, LEUKEMIA, V18, P356, DOI 10.1038/sj.leu.2403216; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Komazaki T, 2004, JPN J CLIN ONCOL, V34, P191, DOI 10.1093/jjco/hyh035; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Melzner I, 2006, INT J CANCER, V118, P1941, DOI 10.1002/ijc.21485; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Ritz O, 2005, J PATHOL, V205, P336, DOI 10.1002/path.1688; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Skinnider BF, 2002, BLOOD, V99, P618, DOI 10.1182/blood.V99.2.618; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	25	200	206	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2679	2684		10.1038/sj.onc.1209151	http://dx.doi.org/10.1038/sj.onc.1209151			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532038				2022-12-17	WOS:000237099400012
J	Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE			RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine	ONCOGENE			English	Article						pancreatic adenocarcinoma; cancer; gemcitabine; ribonucleotide reductase; siRNA; RNA interference	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; GENE AMPLIFICATION; CELL-LINES; CANCER; RESISTANCE; MOUSE; OVEREXPRESSION; HYDROXYUREA; EXPRESSION	Ribonucleotide reductase is emerging as an important determinant of gemcitabine chemoresistance in human cancers. Activity of this enzyme, which catalyses conversion of ribonucleotide 5'-diphosphates to their 2'-deoxynucleotides, is modulated by levels of its M2 subunit (RRM2). Here we show that RRM2 overexpression is associated with gemcitabine chemoresistance in pancreatic adenocarcinoma cells, and that suppression of RRM2 expression using RNA interference mediated by small interfering RNA (siRNA) enhances gemcitabine-induced cytotoxicity in vitro. We demonstrate the ability of systemically administered RRM2 siRNA to suppress tumoral RRM2 expression in an orthotopic xenograft model of pancreatic adenocarcinoma. Synergism between RRM2 siRNA and gemcitabine results in markedly suppressed tumor growth, increased tumor apoptosis and inhibition of metastasis. Our findings confirm the importance of RRM2 in pancreatic adenocarcinoma gemcitabine chemoresistance. This is the first demonstration that systemic delivery of siRNA-based therapy can enhance the efficacy of an anticancer nucleoside analog.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						Adjei AA, 2003, CLIN CANCER RES, V9, P115; [Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Aoki Y, 2003, CLIN EXP PHARMACOL P, V30, P96, DOI 10.1046/j.1440-1681.2003.03801.x; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Calzado MA, 2000, CLIN EXP IMMUNOL, V120, P317, DOI 10.1046/j.1365-2249.2000.01203.x; CORY JG, 1997, BIOCH CLIN CORRELATI, P489; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERIKSSON S, 1981, J BIOL CHEM, V256, P9436; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Filleur S, 2003, CANCER RES, V63, P3919; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Goan YG, 1999, CANCER RES, V59, P4204; GORELIK E, 1993, CLIN EXP METASTAS, V11, P439, DOI 10.1007/BF00054935; GRANT CE, 1994, CANCER RES, V54, P357; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; HEINEMANN V, 1988, CANCER RES, V48, P4024; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jong AY, 1998, J BIOMED SCI, V5, P62, DOI 10.1007/BF02253357; Jung CP, 2001, CLIN CANCER RES, V7, P2527; Kelley JR, 2001, SURGERY, V130, P280, DOI 10.1067/msy.2001.115899; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lee Y, 2003, CANCER RES, V63, P2802; LI K, 2003, CANCER RES, V63, P3953; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; Monteith DK, 1997, ANTI-CANCER DRUG DES, V12, P421; Muerkoster S, 2003, INT J CANCER, V104, P469, DOI 10.1002/ijc.10963; Nieth C, 2003, FEBS LETT, V545, P144, DOI 10.1016/S0014-5793(03)00523-4; PAVLOFF N, 1992, J DNA SEQUENCING MAP, V2, P227; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; Plunkett W, 1996, SEMIN ONCOL, V23, P3; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; RAITANO AB, 1990, PANCREAS, V5, P267, DOI 10.1097/00006676-199005000-00005; Reichard P, 1985, Basic Life Sci, V31, P33; REICHARD P, 1978, FED PROC, V37, P9; SCALABAS GM, 2003, INT J GASTROINT CANC, V33, P15; Shen Z, 2002, BIOTECHNIQUES, V32, P1168, DOI 10.2144/02325dd07; Sun FX, 2003, CANCER RES, V63, P80; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; Zhou B, 2001, CYTOGENET CELL GENET, V95, P34, DOI 10.1159/000057014; ZHOU BS, 1995, CANCER RES, V55, P1328; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	50	200	225	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1539	1548		10.1038/sj.onc.1207272	http://dx.doi.org/10.1038/sj.onc.1207272			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14661056				2022-12-17	WOS:000189219500007
J	Fonsatti, E; Altomonte, M; Nicotra, MR; Natali, PG; Maio, M				Fonsatti, E; Altomonte, M; Nicotra, MR; Natali, PG; Maio, M			Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels	ONCOGENE			English	Review						angiogenesis; CD105; endoglin; endothelial cells; soluble CD105; transforming growth factor	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; HUMAN SOLID TUMORS; CELL LUNG-CANCER; ENDOTHELIAL-CELLS; BINDING-PROTEIN; RECEPTOR-COMPLEX; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROVESSEL DENSITY; BREAST-CARCINOMA	Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which functions as an accessory component of the transforming growth factor -beta receptor complex and is involved in vascular development and remodelling. Quanti. cation of intratumoral microvessel density by CD105 staining and of circulating soluble CD105 has been suggested to have prognostic significance in selected neoplasias. In addition, the potential usefulness of CD105 in tumor imaging and antiangiogenetic therapy has been well documented utilizing different animal models.	IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, I-33081 Aviano, Italy; CNR, Ist Biol & Patol Mol, I-00156 Rome, Italy; Ist Regina Elena, Ctr Ric Sperimentale, Immunol Lab, I-00158 Rome, Italy	IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Maio, M (corresponding author), IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occle 12, I-33081 Aviano, Italy.	mmaio@cro.it	altomonte, maresa/G-7734-2011	Altomonte, Maresa/0000-0001-8021-1921; Maio, Michele/0000-0002-0323-6321; coral, sandra/0000-0002-1308-3082				Abdalla SA, 2000, HUM MOL GENET, V9, P1227, DOI 10.1093/hmg/9.8.1227; Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Akagi K, 2002, SURGERY, V131, pS109, DOI 10.1067/msy.2002.119361; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Balza E, 2001, INT J CANCER, V94, P579, DOI 10.1002/ijc.1505; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Bourdeau A, 2001, AM J PATHOL, V158, P2011, DOI 10.1016/S0002-9440(10)64673-1; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Bredow S, 2000, EUR J CANCER, V36, P675, DOI 10.1016/S0959-8049(99)00335-4; Brekken RA, 2002, INT J CANCER, V100, P123, DOI 10.1002/ijc.10462; Brewer CA, 2000, OBSTET GYNECOL, V96, P224, DOI 10.1016/S0029-7844(00)00864-4; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Calabro L, 2003, J CELL PHYSIOL, V194, P171, DOI 10.1002/jcp.10200; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Cho SK, 2001, BLOOD, V98, P3635, DOI 10.1182/blood.V98.13.3635; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Cowan PJ, 2003, XENOTRANSPLANTATION, V10, P223, DOI 10.1034/j.1399-3089.2003.01140.x; Dales JP, 2003, AM J CLIN PATHOL, V119, P374, DOI 10.1309/1KF54L6RB625556W; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V64, P204, DOI 10.1159/000133576; Fonsatti E, 2000, CLIN CANCER RES, V6, P2037; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Graulich W, 1999, GENE, V227, P55, DOI 10.1016/S0378-1119(98)00585-X; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; HENRIKSEN R, 1995, LAB INVEST, V73, P213; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Jonker L, 2002, MECH DEVELOP, V110, P193, DOI 10.1016/S0925-4773(01)00562-7; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Kumar S, 1999, CANCER RES, V59, P856; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2000, INT J CANCER, V89, P122, DOI 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; LOPARDO C, 1997, LEUCOCYTE TYPING, V6, P711; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; Maier JAM, 1997, ANTI-CANCER DRUG, V8, P238, DOI 10.1097/00001813-199703000-00004; Maio M, 2001, FRONT BIOSCI-LANDMRK, V6, pD776, DOI 10.2741/Maio; Matsuno F, 1999, CLIN CANCER RES, V5, P371; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MCALLISTER KA, 1995, HUM MOL GENET, V4, P1983, DOI 10.1093/hmg/4.10.1983; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; Nettelbeck DM, 2001, MOL THER, V3, P882, DOI 10.1006/mthe.2001.0342; OCONNELL PJ, 1992, CLIN EXP IMMUNOL, V90, P154; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Pierelli L, 2001, LEUKEMIA LYMPHOMA, V42, P1195, DOI 10.3109/10428190109097744; Pruneri G, 2002, BRIT J HAEMATOL, V118, P817, DOI 10.1046/j.1365-2141.2002.03654.x; Pruneri G, 2003, BRIT J HAEMATOL, V120, P695, DOI 10.1046/j.1365-2141.2003.04133.x; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Rajkumar SV, 2002, J HEMATOTH STEM CELL, V11, P33, DOI 10.1089/152581602753448522; Rius C, 1998, BLOOD, V92, P4677; Robledo MM, 1996, BRIT J HAEMATOL, V93, P507, DOI 10.1046/j.1365-2141.1996.d01-1698.x; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.3.CO;2-J; ROKHLIN OW, 1995, J IMMUNOL, V154, P4456; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Savontaus MJ, 2002, GENE THER, V9, P972, DOI 10.1038/sj.gt.3301747; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Schimming R, 2002, HEAD NECK-J SCI SPEC, V24, P151, DOI 10.1002/hed.10040.abs; Seon BK, 1997, CLIN CANCER RES, V3, P1031; Seon BK, 2002, INT J CANCER, V99, P310, DOI 10.1002/ijc.10378; Tabata M, 1999, INT J CANCER, V82, P737, DOI 10.1002/(SICI)1097-0215(19990827)82:5<737::AID-IJC18>3.3.CO;2-#; Takahashi N, 2001, CLIN CANCER RES, V7, P524; Takahashi N, 2001, CANCER RES, V61, P7846; Tanaka F, 2001, CLIN CANCER RES, V7, P3410; Tanaka F, 2003, LUNG CANCER-J IASLC, V39, P289, DOI 10.1016/S0169-5002(02)00534-2; Tanaka F, 2002, CANCER RES, V62, P7124; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; van den Driesche S, 2003, CARDIOVASC RES, V58, P20, DOI 10.1016/S0008-6363(02)00852-0; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; WANG JM, 1994, J NATL CANCER I, V86, P386, DOI 10.1093/jnci/86.5.386; WANG JM, 1993, INT J CANCER, V54, P363, DOI 10.1002/ijc.2910540303; Wikstrom P, 2002, PROSTATE, V51, P268, DOI 10.1002/pros.10083; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301	88	200	226	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6557	6563		10.1038/sj.onc.1206813	http://dx.doi.org/10.1038/sj.onc.1206813			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528280				2022-12-17	WOS:000185700700012
J	Mischel, PS; Shai, R; Shi, T; Horvath, S; Lu, KV; Choe, G; Seligson, D; Kremen, TJ; Palotie, A; Liau, LM; Cloughesy, TF; Nelson, SF				Mischel, PS; Shai, R; Shi, T; Horvath, S; Lu, KV; Choe, G; Seligson, D; Kremen, TJ; Palotie, A; Liau, LM; Cloughesy, TF; Nelson, SF			Identification of molecular subtypes of glioblastoma by gene expression profiling	ONCOGENE			English	Article						glioblastoma; EGFR; microarray; 12q13-15	ENDOTHELIAL GROWTH-FACTOR; HUMAN-MALIGNANT GLIOMAS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; CLINICAL-SIGNIFICANCE; TUMOR GRADE; CELL; AMPLIFICATION; INHIBITION; OVEREXPRESSION	Epidermal growth factor receptor (EGFR) overexpression occurs in nearly 50% of cases of glioblastoma (GBM), but its clinical and biological implications are not well understood. We have used Affymetrix high-density oligonucleotide arrays to demonstrate that EGFR-over-expressing GBMs (EGFR +) have a distinct global gene transcriptional profile. We show that the expression of 90 genes can distinguish EGFR + from EGFR nonexpressing (EGFR-) GBMs, including a number of genes known to act as growth/survival factors for GBMs. We have also uncovered two additional novel molecular subtypes of GBMs, one of which is characterized by coordinate upregulation of contiguous genes on chromosome 12q13-15 and expression of both astrocytic and oligodendroglial genes. These results define distinct molecular subtypes of GBMs that may be important in disease stratification, and in the discovery and assessment of GBM treatment strategies.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Henry E Singleton Brain Tumor Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mischel, PS (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Cloughesy, Timothy Francis/AGV-1013-2022; Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114; Liau, Linda/0000-0002-4053-0052; , Tao/0000-0001-5489-2655; Kremen, Thomas/0000-0003-1643-4869	NATIONAL CANCER INSTITUTE [T32CA009056, U01CA088127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS043147] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA88127, T32 CA 09056] Funding Source: Medline; NINDS NIH HHS [K08NS43147-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Barker FG, 2001, INT J RADIAT ONCOL, V51, P410, DOI 10.1016/S0360-3016(01)01609-1; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Brat DJ, 2001, AM J PATHOL, V158, P789, DOI 10.1016/S0002-9440(10)64025-4; Chan ASY, 1998, AM J SURG PATHOL, V22, P816, DOI 10.1097/00000478-199807000-00004; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Egidy G, 2000, LAB INVEST, V80, P1681, DOI 10.1038/labinvest.3780178; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; Fu H, 2002, DEVELOPMENT, V129, P681; Galanis E, 1998, INT J ONCOL, V13, P717; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Griffin J, 2001, SEMIN ONCOL, V28, P3, DOI 10.1016/S0093-7754(01)90097-1; Hajihosseini M, 1996, J NEUROSCI, V16, P7981; HAMADA H, 1988, CANCER RES, V48, P3173; Hastie T., 2001, ELEMENTS STAT LEARNI, P236, DOI DOI 10.1007/978-0-387-21606-5; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Hoos A, 2002, AM J PATHOL, V160, P175, DOI 10.1016/S0002-9440(10)64361-1; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hui ABY, 2001, LAB INVEST, V81, P717, DOI 10.1038/labinvest.3780280; Kaufman L, 2009, FINDING GROUPS DATA; Kilic T, 2000, CANCER RES, V60, P5143; KLEIHUES P, 1999, NEURO-ONCOLOGY, V1, P4; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; Kuan C T, 2000, Brain Tumor Pathol, V17, P71, DOI 10.1007/BF02482738; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lal A, 2002, CANCER RES, V62, P3335; Landry CF, 1997, CANCER RES, V57, P4098; Leegwater PAJ, 2002, HUM GENET, V110, P279, DOI 10.1007/s00439-002-0682-x; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Ljubimova JY, 2001, CANCER RES, V61, P5601; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Maity A, 2000, CANCER RES, V60, P5879; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; NAGANE M, 2001, CANC LETT, V161, pS17; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; PRESTONMARTIN S, 1999, GLIOMAS, P2; REIFENBERGER G, 1995, CANCER RES, V55, P731; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Venables W., 2013, MODERN APPL STAT S, V53, P86; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7	70	200	206	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2361	2373		10.1038/sj.onc.1206344	http://dx.doi.org/10.1038/sj.onc.1206344			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700671				2022-12-17	WOS:000182231500014
J	Arnuthan, G; Biswas, G; Ananadatheerthavarada, HK; Vijayasarathy, C; Shephard, HM; Avadhani, NG				Arnuthan, G; Biswas, G; Ananadatheerthavarada, HK; Vijayasarathy, C; Shephard, HM; Avadhani, NG			Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells	ONCOGENE			English	Article						mitochondria; calcium signaling; cathepsin L; TGF beta; tumor invasion; MAP kinases	CYTOSOLIC CALCIUM; EPITHELIAL-CELLS; ACTIVATED RAS; CYTOCHROME-C; CANCER-CELLS; APOPTOSIS; DNA; CA2+; SUPPRESSION; TUMORS	We have investigated mechanisms of mitochondrial stress-induced phenotypic changes and cell invasion in tumorigenic but poorly invasive human pulmonary carcinoma A549 cells that were partly depleted of mitochondrial DNA (mtDNA). Depletion of mtDNA (genetic stress) caused a markedly lower electron transport-coupled ATP synthesis, loss of mitochondrial membrane potential, elevation of steady state [Ca2+](c), and notably induction of both glycolysis and gluconeogenic pathway enzymes. Markers of tumor invasion, cathepsin L and TGFbeta1, were overexpressed; calcium-dependent MAP kinases (ERK1 and ERK2) and calcineurin were activated. The levels of anti-apoptotic proteins Bcl2 and BCl-X-L were increased, and the cellular levels of pro-apoptotic proteins Bid and Bax were reduced. Both mtDNA-depleted cells (genetic stress) and control cells treated with carbonyl cyanide m-chlorophenylhydrazone (metabolic stress) exhibited higher invasive behavior than control cells in a Matrigel basement membrane matrix assay system. MtDNA-depleted cells stably expressing anti-sense cathepsin L RNA, TGFbeta1 RNA, or treated with specific inhibitors showed reduced invasion. Reverted cells with 80% of control cell mtDNA exhibited marker protein levels, cell morphology and invasive property closer to control cells. Our results suggest that the mitochondria-to-nucleus signaling pathway operating through increased [Ca2+](c) plays an important role in cancer progression and metastasis.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Shephard, Henry M./ABG-4547-2021; Datta, Sayantan/D-1369-2010	Shephard, Henry M./0000-0003-0168-5462; 	NATIONAL CANCER INSTITUTE [R01CA022762, R37CA022762] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Buckman JF, 2001, J NEUROSCI METH, V104, P165, DOI 10.1016/S0165-0270(00)00340-X; Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189; Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; GIGUERE L, 1981, SOMAT CELL GENET, V7, P457, DOI 10.1007/BF01542990; Gutierrez AA, 1999, J PHYSIOL-LONDON, V517, P95, DOI 10.1111/j.1469-7793.1999.0095z.x; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hata A, 2001, EXP CELL RES, V264, P111, DOI 10.1006/excr.2000.5140; Hehl S, 1996, CELL CALCIUM, V20, P515, DOI 10.1016/S0143-4160(96)90094-9; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; Hofhaus G, 1999, BIOL CHEM, V380, P871, DOI 10.1515/BC.1999.107; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; HOWELL AN, 1978, P NATL ACAD SCI USA, V75, P2358, DOI 10.1073/pnas.75.5.2358; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; ISRAEL BA, 1987, IN VITRO CELL DEV B, V23, P627; ISRAEL BA, 1988, IN VITRO CELL DEV B, V24, P487; Iwakura T, 2000, BIOCHEM BIOPH RES CO, V271, P422, DOI 10.1006/bbrc.2000.2616; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; JONASSON J, 1977, J CELL SCI, V24, P217; JONES CT, 1976, ARCH BIOCHEM BIOPHYS, V174, P506, DOI 10.1016/0003-9861(76)90378-7; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kim K, 1998, INT J CANCER, V79, P324, DOI 10.1002/(SICI)1097-0215(19980821)79:4<324::AID-IJC4>3.3.CO;2-N; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Luo Y, 1997, P NATL ACAD SCI USA, V94, P9705, DOI 10.1073/pnas.94.18.9705; MIRA N, 1967, METHOD ENZYMOL, V9, P371; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; MORAIS R, 1994, CANCER RES, V54, P3889; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Riccardi D, 1999, CELL CALCIUM, V26, P77, DOI 10.1054/ceca.1999.0066; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROTHERMEL BA, 1995, J BIOL CHEM, V270, P29476, DOI 10.1074/jbc.270.49.29476; SHEAHAN K, 1989, CANCER RES, V49, P3809; SMITH L, 1955, Methods Biochem Anal, V2, P427, DOI 10.1002/9780470110188.ch13; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WARBURG OTTO, 1926, KLIN WOCHENSCHR, V5, P829, DOI 10.1007/BF01726240; Wen HC, 2000, J CELL BIOCHEM, V79, P601, DOI 10.1002/1097-4644(20001215)79:4<601::AID-JCB90>3.0.CO;2-W; Werth JL, 1996, J NEUROSCI, V16, P1008; YAGEL S, 1989, CANCER RES, V49, P3553; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; ZAFAR MN, 1982, J ULTRA MOL STRUCT R, V81, P133	62	200	207	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7839	7849		10.1038/sj.onc.1205983	http://dx.doi.org/10.1038/sj.onc.1205983			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420221				2022-12-17	WOS:000178946000009
J	Lin, TS; Mahajan, S; Frank, DA				Lin, TS; Mahajan, S; Frank, DA			STAT signaling in the pathogenesis and treatment of leukemias	ONCOGENE			English	Article						STAT; cytokines; cancer; leukemia; therapy	CHRONIC LYMPHOCYTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW TRANSPLANTATION; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; BCR-ABL; INTERFERON-GAMMA; MYELOID-LEUKEMIA; MONOCLONAL-ANTIBODY	Leukemias continue to cause significant mortality in adults and children, and the use of standard cytotoxic chemotherapy has reached a therapeutic plateau, Thus, there is great interest in treatments directed against inappropriately activated cell signaling pathways which stimulate the uncontrolled growth of neoplastic cells. Increasing evidence suggests that the STAT signaling cascade may be one target of these therapies. Signal transducer and activator of transcription (STAT) proteins are critical in mediating the response of hematopoietic cells to a diverse spectrum of cytokines. Constitutive STAT activation is present in many malignancies and has been especially well characterized in acute and chronic leukemias. While STAT activation is a common characteristic of leukemias, the specific pattern of activated STATs and the manner by which STAT activation occurs vary with each disease. STAT tyrosine phosphorylation can occur through inappropriate Jak activation or by direct activation of an oncoprotein such as Bcr/Abl, and STAT serine phosphorylation may play an important role in leukemias as well. Thus, the STAT signaling pathway is an attractive target for therapeutic intervention, and strategies designed to inhibit STAT activation and STAT mediated gene transcription may play an important role in the next generation of anti-leukemia therapies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Frank, DA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA079547] Funding Source: NIH RePORTER; NCI NIH HHS [CA79547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Frank DA, 1996, LEUKEMIA, V10, P1724; Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445; Frank DA, 1999, MOL MED, V5, P432; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Holland JF, 1997, CANC MED; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ILAND H, 1995, POLYCYTHEMIA VERA MY, P292; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KAWANO F, 1985, CANCER-AM CANCER SOC, V55, P851, DOI 10.1002/1097-0142(19850215)55:4<851::AID-CNCR2820550424>3.0.CO;2-J; KLEIN B, 1991, BLOOD, V78, P1198; Lee SJ, 1997, ANN INTERN MED, V127, P1080, DOI 10.7326/0003-4819-127-12-199712150-00005; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; NAJEAN Y, 1994, BRIT J HAEMATOL, V86, P233, DOI 10.1111/j.1365-2141.1994.tb03289.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 1999, CANCER RES, V59, P5059; Palmer Alyson M., 1997, Blood, V90, p178A; RABINOWE SN, 1993, BLOOD, V82, P1366; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, ONCOGENE, V13, P247; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; Thiesing JT, 1999, BLOOD, V94, p100A; VERWILGHEN R L, 1987, Blood Reviews, V1, P34, DOI 10.1016/0268-960X(87)90017-8; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xia Z, 1998, CANCER RES, V58, P3173; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	52	200	226	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2496	2504		10.1038/sj.onc.1203486	http://dx.doi.org/10.1038/sj.onc.1203486			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851048				2022-12-17	WOS:000087459400005
J	TSUZUKI, T; TAKAHASHI, M; ASAI, N; IWASHITA, T; MATSUYAMA, M; ASAI, JP				TSUZUKI, T; TAKAHASHI, M; ASAI, N; IWASHITA, T; MATSUYAMA, M; ASAI, JP			SPATIAL AND TEMPORAL EXPRESSION OF THE RET PROTOONCOGENE PRODUCT IN EMBRYONIC, INFANT AND ADULT-RAT TISSUES	ONCOGENE			English	Note						C-RET; RECEPTOR TYROSINE KINASE; RAT EMBRYOGENESIS; NERVOUS SYSTEM; EXCRETORY SYSTEM	PROTOONCOGENE PRODUCTS; SEQUENCE SIMILARITY; TYROSINE KINASE; CADHERIN; NEUROBLASTOMA; MUTATIONS; CLONING; CELLS; CDNA	Immunohistochemical analysis with the anti-Ret antibody was performed to investigate the expression of the c-ret proto-oncogene product (c-Ret protein) in embryonic, infant and adult rat tissues. During embryogenesis, the c-Ret expression became detectable by day 11.5 in the developing peripheral and central nervous systems as well as in the excretory system. In the peripheral nervous system of the trunk, it was expressed at high levels in the enteric neuroblasts and the autonomic and dorsal root ganglia, c-Ret positive cells appeared in the mesenchyme around the foregut and the dorsal aorta at day 11.5 and formed the myenteric plexus of the whole embryonic gut and the sympathetic trunk at later stages respectively. Examination of the cranial region revealed that the c-Ret protein was expressed in neural crest cells migrating from rhombomere 4 at day 11.5 and then became positive in the facial, glossopharyngeal and vagus cranial ganglia at day 12.5-13.5. After day 16.5 of gestation, the c-Ret expression was also observed in the trigeminal ganglion. In the central nervous system, the c-Ret protein was expressed in the neuroepithelial cells of the ventral neural tube (day 11.5-14.5), the motor neurons of the spinal cord (day 18.5) as well as in the embryonic neuroretina (day 18.5). In addition to the nervous system, the c-Ret expression was detected in the nephric duct (day 11.5), the ureteric bud (day 13.5) and the collecting ducts of the kidney (day 16.5). After birth, neurons in the nervous systems mentioned above continued to express the c-Ret protein at variable levels while no c-Ret expression was observed in the kidney of adult rats. Furthermore, the c-Ret expression was found in the acinar cells of the salivary gland, the epithelial cells of the thymus and the follicular dendritic cells of the spleen and lymph node in infant and adult rats. A small number of adrenal chromaffin cells and thyroid C cells also expressed the c-Ret protein. These results demonstrated that the c-Ret protein is expressed in several cell lineages in spatially and temporally controlled manner throughout life of the rat.	NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University			ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Tsuzuki, Toyonori/0000-0002-4855-4366				ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARNAHAN JF, 1991, DEV BIOL, V148, P552, DOI 10.1016/0012-1606(91)90273-6; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1993, MOL BIOL EVOL, V10, P539; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1990, ONCOGENE, V5, P1595; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571	21	200	204	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					191	198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824273				2022-12-17	WOS:A1995QA98000022
J	CAIRNS, P; SHAW, ME; KNOWLES, MA				CAIRNS, P; SHAW, ME; KNOWLES, MA			INITIATION OF BLADDER-CANCER MAY INVOLVE DELETION OF A TUMOR-SUPPRESSOR GENE ON CHROMOSOME-9	ONCOGENE			English	Note							TRANSITIONAL CELL-CARCINOMA; INTERFERON GENES	Although many genetic lesions including suppressor gene inactivation have been identified in sporadic tumours, the identity of the common initiating or early genetic events in most cases remains obscure. We have analysed tumour and leucocyte DNA from a series of 252 primary human bladder tumours of all grades and stages for deletions of chromosome 9. Probes from four polymorphic loci were used to detect loss of heterozygosity (LOH) in tumour specimens. Fifty-nine per cent of tumours from patients informative at one or more of these loci showed LOH. A comparison of LOH for markers on 9p and 9q indicated that proximal 9p or 9q is the likely site for a candidate bladder tumour-suppressor gene. Most strikingly, LOH was observed not only in tumours of high grade or stage but also in > 50% of grade 1 and 2 superficial (pTa) tumours. This is the first change to be identified at significant frequency in such tumours. Inactivation of a tumour-suppressor gene on chromosome 9 may therefore be an early genetic event in the development of bladder cancer.			CAIRNS, P (corresponding author), MARIE CURIE SKLODOWSKA MEM INST,EPITHELIAL CARCINOGENESIS LAB,OXTED RHS 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; CAIRNS P, 1991, ONCOGENE, V6, P2305; COOK PJ, 1969, INT J CANCER, V4, P93, DOI 10.1002/ijc.2910040113; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; CZERNIAK B, 1990, BRIT J CANCER, V62, P762, DOI 10.1038/bjc.1990.374; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIBAS Z, 1984, CANCER RES, V44, P1257; JAMES CD, 1991, CANCER RES, V51, P1684; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; LATHROP GM, 1988, GENOMICS, V3, P361; MOSTOFI FK, 1988, DIAGNOSIS MANAGEMENT, P83; Mostofi FK, 1973, INT CLASSIFICATION T; OLUMI AF, 1990, CANCER RES, V50, P7081; PRESTI JC, 1991, CANCER RES, V51, P5405; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; Sambrook J., 1989, MOL CLONING LAB MANU; TRENT JM, 1982, P NATL ACAD SCI-BIOL, V79, P7809, DOI 10.1073/pnas.79.24.7809; TSAI YC, 1990, CANCER RES, V50, P44; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1988, HMSO CANCER STATISTI; 1978, TNM CLASSIFICAITON M	24	200	204	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1083	1085						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096074				2022-12-17	WOS:A1993KT22000034
J	MUSTELIN, T; ALTMAN, A				MUSTELIN, T; ALTMAN, A			DEPHOSPHORYLATION AND ACTIVATION OF THE T-CELL TYROSINE KINASE PP56LCK BY THE LEUKOCYTE COMMON ANTIGEN (CD45)	ONCOGENE			English	Article											MUSTELIN, T (corresponding author), SCRIPPS CLIN & RES FDN,RES INST,DEPT IMMUNOL,10666 N TORREY PINES RD IMM3,LA JOLLA,CA 92037, USA.			Mustelin, Tomas/0000-0001-5912-8840				ALTMAN A, IN PRESS ADV IMMUNOL; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EMMRICH F, 1988, IMMUNOL TODAY, V9, P296, DOI 10.1016/0167-5699(88)91320-5; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; KIENER PA, 1989, J IMMUNOL, V143, P23; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KUPFER A, 1988, P NATL ACAD SCI USA, V85, P8216, DOI 10.1073/pnas.85.21.8216; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MORIKAWA S, 1978, INT J CANCER, V21, P166, DOI 10.1002/ijc.2910210207; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1989, IMMUNOL TODAY, V10, P189, DOI 10.1016/0167-5699(89)90322-8; MUSTELIN T, 1990, IN PRESS SCIENCE; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RIVAS A, 1988, J IMMUNOL, V140, P2912; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0	42	200	209	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					809	813						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2141684				2022-12-17	WOS:A1990DP55300005
J	Liu, Y; Cheng, Y; Xu, Y; Wang, Z; Du, X; Li, C; Peng, J; Gao, L; Liang, X; Ma, C				Liu, Y.; Cheng, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Peng, J.; Gao, L.; Liang, X.; Ma, C.			Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; LIGAND 1 EXPRESSION; HEPATOCELLULAR-CARCINOMA; TUMOR MICROENVIRONMENT; IMMUNE-RESPONSES; PD-1 EXPRESSION; GASTRIC-CANCER; T-CELLS; VIRUS; DYSFUNCTION	Abnormal expression of activating/inhibitory receptors leads to natural killer (NK) cells dysfunction in tumor. Here we show that programmed cell death protein 1 (PD-1), a well-known immune checkpoint of T cells, is highly expressed on peripheral and tumor-infiltrating NK cells from patients with digestive cancers including esophageal, liver, colorectal, gastric and biliary cancer. The increased PD-1 expression on NK cells indicates poorer survival in esophageal and liver cancers. Blocking PD-1/PD-L1 signaling markedly enhances cytokines production and degranulation and suppresses apoptosis of NK cells in vitro. PD-1/PD-L1 exerts inhibitory effect through repressing the activation of PI3K/AKT signaling in NK cells. More importantly, a PD-1 blocking antibody was found to significantly suppress the growth of xenografts in nude mice, and this inhibition of tumor growth was completely abrogated by NK depletion. These findings strongly suggested that PD-1 is an inhibitory regulator of NK cells in digestive cancers. PD-1 blockade might be an efficient strategy in NK cell-based tumor immunotherapy.	[Liu, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Gao, L.; Liang, X.; Ma, C.] Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Gao, L.; Liang, X.; Ma, C.] Shandong Univ, Sch Med, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Y.; Cheng, Y.] Shandong Univ, Dept Radiat Oncol, Qilu Hosp, Jinan, Shandong, Peoples R China; [Peng, J.] Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University	Ma, C (corresponding author), Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Ma, C (corresponding author), Shandong Univ, Sch Med, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	machunhong@sdu.edu.cn	ma, chunhong/C-6043-2008	ma, chunhong/0000-0002-8121-4718; Liu, Yuan/0000-0002-4425-2213; Li, Chunyang/0000-0002-5798-2274	National Science Foundation for Distinguished Young Scholars of China [81425012]; NSFC [91529305, 81371831]; Shandong Provincial Natural Science Foundation [ZR2015HZ005]	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); NSFC(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province)	We would like to thank Professor Weiming Zhao from the Department of Pathogenic Biology for the gift of anti-asialoGM1. We would like to thank Mingsheng Zhao from the Department of Immunology for help with the in vivo experiments. This work was supported by grants from the National Science Foundation for Distinguished Young Scholars of China (81425012), NSFC (91529305 and 81371831) and the Shandong Provincial Natural Science Foundation (ZR2015HZ005).	Ali AK, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00355; Beldi-Ferchiou A, 2016, ONCOTARGET, V7, P72961, DOI 10.18632/oncotarget.12150; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Blank C, 2005, CANCER IMMUNOL IMMUN, V54, P307, DOI 10.1007/s00262-004-0593-x; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bucklein V, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1178421; Chen KY, 2016, ONCOTARGET, V7, P30772, DOI 10.18632/oncotarget.8956; Chen Y, 2017, CELL MOL IMMUNOL, V14, P293, DOI 10.1038/cmi.2015.81; Chen YW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001347; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Ferrone C, 2010, J CLIN ONCOL, V28, P4045, DOI 10.1200/JCO.2010.27.9992; Giannelli G, 2014, GUT, V63, P1668, DOI 10.1136/gutjnl-2014-307323; Golden-Mason L, 2008, J IMMUNOL, V180, P3637, DOI 10.4049/jimmunol.180.6.3637; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hassan SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137646; Huang BY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134715; Hydes Theresa, 2015, Lancet, V385 Suppl 1, pS45, DOI 10.1016/S0140-6736(15)60360-9; Kamphorst AO, 2013, CURR OPIN IMMUNOL, V25, P381, DOI 10.1016/j.coi.2013.03.003; Kinter AL, 2008, J IMMUNOL, V181, P6738, DOI 10.4049/jimmunol.181.10.6738; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Li YY, 2016, INT J POLYM SCI, V2016, DOI 10.1155/2016/8769360; Lin EW, 2016, ONCOGENE, V35, P5337, DOI 10.1038/onc.2016.34; Ma CQ, 2016, AM J SURG PATHOL, V40, P1496, DOI 10.1097/PAS.0000000000000698; Moreno-Cubero E, 2016, WORLD J GASTROENTERO, V22, P6469, DOI 10.3748/wjg.v22.i28.6469; Norris S, 2012, VIRAL IMMUNOL, V25, P329, DOI 10.1089/vim.2011.0096; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004; Riley JL, 2009, IMMUNOL REV, V229, P114, DOI 10.1111/j.1600-065X.2009.00767.x; Saito H, 2013, J SURG ONCOL, V107, P517, DOI 10.1002/jso.23281; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shi LR, 2016, CLIN CANCER RES, V22, P1173, DOI 10.1158/1078-0432.CCR-15-1352; Solaymani-Mohammadi S, 2016, J LEUKOCYTE BIOL, V99, P475, DOI 10.1189/jlb.4A0115-003RR; Tarazona R, 2017, CANCER IMMUNOL IMMUN, V66, P233, DOI 10.1007/s00262-016-1882-x; Toh JWT, 2016, CLIN COLORECTAL CANC, V15, P285, DOI 10.1016/j.clcc.2016.07.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wargo JA, 2016, CURR OPIN IMMUNOL, V41, P23, DOI 10.1016/j.coi.2016.05.006; Watanabe M, 2010, DIS ESOPHAGUS, V23, P675, DOI 10.1111/j.1442-2050.2010.01073.x; Wiesmayr S, 2012, EUR J IMMUNOL, V42, P541, DOI 10.1002/eji.201141832; Wu Y, 2013, HEPATOLOGY, V57, P1107, DOI 10.1002/hep.26192; Yan WJ, 2015, GUT, V64, P1593, DOI 10.1136/gutjnl-2014-307671; Zhang G, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/384726; Zhang L, 2015, CURR STEM CELL RES T, V10, P245, DOI 10.2174/1574888X09666140812112305	48	199	207	5	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6143	6153		10.1038/onc.2017.209	http://dx.doi.org/10.1038/onc.2017.209			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692048	hybrid, Green Published			2022-12-17	WOS:000414249800008
J	Chouaib, S; Noman, MZ; Kosmatopoulos, K; Curran, MA				Chouaib, S.; Noman, M. Z.; Kosmatopoulos, K.; Curran, M. A.			Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer	ONCOGENE			English	Review							CYTOTOXIC T-LYMPHOCYTES; REGULATORY T; INDUCIBLE FACTOR-1-ALPHA; TUMOR MICROENVIRONMENT; INDUCED AUTOPHAGY; INTRATUMORAL INFILTRATION; CELL CYTOTOXICITY; SUPPRESSOR-CELLS; EXTRACELLULAR PH; GENE-EXPRESSION	Tumors use several strategies to evade the host immune response, including creation of an immune-suppressive and hostile tumor environment. Tissue hypoxia due to inadequate blood supply is reported to develop very early during tumor establishment. Hypoxic stress has a strong impact on tumor cell biology. In particular, tissue hypoxia contributes to therapeutic resistance, heterogeneity and progression. It also interferes with immune plasticity, promotes the differentiation and expansion of immune-suppressive stromal cells, and remodels the metabolic landscape to support immune privilege. Therefore, tissue hypoxia has been regarded as a central factor for tumor aggressiveness and metastasis. In this regard, manipulating host-tumor interactions in the context of the hypoxic tumor microenvironment may be important in preventing or reverting malignant conversion. We will discuss how tumor microenvironmentdriven transient compositional tumor heterogeneity involves hypoxic stress. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of conventional therapies as well as cancer immunotherapy. Thus, understanding how tumor and stromal cells respond to hypoxia will allow for the design of innovative cancer therapies that can overcome these barriers. A better understanding of hypoxia-dependent mechanisms involved in the regulation of immune tolerance could lead to new strategies to enhance antitumor immunity. Therefore, discovery and validation of therapeutic targets derived from the hypoxic tumor microenvironment is of major importance. In this context, critical hypoxia-associated pathways are attractive targets for immunotherapy of cancer. In this review, we summarize current knowledge regarding the molecular mechanisms induced by tumor cell hypoxia with a special emphasis on therapeutic resistance and immune suppression. We emphasize mechanisms of manipulating hypoxic stress and its associated pathways, which may support the development of more durable and successful cancer immunotherapy approaches in the future.	[Chouaib, S.; Noman, M. Z.] INSERM, UMR1186, Lab Integrat Tumor Immunol & Genet Oncol, Villejuif, France; [Chouaib, S.; Noman, M. Z.] Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, INSERM, Villejuif, France; [Kosmatopoulos, K.] Vaxon Biotech, Paris, France; [Curran, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Texas System; UTMD Anderson Cancer Center	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U1186, 39 Camille Desmoulins, F-94805 Villejuif, Ile De France, France.	salem.chouaib@gustaveroussy.fr	Chouaib, Salem/F-7939-2016; NOMAN, Muhammmad Zaeem/AAJ-1465-2021; NOMAN, Muhammmad Zaeem/AAJ-1466-2021; Noman, Muhammad zaeem/AAF-8483-2020	NOMAN, Muhammmad Zaeem/0000-0002-1837-3097; NOMAN, Muhammmad Zaeem/0000-0002-1837-3097; Curran, Michael/0000-0003-4996-7207	NCI NIH HHS [P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allavena P, 2012, CLIN EXP IMMUNOL, V167, P195, DOI 10.1111/j.1365-2249.2011.04515.x; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Becker JC, 2013, CANCER IMMUNOL IMMUN, V62, P1137, DOI 10.1007/s00262-013-1434-6; Bellone M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00231; Ben-Shoshan J, 2008, EUR J IMMUNOL, V38, P2412, DOI 10.1002/eji.200838318; Blay J, 1997, CANCER RES, V57, P2602; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856; Caldwell CC, 2001, J IMMUNOL, V167, P6140, DOI 10.4049/jimmunol.167.11.6140; Cary, 2014, NEURO-ONCOLOGY, V16, pII3; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Chafe SC, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1048955; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Doedens AL, 2013, NAT IMMUNOL, V14, P1173, DOI 10.1038/ni.2714; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; DROGE W, 1987, CELL IMMUNOL, V108, P405, DOI 10.1016/0008-8749(87)90223-1; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Hamai A, 2010, TISSUE ANTIGENS, V75, P1, DOI 10.1111/j.1399-0039.2009.01401.x; Hasmim M, 2013, J IMMUNOL, V191, P5802, DOI 10.4049/jimmunol.1302140; Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260; Hoskin DW, 2008, INT J ONCOL, V32, P527; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Kobie JJ, 2006, J IMMUNOL, V177, P6780, DOI 10.4049/jimmunol.177.10.6780; Kotsakis A, 2012, ANN ONCOL, V23, P442, DOI 10.1093/annonc/mdr396; Kryczek I, 2011, J IMMUNOL, V186, P4388, DOI 10.4049/jimmunol.1003251; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lee JH, 2015, IMMUNITY, V42, P1062, DOI 10.1016/j.immuni.2015.05.016; Lin Q, 2010, CANCER BIOL THER, V9, P949, DOI 10.4161/cbt.9.12.12347; Lin SS, 2012, CANCER SCI, V103, P904, DOI 10.1111/j.1349-7006.2012.02259.x; Lugini L, 2006, CANCER RES, V66, P3629, DOI 10.1158/0008-5472.CAN-05-3204; Lukashev D, 2007, CANCER METAST REV, V26, P273, DOI 10.1007/s10555-007-9054-2; Lukashev D, 2001, J BIOL CHEM, V276, P48754, DOI 10.1074/jbc.M104782200; Lukashev D, 2006, J IMMUNOL, V177, P4962, DOI 10.4049/jimmunol.177.8.4962; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mellor AL, 2008, NAT REV IMMUNOL, V8, P74, DOI 10.1038/nri2233; Messai Y, 2015, AUTOPHAGY; Messai Y, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985951; Messai Y, 2014, CANCER RES, V74, P6820, DOI 10.1158/0008-5472.CAN-14-0303; Metelo AM, 2015, ONCOTARGET, V6, P23036, DOI 10.18632/oncotarget.4564; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Nagaraj S, 2007, NAT MED, V13, P828, DOI 10.1038/nm1609; Nakagawa Y, 2015, IMMUNOL LETT, V167, P72, DOI 10.1016/j.imlet.2015.07.003; Nakamura H, 2005, J IMMUNOL, V174, P7592, DOI 10.4049/jimmunol.174.12.7592; Noman MZ, 2016, CANCER LETT, V380, P257, DOI 10.1016/j.canlet.2015.10.026; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Noman MZ, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954463; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Noman MZ, 2012, AUTOPHAGY, V8, P704, DOI 10.4161/auto.19572; Noman MZ, 2011, CRIT REV IMMUNOL, V31, P357, DOI 10.1615/CritRevImmunol.v31.i5.10; Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094; Noman MZ, 2011, B CANCER, V98, pE19, DOI 10.1684/bdc.2010.1295; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Ohta A, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00027; Palazon A, 2012, CANCER DISCOV, V2, P608, DOI 10.1158/2159-8290.CD-11-0314; Payen VL, 2016, CELL MOL LIFE SCI, V73, P1333, DOI 10.1007/s00018-015-2098-5; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; RATNER S, 1990, J NATL CANCER I, V82, P612, DOI 10.1093/jnci/82.7.612; REDEGELD F, 1991, J IMMUNOL, V147, P3638; Robbins JR, 2005, J PHYSIOL-LONDON, V564, P131, DOI 10.1113/jphysiol.2004.081893; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Saggar JK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00154; Sarkar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064835; Scardino A, 2002, J IMMUNOL, V168, P5900, DOI 10.4049/jimmunol.168.11.5900; Sceneay J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22355; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Semenza GL, 2009, CURR PHARM DESIGN, V15, P3839, DOI 10.2174/138161209789649402; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Sitkovsky MV, 2008, BLOOD, V111, P5424, DOI 10.1182/blood-2008-03-143990; Takehara H, 2006, DIGEST DIS SCI, V51, P2188, DOI 10.1007/s10620-006-9436-2; Tan S, 1998, J NEUROPATH EXP NEUR, V57, P544, DOI 10.1097/00005072-199806000-00002; Terry Stephane, 2015, Oncoscience, V2, P841; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thiel M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000853; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; Viry E, 2014, AUTOPHAGY, V10, P173, DOI 10.4161/auto.26924; Widmer DS, 2013, J INVEST DERMATOL, V133, P2436, DOI 10.1038/jid.2013.115; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Wolter F, 2015, J HEPATOL, V63, P1334, DOI 10.1016/j.jhep.2015.08.008; Xia Y, 2012, EUR J MED CHEM, V49, P24, DOI 10.1016/j.ejmech.2012.01.033; Yamada N, 2012, INT J ONCOL, V41, P2005, DOI 10.3892/ijo.2012.1630; Yeung TM, 2011, P NATL ACAD SCI USA, V108, P4382, DOI 10.1073/pnas.1014519107; Zhang JJ, 2016, J AM SOC NEPHROL, V27, P92, DOI 10.1681/ASN.2014121248	100	199	203	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					439	445		10.1038/onc.2016.225	http://dx.doi.org/10.1038/onc.2016.225			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345407	Green Accepted			2022-12-17	WOS:000394166700001
J	Talotta, F; Cimmino, A; Matarazzo, MR; Casalino, L; De Vita, G; D'Esposito, M; Di Lauro, R; Verde, P				Talotta, F.; Cimmino, A.; Matarazzo, M. R.; Casalino, L.; De Vita, G.; D'Esposito, M.; Di Lauro, R.; Verde, P.			An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation	ONCOGENE			English	Article						miR-21; AP-1; PDCD4; PTEN; RAS; thyroid tumorigenesis	TUMOR-SUPPRESSOR PDCD4; GENE-EXPRESSION; C-JUN; MICRORNA-21 TARGETS; CELLS; TRANSLATION; INVASION; SURVIVAL; PROTEIN; PHOSPHORYLATION	The transcription factor AP-1 plays key roles in tumorigenesis, by regulating a variety of protein-coding genes, implicated in multiple hallmarks of cancer. Among non-coding genes, no AP-1 target has been described yet in tumorigenesis. MicroRNAs (miRNAs) are negative post-transcriptional regulators of protein-coding genes. miRNA expression signatures are highly relevant in cancer and several tumor-associated miRNAs (oncomirs) play critical roles in oncogenesis. Here, we show that the miRNA miR-21, which represents the most frequently upregulated oncomir in solid tumors, is induced by AP-1 in response to RAS. By analyzing validated miR-21 targets, we have found that the tumor suppressors PTEN and PDCD4 are downregulated by RAS in an AP-1- and miR-21-dependent fashion. We further show that, given the role of PDCD4 as negative regulator of AP-1, the miR-21-mediated downregulation of PDCD4 is essential for the maximal induction of AP-1 activity in response to RAS. Our data reveal a novel mechanism of positive autoregulation of the AP-1 complex in RAS transformation and disclose the function of oncomirs as critical targets and regulators of AP-1 in tumorigenesis.	[Verde, P.] CNR, Inst Genet & Biophys A Buzzati Traverso, Inst Genet & Biophys, I-80131 Naples, Italy; [Cimmino, A.] Univ Naples 2, Dept Biochem & Biophys, Sch Med, Naples, Italy; [De Vita, G.; Di Lauro, R.] Univ Naples Federico II, Dept Mol & Cellular Biol & Pathol, Sch Med, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universita della Campania Vanvitelli; University of Naples Federico II	Verde, P (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Inst Genet & Biophys, Via P Castellino 111, I-80131 Naples, Italy.	verde@igb.cnr.it	Casalino, Laura/C-1506-2015; D'Esposito, Maurizio/J-9205-2016; Di Lauro, Roberto/A-2746-2012; De Vita, Gabriella/H-4422-2011; D'Esposito, Maurizio/AAY-6376-2020	Casalino, Laura/0000-0002-2557-0443; Di Lauro, Roberto/0000-0001-9493-3036; De Vita, Gabriella/0000-0002-7302-1174; Cimmino, Amelia/0000-0002-0004-9299	AIRC (Associazione Italiana per la Ricerca sul Cancro); AICR (Association for International Cancer Research, UK); AIRC and EU-Project-SIROCCO [LSHG-CT2006037900]	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AICR (Association for International Cancer Research, UK); AIRC and EU-Project-SIROCCO(Fondazione AIRC per la ricerca sul cancro)	We thank Robert Hennigan (University of Cincinnati, USA), Nancy Colburn (NCI, NIH, USA), Anders Lund (University of Copenhagen, Denmark) and Hideo Iba (University of Tokyo, Japan) for expression and reporter constructs. We also thank Floriana Della Ragione and Ingram Iaccarino (IGB) for technical help and critical reading of the paper. This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) and AICR (Association for International Cancer Research, UK) to PV and AIRC and EU-Project-SIROCCO (Grant LSHG-CT2006037900) to RDL.	Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bahassi EM, 2004, CLIN EXP METASTAS, V21, P293, DOI 10.1023/B:CLIN.0000046132.46946.dd; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	53	199	214	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					73	84		10.1038/onc.2008.370	http://dx.doi.org/10.1038/onc.2008.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18850008				2022-12-17	WOS:000262294100008
J	Senderowicz, AM				Senderowicz, AM			Small-molecule cyclin-dependent kinase modulators	ONCOGENE			English	Review						cell cycle; molecular targets; cyclin-dependent kinases; flavopiridol; UCN-01; CYC202; BMS 387032; drug development	CANCER-CELL-LINES; BREAST-CARCINOMA CELLS; FLAVOPIRIDOL INDUCES APOPTOSIS; HUMAN EPIDERMOID CARCINOMA; SKIN TUMOR-DEVELOPMENT; ACTIVITY IN-VIVO; PROTEIN-KINASE; SELECTIVE INHIBITOR; LUNG-CANCER; ANTITUMOR-ACTIVITY	Aberrations in cell cycle progression occur in the majority of human malignancies. The main pathway affected is the retinoblastoma (Rb) pathway. The tumor suppressor gene Rb is an important component in the G(1)/S transition and its function is abnormal in most human neoplasms. Loss in Rb function occurs by the hyperactivation of the cyclin-dependent kinases (cdk's). Therefore, modulation of cdk's may have an important use for the therapy and prevention of human neoplasms. Efforts to obtain small-molecule cdk modulators yielded two classes of modulators: direct and indirect modulators. Direct cdk modulators are small molecules that specifically target the ATP binding site of cdk's. Examples for this group include. avopiridol, roscovitine and BMS-387032. In contrast, indirect cdk modulators affect cdk function due to modulation of upstream pathways required for cdk activation. Some examples include perifosine, lovastatin, and UCN-01. The first example of a direct small-molecule cdk modulator tested in the clinic,. avopiridol, is a pan-cdk inhibitor that not only promotes cell cycle arrest but also halts transcriptional elongation, promotes apoptosis, induces differentiation, and has antiangiogenic properties. Clinical trials with this agent were performed with at least three different schedules of administration: 1-, 24- and 72-h infusions. The main toxicities for infusions greater than or equal to24-h are secretory diarrhea and proinflammatory syndrome. In addition, patients receiving shorter infusions have nausea/ vomiting and neutropenia. A phase II trial of patients with advanced non-small-cell lung carcinoma using the 72-h infusion every 2 weeks was recently completed. The median overall survival for the 20 patients who received treatment was 7.5 months, a survival similar to that obtained in a randomized trial of four chemotherapy regimens containing platinum analogues in combination with taxanes or gemcitabine, or with gefitinib, a recently approved EGFR inhibitor for the treatment of advanced lung cancer. Based on these encouraging results, a phase III trial comparing standard combination chemotherapy versus combination chemotherapy plus. avopiridol is currently under investigation. The second example of direct small-molecule cdk modulator tested in clinical trials is UCN-01(7-hydroxystaurosporine). UCN-01 has interesting preclinical features: it inhibits Ca2+-dependent PKCs, promotes apoptosis, arrests cell cycle progression at G(1)/S, and abrogates checkpoints upon DNA damage. The first phase I trial of UCN-01 demonstrated a very prolonged half-life. Based on this novel feature, UCN-01 is administered as a 72-h continuous infusion every 4 weeks ( in second and subsequent cycles UCN-01 is administered as a 36-h infusion). Other shorter schedules (i.e. 3 h) are being tested. Dose-limiting toxicities include nausea/vomiting, hypoxemia, and insulin-resistant hyperglycemia. Combination trials with cisplatin and other DNA-damaging agents are being tested. Recently, phase I trials with two novel small-molecule cdk modulators, BMS 387032 and R-Roscovitine (CYC202), have commenced with good tolerability. In summary, novel small-molecule cdk modulators are being tested in the clinic with interesting results. Although these small molecules are directed towards a very prevalent cause of carcinogenesis, we need to test them in advanced clinical trials to determine the future of this class of agents for the prevention and therapy of human malignancies.	NICDR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Senderowicz, AM (corresponding author), NICDR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 212, Bethesda, MD 20892 USA.	sendero@helix.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000706] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1994, CANCER CHEMOTH PHARM, V33, P273; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; Akiyama T, 1997, CANCER RES, V57, P1495; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Arguello F, 1998, BLOOD, V91, P2482; BARATTE B, 1992, ANTICANCER RES, V12, P873; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; BARTKOVA J, 1995, CANCER RES, V55, P949; Bartkova J, 1996, CANCER RES, V56, P5475; BENNETT S, 1999, P AN M AM SOC CLIN, V18, P156; Bible KC, 1996, CANCER RES, V56, P4856; Bible KC, 1997, CANCER RES, V57, P3375; Blanchard JL, 1999, BIOORG MED CHEM LETT, V9, P2537, DOI 10.1016/S0960-894X(99)00431-X; Bonfanti M, 1997, CANCER RES, V57, P1442; Bramson HN, 2001, J MED CHEM, V44, P4339, DOI 10.1021/jm010117d; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Brusselbach S, 1998, INT J CANCER, V77, P146; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; BuquetFagot C, 1997, ANTI-CANCER DRUG, V8, P623, DOI 10.1097/00001813-199707000-00011; Busby EC, 2000, CANCER RES, V60, P2108; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Cagnoli M, 1998, GYNECOL ONCOL, V70, P372, DOI 10.1006/gyno.1998.5062; Carlson B, 1999, CANCER RES, V59, P4634; Carlson B. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P424; Carlson BA, 1996, CANCER RES, V56, P2973; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chen XM, 1999, ONCOGENE, V18, P5691, DOI 10.1038/sj.onc.1202948; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Chien M, 1999, CANCER CHEMOTH PHARM, V44, P81, DOI 10.1007/s002800050948; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEES E, 2000, P AN M AM SOC CLIN, V19, P154; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dermatakis A, 2003, BIOORGAN MED CHEM, V11, P1873, DOI 10.1016/S0968-0896(03)00036-1; Dodo K, 2000, BIOORG MED CHEM LETT, V10, P615, DOI 10.1016/S0960-894X(00)00065-2; Drees M, 1997, CLIN CANCER RES, V3, P273; Driscoll B, 1999, AM J PHYSIOL-LUNG C, V276, pL679, DOI 10.1152/ajplung.1999.276.4.L679; EASTHAM JA, 1995, CANCER RES, V55, P5151; Eicher SA, 1996, CLIN CANCER RES, V2, P1659; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FINGERT HJ, 1988, CANCER RES, V48, P4375; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Fuse E, 1998, CANCER RES, V58, P3248; Gansauge S, 1997, CANCER RES, V57, P1634; Gius DR, 1999, CANCER RES, V59, P2577; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GrayBablin J, 1997, CANCER RES, V57, P604; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hsueh CT, 1998, CLIN CANCER RES, V4, P2201; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Husain A, 1997, CLIN CANCER RES, V3, P2089; Ichimura K, 1996, ONCOGENE, V13, P1065; Innocenti F, 2000, CLIN CANCER RES, V6, P3400; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Jeong HW, 2000, BIOORG MED CHEM LETT, V10, P1819, DOI 10.1016/S0960-894X(00)00357-7; JIN XM, 1995, CANCER RES, V55, P3250; Jones CB, 2000, CANCER CHEMOTH PHARM, V45, P252, DOI 10.1007/s002800050037; Kanoe H, 1998, ANTICANCER RES, V18, P2317; Katayose Y, 1997, CANCER RES, V57, P5441; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Kent LL, 1999, BIOCHEM BIOPH RES CO, V260, P768, DOI 10.1006/bbrc.1999.0891; Kerr JS, 1999, ANTICANCER RES, V19, P959; Kim KS, 2002, J MED CHEM, V45, P3905, DOI 10.1021/jm0201520; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Konig A, 1997, BLOOD, V90, P4307; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; KRIS MG, 2002, P AN M AM SOC CLIN, V21, P1166; Lahusen J, 2000, P 20 ANN M AM ASS CA; Lahusen T, 2003, MOL CARCINOGEN, V36, P183, DOI 10.1002/mc.10114; Lane ME, 2001, CANCER RES, V61, P6170; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee HR, 1999, INT J ONCOL, V15, P161; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; LOWE SW, 1994, COLD SPRING HARB SYM, V59, P419, DOI 10.1101/SQB.1994.059.01.047; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, CANCER RES, V55, P4818; MARCHETTI A, 1993, CANCER RES, V53, P2846; Masciullo V, 1997, INT J CANCER, V74, P390, DOI 10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; Melillo G, 1999, CANCER RES, V59, P5433; Mesguiche V, 2003, BIOORG MED CHEM LETT, V13, P217, DOI 10.1016/S0960-894X(02)00884-3; Mettey Y, 2003, J MED CHEM, V46, P222, DOI 10.1021/jm020319p; MICHALIDES R, 1995, CANCER RES, V55, P975; Misra RN, 2003, BIOORG MED CHEM LETT, V13, P1133, DOI 10.1016/S0960-894X(03)00034-9; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nugiel DA, 2001, J MED CHEM, V44, P1334, DOI 10.1021/jm0100032; Ortega MA, 2002, BIOORGAN MED CHEM, V10, P2177, DOI 10.1016/S0968-0896(02)00069-X; Park SG, 1996, MOL CELLS, V6, P679; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Patel V, 2002, CLIN CANCER RES, V8, P3549; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Patel V, 2002, CANCER RES, V62, P1401; Pollack IF, 1996, J NEUROSURG, V84, P1024, DOI 10.3171/jns.1996.84.6.1024; ROBERGE M, 1994, CANCER RES, V54, P6115; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; Ryu CK, 2000, BIOORG MED CHEM LETT, V10, P461, DOI 10.1016/S0960-894X(00)00014-7; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Sausville EA, 1998, CANCER CHEMOTH PHARM, V42, pS54, DOI 10.1007/s002800051080; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schoepfer J, 2002, J MED CHEM, V45, P1741, DOI 10.1021/jm0108348; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; Schwartz GK, 2002, J CLIN ONCOL, V20, P2157, DOI 10.1200/JCO.2002.08.080; Schwartz GK, 1997, CLIN CANCER RES, V3, P1467; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Senderowicz A M, 2001, Cancer Chemother Biol Response Modif, V19, P165; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Senderowicz AM, 2002, HEMATOL ONCOL CLIN N, V16, P1229, DOI 10.1016/S0889-8588(02)00049-7; Senderowicz AM, 2002, ONCOLOGIST, V7, P12; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; SENDEROWICZ AM, 1999, P 25 ANN M AM SOC CL; SENDEROWICZ AM, 1998, 10 NAT CANC I EUR OR, P78; SENDEROWICZ AM, 2000, P ANN M AM SOC CLIN; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, CANCER RES, V57, P4029; SHAPIRO G, 1999, P AM SOC CLIN ONC AT, V18; Shapiro GI, 1999, CLIN CANCER RES, V5, P2925; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu E, 1996, ONCOLOGY-BASEL, V53, P494; Sielecki TM, 2001, BIOORG MED CHEM LETT, V11, P1157, DOI 10.1016/S0960-894X(01)00185-8; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Soni R, 2001, JNCI-J NATL CANCER I, V93, P436, DOI 10.1093/jnci/93.6.436; SONODA Y, 1995, ONCOGENE, V11, P2145; Spitz FR, 1996, ANTICANCER RES, V16, P3415; Stadler WM, 2000, J CLIN ONCOL, V18, P371, DOI 10.1200/JCO.2000.18.2.371; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAMURA T, 1999, P AN M AM SOC CLIN, V18, P159; Tan AR, 2002, J CLIN ONCOL, V20, P4074, DOI 10.1200/JCO.2002.01.043; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2; Tsuchida E, 1997, INT J RADIAT ONCOL, V39, P1153, DOI 10.1016/S0360-3016(97)00549-X; Usuda J, 2000, INT J CANCER, V85, P275, DOI 10.1002/(SICI)1097-0215(20000115)85:2<275::AID-IJC20>3.0.CO;2-5; Walker DH, 1998, CURR TOP MICROBIOL, V227, P149; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang MB, 1998, OTOLARYNG HEAD NECK, V119, P593, DOI 10.1016/S0194-5998(98)70017-8; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WERNER J, 1998, P AM SOC CLIN ONC LO, V17; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Wilson WH, 2000, CLIN CANCER RES, V6, P415; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; Wright J, 1998, Oncology (Williston Park), V12, P1023; Yu JT, 2001, MOL CELL BIOL, V21, P3325, DOI 10.1128/MCB.21.10.3325-3335.2001; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zaharevitz DW, 1999, CANCER RES, V59, P2566; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu GX, 2003, J MED CHEM, V46, P2027, DOI 10.1021/jm0256169; Zhu GX, 2003, BIOORG MED CHEM LETT, V13, P1231, DOI 10.1016/S0960-894X(03)00133-1	185	199	210	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6609	6620		10.1038/sj.onc.1206954	http://dx.doi.org/10.1038/sj.onc.1206954			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528286	Bronze			2022-12-17	WOS:000185700700018
J	Gong, LJ; Li, YW; Nedeljkovic-Kurepa, A; Sarkar, FH				Gong, LJ; Li, YW; Nedeljkovic-Kurepa, A; Sarkar, FH			Inactivation of NF-kappa B by genistein is mediated via Akt signaling pathway in breast cancer cells	ONCOGENE			English	Article						genistein; NF-kappa B; Akt; breast cancer cells	INDUCED APOPTOSIS; LEUKEMIA-CELLS; UP-REGULATION; CYCLE ARREST; BETA-CATENIN; IN-VITRO; KINASE; ACTIVATION; INHIBITION; INDUCTION	Genistein, a natural isoflavonoid found in soybean products, has been proposed to be associated with a lower rate of breast cancer in Asian women. Studies from our laboratory and others have shown that genistein can induce apoptosis by regulating the expression of apoptosis-related genes in breast cancer cells. However, the precise molecular mechanism(s) by which genistein induces apoptotic cell death is not clear. In order to investigate such mechanism, we tested the role of Akt and NF-kappaB in genistein-treated MDA-MB-231 breast cancer cells. We found that inhibition of cell growth and induction of apoptosis by genistein are partly mediated through the downregulation of Akt and NF-kappaB pathways. Gel shift assay showed that NF-kappaB DNA-binding activity in MDA-MB-231 cells transfected with Akt cDNA was induced, suggesting that there is a cross-talk between NF-kappaB and Akt signaling pathway. Moreover, we found that genistein could abrogate EGF and Akt induced NF-kappaB activation. From these results, we conclude that the inactivation of NF-kappaB by genistein in MDA-MB-231 breast cancer cells is partly mediated via Akt pathway, which could be useful for rational design of strategies for the prevention and/or treatment of breast cancer.	Wayne State Univ, Sch Med, Karmanos Canc Inst, Hudson Webber Canc Res Ctr 715,Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Hudson Webber Canc Res Ctr 715,Dept Pathol, 110 E Warren, Detroit, MI 48201 USA.	fsarkar@med.wayne.edu			NCI NIH HHS [CA83695-O1A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083695] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alhasan SA, 1999, NUTR CANCER, V34, P12, DOI 10.1207/S15327914NC340102; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bradlow HL, 2002, ANN NY ACAD SCI, V963, P247; Brownson DM, 2002, J NUTR, V132, p3482S, DOI 10.1093/jn/132.11.3482S; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; Chen M, 2000, Biostatistics, V1, P293, DOI 10.1093/biostatistics/1.3.293; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; Dale TC, 1998, BIOCHEM J, V329, P209; Davis JN, 1998, NUTR CANCER, V32, P123, DOI 10.1080/01635589809514730; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Fotsis T, 1997, CANCER RES, V57, P2916; GRAY GE, 1979, BRIT J CANCER, V39, P1, DOI 10.1038/bjc.1979.1; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIRAYAMA T, 1978, PREV MED, V7, P173, DOI 10.1016/0091-7435(78)90244-X; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650; Li YW, 1999, INT J ONCOL, V15, P525; Li YW, 2002, CLIN CANCER RES, V8, P2369; Lian FR, 1998, NUTR CANCER, V31, P184, DOI 10.1080/01635589809514701; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; MILLER AB, 1977, CANCER-AM CANCER SOC, V39, P2704, DOI 10.1002/1097-0142(197706)39:6<2704::AID-CNCR2820390657>3.0.CO;2-G; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Ozes ON, 1999, NATURE, V401, P82; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Santibanez JF, 2000, NUTR CANCER, V37, P49, DOI 10.1207/S15327914NC3701_6; Shao ZM, 1998, CANCER RES, V58, P4851; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; VAN AD, 1996, SCIENCE, V274, P787; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	49	199	207	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4702	4709		10.1038/sj.onc.1206583	http://dx.doi.org/10.1038/sj.onc.1206583			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879015				2022-12-17	WOS:000184157000011
J	Sato, S; Fujita, N; Tsuruo, T				Sato, S; Fujita, N; Tsuruo, T			Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)	ONCOGENE			English	Article						UCN-01; PDK1; Akt; apoptosis; PKC	PROTEIN-KINASE-B; CANCER-CELLS; SELECTIVE INHIBITOR; ACTIVATION; APOPTOSIS; PHOSPHORYLATION; GROWTH; SUBSTRATE; CLEAVAGE; IDENTIFICATION	3-Phosphoinositide-dependent protein kinase-1 (PDKI) plays a central role in activating the AGC subfamily of protein kinases. In particular, PDKI plays an important role in the regulation of Akt/PKB survival pathway by phosphorylating Akt on Thr(308). Here we show that UCN-01 (7-hydroxystaurosporine), a drug now in clinical trials and with a unique fingerprint pattern, induced dephosphorylation and inactivation of Akt, resulting in the turnoff of the survival signals and the induction of apoptosis. Further analysis revealed that UCN-01-mediated Akt inactivation was caused by inhibiting upstream Akt kinase PDKI (IC50=33 nm) both in vitro and from cells, but not by suppressing Akt itself or phosphatidylinositide-3-OH kinase. UCN-01-induced PDKI inhibition was also observed in in vivo murine and human tumor xenografts. Overexpression of active form of Akt diminished the cytotoxic effects of UCN-01, suggesting that UCN-01 may in part exert its cytotoxicity by inhibiting PDKI-Akt survival pathway. Because UCN-01 has already proved to have potent anti-tumor activity in vivo, PDKI-Akt survival pathway is a new, attractive target for cancer chemotherapy.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Abe S, 2001, JPN J CANCER RES, V92, P537, DOI 10.1111/j.1349-7006.2001.tb01127.x; AKINAGA S, 1991, CANCER RES, V51, P4888; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Danley DE, 1996, J IMMUNOL, V157, P500; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; FUJITA N, 2002, IN PRESS J BIOL CHEM; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kurata N, 1999, CANCER CHEMOTH PHARM, V44, P12, DOI 10.1007/s002800050939; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nakashio A, 2000, CANCER RES, V60, P5303; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sugiyama K, 1999, CANCER RES, V59, P4406; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	45	199	208	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1727	1738		10.1038/sj.onc.1205225	http://dx.doi.org/10.1038/sj.onc.1205225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896604				2022-12-17	WOS:000174214200011
J	Attwell, S; Roskelley, C; Dedhar, S				Attwell, S; Roskelley, C; Dedhar, S			The integrin-linked kinase (ILK) suppresses anoikis	ONCOGENE			English	Article						apoptosis; protein kinase B; fibronectin; caspases	DEPENDENT CELL-SURVIVAL; FOCAL ADHESION KINASE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; APOPTOSIS; DEATH; B/AKT; AKT; PATHWAYS; GROWTH	Disruption of integrin-extracellular matrix interactions in normal epithelial cells induces apoptosis, a process termed anoikis, Reduced sensitivity to anoikis appears to be an important hallmark of oncogenic transformation, particularly in the process of metastasis, Several pathways have been implicated in the suppression of anoikis, however, the events which take place proximal to the integrin receptors remain unclear. Integrin-linked kinase (ILK) is an integrin-interacting protein kinase which has been identified as a potential PDK-2, as it is capable of phosphorylating PKB/Akt on Ser-473, and stimulating its activity, Here, we show that ILK activity is stimulated upon adhesion of SCP2 mouse mammary epithelial cells to fibronectin, and inhibited in suspended cells. Overexpression of ILK in the anoikis-sensitive SCP2 cells results in a profound inhibition of anoikis, as determined by annexin V binding and activation of caspases 8 and 3, This effect is reversible by the transfection and expression of a dominant-negative, kinase deficient ILK (ILK KD), as well as by a dominant negative PKB/Akt (PKB AAA). On the other hand, transfection of a dominant negative form of FAK (FRNK) failed to reverse the suppression of anoikis by ILK, Furthermore, inhibition of ILK activity induced anoikis in tno anoikis-resistant human breast cancer cell lines. These findings suggest that ILK plays a major role in the suppression of anoikis.	British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6P 6P2, Canada; Univ British Columbia, Dept Anat, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Agcy, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	28	199	210	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3811	3815		10.1038/sj.onc.1203711	http://dx.doi.org/10.1038/sj.onc.1203711			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949937				2022-12-17	WOS:000088568400015
J	Okamoto, I; Kawano, Y; Tsuiki, H; Sasaki, J; Nakao, M; Matsumoto, M; Suga, M; Ando, M; Nakajima, M; Saya, H				Okamoto, I; Kawano, Y; Tsuiki, H; Sasaki, J; Nakao, M; Matsumoto, M; Suga, M; Ando, M; Nakajima, M; Saya, H			CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration	ONCOGENE			English	Article						CD44; cleavage; metalloprotease; hyaluronic acid; tumor cell migration	LYMPHOCYTE HOMING RECEPTOR; MATRIX METALLOPROTEINASE; HYALURONATE BINDING; CARCINOMA-CELLS; MELANOMA-CELLS; CYTOPLASMIC DOMAIN; GLYCOPROTEIN CD44; BREAST-CARCINOMA; COLON CARCINOMAS; SPLICED EXONS	CD44 is a cell surface receptor for hyaluronate, a component of the extracellular matrix (ECM), Although CD44 has been implicated in tumor invasion and metastasis, the molecular mechanisms remain to be elucidated. Here we find that CD44 expressed in cancer cells is cleaved at the membrane-proximal region of the ectodomain and the membrane-bound cleavage product can be detected using an antibody against the cytoplasmic domain of CD44, Furthermore, we report that CD44 cleavage is mediated by a membrane-associated metalloprotease expressed in cancer cells, A tissue inhibitor of metalloproteases-l (TIMP-1), as well as metalloprotease inhibitor's, inhibit CD44 cleavage in the cell-free assay. Contrary, serine protease inhibitors enhance CD44 cleavage, and the enhancement can be prevented by pretreatment with a metalloprotease inhibitor. Thus, CD44 cleavage is regulated by an intricate balance between some proteases and their inhibitors. Interestingly, treatment with the metalloprotease blocker l,10-phenanthroline, which strongly prevent the CD44 cleavage, suppressed RERF-LC-OK lung cancer cell migration on a hyaluronate substrate, but not on several other substrates. These results suggest that CD44 cleavage plays a critical role in an efficient cell-detachment from a hyaluronate substrate during the cell migration and consequently promotes CD44-mediated cancer cell migration. Our present data indicate that CD44, not only ECM per se, is one of the targets of pericellular proteolysis involved in tumor invasion and metastasis.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Novartis Pharma KK, Oncol Res, Takarazuka, Hyogo 6650042, Japan	Kumamoto University; Novartis	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ALBELDA SM, 1993, LAB INVEST, V68, P4; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1994, J IMMUNOL, V152, P1314; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Friedl P, 1997, CANCER RES, V57, P2061; Goebeler M, 1996, J CELL SCI, V109, P1957; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; ISACKE CM, 1994, J CELL SCI, V107, P2353; Iwamura T, 1997, CANCER RES, V57, P1206; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; Okamoto I, 1998, J NATL CANCER I, V90, P307, DOI 10.1093/jnci/90.4.307; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Puente XS, 1996, CANCER RES, V56, P944; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Sasaki J, 1998, INT J ONCOL, V12, P525; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sheng Y, 1997, INT J CANCER, V73, P850, DOI 10.1002/(SICI)1097-0215(19971210)73:6<850::AID-IJC15>3.0.CO;2-8; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Takahashi K, 1995, ONCOGENE, V11, P2223; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TANABE KK, 1993, MOL CARCINOGEN, V7, P212, DOI 10.1002/mc.2940070403; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x	49	199	203	1	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1435	1446		10.1038/sj.onc.1202447	http://dx.doi.org/10.1038/sj.onc.1202447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050880				2022-12-17	WOS:000078651600005
J	Shaw, P; Freeman, J; Bovey, R; Iggo, R				Shaw, P; Freeman, J; Bovey, R; Iggo, R			Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy-terminus	ONCOGENE			English	Article						p53; transcription factor; DNA binding; PAb421; O-glycosylation; peptides	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; MONOCLONAL-ANTIBODIES; TRANSCRIPTION FACTOR; PHOSPHORYLATION; EXPRESSION; FORMS; CELLS; SITE	The carboxy-terminus of p53 contains a basic region which represses DNA binding, and this repression can be relieved by PAb421, an antibody against the basic region. The EB-1 human cell line contains wild type p53 protein which fails to express the PAb421 epitope and is highly active both in biological assays and in DNA binding assays. We show by wheat germ agglutinin chromatography and galactosyl-transferase labelling that this p53 is O-glycosylated, and that at least one of the sugar residues masks the PAb421 epitope, as demonstrated by recovery of reactivity with PAb421 after digestion of Western blots of EB-1 cell extract with hexosaminidase. A minor population of p53 molecules in EB-1 cells lacks the modification, and there is a correlation between the ability to bind DNA with high affinity and masking of the PAb421 epitope. We also show that strongly positively charged peptides, including short peptides from the basic region of p53, can derepress DNA binding, probably by disruption of an intramolecular interaction involving the basic region. We propose that any intervention which prevents this intramolecular interaction, including addition of bulky residues such as sugar groups, can activate DNA binding by p53.	INST PATHOL, DIV EXPTL ONCOL, CH-1011 LAUSANNE, SWITZERLAND		Shaw, P (corresponding author), SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND.		Iggo, Richard/G-3546-2014					ABARZUA P, 1995, CANCER RES, V55, P3490; ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACOB GS, 1994, METHOD ENZYMOL, V230, P280; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	62	199	207	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					921	930						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632915				2022-12-17	WOS:A1996TW68600024
J	Frank, R; Zhang, J; Uchida, H; Meyers, S; Hiebert, SW; Nimer, SD				Frank, R; Zhang, J; Uchida, H; Meyers, S; Hiebert, SW; Nimer, SD			The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B	ONCOGENE			English	Article						AML1/ETO; AML1B; GM-CSF promoter; transcriptional activation	COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; CELL RECEPTOR-DELTA; TRANSCRIPTIONAL ENHANCER; DNA-BINDING; TRANSLOCATION PROTEIN; REGULATORY ELEMENTS; ENDOTHELIAL-CELLS; GENE; RUNT	The t(8;21) translocation, commonly found myelogenous leukemia (AML), generates protein containing N-terminal AML1 and C-terminal ETO amino acids. The human AML1 gene encodes several related proteins that specifically bind to the sequence TGT/cGGT, located in the promoter regions of a variety of hematopoietic growth factor genes. To examine the abilities of the AML1B protein (which contains 479 amino acids), a shorter AML1A isoform (which contains amino acids 1-250), and the AML1/ETO fusion protein (which contains AML1A amino acids 1-177) to stimulate transcription from the GMCSF promoter, we performed co-transfection experiments in T cells using a human GM-CSF promoter-CAT reporter gene plasmid and expression vectors that contain the cDNAs for one of the above proteins, Our data demonstrate that AML1B, but not AML1A or AML1/ETO transactivates the GM-CSF promoter, requiring the TGTGGT sequence contained between base pairs -68 and -53. Furthermore, we show that AML1/ETO, but not AML1A, inhibits the ability of AML1B to stimulate CAT expression. Electrophoretic mobility shift assays demonstrated the specific binding of AML1 proteins to the GM-CSF promoter TGTGGT sequence, which does not require GM-CSF sequences immediately upstream of this binding site. Our data support a role for AML1B as a transcriptional activator and establish that the AML1/ETO fusion protein can act as a dominant negative protein on the human GMCSF promoter. Although AML1/ETO does not stimulate the transcription of GM-CSF, it may function by inhibiting the normal activity of AML1B in AML cells with the t(8;21) translocation.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, LAB MOLEC ASPECTS HEMATOPOIESIS, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [R01CA064140, T32CA009512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NCI NIH HHS [CA09512, R01 CA64140] Funding Source: Medline; NIDDK NIH HHS [R01 DK43025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BEGLEY CG, 1987, LEUKEMIA, V1, P1; BRADBURY D, 1990, LEUKEMIA, V4, P44; BROUDY VC, 1986, P NATL ACAD SCI USA, V83, P7467, DOI 10.1073/pnas.83.19.7467; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON P, 1992, BLOOD, V80, P1825; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GILL LL, 1991, EUR J IMMUNOL, V21, P807, DOI 10.1002/eji.1830210339; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NICHOLS J, 1992, BLOOD, V80, P2953; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1989, J IMMUNOL, V143, P2374; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; YOUNG DR, 1986, BLOOD, V68, P1168; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	48	199	208	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2667	2674						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545124				2022-12-17	WOS:A1995TP18800023
J	LIU, XQ; BRODEUR, SR; GISH, G; SONGYANG, Z; CANTLEY, LC; LAUDANO, AP; PAWSON, T				LIU, XQ; BRODEUR, SR; GISH, G; SONGYANG, Z; CANTLEY, LC; LAUDANO, AP; PAWSON, T			REGULATION OF C-SRC TYROSINE KINASE-ACTIVITY BY THE SRC SH2 DOMAIN	ONCOGENE			English	Article							PHOSPHORYLATED CELLULAR PROTEINS; GROWTH-FACTOR RECEPTORS; MIDDLE-T-ANTIGEN; CARBOXY TERMINUS; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; PP60C-SRC; ACTIVATION; P60C-SRC; BINDING	The protein-tyrosine kinase activity of pp60c-src (c-Src) is inhibited by phosphorylation of tyr527, within the c-Src c-terminal tail. Genetic and biochemical data have suggested that this negative regulation requires an intact Src homology 2 (SH2) domain. Since SH2 domains recognize phosphotyrosine, it is possible that these two noncatalytic domains associate, and thereby repress c-Src kinase activity. Consistent with this model, an isolated Src SH2 domain expressed in bacteria as a GST fusion protein bound in vitro to a synthetic phosphotyrosine-containing peptide modeled on the C-terminal 13 residues of the c-Src tail. Binding was absolutely dependent on phosphorylation of tyr527 in the tail peptide, and was modified by both the length and sequence of the peptide. Competition experiments indicated only a moderate binding affinity between the Src SH2 domain and the phosphorylated tail. A distinct phosphotyrosine-containing peptide previously identified as binding the Src SH2 domain with high affinity stimulated c-Src tyrosine kinase activity in vitro, possibly by competing with the endogenous tail phosphorylation site for binding to the SH2 domain. Indeed, this activation was competitively inhibited by purified bacterial Src SH2 domain. These data provide direct evidence that the c-Src tail has an intrinsic affinity for the Src SH2 domain, and suggest that such an interaction in the intact molecule contributes to maintaining c-Src in an inactive form.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03825; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University System Of New Hampshire; University of New Hampshire; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Toronto			Gish, Gerald D/C-7228-2017; Cantley, Lewis C/D-1800-2014; Pawson, Tony J/E-4578-2013	Cantley, Lewis C/0000-0002-1298-7653; Liu, X. Johne/0000-0003-3381-5030				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CH, 1987, CELL, V40, P83; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HU P, 1992, MOL CELL BIOL, V981, P990; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MACAULEY A, 1990, New Biologist, V2, P828; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1987, ONCOGENE, V1, P181; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VEILLETTE A, 1992, ONCOGENE, V7, P971; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989	42	199	208	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1119	1126						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683128				2022-12-17	WOS:A1993KY32800002
J	Webber, JP; Spary, LK; Sanders, AJ; Chowdhury, R; Jiang, WG; Steadman, R; Wymant, J; Jones, AT; Kynaston, H; Mason, MD; Tabi, Z; Clayton, A				Webber, J. P.; Spary, L. K.; Sanders, A. J.; Chowdhury, R.; Jiang, W. G.; Steadman, R.; Wymant, J.; Jones, A. T.; Kynaston, H.; Mason, M. D.; Tabi, Z.; Clayton, A.			Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes	ONCOGENE			English	Article						exosomes; prostate; stroma; fibroblast; TGF beta	HUMAN PROSTATE-CANCER; TGF-BETA; LUNG FIBROBLASTS; REACTIVE STROMA; BREAST-CANCER; CELLS; ANGIOGENESIS; GROWTH; EXPRESSION; INDUCTION	Activation of myofibroblast rich stroma is a rate-limiting step essential for cancer progression. The responsible factors are not fully understood, but TGF beta 1 is probably critical. A proportion of TGF beta 1 is associated with extracellular nano-vesicles termed exosomes, secreted by carcinoma cells, and the relative importance of soluble and vesicular TGF beta in stromal activation is presented. Prostate cancer exosomes triggered TGF beta 1-dependent fibroblast differentiation, to a distinctive myofibroblast phenotype resembling stromal cells isolated from cancerous prostate tissue; supporting angiogenesis in vitro and accelerating tumour growth in vivo. Myofibroblasts generated using soluble TGF beta 1 were not pro-angiogenic or tumour-promoting. Cleaving heparan sulphate side chains from the exosome surface had no impact on TGF beta levels yet attenuated SMAD-dependent signalling and myofibroblastic differentiation. Eliminating exosomes from the cancer cell secretome, targeting Rab27a, abolished differentiation and lead to failure in stroma-assisted tumour growth in vivo. Exosomal TGF beta 1 is therefore required for the formation of tumour-promoting stroma.	[Webber, J. P.; Spary, L. K.; Chowdhury, R.; Mason, M. D.; Tabi, Z.; Clayton, A.] Cardiff Univ, Sch Med, Inst Canc & Genet, Sect Oncol, Cardiff CF14 2TL, S Glam, Wales; [Sanders, A. J.; Jiang, W. G.; Kynaston, H.] Cardiff Univ, Sch Med, Inst Canc & Genet, Sect Surg, Cardiff CF14 2TL, S Glam, Wales; [Steadman, R.] Cardiff Univ, Sch Med, Inst Canc & Genet, Nephrol Sect, Cardiff CF14 2TL, S Glam, Wales; [Wymant, J.; Jones, A. T.] Cardiff Sch Pharm & Pharmaceut Sci, Cardiff, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Clayton, A (corresponding author), Cardiff Univ, Sch Med, Inst Canc & Genet, Sect Oncol, Cardiff CF14 2TL, S Glam, Wales.	claytona@cf.ac.uk	Jones, Arwyn/ABE-8709-2020; Steadman, Robert/O-1614-2016; Jones, Arwyn T/E-4787-2010; Webber, Jason P/O-1960-2017; Jiang, Wen G/B-1293-2010; Jiang, Wen G./AAF-1876-2020; Mason, Malcolm D/H-6979-2013; jiang, wen/GYI-9662-2022	Jones, Arwyn/0000-0003-2781-8905; Steadman, Robert/0000-0002-1303-2496; Jones, Arwyn T/0000-0003-2781-8905; Webber, Jason P/0000-0003-4772-3014; Jiang, Wen G/0000-0002-3283-1111; Jiang, Wen G./0000-0002-3283-1111; 	Cancer Research Wales programme; CR-UK studentship; CR-UK development	Cancer Research Wales programme; CR-UK studentship; CR-UK development	This work was supported by a Cancer Research Wales programme grant awarded to AC, ZT, WGJ and MDM. Confocal microscopy studies were supported by a CR-UK studentship awarded to JPW and ATJ. In vivo studies were supported by a CR-UK development grant to AC and JPW. Drs Jane Lane and Tracey Martin are acknowledged for their help with the in vivo work. Dr H Sheldon and Professor A Harris, Oxford University, UK assisted with establishing in vitro angiogenesis assays.	Clayton A, 2008, J IMMUNOL, V180, P7249, DOI 10.4049/jimmunol.180.11.7249; Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456; Clayton A, 2011, J IMMUNOL, V187, P676, DOI 10.4049/jimmunol.1003884; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Gesierich S, 2006, CANCER RES, V66, P7083, DOI 10.1158/0008-5472.CAN-06-0391; Gu JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052465; Hashizume H, 2010, CANCER RES, V70, P2213, DOI 10.1158/0008-5472.CAN-09-1977; Hetheridge C, 2011, BIOCHEM SOC T, V39, P1597, DOI 10.1042/BST20110738; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Hood JL, 2009, LAB INVEST, V89, P1317, DOI 10.1038/labinvest.2009.94; Jiang WG, 2006, INT J MOL MED, V18, P981; Jones JL, 2010, BRAIN, V133, P2232, DOI 10.1093/brain/awq176; Junji W, 2010, ANTICANCER RES, V30, P3747; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7; LORIES V, 1989, J BIOL CHEM, V264, P7009; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Mesker WE, 2009, CELL ONCOL, V31, P169, DOI 10.3233/CLO-2009-0478; Mitchell JP, 2008, J IMMUNOL METHODS, V335, P98, DOI 10.1016/j.jim.2008.03.001; Moorman AM, 2012, EJSO-EUR J SURG ONC, V38, P307, DOI 10.1016/j.ejso.2012.01.002; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Olumi AF, 1999, CANCER RES, V59, P5002; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24; RICHMAN PI, 1987, J CLIN PATHOL, V40, P593, DOI 10.1136/jcp.40.6.593; Sheldon H, 2010, BLOOD, V116, P2385, DOI 10.1182/blood-2009-08-239228; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Verona EV, 2007, CANCER RES, V67, P5737, DOI 10.1158/0008-5472.CAN-07-0444; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Webber J, 2009, J BIOL CHEM, V284, P9083, DOI 10.1074/jbc.M806989200; Welton JL, 2010, MOL CELL PROTEOMICS, V9, P1324, DOI 10.1074/mcp.M000063-MCP201; Yanagisawa N, 2007, HUM PATHOL, V38, P1611, DOI 10.1016/j.humpath.2007.04.008; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	43	198	211	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					319	331		10.1038/onc.2013.560	http://dx.doi.org/10.1038/onc.2013.560			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY		Green Accepted			2022-12-17	WOS:000348145500006
J	Baker, AM; Bird, D; Lang, G; Cox, TR; Erler, JT				Baker, A-M; Bird, D.; Lang, G.; Cox, T. R.; Erler, J. T.			Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK	ONCOGENE			English	Article						colorectal cancer; metastasis; lysyl oxidase; focal adhesion kinase	FOCAL ADHESION KINASE; TUMOR-GROWTH; METASTASIS; TENSION; CELLS; SRC	The extracellular, matrix-modifying enzyme lysyl oxidase (LOX) has recently been linked to colorectal cancer (CRC) progression, in particular to the stages of invasion and metastasis. In this report, we use cell lines expressing a catalytically inactive mutant form of LOX to show that catalytic activity is required for LOX-mediated effects on proliferation and invasion in both in vitro and in vivo models of CRC. Furthermore, we use rheology to measure the relative stiffness of modified collagen matrices and subcutaneous tumors, and show that LOX-induced collagen cross-linking results in stiffening of the matrix both in vitro and in vivo. We observe a strong association between matrix stiffness and activation of the FAK (focal adhesion kinase)/SRC-signaling pathway, with a stiffer environment resulting in increased FAK/SRC phosphorylation and a more proliferative and invasive phenotype. We are the first to show a direct relationship between LOX enzymatic activity and tissue stiffness, and to demonstrate a role for stiffness in driving CRC progression. Our findings provide significant evidence to suggest that therapeutic inhibition of LOX activity may provide a novel effective treatment option for patients with metastatic CRC. Oncogene (2013) 32, 1863-1868; doi: 10.1038/onc.2012.202; published online 28 May 2012	[Baker, A-M; Bird, D.; Lang, G.; Cox, T. R.; Erler, J. T.] Inst Canc Res, Div Canc Biol, Hypoxia & Metastasis Team, London SW3 6JB, England; [Bird, D.; Lang, G.; Cox, T. R.; Erler, J. T.] Inst Canc Res, Div Canc Biol, CRUK Tumour Cell Signalling Unit, London SW3 6JB, England; [Cox, T. R.; Erler, J. T.] Univ Copenhagen, BRIC, DK-2200 Copenhagen N, Denmark	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Copenhagen	Erler, JT (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen N, Denmark.	janine.erler@bric.ku.dk		Baker, Ann-Marie/0000-0001-8905-9137; Cox, Thomas/0000-0001-9294-1745; Erler, Janine/0000-0001-8675-6527	Medical Research Council [G0800102]; Institute of Cancer Research, Cancer Research UK [C107/A10433]; BRIC; Worldwide Cancer Research [09-0796] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Institute of Cancer Research, Cancer Research UK(Cancer Research UK); BRIC; Worldwide Cancer Research	We would like to thank the staff of the BSU and histopathology departments at the Institute of Cancer Research for assistance with in vivo work and processing of tissue samples. Funding was provided by the Medical Research Council (G0800102 to AMB), the Institute of Cancer Research (JTE), Cancer Research UK (C107/A10433 to TRC, DB, GL and JTE) and BRIC (TRC and JTE).	Baker AM, 2011, JNCI-J NATL CANCER I, V103, P407, DOI 10.1093/jnci/djq569; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Colpaert C, 2001, AM J SURG PATHOL, V25, P1557, DOI 10.1097/00000478-200112000-00016; Csiszar K, 2002, INT J CANCER, V97, P636, DOI 10.1002/ijc.10035; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Girton TS, 1999, J BIOMED MATER RES, V46, P87, DOI 10.1002/(SICI)1097-4636(199907)46:1<87::AID-JBM10>3.0.CO;2-K; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kim Y, 2009, ONCOL REP, V22, P799, DOI 10.3892/or_00000502; Le QT, 2009, J CLIN ONCOL, V27, P4281, DOI 10.1200/JCO.2008.20.6003; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Pez F, 2011, CANCER RES, V71, P1647, DOI 10.1158/0008-5472.CAN-10-1516; Samuel MS, 2011, CANCER CELL, V19, P776, DOI 10.1016/j.ccr.2011.05.008; Sinkus R, 2000, PHYS MED BIOL, V45, P1649, DOI 10.1088/0031-9155/45/6/317; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tilghman RW, 2008, SEMIN CANCER BIOL, V18, P45, DOI 10.1016/j.semcancer.2007.08.002	18	198	202	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1863	1868		10.1038/onc.2012.202	http://dx.doi.org/10.1038/onc.2012.202			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22641216				2022-12-17	WOS:000317043900012
J	Tsai, WL; Chung, RT				Tsai, W-L; Chung, R. T.			Viral hepatocarcinogenesis	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis B virus; hepatitis C virus; genomics; signaling pathways pathogenesis	HEPATITIS-B-VIRUS; HCV CORE PROTEIN; COMPARATIVE GENOMIC HYBRIDIZATION; NONSTRUCTURAL 5A PROTEIN; CHRONIC LIVER-DISEASE; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA RISK; ENDOPLASMIC-RETICULUM STRESS; INDUCED OXIDATIVE STRESS; C-VIRUS	Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Despite recent advances in the diagnosis and treatment of HCC, its prognosis remains dismal. Infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major risk factors for HCC. Although both are hepatotropic viral infections, there are important differences between the oncogenic mechanisms of these two viruses. In addition to the oncogenic potential of its viral proteins, HBV, as a DNA virus, can integrate into host DNA and directly transform hepatocytes. In contrast, HCV, an RNA virus, is unable to integrate into the host genome, and viral protein expression has a more critical function in hepatocarcinogenesis. Both HBV and HCV proteins have been implicated in disrupting cellular signal transduction pathways that lead to unchecked cell growth. Most HCC develops in the cirrhotic liver, but the linkage between cirrhosis and HCC is likely multifactorial. In this review, we summarize current knowledge regarding the pathogenetic mechanisms of viral HCC. Oncogene (2010) 29, 2309-2324; doi:10.1038/onc.2010.36; published online 15 March 2010	[Tsai, W-L; Chung, R. T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit,Dept Med, Boston, MA 02114 USA; [Tsai, W-L] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan	Harvard University; Harvard Medical School; Massachusetts General Hospital; Kaohsiung Veterans General Hospital	Chung, RT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit,Dept Med, 55 Fruit St,Warren 1007, Boston, MA 02114 USA.	rtchung@partners.org			NIH [DK078772, AI069939]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK078772] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH Grants DK078772 and AI069939 (both to RTC).	Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; Anzola M, 2004, J VIRAL HEPATITIS, V11, P383, DOI 10.1111/j.1365-2893.2004.00521.x; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Arora P, 2008, CANCER LETT, V261, P244, DOI 10.1016/j.canlet.2007.11.033; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; Barth H, 2008, J HEPATOL, V49, P134, DOI 10.1016/j.jhep.2008.03.012; Bassett SE, 1999, HEPATOLOGY, V29, P1884, DOI 10.1002/hep.510290623; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bonte D, 2004, ARCH VIROL, V149, P1353, DOI 10.1007/s00705-003-0291-6; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Branda M, 2006, HEPATOLOGY, V43, P891, DOI 10.1002/hep.21196; BRECHOT C, 1980, NATURE, V286, P533, DOI 10.1038/286533a0; Bureau C, 2001, J BIOL CHEM, V276, P23077, DOI 10.1074/jbc.M100698200; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Caldwell S, 2009, J GASTROENTEROL, V44, P96, DOI 10.1007/s00535-008-2258-6; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; Cassiman D, 2001, HEPATOLOGY, V33, P148, DOI 10.1053/jhep.2001.20793; Chami M, 2006, BBA-MOL CELL RES, V1763, P1344, DOI 10.1016/j.bbamcr.2006.09.025; Chan HLY, 2008, J CLIN ONCOL, V26, P177, DOI 10.1200/JCO.2007.13.2043; Chan HLY, 2004, GUT, V53, P1494, DOI 10.1136/gut.2003.033324; Chen CH, 2007, AM J TROP MED HYG, V77, P747, DOI 10.4269/ajtmh.2007.77.747; Chen CJ, 2009, HEPATOLOGY, V49, pS72, DOI 10.1002/hep.22884; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Chen J, 2007, J VIROL, V81, P6757, DOI 10.1128/JVI.00172-07; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chisari FV, 2005, NATURE, V436, P930, DOI 10.1038/nature04076; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chiu CM, 2007, P NATL ACAD SCI USA, V104, P2571, DOI 10.1073/pnas.0609498104; Cho JW, 2001, BBA-MOL CELL RES, V1538, P59, DOI 10.1016/S0167-4889(00)00137-3; Choi J, 2006, AM J PHYSIOL-GASTR L, V290, pG847, DOI 10.1152/ajpgi.00522.2005; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Chou YC, 2008, GUT, V57, P91, DOI 10.1136/gut.2006.114066; Chu CJ, 2002, GASTROENTEROLOGY, V122, P1756, DOI 10.1053/gast.2002.33588; Chung YL, 2003, INT J CANCER, V107, P65, DOI 10.1002/ijc.11303; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; Czaja MJ, 2007, SEMIN LIVER DIS, V27, P378, DOI 10.1055/s-2007-991514; Dandri M, 2002, HEPATOLOGY, V35, P217, DOI 10.1053/jhep.2002.30203; de Lucas S, 2003, ANTIVIR RES, V60, P117, DOI 10.1016/j.antiviral.2003.08.006; Deng L, 2006, J GEN VIROL, V87, P1703, DOI 10.1099/vir.0.81735-0; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Donato F, 2002, AM J EPIDEMIOL, V155, P323, DOI 10.1093/aje/155.4.323; Ebara M, 2003, ONCOLOGY-BASEL, V65, P323, DOI 10.1159/000074645; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Fang ZL, 2008, AM J GASTROENTEROL, V103, P2254, DOI 10.1111/j.1572-0241.2008.01974.x; Fattovich G, 2003, SEMIN LIVER DIS, V23, P47, DOI 10.1055/s-2003-37590; Feitelson MA, 2007, CANCER LETT, V252, P157, DOI 10.1016/j.canlet.2006.11.010; Feitelson MA, 2009, CANCER LETT, V286, P69, DOI 10.1016/j.canlet.2008.12.010; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; Fujie H, 2001, GASTROENTEROLOGY, V120, P1564, DOI 10.1053/gast.2001.24501; FUJIO K, 1994, LAB INVEST, V70, P511; Fukutomi T, 2005, HEPATOLOGY, V41, P1096, DOI 10.1002/hep.20668; Furutani T, 2006, GASTROENTEROLOGY, V130, P2087, DOI 10.1053/j.gastro.2006.02.060; Gaudio E, 2009, DIGEST LIVER DIS, V41, P455, DOI 10.1016/j.dld.2009.03.009; Ghosh AK, 2000, VIRUS RES, V67, P173, DOI 10.1016/S0168-1702(00)00141-6; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gu X, 2010, HUM GENET, V127, P75, DOI 10.1007/s00439-009-0750-6; Guerrero RB, 2005, J HEPATOL, V42, P760, DOI 10.1016/j.jhep.2005.02.005; Hassan M, 2005, VIROLOGY, V333, P324, DOI 10.1016/j.virol.2005.01.008; Hassan M, 2007, CELL SIGNAL, V19, P301, DOI 10.1016/j.cellsig.2006.07.002; Hassan M, 2009, HEPATOLOGY, V49, P1469, DOI 10.1002/hep.22849; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Hildt E, 2002, EMBO J, V21, P525, DOI 10.1093/emboj/21.4.525; Hirankarn N, 2006, WORLD J GASTROENTERO, V12, P776, DOI 10.3748/wjg.v12.i5.776; Honda M, 2006, HEPATOLOGY, V44, P1122, DOI 10.1002/hep.21383; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Hourigan LF, 1999, HEPATOLOGY, V29, P1215, DOI 10.1002/hep.510290401; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Iizuka N, 2002, CANCER RES, V62, P3939; Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016; Irshad M, 2006, MED PRIN PRACT, V15, P405, DOI 10.1159/000095485; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.0.CO;2-Z; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kamegaya Y, 2005, HEPATOLOGY, V41, P660, DOI 10.1002/hep.20621; Kanda T, 2008, J VIROL, V82, P11066, DOI 10.1128/JVI.01300-08; Kao JH, 2000, GASTROENTEROLOGY, V118, P554, DOI 10.1016/S0016-5085(00)70261-7; Kao JH, 2003, GASTROENTEROLOGY, V124, P327, DOI 10.1053/gast.2003.50053; Kato J, 2007, J GASTROENTEROL, V42, P830, DOI 10.1007/s00535-007-2095-z; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; Keasler VV, 2007, J VIROL, V81, P2656, DOI 10.1128/JVI.02020-06; Kew MC, 2009, CANCER LETT, V286, P38, DOI 10.1016/j.canlet.2008.11.001; Kidd-Ljunggren K, 2002, J GEN VIROL, V83, P1267, DOI 10.1099/0022-1317-83-6-1267; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim KH, 2007, GASTROENTEROLOGY, V132, P1955, DOI 10.1053/j.gastro.2007.03.039; Kim K, 2008, BIOCHEM J, V416, P219, DOI 10.1042/BJ20081336; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; Koike K, 2007, HEPATOL RES, V37, pS115, DOI 10.1111/j.1872-034X.2007.00173.x; Koike K, 2009, J GASTROENTEROL, V44, P82, DOI 10.1007/s00535-008-2276-4; Kordes C, 2007, BIOCHEM BIOPH RES CO, V352, P410, DOI 10.1016/j.bbrc.2006.11.029; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Kremsdorf D, 2006, ONCOGENE, V25, P3823, DOI 10.1038/sj.onc.1209559; Kummee P, 2007, J VIRAL HEPATITIS, V14, P841, DOI 10.1111/j.1365-2893.2007.00880.x; Kuo MT, 2006, MOL CARCINOGEN, V45, P701, DOI 10.1002/mc.20240; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Kusano N, 2002, CANCER, V94, P746, DOI 10.1002/cncr.10254; Kwun HJ, 2003, J VIRAL HEPATITIS, V10, P249, DOI 10.1046/j.1365-2893.2003.00434.x; Kwun HJ, 2001, J GEN VIROL, V82, P2235, DOI 10.1099/0022-1317-82-9-2235; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Leenders MWH, 2008, WORLD J GASTROENTERO, V14, P6915, DOI 10.3748/wjg.14.6915; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li BZ, 2007, VIRUS RES, V124, P44, DOI 10.1016/j.virusres.2006.09.011; Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu CJ, 2005, LIVER INT, V25, P1097, DOI 10.1111/j.1478-3231.2005.01177.x; Liu H, 2007, BIOCHEM BIOPH RES CO, V355, P379, DOI 10.1016/j.bbrc.2007.01.160; Livingston SE, 2007, J INFECT DIS, V195, P5, DOI 10.1086/509894; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; Locarnini S, 2003, SEMIN LIVER DIS, V23, P5, DOI 10.1055/s-2003-37587; Lonardo A, 2004, GASTROENTEROLOGY, V126, P586, DOI 10.1053/j.gastro.2003.11.020; Longato L, 2009, HEPATOLOGY, V49, P1935, DOI 10.1002/hep.22856; Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361; Luber B, 1996, ONCOGENE, V12, P1597; Machida K, 2006, J VIROL, V80, P7199, DOI 10.1128/JVI.00321-06; Mahmood S, 2004, ANTIOXID REDOX SIGN, V6, P19, DOI 10.1089/152308604771978318; Majumder M, 2003, FEBS LETT, V555, P528, DOI 10.1016/S0014-5793(03)01337-1; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Martin-Lluesma S, 2008, HEPATOLOGY, V48, P1467, DOI 10.1002/hep.22542; Martin-Vilchez S, 2008, HEPATOLOGY, V47, P1872, DOI 10.1002/hep.22265; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mas VR, 2009, MOL MED, V15, P85, DOI 10.2119/molmed.2008.00110; Matsuzaki K, 2007, HEPATOLOGY, V46, P48, DOI 10.1002/hep.21672; Matsuzaki K, 2009, FRONT BIOSCI-LANDMRK, V14, P2923, DOI 10.2741/3423; Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366; Missiha SB, 2008, GASTROENTEROLOGY, V134, P1699, DOI 10.1053/j.gastro.2008.02.069; Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 2001, CANCER RES, V61, P4365; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Moriyama M, 2006, DIGEST DIS SCI, V51, P1967, DOI 10.1007/s10620-005-9051-7; Murakami Y, 2005, GUT, V54, P1162, DOI 10.1136/gut.2004.054452; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Myung SJ, 2007, FEBS LETT, V581, P2954, DOI 10.1016/j.febslet.2007.05.050; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; Naas T, 2005, J GEN VIROL, V86, P2185, DOI 10.1099/vir.0.80969-0; Newell P, 2008, J HEPATOL, V48, P858, DOI 10.1016/j.jhep.2008.01.008; Niki T, 1999, HEPATOLOGY, V29, P520, DOI 10.1002/hep.510290232; Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110; Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364; Oh JC, 2003, EXP MOL MED, V35, P301, DOI 10.1038/emm.2003.41; Ohata K, 2003, CANCER-AM CANCER SOC, V97, P3036, DOI 10.1002/cncr.11427; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Okabe H, 2001, CANCER RES, V61, P2129; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Pang R, 2007, GASTROENTEROLOGY, V132, P1088, DOI 10.1053/j.gastro.2006.12.030; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parsons CJ, 2007, J GASTROEN HEPATOL, V22, pS79, DOI 10.1111/j.1440-1746.2006.04659.x; Pekow JR, 2007, CANCER-AM CANCER SOC, V109, P2490, DOI 10.1002/cncr.22701; Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013; Pinzani M, 1996, AM J PATHOL, V148, P785; Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014; Qadri I, 2004, BIOCHEM J, V378, P919, DOI 10.1042/BJ20031587; QADRI I, 2002, BIOCHIM BIOPHYS ACTA, V21, P193; Qi P, 2009, CANCER IMMUNOL IMMUN, V58, P1433, DOI 10.1007/s00262-009-0660-4; Ray RB, 1997, J BIOL CHEM, V272, P10983; Roskams T, 2006, J HEPATOL, V45, P1, DOI 10.1016/j.jhep.2006.05.002; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Schaefer S, 2005, J VIRAL HEPATITIS, V12, P111, DOI 10.1111/j.1365-2893.2005.00584.x; SCHLUTER V, 1994, ONCOGENE, V9, P3335; Severi T, 2007, CHEM-BIOL INTERACT, V168, P128, DOI 10.1016/j.cbi.2007.03.006; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; Shin HD, 2003, HUM MOL GENET, V12, P901, DOI 10.1093/hmg/ddg104; Shin JY, 2005, EXP MOL MED, V37, P138, DOI 10.1038/emm.2005.19; Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sorrell MF, 2009, HEPATOLOGY, V49, pS4, DOI 10.1002/hep.22946; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su PF, 2007, INT J CANCER, V121, P1257, DOI 10.1002/ijc.22849; SUMIDA Y, 2000, J HEPATOL, V13, P159; Sy SMH, 2005, MODERN PATHOL, V18, P686, DOI 10.1038/modpathol.3800345; Tai AW, 2009, J HEPATOL, V50, P412, DOI 10.1016/j.jhep.2008.11.010; Tai PC, 2002, VIROLOGY, V292, P44, DOI 10.1006/viro.2001.1239; Takeya R, 2006, ANTIOXID REDOX SIGN, V8, P1523, DOI 10.1089/ars.2006.8.1523; Tanaka N, 2008, J CLIN INVEST, V118, P683, DOI 10.1172/JCI33594; Tanaka N, 2008, INT J CANCER, V122, P124, DOI 10.1002/ijc.23056; Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x; Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581; Taniguchi H, 2004, J MED VIROL, V72, P52, DOI 10.1002/jmv.10545; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Tennant BC, 2004, GASTROENTEROLOGY, V127, pS283, DOI 10.1053/j.gastro.2004.09.043; Thakur V, 2002, J GASTROEN HEPATOL, V17, P165, DOI 10.1046/j.1440-1746.2002.02605.x; Tsuchiya H, 2009, GASTROENTEROLOGY, V136, P341, DOI 10.1053/j.gastro.2008.09.027; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Villanueva A, 2007, SEMIN LIVER DIS, V27, P55, DOI 10.1055/s-2006-960171; Wang HC, 2006, CANCER SCI, V97, P683, DOI 10.1111/j.1349-7006.2006.00235.x; WANG J, 1992, ONCOGENE, V7, P1653; Wang T, 2006, J GASTROEN HEPATOL, V21, pS34, DOI 10.1111/j.1440-1746.2006.04591.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wong CM, 2008, LIVER INT, V28, P160, DOI 10.1111/j.1478-3231.2007.01637.x; Wu CF, 2008, CARCINOGENESIS, V29, P106, DOI 10.1093/carcin/bgm252; Wu SC, 2008, J BIOL CHEM, V283, P29396, DOI 10.1074/jbc.M802821200; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; Yamanaka T, 2002, BIOCHEM BIOPH RES CO, V294, P528, DOI 10.1016/S0006-291X(02)00508-9; Yanagitani A, 2004, HEPATOLOGY, V40, P366, DOI 10.1002/hep.20335; Yang HI, 2008, JNCI-J NATL CANCER I, V100, P1134, DOI 10.1093/jnci/djn243; Yang JC, 2009, HEPATOLOGY, V49, P1962, DOI 10.1002/hep.22889; Yang L, 2008, J HEPATOL, V48, P98, DOI 10.1016/j.jhep.2007.07.032; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yu MW, 2005, JNCI-J NATL CANCER I, V97, P265, DOI 10.1093/jnci/dji043; Yu MW, 1999, AM J EPIDEMIOL, V150, P367, DOI 10.1093/oxfordjournals.aje.a010016; Yu MW, 2003, J NATL CANCER I, V95, P1485, DOI 10.1093/jnci/djg051; Yu MW, 2001, J NATL CANCER I, V93, P1644, DOI 10.1093/jnci/93.21.1644; Yuan JM, 2006, JNCI-J NATL CANCER I, V98, P482, DOI 10.1093/jnci/djj104; YUAN JM, 2009, CANCER EPIDEM BIOMAR, V18, P1762; Zemel R, 2001, J VIRAL HEPATITIS, V8, P96, DOI 10.1046/j.1365-2893.2001.00283.x; Zhao LJ, 2005, EXP CELL RES, V305, P23, DOI 10.1016/j.yexcr.2004.12.024; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	234	198	212	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2309	2324		10.1038/onc.2010.36	http://dx.doi.org/10.1038/onc.2010.36			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20228847	Green Accepted			2022-12-17	WOS:000276951500001
J	Usary, J; Llaca, V; Karaca, G; Presswala, S; Karaca, M; He, XP; Langerod, A; Karesen, R; Oh, DS; Dressler, LG; Lonning, PE; Strausberg, RL; Chanock, S; Borresen-Dale, AL; Perou, CM				Usary, J; Llaca, V; Karaca, G; Presswala, S; Karaca, M; He, XP; Langerod, A; Karesen, R; Oh, DS; Dressler, LG; Lonning, PE; Strausberg, RL; Chanock, S; Borresen-Dale, AL; Perou, CM			Mutation of GATA3 in human breast tumors	ONCOGENE			English	Article						breast cancer; microarrays; estrogen receptor; transcription factor; GATA3	GENE-EXPRESSION PATTERNS; CELL RECEPTOR-ALPHA; TRANSCRIPTION FACTOR; ACQUIRED MUTATIONS; ESTROGEN-RECEPTOR; NERVOUS-SYSTEM; HDR SYNDROME; CANCER; BINDING; BENIGN	GATA3 is an essential transcription factor that was first identified as a regulator of immune cell function. In recent microarray analyses of human breast tumors, both normal breast luminal epithelium and estrogen receptor (ESR1)positive tumors showed high expression of GATA3. We sequenced genomic DNA from 111 breast tumors and three breast-tumor-derived cell lines and identified somatic mutations of GATA3 in five tumors and the MCF-7 cell line. These mutations cluster in the vicinity of the highly conserved second zinc-finger that is required for DNA binding. In addition to these five, we identified using cDNA sequencing a unique mis-splicing variant that caused a frameshift mutation. One of the somatic mutations we identified was identical to a germline GATA3 mutation reported in two kindreds with HDR syndrome/OMIM # 146255, which is an autosomal dominant syndrome caused by the haplo-insufficiency of GATA3. The ectopic expression of GATA3 in human 293T cells caused the induction of 73 genes including six cytokeratins, and inhibited cell line doubling times. These data suggest that GATA3 is involved in growth control and the maintenance of the differentiated state in epithelial cells, and that GATA3 variants may contribute to tumorigenesis in ESR1-positive breast tumors.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; NCI, Sect Genom Variat, Pediat Oncol Branch, Ctr Adv Technol, Bethesda, MD 20892 USA; Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway; Ullevaal Univ Hosp, Dept Surg, Oslo, Norway; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Haukeland Hosp, Dept Med, Sect Oncol, N-5021 Bergen, Norway; Inst Genom Res, Rockville, MD 20850 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; University of Oslo; University of North Carolina; University of North Carolina Chapel Hill; University of Bergen; Haukeland University Hospital; J. Craig Venter Institute; University of North Carolina; University of North Carolina Chapel Hill	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	cperou@med.unc.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247; Lonning, Per Eystein/0000-0002-8890-6303	NATIONAL CANCER INSTITUTE [P50CA058223, Z01SC010083] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58223-09A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOCKER W, 1992, VIRCHOWS ARCH A, V421, P315, DOI 10.1007/BF01660978; Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FINLIN BS, 2001, J BIOL CHEM, V31, P31; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Gruvberger S, 2001, CANCER RES, V61, P5979; GUELSTEIN VI, 1988, INT J CANCER, V42, P147, DOI 10.1002/ijc.2910420202; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Hoch RV, 1999, INT J CANCER, V84, P122; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Ma GT, 1997, DEVELOPMENT, V124, P907; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muroya K, 2001, J MED GENET, V38, P374, DOI 10.1136/jmg.38.6.374; Nawijn MC, 2001, J IMMUNOL, V167, P715, DOI 10.4049/jimmunol.167.2.715; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; ORKIN SH, 1992, BLOOD, V80, P575; Packer BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531; Sena-Esteves M, 1999, J VIROL, V73, P10426, DOI 10.1128/JVI.73.12.10426-10439.1999; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tavassoli FA, 1992, PATHOLOGY BREAST, P193; Troester MA, 2002, TOXICOL SCI, V68, P314, DOI 10.1093/toxsci/68.2.314; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201	41	198	205	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7669	7678		10.1038/sj.onc.1207966	http://dx.doi.org/10.1038/sj.onc.1207966			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361840				2022-12-17	WOS:000224306700008
J	Agarwal, C; Singh, RP; Dhanalakshmi, S; Tyagi, AK; Tecklenburg, M; Sclafani, RA; Agarwal, R				Agarwal, C; Singh, RP; Dhanalakshmi, S; Tyagi, AK; Tecklenburg, M; Sclafani, RA; Agarwal, R			Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells	ONCOGENE			English	Article						cyclin-dependent kinase inhibitor; apoptosis; colon cancer; silibinin	FLAVONOID ANTIOXIDANT SILYMARIN; CANCER CELLS; PROTEIN-KINASE; DU145 CELLS; PROGNOSTIC-SIGNIFICANCE; P27(KIP1) PROTEIN; GROWTH-INHIBITION; COLORECTAL-CANCER; SILYBUM-MARIANUM; MAMMALIAN-CELLS	Silymarin, a defined mixture of natural flavonoid, has recently been shown to have potent cancer chemopreventive efficacy against colon carcinogenesis in rat model; however, the mechanism of such efficacy is not elucidated. Here, using pure active agent in silymarin, namely silibinin, we show its antiproliferative and apoptotic effects, and associated molecular alterations in human colon carcinoma HT-29 cells. Silibinin treatment of cells at 50-100 mug/ml doses resulted in a moderate to very strong growth inhibition in a dose- and a time-dependent manner, which was largely due to a G0/G1 arrest in cell cycle progression; higher dose and longer treatment time also caused a G2/M arrest. In mechanistic studies related its effect on cell cycle progression, silibinin treatment resulted in an upregulation of Kip1/p27 and Cip1/p21 protein as well as mRNA levels, and decreased CDK2, CDK4, cyclin E and cyclin D1 protein levels together with an inhibition in CDK2 and CDK4 kinase activities. In other studies, we observed that G2/M arrest by silibinin was associated with a decrease in cdc25C, cdc2/p34 and cyclin B1 protein levels, as well as cdc2/p34 kinase activity. In the studies assessing biological fate of silibinin-treated cells, silibinin-induced cell cycle arrest and growth inhibition were not associated with cellular differentiation, but caused apoptotic death. The quantitative apoptosis analysis showed up to 15% apoptotic cell death after 48 h of silibinin treatment. Interestingly, silibinin-induced apoptosis in HT-29 cells was independent of caspases activation, as all caspases inhibitor did not reverse silibinin-induced apoptosis. This observation was further confirmed by the findings showing a lack in caspases activity increase and caspases and PARP cleavage as well as a lack in cytochrome c release in cytosol following silibinin treatment of HT-29 cells. Additional studies conducted in mice showed that doses found effective in HT-29 cells are achievable in plasma, which increases the significance of the present findings and their possible translation in in vivo anticancer efficacy of silibinin against colon cancer. Together, these results identify molecular mechanisms of silibinin efficacy as a cell cycle regulator and apoptosis inducer in human colon carcinoma HT-29 cells, and justify further studies to investigate potential usefulness of this nontoxic agent in colon cancer prevention and intervention.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Univ Colorado Canc Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th St,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu		Sclafani, Robert/0000-0002-1100-6489; Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R03CA099079, R01CA064514, R29CA064514, R01CA091883] Funding Source: NIH RePORTER; NCI NIH HHS [CA91883, CA99079, CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DING QM, 1998, AM J PHYSIOL, V275, pC1191; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Flora K, 1998, AM J GASTROENTEROL, V93, P139, DOI 10.1111/j.1572-0241.1998.00139.x; GILFIX BM, 1985, J BIOL CHEM, V260, P4026; GRANA X, 1995, ONCOGENE, V11, P211; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAHN G, 1968, ARZNEI-FORSCHUNG, V18, P698; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jordan RCK, 1998, AM J PATHOL, V152, P585; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kohno H, 2002, INT J CANCER, V101, P461, DOI 10.1002/ijc.10625; Lahiri-Chatterjee M, 1999, CANCER RES, V59, P622; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Moragoda L, 2001, ANTICANCER RES, V21, P873; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Samowitz WS, 2002, INT J CANCER, V99, P597, DOI 10.1002/ijc.10405; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh RP, 2002, CARCINOGENESIS, V23, P499, DOI 10.1093/carcin/23.3.499; Singh RP, 2002, CANCER RES, V62, P3063; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; TSAI LH, 1993, ONCOGENE, V8, P1593; Tyagi AK, 2002, CLIN CANCER RES, V8, P3512; VOGEL G, 1975, ARZNEIMITTEL-FORSCH, V25, P82; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1997, BIOCHEM BIOPH RES CO, V239, P334, DOI 10.1006/bbrc.1997.7375; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi XL, 1999, BIOCHEM BIOPH RES CO, V263, P528, DOI 10.1006/bbrc.1999.1398; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	51	198	212	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8271	8282		10.1038/sj.onc.1207158	http://dx.doi.org/10.1038/sj.onc.1207158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614451				2022-12-17	WOS:000186541500006
J	Thorland, EC; Myers, SL; Gostout, BS; Smith, DI				Thorland, EC; Myers, SL; Gostout, BS; Smith, DI			Common fragile sites are preferential targets for HPV16 integrations in cervical tumors	ONCOGENE			English	Article						common fragile sites; cervical cancer; human papillomavirus; viral integration; RS-PCR	HUMAN-PAPILLOMAVIRUS TYPE-16; VIRAL INTEGRATION; MOLECULAR CHARACTERIZATION; CELL-LINE; E2 GENE; CANCER; CARCINOMA; REGION; DNA; ONCOGENES	The development of cervical cancer is highly associated with human papillomavirus (HPV) infection. HPV integration into the genome of infected cervical cells is temporally associated with the acquisition of the malignant phenotype. A relationship between the sites of HPV integration in cervical cancer and the position of the common fragile sites (CFSs) has been observed at both the cytogenetic and molecular levels. To further explore this relationship at the molecular level, we used RS-PCR to rapidly isolate cellular sequences flanking the sites of HPV16 integration in 26 primary cervical tumors. Human bacterial artificial chromosome clones were isolated based on these flanking sequences and used as probes for fluorescence in situ hybridization on aphidicolin-stimulated metaphases. Our data demonstrate that 11/23 HPV16 integrations in cervical tumors occurred within CFSs (P < 0.001). In addition, we show that deletions and complex rearrangements frequently occur in the cellular sequences targeted by the integrations and that integrations cluster in FRA13C (13q22), FRA3B (3p14.2), and FRA17B (17q23). Finally, our data suggest that cellular genes, such as Notch 1, are disrupted by the HPV16 integrations, which may contribute to the malignant phenotype.	Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Tumor Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol, Hilton 8,200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BauerHofmann R, 1996, VIROLOGY, V217, P33, DOI 10.1006/viro.1996.0090; BECKER NA, 2002, IN PRESS ONCOGENE; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Choo KB, 1996, J MED VIROL, V49, P15, DOI 10.1002/(SICI)1096-9071(199605)49:1<15::AID-JMV3>3.3.CO;2-4; CHOO KB, 1995, CANCER LETT, V93, P249, DOI 10.1016/0304-3835(95)03817-G; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CHOO KB, 1990, VIROLOGY, V178, P621, DOI 10.1016/0042-6822(90)90366-Y; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; Dong JT, 2000, CANCER RES, V60, P3880; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GLOVER TW, 1986, CANCER GENET CYTOGEN, V19, P141, DOI 10.1016/0165-4608(86)90381-X; Gostout BS, 1998, AM J OBSTET GYNECOL, V179, P56, DOI 10.1016/S0002-9378(98)70251-0; HECHT F, 1988, CANCER GENET CYTOGEN, V31, P17, DOI 10.1016/0165-4608(88)90005-2; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Ji YG, 2000, GENOME RES, V10, P597, DOI 10.1101/gr.10.5.597; KAHN T, 1994, CANCER RES, V54, P1305; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Kalantari M, 1998, INT J GYNECOL PATHOL, V17, P146, DOI 10.1097/00004347-199804000-00009; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mangelsdorf M, 2000, CANCER RES, V60, P1683; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; Paige AJW, 2000, CANCER RES, V60, P1690; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; POPESCU NC, 1989, CANCER GENET CYTOGEN, V42, P157, DOI 10.1016/0165-4608(89)90084-8; POPESCU NC, 1990, HUM GENET, V84, P383; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Sarkar G, 1993, PCR Methods Appl, V2, P318; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith DI, 1998, INT J ONCOL, V12, P187; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thorland EC, 2000, CANCER RES, V60, P5916; VERMA RS, 1989, HUMAN CHROMOSOME MAN; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	61	198	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1225	1237		10.1038/sj.onc.1206170	http://dx.doi.org/10.1038/sj.onc.1206170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606949				2022-12-17	WOS:000181249700011
J	Yang, L; Xia, L; Wu, DY; Wang, HB; Chansky, HA; Schubach, WH; Hickstein, DD; Zhang, Y				Yang, L; Xia, L; Wu, DY; Wang, HB; Chansky, HA; Schubach, WH; Hickstein, DD; Zhang, Y			Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor	ONCOGENE			English	Article						histone methyltransferase; ESET; ERG	HUMAN MYELOID-LEUKEMIA; EWINGS-SARCOMA; CHROMOSOMAL TRANSLOCATION; EWS-ERG; GENE; PROTEINS; DOMAIN; FAMILY; RNA; METHYLATION	The ets-related gene erg encodes a transcription factor that is implicated in the control of cell growth and differentiation. To identify interacting partners of ERG, we screened a yeast two-hybrid cDNA library constructed from mouse hematopoietic cells using the N-terminal region of ERG as a bait. We isolated a 4.6 kb full-length mouse cDNA encoding a 1307-amino acid protein migrating as a 180 kD band, which was termed ESET (ERG-associated protein with SET domain). ESET is 92% identical to the human protein SETDB1 (SET domain, bifurcated 1). The interaction between ESET and ERG was supported by in vitro pull-down using glutathione S-transferase (GST) fusion protein, by transfection and co-immunoprecipitation experiments, and by association of endogenous SETDB1 with ERG. Since ESET possesses evolutionarily conserved SET, preSET, and postSET domains implicated in histone methylation, we tested the ability of ESET to methylate core histones. The results of these studies demonstrated that ESET is a histone H3-specific methyltransferase, and that mutations within ESET abolished its methyltransferase activity. Together, these findings raise the possibility that transcription factor ERG may participate in transcriptional regulation through ESET-mediated histone methylation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; NCI, Dept Expt Transplantat & Immunol, Bethesda, MD 20892 USA; Univ Washington, Dept Med Oncol, Seattle, WA 98108 USA; Univ Washington, Dept Orthoped, Seattle, WA 98108 USA; Univ Washington, VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.			Wang, Hengbin/0000-0003-2414-0609	NIGMS NIH HHS [GM63067-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Harte PJ, 1999, CYTOGENET CELL GENET, V84, P83, DOI 10.1159/000015220; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Im YH, 2000, CANCER RES, V60, P1536; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TACHIBANA M, 2001, J BIOL CHEM, V20, P20; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	30	198	207	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					148	152		10.1038/sj.onc.1204998	http://dx.doi.org/10.1038/sj.onc.1204998			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791185				2022-12-17	WOS:000172887800015
J	PerezRoger, I; Solomon, DLC; Sewing, A; Land, H				PerezRoger, I; Solomon, DLC; Sewing, A; Land, H			Myc activation of cyclin E Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes	ONCOGENE			English	Article						cell cycle; Cdk2; cyclin E; Myc; p27; Kip1	C-MYC; DNA-BINDING; DEPENDENT KINASES; PHASE PROGRESSION; PROTEIN; EXPRESSION; G(1); MAX; CELLS; FIBROBLASTS	Induction of the Myc-oestrogen receptor fusion protein (MycER) by 4-OH-tamoxifen (OHT) leads to the activation of Cyclin E/Cyclin-dependent kinase 2 (CycE/Cdk2) complexes followed by the induction of DNA synthesis. As CycE/Cdk2 activity is essential for G1/S transition, we have investigated the mechanism by which Myc can activiate CycE/Cdk2. Our results suggest that this activation may involve at least two Myc-dependent steps: the induction of cyclin E gene transcription followed by accumulation of cyclin E mRNA in a protein synthesis-independent manner and the inhibition of p27(Kip1) association with CycE/Cdk2 complexes containing newly synthesised CycE. As a consequence phosphorylation of CycE-bound Cdk2 by cyclin activating kinase (CAK) is accelerated. We propose a model in which the active newly synthesised CycE/Cdk2 complexes trigger a positive feed-back mechanism to activate preexisting complexes through phosphorylation-dependent p27(Kip1) release.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Pérez Roger, Ignacio/K-1346-2014	Pérez Roger, Ignacio/0000-0002-5564-6912				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Geng Y, 1996, ONCOGENE, V12, P1173; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WIMMEL A, 1994, ONCOGENE, V9, P995	59	198	203	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2373	2381		10.1038/sj.onc.1201197	http://dx.doi.org/10.1038/sj.onc.1201197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188852				2022-12-17	WOS:A1997WZ68000001
J	Borkhardt, A; Repp, R; Haas, OA; Leis, T; Harbott, J; Kreuder, J; Hammermann, J; Henn, T; Lampert, F				Borkhardt, A; Repp, R; Haas, OA; Leis, T; Harbott, J; Kreuder, J; Hammermann, J; Henn, T; Lampert, F			Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23)	ONCOGENE			English	Article						acute leukemias; MLL-rearrangement; AFX-gene; forkhead domain	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ALL-1 GENE; CHROMOSOMAL TRANSLOCATIONS; T(10-11) TRANSLOCATION; DROSOPHILA-TRITHORAX; B-MYB; PROTEIN; FAMILY; REARRANGEMENTS	We report the cloning and characterization of the entire AFX gene which fuses to MLL in acute leukemias with a t(X;11)(q13;q23). AFX consists of two exons and encodes for a protein of 501 amino acids. We found that normal B- and T-cells contain similar levels of AFX mRNA and that both the MLL/AFX as well as the AFX/MLL fusion transcripts are present in the cell line and the ANLL sample with a t(X;11)(q13;q23), The single intron of the AFX gene consists of 3706 nucleotides, It contains five simple sequence repeats with lengths of at least 12 bps, a chi-like octamer sequence (GCA/TGGA/TGG) and several immunoglobulin heptamer-like sequences (GATAGTG) that are distributed throughout the entire AFX intron sequence. In the KARPAS 45 cell line the breakpoints occur at nucleotides 2913/2914 of the AFX intron and at nucleotides 4900/4901 of the breakpoint cluster region of the MLL gene, The AFX protein belongs to the forkhead protein family. It is highly homologous to the human FKHR protein, the gene of which is disrupted by the t(2;13)(q35;q14), a chromosome rearrangement characteristic of alveolar rhabdomyosarcomas. It is noteworthy that the t(X;11)(q13;q23) in the KARPAS 45 cell line and in one acute nonlymphoblastic leukemia (ANLL) disrupts the forkhead domain of the AFX protein exactly at the same amino acids as does the t(2;13)(q35;q14) in case of the FKHR protein. In addition, the 5'-part of the AFX protein contains a conserved hexapeptide motif (QIYEWM) that is homologous to the functionally important conserved hexapeptide QIYPWM upstream of the homeobox domain in Hox proteins. This motif mediates the co-operative DNA binding of Pbx family members and Hox proteins and, therefore, plays an important role in physiologic and oncogenic processes. In acute leukemias with t(X;11)(q13;q23), this hexapeptide motif is separated from the remaining forkhead domain within the AFX protein. The predicted amino acid sequence of AFX differs significantly from the partial AFX protein sequence published previously (Genes, Chromosomes and Cancer, 1994, 11, 79-84). This discrepancy can be explained by the occurrence of two sequencing errors in the earlier work at nucleotide number 783 and 844 (loss of a cytosine residue or guanosine residue, respectively) that lead to two reading frame shifts.	UNIV GIESSEN,DEPT PEDIAT HEMATOL & ONCOL,D-35392 GIESSEN,GERMANY; ST ANNA CHILDRENS HOSP,CHILDRENS CANC INST,A-1090 VIENNA,AUSTRIA	Justus Liebig University Giessen; Saint Anna Children's Hospital			Haas, Oskar/AAM-5794-2020					BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BARLETTA C, 1991, CANCER RES, V51, P3821; BERNARD OA, 1994, ONCOGENE, V9, P1039; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BORKHARDT A, 1994, LEUKEMIA, V8, P549; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHERVINSKY DS, 1995, GENE CHROMOSOME CANC, V14, P76, DOI 10.1002/gcc.2870140114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; Dreyling M. H., 1995, Blood, V86, p430A; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; HROMAS R, 1993, BLOOD, V81, P2854; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARPAS A, 1977, LEUKEMIA RES, V1, P35, DOI 10.1016/0145-2126(77)90063-7; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; NACHEVA E, 1982, HEREDITAS, V97, P273, DOI 10.1111/j.1601-5223.1982.tb00771.x; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; RIENITZ A, 1989, EMBO J, V8, P2879, DOI 10.1002/j.1460-2075.1989.tb08436.x; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; Sambrock J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	46	198	202	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					195	202		10.1038/sj.onc.1200814	http://dx.doi.org/10.1038/sj.onc.1200814			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010221				2022-12-17	WOS:A1997WC81800007
J	MARTI, A; JEHN, B; COSTELLO, E; KEON, N; KE, G; MARTIN, F; JAGGI, R				MARTI, A; JEHN, B; COSTELLO, E; KEON, N; KE, G; MARTIN, F; JAGGI, R			PROTEIN KINASE-A AND AP-1 (C-FOS/JUND) ARE INDUCED DURING APOPTOSIS OF MOUSE MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							GENE-EXPRESSION; NUCLEAR FACTOR; BETA-CASEIN; TISSUE TRANSGLUTAMINASE; TRANSGENIC MICE; FOS EXPRESSION; ONCOGENE FOS; DEATH; JUN; INDUCTION	At weaning the mammary gland undergoes a reductive remodelling process (involution) which is associated with the cessation of milk protein gene expression and programmed cell death of milk-producing epithelial cells. Elevated nuclear protein kinase A (PKA) activity was observed from one day post-lactation, paralleled by increased c-fos, junB, junD and to a lesser extent c-jun mRNA levels. AP-1 DNA binding activity was transiently induced and the AP-1 complex was shown to consist principally of cFos/JunD. Oct-1 DNA binding activity and Oct-1 protein were gradually lost from the gland over the first 4 days of involution, whereas Oct-1 mRNA levels remained unchanged. Comparing nuclear extracts from normal mammary glands with nuclear extracts from glands which had been cleared of all epithelial cells 3 weeks after birth, revealed that PKA activation, AP-1 induction and Oct-1 inactivation all are dependent on the presence of the epithelial compartment. The increased Fos/Jun expression and the inactivation of Oct-1 may be consequences of the increased PKA activity. A similar induction of AP-1 (cFos/JunD) was also observed in the involuting rat ventral prostate pointing to a possible role for AP-1 in programmed cell death.	UNIV BERN,CLIN & EXPTL RES LAB,TIEFENAUSTR 120,CH-3004 BERN,SWITZERLAND; ISREC,CH-1066 EPALINGES,SWITZERLAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PHARMACOL,DUBLIN 4,IRELAND	University of Bern; Swiss Institute Experimental Cancer Research; University College Dublin				Costello, Eithne/0000-0002-0104-8992				ABATE C, 1991, ONCOGENE, V6, P2179; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Angel P, 1992, Matrix Suppl, V1, P156; BANDYK MG, 1990, J UROLOGY, V143, P407, DOI 10.1016/S0022-5347(17)39975-5; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GINZBURG I, 1980, NUCLEIC ACIDS RES, V8, P3553, DOI 10.1093/nar/8.16.3553; GONZALEZMARTIN C, 1992, DEV BRAIN RES, V68, P83, DOI 10.1016/0165-3806(92)90250-Z; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MEDINA D, 1978, BREAST CANCER PLENUM, P47; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; THOMPSON HJ, 1992, CANCER EPIDEM BIOMAR, V1, P597; TOURAY M, 1991, ONCOGENE, V6, P211; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	70	198	198	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1213	1223						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134124				2022-12-17	WOS:A1994NC04800025
J	ADNANE, J; GAUDRAY, P; SIMON, MP; SIMONYLAFONTAINE, J; JEANTEUR, P; THEILLET, C				ADNANE, J; GAUDRAY, P; SIMON, MP; SIMONYLAFONTAINE, J; JEANTEUR, P; THEILLET, C			PROTO-ONCOGENE AMPLIFICATION AND HUMAN-BREAST TUMOR PHENOTYPE	ONCOGENE			English	Article									CTR PAUL LAMARQUE,BIOCHIM LAB,F-34094 MONTPELLIER 2,FRANCE; UER MED & PHARM,LGMCH,F-06034 NICE,FRANCE; CTR PAUL LAMARQUE,VAL AURELLE PARC EUROMED,SERV ANAT PATHOL,F-34094 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,UA 1191,F-34060 MONTPELLIER,FRANCE	Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Theillet, Charles/O-7634-2018; SIMON, Marie-Pierre/B-8017-2012	Theillet, Charles/0000-0001-5555-2759				ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1988, ONCOGENE RES, V3, P139; ALI IU, 1988, BREAST CANCER CELLUL; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BERGER MS, 1988, CANCER RES, V48, P1238; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CROCE CM, 1986, CANCER RES, V46, P6019; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GOMPEL G, 1983, BREAST PRINCIPLES PR, V1, P11; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P150, DOI 10.1159/000132313; GUERIN M, 1988, ONCOGENE RES, V3, P21; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MATHIEUMAHUL D, 1985, HUM GENET, V71, P41, DOI 10.1007/BF00295666; MCGUIRE WL, 1986, CANCER SURV, V5, P527; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; RIOU G, 1987, LANCET, V1, P761; SAINSBURY JRC, 1987, LANCET, V1, P1398; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THEILLET C, 1989, ONCOGENE, V4, P915; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VARLEY JM, 1988, ONCOGENE, V3, P87; WAHL GM, 1986, INT C PROGR CANCER R, P71; ZEILLINGER R, 1989, ONCOGENE, V4, P109; ZHOU DJ, 1989, ONCOGENE, V4, P105; ZHOU DJ, 1988, ONCOGENE, V2, P279	29	198	199	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1389	1395						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2554239				2022-12-17	WOS:A1989AX65900017
J	Martens-Uzunova, ES; Jalava, SE; Dits, NF; van Leenders, GJLH; Moller, S; Trapman, J; Bangma, CH; Litman, T; Visakorpi, T; Jenster, G				Martens-Uzunova, E. S.; Jalava, S. E.; Dits, N. F.; van Leenders, G. J. L. H.; Moller, S.; Trapman, J.; Bangma, C. H.; Litman, T.; Visakorpi, T.; Jenster, G.			Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer	ONCOGENE			English	Article						prostate cancer; microRNA; snoRNA; microarray; deep sequencing; Q-PCR	MICRORNA EXPRESSION; GENE-EXPRESSION; UP-REGULATION; RECEPTOR; SNORNA; ACTIVATION; INVASION; REVEALS; PROFILE; KINASE	Prostate cancer (PCa) is the most frequent male malignancy and the second most common cause of cancer-related death in Western countries. Current clinical and pathological methods are limited in the prediction of postoperative outcome. It is becoming increasingly evident that small non-coding RNA (ncRNA) species are associated with the development and progression of this malignancy. To assess the diversity and abundance of small ncRNAs in PCa, we analyzed the composition of the entire small transcriptome by Illumina/Solexa deep sequencing. We further analyzed the microRNA (miRNA) expression signatures of 102 fresh-frozen patient samples during PCa progression by miRNA microarrays. Both platforms were cross-validated by quantitative reverse transcriptase-PCR. Besides the altered expression of several miRNAs, our deep sequencing analyses revealed strong differential expression of small nucleolar RNAs (snoRNAs) and transfer RNAs (tRNAs). From microarray analysis, we derived a miRNA diagnostic classifier that accurately distinguishes normal from cancer samples. Furthermore, we were able to construct a PCa prognostic predictor that independently forecasts postoperative outcome. Importantly, the majority of miRNAs included in the predictor also exhibit high sequence counts and concordant differential expression in Illumina PCa samples, supported by quantitative reverse transcriptase-PCR. Our findings provide miRNA expression signatures that may serve as an accurate tool for the diagnosis and prognosis of PCa. Oncogene (2012) 31, 978-991; doi:10.1038/onc.2011.304; published online 18 July 2011	[Martens-Uzunova, E. S.; Dits, N. F.; Bangma, C. H.; Jenster, G.] Erasmus MC, Dept Urol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands; [Jalava, S. E.; Visakorpi, T.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; [Jalava, S. E.; Visakorpi, T.] Tampere Univ Hosp, Tampere, Finland; [van Leenders, G. J. L. H.; Trapman, J.] Erasmus MC, Dept Pathol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands; [Moller, S.; Litman, T.] Exiqon AS, Vedbaek, Denmark	Erasmus University Rotterdam; Erasmus MC; Tampere University; Tampere University; Tampere University Hospital; Erasmus University Rotterdam; Erasmus MC; Exiqon	Jenster, G (corresponding author), Erasmus MC, Dept Urol, Josephine Nefkens Inst, Room BE362A,POB 2040, NL-3000 CA Rotterdam, Netherlands.	g.jenster@erasmusmc.nl	Martens-Uzunova, Elena/D-9768-2012	Martens-Uzunova, Elena/0000-0002-5363-2525; Visakorpi, Tapio/0000-0002-5004-0364; Litman, Thomas/0000-0002-6068-901X	European Community [HEALTH-F2-2007-201438]; Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; Tampere University Hospital	European Community(European Commission); Academy of Finland(Academy of Finland); Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Tampere University Hospital	We thank Theo van der Kwast for histo-pathological examination of patient samples. We also thank Mark Wildhagen for providing the coded clinical data. We acknowledge the European Community's Seventh Framework Program (FP7/2007-2013), grant agreement No HEALTH-F2-2007-201438, the Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; and the Medical Research Fund of Tampere University Hospital for their support.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Berezikov E, 2006, NAT GENET, V38, P1375, DOI 10.1038/ng1914; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Brameier M, 2011, NUCLEIC ACIDS RES, V39, P675, DOI 10.1093/nar/gkq776; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Catto JWF, 2011, EUR UROL, V59, P671, DOI 10.1016/j.eururo.2011.01.044; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; de Wit E, 2009, GENOME RES, V19, P2064, DOI 10.1101/gr.093781.109; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; Git A, 2010, RNA, V16, P991, DOI 10.1261/rna.1947110; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Lee JT, 2008, CELL CYCLE, V7, P1745, DOI 10.4161/cc.7.12.6166; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Majid S, 2010, CANCER-AM CANCER SOC, V116, P5637, DOI 10.1002/cncr.25488; Marberger M, 2009, EUR UROL SUPPL, V8, P89, DOI 10.1016/j.eursup.2008.10.003; Marshall L, 2008, NAT REV CANCER, V8, P911, DOI 10.1038/nrc2539; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Michael MZ, 2003, MOL CANCER RES, V1, P882; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Mukherjee R, 2011, BRIT J CANCER, V104, P1920, DOI 10.1038/bjc.2011.163; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Paronetto MP, 2004, AM J PATHOL, V164, P1243, DOI 10.1016/S0002-9440(10)63212-9; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Radmacher MD, 2002, J COMPUT BIOL, V9, P505, DOI 10.1089/106652702760138592; Reis EM, 2004, ONCOGENE, V23, P6684, DOI 10.1038/sj.onc.1207880; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Royo H, 2006, CYTOGENET GENOME RES, V113, P99, DOI 10.1159/000090820; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Szczyrba J, 2010, MOL CANCER RES, V8, P529, DOI 10.1158/1541-7786.MCR-09-0443; Taft RJ, 2009, RNA, V15, P1233, DOI 10.1261/rna.1528909; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Willenbrock H, 2009, RNA, V15, P2028, DOI 10.1261/rna.1699809; Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200	50	197	213	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					978	991		10.1038/onc.2011.304	http://dx.doi.org/10.1038/onc.2011.304			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765474				2022-12-17	WOS:000300709700004
J	Cuevas, BD; Abell, AN; Johnson, GL				Cuevas, B. D.; Abell, A. N.; Johnson, G. L.			Role of mitogen-activated protein kinase kinase kinases in signal integration	ONCOGENE			English	Review						MAPK kinase kinases; MKKKs; signaling hubs	CEREBRAL CAVERNOUS MALFORMATIONS; RENAL-CELL CARCINOMA; RANDOMIZED DISCONTINUATION TRIAL; KAPPA-B PATHWAY; C-JUN; GENE-EXPRESSION; GROWTH-FACTOR; REGULATED KINASE-5; JNK ACTIVATION; BINDING DOMAIN	Mitogen-activated protein kinases (MAPKs) are members of a dynamic protein kinase network through which diverse stimuli regulate the spatio-temporal activities of complex biological systems. MAPKs regulate critical cellular functions required for homeostasis such as the expression of cytokines and proteases, cell cycle progression, cell adherence, motility and metabolism. MAPKs therefore influence cell proliferation, differentiation, survival, apoptosis and development. In vertebrates, five MAPK families are regulated by MAPK kinase kinase-MAPK kinase-MAPK (MKKK-MKK-MAPK) phosphorelay systems. There are at least 20 MKKKs that selectively phosphorylate and activate different combinations of the seven MKKs, resulting in a specific activation profile of members within the five MAPK families. MKKKs are differentially activated by upstream stimuli including cytokines, antigens, toxins and stress insults providing a mechanism to integrate the activation of different MAPKs with the cellular response to each stimulus. Thus, MKKKs can be considered as 'signaling hubs' that regulate the specificity of MAPK activation. In this review, we describe how the MKKK 'hub' function regulates the specificity of MAPK activation, highlighting MKKKs as targets for therapeutic intervention in cancer and other diseases.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, 1108 Mary Ellen Jones Bldg,Campus Box 7365, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu						Abell AN, 2005, MOL CELL BIOL, V25, P8948, DOI 10.1128/MCB.25.20.8948-8959.2005; Abell AN, 2005, J BIOL CHEM, V280, P35793, DOI 10.1074/jbc.C500260200; Akaike M, 2004, MOL CELL BIOL, V24, P8691, DOI 10.1128/MCB.24.19.8691-8704.2004; Beeram M, 2005, J CLIN ONCOL, V23, P6771, DOI 10.1200/JCO.2005.08.036; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670-3681.2005; Brown K, 2005, J MOL BIOL, V354, P1013, DOI 10.1016/j.jmb.2005.09.098; Camarero G, 2006, MOL CELL BIOL, V26, P7103, DOI 10.1128/MCB.00424-06; Castro A, 2001, BIOL CELL, V93, P15, DOI 10.1016/S0248-4900(01)01128-5; CHEN SJ, 1995, APPL SUPERCOND, V3, P15, DOI 10.1016/0964-1807(95)00026-2; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Chi HB, 2005, P NATL ACAD SCI USA, V102, P3846, DOI 10.1073/pnas.0500026102; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; Christoforidou AV, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-34; Cuevas BD, 2006, ONCOGENE, V25, P4998, DOI 10.1038/sj.onc.1209507; Cuevas BD, 2005, ONCOGENE, V24, P801, DOI 10.1038/sj.onc.1208239; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng MX, 2006, MOL BIOL CELL, V17, P3446, DOI 10.1091/mbc.E06-02-0102; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FIDLER IJ, 1997, ACTA ONCOL, V30, P668; Gallagher ED, 2004, J BIOL CHEM, V279, P1872, DOI 10.1074/jbc.M309525200; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Gorgoulis VG, 2001, CANCER RES, V61, P538; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Hayakawa T, 2006, MICROBES INFECT, V8, P1098, DOI 10.1016/j.micinf.2005.12.001; Hollenbach E, 2004, FASEB J, V18, P1550, DOI 10.1096/fj.04-1642fje; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Izumi Y, 2003, CIRCULATION, V108, P2812, DOI 10.1161/01.CIR.0000096486.01652.FC; Jadrich JL, 2006, DEVELOPMENT, V133, P1529, DOI 10.1242/dev.02333; Johnson GL, 2005, CURR OPIN CHEM BIOL, V9, P325, DOI 10.1016/j.cbpa.2005.04.004; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Larkin JMG, 2006, CRIT REV ONCOL HEMAT, V60, P216, DOI 10.1016/j.critrevonc.2006.06.008; Lee JW, 2005, APMIS, V113, P54, DOI 10.1111/j.1600-0463.2005.apm1130108.x; Li Y, 2005, CIRCULATION, V111, P1672, DOI 10.1161/01.CIR.0000160350.20810.0F; Liquori CL, 2003, AM J HUM GENET, V73, P1459, DOI 10.1086/380314; Lund S, 2005, J NEUROCHEM, V92, P1439, DOI 10.1111/j.1471-4159.2005.03014.x; Luo W, 2003, J BIOL CHEM, V278, P37451, DOI 10.1074/jbc.M305277200; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; OKA H, 1995, CANCER RES, V55, P4182; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Parameswaran N, 2006, J BIOL CHEM, V281, P34159, DOI 10.1074/jbc.M605376200; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Sahoo T, 1999, HUM MOL GENET, V8, P2325, DOI 10.1093/hmg/8.12.2325; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Uhlik MT, 2004, BIOCHEM CELL BIOL, V82, P658, DOI 10.1139/O04-114; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; Waldmeier P, 2006, BIOCHEM PHARMACOL, V72, P1197, DOI 10.1016/j.bcp.2006.06.031; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wei XD, 2003, EUR J IMMUNOL, V33, P2903, DOI 10.1002/eji.200324127; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Wong CK, 2004, J BIOL CHEM, V279, P39366, DOI 10.1074/jbc.M404598200; Xia Y, 2007, MOL CELL BIOL, V27, P510, DOI 10.1128/MCB.01355-06; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; Yue JB, 2006, MOL CELL BIOL, V26, P5300, DOI 10.1128/MCB.00273-06; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zawistowski JS, 2005, HUM MOL GENET, V14, P2521, DOI 10.1093/hmg/ddi256; Zhang L, 2003, EMBO J, V22, P4443, DOI 10.1093/emboj/cdg440	100	197	216	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3159	3171		10.1038/sj.onc.1210409	http://dx.doi.org/10.1038/sj.onc.1210409			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496913				2022-12-17	WOS:000246603600006
J	Chan, AY; Coniglio, SJ; Chuang, YY; Michaelson, D; Knaus, UG; Philips, MR; Symons, M				Chan, AY; Coniglio, SJ; Chuang, YY; Michaelson, D; Knaus, UG; Philips, MR; Symons, M			Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion	ONCOGENE			English	Article						Rac1; Rac3; glioma; invasion; migration; RNA interference	GUANINE-NUCLEOTIDE EXCHANGE; RHO-FAMILY GTPASES; ALPHA-6-BETA-4 INTEGRIN; GROWTH-FACTOR; MIGRATION; ACTIVATION; KINASE; RNAS; CDC42; LOCALIZATION	Members of the Rho family of small GTPases have been shown to be involved in tumorigenesis and metastasis. Currently, most of the available information on the function of Rho proteins in malignant transformation is based on the use of dominant-negative mutants of these GTPases. The specificity of these dominant-negative mutants is limited however. In this study, we used small interfering RNA directed against either Rac1 or Rac3 to reduce their expression specifically. In line with observations using dominant-negative Rac1 in other cell types, we show that RNA interference-mediated depletion of Rac1 strongly inhibits lamellipodia formation, cell migration and invasion in SNB19 glioblastoma cells. Surprisingly however, Rac1 depletion has a much smaller inhibitory effect on SNB19 cell proliferation and survival. Interestingly, whereas depletion of Rac3 strongly inhibits SNB19 cell invasion, it does not affect lamellipodia formation and has only minor effects on cell migration and proliferation. Similar results were obtained in BT549 breast carcinoma cells. Thus, functional analysis of Rac1 and Rac3 using RNA interference reveals a critical role for these GTPases in the invasive behavior of glioma and breast carcinoma cells.	N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, Dept Surg, Manhasset, NY 11030 USA; N Shore LIJ, Med Res Inst, Manhasset, NY 11030 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; NYU, Dept Med, Sch Med, New York, NY 10016 USA; NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Northwell Health; Northwell Health; Yeshiva University; Albert Einstein College of Medicine; New York University; New York University; Scripps Research Institute	Symons, M (corresponding author), N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, Dept Surg, 350 Community Dr, Manhasset, NY 11030 USA.	msymons@nshs.edu		Mark, Philips/0000-0002-1179-8156; Chan, yan fan (Amanda)/0000-0001-5720-7270	NATIONAL CANCER INSTITUTE [R01CA087567] Funding Source: NIH RePORTER; NCI NIH HHS [CA87567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chuang YY, 2004, CANCER RES, V64, P8271, DOI 10.1158/0008-5472.CAN-04-2097; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joyce PL, 2003, CANCER RES, V63, P7959; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; REPESH LA, 1989, INVAS METAST, V9, P192; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Ruggieri R, 2001, MOL MED, V7, P293, DOI 10.1007/BF03402212; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Senger DL, 2002, CANCER RES, V62, P2131; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; VAN AL, 1997, GENE DEV, V11, P2295; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	50	197	207	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7821	7829		10.1038/sj.onc.1208909	http://dx.doi.org/10.1038/sj.onc.1208909			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16027728				2022-12-17	WOS:000233463000001
J	Kulms, D; Zeise, E; Poppelmann, B; Schwarz, T				Kulms, D; Zeise, E; Poppelmann, B; Schwarz, T			DNA damage, death receptor activation and reactive oxygen species contribute to ultraviolet radiation-induced apoptosis in an essential and independent way	ONCOGENE			English	Article						apoptosis; cytochrome c; DNA damage; reactive oxygen species; UV radiation	SUNBURN CELL-FORMATION; CYTOCHROME-C RELEASE; SKIN-CANCER; MITOCHONDRIAL CONTROL; RADICAL REACTIONS; OXIDATIVE STRESS; CD95 FAS/APO-1; REPAIR; LIGHT; CARCINOGENESIS	Nuclear DNA damage and death receptor (CD95) activation by ultraviolet-B radiation (UVB) play a major role in UVB-induced apoptosis. Removal of DNA damage combined with inhibition of death receptor activation resulted in pronounced but not complete suppression of apoptosis, indicating that a third independent pathway is involved. Since reactive oxygen species (ROS) cause apoptosis and are induced by UVB, the radical scavenger pyrrolidene-dithiocarbamate (PDTC) was used. PDTC prevented UVB-induced apoptosis partially, H2O2-induced cell death largely, but not CD95-mediated apoptosis. The same was observed for cytochrome c release from mitochondria, another important event during apoptosis. The proapoptotic protein Bid was cleaved upon exposure to UVB or to agonistic anti-CD95-antibodies, but not to H2O2, indicating that H2O2 uses a different pathway. The fact that PDTC neither inhibited CD95-mediated apoptosis nor affected UV-induced DNA damage indicated that ROS generated during UVB irradiation may directly trigger mitochondrial cytochrome c release, thereby contributing to apoptosis. Accordingly, complete inhibition of apoptosis was observed when in addition to DNA damage removal via photoreactivation and blockade of CD95 signaling by caspase-8 inhibitor zIETD, PDTC was added before UVB exposure. This indicates that DNA damage, death receptor activation and ROS formation contribute to UVB-induced apoptosis in an essential and independent way.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany	University of Munster	Schwarz, T (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, von Esmarchstr 58, D-48149 Munster, Germany.	schwtho@uni-muenster.de	Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014					Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Black HS, 2001, CURR PROBL DERMATOL, V29, P140; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BONGARZONE ER, 1995, J NEUROSCI RES, V41, P213, DOI 10.1002/jnr.490410209; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEKOK TMCM, 1994, CARCINOGENESIS, V15, P1399, DOI 10.1093/carcin/15.7.1399; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dreher F, 2001, CURR PROBL DERMATOL, V29, P157; EKER APM, 1990, J BIOL CHEM, V265, P8009; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kuluncsics Z, 1999, J PHOTOCH PHOTOBIO B, V49, P71, DOI 10.1016/S1011-1344(99)00034-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Petit-Frere C, 2000, J INVEST DERMATOL, V115, P687, DOI 10.1046/j.1523-1747.2000.00093.x; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; TYRRELL RM, 1994, MOL ASPECTS MED, V15, P3; TYRRELL RM, 1995, BIOCH SOC S, V61, P547; Wenk J, 2001, CURR PROBL DERMATOL, V29, P83; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; WOODCOCK A, 1976, BRIT J DERMATOL, V95, P459, DOI 10.1111/j.1365-2133.1976.tb00854.x; YAROSH D, 1992, CANCER RES, V52, P4227; YAROSH D, 1994, TRENDS PHOTOCHEM PHO, V3, P175; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	45	197	202	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5844	5851		10.1038/sj.onc.1205743	http://dx.doi.org/10.1038/sj.onc.1205743			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185583				2022-12-17	WOS:000177520900003
J	Chevillard, S; Radicella, JP; Levalois, C; Lebeau, J; Poupon, MF; Oudard, S; Dutrillaux, B; Boiteux, S				Chevillard, S; Radicella, JP; Levalois, C; Lebeau, J; Poupon, MF; Oudard, S; Dutrillaux, B; Boiteux, S			Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours	ONCOGENE			English	Article						oxidative DNA damage; DNA repair; missense mutations of OGG1 gene; human lung and kidney cancer; tumour suppressor gene	GENERATES G.C->T.A TRANSVERSIONS; NONPOLYPOSIS COLON-CANCER; ESCHERICHIA-COLI; MUTATOR LOCUS; BREAST-CANCER; MUTY GENE; GLYCOSYLASE; CLONING; HOMOLOG; 7,8-DIHYDRO-8-OXOGUANINE	The human OGG1 gene encodes a DNA glycosylase activity catalysing the excision of the mutagenic lesion 7,8-dihydro-8-oxoguanine from oxidatively damaged DNA, The OGG1 gene was localized to chromosome 3p25, a region showing frequent loss of heterozygosity (LOH) in lung and kidney tumours. In this study, we have analysed by RT-PCR the expression of OGG1 in 25 small cell lung cancers, in 15 kidney carcinomas and the 15 normal kidney counterparts. The results show that OGG1 messenger RNA can be detected in all tumours tested and that no significant difference was observed in the level of expression between normal and tumoral kidney tissues. Denaturing gradient gel electrophoresis (DGGE) was used to screen this series of human tumours for alterations in the OGG1 cDNA. The study revealed homozygous mutations in three tumours, two from lung and one from kidney, Sequencing analysis of the mutants identified a single base substitution in each of the three cases: two tranversions (GC to TA and TA to AT) and one transition (GC to AT), All three substitutions cause an amino acid change in the hOgg1 protein. For the mutant kidney tumour, the normal tissue counterpart shows a wild-type profile, These results suggest a role for OGG1 mutations in the course of the multistage process of carcinogenesis in lung or kidney.	CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Radiobiol DNA, F-92265 Fontenay Aux Roses, France; CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Cancerogenese Expt, F-92265 Fontenay Aux Roses, France; CNRS UMR147, Inst Curie, F-75005 Paris, France; Hotel Dieu, Med Oncol Serv, F-75004 Paris, France; CEA, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; CEA	Boiteux, S (corresponding author), CNRS CEA Radiobiol Mol & Cellulaire UMR217, Dept Radiobiol & Radiopathol, Lab Radiobiol DNA, F-92265 Fontenay Aux Roses, France.		Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; Chevillard, Sylvie/0000-0001-5889-4041; OUDARD, Stephane/0000-0003-0893-285X				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1998, IN PRESS DNA DAMAGE; Boiteux S., 1997, BASE EXCISION REPAIR, P31; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chevillard S, 1997, CLIN CANCER RES, V3, P2471; Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X; Chevillard S, 1996, BREAST CANCER RES TR, V41, P81, DOI 10.1007/BF01807039; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Richards B, 1997, SCIENCE, V277, P1523, DOI 10.1126/science.277.5331.1523; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	43	197	202	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3083	3086		10.1038/sj.onc.1202096	http://dx.doi.org/10.1038/sj.onc.1202096			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662341				2022-12-17	WOS:000074125300015
J	Hankins, GR; DeSouza, AT; Bentley, RC; Patel, MR; Marks, JR; Iglehart, JD; Jirtle, RL				Hankins, GR; DeSouza, AT; Bentley, RC; Patel, MR; Marks, JR; Iglehart, JD; Jirtle, RL			M6P/IGF2 receptor: A candidate breast tumor suppressor gene	ONCOGENE			English	Article						loss of heterozygosity; M6P/IGF2 receptor; breast cancer; mutation; tumor suppressor	FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE BINDING; GROWTH-FACTOR-BETA; EXPRESSION CLONING; CANCER; PROTEIN; TAMOXIFEN; KINASE; HETEROZYGOSITY; POLYMORPHISM	The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2r) functions in the activation of TGF beta, a potent growth inhibitor for most cell types, the degradation of the mitogen, IGF2, and the intracellular trafficking of lysosomal enzymes, We have found its expression to be significantly reduced in both rat and human hepatocellular carcinomas (HCCs) and recently reported loss of heterozygosity (LOH) at this locus with mutations in the remaining allele in human liver tumors, Using the polymerase chain reaction, we utilized two polymorphisms in the 3' untranslated region of M6P/IGF2r to screen breast tumors for LOH, Forty of 62 (65%) patients were informative (heterozygous) and 12/40 (30%) breast tumors had LOH; 5/19 (26%) carcinomas in situ (CIS) and 7/21 (33%) invasive carcinomas, To investigate the early molecular genetic events in breast carcinogenesis, we screened the CIS with LOH for mutations, In 2/5 (40%) of these tumors, missense mutations were found in the remaining allele that gave rise to significant amino acid substitutions. These findings provide evidence that M6P/IGF2r allelic loss is an early event in the etiology of breast cancer, and that this gene functions as a tumor suppressor gene in the breast.	DUKE UNIV, MED CTR, DEPT RADIAT ONCOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; ZENECA PHARMACEUT, DEPT SAFETY MED, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND	Duke University; Duke University; Duke University					NCI NIH HHS [CA 25951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DM, 1993, J CELL BIOCHEM, P132; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BUTTA A, 1992, CANCER RES, V52, P4261; CATHERINO WH, 1993, DRUG SAFETY, V8, P381, DOI 10.2165/00002018-199308050-00005; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DEBLESER PJ, 1995, HEPATOLOGY, V21, P1429, DOI 10.1016/0270-9139(95)90066-7; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; DICKSON RB, 1990, J STEROID BIOCHEM, V37, P795, DOI 10.1016/0960-0760(90)90422-H; DICKSON RB, 1996, DIS BREAST, P221; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; FORSYTH IA, 1991, BAILLIERE CLIN ENDOC, V5, P809, DOI 10.1016/S0950-351X(10)80016-3; GOTO J, 1992, NUCLEIC ACIDS RES, V20, P923, DOI 10.1093/nar/20.4.923; HEBERT E, 1994, BRIT J CANCER, V69, P120, DOI 10.1038/bjc.1994.19; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; JORDAN VC, 1993, CANCER, V72, P1, DOI 10.1002/1097-0142(19930701)72:1<1::AID-CNCR2820720102>3.0.CO;2-F; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LOUIS DN, 1992, AM J PATHOL, V141, P777; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MELTZER SJ, 1993, PCR PROTOCOLS CURREN, P137; MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORROW M, 1996, DIS BREAST, P355; OMALLEY FP, 1994, LAB INVEST, V71, P67; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; RADFORD DM, 1995, CANCER RES, V55, P3399; SACKS NPM, 1993, EUR J CANCER, V29A, P426, DOI 10.1016/0959-8049(93)90401-Z; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SLEAT DE, 1995, CANCER RES, V55, P3424; SMITH HS, 1993, J CELL BIOCHEM, P144; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; TROCK BJ, 1996, DIS BREAST, P213; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZHAO Y, 1993, CANCER RES, V53, P2901; ZHUANG ZP, 1995, CANCER RES, V55, P467	68	197	202	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					2003	2009						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649861				2022-12-17	WOS:A1996UK49800019
J	Winston, JT; Coats, SR; Wang, YZ; Pledger, WJ				Winston, JT; Coats, SR; Wang, YZ; Pledger, WJ			Regulation of the cell cycle machinery by oncogenic ras	ONCOGENE			English	Article						ras; cell cycle; cyclins; cdk4; Kip1	EPIDERMAL GROWTH-FACTOR; FIBROBLASTS; INHIBITION; G(1); TRANSFORMATION; EXPRESSION; INDUCTION; KINASE; RAF-1; DNA	The ras proto-oncogene has been implicated during the formation of tumors in vivo as well as the transformation of cell lines in culture. Conditional expression of an activated ras mutant in Balb/c-3T3 fibroblasts failed to stimulate S phase entry in the absence of plasma-derived progression factors, but did shorten the G(1) interval from 12 to 6 h and abrogate the normal proliferative requirement for platelet-derived growth factor. Ras-dependent alteration of the 3T3 cell cycle was accompanied by a dramatic increase in the expression of the G(1) regulatory protein, cyclin D1, while expression of cyclin E and cyclin A proteins were only weakly induced. Cyclin/cdk complexes assembled in response to ectopic ras expression in the absence of growth factor stimulation bound the cdk inhibitory factor, Kip1, and were inactive. However, plasma-stimulated regulatory pathways functioned co-operatively with the oncogenic ras molecule to decrease Kip1 levels, induce the kinase activities associated with cyclins D, E and A, and trigger the initiation of DNA replication. Our results suggest that a ras-activated signal transduction pathway may link environmental mitogenic stimuli to the cell cycle machinery via modulation of G(1) cyclin expression.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,TAMPA,FL 33612; UNIV S FLORIDA,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED MICROBIOL,TAMPA,FL 33612; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Vanderbilt University					NATIONAL CANCER INSTITUTE [P01CA043720, R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA43720, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1975, P NATL ACAD SCI USA, V74, P1973; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COATS SR, 1992, J CELL BIOCHEM, V48, P242, DOI 10.1002/jcb.240480304; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LEOF EB, 1989, CANCER RES, V49, P2356; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJITEK AB, 1993, CELL, V74, P206; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	39	197	200	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					127	134						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552383				2022-12-17	WOS:A1996TQ01400016
J	RASHEED, BKA; MCLENDON, RE; FRIEDMAN, HS; FRIEDMAN, AH; FUCHS, HE; BIGNER, DD; BIGNER, SH				RASHEED, BKA; MCLENDON, RE; FRIEDMAN, HS; FRIEDMAN, AH; FUCHS, HE; BIGNER, DD; BIGNER, SH			CHROMOSOME-10 DELETION MAPPING IN HUMAN GLIOMAS - A COMMON DELETION REGION IN 10Q25	ONCOGENE			English	Note						GLIOBLASTOMA; CHROMOSOME 10; LOSS OF HETEROZYGOSITY	FACTOR RECEPTOR GENE; MALIGNANT GLIOMAS; GLIOBLASTOMA-MULTIFORME; HUMAN ASTROCYTOMAS; GLIAL ORIGIN; HETEROZYGOSITY; AMPLIFICATION; MUTATIONS; TUMOR; OLIGODENDROGLIOMAS	The high incidence of loss of chromosome 10 alleles in glioblastoma multiforme suggests the presence on this chromosome of a tumor suppressor gene that is important in glioma tumorigenesis and progression. Our initial deletion mapping studies using restriction fragment length polymorphism markers indicated a common deletion region in 10q24-qter. In an attempt to localize the deleted region further, we screened a panel of 117 gliomas for loss of heterozygosity for chromosome 10 loci using 10 microsatellite markers. Seventeen tumors showed partial loss of a copy of chromosome 10 and;were further analysed using 28 additional microsatellite markers. Of these, 10 had terminal deletion in the q arm, three had deletions in both p and q arms, two contained interstitial deletion in 10q and two carried deletions in 10p. In the 15 tumors with deletions in 10q, the minimal overlapping deletion region was in distal 10q between markers D10S587 and D10S216. Loci D10S587 and D10S216 are approximately mapped to a 5 cM region in 10q25.1.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,PREUSS LAB BRAIN TUMOR RES,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University					NATIONAL CANCER INSTITUTE [R37CA043722, R01CA043722] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGNER SH, 1988, CANCER RES, V48, P405; BURGER PC, 1991, SURGICAL PATHOLOGY N; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1989, CANCER RES, V49, P6572; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HE J, 1994, CANCER RES, V54, P5804; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KUMABE T, 1992, ONCOGENE, V7, P627; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MIYAKOSHI J, 1990, CANCER RES, V50, P278; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P348, DOI 10.1002/gcc.2870050411; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REY JA, 1992, INT J CANCER, V51, P703, DOI 10.1002/ijc.2910510507; VONDEIMLING A, 1992, CANCER RES, V52, P4277; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	24	197	205	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2243	2246						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784070				2022-12-17	WOS:A1995RB70300021
J	LEECHANACHAI, P; BANKS, L; MOREAU, F; MATLASHEWSKI, G				LEECHANACHAI, P; BANKS, L; MOREAU, F; MATLASHEWSKI, G			THE E5 GENE FROM HUMAN PAPILLOMAVIRUS TYPE-16 IS AN ONCOGENE WHICH ENHANCES GROWTH FACTOR-MEDIATED SIGNAL TRANSDUCTION TO THE NUCLEUS	ONCOGENE			English	Article								Although human papillomavirus type 16 (HPV-16) is believed to be a major etiological agent in the development of cervical cancer, the biological function of several of its early genes remains to be established. In the present study, we have defined some of the biological properties of the E5 gene from HPV-16. Expression of the HPV-16 E5 gene in 3T3-A31 cells induced transformation to anchorage-independent growth (colony formation in soft agar). Addition of epidermal growth factor (EGF) to the soft-agar medium caused the E5-expressing cells to form larger colonies than those formed in the absence of EGF. Parental 3T3-A31 cells did not form colonies in soft agar either in the presence or in the absence of EGF. Analysis of clones expressing high levels of E5 mRNA revealed that these cells also expressed higher levels of c-fos mRNA in response to serum, EGF and platelet-derived growth factor (PDGF) than did the parental 3T3-A31 cells. Cells expressing the E5 gene were also capable of accelerated growth in low serum and were more tumorigenic in nude mice than were control cells. We conclude that the E5 gene from HPV-16 is an oncogene which transforms cells in part through enhancing signal transduction from growth factors to the nucleus.	MCGILL UNIV, INST PARASITOL, MACDONALD CAMPUS, 21111 LAKESHORE RD, ST ANNE BELLEVUE H9X 1C0, QUEBEC, CANADA; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	McGill University; International Center for Genetic Engineering & Biotechnology (ICGEB)								BANKS L, 1990, ONCOGENE, V5, P1383; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; HARRIS AL, 1990, CANCER CELL-MON REV, V2, P321; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; KOHLER M, 1989, ANTICANCER RES, V9, P1537; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUNGER K, 1989, J VIROL, V63, P4417; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RO J, 1988, CANCER RES, V48, P161; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	35	197	202	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					19	25						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311062				2022-12-17	WOS:A1992HC22700003
J	STORM, SM; CLEVELAND, JL; RAPP, UR				STORM, SM; CLEVELAND, JL; RAPP, UR			EXPRESSION OF RAF FAMILY PROTOONCOGENES IN NORMAL MOUSE-TISSUES	ONCOGENE			English	Article									NCI,VIRAL PATHOL SECT,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; CLEVELAND JL, 1987, J IMMUNOL, V138, P3495; FREDRICKSON TN, 1988, AM J PATHOL, V131, P444; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KESHET E, 1988, ONCOGENE, V2, P235; LEGUELLEC R, 1988, NUCLEIC ACIDS RES, V16, P10357; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PERRIMON N, 1984, GENETICS, V108, P559; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1988, HDB ONCOGENES, P213; REDDY EPA, 1988, ONCOGENE HDB; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; Robaire B., 1988, P999; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	34	197	202	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					345	351						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690378				2022-12-17	WOS:A1990CW41500012
J	Fullgrabe, J; Kavanagh, E; Joseph, B				Fullgrabe, J.; Kavanagh, E.; Joseph, B.			Histone onco-modifications	ONCOGENE			English	Review						histone modification; histone-modifying enzymes; carcinogenesis; acetylation; methylation	DNA-DAMAGE RESPONSE; H3 LYSINE 9; MODIFICATIONS PREDICT PROGNOSIS; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER CELLS; MODIFICATION PATTERNS; PROSTATE-CANCER; TRANSCRIPTIONAL REPRESSION; METHYLTRANSFERASE G9A; LUNG-CANCER	Post-translational modification of histones provides an important regulatory platform for processes such as gene expression, DNA replication and repair, chromosome condensation and segregation and apoptosis. Disruption of these processes has been linked to the multistep process of carcinogenesis. We review the aberrant covalent histone modifications observed in cancer, and discuss how these epigenetic changes, caused by alterations in histone-modifying enzymes, can contribute to the development of a variety of human cancers. As a conclusion, a new terminology 'histone onco-modifications' is proposed to describe post-translational modifications of histones, which have been linked to cancer. This new term would take into account the active contribution and importance of these histone modifications in the development and progression of cancer. Oncogene (2011) 30, 3391-3403; doi:10.1038/onc.2011.121; published online 25 April 2011	[Fullgrabe, J.; Kavanagh, E.; Joseph, B.] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, R8 03, S-17176 Stockholm, Sweden.	Bertrand.joseph@ki.se		Fullgrabe, Jens/0000-0003-0047-4719; Joseph, Bertrand/0000-0001-5655-9979	Karolinska Institutet Foundations; Swedish Cancer Society; Swedish Research Council	Karolinska Institutet Foundations(Karolinska Institutet); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	We apologize to authors whose primary references could not be cited owing to space limitations. JF is supported by a fellowship from Karolinska Institutet Foundations (KID medel). This work was supported by the Swedish Cancer Society, the Swedish Research Council, and the Karolinska Institutet Foundations (KI Cancer).	Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Ajiro K, 2010, CELL DEATH DIFFER, V17, P984, DOI 10.1038/cdd.2009.199; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120; ANDERTON JA, 2011, ONCOGENE, P17; Ashktorab H, 2009, DIGEST DIS SCI, V54, P2109, DOI 10.1007/s10620-008-0601-7; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bagnyukovay TV, 2008, CARCINOGENESIS, V29, P638, DOI 10.1093/carcin/bgm303; Bai X, 2008, J CANCER RES CLIN, V134, P83, DOI 10.1007/s00432-007-0252-7; Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Dutta D, 2010, J BIOL CHEM, V285, P41567, DOI 10.1074/jbc.M110.190025; Ebbs ML, 2005, MOL CELL BIOL, V25, P10507, DOI 10.1128/MCB.25.23.10507-10515.2005; Ellinger J, 2010, INT J CANCER, V127, P2360, DOI 10.1002/ijc.25250; Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fullgrabe J, 2010, CELL DEATH DIFFER, V17, P1238, DOI 10.1038/cdd.2010.58; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Guo JF, 2011, CANCER SCI, V102, P530, DOI 10.1111/j.1349-7006.2010.01836.x; Hajji N, 2008, ONCOGENE, V27, P3134, DOI 10.1038/sj.onc.1210976; Hajji N, 2010, ONCOGENE, V29, P2192, DOI 10.1038/onc.2009.505; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; He LR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-461; Henckel A, 2009, HUM MOL GENET, V18, P3375, DOI 10.1093/hmg/ddp277; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141; Khare SP, 2011, EXP BIOL MED, V236, P30, DOI 10.1258/ebm.2010.010140; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x; Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kurdistani SK, 2011, PROG DRUG RES, V67, P91, DOI 10.1007/978-3-7643-8989-5_5; Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10; Li Z, 2010, INT J GYNECOL CANCER, V20, P82, DOI 10.1111/IGC.0b013e3181ae3efa; Liu BL, 2010, CANCER EPIDEM BIOMAR, V19, P2888, DOI 10.1158/1055-9965.EPI-10-0454; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639; Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Maze I, 2010, SCIENCE, V327, P213, DOI 10.1126/science.1179438; Michaud-Levesque J, 2009, J BIOL CHEM, V284, P21338, DOI 10.1074/jbc.M109.005322; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Mohamed MA, 2007, BJU INT, V99, P908, DOI 10.1111/j.1464-410X.2006.06704.x; Muller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Nguyen CT, 2002, CANCER RES, V62, P6456; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; ORZAN F, 2010, NEUROPATHOL APPL NEU, P1365; Ozdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90; Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9; Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108; Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283; Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S; Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364; RAJENDRAN G, 2011, J NEUROONCOL, P13; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Ren T.-N., 2010, MED ONCOL; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rufiange A, 2007, MOL CELL, V27, P393, DOI 10.1016/j.molcel.2007.07.011; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Shogren-Knaak M, 2006, CELL CYCLE, V5, P1361, DOI 10.4161/cc.5.13.2891; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Tzao C, 2009, MODERN PATHOL, V22, P252, DOI 10.1038/modpathol.2008.172; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vempati RK, 2010, J BIOL CHEM, V285, P28553, DOI 10.1074/jbc.M110.149393; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568	141	196	207	14	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3391	3403		10.1038/onc.2011.121	http://dx.doi.org/10.1038/onc.2011.121			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21516126				2022-12-17	WOS:000293508100001
J	Roy, LD; Sahraei, M; Subramani, DB; Besmer, D; Nath, S; Tinder, TL; Bajaj, E; Shanmugam, K; Lee, YY; Hwang, SIL; Gendler, SJ; Mukherjee, P				Roy, L. D.; Sahraei, M.; Subramani, D. B.; Besmer, D.; Nath, S.; Tinder, T. L.; Bajaj, E.; Shanmugam, K.; Lee, Y. Y.; Hwang, S. I. L.; Gendler, S. J.; Mukherjee, P.			MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition	ONCOGENE			English	Article						MUCI; pancreatic cancer; epithelial to mesenchymal transition; metastasis	CARCINOMA-ASSOCIATED ANTIGEN; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; SOLUBLE P-SELECTIN; BETA-CATENIN; TUMOR PROGRESSION; CYTOPLASMIC TAIL; MAMMARY-GLAND; C-SRC; PROTEIN	Increased motility and invasiveness of pancreatic cancer cells are associated with epithelial to mesenchymal transition (EMT). Snai1 and Slug are zinc-finger transcription factors that trigger this process by repressing E-cadherin and enhancing vimentin and N-cadherin protein expression. However, the mechanisms that regulate this activation in pancreatic tumors remain elusive. MUC1, a transmembrane mucin glycoprotein, is associated with the most invasive forms of pancreatic ductal adenocarcinomas (PDA). In this study, we show that over expression of MUC1 in pancreatic cancer cells triggers the molecular process of EMT, which translates to increased invasiveness and metastasis. EMT was significantly reduced when MUC1 was genetically deleted in a mouse model of PDA or when all seven tyrosines in the cytoplasmic tail of MUC1 were mutated to phenylalanine (mutated MUC1 CT). Using proteomics, RT-PCR and western blotting, we revealed a significant increase in vimentin, Slug and Snail expression with repression of E-Cadherin in MUC1-expressing cells compared with cells expressing the mutated MUC1 CT. In the cells that carried the mutated MUC1 CT, MUC1 failed to co-immunoprecipitate with beta-catenin and translocate to the nucleus, thereby blocking transcription of the genes associated with EMT and metastasis. Thus, functional tyrosines are critical in stimulating the interactions between MUC1 and b-catenin and their nuclear translocation to initiate the process of EMT. This study signifies the oncogenic role of MUC1 CT and is the first to identify a direct role of the MUC1 in initiating EMT during pancreatic cancer. The data may have implications in future design of MUC1-targeted therapies for pancreatic cancer. Oncogene (2011) 30, 1449-1459; doi:10.1038/onc.2010.526; published online 22 November 2010	[Roy, L. D.; Sahraei, M.; Besmer, D.; Nath, S.; Mukherjee, P.] Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; [Subramani, D. B.; Tinder, T. L.; Bajaj, E.; Shanmugam, K.; Gendler, S. J.] Mayo Clin, Sch Med Arizona, Dept Biochem & Mol Biol, Scottsdale, AZ USA; [Lee, Y. Y.; Hwang, S. I. L.] Carolinas Healthcare Ctr, Charlotte, NC USA	University of North Carolina; University of North Carolina Charlotte; Mayo Clinic; Mayo Clinic Phoenix; Carolinas HealthCare System	Mukherjee, P (corresponding author), Univ N Carolina, Dept Biol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	pmukherj@uncc.edu	Nath, Sritama/J-7725-2019; Subramani, Durai/N-1448-2013	Subramani, Durai/0000-0002-2256-3096; Hwang, Sunil/0000-0003-0600-3694	NIH [CA R01CA118944]; NATIONAL CANCER INSTITUTE [P50CA102701, R01CA064389, R01CA118944] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Drs Mukherjee and Gendler work have been funded by the NIH. All other authors declare no conflict of interest.; We acknowledge the funding provided by NIH CA R01CA118944. We thank Dr Jennifer Curry for critically reviewing the manuscript. We thank Cathy S Madison and Carole M Viso for their technical help with the confocal microscopy. We also acknowledge all the technicians in the animal facility and in the histology core facilities at The Mayo Clinic.	Al Masri A, 2005, ONCOGENE, V24, P5799, DOI 10.1038/sj.onc.1208738; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chang BW, 2010, J PANCREAS, V11, P313; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Das Roy L, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2345; Dymicka-Piekarska V, 2007, THROMB RES, V120, P585, DOI 10.1016/j.thromres.2006.11.002; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Glinskii AB, 2003, CANCER RES, V63, P4239; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hwang SI, 2006, MOL CELL PROTEOMICS, V5, P1131, DOI 10.1074/mcp.M500162-MCP200; Justinger C, 2008, ONCOL REP, V20, P1527, DOI 10.3892/or_00000175; KAIKITA K, 1995, CIRCULATION, V92, P1726, DOI 10.1161/01.CIR.92.7.1726; Kufe DW, 2008, CANCER BIOL THER, V7, P81, DOI 10.4161/cbt.7.1.5631; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Mroczko B, 2005, CLIN CHEM LAB MED, V43, P146, DOI 10.1515/CCLM.2005.024; Mukherjee P, 2005, J LEUKOCYTE BIOL, V77, P90, DOI 10.1189/jlb.0604333; Mukherjee P, 2009, J IMMUNOL, V182, P216, DOI 10.4049/jimmunol.182.1.216; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Quin RJ, 2000, INT J CANCER, V87, P499, DOI 10.1002/1097-0215(20000815)87:4<499::AID-IJC6>3.0.CO;2-9; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIMPSONHERREN L, 1970, CANCER CHEMOTH REP 1, V54, P143; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EJ, 2006, MOL CANCER RES, V4, P489, DOI 10.1158/1541-7786.MCR-06-0038; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Wolpin BM, 2007, BRIT J CANCER, V97, P98, DOI 10.1038/sj.bjc.6603826; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	44	196	206	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1449	1459		10.1038/onc.2010.526	http://dx.doi.org/10.1038/onc.2010.526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102519	Green Accepted			2022-12-17	WOS:000288743800007
J	Yamashita, Y; Yuan, J; Suetake, I; Suzuki, H; Ishikawa, Y; Choi, YL; Ueno, T; Soda, M; Hamada, T; Haruta, H; Takada, S; Miyazaki, Y; Kiyoi, H; Ito, E; Naoe, T; Tomonaga, M; Toyota, M; Tajima, S; Iwama, A; Mano, H				Yamashita, Y.; Yuan, J.; Suetake, I.; Suzuki, H.; Ishikawa, Y.; Choi, Y. L.; Ueno, T.; Soda, M.; Hamada, T.; Haruta, H.; Takada, S.; Miyazaki, Y.; Kiyoi, H.; Ito, E.; Naoe, T.; Tomonaga, M.; Toyota, M.; Tajima, S.; Iwama, A.; Mano, H.			Array-based genomic resequencing of human leukemia	ONCOGENE			English	Article						resequencing; AML; JAK3; DNMT3A	ACUTE MYELOID-LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; DNA METHYLTRANSFERASES DNMT3A; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM; ACTIVATING MUTATION; JAK3 MUTATIONS; DOWN-SYNDROME; CELLS; METHYLATION	To identify oncogenes in leukemias, we performed large-scale resequencing of the leukemia genome using DNA sequence arrays that determine similar to 9 Mbp of sequence corresponding to the exons or exon-intron boundaries of 5648 protein-coding genes. Hybridization of genomic DNA from CD34-positive blasts of acute myeloid leukemia (n = 19) or myeloproliferative disorder (n = 1) with the arrays identified 9148 nonsynonymous nucleotide changes. Subsequent analysis showed that most of these changes were also present in the genomic DNA of the paired controls, with 11 somatic changes identified only in the leukemic blasts. One of these latter changes results in a Met-to-Ile substitution at amino-acid position 511 of Janus kinase 3 (JAK3), and the JAK3(M511I) protein exhibited transforming potential both in vitro and in vivo. Further screening for JAK3 mutations showed novel and known transforming changes in a total of 9 out of 286 cases of leukemia. Our experiments also showed a somatic change responsible for an Arg-to-His substitution at amino-acid position 882 of DNA methyltransferase 3A, which resulted in a loss of DNA methylation activity of >50%. Our data have thus shown a unique profile of gene mutations in human leukemia. Oncogene (2010) 29, 3723-3731; doi: 10.1038/onc.2010.117; published online 19 April 2010	[Yamashita, Y.; Choi, Y. L.; Ueno, T.; Soda, M.; Hamada, T.; Haruta, H.; Takada, S.; Mano, H.] Jichi Med Univ, Div Funct Genom, Shimotsukeshi, Tochigi 3290498, Japan; [Yuan, J.; Iwama, A.] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan; [Suetake, I.; Tajima, S.] Osaka Univ, Inst Prot Res, Lab Epigenet, Osaka, Japan; [Suzuki, H.] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; [Ishikawa, Y.] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi 4648601, Japan; [Choi, Y. L.; Mano, H.] Univ Tokyo, Grad Sch Med, Dept Med Genom, Tokyo, Japan; [Miyazaki, Y.; Tomonaga, M.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Med & Hematol, Nagasaki 852, Japan; [Kiyoi, H.] Nagoya Univ, Sch Med, Dept Infect Dis, Nagoya, Aichi 466, Japan; [Ito, E.] Hirosaki Univ, Grad Sch Med, Dept Paediat, Aomori, Japan; [Toyota, M.] Sapporo Med Univ, Dept Biochem, Sapporo, Hokkaido, Japan; [Iwama, A.; Mano, H.] Japan Sci & Technol Agcy, CREST, Saitama, Japan	Jichi Medical University; Chiba University; Osaka University; Sapporo Medical University; Nagoya University; University of Tokyo; Nagasaki University; Nagoya University; Hirosaki University; Sapporo Medical University; Japan Science & Technology Agency (JST)	Mano, H (corresponding author), Jichi Med Univ, Div Funct Genom, 3311-1 Yakushiji, Shimotsukeshi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Suetake, Isao/G-3144-2013; Suetake, Isao/D-4326-2009; Naoe, Tomoki/I-1888-2012	Suetake, Isao/0000-0002-1246-8474; Takada, Shuji/0000-0002-9406-4683	Ministry of Health, Labor, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Grants-in-Aid for Scientific Research [22300326] Funding Source: KAKEN	Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank D Cox, KA Frazer, DG Ballinger, J Montgomery, H Tao, C Chen, L Stuve, J Kwon, J Sheehan and Y Zhan for discussion on the wafer experiments, as well as JN Ihle, T Kitamura and SB Baylin for human JAK3 cDNA, the pMX plasmid and human DNMT3A cDNA, respectively. This study was supported in part by a grant for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labor, and Welfare of Japan, and by a grant for Scientific Research on Priority Areas 'Applied Genomics' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Choi YL, 2007, LEUKEMIA RES, V31, P203, DOI 10.1016/j.leukres.2006.05.006; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; El-Osta A, 2004, LEUKEMIA, V18, P233, DOI 10.1038/sj.leu.2403218; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Imanishi D, 2007, BLOOD, V110, P2231, DOI 10.1182/blood-2007-02-071423; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146; Kiyoi H, 2007, LEUKEMIA, V21, P574, DOI 10.1038/sj.leu.2404527; Koinuma K, 2005, CARCINOGENESIS, V26, P2078, DOI 10.1093/carcin/bgi184; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; Kwong YL, 1996, CANCER GENET CYTOGEN, V88, P151, DOI 10.1016/0165-4608(95)00282-0; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Nimer SD, 2004, ONCOGENE, V23, P4249, DOI 10.1038/sj.onc.1207673; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Onishi M, 1996, EXP HEMATOL, V24, P324; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sato T, 2008, BRIT J HAEMATOL, V141, P681, DOI 10.1111/j.1365-2141.2008.07081.x; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schwonzen M, 2007, LEUKEMIA RES, V31, P113, DOI 10.1016/j.leukres.2006.03.022; Shimada A, 2006, BLOOD, V107, P1806, DOI 10.1182/blood-2005-08-3408; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Suetake I, 2003, J BIOCHEM, V133, P737, DOI 10.1093/jb/mvg095; Tallman Martin S, 2008, Hematology Am Soc Hematol Educ Program, P391, DOI 10.1182/asheducation-2008.1.391; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434	36	196	208	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3723	3731		10.1038/onc.2010.117	http://dx.doi.org/10.1038/onc.2010.117			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20400977				2022-12-17	WOS:000279108600012
J	Lee, SG; Su, ZZ; Emdad, L; Sarkar, D; Franke, TF; Fisher, PB				Lee, S-G; Su, Z-Z; Emdad, L.; Sarkar, D.; Franke, T. F.; Fisher, P. B.			Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling	ONCOGENE			English	Article						AEG-1; Ras; PI3K; Akt; apoptosis	RAPID SUBTRACTION HYBRIDIZATION; NF-KAPPA-B; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR PROGRESSION; HUMAN CANCER; AKT; APOPTOSIS; KINASE; PROTEIN	Astrocyte elevated gene-1 ( AEG-1) displays oncogenic properties. Its expression is elevated in diverse neoplastic states and it cooperates with Ha-ras to promote cellular transformation. Overexpression of AEG-1 augments invasion and anchorage-independent growth of transformed cells, while AEG-1 siRNA inhibits Ha-ras-mediated colony formation, supporting a potential functional role in tumorigenesis. Additionally, oncogenic Ha-ras induces AEG-1 expression through the phosphatidylinositol 3-kinase ( PI3K)-Akt signaling pathway. In the present study, we investigated whether AEG-1 could induce serum-independent cell growth, another property of oncogenes. Overexpression of AEG-1 inhibited serum starvation-induced apoptosis through activation of PI3K-Akt signaling, one of the effector pathways induced by activated Ras. AEG-1 also affected the phosphorylation state of Akt substrates that are implicated in apoptosis suppression, including glycogen synthase kinase 3 beta, c-Myc, murine double minute 2, p53, p21/ mda-6 and Bad. Additionally, AEG-1 blocked the activity of serum starvation-induced caspases. Taken together, these observations provide evidence that AEG-1 is an oncogene cooperating with Ha-ras as well as functioning as a downstream target gene of Ha-ras and may perform a central role in Ha-ras-mediated carcinogenesis. Activation of survival pathways may be one mechanism by which AEG-1 exerts its oncogenic properties.	[Lee, S-G; Su, Z-Z; Emdad, L.; Sarkar, D.; Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Urol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Emdad, L.; Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Neurosurg, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Franke, T. F.] NYU, Sch Med, Dept Psychiat, New York, NY USA; [Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Pathol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; New York University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Urol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.	pbf1@columbia.edu	Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777	NINDS NIH HHS [5 P01 NS31492] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Britt DE, 2004, EXP CELL RES, V300, P134, DOI 10.1016/j.yexcr.2004.06.026; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1984, MECHANISMS TUMOR PRO, P57; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lebedeva IV, 2007, ONCOGENE, V26, P733, DOI 10.1038/sj.onc.1209813; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li YH, 2002, J INFRARED MILLIM W, V21, P1; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ozes ON, 1999, NATURE, V401, P82; Rich JN, 2001, CANCER RES, V61, P3556; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Sutherland HGE, 2004, EXP CELL RES, V294, P94, DOI 10.1016/j.yexcr.2003.11.020; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WHITE JA, 1992, EXP CELL RES, V203, P157, DOI 10.1016/0014-4827(92)90051-9; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	196	211	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1114	1121		10.1038/sj.onc.1210713	http://dx.doi.org/10.1038/sj.onc.1210713			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704808				2022-12-17	WOS:000253136700011
J	Michaloglou, C; Vredeveld, LCW; Mooi, WJ; Peeper, DS				Michaloglou, C.; Vredeveld, L. C. W.; Mooi, W. J.; Peeper, D. S.			BRAF(E600) in benign and malignant human tumours	ONCOGENE			English	Review						BRAF/B-RAF; melanoma; naevus/nevus; thyroid; senescence; cancer	ONCOGENE-INDUCED SENESCENCE; PAPILLARY THYROID-CARCINOMA; GENE-EXPRESSION PROFILES; FACIO-CUTANEOUS SYNDROME; HUMAN-MELANOMA CELLS; N-RAS MUTATIONS; V600E B-RAF; CONGENITAL MELANOCYTIC NEVI; KINASE SIGNALING PATHWAY; VERTICAL GROWTH-PHASE	Of the RAF family of protein kinases, BRAF is the only member to be frequently activated by mutation in cancer. A single amino acid substitution (V600E) accounts for the vast majority and results in constitutive activation of BRAF kinase function. Its expression is required to maintain the proliferative and oncogenic characteristics of BRAF(E600)-expressing human tumour cells. Although BRAF(E600) acts as an oncogene in the context of additional genetic lesions, in primary cells it appears to be associated rather with transient stimulation of proliferation. Eventually, BRAF(E600) signalling triggers cell cycle arrest with the hallmarks of cellular senescence, as is illustrated by several recent studies in cultured cells, animal models and benign human lesions. In this review, we will discuss recent advances in our understanding of the role of BRAF(E600) in benign and malignant human tumours and the implications for therapeutic intervention.	[Michaloglou, C.; Vredeveld, L. C. W.; Peeper, D. S.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [Mooi, W. J.] Vrije Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands	Netherlands Cancer Institute; Vrije Universiteit Amsterdam	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020					Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Baloch ZW, 2006, ADV ANAT PATHOL, V13, P69, DOI 10.1097/01.pap.0000213006.10362.17; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Bennett DC, 2002, PIGM CELL RES, V15, P242, DOI 10.1034/j.1600-0749.2002.02036.x; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Brummer T, 2006, ONCOGENE, V25, P6262, DOI 10.1038/sj.onc.1209640; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Casula M, 2004, J CLIN ONCOL, V22, P286, DOI 10.1200/JCO.2004.07.112; Chan TL, 2003, CANCER RES, V63, P4878; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Christensen C, 2005, ONCOGENE, V24, P6292, DOI 10.1038/sj.onc.1208758; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Ciampi R, 2005, ENDOCR PATHOL, V16, P163, DOI 10.1385/EP:16:3:163; Ciampi R, 2005, ENDOCR PATHOL, V16, P99, DOI 10.1385/EP:16:2:099; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cohen Y, 2004, CLIN CANCER RES, V10, P3444, DOI 10.1158/1078-0432.CCR-03-0562; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collisson EA, 2003, CANCER RES, V63, P5669; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Raeve LE, 2006, BRIT J DERMATOL, V154, P485, DOI 10.1111/j.1365-2133.2005.07055.x; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Errico ME, 2003, ANTICANCER RES, V23, P2701; Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Goding CR, 2000, GENE DEV, V14, P1712; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Goodall J, 2004, MOL CELL BIOL, V24, P2923, DOI 10.1128/MCB.24.7.2923-2931.2004; Gorden A, 2003, CANCER RES, V63, P3955; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Guldberg P, 1997, CANCER RES, V57, P3660; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Hingorani SR, 2003, CANCER RES, V63, P5198; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Hussein MR, 2003, EUR J CANCER PREV, V12, P93, DOI 10.1097/00008469-200304000-00002; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichii-Nakato N, 2006, J INVEST DERMATOL, V126, P2111, DOI 10.1038/sj.jid.5700366; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jackson S, 2005, CANCER EPIDEM BIOMAR, V14, P913, DOI 10.1158/1055-9965.EPI-04-0568; James MR, 2005, J INVEST DERMATOL, V125, P1252, DOI 10.1111/j.0022-202X.2005.23937.x; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kimura ET, 2003, CANCER RES, V63, P1454; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Kumar R, 2003, CLIN CANCER RES, V9, P3362; KUWATA T, 1993, VIRCHOWS ARCH A, V423, P359, DOI 10.1007/BF01607148; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; Lang J, 2003, HUM MUTAT, V21, P327, DOI 10.1002/humu.10188; LASSAM NJ, 1993, CANCER RES, V53, P2235; Laud K, 2003, CANCER RES, V63, P3061; Lee JW, 2005, APMIS, V113, P54, DOI 10.1111/j.1600-0463.2005.apm1130108.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Lima J, 2004, J CLIN ENDOCR METAB, V89, P4267, DOI 10.1210/jc.2003-032224; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MCGREGOR JM, 1993, BRIT J DERMATOL, V128, P606, DOI 10.1111/j.1365-2133.1993.tb00253.x; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; McPhillips F, 2006, CARCINOGENESIS, V27, P729, DOI 10.1093/carcin/bgi289; Meier F, 2007, BRIT J DERMATOL, V156, P1204, DOI 10.1111/j.1365-2133.2007.07821.x; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Mesa C, 2006, CANCER RES, V66, P6521, DOI 10.1158/0008-5472.CAN-06-0739; Meyer P, 2003, INT J CANCER, V106, P78, DOI 10.1002/ijc.11199; Meyer Peter, 2003, J Carcinog, V2, P7, DOI 10.1186/1477-3163-2-7; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Minoo P, 2006, J PATHOL, V210, P137, DOI 10.1002/path.2047; Miracco C, 2002, BRIT J DERMATOL, V146, P399, DOI 10.1046/j.1365-2133.2002.04600.x; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; Miyamura Y, 2007, PIGM CELL RES, V20, P2, DOI 10.1111/j.1600-0749.2006.00358.x; Molhoek KR, 2005, J TRANSL MED, V3, P1, DOI 10.1186/1479-5876-3-39; MOOI WJ, 2006, NEW ENGL J MED, V355, P55; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Papp T, 2005, MELANOMA RES, V15, P401, DOI 10.1097/00008390-200510000-00008; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, LUNG CANCER, V4, P162; Rauen KA, 2006, AM J MED GENET A, V140A, P1681, DOI 10.1002/ajmg.a.31315; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rotolo S, 2005, INT J CANCER, V115, P164, DOI 10.1002/ijc.20865; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Salvatore G, 2006, CLIN CANCER RES, V12, P1623, DOI 10.1158/1078-0432.CCR-05-2378; Schreck R, 2006, INT J CANCER, V119, P2261, DOI 10.1002/ijc.22144; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Straume O, 2002, AM J PATHOL, V161, P229, DOI 10.1016/S0002-9440(10)64174-0; Straume O, 2000, CLIN CANCER RES, V6, P1845; Sturm RA, 2002, MELANOMA RES, V12, P405, DOI 10.1097/00008390-200209000-00001; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sviderskaya EV, 2003, J NATL CANCER I, V95, P723, DOI 10.1093/jnci/95.10.723; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022-202X.2005.23812.x; Talve L, 1997, INT J CANCER, V74, P255, DOI 10.1002/(SICI)1097-0215(19970620)74:3<255::AID-IJC4>3.0.CO;2-Y; Thomas NE, 2006, J INVEST DERMATOL, V126, P1693, DOI 10.1038/sj.jid.5700458; Trotter MJ, 1997, J CUTAN PATHOL, V24, P265, DOI 10.1111/j.1600-0560.1997.tb00790.x; Trovisco V, 2006, HUM PATHOL, V37, P781, DOI 10.1016/j.humpath.2006.03.013; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Van den Berg H, 1999, J MED GENET, V36, P799, DOI 10.1136/jmg.36.10.799; Vance KW, 2004, PIGM CELL RES, V17, P318, DOI 10.1111/j.1600-0749.2004.00164.x; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang YL, 1996, BRIT J DERMATOL, V134, P269; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Willmore-Payne C, 2006, HUM PATHOL, V37, P520, DOI 10.1016/j.humpath.2006.01.003; Willmore-Payne C, 2005, HUM PATHOL, V36, P486, DOI 10.1016/j.humpath.2005.03.015; WILSON RE, 1989, CANCER RES, V49, P711; Wong TH, 2005, PEPTIDES, V26, P1965, DOI 10.1016/j.peptides.2004.11.021; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Yeh AH, 2006, ONCOGENE, V25, P6574, DOI 10.1038/sj.onc.1209674; Zebisch A, 2006, CANCER RES, V66, P3401, DOI 10.1158/0008-5472.CAN-05-0115; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zuo H, 2007, PATHOL INT, V57, P12, DOI 10.1111/j.1440-1827.2007.02050.x; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	209	196	201	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					877	895		10.1038/sj.onc.1210704	http://dx.doi.org/10.1038/sj.onc.1210704			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17724477				2022-12-17	WOS:000252946300001
J	Saadi-Kheddouci, S; Berrebi, D; Romagnolo, B; Cluzeaud, F; Peuchmaur, M; Kahn, A; Vandewalle, A; Perret, C				Saadi-Kheddouci, S; Berrebi, D; Romagnolo, B; Cluzeaud, F; Peuchmaur, M; Kahn, A; Vandewalle, A; Perret, C			Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene	ONCOGENE			English	Article						polycystic kidney disease; beta-catenin; transgenic mice	EPITHELIAL-CELLS; MOLECULAR-BASIS; ALDOLASE-B; E-CADHERIN; C-MYC; PKD1; PROTEIN; PRODUCT; TRANSCRIPTION; PROLIFERATION	Autosomal dominant polycystic kidney disease (ADPKD) is common and is a major cause of renal failure. Although the genetics of ADPKD are well known and have led to the discovery of polycystins, a new protein family, the pathogenesis of the disease remains largely unknown. Recent studies have indicated that the beta -catenin signaling pathway is one of the targets of the transduction pathway controlled by the polycystins. We have generated transgenic mice that overproduce an oncogenic form of beta -catenin in the epithelial cells of the kidney. These mice developed severe polycystic lesions soon after birth that affected the glomeruli, proximal, distal tubules and collecting ducts. The phenotype of these mice mimicked the human ADPKD phenotype. Cyst formation was associated with an increase in cell proliferation and apoptosis. The cell proliferation and apoptotic indexes was increased 4-5-fold and 3-4-fold, respectively, in cystic tubules of the transgenic mice compared to that of littermate controls. Our findings provide experimental genetic evidence that activation of the Wnt/beta -catenin signaling pathway causes polycystic kidney disease and support the view that dysregulation of the Wnt/beta -catenin signaling is involved in its pathogenesis.	ICGM, INSERM, U129, F-75014 Paris, France; Univ Paris 07, Hop Robert Debre, Serv Anatomopathol, EA3102, F-75019 Paris, France; Univ Paris 07, Inst Fed Rech 02, INSERM, U478, F-75870 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Perret, C (corresponding author), ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Perret-Mayeux, Christine/L-3297-2017; Romagnolo, Béatrice/D-5017-2017	Romagnolo, Béatrice/0000-0001-8772-3604; perret, christine/0000-0003-4710-7051				BARISONI L, 1995, AM J PATHOL, V147, P1728; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43913; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bieche I, 1999, CANCER RES, V59, P2759; Cadoret A, 2001, CANCER RES, V61, P3245; Calvet JP, 1998, J NEPHROL, V11, P24; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; EKBLOM P, 1992, RENAL DEV, P475; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Grantham JJ, 1996, AM J KIDNEY DIS, V28, P788, DOI 10.1016/S0272-6386(96)90378-9; Gregori C, 1998, J BIOL CHEM, V273, P25237, DOI 10.1074/jbc.273.39.25237; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lanoix J, 1996, ONCOGENE, V13, P1153; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Romagnolo B, 1999, CANCER RES, V59, P3875; Romagnolo B, 1996, J BIOL CHEM, V271, P16820, DOI 10.1074/jbc.271.28.16820; Saez DE, 2000, J CELL BIOCHEM, V78, P62, DOI 10.1002/(SICI)1097-4644(20000701)78:1<62::AID-JCB6>3.3.CO;2-N; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Sorenson CM, 1996, AM J PHYSIOL-RENAL, V271, pF184, DOI 10.1152/ajprenal.1996.271.1.F184; Sorenson CM, 1999, AM J PHYSIOL-RENAL, V276, pF210, DOI 10.1152/ajprenal.1999.276.2.F210; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vainio SJ, 1999, INT J DEV BIOL, V43, P419; van Adelsberg J, 1999, DEV GENET, V24, P299, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<299::AID-DVG13>3.3.CO;2-A; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WILSON PD, 1991, AM J PHYSIOL, V260, P420; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724	46	196	217	0	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5972	5981		10.1038/sj.onc.1204825	http://dx.doi.org/10.1038/sj.onc.1204825			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593404				2022-12-17	WOS:000171056300004
J	JANES, PW; DALY, RJ; DEFAZIO, A; SUTHERLAND, RL				JANES, PW; DALY, RJ; DEFAZIO, A; SUTHERLAND, RL			ACTIVATION OF THE RAS SIGNALING PATHWAY IN HUMAN BREAST-CANCER CELLS OVEREXPRESSING ERBB-2	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; NIH 3T3 CELLS; EGF RECEPTOR; PROTO-ONCOGENE; SH2 DOMAIN; ADAPTER PROTEIN; OVARIAN-CANCER; TUMOR-CELLS	The c-erbB-2 proto-oncogene encodes a receptor tyrosine kinase (RTK) closely related to the epidermal growth factor receptor (EGFR). Overexpression of erbB-2 occurs in approximately 20% of human breast tumours, where increased expression correlates with poor patient prognosis. The EGFR is coupled to the Pas signalling pathway by interaction with the adaptor protein Grb2, and Sos, a Pas GDP-GTP exchange factor. In this study, activation of the erbB-2 receptor and its association with Grb2 and Sos was investigated in breast cancer cell lines which overexpress erbB-2. The receptor was found to be tyrosine phosphorylated in all cell lines in which it is overexpressed. Western blotting of Grb2 and Sos immuneprecipitates from such cells revealed co-precipitation of erbB-2, demonstrating association of the Grb2/Sos complex with erbB-2 in vivo. Furthermore, a fusion protein containing only the SH2 domain of Grb2 bound to erbB-2 immobilized on nitrocellulose, indicating that association with Grb2 is direct and mediated by the SH2 domain of Grb2. The degree of association between the erbB-2 receptor and Grb2 in vivo was related to erbB-2 overexpression, and MAP kinase, which functions downstream from Ras, displayed markedly increased activity in cell Lines overexpressing erbB-2. These results demonstrate that erbB-2 is coupled to Pas signalling via the Grb2/Sos complex, and that overexpression of this receptor in breast cancer cells leads to amplification of the Ras signalling pathway.	ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			DeFazio, Anna/O-2385-2019; Sutherland, Robert L/A-8378-2008; deFazio, Anna/D-3939-2013; Daly, Roger J/C-8179-2009	DeFazio, Anna/0000-0003-0057-4744; deFazio, Anna/0000-0003-0057-4744; Daly, Roger/0000-0002-5739-8027				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BERCHUCK A, 1990, CANCER RES, V50, P4087; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DALY RJ, 1994, IN PRESS ONCOGENE; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULLICK WJ, 1990, INT J CANCER, P55; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KAMEDA T, 1990, CANCER RES, V50, P8002; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEGATTO O, 1993, ONCOGENE, V8, P2105; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	196	207	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3601	3608						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970720				2022-12-17	WOS:A1994PT39200023
J	ADAMS, JM; HOUSTON, H; ALLEN, J; LINTS, T; HARVEY, R				ADAMS, JM; HOUSTON, H; ALLEN, J; LINTS, T; HARVEY, R			THE HEMATOPOIETICALLY EXPRESSED VAV PROTOONCOGENE SHARES HOMOLOGY WITH THE DBL GDP-GTP EXCHANGE FACTOR, THE BCR GENE AND A YEAST GENE (CDC24) INVOLVED IN CYTOSKELETAL ORGANIZATION	ONCOGENE			English	Article							CEREVISIAE CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CDNA SEQUENCE; ZINC-FINGER; BINDING; MYC; PROTEINS; PRODUCT; CDC42	The vav proto-oncogene encodes a protein of unknown function that is rendered oncogenic by loss of a short N-terminal domain. A correction reported here to the vav sequence reveals that a central domain of some 230 amino acids is similar to the products of three genes: the human dbl oncogene, now known to encode a GDP-GTP exchange factor for the Ras-like polypeptide CDC42Hs; the CDC24 gene of Saccharomyces cerevisiae, which participates with CDC42Sc in organization of the cytoskeleton for budding; and the human bcr gene, which recombines with the abl oncogene in certain forms of leukemia. Furthermore. the N-terminal portion of Vav (and of CDC24) is similar to that of certain proteins that associate with filamentous structures. These similarities suggest that Vav, and perhaps also Bcr, may function as a GDP-GTP exchange factor for a Ras-like molecule such as CDC42Hs, and that its action may coordinate cytoplasmic architecture with the cell cycle. Reported evidence that the vav proto-oncogene is widely expressed in hematopoietic cells but not other cell types is extended here by detection of vav mRNA in 49 of 50 murine hematopoietic cell lines representing diverse hematopoietic lineages, and by in situ hybridization in embryos showing expression confined to the only hematopoietic tissue, fetal liver. Thus, like Dbl in other cell types, Vav may function throughout the hematopoietic compartment to govern a Ras-like signal transduction pathway.			ADAMS, JM (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Adams, Jerry M/E-1199-2013; Lints, Thierry/K-4408-2012	Harvey, Richard/0000-0002-9950-9792; Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA012421] Funding Source: NIH RePORTER; NCI NIH HHS [CA12421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ALMENDRAL JM, 1989, EXP CELL RES, V181, P518, DOI 10.1016/0014-4827(89)90108-0; AYMESOUTHGATE A, 1989, J CELL BIOL, V108, P521, DOI 10.1083/jcb.108.2.521; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DALEY GQ, 1991, IN PRESS ADV CANCER, V57; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EFLANTY A, 1992, IN PRESS BLOOD; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GRAZIANI G, 1989, ONCOGENE, V4, P823; GREEN A, 1992, IN PRESS ONCOGENE; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEARLSTONE JR, 1987, J BIOL CHEM, V262, P5985; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	59	196	203	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					611	618						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565462				2022-12-17	WOS:A1992HQ68200001
J	Bobrovnikova-Marjon, E; Grigoriadou, C; Pytel, D; Zhang, F; Ye, J; Koumenis, C; Cavener, D; Diehl, JA				Bobrovnikova-Marjon, E.; Grigoriadou, C.; Pytel, D.; Zhang, F.; Ye, J.; Koumenis, C.; Cavener, D.; Diehl, J. A.			PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage	ONCOGENE			English	Article						PERK; Nrf2; ROS; DNA damage; cell cycle checkpoints	INTEGRATED STRESS-RESPONSE; SUBUNIT GENE-EXPRESSION; CUL3-BASED E3 LIGASE; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; LUNG-CANCER; TRANSLATIONAL REGULATION; MESSENGER-RNA; COMPLEX-III; PROTEIN	To proliferate and expand in an environment with limited nutrients, cancer cells co-opt cellular regulatory pathways that facilitate adaptation and thereby maintain tumor growth and survival potential. The endoplasmic reticulum (ER) is uniquely positioned to sense nutrient deprivation stress and subsequently engage signaling pathways that promote adaptive strategies. As such, components of the ER stress-signaling pathway represent potential antineoplastic targets. However, recent investigations into the role of the ER resident protein kinase, RNA-dependent protein kinase (PKR)-like ER kinase (PERK) have paradoxically suggested both pro- and anti-tumorigenic properties. We have used animal models of mammary carcinoma to interrogate the contribution of PERK in the neoplastic process. The ablation of PERK in tumor cells resulted in impaired regeneration of intracellular antioxidants and accumulation of reactive oxygen species triggering oxidative DNA damage. Ultimately, PERK deficiency impeded progression through the cell cycle because of the activation of the DNA damage checkpoint. Our data reveal that PERK-dependent signaling is used during both tumor initiation and expansion to maintain redox homeostasis, thereby facilitating tumor growth. Oncogene (2010) 29, 3881-3895; doi:10.1038/onc.2010.153; published online 10 May 2010	[Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; [Bobrovnikova-Marjon, E.; Grigoriadou, C.; Pytel, D.; Zhang, F.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Bobrovnikova-Marjon, E.; Grigoriadou, C.; Pytel, D.; Zhang, F.; Diehl, J. A.] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; [Ye, J.; Koumenis, C.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Cavener, D.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu	Cavener, Douglas R/E-3524-2010; Koumenis, Constantinos/B-2002-2008; Ye, Jiangbin/A-1094-2007	Ye, Jiangbin/0000-0003-1117-4869; Koumenis, Costas/0000-0001-5945-4726	National Institutes of Health [F32CA1238252, P01 CA104838]; Leukemia & Lymphoma Scholar award; NATIONAL CANCER INSTITUTE [P01CA104838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088140] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Scholar award(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Serge Fuchs for critical reading of the paper, Margarita Romero for outstanding technical assistance and the AFCRI histology core. This work was supported by the National Institutes of Health Grants F32CA1238252 (to EBM), P01 CA104838 and a Leukemia & Lymphoma Scholar award (to JAD).	Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Back SH, 2009, CELL METAB, V10, P13, DOI 10.1016/j.cmet.2009.06.002; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2004, CELL CYCLE, V3, P149; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Bruns CJ, 2004, CLIN CANCER RES, V10, P2109, DOI 10.1158/1078-0432.CCR-03-0502; BUETLER TM, 1995, TOXICOL APPL PHARM, V135, P45, DOI 10.1006/taap.1995.1207; Clanton TL, 2007, J APPL PHYSIOL, V102, P2379, DOI 10.1152/japplphysiol.01298.2006; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Evans, 2000, Mol Med Today, V6, P459, DOI 10.1016/S1357-4310(00)01824-4; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; FOLKMAN J, 1966, ANN SURG, V164, P491, DOI 10.1097/00000658-196609000-00012; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Lee HK, 2008, NEURO-ONCOLOGY, V10, P236, DOI 10.1215/15228517-2008-006; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200; Lo SC, 2006, EMBO J, V25, P3605, DOI 10.1038/sj.emboj.7601243; Nicco C, 2005, BIOMED PHARMACOTHER, V59, P169, DOI 10.1016/j.biopha.2005.03.009; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Ranganathan AC, 2008, CANCER RES, V68, P3260, DOI 10.1158/0008-5472.CAN-07-6215; Reddy NM, 2008, ONCOGENE, V27, P5821, DOI 10.1038/onc.2008.188; Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615; Shenvi SV, 2009, PHARMACOL RES, V60, P229, DOI 10.1016/j.phrs.2009.06.003; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shimizu Y, 2009, ANTIOXID REDOX SIGN, V11, P2317, DOI [10.1089/ars.2009.2501, 10.1089/ARS.2009.2501]; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Stracker TH, 2008, MOL CELL, V31, P21, DOI 10.1016/j.molcel.2008.04.028; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tommiska J, 2008, ONCOGENE, V27, P2501, DOI 10.1038/sj.onc.1210885; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Wu WG, 1998, CANCER RES, V58, P4082; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang F, 2006, J BIOL CHEM, V281, P30036, DOI 10.1074/jbc.M604674200; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zhang YW, 2009, MOL CELL, V35, P442, DOI 10.1016/j.molcel.2009.06.030; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	74	195	209	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3881	3895		10.1038/onc.2010.153	http://dx.doi.org/10.1038/onc.2010.153			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453876	Green Accepted			2022-12-17	WOS:000279603200002
J	Kauffmann, A; Rosselli, F; Lazar, V; Winnepenninckx, V; Mansuet-Lupo, A; Dessen, P; van den Oord, JJ; Spatz, A; Sarasin, A				Kauffmann, A.; Rosselli, F.; Lazar, V.; Winnepenninckx, V.; Mansuet-Lupo, A.; Dessen, P.; van den Oord, J. J.; Spatz, A.; Sarasin, A.			High expression of DNA repair pathways is associated with metastasis in melanoma patients	ONCOGENE			English	Article						melanoma; metastasis; DNA repair; microarray	TOPOISOMERASE-II; CUTANEOUS MELANOMA; P53 MUTATIONS; DAMAGE; CARCINOMA; GENETICS; CELLS; FOXM1	We have identified a gene-profile signature for human primary malignant melanoma associated with metastasis to distant sites and poor prognosis. We analyse the differential gene expression by looking at whole biological pathways rather than individual genes. Among the most significant pathways associated with progression to metastasis, we found the DNA replication (P = 10(-14)) and the DNA repair pathways (P = 10(-16)). We concentrated our analysis on DNA repair and found that 48 genes of this category, among a list of 234 genes, are associated with metastatic progression. These genes belong essentially to the pathways allowing recovery of stalled replication forks due to spontaneous blockage or induced DNA lesions. Because almost all these differentially expressed repair genes were overexpressed in primary tumors with bad prognosis, we speculate that primary melanoma cells that will metastasize try to replicate in a fast and error-free mode. In contrast to the progression from melanocytes to primary melanoma, genetic stability appears to be necessary for a melanoma cell to give rise to distant metastasis. This overexpression of repair genes explains nicely the extraordinary resistance of metastatic melanoma to chemo- and radio-therapy. Our results may open a new avenue for the discovery of drugs active on human metastatic melanoma.	[Kauffmann, A.; Rosselli, F.; Dessen, P.; Sarasin, A.] Inst Gustave Roussy, CNRS, Lab Genomes & Canc, FRE2939,PR2, F-94805 Villejuif, France; [Kauffmann, A.; Rosselli, F.; Dessen, P.; Sarasin, A.] Univ Paris Sud, Orsay, France; [Lazar, V.] Inst Gustave Roussy, Unit Funct Genom, F-94805 Villejuif, France; [Winnepenninckx, V.] Univ Hosp Maastricht, Dept Pathol, Maastricht, HX, Netherlands; [Mansuet-Lupo, A.; Spatz, A.] Inst Gustave Roussy, Dept Biopathol, F-94805 Villejuif, France; [van den Oord, J. J.] Katholieke Univ Leuven, Dept Morphol & Mol Pathol, Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Maastricht University; Maastricht University Medical Centre (MUMC); UNICANCER; Gustave Roussy; KU Leuven	Sarasin, A (corresponding author), Inst Gustave Roussy, CNRS, Lab Genomes & Canc, FRE2939,PR2, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	sarasin@igr.fr	Lazar, Vladimir/AAV-2087-2020; SPATZ, ALAN/B-8645-2009; Filippo, Rosselli/AAO-6393-2020; Lazar, Vladimir/AAQ-2086-2020	SPATZ, ALAN/0000-0003-3020-1420; Filippo, Rosselli/0000-0003-1080-5745; 				Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; EDER JP, 1995, CANCER RES, V55, P6109; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Halazonetis TD, 2004, DNA REPAIR, V3, P1057, DOI 10.1016/j.dnarep.2004.03.036; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Munoz P, 2005, NAT GENET, V37, P1063, DOI 10.1038/ng1633; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; SCHUUR ER, 1995, CELL GROWTH DIFFER, V6, P219; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Spatz A, 2001, CANCER RES, V61, P2480; Stary A, 2002, BIOCHIMIE, V84, P49, DOI 10.1016/S0300-9084(01)01358-X; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang L, 2002, ENVIRON MOL MUTAGEN, V39, P348, DOI 10.1002/em.10072; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Warters RL, 2005, J INVEST DERMATOL, V124, P807, DOI 10.1111/j.0022-202X.2005.23674.x; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103	32	195	198	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					565	573		10.1038/sj.onc.1210700	http://dx.doi.org/10.1038/sj.onc.1210700			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17891185				2022-12-17	WOS:000252674900001
J	Bauer, S; Duensing, A; Demetri, GD; Fletcher, JA				Bauer, S.; Duensing, A.; Demetri, G. D.; Fletcher, J. A.			KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway	ONCOGENE			English	Article						KIT; oncogenic signaling; sarcoma; gastrointestinal; neoplasm; PI3-K	C-KIT; ACQUIRED-RESISTANCE; MUTATIONS; INHIBITION; ACTIVATION; MESYLATE; MUTANTS; ABL	Most gastrointestinal stromal tumor (GIST) patients respond to KIT inhibition with imatinib, yet will eventually exhibit resistance. Imatinib-resistance mechanisms are heterogeneous, and little is known about KIT functional roles in imatinib-resistant GIST. Biological consequences of biochemical inhibition of KIT, phospha-tidyl-inositol- 3-kinase (PI3-K), PLC gamma, MAPK/ERK kinase/mitogen-activated protein kinase (MEK/MAPK), mammalian target of rapamycin (mTOR) and JAK were determined by immunoblotting for protein activation, and by cell proliferation and apoptosis assays in GIST cell lines from imatinib-sensitive GIST (GIST882), imatinib-resistant GISTs (GIST430 and GIST48) and KIT-negative GIST (GIST62). KIT activation was 3- to 6-fold higher in GIST430 and GIST48 than in GIST882, whereas total KIT expression was comparable in these three GIST lines. In addition to the higher set point for KIT activation, GIST430 and GIST48 had intrinsic imatinib resistance. After treatment with 1 mu M imatinib, residual KIT activation was 6- and 2.8-fold higher in GIST430 and GIST48, respectively, compared to GIST882. In all GIST lines, cell growth arrest resulted from PI3-K inhibition, and - to a lesser extent - from MEK/MAPK and mTOR inhibition. Inhibition of JAK/STAT or PLC gamma did not affect cell proliferation. Similarly, only PI3-K inhibition resulted in substantial apoptosis in the imatinib-resistant GISTs. We conclude that GIST secondary KIT mutations can be associated with KIT hyperactivation and imatinib resistance. Targeting critical downstream signaling proteins, such as PI3-K, is a promising therapeutic strategy in imatinib-resistant GISTs.	Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; Harvard Med Sch, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Bauer, S (corresponding author), W German Canc Res Ctr, Dept Internal Med, Ctr Canc Res, Hufelandstr 55, D-45122 Essen, Germany.	sebastian.bauer@uni-due.de; jflecher@partners.org	Bauer, Sebastian/D-8120-2012; ravegnini, gloria/K-1330-2016	Bauer, Sebastian/0000-0001-5949-8120; ravegnini, gloria/0000-0002-7774-402X; Duensing, Anette/0000-0002-0168-4067				Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bauer S, 2005, INT J CANCER, V117, P316, DOI 10.1002/ijc.21164; BAUER S, 2005, P AN M AM SOC CLIN, V23, pA9034; Bauer S, 2006, CANCER RES, V66, P9153, DOI 10.1158/0008-5472.CAN-06-0165; Cammenga J, 2005, BLOOD, V106, P3958, DOI 10.1182/blood-2005-02-0583; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; FLETCHER JA, 2003, P AN M AM SOC CLIN, V22, pA3275; Frank DA, 1999, MOL MED, V5, P432; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2001, CANCER RES, V61, P8118; Sawka-Verhelle D, 2000, ENDOCRINOLOGY, V141, P1977, DOI 10.1210/en.141.6.1977; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shivas T, 2003, AM J BIOETHICS, V3, P63, DOI 10.1162/152651603321612042; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wardelmann E, 2006, CLIN CANCER RES, V12, P1743, DOI 10.1158/1078-0432.CCR-05-1211; Wardelmann E, 2005, LANCET ONCOL, V6, P249, DOI 10.1016/S1470-2045(05)70097-8	29	195	205	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7560	7568		10.1038/sj.onc.1210558	http://dx.doi.org/10.1038/sj.onc.1210558			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546049				2022-12-17	WOS:000251282100008
J	Schulmann, K; Sterian, A; Berki, A; Yin, J; Sato, F; Xu, Y; Olaru, A; Wang, S; Mori, Y; Deacu, E; Hamilton, J; Kan, T; Krasna, MJ; Beer, DG; Pepe, MS; Abraham, JM; Feng, ZD; Schmiegel, W; Greenwald, BD; Meltzer, SJ				Schulmann, K; Sterian, A; Berki, A; Yin, J; Sato, F; Xu, Y; Olaru, A; Wang, S; Mori, Y; Deacu, E; Hamilton, J; Kan, T; Krasna, MJ; Beer, DG; Pepe, MS; Abraham, JM; Feng, ZD; Schmiegel, W; Greenwald, BD; Meltzer, SJ			Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk	ONCOGENE			English	Article						esophageal cancer; Barrett's esophagus; hypermethylation; early cancer detection; neoplastic progression; cancer biomarkers	HIGH-GRADE DYSPLASIA; CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; FOLLOW-UP; ENDOSCOPIC SURVEILLANCE; ESOPHAGEAL CANCER; CLONAL EXPANSION; DNA METHYLATION; ALLELIC LOSS	Patients with Barrett's esophagus ( BE) are at increased risk of developing esophageal adenocarcinoma (EAC). Clinical neoplastic progression risk factors, such as age and the length of the esophageal BE segment, have been identified. However, improved molecular biomarkers predicting increased progression risk are needed for improved risk assessment and strati. cation. Using real-time quantitative methylation-specific PCR, we screened 10 genes (HPP1, RUNX3, RIZ1, CRBP1, 3-OST-2, APC, TIMP3, p16, MGMT, p14) for promoter hypermethylation in 77 EAC, 93 BE, and 64 normal esophagus ( NE) specimens. A subset of genes manifesting significant differences in methylation frequencies between BE and EAC was then analysed in 20 dysplastic specimens. All 10 genes except p14 were frequently methylated in EACs, with RUNX3, HPP1, CRBP1, RIZ1, and OST-2 representing novel methylation targets in EAC and/or BE. p16, RUNX3, and HPP1 displayed increasing methylation frequencies in BE vs EAC. Furthermore, these increases in methylation occurred early, at the interface between BE and low-grade dysplasia (LGD). To demonstrate the silencing effect of hypermethylation, we selected the EAC cells BIC1, in which the HPP1 promoter is natively methylated, and subjected them to 5-aza-2'-deoxycytidine (Aza-C) treatment. Real-time RT-PCR indicated increased HPP1 mRNA levels after 3 days of Aza-C treatment, as well as decreased levels of methylated HPP1 DNA. Hypermethylation of a subset of six genes ( APC, TIMP3, CRBP1, p16, RUNX3, and HPP1) was then tested in a retrospective longitudinal study of 99 BE and nine LGD specimens obtained from 53 BE patients undergoing surveillance endoscopy. Only high-grade dysplasia (HGD) or EACwere defined as progression end points. Two patient groups were compared: eight progressors ( P) and 45 nonprogressors (NP), using Cox proportional hazards models to determine the relative progression risks of age, BE segment length, and methylation events. Multivariate analyses revealed that only hypermethylation of p16 ( odds ratio ( OR) 1.74, 95% confidence interval (CI) 1.33 - 2.20), RUNX3 ( OR 1.80, 95% CI 1.08 - 2.81), and HPP1 ( OR 1.77, 95% CI 1.06 - 2.81) were independently associated with an increased risk of progression, whereas age, BE segment length, and hypermethylation of TIMP3, APC, or CRBP1 were not independent risk factors. In combined analyses, risk was detectable up to, but not earlier than, 2 years preceding neoplastic progression. Hypermethylation of p16, RUNX3, and HPP1 in BE or LGD may represent independent risk factors for the progression of BE to HGD or EAC. These findings have implications regarding risk strati. cation, early EAC detection, and the appropriate endoscopic surveillance interval for patients with BE.	Univ Maryland, Sch Med, Div Gastroenterol, Baltimore, MD 21201 USA; Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Med, D-4630 Bochum, Germany; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Fred Hutchinson Canc Res Ctr, Data Management & Coordinating Ctr, Seattle, WA 98104 USA; Baltimore VA Hosp, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Ruhr University Bochum; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; Fred Hutchinson Cancer Center	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA.	smeltzer@medicine.umaryland.edu	Schulmann, Karsten/N-2230-2016	Berki, Agnes/0000-0003-1515-016X	NATIONAL CANCER INSTITUTE [R01CA095323, R01CA001808, R21CA098450, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [CA95323, CA77057, CA01808, CA85069, CA098450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alikhan M, 1999, GASTROINTEST ENDOSC, V50, P23, DOI 10.1016/S0016-5107(99)70339-1; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Avidan B, 2002, AM J GASTROENTEROL, V97, P1930, DOI 10.1111/j.1572-0241.2002.05902.x; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Barrett MT, 1996, ONCOGENE, V13, P1867; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bian YS, 2002, GASTROENTEROLOGY, V122, P1113, DOI 10.1053/gast.2002.32370; Blot WJ, 1999, SEMIN ONCOL, V26, P2; BROWN LM, 2002, CANC UPPER GASTROINT, P1; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; Carling T, 2003, SURGERY, V134, P932, DOI 10.1016/S0039-6060(03)00422-7; Chang HW, 2003, CLIN CANCER RES, V9, P1033; Conio M, 2003, AM J GASTROENTEROL, V98, P1931, DOI 10.1016/S0002-9270(03)00629-4; Corley DA, 2002, GASTROENTEROLOGY, V122, P633, DOI 10.1053/gast.2002.31879; Corn PG, 2001, CLIN CANCER RES, V7, P2765; Cox D.R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212; Du Y, 2001, CANCER RES, V61, P8094; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Esteller M, 2002, CANCER RES, V62, P5902; Galipeau PC, 1999, J NATL CANCER I, V91, P2087, DOI 10.1093/jnci/91.24.2087; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Geddert H, 2004, INT J CANCER, V110, P208, DOI 10.1002/ijc.20058; Gopal DV, 2003, DIGEST DIS SCI, V48, P1537, DOI 10.1023/A:1024715824149; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Heath EI, 2003, DIS ESOPHAGUS, V16, P177, DOI 10.1046/j.1442-2050.2003.00325.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; IFTIKHAR SY, 1992, GUT, V33, P1155, DOI 10.1136/gut.33.9.1155; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jankowski J, 2004, ALIMENT PHARM THER, V19, P54, DOI 10.1111/j.0953-0673.2004.01839.x; Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Maley CC, 2004, CANCER RES, V64, P3414, DOI 10.1158/0008-5472.CAN-03-3249; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; MELTZER SJ, 1990, CANCER RES, V50, P3627; MENKEPLUYMERS MBE, 1993, CANCER, V72, P1155, DOI 10.1002/1097-0142(19930815)72:4<1155::AID-CNCR2820720404>3.0.CO;2-C; MIROS M, 1991, GUT, V32, P1441, DOI 10.1136/gut.32.12.1441; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Montgomery E, 2001, HUM PATHOL, V32, P379, DOI 10.1053/hupa.2001.23511; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; O'Connor JB, 1999, AM J GASTROENTEROL, V94, P2037; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; PETERS JH, 1994, J THORAC CARDIOV SUR, V108, P813, DOI 10.1016/S0022-5223(94)70178-4; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; Rabinovitch PS, 2001, AM J GASTROENTEROL, V96, P3071, DOI 10.1111/j.1572-0241.2001.05261.x; Reid BJ, 2001, AM J GASTROENTEROL, V96, P2839; Sampliner RE, 2002, AM J GASTROENTEROL, V97, P1888; Sarbia M, 2004, INT J CANCER, V111, P224, DOI 10.1002/ijc.20212; Sato F, 2002, CANCER RES, V62, P1148; Sato F, 2002, CANCER RES, V62, P6820; Schnell TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/gast.2001.25065; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; Shaheen N, 2002, JAMA-J AM MED ASSOC, V287, P1972, DOI 10.1001/jama.287.15.1972; Sharma P, 2000, GUT, V46, P9, DOI 10.1136/gut.46.1.9; Sharma P, 2001, GASTROENTEROLOGY, V120, pA16, DOI 10.1016/S0016-5085(01)80081-0; Shibata DM, 2002, CANCER RES, V62, P5637; Skacel M, 2000, AM J GASTROENTEROL, V95, P3383; Soldes OS, 1999, BRIT J CANCER, V79, P595, DOI 10.1038/sj.bjc.6690094; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; STREITZ JM, 1993, J THORAC CARDIOV SUR, V105, P383; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; Teodori L, 1998, CYTOMETRY, V34, P257, DOI 10.1002/(SICI)1097-0320(19981215)34:6<257::AID-CYTO3>3.0.CO;2-S; Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403; Tseng EE, 2003, J GASTROINTEST SURG, V7, P164, DOI 10.1016/S1091-255X(02)00153-1; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Weston AP, 2001, AM J GASTROENTEROL, V96, P1355, DOI 10.1111/j.1572-0241.2001.03851.x; Weston AP, 1997, AM J GASTROENTEROL, V92, P407; Weston AP, 1999, AM J GASTROENTEROL, V94, P3413, DOI 10.1111/j.1572-0241.1999.01602.x; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212; Wong DJ, 1997, CANCER RES, V57, P2619; Wong DJ, 2001, CANCER RES, V61, P8284; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376	92	195	205	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4138	4148		10.1038/sj.onc.1208598	http://dx.doi.org/10.1038/sj.onc.1208598			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15824739				2022-12-17	WOS:000229680300012
J	Dean, NM; Bennett, CF				Dean, NM; Bennett, CF			Antisense oligonucleotide-based therapeutics for cancer	ONCOGENE			English	Article						antisense oligonucleotides; RNase H; siRNA; survivin	KINASE-C-ALPHA; SMALL INTERFERING RNAS; CULTURED-MAMMALIAN-CELLS; PEPTIDE NUCLEIC-ACID; ICAM-1 MESSENGER-RNA; DOUBLE-STRANDED-RNA; IN-VIVO STABILITY; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; CAENORHABDITIS-ELEGANS; FULMINANT-HEPATITIS	There has been steady progress in antisense technology over the past 14 years. We now have a far better appreciation of the attributes and limitations of the technology. Antisense oligonucleotides have been used to selectively inhibit thousands of genes in mammalian cells, hundreds, if not thousands, of genes in rodents and other species and multiple genes in humans. There are over 20 antisense drugs currently in clinical trials, several of which are showing promising results. Like any other class of drugs in development, there will continue to be successes and failures in the clinic. Despite some disappointments with the technology, it appears to be a valid platform for both drug discovery and as an experimental tool for functionalizing genes. Advances in the medicinal chemistry and formulation of antisense oligonucleotides will further enhance their therapeutic and commercial potential.	ISIS Pharmaceut, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Bennett, CF (corresponding author), ISIS Pharmaceut, 2282 Faraday Ave, Carlsbad, CA 92008 USA.							AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Agrawal S, 2002, INT J ONCOL, V21, P65; AGRAWAL S, 1995, BIOCHEM PHARMACOL, V50, P571, DOI 10.1016/0006-2952(95)00160-2; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Butler M, 1997, LAB INVEST, V77, P379; Butler M, 2000, J PHARMACOL EXP THER, V292, P489; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; CECH TR, 1994, NATURE, V372, P39, DOI 10.1038/372039a0; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Cook PD, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P29; COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1181; Crooke ST, 1999, BIOCHIM BIOPHYS ACTA, V1489, P30; De Backer MD, 2001, NAT BIOTECHNOL, V19, P235, DOI 10.1038/85677; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Flanagan WM, 1999, P NATL ACAD SCI USA, V96, P3513, DOI 10.1073/pnas.96.7.3513; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; Geary RS, 1997, ANTI-CANCER DRUG DES, V12, P383; Geary RS, 2001, J PHARMACOL EXP THER, V296, P890; Gottschalk AR, 2001, CANCER RES, V61, P2105; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; Harborth J, 2001, J CELL SCI, V114, P4557; Henry S, 2000, J PHARMACOL EXP THER, V292, P468; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Kuss BJ, 2002, INT J CANCER, V98, P128, DOI 10.1002/ijc.10159; Larsen HJ, 1999, BBA-GENE STRUCT EXPR, V1489, P159, DOI 10.1016/S0167-4781(99)00145-1; Leaman DW, 2002, VIROLOGY, V292, P70, DOI 10.1006/viro.2001.1213; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Lee Y, 2003, CANCER RES, V63, P2802; Levin AA, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P201; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Lima WF, 2001, METHOD ENZYMOL, V341, P430, DOI 10.1016/S0076-6879(01)41168-2; Mani S, 2002, CLIN CANCER RES, V8, P1042; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; McMahon BM, 2002, ANTISENSE NUCLEIC A, V12, P65, DOI 10.1089/108729002760070803; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Miyake H, 2001, CLIN CANCER RES, V7, P4245; Mohammad R, 2002, CLIN CANCER RES, V8, P1277; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; Nylandsted J, 2002, CANCER RES, V62, P7139; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Rankin R, 2001, ANTISENSE NUCLEIC A, V11, P333, DOI 10.1089/108729001753231713; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Sazani P, 2001, NUCLEIC ACIDS RES, V29, P3965, DOI 10.1093/nar/29.19.3965; Sewell KL, 2002, J PHARMACOL EXP THER, V303, P1334, DOI 10.1124/jpet.102.036749; Sheehan JP, 2001, BIOCHEMISTRY-US, V40, P4980, DOI 10.1021/bi002396x; Shen LJ, 2003, ANTISENSE NUCLEIC A, V13, P129, DOI 10.1089/108729003768247592; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; STEHELIN D, 1976, NATURE, V260, P70; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Taylor J K, 1999, Curr Opin Drug Discov Devel, V2, P147; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Thallinger C, 2003, J INVEST DERMATOL, V120, P1081, DOI 10.1046/j.1523-1747.2003.12252.x; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; Tortora G, 2001, CLIN CANCER RES, V7, P2537; Urban G, 2001, J BIOL CHEM, V276, P27638, DOI 10.1074/jbc.M103512200; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; Vickers TA, 2001, NUCLEIC ACIDS RES, V29, P1293, DOI 10.1093/nar/29.6.1293; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Wang H, 2002, INT J ONCOL, V21, P73; Weng D E, 2001, Curr Oncol Rep, V3, P141, DOI 10.1007/s11912-001-0014-7; Wengel J, 1999, ACCOUNTS CHEM RES, V32, P301, DOI 10.1021/ar980051p; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 1998, J BIOL CHEM, V273, P2532, DOI 10.1074/jbc.273.5.2532; Yu RZ, 2001, J PHARMACOL EXP THER, V296, P388; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475; Zhang H, 2003, J PHARMACOL EXP THER, V307, P24, DOI 10.1124/jpet.103.050435; ZHANG RW, 1995, BIOCHEM PHARMACOL, V50, P545, DOI 10.1016/0006-2952(95)00159-W; Zhao QY, 1996, BIOCHEM PHARMACOL, V51, P173, DOI 10.1016/0006-2952(95)02177-9	94	195	223	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 8	2003	22	56					9087	9096		10.1038/sj.onc.1207231	http://dx.doi.org/10.1038/sj.onc.1207231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663487				2022-12-17	WOS:000187043600012
J	Hackett, JA; Greider, CW				Hackett, JA; Greider, CW			Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis	ONCOGENE			English	Article						telomeres; telomerase; chromosomal instability	INDUCED DNA-REPLICATION; STRAND BREAK REPAIR; TO-END FUSIONS; BINDING-PROTEIN; FISSION YEAST; NONRECIPROCAL TRANSLOCATIONS; IMMORTAL CELLS; CANCER; KU; TRF2	Telomere shortening and telomerase activation both occur in human tumors. Telomere shortening has been proposed to have two conflicting roles in tumorigenesis: tumor suppression and initiation of chromosomal instability. Similarly, while telomerase activation is suggested to be necessary for tumor growth, telomerase may help to stabilize genomic instability. Here we review what is known about these conflicting roles and propose a framework to understand the role of telomerase in cancer progression.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet & Mol Bi, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Greider, CW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 617 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.			Greider, Carol/0000-0002-5494-8126	NIGMS NIH HHS [GM43080] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043080] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Baumann P, 2000, MOL BIOL CELL, V11, P3265, DOI 10.1091/mbc.11.10.3265; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bosco G, 1998, GENETICS, V150, P1037; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 2002, HARVEY LECT SERIES, V96, P2000; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, P NATL ACAD SCI USA, V97, P11409, DOI 10.1073/pnas.210388397; Muller H, 1938, COLLECTING NET, V13, P181; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; SHAY JW, 1997, EUR J CAN, V33, P789; Shih IM, 2001, CANCER RES, V61, P818; Tang RP, 1998, CANCER RES, V58, P4052; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WANG WL, 1992, NUCLEIC ACIDS RES, V20, P6621, DOI 10.1093/nar/20.24.6621; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	62	195	202	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					619	626		10.1038/sj.onc.1205061	http://dx.doi.org/10.1038/sj.onc.1205061			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850787				2022-12-17	WOS:000173390500014
J	Meplan, C; Richard, MJ; Hainaut, P				Meplan, C; Richard, MJ; Hainaut, P			Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells	ONCOGENE			English	Article						p53; zinc; chelator; metallothionein; metals	WILD-TYPE P53; DNA-BINDING ACTIVITY; IN-VITRO; NNN'N'-TETRAKIS-(2-PYRIDYLMETHYL)ETHYLENE DIAMINE; TRANSITION-METALS; KAPPA-B; METALLOTHIONEIN; CONFORMATION; ACTIVATION; EXPRESSION	The tumor suppressor p53 is a transcription factor which binds DNA through a structurally complex domain stabilized by a zinc atom. Zinc chelation disrupts the architecture of this domain, inducing the protein to adopt an immunological phenotype identical to that of many mutant forms of p53, In this report, we used Zn-65 to show that incorporation of zinc within the protein was required for folding in the 'wild-type' conformation capable of specific DNA-binding, Using a cellular assay, we show that addition of extracellular zinc at concentrations within the physiological range (5 muM) was required for renaturation and reactivation of wild-type p53, Among other divalent metals tested (Cd2+, Cu2+, Co2+, Fe2+ and Ni2+), only Co2+ at 125 muM had a similar effect. Recombinant metallothionein (MT), a metal chelator protein, was found to modulate p53 conformation in vitro. In cultured cells, overexpression of MT by transfection could modulate p53 transcriptional activity. Taken together, these results suggest that zinc binding plays a regulatory role in the control of p53 folding and DNA-binding activity.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France; Ctr Hosp & Univ Albert Michalon, Biochim Lab C, F-38043 Grenoble 9, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biochem Res Ctr, Dundee DD1 9SY, Scotland.		Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; Canzoniero LMT, 1997, NEUROBIOL DIS, V4, P275, DOI 10.1006/nbdi.1997.0160; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fojta M, 1999, J BIOL CHEM, V274, P25749, DOI 10.1074/jbc.274.36.25749; FREBOURG T, 1992, CANCER RES, V52, P6976; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; Kaelin WG, 1998, SCIENCE, V281, P57, DOI 10.1126/science.281.5373.57; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; KILLE P, 1991, FEBS LETT, V295, P171, DOI 10.1016/0014-5793(91)81411-Z; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Linke SP, 1997, CANCER RES, V57, P1171; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAGEL WW, 1995, P NATL ACAD SCI USA, V92, P579, DOI 10.1073/pnas.92.2.579; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Parat MO, 1999, BIOL TRACE ELEM RES, V70, P51, DOI 10.1007/BF02783849; Parat MO, 1998, BIOL TRACE ELEM RES, V65, P261, DOI 10.1007/BF02789101; PATTISON SE, 1986, FASEB J, V45, P2805; PATTISON SE, 1986, AM J PHYSIOL, V250, pE677, DOI 10.1152/ajpendo.1986.250.6.E677; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Roesijadi G, 1998, J BIOL CHEM, V273, P17425, DOI 10.1074/jbc.273.28.17425; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; Schmidt C, 1999, ARCH BIOCHEM BIOPHYS, V364, P91, DOI 10.1006/abbi.1999.1107; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TSUJIKAWA K, 1994, EUR J CELL BIOL, V63, P240; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; VALLEE BL, 1991, METHOD ENZYMOL, V205, P3; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WLOSTOWSKI T, 1993, BIOMETALS, V6, P71, DOI 10.1007/BF00140106; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zalewski P D, 1994, Chem Biol, V1, P153, DOI 10.1016/1074-5521(94)90005-1; Zalewski PD, 1996, REPROD FERT DEVELOP, V8, P1097, DOI 10.1071/RD9961097; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	63	195	199	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5227	5236		10.1038/sj.onc.1203907	http://dx.doi.org/10.1038/sj.onc.1203907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077439				2022-12-17	WOS:000165059700003
J	BATES, S; PARRY, D; BONETTA, L; VOUSDEN, K; DICKSON, C; PETERS, G				BATES, S; PARRY, D; BONETTA, L; VOUSDEN, K; DICKSON, C; PETERS, G			ABSENCE OF CYCLIN-D CDK COMPLEXES IN CELLS LACKING FUNCTIONAL RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; HUMAN BREAST-CANCER; GENE-PRODUCT; DEPENDENT KINASES; RB GENE; P53; LINES; ASSOCIATION; PHOSPHORYLATION; EXPRESSION	Cyclins D1, D2 and D3 are thought to function in the G1 phase of the cell division cycle by regulating the activity of cyclin-dependent protein kinases. All three D-type cyclins can be shown to associate with two specific kinases, cdk4 and cdk6, providing at least six possible combinations. To establish whether different cell types require different subsets of these complexes and whether they are altered in tumours where D-cyclin expression is perturbed, we surveyed a series of tumour cell lines and compared them where possible to non-tumorigenic counterparts. Although complexes involving cdk4 or cdk6 were readily observed in many of the cell lines, no complexes were detectable in human cells harbouring, DNA tumour virus oncoproteins or in which the retinblastoma gene product (pRb) is mutated or missing. These data suggest that as well as being a potential substrate for D-cyclin-kinases, functional pRb contributes to the formation or stability of the complexes, at least in human cells.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BARTEK J, 1990, ONCOGENE, V5, P893; BATES S, 1994, ONCOGENE, V9, P71; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1994, IN PRESS CANCER SURV, V18; FAUST JB, 1992, CANCER RES, V52, P2460; GOLDFARB M, 1991, ONCOGENE, V6, P65; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OOKAWA K, 1993, ONCOGENE, V8, P2175; PALMERO I, 1993, ONCOGENE, V8, P1049; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHUURING E, 1992, ONCOGENE, V7, P355; SOULE HD, 1990, CANCER RES, V50, P6075; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	195	203	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1633	1640						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183557				2022-12-17	WOS:A1994NL81500014
J	TAKAISHI, K; SASAKI, T; KATO, M; YAMOCHI, W; KURODA, S; NAKAMURA, T; TAKEICHI, M; TAKAI, Y				TAKAISHI, K; SASAKI, T; KATO, M; YAMOCHI, W; KURODA, S; NAKAMURA, T; TAKEICHI, M; TAKAI, Y			INVOLVEMENT OF RHO-P21 SMALL GTP-BINDING PROTEIN AND ITS REGULATOR IN THE HGF-INDUCED CELL MOTILITY	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; SCATTER FACTOR; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; FACTOR RECEPTOR; PARTIAL-PURIFICATION; MET PROTOONCOGENE; EXCHANGE PROTEINS	Hepatocyte growth factor (HGF) induced motility of cultured mouse keratinocytes (308R cells). This HGF-induced cell motility was inhibited by microinjection of either rho GDI, an inhibitory GDP/GTP exchange protein for rho p21 small GTP-binding protein, or a botulinum exoenzyme C3 which is known to selectively impair the function of who p21 by ADP-ribosylating its effector domain. The rho GDI action was prevented by comicroinjection with the guanosine 5'-(3-O-thio)triphosphate (GTP gamma S)-bound active form of rhoA p21, and the C3 action was prevented by comicroinjection with a rhoA p21 mutant (rhoA(Ile41) p21) which is resistant to the C3 action. The HGF-induced cell motility was not inhibited by microinjection of a dominant negative rac1 p21 mutant (rac1(Asn17) p21) or a dominant negative Ki-ras p21 mutant (Ki-ras(Asn17) p21). Microinjection of the GTP gamma S-bound form of rac1 p21 or a dominant active Ki-ras p21 mutant (Ki-ras(Val12) p21) did not induce cell motility. These results indicate that both rho p21 and who GDI, but neither rac p21 nor ras p21, are involved in the HGF-induced cell motility. However, microinjection of the GTP gamma S-bound form of rhoA p21 alone did not induce cell motility in the absence of HGF, suggesting that activation of who p21 is necessary but not sufficient for the HGF-induced cell motility. The HGF-induced cell motility was mimicked by 12-O-tetradecanoylphorbol-13-acetate, a protein kinase C-activating phorbol ester, but not by Ca2+ ionophore. The phorbol ester-induced cell motility was also inhibited by microinjection of rho GDI or C3. These results indicate that both rho p21 and rho GDI are also involved in the phorbol ester-induced cell motility.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA,OSAKA 565,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; Osaka University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Takeichi, Masatoshi/G-5903-2012; KURODA, SHINYA/G-4961-2014	Takeichi, Masatoshi/0000-0002-9931-3378; 				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; FURLONG RA, 1991, J CELL SCI, V100, P173; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; KURODA S, 1992, BIOCHEM BIOPH RES CO, V185, P473, DOI 10.1016/S0006-291X(05)81009-5; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1992, J BIOL CHEM, V267, P20921; MORIISHI K, 1991, J BACTERIOL, V173, P6025, DOI 10.1128/jb.173.19.6025-6029.1991; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J., 1989, MOL CLONING LAB MANU; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; WATABE M, 1993, CELL STRUCT FUNCT, V18, P111; Weber K, 1972, Methods Enzymol, V26, P3; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	59	195	198	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					273	279						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302589				2022-12-17	WOS:A1994MW24700033
J	NAKAMURA, K; HORI, T; SATO, N; SUGIE, K; KAWAKAMI, T; YODOI, J				NAKAMURA, K; HORI, T; SATO, N; SUGIE, K; KAWAKAMI, T; YODOI, J			REDOX REGULATION OF A SRC FAMILY PROTEIN-TYROSINE KINASE P56(LCK) IN T-CELLS	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIGEN RECEPTOR; IL-2 RECEPTOR; KAPPA-B; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAINS; BINDING-ACTIVITY; CD4 RECEPTOR; HTLV-I; ACTIVATION	Protein tyrosine phosphorylation was examined after T cells were exposed to oxidative stress in vitro to investigate the possible involvement of redox regulation in T-cell signaling. Oxidative reagents such as hydrogen peroxide (H2O2) and diamide, which oxidize the free sulfhydryl groups in the cells, markedly induced tyrosine phosphorylation of multiple cellular proteins, especially a 55-kDa protein, of cultured peripheral blood T lymphocytes (PBL blasts). The 55-kDa molecule phosphorylated by diamide turned out to be a src family protein tyrosine kinase, p56lck. The immune complex kinase assay showed that the kinase activity of p56lck of diamide-treated PBL blasts was enhanced. The tryptic peptide mapping of p56lck demonstrated that diamide induced the phosphorylation both at Tyr-394 (autophosphorylation site) and at Tyr-505 (negative regulatory site). Taken together, the tyrosine phosphorylation and presumably kinase activity of p56lck were swiftly enhanced by oxidative stress, indicating that T cells have a redox-sensitive signaling mechanism, which is partly mediated by the lymphocyte-specific protein tyrosine kinase p56lck.	KYOTO UNIV, INST VIRUS RES, DEPT BIOL RESPONSES, KYOTO 60601, JAPAN; KYOTO UNIV, CTR RADIAT BIOL, DEPT LATE EFFECT STUDIES, KYOTO 60601, JAPAN; LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA	Kyoto University; Kyoto University; La Jolla Institute for Immunology			Kawakami, Toshiaki/O-1616-2015					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1989, ONCOGENE, V4, P265; JUNE CH, 1990, J IMMUNOL, V144, P1591; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LUO K, 1990, ONCOGENE, V5, P921; LUO K, 1990, ONCOGENE, V5, P803; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YODOI J, 1985, J IMMUNOL, V134, P1623; YODOI J, 1991, ADV CANCER RES, V57, P381	43	195	198	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3133	3139						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414515				2022-12-17	WOS:A1993MC09300030
J	Yang, L; Wu, X; Wang, Y; Zhang, K; Wu, J; Yuan, YC; Deng, X; Chen, L; Kim, CCH; Lau, S; Somlo, G; Yen, Y				Yang, L.; Wu, X.; Wang, Y.; Zhang, K.; Wu, J.; Yuan, Y-C; Deng, X.; Chen, L.; Kim, C. C. H.; Lau, S.; Somlo, G.; Yen, Y.			FZD7 has a critical role in cell proliferation in triple negative breast cancer	ONCOGENE			English	Article						FZD7; TNBC; Wnt canonical signaling pathway; proliferation; potential therapeutic target	MAMMARY-GLAND DEVELOPMENT; STEM-CELLS; WNT; THERAPY; RECEPTOR; FAMILY; MEMBER; TUMORS; LRP6; MICE	Breast cancer is genetically and clinically heterogeneous. Triple negative breast cancer (TNBC) is a subtype of breast cancer that is usually associated with poor outcome and lack of benefit from targeted therapy. We used microarray analysis to perform a pathway analysis of TNBC compared with non-triple negative breast cancer (non-TNBC). Overexpression of several Wnt pathway genes, such as frizzled homolog 7 (FZD7), low density lipoprotein receptor-related protein 6 and transcription factor 7 (TCF7) was observed in TNBC, and we directed our focus to the Wnt pathway receptor, FZD7. To validate the function of FZD7, FZD7shRNA was used to knock down FZD7 expression. Notably, reduced cell proliferation and suppressed invasiveness and colony formation were observed in TNBC MDA-MB-231 and BT-20 cells. Study of the possible mechanism indicated that these effects occurred through silencing of the canonical Wnt signaling pathway, as evidenced by loss of nuclear accumulation of beta-catenin and decreased transcriptional activity of TCF7. In vivo studies revealed that FZD7shRNA significantly suppressed tumor formation, through reduced cell proliferation, in mice bearing xenografts without FZD7 expression. Our findings suggest that FZD7-involved canonical Wnt signaling pathway is essential for tumorigenesis of TNBC, and thus, FZD7 shows promise as a biomarker and a potential therapeutic target for TNBC. Oncogene (2011) 30, 4437-4446; doi:10.1038/onc.2011.145; published online 2 May 2011	[Yang, L.; Kim, C. C. H.; Yen, Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Duarte, CA 91010 USA; [Wu, X.; Yuan, Y-C; Deng, X.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Wang, Y.; Zhang, K.; Chen, L.] City Hope Natl Med Ctr, Beckman Res Inst, Translat Res Lab, Duarte, CA 91010 USA; [Wu, J.] City Hope Natl Med Ctr, Beckman Res Inst, Div Comparat Med, Duarte, CA 91010 USA; [Lau, S.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA; [Somlo, G.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Yen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Pharmacol, Beckman Bldg,Room 4117,1500 E Duarte Rd, Duarte, CA 91010 USA.	yyen@coh.org	Zhang, Keqiang/P-7082-2019; Yen, Yun/H-9591-2016		City of Hope National Medical Center for Translational Research	City of Hope National Medical Center for Translational Research	We thank Mariko Lee in the Light Microscopy and Digital Imaging Core for assistance with immunofluorescence and immunohistochemical microscopy, Arthur Li in the Division of Information Science for statistical analysis and Yan Wang in the Division of Comparative Medicine for tumor inoculation, tumor measurement and tumor collection. We thank Dr Keely Walker and Mansze Kong for critical editing of the manuscript. Grant Support was received from City of Hope National Medical Center for Translational Research.	Amir E, 2010, NAT REV CLIN ONCOL, V7, P79, DOI 10.1038/nrclinonc.2009.231; Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Jones KA, 2008, GENE DEV, V22, P3077, DOI 10.1101/gad.1741008; Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005; Komiya Yuko, 2008, Organogenesis, V4, P68; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Li Y, 2005, J MAMMARY GLAND BIOL, V10, P17, DOI 10.1007/s10911-005-2537-2; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813; Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Ojalvo LS, 2010, J IMMUNOL, V184, P702, DOI 10.4049/jimmunol.0902360; Perez EA, 2010, BREAST CANCER RES TR, V120, P285, DOI 10.1007/s10549-010-0736-z; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Rahman M, 2009, ADV CANCER RES, V103, P43, DOI 10.1016/S0065-230X(09)03003-6; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sonderegger S, 2007, PLACENTA, V28, pS97, DOI 10.1016/j.placenta.2006.11.003; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192	33	194	207	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	43					4437	4446		10.1038/onc.2011.145	http://dx.doi.org/10.1038/onc.2011.145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21532620	hybrid			2022-12-17	WOS:000296356500006
J	Polager, S; Ofir, M; Ginsberg, D				Polager, S.; Ofir, M.; Ginsberg, D.			E2F1 regulates autophagy and the transcription of autophagy genes	ONCOGENE			English	Article						E2F; autophagy; LC3; ATG1; DRAM	PROGRAMMED CELL-DEATH; APOPTOSIS; TARGET; PATHWAYS; ROLES; YEAST; DRAM; P53	The retinoblastoma pathway is often inactivated in human tumors resulting in deregulated E2F activity that can induce both proliferation and cell death. Although the role of E2F in apoptosis is well characterized, little is known regarding its putative participation in other cell death pathways. We show here that activation of E2F1 upregulates the expression off our autophagy genes microtubule-associated protein-1 light chain-3 (LC3), autophagy-related gene-1 (ATG1), ATG5 and damage-regulated autophagy modulator (DRAM). E2F1-mediated induction of LC3, ATG1 and DRAM is direct and indeed, endogenous E2F1 can be found bound to regions encompassing the promoters of these genes. Regulation of ATG5 by E2F1 is indirect. Importantly, we demonstrate that E2F1 activation enhances autophagy and conversely, reducing endogenous E2F1 expression inhibits DNA damage-induced autophagy. These studies identify E2F1 as a transcriptional regulator of autophagy, and for the first time establish a role for E2F1 in DNA damage-induced autophagy.	[Polager, S.; Ofir, M.; Ginsberg, D.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Ginsberg, D (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	ginsbed@mail.biu.ac.il		ginsberg, doron/0000-0002-1257-4920				Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; DeGregori J, 2006, CURR MOL MED, V6, P739; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fortin A, 2004, J BIOL CHEM, V279, P28706, DOI 10.1074/jbc.M400376200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Tsuneoka M, 2003, CELL STRUCT FUNCT, V28, P195; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	23	194	200	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4860	4864		10.1038/onc.2008.117	http://dx.doi.org/10.1038/onc.2008.117			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18408756				2022-12-17	WOS:000258445100011
J	Carlomagno, F; Guida, T; Anaganti, S; Vecchio, G; Fusco, A; Ryan, AJ; Billaud, M; Santoro, M				Carlomagno, F; Guida, T; Anaganti, S; Vecchio, G; Fusco, A; Ryan, AJ; Billaud, M; Santoro, M			Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors	ONCOGENE			English	Article						thyroid; tyrosine kinase inhibitors; RET; MEN2	MEDULLARY-THYROID CARCINOMA; NEOPLASIA TYPE 2B; IMATINIB MESYLATE; BLAST CRISIS; GROWTH; ABL; GERMLINE; ACTIVATION; DOMAIN; ZD6474	We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC(50)less than or equal to100 nM) towards constitutively active oncogenic RET kinases. Here, we show that most oncogenic MEN2-associated RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition. In contrast, MEN2-associated swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compounds. Substitution of valine 804 with the small amino-acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase. Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Astra Zeneca Mereside, Canc Discovery, Macclesfield, Cheshire, England; CNRS, Genet Lab, Lyon, France	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; AstraZeneca; Centre National de la Recherche Scientifique (CNRS)	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	RYAN, Anderson/ACG-0319-2022; Billaud, Marc N/M-6954-2013; Ryan, Anderson J/O-7701-2015	RYAN, Anderson/0000-0001-6241-7969; Ryan, Anderson J/0000-0001-6241-7969; Fusco, Alfredo/0000-0003-3332-5197				Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bartsch DK, 2000, EXP CLIN ENDOCR DIAB, V108, P128, DOI 10.1055/s-2000-5806; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; BOLINO A, 1995, ONCOGENE, V10, P2415; Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 1997, CANCER RES, V57, P391; Carlomagno F, 2003, J CLIN ENDOCR METAB, V88, P1897, DOI 10.1210/jc.2002-021278; Carlomagno F, 2002, CANCER RES, V62, P1077; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Ciardiello F, 2003, CLIN CANCER RES, V9, P1546; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; Frohnauer MK, 2000, SURGERY, V128, P1052, DOI 10.1067/msy.2000.11/6/111080; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Kasprzak L, 2001, J MED GENET, V38, P784, DOI 10.1136/jmg.38.11.784; La Rosee P, 2002, CANCER RES, V62, P7149; Lombardo F, 2002, J CLIN ENDOCR METAB, V87, P1674, DOI 10.1210/jcem.87.4.8403; Machens A, 2003, NEW ENGL J MED, V349, P1517, DOI 10.1056/NEJMoa012915; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Menko FH, 2002, J CLIN ENDOCR METAB, V87, P393, DOI 10.1210/jc.87.1.393; Nagar B, 2002, CANCER RES, V62, P4236; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Sawyers CL, 2002, J CLIN ONCOL, V20, P3568, DOI 10.1200/JCO.2002.20.17.3568; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Wedge SR, 2002, CANCER RES, V62, P4645; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	45	194	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6056	6063		10.1038/sj.onc.1207810	http://dx.doi.org/10.1038/sj.onc.1207810			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15184865				2022-12-17	WOS:000223261000005
J	Muratovska, A; Zhou, CM; He, SJ; Goodyer, P; Eccles, MR				Muratovska, A; Zhou, CM; He, SJ; Goodyer, P; Eccles, MR			Paired-box genes are frequently expressed in cancer and often required for cancer cell survival	ONCOGENE			English	Article						PAX genes; siRNA; cell survival; tumor	HUMAN FETAL KIDNEY; HUMAN PAX6 GENE; TRANSCRIPTION FACTOR; ALVEOLAR RHABDOMYOSARCOMA; WILMS-TUMOR; APOPTOSIS; MUTATIONS; CARCINOMA; PROTEIN; ONCOGENE	The paired-box (PAX) genes encode a family of nine well-characterized paired-box transcription factors, with important roles in development and disease. Although PAX genes are primarily expressed in the embryo, constitutive expression promotes tissue hyperplasia. Rare tumor-specific mutations of PAX genes implicate an oncogenic role, and persistent PAX expression characterizes several tumors. Yet, a cancer-wide analysis of PAX gene expression to investigate a general role for PAX genes has not been performed. We analysed the pattern and requirement for PAX gene expression in a panel of common cancer cell lines. Very frequent PAX gene expression was identified in tumor cell lines, including lymphoma, breast, ovarian, lung, and colon cancer. In addition, the PAX2 gene was frequently expressed in a panel of 406 common primary tumor tissues. Apoptosis was rapidly induced in ovarian and bladder cancer cell lines following RNA interference to silence PAX2 expression, despite concomitant TP53 and/or HRAS mutations. These data suggest that PAX genes are frequently expressed in cancer, and that endogenous PAX gene expression is required for the growth and survival of cancer cells.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Pediat, Westmount, PQ H3Z 2Z3, Canada	University of Otago; McGill University	Eccles, MR (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin, New Zealand.			Filipovska, Aleksandra/0000-0002-6998-8403				BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Borycki AG, 1999, DEVELOPMENT, V126, P1665; Bouchard M, 2000, DEVELOPMENT, V127, P3703; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; ECCLES MR, 1995, AM J PATHOL, V146, P40; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FABBRO D, 1994, CANCER RES, V54, P4744; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GNARRA JR, 1995, CANCER RES, V55, P4092; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Hewitt SM, 1997, ANTICANCER RES, V17, P3211; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Mansouri A, 1998, MECH DEVELOP, V78, P171, DOI 10.1016/S0925-4773(98)00168-3; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Morrison AM, 1998, BLOOD, V92, P3865, DOI 10.1182/blood.V92.10.3865.422k01_3865_3878; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; Murer L, 2002, NEPHRON, V91, P588, DOI 10.1159/000065017; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Scholl FA, 2001, CANCER RES, V61, P823; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Steinbach JP, 2001, INT J CANCER, V93, P459, DOI 10.1002/ijc.1371; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; STUART ET, 1995, CLIN CANCER RES, V1, P207; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Torban E, 2000, AM J PATHOL, V157, P833, DOI 10.1016/S0002-9440(10)64597-X; van Raamsdonk CD, 2000, DEVELOPMENT, V127, P5439; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811	50	194	209	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7989	7997		10.1038/sj.onc.1206766	http://dx.doi.org/10.1038/sj.onc.1206766			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970747				2022-12-17	WOS:000185388200014
J	Krug, U; Ganser, A; Koeffler, HP				Krug, U; Ganser, A; Koeffler, HP			Tumor suppressor genes in normal and malignant hematopoiesis	ONCOGENE			English	Review						tumor suppressor gene; hematopoiesis; malignancies; myeloid differentiation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; BINDING-PROTEIN-ALPHA; ACUTE MYELOGENOUS LEUKEMIA; NON-HODGKINS-LYMPHOMA; 2 DISTINCT REGIONS; DEPENDENT KINASE INHIBITORS; DOMINANT-NEGATIVE MUTATIONS; COLORECTAL-CARCINOMA GENE	Over the last decade, a growing number of tumor suppressor genes have been discovered to play a role in tumorigenesis. Mutations of p53 have been found in hematological malignant diseases, but the frequency of these alterations is much lower than in solid tumors. These mutations occur especially as hematopoietic abnormalities become more malignant such as going from the chronic phase to the blast crisis of chronic myeloid leukemia. A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myeloproliferative disorders. Tumor suppressor genes are altered via different mechanisms, including deletions and point mutations, which may result in an inactive or dominant negative protein. Methylation of the promoter of the tumor suppressor gene can blunt its expression. Chimeric proteins formed by chromosomal translocations (i.e. AML1-ETO, PML-RARalpha, PLZF-RARalpha) can produce a dominant negative transcription factor that can decrease expression of tumor suppressor genes. This review provides an overview of the current knowledge about the involvement of tumor suppressor genes in hematopoietic malignancies including those involved in cell cycle control, apoptosis and transcriptional control.	Univ Calif Los Angeles, Div Hematol Oncol, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Hannover Med Sch, Dept Hematol Oncol, D-3000 Hannover, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Hannover Medical School	Krug, U (corresponding author), Univ Calif Los Angeles, Div Hematol Oncol, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd,Suite B213, Los Angeles, CA 90048 USA.	utzkrug@hotmail.com						ADAMSON DJA, 1995, BRIT J HAEMATOL, V89, P61, DOI 10.1111/j.1365-2141.1995.tb08910.x; ADAMSON DJA, 1995, BRIT J CANCER, V72, P150, DOI 10.1038/bjc.1995.292; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AHUJA HG, 1991, BLOOD, V78, P3259; Algar E, 1997, LEUKEMIA, V11, P110, DOI 10.1038/sj.leu.2400521; Amiel A, 1997, CANCER GENET CYTOGEN, V97, P97, DOI 10.1016/S0165-4608(96)00341-X; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAIRD PN, 1992, ONCOGENE, V7, P2141; Baird PN, 1997, EXP HEMATOL, V25, P312; Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARBOSA DM, 1998, LEUKEMIA RES, V22, P787; Barnabas N, 2001, CANCER, V91, P285, DOI 10.1002/1097-0142(20010115)91:2<285::AID-CNCR1000>3.0.CO;2-X; Batova A, 1999, CANCER RES, V59, P1492; Batova A, 1997, CANCER RES, V57, P832; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; Beck Z, 2000, LEUKEMIA LYMPHOMA, V38, P587, DOI 10.3109/10428190009059278; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Beltinger C, 1998, BLOOD, V91, P3943; Bench AJ, 2000, ONCOGENE, V19, P3902, DOI 10.1038/sj.onc.1203728; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; Bergh G, 1999, BLOOD, V94, P1971; Bergmann L, 1997, BLOOD, V90, P1217, DOI 10.1182/blood.V90.3.1217.1217_1217_1225; BHATIA KG, 1992, CANCER RES, V52, P4273; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; BROWN KW, 1992, ONCOGENE, V7, P763; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Bullinger L, 2000, LEUKEMIA, V14, P1490, DOI 10.1038/sj.leu.2401834; Bullrich F, 1999, CANCER RES, V59, P24; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cano I, 1996, CANCER GENET CYTOGEN, V90, P118, DOI 10.1016/S0165-4608(96)00063-5; Carapeti M, 1997, EUR J HAEMATOL, V58, P346; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Castro PD, 1998, LEUKEMIA LYMPHOMA, V30, P443, DOI 10.3109/10428199809057556; Cave H, 1997, LEUKEMIA, V11, P1459, DOI 10.1038/sj.leu.2400798; CESARMAN E, 1992, BLOOD, V80, P3205; Chambon-Pautas C, 1998, LEUKEMIA, V12, P1107, DOI 10.1038/sj.leu.2401069; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen PM, 1999, CANCER, V85, P718, DOI 10.1002/(SICI)1097-0142(19990201)85:3<718::AID-CNCR22>3.0.CO;2-Y; Chim CS, 2001, CANCER, V91, P2222, DOI 10.1002/1097-0142(20010615)91:12<2222::AID-CNCR1252>3.0.CO;2-R; Chim CS, 2001, J CLIN ONCOL, V19, P2033, DOI 10.1200/JCO.2001.19.7.2033; Christiansen DH, 2001, J CLIN ONCOL, V19, P1405, DOI 10.1200/JCO.2001.19.5.1405; Cinti C, 2000, CANCER RES, V60, P383; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Clodi K, 1997, BRIT J HAEMATOL, V98, P913, DOI 10.1046/j.1365-2141.1997.3143131.x; CONDORELLI GL, 1995, P NATL ACAD SCI USA, V92, P4808, DOI 10.1073/pnas.92.11.4808; Cook DM, 1996, ONCOGENE, V13, P1789; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; Corn PG, 1999, CANCER RES, V59, P3352; CORRADINI P, 1994, LEUKEMIA, V8, P758; DAO DD, 1994, LEUKEMIA, V8, P1280; Davies R, 1999, CANCER RES, V59, p1747S; Deuel TF, 1999, BIOCHEM BIOPH RES CO, V254, P192, DOI 10.1006/bbrc.1998.9896; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Di Bacco A, 2000, Oncologist, V5, P405, DOI 10.1634/theoncologist.5-5-405; DICCIANNI MB, 1994, BLOOD, V84, P3105; Dictor M, 1999, AM J CLIN PATHOL, V112, pS40; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Dreyling MH, 1998, GENE CHROMOSOME CANC, V22, P72, DOI 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.3.CO;2-G; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; ELROUBY S, 1993, BLOOD, V82, P3452; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Englert C, 1997, CANCER RES, V57, P1429; Faderl S, 2001, LEUKEMIA RES, V25, P39, DOI 10.1016/S0145-2126(00)00084-9; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FELIX CA, 1994, LEUKEMIA, V8, P963; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FENAUX P, 1992, LEUKEMIA, V6, P42; FENAUX P, 1992, LEUKEMIA, V6, P246; FENAUX P, 1991, BLOOD, V78, P1652; FENAUX P, 1990, NOUV REV FR HEMATOL, V32, P341; FINNEGAN MCM, 1994, CANCER LETT, V86, P215, DOI 10.1016/0304-3835(94)90081-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GAIDANO G, 1993, LEUKEMIA, V7, P946; Gaidano G, 1997, GENE CHROMOSOME CANC, V19, P250; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAIDANO G, 1994, ANN HEMATOL, V68, P3, DOI 10.1007/BF01695912; GAIDANO G, 1994, LEUKEMIA, V8, pS27; Gaiger A, 1999, EUR J HAEMATOL, V63, P86; Garcia JF, 1999, LAB INVEST, V79, P1453; GarciaMarco JA, 1996, BLOOD, V88, P1568; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENE CHROMOSOME CANC, V7, P131, DOI 10.1002/gcc.2870070304; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gombart AF, 1997, LEUKEMIA, V11, P1673, DOI 10.1038/sj.leu.2400840; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gonzalez M, 2000, LEUKEMIA, V14, P183, DOI 10.1038/sj.leu.2401617; Gronbaek K, 1998, BLOOD, V92, P3018; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; Gustafsson B, 1998, PEDIATR HEMAT ONCOL, V15, P519, DOI 10.3109/08880019809018313; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hatta Y, 1998, BLOOD, V92, P2113, DOI 10.1182/blood.V92.6.2113.418k25_2113_2117; Hatta Y, 1999, BLOOD, V93, P613, DOI 10.1182/blood.V93.2.613.402k13_613_616; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; Herman JG, 1997, CANCER RES, V57, P837; HERNANDEZ A, 1993, ANN HEMATOL, V66, P81, DOI 10.1007/BF01695889; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HEWITT SM, 1995, CANCER RES, V55, P5386; HIRAMA T, 1995, BLOOD, V86, P841; Hofmann WK, 2001, LEUKEMIA RES, V25, P855, DOI 10.1016/S0145-2126(01)00037-6; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Horiike S, 1999, LEUKEMIA, V13, P1235, DOI 10.1038/sj.leu.2401466; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Horwitz M, 1997, AM J HUM GENET, V61, P873, DOI 10.1086/514894; Hosoya N, 1998, JPN J CANCER RES, V89, P821, DOI 10.1111/j.1349-7006.1998.tb00634.x; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; ICHIKAWA A, 1992, BLOOD, V79, P2701; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; Im HJ, 1999, PEDIATR HEMAT ONCOL, V16, P109; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Inokuchi K, 1996, J CLIN INVEST, V97, P852, DOI 10.1172/JCI118486; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; Iolascon A, 1997, LEUKEMIA, V11, P359, DOI 10.1038/sj.leu.2400596; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jadayel DM, 1997, LEUKEMIA, V11, P64, DOI 10.1038/sj.leu.2400555; Jamal R, 1996, BRIT J HAEMATOL, V94, P342, DOI 10.1046/j.1365-2141.1996.d01-1804.x; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; JONVEAUX P, 1991, LEUKEMIA, V5, P839; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KANEKO H, 1995, INT J HEMATOL, V61, P113; Kaneko H, 1996, LEUKEMIA LYMPHOMA, V21, P449, DOI 10.3109/10428199609093443; Kawamata N, 1996, DIAGN MOL PATHOL, V5, P33, DOI 10.1097/00019606-199603000-00006; Kawamua M, 1997, Rinsho Ketsueki, V38, P719; KAWAMURA M, 1995, BLOOD, V85, P2546, DOI 10.1182/blood.V85.9.2546.bloodjournal8592546; Kawamura M, 1999, LEUKEMIA RES, V23, P115, DOI 10.1016/S0145-2126(98)00146-5; Kawano S, 1999, BLOOD, V94, P1113; Kees UR, 1997, BLOOD, V89, P4161, DOI 10.1182/blood.V89.11.4161; KELMAN Z, 1989, BLOOD, V74, P2318; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; King-Underwood L, 1998, BLOOD, V91, P2961, DOI 10.1182/blood.V91.8.2961.2961_2961_2968; KingUnderwood L, 1996, BLOOD, V87, P2171, DOI 10.1182/blood.V87.6.2171.bloodjournal8762171; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOCIALKOWSKI S, 1995, BRIT J HAEMATOL, V89, P55, DOI 10.1111/j.1365-2141.1995.tb08911.x; Koduru PRK, 1997, BLOOD, V90, P4078, DOI 10.1182/blood.V90.10.4078; Koike M, 1999, LEUKEMIA RES, V23, P307, DOI 10.1016/S0145-2126(98)00159-3; Kornblau SM, 1998, CLIN CANCER RES, V4, P1955; Kornblau SM, 1999, LEUKEMIA LYMPHOMA, V35, P283, DOI 10.3109/10428199909145731; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krskova-Honzatkova L, 2001, LEUKEMIA RES, V25, P45, DOI 10.1016/S0145-2126(00)00086-2; Kung AL, 2000, GENE DEV, V14, P272; Kupper M, 2001, BRIT J HAEMATOL, V112, P768, DOI 10.1046/j.1365-2141.2001.02566.x; KUROSAWA M, 1995, ANN HEMATOL, V71, P83, DOI 10.1007/BF01699251; LAI JL, 1995, LEUKEMIA, V9, P370; Lai R, 1998, MODERN PATHOL, V11, P642; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lane MD, 1996, INT J OBESITY, V20, pS91; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lazaridou A, 2000, LEUKEMIA LYMPHOMA, V36, P503, DOI 10.3109/10428190009148398; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LEE YY, 1995, STEM CELLS, V13, P556, DOI 10.1002/stem.5530130514; Leoncini L, 1999, CLIN CANCER RES, V5, P4065; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lewis JL, 2001, BLOOD, V97, P2604, DOI 10.1182/blood.V97.9.2604; Liang DC, 1996, LEUKEMIA, V10, P991; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Liu ML, 2001, LEUKEMIA RES, V25, P441, DOI 10.1016/S0145-2126(00)00148-X; LO CF, 1993, BLOOD, V82, P2289; Lo YMD, 1999, CANCER RES, V59, P3899; LUDWIG L, 1993, LEUKEMIA, V7, P1058; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacGrogan D, 2001, ONCOGENE, V20, P4150, DOI 10.1038/sj.onc.1204540; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; Marasca R, 1996, LEUKEMIA LYMPHOMA, V24, P175, DOI 10.3109/10428199609045726; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; Martin A, 1998, BRIT J HAEMATOL, V101, P311, DOI 10.1046/j.1365-2141.1998.00692.x; MASHAL R, 1990, BLOOD, V75, P180; Massaro-Giordano M, 1999, CLIN CANCER RES, V5, P1455; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Mateo M, 1999, AM J PATHOL, V154, P1583, DOI 10.1016/S0002-9440(10)65411-9; Maurer U, 1997, EXP HEMATOL, V25, P945; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; McLean TW, 1996, BLOOD, V88, P4252; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; Misawa Shinichi, 1997, Leukemia (Basingstoke), V11, P533; MIWA H, 1992, LEUKEMIA, V6, P405; Miyagawa K, 1999, GENE CHROMOSOME CANC, V25, P176, DOI 10.1002/(SICI)1098-2264(199906)25:2<176::AID-GCC14>3.3.CO;2-6; MIYAGI T, 1993, LEUKEMIA, V7, P970; MIYAKE K, 1993, BLOOD, V82, P927; Moller MB, 1999, LEUKEMIA, V13, P453, DOI 10.1038/sj.leu.2401315; Montesinos-Rongen M, 1999, BLOOD, V94, P1755, DOI 10.1182/blood.V94.5.1755.417a26_1755_1760; Moreno TC, 2000, EUR J HAEMATOL, V65, P390; Morente MM, 1997, BLOOD, V90, P2429; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mori N, 1995, LEUKEMIA RES, V19, P869, DOI 10.1016/0145-2126(95)00058-5; Mori N, 1999, BRIT J HAEMATOL, V105, P844, DOI 10.1046/j.1365-2141.1999.01497.x; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Murata Y, 1997, FEBS LETT, V409, P41, DOI 10.1016/S0014-5793(97)00477-8; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Nagai H, 1999, GENE CHROMOSOME CANC, V25, P277, DOI 10.1002/(SICI)1098-2264(199907)25:3<277::AID-GCC10>3.0.CO;2-L; Nakahara Y, 1998, LEUKEMIA, V12, P1277, DOI 10.1038/sj.leu.2401099; NAKAI H, 1992, CANCER RES, V52, P6588; NAKAMURA H, 1993, BLOOD, V82, P920, DOI 10.1182/blood.V82.3.920.bloodjournal823920; Nakano Y, 2000, EUR J HAEMATOL, V65, P23, DOI 10.1034/j.1600-0609.2000.90138.x; Neri A, 1996, BRIT J HAEMATOL, V93, P670, DOI 10.1046/j.1365-2141.1996.d01-1690.x; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEWCOMB EW, 1995, MOL CARCINOGEN, V14, P141, DOI 10.1002/mc.2940140302; Ng M, 1999, LEUKEMIA LYMPHOMA, V34, P463, DOI 10.3109/10428199909058473; Nieder C, 2001, ANN HEMATOL, V80, P2, DOI 10.1007/s002770000226; Niegemann E, 1999, ACTA HAEMATOL-BASEL, V102, P72, DOI 10.1159/000040973; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NISHIMURA S, 1995, LEUKEMIA, V9, P598; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; NUCIFORA G, 1995, BLOOD, V86, P1; Ohnishi H, 1996, LEUKEMIA, V10, P1104; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMarcaigh AS, 1997, J PEDIAT HEMATOL ONC, V19, P551, DOI 10.1097/00043426-199711000-00015; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Padua RA, 1998, LEUKEMIA, V12, P887, DOI 10.1038/sj.leu.2401044; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Patmasiriwat P, 1999, LEUKEMIA, V13, P891, DOI 10.1038/sj.leu.2401414; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; PIGNON JM, 1994, HUM MUTAT, V3, P126, DOI 10.1002/humu.1380030207; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; PREUDHOMME C, 1994, BRIT J HAEMATOL, V87, P61, DOI 10.1111/j.1365-2141.1994.tb04871.x; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; PREUDHOMME C, 1993, LEUKEMIA, V7, P1291; PREUDHOMME C, 1992, BRIT J HAEMATOL, V81, P440, DOI 10.1111/j.1365-2141.1992.tb08253.x; PREUDHOMME C, 1994, LEUKEMIA, V8, P1589; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; QUELLE DE, 1995, CELL, V83, P993; Quesnel B, 1996, BRIT J HAEMATOL, V95, P291, DOI 10.1046/j.1365-2141.1996.d01-1913.x; QUESNEL B, 1994, LEUKEMIA, V8, P878; Quesnel B, 1998, BLOOD, V91, P2985, DOI 10.1182/blood.V91.8.2985.2985_2985_2990; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; Ramakers-van Woerden NL, 2001, BRIT J HAEMATOL, V112, P680, DOI 10.1046/j.1365-2141.2001.02586.x; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33, DOI 10.1093/oxfordjournals.aje.a010118; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; RIDGE SA, 1994, BRIT J HAEMATOL, V86, P407, DOI 10.1111/j.1365-2141.1994.tb04754.x; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROVIRA A, 1995, ANN HEMATOL, V70, P129; Rowley JD, 1997, BLOOD, V90, P535; Rubnitz JE, 1997, LEUKEMIA, V11, P1201, DOI 10.1038/sj.leu.2400779; SAKASHITA A, 1992, BLOOD, V79, P477; SanchezBeato M, 1996, BRIT J CANCER, V74, P1056, DOI 10.1038/bjc.1996.489; Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973; SANTOS A, 1993, HUM GENET, V92, P83, DOI 10.1007/BF00216151; Sauerbrey A, 1998, LEUKEMIA LYMPHOMA, V28, P275, DOI 10.3109/10428199809092683; Scarisbrick JJ, 2000, BLOOD, V95, P2937, DOI 10.1182/blood.V95.9.2937.009k15_2937_2942; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Schmid D, 1997, LEUKEMIA, V11, P639, DOI 10.1038/sj.leu.2400620; SCHOTTELIUS A, 1994, LEUKEMIA, V8, P1673; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Seeberger H, 2001, LAB INVEST, V81, P977, DOI 10.1038/labinvest.3780310; SEKIYA M, 1994, BLOOD, V83, P1876; Seliger B, 1996, EUR J HAEMATOL, V57, P230; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHANNON KM, 1992, BLOOD, V79, P1311; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CANCER RES, V60, P3689; Shieh SY, 2000, GENE DEV, V14, P289; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Sidransky D, 1996, CURR BIOL, V6, P523, DOI 10.1016/S0960-9822(02)00532-8; SIRAGANIAN PA, 1989, MED PEDIATR ONCOL, V17, P485; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SLINGERLAND JM, 1991, BLOOD, V77, P1500; Smith SI, 1998, BLOOD, V91, P764, DOI 10.1182/blood.V91.3.764.764_764_773; Smith SI, 2000, CANCER RES, V60, P808; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; Starostik P, 1998, CANCER RES, V58, P4552; Stilgenbauer S, 1999, BLOOD, V94, P3262, DOI 10.1182/blood.V94.9.3262.421a33_3262_3264; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; Stilgenbauer S, 1998, ONCOGENE, V16, P1891, DOI 10.1038/sj.onc.1201764; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Stokke T, 2000, INT J CANCER, V89, P313, DOI 10.1002/1097-0215(20000720)89:4<313::AID-IJC1>3.0.CO;2-D; Stoppa-Lyonnet D, 1998, BLOOD, V91, P3920, DOI 10.1182/blood.V91.10.3920.3920_3920_3926; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Takeuchi S, 1996, BLOOD, V87, P3368, DOI 10.1182/blood.V87.8.3368.bloodjournal8783368; Takeuchi S, 1998, CANCER RES, V58, P2618; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Takimoto H, 1998, BIOCHEM BIOPH RES CO, V251, P264, DOI 10.1006/bbrc.1998.9459; Tamaki H, 1999, LEUKEMIA, V13, P393, DOI 10.1038/sj.leu.2401341; Tanaka N, 1999, ORAL ONCOL, V35, P321, DOI 10.1016/S1368-8375(98)00089-X; Tanaka N, 2001, ORAL ONCOL, V37, P308, DOI 10.1016/S1368-8375(00)00107-X; Tasaka T, 1998, BRIT J HAEMATOL, V101, P558, DOI 10.1046/j.1365-2141.1998.00724.x; Tavor S, 2001, LEUKEMIA LYMPHOMA, V42, P517, DOI 10.3109/10428190109064610; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Tien HF, 2001, BRIT J HAEMATOL, V112, P148, DOI 10.1046/j.1365-2141.2001.02496.x; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; TOWATARI M, 1991, BLOOD, V78, P2178, DOI 10.1182/blood.V78.9.2178.bloodjournal7892178; TRECCA D, 1994, AM J HEMATOL, V46, P304, DOI 10.1002/ajh.2830460409; Tsai T, 1996, LEUKEMIA, V10, P1901; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Uchida T, 2001, LEUKEMIA, V15, P157, DOI 10.1038/sj.leu.2401991; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; WADA M, 1993, BLOOD, V82, P3163; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang XW, 1999, ANTICANCER RES, V19, P4759; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WATANABE T, 1994, BLOOD, V84, P3158; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Wu XS, 1999, GENOMICS, V60, P161, DOI 10.1006/geno.1999.5911; XERRI L, 1995, AM J CLIN PATHOL, V104, P424; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; YOUNES A, 1995, BLOOD, V85, P2813, DOI 10.1182/blood.V85.10.2813.bloodjournal85102813; Zamparelli A, 2001, HUM PATHOL, V32, P4, DOI 10.1053/hupa.2001.20371; ZANDECKI M, 1995, LEUKEMIA LYMPHOMA, V18, P497, DOI 10.3109/10428199509059651; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhou M, 2000, LEUKEMIA, V14, P61, DOI 10.1038/sj.leu.2401619; Zhou MX, 1997, PEDIATR HEMAT ONCOL, V14, P141, DOI 10.3109/08880019709030900; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhu JH, 1998, CANCER RES, V58, P5061; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	389	194	207	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3475	3495		10.1038/sj.onc.1205322	http://dx.doi.org/10.1038/sj.onc.1205322			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032783				2022-12-17	WOS:000175633300018
J	Schempp, CM; Kirkin, V; Simon-Haarhaus, B; Kersten, A; Kiss, J; Termeer, CC; Gilb, B; Kaufmann, T; Borner, C; Sleeman, JP; Simon, JC				Schempp, CM; Kirkin, V; Simon-Haarhaus, B; Kersten, A; Kiss, J; Termeer, CC; Gilb, B; Kaufmann, T; Borner, C; Sleeman, JP; Simon, JC			Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis	ONCOGENE			English	Article						programmed cell death; Hypericum perforatum; mitochondrial membrane permeabilization; caspases; cytochrome c	CYTOCHROME-C; LIGAND TRAIL; MITOCHONDRIA; ACTIVATION; BCL-2; RELEASE; INVOLVEMENT; METABOLITE; DEATH; CD44	Hyperforin is a plant derived antibiotic from St. John's wort. Here we describe a novel activity of hyperforin, namely its ability to inhibit the growth of tumour cells by induction of apoptosis. Hyperforin inhibited the growth of various human and rat tumour cell lines in vivo, with IC50 values between 3-15 muM. Treatment of tumour cells with hyperforin resulted in a dose-dependent generation of apoptotic oligonucleosomes, typical DNA-laddering and apoptosis-specific morphological changes. In MT-450 mammary carcinoma cells hyperforin increased the activity of caspase-9 and caspase-3, and hyperforin-mediated apoptosis was blocked by the broad-range caspase inhibitor zVAD.fmk. When added to MT-450 cells, hyperforin, but not paclitaxel, induced a rapid loss of the mitochondrial transmembrane potential Deltapsi(m), and subsequent morphological changes such as homogenization and vacuolization of mitochondria. Monitoring of Deltapsi(m) revealed that the hyperforin-mediated mitochondrial permeability transition can not be prevented by zVAD.fmk. This indicates that mitochondrial permeabilization is a cause rather than a consequence of caspase activation. Moreover, hyperforin was capable of releasing cytochrome c from isolated mitochondria. These findings suggest that hyperforin activates a mitochondria-mediated apoptosis pathway. In vivo, hyperforin inhibited the growth of autologous MT-450 breast carcinoma in immunocompetent Wistar rats to a similar extent as the cytotoxic drug paclitaxel, without any signs of acute toxicity. Owing to the combination of significant antitumour activity, low toxicity in vivo and natural abundance of the compound, hyperforin holds the promise of being an interesting novel antineoplastic agent that deserves further laboratory and in vivo exploration.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany; HWI Analyt, D-78106 Rheinzabern, Germany; Univ Freiburg, Inst Mol Med, D-79106 Freiburg, Germany	University of Freiburg; Helmholtz Association; Karlsruhe Institute of Technology; University of Freiburg; University of Freiburg	Schempp, CM (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	schempp@haut.ukl.uni-freiburg.de	Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; Kirkin, Vladimir/0000-0002-8049-3663; Kaufmann, Thomas/0000-0001-9906-874X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BYSTROV NS, 1975, TETRAHEDRON LETT, P2791; Castedo M, 1996, J IMMUNOL, V157, P512; Debatin KM, 1999, ADV EXP MED BIOL, V457, P237; DECOSTERD LA, 1989, HELV CHIM ACTA, V72, P464, DOI 10.1002/hlca.19890720307; Erdelmeier CAJ, 1998, PHARMACOPSYCHIATRY, V31, P2, DOI 10.1055/s-2007-979339; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUREVICH AI, 1971, ANTIBIOT MED BIOTEK, V16, P510; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; KIM U, 1986, J SURG ONCOL, V33, P151, DOI 10.1002/jso.2930330303; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAISENBACHER P, 1992, PLANTA MED, V58, P351, DOI 10.1055/s-2006-961483; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Muller WE, 1998, PHARMACOPSYCHIATRY, V31, P16, DOI 10.1055/s-2007-979341; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Revillard JP, 1998, IMMUNOL TODAY, V19, P291, DOI 10.1016/S0167-5699(98)01279-1; ROTH L, 1990, ECOMED, P97; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Schempp CM, 1999, LANCET, V353, P2129, DOI 10.1016/S0140-6736(99)00214-7; Schempp CM, 2000, BRIT J DERMATOL, V142, P979, DOI 10.1046/j.1365-2133.2000.03482.x; Schempp CM, 2001, FEBS LETT, V493, P26, DOI 10.1016/S0014-5793(01)02268-2; Sleeman JP, 1996, CANCER RES, V56, P3134; Sleeman JP, 1999, ONCOGENE, V18, P4485, DOI 10.1038/sj.onc.1202808; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Termeer C, 2001, J LEUKOCYTE BIOL, V70, P715; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	44	194	213	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1242	1250		10.1038/sj.onc.1205190	http://dx.doi.org/10.1038/sj.onc.1205190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850844				2022-12-17	WOS:000173729400012
J	Wang, S; Nath, N; Adlam, M; Chellappan, S				Wang, S; Nath, N; Adlam, M; Chellappan, S			Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function	ONCOGENE			English	Article						Rb; E2F; cell cycle; transformation; tumor suppression	CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA GENE-PRODUCT; HISTONE DEACETYLASE; VIRAL ONCOPROTEINS; DEPENDENT KINASES; BREAST-CANCER; REPRESS TRANSCRIPTION; BINDING PROTEIN; MESSENGER-RNA	The retinoblastoma tumor suppressor protein and its family members, p107 and p130, are major regulators of the mammalian cell cycle. They exert their growth suppressive effects at least in part by binding the E2F family of transcription factors and inhibiting their transcriptional activity. Agents that disrupt the interaction between Rb family proteins and E2F promote cell proliferation. Here we describe the characterization of a novel interaction between Rb family proteins and a potential tumor suppressor protein, prohibitin. Prohibitin physically interacts with all three Rb family proteins in vitro and in vivo, and was very effective in repressing E2F-mediated transcription. Prohibitin could inhibit the activity of E2Fs 1, 2, 3, 4 and 5, but could not affect the activity of promoters lacking an E2F site. Surprisingly, prohibitin-mediated repression of E2F could not be reversed by adenovirus E1A protein. A prohibitin mutant that could not bind to Rb was impaired in its ability to repress E2F activity and inhibit cell proliferation. We believe that prohibitin is a novel regulator of E2F activity that responds to specific signaling cascades.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA	Columbia University; Columbia University	Chellappan, S (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COBRINIK D, 1996, CURR TOP MICROBIOL I, V208, P32; CORBEIL HB, 1995, ONCOGENE, V11, P909; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; CROOP CS, 1995, CANCER LETT, V90, P51, DOI 10.1016/0304-3835(94)03677-B; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Franklin D.S., 1993, J CELL BIOCHEM, V17D, P159; GRANA X, 1995, ONCOGENE, V11, P211; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JIANG H, 1995, IN PRESS ONCOGENE, V11; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JUNAIEF JL, 1994, CELL, V79, P119; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; Kohn KW, 1998, ONCOGENE, V16, P1065, DOI 10.1038/sj.onc.1201608; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIU XT, 1994, BIOCHEM BIOPH RES CO, V201, P409, DOI 10.1006/bbrc.1994.1716; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; MEYERSON M, 1992, GENE DEV, V6, P1874; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; QIN XQ, 1995, MOL CELL BIOL, V15, P742; ROSKAMS AJI, 1993, J CELL PHYSIOL, V157, P289, DOI 10.1002/jcp.1041570211; SATO T, 1993, GENOMICS, V17, P762, DOI 10.1006/geno.1993.1402; SATO T, 1992, CANCER RES, V52, P1643; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; SUTHERLAND RL, 1995, ACTA ONCOL, V34, P651, DOI 10.3109/02841869509094043; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, SCIENCE, V243, P934; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhang YH, 1996, MOL CELL DIFFER, V4, P297	81	194	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3501	3510		10.1038/sj.onc.1202684	http://dx.doi.org/10.1038/sj.onc.1202684			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376528				2022-12-17	WOS:000080850600008
J	MOLES, JP; MOYRET, C; GUILLOT, B; JEANTEUR, P; GUILHOU, JJ; THEILLET, C; BASSETSEGUIN, N				MOLES, JP; MOYRET, C; GUILLOT, B; JEANTEUR, P; GUILHOU, JJ; THEILLET, C; BASSETSEGUIN, N			P53-GENE MUTATIONS IN HUMAN EPITHELIAL SKIN CANCERS	ONCOGENE			English	Article							RAS GENE; ONCOGENE; HETEROZYGOSITY; AMPLIFICATION; PROGRESSION; SPECIFICITY; CARCINOMAS; CELLS	In the present study we analysed 38 epithelial skin cancers, 19 basal cell carcinomas (BCCs), 13 squamous cell carcinomas (SCCs) and six Bowen diseases (BwDs), using a combination of polymerase chain reaction (PCR) and single-stranded conformation polymorphism (SSCP) techniques for the presence of p53 and RAS gene mutations. Whereas 48% (9/19) of the BCCs tested presented a mutated p53 gene, the frequency was lower (15%, 2/13) in our series of SCCs and negatve in the BwDs. Nine of the 11 characterized mutations were single-nucleotide substitutions and, interestingly, seven of these involved CC dimers, where a C was changed into a T or a G (three C-->T transitions and four C-->G transversions). This mutational pattern, added to the fact that all the mutated tumors occurred at sun-exposed body sites, implicates UV light in their genesis. Furthermore, we observed two internal deletions of 6 and 24 bp whose flanking sequences contained two or three Cs on either strand. In addition to molecular detection, we searched for p53 protein accumulation, by immunocytochemical staining, in a subset of 23 epithelial skin tumors (nine bearing a mutation, 14 which scored negative in our assay). Three commercially available anti-p53 antibodies (PAb CM1, mAbs DO7 and 1801) were used, and 3/23 (all showing a mutated p53 gene) presented specific nuclear staining. In contrast to other reported data we could not detect any activating RAS gene mutation in our series of human skin cancers.	CNRS,CRBM,DERMATOL MOLEC LAB,BP 5051,ROUTE DE MENDE,F-34033 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,CNRS,URA 1191,F-34095 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Molès, Jean-Pierre/M-2286-2017; Theillet, Charles/O-7634-2018	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1989, ONCOGENE, V4, P1389; BENNETT WP, 1991, ONCOGENE, V6, P1779; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; Brash D., 1991, P NATL ACAD SCI USA, V88, P1012; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BURNS PA, 1991, ONCOGENE, V6, P2363; CARBONE D, 1991, NUCLEIC ACIDS RES, V6, P1691; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; MAZARS GR, 1992, ONCOGENE, V7, P781; MAZARS R, 1991, ONCOGENE, V6, P1685; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; PORTIER M, 1992, IN PRESS ONCOGENE; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504	29	194	195	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					583	588						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437842				2022-12-17	WOS:A1993KN00800008
J	STURZBECHER, HW; MAIMETS, T; CHUMAKOV, P; BRAIN, R; ADDISON, C; SIMANIS, V; RUDGE, K; PHILP, R; GRIMALDI, M; COURT, W; JENKINS, JR				STURZBECHER, HW; MAIMETS, T; CHUMAKOV, P; BRAIN, R; ADDISON, C; SIMANIS, V; RUDGE, K; PHILP, R; GRIMALDI, M; COURT, W; JENKINS, JR			P53 INTERACTS WITH P34CDC2 IN MAMMALIAN-CELLS - IMPLICATIONS FOR CELL-CYCLE CONTROL AND ONCOGENESIS	ONCOGENE			English	Article									TARTU BIOCTR, TARTU, ESTONIA, USSR; SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; ACAD SCI USSR, INST MOLEC BIOL, MOSCOW V-71, USSR	Swiss Institute Experimental Cancer Research	STURZBECHER, HW (corresponding author), MARIE SKLODOWSKA CURIE MEM INST, CELL PROLIFERAT LAB, CHART, OXTED RH8 0TL, SURREY, ENGLAND.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365; Chumakov, Peter/0000-0002-8078-2908				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYLES J, 1986, J CELL SCI, P155; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1989, CANCER CELLS MOL DIA, P127; JENKINS JR, 1988, ONCOGENE HDB, P403; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V17, P8375, DOI 10.1093/nar/17.20.8375; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, CANCER CELL, V6, P159; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THURIAUX P, 1978, MOL GEN GENET, V161, P215, DOI 10.1007/BF00274190; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	58	194	194	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1990	5	6					795	801						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2141683				2022-12-17	WOS:A1990DP55300003
J	THEILLET, C; LEROY, X; DELAPEYRIERE, O; GROSGEORGES, J; ADNANE, J; RAYNAUD, SD; SIMONYLAFONTAINE, J; GOLDFARB, M; ESCOT, C; BIRNBAUM, D; GAUDRAY, P				THEILLET, C; LEROY, X; DELAPEYRIERE, O; GROSGEORGES, J; ADNANE, J; RAYNAUD, SD; SIMONYLAFONTAINE, J; GOLDFARB, M; ESCOT, C; BIRNBAUM, D; GAUDRAY, P			AMPLIFICATION OF FGF-RELATED GENES IN HUMAN-TUMORS - POSSIBLE INVOLVEMENT OF HST IN BREAST CARCINOMAS	ONCOGENE			English	Article									UER MED, LGMCH, AVE VALOMBROSE, F-06034 NICE, FRANCE; CTR PAUL LAMARQUE, CNRS, URA 199, F-34094 MONTPELLIER, FRANCE; INSERM, U148, F-34100 MONTPELLIER, FRANCE; INSERM, U119, F-13009 MARSEILLE, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADELAIDE J, 1988, ONCOGENE, V2, P413; Bisconte J C, 1979, Int Rev Cytol, V57, P75, DOI 10.1016/S0074-7696(08)61462-X; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CROCE CM, 1986, CANCER RES, V46, P6019; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GEBHART E, 1986, BREAST CANCER RES TR, V8, P125, DOI 10.1007/BF01807701; GEORGE DL, 1984, CANCER SURV, V3, P497; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; JEWETT HJ, 1946, J UROLOGY, V55, P366, DOI 10.1016/S0022-5347(17)69924-5; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LIDEREAU R, 1985, P NATL ACAD SCI USA, V82, P7068, DOI 10.1073/pnas.82.20.7068; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Maniatis T., 1982, MOL CLONING; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARICS I, 1989, ONCOGENE, V4, P335; MARSHALL VF, 1956, CANCER, V9, P543, DOI 10.1002/1097-0142(195605/06)9:3<543::AID-CNCR2820090318>3.0.CO;2-0; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NGUYEN C, 1988, ONCOGENE, V3, P703; RAYBAUD F, 1988, CANCER RES, V48, P950; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; THEILLET C, 1988, IN PRESS CANCER CELL, V7; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TRENT JM, 1987, GROWTH FACTORS ONCOG, P142; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; VARLEY JM, 1988, ONCOGENE, V3, P87; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279; 1982, WHO HISTOLOGICAL TYP	52	194	195	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1989	4	7					915	922						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2474139				2022-12-17	WOS:A1989AE58400015
J	Strano, S; Dell'Orso, S; Di Agostino, S; Fontemaggi, G; Sacchi, A; Blandino, G				Strano, S.; Dell'Orso, S.; Di Agostino, S.; Fontemaggi, G.; Sacchi, A.; Blandino, G.			Mutant p53: an oncogenic transcription factor	ONCOGENE			English	Review						mutant p53; transcription; interaction; signature chip	GAIN-OF-FUNCTION; ADVANCED BREAST-CANCER; LI-FRAUMENI-SYNDROME; WILD-TYPE P53; TUMOR-SUPPRESSOR; GENE-EXPRESSION; SV40-TRANSFORMED CELLS; FUNCTIONAL-ANALYSIS; TERMINAL DOMAIN; TARGET GENES	Inactivation of tumor-suppressor genes is one of the key hallmarks of a tumor. Unlike other tumor-suppressor genes, p53 is inactivated by missense mutations in half of all human cancers. It has become increasingly clear that the resulting mutant p53 proteins do not represent only the mere loss of wild-type p53 tumor suppressor activity, but gain new oncogenic properties favoring the insurgence, the maintenance, the spreading and the chemoresistance of malignant tumors. The actual challenge is the. ne deciphering of the molecular mechanisms underlying the gain of function of mutant p53 proteins. In this review, we will focus mainly on the transcriptional activity of mutant p53 proteins as one of the potential molecular mechanisms. To date, the related knowledge is still quite scarce and many of the raised questions of this review are yet unanswered.	Regina Elena Inst Canc Res, Dept Expt Oncol, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Rome Oncogenom Ctr, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	blandino@ifo.it	Di Agostino, Silvia/S-8566-2019; Blandino, Giovanni/B-1137-2013; strano, sabrina/B-6743-2013; Di Agostino, Silvia/H-1121-2018; Strano, Sabrina/K-9654-2016; Fontemaggi, Giulia/K-9702-2016	Blandino, Giovanni/0000-0002-6970-2241; strano, sabrina/0000-0002-6341-4230; Di Agostino, Silvia/0000-0003-3730-1125; Fontemaggi, Giulia/0000-0001-8332-8842; Dell'Orso, Stefania/0000-0002-1634-5631				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Augustin M, 1998, MAMM GENOME, V9, P899, DOI 10.1007/s003359900891; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Berns EMJJ, 2000, CANCER RES, V60, P2155; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buck MJ, 2004, GENOMICS, V83, P349, DOI 10.1016/j.ygeno.2003.11.004; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hussain SP, 1998, CANCER RES, V58, P4023; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwanaga Y, 2002, CANCER RES, V62, P2618; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JOERGER AC, 2005, WILD TYPE P53 CONFOR, P377; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim E, 2006, CELL DEATH DIFFER, V13, P885, DOI 10.1038/sj.cdd.4401909; Koga H, 2000, ONCOGENE, V19, P4178, DOI 10.1038/sj.onc.1203745; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAIN S, 2005, NOVEL P53 BASED THER, P353; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Levrero M, 2000, J CELL SCI, V113, P1661; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MCKINNEY C, 2005, REGULATION P53 DNA B, P27; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Moll UM, 2003, MOL CANCER RES, V1, P1001; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MONTI O, 2005, P73 P63 MUTANT P53 M, P223; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OREN M, 1983, P NATL ACAD SCI-BIOL, V80, P56, DOI 10.1073/pnas.80.1.56; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prives C, 1999, J PATHOL, V187, P112; PURDIE CA, 1994, ONCOGENE, V9, P603; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, CANCER RES, V60, P1777; SOUSSI T, 2005, ANAL P53 GENE ALTERA, P255; Stiewe T, 2003, J BIOL CHEM, V278, P14230, DOI 10.1074/jbc.M300357200; Strano S, 2005, MOL CELL, V19, P429, DOI 10.1016/j.molcel.2005.07.010; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Strano S, 2003, CELL CYCLE, V2, P348, DOI 10.4161/cc.2.4.426; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; WEISZ L, 2004, CANCER RES, V64, P7447; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Wu JJ, 2006, CANCER RES, V66, P6899, DOI 10.1158/0008-5472.CAN-06-0276; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061	96	193	204	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2212	2219		10.1038/sj.onc.1210296	http://dx.doi.org/10.1038/sj.onc.1210296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401430				2022-12-17	WOS:000245394800010
J	Burgers, WA; Blanchon, L; Pradhan, S; de Launoit, Y; Kouzarides, T; Fuks, F				Burgers, W. A.; Blanchon, L.; Pradhan, S.; de Launoit, Y.; Kouzarides, T.; Fuks, F.			Viral oncoproteins target the DNA methyltransferases	ONCOGENE			English	Article						E1A; E7; Dnmt1; DNA methyltransferase; viral oncoproteins	RETINOBLASTOMA GENE-PRODUCT; CYTOSINE-5 METHYLTRANSFERASE; ACETYLTRANSFERASE ACTIVITY; CELLULAR-TRANSFORMATION; HISTONE DEACETYLASE; DE-NOVO; E1A; METHYLATION; TRANSCRIPTION; EXPRESSION	Small DNA tumour viruses have evolved a number of mechanisms to drive nondividing cells into S phase. Virally encoded oncoproteins such as adenovirus E1A and human papillomavirus (HPV) E7 can bind an array of cellular proteins to override proliferation arrest. The DNA methyltransferase Dnmt1 is the major mammalian enzyme responsible for maintaining CpG methylation patterns in the cell following replication. One of the hallmarks of tumour cells is disrupted DNA methylation patterns, highlighting the importance of the proper regulation of DNA methyltransferases in normal cell proliferation. Here, we show that adenovirus 5 E1A and HPV-16 E7 associate in vitro and in vivo with the DNA methyltransferase Dnmt1. Consistent with this interaction, we find that E1A and E7 can purify DNA methyltransferase activity from nuclear extracts. These associations are direct and mediated by the extreme N-terminus of E1A and the CR3 zinc-finger domain of E7. Furthermore, we find that a point mutant at leucine 20 of E1A, a residue known to be critical for its transformation functions, is unable to bind Dnmt1 and DNA methyltransferase activity. Finally, both E1A and E7 can stimulate the methyltransferase activity of Dnmt1 in vitro. Our results provide the first indication that viral oncoproteins bind and regulate Dnmt1 enzymatic activity. These observations open up the possibility that this association may be used to control cellular proliferation pathways and suggest a new mechanism by which small DNA tumour viruses can steer cells through the cell cycle.	Free Univ Brussels, Fac Med, Lab Canc Epigenet, B-1070 Brussels, Belgium; Univ Cambridge, CRUK Gurdon Inst, Wellcome Trust, Cambridge CB2 1TN, England; Univ Cape Town, Fac Hlth Sci, Div Med Virol, ZA-7925 Cape Town, South Africa; Univ Lille 1, CNRS, Inst Pasteur, Inst Biol Lille,UMR 8161, Lille, France; Univ Lille 2, CNRS, Inst Pasteur, Inst Biol Lille,UMR 8161, F-59800 Lille, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Cambridge; Wellcome Trust Sanger Institute; University of Cape Town; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Fuks, F (corresponding author), Free Univ Brussels, Fac Med, Lab Canc Epigenet, 808 Route Lennik, B-1070 Brussels, Belgium.	ffuks@ulb.ac.be		Burgers, Wendy/0000-0003-3396-9398; Kouzarides, Tony/0000-0002-8918-4162; BLANCHON, LOIC/0000-0001-8842-0162	Wellcome Trust [092096] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gowher H, 2005, J BIOL CHEM, V280, P13341, DOI 10.1074/jbc.M413412200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; McCance DJ, 2005, CURR OPIN GENET DEV, V15, P515, DOI 10.1016/j.gde.2005.08.003; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; Ordway JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-19; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	24	193	201	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1650	1655		10.1038/sj.onc.1209950	http://dx.doi.org/10.1038/sj.onc.1209950			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983344	Green Accepted, Bronze			2022-12-17	WOS:000244782500015
J	Saji, S; Kawakami, M; Hayashi, S; Yoshida, N; Hirose, M; Horiguchi, SI; Itoh, A; Funata, N; Schreiber, SL; Yoshida, M; Toi, M				Saji, S; Kawakami, M; Hayashi, S; Yoshida, N; Hirose, M; Horiguchi, SI; Itoh, A; Funata, N; Schreiber, SL; Yoshida, M; Toi, M			Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer	ONCOGENE			English	Article						breast cancer; estrogen receptor; HDAC6; tamoxifen	PROGESTERONE-RECEPTOR; HISTONE DEACETYLASES; ENDOCRINE THERAPY; EXPRESSION; TAMOXIFEN; PROTEIN; PREDICTION; CHROMATIN; GENES; BETA	Histone deacetylase ( HDAC) 6 is a subtype of the HDAC family; it deacetylates alpha-tubulin and increases cell motility. Here, we investigate the impact of an alteration of HDAC6 expression in estrogen receptor a ( ER)positive breast cancer MCF-7 cells, as we identified that HDAC6 is a novel estrogen-regulated gene. MCF-7 treated with estradiol showed increased expression of HDAC6 mRNA and protein and a four-fold increase in cell motility in a migration assay. Cell motility was increased to the same degree by stably transfecting the HDAC6 expression vector into MCF-7 cells. In both cases, the cells changed in appearance from their original round shape to an axon-extended shape, like a neuronal cell. This HDAC6 accumulation caused the deacetylation of alpha-tubulin. Either the selective estrogen receptor modulator tamoxifen (TAM) or the pure antiestrogen ICI 182,780 prevented estradiol-induced HDAC6 accumulation and deacetylation of alpha-tubulin, leading to reduced cell motility. Tubacin, an inhibitory molecule that binds to the tubulin deacetylation domain of HDAC6, also prevented estradiol-stimulated cell migration. Finally, we evaluated HDAC6 protein expression in 139 consecutively archived human breast cancer tissues by immunohistochemical staining. The prognostic analyses for these patients revealed no significant differences based on HDAC6 expression. However, subset analysis of ER-positive patients who received adjuvant treatment with TAM (n = 67) showed a statistically significant difference in relapse-free survival and overall survival in favor of the HDAC6-positive group (P < 0.02 and P < 0.05, respectively). HDAC 6 expression was an independent prognostic indicator by multivariate analysis ( odds ratio = 2.82, P = 0.047). These results indicate the biological significance of HDAC6 regulation via estrogen signaling.	Tokyo Metropolitan Komagome Hosp, Dept Clin Trials & Res, Bunkyo Ku, Tokyo 1138677, Japan; Tohoku Univ, Fac Med, Dept Mol Med Technol, Sendai, Miyagi 980, Japan; Saitama Canc Ctr, Inst Res, Div Endocrinol, Ina, Saitama, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo, Japan; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tohoku University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Harvard University	Saji, S (corresponding author), Tokyo Metropolitan Komagome Hosp, Dept Clin Trials & Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	ss-saji@wa2.so-net.ne.jp	Ito, Akihiro/A-6100-2015; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Bardou VJ, 2003, J CLIN ONCOL, V21, P1973, DOI 10.1200/JCO.2003.09.099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Ciocca DR, 2000, ENDOCRINE, V13, P1, DOI 10.1385/ENDO:13:1:1; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; Clarke M, 1998, LANCET, V351, P1451; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Palazzo A, 2003, NATURE, V421, P230, DOI 10.1038/421230a; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; Saji S, 2002, CANCER RES, V62, P4849; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455	23	193	206	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 30	2005	24	28					4531	4539		10.1038/sj.onc.1208646	http://dx.doi.org/10.1038/sj.onc.1208646			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15806142				2022-12-17	WOS:000230157100006
J	Li, Y; Hively, WP; Varmus, HE				Li, Y; Hively, WP; Varmus, HE			Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer	ONCOGENE			English	Review						Wnt-1; breast cancer; cancer models; mammary; transgenic; MMTV	MAMMARY-TUMOR VIRUS; PROTO-ONCOGENE INT-1; PROVIRAL INSERTION; ESTROGEN-RECEPTOR; GROWTH-FACTOR; BETA-CATENIN; CHROMOSOMAL INSTABILITY; PROGESTERONE RECEPTORS; CELL-PROLIFERATION; CANDIDATE ONCOGENE	Wnt-1 was first identified as a protooncogene activated by viral insertion in mouse mammary tumors. Transgenic expression of this gene using a mouse mammary tumor virus LTR enhancer causes extensive ductal hyperplasia early in life and mammary adenocarcinomas in approximately 50% of the female transgenic (TG) mice by 6 months of age. Metastasis to the lung and proximal lymph nodes is rare at the time tumors are detected but frequent after the removal of the primary neoplasm, The potent mitogenic effect mediated by Wnt-1 expression does not require estrogen stimulation; tumors form after an increased latency in estrogen receptor alpha-null mice. Several genetic lesions, including inactivation of p53 and over-expression of Fgf-3, collaborate with Wnt-1 in leading to mammary tumors, but loss of Sky and inactivation of one allele of Rb do not affect the rate of tumor formation in Wnt-1 TG mice.	NCI, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, Y (corresponding author), NCI, Div Basic Sci, 49 Convent Dr,Bldg 49,Room 4A56, Bethesda, MD 20892 USA.		Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X				Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; BARISH GD, 1999, SIGNAL NETWORKS CELL; BERGSTEIN I, 1999, BREAST CANC MOL GENE, P181; BERNS EMJJ, 1995, INT J CANCER, V64, P140, DOI 10.1002/ijc.2910640212; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bieche I, 1999, CANCER RES, V59, P2759; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; DANIEL CW, 1987, CANCER RES, V47, P6052; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; de Lange T, 1999, SCIENCE, V283, P947, DOI 10.1126/science.283.5404.947; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; ELSON A, 1995, ONCOGENE, V11, P181; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Fisher GH, 1999, ONCOGENE, V18, P5253, DOI 10.1038/sj.onc.1203087; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 1999, CANCER RES, V59, P1572; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Li YX, 1999, VIROLOGY, V255, P138, DOI 10.1006/viro.1998.9571; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; LIN TP, 1992, CANCER RES, V52, P4413; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MCGUIRE WL, 1985, SEMIN ONCOL, V12, P12; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOOLGAVKAR SH, 1980, J NATL CANCER I, V65, P559; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; Patapoutian A, 1999, SCIENCE, V283, P1180, DOI 10.1126/science.283.5405.1180; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERSEN OW, 1987, CANCER RES, V47, P5748; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Prives C, 1999, J PATHOL, V187, P112; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Redston M, 1998, NAT GENET, V20, P13, DOI 10.1038/1666; RICKETTS D, 1991, CANCER RES, V51, P1817; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wiesen JF, 1999, DEVELOPMENT, V126, P335; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Woodage T, 1998, NAT GENET, V20, P62, DOI 10.1038/1722; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	106	193	196	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1002	1009		10.1038/sj.onc.1203273	http://dx.doi.org/10.1038/sj.onc.1203273			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713683				2022-12-17	WOS:000085796400005
J	Obaya, AJ; Mateyak, MK; Sedivy, JM				Obaya, AJ; Mateyak, MK; Sedivy, JM			Mysterious liaisons: the relationship between c-Myc and the cell cycle	ONCOGENE			English	Review						c-myc; cell cycle; regulation of gene expression; cyclin-dependent kinase activity	DEPENDENT-KINASE INHIBITOR; INITIATION-FACTOR 4E; E CDK2 KINASE; RETINOBLASTOMA PROTEIN; DNA-BINDING; MESSENGER-RNA; GROWTH ARREST; E GENE; MALIGNANT TRANSFORMATION; FUNCTIONAL INACTIVATION	A large body of physiological evidence shows that either upregulation or downregulation of intracellular c-Myc activity has profound consequences on cell cycle progression. Recent work suggests that c-Myc may stimulate the activity of cyclin E/cyclin-dependent kinase 2 (Cdk2) complexes and antagonize the action of the Cdk inhibitor p27(KIP1). Cyclin D/Cdk4/6 complexes have also been implicated as targets of c-Myc activity. However, in spite of considerable effort, the mechanisms by which c-Myc interacts with the intrinsic cyclin/Cdk cell cycle machinery remain undefined.	Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	Brown University	Sedivy, JM (corresponding author), Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA.		Obaya, Alvaro J./AAQ-6115-2021	Obaya, Alvaro J./0000-0002-4163-2173; Mateyak, Maria/0000-0003-0859-1901				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOU GP, 1994, J BIOL CHEM, V169, P1306; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Geng Y, 1996, ONCOGENE, V12, P1173; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OSWALD F, 1994, ONCOGENE, V9, P2029; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WATERS CM, 1991, ONCOGENE, V6, P797; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	119	193	202	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2934	2941		10.1038/sj.onc.1202749	http://dx.doi.org/10.1038/sj.onc.1202749			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378690				2022-12-17	WOS:000080387800004
J	Lebowitz, PF; Prendergast, GC				Lebowitz, PF; Prendergast, GC			Non-Ras targets of farnesyltransferase inhibitors: focus on Rho	ONCOGENE			English	Review						protein prenylation; transformation; apoptosis; cell adhesion; signal transduction	FARNESYL TRANSFERASE INHIBITORS; ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELL LINES; H-RAS; TRANSFORMED-CELLS; ACTIN CYTOSKELETON; IN-VIVO; GERANYLGERANYLTRANSFERASE-I; PROTEIN PRENYLTRANSFERASES; SIGNALING PATHWAY	Farnesyltransferase inhibitors (FTIs) are a novel class of cancer therapeutics whose development was based on the discovery that the function of oncogenic Ras depends upon its posttranslational farnesylation. Significantly, experiments in animal models have shown that FTIs have promise as nontoxic cancer therapeutics. However, cell biological studies have suggested that FTIs may act at a level beyond that of suppressing Ras function, so the exact mechanism of action has emerged as a question of major interest. Here, we review evidence that proteins other than Ras are important targets for inhibition, summarize findings suggesting a role for farnesylated Rho proteins prompted by studies on RhoB, and suggest a new model for how FTIs exert their biological effects. The 'FIT-Rho hypothesis' proposes that FTIs act in part by altering Rho-dependent cell adhesion signals which are linked to pathways controlling cell cycle and cell survival and which are subverted or defective in neoplastic cells. This model offers a novel framework for addressing the questions about FTI biology, including the basis for Lack of toxicity to normal cells, cytotoxic verses cytostatic effects on tumor cells, and the persistence and drug resistance of malignant cells in FTI-treated animals.	Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Prendergast, GC (corresponding author), Wistar Inst, Philadelphia, PA 19104 USA.							ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; COX AD, 1994, J BIOL CHEM, V269, P1; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DALTON MB, 1995, CANCER RES, V55, P3295; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; Foster R, 1996, MOL CELL BIOL, V16, P2689; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1996, CANCER SURV, V27, P311; JAHNER D, 1991, ONCOGENE, V6, P1259; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JIMENEZ B, 1995, ONCOGENE, V10, P811; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Krajewska M, 1996, CANCER RES, V56, P2422; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Larcher F, 1996, CANCER RES, V56, P5391; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEBOWITZ PF, 1998, IN PRESS CELL ADHES; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MANNE V, 1995, ONCOGENE, V10, P1763; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Miquel K, 1997, CANCER RES, V57, P1846; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nagase T, 1996, INT J CANCER, V65, P620, DOI 10.1002/(SICI)1097-0215(19960301)65:5<620::AID-IJC11>3.0.CO;2-B; NAGASU T, 1995, CANCER RES, V55, P5310; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Prendergast GC, 1996, CANCER RES, V56, P2626; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAK J, 1995, CANCER RES, V55, P4575; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sebti Said, 1997, Current Opinion in Oncology, V9, P557, DOI 10.1097/00001622-199711000-00011; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SUN JZ, 1995, CANCER RES, V55, P4243; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	76	193	197	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1439	1445		10.1038/sj.onc.1202175	http://dx.doi.org/10.1038/sj.onc.1202175			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779989				2022-12-17	WOS:000076161900010
J	DeYoung, KL; Ray, ME; Su, YA; Anzick, SL; Johnstone, RW; Trapani, JA; Meltzer, PS; Trent, JM				DeYoung, KL; Ray, ME; Su, YA; Anzick, SL; Johnstone, RW; Trapani, JA; Meltzer, PS; Trent, JM			Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma	ONCOGENE			English	Article						interferon-inducible; melanoma; tumorigenicity	HUMAN-MALIGNANT MELANOMA; CHROMOSOME-6; IDENTIFICATION; CLUSTER; CELLS	Chromosome 6-mediated suppression of tumorigenicity in malignant melanoma cell lines provides a model system to identify genes associated with the reversion of the tumorigenic phenotype. Using subtractive cDNA selection, we recently identified a series of novel genes which are differentially expressed in association with chromosome 6-mediated suppression. We now report the molecular characterization of a novel gene termed AIM2 for (Absent In Melanoma), which represents a 1485 bp cDNA. An open reading frame of 1032 base pairs, corresponding to 344 amino acid residues, is predicted. The predicted protein shares a conserved sequence domain of approximately 200 amino acids with known interferon-inducible genes of both human and mouse. We demonstrate that the AIM2 gene encodes a transcript of approximately 2 kb which is expressed in spleen, small intestine, and peripheral blood leukocytes. In addition, we have localized AIM2 to the long arm of human chromosome 1 (band q22) in a highly conserved region which also contains the known interferon-inducible genes IFI16 and MNDA. We have also demonstrated that, like IFI16 and MNDA, AIM2 is induced in HL60 cells by interferon gamma. Our findings support the existence of a family of genes in this region similar to the well-characterized mouse Ifi200 gene family.	NATL HUMAN GENOME RES INST,CANC GENET LAB,NIH,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; AUSTIN HOSP,AUSTIN RES INST,HEIDELBERG,VIC 3084,AUSTRALIA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan; Austin Research Institute; Florey Institute of Neuroscience & Mental Health			Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRIGGS RC, 1994, BLOOD, V83, P2153; BURDE S, 1996, IN PRESS CYTOMETRY; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; KINGSTON RE, 1991, CURRENT PROTOCOL S14, V1; KRAEHN GM, 1995, CANCER-AM CANCER SOC, V75, P1228, DOI 10.1002/1097-0142(19950315)75:6<1228::AID-CNCR2820750604>3.0.CO;2-T; MILLIKIN D, 1991, CANCER RES, V51, P5449; PETERS J, 1989, MOUSE NEWS LETT, V84, P52; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Ray ME, 1996, ONCOGENE, V12, P2527; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SKOLNICK MH, 1994, EUR J CANCER, V30A, P1991, DOI 10.1016/0959-8049(94)00392-I; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; YOU J, 1995, BIOCHEM BIOPH RES CO, V208, P476, DOI 10.1006/bbrc.1995.1363	23	193	213	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					453	457		10.1038/sj.onc.1201206	http://dx.doi.org/10.1038/sj.onc.1201206			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242382				2022-12-17	WOS:A1997XM23800010
J	Mekeel, KL; Tang, W; Kachnic, LA; Luo, CM; DeFrank, JS; Powell, SN				Mekeel, KL; Tang, W; Kachnic, LA; Luo, CM; DeFrank, JS; Powell, SN			Inactivation of p53 results in high rates of homologous recombination	ONCOGENE			English	Article						p53; genetic stability; homologous recombination; plasmid	CELL-CYCLE CONTROL; C-TERMINAL DOMAIN; WILD-TYPE P53; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; INDUCED MUTATION; HAMSTER-CELLS; COLON-CANCER; GENE; APOPTOSIS	Using a plasmid substrate which integrates into the genome, we determined that the rate of homologous recombination was suppressed by p53, Human tumor cell lines, mutant or null for p53 had recombination rates 10 000-times greater than primary fibroblasts. When isogenic cell pairs from tumor cells or primary fibroblasts were compared, differing only in one genetic change which inactivated p53, the recombination rate increased >100-fold. Functional inactivation of p53 by dominant mutant p53, by large T antigen of SV40 virus, by E6 protein of human papilloma virus, or by genetic deletion led to the same result. Our results suggest that p53 suppresses spontaneous homologous recombination, and that p53 is not required for recombination to proceed, The mechanism of recombination suppression may be related to the reported association of p53 with Rad 51, but the functional consequences of this association are not yet established. It is suggested that suppression of homologous recombination is the means by which p53 maintains genetic stability.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital					NCI NIH HHS [CA58985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COLE J, 1976, MUTAT RES, V41, P377, DOI 10.1016/0027-5107(76)90110-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FAN SJ, 1995, CANCER RES, V55, P1649; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; KIM HG, 1994, AM J PATHOL, V145, P148; KINZLER KW, 1994, NEW ENGL J MED, V331, P49, DOI 10.1056/NEJM199407073310113; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luo CM, 1996, J BIOL CHEM, V271, P4497; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MICHIELI P, 1994, CANCER RES, V54, P3391; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; POWELL SN, 1995, CANCER RES, V55, P1643; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SMITHRAVIN J, 1989, INT J RADIAT BIOL, V56, P951, DOI 10.1080/09553008914552411; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; TLSTY TD, 1993, COLD SPRING HARB SYM, V58, P645, DOI 10.1101/SQB.1993.058.01.072; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wiesmuller L, 1996, J VIROL, V70, P737; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12	45	193	198	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1847	1857		10.1038/sj.onc.1201143	http://dx.doi.org/10.1038/sj.onc.1201143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150391				2022-12-17	WOS:A1997WW16600011
J	TAKAISHI, K; SASAKI, T; KAMEYAMA, T; TSUKITA, S; TSUKITA, S; TAKAI, Y				TAKAISHI, K; SASAKI, T; KAMEYAMA, T; TSUKITA, S; TSUKITA, S; TAKAI, Y			TRANSLOCATION OF ACTIVATED RHO FROM THE CYTOPLASM TO MEMBRANE RUFFLING AREA, CELL-CELL ADHESION SITES AND CLEAVAGE FURROWS	ONCOGENE			English	Article						SMALL GTP-BINDING PROTEIN; RHOA; ERM FAMILY; CD44; MEMBRANE RUFFLING; CELL-CELL ADHESION; CYTOKINESIS	GTP-BINDING-PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; SWISS 3T3 CELLS; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; FOCAL ADHESIONS; BRAIN CYTOSOL; RIBOSYLATION; PURIFICATION; GDI	Rho small GTP-binding protein regulates various cell functions, such as formation of stress fibers and focal adhesions, cell motility, membrane ruffling, cytokinesis and smooth muscle contraction in mammalian cells and bud formation in the yeast Saccharomyces cerevisiae. As to the functioning sites of Rho in Saccharomyces cerevisiae, we have recently shown that RHO1 protein, a homologue of mammalian RhoA, is concentrated to the growth region of the cells where cortical actin patches are clustered. However, in mammalian cells, the functioning sites of Rho have not yet been studied. In the present study, MDCK cell lines stably expressing myc-tagged RhoA (myc-RhoA) were prepared and localization of myc-RhoA was first immunohistochemically examined using an anti-myc antibody. In the resting cells, almost all of myc-RhoA was observed in the cytosol. When the cells were stimulated with phorbol ester or hepatocyte growth factor, membrane rufflings were induced and myc-RhoA was translocated to the membrane ruffling area. Moreover, myc-RhoA was translocated from the cytosol to the cell-cell adhesion sites when the cells were transferred from a low to normal Ca2+ medium. RhoA was also concentrated to the cleavage furrows during cytokinesis in Swiss 3T3 cells. Translocation of myc-RhoA to the membrane ruffling area was inhibited by prior microinjection into the cells of Rho GDI, a negative regulator of Rho which inhibits activation of Rho, or of C3, an exoenzyme of Clostridium botulinum which ADP-ribosylates Rho and inhibits its functions, indicating that both activation and functioning of Rho are essential for the translocation of Rho. The ERM (Ezrin, Radixin, Moesin) family members were colocalized with RhoA at all of these sites. However, RhoA was not apparently observed at the focal adhesion plaque where vinculin was localized. These results suggest that at least one of the functioning sites of Rho is the ERM family-controlled actin filament/plasma membrane association sites.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,COLL MED TECHNOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CELL BIOL,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; Kyoto University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								ABERCROMBIE M, 1970, EXP CELL RES, V60, P437, DOI 10.1016/0014-4827(70)90537-9; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DIPASQUALE A, 1975, EXP CELL RES, V94, P191, DOI 10.1016/0014-4827(75)90545-5; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HIRATA K, 1992, J BIOL CHEM, V267, P8719; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1992, J BIOL CHEM, V267, P11677; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORII N, 1992, J BIOL CHEM, V267, P20921; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V135, P809; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATO N, 1992, J CELL SCI, V103, P131; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHANG J, 1993, J BIOL CHEM, V268, P22251	50	193	196	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					39	48						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624130				2022-12-17	WOS:A1995RJ29500006
J	RAGIMOV, N; KRAUSKOPF, A; NAVOT, N; ROTTER, V; OREN, M; ALONI, Y				RAGIMOV, N; KRAUSKOPF, A; NAVOT, N; ROTTER, V; OREN, M; ALONI, Y			WILD-TYPE BUT NOT MUTANT-P53 CAN REPRESS TRANSCRIPTION INITIATION INVITRO BY INTERFERING WITH THE BINDING OF BASAL TRANSCRIPTION FACTORS TO THE TATA MOTIF	ONCOGENE			English	Article							RNA POLYMERASE-II; HIGH-LEVEL EXPRESSION; LARGE T-ANTIGEN; C-MYC-GENE; P53 PROTEIN; ACCURATE TRANSCRIPTION; NUCLEAR-LOCALIZATION; DNA-REPLICATION; TFIID COMPLEX; PROMOTER	It has previously been shown that excess wild type (wt) p53 can repress the transcriptional activity of a variety of promoters in intact cells. To determine whether this transcriptional repression represented a direct effect of p53, wt and mutant p53 were prepared from E. coli-produced p53 and from insect cells infected with a recombinant baculovirus. When added into an in vitro transcription system, wt p53, but not mutant p53 reduced markedly transcription from the c-myc promoter, as well as from an array of other promoters, with the exception of an MHC class I gene promoter. The presence of wt p53 seemed to affect specifically the formation of the transcription preinitiation complex because preformed initiation complexes were completely refractory to wt p53, as was also the process of transcript elongation. Wild-type but not mutant p53 interfered with the stable binding of TBP and TFIIA to the TATA motif, although both wt and mutant p53 could associate in vitro with purified TBP. We propose that upon binding to TBP, wt but not mutant p53 specifically blocks the ability of TBP to engage in interactions required for efficient transcriptional initiation. This may account, at least in part, for the ability of excess wt p53 to inhibit cell proliferation and to interfere with neoplastic processes.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science					NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BENGAL E, 1991, J VIROL, V65, P4910, DOI 10.1128/JVI.65.9.4910-4918.1991; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CASEY G, 1991, ONCOGENE, V6, P1791; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIRE A, 1984, J BIOL CHEM, V259, P2509; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAHN SR, 1985, NATURE, V314, P366; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V34, P752; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OROURKE RW, 1990, ONCOGENE, V5, P1829; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REISMAN D, 1993, IN PRESS CELL GROWTH; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Seiberg M, 1987, Virus Genes, V1, P97; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Summers MD, 1987, TEXAS AGR EXPT STATI; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; Weinmann Roberto, 1992, Gene Expression, V2, P81; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIMAN KG, 1991, ONCOGENE, V6, P1633; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAWEL L, 1992, IN PRESS PROG NUCLEI	87	193	195	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1183	1193						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479742				2022-12-17	WOS:A1993KY32800009
J	LIU, E; THOR, A; HE, M; BARCOS, M; LJUNG, BM; BENZ, C				LIU, E; THOR, A; HE, M; BARCOS, M; LJUNG, BM; BENZ, C			THE HER2 (C-ERBB-2) ONCOGENE IS FREQUENTLY AMPLIFIED IN INSITU CARCINOMAS OF THE BREAST	ONCOGENE			English	Note							SURGICAL ADJUVANT BREAST; PROTEIN OVEREXPRESSION; CANCER; AMPLIFICATION; EXPRESSION; SURVIVAL; PROJECT; GENE	Amplification and overexpression of the HER2 (c-erbB-2) oncogene was assessed in paraffin-embedded specimens from 27 in situ carcinomas of the breast and from 122 stage II breast cancers. Gene amplification detected in these archival tissues by differential polymerase chain reaction (PCR) was found in 48% of in situ carcinomas and in 21% of stage II lesions (chi(2) = 7.62, p less-than-or-equal-to 0.01). In addition, the level of gene amplification correlated with the level of HER2 oncoprotein expression as measured by immunohistochemistry for both in situ cancers (p less-than-or-equal-to 0.025) and stage II cancers (p less-than-or-equal-to 0.0005). This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.	UNIV CALIF SAN FRANCISCO,CANC RES INST,M-1283,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; UNIV N CAROLINA,DEPT MED,CURRICULUM GENET,CHAPEL HILL,NC 27599; ROSWELL PK CANC INST,DEPT PATHOL,BUFFALO,NY; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; Roswell Park Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [U10CA037055, U10CA031946, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [5U10-CA31946-08, 5U10-CA37055-08, P01 CA 44768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; BRESEN AL, 1990, BRIT J CANCER, V62, P585; CLARK GM, 1991, CANCER RES, V51, P944; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FRYE RA, 1989, ONCOGENE, V4, P1153; HANNA W, 1990, MODERN PATHOL, V3, P455; IGLEHART JD, 1990, CANCER RES, V50, P6701; LODATO RF, 1990, MODERN PATHOL, V3, P449; NEUBAUER A, 1992, ONCOGENE, V7, P1019; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; ROGERS LW, 1989, DIAGNOSTIC HISTOPATH; RUSSO J, 1990, LAB INVEST, V62, P244; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SESHADRI R, 1989, INT J CANCER, V43, P270, DOI 10.1002/ijc.2910430218; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1989, INT J CANCER, V43, P270; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOR AD, 1989, CANCER RES, V49, P7147; TSUDA H, 1990, CANCER, V65, P1794, DOI 10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902	24	193	205	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1027	1032						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349163				2022-12-17	WOS:A1992HP64200026
J	MATSUI, M; TOKUHARA, M; KONUMA, Y; NOMURA, N; ISHIZAKI, R				MATSUI, M; TOKUHARA, M; KONUMA, Y; NOMURA, N; ISHIZAKI, R			ISOLATION OF HUMAN FOS-RELATED GENES AND THEIR EXPRESSION DURING MONOCYTE-MACROPHAGE DIFFERENTIATION	ONCOGENE			English	Article											MATSUI, M (corresponding author), NIPPON VET & ZOOTECH COLL, MOLEC ONCOL LAB, 1-10-19 UENOSAKURAGI, TAITO KU, TOKYO 110, JAPAN.		Matsui, Minami/A-5235-2016	Matsui, Minami/0000-0001-5162-2668				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLLART MA, 1989, ONCOGENE, V4, P237; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1984, DNA-J MOLEC CELL BIO, V3, P437, DOI 10.1089/dna.1.1984.3.437; DIALYNAS DP, 1986, P NATL ACAD SCI USA, V83, P2619, DOI 10.1073/pnas.83.8.2619; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; GRASSO RJ, 1969, NATURE, V224, P882, DOI 10.1038/224882a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRENTZ R, 1989, SCIENCE, V243, P1695; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOGNESS RW, 1974, J VIROL, V14, P8; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P203, DOI 10.1093/nar/12.1Part1.203; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MILLAN JL, 1987, P NATL ACAD SCI USA, V84, P5311, DOI 10.1073/pnas.84.15.5311; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; Nilsson K, 1981, Haematol Blood Transfus, V26, P215; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAUSCHER FJ, 1989, GENE DEV, V2, P1689; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SALSER W, 1970, J MOL BIOL, V49, P271, DOI 10.1016/0022-2836(70)90246-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIBAN E, 1988, MOL CELL BIOL, V8, P340, DOI 10.1128/MCB.8.1.340; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	193	197	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1990	5	3					249	255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2107490				2022-12-17	WOS:A1990CW41500001
J	ROVINSKI, B; BENCHIMOL, S				ROVINSKI, B; BENCHIMOL, S			IMMORTALIZATION OF RAT EMBRYO FIBROBLASTS BY THE CELLULAR P53 ONCOGENE	ONCOGENE			English	Article									ONTARIO CANC INST,DIV BIOL RES,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X				BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PELLEGRINI S, 1986, J CELL PHYSIOL, V126, P107, DOI 10.1002/jcp.1041260115; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; ROVINSKI B, 1987, UCLA S MOL CELLULAR, V61, P31; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIROKI K, 1986, MOL CELL BIOL, V6, P4379, DOI 10.1128/MCB.6.12.4379; SHOHAT O, 1987, ONCOGENE, V1, P277; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERLIN M, 1987, ONCOGENE, V1, P19	50	193	196	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					445	452						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3287278				2022-12-17	WOS:A1988N434800005
J	Lin, EW; Karakasheva, TA; Hicks, PD; Bass, AJ; Rustgi, AK				Lin, E. W.; Karakasheva, T. A.; Hicks, P. D.; Bass, A. J.; Rustgi, A. K.			The tumor microenvironment in esophageal cancer	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; REGULATORY T-CELLS; GROWTH-FACTOR-BETA; OXIDATIVE DNA-DAMAGE; DYSPLASIA-ADENOCARCINOMA SEQUENCE; UPPER GASTROINTESTINAL-TRACT; TRANSFORMED BARRETTS CELLS; SUPPRESSOR-CELLS; SIGNALING PATHWAY	Esophageal cancer is a deadly disease, ranking sixth among all cancers in mortality. Despite incremental advances in diagnostics and therapeutics, esophageal cancer still carries a poor prognosis, and thus, there remains a need to elucidate the molecular mechanisms underlying this disease. There is accumulating evidence that a comprehensive understanding of the molecular composition of esophageal cancer requires attention to not only tumor cells but also the tumor microenvironment (TME), which contains diverse cell populations, signaling factors and structural molecules that interact with tumor cells and support all stages of tumorigenesis. In esophageal cancer, environmental exposures can trigger chronic inflammation, which leads to constitutive activation of pro-inflammatory signaling pathways that promote survival and proliferation. Antitumor immunity is attenuated by cell populations such as myeloid-derived suppressor cells and regulatory T cells, as well as immune checkpoints like programmed death-1. Other immune cells such as tumor-associated macrophages can have other pro-tumorigenic functions, including the induction of angiogenesis and tumor cell invasion. Cancer-associated fibroblasts secrete growth factors and alter the extracellular matrix to create a tumor niche and enhance tumor cell migration and metastasis. Further study of how these TME components relate to the different stages of tumor progression in each esophageal cancer subtype will lead to development of novel and specific TME-targeting therapeutic strategies, which offer considerable potential especially in the setting of combination therapy.	[Lin, E. W.; Karakasheva, T. A.; Hicks, P. D.; Rustgi, A. K.] Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, 951 BRB 421 Curie Blvd, Philadelphia, PA 19104 USA; [Lin, E. W.; Karakasheva, T. A.; Hicks, P. D.; Rustgi, A. K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Bass, A. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Rustgi, A. K.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, 951 BRB 421 Curie Blvd, Philadelphia, PA 19104 USA.	anil2@mail.med.upenn.edu	Karakasheva, Tatiana/F-4246-2018	Karakasheva, Tatiana/0000-0001-9070-2804; Lin, Eric/0000-0002-1064-2010; Hicks, Philip/0000-0002-1574-5692	NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA098101] Funding Source: Medline; NIDDK NIH HHS [P30 DK050306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-Latif MMM, 2004, ANN SURG, V239, P491, DOI 10.1097/01.sla.0000118751.95179.c6; Abdel-Latif MMM, 2009, CURR OPIN PHARMACOL, V9, P396, DOI 10.1016/j.coph.2009.06.010; Akutsu Y, 2011, ANN SURG ONCOL, V18, P2946, DOI 10.1245/s10434-011-1645-z; Anderson MR, 2006, CLIN CANCER RES, V12, P5936, DOI 10.1158/1078-0432.CCR-06-1208; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bailey SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00276; Bao CH, 2015, BIOCHEM BIOPH RES CO, V458, P441, DOI 10.1016/j.bbrc.2015.02.001; Bardou M, 2004, CLIN GASTROENTEROL H, V2, P880, DOI 10.1016/S1542-3565(04)00389-1; Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100; Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Chalmin F, 2012, IMMUNITY, V36, P362, DOI 10.1016/j.immuni.2011.12.019; Chen DY, 2012, CELL IMMUNOL, V272, P166, DOI 10.1016/j.cellimm.2011.10.015; Chen LY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05911; Chen LJ, 2014, INT J CLIN EXP PATHO, V7, P6015; Chen ML, 2012, CANCER EPIDEM BIOMAR, V21, P1126, DOI 10.1158/1055-9965.EPI-12-0020; Chen MF, 2014, ONCOTARGET, V5, P8716, DOI 10.18632/oncotarget.2368; Chen MF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-26; Chen YS, 2014, TUMOR BIOL, V35, P7275, DOI 10.1007/s13277-014-1987-9; Chung Y, 2007, ANN SURG ONCOL, V14, P3260, DOI 10.1245/s10434-007-9511-8; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Couvelard A, 2000, J PATHOL, V192, P14; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Derks S, 2015, CANCER IMMUNOL RES, V3, P1123, DOI 10.1158/2326-6066.CIR-15-0046; Dreikhausen L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1120-5; Duggan C, 2013, CLIN GASTROENTEROL H, V11, P934, DOI 10.1016/j.cgh.2013.02.017; Dvorak K, 2007, CLIN CANCER RES, V13, P5305, DOI 10.1158/1078-0432.CCR-07-0483; Dvorak K, 2007, GUT, V56, P763, DOI 10.1136/gut.2006.103697; Dvorak K, 2013, WORLD J GASTROENTERO, V19, P2307, DOI 10.3748/wjg.v19.i15.2307; Dvorakova K, 2004, CLIN CANCER RES, V10, P2020, DOI 10.1158/1078-0432.CCR-0437-03; Eder K, 2009, INFLAMM RES, V58, P727, DOI 10.1007/s00011-009-0060-4; Ekman S, 2007, ONCOLOGIST, V12, P1165, DOI 10.1634/theoncologist.12-10-1165; Farhadi A, 2002, AM J GASTROENTEROL, V97, P22; Fitzgerald RC, 2002, GUT, V51, P316, DOI 10.1136/gut.51.3.316; Fong SFT, 2007, GENE CHROMOSOME CANC, V46, P644, DOI 10.1002/gcc.20444; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929; Fukuchi M, 2002, CANCER, V95, P737, DOI 10.1002/cncr.10727; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104453; GILLISON EW, 1972, SURG GYNECOL OBSTETR, V134, P419; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goldman L, 2015, GOLDMAN CECIL MED EX; Gomez-Rodriguez J, 2014, J EXP MED, V211, P529, DOI 10.1084/jem.20131459; Gong JJ, 2014, CLIN CANCER RES, V20, P1259, DOI 10.1158/1078-0432.CCR-13-1664; Grimm M, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-99; Groblewska M, 2012, CLIN CHIM ACTA, V413, P1583, DOI 10.1016/j.cca.2012.05.009; Gros SJ, 2012, IN VIVO, V26, P711; Grugan KD, 2010, P NATL ACAD SCI USA, V107, P11026, DOI 10.1073/pnas.0914295107; Gu ZD, 2005, AM J GASTROENTEROL, V100, P1835, DOI 10.1111/j.1572-0241.2005.50018.x; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Ha Tai-You, 2009, Immune Netw, V9, P209, DOI 10.4110/in.2009.9.6.209; Hardikar S, 2014, CANCER EPIDEM BIOMAR, V23, P2393, DOI 10.1158/1055-9965.EPI-14-0384; Hatata T, 2012, DIS ESOPHAGUS, V25, P716, DOI 10.1111/j.1442-2050.2011.01308.x; Hayden AL, 2012, GUT, V61, pA52, DOI 10.1136/gutjnl-2012-302514a.121; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; Hou J, 2013, CANCER PREV RES, V6, P791, DOI 10.1158/1940-6207.CAPR-12-0352; Howard JM, 2010, BRIT J SURG, V97, P1020, DOI 10.1002/bjs.7072; Huang JX, 2013, ONCOL LETT, V6, P13, DOI 10.3892/ol.2013.1348; Ichihara F, 2003, CLIN CANCER RES, V9, P4404; Ito TK, 2007, ONCOGENE, V26, P7194, DOI 10.1038/sj.onc.1210535; Izzo JG, 2007, CANCER EPIDEM BIOMAR, V16, P1200, DOI 10.1158/1055-9965.EPI-06-1083; Izzo JG, 2006, MOL CANCER THER, V5, P2844, DOI 10.1158/1535-7163.MCT-06-0351; Jayaraman P, 2012, J IMMUNOL, V188, P5365, DOI 10.4049/jimmunol.1103553; Jenkins GJS, 2004, CARCINOGENESIS, V25, P317, DOI 10.1093/carcin/bgh032; Jiao ZJ, 2012, WORLD J GASTROENTERO, V18, P5454, DOI 10.3748/wjg.v18.i38.5454; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kant P, 2011, NAT REV GASTRO HEPAT, V8, P224, DOI 10.1038/nrgastro.2011.23; Karakasheva TA, 2015, CANCER RES, V75, P4074, DOI 10.1158/0008-5472.CAN-14-3639; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KAUER WKH, 1995, ANN SURG, V222, P525; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim AH, 2003, INT J ONCOL, V23, P1593; Kitadai Y, 2004, ONCOL REP, V11, P315; Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453; Koide N, 2004, AM J GASTROENTEROL, V99, P1667, DOI 10.1111/j.1572-0241.2004.30733.x; Kono K, 2006, CANCER IMMUNOL IMMUN, V55, P1064, DOI 10.1007/s00262-005-0092-8; Kubo N, 2014, DIS ESOPHAGUS, V27, P285, DOI 10.1111/dote.12107; Lebman DA, 2002, INT J ONCOL, V20, P1241; Lee JS, 2001, MUTAT RES-FUND MOL M, V480, P189, DOI 10.1016/S0027-5107(01)00199-3; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Li HY, 2014, INT J CLIN EXP PATHO, V7, P7989; Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87; Lin CY, 2013, CANCER RES, V73, P3638, DOI 10.1158/0008-5472.CAN-12-4028; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; Lord RVN, 2003, J THORAC CARDIOV SUR, V125, P246, DOI 10.1067/mtc.2003.203; Lukaszewicz-Zajac M, 2012, DIS ESOPHAGUS, V25, P242, DOI 10.1111/j.1442-2050.2011.01242.x; Macfarlane S, 2007, CLIN INFECT DIS, V45, P29, DOI 10.1086/518578; Makuuchi Y, 2013, CANCER SCI, V104, P1045, DOI 10.1111/cas.12187; Malhotra U, 2005, CANCER RES, V65, P548; Martin RCG, 2007, CLIN CANCER RES, V13, P5176, DOI 10.1158/1078-0432.CCR-07-1152; Mazzoni A, 2002, J IMMUNOL, V168, P689, DOI 10.4049/jimmunol.168.2.689; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Miyashita T, 2014, ANN SURG ONCOL, V21, P2012, DOI 10.1245/s10434-014-3537-5; Mobius C, 2007, WORLD J SURG, V31, P1768, DOI 10.1007/s00268-006-0373-1; Morris CD, 2001, AM J GASTROENTEROL, V96, P990; Nabeki B, 2015, ANTICANCER RES, V35, P2941; Nguyen DM, 2004, J THORAC CARDIOV SUR, V127, P365, DOI 10.1016/j.jtcvs.2003.09.033; Noma K, 2008, GASTROENTEROLOGY, V134, P1981, DOI 10.1053/j.gastro.2008.02.061; O'Riordan JM, 2005, AM J GASTROENTEROL, V100, P1257, DOI 10.1111/j.1572-0241.2005.41338.x; Ogunwobi O, 2006, ENDOCRINOLOGY, V147, P4505, DOI 10.1210/en.2006-0224; Ogura M, 2013, SURGERY, V154, P512, DOI 10.1016/j.surg.2013.06.013; Oh DS, 2007, ARCH SURG-CHICAGO, V142, P554, DOI 10.1001/archsurg.142.6.554; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Oka M, 1996, J INTERF CYTOK RES, V16, P1001, DOI 10.1089/jir.1996.16.1001; Okawa T, 2007, GENE DEV, V21, P2788, DOI 10.1101/gad.1544507; Onwuegbusi BA, 2006, GUT, V55, P764, DOI 10.1136/gut.2005.076430; Osaki T, 2009, DIS ESOPHAGUS, V22, P49, DOI 10.1111/j.1442-2050.2008.00855.x; Oshima H, 2012, J GASTROENTEROL, V47, P97, DOI 10.1007/s00535-011-0523-6; Ostrand-Rosenberg S, 2014, J IMMUNOL, V193, P3835, DOI 10.4049/jimmunol.1401572; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007; Patel ZS, 2012, RADIAT RES, V177, P200, DOI 10.1667/RR2790.1; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; Prins MJD, 2012, J GASTROINTEST SURG, V16, P956, DOI 10.1007/s11605-011-1814-1; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004; Radojicic J, 2012, INT J BIOL MARKER, V27, P1, DOI 10.5301/JBM.2011.8737; Rafiee P, 2009, AM J PHYSIOL-GASTR L, V296, pG388, DOI 10.1152/ajpgi.90428.2008; Ren Y, 2005, CLIN CANCER RES, V11, P6190, DOI 10.1158/1078-0432.CCR-04-2553; Rubenstein JH, 2009, GUT, V58, P1583, DOI 10.1136/gut.2008.171553; Rubenstein JH, 2014, CLIN GASTROENTEROL H, V12, P239, DOI 10.1016/j.cgh.2013.08.029; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Salmela MT, 2001, BRIT J CANCER, V85, P383, DOI 10.1054/bjoc.2001.1929; Sasaki K, 2009, ONCOL REP, V21, P65, DOI 10.3892/or_00000190; Seo BR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010467; Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621; Shigeoka M, 2013, CANCER SCI, V104, P1112, DOI 10.1111/cas.12188; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Shivappa N, 2015, CANCER CAUSE CONTROL, V105, P9250; Sihvo EIT, 2002, INT J CANCER, V102, P551, DOI 10.1002/ijc.10755; Song S, 2007, GUT, V56, P1512, DOI 10.1136/gut.2007.121244; Song SM, 2013, CANCER RES, V73, P2159, DOI 10.1158/0008-5472.CAN-12-1962; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Souza RF, 2000, CANCER RES, V60, P5767; Srivastava MK, 2010, CANCER RES, V70, P68, DOI 10.1158/0008-5472.CAN-09-2587; Stachler MD, 2015, NAT GENET, V47, P1047, DOI 10.1038/ng.3343; Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007; Suchi K, 2011, ANTICANCER RES, V31, P67; Sun NX, 2014, TUMOR BIOL, V35, P11359, DOI 10.1007/s13277-014-2434-7; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Sunpaweravong P, 2005, J CANCER RES CLIN, V131, P111, DOI 10.1007/s00432-004-0610-7; Taccioli C, 2012, ONCOGENE, V31, P4550, DOI 10.1038/onc.2011.592; Tachezy M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-238; TAKADA N, 1995, CANCER LETT, V97, P145, DOI 10.1016/0304-3835(95)03967-2; Tanaka K, 2015, CARCINOGENESIS, V36, P894, DOI 10.1093/carcin/bgv067; Thelin MA, 2012, CANCER RES, V72, P1943, DOI 10.1158/0008-5472.CAN-11-1351; Tian F, 2006, ACTA BIOCH BIOPH SIN, V38, P318, DOI 10.1111/j.1745-7270.2006.00166.x; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tselepis C, 2002, ONCOGENE, V21, P6071, DOI 10.1038/sj.onc.1205731; Tuynman JB, 2008, BRIT J CANCER, V98, P1102, DOI 10.1038/sj.bjc.6604251; Twarock S, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-30; Underwood TJ, 2015, J PATHOL, V235, P466, DOI 10.1002/path.4467; Vacchelli E, 2015, ONCOTARGET, V6, P20840, DOI 10.18632/oncotarget.4428; von Boehmer H, 2013, NAT REV DRUG DISCOV, V12, P51, DOI 10.1038/nrd3683; von Rahden BHA, 2006, MOL CARCINOGEN, V45, P786, DOI 10.1002/mc.20259; Waldron TJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24117; Walker MM, 2014, ALIMENT PHARM THER, V39, P767, DOI 10.1111/apt.12666; Wang C, 1996, AM J PATHOL, V148, P1861; Wang Dao-Feng, 2009, Ai Zheng, V28, P154; Wang DH, 2010, GASTROENTEROLOGY, V138, P1810, DOI 10.1053/j.gastro.2010.01.048; Wang T, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-104; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei XL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1379-6; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wong GS, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.17; Wu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095509; Xia M, 2013, J INT MED RES, V41, P1002, DOI 10.1177/0300060513488504; Xu TY, 2011, CELL BIOCHEM BIOPHYS, V61, P389, DOI 10.1007/s12013-011-9197-1; [Xu Weiguo 徐卫国], 2004, Chinese Journal of Cancer Research, V16, P85, DOI 10.1007/s11670-004-0002-1; Xu ZB, 2013, ONCOL LETT, V6, P401, DOI 10.3892/ol.2013.1409; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; Yang LY, 2012, CLIN CANCER RES, V18, P2138, DOI 10.1158/1078-0432.CCR-11-0934; Yang LY, 2009, GASTROENTEROLOGY, V137, P588, DOI 10.1053/j.gastro.2009.04.046; Yoneda M, 2013, ANTICANCER RES, V33, P2699; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Yu CH, 2012, AM J PHYSIOL-GASTR L, V303, pG561, DOI 10.1152/ajpgi.00033.2012; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang CY, 2009, CLIN CANCER RES, V15, P4017, DOI 10.1158/1078-0432.CCR-08-2824; Zhang H, 2007, CANC BIOL MED, V4, P83; Zhang HY, 2011, AM J PHYSIOL-GASTR L, V300, pG454, DOI 10.1152/ajpgi.00458.2010; Zhang J, 2005, J PATHOL, V207, P402, DOI 10.1002/path.1846; Zhang Q, 2015, TUMOR BIOL, V36, P2135, DOI 10.1007/s13277-014-2823-y; Zhang YL, 2014, ONCOL REP, V31, P2298, DOI 10.3892/or.2014.3095; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zhi HY, 2006, CARCINOGENESIS, V27, P1214, DOI 10.1093/carcin/bgi304; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742	208	192	203	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5337	5349		10.1038/onc.2016.34	http://dx.doi.org/10.1038/onc.2016.34			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	26923327	Green Accepted			2022-12-17	WOS:000386677800001
J	Banjac, A; Perisic, T; Sato, H; Seiler, A; Bannai, S; Weiss, N; Kolle, P; Tschoep, K; Issels, RD; Daniel, PT; Conrad, M; Bornkamm, GW				Banjac, A.; Perisic, T.; Sato, H.; Seiler, A.; Bannai, S.; Weiss, N.; Koelle, P.; Tschoep, K.; Issels, R. D.; Daniel, P. T.; Conrad, M.; Bornkamm, G. W.			The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death	ONCOGENE			English	Article						cystine-glutamate exchange; glutathione metabolism; lipid peroxidation; redox regulation; system x(c)(-)	CYSTINE TRANSPORT ACTIVITY; BURKITT-LYMPHOMA CELLS; THIOREDOXIN REDUCTASE; GLUTATHIONE SYNTHESIS; GLUTAMATE TOXICITY; APOPTOSIS; INDUCTION; FIBROBLASTS; METABOLISM; INHIBITION	The glutathione-dependent system is one of the key systems regulating cellular redox balance, and thus cell fate. Cysteine, typically present in its oxidized form cystine in the extracellular space, is regarded as the rate-limiting substrate for glutathione (GSH) synthesis. Cystine is transported into cells by the highly specific amino-acid antiporter system x(c)(-). Since Burkitt's Lymphoma (BL) cells display limited uptake capacity for cystine, and are thus prone to oxidative stress-induced cell death, we stably expressed the substrate-specific subunit of system x(c)(-), xCT, in HH514 BL cells. xCT-overexpressing cells became highly resistant to oxidative stress, particularly upon GSH depletion. Contrary to previous predictions, the increase of intracellular cysteine did not affect the cellular GSH pool, but concomitantly boosted extracellular cysteine concentrations. Even though cells were depleted of bulk GSH, xCT overexpression maintained cellular integrity by protecting against lipid peroxidation, a very early event in cell death progression. Our results show that system x(c)(-) protects against oxidative stress not by elevating intracellular GSH levels, but rather creates a reducing extracellular environment by driving a highly efficient cystine/cysteine redox cycle. Our findings show that the cystine/cysteine redox cycle by itself must be viewed as a discrete major regulator of cell survival.	[Banjac, A.; Seiler, A.; Conrad, M.; Bornkamm, G. W.] GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumor Genet, Munich, Germany; [Perisic, T.; Seiler, A.] Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 305, Japan; [Weiss, N.; Koelle, P.] Univ Munich, Med Poliklin Innnenstadt, D-8000 Munich, Germany; [Tschoep, K.; Issels, R. D.] Univ Munich, GSF, Klin Kooperat Grp Hyperthermie, Med Clin 3, Munich, Germany; [Daniel, P. T.] Humboldt Univ, Med Klin Schwerpunkt Hamatol & Onkol, Berlin, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Tsukuba; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Humboldt University of Berlin	Conrad, M (corresponding author), GSF, Res Ctr, Inst Clin Mol Biol & Tumor Genet, Marchioninistr 25, D-81377 Munich, Germany.	marcus.conrad@gsf.de	Conrad, Marcus/E-8792-2015	Conrad, Marcus/0000-0003-1140-5612; Issels, Rolf/0000-0002-3494-6561				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1989, J BIOL CHEM, V264, P18480; BANNAI S, 1982, J CELL PHYSIOL, V112, P265, DOI 10.1002/jcp.1041120216; Brielmeier M, 1998, NUCLEIC ACIDS RES, V26, P2082, DOI 10.1093/nar/26.9.2082; BROOME JD, 1973, J EXP MED, V138, P574, DOI 10.1084/jem.138.3.574; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; DROGE W, 1991, AM J MED, V91, P140; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; FALK MH, 1993, INT J CANCER, V55, P485, DOI 10.1002/ijc.2910550327; FalK MH, 1998, INT J CANCER, V75, P620, DOI 10.1002/(SICI)1097-0215(19980209)75:4<620::AID-IJC21>3.0.CO;2-B; Feussner A, 1997, EUR J CLIN CHEM CLIN, V35, P687; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Hattori H, 2005, BIOCHEM BIOPH RES CO, V337, P464, DOI 10.1016/j.bbrc.2005.09.076; ISHII T, 1987, J CELL PHYSIOL, V133, P330, DOI 10.1002/jcp.1041330217; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Jonas CR, 2002, FREE RADICAL BIO MED, V33, P1499, DOI 10.1016/S0891-5849(02)01081-X; Kuppner MC, 2003, BLOOD, V102, P3668, DOI 10.1182/blood-2003-05-1408; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; METCALF D, 1976, J IMMUNOL, V116, P635; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nicotera P, 2004, ONCOGENE, V23, P2757, DOI 10.1038/sj.onc.1207559; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; NOVOGRODSKY A, 1979, P NATL ACAD SCI USA, V76, P4932, DOI 10.1073/pnas.76.10.4932; Okita C, 2004, BIOTECHNIQUES, V36, P418, DOI 10.2144/04363ST01; Okuno S, 2003, BRIT J CANCER, V88, P951, DOI 10.1038/sj.bjc.6600786; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Sonoda Y, 2004, BBA-MOL CELL BIOL L, V1683, P22, DOI 10.1016/j.bbalip.2004.04.002; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Ye ZC, 1999, CANCER RES, V59, P4383	42	192	200	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1618	1628		10.1038/sj.onc.1210796	http://dx.doi.org/10.1038/sj.onc.1210796			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828297	Bronze			2022-12-17	WOS:000253815800014
J	Antoniou, AC; Easton, DF				Antoniou, A. C.; Easton, D. F.			Models of genetic susceptibility to breast cancer	ONCOGENE			English	Review						polygenic inheritance; genetic model; twin studies; mathematical model; association; linkage	ATAXIA-TELANGIECTASIA; MAMMOGRAPHIC DENSITY; LINKAGE ANALYSIS; EARLY-ONSET; FAMILY-HISTORY; GROWTH-HORMONE; ATM MUTATIONS; RISK-FACTORS; BRCA1; AGE	One of the most important risk factors for breast cancer is family history of the disease, indicating that genetic factors are important determinants of breast cancer risk. A number of breast cancer susceptibility genes have been identified, the most important being BRCA1 and BRCA2. However, it is estimated that all the currently known breast cancer susceptibility genes accounts for less than 25% of the familial aggregation of breast cancer. In this paper, we review the evidence for other breast cancer susceptibility genes arising from twin studies, pedigree analysis and studies of phenotypes associated with breast cancer, and the progress towards finding other breast cancer susceptibility genes through linkage and association studies. Taken together, the available evidence indicates that susceptibility to breast cancer is mediated through variants in many genes, each conferring a moderate risk of the disease. Such a model of susceptibility has implications for both risk prediction and for future gene identification studies.	Univ Cambridge, Genet Epidemiol Unit, Dept Publ Hlth & Primary Care, Strangeways Res Lab,Canc Res UK, Cambridge CB1 8RN, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Antoniou, AC (corresponding author), Univ Cambridge, Genet Epidemiol Unit, Dept Publ Hlth & Primary Care, Strangeways Res Lab,Canc Res UK, Worts Causeway, Cambridge CB1 8RN, England.	antonis@srl.cam.ac.uk						Ahmed M, 2006, ONCOGENE, V25, P5906, DOI 10.1038/sj.onc.1209873; AMOS CI, 1991, CANCER RES, V51, P1793; Andrieu N, 2006, JNCI-J NATL CANCER I, V98, P535, DOI 10.1093/jnci/djj132; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Antoniou AC, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1365; Antoniou AC, 2004, BRIT J CANCER, V91, P1580, DOI 10.1038/sj.bjc.6602175; Antoniou Antonis C, 2006, Future Oncol, V2, P257, DOI 10.2217/14796694.2.2.257; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; BORRESEN AL, 1992, CANCER RES, V52, P3234; Boyd NF, 2005, LANCET ONCOL, V6, P798, DOI 10.1016/S1470-2045(05)70390-9; Boyd NF, 2002, NEW ENGL J MED, V347, P886, DOI 10.1056/NEJMoa013390; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; *BREAST CANC ASS C, 2006, IN PRESS J NATL CANC; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; BYRNE C, 1995, J NATL CANCER I, V87, P1622, DOI 10.1093/jnci/87.21.1622; Canzian F, 2005, CANCER EPIDEM BIOMAR, V14, P2316, DOI 10.1158/1055-9965.EPI-04-0874; Cavaciuti E, 2005, GENE CHROMOSOME CANC, V42, P1, DOI 10.1002/gcc.20101; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Cui JS, 2001, AM J HUM GENET, V68, P420, DOI 10.1086/318187; de Bruin JP, 2001, HUM REPROD, V16, P2014, DOI 10.1093/humrep/16.9.2014; de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dunning AM, 2004, JNCI-J NATL CANCER I, V96, P936, DOI 10.1093/jnci/djh167; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Fletcher O, 2005, CANCER EPIDEM BIOMAR, V14, P2; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; GARBER JE, 1991, CANCER RES, V51, P6094; Harvey JA, 2004, RADIOLOGY, V230, P29, DOI 10.1148/radiol.2301020870; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki K, 2002, INT J CANCER, V99, P873, DOI 10.1002/ijc.10441; Hong CC, 2004, BREAST CANCER RES TR, V88, P217, DOI 10.1007/s10549-004-0780-7; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; Hunter DJ, 2001, OSTEOPOROSIS INT, V12, P406, DOI 10.1007/s001980170110; Jaquish CE, 1997, METABOLISM, V46, P988, DOI 10.1016/S0026-0495(97)90266-3; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kok HS, 2005, HUM REPROD UPDATE, V11, P483, DOI 10.1093/humupd/dmi024; Lalloo F, 2003, LANCET, V361, P1101, DOI 10.1016/S0140-6736(03)12856-5; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Mack TM, 2002, BRIT J CANCER, V87, P294, DOI 10.1038/sj.bjc.6600429; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mitchell G, 2006, CANCER RES, V66, P1866, DOI 10.1158/0008-5472.CAN-05-3368; Mulhall C, 2005, CANCER EPIDEM BIOMAR, V14, P2648, DOI 10.1158/1055-9965.EPI-04-0374; Murabito JM, 2005, J CLIN ENDOCR METAB, V90, P3427, DOI 10.1210/jc.2005-0181; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; Pankow JS, 1997, J NATL CANCER I, V89, P549, DOI 10.1093/jnci/89.8.549; Pe'er I, 2006, NAT GENET, V38, P663, DOI 10.1038/ng1816; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Pharoah PDP, 2004, NAT REV CANCER, V4, P850, DOI 10.1038/nrc1476; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; SIDRANSKY D, 1992, CANCER RES, V52, P2984; Smith P, 2006, GENE CHROMOSOME CANC, V45, P646, DOI 10.1002/gcc.20330; Snieder H, 1998, J CLIN ENDOCR METAB, V83, P1875, DOI 10.1210/jc.83.6.1875; Stone J, 2006, CANCER EPIDEM BIOMAR, V15, P612, DOI 10.1158/1055-9965.EPI-05-0127; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; SWIFT M, 1986, AM J HUM GENET, V39, P573; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Thompson Deborah, 2005, Hum Mutat, V25, P594, DOI 10.1002/humu.9344; Treloar SA, 1998, LANCET, V352, P1084, DOI 10.1016/S0140-6736(05)79753-1; Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668; Vaittinen P, 2000, INT J CANCER, V88, P998, DOI 10.1002/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0; van Asselt KM, 2004, FERTIL STERIL, V82, P1348, DOI 10.1016/j.fertnstert.2004.04.047; van Duijnhoven FJB, 2005, CANCER EPIDEM BIOMAR, V14, P2655, DOI 10.1158/1055-9965.EPI-05-0398; Velde ERT, 2002, HUM REPROD UPDATE, V8, P141, DOI 10.1093/humupd/8.2.141; Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Ziv E, 2004, CANCER EPIDEM BIOMAR, V13, P2090; Ziv E, 2003, J NATL CANCER I, V95, P556, DOI 10.1093/jnci/95.7.556	86	192	200	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5898	5905		10.1038/sj.onc.1209879	http://dx.doi.org/10.1038/sj.onc.1209879			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998504				2022-12-17	WOS:000240765900010
J	Ogata, H; Chinen, T; Yoshida, T; Kinjyo, I; Takaesu, G; Shiraishi, H; Iida, M; Kobayashi, T; Yoshimura, A				Ogata, H; Chinen, T; Yoshida, T; Kinjyo, I; Takaesu, G; Shiraishi, H; Iida, M; Kobayashi, T; Yoshimura, A			Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta 1 production	ONCOGENE			English	Article						SOCS; STAT; TGF-beta 1; liver fibrosis	GROWTH-FACTOR-BETA; PHYSIOLOGICAL NEGATIVE REGULATOR; HUMAN HEPATOCELLULAR-CARCINOMA; GP130 MUTANT MICE; TGF-BETA; CYTOKINE SIGNALING-3; IMMUNE-RESPONSES; CELL-GROWTH; HEPATITIS-C; IN-VIVO	Recently, DNA methylation and reduced expression of the suppressor of the cytokine signaling-3 (SOCS3) gene in human hepatocellular carcinoma (HCC) patients have been reported. However, the roles of SOCS3 in HCC development in vivo have not been clarified. Using RT-PCR analysis and Western blotting, we confirmed that SOCS3 expression was reduced in HCC patients. However, reduced expression of SOCS3 occurred not only in HCC but also in nontumor regions, and this reduction was stronger as the fibrosis grade increased. Furthermore, SOCS3 levels were inversely correlated with signal transducers and activators of transcription-3 (STAT3) activation as well as transforming growth factor (TGF)-beta 1 levels in the non-HCC region. To de. ne the molecular consequences of SOCS3 silencing/STAT3 hyperactivation and liver fibrosis, we examined liver-specific SOCS3-deficient mice. We demonstrated that SOCS3 deletion in the liver resulted in hyperactivation of STAT3 and promoted ConA- and chemical-induced liver fibrosis. The expression of TGF-beta 1, a mediator of fibrosis, was enhanced by SOCS3 gene deletion, but suppressed by the overexpression of a dominant-negative STAT3 or SOCS3 both in vivo and in vitro. These data suggest that TGF-beta 1 is a target gene of STAT3 and could be one of the mechanisms for enhanced fibrosis in SOCS3-deficient mice. Thus, our present study provides a novel role of SOCS3 and STAT3 in HCC development: in addition to the previously characterized oncogenic potentials, STAT3 enhances hepatic fibrosis through the upregulation of TGF-beta 1 expression, and SOCS3 prevents this process.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka, Japan	Kyushu University; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Kinjyo, Ichiko/0000-0001-7051-3790; Takaesu, Giichi/0000-0002-1581-1055				Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Boer AK, 2002, BLOOD, V100, P467, DOI 10.1182/blood.V100.2.467; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Factor VM, 1997, CANCER RES, V57, P2089; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Huang KC, 2003, FEBS LETT, V555, P385, DOI 10.1016/S0014-5793(03)01297-3; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Nakamura T, 2000, HEPATOLOGY, V32, P247, DOI 10.1053/jhep.2000.9109; Natsume M, 1999, J LEUKOCYTE BIOL, V66, P601, DOI 10.1002/jlb.66.4.601; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Saeki A, 2000, CANCER, V88, P1025, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1025::AID-CNCR11>3.0.CO;2-U; Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Theiss AL, 2005, GASTROENTEROLOGY, V129, P204, DOI 10.1053/j.gastro.2005.05.019; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshimura A, 2005, ARTHRITIS RES THER, V7, P100, DOI 10.1186/ar1741	42	192	205	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2520	2530		10.1038/sj.onc.1209281	http://dx.doi.org/10.1038/sj.onc.1209281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16474852				2022-12-17	WOS:000236948000010
J	Tahara, H; Shin-ya, K; Seimiya, H; Yamada, H; Tsuruo, T; Ide, T				Tahara, H; Shin-ya, K; Seimiya, H; Yamada, H; Tsuruo, T; Ide, T			G-quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3 ' telomeric overhang in cancer cells	ONCOGENE			English	Article						telomere; telomestatin; G-quadruplex; TRF2; 3 ' telomeric overhang	HYBRIDIZATION PROTECTION ASSAY; G-QUARTET FORMATION; BINDING-PROTEIN; HEPATOCELLULAR CARCINOMAS; HUMAN-CHROMOSOMES; BETA-SUBUNIT; DRUG DESIGN; IN-VITRO; DNA; INHIBITION	Inhibition of telomerase activity by telomerase inhibitors induces a gradual loss of telomeres, and this in turn causes cancer cells to enter to a crisis stage. Here, we report the telomerase inhibitor telomestatin, which is known to stabilize G-quadruplex structures at 30 single-stranded telomeric overhangs ( G-tails), rapidly dissociates TRF2 from telomeres in cancer cells within a week, when given at a concentration that does not cause normal cells to die. The G-tails were dramatically reduced upon short-term treatment with the drug in cancer cell lines, but not in normal. broblasts and epithelial cells. In addition, telomestatin also induced anaphase bridge formation in cancer cell lines. These effects of telomestatin were similar to those of dominant negative TRF2, which also causes a prompt loss of the telomeric G-tails and induces an anaphase bridge. These results indicate that telomestatin exerts its anticancer effect not only through inhibiting telomere elongation, but also by rapidly disrupting the capping function at the very ends of telomeres. Unlike conventional telomerase inhibitors that require long-term treatments, the G-quadruplex stabilizer telomestatin induced prompt cell death, and it was selectively effective in cancer cells. This study also identifies the TRF2 protein as a therapeutic target for treating many types of cancer which have the TRF2 protein at caps of the telomere DNA of each chromosome.	Hiroshima Univ, Sch Biomed Sci, Div Integrated Med Sci, Dept Cellular & Mol Biol, Hiroshima, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan	Hiroshima University; University of Tokyo; Japanese Foundation for Cancer Research	Tahara, H (corresponding author), Hiroshima Univ, Sch Biomed Sci, Div Integrated Med Sci, Dept Cellular & Mol Biol, Hiroshima, Japan.	toshi@hiroshima-u.ac.jp; kshinya@jbirc.aist.go.jp		Seimiya, Hiroyuki/0000-0003-3314-9736				Akiyama M, 2003, CANCER RES, V63, P6187; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gu J, 2005, CARCINOGENESIS, V26, P1741, DOI 10.1093/carcin/bgi126; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Hanaoka S, 2005, PROTEIN SCI, V14, P119, DOI 10.1110/ps.04983705; Hirose M, 1997, J CANCER RES CLIN, V123, P337, DOI 10.1007/BF01438310; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Nakamura Y, 1999, CLIN CHEM, V45, P1718; Nakanishi K, 2003, CLIN CANCER RES, V9, P1105; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Rosu F, 2003, CHEM COMMUN, P2702, DOI 10.1039/b309394h; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; Seimiya H, 2004, MOL CELL BIOL, V24, P1944, DOI 10.1128/MCB.24.5.1944-1955.2004; Seimiya H, 2002, MOL CANCER THER, V1, P657; Shay JW, 2005, CANCER CELL, V7, P1, DOI 10.1016/j.ccr.2004.12.012; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 2005, NAT METHODS, V2, P829, DOI 10.1038/NMETH797; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	45	192	202	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1955	1966		10.1038/sj.onc.1209217	http://dx.doi.org/10.1038/sj.onc.1209217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302000				2022-12-17	WOS:000236224800012
J	He, GG; Siddik, ZH; Huang, ZF; Wang, RN; Koomen, J; Kobayashi, R; Khokhar, AR; Kuang, J				He, GG; Siddik, ZH; Huang, ZF; Wang, RN; Koomen, J; Kobayashi, R; Khokhar, AR; Kuang, J			Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities	ONCOGENE			English	Article						p21 functions; Cdk inhibition; cisplatin analog; DNA-damaging agents; G(1)-phase checkpoint	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; S-PHASE CHECKPOINTS; HUMAN CELL-CYCLE; TYROSINE PHOSPHORYLATION; IONIZING-RADIATION; PROTEIN-KINASE; CANCER-CELLS; ULTRAVIOLET-IRRADIATION; PLATINUM(IV) COMPLEXES	DNA damage often activates the p53-p21 pathway and causes G(1)-phase arrest in mammalian cells. Although there is ample evidence that p21 induction by p53 leads to Cdk2 inhibition, it is unclear whether this checkpoint event also leads to Cdk4 inhibition. Diaminocyclohexane(trans-diacetato)(dichloro) platinum(IV) (DAP), a platinum-based coordination complex, is a DNA-damaging agent that is effective against a variety of tumor cells resistant to the parental drug cisplatin. Our previous studies established that treatment of human cancer cells with low effective concentrations of DAP specifically activates the G(1)-phase checkpoint and simultaneously inhibit Cdk4 and Cdk2 activities. Here we demonstrate that DAP treatment of human cancer cells activates the p53-p21 pathway without activating other known mechanisms that inhibit Cdk4 and Cdk2 activities. The induced p21 binds to both the Cdk4/cyclin D and Cdk2/cyclin E complexes and inhibits both of their kinase activities. Conversely, inhibition of p21 induction by cycloheximide or by p21 gene deletion prevents DAP-induced inhibition of Cdk4 and Cdk2 activities. Attenuated p53 expression and p21 induction also eliminates DAP-induced G(1)-phase arrest and inhibition of Cdk4 and Cdk2 activities. Together, these findings establish that activation of the p53-p21 pathway is responsible for the DAP-induced G(1)-phase checkpoint response and provide the first solid evidence that p21 induction by p53 during a DNA damage-induced G(1)-phase checkpoint response inhibits both Cdk4 and Cdk2 activities.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuang, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.	jkuang@mdanderson.org	Wang, Ruoning/C-1683-2014; Koomen, John/D-1844-2013		NCI NIH HHS [CA-77332, CA-82361, CA-93941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082361, R01CA093941, R01CA077332] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Boulaire J, 2000, PATHOL BIOL, V48, P190; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eastman A, 2002, MOL CANCER THER, V1, P1067; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goldwasser F, 1996, CLIN CANCER RES, V2, P687; GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hagopian GS, 1999, CLIN CANCER RES, V5, P655; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Khokhar AR, 1997, J MED CHEM, V40, P112, DOI 10.1021/jm960587l; KIDO Y, 1993, CANCER RES, V53, P4567; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kuang J, 2001, CLIN CANCER RES, V7, P3629; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lenferink AEG, 2001, CANCER RES, V61, P6583; LI Y, 1994, ONCOGENE, V9, P2261; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nahum A, 2001, ONCOGENE, V20, P3428, DOI 10.1038/sj.onc.1204452; OConnor PM, 1997, CANCER SURV, V29, P151; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Perdiguero E, 2003, EMBO J, V22, P5746, DOI 10.1093/emboj/cdg559; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Petrocelli T, 1996, ONCOGENE, V12, P1387; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIDDIK ZH, 1994, ANTI-CANCER DRUG DES, V9, P139; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	76	192	199	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2929	2943		10.1038/sj.onc.1208474	http://dx.doi.org/10.1038/sj.onc.1208474			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735718				2022-12-17	WOS:000228649500002
J	Castro, A; Bernis, C; Vigneron, S; Labbe, JC; Lorca, T				Castro, A; Bernis, C; Vigneron, S; Labbe, JC; Lorca, T			The anaphase-promoting complex: a key factor in the regulation of cell cycle	ONCOGENE			English	Review						APC; cdc20; cdh1; proteolysis; mitosis	SISTER-CHROMATID SEPARATION; UBIQUITIN LIGASE ACTIVITY; CHECKPOINT PROTEIN MAD2; MEIOSIS-II TRANSITION; D-BOX; AURORA-A; DEPENDENT DEGRADATION; CHROMOSOME ALIGNMENT; MITOTIC DEGRADATION; DROSOPHILA FIZZY	Events controlling cell division are governed by the degradation of different regulatory proteins by the ubiquitin-dependent pathway. In this pathway, the attachment of a polyubiquitin chain to a substrate by an ubiquitin-ligase targets this substrate for degradation by the 26S proteasome. Two different ubiquitin ligases play an important role in the cell cycle: the SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC). In this review, we describe the present knowledge about the APC. We pay particular attention to the latest results concerning APC structure, APC regulation and substrate recognition, and we discuss the implication of these findings in the understanding the APC function.	Ctr Rech Biochim Macromol, CNRS, FRE 2593, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Castro, A (corresponding author), Ctr Rech Biochim Macromol, CNRS, FRE 2593, 1919 Route Mende, F-34293 Montpellier 5, France.	castro@crbm.cnrs-mop.fr; lorca@crbm.cnrs-mop.fr	CASTRO, ANNA/F-4350-2010; labbe, jean-claude/B-2277-2009	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; Castro A, 2002, EMBO REP, V3, P1209, DOI 10.1093/embo-reports/kvf241; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Furuta T, 2000, MOL BIOL CELL, V11, P1401, DOI 10.1091/mbc.11.4.1401; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gordon DM, 2001, P NATL ACAD SCI USA, V98, P12515, DOI 10.1073/pnas.231212498; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Hall MC, 2003, J BIOL CHEM, V278, P16698, DOI 10.1074/jbc.M213109200; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HARTWELL LH, 1985, GENETICS, V110, P381; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jorgensen PM, 2001, GENE, V262, P51, DOI 10.1016/S0378-1119(00)00511-4; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Ke PY, 2004, MOL CELL BIOL, V24, P514, DOI 10.1128/MCB.24.2.514-526.2004; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kominami K, 1998, EMBO J, V17, P5388, DOI 10.1093/emboj/17.18.5388; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1992, FEBS LETT, V306, P90, DOI 10.1016/0014-5793(92)80844-7; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mechali F, 2004, J VIROL, V78, P2615, DOI 10.1128/JVI.78.5.2615-2619.2004; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Perez LH, 2002, NAT CELL BIOL, V4, P737, DOI 10.1038/ncb850; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; STARBORG M, 1994, J BIOL CHEM, V269, P24133; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Stroschein SL, 2001, GENE DEV, V15, P2822; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Terret ME, 2003, CURR BIOL, V13, P1797, DOI 10.1016/j.cub.2003.09.032; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vodermaier HC, 2004, CELL CYCLE, V3, P265; Vodermaier HC, 2003, CURR BIOL, V13, P1459, DOI 10.1016/S0960-9822(03)00581-5; Wan Y, 2001, P NATL ACAD SCI USA, V98, P13066, DOI 10.1073/pnas.231487598; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Wendt KS, 2001, NAT STRUCT BIOL, V8, P784, DOI 10.1038/nsb0901-784; Yamada H, 1997, J CELL SCI, V110, P1793; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yanagida M, 2000, GENES CELLS, V5, P1, DOI 10.1046/j.1365-2443.2000.00306.x; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	125	192	205	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					314	325		10.1038/sj.onc.1207973	http://dx.doi.org/10.1038/sj.onc.1207973			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15678131				2022-12-17	WOS:000226279700002
J	Xia, WL; Liu, LH; Ho, P; Spector, NL				Xia, WL; Liu, LH; Ho, P; Spector, NL			Truncated ErbB2 receptor (p95(ErbB2)) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016	ONCOGENE			English	Article						truncated ErbB2; heterodimers; ErbB3; tyrosine kinase; heregulin	GROWTH-FACTOR RECEPTORS; HUMAN-BREAST; EXTRACELLULAR DOMAIN; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; STRUCTURAL ALTERATIONS; PROTOONCOGENE PRODUCT; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; HER2 ECTODOMAIN	The expression of the NH2 terminally truncated ErbB2 receptor (p95(ErbB2)) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185(ErbB2). We now show that heregulin (HRG), but not EGF, stimulates p95(ErbB2) phosphorylation in BT474 breast cancer cells. Furthermore, phospho-p95(ErbB2) forms heterodimers with ErbB3, but not EGFR, while p185(ErbB2) heterodimerizes with both EGFR and ErbB3. The predilection of p95(ErbB2) to heterodimerize with ErbB3 provides an explanation for its regulation by HRG, an ErbB3 ligand. GW572016, a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95(ErbB2) phosphorylation in BT474 cells and tumor xenografts. Inhibition of p95(ErbB2), p185(ErbB2), and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels. Increased phosphorylation of p95(ErbB2) and AKT in response to HRG was abrogated to varying degrees by GW572016. In contrast, trastuzumab did not inhibit p95(ErbB2) phosphorylation or the expression of downstream phospho-Erk1/2, phospho-AKT, or cyclin D. It is tempting to speculate that trastuzumab resistance may be mediated in part by the selection of p95(ErbB2)-expressing breast cancer cells capable of exerting potent growth and prosurvival signals through p95(ErbB2)-ErbB3 heterodimers. Thus, p95(ErbB2) represents a target for therapeutic intervention, and one that is sensitive to GW572016 therapy.	GlaxoSmithKline, Dept Discovery Med, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Spector, NL (corresponding author), GlaxoSmithKline, Dept Discovery Med, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	Neil.L.Spector@gsk.com						ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BrandtRauf PW, 1995, MUTAT RES-FUND MOL M, V333, P203, DOI 10.1016/0027-5107(95)00146-8; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Christianson TA, 1998, CANCER RES, V58, P5123; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cockerill S, 2001, BIOORG MED CHEM LETT, V11, P1401, DOI 10.1016/S0960-894X(01)00219-0; Codony-Servat J, 1999, CANCER RES, V59, P1196; Colomer R, 2000, CLIN CANCER RES, V6, P2356; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; KANDL H, 1994, BRIT J CANCER, V70, P739, DOI 10.1038/bjc.1994.387; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 2000, ADV CANCER RES, V77, P25; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Levkowitz G, 1996, ONCOGENE, V12, P1117; LIN YZJ, 1991, ONCOGENE, V6, P639; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PUPA SM, 1993, ONCOGENE, V8, P2917; RAJIKUMAR T, 1994, BREAST CANC RES TREA, V29, P3; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rusnak DW, 2001, MOL CANCER THER, V1, P85; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yakes FM, 2002, CANCER RES, V62, P4132; Yamauchi H, 1997, J CLIN ONCOL, V15, P2518, DOI 10.1200/JCO.1997.15.7.2518; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	52	192	219	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					646	653		10.1038/sj.onc.1207166	http://dx.doi.org/10.1038/sj.onc.1207166			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737100				2022-12-17	WOS:000188304900003
J	Galderisi, U; Jori, FP; Giordano, A				Galderisi, U; Jori, FP; Giordano, A			Cell cycle regulation and neural differentiation	ONCOGENE			English	Review						neurogenesis; cyclin-dependent kinases; cyclin kinase inhibitors; Rb family; p53; N-Myc	LOOP-HELIX PROTEINS; RETINOBLASTOMA FAMILY PROTEINS; KINASE INHIBITOR P27(KIP1); BRAIN-SPECIFIC ACTIVATOR; N-MYC GENE; NEURONAL DIFFERENTIATION; TUMOR-SUPPRESSOR; NERVOUS-SYSTEM; DEPENDENT KINASE-5; MICE LACKING	The general mechanisms that control the cell cycle in mammalian cells have been studied in depth and several proteins that are involved in the tight regulation of cell cycle progression have been identified. However, the analysis of which molecules participate in cell cycle exit of specific cell lineages is not exhaustive yet. Moreover, the strict relation between cell cycle exit and induction of differentiation has not been fully understood and seems to depend on the cell type. Several in vivo and in vitro studies have been performed in the last few years to address these issues in cells of the nervous system. In this review, we focus our attention on cyclin-cyclin-dependent kinase complexes, cyclin kinase inhibitors, genes of the retinoblastoma family, p53 and N-Myc, and we aim to summarize the latest evidence indicating their involvement in the control of the cell cycle and induction of differentiation in different cell types of the peripheral and central nervous systems. Studies on nervous system tumors and a possible contributory role in tumorigenesis of polyomavirus T antigen are reported to point out the critical contribution of some cell cycle regulators to normal neural and glial development.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA; Univ Naples 2, Dept Expt Med, Sect Biotechnol & Mol Biol, Sch Med, Naples, Italy; Univ Naples 2, Dept Neurol Sci, Sch Med, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	Giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; GALDERISI, Umberto/0000-0003-0909-7403				Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BAYER SA, 1991, J COMP NEUROL, V307, P499, DOI 10.1002/cne.903070312; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P561; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; Coskun V, 2001, J NEUROSCI, V21, P3092, DOI 10.1523/JNEUROSCI.21-09-03092.2001; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Del Valle L, 2002, NEUROLOGY, V58, P895, DOI 10.1212/WNL.58.6.895; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ElShamy WM, 1998, NEURON, V21, P1003, DOI 10.1016/S0896-6273(00)80619-4; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Flaegstad T, 1999, CANCER RES, V59, P1160; Galderisi U, 2001, MOL CELL NEUROSCI, V17, P415, DOI 10.1006/mcne.2000.0949; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gloster A, 1999, J COMP NEUROL, V405, P45, DOI 10.1002/(SICI)1096-9861(19990301)405:1<45::AID-CNE4>3.0.CO;2-M; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Gordon J, 1998, DEV BIOL STAND, V94, P93; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYES TE, 1991, NEW BIOL, V3, P259; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOFBAUER R, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P247; Horsfield J, 1998, DEVELOPMENT, V125, P5069; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jori FP, 2001, BIOCHEM J, V360, P569, DOI 10.1042/0264-6021:3600569; Kabos P, 2002, J BIOL CHEM, V277, P8763, DOI 10.1074/jbc.C100758200; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Norton JD, 2000, J CELL SCI, V113, P3897; Nozaki M, 1999, Neuro Oncol, V1, P124, DOI 10.1093/neuonc/1.2.124; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Piette J, 1997, EXP CELL RES, V234, P193, DOI 10.1006/excr.1997.3588; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Puduvalli VK, 2000, INT J ONCOL, V17, P963; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; Rathore A, 1999, Pathol Oncol Res, V5, P21, DOI 10.1053/paor.1999.0021; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Schwab MH, 2000, J NEUROSCI, V20, P3714, DOI 10.1523/JNEUROSCI.20-10-03714.2000; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Stiegler P, 1998, J CELL BIOCHEM, P30; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAMARU T, 1993, NEUROSCI LETT, V153, P169, DOI 10.1016/0304-3940(93)90314-B; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tikoo R, 1997, J BIOL CHEM, V272, P442; Tokumoto YM, 2001, EMBO J, V20, P5261, DOI 10.1093/emboj/20.18.5261; Toma JG, 2000, J NEUROSCI, V20, P7648; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Ueki K, 1996, CANCER RES, V56, P150; vanGrunsven LA, 1996, ONCOGENE, V12, P855; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	127	192	210	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5208	5219		10.1038/sj.onc.1206558	http://dx.doi.org/10.1038/sj.onc.1206558			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910258				2022-12-17	WOS:000184615100012
J	Ghiso, JAA				Ghiso, JAA			Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo	ONCOGENE			English	Article						FAK; uPAR; integrins; MAPK	FOCAL ADHESION KINASE; INTEGRIN-MEDIATED ADHESION; MALIGNANT PHENOTYPE; DOWN-REGULATION; INVASION; FIBRONECTIN; EXPRESSION; REDUCTION; CAVEOLIN; SRC	Activation of focal adhesion kinase (FAK), overexpressed in several human cancers, induces survival, proliferation and motility of cells in culture, but its functional importance in human tumor growth in vivo has not been elucidated. I explored the role of FAK in regulating tumorigenicity of human carcinoma cells, HEp3. These cells overexpress urokinase receptor (uPAR) which, by activating x5beta1 integrin, initiates an intracellular signal through FAK and Src leading to ERK activation and tumorigenicity in vivo. Down regulation of uPAR in these cells led to a similar to3-5-fold reduction in FAK phosphorylation and association with Src and dormancy in vivo. Both FAK phosphorylation and ability to grow in vivo were restored by re-expression of uPAR. The FAK signaling pathway in T-HEp3 cells, measured by FAK phosphorylation, GTP-loaded Ras and ERK activation, was inhibited by transient or stable transfection of FAK related non-kinase (FRNK), known to have a dominant negative function, but not by a FRNK mutant version (S1034-FRNK). Most importantly, while vector- and mutant-S1034-FRNK transfected cells inoculated onto chicken embryo CAMs formed progressively growing tumors, the HA-FRNK-expressing T-HEp3 cells did not proliferate in vivo and remained dormant for at least 6 weeks. Both cell types had similar rate of apoptosis in vivo and the p38(SAPK) or PI3K-Akt signaling pathways were unaffected by FRNK. FRNK induced dormancy could be reverted by expression of an active-R4F-Mek1 mutant. These results show that active FAK is an important mediator of uPAR-regulated tumorigenicity of HEp3 cells and that interruption of FAK mitogenic signaling either through down-regulation of uPAR or by expression of FRNK can force human carcinoma cells into dormancy.	NYU, Mt Sinai Sch Med, Div Med Oncol, Dept Med,Rochelle Belfer Chemotherapy Fdn Lab, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Ghiso, JAA (corresponding author), NYU, Mt Sinai Sch Med, Div Med Oncol, Dept Med,Rochelle Belfer Chemotherapy Fdn Lab, Atran Bldg Room 610,Box 1178, New York, NY 10029 USA.	aguirj01@doc.mssm.edu			NATIONAL CANCER INSTITUTE [R01CA040758] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Bender FC, 2000, CANCER RES, V60, P5870; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARY LA, 1999, FRONT BIOSCI, V4, P102; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; OWENS LV, 1995, CANCER RES, V55, P2752; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; SCHILLER JH, 1995, CANCER RES, V55, P6215; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TOOLAN HW, 1954, CANCER RES, V14, P660; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Wang DY, 2000, J CELL SCI, V113, P4221; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	35	192	196	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2513	2524		10.1038/sj/onc/1205342	http://dx.doi.org/10.1038/sj/onc/1205342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971186				2022-12-17	WOS:000174918400008
J	Huang, EY; Madireddi, MT; Gopalkrishnan, RV; Leszczyniecka, M; Su, ZZ; Lebedeva, IV; Kang, DC; Jiang, HP; Lin, JJ; Alexandre, D; Chen, YM; Vozhilla, N; Mei, MX; Christiansen, KA; Sivo, F; Goldstein, NI; Mhashilkar, AB; Chada, S; Huberman, E; Pestka, S; Fisher, PB				Huang, EY; Madireddi, MT; Gopalkrishnan, RV; Leszczyniecka, M; Su, ZZ; Lebedeva, IV; Kang, DC; Jiang, HP; Lin, JJ; Alexandre, D; Chen, YM; Vozhilla, N; Mei, MX; Christiansen, KA; Sivo, F; Goldstein, NI; Mhashilkar, AB; Chada, S; Huberman, E; Pestka, S; Fisher, PB			Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties	ONCOGENE			English	Article						melanoma differentiation associated gene-7; terminal cell differentiation; gene expression; genomic structure; IL-10 cytokine family	HUMAN ADENOVIRUS TYPE-5; TERMINAL DIFFERENTIATION; IMMUNE INTERFERONS; LEUKEMIA-CELLS; IN-VITRO; PROGRESSION; DNA; ARREST; IDENTIFICATION; COMBINATION	Abnormalities in cellular differentiation are frequent occurrences in human cancers. Treatment of human melanoma cells with recombinant fibroblast interferon (IFN-beta) and the protein kinase C activator mezerein (MEZ) results in an irreversible loss in growth potential, suppression of tumorigenic properties and induction of terminal cell differentiation. Subtraction hybridization identified melanoma differentiation associated gene-7 (mda-7), as a gene induced during these physiological changes in human melanoma cells. Ectopic expression of mda-7 by means of a replication defective adenovirus results in growth suppression and induction of apoptosis in a broad spectrum of additional cancers, including melanoma, glioblastoma multiforme, osteosarcoma and carcinomas of the breast, cervix, colon, lung, nasopharynx and prostate. In contrast, no apparent harmful effects occur when mda-7 is expressed in normal epithelial or fibroblast cells. Human clones of mda-7 were isolated and its organization resolved in terms of intron/exon structure and chromosomal localization. Hu-mda-7 encompasses seven exons and six introns and encodes a protein with a predicted size of 23.8 kDa, consisting of 206 amino acids. Hu-mda-7 mRNA is stably expressed in the thymus, spleen and peripheral blood leukocytes. De novo mda-7 mRNA expression is also detected in human melanocytes and expression is inducible in cells of melanocyte/melanoma lineage and in certain normal and cancer cell types following treatment with a combination of IFN-beta plus MEZ. Mda-7 expression is also induced during megakaryocyte differentiation induced in human hematopoietic cells by treatment with TPA (12-O-tetradecanoyl phorbol-13-acetate). In contrast, de novo expression of mda-7 is not detected nor is it inducible by IFN-beta +MEZ in a spectrum of additional normal and cancer cells. No correlation was observed between induction of mda-7 mRNA expression and growth suppression following treatment with IFN-beta +MEZ and induction of endogenous mda-7 mRNA by combination treatment did not result in significant intracellular MDA-7 protein. Radiation hybrid mapping assigned the mda-7 gene to human chromosome 1q, at 1q 32.2 to 1q41, an area containing a cluster of genes associated with the IL-10 family of cytokines. Mda-7 represents a differentiation, growth and apoptosis associated gene with potential utility for the gene-based therapy of diverse human cancers.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Introgen Therapeut Inc, Houston, TX 77030 USA; Argonne Natl Lab, Ctr Mechanist Biol & Biotechnol, Argonne, IL 60439 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Columbia University; Columbia University; Columbia University; United States Department of Energy (DOE); Argonne National Laboratory; Rutgers State University New Brunswick; Rutgers State University Medical Center	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB 15-1501,630 W 168th St, New York, NY 10032 USA.	pbf@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NCI NIH HHS [CA35675, CA80826] Funding Source: Medline; NIAMS NIH HHS [P30-AR44535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080826, R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; Chu XH, 1999, CELL TISSUE RES, V296, P331, DOI 10.1007/s004410051293; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; DeRisi J, 1996, NAT GENET, V14, P457; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GUARINI L, 1990, INT J CANCER, V46, P1041, DOI 10.1002/ijc.2910460616; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; JIANG H, 2000, P NATL ACAD SCI USA, V93, P9160; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; KERBEL RS, 1984, INVAS METAST, V4, P31; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; LESZCZYNIECKA M, 2001, IN PRESS PHARM THERA; Li DQ, 1999, CURR EYE RES, V19, P154, DOI 10.1076/ceyr.19.2.154.5321; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Madireddi MT, 2000, ONCOGENE, V19, P1362, DOI 10.1038/sj.onc.1203424; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miller M S, 1999, J Foot Ankle Surg, V38, P227; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Saito I, 2000, CRIT REV IMMUNOL, V20, P153; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Soo C, 1999, J CELL BIOCHEM, V74, P1; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; SU ZZ, 1995, INT J ONCOL, V7, P1279; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; VITA JR, 1988, ANTICANCER RES, V8, P297; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; WAXMAN S, 1996, DIFFERENTIATION THER, P1; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	55	192	240	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7051	7063		10.1038/sj.onc.1204897	http://dx.doi.org/10.1038/sj.onc.1204897			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704829				2022-12-17	WOS:000171739300008
J	Jeronimo, C; Nomoto, S; Caballero, OL; Usadel, H; Henrique, R; Varzim, G; Oliveira, J; Lopes, C; Fliss, MS; Sidransky, D				Jeronimo, C; Nomoto, S; Caballero, OL; Usadel, H; Henrique, R; Varzim, G; Oliveira, J; Lopes, C; Fliss, MS; Sidransky, D			Mitochondrial mutations in early stage prostate cancer and bodily fluids	ONCOGENE			English	Article						prostate cancer; prostate intraepithelial neoplasia; mitochondrial mutations; bodily fluids	MICROSATELLITE ANALYSIS; MOLECULAR-DETECTION; BLADDER-CANCER; DNA MUTATIONS; CARCINOMA; NUCLEAR; REPAIR; TUMORS; GENOME; CELLS	We recently demonstrated the existence of specific patterns of somatic mitochondrial DNA (mtDNA) mutations in several cancers. Here we sought to identify the presence of mtDNA mutations in prostate cancer an their paired PIN lesions. The D-loop region, 16S rRNA, and the NADH subunits of complex I were sequenced to identify mtDNA mutations in 16 matched PIN lesions and primary prostate cancers. Twenty mtDNA mutations were detected in the tumor tissue of three patients. Identical mutations were also identified in the PIN lesion from one patient. This patient with multiple point mutations also harbored a high frequency of microsatellite instability (MSI-H) in nuclear mononucleotide repeat markers. Remarkably, identical mutations were also detected in all (3/3) matched urine and plasma samples obtained from these patients. Although mitochondrial mutations are less common in prostate adenocareinoma, they occur early in cancer progression and they can be detected in bodily fluids of early stage disease patients. The identification of MtDNA mutations may complement other early detection approaches for prostate cancer.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Inst Portugues Oncol Francisco Gentil, Ctr Reg Porto, Dept Pathol, Unit Mol Pathol, Oporto, Portugal; Inst Portugues Oncol Francisco Gentil, Ctr Reg Porto, Dept Urol, Oporto, Portugal	Johns Hopkins University; Portuguese Institute of Oncology; Portuguese Institute of Oncology	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Jerónimo, Carmen/H-3284-2013; Henrique, Rui Manuel Ferreira/I-2757-2013	Jerónimo, Carmen/0000-0003-4186-5345; Henrique, Rui Manuel Ferreira/0000-0003-3171-4666	NCI NIH HHS [P01 CA 58184, R01 CA 77664, UO1 CA 84986] Funding Source: Medline; NIDCR NIH HHS [R01 DE 012488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084986, P50CA058184, P01CA077664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cairns P, 1997, CANCER RES, V57, P4997; CAIRNS P, 2000, IN PRESS P AM ASS CA, V41, P241; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; ISAACS WB, 1996, PRINCIPLES PRACTICE, P403; JEN J, 1994, CANCER RES, V54, P5523; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4	20	192	207	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5195	5198		10.1038/sj.onc.1204646	http://dx.doi.org/10.1038/sj.onc.1204646			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526508				2022-12-17	WOS:000170464000013
J	Kim, DW; Gazourian, L; Quadri, SA; Romieu-Mourez, R; Sherr, DH; Sonenshein, GE				Kim, DW; Gazourian, L; Quadri, SA; Romieu-Mourez, R; Sherr, DH; Sonenshein, GE			The RelA NF-kappa B subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells	ONCOGENE			English	Article						NF-kappa B; RelA; AhR; c-myc oncogene; breast cancer	BREAST-CANCER; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; PROGNOSTIC FACTOR; PROTEIN; DIOXIN; TRANSCRIPTION; ACTIVATION; BINDING; LIGAND; GENE	NF-kappaB/Rel transcription factors regulate many genes involved in control of cellular proliferation, neoplastic transformation, and apoptosis, including the c-myc oncogene, Recently, we have observed that levels of NF-kappaB and aryl hydrocarbon receptor (AhR), which mediates malignant transformation by environmental carcinogens, are highly elevated and appear constitutively active in breast cancer cells. ReI factors have been found to functionally interact with other transcription factors. Here we demonstrate a physical and functional association between the RelA subunit of NF-kappaB and AhR resulting in the activation of c-myc gene transcription in breast cancer cells. RelA and AhR proteins were coimmunoprecipitated from cytoplasmic and nuclear extracts of non-malignant MCF-10F breast epithelial and malignant Hs578T breast cancer cells. In transient cotransfection, RelA and AhR gene products demonstrated cooperation in transactivation of the c-myc promoter, which was dependent on the NF-kappaB elements, and in induction of endogenous c-Myc protein levels. A novel AhR/RelA-containing NF-kappaB element binding complex was identified by electrophoretic mobility shift analysis of nuclear extracts from RelA and AhR co-transfected Hs578T cells. Thus, the RelA and AhR proteins functionally cooperate to bind to NF-kappaB elements and induce c-myc gene expression. These findings suggest a novel signaling mechanism whereby the Ah receptor can stimulate proliferation and tumorigenesis of mammary cells.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Program Res Womens Hlth, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Program Res Womens Hlth, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University; Boston University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.			Sherr, David/0000-0003-3353-0553	NCI NIH HHS [R01 CA 82742] Funding Source: Medline; NIEHS NIH HHS [1P42ES 07381, R01 ES06086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006086, P42ES007381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1999, TOXICOL APPL PHARM, V155, P62, DOI 10.1006/taap.1998.8601; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Dickinson LA, 1999, J BIOL CHEM, V274, P12765, DOI 10.1074/jbc.274.18.12765; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508; JAIN S, 1994, J BIOL CHEM, V269, P31518; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NEBERT DW, 1990, ENVIRON HEALTH PERSP, V88, P13, DOI 10.2307/3431045; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; PAVELIC ZP, 1991, ANTICANCER RES, V11, P1421; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Robles R, 2000, ENDOCRINOLOGY, V141, P450, DOI 10.1210/en.141.1.450; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Yamaguchi K, 1997, TOXICOL APPL PHARM, V147, P190, DOI 10.1006/taap.1997.8263; Yamaguchi K, 1997, J IMMUNOL, V158, P2165	50	192	203	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5498	5506		10.1038/sj.onc.1203945	http://dx.doi.org/10.1038/sj.onc.1203945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114727				2022-12-17	WOS:000165396100010
J	Yen, L; You, XL; Al Moustafa, AE; Batist, G; Hynes, NE; Mader, S; Meloche, S; Alaoui-Jamali, MA				Yen, L; You, XL; Al Moustafa, AE; Batist, G; Hynes, NE; Mader, S; Meloche, S; Alaoui-Jamali, MA			Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis	ONCOGENE			English	Article						ErbB receptors; heregulin beta 1; VEGF; cell proliferation; HUVEC	NEU DIFFERENTIATION FACTOR; RECEPTOR TYROSINE KINASES; NIH 3T3 CELLS; PERMEABILITY FACTOR; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; BREAST-CANCER; MESSENGER-RNA; FACTOR VEGF; MAP KINASE	The interaction between the erbB tyrosine kinase receptors and their ligands plays an important role in tumor growth via the regulation of autocrine and paracrine loops. We report the effect of heregulin beta 1, the ligand for erbB-3 and erbB-4 receptors, on the regulation of vascular endothelial growth factor (VEGF) expression, using a panel of breast and lung cancer cell lines with constitutive erbB-2 overexpression or engineered to stably overexpress the erbB-2 receptor. We demonstrate that heregulin beta 1 induces VEGF secretion in most cancer cell lines, while no significant effect was observed in normal human mammary and bronchial primary cells. Overexpression of erbB-2 receptor results in induction of the basal level of VEGF and exposure to heregulin further enhances VEGF secretion. This is associated with increased VEGF mRNA expression. In contrast, VEGF induction is significantly decreased in a T47D cell line where erbB-2 is functionally inactivated. Conditioned media from heregulin-treated cancer cells, but not from normal cells, stimulates endothelial cell proliferation; this paracrine stimulation is inhibited by co-exposure to a specific VEGF neutralizing antibody, Furthermore, heregulin-mediated angiogenesis is observed in the in vivo CAM assay. This study reports the first evidence of VEGF regulation by heregulin in cancer cells.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Pharmacol Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1P1, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1T8, Canada; Hotel Dieu Montreal, Ctr Rech, Montreal, PQ H2W 1T8, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; Friedrich Miescher Institute for Biomedical Research; Universite de Montreal; Universite de Montreal; Universite de Montreal	Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Room 523,3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.							ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Balbay MD, 1999, CLIN CANCER RES, V5, P783; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROWN LF, 1997, EXS, V79, P233; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; Claffey KP, 1996, CANCER RES, V56, P172; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO;2-5; Feleszko W, 1999, INT J CANCER, V81, P560, DOI 10.1002/(SICI)1097-0215(19990517)81:4<560::AID-IJC10>3.0.CO;2-7; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Im SA, 1999, CANCER RES, V59, P895; Jannot CB, 1996, ONCOGENE, V13, P275; Joukov V, 1996, EMBO J, V15, P290; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Liu JJ, 1999, INVEST OPHTH VIS SCI, V40, P752; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MARTE BM, 1995, ONCOGENE, V10, P167; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Melnyk O, 1999, J UROLOGY, V161, P960, DOI 10.1016/S0022-5347(01)61829-9; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NOGUCHI M, 1993, CANCER RES, V53, P2035; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Pluda JM, 1997, SEMIN ONCOL, V24, P203; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, CANCER RES, V60, P490; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rofstad EK, 1999, BRIT J CANCER, V80, P1697, DOI 10.1038/sj.bjc.6690586; Rossler J, 1999, INT J CANCER, V81, P113; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tan M, 1997, CANCER RES, V57, P1199; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246; YU DH, 1994, CANCER RES, V54, P3260; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhang K, 1996, J BIOL CHEM, V271, P3884	78	192	210	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2000	19	31					3460	3469		10.1038/sj.onc.1203685	http://dx.doi.org/10.1038/sj.onc.1203685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918604				2022-12-17	WOS:000088346500002
J	Wu, GS; Saftig, P; Peters, C; El-Deiry, WS				Wu, GS; Saftig, P; Peters, C; El-Deiry, WS			Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity	ONCOGENE			English	Article						p53; protease; apoptosis; transcription	PROGRAMMED CELL-DEATH; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; APOPTOSIS; P53; DEFICIENT; GENE; MICE; P21; BAX	Cathepsin D (CD), the major intracellular aspartyl protease, is a mediator of IFN-gamma and TNF-alpha induced apoptosis, Using subtractive hybridization screening we isolated CD as an upregulated transcript in PA1 human ovarian cancer cells undergoing adriamycin-induced apoptosis, CD mRNA levels increased in wild-type p53-expressing PA1, ML1 leukemia and U1752 lung cancer cells but not in mutant p53-expressing cells following adriamycin exposure, Overexpression of CD inhibited growth of colon, liver, and ovarian cancer cells, CD protein expression was increased by exposure of ML1 cells to etoposide, adriamycin or gamma-radiation. Inhibition of CD protease with Pepstatin A suppressed p53-dependent apoptosis in lymphoid cells, suggesting a possible role for CD in p53-dependent cell death, CD-/- fibroblasts mere found to be more resistant to killing by adriamycin and etoposide, as compared to CD+/+ cells, Two p53 DNA-binding sites located in the CD-promoter specifically bound to p53 protein in vitro and appeared to mediate transactivation of a CD-promoter luciferase-reporter during p53-dependent apoptosis, These observations link CD protease to p53-dependent tumor suppression and chemosensitivity.	Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Genet & Canc Ctr,Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Uniklin Freiburg Hugstetterstra DFe55, Innere Med Abt 1, Arbeitsgrp Med Mol Biol, D-79106 Freiburg, Germany	Howard Hughes Medical Institute; University of Pennsylvania; University of Gottingen	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Genet & Canc Ctr,Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020; Saftig, Paul/A-7966-2010	El-Deiry, Wafik/0000-0002-9577-8266; 				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	31	192	198	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2177	2183		10.1038/sj.onc.1201755	http://dx.doi.org/10.1038/sj.onc.1201755			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619826				2022-12-17	WOS:000073298000002
J	Wang, XT; Gorospe, M; Huang, Y; Holbrook, NJ				Wang, XT; Gorospe, M; Huang, Y; Holbrook, NJ			p27(Kip1) overexpression causes apoptotic death of mammalian cells	ONCOGENE			English	Article						apoptosis; cdk inhibitor; cell growth; Bcl-2	DEPENDENT KINASE INHIBITOR; ANTICANCER AGENTS; CARCINOMA CELLS; CDK INHIBITORS; MICE LACKING; CYCLE ARREST; G(1) ARREST; GROWTH; P21; DIFFERENTIATION	p27(Kip1), a member of the Cip/Kip family of cyclin-dependent kinase (cdk) inhibitors, has been Implicated in mediating G1 arrest in response to a variety of growth inhibitory signals, Its importance in regulating cell growth is emphasized by the fact that mice lacking p27(Kip1) are abnormally large and display hyperplasia of multiple tissues, However, these mice retain the ability to undergo G1 arrest in response to growth inhibitory signals, suggesting that p27(Kip1) may serve other functions important for controlling tissue growth, In the present study, we utilized an adenoviral vector-based expression system to examine the consequences of p27(Kip1) overexpression in the human carcinoma cell lines A549, HeLa and RKO, in human melanoma SK-MEL-110 cells, in human lung fibroblasts IMR90 and in the rat fibroblast line Rat1, We demonstrate that overexpression of p27(Kip1) leads to apoptotic cell death in all cell types, and further show that ectopic expression of Bcl-2 can protect HeLa cells from apoptosis mediated by p27(Kip1) overexpression, To our knowledge, this is the first study demonstrating that p27(Kip1) can induce apoptosis, Our findings provide new insight into the possible functions of this growth regulatory protein, and support the potential utility of gene therapeutic approaches aimed at elevating p27(Kip1) expression for treatment of human cancers.	NIA,GENE EXPRESS & AGING SECT,BIOL CHEM LAB,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu XP, 1996, ONCOGENE, V12, P1397; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	31	192	211	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2991	2997		10.1038/sj.onc.1201450	http://dx.doi.org/10.1038/sj.onc.1201450			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416843				2022-12-17	WOS:A1997YK37700012
J	DESOUZA, AT; HANKINS, GR; WASHINGTON, MK; FINE, RL; ORTON, TC; JIRTLE, RL				DESOUZA, AT; HANKINS, GR; WASHINGTON, MK; FINE, RL; ORTON, TC; JIRTLE, RL			FREQUENT LOSS OF HETEROZYGOSITY ON 6Q AT THE MANNOSE 6-PHOSPHATE/INSULIN-LIKE GROWTH-FACTOR-II RECEPTOR LOCUS IN HUMAN HEPATOCELLULAR TUMORS	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; MGP/IGFII RECEPTOR; HEPATOCELLULAR CARCINOMA	FACTOR TYPE-2 RECEPTOR; HUMAN BREAST-CANCER; P53 GENE-MUTATIONS; FACTOR-BETA-1 PRECURSOR; 6-PHOSPHATE RECEPTORS; COLORECTAL CANCERS; SUPPRESSOR GENES; WILMS TUMOR; FACTOR-BETA; CARCINOMA	The mannose 6-phosphate/insulin-like growth factor III receptor (M6P/IGFIIr) is required for the activation of transforming growth factor beta, and previously we have found its expression to be significantly reduced in both rat and human hepatocellular carcinomas (HCCs). Therefore, we have postulated that loss of the M6P/IGFIIr gene may be mechanistically involved in liver carcinogenesis. Using the polymerase chain reaction, we utilized two polymorphisms in the 3' untranslated region of the M6P/IGFIIr gene to screen non-cirrhotic, hepatitis virus negative patients with hepatocellular tumors for LOH. Twenty-two of 36 (61%) patients were informative (heterozygous), and 14/22 (64%) liver tumors had LOH; 11/16 (69%) carcinomas, 1/3 (33%) fibrolamellar tumors and 2/3 (67%) adenomas. This is the first report of LOH at the M6P/IGFIIr locus in human hepatocellular tumors, and the presence of LOH in adenomas suggests that allelic loss may be an early event in the etiology of HCCs. These results support the hypothesis that the M6P/IGFIIr gene may function as a tumor suppressor gene in the liver.	DUKE UNIV,MED CTR,DEPT RADIAT ONCOL,DURHAM,NC 27710; ZENECA PHARMACEUT,DEPT SAFETY MED,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University					NCI NIH HHS [CA25951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DEVILEE P, 1991, ONCOGENE, V6, P1705; DRAGAN YP, 1992, CARCINOGENESIS, V5, P739; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; HEDRUM A, 1994, BIO-TECHNOL, V7, P118; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LEE JH, 1990, CANCER RES, V50, P2724; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOUIS DN, 1992, AM J PATHOL, V141, P777; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLIKIN D, 1991, CANCER RES, V51, P5449; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORITA R, 1991, CANCER RES, V51, P5817; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOSE H, 1993, CANCER, V72, P355, DOI 10.1002/1097-0142(19930715)72:2<355::AID-CNCR2820720208>3.0.CO;2-W; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SAITO S, 1992, CANCER RES, V52, P5812; SANGER F, 1987, P NATL ACAD SCI USA, V74, P5463; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; SLAGLE BL, 1991, CANCER RES, V51, P49; SMITH M, 1986, AM J HUM GENET, V39, P654; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUE SR, 1994, IN PRESS ANN SURGERY; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1993, TRENDS GENET, V4, P138; WALKER GJ, 1991, CANCER RES, V51, P4367; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	64	192	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1725	1729						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753549				2022-12-17	WOS:A1995QX46900005
J	BELLUSCI, S; MOENS, G; GAUDINO, G; COMOGLIO, P; NAKAMURA, T; THIERY, JP; JOUANNEAU, J				BELLUSCI, S; MOENS, G; GAUDINO, G; COMOGLIO, P; NAKAMURA, T; THIERY, JP; JOUANNEAU, J			CREATION OF AN HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR AUTOCRINE LOOP IN CARCINOMA-CELLS INDUCES INVASIVE PROPERTIES ASSOCIATED WITH INCREASED TUMORIGENICITY	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; TYROSINE KINASE-ACTIVITY; EPITHELIAL-CELLS; MET PROTOONCOGENE; C-MET; EXTRACELLULAR-MATRIX; FACTOR RECEPTOR; RAT; IDENTIFICATION; EXPRESSION	Exogenous HGF/SF converts subconfluent cultures of NBT-II epithelial carcinoma cells into mobile fibroblast-like cells while being only mitogenic for cells maintained at high density. To investigate the potential rote of such factor in tumor progression, we generated HGF/SF-producing NBT-II cells by transfection with an expression plasmid containing human HGF/SF cDNA. HGF/SF-producing cells also exhibit a fibroblastic phenotype. Media conditioned by these cells are potent inducers of in vitro tubulogenesis which can be inhibited with specific anti-HGF/SF antibodies; these antibodies are also able to reverse the scattered phenotype of the HGF/SF-producing cells. In addition spheroids of HGF/SF-producing cells are dispersed into 3D collagen gels suggesting an increase of invasive properties of these cells. When injected in nude mice, these HGF/SF-producing cells induce tumors appearing more rapidly than did those obtained with untransfected cells. These results show that HGF/SF can promote motility and invasive properties of NBT-II bladder carcinoma cells and also confers a tumorigenic advantage when acting as an autocrine factor.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN	University of Turin; Osaka University	BELLUSCI, S (corresponding author), ECOLE NORMALE SUPER,PHYSIOPATHOL DEV LAB,CNRS,URA 1337,46 RUE ULM,F-75231 PARIS 05,FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Comoglio, Paolo/0000-0002-7056-5328; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADAMS JC, 1991, J CELL SCI, V98, P385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COLBEREGARAPIN F, 1981, J MOL BIOL, V105, P1; Cowin P, 1985, CELL CONTACT, P427; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAVRILOVIC J, 1990, CELL REGUL, V1, P1003, DOI 10.1091/mbc.1.13.1003; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; JIANG WG, 1993, CLIN EXP METASTAS, V11, P235, DOI 10.1007/BF00121166; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KENWORTHY P, 1992, BRIT J CANCER, V66, P243, DOI 10.1038/bjc.1992.251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SPORN MB, 1985, NATURE, V327, P239; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TUCKER GC, 1991, INVAS METAST, V11, P297; TUCKER GC, 1991, J CELL SCI, V100, P371; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	54	192	201	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1091	1099						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134112				2022-12-17	WOS:A1994NC04800011
J	KNOWLES, MA; SHAW, ME; PROCTOR, AJ				KNOWLES, MA; SHAW, ME; PROCTOR, AJ			DELETION MAPPING OF CHROMOSOME-8 IN CANCERS OF THE URINARY-BLADDER USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS AND MICROSATELLITE POLYMORPHISMS	ONCOGENE			English	Article							TRANSITIONAL CELL-CARCINOMA; DINUCLEOTIDE REPEAT POLYMORPHISM; POLYMERASE CHAIN-REACTION; COLORECTAL CANCERS; CLONAL EVOLUTION; GENE; IDENTIFICATION; ADENOCARCINOMAS; LEUKEMIA; LOCUS	We have used a combination of restriction fragment length polymorphism (RFLP) markers and highly informative microsatellite polymorphisms to map a common region of deletion on chromosome 8p in cancers of the urinary bladder. Analysis of loss of heterozygosity (LOH) using microsatellite polymorphisms was shown to be at least as sensitive as detection of RFLPs by Southern blotting. A total of 110 tumours was analysed for loss of heterozygosity (LOH) on 8p and 8q; 109 patients were informative for at least one marker on each chromosome arm and 29 tumours (26%) showed LOH of chromosome 8 markers, 26 of which (25%) showed LOH on 8p. Sixteen tumours (14%) showed LOH on 8q. Thirteen of these also had LOH on 8p. Of the 29 tumours with LOH, five had LOH at all informative loci, indicating loss of an entire copy of chromosome 8. An association was found between high tumour grade and stage and chromosome 8 LOH. Fifty-three per cent of grade 3 muscle-invasive tumours showed LOH compared with 11% of grade 1 non-invasive tumours (0.01 < P < 0.025 and 0.025 < P < 0.05 for grade and stage respectively). Deletion mapping of tumours with chromosome 8 LOH suggests the presence of a suppressor gene(s) for urothelial cancer within a region defined by the loci NEFL and PLAT (8p21 - q11.2). If there is a common target for deletions in bladder and those in hepatocellular and colorectal tumours reported previously, this defines a common region of deletion at 8p21.3.			KNOWLES, MA (corresponding author), MARIE CURIE SKLODOWSKA MEM INST,EPITHELIAL CARCINOGENESIS LAB,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; DEVILEE P, 1991, ONCOGENE, V6, P1705; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERTI AD, 1988, CANCER GENET CYTOGEN, V34, P101, DOI 10.1016/0165-4608(88)90174-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GRANBERGOHMAN I, 1984, CANCER GENET CYTOGEN, V11, P69, DOI 10.1016/0165-4608(84)90100-6; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JIN YS, 1988, CANCER GENET CYTOGEN, V33, P11, DOI 10.1016/0165-4608(88)90043-X; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LEVERGER G, 1988, MED PEDIATR ONCOL, V16, P227, DOI 10.1002/mpo.2950160402; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MITELMAN F, 1981, CANCER GENET CYTOGEN, V4, P197, DOI 10.1016/0165-4608(81)90014-5; MULERIS M, 1986, INT J CANCER, V38, P167, DOI 10.1002/ijc.2910380204; OCHI H, 1986, CANCER GENET CYTOGEN, V22, P295, DOI 10.1016/0165-4608(86)90022-1; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; PROCTOR AJ, 1991, ONCOGENE, V61, P787; STOLL C, 1979, LEUKEMIA RES, V3, P61, DOI 10.1016/0145-2126(79)90063-8; TAUTZ D, 1990, BIOESSAYS, V12, P44, DOI 10.1002/bies.950120111; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2200; WOOD S, 1991, NUCLEIC ACIDS RES, V19, P6664, DOI 10.1093/nar/19.23.6664-a; ZULIANI G, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958-a; 1978, TNM CLASSIFICATION M, P113; 1973, INT HISTOLOGICAL CLA; 1991, CYTOGENET CELL GENET, V58, P1	44	192	194	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1357	1364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8097582				2022-12-17	WOS:A1993KY32800029
J	FUJII, M; NIKI, T; MORI, T; MATSUDA, T; MATSUI, M; NOMURA, N; SEIKI, M				FUJII, M; NIKI, T; MORI, T; MATSUDA, T; MATSUI, M; NOMURA, N; SEIKI, M			HTLV-1 TAX INDUCES EXPRESSION OF VARIOUS IMMEDIATE EARLY SERUM RESPONSIVE GENES	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; JUN PROTO-ONCOGENE; LEUCINE ZIPPER STRUCTURE; C-FOS PROTEIN; TRANSCRIPTIONAL ACTIVATOR; TRANS-ACTIVATION; RECEPTOR EXPRESSION; HUMAN INTERLEUKIN-2	Human T-cell leukemia virus type 1 (HTLV-1) is an etiological agent of adult T-cell leukemia (ATL). We showed here by mobility-shift assay that T-cell lines transformed with the virus contained high levels of AP-1 activities. Consistent with this result, these cell lines expressed increased levels of mRNAs encoding the AP-1 proteins, c-Fos, Fra-1, c-Jun, JunB, and JunD. Previously, transcription of the c-fos gene has been reported to be transactivated by the viral transcription factor, Tax1. By using the human T-cell line (JPX-9), in which expression of the Tax1 is inducible, we showed that expression of mRNAs for Fra-1, c-Jun, and JunD was also transactivated by Tax1. Moreover, Tax1 activated expression of two other transcription factors having zinc finger motifs, Egr-1 and Egr-2, in the same cells. The Tax1-inducible transcription factors identified here are encoded by the members of immediate early genes under the control of growth signals. Thus, Tax1 was suggested to replace growth signals, at least in part, by this mechanism.	KANAZAWA UNIV, CANC RES INST, DEPT VIROL, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, DEPT INTERNAL MED 3, KANAZAWA, ISHIKAWA 920, JAPAN; NIPPON MED COLL, INST GERONTOL, MOLEC BIOL LAB, KAWASAKI, KANAGAWA 211, JAPAN	Kanazawa University; Kanazawa University; Nippon Medical School	SEIKI, M (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT VIROL, KANAZAWA, ISHIKAWA 920, JAPAN.		Matsui, Minami/A-5235-2016; Seiki, Motoharu/K-9443-2015	Matsui, Minami/0000-0001-5162-2668; 				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALLER DV, 1988, J VIROL, V62, P2942, DOI 10.1128/JVI.62.8.2942-2950.1988; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; HATAKEYAMA M, 1985, NATURE, V318, P467, DOI 10.1038/318467a0; HATTORI T, 1981, BLOOD, V58, P645; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATSUI M, 1990, ONCOGENE, V5, P249; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WANO Y, 1988, P NATL ACAD SCI USA, V63, P3234; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	66	192	192	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1023	1029						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906155				2022-12-17	WOS:A1991GU62200018
J	RUTA, M; HOWK, R; RICCA, G; DROHAN, W; ZABELSHANSKY, M; LAUREYS, G; BARTON, DE; FRANCKE, U; SCHLESSINGER, J; GIVOL, D				RUTA, M; HOWK, R; RICCA, G; DROHAN, W; ZABELSHANSKY, M; LAUREYS, G; BARTON, DE; FRANCKE, U; SCHLESSINGER, J; GIVOL, D			A NOVEL PROTEIN TYROSINE KINASE GENE WHOSE EXPRESSION IS MODULATED DURING ENDOTHELIAL-CELL DIFFERENTIATION	ONCOGENE			English	Article									RORER BIOTECHNOL INC,ROCKVILLE,MD 20850				laureys, genevieve/AAG-2390-2021; Barton, David E/I-1795-2019; Barton, David E/B-9460-2008	Barton, David E/0000-0002-2031-9719; 				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; FREIDHOFF F, 1983, CANCER GENET CYTOGEN, V9, P391; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HIESTERKAMP N, 1983, VIROLOGY, V126, P248; HIESTERKAMPF N, 1982, NATURE, V299, P747; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; LEBEAU MM, 1986, SCIENCE, V231, P984, DOI 10.1126/science.3484837; LEWIS JP, 1983, AM J PEDIAT HEMATOL, V5, P265; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1988, IN PRESS BIOCHEMISTR; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679; YANGFENG TL, 1986, AM J HUM GENET, V39, P79; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YARDEN Y, 1988, IN PRESS ANN REV BIO	30	192	212	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					9	15						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400002
J	Nagano, O; Okazaki, S; Saya, H				Nagano, O.; Okazaki, S.; Saya, H.			Redox regulation in stem-like cancer cells by CD44 variant isoforms	ONCOGENE			English	Review						cancer stem cell; CD44; reactive oxygen species; cystine-glutamate transporter	EPITHELIAL-MESENCHYMAL TRANSITION; CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; BREAST-CANCER; OXIDATIVE STRESS; CARCINOMA-CELLS; INITIATING CELLS; GROWTH-FACTOR; TUMOR-GROWTH; PROSPECTIVE IDENTIFICATION; GLUTATHIONE METABOLISM	Increasing evidence indicates that several types of solid tumor are hierarchically organized and sustained by a distinct population of cancer stem cells (CSCs). CSCs possess enhanced mechanisms of protection from stress induced by reactive oxygen species (ROS) that render them resistant to chemo- and radiotherapy. Expression of CD44, especially variant isoforms (CD44v) of this major CSC marker, contributes to ROS defense through upregulation of the synthesis of reduced glutathione (GSH), the primary intracellular antioxidant. CD44v interacts with and stabilizes xCT, a subunit of the cystine-glutamate transporter xc(-), and thereby promotes cystine uptake for GSH synthesis. Given that cancer cells are often exposed to high levels of ROS during tumor progression, the ability to avoid the consequences of such exposure is required for cancer cell survival and propagation in vivo. CSCs, in which defense against ROS is enhanced by CD44v are thus thought to drive tumor growth, chemoresistance and metastasis. Therapy targeted to the CD44v-xCT system may therefore impair the ROS defense ability of CSCs and thereby sensitize them to currently available treatments.	[Nagano, O.; Okazaki, S.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo 1608582, Japan; [Saya, H.] Japan Sci & Technol Agcy, CREST, Chiyoda Ku, Tokyo, Japan	Keio University; Japan Science & Technology Agency (JST)	Nagano, O (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	osmna@sb3.so-net.ne.jp	Okazaki, Shogo/A-8119-2014; Saya, Hideyuki/J-4325-2013	Saya, Hideyuki/0000-0001-6610-1902	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Ministry's Project for Development of Innovative Research on Cancer Therapeutics	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry's Project for Development of Innovative Research on Cancer Therapeutics	We thank K Arai for help in preparation of the manuscript. The work in the authors' laboratory was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to HS) as well as by the Ministry's Project for Development of Innovative Research on Cancer Therapeutics (P-Direct, to ON).	Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; ARRICK BA, 1984, CANCER RES, V44, P4224; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Baek S, 2012, CLIN CANCER RES, V18, P5427, DOI 10.1158/1078-0432.CCR-12-0214; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024; Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dalton TP, 2004, FREE RADICAL BIO MED, V37, P1511, DOI 10.1016/j.freeradbiomed.2004.06.040; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Golden EB, 2012, FRONT ONCOL, V2, P1, DOI [10.3389/fonc.2012.00088, 10.3389/fonc.2012.00153]; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; ISHII T, 1987, J CELL PHYSIOL, V133, P330, DOI 10.1002/jcp.1041330217; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kannagi R, 2010, CANCER SCI, V101, P586, DOI 10.1111/j.1349-7006.2009.01455.x; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lewerenz J, 2012, CELL DEATH DIFFER, V19, P847, DOI 10.1038/cdd.2011.165; Lewerenz J, 2009, J BIOL CHEM, V284, P1106, DOI 10.1074/jbc.M807325200; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li J, 2006, MOL BIOL CELL, V17, P3978, DOI 10.1091/mbc.E05-06-0532; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863; Macleod KF, 2008, NAT REV CANCER, V8, P769, DOI 10.1038/nrc2504; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Mielgo A, 2006, CELL DEATH DIFFER, V13, P465, DOI 10.1038/sj.cdd.4401763; Mima K, 2012, CANCER RES, V72, P3414, DOI 10.1158/0008-5472.CAN-12-0299; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Naor D, 2008, SEMIN CANCER BIOL, V18, P260, DOI 10.1016/j.semcancer.2008.03.015; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; OBrien ML, 1996, EUR J CANCER, V32A, P967, DOI 10.1016/0959-8049(96)00051-2; Ohata H, 2012, CANCER RES, V72, P5101, DOI 10.1158/0008-5472.CAN-11-3812; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Owusu-Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pham PV, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-209; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Preston Marnie, 2011, Front Biosci (Schol Ed), V3, P1165; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Qu Y, 2011, J CLIN INVEST, V121, P212, DOI 10.1172/JCI43144; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shi XK, 2012, ANTIOXID REDOX SIGN, V16, P1215, DOI 10.1089/ars.2012.4529; Slomiany MG, 2009, CANCER RES, V69, P1293, DOI 10.1158/0008-5472.CAN-08-2491; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; Sun SR, 2009, KIDNEY INT, V75, P1278, DOI 10.1038/ki.2009.62; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TEW KD, 1994, CANCER RES, V54, P4313; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toole BP, 2008, DRUG RESIST UPDATE, V11, P110, DOI 10.1016/j.drup.2008.04.002; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang HY, 2003, BIOCHEM BIOPH RES CO, V305, P611, DOI 10.1016/S0006-291X(03)00808-8; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Weber GF, 2002, CANCER RES, V62, P2281; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	115	191	195	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5191	5198		10.1038/onc.2012.638	http://dx.doi.org/10.1038/onc.2012.638			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23334333				2022-12-17	WOS:000326497100001
J	Billen, LP; Shamas-Din, A; Andrews, DW				Billen, L. P.; Shamas-Din, A.; Andrews, D. W.			Bid: a Bax-like BH3 protein	ONCOGENE			English	Review						Bid; apoptosis; BH-regions; structural homology; multidomain apoptosis proteins	CYTOCHROME-C RELEASE; BCL-X-L; PRO-APOPTOTIC ACTIVITY; CELL-DEATH MACHINERY; DNA-DAMAGE RESPONSE; CONFORMATIONAL-CHANGE; MEMBRANE PERMEABILIZATION; PEPTIDE COMPLEX; GRANZYME-B; MITOCHONDRIAL LOCALIZATION	Bid, a pro-apoptotic member of the Bcl-2 family, was initially discovered through binding to both pro-apoptotic Bax and anti-apoptotic Bcl-2. During apoptosis, Bid can be cleaved not only by caspase-8 during death receptor apoptotic signaling, but also by other caspases, granzyme B, calpains and cathepsins. Protease-cleaved Bid migrates to mitochondria where it inducespe rmeabilization of the outer mitochondrial membrane that isdependent on the pro-apoptotic proteinsBax and/or Bak, and thus Bid acts as a sentinel for protease-mediated death signals. Although sequence analysis suggests that Bid belongs to the BH3-only subgroup of the Bcl-2 family, structural and phylogenetic analysis suggests that Bid may be more related to multi-BH region proteinss such as pro-apoptotic Bax. Analysis of membrane binding by protease-cleaved Bid reveals mechanistic similarities with the membrane binding of Bax. For both proteins, membrane binding is characterized by relief of N-terminal inhibition of sequences promoting migration to membranes, insertion into the bilayer of the central hydrophobic hairpin helices and exposure of the BH3 region. These findings implicate Bid as a BH3-only protein that is both structurally and functionally related to multi-BH region Bcl-2 family proteins such as Bax. Oncogene (2009) 27, S93-S104; doi: 10.1038/onc.2009.47	[Billen, L. P.; Shamas-Din, A.; Andrews, D. W.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada	McMaster University; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada.	andrewsd@mcmaster.ca		Andrews, David/0000-0002-9266-7157	Canadian Institute of Health Research (CIHR) [FRN12517]; Tier I Canada Research Chair in Membrane Biogenesis	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Tier I Canada Research Chair in Membrane Biogenesis(Canada Research Chairs)	The work in the author's laboratory was supported by grant FRN12517 from the Canadian Institute of Health Research (CIHR), a Tier I Canada Research Chair in Membrane Biogenesis to DWA and a CIHR Canada Graduate Scholarship to LPB.	Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Arokium H, 2004, J BIOL CHEM, V279, P52566, DOI 10.1074/jbc.M408373200; Arokium H, 2007, J BIOL CHEM, V282, P35104, DOI 10.1074/jbc.M704891200; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Garcia-Saez AJ, 2005, BIOPHYS J, V88, P3976, DOI 10.1529/biophysj.104.058008; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gong XM, 2004, J BIOL CHEM, V279, P28954, DOI 10.1074/jbc.M403490200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Hu X, 2003, APOPTOSIS, V8, P277, DOI 10.1023/A:1023676906857; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Klumpp S, 2003, NEUROCHEM INT, V42, P555, DOI 10.1016/S0197-0186(02)00174-2; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kutuk O, 2008, CURR MOL MED, V8, P102; Kvansakul M, 2008, CELL DEATH DIFFER, V15, P1564, DOI 10.1038/cdd.2008.83; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oh KJ, 2005, J BIOL CHEM, V280, P753, DOI 10.1074/jbc.M405428200; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Peyerl FW, 2007, CELL DEATH DIFFER, V14, P447, DOI 10.1038/sj.cdd.4402025; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Smits C, 2008, STRUCTURE, V16, P818, DOI 10.1016/j.str.2008.02.009; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Uren RT, 2007, J CELL BIOL, V177, P277, DOI 10.1083/jcb.200606065; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2000, GENE DEV, V14, P2060; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xin MG, 2007, J BIOL CHEM, V282, P21268, DOI 10.1074/jbc.M701613200; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	102	191	193	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S93	S104		10.1038/onc.2009.47	http://dx.doi.org/10.1038/onc.2009.47			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641510				2022-12-17	WOS:000268566800008
J	Kikuno, N; Shiina, H; Urakami, S; Kawamoto, K; Hirata, H; Tanaka, Y; Place, RF; Pookot, D; Majid, S; Igawa, M; Dahiya, R				Kikuno, N.; Shiina, H.; Urakami, S.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Place, R. F.; Pookot, D.; Majid, S.; Igawa, M.; Dahiya, R.			RETRACTED: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity (Retracted article. See vol. 41, pg. 4981, 2022)	ONCOGENE			English	Article; Retracted Publication						AEG-1; FOXO3a; AKT; PTEN; prostate cancer	FACTOR-KAPPA-B; RAPID SUBTRACTION HYBRIDIZATION; PROTEIN-KINASE; ANDROGEN RECEPTOR; SIGNALING PATHWAY; AKT ACTIVATION; EXPRESSION; CELLS; TRANSCRIPTION; APOPTOSIS	Astrocyte-elevated gene-1 (AEG-1) has been reported to be upregulated in several malignancies and play a critical role in Ha-ras-mediated oncogenesis through the phosphatidylinositol 3-kinase/AKT signaling pathway. However, the role of AEG-1 in prostate cancer ( PC) has never been reported. We now show that AEG-1 is overexpressed in clinical PC tissue samples and cultured PC cells compared to benign prostatic hyperplasia tissue samples and normal prostate epithelial cells. Interestingly, AEG-1 knockdown induced cell apoptosis through upregulation of forkhead box (FOXO) 3a activity. This alteration of FOXO3a activity was dependent on reduction of AKT activity in LNCaP and PC-3 cells with high constitutive AKT activity, but not in DU145 cells with low constitutive AKT activity, although AEG-1 knockdown had no impact on phosphatase and tensin homolog expression in these cells. AEG-1 knockdown also attenuated the constitutive activity of the nuclear factor kB (NF-kB) and the activator protein 1 (AP-1) with a corresponding depletion in the expression of NF-kappa B and AP-1-regulated genes ( interleukin (IL)-6, IL-8 and matrix metalloproteinase-9) and significantly decreased cell invasion properties of PC-3 and DU145 cells. Overall, our findings suggest that aberrant AEG-1 expression plays a dominant role as a positive auto-feedback activator of AKT and as a suppressor of FOXO3a in PC cells. AEG-1 may therefore represent a novel genetic biomarker to serve as an attractive molecular target for new anticancer agents to prevent PC cell progression and metastasis.	[Kikuno, N.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Place, R. F.; Pookot, D.; Majid, S.; Dahiya, R.] Vet Affairs Med Ctr, Urol Res Ctr 112F, Dept Urol, San Francisco, CA 94121 USA; [Kikuno, N.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Place, R. F.; Pookot, D.; Majid, S.; Dahiya, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Shiina, H.; Urakami, S.; Igawa, M.] Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Shimane University	Dahiya, R (corresponding author), Vet Affairs Med Ctr, Urol Res Ctr 112F, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.	rdahiya@urology.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA101844, R01CA111470, R01CA108612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021418] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bentires-Alj M, 1999, CANCER RES, V59, P811; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Festuccia C, 2005, ENDOCR-RELAT CANCER, V12, P983, DOI 10.1677/erc.1.00986; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; Nakashima H, 2006, CANCER RES, V66, P7041, DOI 10.1158/0008-5472.CAN-05-4588; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Place RF, 2005, BIOCHEM PHARMACOL, V70, P394, DOI 10.1016/j.bcp.2005.04.030; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; Zerbini LF, 2003, CANCER RES, V63, P2206; Zhang MC, 2007, BIOCHEM PHARMACOL, V73, P15, DOI 10.1016/j.bcp.2006.07.034	28	191	210	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7647	7655		10.1038/sj.onc.1210572	http://dx.doi.org/10.1038/sj.onc.1210572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563745				2022-12-17	WOS:000251537800006
J	Zucman-Rossi, J; Benhamouche, S; Godard, C; Boyault, S; Grimber, G; Balabaud, C; Cunha, AS; Bioulac-Sage, P; Perret, C				Zucman-Rossi, J.; Benhamouche, S.; Godard, C.; Boyault, S.; Grimber, G.; Balabaud, C.; Cunha, A. S.; Bioulac-Sage, P.; Perret, C.			Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; beta-catenin; Axin1; target genes; Wnt pathway	COLON-CARCINOMA; PROTEIN-KINASE; CYCLIN D1; GENE; COMPLEX; VIRUS; LIVER; IDENTIFICATION; EXPRESSION; FREQUENT	Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of b-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated b-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR) 49 and glutamate transporter (GLT)-1 (P = 0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of b-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. beta-Catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.	Univ Paris 05, INSERM, U567,Inst Cochin, CNRS,UMR 8104,Dept EMC,Fac Med Cochin Port Royal, F-75014 Paris, France; INSERM, U674, IFR105, CEPH, Paris, France; Ctr Hosp Univ Bordeaux, Dept Hepatol, Bordeaux, France; Ctr Hosp Univ Bordeaux, Hop Pellegrin, Serv Anat Pathol, Bordeaux, France; Univ Bordeaux 2, INSERM, E362, GREF, F-33076 Bordeaux, France; CHU Bordeaux, Hop St Andre, Serv Chirurg Digest, Bordeaux, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux	Perret, C (corresponding author), Univ Paris 05, INSERM, U567,Inst Cochin, CNRS,UMR 8104,Dept EMC,Fac Med Cochin Port Royal, 24,Bat Fac,Rue Faubourg St Jacques, F-75014 Paris, France.	perret@cochin.inserm.fr	cunha, antonio sa/B-5781-2012; j, zucman-rossi/AAV-3594-2021; zucman-rossi, Jessica/B-5098-2009; Perret-Mayeux, Christine/L-3297-2017	cunha, antonio sa/0000-0003-4015-5368; j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; perret, christine/0000-0003-4710-7051; Godard, Cecile/0000-0003-3016-0980				Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Miyoshi Y, 1998, CANCER RES, V58, P2524; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueta T, 2002, ONCOL REP, V9, P1197; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	26	191	196	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					774	780		10.1038/sj.onc.1209824	http://dx.doi.org/10.1038/sj.onc.1209824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16964294				2022-12-17	WOS:000243902200014
J	Wang, X; Zhou, YX; Qiao, W; Tominaga, Y; Ouchi, M; Ouchi, T; Deng, CX				Wang, X.; Zhou, Y-X; Qiao, W.; Tominaga, Y.; Ouchi, M.; Ouchi, T.; Deng, C-X			Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation	ONCOGENE			English	Article						cyclin D1; mTOR; centrosome; chromosome tetraploidization; premature sister chromatid segregation	SPINDLE ASSEMBLY CHECKPOINT; BREAST-CANCER; CENTROSOME AMPLIFICATION; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; CELL-CYCLE; COLORECTAL CANCERS; AMPLIFIED KINASE; MAMMALIAN-CELLS; PROTEIN-KINASE	Aurora-A/ STK15/ BTAK, which encodes a centrosome-associated kinase, is amplified and overexpressed in multiple types of human tumors, including breast cancer. However, the causal relationship between overexpression of Aurora-A and tumorigenesis has not been fully established due to contradictory data obtained from different experimental systems. To investigate this, we generated a mouse strain that carries an MMTV-Aurora-A transgene. We showed that all the MMTV-Aurora-A mice displayed enhanced branch morphogenesis in the mammary gland and about 40% developed mammary tumors at 20 months of age. The tumor incidence was significantly increased in a p53(+/-) mutation background with about 70% MMTV-Aurora-A; p53(+/-) animals developed tumors at 18 months of age. Of note, overexpression of Aurora-A led to genetic instability, characterized by centrosome amplification, chromosome tetraploidization and premature sister chromatid segregation, at stages prior to tumor formation. Most notably, the severe chromosomal abnormality did not cause cell death owing to the activation of AKT pathway, including elevated levels of phosphorylated AKT and mammalian target of rapamycin, and nuclear accumulation of cyclin D1, which enabled continuous proliferation of the tetraploid cells. These data establish Aurora-A as an oncogene that causes malignant transformation through inducing genetic instability and activating oncogenic pathways such as AKT and its downstream signaling.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Icahn School of Medicine at Mount Sinai; New York University	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056011, ZIADK056011, ZIADK056001, Z01DK056007, Z01DK056001] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Aust DE, 2004, SCAND J GASTROENTERO, V39, P766, DOI 10.1080/00365520410003191; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Crane R, 2004, BIOL CELL, V96, P215, DOI 10.1016/j.biolcel.2003.09.008; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ducat D, 2004, EXP CELL RES, V301, P60, DOI 10.1016/j.yexcr.2004.08.016; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101; Kamada K, 2004, ONCOL REP, V12, P593; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kufer TA, 2003, CHROMOSOMA, V112, P159, DOI 10.1007/s00412-003-0265-1; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mita Monica M, 2003, Clin Breast Cancer, V4, P126, DOI 10.3816/CBC.2003.n.018; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Shah A, 2005, CLIN CANCER RES, V11, P2930, DOI 10.1158/1078-0432.CCR-04-1385; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tanaka T, 1999, CANCER RES, V59, P2041; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	51	191	196	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7148	7158		10.1038/sj.onc.1209707	http://dx.doi.org/10.1038/sj.onc.1209707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16715125				2022-12-17	WOS:000242046900004
J	Lebedeva, IV; Su, ZZ; Chang, Y; Kitada, S; Reed, JC; Fisher, PB				Lebedeva, IV; Su, ZZ; Chang, Y; Kitada, S; Reed, JC; Fisher, PB			The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells	ONCOGENE			English	Article						melanoma differentiation associated gene-7; tumor suppressor cell cycle; cancer specific cytokine; gene therapy; BCL-family	DIFFERENTIATION-ASSOCIATED GENE; TERMINAL DIFFERENTIATION; NUDE-MICE; IN-VITRO; EXPRESSION; PROGRESSION; DNA; INHIBITOR; CLONING; ARREST	Human melanoma cells growth arrest irreversibly, lose tumorigenic potential and terminally differentiate after treatment with a combination of fibroblast interferon (IFN-beta) and the protein kinase C activator mezerein (MEZ). Applying subtraction hybridization to this model differentiation system permitted cloning of melanoma differentiation associated gene-7, mda-7. Expression of mda-7 inversely correlates with melanoma development and progression, with elevated expression in normal melanocytes and nevi and increasingly reduced expression in radial growth phase, vertical growth phase and metastatic melanoma. When expressed by means of a replication incompetent adenovirus (Ad.mda-7) growth of melanoma, but not normal early passage or immortal human melanocytes, is dramatically suppressed and cells undergo programmed cell death (apoptosis). Infection of metastatic melanoma cells with Ad.mda-7 results in an increase in cells in the G(2)/M phase of the cell cycle and changes in the ratio of pro-apoptotic (BAX, BAK) to anti-apoptotic (BCL-2, BCL-XL) proteins. Ad.mda-7 infection results in a temporal increase in mda-7 mRNA and intracellular MDA-7 protein in most of the melanocyte/melanoma cell lines and secretion of MDA-7 protein is readily detected following Ad.mda-7 infection of both melanocytes and melanoma cells. The present studies document a differential response of melanocytes versus melanoma cells to ectopic expression of mda-7 and support future applications of mda-7 for the gene-based therapy of metastatic melanoma.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, 630 W 168th St,BB-1501, New York, NY 10032 USA.	pbfl@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R21CA087170] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA87170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Hidaka C, 1999, J CLIN INVEST, V103, P579, DOI 10.1172/JCI5309; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; JIAN Y, 1993, GAIT POSTURE, V1, P1; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; KERBEL RS, 1984, J NATL CANCER I, V72, P93, DOI 10.1093/jnci/72.1.93; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Madireddi MT, 2000, ONCOGENE, V19, P1362, DOI 10.1038/sj.onc.1203424; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MELBER K, 1989, CANCER RES, V49, P3650; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pearson AS, 1999, CLIN CANCER RES, V5, P4208; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 1995, ANTICANCER RES, V15, P1841; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; WAXMAN S, 1996, DIFFERENTIATION THER; Wilson MR, 1998, CELL DEATH DIFFER, V5, P646, DOI 10.1038/sj.cdd.4400394; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	57	191	227	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					708	718		10.1038/sj.onc.1205116	http://dx.doi.org/10.1038/sj.onc.1205116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850799				2022-12-17	WOS:000173427000002
J	Shi, Q; Le, XD; Wang, BL; Abbruzzese, JL; Xiong, QH; He, YJ; Xie, KP				Shi, Q; Le, XD; Wang, BL; Abbruzzese, JL; Xiong, QH; He, YJ; Xie, KP			Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells	ONCOGENE			English	Article						angiogenesis; VEGF; regulation; acidosis; pancreatic cancer	FACTOR MESSENGER-RNA; HUMAN PANCREATIC-CANCER; TUMOR-CELLS; FACTOR GENE; TRANSCRIPTION FACTOR; HYPOXIA; PH; METASTASIS; IDENTIFICATION; ANGIOGENESIS	The influence of acidosis on the expression of the vascular endothelial growth factor (VEGF) gene was determined, FG human pancreatic adenocarcinoma cells were incubated for various time periods in media at a physiologically relevant pH level (6.7-7.4), The expression of VEGF mRNA and protein secretion was inversely correlated with pH in a pH- and time-dependent manner. Transient acidosis also activated the VEGF promoter/enhancer luciferase reporter, which was consistent with an increased VEGF gene transcription rate and VEGF mRNA half-life. These data indicated that acidosis transcriptionally and posttranscriptionally regulates VEGF expression, suggesting that an acidic tumor microenvironment contributes to tumor angiogenesis and progression.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; BOUCHER Y, 1990, CANCER RES, V50, P4478; Brooks SE, 1998, CURR EYE RES, V17, P875, DOI 10.1076/ceyr.17.9.875.5134; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; D'Arcangelo D, 2000, CIRC RES, V86, P312, DOI 10.1161/01.RES.86.3.312; Damert A, 1997, CANCER RES, V57, P3860; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Griffiths L, 1997, CANCER RES, V57, P570; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; HUNAG S, 2000, CANCER RES, V60, P5334; INTAGLIETTA M, 1977, MED INSTRUM, V11, P149; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Jang A, 1997, CLIN EXP METASTAS, V15, P469, DOI 10.1023/A:1018470709523; KALLINOWSKI F, 1988, BRIT J CANCER, V58, P314, DOI 10.1038/bjc.1988.210; LADOUX A, 1994, BIOCHEM BIOPH RES CO, V204, P794, DOI 10.1006/bbrc.1994.2529; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; ROTIN D, 1989, CANCER RES, V49, P205; Scott PAE, 1998, INT J CANCER, V75, P706, DOI 10.1002/(SICI)1097-0215(19980302)75:5<706::AID-IJC8>3.0.CO;2-2; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHI Q, 1999, CLIN CANCER RES, V5, P7234; SHI Q, 2000, J INTERFERON CYTOKIN, V20, P1544; SHUBIK P, 1982, J CANCER RES CLIN, V103, P211, DOI 10.1007/BF00409698; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tannock IF, 1996, J CLIN ONCOL, V14, P3156, DOI 10.1200/JCO.1996.14.12.3156; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAUPEL P, 1989, CANCER RES, V49, P6449; VEZERIDIS MP, 1989, J SURG ONCOL, V40, P261, DOI 10.1002/jso.2930400412; Watanabe Y, 1998, LIFE SCI, V63, P1037, DOI 10.1016/S0024-3205(98)00365-8; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; XIE K, 2001, IN PRESS CYTOKINE GR	39	191	199	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3751	3756		10.1038/sj.onc.1204500	http://dx.doi.org/10.1038/sj.onc.1204500			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439338	Bronze			2022-12-17	WOS:000169400200016
J	Chene, P				Chene, P			The role of tetramerization in p53 function	ONCOGENE			English	Review						p53; tetramerization; cancer	TUMOR-SUPPRESSOR P53; DNA-BINDING DOMAIN; GAIN-OF-FUNCTION; FRAUMENI LIKE FAMILY; XENOPUS-LAEVIS P53; OLIGOMERIZATION DOMAIN; MUTANT P53; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; IN-VITRO	The tumour suppressor gene p53 is extensively studied for its importance in cancer, In its active conformation, p53 is tetrameric and one domain - the tetramerization domain - permits the oligomerization of this protein. Until recently, little attention was given to this domain because, in contrast to the DNA-binding domain, it is not often mutated in cancer, However, various experimental studies have shown evidence that the tetramerization domain is essential for DNA binding, protein-protein interactions, post-translational modifications, and p53 degradation. Moreover, single mutations in the tetramerization domain can inactivate the wild-type protein in a manner similar to that seen with mutations in the DNA-binding domain, Interestingly, the phenotype of several tetramerization domain mutants differs from that observed with DNA-binding domain mutants. In this review, current knowledge about the importance of the tetramerization domain to the function of p53 will be summarized.	Novartis, CH-4002 Basel, Switzerland		Chene, P (corresponding author), Novartis, K125 420, CH-4002 Basel, Switzerland.							Appella E, 2000, PATHOL BIOL, V48, P227; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; Chene P, 2000, BIOTECHNIQUES, V28, P240; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; Chene P, 1999, J MOL BIOL, V288, P883, DOI 10.1006/jmbi.1999.2734; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ELIYAHU D, 1988, ONCOGENE, V3, P313; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; Hixon ML, 2000, HISTOL HISTOPATHOL, V15, P551, DOI 10.14670/HH-15.551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin Y, 1997, CANCER RES, V57, P5137; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Mateu MG, 1999, NAT STRUCT BIOL, V6, P191; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; McCoy M, 1997, EMBO J, V16, P6230, DOI 10.1093/emboj/16.20.6230; McLure KG, 1996, ONCOGENE, V13, P1297; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Rollenhagen C, 1998, INT J CANCER, V78, P372, DOI 10.1002/(SICI)1097-0215(19981029)78:3<372::AID-IJC19>3.0.CO;2-8; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SANG BC, 1994, ONCOGENE, V9, P853; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; Shieh SY, 2000, GENE DEV, V14, P289; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1990, ONCOGENE, V5, P945; Stavridi ES, 1999, PROTEIN SCI, V8, P1773, DOI 10.1110/ps.8.9.1773; Steele RJC, 1998, BRIT J SURG, V85, P1460; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SURRIDGE C, 1994, NATURE, V372, P482, DOI 10.1038/372482a0; TARUNINA M, 1993, ONCOGENE, V8, P3165; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Varley JM, 1996, ONCOGENE, V12, P2437; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, ONCOGENE, V10, P779; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; ZHANG W, 1994, ONCOGENE, V9, P2513	105	191	193	1	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2611	2617		10.1038/sj.onc.1204373	http://dx.doi.org/10.1038/sj.onc.1204373			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420672				2022-12-17	WOS:000168652600001
J	Nakano, K; Balint, E; Ashcroft, M; Vousden, KH				Nakano, K; Balint, E; Ashcroft, M; Vousden, KH			A ribonucleotide reductase gene is a transcriptional target of p53 and p73	ONCOGENE			English	Article						p53; p73; DNA damage; ribonucleotide reductase; p53R2	CELL-CYCLE ARREST; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; TUMOR SUPPRESSION; INDUCE APOPTOSIS; ENDOREDUPLICATION; PROLIFERATION; MUTANTS; CANCER	Many p53-inducible genes have been identified that might play a role in mediating the various downstream activities of p53, We have identified a close relative of ribonucleotide reductase, recently named p53R2, as a p53-inducible gene, and show that this gene is activated by several stress signals that activate a p53 response, including DNA damaging agents and p14(ARF), p53R2 expression was induced by p53 mutants that are defective for the activation of apoptosis, but retain cell cycle arrest function, although no induction of p53R2 was seen in response to p21(WAF1/CIP1)-mediated cell cycle arrest. Several isoforms of the p53 family member p73 were also shown to induce p53R2 expression. Transient ectopic expression of either wild type p53R2 or p53R2 targeted to the nucleus, did not significantly alter cell cycle progression in unstressed cells, The identification of this gene as a p53 target supports a direct role for p53 in DNA repair, in addition to inhibition of growth of damaged cells.	NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.		Balint, Eva/B-8695-2008	Balint, Eva/0000-0002-1258-6892				Agami R, 1999, NATURE, V399, P809; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gong JG, 1999, NATURE, V399, P806; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	32	191	199	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4283	4289		10.1038/sj.onc.1203774	http://dx.doi.org/10.1038/sj.onc.1203774			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980602				2022-12-17	WOS:000089032900011
J	BRAUCHLE, M; ANGERMEYER, K; HUBNER, G; WERNER, S				BRAUCHLE, M; ANGERMEYER, K; HUBNER, G; WERNER, S			LARGE INDUCTION OF KERATINOCYTE GROWTH-FACTOR EXPRESSION BY SERUM GROWTH-FACTORS AND PRO-INFLAMMATORY CYTOKINES IN CULTURED FIBROBLASTS	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; NECROSIS FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; CELL GROWTH; MACROPHAGES; SECRETION; CLONING; FAMILY; PDGF	We have recently demonstrated a large induction of keratinocyte growth factor expression in dermal fibroblasts during wound healing. To identify possible mediators of KGF induction, we have now analysed the regulation of KGF expression in vitro in cultured murine and human fibroblasts. Here we demonstrate that KGF mRNA and protein expression is low in quiescent fibroblasts but is strongly induced upon serum stimulation. This induction can be mediated by at least two different intracellular pathways involving protein kinase C or cAMP-dependent kinases. Our finding that induction of KGF expression by serum is independent of de novo protein synthesis demonstrates, that KGF is the product of a primary response gene. The stimulatory effect of serum on KGF expression is likely to be a combinatorial effect of different mitogens, since several purified serum growth factors also stimulated KGF expression but to a lesser extent compared to serum. Furthermore, we also found a strong KGF induction by interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6, cytokines which are released by polymorphonuclear leukocytes and activated macrophages during wound healing. These data suggest that serum which is released upon hemorrhage as well as pro-inflammatory cytokines might be responsible for the KGF induction in vivo during skin repair.	MAX PLANCK INST BIOCHEM,VIRUS FORSCH ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CICCO NA, 1990, BLOOD, V75, P2049; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; DINARELLO CA, 1991, CYTOKINE HDB, P47; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1991, SCIENCE, V251, P335; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WERNER S, 1991, ONCOGENE, V6, P2137; WERNER S, IN PRESS J INVEST DE; Wong H. L., 1989, HUMAN MONOCYTES, P383; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	30	191	193	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3199	3204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936642				2022-12-17	WOS:A1994PM65800011
J	MAROULAKOU, IG; PAPAS, TS; GREEN, JE				MAROULAKOU, IG; PAPAS, TS; GREEN, JE			DIFFERENTIAL EXPRESSION OF ETS-1 AND ETS-2 PROTOONCOGENES DURING MURINE EMBRYOGENESIS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; DNA-BINDING MOTIF; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; PROMOTER SEQUENCES; TRANSFORMING GENE; CELLS; DOMAIN; PROTEINS	ets-l and ets-2 genes have previously been identified by their sequence homology to the v-ets oncogene of the avian erythroblastosis virus, E26. These cellular genes have been shown to function as transcription factors important in lymphoid differentiation and activation and cellular proliferation. In this study, we have broadly analysed the differential expression of ets-l and ets-2 during murine development using in situ hybridization. Our results indicate that these transcription factors are expressed in multiple tissues during critical stages of embryo formation and organogenesis, suggesting that these genes may serve multiple functions during mouse development. The patterns of expression of both genes are quite different as early as day 8.0 of gestation. ets-l expression is clearly observed during a narrow developmental stage in the developing nervous system, including the presumptive hindbrain regions, the neural tube, as well as neural crest and the first and second branchial arches. ets-2 expression is limited to the developing limb buds and distal tail. At later times, ets-l expression is observed in developing vascular structures, including the heart, arteries, capillaries and meninges, whereas ets-2 is highly expressed in developing bone, tooth buds, epithelial layers of the gut, nasal sinus and uterus, and several regions of the developing brain. Both ets-l and ets-2 are expressed in developing lung, gut and skin. High levels of expression in both genes is observed in adult lymphoid tissues, but in different tissue subsets. ets-l is expressed in the adult lung, gut mesenchyme and bone marrow. ets-2 continues to be expressed at low levels in several adult tissues, except in the differentiated brain, where substantial levels of expression are found in particular regions of the mature brain. These results demonstrate that ets-l and ets-2 are differentially regulated, are widely expressed in many tissues during murine embryogenesis and may play important roles in cellular proliferation and differentiation during mouse development.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Ascione R., 1993, Genome research in molecular medicine and virology., P199; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVAL JL, 1989, J NEUROCHEM, V52, P1954, DOI 10.1111/j.1471-4159.1989.tb07285.x; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; PAPAS TS, 1989, CURR TOP MICROBIOL, P143; PARMA DL, 1991, INT J DEV NEUROSCI, V9, P613, DOI 10.1016/0736-5748(91)90023-F; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; QUEVA C, 1993, ONCOGENE, V8, P2511; ROWE A, 1992, EXP CELL RES, V202, P199, DOI 10.1016/0014-4827(92)90420-D; SACCHI N, 1991, ONCOGENE, V6, P2149; Sambrook J., 1989, MOL CLONING LAB MANU; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WERNERT N, 1992, AM J PATHOL, V140, P119; YOUNG WS, 1990, METHODS ANAL NEURONA, P481	48	191	194	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1551	1565						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183549				2022-12-17	WOS:A1994NL81500005
J	EHLEN, T; DUBEAU, L				EHLEN, T; DUBEAU, L			LOSS OF HETEROZYGOSITY ON CHROMOSOMAL SEGMENTS 3P, 6Q AND 11P IN HUMAN OVARIAN CARCINOMAS	ONCOGENE			English	Article									UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT PATHOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT GYNECOL ONCOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California								ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; DUBEAU L, 1988, AM J PATHOL, V130, P588; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAREAU JLP, 1988, NUCLEIC ACIDS RES, V16, P1223, DOI 10.1093/nar/16.3.1223; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; LEE JH, 1989, CANCER RES, V49, P1220; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9889; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PANANI A, 1985, CANCER GENET CYTOGEN, V16, P65, DOI 10.1016/0165-4608(85)90078-0; SITHANANDAM G, 1989, ONCOGENE, V4, P451; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; VANDERHOUT AH, 1988, CANCER GENET CYTOGEN, V32, P281, DOI 10.1016/0165-4608(88)90292-0; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAKE N, 1980, CANCER RES, V40, P4512; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHOU DJ, 1988, CANCER, V62, P1573, DOI 10.1002/1097-0142(19881015)62:8<1573::AID-CNCR2820620819>3.0.CO;2-M	25	191	193	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					219	223						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2320374				2022-12-17	WOS:A1990CU02900008
J	TAHIRA, T; ISHIZAKA, Y; ITOH, F; SUGIMURA, T; NAGAO, M				TAHIRA, T; ISHIZAKA, Y; ITOH, F; SUGIMURA, T; NAGAO, M			CHARACTERIZATION OF RET PROTO-ONCOGENE MESSENGER-RNAS ENCODING 2 ISOFORMS OF THE PROTEIN PRODUCT IN A HUMAN NEUROBLASTOMA CELL-LINE	ONCOGENE			English	Article											TAHIRA, T (corresponding author), NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN.							BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BIEDLER JL, 1973, CANCER RES, V33, P2643; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIKAWA S, 1979, ACTA PATHOL JAPON, V29, P289; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	26	191	195	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					97	102						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181380				2022-12-17	WOS:A1990CM62000013
J	Liu, Z; Li, Q; Li, K; Chen, L; Li, W; Hou, M; Liu, T; Yang, J; Lindvall, C; Bjorkholm, M; Jia, J; Xu, D				Liu, Z.; Li, Q.; Li, K.; Chen, L.; Li, W.; Hou, M.; Liu, T.; Yang, J.; Lindvall, C.; Bjorkholm, M.; Jia, J.; Xu, D.			Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells	ONCOGENE			English	Article						CSCs; EMT; gastric cancer; hTERT	TUMOR-INITIATING CELLS; INDUCED APOPTOSIS; GASTRIC-CANCER; BETA-CATENIN; EXPRESSION; SNAIL; GROWTH; CARCINOMA; SURVIVAL; METASTASIS	Telomerase activation through induction of telomerase reverse transcriptase (hTERT) contributes to malignant transformation by stabilizing telomeres. Clinical studies demonstrate that higher hTERT expression is associated with cancer progression and poor outcomes, but the underlying mechanism is unclear. Because epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are key factors in cancer metastasis and relapse, and hTERT has been shown to exhibit multiple biological activities independently of its telomere-lengthening function, we address a potential role of hTERT in EMT and CSCs using gastric cancer (GC) as a model. hTERT overexpression promotes, whereas its inhibition suppresses, EMT and stemness of GC cells, respectively. Transforming growth factor (TGF)-beta 1 and beta-catenin-mediated EMT was abolished by small interfering RNA depletion of hTERT expression. hTERT interacts with beta-catenin, enhances its nuclear localization and transcriptional activity, and occupies the beta-catenin target vimentin promoter. All these hTERT effects were independent of its telomere-lengthening function or telomerase activity. hTERT and EMT marker expression correlates positively in GC samples. Mouse experiments demonstrate the in vivo stimulation of hTERT on cancer cell colonization. Collectively, hTERT stimulates EMT and induces stemness of cancer cells, thereby promoting cancer metastasis and recurrence. Thus, targeting hTERT may prevent cancer progression by inhibiting EMT and CSCs.	[Liu, Z.; Li, Q.; Chen, L.; Li, W.; Jia, J.] Shandong Univ, Sch Med, Chinese Minist Educ, Dept Microbiol,Key Lab Expt Teratol, Jinan 250012, Peoples R China; [Liu, Z.; Li, Q.; Chen, L.; Li, W.; Jia, J.] Shandong Univ, Hosp 2, Jinan 250012, Peoples R China; [Liu, Z.; Li, Q.; Liu, T.; Yang, J.; Bjorkholm, M.; Xu, D.] Karolinska Univ Hosp, Dept Med, Div Haematol, Stockholm, Sweden; [Liu, Z.; Li, Q.; Liu, T.; Yang, J.; Bjorkholm, M.; Xu, D.] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden; [Liu, Z.; Li, Q.; Li, K.; Hou, M.; Liu, T.; Yang, J.; Bjorkholm, M.; Xu, D.] Karolinska Inst, Stockholm, Sweden; [Li, K.] Karolinska Univ Hosp, Dept Biosci & Nutr, Stockholm, Sweden; [Hou, M.] Karolinska Univ Hosp, Dept Women & Child Hlth, Stockholm, Sweden; [Lindvall, C.] Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI USA; [Xu, D.] Shandong Univ, Hosp 2, Cent Res Lab, Jinan 250012, Peoples R China	Shandong University; Shandong University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Van Andel Institute; Shandong University	Jia, J (corresponding author), Shandong Univ, Sch Med, Chinese Minist Educ, Dept Microbiol,Key Lab Expt Teratol, Jinan 250012, Peoples R China.	jiajihui@sdu.edu.cn; Dawei.Xu@ki.se		Hou, Mi/0000-0002-4573-7028; Xu, Dawei/0000-0003-3141-4524	National Basic Research Program of China [973 Program 2012CB911202]; Swedish Cancer Society; Swedish Research Council; Cancer Society in Stockholm; Swedish Child Cancer Society; Karolinska Institutet Foundations; National Natural Science Foundation of China [30770118, 30800406, 30972775, 81071721, 81000868, 81171536]; National Key Scientific Program of China [2007CB914801]; Science Foundation of Shandong Province [ZR2009CZ001, ZR2009CM002, BS2010YY040]	National Basic Research Program of China(National Basic Research Program of China); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancer Society in Stockholm; Swedish Child Cancer Society; Karolinska Institutet Foundations(Karolinska Institutet); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Program of China; Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	We thank Drs RA Weinberg (Massachusetts Institute of Technology), CM Counter (Duke University), JM Wong and K Collins (University of California, Berkeley), Y Cong (Beijing Normal University) and W Cui (Imperial College London) for retroviral vectors and plasmids. This study was supported by the National Basic Research Program of China (grant No. 973 Program 2012CB911202), the Swedish Cancer Society, the Swedish Research Council, Cancer Society in Stockholm, Swedish Child Cancer Society, the Karolinska Institutet Foundations, National Natural Science Foundation of China (No.: 30770118, 30800406, 30972775, 81071721, 81000868, 81171536), the National Key Scientific Program of China (2007CB914801) and the Science Foundation of Shandong Province (No.: ZR2009CZ001, ZR2009CM002 and BS2010YY040)	Boukamp P, 2007, EXP DERMATOL, V16, P71, DOI 10.1111/j.1600-0625.2006.00517.x; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen HP, 2009, MOL BIOTECHNOL, V41, P194, DOI 10.1007/s12033-008-9117-9; Cong YS, 2008, CELL RES, V18, P725, DOI 10.1038/cr.2008.74; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Domomt J, 2005, J CLIN ONCOL, V23, P3086, DOI 10.1200/JCO.2005.06.944; Dudognon C, 2004, ONCOGENE, V23, P7469, DOI 10.1038/sj.onc.1208029; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Gerrard L, 2005, STEM CELLS, V23, P124, DOI 10.1634/stemcells.2004-0102; Gertler R, 2004, J CLIN ONCOL, V22, P1807, DOI 10.1200/JCO.2004.09.160; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; Hayry V, 2009, ENDOCR-RELAT CANCER, V16, P1211, DOI 10.1677/ERC-09-0049; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim MA, 2009, HISTOPATHOLOGY, V54, P442, DOI 10.1111/j.1365-2559.2009.03247.x; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu JP, 2010, AGEING RES REV, V9, P245, DOI 10.1016/j.arr.2010.03.002; Liu L, 2011, J PATHOL, V225, P203, DOI 10.1002/path.2914; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marian CO, 2010, CLIN CANCER RES, V16, P154, DOI 10.1158/1078-0432.CCR-09-2850; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ohali A, 2003, J CLIN ONCOL, V21, P3836, DOI 10.1200/JCO.2003.05.059; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Shay JW, 2007, J PATHOL, V211, P114, DOI 10.1002/path.2090; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Strong MA, 2011, MOL CELL BIOL, V31, P2369, DOI 10.1128/MCB.05312-11; Tabori U, 2006, J CLIN ONCOL, V24, P1522, DOI 10.1200/JCO.2005.04.2127; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Terrin L, 2008, CLIN CANCER RES, V14, P7444, DOI 10.1158/1078-0432.CCR-08-0478; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; van Zijl F, 2009, FUTURE ONCOL, V5, P1169, DOI 10.2217/FON.09.91; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Waldmann J, 2008, BRIT J CANCER, V99, P1900, DOI 10.1038/sj.bjc.6604755; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou LL, 2009, BIOCHEM BIOPH RES CO, V386, P739, DOI 10.1016/j.bbrc.2009.06.116	55	190	198	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4203	4213		10.1038/onc.2012.441	http://dx.doi.org/10.1038/onc.2012.441			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045275				2022-12-17	WOS:000324168000002
J	Chen, D; Zhang, Z; Li, M; Wang, W; Li, Y; Rayburn, ER; Hill, DL; Wang, H; Zhang, R				Chen, D.; Zhang, Z.; Li, M.; Wang, W.; Li, Y.; Rayburn, E. R.; Hill, D. L.; Wang, H.; Zhang, R.			Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function	ONCOGENE			English	Article						p53; MDM2; RPS7; protein degradation; proteasome; ubiquitination; tumor suppressor	IN-VIVO ACTIVITIES; RIBOSOME BIOGENESIS; NEGATIVE REGULATOR; TUMOR SUPPRESSION; ONCOPROTEIN MDM2; PROSTATE-CANCER; PATHWAY; INHIBITION; UBIQUITINATION; DEGRADATION	As a major negative regulator of p53, the MDM2 oncogene plays an important role in carcinogenesis and tumor progression. MDM2 promotes p53 proteasomal degradation and negatively regulates p53 function. The mechanisms by which the MDM2-p53 interaction is regulated are not fully understood, although several MDM2interacting molecules have recently been identified. To search for novel MDM2-binding partners, we screened a human prostate cDNA library by the yeast two-hybrid assay using full-length MDM2 protein as the bait. Among the candidate proteins, ribosomal protein S7 was identified and confirmed as a novel MDM2-interacting protein. Herein, we demonstrate that S7 binds to MDM2, in vitro and in vivo, and that the interaction between MDM2 and S7 leads to modulation of MDM2-p53 binding by forming a ternary complex among MDM2, p53 and S7. This results in the stabilization of p53 protein through abrogation of MDM2-mediated p53 ubiquitination. Consequently, S7 overexpression increases p53 transactivational activities, induces apoptosis, and inhibits cell proliferation. The identification of S7 as a novel MDM2-interacting partner contributes to elucidation of the complex regulation of the MDM2-p53 interaction and has implications in cancer prevention and therapy.	Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, H (corresponding author), Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, VH 113,1670 Univ Blvd, Birmingham, AL 35294 USA.	hui.wang@ccc.uab.edu; ruiwen.zhang@ccc.uab.edu	高, 雨莉/HGU-8187-2022		NATIONAL CANCER INSTITUTE [R01CA112029] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P16; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li M, 2005, CANCER RES, V65, P8200, DOI 10.1158/0008-5472.CAN-05-1302; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Zhang RW, 2005, CURR CANCER DRUG TAR, V5, P43, DOI 10.2174/1568009053332663; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	190	198	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5029	5037		10.1038/sj.onc.1210327	http://dx.doi.org/10.1038/sj.onc.1210327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310983				2022-12-17	WOS:000248487400001
J	Yang, HY; Asaad, N; Held, KD				Yang, HY; Asaad, N; Held, KD			Medium-mediated intercellular communication is involved in bystander responses of X-ray-irradiated normal human fibroblasts	ONCOGENE			English	Article						bystander responses; X-ray; fibroblasts; transwell system; reactive oxygen species	INDUCED GENOMIC INSTABILITY; STRAND BREAK REPAIR; SISTER-CHROMATID EXCHANGES; ALPHA-PARTICLES; MAMMALIAN-CELLS; UNIRRADIATED CELLS; IONIZING-RADIATION; DAMAGE SIGNALS; DNA-DAMAGE; INDUCTION	Although radiation-induced bystander effects have been demonstrated in a number of cell types, the studies have largely been performed using high linear energy transfer (LET) radiation, such as alpha-particles. The literature is contradictory on whether fibroblasts show bystander responses, especially after low LET radiation such as X- or gamma-rays and whether the same signal transmission pathways are involved. Herein, a novel transwell insert culture dish method is used to show that X- irradiation induces medium-mediated bystander effects in AGO1522 normal human fibroblasts. The frequency of micronuclei formation in unirradiated bystander cells increases from a background of about 6.5% to about 9-13% at all doses from 0.1 to 10Gy to the irradiated cells. Induction of p21(Waf1) protein and foci of gamma-H(2)AX in bystander cells is also independent of dose to the irradiated cells above 0.1 Gy. In addition, levels of reactive oxygen species (ROS) were increased persistently in directly irradiated cells up to 60 h after irradiation and in bystander cells for 30 h. Adding Cu-Zn superoxide dismutase ( SOD) and catalase to the medium decreases the formation of micronuclei and induction of p21(Waf1) and gamma-H(2)AX foci in bystander cells, suggesting oxidative metabolism plays a role in the signaling pathways in bystander cells. The results of clonogenic assay of bystander cells showed that survival of bystander cells decreases from 0 to 0.5 Gy, and then is independent of the dose to irradiated cells from 0.5 to 10 Gy. Unlike the response with p21(Waf1) expression, gamma-H(2)AX foci and micronuclei, adding SOD and catalase has no effect on the survival of bystander cells. The data suggest that irradiated cells release toxic factors other than ROS into the medium.	Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Held, KD (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, COX 302,Fruit St, Boston, MA 02114 USA.	kheld@partners.org						Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Ballarini F, 2002, MUTAT RES-FUND MOL M, V501, P1, DOI 10.1016/S0027-5107(02)00010-6; Baverstock K, 2000, MUTAT RES-FUND MOL M, V454, P89, DOI 10.1016/S0027-5107(00)00100-7; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 2001, RADIAT RES, V155, P335, DOI 10.1667/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; Fimognari C, 1997, MUTAGENESIS, V12, P91, DOI 10.1093/mutage/12.2.91; GOH KO, 1968, RADIAT RES, V35, P171, DOI 10.2307/3572443; Hall EJ, 2003, ONCOGENE, V22, P7034, DOI 10.1038/sj.onc.1206900; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; HOLLOWELL JG, 1967, J S C MED ASS, V63, P437; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Khan MA, 1998, INT J RADIAT ONCOL, V40, P467, DOI 10.1016/S0360-3016(97)00736-0; Lehnert BE, 1997, CANCER RES, V57, P2164; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Little JB, 2003, RADIAT RES, V159, P262, DOI 10.1667/0033-7587(2003)159[0262:IOTNEJ]2.0.CO;2; Little JB, 2002, RADIAT PROT DOSIM, V99, P159, DOI 10.1093/oxfordjournals.rpd.a006751; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Mothersill C, 2000, BRIT J CANCER, V82, P1740; Mothersill C, 2003, ONCOGENE, V22, P7028, DOI 10.1038/sj.onc.1206882; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Olive PL, 1997, ONCOL RES, V9, P287; PARSONS WB, 1954, CANCER, V7, P170; Prise KM, 2003, ONCOGENE, V22, P7043, DOI 10.1038/sj.onc.1206991; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rugo RE, 2002, RADIAT RES, V158, P210, DOI 10.1667/0033-7587(2002)158[0210:XRCAPI]2.0.CO;2; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Seymour C, 1999, RADIAT RES, V151, P505, DOI 10.2307/3579842; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao C, 2003, CANCER RES, V63, P8437; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; SOUTO J, 1962, NATURE, V195, P1317, DOI 10.1038/1951317a0; Wang B, 2004, RADIAT RES, V161, P9, DOI 10.1667/RR3106; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8	52	190	205	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2096	2103		10.1038/sj.onc.1208439	http://dx.doi.org/10.1038/sj.onc.1208439			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688009				2022-12-17	WOS:000227681900014
J	Petrovics, G; Zhang, W; Makarem, M; Street, JP; Connelly, R; Sun, L; Sesterhenn, IA; Srikantan, V; Moul, JW; Srivastava, S				Petrovics, G; Zhang, W; Makarem, M; Street, JP; Connelly, R; Sun, L; Sesterhenn, IA; Srikantan, V; Moul, JW; Srivastava, S			Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients	ONCOGENE			English	Article						PCGEM1; prostate-specific gene; prostate cancer; high-risk patients; cell proliferation	VIRUS-INDUCED LYMPHOMAS; AFRICAN-AMERICAN; RETINOBLASTOMA PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; INSERTIONS; RACEMASE; MARKERS; RNA	PCGEM1 is a novel, highly prostate tissue-specific, androgen-regulated gene. Here, we demonstrate that PCGEM1 expression is significantly higher in prostate cancer (CaP) cells of African-American men than in Caucasian-American men (P=0.0002). Further, increased PCGEM1 expression associates with normal prostate epithelial cells of CaP patients with a family history of CaP (P=0.0400). PCGEM1 overexpression in LNCaP and in NIH3T3 cells promotes cell proliferation and a dramatic increase in colony formation, suggesting a biological role of PCGEM1 in cell growth regulation. Taken together, the cell proliferation/colony formation-promoting functions of PCGEM1 and the association of its increased expression with high-risk CaP patients suggest the potential roles of PCGEM1 in CaP onset/progression, especially in these high-risk groups.	Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, US Mil Canc Inst, Bethesda, MD 20814 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; Walter Reed Army Med Ctr, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Petrovics, G (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	gpetrovics@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X	NCI NIH HHS [1R01CA85596-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1994, MOL CELL BIOL, V14, P1743, DOI 10.1128/MCB.14.3.1743; Brantey MA, 2000, CANCER RES, V60, P4320; Brawley O W, 1998, Semin Urol Oncol, V16, P193; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Cussenot O, 2001, Eur J Intern Med, V12, P11, DOI 10.1016/S0953-6205(00)00136-9; de Kok JB, 2002, CANCER RES, V62, P2695; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Guo YP, 2000, PROSTATE, V42, P130, DOI 10.1002/(SICI)1097-0045(20000201)42:2<130::AID-PROS7>3.0.CO;2-3; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Luo J, 2002, CANCER RES, V62, P2220; Magee JA, 2001, CANCER RES, V61, P5692; MOUL JW, 1995, JAMA-J AM MED ASSOC, V274, P1277, DOI 10.1001/jama.274.16.1277; Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x; Paris PL, 1999, CANCER EPIDEM BIOMAR, V8, P901; Platz EA, 2000, JNCI-J NATL CANCER I, V92, P2009, DOI 10.1093/jnci/92.24.2009; Powell I J, 1998, Semin Urol Oncol, V16, P221; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Szymanski M, 2002, GENOME BIOL, V3; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Taylor JA, 1996, CANCER RES, V56, P4108; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Welsh JB, 2001, CANCER RES, V61, P5974; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yang G, 2000, CLIN CANCER RES, V6, P3430	33	190	211	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					605	611		10.1038/sj.onc.1207069	http://dx.doi.org/10.1038/sj.onc.1207069			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724589				2022-12-17	WOS:000188098300032
J	Lundberg, AS; Randell, SH; Stewart, SA; Elenbaas, B; Hartwell, KA; Brooks, MW; Fleming, MD; Olsen, JC; Miller, SW; Weinberg, RA; Hahn, WC				Lundberg, AS; Randell, SH; Stewart, SA; Elenbaas, B; Hartwell, KA; Brooks, MW; Fleming, MD; Olsen, JC; Miller, SW; Weinberg, RA; Hahn, WC			Immortalization and transformation of primary human airway epithelial cells by gene transfer	ONCOGENE			English	Article						transformation; lung cancer; immortalization; ras oncogene	LARGE T-ANTIGEN; TELOMERASE ACTIVITY; RAS ONCOGENE; LIFE-SPAN; NEOPLASTIC TRANSFORMATION; CELLULAR SENESCENCE; CLONAL GROWTH; TUMOR-CELLS; HUMAN-LUNG; IN-VITRO	One critical step in the development of a cancerous cell is its acquisition of an unlimited replicative lifespan, the process termed immortalization. Experimental model systems designed to study cellular transformation ex vivo have relied to date on the in vitro selection of a subpopulation of cells that have become immortalized through treatment with chemical or physical mutagens and the selection of rare clonal variants. In this study, we describe the direct immortalization of primary human airway epithelial cells through the successive introduction of the Simian Virus 40 Early Region and the telomerase catalytic subunit hTERT. Cells immortalized in this way are now responsive to malignant transformation by an introduced H-ras or K-ras oncogene. These immortalized human airway epithelial cells, which have been created through the stepwise introduction of genetic alterations, provide a novel experimental model system with which to study further the biology of the airway epithelial cell and to dissect the molecular basis of lung cancer pathogenesis.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Childrens Hosp, Dept Pathol, Boston, MA 02215 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT)	Randell, SH (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.		Stewart, Sheila A/C-5213-2012	Fleming, Mark/0000-0003-0948-4024				Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LECHNER JF, 1981, CANCER RES, V41, P2294; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613, DOI 10.1165/ajrcmb.10.6.8003339; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Olumi AF, 1999, CANCER RES, V59, P5002; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reddel R R, 1988, Oncogene Res, V3, P401; REDDEL RR, 1988, CANCER RES, V48, P1904; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; Rich JN, 2001, CANCER RES, V61, P3556; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Stoner G D, 1980, Methods Cell Biol, V21A, P15, DOI 10.1016/S0091-679X(08)60756-6; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	44	190	203	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4577	4586		10.1038/sj.onc.1205550	http://dx.doi.org/10.1038/sj.onc.1205550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085236				2022-12-17	WOS:000176476700012
J	Liang, Y; Yan, CH; Schor, NF				Liang, Y; Yan, CH; Schor, NF			Apoptosis in the absence of caspase 3	ONCOGENE			English	Article						breast cancer; programmed cell death; caspases	CYTOCHROME-C; CELL-DEATH; NEUROBLASTOMA-CELLS; DNA FRAGMENTATION; PROTEASE CASCADE; GRANZYME-B; BCL-2; ACTIVATION; RELEASE; MITOCHONDRIA	MCF-7 human breast cancer cells do not express caspase 3, thought by some to be a critical component of the apoptosis cascade. Nonetheless, both mock- and bcl-2-transfected MCF-7 cells undergo apoptosis after treatment with a variety of stimuli, including the DNA-cleaving antimitotic agent, neocarzinostatin (NCS). Transfection with bcl-2 shifts the concentration-response curve to NCS but does not change the phenomenology of apoptosis when it occurs. In both cases, NCS treatment results in condensation and fragmentation of MCF-7 cell nuclei and release of cytochrome c from the mitochondria to the cytosol. This apoptosis is accompanied by decreased levels of Bcl-2 and increased levels of Bax. Using a series of caspase inhibitors with overlapping specificities, enzyme-specific chromogenic substrates, and an antibody specific for activated caspase 7, we have determined that apoptosis in MCF-7 cells proceeds via sequential activation of caspases 9, 7 and 6. P21 is detected only after activation of caspase 7, and P53 is neither expressed at baseline nor upregulated with apoptosis induction. This pathway bypasses the need for activated caspase 3 in these cells.	Childrens Hosp Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schor, NF (corresponding author), Childrens Hosp Pittsburgh, Range Res Ctr, 3460 5th Ave, Pittsburgh, PA 15213 USA.			Schor, Nina/0000-0002-3817-7376	NCI NIH HHS [R01-CA74289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cortazzo M, 1996, CANCER RES, V56, P1199; Eck-Enriquez K, 2000, BREAST CANCER RES TR, V61, P229, DOI 10.1023/A:1006442017658; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Hartsell TL, 1996, J PHARMACOL EXP THER, V277, P1158; HARTSELL TL, 1995, J PHARMACOL EXP THER, V275, P479; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lecoeur H, 1996, J IMMUNOL METHODS, V198, P87, DOI 10.1016/0022-1759(96)00148-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang Ye, 2001, Pediatric Research, V49, p211A; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PARK J, 2001, BIOCHEM BIOPH RES CO, V199, P93; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHOR NF, 1992, J CLIN INVEST, V89, P774, DOI 10.1172/JCI115655; Schor NF, 2000, ONCOGENE, V19, P472, DOI 10.1038/sj.onc.1203324; Shimizu S, 1996, ONCOGENE, V12, P2251; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	190	198	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6570	6578		10.1038/sj.onc.1204815	http://dx.doi.org/10.1038/sj.onc.1204815			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641782				2022-12-17	WOS:000171404200010
J	O'Brien, PJ; Molino, M; Kahn, M; Brass, LF				O'Brien, PJ; Molino, M; Kahn, M; Brass, LF			Protease activated receptors: theme and variations	ONCOGENE			English	Review						protease-activated receptors; thrombin; platelets; endothielial cells; G proteins; G protein coupled receptors	PLATELET THROMBIN RECEPTOR; HUMAN-ENDOTHELIAL-CELLS; CATHEPSIN-G; TETHERED-LIGAND; MOLECULAR-CLONING; MAST-CELL; FUNCTIONAL EXPRESSION; AGONIST RECOGNITION; CROSS-REACTIVITY; CYTOPLASMIC TAIL	The four PAR family members are G protein coupled receptors that are normally activated by proteolytic exposure of an occult tethered ligand, Three of the family members are thrombin receptors, The fourth (PAR2) is not activated by thrombin, but can be activated by other proteases, including trypsin, tryptase and Factor Xa, This review focuses on recent information about the manner in which signaling through these receptors is initiated and terminated, including evidence for inter- as well as intramolecular modes of activation, and continuing efforts to identify additional, biologically-relevant proteases that can activate PAR family members.	Univ Penn, Dept Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy	University of Pennsylvania; University of Pennsylvania; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Brass, LF (corresponding author), Univ Penn, Dept Med, Ctr Expt Therapeut, Room 913 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		O'Brien, Peter J/B-5182-2013	O'Brien, Peter J/0000-0003-4127-2718	NHLBI NIH HHS [HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Ani B, 1999, BRIT J PHARMACOL, V128, P1105, DOI 10.1038/sj.bjp.0702834; Alm AK, 2000, BIOCHEM BIOPH RES CO, V275, P77, DOI 10.1006/bbrc.2000.3267; Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BAHOU WF, 1994, BLOOD, V84, P4195, DOI 10.1182/blood.V84.12.4195.bloodjournal84124195; Bernatowicz MS, 1996, J MED CHEM, V39, P4879, DOI 10.1021/jm960455s; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bohm SK, 1996, J BIOL CHEM, V271, P22003; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRASS LF, 1992, J BIOL CHEM, V267, P13795; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; CHEN J, 1994, J BIOL CHEM, V269, P16041; Chen XL, 1996, BIOCHEM J, V314, P603, DOI 10.1042/bj3140603; Cheung WM, 1999, ARTERIOSCL THROM VAS, V19, P3014, DOI 10.1161/01.ATV.19.12.3014; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P282, DOI 10.1021/bi00726a017; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P2462, DOI 10.1021/bi00737a015; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HEIN L, 1994, J BIOL CHEM, V269, P27719; Hoekstra WJ, 1998, BIOORG MED CHEM LETT, V8, P1649, DOI 10.1016/S0960-894X(98)00292-3; Hollenberg MD, 1999, CAN J PHYSIOL PHARM, V77, P458, DOI 10.1139/cjpp-77-6-458; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; HOLLENBERG MD, 1992, MOL PHARMACOL, V42, P186; HORVAT R, 1995, J CELL SCI, V108, P1155; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; Iaccarino G, 1998, AM J PHYSIOL-HEART C, V275, pH1298, DOI 10.1152/ajpheart.1998.275.4.H1298; Ido M, 2000, THROMB HAEMOSTASIS, V83, P617, DOI 10.1055/s-0037-1613873; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jenkins AL, 2000, DEV DYNAM, V218, P465, DOI 10.1002/1097-0177(200007)218:3<465::AID-DVDY1013>3.3.CO;2-X; Jia M, 1999, J NEUROBIOL, V38, P369, DOI 10.1002/(SICI)1097-4695(19990215)38:3<369::AID-NEU6>3.0.CO;2-Q; Kahn ML, 1998, J BIOL CHEM, V273, P23290, DOI 10.1074/jbc.273.36.23290; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; LEROY EC, 1984, J CLIN INVEST, V74, P1003, DOI 10.1172/JCI111467; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; McComsey DF, 1999, BIOORG MED CHEM LETT, V9, P255, DOI 10.1016/S0960-894X(98)00731-8; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; MOLINO M, 1992, BIOCHEM J, V288, P741, DOI 10.1042/bj2880741; Molino M, 1997, J BIOL CHEM, V272, P6011, DOI 10.1074/jbc.272.9.6011; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Molino M, 1997, J BIOL CHEM, V272, P11133; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NATARAJAN S, 1995, INT J PEPT PROT RES, V45, P145; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NGAIZA JR, 1992, J CELL PHYSIOL, V151, P190, DOI 10.1002/jcp.1041510124; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; Petersen LC, 2000, THROMB HAEMOSTASIS, V83, P571; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Renesto P, 1997, BLOOD, V89, P1944, DOI 10.1182/blood.V89.6.1944; RIEWALD M, 2000, BLOOD S1; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; SEILER SM, 1995, BIOCHEM PHARMACOL, V49, P519, DOI 10.1016/0006-2952(94)00473-Y; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Suidan HS, 1996, BIOCHEM J, V315, P939, DOI 10.1042/bj3150939; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TOTANI L, 1994, ARTERIOSCLER THROMB, V14, P125, DOI 10.1161/01.ATV.14.1.125; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WEKSLER BB, 1989, BLOOD, V74, P1627; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; WOOLKALIS MJ, 1995, THROMB HAEMOSTASIS, V73, P929; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	115	190	198	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1570	1581		10.1038/sj.onc.1204194	http://dx.doi.org/10.1038/sj.onc.1204194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313904	Bronze			2022-12-17	WOS:000168089800007
J	Cross, T; Griffiths, G; Deacon, E; Sallis, R; Gough, M; Watters, D; Lord, JM				Cross, T; Griffiths, G; Deacon, E; Sallis, R; Gough, M; Watters, D; Lord, JM			PKC-delta is an apoptotic lamin kinase	ONCOGENE			English	Article						apoptosis; nuclear lamina; PKC-delta	PROTEIN-KINASE; C-DELTA; PROTEOLYTIC ACTIVATION; NUCLEAR TRANSLOCATION; HL-60 CELLS; PHOSPHORYLATION; ALPHA; DYNAMICS; SITES; DEATH	Protein kinase C-delta is activated during apoptosis, following proteolytic cleavage by caspase 3. Furthermore, overexpression of the catalytic kinase fragment of PKC-delta induces the nuclear phenotype associated with apoptosis, though the molecular basis of this effect has not been determined. In these studies we have examined the role of PKC-delta in the disassembly of the nuclear Lamina at apoptosis. The nuclear lamina is disassembled during mitosis and apoptosis and mitotic disassembly involves hyperphosphorylation of lamin proteins by mitotic lamin kinases. During apoptosis, lamin proteins are degraded by caspase 6 and the contribution made by phosphorylation has not been proven. We show here that protein kinase C-delta co-localized with lamin B during apoptosis and activation of PKC-delta by caspase 3 was concomitant with lamin B phosphorylation and proteolysis. Inhibition of PKC-delta delayed lamin proteolysis, even in the presence of active caspase 6, whilst inhibitors of mitotic lamin kinases were without effect. In addition recombinant human PKC-delta was able to phosphorylate lamin B in vitro suggesting that its actions are direct and not via an intermediary kinase. We propose that PKC-delta is an apoptotic lamin kinase and that efficient lamina disassembly at apoptosis requires both lamin hyperphosphorylation and caspase mediated proteolysis.	Univ Birmingham, Ctr Immune Regulat, MRC, Birmingham B15 2TT, W Midlands, England; Queensland Inst Med Res, Brisbane, Qld 4006, Australia	University of Birmingham; QIMR Berghofer Medical Research Institute	Lord, JM (corresponding author), Univ Birmingham, Ctr Immune Regulat, MRC, Birmingham B15 2TT, W Midlands, England.		Watters, Dianne J/E-6007-2010; Gough, Michael/AAY-3419-2020; Sallis, Rosemary/H-4241-2014	Watters, Dianne J/0000-0002-2555-5825; Gough, Michael/0000-0002-5575-0074; Lord, Janet/0000-0003-1030-6786				Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EVANS CA, 1995, J CELL SCI, V108, P2591; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOZAK P, 1995, J CELL SCI, V108, P635; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Mikulits W, 1997, DNA CELL BIOL, V16, P849, DOI 10.1089/dna.1997.16.849; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Owen PJ, 1996, EXP CELL RES, V225, P366, DOI 10.1006/excr.1996.0187; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; WHELAN RDH, 1998, EMBO J, V14, P6148; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Yazaki T, 1996, MOL PHARMACOL, V50, P236; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	31	190	193	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2331	2337		10.1038/sj.onc.1203555	http://dx.doi.org/10.1038/sj.onc.1203555			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822384				2022-12-17	WOS:000086974300008
J	Balint, E; Bates, S; Vousden, KH				Balint, E; Bates, S; Vousden, KH			Mdm2 binds p73 alpha without targeting degradation	ONCOGENE			English	Article						p73; p53; Mdm2; E6; protein degradation	P53 TUMOR-SUPPRESSOR; IN-VIVO; P73; PROTEIN; GROWTH; GENE; E6; TRANSACTIVATION; ONCOPROTEINS; ACTIVATION	The function of the p53 tumor suppressor protein is regulated by interaction with Mdm2, which targets p53 for ubiquitin dependent degradation. We show here that like p53, p73 alpha forms an interaction with Mdm2, both in vitro and in cells, but this does not result in the degradation of the p73 alpha protein. The human papillomavirus E6 protein also fails to degrade p73 alpha, suggesting that the mechanisms governing p73 alpha stability are distinct from those known to regulate p53 stability. However, the interaction of Mdm2 with 73 alpha is sufficient to impede p73 alpha transcriptional function, despite the lack of degradation.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.		Balint, Eva/B-8695-2008	Balint, Eva/0000-0002-1258-6892				Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUBBUTAT MHG, 1999, IN PRESS CELL GROWTH; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Zhu JH, 1998, CANCER RES, V58, P5061	28	190	193	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3923	3929		10.1038/sj.onc.1202781	http://dx.doi.org/10.1038/sj.onc.1202781			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435614				2022-12-17	WOS:000081327800001
J	Morrison, EE; Wardleworth, BN; Askham, JM; Markham, AF; Meredith, DM				Morrison, EE; Wardleworth, BN; Askham, JM; Markham, AF; Meredith, DM			EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle	ONCOGENE			English	Article						EB1; APC; microtubules; mitosis; cancer	ADENOMATOUS POLYPOSIS; BETA-CATENIN; IN-VITRO; DYNAMICS; BINDING; GENE; EXPRESSION; MUTATIONS; MIGRATION; HOMOLOG	The characteristics of the adenomatous polyposis coli (APC) associated protein EB1 were examined in mammalian cells. By immunocytochemistry EB1 was shown to be closely associated with the microtubule cytoskeleton throughout the cell cycle, In interphase cells EB1 was associated with microtubules along their full length but was often particularly concentrated at their tips, During early mitosis, EB1 was localized to separating centrosomes and associated microtubules, while at metaphase it was associated with the spindle poles and associated microtubules. During cytokinesis EB1 was strongly associated with the midbody microtubules, Treatment with nocodazole caused a diffuse redistribution of EB1 immunoreactivity, whereas treatment with cytochalasin D had no effect. Interestingly, treatment with taxol abolished the EB1 association with microtubules, In nocodazole washout experiments EB1 rapidly became associated with the centrosome and repolymerizing microtubules. In taxol wash-out experiments EB1 rapidly re-associated with the microtubule cytoskeleton, resembling untreated control cells within 10 min, Immunostaining of SW480 cells, which contain truncated APC incapable of interaction with EEL, showed that the association of EB1 with microtubules throughout the cell cycle was not dependent upon an interaction with APC. These results suggest a role for EB1 in the control of microtubule dynamics in mammalian cells.	Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Morrison, EE (corresponding author), Univ Leeds, St James Hosp, Mol Med Unit, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.							Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; GRODEN J, 1993, AM J HUM GENET, V52, P263; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JORDAN MA, 1992, J CELL SCI, V102, P401; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVY DB, 1994, CANCER RES, V54, P5953; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1997, NEUROSCI LETT, V235, P129, DOI 10.1016/S0304-3940(97)00739-8; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Renner C, 1997, J IMMUNOL, V159, P1276; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1995, CANCER RES, V55, P2972; SU LK, 1998, P AM ASS CANC RES, V39; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	24	190	193	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 31	1998	17	26					3471	3477		10.1038/sj.onc.1202247	http://dx.doi.org/10.1038/sj.onc.1202247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030671				2022-12-17	WOS:000078086200008
J	Amarante-Mendes, GP; McGahon, AJ; Nishioka, WK; Afar, DEH; Witte, ON; Green, DR				Amarante-Mendes, GP; McGahon, AJ; Nishioka, WK; Afar, DEH; Witte, ON; Green, DR			Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-x(L)	ONCOGENE			English	Article						Bcr-Abl; Bcl-x; Bcl-2; apoptosis; transformation; tyrosine kinase; HL-60	CHRONIC MYELOGENOUS LEUKEMIA; POSITIVE HUMAN LEUKEMIAS; CELL-DEATH; TYROSINE KINASE; PHOSPHATIDYLINOSITOL-3 KINASE; GROWTH-FACTOR; K562 CELLS; BCL-2; ONCOGENE; TRANSFORMATION	Bcr-Abl is the molecule responsible for both the transformation phenotype and the resistance to chemotherapeutic drugs found in chronic myelogenous leukemia (CML) cells, Wild-type HL-60, a transformed pro-myelocytic cell line, is very susceptible to apoptosis-inducing agents, We show here that expression of Bcr-Abl in HL-60 cells rendered them extremely resistant to apoptosis induced by a wide variety of agents, The anti-apoptotic effect of Bcr-Abl was found to be independent of the phase of the cell cycle, Treatment with antisense oligonucleotides directed to bcr decreased the expression of the ectopic bcr-abl and restored susceptibility to apoptosis, Double mutations affecting the autophosphorylation site and the phosphotyrosine-binding motif (FLVRES) have been previously shown to impair the transforming activity of Bcr-Abl in fibroblasts and hematopoietic cells, however HL-60 cells expressing this double mutant molecule exhibited the same level of resistance to apoptosis as those expressing the wild-type Bcr-Abl. Interestingly, wild type and mutant Bcr-Abl induced in HL-60 cells a dramatic down regulation of Bcl-2 and increased the levels of Bcl-x(L). The level of Bar did not change in response to the presence of Bcr-Abl, Antisense oligonucleotides targeted to bcl-x downregulated the expression of Bcl-x(L) and increased the susceptibility of HL-60.Bcr-Abl cells to staurosporine. Importantly, HL-60 cells overexpressing Bcl-x(L) showed higher expression of Bcl-x(L) but lower resistance to apoptosis when compared to HL-60.Bcr-Abl cells. The results described here show that Bcr-Abl is a powerful mammalian anti-apoptotic molecule and can act independently of Bcl-2, Bcl-x(L), however, seems to participate in part in Bcr-Abl-mediated resistance to apoptosis in HL-60 cells.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA	La Jolla Institute for Immunology; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Amarante-Mendes, GP (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508900 Sao Paulo, Brazil.		Mendes, Gustavo P Amarante/C-8187-2012; Green, Douglas R/N-8083-2018	Mendes, Gustavo P Amarante/0000-0002-7851-6205; Green, Douglas R/0000-0002-7332-1417				ADAMS JM, 1992, CANCER SURV, V15, P119; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRESCIANI F, 1974, CANCER RES, V34, P2405; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARLESSO N, 1994, ONCOGENE, V9, P149; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; GARCIA IS, 1995, P NATL ACAD SCI USA, V92, P5287; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; ITOH N, 1993, J IMMUNOL, V151, P621; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MARTIAT P, 1993, BLOOD, V81, P502; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MEMON SA, 1995, J IMMUNOL, V155, P4644; Minshall C, 1996, J IMMUNOL, V156, P939; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRIFE A, 1988, SEMIN HEMATOL, V25, P37; STRYCKMANS P, 1976, CANCER RES, V36, P3034; SZCYLIK C, 1991, SCIENCE, V253, P562; WANG ZH, 1995, J IMMUNOL, V155, P3722; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	44	190	201	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1383	1390		10.1038/sj.onc.1201664	http://dx.doi.org/10.1038/sj.onc.1201664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525737				2022-12-17	WOS:000072572400002
J	Craig, C; Wersto, R; Kim, M; Ohri, E; Li, ZW; Katayose, D; Lee, SJ; Trepel, J; Cowan, K; Seth, P				Craig, C; Wersto, R; Kim, M; Ohri, E; Li, ZW; Katayose, D; Lee, SJ; Trepel, J; Cowan, K; Seth, P			A recombinant adenovirus expressing p27(Kip1) induces cell cycle arrest and lass of cyclin-Cdk activity in human breast cancer cells	ONCOGENE			English	Article						cyclin kinase inhibitors; cell growth; cell cycle; G(1)/S arrest	DEPENDENT KINASE INHIBITOR; POTENTIAL MEDIATOR; P21; P16; GROWTH	In order to elucidate the biochemical mechanisms by which the universal cyclin kinase inhibitor p27(Kip1) regulates cell cycle progression in human breast cancer cells, a recombinant adenovirus expressing human p27 was constructed (Adp27). Upon infection of human breast cancer cells MDA-MB-231 and MCF-7 with Adp27, a high level of p27 expression was observed, and this resulted in a marked decrease in the proportion of cells in S-phase, In multiple cell lines, comparison of the cytotoxicity of Adp27 with another adenovirus vector expressing the related universal cyclin kinase inhibitor WAF1/Cip1 (AdWAF1), showed Adp27 to be markedly more (up to 56-fold) toxic than AdWAF1, DNA histograms showed Adp27 to cause a G(1)/S arrest at lower viral doses than AdWAF1, Analysis of cyclin dependent kinase activity following Adp27 infections showed decreased Cdk2 and cyclin B1-Cdc2 activity at lower viral doses when compared with AdWAF1, Adp27 is therefore potentially useful for studies of growth regulation and for gene therapy when growth inhibition is desired.	NCI,MED BRANCH,NIH,BETHESDA,MD 20892; NCI,PATHOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GINSBERG HS, 1988, VIROLOGY, P147; GOTTESMAN MM, 1994, J NATL CANCER I, V86, P1277, DOI 10.1093/jnci/86.17.1277; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; Gudas JM, 1996, CARCINOGENESIS, V17, P1417, DOI 10.1093/carcin/17.7.1417; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Katayose D, 1995, CLIN CANCER RES, V1, P889; Kopp WC, 1992, MANUAL CLIN LABORATO, P933; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHUTTE B, 1987, CYTOMETRY, V8, P372, DOI 10.1002/cyto.990080405; SETH P, 1984, MOL CELL BIOL, V4, P1528, DOI 10.1128/MCB.4.8.1528; SETH P, 1986, VIRUS ATTACHMENT ENT, P191; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	28	190	196	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2283	2289		10.1038/sj.onc.1201064	http://dx.doi.org/10.1038/sj.onc.1201064			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178904				2022-12-17	WOS:A1997WY88300005
J	Eliopoulos, AG; Dawson, CW; Mosialos, G; Floettmann, JE; Rowe, M; Armitage, RJ; Dawson, J; Zapata, JM; Kerr, DJ; Wakelam, MJO; Reed, JC; Kieff, E; Young, LS				Eliopoulos, AG; Dawson, CW; Mosialos, G; Floettmann, JE; Rowe, M; Armitage, RJ; Dawson, J; Zapata, JM; Kerr, DJ; Wakelam, MJO; Reed, JC; Kieff, E; Young, LS			CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator	ONCOGENE			English	Article						CD40; TNF alpha; Fas; LMP1; TRAF3; epithelial	LATENT MEMBRANE-PROTEIN; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; BCL-2 HOMOLOG BAK; CD40 LIGAND; ACTIVATION MOLECULE; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; IMMUNE-RESPONSES; DRUG-RESISTANCE	CD40, a member of the tumour necrosis factor receptor family, is expressed on the surface of B lymphocytes where its ligation provides a potent survival signal. CD40 is also expressed in basal epithelial cells and in a number of different carcinomas where its function remains unknown. We observed that contrary to the studies in normal B cells, CD40 Ligation in carcinoma cell lines and in normal primary epithelial cells resulted in growth inhibition and enhanced susceptibility to apoptosis induced by anti-neoplastic drugs, TNF-alpha, Fas and ceramide. This effect was also observed in CD40-transfected Rat-1 fibroblasts. The expression of Bcl-2 did not affect growth inhibition induced by CD40 ligation in epithelial cells but the Epstein - Barr Virus-encoded latent membrane protein 1 (LMP1) blocked the effect. Whilst transient expression of LMP-1 resulted in the inhibition of epithelial cell growth, this effect was not observed with a LMP1 mutant lacking the binding domain for TRAF3, a protein which may mediate signal transduction by interacting with the cytoplasmic domains of both CD40 and LMP1. Transient expression of TRAF3 also inhibited epithelial cell growth, whilst expression of a dominant-negative TRAF3 partially blocked the inhibitory effect of CD40 ligation and of transient LMP1 expression. These results suggest that CD40 regulates epithelial cell growth in a manner mimicked by LMP1 and implicate TRAF3 as a common mediator in the transduction of the growth inhibitory signals generated via the CD40 and LMP1 pathways.	UNIV BIRMINGHAM,SCH MED,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TJ,AL,ENGLAND; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101; BURNHAM INST,CANC RES CTR,LA JOLLA,CA 92037	University of Birmingham; Harvard University; Harvard Medical School; Cardiff University; Sanford Burnham Prebys Medical Discovery Institute			Rowe, Martin/B-2880-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020; Zapata, Juan M/J-6304-2014; Young, Lawrence S/B-7213-2009	Rowe, Martin/0000-0003-4139-7326; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Zapata, Juan M/0000-0002-0110-0009; Young, Lawrence S/0000-0003-3919-4298; Wakelam, Michael/0000-0003-4059-9276	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FLOETTMANN JE, IN PRESS VIROLOGY; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2366; HORNER AA, 1995, J EXP MED, V181, P1239, DOI 10.1084/jem.181.3.1239; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KATIRA A, 1995, LEUKOCYTE TYPING, V5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MORIMOTO H, 1993, CANCER RES, V53, P2591; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PENG M, 1992, ONCOGENE, V7, P1775; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUBY J, 1995, NAT MED, V1, P437, DOI 10.1038/nm0595-437; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	58	190	199	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2243	2254						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950992				2022-12-17	WOS:A1996VV14500022
J	HALL, M; BATES, S; PETERS, G				HALL, M; BATES, S; PETERS, G			EVIDENCE FOR DIFFERENT MODES OF ACTION OF CYCLIN-DEPENDENT KINASE INHIBITORS - P15 AND P16 BIND TO KINASES, P21 AND P27 BIND TO CYCLINS	ONCOGENE			English	Article						CDKN1; CDKN2; CYCLINS; IN VITRO BINDING	SUBUNIT	A number of low molecular weight proteins have recently been identified that specifically inhibit the function of cyclin-dependent protein kinases in mammalian cells. These fall into two distinct families based on primary sequence comparisons and probable modes of action. Using a simple in vitro binding assay, we show that p21(CDKN1) and the related p27(KIP1) can efficiently interact with cyclins D1, D2, D3, E and A, and to a lesser extent with cyclin B. By generating a deleted form of cyclin D1 that binds to p21 and p27 but not to Cdks, we confirm that these interactions do not depend on stoichiometric amounts of the relevant kinase subunit. Moreover, p21 and p27 do not detectably associate with kinase subunits unless a cyclin is present. This is in sharp contrast to the properties of p16(CDKN2) and p15(MTS2/INK4b) which bind to Cdk4 and Cdk6 in the absence of any cyclin. These data suggest that p21 and p27 act as broad spectrum regulators of cyclin dependent kinase function by participating in ternary complexes whereas the p16 family specifically interfere with the formation of cyclin D-dependent kinase complexes.	IMPERIAL CANC RES FUND, ONCOL MOLEC LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Hall, marcia/0000-0003-0039-5041				BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAHARA H, 1995, ONCOGENE, V10, P835; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	52	190	200	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1581	1588						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478582				2022-12-17	WOS:A1995TC53500016
J	CHIAPPETTA, G; BANDIERA, A; BERLINGIERI, MT; VISCONTI, R; MANFIOLETTI, G; BATTISTA, S; MARTINEZTELLO, FJ; SANTORO, M; GIANCOTTI, V; FUSCO, A				CHIAPPETTA, G; BANDIERA, A; BERLINGIERI, MT; VISCONTI, R; MANFIOLETTI, G; BATTISTA, S; MARTINEZTELLO, FJ; SANTORO, M; GIANCOTTI, V; FUSCO, A			THE EXPRESSION OF THE HIGH-MOBILITY GROUP HMGI (Y) PROTEINS CORRELATES WITH THE MALIGNANT PHENOTYPE OF HUMAN THYROID NEOPLASIAS	ONCOGENE			English	Article						HMGI (Y) PROTEINS; THYROID; CARCINOMAS; TUMOR MARKER; IMMUNOHISTOCHEMISTRY	NUCLEAR PROTEINS; HISTONE H1; CELLS; BINDING; MOUSE; GENE; DNA; TRANSFORMATION; CARCINOMAS; SEQUENCE	High Mobility Group I(HMGI) proteins are nuclear proteins involved in the regulation of chromatin structure and function, Elevated expression of the HMGI proteins (HMGI, HMGY and HMGI-C) has been correlated with the presence of a highly malignant phenotype in epithelial and fibroblastic rat thyroid cells, and in several experimental carcinomas, Here, we demonstrate that HMGI and HMGY proteins are expressed in human thyroid carcinomas and thyroid carcinoma cell lines, but not in adenomas, goiters, normal thyroid tissues and cells, These results indicate a correlation between HMGI and HMGY expression and the malignant phenotype of thyroid neoplasias, suggesting that these proteins may be used as markers in thyroid cancer.	UNIV REGGIO CALABRIA, FAC MED & CHIRURG, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY; IST NAZL TUMORI, FDN SENATORE PASCALE, I-80131 NAPLES, ITALY; UNIV TRIESTE, DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC, I-34127 TRIESTE, ITALY; UNIV NAPLES, FAC MED & CHIRURG, CNR, CTR ENDOCRINOL ONCOL SPERIMENTALE, I-80131 NAPLES, ITALY; UNIV COMPLUTENSE MADRID, HOSP UNIV 12 OCTUBRE, DEPT PATHOL, E-28041 MADRID, SPAIN	Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Complutense University of Madrid; Hospital Universitario 12 de Octubre			Visconti, Roberta/C-5299-2009	MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Visconti, Roberta/0000-0001-7613-3801; Fusco, Alfredo/0000-0003-3332-5197				BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MARTINEZTELLO FJ, 1993, CANCER-AM CANCER SOC, V71, P4022, DOI 10.1002/1097-0142(19930615)71:12<4022::AID-CNCR2820711236>3.0.CO;2-O; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8573; SANTORO M, 1990, ONCOGENE, V5, P1595; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; TAMIMI Y, 1993, CANCER RES, V53, P5512; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; [No title captured]	34	190	191	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1307	1314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731681				2022-12-17	WOS:A1995QR65100007
J	COTTER, FE; JOHNSON, P; HALL, P; POCOCK, C; ALMAHDI, N; COWELL, JK; MORGAN, G				COTTER, FE; JOHNSON, P; HALL, P; POCOCK, C; ALMAHDI, N; COWELL, JK; MORGAN, G			ANTISENSE OLIGONUCLEOTIDES SUPPRESS B-CELL LYMPHOMA GROWTH IN A SCID-HU MOUSE MODEL	ONCOGENE			English	Article							NON-HODGKINS LYMPHOMA; T(14-18) CHROMOSOMAL TRANSLOCATION; BCL-2 GENE; FOLLICULAR LYMPHOMA; MEMBRANE PROTEIN; LEUKEMIA; DISEASE; MICE; PROGRESSION; APOPTOSIS	The t(14;18) translocation is found in the majority follicular lymphomas and some high grade B-cell lymphomas. This is results in deregulation of the BCL-2 gene and appears to play a role in oncogenesis. Various numbers of cells from a cell line derived spontaneously from a patient with B-cell lymphoma bearing the t(14;18) translocation and negative for the Epstein-Barr virus (EBV) were injected by IP, IV, and SC routes into SCID mice. The mice developed lymphoma bearing the t(14;18) translocation with as few as 5 x 10(6) cells within 28 days. This was determined by histological examination. The higher the cell inoculation the more rapidly the lymphoma developed. Engraftment of the tumour cells was determined by PCR for the t(14;18) breakpoint region on peripheral blood samples and could be detected prior to development of overt lymphoma. Having established a lymphoma model the cells were treated with antisense oligonucleotides to the first open reading frame of the BCL-2 gene prior to inoculation of the SCID mice. Control treatments with sense and nonsense oligonucleotides was also performed. At 28 days the sense, nonsense and untreated cell SCID mice had developed lymphoma, however, the antisense treated group failed to develop lymphoma. The findings demonstrate the modelling of B-cell lymphoma bearing the t(14;18) translocation and the ability to modify the lymphoma process with the use of antisense oligonucleotides to the BCL-2 gene. Reduction of the BCL2 protein suppresses the oncogenic potential of these lymphoma cells confirming that it plays an essential role in the development of malignancy.	IMPERIAL CANC RES FUND,ONCOL GRP,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT ONCOL,LONDON EC1 1BB,ENGLAND; ST THOMAS HOSP,DEPT HISTOPATHOL,LONDON SE1 7EH,ENGLAND	Cancer Research UK; University of London; University College London; Cancer Research UK; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust	COTTER, FE (corresponding author), LRF,DEPT HAEMATOL & ONCOL,LONDON WC1N 1EH,ENGLAND.		Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Cowell, John/0000-0002-2079-5950				AMADORI A, 1992, LEUKEMIA, V6, pS23; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y; ERSBOLL J, 1989, EUR J HAEMATOL, V42, P155; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARVIN AJ, 1983, CANCER-AM CANCER SOC, V52, P393, DOI 10.1002/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M; HAGENBEEK A, 1992, LEUKEMIA, V6, P12; HALL PA, 1980, HISTOPATHOLOGY, V13, P149; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUA C, 1988, ONCOGENE RES, V2, P263; KAMELREID S, 1991, BLOOD, V78, P2973; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KNOWLES DM, 1989, BLOOD, V73, P1635; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; NGAN BY, 1989, BLOOD, V73, P1735; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PEZELLA F, 1990, NOUV REV FR HEMATOL, V32, P397; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RISDALL R, 1979, CANCER, V44, P529, DOI 10.1002/1097-0142(197908)44:2<529::AID-CNCR2820440222>3.0.CO;2-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; THOMAS JA, 1993, BLOOD, V81, P3350; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YANO T, 1992, BLOOD, V80, P758	32	190	204	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3049	3055						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084613				2022-12-17	WOS:A1994PG82200036
J	HENKEMEYER, M; MARENGERE, LEM; MCGLADE, J; OLIVIER, JP; CONLON, RA; HOLMYARD, DP; LETWIN, K; PAWSON, T				HENKEMEYER, M; MARENGERE, LEM; MCGLADE, J; OLIVIER, JP; CONLON, RA; HOLMYARD, DP; LETWIN, K; PAWSON, T			IMMUNOLOCALIZATION OF THE NUK RECEPTOR TYROSINE KINASE SUGGESTS ROLES IN SEGMENTAL PATTERNING OF THE BRAIN AND AXONOGENESIS	ONCOGENE			English	Article							CELL-ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; MOUSE DEVELOPMENT; NERVOUS-SYSTEM; INT-1 PROTOONCOGENE; ECTOPIC EXPRESSION; NEURITE OUTGROWTH; XENOPUS EMBRYOS; PROTEIN-KINASES; OPTIC CHIASM	Neural kinase (Nuk) encodes a murine receptor-like tyrosine kinase belonging to the Eph/Elk/Eck family. Protein localization studies indicate that during early embryogenesis Nuk is confined to the developing nervous system, where it marks segments along the axis of the neural tube in the hindbrain (rhombomeres r2, r3 and r5) and specific morphological bulges of the midbrain and forebrain. Subcellular localization of Nuk indicates that this receptor is concentrated at sites of cell-cell contact, often involving migrating neuronal cells or their extensions. Most notably, high levels of Nuk protein are found within initial axon outgrowths and associated nerve fibers. The axonal localization of Nuk is transient and is not detected after migrations have ceased, suggesting a role for this tyrosine kinase during the early pathfinding and/or fasciculation stages of axonogenesis. The subcellular localization of Nuk, as well as the presence of fibronectin type III and immunoglobulin-like adhesive domains on the extracellular region, suggest this receptor tyrosine kinase may function to regulate specific cell-cell interactions during early development of the murine nervous system.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto	HENKEMEYER, M (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Pawson, Tony J/E-4578-2013	Henkemeyer, Mark/0000-0002-7525-1061				BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Carpenter M.B., 1985, CORE TEXT NEUROANATO, V3rd; CHAN J, 1991, ONCOGENE, V6, P1057; CHITNIS AB, 1990, J NEUROSCI, V10, P1892; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; Edelman GM, 1985, CELL CONTACT ADHESIO; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; Guild SR, 1927, AM J ANAT, V39, P57, DOI 10.1002/aja.1000390103; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HENDRIKS DM, 1973, S AFR MED J, V47, P2294; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KLEIN R, 1990, DEVELOPMENT, V109, P845; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LANDMESSER L, 1992, NEURON, V8, P291, DOI 10.1016/0896-6273(92)90296-P; LETWIN K, 1988, ONCOGENE, V3, P621; LEVITT P, 1981, J NEUROSCI, V1, P27, DOI 10.1523/JNEUROSCI.01-01-00027.1981; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LIESI P, 1985, EMBO J, V4, P1163, DOI 10.1002/j.1460-2075.1985.tb03755.x; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NAKANISHI S, 1983, DEV BIOL, V95, P305, DOI 10.1016/0012-1606(83)90031-3; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RUGH R, 1968, MOUSE ITS REPRODUCTI; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHER AE, 1971, ACTA OTO-LARYNGOL, P1; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THEILER K, 1989, HOUSE MOUSE; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; VANDEWATER TR, 1991, ANN NY ACAD SCI, V630, P116; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILSON SW, 1990, DEVELOPMENT, V108, P121; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	89	190	195	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1001	1014						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134103				2022-12-17	WOS:A1994NC04800001
J	NIKOLAKAKI, E; COFFER, PJ; HEMELSOET, R; WOODGETT, JR; DEFIZE, LHK				NIKOLAKAKI, E; COFFER, PJ; HEMELSOET, R; WOODGETT, JR; DEFIZE, LHK			GLYCOGEN-SYNTHASE KINASE-3 PHOSPHORYLATES JUN FAMILY MEMBERS INVITRO AND NEGATIVELY REGULATES THEIR TRANSACTIVATING POTENTIAL IN INTACT-CELLS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; PROTEIN-KINASE; C-JUN; FOS PROTEINS; METALLOTHIONEIN GENE; TRANSCRIPTION; ACTIVATION; PRODUCT; EXPRESSION; AP-1	Expression of immediate-early genes involving the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive element (TRE) is modulated by post-translational modification of pre-existing activator protein 1 (AP-1) constituents. One of the components of AP-1, c-Jun, has been shown to be phosphorylated by glycogen synthase kinase 3 (GSK-3) in vitro in a region proximal to the DNA-binding domain, resulting in decreased DNA binding. Here, we have used transient transfection to show that AP-1 activity is inhibitable by coexpression of GSK-3 in intact cells. Furthermore, we show that the c-Jun-related proteins JunD and JunB are subject to similar regulation by GSK-3 in intact cells. Comparison of tryptic phosphopeptide maps of the three Jun proteins incubated with GSK-3 in vitro with maps of the same proteins immunoprecipitated from P-32-labelled cells indicates similar sites of phosphorylation. Together, these data support the hypothesis that GSK-3 is an important regulator of AP-1 activity in vivo.	HUBRECHT LAB DEV BIOL,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Ludwig Institute for Cancer Research			Coffer, Paul/AAF-7970-2020; Woodgett, Jim/F-1087-2010; Coffer, Paul J/A-5769-2009	Woodgett, Jim/0000-0003-3731-5797; 				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DWARKI VJ, 1990, EMBO J, V9003, P2253; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODE N, 1992, J BIOL CHEM, V267, P16878; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MULLER R, 1987, ONCOGENE RES, V2, P19; PULVERER B, 1992, IN PRESS ONCOGENE; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	40	190	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384354				2022-12-17	WOS:A1993KT22000003
J	Surova, O; Zhivotovsky, B				Surova, O.; Zhivotovsky, B.			Various modes of cell death induced by DNA damage	ONCOGENE			English	Review						DNA damage; cell death; p53; senescence; response	REPLICATIVE SENESCENCE; P53; AUTOPHAGY; APOPTOSIS; CANCER; POLY(ADP-RIBOSE); CHECKPOINT; PATHWAYS; CONTRIBUTES; ACTIVATION	The consequences of DNA damage depend on the cell type and the severity of the damage. Mild DNA damage can be repaired with or without cell-cycle arrest. More severe and irreparable DNA injury leads to the appearance of cells that carry mutations or causes a shift towards induction of the senescence or cell death programs. Although for many years it was argued that DNA damage kills cells via apoptosis or necrosis, technical and methodological progress during the last few years has helped to reveal that this injury might also activate death by autophagy or mitotic catastrophe, which may then be followed by apoptosis or necrosis. The molecular basis underlying the decision-making process is currently the subject of intense investigation. Here, we review current knowledge about the response to DNA damage and subsequent signaling, with particular attention to cell death induction and the molecular switches between different cell death modalities following damage.	[Surova, O.; Zhivotovsky, B.] Karolinska Inst, Div Toxicol, Inst Environm Med, SE-17177 Stockholm, Sweden	Karolinska Institutet	Zhivotovsky, B (corresponding author), Karolinska Inst, Div Toxicol, Inst Environm Med, Nobels Vag 13,Box 210, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482	Swedish Research Council; Swedish Cancer Society; Stockholm Cancer Society; Swedish Childhood Cancer Foundation; FP7 (Apo-Sys) program; Swedish Institute; Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Stockholm Cancer Society; Swedish Childhood Cancer Foundation(European Commission); FP7 (Apo-Sys) program; Swedish Institute; Karolinska Institutet(Karolinska Institutet)	The work in the author's laboratory was supported by grants from the Swedish Research Council, the Swedish and the Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation, and the FP7 (Apo-Sys) program. OS was supported by a fellowship from the Swedish Institute and Karolinska Institutet. We apologize to those authors whose primary references could not be cited due to space limitations.	Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alexander A, 2010, AUTOPHAGY, V6, P672, DOI 10.4161/auto.6.5.12509; Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Bai SC, 2004, MOL CANCER THER, V3, P613; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Borges HL, 2008, CELL RES, V18, P17, DOI 10.1038/cr.2007.110; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Leseleuc L, 2006, CELL DEATH DIFFER, V13, P293, DOI 10.1038/sj.cdd.4401737; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Freeman AK, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-27; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hock AK, 2012, CELL, V149, P1183, DOI 10.1016/j.cell.2012.05.024; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim H, 2011, MOL CELL, V44, P797, DOI 10.1016/j.molcel.2011.09.023; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537; Morandell S, 2012, PROG MOL BIOL TRANSL, V110, P289, DOI 10.1016/B978-0-12-387665-2.00011-0; Moubarak RS, 2007, MOL CELL BIOL, V27, P4844, DOI 10.1128/MCB.02141-06; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Nelyudova A, 2007, CELL CYCLE, V6, P2171, DOI 10.4161/cc.6.17.4610; Norberg E, 2010, EMBO J, V29, P3869, DOI 10.1038/emboj.2010.253; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oral O, 2012, APOPTOSIS, V17, P810, DOI 10.1007/s10495-012-0735-0; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Pallis AG, 2010, CANCER METAST REV, V29, P677, DOI 10.1007/s10555-010-9258-8; Paull TT, 2005, CELL CYCLE, V4, P737, DOI 10.4161/cc.4.6.1715; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Saretzki G, 2010, CURR PHARM DESIGN, V16, P79, DOI 10.2174/138161210789941874; Sasaki M, 2010, LAB INVEST, V90, P835, DOI 10.1038/labinvest.2010.56; Sayan AE, 2008, ONCOGENE, V27, P4363, DOI 10.1038/onc.2008.64; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang JYJ, 2004, ADV PROTEIN CHEM, V69, P101; Ward I, 2004, CURR TOP DEV BIOL, V63, P1, DOI 10.1016/S0070-2153(04)63001-8; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zeng XH, 2010, CELL RES, V20, P665, DOI 10.1038/cr.2010.40	72	189	193	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3789	3797		10.1038/onc.2012.556	http://dx.doi.org/10.1038/onc.2012.556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	23208502				2022-12-17	WOS:000323210200001
J	Kallunki, T; Olsen, OD; Jaattela, M				Kallunki, T.; Olsen, O. D.; Jaattela, M.			Cancer-associated lysosomal changes: friends or foes?	ONCOGENE			English	Review						Lysosome; Cancer; metastasis; cell death	HUMAN CATHEPSIN-B; EXTRACELLULAR-MATRIX PROTEINS; HEPARANASE INHIBITOR PI-88; PROTON PUMP INHIBITORS; VACUOLAR H+-ATPASE; BREAST-CANCER; CYSTEINE CATHEPSINS; ACID SPHINGOMYELINASE; CELL-DEATH; V-ATPASES	Rapidly dividing and invasive cancer cells are strongly dependent on effective lysosomal function. Accordingly, transformation and cancer progression are characterized by dramatic changes in lysosomal volume, composition and cellular distribution. Depending on one's point of view, the cancer-associated changes in the lysosomal compartment can be regarded as friends or foes. Most of them are clearly transforming as they promote invasive growth, angiogenesis and drug resistance. The same changes can, however, strongly sensitize cells to lysosomal membrane permeabilization and thereby to lysosome-targeting anti-cancer drugs. In this review we compile our current knowledge on cancer-associated changes in lysosomal composition and discuss the consequences of these alterations to cancer progression and the possibilities they can bring to cancer therapy. Oncogene (2013) 32, 1995-2004; doi:10.1038/onc.2012.292; published online 9 July 2012	[Jaattela, M.] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark; [Jaattela, M.] Danish Canc Soc, Res Ctr, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Jaattela, M (corresponding author), Danish Canc Soc, Res Ctr, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	mj@cancer.dk	Jäättelä, Marja/AAT-7932-2021	Jäättelä, Marja/0000-0001-5950-7111; Kallunki, Tuula/0000-0002-8571-383X	Danish Cancer Society; Danish Medical Research Council; Danish National Research Foundation; European Commission FP7 APO-SYS network; Association for International Cancer Research; Meyer Foundation; Lundbeck Foundation; Novo Nordisk Foundation; Worldwide Cancer Research [11-0226] Funding Source: researchfish	Danish Cancer Society(Danish Cancer Society); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish National Research Foundation(Danmarks Grundforskningsfond); European Commission FP7 APO-SYS network; Association for International Cancer Research; Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Worldwide Cancer Research	The authors' own work has been supported by grants from the Danish Cancer Society, the Danish Medical Research Council, the Danish National Research Foundation, the European Commission FP7 APO-SYS network, the Association for International Cancer Research, the Meyer Foundation, the Lundbeck Foundation and the Novo Nordisk Foundation.	Abboud-Jarrous G, 2008, J BIOL CHEM, V283, P18167, DOI 10.1074/jbc.M801327200; Adams-Cioaba MA, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1204; Al-Shamahi A, 2009, IDRUGS, V12, P799; Basche M, 2006, CLIN CANCER RES, V12, P5471, DOI 10.1158/1078-0432.CCR-05-2423; Beckham TH, 2012, INT J CANCER, V131, P2034, DOI 10.1002/ijc.27480; Benavides F, 2012, MOL CARCINOGEN, V51, P352, DOI 10.1002/mc.20792; Benes P, 2008, CRIT REV ONCOL HEMAT, V68, P12, DOI 10.1016/j.critrevonc.2008.02.008; Benes P, 2006, CANCER LETT, V239, P46, DOI 10.1016/j.canlet.2005.07.030; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Boudreau F, 2007, FASEB J, V21, P3853, DOI 10.1096/fj.07-8113com; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Braulke T, 2009, BBA-MOL CELL RES, V1793, P605, DOI 10.1016/j.bbamcr.2008.10.016; Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; Canals D, 2011, BRIT J PHARMACOL, V163, P694, DOI 10.1111/j.1476-5381.2011.01279.x; Carpinteiro A, 2008, CANCER LETT, V264, P1, DOI 10.1016/j.canlet.2008.02.020; Ceru S, 2010, J BIOL CHEM, V285, P10078, DOI 10.1074/jbc.M109.034793; Corvo I, 2009, MOL BIOCHEM PARASIT, V167, P41, DOI 10.1016/j.molbiopara.2009.04.005; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Davidson D, 2007, GYNECOL ONCOL, V104, P311, DOI 10.1016/j.ygyno.2006.08.045; De Milito A, 2010, INT J CANCER, V127, P207, DOI 10.1002/ijc.25009; Dennemarker J, 2010, ONCOGENE, V29, P1611, DOI 10.1038/onc.2009.466; Dredge K, 2011, BRIT J CANCER, V104, P635, DOI 10.1038/bjc.2011.11; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Duncan EM, 2008, CELL, V135, P284, DOI 10.1016/j.cell.2008.09.055; Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gerasimenko JV, 2001, CURR BIOL, V11, pR971, DOI 10.1016/S0960-9822(01)00577-2; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gocheva V, 2010, BIOL CHEM, V391, P937, DOI 10.1515/BC.2010.080; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619; Groth-Pedersen L, CANC LETT; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hantschel M, 2000, CELL STRESS CHAPERON, V5, P438, DOI 10.1379/1466-1268(2000)005<0438:HPMEOP>2.0.CO;2; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Hernandez A, 2010, RECENT PAT ANTI-CANC, V5, P88, DOI 10.2174/157489210790936216; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Huss M, 2009, J EXP BIOL, V212, P341, DOI 10.1242/jeb.024067; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Ishidoh K, 1995, BIOCHEM BIOPH RES CO, V217, P624, DOI 10.1006/bbrc.1995.2820; Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Jenkins RW, 2009, CELL SIGNAL, V21, P836, DOI 10.1016/j.cellsig.2009.01.026; Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Katunuma N, 2002, ADV ENZYME REGUL, V42, P159, DOI 10.1016/S0065-2571(01)00060-7; Katunuma N, 2011, P JPN ACAD B-PHYS, V87, P29, DOI 10.2183/pjab.87.29; Kim K, 1998, INT J CANCER, V79, P324, DOI 10.1002/(SICI)1097-0215(19980821)79:4<324::AID-IJC4>3.3.CO;2-N; Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kolter T, 2010, FEBS LETT, V584, P1700, DOI 10.1016/j.febslet.2009.10.021; Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kuester D, 2008, PATHOL RES PRACT, V204, P491, DOI 10.1016/j.prp.2008.04.010; Lankelma JM, 2010, LIFE SCI, V86, P225, DOI 10.1016/j.lfs.2009.11.016; Le Gall C, 2007, CANCER RES, V67, P9894, DOI 10.1158/0008-5472.CAN-06-3940; Leto G, 2004, CLIN EXP METASTAS, V21, P91, DOI 10.1023/B:CLIN.0000024740.44602.b7; Leto G, 2010, BIOL CHEM, V391, P655, DOI 10.1515/BC.2010.069; Li JP, 2008, ANTI-CANCER AGENT ME, V8, P64, DOI 10.2174/187152008783330824; Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007; Linke T, 2001, BIOL CHEM, V382, P283, DOI 10.1515/BC.2001.035; LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386; Liu CJ, 2009, J HEPATOL, V50, P958, DOI 10.1016/j.jhep.2008.12.023; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; Maeda I, 1999, INT J CANCER, V81, P700, DOI 10.1002/(SICI)1097-0215(19990531)81:5<700::AID-IJC5>3.3.CO;2-4; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; Marchetti D, 2003, INT J CANCER, V104, P167, DOI 10.1002/ijc.10930; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Matarrese P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-207; Miao HQ, 2006, CURR MED CHEM, V13, P2101, DOI 10.2174/092986706777935230; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Miyagi T, 2008, P JPN ACAD B-PHYS, V84, P407, DOI 10.2183/pjab.84.407; Mobius W, 2003, TRAFFIC, V4, P222; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Morgan AJ, 2011, BIOCHEM J, V439, P349, DOI 10.1042/BJ20110949; Nagaraj NS, 2007, TOXICOL LETT, V170, P134, DOI 10.1016/j.toxlet.2007.02.014; Ni XY, 2006, TRAFFIC, V7, P889, DOI 10.1111/j.1600-0854.2006.00429.x; Nishisho T, 1916, MOL CANCER RES, V9, P845; Norrby K, 2006, APMIS, V114, P79, DOI 10.1111/j.1600-0463.2006.apm_235.x; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Otero-Rey EM, 2008, ORAL ONCOL, V44, P193, DOI 10.1016/j.oraloncology.2007.02.011; Ozbayraktar Fatma Betul Kavun, 2009, Biotechnology Journal, V4, P1028, DOI 10.1002/biot.200800322; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257; Perez-Sayans M, 2009, CANCER TREAT REV, V35, P707, DOI 10.1016/j.ctrv.2009.08.003; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Pryor PR, 2009, BBA-MOL CELL RES, V1793, P615, DOI 10.1016/j.bbamcr.2008.12.022; Quintanilla-Dieck MJ, 2008, J INVEST DERMATOL, V128, P2281, DOI 10.1038/jid.2008.63; Quiros RM, 2006, CANCER-AM CANCER SOC, V106, P532, DOI 10.1002/cncr.21648; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI [10.1093/nar/gkh071, 10.1093/nar/gkp971]; Rebbaa A, 2009, ANTICANCER RES, V29, P4473; Reczek D, 2007, CELL, V131, P770, DOI 10.1016/j.cell.2007.10.018; REID TR, 1989, J BIOL CHEM, V264, P4583; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Ruckhaberle E, 2009, CLIMACTERIC, V12, P502, DOI 10.3109/13697130902939913; Saddoughi Sahar A., 2008, V49, P413, DOI 10.1007/978-1-4020-8831-5_16; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Scaringi L, 2004, INT J IMMUNOPATH PH, V17, P331, DOI 10.1177/039463200401700313; Schneede A, 2011, J CELL MOL MED, V15, P280, DOI 10.1111/j.1582-4934.2009.00973.x; Schurigt U, 2008, BIOL CHEM, V389, P1067, DOI 10.1515/BC.2008.115; Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Settembre C, 2011, AUTOPHAGY, V7, P1379, DOI 10.4161/auto.7.11.17166; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Sevenich L, 2011, ONCOGENE, V30, P54, DOI 10.1038/onc.2010.387; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Shafat I, 2006, J BIOL CHEM, V281, P23804, DOI 10.1074/jbc.M602762200; Shafat I, 2011, J CELL MOL MED, V15, P1857, DOI 10.1111/j.1582-4934.2010.01190.x; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; SHIRAISHI N, 1986, CANCER LETT, V30, P251, DOI 10.1016/0304-3835(86)90049-2; SLOANE BF, 1994, J CELL SCI, V107, P373; Spugnini EP, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-44; Strojnik T, 2005, CANCER DETECT PREV, V29, P448, DOI 10.1016/j.cdp.2005.07.006; Sugimoto Y, 2009, J MED CHEM, V52, P798, DOI 10.1021/jm801265e; Sullivan S, 2009, INT J CANCER, V125, P54, DOI 10.1002/ijc.24275; Toei M, 2010, BIOCHEMISTRY-US, V49, P4715, DOI 10.1021/bi100397s; Tomoo K, 2010, CURR TOP MED CHEM, V10, P696, DOI 10.2174/156802610791113441; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Uemura T, 2009, ONCOGENE, V28, P1218, DOI 10.1038/onc.2008.471; van der Goot FG, 2006, TRENDS CELL BIOL, V16, P514, DOI 10.1016/j.tcb.2006.08.003; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2008, BIOCHIMIE, V90, P380, DOI 10.1016/j.biochi.2007.10.004; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Victor BC, 2007, BIOL CHEM, V388, P1131, DOI 10.1515/BC.2007.150; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Walz M, 2007, EXP DERMATOL, V16, P715, DOI 10.1111/j.1600-0625.2007.00579.x; Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759; Yan SQ, 2003, BIOL CHEM, V384, P845, DOI 10.1515/BC.2003.095; Yogalingam G, 2008, DEV CELL, V15, P74, DOI 10.1016/j.devcel.2008.05.005; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937	152	189	191	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					1995	2004		10.1038/onc.2012.292	http://dx.doi.org/10.1038/onc.2012.292			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22777359				2022-12-17	WOS:000317919900001
J	Liu, TJ; Sun, BC; Zhao, XL; Zhao, XM; Sun, T; Gu, Q; Yao, Z; Dong, XY; Zhao, N; Liu, N				Liu, T. J.; Sun, B. C.; Zhao, X. L.; Zhao, X. M.; Sun, T.; Gu, Q.; Yao, Z.; Dong, X. Y.; Zhao, N.; Liu, N.			CD133(+) cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer	ONCOGENE			English	Article						cancer stem cells; vasculogenic mimicry; triple-negative breast cancer	FUNCTIONAL-SIGNIFICANCE; HEPATOCELLULAR-CARCINOMA; EXPRESSION; VASCULARIZATION; CD44(+)/CD24(-); IDENTIFICATION; MARKER	Vasculogenic mimicry (VM) refers to the unique capability of aggressive tumor cells to mimic the pattern of embryonic vasculogenic networks. In the study we demonstrated that CD133 expression was the highest in triple-negative (TN) breast cancer specimens. Importantly, VM showed statistical correlation with CD133(+) expression. The presence of the close relationship between VM and CD133(+) expression might be central for TN tumor relapse and progression. The TN breast cancer cell line, MDA-MB-231 cells developed a range of colony morphologies paralleling the holoclone, meroclone and paraclone morphologies produced by normal keratinocytes and other epithelial cancer cell lines when plated at clonal densities. Holoclone cells were capable of forming more colonies on soft agar than meroclone cells and paraclone cells, suggesting that holoclone cells had higher self-renew potential and might harbors cancer stem cells (CSCs) subpopulation. Strikingly, it was holoclone that displayed CD133(+) phenotype and formed VM. In addition, holoclone acquired endothelial cell marker vascular endothelial-cadherin expression and upregulated VM mediators matrix nnetalloproteinase (MMP)-2 and MMP-9 expression. The subpopulation with holoclone morphology, CD133(+) phenotype and CSCs characteristics might have the capacity of transdifferentiation and contributed to VM in TN breast cancer. The related molecular pathways may be used as novel therapeutic targets for the inhibition of angiogenesis and metastasis in TN breast carcinoma. Oncogene (2013) 32, 544-553; doi:10.1038/onc.2012.85; published online 2 April 2012	[Liu, T. J.; Sun, B. C.; Zhao, X. L.; Zhao, X. M.; Sun, T.; Gu, Q.; Yao, Z.; Dong, X. Y.; Zhao, N.; Liu, N.] Tianjin Med Univ, Dept Pathol, Tianjin 300070, Peoples R China; [Sun, B. C.] Tianjin Med Univ, Tianjin Canc Hosp, Dept Pathol, Tianjin 300070, Peoples R China; [Liu, T. J.; Sun, B. C.; Zhao, X. L.; Gu, Q.] Tianjin Med Univ, Tianjin Gen Hosp, Dept Pathol, Tianjin 300070, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Sun, BC (corresponding author), Tianjin Med Univ, Dept Pathol, Tianjin 300070, Peoples R China.	sunbaocun@yahoo.com.cn	liu, tieju/AAU-2050-2020		National Natural Science Foundation of China [30830049, 81172046, 81173091]; International Cooperation project of China-Sweden [09ZCZDSF04400]; Ministry of Science and Technology of China [2009CB918903]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Cooperation project of China-Sweden; Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was partly supported by a Grant from Key project of the National Natural Science Foundation of China (No. 30830049), the International Cooperation project of China-Sweden (No. 09ZCZDSF04400), the National Natural Science Foundation of China (No. 81172046 and No. 81173091) and the 973 Program from the Ministry of Science and Technology of China (No. 2009CB918903).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chen LX, 2011, CANCER BIOL THER, V11, P229, DOI 10.4161/cbt.11.2.13842; Dean M, 2006, MOL INTERV, V6, P140, DOI 10.1124/mi.6.3.5; Dong J, 2011, STEM CELL REV REP, V7, P141, DOI 10.1007/s12015-010-9169-7; Eaton CL, 2010, PROSTATE, V70, P875, DOI 10.1002/pros.21121; Florek M, 2005, CELL TISSUE RES, V319, P15, DOI 10.1007/s00441-004-1018-z; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Immervoll H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-48; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Liu WB, 2011, MED ONCOL, V28, pS228, DOI 10.1007/s12032-010-9706-x; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; Monzani E, 2008, STEM CELL REV, V4, P51, DOI 10.1007/s12015-008-9009-1; Ping YF, 2011, CURR MOL MED, V11, P69, DOI 10.2174/156652411794474383; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Shen RL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001652; Shevde LA, 2010, J CELL MOL MED, V14, P1693, DOI 10.1111/j.1582-4934.2009.00821.x; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Wang JY, 2008, CANCER BIOL THER, V7, P758, DOI 10.4161/cbt.7.5.5765; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yan XW, 2011, P NATL ACAD SCI USA, V108, P1591, DOI 10.1073/pnas.1018696108; Yeh CT, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-324; Zhang KX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-319; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhong XF, 2007, INT J CANCER, V121, P2125, DOI 10.1002/ijc.22880	29	189	211	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					544	553		10.1038/onc.2012.85	http://dx.doi.org/10.1038/onc.2012.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22469978				2022-12-17	WOS:000316164700002
J	Mudduluru, G; Ceppi, P; Kumarswamy, R; Scagliotti, GV; Papotti, M; Allgayer, H				Mudduluru, G.; Ceppi, P.; Kumarswamy, R.; Scagliotti, G. V.; Papotti, M.; Allgayer, H.			Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer	ONCOGENE			English	Article						non-small cell lung cancer; breast cancer; colorectal cancer; Axl; microRNA	VASCULAR SMOOTH-MUSCLE; TUMOR-SUPPRESSOR GENES; DNA METHYLATION; CPG METHYLATION; GAS6; CELLS; APOPTOSIS; METASTASIS; MICRORNAS; SURVIVAL	Axl is a receptor that induces proliferation, migration and invasion in cancer. In this study, we show that specific microRNAs (miRNAs) target the 3'-UTR of Axl. Luciferase-reporter assays with wild-type and deleted miR-34 and miR-199a/b seed sequences of Axl 3'-UTR confirmed the specificity of targeting. An inverse correlation between Axl protein and miR-34a expression in a panel of non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BRC) cell lines was observed, while miR-199a/b expression was completely suppressed. Pre-miR transfection inhibited in vitro migration and invasion and, in vivo, reduced the number of distant lung-or liver-metastases in a chorion-allantoic-membrane (CAM) assay. Moreover, methylation-specific PCR on bisulfite-converted DNA obtained from the cell lines showed that the miR-34a promoter methylation status was inversely correlated with its expression, and that miR-199a/b promoter regions were methylated in all cells tested. In a panel of NSCLC tissues (n = 44), miR-34a and miR-199a/b were found to be downregulated and significantly co-expressed. A lower expression of all three miRs was significantly associated with squamous histo-types, and, in a preliminary series, NSCLC patients with miR-34a upregulation showed a positive association towards a longer survival. These results indicate that Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells. Oncogene (2011) 30, 2888-2899; doi:10.1038/onc.2011.13; published online 14 February 2011	[Allgayer, H.] Univ Heidelberg, Dept Expt Surg Mol Oncol Solid Tumors, Collaborat Unit German Canc Res Ctr DKFZ Heidelbe, Med Fac Mannheim, D-68167 Mannheim, Germany; [Mudduluru, G.; Ceppi, P.; Kumarswamy, R.; Allgayer, H.] German Canc Res Ctr DKFZ Heidelberg, Mannheim, Germany; [Ceppi, P.; Scagliotti, G. V.; Papotti, M.] Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Orbassano, Italy	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Turin	Allgayer, H (corresponding author), Univ Heidelberg, Dept Expt Surg Mol Oncol Solid Tumors, Collaborat Unit German Canc Res Ctr DKFZ Heidelbe, Med Fac Mannheim, D-68167 Mannheim, Germany.	heike.allgayer@umm.de	Kumarswamy, Regalla/AAC-5766-2019; Ceppi, Paolo/GPS-8668-2022	Ceppi, Paolo/0000-0002-3632-8476; Scagliotti, Giorgio/0000-0001-6646-958X	Alfried Krupp von Bohlen und Halbach Foundation, Essen; Hella-Buhler-Foundation, Heidelberg; Dr Ingrid zu Solms Foundation, Frankfurt/Main; Hector Foundation, Weinheim, Germany; FRONTIER Excellence Initiative of the University of Heidelberg; BMBF, Bonn, Germany; Walter Schulz Foundation, Munich, Germany	Alfried Krupp von Bohlen und Halbach Foundation, Essen; Hella-Buhler-Foundation, Heidelberg; Dr Ingrid zu Solms Foundation, Frankfurt/Main; Hector Foundation, Weinheim, Germany; FRONTIER Excellence Initiative of the University of Heidelberg; BMBF, Bonn, Germany(Federal Ministry of Education & Research (BMBF)); Walter Schulz Foundation, Munich, Germany	HA was supported by Alfried Krupp von Bohlen und Halbach Foundation, Essen, Hella-Buhler-Foundation, Heidelberg, Dr Ingrid zu Solms Foundation, Frankfurt/Main, Hector Foundation, Weinheim, Germany, FRONTIER Excellence Initiative of the University of Heidelberg, the BMBF, Bonn, Germany, and Walter Schulz Foundation, Munich, Germany. We thank Erika Hillerich and Laura Nelson for excellent help and critical appraisal of the manuscript.	Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Budagian V, 2005, MOL CELL BIOL, V25, P9324, DOI 10.1128/MCB.25.21.9324-9339.2005; Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Erson AE, 2008, CLIN GENET, V74, P296, DOI 10.1111/j.1399-0004.2008.01076.x; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Garzia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004998; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; Melaragno MG, 2004, J MOL CELL CARDIOL, V37, P881, DOI 10.1016/j.yjmcc.2004.06.018; Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Valeri N, 2009, MAMM GENOME, V20, P573, DOI 10.1007/s00335-009-9206-5; van Ginkel PR, 2004, CANCER RES, V64, P128, DOI 10.1158/0008-5472.CAN-03-0245; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yeligar S, 2009, J IMMUNOL, V183, P5232, DOI 10.4049/jimmunol.0901084; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006	45	189	201	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	25					2888	2899		10.1038/onc.2011.13	http://dx.doi.org/10.1038/onc.2011.13			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317930				2022-12-17	WOS:000291977800008
J	Kaler, P; Augenlicht, L; Klampfer, L				Kaler, P.; Augenlicht, L.; Klampfer, L.			Macrophage-derived IL-1 beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D-3	ONCOGENE			English	Article						Wnt; IL-1; colon cancer; STAT1; macrophages; vitamin D	TUMOR-ASSOCIATED MACROPHAGES; NF-KAPPA-B; BETA-CATENIN; COLORECTAL-CANCER; ACTIVATED MACROPHAGES; D-RECEPTOR; INHIBITION; EXPRESSION; MICROENVIRONMENT; TRANSCRIPTION	Tumor-associated macrophages mediate the link between inflammation and cancer progression. Here, we showed that macrophage-derived soluble factors induce canonical Wnt signaling in colon cancer cells and promote their growth. Tumor cells induced the release of interleukin (IL)-1 beta from macrophages, which induced phosphorylation of GSK3 beta, stabilized beta-catenin, enhanced T-cell factor (TCF)-dependent gene activation and induced the expression of Wnt target genes in tumor cells. Neutralization experiments using anti-IL-1 beta-specific antibodies, or silencing of IL-1 beta in THP1 macrophages, showed that IL-1 beta was required for macrophages to induce Wnt signaling and to support the growth of tumor cells. Constitutive activation of signal transducer and activator of transcription (STAT) 1 in THP1 macrophages was essential for the induction of IL-1 beta and thus for the activation of beta-catenin signaling in tumor cells. Vitamin D-3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1 beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells. Our data therefore established that vitamin D-3 exerts its chemopreventive activity by interrupting a crosstalk between tumor epithelial cells and the tumor microenvironment. Oncogene (2009) 28, 3892-3902; doi:10.1038/onc.2009.247; published online 24 August 2009	[Kaler, P.; Augenlicht, L.; Klampfer, L.] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Med, 111 E 210th St,Room 316, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NCI [CA 111361, U54 CA 100926, P30-13330]; NATIONAL CANCER INSTITUTE [U54CA100926, R01CA111361] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Paolo Norio for reading the paper. This work was supported by CA 111361 (to LK), U54 CA 100926 (to LA) and P30-13330 from NCI.	Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Biswas SK, 2006, BLOOD, V107, P2112, DOI 10.1182/blood-2005-01-0428; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Etoh T, 2000, CLIN CANCER RES, V6, P3545; Fichera A, 2007, J SURG RES, V142, P239, DOI 10.1016/j.jss.2007.02.038; Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073; GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140-6736(89)91789-3; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; Gunter MJ, 2006, CANCER EPIDEM BIOMAR, V15, P1126, DOI 10.1158/1055-9965.EPI-06-0042; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Kampman E, 2000, CANCER CAUSE CONTROL, V11, P459, DOI 10.1023/A:1008914108739; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Klampfer L, 2005, ONCOGENE, V24, P3932, DOI 10.1038/sj.onc.1208552; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Klampfer L, 2007, CANCER RES, V67, P8477, DOI 10.1158/0008-5472.CAN-07-0210; Kumagai T, 2003, J NATL CANCER I, V95, P896, DOI 10.1093/jnci/95.12.896; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Lee C, 2006, MOL PHARMACOL, V69, P1041, DOI 10.1124/mol.105.018481; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lipkin M, 2006, J MED FOOD, V9, P135, DOI 10.1089/jmf.2006.9.135; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; NEWMARK HL, 1992, CANCER RES, V52, pS2067; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Oosterling SJ, 2005, J PATHOL, V207, P147, DOI 10.1002/path.1830; Oyama T, 2008, CARCINOGENESIS, V29, P666, DOI 10.1093/carcin/bgn001; Pai R, 2008, CANCER RES, V68, P5086, DOI 10.1158/0008-5472.CAN-07-2325; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pendas-Franco N, 2008, ANTICANCER RES, V28, P2613; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Rasola A, 2007, ONCOGENE, V26, P1078, DOI 10.1038/sj.onc.1209859; Robsahm TE, 2004, CANCER CAUSE CONTROL, V15, P149, DOI 10.1023/B:CACO.0000019494.34403.09; Shah S, 2006, MOL CELL, V21, P799, DOI 10.1016/j.molcel.2006.01.037; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SIZIOPIKOU KP, 1991, CANCER, V68, P1035, DOI 10.1002/1097-0142(19910901)68:5<1035::AID-CNCR2820680522>3.0.CO;2-D; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036	51	189	196	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3892	3902		10.1038/onc.2009.247	http://dx.doi.org/10.1038/onc.2009.247			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19701245	Green Accepted			2022-12-17	WOS:000271471900004
J	Hirsch, FR; Varella-Garcia, M; Cappuzzo, F				Hirsch, F. R.; Varella-Garcia, M.; Cappuzzo, F.			Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer	ONCOGENE			English	Review						non-small-cell lung cancer; EGFR; HER2; biomarker; EGFR TKI	GROWTH-FACTOR-RECEPTOR; GENE COPY NUMBER; MOLECULAR PREDICTORS; GEFITINIB THERAPY; EXPRESSION; MUTATIONS; SENSITIVITY; ERLOTINIB; PROTEIN; RESPONSIVENESS	Epidermal growth factor receptor (EGFR) and HER2 are cell surface receptor tyrosine kinases (TKs) that transduce growth signals through dimerization with HER family receptors. The heterodimerization of EGFR with HER2 induces a more potent activation of EGFR TK than does EGFR homodimerization. When tumor cells overexpress both EGFR and HER2, they exhibit aggressive tumor cell growth, owing to the increased potential for EGFR/HER2 heterodimerization and signaling. Gefitinib and erlotinib are EGFR TK inhibitors (EGFR TKIs) and have antitumor activity in 8-18% of patients with advanced non-small-cell lung cancer (NSCLC). Certain patient subsets are particularly responsive to EGFR TKIs. Analyses of biomarkers from patients in clinical studies of EGFR TKIs show correlations between objective tumor response and EGFR overexpression, as detected by immunohistochemistry and increased gene copy number measured by fluorescence in situ hybridization analysis. Furthermore, NSCLC tumors that overexpress both EGFR and HER2 are more sensitive to EGFR TKIs than are tumors that overexpress EGFR but are HER2 negative. Therefore, the measurement of EGFR and HER2 protein expression and the gene copy number in NSCLC tumors may have a prognostic value in NSCLC and a predictive value for identifying patients likely to benefit from an EGFR TKI. These considerations suggest that the simultaneous inhibition of EGFR and HER2 may warrant further study in patients with NSCLC. Oncogene (2009) 28, S32-S37; doi:10.1038/onc.2009.199	[Hirsch, F. R.; Varella-Garcia, M.] Univ Colorado, Ctr Canc, Aurora, CO 80045 USA; [Cappuzzo, F.] IRCCS, Ist Clin Humanitas, Rozzano, Italy	University of Colorado System; University of Colorado Anschutz Medical Campus; IRCCS Humanitas Research Hospital	Hirsch, FR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, MS 8117,POB 6511, Aurora, CO 80045 USA.	fred.hirsch@uchsc.edu	Cappuzzo, federico/R-2827-2016	Cappuzzo, federico/0000-0002-6295-6767	Boehringer Ingelheim Pharmaceuticals	Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim)	The authors thank Johnathan C Maher, PhD, of BlueSpark Heathcare Communications for medical and editorial assistance in this paper. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals.	Brabender J, 2001, CLIN CANCER RES, V7, P1850; Cappuzzo F, 2005, J CLIN ONCOL, V23, P5007, DOI 10.1200/JCO.2005.09.111; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cappuzzo F, 2007, J CLIN ONCOL, V25, P2248, DOI 10.1200/JCO.2006.09.4300; Daniele L, 2007, MOL CANCER THER, V6, P1223, DOI 10.1158/1535-7163.MCT-06-0719; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HERBST RS, 2007, 43 ANN M AM SOC CLIN; Hirsch FR, 2007, ANN ONCOL, V18, P752, DOI 10.1093/annonc/mdm003; Hirsch FR, 2005, J CLIN ONCOL, V23, P6838, DOI 10.1200/JCO.2005.01.2823; Hirsch FR, 2002, SEMIN ONCOL, V29, P51, DOI 10.1053/sonc.2002.31523; Hirsch FR, 2008, J CLIN ONCOL, V26, P3351, DOI 10.1200/JCO.2007.14.0111; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Meert AP, 2002, EUR RESPIR J, V20, P975, DOI 10.1183/09031936.02.00296502; Merrick DT, 2006, CLIN CANCER RES, V12, P2281, DOI 10.1158/1078-0432.CCR-05-2291; Onn A, 2004, CLIN CANCER RES, V10, P136, DOI 10.1158/1078-0432.CCR-0373-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; PIRKER R, 2008, J CLIN ONCOL S, V26, pS1006; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Soh J, 2007, INT J CANCER, V121, P1162, DOI 10.1002/ijc.22818; Tokumo M, 2005, CLIN CANCER RES, V11, P1167; Tsai CM, 1996, CANCER RES, V56, P206; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	29	189	200	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S32	S37		10.1038/onc.2009.199	http://dx.doi.org/10.1038/onc.2009.199			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680294				2022-12-17	WOS:000269515400005
J	Wang, XH; Ling, MT; Guan, XY; Tsao, SW; Cheung, HW; Lee, DT; Wong, YC				Wang, XH; Ling, MT; Guan, XY; Tsao, SW; Cheung, HW; Lee, DT; Wong, YC			Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells	ONCOGENE			English	Article						TWIST; taxol; cancer; resistance	SAETHRE-CHOTZEN-SYNDROME; HELIX TRANSCRIPTION FACTOR; CARCINOMA-CELLS; PROSTATE-CANCER; BCL-2 PHOSPHORYLATION; ALTERED EXPRESSION; SIGNALING PATHWAY; HUMAN OVARIAN; TUMOR-CELLS; PACLITAXEL	Taxol is one of the widely used chemotherapeutic drugs against many types of human cancer. While it is considered as one of the most effective anticancer drugs, treatment failure often occurs due to development of acquired resistance. Therefore, it is important to understand the molecular mechanisms responsible for the development of drug resistance. Although it is generally believed that taxol induces cell death through interfering with microtubules leading to mitotic arrest, recent evidence has suggested that taxol-induced cell death also occurs through pathways independent of either microtubule or mitotic arrest. In this study, we report the identification of a novel role for TWIST, a basic helix-loop-helix protein, which plays a central role in cell type determination and differentiation, during generation of acquired resistance to taxol in a nasopharyngeal carcinoma cell line, HNE1-T3, using comparative genome hybridization (CGH) and subsequent RT-PCR and Western blotting. We found that upregulation of TWIST was associated with cellular resistance to taxol but not other drugs with different mechanisms of action. The fact that increased TWIST protein levels were also associated with another microtubule-targeting anticancer drug, vincristine, in four types of human cancer including nasopharyngeal, bladder, ovarian and prostate, indicates that it may play a central role in the resistance to microtubule-disrupting agents. In addition, ectopic expression of TWIST into human cancer cells also led to increased resistance to both taxol and vincristine. Our results indicate a novel mechanism that leads to resistance to microtubule-disrupting anticancer drugs through upregulation of TWIST. Our evidence provides a therapeutic strategy to overcome acquired resistance through inactivation of TWIST expression in human cancer.	Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Clin Oncol, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wang, XH (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, 1-F,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk	Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; ElGhouzzi V, 1997, NAT GENET, V15, P42; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gu SU, 1983, CHINESE J CANCER, V2, P70; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Haldar S, 1996, CANCER RES, V56, P1253; Hjiantoniou E, 2003, BIOCHEM BIOPH RES CO, V300, P178, DOI 10.1016/S0006-291X(02)02804-8; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Huang Y, 2000, CANCER RES, V60, P4426; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LIN CT, 1990, LAB INVEST, V62, P713; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Ling MT, 2001, J ENDOCRINOL, V170, P287, DOI 10.1677/joe.0.1700287; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pajer P, 2003, ONCOGENE, V22, P665, DOI 10.1038/sj.onc.1206105; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Urakami S, 2002, J UROLOGY, V168, P2444, DOI 10.1016/S0022-5347(05)64164-X; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2003, ONCOGENE, V22, P109, DOI 10.1038/sj.onc.1206069; Yousfi M, 2002, HUM MOL GENET, V11, P359, DOI 10.1093/hmg/11.4.359	36	189	206	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					474	482		10.1038/sj.onc.1207128	http://dx.doi.org/10.1038/sj.onc.1207128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724576				2022-12-17	WOS:000188098300018
J	Moreno-Bueno, G; Hardisson, D; Sanchez, C; Sarrio, D; Cassia, R; Garcia-Rostan, G; Prat, J; Guo, MZ; Herman, JG; Matias-Guiu, X; Esteller, M; Palacios, J				Moreno-Bueno, G; Hardisson, D; Sanchez, C; Sarrio, D; Cassia, R; Garcia-Rostan, G; Prat, J; Guo, MZ; Herman, JG; Matias-Guiu, X; Esteller, M; Palacios, J			Abnormalities of the APC/beta-catenin pathway in endometrial cancer	ONCOGENE			English	Article						endometrial cancer; APC promoter hypermethylation; beta catenin mutations; gamma-catenin; AXIN1; AXIN2	MONONUCLEOTIDE REPEAT MICROSATELLITES; ABERRANT NUCLEAR EXPRESSION; BETA-CATENIN; PROMOTER HYPERMETHYLATION; OVARIAN CARCINOMAS; GAMMA-CATENIN; COLORECTAL-CANCER; CLINICOPATHOLOGICAL FEATURES; MUTATIONAL ANALYSIS; TUMOR-SUPPRESSOR	The activation of the APC/beta-catenin signalling pathway due to beta-catenin mutations has been implicated in the development of a subset of endometrial carcinomas (ECs). However, up to 25% of ECs have beta-catenin nuclear accumulation without evidence of beta-catenin mutations, suggesting alterations of other molecules that can modulate the Wnt pathway, such as APC, gamma-catenin, AXIN1 and AXIN2. We investigated the expression pattern of beta- and gamma-catenin in a group of 128 endometrial carcinomas, including 95 endometrioid endometrial carcinomas (EECs) and 33 non-endometrioid endometrial carcinomas (NEECs). In addition, we evaluated the presence of loss of heterozygosity and promoter hypermethylation of the APC gene and mutations in the APC, beta- and gamma-catenin, AXIN1, AXIN2, and RAS genes, and phospho-Akt expression. No APC mutations were detected but LOH at the APC locus was found in 24.3% of informative cases. APC promoter 1A hypermethylation was observed in 46.6% of ECs, and was associated with the endometrioid phenotype (P=0.034) and microsatellite instability (P=0.008). Neither LOH nor promoter hypermethylation of APC was associated with nuclear catenin expression. Nuclear beta-catenin expression was found in 31.2% of EECs and 3% of NEECs (P=0.002), and was significantly associated with beta-catenin gene exon 3 mutations (P<0.0001). beta-catenin gene exon 3 mutations were associated with the endometrioid phenotype, and were detected in 14 (14.9%) EECs, but in none of the NEECs (P = 0.02). gamma-catenin nuclear expression was found in 10 ECs; it was not associated with the histological type but was associated with more advanced stages (P=0.042). No mutations in gamma-catenin, AXIN1 and 2 genes were detected in this series. Neither RAS mutations nor phospho-Akt expression, which were found in 16 and 27.6% of the cases, respectively, were associated with beta-catenin nuclear expression. Our results demonstrated a high prevalence of alterations in molecules of the APC/beta-catenin pathway, but only mutations in beta-catenin gene are associated with aberrant nuclear localization of beta-catenin.	Ctr Nacl Invest Oncol, CNIO, Lab Breast & Gynaecol Canc, Mol Pathol Programme, Madrid 28029, Spain; Hosp Univ La Paz, Dept Pathol, Madrid 28029, Spain; Hosp Santa Cruz & San Pablo, Dept Pathol, E-08025 Barcelona, Spain; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Hosp Univ Arnau Vilanova, Serv Pathol, Lleida 25198, Spain; Ctr Nacl Invest Oncol, CNIO, Lab Canc Epigenet, Mol Pathol Programme, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Johns Hopkins University; Johns Hopkins Medicine; University Hospital Arnau de Vilanova; Centro Nacional de Investigaciones Oncologicas (CNIO)	Palacios, J (corresponding author), Ctr Nacl Invest Oncol, CNIO, Lab Breast & Gynaecol Canc, Mol Pathol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.		matias-guiu, xavier/C-3039-2009; Rostan, Ginesa Maria Garcia -/B-6062-2008; Palacios, Jose/AAV-3765-2020; Moreno-Bueno, Gema/K-9354-2016; Rostan, Ginesa Garcia/E-4093-2018; Hardisson, David/E-2832-2010; Esteller, Manel/L-5956-2014; Corominas, Joan Prat/C-6420-2011; Hardisson, David/AAN-3833-2020; Prat, Jaime/G-4679-2011; SARRIO, DAVID/Y-8903-2019; Hardisson, David/A-6259-2011	matias-guiu, xavier/0000-0002-7201-6605; Moreno-Bueno, Gema/0000-0002-5030-6687; Rostan, Ginesa Garcia/0000-0002-9238-1263; Hardisson, David/0000-0002-2183-3699; Esteller, Manel/0000-0003-4490-6093; Sarrio, David/0000-0003-4886-8290				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bailey T, 1998, AM J PATHOL, V152, P135; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boland CR, 1998, CANCER RES, V58, P5248; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Dahmen RP, 2001, CANCER RES, V61, P7039; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dong SM, 2001, CLIN CANCER RES, V7, P1982; Duval A, 1999, ONCOGENE, V18, P6806, DOI 10.1038/sj.onc.1203287; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FUJINO T, 1994, CANCER RES, V54, P4294; Fukuchi T, 1998, CANCER RES, V58, P3526; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda T, 2000, ONCOL REP, V7, P323; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; JONES MH, 1994, GENE CHROMOSOME CANC, V9, P119, DOI 10.1002/gcc.2870090207; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Kolligs FT, 2000, GENE DEV, V14, P1319; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lin YM, 2000, J HUM GENET, V45, P254, DOI 10.1007/s100380070036; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Moreno-Bueno G, 2001, DIAGN MOL PATHOL, V10, P116, DOI 10.1097/00019606-200106000-00008; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Palacios J, 1998, CANCER RES, V58, P1344; Palacios J, 2001, VIRCHOWS ARCH, V438, P464, DOI 10.1007/s004280000371; Perucho M, 1999, CANCER RES, V59, P249; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Saegusa M, 2001, BRIT J CANCER, V84, P209, DOI 10.1054/bjoc.2000.1581; Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Satyamoorthy K, 2001, CANCER RES, V61, P7318; SCHOSSHAUER PW, 2000, MODERN PATHOL, V13, P1066; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Sparks AB, 1998, CANCER RES, V58, P1130; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Valizadeh A, 1997, AM J PATHOL, V150, P1977; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Voeller HJ, 1998, CANCER RES, V58, P2520; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wu R, 2001, CANCER RES, V61, P8247; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4; Zysman M, 2002, CANCER RES, V62, P3663	63	189	193	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7981	7990		10.1038/sj.onc.1205924	http://dx.doi.org/10.1038/sj.onc.1205924			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439748				2022-12-17	WOS:000179097200007
J	Sudol, M				Sudol, M			From Src Homology domains to other signaling modules: proposal of the 'protein recognition code'	ONCOGENE			English	Review						protein modules; protein motifs; genetic code; phosphotyrosine; polyproline	INSULIN-RECEPTOR SUBSTRATE-1; YES-ASSOCIATED PROTEIN; PROLINE-RICH PEPTIDES; WW DOMAIN; SH3 DOMAINS; BINDING-SPECIFICITY; TYROSINE KINASES; STRUCTURAL BASIS; PHOSPHOLIPASE-C; PDZ DOMAINS	The study of oncogenes has illuminated many aspects of cellular signaling. The delineation and characterization of protein modules exemplified by Src Homology domains has revolutionized our understanding of the molecular events underlying signal transduction pathways. Several well characterized intracellular modules which mediate protein-protein interactions, namely SH2, SH3, PH, PTB, EH, PDZ, EVH1 and WW domains, are directly involved in the multitude of membrane, cytoplasmic and nuclear processes in multicellular and/or unicellular organisms. The modular character of these protein domains and their cognate motifs, the universality of their molecular function, their widespread occurrence, and the specificity as well as the degeneracy of their interactions have prompted us to propose the concept of the 'protein recognition code'. By a parallel analogy to the universal genetic code, we propose here that there will be a finite set of precise rules to govern and predict protein-protein interactions mediated by modules. Several rules of the 'protein recognition code' have already emerged.	CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem, 1 Gustave Levy Pl, New York, NY 10029 USA.							ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bork P, 1997, TRENDS BIOCHEM SCI, V22, P296, DOI 10.1016/S0968-0004(97)01084-0; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIM WA, 1994, STRUCT BIOL, V1, P221; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Niethammer M, 1996, J NEUROSCI, V16, P2157; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SIDDIQUI AS, 1995, PROTEIN SCI, V4, P872; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STICKER NL, 1997, NAT BIOTECHNOL, V15, P336; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	64	189	196	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1469	1474		10.1038/sj.onc.1202182	http://dx.doi.org/10.1038/sj.onc.1202182			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779993				2022-12-17	WOS:000076161900014
J	Seyfert, VL; Allman, D; He, YS; Staudt, LM				Seyfert, VL; Allman, D; He, YS; Staudt, LM			Transcriptional repression by the proto-oncogene BCL-6	ONCOGENE			English	Article						BCL-6; repression; lymphoma; POZ domain	GERMINAL-CENTERS; CONSERVED DOMAIN; GENE; DROSOPHILA; PROTEINS; IDENTIFICATION; TRANSLOCATIONS; EXPRESSION; ACTIVATORS; LYMPHOMAS	In up to 45% of reported cases of the non-Hodgkin's lymphoma, diffuse large cell lymphoma, there are translocations of the BCL-6 gene, which are presumed to deregulate its expression, The BCL-6 protein, which is unmutated in these lymphomas, contains six Kruppel-like zinc fingers at its carboxy terminus and a 121 amino acid domain at its amino terminus, termed the POZ domain, which bears homology with amino terminal domains in a subset zinc finger transcription factors, In this study, we tested whether BCL-6 regulates transcription and if the POZ domain has a role in this function. The BCL-6 POZ domain, when fused to the GAL4 DNA binding domain, strongly repressed transcriptional activation initiated from several different promoters including the SV40 enhancer/promoter. Repression was also observed when the fusion protein was bound at a distance of 200 bp 5' of the promoter, When the GAL4/BCL6 POZ domain fusion protein was expressed in yeast, it was able to homodimerize in the nucleus, Nevertheless, in contrast with mammalian cells, the fusion protein did not repress transcription, To test the ability of the full length BCl-6 protein to repress transcription when bound to DNA through its zinc finger DNA binding domain, high affinity BCL-6 binding sites were selected from a pool of random oligonucleotides. Full length BCL-6 was able to strongly repress transcription when bound to its cognate site cloned upstream of the thymidine kinase promoter, This repression was mediated, in large measure, by the POZ domain, although a variant of BCL-6 lacking the POZ domain was able to repress transcription modestly, The ability of BCL-6 to function as a transcriptional repressor may contribute to its ability to transform B lymphocytes in diffuse large cell lymphoma.	NCI,METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Staudt, Louis/AAC-5324-2019					Ausubel FM., 2006, ENZYMATIC MANIPULATI; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DALLERY E, 1995, ONCOGENE, V10, P2171; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAIDANO G, 1994, BLOOD, V84, P397; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, p3P66; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAGRATH IT, 1990, NONHODGKINS LYMPHOMA, P1; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIKI T, 1994, BLOOD, V83, P217; NAKAMURA Y, 1995, BRIT J HAEMATOL, V90, P404, DOI 10.1111/j.1365-2141.1995.tb05166.x; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; ROSE MD, 1990, METHODS YEAST GENETI; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; Sambrook J, 1989, MOL CLONING LAB MANU; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	47	189	193	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2331	2342						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649773				2022-12-17	WOS:A1996UQ22000010
J	KERN, SE; KINZLER, KW; BAKER, SJ; NIGRO, JM; ROTTER, V; LEVINE, AJ; FRIEDMAN, P; PRIVES, C; VOGELSTEIN, B				KERN, SE; KINZLER, KW; BAKER, SJ; NIGRO, JM; ROTTER, V; LEVINE, AJ; FRIEDMAN, P; PRIVES, C; VOGELSTEIN, B			MUTANT P53 PROTEINS BIND DNA ABNORMALLY INVITRO	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; TRANSFORMATION-RELATED PROTEIN; RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODY; LAC REPRESSOR; HOST PROTEIN; 3T3 CELLS; COS CELLS	The p53 gene encodes a phosphoprotein which binds DNA. Many types of tumors contain mutant p53 genes, but the effects of these mutations on the intrinsic properties of p53 are largely unknown. In the present study, we tested the effect of p53 mutations on DNA-binding. Each of 15 different mutant p53 gene products derived from human tumors or mouse transformants bound calf thymus DNA more weakly than did wild-type products. A significant subset of mutant proteins were also found to be underphosphorylated compared to the wild-type protein when produced in a reticulocyte lysate system, but this did not appear to explain the pattern of alterations of DNA-binding. The tested mutations were dispersed over several regions of the p53 gene and included representatives of all four of the evolutionarily conserved domains that are the known 'hot spots' for p53 mutation. The results suggest common pathways by which these various mutations affect the normal function of p53.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,424 N BOND ST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Princeton University; Columbia University			Baker, Suzanne J/N-8167-2018		NATIONAL CANCER INSTITUTE [R01CA043460, R37CA035494, T32CA009243, R37CA043460, R01CA035494] Funding Source: NIH RePORTER; NCI NIH HHS [CA09243, CA35494, CA43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MCCORMICK F, 1981, NATURE, V292, P62; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	51	189	201	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					131	136						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846954				2022-12-17	WOS:A1991EY03900018
J	Goldenson, B; Crispino, JD				Goldenson, B.; Crispino, J. D.			The aurora kinases in cell cycle and leukemia	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; SMALL-MOLECULE INHIBITOR; TUMOR-AMPLIFIED KINASE; CHROMOSOMAL PASSENGER PROTEIN; ACUTE MYELOGENOUS LEUKEMIA; BIPOLAR SPINDLE FORMATION; A KINASE; MITOTIC ENTRY; B-KINASE	The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and AURKB) and meiosis (AURKC). Since their discovery nearly 20 years ago, Aurora kinases have been studied extensively in cell and cancer biology. Several early studies found that Aurora kinases are amplified and overexpressed at the transcript and protein level in various malignancies, including several types of leukemia. These discoveries and others provided a rationale for the development of small-molecule inhibitors of Aurora kinases as leukemia therapies. The first generation of Aurora kinase inhibitors did not fare well in clinical trials, owing to poor efficacy and high toxicity. However, the creation of second-generation, highly selective Aurora kinase inhibitors has increased the enthusiasm for targeting these proteins in leukemia. This review will describe the functions of each Aurora kinase, summarize their involvement in leukemia and discuss inhibitor development and efficacy in leukemia clinical trials.	[Goldenson, B.; Crispino, J. D.] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA	Northwestern University	Crispino, JD (corresponding author), Northwestern Univ, Div Hematol Oncol, 303 East Super St,Lurie 5-113, Chicago, IL 60611 USA.	j-crispino@northwestern.edu		Goldenson, Benjamin/0000-0001-6724-7858; Crispino, John/0000-0002-8182-8306	NIH [R01s CA101774, HL112792]; Samuel Waxman Cancer Research Foundation; Leukemia and Lymphoma Society; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS) [TL1R000108]; NATIONAL CANCER INSTITUTE [R01CA101774] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112792] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We apologize to those whose work could not be discussed due to space limitations. This review was supported by grants from the NIH (R01s CA101774 and HL112792), the Samuel Waxman Cancer Research Foundation and the Leukemia and Lymphoma Society. BG is supported by the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Sciences (NCATS) (TL1R000108).	Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; Arlot-Bonnemains Y, 2001, FEBS LETT, V508, P149, DOI 10.1016/S0014-5793(01)03048-4; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BREITMAN TR, 1981, BLOOD, V57, P1000; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Cowley DO, 2009, MOL CELL BIOL, V29, P1059, DOI 10.1128/MCB.01062-08; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; de Rooij JDE, 2013, LEUKEMIA, V27, P2280, DOI 10.1038/leu.2013.87; Dennis M, 2012, CANCER CHEMOTH PHARM, V70, P461, DOI 10.1007/s00280-012-1939-2; Dieterich K, 2007, NAT GENET, V39, P661, DOI 10.1038/ng2027; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fei F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-42; Fernandez-Miranda G, 2011, DEVELOPMENT, V138, P2661, DOI 10.1242/dev.066381; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Fu JY, 2009, P NATL ACAD SCI USA, V106, P6939, DOI 10.1073/pnas.0900833106; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Geddis AE, 2004, BLOOD, V104, P1017, DOI 10.1182/blood-2004-02-0419; Geddis AE, 2007, CELL CYCLE, V6, P455, DOI 10.4161/cc.6.4.3836; Geddis AE, 2006, CELL CYCLE, V5, P538, DOI 10.4161/cc.5.5.2537; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goldberg SL, 2010, BLOOD, V6, P3273; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Graux C, 2013, LEUKEMIA RES, V37, P1100, DOI 10.1016/j.leukres.2013.04.025; Gruber TA, 2012, CANCER CELL, V22, P683, DOI 10.1016/j.ccr.2012.10.007; Gu J, 2007, CARCINOGENESIS, V28, P350, DOI 10.1093/carcin/bgl149; Hachet V, 2007, DEV CELL, V12, P531, DOI 10.1016/j.devcel.2007.02.015; Hans F, 2009, MOL BIOL CELL, V20, P3491, DOI 10.1091/mbc.E09-05-0370; Hartsink-Segers SA, 2013, LEUKEMIA, V27, P560, DOI 10.1038/leu.2012.256; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Hegarat N, 2011, J CELL BIOL, V195, P1103, DOI 10.1083/jcb.201105058; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Howard S, 2009, J MED CHEM, V52, P379, DOI 10.1021/jm800984v; Ikezoe T, 2007, MOL CANCER THER, V6, P1851, DOI 10.1158/1535-7163.MCT-07-0067; Jayanthan A, 2013, LEUKEMIA LYMPHOMA, V54, P1505, DOI 10.3109/10428194.2012.752079; Jelinek J, 2005, BLOOD, V106, P3370, DOI 10.1182/blood-2005-05-1800; Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323; Kantarjian HM, 2013, CANCER-AM CANCER SOC, V119, P2611, DOI 10.1002/cncr.28113; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152; Kelly KR, 2012, INT J CANCER, V131, P2693, DOI 10.1002/ijc.27579; Kelly KR, 2011, J CELL MOL MED, V15, P2057, DOI 10.1111/j.1582-4934.2010.01218.x; Khan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026512; Kimmins S, 2007, MOL ENDOCRINOL, V21, P726, DOI 10.1210/me.2006-0332; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kimura M, 1998, CYTOGENET CELL GENET, V82, P147, DOI 10.1159/000015089; Kimura M, 2004, BIOCHEM BIOPH RES CO, V316, P930, DOI 10.1016/j.bbrc.2004.01.178; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kiyoi H, 2007, LEUKEMIA, V21, P574, DOI 10.1038/sj.leu.2404527; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Krystyniak A, 2006, ONCOGENE, V25, P338, DOI 10.1038/sj.onc.1209056; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Leow S, 2011, HEMATOL ONCOL, V29, P211, DOI 10.1002/hon.987; Li QY, 2004, J BIOL CHEM, V279, P52175, DOI 10.1074/jbc.M406802200; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Liu Q, 2006, P NATL ACAD SCI USA, V103, P5811, DOI 10.1073/pnas.0601425103; Lordier L, 2008, BLOOD, V112, P3164, DOI 10.1182/blood-2008-03-144956; Lordier L, 2010, BLOOD, V116, P2345, DOI 10.1182/blood-2010-01-265785; Lowenberg B, 2011, BLOOD, V118, P6030, DOI 10.1182/blood-2011-07-366930; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Malinge S, 2008, BLOOD, V112, P4220, DOI 10.1182/blood-2008-01-136366; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2007, CANCER CELL, V11, P161, DOI 10.1016/j.ccr.2006.11.025; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Mercher T, 2009, J CLIN INVEST, V119, P852, DOI 10.1172/JCI35901; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Mita M, 2013, TARGET ONCOL; Mori D, 2007, MOL CELL BIOL, V27, P352, DOI 10.1128/MCB.00878-06; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nair JS, 2012, CELL CYCLE, V11, P807, DOI 10.4161/cc.11.4.19323; Nguyen HG, 2009, FASEB J, V23, P2741, DOI 10.1096/fj.09-130963; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nikolaev SI, 2013, BLOOD, V122, P554, DOI 10.1182/blood-2013-03-491936; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Okabe S, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-32; Oke A, 2009, CANCER RES, V69, P4150, DOI 10.1158/0008-5472.CAN-08-3203; Ota T, 2002, CANCER RES, V62, P5168; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Petretti C, 2006, EMBO REP, V7, P418, DOI 10.1038/sj.embor.7400639; Portier N, 2007, DEV CELL, V12, P515, DOI 10.1016/j.devcel.2007.01.019; Qi WQ, 2012, INT J CANCER, V130, P2997, DOI 10.1002/ijc.26324; Radtke I, 2009, P NATL ACAD SCI USA, V106, P12944, DOI 10.1073/pnas.0903142106; Raymond E, 2014, INVEST NEW DRUG, V32, P94, DOI 10.1007/s10637-013-9950-y; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039; Satinover DL, 2006, CELL CYCLE, V5, P2268, DOI 10.4161/cc.5.19.3316; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shah M, 2012, BLOOD CELL MOL DIS, V48, P199, DOI 10.1016/j.bcmd.2012.01.005; Shu FJ, 2003, MOL CELL BIOCHEM, V254, P157, DOI 10.1023/A:1027317014159; Steensma DP, 2006, LEUKEMIA, V20, P971, DOI 10.1038/sj.leu.2404206; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Stewart S, 2005, CANCER RES, V65, P8730, DOI 10.1158/0008-5472.CAN-05-1500; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; SUNKEL CE, 1988, J CELL SCI, V89, P25; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Tatsuka M, 2005, ONCOGENE, V24, P1122, DOI 10.1038/sj.onc.1208293; Terada Y, 2003, J CELL BIOL, V162, P757, DOI 10.1083/jcb.200305048; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Thiollier C, 2012, J EXP MED, V209, P2017, DOI 10.1084/jem.20121343; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tsou JH, 2011, J PATHOL, V225, P243, DOI 10.1002/path.2934; Tsuboi K, 2011, LEUKEMIA RES, V35, P1384, DOI 10.1016/j.leukres.2011.04.008; Vader G, 2008, BBA-REV CANCER, V1786, P60, DOI 10.1016/j.bbcan.2008.07.003; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; Vitrat N, 1998, BLOOD, V91, P3711; Walsby E, 2008, HAEMATOLOGICA, V93, P662, DOI 10.3324/haematol.12148; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wen Q, 2012, CELL, V150, P575, DOI 10.1016/j.cell.2012.06.032; Wen Q, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002043; Wysong DR, 2009, CELL CYCLE, V8, P876, DOI 10.4161/cc.8.6.7897; Yamauchi T, 2013, CANCER SCI, V104, P926, DOI 10.1111/cas.12164; Yan XM, 2005, GENES CELLS, V10, P617, DOI 10.1111/j.1365-2443.2005.00863.x; Yang J, 2007, BLOOD, V110, P2034, DOI 10.1182/blood-2007-02-073700; Yang J, 2013, INT J CANCER, V133, P2706, DOI 10.1002/ijc.28277; Ye Dongjiu, 2009, J Hematop, V2, P2, DOI 10.1007/s12308-008-0019-3; Yoon Y, 2012, DEV BIOL, V371, P77, DOI 10.1016/j.ydbio.2012.08.010; Yoshida K, 2013, NAT GENET; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Yuan HF, 2012, CARCINOGENESIS, V33, P285, DOI 10.1093/carcin/bgr278; Zekri A, 2012, ONCOL RES, V20, P241, DOI 10.3727/096504013X13589503482978; Zhang Y, 2004, BLOOD, V103, P3717, DOI 10.1182/blood-2003-09-3365; Zhang Y, 2001, BIOCHEM BIOPH RES CO, V282, P844, DOI 10.1006/bbrc.2001.4635; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	153	188	193	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					537	545		10.1038/onc.2014.14	http://dx.doi.org/10.1038/onc.2014.14			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24632603	Green Accepted			2022-12-17	WOS:000348853500001
J	Asiedu, MK; Beauchamp-Perez, FD; Ingle, JN; Behrens, MD; Radisky, DC; Knutson, KL				Asiedu, M. K.; Beauchamp-Perez, F. D.; Ingle, J. N.; Behrens, M. D.; Radisky, D. C.; Knutson, K. L.			AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells	ONCOGENE			English	Article						AXL; EMT; CSCs; BCSCs; tyrosine kinase	TYROSINE KINASE INHIBITOR; TUMOR-GROWTH; THERAPEUTIC TARGET; METASTASIS; EXPRESSION; PROGRESSION; ACTIVATION; INVASION; MP470	Despite significant progress in the treatment of breast cancer, particularly through the use of targeted therapy, relapse and chemoresistance remain a major hindrance to the fight to minimize the burden of the disease. It is becoming increasingly clear that a rare subpopulation of cells known as cancer stern cells (CSC), able to be generated through epithelial-to-mesenchymal transition (EMT) and capable of tumor initiation and self-renewal, contributes to treatment resistance and metastases. This means that a more effective therapy should target both the chemoresistant CSCs and the proliferating epithelial cells that give rise to them to reverse EMT and to attenuate their conversion to CSCs. Here, we demonstrate a novel function of AXL in acting upstream to induce EMT in normal and immortalized human mammary epithelial cells in an apparent positive feedback loop mechanism and regulate breast CSC (BCSC) self-renewal and chemoresistance. Downregulation of AXL using MP470 (Amuvatinib) reversed EMT in mesenchymal normal human mammary epithelial cells and murine BCSCs attenuating self-renewal and restored chemosensitivity of the BCSCs. AXL expression was also found to be associated with the expression of stem cell genes, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and migration. Inactivation of AXL also led to the downregulation of nuclear factor-kappa B pathway and reduced tumor formation in vivo. Taken together, our data suggest that targeted therapy against AXL, in combination with systemic therapies, has the potential to improve response to anticancer therapies and to reduce breast cancer recurrence and metastases.	[Asiedu, M. K.; Beauchamp-Perez, F. D.; Behrens, M. D.; Knutson, K. L.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA; [Ingle, J. N.] Mayo Clin, Coll Med, Dept Oncol, Rochester, MN 55905 USA; [Radisky, D. C.] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Asiedu, MK (corresponding author), Mayo Clin, Coll Med, 228 Med Sci Bldg,200 First St SW, Rochester, MN 55905 USA.	asiedu.michael@mayo.edu; knutson.keith@mayo.edu	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784	Martha; Bruce Atwater; Howard Temin Award [K01-CA100764, R01-CA122086]; Mayo Clinic Breast Cancer Specialized Program of Research Excellence Award [P50-CA116201]; NIH/NCRR CTSA [UL1 RR024150]; NATIONAL CANCER INSTITUTE [K01CA100764, P50CA116201, R01CA122086, P30CA015083] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024150] Funding Source: NIH RePORTER	Martha; Bruce Atwater; Howard Temin Award; Mayo Clinic Breast Cancer Specialized Program of Research Excellence Award; NIH/NCRR CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)NIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by a generous gift from Martha and Bruce Atwater (KLK); Howard Temin Award, K01-CA100764 (KLK); R01-CA122086 (DCR); and the Mayo Clinic Breast Cancer Specialized Program of Research Excellence Award, P50-CA116201 (JNI). This publication was also supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We acknowledge the strong support of the Mayo Clinic Comprehensive Cancer Center for providing access to core facilities.	Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bose R, 2006, P NATL ACAD SCI USA, V103, P9773, DOI 10.1073/pnas.0603948103; Chen WS, 2011, FRONT BIOSCI-LANDMRK, V16, P1172, DOI 10.2741/3782; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Gangemi R, 2009, CURR MED CHEM, V16, P1688, DOI 10.2174/092986709788186147; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; Han JS, 2009, INT J ONCOL, V34, P1449, DOI 10.3892/ijo_00000273; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Qi WQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-142; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shipitsin M, 2008, LAB INVEST, V88, P459, DOI 10.1038/labinvest.2008.14; Song X, CANCER, V117, P734; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; van Ginkel PR, 2004, CANCER RES, V64, P128, DOI 10.1158/0008-5472.CAN-03-0245; Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20; Vicente-Duenas C, 2010, DIS MODEL MECH, V3, P149, DOI 10.1242/dmm.002774; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Welsh JW, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-69; Wicha MS, 2006, CLIN CANCER RES, V12, P5606, DOI 10.1158/1078-0432.CCR-06-1537; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	47	188	192	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1316	1324		10.1038/onc.2013.57	http://dx.doi.org/10.1038/onc.2013.57			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474758	Green Accepted			2022-12-17	WOS:000332631100012
J	Wang, J; Tian, X; Han, R; Zhang, X; Wang, X; Shen, H; Xue, L; Liu, Y; Yan, X; Shen, J; Mannoor, K; Deepak, J; Donahue, JM; Stass, SA; Xing, L; Jiang, F				Wang, J.; Tian, X.; Han, R.; Zhang, X.; Wang, X.; Shen, H.; Xue, L.; Liu, Y.; Yan, X.; Shen, J.; Mannoor, K.; Deepak, J.; Donahue, J. M.; Stass, S. A.; Xing, L.; Jiang, F.			Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer	ONCOGENE			English	Article						miR-486-5p; tumor-suppressor gene; lung cancer; ARHGAP5; therapy	MICRORNA MARKERS; P190B RHOGAP; CELL; SUPPRESSOR; CARCINOMA; IDENTIFICATION; TUMORIGENESIS; ACTIVATION; BIOMARKERS; DIAGNOSIS	We have previously shown that miR-486-5p is one of the most downregulated micro RNAs in lung cancer. The objective of the study was to investigate the role of miR-486-5p in the progression and metastasis of non-small-cell lung cancer (NSCLC). We evaluated miR-486-5p expression status on 76 frozen and 33 formalin-fixed paraffin-embedded tissues of NSCLC by quantitative reverse transcriptase PCR to determine its clinicopathologic significance. We then performed function analysis of miR-486-5p to determine its potential roles on cancer cell migration and invasion in vitro and metastasis in vivo. We also investigated the target genes of miR-486-5p in lung tumorigenesis. miR-486-5p expression level was significantly lower in lung tumors compared with their corresponding normal tissues (P<0.0001), and associated with stage (P = 0.0001) and lymph node metastasis of NSCLC (P = 0.0019). Forced expression of miR-486-5p inhibited NSCLC cell migration and invasion in vitro and metastasis in mice by inhibiting cell proliferation. Furthermore, ectopic expression of miR-486-5p in cancer cells reduced ARHGAP5 expression level, whereas miR-486-5p silencing increased its expression. Luciferase assay demonstrated that miR-486-5p could directly bind to the 30-untranslated region of ARHGAP5. The expression level of miR-486-5p was inversely correlated with that of ARHGAP5 in lung tumor tissues (P = 0.0156). Reduced expression of ARHGAP5 considerably inhibited lung cancer cell migration and invasion, resembling that of miR-486-5p overexpression. miR-486-5p may act as a tumor-suppressor contributing to the progression and metastasis of NSCLC by targeting ARHGAP5. miR-486-5p would provide potential diagnostic and therapeutic targets for the disease.	[Wang, J.; Tian, X.; Han, R.; Shen, H.; Xue, L.; Yan, X.; Xing, L.] Hebei Med Univ, Dept Pathol, Shijiazhuang 050017, Peoples R China; [Zhang, X.] Hebei Med Univ, Hosp 2, Dept Pathol, Shijiazhuang 050017, Peoples R China; [Wang, X.; Liu, Y.] Hebei Med Univ, Tumor Hosp, Dept Pathol, Shijiazhuang 050017, Peoples R China; [Shen, J.; Mannoor, K.; Stass, S. A.; Jiang, F.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Deepak, J.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Donahue, J. M.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA	Hebei Medical University; Hebei Medical University; Hebei Medical University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Xing, L (corresponding author), Hebei Med Univ, Dept Pathol, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China.	xinglingxiao@hotmail.com; fjiang@som.umaryland.edu			National Natural Science Foundation of China [81101482]; Natural Science Foundation of Hebei province, China [C2011206001]; American Cancer Society-Research Scholar Grant in Basic, Preclinical, Clinical and Epidemiology Research [115154AF109040]; National Cancer Institute (NCI) [R01CA161837-01]; Maryland Stem Cell Research Fund; VA-Merit grant [I01 CX000512-01]; NATIONAL CANCER INSTITUTE [R01CA161837] Funding Source: NIH RePORTER; Veterans Affairs [I01CX000512] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hebei province, China(Natural Science Foundation of Hebei Province); American Cancer Society-Research Scholar Grant in Basic, Preclinical, Clinical and Epidemiology Research; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Maryland Stem Cell Research Fund; VA-Merit grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by Grants 81101482 from the National Natural Science Foundation of China and Grants C2011206001 from the Natural Science Foundation of Hebei province, China (to LX) and American Cancer Society-Research Scholar Grant in Basic, Preclinical, Clinical and Epidemiology Research-115154AF109040, National Cancer Institute (NCI)-R01CA161837-01, an exploratory research grant from the Maryland Stem Cell Research Fund, and VA-Merit grant-I01 CX000512-01 (to FJ).	Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bansal A, 2011, AM J GASTROENTEROL, V106, P1055, DOI 10.1038/ajg.2011.37; Chakravarty G, 2003, MOL ENDOCRINOL, V17, P1054, DOI 10.1210/me.2002-0428; Fan T, CANC RES; Feng J, 2004, NEOPLASIA, V6, P623, DOI 10.1593/neo.04142; Gao SM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-110; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gen Y, 2009, CANCER LETT, V275, P27, DOI 10.1016/j.canlet.2008.09.036; Heckman-Stoddard BM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2352; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P733, DOI 10.1023/B:CLIN.0000006815.49932.98; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; McHenry PR, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2643; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Midorikawa Y, 2009, HEPATOLOGY, V49, P513, DOI 10.1002/hep.22698; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Oh HK, 2011, CLIN CANCER RES, V17, P2657, DOI 10.1158/1078-0432.CCR-10-3152; Ragusa M, 2010, MOL CANCER THER, V9, P3396, DOI 10.1158/1535-7163.MCT-10-0137; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Shen J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-374; Small EM, 2010, P NATL ACAD SCI USA, V107, P4218, DOI 10.1073/pnas.1000300107; Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534-5807(02)00162-4; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Teng DHF, 1997, CANCER RES, V57, P5221; Wang HJ, 2005, INT J CANCER, V116, P285, DOI 10.1002/ijc.21035; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Xing LX, 2010, MODERN PATHOL, V23, P1157, DOI 10.1038/modpathol.2010.111; Yu L, 2010, INT J CANCER, V127, P2870, DOI 10.1002/ijc.25289	32	188	198	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1181	1189		10.1038/onc.2013.42	http://dx.doi.org/10.1038/onc.2013.42			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23474761	Green Accepted			2022-12-17	WOS:000331933800011
J	Zeller, C; Dai, W; Steele, NL; Siddiq, A; Walley, AJ; Wilhelm-Benartzi, CSM; Rizzo, S; van der Zee, A; Plumb, JA; Brown, R				Zeller, C.; Dai, W.; Steele, N. L.; Siddiq, A.; Walley, A. J.; Wilhelm-Benartzi, C. S. M.; Rizzo, S.; van der Zee, A.; Plumb, J. A.; Brown, R.			Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling	ONCOGENE			English	Article						drug resistance; cisplatin; DNA methylation; ovarian cancer; DNMTi; HDACi	HISTONE DEACETYLASE INHIBITION; DRUG-RESISTANCE; CPG ISLANDS; MISMATCH REPAIR; CELL-LINES; GENES; CHEMOTHERAPY; DEMETHYLATION; PROMOTER; STEM	Multiple DNA methylation changes in the cancer methylome are associated with the acquisition of drug resistance; however it remains uncertain how many represent critical DNA methylation drivers of chemoresistance. Using isogenic, cisplatin-sensitive/resistant ovarian cancer cell lines and inducing resensitizaton with demethylating agents, we aimed to identify consistent methylation and expression changes associated with chemoresistance. Using genome-wide DNA methylation profiling across 27 578 CpG sites, we identified loci at 4092 genes becoming hypermethylated in chemoresistant A2780/cp70 compared with the parental-sensitive A2780 cell line. Hypermethylation at gene promoter regions is often associated with transcriptional silencing; however, expression of only 245 of these hypermethylated genes becomes downregulated in A2780/cp70 as measured by microarray expression profiling. Treatment of A2780/cp70 with the demethylating agent 2-deoxy-5'-azacytidine induces resensitization to cisplatin and re-expression of 41 of the downregulated genes. A total of 13/41 genes were consistently hypermethylated in further independent cisplatin-resistant A2780 cell derivatives. CpG sites at 9 of the 13 genes (ARHGDIB, ARMCX2, COL1A, FLNA, FLNC, MEST, MLH1, NTS and PSMB9) acquired methylation in ovarian tumours at relapse following chemotherapy or chemoresistant cell lines derived at the time of patient relapse. Furthermore, 5/13 genes (ARMCX2, COL1A1, MDK, MEST and MLH1) acquired methylation in drug-resistant ovarian cancer-sustaining (side population) cells. MLH1 has a direct role in conferring cisplatin sensitivity when reintroduced into cells in vitro. This combined genomics approach has identified further potential key drivers of chemoresistance whose expression is silenced by DNA methylation that should be further evaluated as clinical biomarkers of drug resistance. Oncogene (2012) 31, 4567-4576; doi:10.1038/onc.2011.611; published online 16 January 2012	[Zeller, C.; Dai, W.; Wilhelm-Benartzi, C. S. M.; Brown, R.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London W12 0NN, England; [Steele, N. L.] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Siddiq, A.; Walley, A. J.] Hammersmith Hosp, Sch Publ Hlth, Dept Genom Common Dis, London, England; [Rizzo, S.; Brown, R.] Inst Canc Res, Med Sect, Sutton, Surrey, England; [van der Zee, A.] Univ Groningen, Dept Obstet & Gynecol, Univ Med Ctr Groningen, Groningen, Netherlands; [Plumb, J. A.] Univ Glasgow, Inst Canc Sci, Canc Res UK Beatson Labs, Glasgow, Lanark, Scotland	Imperial College London; Beatson Oncology Centre; Imperial College London; University of London; Institute of Cancer Research - UK; University of Groningen; Beatson Institute; University of Glasgow	Brown, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, Hammersmith Campus,IRDB 4th Floor, London W12 0NN, England.	b.brown@imperial.ac.uk	Walley, Andrew J/D-2573-2009; Dai, Wei/T-8889-2019	Walley, Andrew J/0000-0001-7707-7549; Dai, Wei/0000-0002-5558-0685; Wilhelm-Benartzi, Charlotte/0000-0003-4927-6158; Siddiq, Afshan/0000-0002-9110-1434; Brown, Robert/0000-0001-7960-5755	Cancer Research UK [C536/A6689]; Imperial Experimental Cancer Medicine Centre; Imperial Biomedical Research Centre; Ovarian Cancer Action; Cancer Research UK [13086] Funding Source: researchfish; Ovarian Cancer Action [OCA3] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Imperial Experimental Cancer Medicine Centre; Imperial Biomedical Research Centre; Ovarian Cancer Action(Ovarian Cancer Action); Cancer Research UK(Cancer Research UK); Ovarian Cancer Action(Ovarian Cancer Action)	We thank Lisa McMillan for her valuable contribution to the initial analysis of the Affymetrix expression data. We also thank Nahal Masrour for preparation of samples and Kerra Pearce for running the Infinium HumanMethylation450 BeadChips at the UCL Genomics Center, London. This work was supported by a Cancer Research UK (CZ, WD and RB) grant (C536/A6689), Imperial Experimental Cancer Medicine Centre, Imperial Biomedical Research Centre and Ovarian Cancer Action (SR and CSMWB).	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Anthoney DA, 1996, CANCER RES, V56, P1374; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Broxterman HJ, 2009, DRUG RESIST UPDATE, V12, P114, DOI 10.1016/j.drup.2009.07.001; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427; Dai W, 2011, CLIN CANCER RES, V17, P4052, DOI 10.1158/1078-0432.CCR-10-3021; Dai W, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-337; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Eckstein N, 2009, CANCER RES, V69, P2996, DOI 10.1158/0008-5472.CAN-08-3153; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jung H, 2011, BIOCHEM J, V436, P263, DOI 10.1042/BJ20101512; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/S0027-5107(01)00142-7; LANGDON SP, 1988, CANCER RES, V48, P6166; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183; Nakanishi H, 2004, ONCOL REP, V12, P1273; O'Brien V, 2006, CARCINOGENESIS, V27, P682, DOI 10.1093/carcin/bgi298; Ozols Robert F, 2004, J Natl Compr Canc Netw, V2 Suppl 2, pS60; Papouli E, 2004, CANCER RES, V64, P3391, DOI 10.1158/0008-5472.CAN-04-0513; Pedersen IS, 2002, HUM MOL GENET, V11, P1449, DOI 10.1093/hmg/11.12.1449; Peng CJ, 2011, INT J GYNECOL CANCER, V21, P280, DOI 10.1097/IGC.0b013e31820aaadb; Plumb JA, 2000, CANCER RES, V60, P6039; Rajasekhar Vinagolu K, 2008, Stem Cells, V26, P292; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Smith CA, 2005, DEV DYNAM, V233, P188, DOI 10.1002/dvdy.20309; Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yoshioka K, 2006, MOL CELL, V22, P501, DOI 10.1016/j.molcel.2006.04.023	50	188	193	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	42					4567	4576		10.1038/onc.2011.611	http://dx.doi.org/10.1038/onc.2011.611			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22249249	Green Submitted			2022-12-17	WOS:000309982100008
J	Mitra, AK; Sawada, K; Tiwari, P; Mui, K; Gwin, K; Lengyel, E				Mitra, A. K.; Sawada, K.; Tiwari, P.; Mui, K.; Gwin, K.; Lengyel, E.			Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis	ONCOGENE			English	Article						ovarian cancer; alpha(5)beta(1)-integrin; c-Met; Src; FAK; fibronectin	HEPATOCYTE GROWTH-FACTOR; FOCAL ADHESION KINASE; CONSTITUTIVE ACTIVATION; EMBRYOID BODIES; MMP-2 FUNCTIONS; CELL INVASION; INTEGRIN; DISSEMINATION; EXPRESSION; RECEPTOR	The role of the fibronectin receptor, alpha(5)beta(1)-integrin, as an adhesion receptor and in angiogenesis is well established. However, its role in cancer cell invasion and metastasis is less clear. We describe a novel mechanism by which fibronectin regulates ovarian cancer cell signaling and promotes metastasis. Fibronectin binding to alpha(5)beta(1)-integrin led to a direct association of alpha(5)-integrin with the receptor tyrosine kinase, c-Met, activating it in a hepatocyte growth factor/scatter factor (HGF/SF) independent manner. Subsequently, c-Met associated with Src, and activated Src and focal adhesion kinase (FAK). Inhibition of alpha(5)beta(1)-integrin decreased the phosphorylation of c-Met, FAK and Src, both in vitro and in vivo. Independent activation of c-Met by its native ligand, HGF/SF, or overexpression of a constitutively active FAK in HeyA8 cells could overcome the effect of alpha(5)beta(1)-integrin inhibition on tumor cell invasion, indicating that alpha(5)beta(1)-integrin is upstream of c-Met, Src and FAK. Inhibition of alpha(5)beta(1)-integrin on cancer cells in two xenograft models of ovarian cancer metastasis resulted in a significant decrease of tumor burden, which was independent of the effect of alpha(5)beta(1)-integrin on angiogenesis. These data suggest that fibronectin promotes ovarian cancer invasion and metastasis through an alpha(5)beta(1)-integrin/c-Met/FAK/Src-dependent signaling pathway, transducing signals through c-Met in an HGF/SF-independent manner. Oncogene (2011) 30, 1566-1576; doi: 10.1038/onc.2010.532; published online 29 November 2010	[Mitra, A. K.; Sawada, K.; Tiwari, P.; Mui, K.; Lengyel, E.] Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, Chicago, IL 60637 USA; [Gwin, K.] Univ Chicago, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Ctr Integrat Sci, 5841 S Maryland Ave,MC 2050, Chicago, IL 60637 USA.	elengyel@uchicago.edu	Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507; Tiwari, Payal/0000-0002-7822-6857	Facet Biotech Corp.; Burroughs Wellcome Fund; Ovarian Cancer Research Fund; NCI [RO1 CA111882]; NATIONAL CANCER INSTITUTE [R01CA111882] Funding Source: NIH RePORTER	Facet Biotech Corp.; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Ovarian Cancer Research Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Facet Biotech Corp. provided funding and antibodies for the animal experiments (Figure 1).; We thank Dr Alan Horwitz, Department of Cell Biology, University of Virginia School of Medicine for providing us with the FAK constructs. We thank Gail Isenberg for critically reviewing the manuscript. We appreciate the inputs of Dr Vinay Bhaskar and Dr Vanitha Ramakrishnan during the initial part of the project. Funding: Ernst Lengyel holds a Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund and is supported by grants from the Ovarian Cancer Research Fund (Liz Tilberis Scholars Program), and the NCI (RO1 CA111882).	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Bhaskar V, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-61; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Chan PC, 2006, J BIOMED SCI, V13, P215, DOI 10.1007/s11373-005-9061-7; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; Francis SE, 2002, ARTERIOSCL THROM VAS, V22, P927, DOI 10.1161/01.ATV.0000016045.93313.F2; Franke FE, 2003, ANTICANCER RES, V23, P4261; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; HAFTER R, 1984, THROMB RES, V35, P53, DOI 10.1016/0049-3848(84)90312-8; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jin EJ, 2007, DEV BIOL, V308, P474, DOI 10.1016/j.ydbio.2007.06.003; Kenny HA, 2009, CELL CYCLE, V8, P683, DOI 10.4161/cc.8.5.7703; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Magnussen A, 2005, CANCER RES, V65, P2712, DOI 10.1158/0008-5472.CAN-04-2691; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Radjabi AR, 2008, J BIOL CHEM, V283, P2822, DOI 10.1074/jbc.M704855200; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Rusciano D, 1996, J BIOL CHEM, V271, P20763, DOI 10.1074/jbc.271.34.20763; Saga Y, 2001, GENE THER, V8, P1450, DOI 10.1038/sj.gt.3301553; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Taverna D, 2001, CANCER RES, V61, P5255; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; WINGERTER P, 2005, AM J PATHOL, V167, P193; Wong AST, 2004, EXP CELL RES, V299, P248, DOI 10.1016/j.yexcr.2004.06.002; YANG JT, 1993, DEVELOPMENT, V119, P1093; Yokoyama Y, 2007, CANCER RES, V67, P10813, DOI 10.1158/0008-5472.CAN-07-0172; Yu D, 1992, CANCER RES, V53, P891; Zillhardt M, 2010, NEOPLASIA, V12, P1, DOI 10.1593/neo.09948	38	188	193	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1566	1576		10.1038/onc.2010.532	http://dx.doi.org/10.1038/onc.2010.532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119598	Green Accepted			2022-12-17	WOS:000288998300007
J	Meng, F; Wehbe-Janek, H; Henson, R; Smith, H; Patel, T				Meng, F.; Wehbe-Janek, H.; Henson, R.; Smith, H.; Patel, T.			Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes	ONCOGENE			English	Article						noncoding RNA; cytokine; liver cancer	CHOLANGIOCARCINOMA CELL-LINE; PROMOTER METHYLATION; CANCER-CELLS; KINASE; GROWTH; ACTIVATION; EXPRESSION; GENE; IDENTIFICATION; CONTRIBUTES	Interleukin-6 (IL-6) is overexpressed and contributes to tumor cell growth in cholangiocarcinoma. Enforced IL-6 production can alter the expression of specific microRNAs ( miRNAs) involved in tumor growth, and moreover can modulate expression of methylation-dependent genes. Thus, we assessed the methylation-dependent regulation of miRNA expression in human malignant cholangiocytes stably transfected to overexpress IL-6. The expression of the methyltransferases DNA methyltransferase enzyme-1 and HASJ4442 was increased by IL-6 overexpression, but was decreased by the methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). Expression pro. ling identified seven miRNAs that were significantly downregulated by IL-6 overexpression (<0.4-fold) and upregulated (>2- fold) by 5-aza-CdR. One of these, miR-370, is embedded in a CpG island. Although 5-aza-CdR increased miR-370 expression by 2.1-fold in malignant cells, the expression in nonmalignant cells was unchanged. The oncogene mitogen- activated protein kinase kinase kinase 8 (MAP3K8) was identified as a target of miR-370, and its expression was decreased by 5-aza-CdR in cholangiocarcinoma cells. Overexpression of IL-6 reduced miR-370 expression and reinstated MAP3K8 expression in vitro as well as in tumor cell xenografts in vivo. Thus, IL-6 may contribute to tumor growth by modulation of expression of selected miRNAs, such as miR-370. These studies de. ne a mechanism by which inflammation-associated cytokines can epigenetically modulate gene expression and directly contribute to tumor biology.	[Meng, F.; Patel, T.] Ohio State Univ, Med Ctr, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Meng, F.; Wehbe-Janek, H.; Henson, R.; Smith, H.; Patel, T.] Texas A&M Univ, Coll Med, Syst Hlth Sci Ctr, Scott & White Clin,Dept Internal Med, Temple, TX 76508 USA	University System of Ohio; Ohio State University; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Patel, T (corresponding author), Ohio State Univ, Med Ctr, Coll Med, Dept Internal Med, N2 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA.	tushar.patel@osumc.edu	patel, tushar/A-6382-2008		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069370] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK069370, R01 DK069370, R01 DK069370-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOKI M, 1993, J BIOL CHEM, V268, P22723; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Meng F, 2006, J HEPATOL, V44, P1055, DOI 10.1016/j.jhep.2005.10.030; Meng FM, 2005, AM J PHYSIOL-CELL PH, V289, pC971, DOI 10.1152/ajpcell.00081.2005; OHARA R, 1995, J CELL SCI, V108, P97; OKADA K, 1994, J GASTROEN HEPATOL, V9, P462, DOI 10.1111/j.1440-1746.1994.tb01275.x; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Patel T, 2006, NAT CLIN PRACT GASTR, V3, P33, DOI 10.1038/ncpgasthep0389; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Tadlock L, 2001, HEPATOLOGY, V33, P43, DOI 10.1053/jhep.2001.20676; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Yamagiwa Y, 2003, HEPATOLOGY, V38, P158, DOI 10.1053/jhep.2003.50257	31	188	214	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					378	386		10.1038/sj.onc.1210648	http://dx.doi.org/10.1038/sj.onc.1210648			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621267				2022-12-17	WOS:000252256000014
J	Smeets, SJ; Braakhuis, BJM; Abbas, S; Snijders, PJF; Ylstra, B; van de Wiel, MA; Meijer, GA; Leemans, CR; Brakenhoff, RH				Smeets, SJ; Braakhuis, BJM; Abbas, S; Snijders, PJF; Ylstra, B; van de Wiel, MA; Meijer, GA; Leemans, CR; Brakenhoff, RH			Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus	ONCOGENE			English	Article						cancer genetics; head and neck cancer; human papillomavirus; array CGH; multi-step carcinogenesis	GENETICALLY ALTERED FIELDS; TUMOR-SUPPRESSOR GENE; PROGRESSION MODEL; ALLELIC LOSS; ORAL-CANCER; RISK; IDENTIFICATION; IMBALANCES; IMPACT; DPC4	Oncogene-expressing human papillomavirus type 16 (HPV16) is found in a subset of head and neck squamous cell carcinomas (HNSCC). HPV16 drives carcinogenesis by inactivating p53 and pRb with the viral oncoproteins E6 and E7, paralleled by a low level of mutations in TP53 and allelic loss at 3p, 9p, and 17p, genetic changes frequently found in HNSCCs of nonviral etiology. We hypothesize that two pathways to HNSCC exist: one determined by HPV16 and the other by environmental carcinogens. To de. ne the critical genetic events in these two pathways, we now present a detailed genome analysis of HNSCC with and without HPV16 involvement by employing high-resolution microarray comparative genomic hybridization. Four regions showed alterations in HPV-negative tumors that were absent in HPV-positive tumors: losses at 3p11.2-26.3, 5q11.2-35.2, and 9p21.1-24, and gains/amplifications at 11q12.1-13.4. Also, HPV16-negative tumors demonstrated loss at 18q12.1-23, in contrast to gain in HPV16-positive tumors. Seven regions were altered at high frequency (> 33%) in both groups: gains at 3q22.2-qter, 5p15.2-pter, 8p11.2-qter, 9q22-34.1, and 20p-20q, and losses at 11q14.1-qter and 13q11-33. These data show that HNSCC arising-by environmental carcinogens are characterized by genetic alterations that differ from those observed in HPV16-induced HNSCC, and most likely occur early in carcinogenesis. A number of genetic changes are shared in both tumor groups and can be considered crucial in the later stages of HNSCC progression.	Vrije Univ Amsterdam Med Ctr, Dept Otolaryngol Head & Neck Surg, Sect Tumor Biol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Microarray Core Facil, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Brakenhoff, RH (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Otolaryngol Head & Neck Surg, Sect Tumor Biol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	rh.brakenhoff@vumc.nl	Brakenhoff, Ruud/D-3960-2009; Braakhuis, Boudewijn JM/B-4383-2008; Abbas, Saman/L-1981-2013; Ylstra, Bauke/D-2906-2012; van de Wiel, Mark/F-6759-2013	Ylstra, Bauke/0000-0001-9479-3010; Leemans, C. Rene/0000-0001-7887-083X; van de Wiel, Mark/0000-0003-4780-8472; Meijer, Gerrit/0000-0003-0330-3130				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; Beder LB, 2003, LAB INVEST, V83, P99, DOI 10.1097/01.LAB.0000047489.26246.E1; Bockmuhl U, 2000, AM J PATHOL, V157, P369, DOI 10.1016/S0002-9440(10)64549-X; Braakhuis BJM, 2004, JNCI-J NATL CANCER I, V96, P998, DOI 10.1093/jnci/djh183; Braakhuis BJM, 2004, J ORAL PATHOL MED, V33, P317; Califano J, 1996, CANCER RES, V56, P2488; Dahlgren L, 2003, INT J CANCER, V107, P244, DOI 10.1002/ijc.11371; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]; Jong K, 2004, BIOINFORMATICS, V20, P3636, DOI 10.1093/bioinformatics/bth355; Kim SK, 1996, CANCER RES, V56, P2519; Mao L, 2004, J NATL CANCER I, V96, P978, DOI 10.1093/jnci/djh209; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; Partridge M, 2000, CANCER RES, V60, P3893; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Rosin MP, 2000, CLIN CANCER RES, V6, P357; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Tabor MP, 2004, CLIN CANCER RES, V10, P3607, DOI 10.1158/1078-0432.CCR-03-0632; Tabor MP, 2003, J PATHOL, V199, P354, DOI 10.1002/path.1285; Tabor MP, 2001, CLIN CANCER RES, V7, P1523; Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150; van de Wiel MA, 2005, BIOINFORMATICS, V21, P3193, DOI 10.1093/bioinformatics/bti489; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; VANDERRIET P, 1994, CANCER RES, V54, P1156; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wreesmann VB, 2004, J CLIN ONCOL, V22, P3965, DOI 10.1200/JCO.2004.01.094; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	30	188	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2558	2564		10.1038/sj.onc.1209275	http://dx.doi.org/10.1038/sj.onc.1209275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16314836				2022-12-17	WOS:000236948000014
J	Yang, YG; Cortes, U; Patnaik, S; Jasin, M; Wang, ZQ				Yang, YG; Cortes, U; Patnaik, S; Jasin, M; Wang, ZQ			Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks	ONCOGENE			English	Article						poly(ADP-ribose) polymerase-1; Rad51; homologous recombination; DNA double-strand break repair; replication stall and progression	SISTER-CHROMATID EXCHANGES; HOMOLOGY-DIRECTED REPAIR; POLY(ADP-RIBOSE) POLYMERASE; S-PHASE; RECOMBINATION; DAMAGE; RAD51; STABILITY; PROTEIN; GENOME	Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant DNA end-sensing and binding molecule. Inactivation of PARP-1 by chemicals and genetic mutations slows cell proliferation, increases sister chromatid exchange (SCE), micronuclei formation and chromosome instability, and shortens telomeres. Given its affinity to DNA breaks and temporal occupation on DNA strand break sites, PARP-1 is proposed to prevent inappropriate DNA recombination. We investigated the potential role of PARP-1 in repair of DNA double-strand breaks (DSBs) and stalled replication forks. PARP-1-/- embryonic stem cells and embryonic fibroblast cells exhibited normal repair of DNA DSBs by either homologous recombination (HR) or nonhomologous end-joining(NHEJ) pathways. Inactivation of PARP-1 did not interfere with gene-targeting efficiency in ES cells. However, PARP-1-/- cells were hypersensitive to the replication damage agent hydroxyurea (HU)-induced cell death and exhibited enhanced SCE formation. Ablation of PARP-1 delayed reactivation of stalled replication forks imposed by HU and re-entry into the G2-M phase after HU release. These data indicate that PARP-1 is dispensable in HR induced by DSBs, but is involved in the repair and reactivation of stalled replication forks.	Int Agcy Res Canc, F-69008 Lyon, France; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	World Health Organization; International Agency for Research on Cancer (IARC); Memorial Sloan Kettering Cancer Center	Wang, ZQ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	zqwang@iarc.fr	Yang, Yungui/ABF-2507-2021					Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CORTES F, 1993, MUTAT RES, V303, P71, DOI 10.1016/0165-7992(93)90097-F; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; COX MM, 2002, MUTAT RES, V10, P107; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; IKUSHIMA T, 1990, CHROMOSOMA, V99, P360, DOI 10.1007/BF01731724; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; RAINALDI G, 1984, CHROMOSOMA, V90, P46, DOI 10.1007/BF00352277; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2000, COLD SPRING HARB SYM, V65, P583, DOI 10.1101/sqb.2000.65.583; Tong WM, 2002, CANCER RES, V62, P6990; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wesierska-Gadek J, 1999, CANCER RES, V59, P28	45	188	194	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3872	3882		10.1038/sj.onc.1207491	http://dx.doi.org/10.1038/sj.onc.1207491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021907				2022-12-17	WOS:000221242500014
J	Huang, LL; Sowa, Y; Sakai, T; Pardee, AB				Huang, LL; Sowa, Y; Sakai, T; Pardee, AB			Activation of the p21(WAF1/CIP1) promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites	ONCOGENE			English	Article						SAHA; p31 promoter; Sp1/Sp3	WAF1/CIP1 GENE PROMOTER; GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; N-COR; BINDING; REPRESSION; P300; INDUCTION; INDUCERS; HOMOLOG	Suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor with high potency in inducing differentiation of cultured murine erythroleukemia cells. We have recently demonstrated that SAHA induces cell cycle arrest and apoptosis in human breast cancer cells, accompanied by up-regulation of the cyclin-dependent kinase inhibitor, p21(WAF1/CIP1) via a p53-independent mechanism. In this study, we used p21 gene expression as a model system to elucidate the molecular mechanism(s) underlying SAHA-mediated gene activation. Treatment of human breast cancer cell line MICF7 cells with SAHA induced p21 mRNA as a consequence of an immediate-early gene activation. Moreover, SAHA activated the p21 promoter primarily through two Spl sites located at -82 and -69 relative to the transcription start site. Furthermore, Spl and Sp3 proteins were the major factors binding to the Spl site of the p21 promoter. However, SAHA did not alter their DNA binding activities, suggesting that SAHA mediates p21 promoter activity by a mechanism other than altering the DNA binding activities of Spl and Sp3, Further studies using the GAL4 luciferase assay system demonstrated that both GAL4-Sp1 and GAL4-Sp3 fusion proteins supported SAHA-mediated gene activation from a promoter driven by five GAL4 DNA binding sites, and that GAL4-Sp3 fusion protein,vas suppressive in the absence of SAHA treatment. Collectively, our results suggest that SAHA activates the p21 promoter through the Spl sites, and that both Spl and Sp3 proteins can mediate SAHA-induced gene activation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Kyoto Prefectural University of Medicine	Pardee, AB (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Biol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [R01CA61253] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cohen LA, 1999, ANTICANCER RES, V19, P4999; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DESAI D, 1999, P AM ASSOC CANC RES, V40, P2396; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	41	188	193	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5712	5719		10.1038/sj.onc.1203963	http://dx.doi.org/10.1038/sj.onc.1203963			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126357				2022-12-17	WOS:000165477700002
J	Chaudhary, PM; Eby, MT; Jasmin, A; Kumar, A; Liu, L; Hood, L				Chaudhary, PM; Eby, MT; Jasmin, A; Kumar, A; Liu, L; Hood, L			Activation of the NF-kappa B pathway by Caspase 8 and its homologs	ONCOGENE			English	Article						NF-kappa B; caspase; FADD; death effector domain; MRIT; cFLIP	DOMAIN-CONTAINING PROTEIN; NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; INDUCED APOPTOSIS; CD95 FAS/APO-1; KINASE-ALPHA; TNF; FADD; INTERACTS; INDUCTION	Caspase 8 is the most proximal caspase in the caspase cascade and has been known for its role in the mediation of cell death by various death receptors belonging to the TNFR family. We have discovered that Caspase 8 can activate the NF-kappa B pathway independent of its activity as a pro-apoptotic protease, This property is localized to its N-terminal prodomain, which contains two homologous death effector domains (DEDs). Caspase 10 and MRIT, two DEDs-containing homologs of Caspase 8, can similarly activate the NF-kappa B pathway. Dominantnegative mutants of the Caspase 8 prodomain can block NF-kappa B induced by Caspase 8, FADD and several death receptors belonging to the TNFR family. Caspase 8 can interact with multiple proteins known to be involved in the activation of the NF-kappa B pathway, including the serine-threonine kinases RIP, NIK, IKK1 and IKK2, Thus, DEDs-containing caspases and caspase homolog(s) may have functions beyond their known role in the mediation of cell death.	UT, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), UT, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Kumar, Arvind/B-6094-2009; Chaudhary, Preet/E-1970-2018					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1996, ONCOGENE, V12, P1; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	188	200	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4451	4460		10.1038/sj.onc.1203812	http://dx.doi.org/10.1038/sj.onc.1203812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002417				2022-12-17	WOS:000089236800001
J	Zong, S; Hu, P; Ye, TZ; Stan, R; Ellis, NA; Pandolfi, PP				Zong, S; Hu, P; Ye, TZ; Stan, R; Ellis, NA; Pandolfi, PP			A role for PML and the nuclear body in genomic stability	ONCOGENE			English	Article						PML; BLM; APL; Bloom syndrome; nuclear body; sister-chromatid exchange	ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; TRANSGENIC MICE; BLOOMS-SYNDROME; GENE; TRANSLOCATION; INTERFERON; T(15-17); PATHWAYS; PROTEIN	The PML gene of acute promyelocytic leukemia (APL) encodes a cell-growth and tumor suppressor. PML to discrete nuclear bodies (NBs) that are disrupted in APL cells. The Bloom syndrome gene BLM encodes a RecQ DNA helicase, whose absence from the cell results in genomic instability epitomized by high levels of sister-chromatid exchange (SCE) and cancer predisposition, We show here that BLM colocalizes with PML to the NB. In cells from persons with Bloom syndrome the localization of PML is unperturbed, whereas in APL cells carrying the PML-RAR alpha oncoprotein, both PML and BLM are delocalized from the NE into microspeckled nuclear regions. Treatment with retinoic acid (RA) induces the relocalization of both proteins to the NE. In primary PML-/- cells, BLM fails to accumulate in the NE. Strikingly, in PML-/- cells the frequency of SCEs is increased relative to PML +/+ cells. These data demonstrate that BLM is a constituent of the NE and that PML is required for its accumulation in these nuclear domains and for the normal function of BLM. Thus, our findings suggest a role for BLM in APL pathogenesis and implicate the PRL NE in the maintenance of genomic stability.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, Mol & Dev Biol Lab, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Lab Canc Susceptibil, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, Mol & Dev Biol Lab, Program Mol Biol, 1275 York Ave,Box 110, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748, CA71692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beresten SF, 1999, PROTEIN EXPRES PURIF, V17, P239, DOI 10.1006/prep.1999.1135; Boddy MN, 1996, ONCOGENE, V13, P971; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; GERMAN J, 1977, AM J HUM GENET, V29, P248; German J, 1998, GENETIC BASIS HUMAN, P301; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	32	188	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7941	7947		10.1038/sj.onc.1203367	http://dx.doi.org/10.1038/sj.onc.1203367			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637504				2022-12-17	WOS:000084634600002
J	Tsao, HS; Zhang, X; Benoit, E; Haluska, FG				Tsao, HS; Zhang, X; Benoit, E; Haluska, FG			Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines	ONCOGENE			English	Article						cancer; genetics; mutation; PTEN/MMAC1; melanoma	PRIMARY CUTANEOUS MELANOMA; FAMILIAL MELANOMA; HETEROZYGOSITY; DELETIONS; MUTATIONS; GLIOMAS; NEVI; P16	A novel tumor suppressor gene, PTEN/MMAC1, has been recently shown to be mutated in gliomas, breast, prostate, kidney cancers and melanomas, Loss-of-heterozygosity studies in melanoma have suggested the presence of at least one chromosome 10q locus lost early in tumor progression. In this study, we screened 45 melanoma cell lines and 17 paired uncultured metastatic melanoma and peripheral blood specimens for PTEN/MMAC1 alterations using PCR-SSCP and direct sequencing. We found nine melanoma cell lines with homozygous deletions (five with intragenic loss) and four cell lines with mutations (one nonsense and one frameshift; two intronic); from among our uncultured melanoma specimens, me found one tumor with a somatic 17 bp duplication in exon 7 leading to a premature stop codon and one tumor with a possible homozygous deletion. Furthermore, we ha ce identified a novel intragenic polymorphism within intron 4 of PTEN/MMAC1. Taken together, these data suggest that PTEN/MMAC1 may be a chromosome 10q tumor suppressor important in melanoma turner formation or progression.	Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; Dana Farber Partners Canc Care, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Haluska, FG (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Fruit St, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER; NIAMS NIH HHS [5T32AR07098-23] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; Bartkova J, 1996, CANCER RES, V56, P5475; Dahia PLM, 1997, CANCER RES, V57, P4710; DREYLING MH, 1995, CANCER RES, V55, P984; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; FULTS D, 1990, CANCER RES, V50, P5784; Guldberg P, 1997, CANCER RES, V57, P3660; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HERBST RA, 1994, CANCER RES, V54, P3111; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; PARMITER AH, 1988, CANCER GENET CYTOGEN, V30, P313, DOI 10.1016/0165-4608(88)90200-2; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; Risinger JI, 1997, CANCER RES, V57, P4736; SHAPIRO SD, 1988, INT J DERMATOL, V27, P232, DOI 10.1111/j.1365-4362.1988.tb03214.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENES CHROMOSOM CANC, V12, P235; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208	30	188	189	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3397	3402		10.1038/sj.onc.1201881	http://dx.doi.org/10.1038/sj.onc.1201881			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692547				2022-12-17	WOS:000074544100006
J	ALBINO, AP; NANUS, DM; MENTLE, IR; CORDONCARDO, C; MCNUTT, NS; BRESSLER, J; ANDREEFF, M				ALBINO, AP; NANUS, DM; MENTLE, IR; CORDONCARDO, C; MCNUTT, NS; BRESSLER, J; ANDREEFF, M			ANALYSIS OF RAS ONCOGENES IN MALIGNANT-MELANOMA AND PRECURSOR LESIONS - CORRELATION OF POINT MUTATIONS WITH DIFFERENTIATION PHENOTYPE	ONCOGENE			English	Article									CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Cornell University	ALBINO, AP (corresponding author), MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA-41305, CA-20194, CA-37907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020194, R01CA041305, R01CA037907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN AB, 1985, HUM PATHOL, V16, P87; ADELAIDE J, 1988, ONCOGENE, V2, P413; Albino A P, 1988, Prog Clin Biol Res, V256, P361; ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; ALBINO AP, 1987, BASIC CLIN ASPECTS M, P3; ALBINO AP, 1988, PIGMENT CELL RES S, V1, P169; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDREEFF M, 1985, TUMOR ANEUPLOIDY, P81; BALABAN G, 1984, CANCER GENET CYTOGEN, V11, P429, DOI 10.1016/0165-4608(84)90024-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CAIRNCROSS JG, 1982, P NATL ACAD SCI USA, V79, P561; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; DEMARTINVILLE B, 1983, NUCLEIC ACIDS RES, V11, P5267, DOI 10.1093/nar/11.15.5267; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; Elder D E, 1980, Am J Dermatopathol, V2, P315, DOI 10.1097/00000372-198000240-00005; ELDER DE, 1980, CANCER, V46, P1787, DOI 10.1002/1097-0142(19801015)46:8<1787::AID-CNCR2820460816>3.0.CO;2-S; ELDER DE, 1984, AM J DERMATOPATH, V6, P55; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GREENE MH, 1983, P NATL ACAD SCI-BIOL, V80, P6071, DOI 10.1073/pnas.80.19.6071; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HAYWARD N, 1988, INT J CANCER, V42, P558, DOI 10.1002/ijc.2910420415; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HOUGHTON AN, 1980, P NATL ACAD SCI-BIOL, V77, P4260, DOI 10.1073/pnas.77.7.4260; HOUGHTON AN, 1983, J EXP MED, V158, P53, DOI 10.1084/jem.158.1.53; HOUGHTON AN, 1987, J EXP MED, V164, P812; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; MARK A, 1987, NUCLEIC ACIDS RES, V15, P8565, DOI 10.1093/nar/15.20.8565; MCBRIDE LJ, 1988, BIOTECHNIQUES, V6, P362; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PEDERSEN MI, 1986, CANCER GENET CYTOGEN, V20, P11, DOI 10.1016/0165-4608(86)90103-2; PIEROTTI M, 1987, CUTANEOUS MELANOMA, P339; RADICE P, 1987, ONCOGENE, V2, P91; RAYBAUD F, 1988, CANCER RES, V48, P950; REAL FX, 1988, CANCER RES, V48, P686; REAL FX, 1985, CANCER RES, V45, P4401; REAL FX, 1986, CANCER RES, V46, P4726; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHARPLESS TK, 1979, FLOW CYTOMETRY SORTI, P359; SMOLLER BR, 1989, AM J SURG PATHOL, V13, P680, DOI 10.1097/00000478-198908000-00006; SUTHERLAND C, 1986, BRIT J CANCER, V54, P787, DOI 10.1038/bjc.1986.241; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; TUCKER MA, 1988, PIGMENT CELL, P95; UEDA R, 1982, P NATL ACAD SCI-BIOL, V79, P4386, DOI 10.1073/pnas.79.14.4386; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; ZIEGLERHEITBROCK HWL, 1985, CANCER RES, V45, P1344; 1984, JAMA-J AM MED ASSOC, V25, P1864	62	188	191	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1363	1374						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682463				2022-12-17	WOS:A1989AX65900014
J	Basuli, D; Tesfay, L; Deng, Z; Paul, B; Yamamoto, Y; Ning, G; Xian, W; McKeon, F; Lynch, M; Crum, CP; Hegde, P; Brewer, M; Wang, X; Miller, LD; Dyment, N; Torti, FM; Torti, SV				Basuli, D.; Tesfay, L.; Deng, Z.; Paul, B.; Yamamoto, Y.; Ning, G.; Xian, W.; McKeon, F.; Lynch, M.; Crum, C. P.; Hegde, P.; Brewer, M.; Wang, X.; Miller, L. D.; Dyment, N.; Torti, F. M.; Torti, S. V.			Iron addiction: a novel therapeutic target in ovarian cancer	ONCOGENE			English	Article							GRADE SEROUS CARCINOMA; STEM-CELLS; ALDEHYDE DEHYDROGENASE; IN-VITRO; INTERLEUKIN-6; PATHOGENESIS; EXPRESSION; PATHWAY; BIOLOGY; DEATH	Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over 30 years. We demonstrate that ovarian cancer exhibits a targetable alteration in iron metabolism. Ferroportin (FPN), the iron efflux pump, is decreased, and transferrin receptor (TFR1), the iron importer, is increased in tumor tissue from patients with high grade but not low grade serous ovarian cancer. A similar profile of decreased FPN and increased TFR1 is observed in a genetic model of ovarian cancer tumor-initiating cells (TICs). The net result of these changes is an accumulation of excess intracellular iron and an augmented dependence on iron for proliferation. A forced reduction in intracellular iron reduces the proliferation of ovarian cancer TICs in vitro, and inhibits both tumor growth and intraperitoneal dissemination of tumor cells in vivo. Mechanistic studies demonstrate that iron increases metastatic spread by facilitating invasion through expression of matrix metalloproteases and synthesis of interleukin 6 (IL-6). We show that the iron dependence of ovarian cancer TICs renders them exquisitely sensitive in vivo to agents that induce iron-dependent cell death (ferroptosis) as well as iron chelators, and thus creates a metabolic vulnerability that can be exploited therapeutically.	[Basuli, D.; Tesfay, L.; Deng, Z.; Paul, B.; Torti, S. V.] Univ Connecticut, Ctr Hlth, Dept Mol Biol & Biophys, 263 Farmington Ave, Farmington, CT 06030 USA; [Yamamoto, Y.] Natl Canc Ctr, Res Inst, Tokyo, Japan; [Ning, G.] Jackson Lab Genom Med, Farmington, CT USA; [Xian, W.] Univ Texas Houston, Ctr Hlth, Ctr Stem Cells & Regenerat Med, Houston, TX USA; [McKeon, F.] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Lynch, M.] Univ Connecticut, Ctr Hlth, Ctr Quantitat Med, Farmington, CT USA; [Crum, C. P.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Hegde, P.; Wang, X.] Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT USA; [Brewer, M.] Univ Connecticut, Ctr Hlth, Dept Obstet & Gynecol, Farmington, CT USA; [Miller, L. D.] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Dyment, N.] Univ Connecticut, Ctr Hlth, Sch Dent Med, Reconstruct Sci, Farmington, CT USA; [Torti, F. M.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA; [Lynch, M.] Los Alamos Natl Lab, Stat Sci Grp CCS 6, Los Alamos, NM USA	University of Connecticut; National Cancer Center - Japan; Jackson Laboratory; University of Texas System; University of Texas Health Science Center Houston; University of Houston System; University of Houston; University of Connecticut; Harvard University; Brigham & Women's Hospital; University of Connecticut; University of Connecticut; Wake Forest University; University of Connecticut; University of Connecticut; United States Department of Energy (DOE); Los Alamos National Laboratory	Torti, SV (corresponding author), Univ Connecticut, Ctr Hlth, Dept Mol Biol & Biophys, 263 Farmington Ave, Farmington, CT 06030 USA.	storti@uchc.edu	Basuli, Debargha/AAD-7351-2021	Basuli, Debargha/0000-0002-4028-9959; Dyment, Nathaniel/0000-0001-8708-112X; Miller, Lance/0000-0003-3799-2528	NIH [R01 CA188025, R01 CA171101]; Department of Defense [W81XWH-10-1-0289]; Cancer Prevention and Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE [P30CA034196, R01CA188025, R01CA171101] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD007070] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Cancer Prevention and Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported in part by NIH grants R01 CA188025 (SVT), R01 CA171101 (FMT), the Department of Defense (W81XWH-10-1-0289 to CC), and Scholar grants from the Cancer Prevention and Research Institute of Texas (CPRIT; to WX and FM). We thank Tara L Arvedson (Amgen, Thousand Oaks, CA) for a generous gift of anti-ferroportin antibody.	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; BAKER VV, 1990, GYNECOL ONCOL, V38, P340, DOI 10.1016/0090-8258(90)90069-W; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Dai JS, 2004, TOXICOLOGY, V203, P199, DOI 10.1016/j.tox.2004.06.009; Deng ZY, 2007, MOL CELL BIOL, V27, P3780, DOI 10.1128/MCB.01761-06; Dietl J, 2014, ARCH GYNECOL OBSTET, V289, P241, DOI 10.1007/s00404-013-3041-3; Dijkgraaf EM, 2012, CURR PHARM DESIGN, V18, P3816; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Gershenson David M, 2013, Am Soc Clin Oncol Educ Book, DOI 10.1200/EdBook_AM.2013.33.e195; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Kurman RJ, 2013, ANN ONCOL, V24, P16, DOI 10.1093/annonc/mdt463; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Leong HS, 2015, J PATHOL, V236, P272, DOI 10.1002/path.4536; Li HX, 2014, INT J CLIN EXP PATHO, V7, P848; Liu XB, 2005, BLOOD CELL MOL DIS, V35, P33, DOI 10.1016/j.bcmd.2005.04.005; Lui GYL, 2015, MOL PHARMACOL, V87, P543, DOI 10.1124/mol.114.096529; Manz DH, 2016, ANN NY ACAD SCI, V1368, P149, DOI 10.1111/nyas.13008; Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870; Ng A, 2015, NAT REV MOL CELL BIO, V16, P625, DOI 10.1038/nrm4056; Nguyen DH, 2013, CANCERINCYTES, V2, DOI DOI 10.1038/PROTEX.2013.097; Ning G, 2014, J PATHOL, V234, P478, DOI 10.1002/path.4417; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Reed JC, 2012, CELL, V149, P963, DOI 10.1016/j.cell.2012.05.009; Ross SL, 2012, CELL METAB, V15, P905, DOI 10.1016/j.cmet.2012.03.017; Schimanski LM, 2005, BLOOD, V105, P4096, DOI 10.1182/blood-2004-11-4502; Schonberg DL, 2015, CANCER CELL, V28, P441, DOI 10.1016/j.ccell.2015.09.002; Shah MM, 2014, GYNECOL ONCOL, V132, P483, DOI 10.1016/j.ygyno.2013.12.001; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Tesfay L, 2015, CANCER RES, V75, P2254, DOI 10.1158/0008-5472.CAN-14-2465; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Torti SV, 2011, CANCER RES, V71, P1511, DOI 10.1158/0008-5472.CAN-10-3614; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vang R, 2009, ADV ANAT PATHOL, V16, P267, DOI 10.1097/PAP.0b013e3181b4fffa; Wang W, 2014, CANCER RES, V74, P497, DOI 10.1158/0008-5472.CAN-13-1224; Yamamoto Y, 2016, J PATHOL, V238, P519, DOI 10.1002/path.4649; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zou M, 2015, METHODS, V83, P3, DOI 10.1016/j.ymeth.2015.05.011	47	187	196	5	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4089	4099		10.1038/onc.2017.11	http://dx.doi.org/10.1038/onc.2017.11			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319068	Green Accepted, Green Submitted			2022-12-17	WOS:000405835800001
J	Yang, C; Li, Z; Bhatt, T; Dickler, M; Giri, D; Scaltriti, M; Baselga, J; Rosen, N; Chandarlapaty, S				Yang, C.; Li, Z.; Bhatt, T.; Dickler, M.; Giri, D.; Scaltriti, M.; Baselga, J.; Rosen, N.; Chandarlapaty, S.			Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence	ONCOGENE			English	Article							KINASE 4/6 INHIBITOR; ESTROGEN-RECEPTOR; CELL-CYCLE; ENDOCRINE THERAPY; PD 0332991; OVEREXPRESSION; D1; DIFFERENTIATION; TRANSCRIPTION; PALBOCICLIB	Dysregulated activation of the CDK4/6 kinases is a hallmark of most mammary-derived carcinomas. ATP-competitive inhibitors against this complex have been recently advanced in the clinic and have shown significant activity, particularly against tumors driven by the estrogen receptor (ER). However, resistance to these compounds has begun to emerge often months to years after their initiation. We investigated potential mechanisms of resistance using cell line models that are highly sensitive to this class of drugs. After prolonged exposure to the selective and potent CDK4/6 inhibitor LY2835219, clones emerged and several were found to harbor amplification of the CDK6 kinase. Amplification of CDK6 resulted in a marked increase in CDK6 expression and reduced response of the CDK4/6 target, phospho-Rb (pRb), to CDK4/6 inhibitors. Knockdown of CDK6 restored drug sensitivity, while enforced overexpression of CDK6 was sufficient to mediate drug resistance. Not only did CDK6 overexpression mediate resistance to CDK4/6 inhibitors but it also led to reduced expression of the ER and progesterone receptor (PR), and diminished responsiveness to ER antagonism. The reduced ER/PR expression after CDK4/6 inhibitor resistance was additionally observed in tumor biopsy specimens from patients treated with these drugs. Alternative mechanisms of resistance to CDK4/6 inhibitors such as loss of pRb and cyclin E1 overexpression also exhibited decreased hormone responsiveness, suggesting that the clinical paradigm of sequential endocrine-based therapy may be ineffective in some settings of acquired CDK4/6 resistance.	[Yang, C.; Li, Z.] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China; [Yang, C.; Li, Z.; Bhatt, T.; Baselga, J.; Chandarlapaty, S.] MSKCC, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA; [Dickler, M.; Baselga, J.; Chandarlapaty, S.] MSKCC, Dept Med, Breast Med Serv, New York, NY 10065 USA; [Dickler, M.; Giri, D.; Scaltriti, M.; Baselga, J.; Rosen, N.; Chandarlapaty, S.] Weill Cornell Med Coll, New York, NY USA; [Giri, D.; Scaltriti, M.] MSKCC, Dept Pathol, New York, NY 10065 USA; [Rosen, N.] MSKCC, Mol Pharmacol Program, New York, NY 10065 USA	Xi'an Jiaotong University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chandarlapaty, S (corresponding author), MSKCC, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10065 USA.	chandars@mskcc.org	Yang, Chengcheng/AAU-1342-2021; Rosen, Neal/ABF-2677-2020		Shen Family Foundation; Susan G Komen; Breast Cancer Research Foundation; NCI Cancer Center Support Grant (CCSG) [P30 CA08748]; NATIONAL CANCER INSTITUTE [P01CA094060, P30CA008748] Funding Source: NIH RePORTER	Shen Family Foundation; Susan G Komen(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; NCI Cancer Center Support Grant (CCSG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was generously supported by funds from the Shen Family Foundation, Susan G Komen and the Breast Cancer Research Foundation. The Marie-Jose and Henry R Kravis Center for Molecular Oncology as well as NCI Cancer Center Support Grant (CCSG, P30 CA08748) additionally supported this work. We thank Weiyi Toy for her critical feedback.	Alves CL, 2016, CLIN CANC RES; Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; CC O'Sullivan, 2015, INT J CANC CLIN RES, V2, pii; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, CELL CYCLE, V11, P2756, DOI 10.4161/cc.21195; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Infante JR, 2014, ASCO ANN M P; Jansen MPHM, 2005, J CLIN ONCOL, V23, P732, DOI 10.1200/JCO.2005.05.145; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; KARNIK PS, 1994, CANCER RES, V54, P349; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; McDermott M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00040; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Navarro F, 2009, BLOOD, V114, P2181, DOI 10.1182/blood-2009-02-205062; Patnaik A, 2014, ASCO ANN M P; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tigan AS, 2016, ONCOGENE, V35, P3083, DOI 10.1038/onc.2015.407; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Umemura S, 2009, BRIT J CANCER, V100, P764, DOI 10.1038/sj.bjc.6604900; VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	38	187	193	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2255	2264		10.1038/onc.2016.379	http://dx.doi.org/10.1038/onc.2016.379			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27748766	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000399782700006
J	Ozes, AR; Miller, DF; Ozes, ON; Fang, F; Liu, Y; Matei, D; Huang, T; Nephew, KP				Ozes, A. R.; Miller, D. F.; Ozes, O. N.; Fang, F.; Liu, Y.; Matei, D.; Huang, T.; Nephew, K. P.			NF-kappa B-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer	ONCOGENE			English	Article							NONCODING RNA HOTAIR; EPITHELIAL-MESENCHYMAL TRANSITION; ONCOGENE-INDUCED SENESCENCE; GENE-EXPRESSION; CISPLATIN RESISTANCE; SECRETORY PHENOTYPE; IN-VIVO; CELLS; METASTASIS; ACTIVATION	The transcription factor nuclear factor kappa B (NF-kappa B) and the long non-coding RNA (lncRNA) HOTAIR (HOX transcript antisense RNA) have diverse functional roles in cancer. In this study, we show that upregulation of HOTAIR induced platinum resistance in ovarian cancer, and increased HOTAIR levels were observed in recurrent platinum-resistant ovarian tumors vs primary ovarian tumors. To investigate the role of HOTAIR during DNA damage induced by platinum, we monitored double-strand breaks and show that HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment. We demonstrate that ectopic expression of HOTAIR induces NF-kappa B activation during DDR and interleukin-6 and interleukin-6 expression, both key NF-kappa B target genes. We show that HOTAIR regulates activation of NF-kappa B by decreasing I kappa-B alpha (NF-kappa B inhibitor) and establish that by inducing prolonged NF-kappa B activation and expression of NF-kappa B target genes during DNA damage, HOTAIR has a critical role in cellular senescence and platinum sensitivity. Our findings suggest that an NF-.B- HOTAIR axis drives a positive-feedback loop cascade during DDR and contributes to cellular senescence and chemotherapy resistance in ovarian and other cancers.	[Ozes, A. R.; Nephew, K. P.] Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN USA; [Miller, D. F.; Fang, F.; Nephew, K. P.] Indiana Univ Sch Med, Med Sci Program, Bloomington, IN USA; [Ozes, O. N.] Akdeniz Univ, Dept Med Biol & Genet, Antalya, Turkey; [Liu, Y.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Liu, Y.] Ctr Computat Biol & Bioinformat, Indianapolis, IN USA; [Liu, Y.; Matei, D.; Nephew, K. P.] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA; [Matei, D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Matei, D.; Nephew, K. P.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Huang, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78229 USA; [Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Akdeniz University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ Sch Med, Med Sci Program, Dept Cellular & Integrat Physiol, Jordan Hall 302,1001 East Third St, Bloomington, IN 47405 USA.	knephew@indiana.edu		Matei, Daniela/0000-0003-2169-5035	National Cancer Institute [CA13001, CA182832]; Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University, Bloomington, IN); NATIONAL CANCER INSTITUTE [U54CA113001, R01CA182832] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001108] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University, Bloomington, IN); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Aaron Buechlein (Indiana University) for help with bioinformatic analysis of TCGA data, Dr Craig Pikaard (Indian University) for the pAV-spinach vector, Dr Howard Chang (Stanford University) for LZRS-HOTAIR vector, and Dr Heather O'Hagan for carefully reading this manuscript and helpful suggestions. This work was made possible by funding from the National Cancer Institute (Awards CA13001 and CA182832), Walther Cancer Foundation (Indianapolis, IN), and the Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University, Bloomington, IN).	Almeida LO, 2014, FEBS OPEN BIO, V4, P96, DOI 10.1016/j.fob.2013.12.003; Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Dijkgraaf EM, 2013, CANCER RES, V73, P2480, DOI 10.1158/0008-5472.CAN-12-3542; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Guil S, 2012, NAT STRUCT MOL BIOL, V19, P664, DOI 10.1038/nsmb.2315; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Heubach J, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0371-8; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jing L, 2014, TUMOR BIOL, V36, P3611; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Liu ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077293; Malek E, 2014, ONCOTARGET, V5, P8027, DOI 10.18632/oncotarget.2469; Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909; Miller DFB, 2013, METHODS, V63, P126, DOI 10.1016/j.ymeth.2013.03.023; Miller DF, 2015, CURR PROTOC HUM GENE; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Ozes ON, 1999, NATURE, V401, P82; Paige JS, 2011, SCIENCE, V333, P642, DOI 10.1126/science.1207339; Qiu JJ, 2014, GYNECOL ONCOL, V134, P121, DOI 10.1016/j.ygyno.2014.03.556; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Tian C, 2014, TUMOR BIOL, V35, P3003, DOI 10.1007/s13277-013-1387-6; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wan GH, 2013, EMBO J, V32, P2833, DOI 10.1038/emboj.2013.221; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197; Wang YN, 2014, CANCER RES, V74, P4922, DOI 10.1158/0008-5472.CAN-14-1022; Wang Y, 2010, CANCER LETT, V295, P110, DOI 10.1016/j.canlet.2010.02.019; Wu ZH, 2014, ONCOL REP, V32, P395, DOI 10.3892/or.2014.3186; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yang G, 2011, CLIN CANCER RES, V17, P2181, DOI 10.1158/1078-0432.CCR-10-3265; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhang XP, 2012, BIOPHYS J, V102, P2251, DOI 10.1016/j.bpj.2012.04.002	57	187	198	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5350	5361		10.1038/onc.2016.75	http://dx.doi.org/10.1038/onc.2016.75			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041570	Green Accepted, Green Submitted			2022-12-17	WOS:000386677800002
J	Musumeci, M; Coppola, V; Addario, A; Patrizii, M; Maugeri-Sacca, M; Memeo, L; Colarossi, C; Francescangeli, F; Biffoni, M; Collura, D; Giacobbe, A; D'Urso, L; Falchi, M; Venneri, MA; Muto, G; De Maria, R; Bonci, D				Musumeci, M.; Coppola, V.; Addario, A.; Patrizii, M.; Maugeri-Sacca, M.; Memeo, L.; Colarossi, C.; Francescangeli, F.; Biffoni, M.; Collura, D.; Giacobbe, A.; D'Urso, L.; Falchi, M.; Venneri, M. A.; Muto, G.; De Maria, R.; Bonci, D.			Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer	ONCOGENE			English	Article						miRNA; microenvironment; cancer progression	FIBROBLAST-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-LINES; STROMA INTERACTIONS; MICRORNA TARGETS; MULTIPLE-MYELOMA; REACTIVE STROMA; FACTOR-2 FGF-2; FACTOR BFGF	The interaction between cancer cells and microenvironment has a critical role in tumor development and progression. Although microRNAs regulate all the major biological mechanisms, their influence on tumor microenvironment is largely unexplored. Here, we investigate the role of microRNAs in the tumor-supportive capacity of stromal cells. We demonstrated that miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed. Such downregulation of miR-15 and miR-16 in cancer-associated fibroblasts (CAFs) promoted tumor growth and progression through the reduced post-transcriptional repression of Fgf-2 and its receptor Fgfr1, which act on both stromal and tumor cells to enhance cancer cell survival, proliferation and migration. Moreover, reconstitution of miR-15 and miR-16 impaired considerably the tumor-supportive capability of stromal cells in vitro and in vivo. Our data suggest a molecular circuitry in which miR-15 and miR-16 and their correlated targets cooperate to promote tumor expansion and invasiveness through the concurrent activity on stromal and cancer cells, thus providing further support to the development of therapies aimed at reconstituting miR-15 and miR-16 in advanced prostate cancer. Oncogene (2011) 30, 4231-4242; doi: 10.1038/onc.2011.140; published online 2 May 2011	[Musumeci, M.; Coppola, V.; Addario, A.; Patrizii, M.; Maugeri-Sacca, M.; Francescangeli, F.; Biffoni, M.; Venneri, M. A.; De Maria, R.; Bonci, D.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Memeo, L.; Colarossi, C.; De Maria, R.] Mediterranean Inst Oncol, Dept Expt Oncol, Catania, Italy; [Collura, D.; Giacobbe, A.; D'Urso, L.; Muto, G.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy; [Falchi, M.] Ist Super Sanita, AIDS Natl Ctr, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Mediterranean Institute of Oncology; Istituto Superiore di Sanita (ISS)	De Maria, R (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	ruggero.demaria@iss.it; desiree.bonci@iss.it	Francescangeli, Federica/K-6500-2016; De Maria, Ruggero/S-6385-2019; Maugeri-Saccà, Marcello/K-2350-2014; Addario, Antonio/AAC-4707-2022; Bonci, Desiree/K-6488-2016; Giacobbe, alessandro/AAC-6802-2022; Biffoni, Mauro/J-8318-2016; Coppola, Valeria/K-5120-2016	Francescangeli, Federica/0000-0002-1086-5265; De Maria, Ruggero/0000-0003-2255-0583; Maugeri-Saccà, Marcello/0000-0003-2287-9581; Addario, Antonio/0000-0001-8527-8738; Bonci, Desiree/0000-0002-2472-5140; Biffoni, Mauro/0000-0002-1304-9060; Coppola, Valeria/0000-0002-5745-2572; Musumeci, Maria/0000-0001-6680-8158; Colarossi, Cristina/0000-0001-5395-8608; Muto, Giovanni/0000-0003-3593-6450; collura, devis/0000-0002-8964-5248; Falchi, Mario/0000-0002-8290-5406; VENNERI, MARY ANNA/0000-0002-0687-8135; Memeo, Lorenzo/0000-0003-4251-7203	Italian Health Ministry; Italian Association for Cancer Research (AIRC)	Italian Health Ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank Giuseppe Loreto and Maria Rita Pulvirenti for technical assistance. This work was supported by the Italian Health Ministry with 'Under forty researchers 2007' and Italy-USA programs and by the Italian Association for Cancer Research (AIRC).	Acevedo VD, 2009, CELL CYCLE, V8, P580, DOI 10.4161/cc.8.4.7657; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; CHUNG LWK, 1989, INT J CANCER, V43, P1179, DOI 10.1002/ijc.2910430636; CHUNG LWK, 1983, PROSTATE, V4, P503, DOI 10.1002/pros.2990040509; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cronauer MV, 1997, PROSTATE, V31, P223; CUNHA GR, 1983, RECENT PROG HORM RES, V39, P559; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Efstathiou E, 2010, CLIN CANCER RES, V16, P1100, DOI 10.1158/1078-0432.CCR-09-1215; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hayward SW, 2001, CANCER RES, V61, P8135; He QM, 2003, J BIOL CHEM, V278, P21831, DOI 10.1074/jbc.M300880200; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Josson S, 2010, SEMIN CELL DEV BIOL, V21, P26, DOI 10.1016/j.semcdb.2009.11.016; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kaminski A, 2006, INT J MOL MED, V18, P941; Karaa ZS, 2009, RNA, V15, P249, DOI 10.1261/rna.1301109; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; NAKAMOTO T, 1992, CANCER RES, V52, P571; Navarro A, 2011, J SURG ONCOL, V103, P411, DOI 10.1002/jso.21847; Polnaszek N, 2003, CANCER RES, V63, P5754; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Risbridger GP, 2008, ENDOCRINOLOGY, V149, P4303, DOI 10.1210/en.2008-0465; Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408; Sahni A, 2008, J THROMB HAEMOST, V6, P176; Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x; Shin VY, 2011, CARCINOGENESIS, V32, P240, DOI 10.1093/carcin/bgq240; Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Wernert Nicolas, 2007, V382, P223, DOI 10.1007/978-1-59745-304-2_14; Winter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yang F, 2008, ONCOGENE, V27, P450, DOI 10.1038/sj.onc.1210663; Zhang YL, 2001, J PHARMACOL EXP THER, V299, P426	54	187	200	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	41					4231	4242		10.1038/onc.2011.140	http://dx.doi.org/10.1038/onc.2011.140			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21532615				2022-12-17	WOS:000296356300002
J	Mochizuki, T; Furuta, S; Mitsushita, J; Shang, W; Ito, M; Yokoo, Y; Yamaura, M; Ishizone, S; Nakayama, J; Konagai, A; Hirose, K; Kiyosawa, K; Kamata, T				Mochizuki, T.; Furuta, S.; Mitsushita, J.; Shang, W. H.; Ito, M.; Yokoo, Y.; Yamaura, M.; Ishizone, S.; Nakayama, J.; Konagai, A.; Hirose, K.; Kiyosawa, K.; Kamata, T.			Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells	ONCOGENE			English	Article						Nox4; apoptosis; AKT; ASK1	PROTEIN-KINASE B; NAD(P)H OXIDASE; ANGIOTENSIN-II; NADPH OXIDASE; SUPEROXIDE; INSULIN; PHOSPHORYLATES; EXPRESSION; MECHANISM; HOMOLOGS	Pancreatic adenocarcinoma is an aggressive human malignancy and is characterized by resistance to apoptosis. Recently, NADPH oxidase ( Nox) 4-mediated generation of intracellular reactive oxygen species ( ROS) was proposed to confer antiapoptotic activity and thus a growth advantage to pancreatic cancer cells. The signaling mechanism by which Nox4 transmits cell survival signals remains unclear. Here, we show that both a flavoprotein inhibitor, diphenylene iodonium ( DPI), and small interfering RNAs designed to target Nox4 mRNA ( siNox4R-NAs) inhibited superoxide production in PANC-1 pancreatic cancer cells, and depletion of ROS by DPI or siNox4RNAs induced apoptosis. Parallely, DPI treatment and siNox4RNA transfection blocked activation of the cell survival kinase AKT by attenuating phosphorylation of AKT. Furthermore, AKT phosphorylation of apoptosis signal-regulating kinase 1 ( ASK1) on Ser-83 was reduced by DPI and siNox4RNAs. When ASK1Ser83Ala ( an AKT phosphorylation-defective ASK1 mutant) was introduced into PANC-1 cells, this mutant alone induced apoptosis. But, addition of DPI or co-transfection of siNox4RNA had no additive effect, indicating that the mutant can substitute for these reagents in apoptosis induction. Taken together, these findings suggest that ROS generated by Nox4, at least in part, transmit cell survival signals through the AKT ASK1 pathway in pancreatic cancer cells and their depletion leads to apoptosis.	Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Grad Sch Med, Dept Internal Med 2, Nagano, Japan; Shinshu Univ, Grad Sch Med, Dept Dermatol, Matsumoto, Nagano, Japan; Shinshu Univ, Grad Sch Med, Dept Surg, Matsumoto, Nagano, Japan; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Nagano, Japan; Kureha Chem Ind Co Ltd, Biomed Res Inst, Tokyo, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University; Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Djordjevic T, 2005, ARTERIOSCL THROM VAS, V25, P519, DOI 10.1161/01.ATV.0000154279.98244.eb; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gorin Y, 2004, BIOCHEM J, V381, P231, DOI 10.1042/BJ20031614; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yu WP, 2003, CANCER RES, V63, P2483	37	187	196	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3699	3707		10.1038/sj.onc.1209406	http://dx.doi.org/10.1038/sj.onc.1209406			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16532036				2022-12-17	WOS:000238448300009
J	de Bruijn, MFTR; Speck, NA				de Bruijn, MFTR; Speck, NA			Core-binding factors in hematopoiesis and immune function	ONCOGENE			English	Review						Runx1; Runx2; Runx3; CBF beta; AML1; hematopoiesis; hematopoietic stem cells	ACUTE MYELOID-LEUKEMIA; RUNX3 TRANSCRIPTION FACTOR; T-CELL DEVELOPMENT; STEM-CELLS; ENDOTHELIAL-CELLS; FETAL LIVER; EMBRYONIC HEMATOPOIESIS; EXPRESSION PATTERN; LINEAGE ANALYSIS; GENE-EXPRESSION	Core binding factors are heterodimeric transcription factors containing a DNA binding Runx1, Runx2, or Runx3 subunit, along with a non DNA binding CBFbeta subunit. All four subunits are required at one or more stages of hematopoiesis. This review describes the role of Runx1 and CBFb in the initiation of hematopoiesis in the embryo, and in the emergence of hematopoietic stem cells. We also discuss the later stages of hematopoiesis for which members of the core binding factor family are required, as well as the recently described roles for these proteins in autoimmunity.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England	Dartmouth College; University of Oxford	Speck, NA (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	nancy.speck@dartmouth.edu			MRC [MC_U137970202] Funding Source: UKRI; Medical Research Council [MC_U137970202] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; BAE SC, 1993, ONCOGENE, V8, P809; Basecke J, 2002, ANN HEMATOL, V81, P254, DOI 10.1007/s00277-002-0453-8; BERGER R, 1982, BLOOD, V59, P171; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; Burel SA, 2001, MOL CELL BIOL, V22, P144; Burns CE, 2002, EXP HEMATOL, V30, P1381, DOI 10.1016/S0301-472X(02)00955-4; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chimienti G, 2000, BLOOD CELL MOL DIS, V26, P186, DOI 10.1006/bcmd.2000.0295; Choi K, 1998, DEVELOPMENT, V125, P725; Chung YS, 2002, DEVELOPMENT, V129, P5511, DOI 10.1242/dev.00149; Ciau-Uitz A, 2000, CELL, V102, P787, DOI 10.1016/S0092-8674(00)00067-2; CURTIS DJ, 2004, BLOOD           0115; de Bruijn MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/emboj/19.11.2465; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DOWTON SB, 1985, BLOOD, V65, P557; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Ehlers M, 2003, J IMMUNOL, V171, P3594, DOI 10.4049/jimmunol.171.7.3594; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Elefanty AG, 1999, BLOOD, V94, P3754, DOI 10.1182/blood.V94.11.3754.423k05_3754_3763; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fraser ST, 2003, DEV GROWTH DIFFER, V45, P63; Fujimoto T, 2001, GENES CELLS, V6, P1113, DOI 10.1046/j.1365-2443.2001.00490.x; GERRARD JM, 1991, BRIT J HAEMATOL, V79, P246, DOI 10.1111/j.1365-2141.1991.tb04529.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gill J, 2003, IMMUNOL REV, V195, P28, DOI 10.1034/j.1600-065X.2003.00077.x; Godin I, 2002, NAT REV IMMUNOL, V2, P593, DOI 10.1038/nri857; Gottgens B, 2004, MOL CELL BIOL, V24, P1870, DOI 10.1128/MCB.24.5.1870-1883.2004; Hall MA, 2003, P NATL ACAD SCI USA, V100, P992, DOI 10.1073/pnas.0237324100; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hayashi K, 2001, J IMMUNOL, V167, P4957, DOI 10.4049/jimmunol.167.9.4957; Helms C, 2003, NAT GENET, V35, P349, DOI 10.1038/ng1268; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Hug BA, 2002, CANCER RES, V62, P2906; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; Jaffredo T, 2000, DEV BIOL, V224, P204, DOI 10.1006/dbio.2000.9799; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lauzurica P, 1997, J EXP MED, V185, P1193, DOI 10.1084/jem.185.7.1193; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Lewis AF, 1999, J VIROL, V73, P5535, DOI 10.1128/JVI.73.7.5535-5547.1999; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lind EF, 2001, J EXP MED, V194, P127, DOI 10.1084/jem.194.2.127; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; LUDDY RE, 1978, CANCER, V41, P1959, DOI 10.1002/1097-0142(197805)41:5<1959::AID-CNCR2820410540>3.0.CO;2-8; Medvinsky AL, 1996, BLOOD, V87, P557, DOI 10.1182/blood.V87.2.557.bloodjournal872557; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Nishimura M, 2004, BLOOD, V103, P562, DOI 10.1182/blood-2003-06-2109; North T, 1999, DEVELOPMENT, V126, P2563; North TE, 2004, STEM CELLS, V22, P158, DOI 10.1634/stemcells.22-2-158; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Oberlin E, 2002, DEVELOPMENT, V129, P4147; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; Puig-Kroger A, 2003, BLOOD, V102, P3252, DOI 10.1182/blood-2003-02-0618; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sanchez MJ, 1999, DEVELOPMENT, V126, P3891; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Sato T, 2003, IMMUNOL LETT, V89, P39, DOI 10.1016/S0165-2478(03)00103-2; Shi MJ, 1998, J IMMUNOL, V161, P6751; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; Sinclair AM, 1999, DEV BIOL, V209, P128, DOI 10.1006/dbio.1999.9236; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; SWIRSKY DM, 1984, BRIT J HAEMATOL, V56, P199, DOI 10.1111/j.1365-2141.1984.tb03948.x; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Telfer JC, 2004, J IMMUNOL, V172, P4359, DOI 10.4049/jimmunol.172.7.4359; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Tracey WD, 1998, DEVELOPMENT, V125, P1371; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yannoutsos N, 2004, NAT IMMUNOL, V5, P443, DOI 10.1038/ni1053; Yano M, 1997, BLOOD, V89, P4317, DOI 10.1182/blood.V89.12.4317; Yokomizo T, 2000, BLOOD, V96, p283A; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhao FQ, 2002, INT IMMUNOL, V14, P1383, DOI 10.1093/intimm/dxf103	126	187	189	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4238	4248		10.1038/sj.onc.1207763	http://dx.doi.org/10.1038/sj.onc.1207763			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156179				2022-12-17	WOS:000221586000008
J	Cao, Y; Li, H; Deb, S; Liu, JP				Cao, Y; Li, H; Deb, S; Liu, JP			TERT regulates cell survival independent of telomerase enzymatic activity	ONCOGENE			English	Article						telomerase; hTERT; p53; PARP cell survival	CATALYTIC SUBUNIT GENE; LIFE-SPAN; WILD-TYPE; CANCER; P53; INHIBITION; ACTIVATION; END	Human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, plays a pivotal role in the maintenance of telomeres and cell proliferation. Here we report that down-regulation of hTERT induces apoptosis independently of telomerase enzymatic activity in human breast cancer cells. Expression of a hTERT mutant lacking telomerase activity rescues the cells with lowered telomerase without inducing cell death. With similar patterns of subcellular distribution to that of the tumor suppressor protein p53 during mitosis, hTERT interacts with p53 and poly(ADP-ribose) polymerase (PARP). Decreasing p53 expression in intact cells worsens, and increasing p53 prevents, cell death induced by lowering hTERT. Thus, hTERT maintains cell survival and proliferation via both telomerase enzymatic activity-dependent telomere lengthening and enzymatic activity-independent intermolecular interactions involving p53 and PARP.	Baker Med Res Inst, Mol Signalling Lab, Prahran, Vic 3181, Australia; Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute; Monash University	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, Commercial Rd, Prahran, Vic 3181, Australia.	jun-ping.liu@med.monash.edu.au		Liu, Jun-Ping/0000-0001-7442-2116				Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cao Y, 2001, FASEB J, V15, P96, DOI 10.1096/fj.01-0447fje; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; GREIDER CW, 1995, TELOMERES, P35; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI H, 2001, IN PRESS BIOGERONTOL; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; LIU JP, 2001, ADV CELL AGING GERON, V8, P33; Liu Jun-Ping, 2000, Molecular Cell Biology Research Communications, V3, P129, DOI 10.1006/mcbr.2000.0203; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Saretzki G, 2001, CANCER GENE THER, V8, P827, DOI 10.1038/sj.cgt.7700383; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wesierska-Gadek J, 2000, J CELL BIOCHEM, V80, P85; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	42	187	201	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3130	3138		10.1038/sj.onc.1205419	http://dx.doi.org/10.1038/sj.onc.1205419			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082628				2022-12-17	WOS:000175373600004
J	Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J				Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J			The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1	ONCOGENE			English	Article						Ras; Nore1; RASSF1; tumor suppressor; apoptosis	PHOSPHOLIPASE-C; IDENTIFICATION; EFFECTOR; KINASE; ACTIVATION; EPSILON; FAMILY	Nore and RASSF1A are noncatalytic proteins that share 50% identity over their carboxyterminal 300 AA, a segment that encompasses a putative Ras-Rap association (RA) domain. RASSF1 is expressed as several splice variants, each of which contain an RA domain, however the 340 AA RASSF1A, but not the shorter RASSF1C variant, is a putative tumor suppressor. Nore binds to Ras and several Ras-like GTPases in a GTP dependent fashion however neither RASSF1 (A or C) or the C. elegans Nore/RASSF1 homolog, T24F1.3 exhibit any interaction with Ras or six other Ras-like GTPases in a yeast two-hybrid expression assay. A low recovery of RASSF1A (but not RASSF1C) in association with RasG12V is observed however on transient expression in COS cells. Nore and RASSF1A can each efficiently homodimerize and heterodimerize with each other through their nonhomologous aminoterminal segments. Recombinant RASSF1C exhibits a much weaker ability to homodimerize or heterodimerize; thus the binding of RASSF1C to Nore is very much less than the binding of RASSF1A to Nore. The association of RASSF1A with RasG12V in COS cells appears to reflect the hetero-dimerization of RASSF1A with Nore, inasmuch the recovery of RASSF1A with RasG12V is increased by concurrent expression of full length Nore, and abolished by expression of Nore deleted of its RA domain. The preferential ability of RASSF1A to heterodimerize with Nore and thereby associate with Ras-like GTPases may be relevant to its putative tumor suppressor function.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabetes Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; City of Hope; Beckman Research Institute of City of Hope	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, 50 Blossom St, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32DK07028] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Baumann R, 1999, BLOOD, V94, P4314, DOI 10.1182/blood.V94.12.4314.424k16_4314_4320; Daniel TF, 2000, SYST BOT, V25, P15, DOI 10.2307/2666669; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ehrhardt GRA, 2001, ONCOGENE, V20, P188, DOI 10.1038/sj.onc.1204053; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; Kalhammer G, 1997, FEBS LETT, V414, P599, DOI 10.1016/S0014-5793(97)01076-4; KEIKHOFT E, 1998, ONCOGENE, V17, P1457; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lerman MI, 2000, CANCER RES, V60, P6116; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	38	187	204	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1381	1390		10.1038/sj.onc.1205192	http://dx.doi.org/10.1038/sj.onc.1205192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857081				2022-12-17	WOS:000173861000008
J	Guo, C; White, PS; Weiss, MJ; Hogarty, MD; Thompson, PM; Stram, DO; Gerbing, R; Matthay, KK; Seeger, RC; Brodeur, GM; Maris, JM				Guo, C; White, PS; Weiss, MJ; Hogarty, MD; Thompson, PM; Stram, DO; Gerbing, R; Matthay, KK; Seeger, RC; Brodeur, GM; Maris, JM			Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas	ONCOGENE			English	Article						neuroblastoma; chromosome, human, pair 11; loss of heterozygosity; genes, suppressor, tumor; deletion mapping	COMPARATIVE GENOMIC HYBRIDIZATION; TANDEM-REPEAT POLYMORPHISMS; FAMILIAL NEUROBLASTOMA; CHROMOSOME 1P; TUMORS; MAP; HETEROZYGOSITY; REGION	Deletions of the long arm of chromosome 11 (11q) have been noted in primary neuroblastomas, but a comprehensive analysis has not been performed. Therefore, we analysed 331 neuroblastomas (295 sporadic, 15 familial and 21 tumor-derived cell Lines) to determine the prevalence of 11q allelic deletions, to map the location of a putative tumor suppressor gene and to perform clinical correlative studies. Assays for loss of heterozygosity (LOH) were performed at 24 microsatellite loci spanning 11q, LOH was observed at multiple 11q loci in 129/295 (44%) sporadic neuroblastomas, 5/15 (33%) familial neuroblastomas, and 5/21 (24%) neuroblastoma cell lines. A single region of 2.1 cM within 11q23,3, flanked by markers D11S1340 and D11S1299, was deleted in all specimens with 11q LOH, Allelic loss at 11q23 was inversely related to MYCN amplification (P < 0,001), Within the subset of cases with a single copy of MYCN 11q LOH was associated with advanced stage disease (P = 0,008), unfavorable histopathology (P = 0,042), and decreased overall survival probability (P = 0,008), However, 11q LOH was not independently prognostic in multivariate analyses, These data support the hypothesis that a tumor suppressor gene mapping within 11q23,3 is commonly inactivated during the malignant evolution of a large subset of neuroblastomas, especially those with unamplified MYCN.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Canc Grp, Arcadia, CA 91066 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Southern California; University of California System; University of California San Francisco	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC 902A,324 S 34th St, Philadelphia, PA 19104 USA.		Thompson, Paul M/C-4194-2018	Thompson, Paul M/0000-0002-4720-8867	NATIONAL CANCER INSTITUTE [U10CA013539, U10CA078966, R01CA078545] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13539, CA-78545, CA-78966] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altura RA, 1997, GENE CHROMOSOME CANC, V19, P176, DOI 10.1002/(SICI)1098-2264(199707)19:3<176::AID-GCC7>3.0.CO;2-V; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BIEDLER JL, 1980, ADV NEUROBLASTOMA RE, P81; BOWN NP, 1993, CANCER GENET CYTOGEN, V69, P166, DOI 10.1016/0165-4608(93)90100-Z; Brinkschmidt C, 1997, J PATHOL, V181, P394; Brodeur Garrett M., 1997, P761; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Caron H, 1996, HUM GENET, V97, P834; COX DR, 1972, J R STAT SOC B, V34, P187; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1992, CANCER RES, V52, P1780; GEHRING M, 1995, CANCER RES, V55, P5366; Hallstensson K, 1997, EUR J CANCER, V33, P1966, DOI 10.1016/S0959-8049(97)00228-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOIFFMANN CP, 1995, AM J MED GENET, V58, P46, DOI 10.1002/ajmg.1320580110; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; Maris JM, 1997, EUR J CANCER, V33, P1923, DOI 10.1016/S0959-8049(97)00265-7; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 1996, GENOMICS, V35, P289, DOI 10.1006/geno.1996.0359; MARTINSSON T, 1995, CANCER RES, V55, P5681; Mertens F, 1997, CANCER RES, V57, P2765; MOORHEAD PS, 1980, PROGR CANCER RES THE, V12, P109; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; NOWAK NJ, 1995, CANC INVEST, V13, P649; PEGELOW CH, 1975, J PEDIATR-US, V87, P763, DOI 10.1016/S0022-3476(75)80304-0; Plantaz D, 1997, AM J PATHOL, V150, P81; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; Takeda O, 1996, BRIT J CANCER, V74, P1620, DOI 10.1038/bjc.1996.598; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; Van Gele M, 1997, EUR J CANCER, V33, P1979, DOI 10.1016/S0959-8049(97)00289-X; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Yuan B, 1997, AM J HUM GENET, V60, P459	42	187	190	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4948	4957		10.1038/sj.onc.1202887	http://dx.doi.org/10.1038/sj.onc.1202887			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490829				2022-12-17	WOS:000082321700007
J	Vadlamudi, R; Mandal, M; Adam, L; Steinbach, G; Mendelsohn, J; Kumar, R				Vadlamudi, R; Mandal, M; Adam, L; Steinbach, G; Mendelsohn, J; Kumar, R			Regulation of cyclooxygenase-2 pathway by HER2 receptor	ONCOGENE			English	Article						NDF; COX-2; colon cancer	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR-ALPHA; HUMAN-COLON-CANCER; PROSTAGLANDIN-H SYNTHASE-2; TYROSINE KINASE-ACTIVITY; EPITHELIAL-CELLS; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; ERBB RECEPTORS; GENE-PRODUCT	Emerging lines of evidence suggest that in addition to growth factors, the process of colorectal tumorigenesis map also be driven by the upregulation of the inducible form of cyclooxygenase-2 (COX-2), an enzyme responsible for the conversion of arachidonic acid to PGEs, The present study was undertaken to investigate the expression and activation of the HER family members, and to explore the regulation of COS-2 expression by the HER2 pathway in human colorectal cancer cells. Here, rye report that human colorectal cancer cell lines express abundant levels of HER2, and HER3 receptors, and are growth-stimulated by recombinant neu-differentiation factor-beta 1 (NDF), NDF-treatment of colorectal cancer cells was accompanied by increased tyrosine phosphorylation and heterodimerization of HER3 with HER2, In addition, we demonstrated that HER2 and HER3 receptors in colorectal cancer cells are constitutively phosphorylated on tyrosine residues and form heterodimeric complexes in the absence of exogenous NDF, Inhibition of HER2/HER3 signaling by an anti-HER3 mAb against the ligand binding site resulted in a decrease in the levels of constitutively activated HER2/HER3 heterodimers, and the unexpected reduction of COS-2 expression, Activation of the HER2/HER3 pathway by NDF induced the activation of COX-2 promoter, expression of COX-2 mRNA, COX-2 protein and accumulation of prostaglandin E2 in the culture medium. Finally, we demonstrated that NDF promotes the ability of colorectal cancer cells to sur,ive in an extracellular matrix milieu, such as Matrigel, and also to invade through a 8 mu m porous membrane. These biological activities of NDF and its stimulation of cell proliferation are blocked by a specific inhibitor of COX-2, Taken together, our findings provide the first biochemical evidence of a possible role of the COS-2 pathway in the mitogenic action of NDF in colorectal cancer cells where it may be constitutively upregulated due to the autocrine/paracrine activation of HER2/HER3 heterodimers.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Gastrointestinal Oncol & Digest Dis, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323; Steinbach, Gideon/0000-0001-7597-0544	NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANZANO MA, 1989, CANCER RES, V49, P2898; Boolbol SK, 1996, CANCER RES, V56, P2556; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chiu CH, 1997, CANCER RES, V57, P4267; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COFFEY RJ, 1987, CANCER RES, V47, P4590; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; Granstrom E, 1978, Adv Prostaglandin Thromboxane Res, V5, P119; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1996, J CELL BIOCHEM, V239, P914; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MANDAL M, 1998, IN PRESS ONCOGENE; Mandel C, 1997, AM BOOK REV, V18, P29; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; REIDEL H, 1988, P NATL ACAD SCI USA, V85, P1477; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1990, CELL, V61, P212; UNTAWALE S, 1993, CANCER RES, V53, P1630; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yang JL, 1997, ANTICANCER RES, V17, P1023; Zhang K, 1996, J BIOL CHEM, V271, P3884	49	187	202	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					305	314		10.1038/sj.onc.1202307	http://dx.doi.org/10.1038/sj.onc.1202307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927187				2022-12-17	WOS:000078166500003
J	Sherman, L; Xu, HM; Geist, RT; SaporitoIrwin, S; Howells, N; Ponta, H; Herrlich, P; Gutmann, DH				Sherman, L; Xu, HM; Geist, RT; SaporitoIrwin, S; Howells, N; Ponta, H; Herrlich, P; Gutmann, DH			Interdomain binding mediates tumor growth suppression by the NF2 gene product	ONCOGENE			English	Article						merlin; negative growth regulator; tumor suppressor gene; schwannomin; schwannoma; ERM proteins	NEUROFIBROMATOSIS TYPE-2 GENE; TERMINAL DOMAIN; CELL LINES; MUTATIONS; MEMBRANE; RADIXIN; MERLIN; EXPRESSION; LOCALIZES; ISOFORMS	The neurofibromatosis 2 (NF2) tumor suppressor gene encodes an intracellular membrane-associated protein, called merlin (or schwannomin), that belongs to the band 4.1 family of cytoskeleton-associated proteins, Inactivating NF2 mutations occur in several sporadic tumor types and have been linked to the NF2 disease, whose hallmark is the development of bilateral Schwann cell tumors (schwannomas) of the eighth cranial nerve, Two major alternatively spliced NI;2 variants are expressed in normal tissues:'NF2-17 lacking exon 16 and 'NF2-16' that contains exon 16 and encodes a merlin protein truncated at the C-terminus, We report that overexpression of NF2-17 in rat schwannoma cells inhibits their growth in vitro and in vivo, while NF2-16 fails to influence schwannoma growth, Tumor growth inhibition by merlin depends on an interdomain association occurring either in cis or in hans between the N- and C-termini, This association does not occur in the truncated NF2-16 protein nor in a mutant NF2-17 protein lacking C-terminal sequences, These data indicate that merlin has a unique mechanism of tumor suppression, inhibiting cell proliferation via self-association.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,D-76021 KARLSRUHE,GERMANY	Washington University (WUSTL); Helmholtz Association; Karlsruhe Institute of Technology				Gutmann, David/0000-0002-3127-5045				BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BIJISMA E, 1995, HUM GENET, V96, P1; DENBAKKER MA, 1995, ONCOGENE, V10, P757; EVANS DGR, 1995, J MED GENET, V32, P470, DOI 10.1136/jmg.32.6.470; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GUTMANN DH, 1995, HUM MOL GENET, V4, P471, DOI 10.1093/hmg/4.3.471; Gutmann DH, 1995, INT J DEV BIOL, V39, P895; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; HAASE VH, 1994, HUM MOL GENET, V3, P407, DOI 10.1093/hmg/3.3.407; HARA T, 1994, CANCER RES, V54, P330; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Parry DM, 1996, AM J HUM GENET, V59, P529; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.0.CO;2-E; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sherman L, 1995, J NEURO-ONCOL, V26, P171, DOI 10.1007/BF01052620; SHORT MP, 1994, NEUROFIBROMATOSES PA, P414; SWAFFIELD JC, 1996, CURRENT PROTOCOLS MO, pCH20; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TOMOZAWA Y, 1978, P NATL ACAD SCI USA, V75, P6305, DOI 10.1073/pnas.75.12.6305; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G	30	187	189	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2505	2509		10.1038/sj.onc.1201418	http://dx.doi.org/10.1038/sj.onc.1201418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395247				2022-12-17	WOS:A1997YE96300013
J	Mechta, F; Lallemand, D; Pfarr, CM; Yaniv, M				Mechta, F; Lallemand, D; Pfarr, CM; Yaniv, M			Transformation by ras modifies AP1 composition and activity	ONCOGENE			English	Article						AP1; cJun; Fra1; Ras; serum inducibility; transformation	SERUM RESPONSE ELEMENT; NIH 3T3 CELLS; TERNARY COMPLEX-FORMATION; JUN ACTIVATION DOMAIN; IMMEDIATE EARLY GENES; C-FOS EXPRESSION; PROTEIN-KINASE; GROWTH-FACTORS; TRANSCRIPTION FACTOR; CYCLIN D1	The Ras proteins play a central role in regulating cell growth and their mutation can lead to abnormal proliferation. To analyse the potential link betwen AP1 activity, encoded by members of the jun and fos gene families, and Ras-mediated cellular transformation, we have studied several NIH3T3 clones which overexpress the Ha-Ras or Ki-Ras oncogenes. These transformed fibroblasts accumulated higher levels of cJun, JunB, Fra1 and Fra2 proteins relative to their normal counterparts. They also displayed increased AP1 DNA binding activity which was predominantly composed of cJun and Fra1 containing diners. Following serum stimulation of Ras clones, the elevated levels of cJun and Fra1 remained steady,,while the induction of JunB and Fra2 was partially attenuated. Moreover, deregulated Ras signaling resulted in a complete loss of the serum inducibility of cFos and FosB. Ectopic co-expression of cJun and Fra1 in NIH3T3 fibroblasts led to a transformed phenotype, attenuation of cFos serum inducibility, increased AP1 activity and Cyclin D1 accumulation, all characteristics of oncogenic Ras expressing cells. These results demonstrate that cJun and Fra1 are crucial mediators of the Ras-transformation process.	INST PASTEUR, UNITE VIRUS ONCOGENES, URA 1644 CNRS, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			lallemand, dominique/O-7445-2017; Pfarr, Curt/HHD-1410-2022; MECHTA-GRIGORIOU, Fatima/C-5253-2017	lallemand, dominique/0000-0002-0212-7342; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSSLINGER M, 1994, INC, V10, P133; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILMUS J, 1994, ONCOGENE, V9, P3627; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERBER, 1994, ONCOGENE, V9, P2105; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MECHTA F, 1989, New Biologist, V1, P297; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHONTHAL A, 1988, NATURE, V354, P325; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SEWING A, 1993, J CELL SCI, V104, P545; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	86	187	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					837	847		10.1038/sj.onc.1200900	http://dx.doi.org/10.1038/sj.onc.1200900			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047391				2022-12-17	WOS:A1997WJ11200010
J	MacCallum, DE; Hupp, TR; Midgley, CA; Stuart, D; Campbell, SJ; Harper, A; Walsh, FS; Wright, EG; Balmain, A; Lane, DP; Hall, PA				MacCallum, DE; Hupp, TR; Midgley, CA; Stuart, D; Campbell, SJ; Harper, A; Walsh, FS; Wright, EG; Balmain, A; Lane, DP; Hall, PA			The p53 response to ionising radiation in adult and developing murine tissues	ONCOGENE			English	Article						p53; radiation; apoptosis; development; heterogeneity; immunochemistry; teratogenesis; transgenesis	CELLULAR TUMOR-ANTIGEN; P53-DEFICIENT MICE; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; GASTROINTESTINAL-TRACT; P53-MEDIATED APOPTOSIS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; GAMMA-IRRADIATION; HELA-CELLS	The induction of the p53 response to ionising radiation has been studied during murine development and in the adult animal. The response has been assessed by precise quantitative assay of p53 protein levels in tissues and by immunohistochemistry. Newly developed transgenic mice in which a lacZ transgene is driven by a p53 response element have also been used to directly assess the transcriptional activity of the induced protein, There is striking developmental control of the p53 response so that in early development all tissues accumulate high levels of p53 following radiation and indeed p53 is present at elevated levels in some unirradiated tissues, Later in development clear heterogeneity of the p53 response becomes apparent, both in terms of the responses of individual tissues and of cell populations, within those tissues, The study of lacZ transgene expression and the occurrence of apoptosis in different tissues that accumulate p53 protein point to a further level of control regulating the nature and degree of the downstream response to elevated levels of p53 in cells, These findings have important implications for the susceptibility of different tissue types to carcinogenic and other insults, The early expression of the p53 response is consistent with novel models of p53 function that suggest it may have evolved principally as a defense against teratogenic insult that permits plasticity of development.	UNIV DUNDEE, DEPT MOL & CELLULAR PATHOL, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, CRC, CELL TRANSFORMAT GRP, DEPT BIOCHEM, DUNDEE DD1 9SY, SCOTLAND; BEATSON INST CANC RES, CRC, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND; UNITED MED & DENT SCH, TRANSGEN UNIT, LONDON SE1 9RT, ENGLAND; UNITED MED & DENT SCH, DEPT EXPT PATHOL, LONDON SE1 9RT, ENGLAND; MRC, RADIAT & GENOME STABIL UNIT, DIDCOT OX11 0RD, OXON, ENGLAND; UNIV DUNDEE, CTR BIOMED RES, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee; Beatson Institute; University of London; King's College London; University of London; King's College London; MRC Harwell; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BELLAMY COC, 1996, UNPUB; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAMPBELL SF, IN PRESS J CELL SCI; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ferreira A, 1996, J CELL SCI, V109, P1509; FORBES RM, 1953, J BIOL CHEM, V203, P359; FREBOURG T, 1992, CANCER RES, V52, P6976; GOTTLIEB ER, UNPUB; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL PA, 1994, J CELL SCI, V107, P3569; Hall PA, 1996, J PATHOL, V180, P1; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HALL PA, 1994, EUR J CANCER, V30A, P2001, DOI 10.1016/0959-8049(94)00394-K; HANSEN S, 1996, IN PRESS J BIOL CHEM; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOEVER M, 1994, ONCOGENE, V9, P109; HOGAN B, 1994, MANIPULATING MOUSE E; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kitada S, 1996, ONCOGENE, V12, P187; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOMAROVA EA, UNPUB; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCCORMICK D, 1993, HISTOPATHOLOGY, V22, P543, DOI 10.1111/j.1365-2559.1993.tb00174.x; MCKEE PH, 1993, HISTOPATHOLOGY, V23, P377, DOI 10.1111/j.1365-2559.1993.tb01223.x; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MERRICK BA, 1995, BIOTECHNIQUES, V18, P292; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; RUGH R, 1963, AMER J ROENTGENOL RA, V89, P182; RUSSELL LB, 1957, P SOC EXP BIOL MED, V95, P174; RUSSELL LB, 1954, J CELL COMPAR PHYSL, V43, pA103, DOI 10.1002/jcp.1030430407; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WEINBERG WC, 1995, ONCOGENE, V10, P2271; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIRNITZER U, 1995, CARCINOGENESIS, V16, P697, DOI 10.1093/carcin/16.4.697; Wubah JA, 1996, CURR BIOL, V6, P60, DOI 10.1016/S0960-9822(02)00422-0	66	187	192	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2575	2587						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000131				2022-12-17	WOS:A1996VZ65400007
J	CHEN, ML; TSAI, CN; LIANG, CL; SHU, CH; HUANG, CR; SULITZEANU, D; LIU, ST; CHANG, YS				CHEN, ML; TSAI, CN; LIANG, CL; SHU, CH; HUANG, CR; SULITZEANU, D; LIU, ST; CHANG, YS			CLONING AND CHARACTERIZATION OF THE LATENT MEMBRANE-PROTEIN (LMP) OF A SPECIFIC EPSTEIN-BARR-VIRUS VARIANT DERIVED FROM THE NASOPHARYNGEAL CARCINOMA IN THE TAIWANESE POPULATION	ONCOGENE			English	Article							EPITHELIAL-CELLS; DNA; TRANSFORMATION; ANTIBODIES; SEQUENCES; AMPLIFICATION; TRANSCRIPTION; REPLICATION; ANTIGENS; REGION	A DNA fragment containing Epstein-Barr virus (EBV) terminal fragment sequence was obtained from a genomic library of nasopharyngeal carcinoma (NPC). One of the clones (clone 1510) contained the gene encoding latent membrane protein (LMP). Sequence analysis revealed that this gene had 95% homology with the LMP sequence of the B95-8 strain. Among the sequence variations, there was a change from G to T at nucleotide position 169 426, resulting in the loss of an XhoI site in exon 1 of the LMP gene. A pair of primers bracketing the XhoI site were designed to synthesize the EBV DNA fragment from nucleotides 169 081-169 577 by using the polymerase chain reaction (PCR) method. The PCR products were then subject to XhoI digestion and to DNA sequencing analysis. This restriction enzyme site polymorphism along with the sequence variations were also observed in 50 biopsy tissues as well as in the throat washings of 6 out of 20 healthy individuals that we examined, indicating that the EBV strain predominantly existing in these biopsy tissues was different from strains of B95-8, Jijoye or nude mouse passaged cells (C15) with an African origin, but closely resembled other nude mouse passaged CAO cells which were originally derived from China. Balb/c 3T3 cells carrying this NPC-LMP gene showed a transformed cell morphology and were tumorigenic in nude mice. The relationship between this unique type of EBV and NPC has yet to be established.	CHANG GUNG MED COLL,DEPT MICROBIOL & IMMUNOL,259 WEN HWA IST RD,TAOYUAN 33332,TAIWAN; NATL YANG MING MED COLL,GRAD INST MICROBIOL & IMMUNOL,SHIH PAI 11221,TAIWAN; VET GEN HOSP TAIPEI,DEPT OTOLARYNGOL,TAIPEI 11217,TAIWAN; HEBREW UNIV JERUSALEM,HADASSAH MED CTR,DEPT IMMUNOL,JERUSALEM,ISRAEL	Chang Gung University; Hebrew University of Jerusalem; Hadassah University Medical Center			Tsai, Chi neu/C-3373-2011; Tsai, Chi-Neu/AAZ-2558-2020	Tsai, Chi neu/0000-0002-5940-0696; Tsai, Chi-Neu/0000-0002-5940-0696; Chang, Yu-Sun/0000-0002-6457-3890				BAICHWAL VR, 1989, ONCOGENE, V4, P67; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; CHANG YS, 1990, LEUKEMIA RES, V14, P309, DOI 10.1016/0145-2126(90)90157-5; CHANG YS, 1991, NUCLEIC ACIDS RES, V20, P139; DAMBAUGH T, 1980, P NATL ACAD SCI-BIOL, V77, P2999, DOI 10.1073/pnas.77.5.2999; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DESGRANGES C, 1975, INT J CANCER, V16, P7, DOI 10.1002/ijc.2910160103; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANTO DW, 1985, TRANSPLANTATION, V39, P461, DOI 10.1097/00007890-198505000-00001; HENLE G, 1971, JNCI-J NATL CANCER I, V46, P861; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE W, 1970, J NATL CANCER I, V44, P225; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; KLEIN G, 1980, P NATL ACAD SCI USA, V77, P6162; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER G, 1973, P NATL ACAD SCI USA, V70, P4006; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHU CH, 1991, IN PRESS J VIROL MET; SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0; SIXBEY JW, 1989, LANCET, V2, P761; SMITH PR, 1992, J VIROL, V66, P706, DOI 10.1128/JVI.66.2.706-714.1992; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988	40	187	203	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2131	2140						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331932				2022-12-17	WOS:A1992JW66500005
J	LACROIX, H; IGLEHART, JD; SKINNER, MA; KRAUS, MH				LACROIX, H; IGLEHART, JD; SKINNER, MA; KRAUS, MH			OVEREXPRESSION OF ERBB-2 OR EGF RECEPTOR PROTEINS PRESENT IN EARLY STAGE MAMMARY-CARCINOMA IS DETECTED SIMULTANEOUSLY IN MATCHED PRIMARY TUMORS AND REGIONAL METASTASES	ONCOGENE			English	Article									NCI,BIOL ANIM LAB,BETHESDA,MD 20205; DUKE UNIV,DEPT SURG,DURHAM,NC 27706	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University					NCI NIH HHS [CA40640] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040640] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BERGER MS, 1988, CANCER RES, V48, P1238; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEGATTO O, 1988, IN PRESS MOL CELL BI; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1988, SCIENCE, V240, P1796, DOI 10.1126/science.240.4860.1796; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WRANN MM, 1979, J BIOL CHEM, V254, P8083; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	34	187	192	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					145	151						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2564657				2022-12-17	WOS:A1989U567500004
J	WOLLERSHEIM, M; DEBELKA, U; HOFSCHNEIDER, PH				WOLLERSHEIM, M; DEBELKA, U; HOFSCHNEIDER, PH			A TRANSACTIVATING FUNCTION ENCODED IN THE HEPATITIS-B VIRUS-X GENE IS CONSERVED IN THE INTEGRATED STATE	ONCOGENE			English	Article									MAX PLANCK INST BIOCHEM,D-8033 MARTINSRIED,FED REP GER	Max Planck Society								Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHANG RSM, 1954, P SOC EXP BIOL MED, V87, P440; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Favaloro J, 1980, Methods Enzymol, V65, P718; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASELTINE WA, 1984, SCIENCE, V225, P419, DOI 10.1126/science.6330894; HUNT T, 1985, NATURE, V316, P580, DOI 10.1038/316580a0; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MILLER RH, 1986, P NATL ACAD SCI USA, V83, P2531, DOI 10.1073/pnas.83.8.2531; MIYAKI M, 1986, J GEN VIROL, V67, P1449, DOI 10.1099/0022-1317-67-7-1449; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NELSONREES WA, 1981, SCIENCE, V212, P446, DOI 10.1126/science.6451928; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONLORINGHOVEN AF, 1985, EMBO J, V4, P249, DOI 10.1002/j.1460-2075.1985.tb02343.x; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891; WOLLERSHEIM M, 1988, VIRAL HEPATITIS LIVE, P334; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAHM P, 1988, IN PRESS ONCOGENE	34	187	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					545	552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856254				2022-12-17	WOS:A1988R516300010
J	Vidal, SJ; Rodriguez-Bravo, V; Galsky, M; Cordon-Cardo, C; Domingo-Domenech, J				Vidal, S. J.; Rodriguez-Bravo, V.; Galsky, M.; Cordon-Cardo, C.; Domingo-Domenech, J.			Targeting cancer stem cells to suppress acquired chemotherapy resistance	ONCOGENE			English	Review						chemotherapy; cancer stem cells; self-renewal; quiescence; differentiation; apoptosis and survival	COLONY-STIMULATING FACTOR; TUMOR-INITIATING CELLS; CHRONIC MYELOID-LEUKEMIA; METASTATIC BREAST-CANCER; MYELOGENOUS LEUKEMIA; PROSTATE-CANCER; SELF-RENEWAL; BETA-CATENIN; TGF-BETA; PROSPECTIVE IDENTIFICATION	Acquired resistance has curtailed cancer survival since the dawn of the chemotherapy age more than half a century ago. Although the application of stem cell (SC) concepts to cancer captured the imagination of scientists for many years, only the last decade has yielded substantial evidence that cancer SCs (CSCs) contribute to chemotherapy resistance. Recent studies suggest that the functional and molecular properties of CSCs constitute therapeutic opportunities to improve the efficacy of chemotherapy. Here we review how these properties have stimulated combination strategies that suppress acquired resistance across a spectrum of malignancies. The clinical implementation of these strategies promises to rejuvenate the effort against an enduring challenge.	[Vidal, S. J.; Cordon-Cardo, C.; Domingo-Domenech, J.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Vidal, S. J.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Rodriguez-Bravo, V.] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; [Galsky, M.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Columbia University; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai	Domingo-Domenech, J (corresponding author), Icahn Sch Med Mt Sinai, Dept Pathol, Annenberg Bldg,Room 24-16,1468 Madison Ave, New York, NY 10029 USA.	carlos.cordon-cardo@mssm.edu; josep.domingo-domenech@mssm.edu		Rodriguez-Bravo, Veronica/0000-0002-7363-3672	Hariri Family Foundation; TJ Martell Foundation	Hariri Family Foundation; TJ Martell Foundation	This work was supported by the Hariri Family Foundation and the TJ Martell Foundation.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Beier D, 2008, CANCER RES, V68, P5706, DOI 10.1158/0008-5472.CAN-07-6878; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borovski T, 2013, ONCOGENE, V32, P1539, DOI 10.1038/onc.2012.172; Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chirasani SR, 2010, BRAIN, V133, P1961, DOI 10.1093/brain/awq128; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes J, 2011, J CLIN ONCOL, V29, P524, DOI 10.1200/JCO.2010.31.3619; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Culig Z, 2011, BBA-MOL CELL RES, V1813, P308, DOI 10.1016/j.bbamcr.2010.12.010; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Gerber JM, 2012, BLOOD, V119, P3571, DOI 10.1182/blood-2011-06-364182; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Goff DJ, 2013, CELL STEM CELL, V12, P316, DOI 10.1016/j.stem.2012.12.011; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris CA, 2011, ANN ONCOL, V22, P1308, DOI 10.1093/annonc/mdq593; Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Hu Y, 2009, LEUKEMIA, V23, P109, DOI 10.1038/leu.2008.262; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Jin LH, 2008, MOL CANCER THER, V7, P48, DOI 10.1158/1535-7163.MCT-07-0042; Jorgensen HG, 2007, BLOOD, V109, P4016, DOI 10.1182/blood-2006-11-057521; Jorgensen HG, 2006, CLIN CANCER RES, V12, P626, DOI 10.1158/1078-0432.CCR-05-0429; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008-5472.CAN-13-0260; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Lang JY, 2011, CANCER CELL, V20, P341, DOI 10.1016/j.ccr.2011.07.017; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020; Li L, 2011, CLIN CANCER RES, V17, P4936, DOI 10.1158/1078-0432.CCR-10-1499; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Liu SP, 2013, GASTROENTEROLOGY, V144, P1031, DOI 10.1053/j.gastro.2013.01.046; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Lonardo E, 2012, CELL CYCLE, V11, P1282, DOI 10.4161/cc.19679; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Lowenberg B, 1997, J CLIN ONCOL, V15, P3496; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406; Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021; Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479; Minami Y, 2012, LEUKEMIA, V26, P2142, DOI 10.1038/leu.2012.73; Nadal R, 2013, INT J CANCER, V133, P2398, DOI 10.1002/ijc.28263; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oak PS, 2012, INT J CANCER, V131, P2808, DOI 10.1002/ijc.27595; Pabst T, 2012, BLOOD, V119, P5367, DOI 10.1182/blood-2011-11-389841; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Persano L, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.153; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Qiu M, 2013, CANCER LETT, V328, P261, DOI 10.1016/j.canlet.2012.09.023; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Rajeshkumar NV, 2010, MOL CANCER THER, V9, P2582, DOI 10.1158/1535-7163.MCT-10-0370; Reedijk M, 2012, ADV EXP MED BIOL, V727, P241, DOI 10.1007/978-1-4614-0899-4_18; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rousseau B, 2010, CANCER J, V16, P202, DOI 10.1097/PPO.0b013e3181ddc5bf; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sakakibara M, 2012, CANCER-AM CANCER SOC, V118, P3899, DOI 10.1002/cncr.26725; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Schott AF, 2013, CLIN CANCER RES, V19, P1512, DOI 10.1158/1078-0432.CCR-11-3326; Schurch C, 2013, J EXP MED, V210, P605, DOI 10.1084/jem.20121229; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Tajima H, 2012, ONCOL LETT, V3, P1186, DOI 10.3892/ol.2012.657; Takeishi S, 2013, CANCER CELL, V23, P347, DOI 10.1016/j.ccr.2013.01.026; Tamaki A, 2011, ESSAYS BIOCHEM, V50, P209, DOI [10.1042/bse0500209, 10.1042/BSE0500209]; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; van Vlerken LE, 2012, J MOL MED, V90, P791, DOI 10.1007/s00109-012-0917-9; Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Voog J, 2010, CELL STEM CELL, V6, P103, DOI 10.1016/j.stem.2010.01.011; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Weisberg E, 2012, LEUKEMIA, V26, P985, DOI 10.1038/leu.2011.360; Wurth R, 2013, CELL CYCLE, V12, P145, DOI 10.4161/cc.23050; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood-2012-02-412890; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011; Zhang GC, 2013, BBA-REV CANCER, V1836, P49, DOI 10.1016/j.bbcan.2013.03.001; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zittoun R, 1996, J CLIN ONCOL, V14, P2150, DOI 10.1200/JCO.1996.14.7.2150; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	164	186	188	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4451	4463		10.1038/onc.2013.411	http://dx.doi.org/10.1038/onc.2013.411			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24096485				2022-12-17	WOS:000341158800001
J	Choi, YJ; Anders, L				Choi, Y. J.; Anders, L.			Signaling through cyclin D-dependent kinases	ONCOGENE			English	Review						CDK4; CDK6; cyclin; cell cycle; senescence; apoptosis	MANTLE CELL LYMPHOMA; DNA-DAMAGE RESPONSE; E2F TARGET GENES; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; BREAST-CANCER; CDK4/6 INHIBITION; STRUCTURAL BASIS	Research over the past quarter century has identified cyclin D-dependent kinases, CDK4 and CDK6, as the major oncogenic drivers among members of the CDK superfamily. CDK4/6 are rendered hyperactive in the majority of human cancers through a multitude of genomic alterations. Sustained activation of these protein kinases provides cancer cells with the power to enter the cell cycle continuously by triggering G1-S-phase transitions and dramatically shortening the duration of the G1 phase. It has also become clear, however, that CDK4/6 effectively counter cancer cell-intrinsic tumor suppression mechanisms, senescence and apoptosis, which must be overcome during cell transformation and kept at bay throughout all stages of tumorigenesis. As a central 'node' in cellular signaling networks, cyclin D-dependent kinases sense a plethora of mitogenic signals to orchestrate specific transcriptional programs. As the complexity of the cellular signaling network regulated by these oncogenic kinases unfolds, much remains to be learned about its architecture, its dynamics and the consequences of its perturbation.	[Choi, Y. J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Choi, Y. J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Anders, L.] MIT, Whitehead Inst Biomed Res, Dept Biol, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Anders, L (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge Ctr, Dept Biol, Cambridge, MA 02142 USA.	lars.anders.hms@gmail.com						Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; [Anonymous], 2014, ONCOGENE, P1890; Antonysamy S, 2012, P NATL ACAD SCI USA, V109, P17960, DOI 10.1073/pnas.1209814109; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BATES S, 1994, ONCOGENE, V9, P71; Baughn LB, 2006, CANCER RES, V66, P7661, DOI 10.1158/0008-5472.CAN-06-1098; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bockstaele L, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-25; Bockstaele L, 2006, MOL CELL BIOL, V26, P5070, DOI 10.1128/MCB.02006-05; Bockstaele L, 2009, MOL CELL BIOL, V29, P4188, DOI 10.1128/MCB.01823-08; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burke JR, 2010, J BIOL CHEM, V285, P16286, DOI 10.1074/jbc.M110.108167; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cato MH, 2011, MOL CELL BIOL, V31, P127, DOI 10.1128/MCB.00650-10; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Cho EC, 2012, EMBO J, V31, P1785, DOI 10.1038/emboj.2012.17; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Costanzo V, 2011, DNA REPAIR, V10, P1060, DOI 10.1016/j.dnarep.2011.07.009; Costello JF, 1997, CANCER RES, V57, P1250; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ERIKSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4144, DOI 10.1073/pnas.81.13.4144; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Fry DW, 2004, MOL CANCER THER, V3, P1427; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gordon GM, 2011, PROTEIN CELL, V2, P864, DOI 10.1007/s13238-011-1117-z; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HE J, 1994, CANCER RES, V54, P5804; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang XG, 2012, BLOOD, V120, P1095, DOI 10.1182/blood-2012-03-415984; Hukkelhoven E, 2012, J BIOL CHEM, V287, P38523, DOI 10.1074/jbc.M112.366542; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jares P, 2007, NAT REV CANCER, V7, P750, DOI 10.1038/nrc2230; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Joshi I, 2009, BLOOD, V113, P1689, DOI 10.1182/blood-2008-03-147967; Kaldis P, 2001, MOL BIOL CELL, V12, P3987, DOI 10.1091/mbc.12.12.3987; Karkhanis V, 2011, TRENDS BIOCHEM SCI, V36, P633, DOI 10.1016/j.tibs.2011.09.001; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; Kerr JFR, 2002, TOXICOLOGY, V181, P471, DOI 10.1016/S0300-483X(02)00457-2; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lenferink AEG, 2001, CANCER RES, V61, P6583; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298; Lesage D, 2005, INT J CANCER, V115, P171, DOI 10.1002/ijc.20907; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Lu FM, 2003, CANCER RES, V63, P7056; Lu H, 2006, J MED CHEM, V49, P3826, DOI 10.1021/jm0600388; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marzec M, 2006, BLOOD, V108, P1744, DOI 10.1182/blood-2006-04-016634; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Matsuzaki K, 2009, CANCER RES, V69, P5321, DOI 10.1158/0008-5472.CAN-08-4203; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Millar EKA, 2009, ONCOGENE, V28, P1812, DOI 10.1038/onc.2009.13; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parry D, 1999, MOL CELL BIOL, V19, P1775; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Peled JU, 2010, CELL RES, V20, P631, DOI 10.1038/cr.2010.55; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Qin HX, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-73; QUELLE DE, 1995, CELL, V83, P993; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Ray A, 2009, MOL CELL BIOL, V29, P986, DOI 10.1128/MCB.00898-08; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ressler S, 2006, AGING CELL, V5, P379, DOI 10.1111/j.1474-9726.2006.00231.x; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Ruas M, 2007, MOL CELL BIOL, V27, P4273, DOI 10.1128/MCB.02286-06; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Takaki T, 2009, P NATL ACAD SCI USA, V106, P4171, DOI 10.1073/pnas.0809674106; Talluri S, 2012, CELL CYCLE, V11, P3189, DOI 10.4161/cc.21263; Tapon N, 2001, CURR OPIN CELL BIOL, V13, P731, DOI 10.1016/S0955-0674(00)00284-2; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; van der Velden PA, 2001, CANCER RES, V61, P5303; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Wierstra I, 2006, BIOL CHEM, V387, P949, DOI 10.1515/BC.2006.119; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wong JV, 2011, CELL CYCLE, V10; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao Fung, 2012, Front Med, V6, P376, DOI 10.1007/s11684-012-0228-0; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	204	186	202	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1890	1903		10.1038/onc.2013.137	http://dx.doi.org/10.1038/onc.2013.137			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23644662				2022-12-17	WOS:000334346300002
J	Xu, J; Li, Y; Wang, F; Wang, X; Cheng, B; Ye, F; Xie, X; Zhou, C; Lu, W				Xu, J.; Li, Y.; Wang, F.; Wang, X.; Cheng, B.; Ye, F.; Xie, X.; Zhou, C.; Lu, W.			Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer	ONCOGENE			English	Article						miR-424; cervical cancer; progression; Chk1; p-Chk1	SQUAMOUS-CELL CARCINOMAS; MICRORNA MIR-21; BREAST-CANCER; CHECKPOINT; IDENTIFICATION; PROFILES; TONGUE; MMP9	MicroRNAs (miRNAs) act as important gene regulators in human genomes and their aberrant expression links to many malignancies. We previously identified a different characteristic miRNA expression profile in cervical cancer from that in cervical normal tissues, including the downregulated miR-424. However, the role and mechanism of miR-424 in cervical cancer still remain unknown. Here, we focused on identifying the tumor-suppressive function and clinical significance of miR-424 and exploring the mechanistic relevance by characterizing its target. We showed a significantly decreased expression of miR-424 in 147 cervical cancer tissues versus 74 cervical normal tissues by performing quantitative RT-PCR. In 147 cervical cancer tissue samples, low-level expression of miR-424 was positively correlated with poor tumor differentiation, advanced clinical stage, lymph node metastasis and other poor prognostic clinicopathological parameters. Further in vitro observations showed that enforced expression of miR-424 inhibited cell growth by both enhancing apoptosis and blocking G1/S transition, and suppressed cell migration and invasion in two human cervical cancer cell lines, SiHa and CaSki, implying that miR-424 functions as a tumor suppressor in the progression of cervical cancer. Interestingly, overexpression of miR-424 inhibited the expression of protein checkpoint kinase 1 (Chk1) and phosphorylated Chk1 (p-Chk1) at residues Ser345 and decreased the activity of luciferase-reporter containing the 3'-untranslated region (UTR) of Chk1 with predicted miR-424-binding site. Moreover, miR-424 expression levels were inversely correlated with Chk1 and p-Chk1 protein levels in both cervical cancer and normal tissues. Furthermore, RNAi-mediated knockdown of Chk1 decreased matrix metalloproteinase 9 expression and phenocopied the tumor suppressive effects of miR-424 in cell models. Taken together, our results identify a crucial tumor suppressive role of miR-424 in the progression of cervical cancer at least partly via upreglating the expression of Chk1 and p-Chk1, and suggest that miR-424 might be a candidate of prognostic predictor or an anticancer therapeutic target for cervical cancer patients. Oncogene (2013) 32, 976-987; doi:10.1038/onc.2012.121; published online 2 April 2012	[Xu, J.; Li, Y.; Wang, F.; Ye, F.] Zhejiang Univ, Sch Med, Womens Hosp, Womens Reprod Hlth Lab Zhejiang Prov, Hangzhou 310006, Zhejiang, Peoples R China; [Wang, X.; Cheng, B.; Xie, X.; Lu, W.] Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China; [Zhou, C.] Zhejiang Univ, Sch Med, Womens Hosp, Dept Pathol, Hangzhou 310006, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Lu, W (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China.	lwg@hzcnc.com		Xu, Junfen/0000-0002-2377-0775; Lv, Weiguo/0000-0003-2062-7145	National Natural Science Foundation of China [81172475]; Zhejiang Provincial Natural Science Foundation of China [Z2110056]; Zhejiang Provincial Medical and Health Science and Technology Project [2009A132, 2011ZDA015]; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Zhejiang Provincial Medical and Health Science and Technology Project; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	We thank pathologist Xiaoduan Chen for histological diagnoses of cervical tissues and Dr Yifan Cheng for sample collections. We also thank continuous financial support by grants from the National Natural Science Foundation of China (Grant No. 81172475), Zhejiang Provincial Natural Science Foundation of China (Grant No. Z2110056), Zhejiang Provincial Medical and Health Science and Technology Project (Grant No. 2009A132 and No. 2011ZDA015) and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents.	Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Chen ZL, 2011, J BIOL CHEM, V286, P10725, DOI 10.1074/jbc.M110.165654; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Ehlen Asa, 2011, Transl Oncol, V4, P212; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Forrest ARR, 2010, LEUKEMIA, V24, P460, DOI 10.1038/leu.2009.246; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gao QL, 2006, APOPTOSIS, V11, P1789, DOI 10.1007/s10495-006-9421-4; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Imig J, 2011, NUCLEIC ACIDS RES, V39, P1880, DOI 10.1093/nar/gkq1043; Kawahigashi Yutaka, 2009, Journal of Nippon Medical School, V76, P188; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Li YL, 2010, EUR J CANCER, V46, P2104, DOI 10.1016/j.ejca.2010.04.015; Li YL, 2009, ANAL BIOCHEM, V394, P110, DOI 10.1016/j.ab.2009.07.022; Li Y, 2011, J PATHOL, V224, P484, DOI 10.1002/path.2873; Lin LF, 2010, CANCER RES, V70, P192, DOI 10.1158/0008-5472.CAN-09-2641; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Madoz-Gurpide J, 2007, MOL CELL PROTEOMICS, V6, P2150, DOI 10.1074/mcp.M700006-MCP200; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Pallasch CP, 2009, BLOOD, V114, P3255, DOI 10.1182/blood-2009-06-229898; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Rentoft M, 2011, INT J ONCOL, V38, P61, DOI 10.3892/ijo_00000824; Rosa A, 2007, P NATL ACAD SCI USA, V104, P19849, DOI 10.1073/pnas.0706963104; Sarkar S, 2010, MOL BIOL CELL, V21, P2138, DOI 10.1091/mbc.E10-01-0062; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Shen YM, 2010, ANAL BIOCHEM, V405, P224, DOI 10.1016/j.ab.2010.06.029; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Wang YX, 2010, J DIGEST DIS, V11, P50, DOI 10.1111/j.1751-2980.2009.00413.x; Wang ZQ, 2009, J CELL PHYSIOL, V221, P213, DOI 10.1002/jcp.21844; Witten D, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-58; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Ye F, 2008, HISTOPATHOLOGY, V53, P224, DOI 10.1111/j.1365-2559.2008.03068.x; Yu WW, 2009, PATHOL RES PRACT, V205, P709, DOI 10.1016/j.prp.2009.05.010; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	44	186	201	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					976	987		10.1038/onc.2012.121	http://dx.doi.org/10.1038/onc.2012.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469983				2022-12-17	WOS:000316523200005
J	Maurer, G; Tarkowski, B; Baccarini, M				Maurer, G.; Tarkowski, B.; Baccarini, M.			Raf kinases in cancer-roles and therapeutic opportunities	ONCOGENE			English	Review						Raf; Ras; ERK pathway; hallmarks of cancer; kinase inhibitors	CELL-CYCLE ARREST; NF-KAPPA-B; MAPK PATHWAY ACTIVATION; C-RAF; WILD-TYPE; INHIBITORY PROTEIN; TUMOR PROGRESSION; SIGNALING PATHWAY; LUNG-CANCER; INCREASED MALIGNANCY	Raf are conserved, ubiquitous serine/protein kinases discovered as the cellular elements hijacked by transforming retroviruses. The three mammalian RAF proteins (A, B and CRAF) can be activated by the human oncogene RAS, downstream from which they exert both kinase-dependent and kinase-independent, tumor-promoting functions. The kinase-dependent functions are mediated chiefly by the MEK/ERK pathway, whose activation is associated with proliferation in a broad range of human tumors. Almost 10 years ago, activating BRAF mutations were discovered in a subset of human tumors, and in the past year treatment with small-molecule RAF inhibitors has yielded unprecedented response rates in melanoma patients. Thus, Raf qualifies as an excellent molecular target for anticancer therapy. This review focuses on the role of BRAF and CRAF in different aspects of carcinogenesis, on the success of molecular therapies targeting Raf and the challenges they present. Oncogene (2011) 30, 3477-3488; doi:10.1038/onc.2011.160; published online 16 May 2011	[Maurer, G.; Tarkowski, B.; Baccarini, M.] Univ Vienna, Ctr Mol Biol, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Baccarini, M (corresponding author), Univ Vienna, Ctr Mol Biol, Max F Perutz Labs, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	manuela.baccarini@univie.ac.at	Baccarini, Manuela/B-6481-2014	Baccarini, Manuela/0000-0002-3033-391X; Tarkowski, Bartosz/0000-0001-8187-1307	Austrian Scientific Research Fund [P19530, SFB 021]; European Community [INFLA-CARE, GROWTHSTOP]	Austrian Scientific Research Fund(Austrian Science Fund (FWF)); European Community(European Commission)	We thank all the members of the Baccarini lab for helpful discussions and apologize to all the colleagues whose work could not be cited in this review for reasons of space. The Baccarini lab is supported by the Austrian Scientific Research Fund (Grants P19530 and SFB 021) and the European Community (Grants INFLA-CARE and GROWTHSTOP).	Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Alavi AS, 2007, CANCER RES, V67, P2766, DOI 10.1158/0008-5472.CAN-06-3648; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Arkenau HT, 2010, BRIT J CANCER, V104, P392; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Beliveau A, 2010, GENE DEV, V24, P2800, DOI 10.1101/gad.1990410; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Calipel A, 2006, J BIOL CHEM, V281, P9238, DOI 10.1074/jbc.M600228200; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Catalanotti F, 2009, NAT STRUCT MOL BIOL, V16, P294, DOI 10.1038/nsmb.1564; Cekanova M, 2007, CANCER-AM CANCER SOC, V109, P1164, DOI 10.1002/cncr.22520; Ceteci F, 2007, CANCER CELL, V12, P145, DOI 10.1016/j.ccr.2007.06.014; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Dai Y, 2008, BLOOD, V112, P2439, DOI 10.1182/blood-2008-05-159392; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Degen A, 2010, DERMATOLOGY, V221, P193, DOI 10.1159/000317081; Dessars B, 2007, J INVEST DERMATOL, V127, P1468, DOI 10.1038/sj.jid.5700725; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Dwyer J, 2007, ANN NY ACAD SCI, V1114, P36, DOI 10.1196/annals.1396.022; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Ehrenreiter K, 2009, CANCER CELL, V16, P149, DOI 10.1016/j.ccr.2009.06.008; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015; Fan S, 2007, ONCOGENE, V26, P4774, DOI 10.1038/sj.onc.1210271; Fedorov LM, 2003, CANCER RES, V63, P2268; Fedorov LM, 2002, CANCER RES, V62, P6297; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fukuyo Y, 2008, CANCER RES, V68, P6324, DOI 10.1158/0008-5472.CAN-07-6602; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Golding SE, 2007, CANCER RES, V67, P1046, DOI 10.1158/0008-5472.CAN-06-2371; Goueli BS, 2004, MOL CELL BIOL, V24, P25, DOI 10.1128/MCB.24.1.25-35.2004; Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Hwang YH, 2004, HEPATOL RES, V29, P113, DOI 10.1016/j.hepres.2004.02.009; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kamata T, 2010, CANCER RES, V70, P8475, DOI 10.1158/0008-5472.CAN-10-0603; Karreth FA, 2009, MOL CELL, V36, P477, DOI 10.1016/j.molcel.2009.10.017; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Kefford R, 2010, ASCO M S, V28; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kinkade R, 2008, CANCER RES, V68, P3810, DOI 10.1158/0008-5472.CAN-07-6672; Klein RM, 2008, MOL BIOL CELL, V19, P498, DOI 10.1091/mbc.E07-09-0895; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Kuznetsov AV, 2008, MOL CELL BIOL, V28, P2304, DOI 10.1128/MCB.00683-07; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Park BJ, 2000, CANCER RES, V60, P3031; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Piazzolla D, 2005, J CELL BIOL, V171, P1013, DOI 10.1083/jcb.200504137; Polzien L, 2009, J BIOL CHEM, V284, P28004, DOI 10.1074/jbc.M109.010702; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Pritchard CA, 2004, MOL CELL BIOL, V24, P5937, DOI 10.1128/MCB.24.13.5937-5952.2004; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Puzanov I, 2011, MOL ONCOL, V5, P116, DOI 10.1016/j.molonc.2011.01.005; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Riva C, 1995, ORAL ONCOL, V31B, P384, DOI 10.1016/0964-1955(95)00045-3; Robert C, 2011, CURR OPIN ONCOL, V23, P177, DOI 10.1097/CCO.0b013e3283436e8c; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Seoane J, 2008, CLIN TRANSL ONCOL, V10, P14, DOI 10.1007/s12094-008-0148-2; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharma A, 2006, CANCER RES, V66, P8200, DOI 10.1158/0008-5472.CAN-06-0809; Shimizu K, 1986, Princess Takamatsu Symp, V17, P85; Simon R, 2001, CANCER RES, V61, P4514; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Sobczak I, 2008, ONCOGENE, V27, P4779, DOI 10.1038/onc.2008.128; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Takezawa K, 2009, CANCER RES, V69, P6515, DOI 10.1158/0008-5472.CAN-09-1076; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Vale T, 2001, CANCER RES, V61, P602; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wang X, 2004, J BIOL CHEM, V279, P2528, DOI 10.1074/jbc.M306489200; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Weber CK, 2001, CANCER RES, V61, P3595; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wimmer R, 2010, TRENDS BIOCHEM SCI, V35, P660, DOI 10.1016/j.tibs.2010.06.001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yu H, 2009, AM J PATHOL, V174, P2367, DOI 10.2353/ajpath.2009.081057; Zebisch A, 2006, CANCER RES, V66, P3401, DOI 10.1158/0008-5472.CAN-05-0115; Zebisch A, 2009, LEUKEMIA, V23, P1049, DOI 10.1038/leu.2009.68; Zeng LC, 2008, EXPERT OPIN THER TAR, V12, P1275, DOI [10.1517/14728222.12.10.1275, 10.1517/14728222.12.10.1275 ]; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	149	186	194	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3477	3488		10.1038/onc.2011.160	http://dx.doi.org/10.1038/onc.2011.160			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21577205				2022-12-17	WOS:000293782300001
J	Ercan, D; Zejnullahu, K; Yonesaka, K; Xiao, Y; Capelletti, M; Rogers, A; Lifshits, E; Brown, A; Lee, C; Christensen, JG; Kwiatkowski, DJ; Engelman, JA; Janne, PA				Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Xiao, Y.; Capelletti, M.; Rogers, A.; Lifshits, E.; Brown, A.; Lee, C.; Christensen, J. G.; Kwiatkowski, D. J.; Engelman, J. A.; Jaenne, P. A.			Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor	ONCOGENE			English	Article						epidermal growth factor receptor; drug resistance; EGFR T790M; amplification; tyrosine kinase inhibitor; non-small cell lung cancer	GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; ACQUIRED-RESISTANCE; DRUG-RESISTANCE; NERATINIB HKI-272; GENE MUTATION; BLAST CRISIS; GEFITINIB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the gatekeeper residue. Irreversible EGFR inhibitors, including PF00299804, are effective in vitro and in vivo against EGFR mutant tumors that contain EGFR T790M and are currently under clinical development. In this study, we generate models of resistance to PF00299804, using cell lines with EGFR T790M and show that the PF00299804-resistant models develop focal amplification of EGFR that preferentially involves the T790M-containing allele. These PF00299804-resistant cell lines remain dependent on EGFR for growth as downregulation of EGFR by shRNA compromises their viability. We show that resistance to PF00299804 arises, at least in part, through selection of a pre-existing EGFR T790M-amplified clone both in vitro and using a xenograft model in vivo. Our findings show that EGFR T790M is a common resistance mechanism to both reversible, and when amplified, the irreversible EGFR kinase inhibitors further emphasizing the need to develop more potent therapies against EGFR T790M. These findings can be used to guide studies of patient tumor specimens from ongoing clinical trials of irreversible EGFR kinase inhibitors. Oncogene (2010) 29, 2346-2356; doi:10.1038/onc.2009.526; published online 1 February 2010	[Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Capelletti, M.; Rogers, A.; Jaenne, P. A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA; [Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Capelletti, M.; Rogers, A.; Jaenne, P. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Xiao, Y.; Lee, C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Lifshits, E.; Engelman, J. A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Brown, A.] Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Cambridge, MA 02138 USA; [Christensen, J. G.] Pfizer Global Res & Dev, Dept Res Pharmacol, La Jolla Labs, La Jolla, CA USA; [Kwiatkowski, D. J.] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA; [Jaenne, P. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Pfizer; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Janne, PA (corresponding author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, D820,44 Binney St, Boston, MA 02115 USA.	pjanne@partners.org	Capelletti, Marzia/L-6317-2016	Capelletti, Marzia/0000-0001-5095-7060	National Institutes of Health [RO1CA114465-04, R01CA135257-01, R01CA137008-01]; National Cancer Institute [P50CA090578]; American Cancer Society [RSG0610201]; Hazel and Samuel Bellin research fund; NATIONAL CANCER INSTITUTE [R01CA114465, R01CA135257, K08CA120060, P50CA090578, R01CA137008] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Hazel and Samuel Bellin research fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Institutes of Health RO1CA114465-04 (PAJ), R01CA135257-01 (PAJ, JAE, CL), R01CA137008-01 (JAE, PAJ), National Cancer Institute Lung SPORE P50CA090578 (PAJ, JAE and DJK), American Cancer Society RSG0610201CCE (PAJ, JAE), and the Hazel and Samuel Bellin research fund (PAJ).	Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Besse B, 2008, EJC SUPPL, V6, P64, DOI 10.1016/S1359-6349(08)72135-9; Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guo T, 2007, CLIN CANCER RES, V13, P4874, DOI 10.1158/1078-0432.CCR-07-0484; Inoue A, 2006, J CLIN ONCOL, V24, P3340, DOI 10.1200/JCO.2005.05.4692; Janne PA, 2008, J CLIN ONCOL, V26; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Ono M, 2004, MOL CANCER THER, V3, P465; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Quintas-Cardama A, 2008, CLIN CANCER RES, V14, P4392, DOI 10.1158/1078-0432.CCR-08-0117; Rothenberg SM, 2008, P NATL ACAD SCI USA, V105, P12480, DOI 10.1073/pnas.0803217105; Sawai A, 2008, CANCER RES, V68, P589, DOI 10.1158/0008-5472.CAN-07-1570; Schellens JH, 2007, J CLIN ONCOL, V25; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shimamura T, 2008, CANCER RES, V68, P5827, DOI 10.1158/0008-5472.CAN-07-5428; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217; Wong KK, 2009, CLIN CANCER RES, V15, P2552, DOI 10.1158/1078-0432.CCR-08-1978; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yuza Y, 2007, CANCER BIOL THER, V6, P661, DOI 10.4161/cbt.6.5.4003; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	44	186	198	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2346	2356		10.1038/onc.2009.526	http://dx.doi.org/10.1038/onc.2009.526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20118985	Green Accepted			2022-12-17	WOS:000276951500004
J	Trauzold, A; Siegmund, D; Schniewind, B; Sipos, B; Egberts, J; Zorenkov, D; Emme, D; Roder, C; Kalthoff, H; Wajant, H				Trauzold, A.; Siegmund, D.; Schniewind, B.; Sipos, B.; Egberts, J.; Zorenkov, D.; Emme, D.; Roeder, C.; Kalthoff, H.; Wajant, H.			TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						pancreatic cancer; metastasis; invasion; TRAIL	INDUCED APOPTOSIS; BCL-X; CANCER; CELLS; ACTIVATION; EXPRESSION; BAX; PROLIFERATION; APO2L/TRAIL; RESISTANCE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention for its potential use in tumor therapy, as some recombinant variants of this ligand induce apoptosis in tumor cells without harming most normal cells. Here, we show that TRAIL strongly induces the expression of the proinflammatory cytokines interleukin-8 and monocyte chemoattractant protein 1 and enhances the invasion of apoptosis-resistant pancreatic ductal adenocarcinoma cells in vitro by upregulation of the urokinase-type plasminogen activator expression. Most importantly, we also demonstrate for the first time that TRAIL treatment results in strongly increased distant metastasis of pancreatic tumors in vivo. We orthotopically transplanted human pancreatic ductal adenocarcinoma cells to the pancreata of severe combined immunodeficiency mice and observed a dramatic increase in metastatic spread including a sixfold increase in the volume and fourfold increase in the number of liver metastases upon TRAIL treatment. Our results point to the necessity to carefully evaluate in vivo side effects of TRAIL and to select therapy conditions that not only enhance apoptosis induction but in addition prevent proinvasive and proinflammatory non-apoptotic TRAIL signaling.	Univ Kiel, Hosp Schleswig Holstein, Clin Gen Surg & Thorac Surg, Sect Mol Oncol, D-24105 Kiel, Germany; Univ Wurzburg, Med Clin & Polyclin 2, Dept Mol Internal Med, D-97070 Wurzburg, Germany; Univ Kiel, Hosp Schleswig Holstein, Inst Gen Pathol, D-24098 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Wurzburg; University of Kiel; Schleswig Holstein University Hospital	Kalthoff, H (corresponding author), Clin Gen Surg & Thorac Surg, Sect Mol Oncol, Campus Kiel,Arnold Heller Str 7, D-24105 Kiel, Germany.	hkalthoff@email.uni-kiel.de	Wajant, Harald/A-3020-2017; Trauzold, Anna/P-4398-2014; Egberts, Jan-Hendrik/E-3211-2015; Kalthoff, Holger/B-1618-2010; Roeder, Christian/F-1068-2010	Wajant, Harald/0000-0002-2005-3949; Roeder, Christian/0000-0001-7881-9110				Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Armeanu S, 2003, CANCER RES, V63, P2369; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baader E, 2005, CANCER RES, V65, P7888, DOI 10.1158/0008-5472.CAN-04-4278; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Evans JD, 2001, PANCREATOLOGY, V1, P254, DOI 10.1159/000055820; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Schniewind B, 2004, INT J CANCER, V109, P182, DOI 10.1002/ijc.11679; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Siegmund D, 2005, MOL CELL BIOL, V25, P6363, DOI 10.1128/MCB.25.15.6363-6379.2005; TEPEL J, 2005, INT J COLORECTAL DIS, V16, P1; Trauzold A, 2005, FASEB J, V19, P620, DOI 10.1096/fj.04-2984fje; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	27	186	193	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7434	7439		10.1038/sj.onc.1209719	http://dx.doi.org/10.1038/sj.onc.1209719			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751802				2022-12-17	WOS:000242419100012
J	Franci, C; Takkunen, M; Dave, N; Alameda, F; Gomez, S; Rodriguez, R; Escriva, M; Montserrat-Sentis, B; Baro, T; Garrido, M; Bonilla, F; Virtanen, I; de Herreros, AG				Franci, C.; Takkunen, M.; Dave, N.; Alameda, F.; Gomez, S.; Rodriguez, R.; Escriva, M.; Montserrat-Sentis, B.; Baro, T.; Garrido, M.; Bonilla, F.; Virtanen, I.; Garcia de Herreros, A.			Expression of Snail protein in tumor-stroma interface	ONCOGENE			English	Article						Snail transcriptional factor; fibroblast; epithelial-mesenchymal transition	TRANSCRIPTION FACTOR SNAIL; EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN EXPRESSION; MAMMARY-CARCINOMA; REPRESSOR SNAIL; BREAST-CANCER; GROWTH; PHOSPHORYLATION; FIBROBLASTS; CELLS	The product of Snail gene is a repressor of E-cadherin transcription and an inductor of the epithelial-to-mesenchymal transition in several epithelial tumor cell lines. In order to examine Snail expression in animal and human tissues, we have raised a monoclonal antibody(MAb) that reacts with the regulatory domain of this protein. Analysis of murine embryos shows that Snail is expressed in extraembryonic tissues and embryonic mesoderm, in mesenchymal cells of lungs and dermis as well as in cartilage. Little reactivity was detected in adult tissues as Snail was not constitutively expressed in most mesenchymal cells. However, Snail expression was observed in activated fibroblasts involved in wound healing in mice skin. Moreover, Snail was detected in pathological conditions causing hyperstimulation of fibroblasts, such as fibromatosis. Analysis of Snail expression in tumors revealed that it was highly expressed in sarcomas and. brosarcomas. In epithelial tumors, it presented a more limited distribution, restricted to stromal cells placed in the vicinity of the tumor and to tumoral cells in the same areas. These results demonstrate that Snail is present in activated mesenchymal cells, indicate its relevance in the communication between tumor and stroma and suggest that it can promote the conversion of carcinoma cells to stromal cells.	Univ Helsinki, Inst Biomed Anat, Biomedicum, FIN-00014 Helsinki, Finland; Univ Pompea Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain; Hosp Mar, Serv Anat Patol, E-08003 Barcelona, Spain; Univ Autonoma Barcelona, Fac Med, E-08193 Barcelona, Spain; Univ Pompau Fabra, Inst Municipal Invest Med, Serv Estab, Barcelona, Spain; Hosp Virgen Salud, Dept Patol, Toledo, Spain; Hosp Univ Puerta Hierro, Med Oncol Serv, Madrid, Spain	University of Helsinki; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; University of Barcelona; Complejo Hospitalario de Toledo; Hospital Puerta de Hierro-Majadahonda	Virtanen, I (corresponding author), Univ Helsinki, Inst Biomed Anat, Biomedicum, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	ismo.virtanen@helsinki.fi; agarcia@imim.es	de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808				Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Galie M, 2005, CARCINOGENESIS, V26, P1868, DOI 10.1093/carcin/bgi158; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; Jamora C, 2005, PLOS BIOL, V3, P131, DOI 10.1371/journal.pbio.0030011; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Moinfar F, 2000, CANCER RES, V60, P2562; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; NIETO MA, 1992, DEVELOPMENT, V116, P227; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Rosivatz E, 2004, INT J CANCER, V111, P711, DOI 10.1002/ijc.20317; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Shekhar MPV, 2001, CANCER RES, V61, P1320; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	43	186	188	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5134	5144		10.1038/sj.onc.1209519	http://dx.doi.org/10.1038/sj.onc.1209519			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16568079				2022-12-17	WOS:000240063700006
J	Rao, G; Pedone, CA; Del Valle, L; Reiss, K; Holland, EC; Fults, DW				Rao, G; Pedone, CA; Del Valle, L; Reiss, K; Holland, EC; Fults, DW			Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice	ONCOGENE			English	Article						medulloblastoma; IGF2; sonic hedgehog; RCAS/tv-a; neural progenitors	HUMAN HOMOLOG; I RECEPTOR; N-MYC; GENE; PROTEIN; PROLIFERATION; MUTATIONS; SYSTEM; ACTIVATION; ALLELE	Medulloblastoma (MB) is a malignant brain tumor that arises in the cerebellum of children. Activation of the Sonic hedgehog/Patched (Shh/Ptc) signaling pathway in neural progenitor cells of the cerebellum induces MBs in mice. The incomplete penetrance of tumor formation in mice, coupled with the low frequency of mutations in Shh/Ptc pathway genes in human tumors, suggests that other signaling molecules cooperate with Shh to enhance MB formation. We modeled the ability of insulin-like growth factor (IGF) signaling to induce MB using the RCAS/tv-a system, which allows postnatal gene transfer and expression in a cell-type-specific manner. We used RCAS retroviral vectors to target expression of Shh, IGF2, and activated Akt to nestin-expressing neural progenitors in the cerebella of newborn mice. The incidence of Shh-induced tumor formation (15%) was enhanced by coexpression with IGF2 (39%) and Akt (48%). Neither IGF2 nor Akt caused tumors when expressed independently. The induced tumors showed upregulated expression of insulin receptor substrate 1 and phosphorylated forms of IGF1 receptor and Akt, mimicking activated IGF signaling found in human MBs. These results indicate that combined activation of the Shh/Ptc and IGF signaling pathways is an important mechanism in MB pathogenesis.	Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84132 USA; Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19112 USA; Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol & Cell Biol, New York, NY 10021 USA	Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Fults, DW (corresponding author), Univ Utah, Sch Med, Dept Neurosurg, 30 North 1900 East, Salt Lake City, UT 84132 USA.	daniel.fults@hsc.utah.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; COFFIN CM, 1990, MODERN PATHOL, V3, P164; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; EASTER SS, 1993, J NEUROSCI, V13, P285; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; Fults D, 2000, NEURO-ONCOLOGY, V2, P71, DOI 10.1093/neuonc/2.2.71; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pietsch T, 1997, CANCER RES, V57, P2085; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2000, CANCER RES, V60, P2239; Wolter M, 1997, CANCER RES, V57, P2581; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	37	186	191	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6156	6162		10.1038/sj.onc.1207818	http://dx.doi.org/10.1038/sj.onc.1207818			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195141				2022-12-17	WOS:000223261000015
J	Suzuki, H; Tomida, A; Tsuruo, T				Suzuki, H; Tomida, A; Tsuruo, T			Dephosphorylated hypoxia-inducible factor 1 alpha as a mediator of p53-dependent apoptosis during hypoxia	ONCOGENE			English	Article						apoptosis; HIF-1 alpha; hypoxia; p53; phosphorylation	RING-FINGER DOMAIN; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS; NUCLEAR EXPORT; SOLID TUMORS; IN-VIVO; P53; PROTEIN; MITOCHONDRIA; HIF-1-ALPHA	Under hypoxia, HIF-1 alpha binds to aryl hydrocarbon receptor nuclear translocator (ARNT, also called HIF-1 alpha) to activate expression of genes important for cell survival. Alternatively, HIF-1 alpha can bind to the tumor suppressor p53 and promote p53-dependent apoptosis. Here we show that the opposite functions of HIF-1 alpha are distinguished by its phosphorylation status. Two distinguishable forms of HIF-1 alpha, phosphorylated and dephosphorylated, were induced during hypoxia-induced apoptosis. The phosphorylated HIF-1 alpha was the major form that bound to ARNT. Ectopically expressed ARNT was consistently able to enhance HIF-1 alpha phosphorylation in a binding-dependent manner. In contrast, the dephosphorylated HIF-1 alpha was the major form that bound to p53. Depletion of the dephosphorylated HIF-1 alpha, by using the Hsp90 inhibitor geldanamycin A that had little effect on the phosphorylated HIF-1 alpha expression, suppressed p53 induction and subsequent apoptosis. Depletion of dephosphorylated HIF-1 alpha also prevented hypoxia-induced nuclear accumulation of HDM2, a negative regulator of p53. Our results indicate that the functions of HIF-1 alpha varied with its phosphorylation status and that dephosphorylated HIF-1 alpha mediated apoptosis by binding to and stabilizing p53.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chavany C, 1996, J BIOL CHEM, V271, P4974; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shimizu S, 1996, CANCER RES, V56, P2161; Tomida A, 1996, ONCOGENE, V13, P2699; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaupel PW, 1997, KLIN PADIATR, V209, P243, DOI 10.1055/s-2008-1043957; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 1997, BIOL CHEM, V378, P609	38	186	212	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5779	5788		10.1038/sj.onc.1204742	http://dx.doi.org/10.1038/sj.onc.1204742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593383				2022-12-17	WOS:000171037200001
J	Benvenuto, G; Li, SW; Brown, SJ; Braverman, R; Vass, WC; Cheadle, JP; Halley, DJJ; Sampson, JR; Wienecke, R; DeClue, JE				Benvenuto, G; Li, SW; Brown, SJ; Braverman, R; Vass, WC; Cheadle, JP; Halley, DJJ; Sampson, JR; Wienecke, R; DeClue, JE			The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination	ONCOGENE			English	Article						tuberous sclerosis (TSC); tumor suppressor genes; growth inhibition; ubiquitination	EKER RAT; NEOPLASTIC PHENOTYPE; PROTEASOME PATHWAY; RENAL-CARCINOMA; TARGET RAP1; IN-VIVO; COMPLEX; PROTEIN; DEGRADATION; HETEROZYGOSITY	We report here that overexpression of the tuberous sclerosis-1 (TSC1) gene product hamartin results in the inhibition of growth, as well as changes in cell morphology, Growth inhibition was associated with an increase in the endogenous level of the product of the tuberous sclerosis-2 (TSC2) gene, tuberin. As over-expression of tuberin inhibits cell growth, and hamartin is known to bind tuberin, these results suggested that hamartin stabilizes tuberin and this contributes to the inhibition of cell growth. Indeed, transient transfection of TSC1 increased the endogenous level of tuberin, and transient co-transfection of TSC1 with TSC2 resulted in higher tuberin levels. The stabilization was explained by the finding that tuberin is highly ubiquitinated in cells, while the fraction of tuberin that is bound to hamartin is not ubiquitinated, Go-expression of tuberin stabilized hamartin, which is weakly ubiquitinated, in transiently transfected cells. The amino-terminal two-thirds of tuberin was responsible for its ubiquitination and for stabilization of hamartin, A mutant of tuberin from a patient missense mutation of TSC2 was also highly ubiquitinated, and was unable to stabilize hamartin, We conclude that hamartin is a growth inhibitory protein whose biological effect is likely dependent on its interaction with tuberin.	NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA; Cardiff Univ, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales; Erasmus Univ, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; Univ Munich, Dept Dermatol, Klinikum Innenstadt, D-80337 Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cardiff University; Erasmus University Rotterdam; University of Munich	DeClue, JE (corresponding author), NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA.		Warfield, Simon/B-3352-2009	Warfield, Simon/0000-0002-7659-3880; BENVENUTO, Giovanna/0000-0001-7155-2935				Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Ciechanover A, 2000, J CELL BIOCHEM, P40; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Maki CG, 1996, CANCER RES, V56, P2649; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mizuguchi M, 2000, ACTA NEUROPATHOL, V99, P503, DOI 10.1007/s004010051152; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Plank TL, 1999, MODERN PATHOL, V12, P539; Plank TL, 1998, CANCER RES, V58, P4766; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	42	186	190	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6306	6316		10.1038/sj.onc.1204009	http://dx.doi.org/10.1038/sj.onc.1204009			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175345				2022-12-17	WOS:000166210500014
J	Moscatello, DK; Montgomery, RB; Sundareshan, P; McDanel, H; Wong, MY; Wong, AJ				Moscatello, DK; Montgomery, RB; Sundareshan, P; McDanel, H; Wong, MY; Wong, AJ			Transformation and altered signal transduction by a naturally occurring mutant EGF receptor	ONCOGENE			English	Article						EGF receptor; mutant; EGFRvIII; neoplastic transformation	GROWTH-FACTOR RECEPTOR; HUMAN-BRAIN-TUMORS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; PROTEIN-KINASE; HUMAN GLIOMAS; BINDING SITE; GENE; EXPRESSION; RAS	An amino-truncated variant form of the epidermal growth factor receptor (EGFRvIII) has been identified in human brain, breast, lung and ovarian tumors, We have found that overexpression of this mutant EGF receptor in NIH3T3 cells results in transformation as a result of the activation of the receptor kinase via ligand-independent dimerization, Transformation was correlated with tyrosine phosphorylation of only a subset of the proteins observed in cells overexpressing the normal EGF receptor. This suggested that further studies on cells expressing the EGFRvIII might provide insights into the pathways most relevant to transformation, In clones expressing high levels of mutant EGF receptor, the levels of both Grb2 and SHC were decreased, Despite this decrease, much of the endogenous Grb2 immunoprecipitated with EGFRvIII, Interestingly, no increase in ras-GTP loading was found in clones expressing the EGFRvIII and MAP kinase assays indicated only a small increase in activity, These results indicate that high-level expression of the EGFRvIII induces downregulation of the ras-MAP kinase pathway and that other components involved in EGF receptor signal transduction may play a greater role in neoplastic transformation by the EGFRvIII.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; VET ADM MED CTR,DIV ONCOL,SEATTLE,WA 98108	Jefferson University; Jefferson University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [T32CA009678, R01CA051093, R01CA053149] Funding Source: NIH RePORTER; NCI NIH HHS [CA51093, CA53149, 5-T32 CA09678-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAZENET CE, 1993, ONCOGENE, V9, P517; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; BIGNER SH, 1990, CANCER RES, V50, P8017; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLUMENSTOCK M, 1991, ANTICANCER RES, V11, P1353; BUDAY L, 1993, CELL, V73, P169; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; EKSTRAND AJ, 1995, ONCOGENE, V13, P1455; FAN Z, 1993, J BIOL CHEM, V268, P21073; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Harris A L, 1989, Recent Results Cancer Res, V113, P70; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUI H, 1991, CANCER RES, V51, P6170; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REIST CJ, 1995, CANCER RES, V55, P4375; SALGALLER M, 1991, CANCER LETT, V57, P243, DOI 10.1016/0304-3835(91)90164-D; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SCHLOTTER NE, 1990, APPL PHYS LETT, V56, P13, DOI 10.1063/1.102648; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SOLER C, 1994, ONCOGENE, V9, P2207; VELU TJ, 1990, MOL CELL ENDOCRINOL, V70, P205, DOI 10.1016/0303-7207(90)90211-P; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WU DG, 1989, J BIOL CHEM, V264, P17469; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x	64	186	207	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					85	96						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700557				2022-12-17	WOS:A1996UX31900010
J	Roche, J; Boldog, F; Robinson, M; Robinson, L; VarellaGarcia, M; Swanton, M; Waggoner, B; Fishel, R; Franklin, W; Gemmill, R; Drabkin, H				Roche, J; Boldog, F; Robinson, M; Robinson, L; VarellaGarcia, M; Swanton, M; Waggoner, B; Fishel, R; Franklin, W; Gemmill, R; Drabkin, H			Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin	ONCOGENE			English	Article						chromosome 3; lung cancer; homozygous deletions; human SemaphorinIV	POLYMERASE CHAIN-REACTION; CHROMOSOMAL REGION 3P21; SQUAMOUS-CELL CARCINOMA; HOMOZYGOUS DELETION; DNA-SEQUENCE; LINE U2020; SHORT ARM; PROTEIN; YEAST; LOCALIZATION	Loss of chromosome 3p is a critical event in the pathogenesis of lung cancer. Overlapping homozygous 3p21.3 deletions in lung cancer cell lines involving GNAI2 were characterized and found to involve a region of genomic instability. A new widely expressed Semaphorin, H.SemaIV, was isolated from the GNAI2 deletion region. Reduced H.SemaIV expression allowed identification of additional cell lines with submicroscopic or larger deletions of the locus which occurred in a heterogeneous manner. We also demonstrate the presence of a distinct 3p21.3 homozygous deletion region, adjacent to the DNA mismatch repair gene, hMLH1, and identified deletions in direct tumors. This appears to represent one of the first demonstrations of homozygous deletions affecting 3p in direct lung tumors.	UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA; UNIV COLORADO, CTR CANC, DENVER, CO 80262 USA; UNIV LYON 1, F-69622 VILLEURBANNE, FRANCE; ELEANOR ROOSEVELT INST, DENVER, CO 80206 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Vermont					NATIONAL CANCER INSTITUTE [R01CA068383, P50CA058187] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA68383, CA58187] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DALY MC, 1993, ONCOGENE, V8, P1721; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; GEMMILL RM, 1995, NATURE, V377, P299; GEMMILL RM, 1991, GENOMICS, V11, P93, DOI 10.1016/0888-7543(91)90105-N; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; Higgins D G, 1994, Methods Mol Biol, V25, P307; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOK K, 1994, CANCER RES, V54, P4183; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; KOLODNER RD, 1995, CANCER RES, V55, P242; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MENDEZ MJ, 1991, GENOMICS, V10, P661, DOI 10.1016/0888-7543(91)90449-O; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAKAMURA H, 1994, HUM MOL GENET, V11, P157; NAKAMURA H, 1994, LUNG CANCER S4, V11, P157; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RIED T, 1994, CANCER RES, V54, P1801; Sherman F., 1986, METHODS YEAST GENETI; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; TODD S, 1995, GENOMICS, V25, P19, DOI 10.1016/0888-7543(95)80105-U; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104	55	186	192	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1289	1297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649831				2022-12-17	WOS:A1996UC06700014
J	NERLOV, C; RORTH, P; BLASI, F; JOHNSEN, M				NERLOV, C; RORTH, P; BLASI, F; JOHNSEN, M			ESSENTIAL AP-1 AND PEA3 BINDING-ELEMENTS IN THE HUMAN UROKINASE ENHANCER DISPLAY CELL TYPE-SPECIFIC ACTIVITY	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR GENE; MIDDLE-T-ONCOGENE; HUMAN-TUMOR-CELLS; TRANSCRIPTION FACTOR; C-JUN; GLUCOCORTICOID RECEPTOR; POLYOMAVIRUS ENHANCER; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; PHORBOL-ESTER	We have characterized a transcriptional enhancer of the human urokinase-type plasminogen activator (uPA) gene in three transformed human cell lines: HeLa, HepG2 and HT1080. The enhancer is located approximately 2 kbp upstream of the mRNA cap site and is active in all three cell lines. By footprinting and gel retardation analysis we found that it contained two binding sites for transcription factor AP-1, encoded by the fos and jun proto-oncogene families. The most upstream of these sites was juxtaposed to a binding site for PEA3, a product of the ets/Spi proto-oncogene family. By transient transfection analysis of deletions, point mutations and subcloned fragments, we found these sites to be crucial for enhancer activity. However, the sites displayed differences in activity in the three different cell lines. The downstream AP-1 site was almost exclusively responsible for enhancer activity in HeLa cells, whereas the AP-1/PEA3 site played a major role in HT1080 and HepG2 cells. The implications of our findings for the known regulation of uPA expression by transforming oncogenes, adenovirus E1A protein and glucocorticoids are discussed.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK	University of Copenhagen			Johnsen, Morten/L-8016-2014; Rørth, Pernille/H-3020-2011	Johnsen, Morten/0000-0003-3763-2362; Blasi, Francesco/0000-0001-9406-1784				ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Blasi F, 1990, Semin Cancer Biol, V1, P117; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLIS V, 1989, J BIOL CHEM, V264, P1180; FRISCH SM, 1990, ONCOGENE, V5, P75; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, CELL, V61, P1165; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; QUAX P, 1991, UNPUB; REICH R, 1988, CANCER RES, V48, P3307; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; STOPPELLI MP, 1986, J CELL BIOL, V102, P1235, DOI 10.1083/jcb.102.4.1235; TANG WJ, 1987, MOL CELL BIOL, V7, P1681, DOI 10.1128/MCB.7.5.1681; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILLIAMS RL, 1988, CELL, V52, P121; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	186	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1583	1592						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923525				2022-12-17	WOS:A1991GX27400013
J	DENHARDT, DT; GREENBERG, AH; EGAN, SE; HAMILTON, RT; WRIGHT, JA				DENHARDT, DT; GREENBERG, AH; EGAN, SE; HAMILTON, RT; WRIGHT, JA			CYSTEINE PROTEINASE CATHEPSIN-L EXPRESSION CORRELATES CLOSELY WITH THE METASTATIC POTENTIAL OF H-RAS-TRANSFORMED MURINE FIBROBLASTS	ONCOGENE			English	Article									IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL,AMES,IA 50011; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MANITOBA,CANADA	Iowa State University; University of Manitoba	DENHARDT, DT (corresponding author), UNIV WESTERN ONTARIO,CANC RES LAB,LONDON N6A 5B7,ONTARIO,CANADA.							DENHARDT DT, 1986, CANCER RES, V46, P4590; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ETHERINGTON DJ, 1980, CIBA F S, V75, P87; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; GAL S, 1986, BIOCHEM BIOPH RES CO, V139, P156, DOI 10.1016/S0006-291X(86)80093-6; GAL S, 1986, J BIOL CHEM, V261, P1760; GARBISA S, 1987, CANCER RES, V47, P1523; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; IVANYI D, 1986, INT J CANCER, V38, P575, DOI 10.1002/ijc.2910380418; JOHNSON DA, 1986, J BIOL CHEM, V261, P4748; KHANDJIAN EW, 1987, BIO-TECHNOL, V5, P165, DOI 10.1038/nbt0287-165; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; KOPPEL P, 1984, EXP CELL BIOL, V52, P293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAU G, 1985, J BIOL CHEM, V260, P531; LIOTTA LA, 1986, CANCER RES, V46, P1; MANIATIS T, 1982, MOL CLONING LABORATO; MASON RW, 1986, BIOCHEM J, V240, P373, DOI 10.1042/bj2400373; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; NILSENHAMILTON M, 1981, BIOCHEM BIOPH RES CO, V101, P411, DOI 10.1016/0006-291X(81)91275-4; OSSAWSKI L, 1983, CELL, V35, P611; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RECKLIES AD, 1985, BIOCHEM BIOPH RES CO, V131, P402, DOI 10.1016/0006-291X(85)91816-9; SAHAGIAN GG, 1982, J BIOL CHEM, V257, P1145; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; SLOANE BF, 1984, CANCER METAST REV, V3, P249, DOI 10.1007/BF00048388; SLOANE BF, 1982, CANCER RES, V42, P980; STACKPOLE CW, 1981, NATURE, V289, P798, DOI 10.1038/289798a0; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; WARBURTON MJ, 1986, BIOCHEM BIOPH RES CO, V137, P161, DOI 10.1016/0006-291X(86)91190-3; WIEMAN J, 1986, BIOCHEM BIOPH RES CO, V140, P365, DOI 10.1016/0006-291X(86)91099-5	33	186	187	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					55	59						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	3438085				2022-12-17	WOS:A1987L481300008
J	Mendonsa, AM; Na, TY; Gumbiner, BM				Mendonsa, Alisha M.; Na, Tae-Young; Gumbiner, Barry M.			E-cadherin in contact inhibition and cancer	ONCOGENE			English	Review							EPIDERMAL-GROWTH-FACTOR; CELL-ADHESION MOLECULE; HIPPO PATHWAY; BETA-CATENIN; BREAST-CANCER; SIGNALING ACTIVITY; MEDIATED ADHESION; TUMOR PROGRESSION; ACTIVATION; MIGRATION	E-cadherin is a key component of the adherens junctions that are integral in cell adhesion and maintaining epithelial phenotype of cells. Homophilic E-cadherin binding between cells is important in mediating contact inhibition of proliferation when cells reach confluence. Loss of E-cadherin expression results in loss of contact inhibition and is associated with increased cell motility and advanced stages of cancer. In this review we discuss the role of E-cadherin and its downstream signaling in regulation of contact inhibition and the development and progression of cancer.	[Mendonsa, Alisha M.; Na, Tae-Young; Gumbiner, Barry M.] Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA 98101 USA; [Gumbiner, Barry M.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Gumbiner, Barry M.] Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Mendonsa, AM (corresponding author), Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA 98101 USA.	alisha.mendonsa@seattlechildrens.org			National Cancer Institute at the National Institutes of Health [R01CA207115-02]; NATIONAL CANCER INSTITUTE [R01CA207115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM122467] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work has been supported by the grant R01CA207115-02 awarded to Dr. Barry Gumbiner from the National Cancer Institute at the National Institutes of Health.	ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Benham-Pyle BW, 2015, SCIENCE, V348, P1024, DOI 10.1126/science.aaa4559; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Chen Q, 2015, GENE DEV, V29, P1285, DOI 10.1101/gad.264234.115; Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Citi Sandra, 2014, Small GTPases, V5, P1, DOI 10.4161/21541248.2014.973760; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Cox RT, 1999, GENETICS, V153, P319; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Das T, 2015, NAT CELL BIOL, V17, P276, DOI 10.1038/ncb3115; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fedor-Chaiken M, 2003, CELL COMMUN ADHES, V10, P105, DOI 10.1080/714040416; FRIEDL P, 1995, CANCER RES, V55, P4557; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gladden AB, 2010, DEV CELL, V19, P727, DOI 10.1016/j.devcel.2010.10.008; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansford S, 2015, JAMA ONCOL, V1, P23, DOI 10.1001/jamaoncol.2014.168; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029; Hirata H, 2017, SCI REP-UK, V7, DOI 10.1038/srep46326; Hirate Y, 2013, CURR BIOL, V23, P1181, DOI 10.1016/j.cub.2013.05.014; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jolly MK, 2017, MOL ONCOL, V11, P755, DOI 10.1002/1878-0261.12083; Kim JH, 2009, P NATL ACAD SCI USA, V106, P11149, DOI 10.1073/pnas.0812651106; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Klezovitch Olga, 2015, F1000Res, V4, P550, DOI 10.12688/f1000research.6445.1; Kourtidis A, 2017, J CELL BIOL, V216, P3073, DOI 10.1083/jcb.201612125; Kourtidis A, 2017, EXP CELL RES, V358, P78, DOI 10.1016/j.yexcr.2017.04.006; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; LEVINE EM, 1965, P NATL ACAD SCI USA, V53, P350, DOI 10.1073/pnas.53.2.350; Li HB, 2016, MAMM GENOME, V27, P556, DOI 10.1007/s00335-016-9662-7; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Liang J, 2017, NATURE, V548, P588, DOI 10.1038/nature23678; LIEBERMAN MA, 1981, J MEMBRANE BIOL, V63, P1, DOI 10.1007/BF01969440; Maiden SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148574; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Mana-Capelli S, 2014, MOL BIOL CELL, V25, P1676, DOI 10.1091/mbc.E13-11-0701; Mayor R, 2010, TRENDS CELL BIOL, V20, P319, DOI 10.1016/j.tcb.2010.03.005; McClatchey AI, 2012, CURR OPIN CELL BIOL, V24, P685, DOI 10.1016/j.ceb.2012.06.009; Motti ML, 2005, CARCINOGENESIS, V26, P1021, DOI 10.1093/carcin/bgi050; Nabeshima K, 1999, HISTOL HISTOPATHOL, V14, P1183, DOI 10.14670/HH-14.1183; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Petrova YI, 2016, MOL BIOL CELL, V27, P3233, DOI 10.1091/mbc.E16-01-0058; Petrova YI, 2012, MOL BIOL CELL, V23, P2092, DOI 10.1091/mbc.E11-12-1060; Priya R, 2015, CURR TOP DEV BIOL, V112, P65, DOI 10.1016/bs.ctdb.2014.11.016; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rauskolb C, 2014, CELL, V158, P143, DOI 10.1016/j.cell.2014.05.035; Ribatti D, 2017, EXP CELL RES, V359, P17, DOI 10.1016/j.yexcr.2017.06.012; Rubsam M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01170-7; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Scarpa E, 2015, DEV CELL, V34, P421, DOI 10.1016/j.devcel.2015.06.012; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Schroeder MC, 2012, SEMIN CELL DEV BIOL, V23, P803, DOI 10.1016/j.semcdb.2012.06.001; Shashikanth N, 2015, J BIOL CHEM, V290, P21749, DOI 10.1074/jbc.M115.657098; Shi XL, 2017, DEVELOPMENT, V144, P3957, DOI 10.1242/dev.157917; Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Sun SG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9402; Szymaniak AD, 2015, DEV CELL, V34, P283, DOI 10.1016/j.devcel.2015.06.020; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; van de Wetering M, 2001, CANCER RES, V61, P278; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WHITTENBERGER B, 1977, P NATL ACAD SCI USA, V74, P2251, DOI 10.1073/pnas.74.6.2251; Yang CC, 2015, P NATL ACAD SCI USA, V112, P1785, DOI 10.1073/pnas.1420850112; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yewale C, 2013, BIOMATERIALS, V34, P8690, DOI 10.1016/j.biomaterials.2013.07.100; Yi C, 2013, HIPPO SIGNALING PATH; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	99	185	196	5	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4769	4780		10.1038/s41388-018-0304-2	http://dx.doi.org/10.1038/s41388-018-0304-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29780167	Green Accepted			2022-12-17	WOS:000443146000001
J	Guo, ST; Jiang, CC; Wang, GP; Li, YP; Wang, CY; Guo, XY; Yang, RH; Feng, Y; Wang, FH; Tseng, HY; Thorne, RF; Jin, L; Zhang, XD				Guo, S. T.; Jiang, C. C.; Wang, G. P.; Li, Y. P.; Wang, C. Y.; Guo, X. Y.; Yang, R. H.; Feng, Y.; Wang, F. H.; Tseng, H-Y; Thorne, R. F.; Jin, L.; Zhang, X. D.			MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; miR-497; IGF1-R; Akt; copy number variations	FACTOR-I-RECEPTOR; EXPRESSION PROFILES; IGF-1; INHIBITION; MUTATIONS; APOPTOSIS; GENES; CELLS; IGF1R	Past studies have shown that amplified insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1-R) signalling has an important role in colorectal cancer (CRC) development, progression and resistance to treatment. In this report, we demonstrate that downregulation of microRNA-497 (miR-497) as a result of DNA copy number reduction is involved in upregulation of IGF1-R in CRC cells. MiR-497 and miR-195 of the miR-15/16/195/424/497 family that share the same 3' untranslated region (3'UTR) binding seed sequence and are predicted to target IGF1-R were concurrently downregulated in the majority of CRC tissues relative to paired adjacent normal mucosa. However, only overexpression of miR-497 led to suppression of the IGF1-R 3'UTR activity and downregulation of the endogenous IGF1-R protein in CRC cells. This was associated with inhibition of cell survival, proliferation and invasion, and increased sensitivity to apoptosis induced by various stimuli including the chemotherapeutic drugs cisplatin and 5-fluorouracil, and the death ligand tumour necrosis factor-related apoptosis-inducing ligand. The biological effect of miR-497 on CRC cells was largely mediated by inhibition of phosphatidylinositol 3-kinase/Akt signalling, as overexpression of an active form of Akt reversed its impact on cell survival and proliferation, recapitulating the effect of overexpression of IGF1-R. Downregulation of miR-497 and miR-195 appeared to associate with copy number loss of a segment of chromosome 17p13.1, where these miRs are located at proximity. Similarly to miR-195, the members of the same miR family, miR-424 that was upregulated, and miR-15a, miR-15b and miR-16 that were unaltered in expression in CRC tissues compared with paired adjacent normal mucosa, did not appear to have a role in regulating the expression of IGF1-R. Taken together, these results identify downregulation of miR-497 as an important mechanism of upregulation of IGF1-R in CRC cells that contributes to malignancy of CRC. Oncogene (2013) 32, 1910-1920; doi:10.1038/onc.2012.214; published online 18 June 2012	[Guo, S. T.; Wang, G. P.; Wang, C. Y.; Guo, X. Y.; Yang, R. H.; Feng, Y.; Wang, F. H.; Zhang, X. D.] Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan, Peoples R China; [Jiang, C. C.; Tseng, H-Y; Thorne, R. F.; Zhang, X. D.] Univ Newcastle, Prior Res Ctr Canc Res, Newcastle, NSW 2300, Australia; [Jiang, C. C.; Tseng, H-Y; Thorne, R. F.; Zhang, X. D.] Hunter Med Res Inst, Canc Res Program, Newcastle, NSW, Australia; [Li, Y. P.] Shanxi Canc Hosp & Inst, Dept Colorectal Surg, Taiyuan, Peoples R China; [Thorne, R. F.] Univ Newcastle, Sch Biomed Sci, Canc Res Unit, Newcastle, NSW 2300, Australia; [Jin, L.] Univ Sydney, Kolling Inst Med Res, Immunol & Oncol Lab, Sydney, NSW 2006, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; University of Sydney; Kolling Institute of Medical Research	Zhang, XD (corresponding author), Univ Newcastle, Prior Res Ctr Canc Res, David Maddison Bldg,Cnr King & Watt St, Newcastle, NSW 2300, Australia.	Xu.Zhang@newcastle.edu.au	Tseng, Cindy Hsin-Yi/AAB-8958-2022; Jin, Lei/J-1896-2019; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022; Jiang, Chenchen/C-2902-2014; Zhang, xiaoyu/GXA-3206-2022; zhang, xian/GYA-0290-2022	Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Jin, Lei/0000-0001-7187-9671; Zhang, Xu Dong/0000-0001-9457-8003	NSW State Cancer Council; Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia; Shanxi Scholarship Council; National '863' High Technology Program, China; NHMRC	NSW State Cancer Council(Cancer Council New South Wales); Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); Shanxi Scholarship Council; National '863' High Technology Program, China(National High Technology Research and Development Program of China); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the NSW State Cancer Council, Cancer Institute NSW, and National Health and Medical Research Council (NHMRC), Australia, and the Shanxi Scholarship Council and National '863' High Technology Program, China. CCJ is a recipient of postdoctoral training Fellowship of NHMRC. XDZ is supported by a senior research fellowship of NHMRC.	Alberobello AT, 2010, J BIOL CHEM, V285, P6563, DOI 10.1074/jbc.M109.097410; Board RE, 2008, CLIN CHEM, V54, P757, DOI 10.1373/clinchem.2007.098376; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Ferte C, 2010, NAT REV CLIN ONCOL, V7, P367, DOI 10.1038/nrclinonc.2010.84; Flavin RJ, 2009, MODERN PATHOL, V22, P197, DOI 10.1038/modpathol.2008.135; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hart LS, 2011, CELL CYCLE, V10, P2331, DOI 10.4161/cc.10.14.16418; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Jiang CC, 2011, CLIN CANCER RES, V17, P721, DOI 10.1158/1078-0432.CCR-10-2225; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; La Rocca G, 2009, J CELL PHYSIOL, V220, P485, DOI 10.1002/jcp.21796; Lerman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020916; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Liang RQ, 2011, AGING CELL, V10, P1080, DOI 10.1111/j.1474-9726.2011.00751.x; Liang Y, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-166; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046; McKinley ET, 2011, CLIN CANCER RES, V17, P3332, DOI 10.1158/1078-0432.CCR-10-2274; Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317; Patel B, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e14131; Pereira PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011780; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Quek R, 2011, CLIN CANCER RES, V17, P871, DOI 10.1158/1078-0432.CCR-10-2621; Schee K, 2010, AM J PATHOL, V177, P1592, DOI 10.2353/ajpath.2010.100024; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Schetter AJ, 2011, SEMIN ONCOL, V38, P734, DOI 10.1053/j.seminoncol.2011.08.009; Sekharam M, 2003, CANCER RES, V63, P7708; Sekharam M, 2011, CANCER RES, V63, P7708; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Wang XQ, 2012, MED ONCOL, V29, P919, DOI 10.1007/s12032-011-9880-5; Weber MM, 2002, CANCER-AM CANCER SOC, V95, P2086, DOI 10.1002/cncr.10945; Wilmott JS, 2011, PATHOLOGY, V43, P657, DOI 10.1097/PAT.0b013e32834a7358; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Yadav S, 2011, J BIOL CHEM, V286, P37347, DOI 10.1074/jbc.M111.235531; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4	53	185	195	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1910	1920		10.1038/onc.2012.214	http://dx.doi.org/10.1038/onc.2012.214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22710713	Green Published			2022-12-17	WOS:000317599900005
J	Zhao, X; Dou, W; He, L; Liang, S; Tie, J; Liu, C; Li, T; Lu, Y; Mo, P; Shi, Y; Wu, K; Nie, Y; Fan, D				Zhao, X.; Dou, W.; He, L.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.; Fan, D.			MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor	ONCOGENE			English	Article						miR-7; IGF1R; gastric cancer; invasion and metastasis; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; HUMAN BREAST-CANCER; CELL LUNG-CANCER; TUMOR PROGRESSION; BETA-CATENIN; METASTASIS; EXPRESSION; INVASION; FAMILY; GENES	Metastasis is a major clinical obstacle in the treatment of gastric cancer (GC) and it accounts for the majority of cancer-related mortality. MicroRNAs have recently emerged as regulators of metastasis by acting on multiple signaling pathways. In this study, we found that miR-7 is significantly downregulated in highly metastatic GC cell lines and metastatic tissues. Both gain-of-function and loss-of-function experiments showed that increased miR-7 expression significantly reduced GC cell migration and invasion, whereas decreased miR-7 expression dramatically enhanced cell migration and invasion. In vivo metastasis assays also demonstrated that overexpression of miR-7 markedly inhibited GC metastasis. Moreover, the insulin-like growth factor-1 receptor (IGF1R) oncogene, which is often mutated or amplified in human cancers and functions as an important regulator of cell growth and tumor invasion, was identified as a direct target of miR-7. Silencing of IGF1R using small interefering RNA (siRNA) recapitulated the anti-metastatic function of miR-7, whereas restoring the IGF1R expression attenuated the function of miR-7 in GC cells. Furthermore, we found that suppression of Snail by miR-7, through targeting IGF1R, increased E-cadherin expression and partially reversed the epithelial-mesenchymal transition (EMT). Finally, analyses of miR-7 and IGF1R levels in human primary GC with matched lymph node metastasis tissue arrays revealed that miR-7 is inversely correlated with IGF1R expression. The present study provides insight into the specific biological behavior of miR-7 in EMT and tumor metastasis. Targeting this novel miR-7/IGF1R/Snail axis would be helpful as a therapeutic approach to block GC metastasis. Oncogene (2013) 32, 1363-1372; doi:10.1038/onc.2012.156; published online 21 May 2012	[Zhao, X.; Dou, W.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Zhao, X.; Dou, W.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China; [He, L.] Fourth Mil Med Univ, Xijing Hosp, Dept Nephrol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Fan, D (corresponding author), Xijing Hosp Digest Dis, State Key Lab Canc Biol, West Changle Rd, Xian 710032, Peoples R China.	yongznie@fmmu.edu.cn; daimingfan@fmmu.edu.cn	juan, xie/F-6556-2014; Cui, Tie Jun/Y-3224-2019; Shi, Yongquan/AAE-3954-2020	Zhao, Xiaodi/0000-0002-1817-803X	National 973 Project of China [2010CB529300, 2010CB529302, 2010CB529305, 2010CB529306]; National Natural Science Foundation of China [81030044, 30970149, 30900675]	National 973 Project of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We acknowledge Dr Tiziana Deangelis from Tomas Jefferson University for providing the pcDNA3-IGF1R plasmid. We thank Professor Zengshan Li and Professor Zhe Wang from Xijing Hospital for their help with pathological analyses. We thank Qing Ye from the Fourth Military Medical University for excellent statistical assistance. This work was supported by the National 973 Project of China (No. 2010CB529300, 02, 05, 06) and the National Natural Science Foundation of China (No. 81030044, 30970149, 30900675).	Aisagbonhi O, 2011, DIS MODEL MECH, V4, P469, DOI 10.1242/dmm.006510; Annunziata M, 2011, ACTA DIABETOL, V48, P1, DOI 10.1007/s00592-010-0227-z; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bai FH, 2007, DIGEST DIS SCI, V52, P1571, DOI 10.1007/s10620-006-9570-x; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauer TW, 2005, CANCER RES, V65, P7775, DOI 10.1158/0008-5472.CAN-05-0946; Chaudhuri K, 2007, DNA CELL BIOL, V26, P321, DOI 10.1089/dna.2006.0549; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Duncavage E, 2010, J THORAC ONCOL, V5, P1755, DOI 10.1097/JTO.0b013e3181f3909d; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 2000, MOL CARCINOGEN, V27, P10, DOI 10.1002/(SICI)1098-2744(200001)27:1<10::AID-MC3>3.0.CO;2-Z; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; He LJ, 2009, CANCER LETT, V276, P88, DOI 10.1016/j.canlet.2008.10.044; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Junn E, 2009, P NATL ACAD SCI USA, V106, P13052, DOI 10.1073/pnas.0906277106; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kim HJ, 2007, MOL CELL BIOL, V27, P3165, DOI 10.1128/MCB.01315-06; Li RS, 2009, J MED CHEM, V52, P4981, DOI 10.1021/jm9002395; Liang SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018409; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Packeisen J, 2002, J CLIN PATHOL, V55, P613, DOI 10.1136/jcp.55.8.613; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Shah MA, 2010, JAMA-J AM MED ASSOC, V303, P1753, DOI 10.1001/jama.2010.553; Sutherland BW, 2008, CANCER RES, V68, P3495, DOI 10.1158/0008-5472.CAN-07-6531; Tang YC, 2003, CANCER RES, V63, P1166; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; White NMA, 2011, NAT REV CLIN ONCOL, V8, P75, DOI 10.1038/nrclinonc.2010.173; Wu H, 2010, MOL CELL, V38, P67, DOI 10.1016/j.molcel.2010.02.021; Wu XM, 2011, ACTA PHARMACOL SIN, V32, P259, DOI 10.1038/aps.2010.204; Xiong SD, 2011, INT J BIOL SCI, V7, P805, DOI 10.7150/ijbs.7.805; Yang SY, 2011, FRONT BIOSCI-LANDMRK, V16, P531, DOI 10.2741/3703; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	53	185	204	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1363	1372		10.1038/onc.2012.156	http://dx.doi.org/10.1038/onc.2012.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22614005				2022-12-17	WOS:000316455600003
J	Leivonen, SK; Makela, R; Ostling, P; Kohonen, P; Haapa-Paananen, S; Kleivi, K; Enerly, E; Aakula, A; Hellstrom, K; Sahlberg, N; Kristensen, VN; Borresen-Dale, AL; Saviranta, P; Perala, M; Kallioniemi, O				Leivonen, S-K; Makela, R.; Ostling, P.; Kohonen, P.; Haapa-Paananen, S.; Kleivi, K.; Enerly, E.; Aakula, A.; Hellstrom, K.; Sahlberg, N.; Kristensen, V. N.; Borresen-Dale, A-L; Saviranta, P.; Perala, M.; Kallioniemi, O.			Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines	ONCOGENE			English	Article						breast cancer; estrogen receptor; miRNA; protein lysate microarray; screening	CYCLE PROGRESSION; MESSENGER-RNAS; EXPRESSION; ALPHA; TARGETS; RESISTANCE; GENES	Predicting the impact of microRNAs (miRNAs) on target proteins is challenging because of their different regulatory effects at the transcriptional and translational levels. In this study, we applied a novel protein lysate microarray (LMA) technology to systematically monitor for target protein levels after high-throughput transfections of 319 pre-miRs into breast cancer cells. We identified 21 miRNAs that downregulated the estrogen receptor-alpha (ER alpha), as validated by western blotting and quantitative real time-PCR, and by demonstrating the inhibition of estrogen-stimulated cell growth. Five potent ER alpha-regulating miRNAs, miR-18a, miR-18b, miR-193b, miR-206 and miR-302c, were confirmed to directly target ER alpha in 3'-untranslated region reporter assays. The gene expression signature that they repressed highly overlapped with that of a small interfering RNA against ER alpha, and across all the signatures tested, was most closely associated with the repression of known estrogen-induced genes. Furthermore, miR-18a and miR-18b showed higher levels of expression in ER alpha-negative as compared with ER alpha-positive clinical tumors. In summary, we present systematic and direct functional evidence of miRNAs inhibiting ER alpha signaling in breast cancer, and demonstrate the high-throughput LMA technology as a novel, powerful technique in determining the relative impact of various miRNAs on key target proteins and associated cellular processes and pathways. Oncogene (2009) 28, 3926-3936; doi:10.1038/onc.2009.241; published online 17 August 2009	[Leivonen, S-K] VTT Tech Res Ctr Finland, VTT Med Biotechnol, FI-20521 Turku, Finland; [Leivonen, S-K; Makela, R.; Ostling, P.; Kohonen, P.; Haapa-Paananen, S.; Kleivi, K.; Aakula, A.; Hellstrom, K.; Sahlberg, N.; Saviranta, P.; Perala, M.; Kallioniemi, O.] Univ Turku, Ctr Biotechnol, Turku, Finland; [Kleivi, K.; Enerly, E.; Kristensen, V. N.; Borresen-Dale, A-L] Univ Hosp, Rikshosp, Norwegian Radiumhosp, Dept Genet,Inst Canc Res, Oslo, Norway; [Enerly, E.; Borresen-Dale, A-L] Univ Oslo, Fac Med, Div Norwegian Radiumhosp, Oslo, Norway; [Kristensen, V. N.] Univ Oslo, Fac Med, Div AHUS, Oslo, Norway; [Kallioniemi, O.] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland	VTT Technical Research Center Finland; University of Turku; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of Helsinki	Leivonen, SK (corresponding author), VTT Tech Res Ctr Finland, VTT Med Biotechnol, Itainen Pitkakatu 4C,POB 106, FI-20521 Turku, Finland.	suvi-katri.leivonen@vtt.fi	Kallioniemi, Olli P/H-5111-2011; Enerly, Espen/P-4666-2019; Kohonen, Pekka/F-9596-2011; Haapa-Paananen, Saija/D-3075-2012; Leivonen, Suvi-Katri/AAK-3096-2021	Kallioniemi, Olli P/0000-0002-3231-0332; Enerly, Espen/0000-0002-2974-2273; Kohonen, Pekka/0000-0002-7845-3611; Ostling, Paivi/0000-0001-5501-466X; Leivonen, Suvi-Katri/0000-0003-3224-0757; Kleivi Sahlberg, Kristine/0000-0002-7281-2759; Saviranta, Petri/0000-0002-3289-0621	Academy of Finland Centre of Excellence on Translational Genome-Scale Biology; Academy of Finland postdoctoral researcher's grant; Sigrid Juselius Foundation; Finnish Cancer Society; EU-FP6 [LSHB-CT-2004-005276, LSHG-CT-2004-5033155]; EU-FP7 [HEALTH-F2-2007-201438]	Academy of Finland Centre of Excellence on Translational Genome-Scale Biology(Academy of Finland); Academy of Finland postdoctoral researcher's grant(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Society; EU-FP6(European Commission); EU-FP7(European Commission)	The technical assistance of Pauliina Toivonen is gratefully acknowledged. We thank Agilent Technologies for their support on the miRNA expression arrays, and Hilde Johnsen (Department of Genetics, Norwegian Radium Hospital) for laboratory handling of miRNA expression arrays on tumors. We are grateful to the Department of Pathology, Norwegian Radium Hospital, for providing ER-IHC. This study was supported by the Academy of Finland Centre of Excellence on Translational Genome-Scale Biology, Academy of Finland postdoctoral researcher's grant (to SKL), Sigrid Juselius Foundation, Finnish Cancer Society, EU-FP6 projects RIGHT (LSHB-CT-2004-005276) and Moltools (LSHG-CT-2004-5033155), and EU-FP7 project ProspeR (HEALTH-F2-2007-201438).	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Efron B, 2007, ANN APPL STAT, V1, P107, DOI 10.1214/07-AOAS101; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Kenealy MR, 2000, ENDOCRINOLOGY, V141, P2805, DOI 10.1210/en.141.8.2805; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Milano A, 2006, EUR J CANCER, V42, P2692, DOI 10.1016/j.ejca.2006.06.022; Naume B, 2001, CLIN CANCER RES, V7, P4122; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Verghese ET, 2008, J PATHOL, V215, P214, DOI 10.1002/path.2359; Wang XW, 2008, BIOINFORMATICS, V24, P325, DOI 10.1093/bioinformatics/btm595; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200	31	185	194	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2009	28	44					3926	3936		10.1038/onc.2009.241	http://dx.doi.org/10.1038/onc.2009.241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19684618				2022-12-17	WOS:000271471900007
J	Stemmer, V; de Craene, B; Berx, G; Behrens, J				Stemmer, V.; de Craene, B.; Berx, G.; Behrens, J.			Snail promotes Wnt target gene expression and interacts with beta-catenin	ONCOGENE			English	Article						beta-catenin; colorectal cancer; epithelial-mesenchymal transition; snail; Wnt	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; TUMOR PROGRESSION; SIGNALING PATHWAY; MODULATION; TUMORIGENESIS; CANCER; CELLS	The transcription factor snail represses epithelial gene expression and thereby promotes epithelial-mesenchymal transitions (EMT) and tumor invasion. The Wnt/beta-catenin pathway is also involved in EMT and was shown to activate snail. Here, we demonstrate that snail increases Wnt reporter gene activity induced by beta-catenin, LRP6 or dishevelled, and also promotes transcription activated by GAL4-beta-catenin fusion proteins. Snail mutants lacking the transcriptional repressor domain also stimulate beta-catenin-dependent transcription indicating that downregulation of snail target genes is not required for this activity. Snail interacts with beta-catenin in immunoprecipitation experiments at its N-terminus, which is required for activation by snail. In colorectal cancer cell lines, overexpression of snail leads to increased expression of Wnt target genes, whereas downregulation of endogenous snail by siRNA reduces target gene expression. Our data indicate a positive feedback stimulation of the Wnt pathway by activation of snail.	[Stemmer, V.; Behrens, J.] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, D-91054 Erlangen, Germany; [de Craene, B.; Berx, G.] Univ Ghent VIB, Dept Mol Biomed Res Mol & Cellular Oncol, Ghent, Zwijnaarde, Belgium	University of Erlangen Nuremberg; Flanders Institute for Biotechnology (VIB); Ghent University	Behrens, J (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Glueckstr 6, D-91054 Erlangen, Germany.	jbehrens@molmed.uni-erlangen.de	De Craene, Bram/B-9373-2009	Berx, Geert/0000-0001-5770-2458				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Dale JK, 2006, DEV CELL, V10, P355, DOI 10.1016/j.devcel.2006.02.011; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Roy HK, 2004, MOL CANCER THER, V3, P1159; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	18	185	197	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5075	5080		10.1038/onc.2008.140	http://dx.doi.org/10.1038/onc.2008.140			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469861				2022-12-17	WOS:000258914800010
J	Subramanian, S; Lui, WO; Lee, CH; Espinosa, I; Nielsen, TO; Heinrich, MC; Corless, CL; Fire, AZ; van de Rijn, M				Subramanian, S.; Lui, W. O.; Lee, C. H.; Espinosa, I.; Nielsen, T. O.; Heinrich, M. C.; Corless, C. L.; Fire, A. Z.; van de Rijn, M.			MicroRNA expression signature of human sarcomas	ONCOGENE			English	Article						miRNA; microarrays; sarcoma	GENE-EXPRESSION; KIT; MUTATIONS; TUMORS; REGIONS; MDM2; RNAS	MicroRNAs (miRNAs) are similar to 22 nucleotide-long noncoding RNAs involved in several biological processes including development, differentiation and proliferation. Recent studies suggest that knowledge of miRNA expression patterns in cancer may have substantial value for diagnostic and prognostic determinations as well as for eventual therapeutic intervention. We performed comprehensive analysis of miRNA expression profiles of 27 sarcomas, 5 normal smooth muscle and 2 normal skeletal muscle tissues using microarray technology and/or small RNA cloning approaches. The miRNA expression profiles are distinct among the tumor types as demonstrated by an unsupervised hierarchical clustering, and unique miRNA expression signatures were identified in each tumor class. Remarkably, the miRNA expression patterns suggested that two of the sarcomas had been misdiagnosed and this was confirmed by reevaluation of the tumors using histopathologic and molecular analyses. Using the cloning approach, we also identified 31 novel miRNAs or other small RNA effectors in the sarcomas and normal skeletal muscle tissues examined. Our data show that different histological types of sarcoma have distinct miRNA expression patterns, reflecting the apparent lineage and differentiation status of the tumors. The identification of unique miRNA signatures in each tumor type may indicate their role in tumorigenesis and may aid in diagnosis of soft tissue sarcomas.	[Subramanian, S.; Lui, W. O.; Lee, C. H.; Espinosa, I.; Fire, A. Z.; van de Rijn, M.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Lee, C. H.; Nielsen, T. O.] Univ British Columbia, Gen Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; [Heinrich, M. C.] Oregon Hlth & Sci Univ, Div Hematol Oncol, Portland, OR 97201 USA; [Corless, C. L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA; [Fire, A. Z.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; University of British Columbia; Oregon Health & Science University; Oregon Health & Science University; Stanford University	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,L-235, Stanford, CA 94305 USA.	mrijn@stanford.edu	Heinrich, Michael/AAC-6745-2019; Lui, Weng-Onn/G-6703-2013; Lui, Weng-Onn/X-5957-2019	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473; Subramanian, Subbaya/0000-0002-2544-480X; Fire, Andrew/0000-0001-6217-8312; Heinrich, Michael/0000-0003-3790-0478; van de Rijn, Matt/0000-0002-1909-9739	NCI NIH HHS [CA112270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Baer C, 2004, INT J CANCER, V110, P687, DOI 10.1002/ijc.20171; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; ESPINOSA I, 2007, IN PRESS AM J SURG; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fletcher JA, 2007, CURR OPIN GENET DEV, V17, P3, DOI 10.1016/j.gde.2006.12.010; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; HE L, 2004, NAT REV GENET, V5, P522; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Michael MZ, 2003, MOL CANCER RES, V1, P882; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Politz JCR, 2006, P NATL ACAD SCI USA, V103, P18957, DOI 10.1073/pnas.0609466103; Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413; Shimada S, 2006, HUM PATHOL, V37, P1123, DOI 10.1016/j.humpath.2006.04.010; Subramanian S, 2004, ONCOGENE, V23, P7780, DOI 10.1038/sj.onc.1208056; WEISS SW, 2001, SOFT TISSUE TUMORS; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	185	213	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2015	2026		10.1038/sj.onc.1210836	http://dx.doi.org/10.1038/sj.onc.1210836			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922033				2022-12-17	WOS:000254359100006
J	Clark, J; Merson, S; Jhavar, S; Flohr, P; Edwards, S; Foster, CS; Eeles, R; Martin, FL; Phillips, DH; Crundwell, M; Christmas, T; Thompson, A; Fisher, C; Kovacs, G; Cooper, CS				Clark, J.; Merson, S.; Jhavar, S.; Flohr, P.; Edwards, S.; Foster, C. S.; Eeles, R.; Martin, F. L.; Phillips, D. H.; Crundwell, M.; Christmas, T.; Thompson, A.; Fisher, C.; Kovacs, G.; Cooper, C. S.			Diversity of TMPRSS2-ERG fusion transcripts in the human prostate	ONCOGENE			English	Article						prostate cancer; ERG gene; TMPRSS2 gene; ERG fusion transcripts	EWINGS-SARCOMA; MYELOID-LEUKEMIA; CANCER; IDENTIFICATION; GENES; TRANSLOCATION; TLS/FUS; RNA; ERG	TMPRSS2-ERG gene fusions have recently been reported to be present in a high proportion of human prostate cancers. In the current study, we show that great diversity exists in the precise structure of TMPRSS2-ERG hybrid transcripts found in human prostates. Fourteen distinct hybrid transcripts are characterized, each containing different combinations of sequences from the TMPRSS2 and ERG genes. The transcripts include two that are predicted to encode a normal full-length ERG protein, six that encode N-terminal truncated ERG proteins and one that encodes a TMPRSS2-ERG fusion protein. Interestingly, distinct patterns of hybrid transcripts were found in samples taken from separate regions of individual cancer-containing prostates, suggesting that TMPRSS2-ERG gene fusions may be arising independently in different regions of a single prostate.	Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England; Univ Liverpool, Royal Liverpool Univ Hosp, Dept Pathol, Liverpool L69 3BX, Merseyside, England; Royal Marsden NHS Trust Fdn Hosp, Surrey, England; Univ Lancaster, Dept Biol Sci, Biomed Sci Unit, Lancaster LA1 4YW, England; Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; Royal Marsden NHS Fdn Trust Hosp, Dept Urol, London, England; Univ Heidelberg, Fac Med, Oncol Mol Lab, Heidelberg, Germany	University of London; Institute of Cancer Research - UK; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Marsden NHS Foundation Trust; Lancaster University; University of Exeter; Royal Marsden NHS Foundation Trust; Ruprecht Karls University Heidelberg	Clark, J (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	jeremy.clark@icr.ac.uk	Martin, Francis L/J-4585-2019	Martin, Francis L/0000-0001-8562-4944; Phillips, David/0000-0001-8509-3485; Eeles, Rosalind/0000-0002-3698-6241	MRC [G0501019] Funding Source: UKRI; Medical Research Council [G0501019] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CARNEY DN, 1985, CANCER RES, V45, P2913; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; COOPER CS, 2001, TRANSLOCATIONS SOLID; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 2002, CHROMOSOMES TRANSLOC; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Jhavar SG, 2005, J CLIN PATHOL, V58, P504, DOI 10.1136/jcp.2004.021808; Kojima T, 2002, BIOL PHARM BULL, V25, P991, DOI 10.1248/bpb.25.991; Kong XT, 1997, BLOOD, V90, P1192; Lin PP, 1999, CANCER RES, V59, P1428; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Soller MJ, 2006, GENE CHROMOSOME CANC, V45, P717, DOI 10.1002/gcc.20329; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679	16	185	205	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2667	2673		10.1038/sj.onc.1210070	http://dx.doi.org/10.1038/sj.onc.1210070			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043636				2022-12-17	WOS:000245831200014
J	Soussi, T				Soussi, T.			p53 alterations in human cancer: more questions than answers	ONCOGENE			English	Review						p53 mutations; apoptosis; cancer; cell cyle; tumour suppressor gene	LARGE T-ANTIGEN; TUMOR-SUPPRESSOR; MUTANT P53; MOUSE MODEL; DNA-DAMAGE; ONCOGENIC MUTATIONS; CRYSTAL-STRUCTURE; POINT MUTATION; PROTEIN; MICE	The strongest and undisputed fact about p53 is the high frequency of p53 alterations in human cancer and that mutant p53 proteins constitute a complex family of several hundred proteins with heterogeneous properties. Beyond these observations, the p53 pathway and its regulation in a normal cell is like a desert trail, always moving with the wind of novel findings. The field is full of black boxes that are often ignored for sake of simplicity or because they do not fit with the current dominant view. Mutant p53 protein accumulation in tumours is the best example of a preconceived idea, as there is no experimental evidence to explain this observation. In this review, we will discuss several questions concerning the activity or selection of p53 mutations. The central domain of the p53 protein targeted by 80% of p53 mutations is associated with the DNA-binding activity of the p53 protein, but it is also the binding site for several proteins that play a key role in p53 regulation such as ASPP proteins or BclxL. The role of impaired DNA binding and/or protein interactions in tumour development has not been fully elucidated. Similarly, novel animal models carrying either missense p53 mutations or inducible p53 have provided abundant observations, some of which could challenge our view on p53 function as a tumour suppressor gene. Finally, the possible clinical applications of p53 will be discussed.	Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Univ Paris 06, Dept Life Sci, Paris, France	Karolinska Institutet; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	thierry.soussi@ki.se		soussi, thierry/0000-0001-8184-3293				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; Deppert W, 2000, J CELL BIOCHEM, P115; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWELL SP, 1994, CANCER RES, V54, P2914; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fei PW, 2002, CANCER RES, V62, P7316; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gudkov AV, 2002, NAT MED, V8, P1196, DOI 10.1038/nm1102-1196; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HELTON ES, 2006, J CELL BIOCH; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; Johnson TM, 2006, CELL DEATH DIFFER, V13, P902, DOI 10.1038/sj.cdd.4401902; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Lozada MC, 2005, MONOGR COTSEN INST A, V53, P206; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 2005, MOL CELL, V19, P719, DOI 10.1016/j.molcel.2005.08.024; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Sigal A, 2000, CANCER RES, V60, P6788; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; Soussi T, 2003, HUM MUTAT, V21, P192, DOI 10.1002/humu.10189; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; Soussi T, 2005, 25 YEARS OF P53 RESEARCH, P255, DOI 10.1007/1-4020-2922-5_12; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tidow H, 2006, J BIOL CHEM, V281, P32526, DOI 10.1074/jbc.M604725200; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174	81	185	193	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2145	2156		10.1038/sj.onc.1210280	http://dx.doi.org/10.1038/sj.onc.1210280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401423				2022-12-17	WOS:000245394800003
J	Naderi, A; Teschendorff, AE; Barbosa-Morais, NI; Pinder, SE; Green, AR; Powe, DG; Robertson, JFR; Aparicio, S; Ellis, IO; Brenton, JD; Caldas, C				Naderi, A.; Teschendorff, A. E.; Barbosa-Morais, N. I.; Pinder, S. E.; Green, A. R.; Powe, D. G.; Robertson, J. F. R.; Aparicio, S.; Ellis, I. O.; Brenton, J. D.; Caldas, C.			A gene-expression signature to predict survival in breast cancer across independent data sets	ONCOGENE			English	Article						breast cancer; microarray; prognosis; gene-signature; survival; Cox-clustering	MICROARRAY PLATFORMS; CLASSIFICATION; VALIDATION; PROGNOSIS; ADJUVANT	Prognostic signatures in breast cancer derived from microarray expression pro. ling have been reported by two independent groups. These signatures, however, have not been validated in external studies, making clinical application problematic. We performed microarray expression pro. ling of 135 early-stage tumors, from a cohort representative of the demographics of breast cancer. Using a recently proposed semisupervised method, we identified a prognostic signature of 70 genes that significantly correlated with survival ( hazard ratio (HR): 5.97, 95% confidence interval: 3.0-11.9, P = 2.7e-07). In multivariate analysis, the signature performed independently of other standard prognostic classifiers such as the Nottingham Prognostic Index and the 'Adjuvant!' software. Using two different prognostic classification schemes and measures, nearest centroid ( HR) and risk ordering (D-index), the 70-gene classifier was also found to be prognostic in two independent external data sets. Overall, the 70- gene set was prognostic in our study and the two external studies which collectively include 715 patients. In contrast, we found that the two previously described prognostic gene sets performed less optimally in external validation. Finally, a common prognostic module of 29 genes that associated with survival in both our cohort and the two external data sets was identified. In spite of these results, further studies that pro. le larger cohorts using a single microarray platform, will be needed before prospective clinical use of molecular classifiers can be contemplated.	Univ Cambridge, Canc Genom Program, Dept Oncol, Hutchison Res Ctr,MRC, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Pathol, MRC, Hutchison Res Ctr, Cambridge CB2 2XZ, England; Univ Nottingham, Nottingham NG7 2RD, England; Nottingham City Hosp NHS Trust, Dept Mol Med Sci, Nottingham, England; Nottingham City Hosp NHS Trust, Dept Med & Surg Sci, Nottingham, England; Nottingham City Hosp NHS Trust, Dept Histopathol, Nottingham, England; Univ Lisbon, Fac Med, Inst Mol Med, P-1699 Lisbon, Portugal	University of Cambridge; University of Cambridge; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Universidade de Lisboa	Brenton, JD (corresponding author), Univ Cambridge, Canc Genom Program, Dept Oncol, Hutchison Res Ctr,MRC, Hills Rd, Cambridge CB2 2XZ, England.	jdb1003@cam.ac.uk; cc234@cam.ac.uk	Caldas, Carlos/A-7543-2008; Green, Andrew/AAF-1991-2020; Barbosa-Morais, Nuno L/I-2743-2013; Brenton, James D/B-3174-2008; Caldas, Carlos/U-7250-2019	Barbosa-Morais, Nuno L/0000-0002-1215-0538; Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; Naderi, Ali/0000-0001-7142-7616; /0000-0003-4167-8910; Ellis, Ian/0000-0001-5292-8474; Aparicio, Samuel/0000-0002-0487-9599; Green, Andrew/0000-0002-0488-5913				Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Cox D.R., 1984, ANAL SURVIVAL DATA; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Eden P, 2004, EUR J CANCER, V40, P1837, DOI 10.1016/j.ejca.2004.02.025; Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Naderi A, 2005, MOL BIOTECHNOL, V30, P151, DOI 10.1385/MB:30:2:151; Naderi A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-9; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Royston P, 2004, STAT MED, V23, P723, DOI 10.1002/sim.1621; Shen RL, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-94; Sollich P, 1996, ADV NEUR IN, V8, P190; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	25	185	193	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1507	1516		10.1038/sj.onc.1209920	http://dx.doi.org/10.1038/sj.onc.1209920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936776				2022-12-17	WOS:000244558800016
J	Pietsch, EC; Humbey, O; Murphy, ME				Pietsch, EC; Humbey, O; Murphy, ME			Polymorphisms in the p53 pathway	ONCOGENE			English	Review						p53; p21/ waf1; MDM2; polymorphism; apoptosis	DEPENDENT KINASE INHIBITOR; LUNG-CANCER SUSCEPTIBILITY; TUMOR-SUPPRESSOR GENE; CODON 72 POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; GERM-LINE POLYMORPHISMS; FAMILIAL BREAST-CANCER; CERVICAL-CANCER; NASOPHARYNGEAL CARCINOMA; PROSTATE-CANCER	The p53 tumor suppressor gene continues to be distinguished as the most frequently mutated gene in human cancer; this gene can be found mutated in up to 50% of human tumors of diverse histological type. It is generally accepted that the ability of p53 to induce either growth arrest or programmed cell death in response to diverse stimuli underlies the powerful selection against this protein in the development of cancer. It is somewhat surprising, then, to find p53 and several target genes in this pathway containing polymorphisms that impair their function. The nature of these polymorphic variants, and the mechanism whereby they impair the function of the p53 pathway, are reviewed here-in. The impact of these polymorphisms on cancer risk and the efficacy of therapy are only now becoming unraveled. Of particular relevance in these efforts will be the generation of mouse models of polymorphic variants in p53 and its target genes. Equally important will be better-controlled human studies, wherein haplotypes for p53 (that is, combinations of different polymorphisms in the p53 gene) and for p53-target genes are taken into account, instead of analyses of single gene variants, which have largely predominated to date. Studies in both regards should shed light on an emerging area in cancer biology, the significance of inter-individual differences in genotype on cancer risk, prognosis, and the efficacy of cancer therapy.	Fox Chase Canc Ctr, Div Med Sci, Program Cell & Dev Biol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Murphy, ME (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Program Cell & Dev Biol, 3333 Cottman Ave, Philadelphia, PA 19111 USA.	Maureen.Murphy@FCCC.edu		Murphy, Maureen/0000-0001-7644-7296				Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Bahl R, 2000, ONCOGENE, V19, P323, DOI 10.1038/sj.onc.1203325; Bastiaens MT, 2001, MOL CARCINOGEN, V30, P56, DOI 10.1002/1098-2744(200101)30:1<56::AID-MC1013>3.0.CO;2-2; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; BHATIA K, 1995, CANCER RES, V55, P1431; Birgander R, 1996, HUM HERED, V46, P148, DOI 10.1159/000154344; Biros E, 2000, NEOPLASMA, V47, P303; Biros E, 2002, LUNG CANCER-J IASLC, V35, P231, DOI 10.1016/S0169-5002(01)00446-9; Biros E, 2001, LUNG CANCER, V31, P157, DOI 10.1016/S0169-5002(00)00188-4; Bonafe M, 2003, CLIN CANCER RES, V9, P4860; Bonafe M, 2002, BIOCHEM BIOPH RES CO, V299, P539, DOI 10.1016/S0006-291X(02)02691-8; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; BOUGEARD G, 2005, J MED GENET     1028; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buyru N, 2005, ANTICANCER RES, V25, P2767; Buyru N, 2003, ONCOL REP, V10, P711; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen WC, 2002, UROL ONCOL, V7, P63, DOI 10.1016/S1078-1439(01)00152-1; Chen YC, 2003, J ENVIRON SCI HEAL A, V38, P201, DOI 10.1081/ESE-120016889; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; de Oliveira WRP, 2004, INT J DERMATOL, V43, P489, DOI 10.1111/j.1365-4632.2004.02289.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Dokianakis DN, 2000, INT J MOL MED, V5, P405; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FACHER EA, 1995, CANCER, V79, P2424; Fan R, 2000, CANCER EPIDEM BIOMAR, V9, P1037; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; Fiszer-Maliszewska L, 2003, J APPL GENET, V44, P547; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GAO X, 1995, ONCOGENE, V11, P1395; Gemignani F, 2004, ONCOGENE, V23, P1954, DOI 10.1038/sj.onc.1207305; GONG JZ, 1995, HEMATOL PATHOL, V9, P171; Gottschlich S, 2000, ANTICANCER RES, V20, P2613; Granja F, 2004, CANCER LETT, V210, P151, DOI 10.1016/j.canlet.2004.01.016; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hachiya T, 1999, GYNECOL ONCOL, V72, P187, DOI 10.1006/gyno.1998.5247; Harima Y, 2001, INT J MOL MED, V7, P261; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Henner WD, 2001, PROSTATE, V49, P263, DOI 10.1002/pros.10021; Hillebrandt S, 1997, MUTAT RES-FUND MOL M, V381, P201, DOI 10.1016/S0027-5107(97)00169-3; Huang SP, 2004, CANCER EPIDEM BIOMAR, V13, P2217; HUPPI K, 1994, ONCOGENE, V9, P3017; Jin SK, 2001, J CELL SCI, V114, P4139; Jones JS, 2004, CLIN CANCER RES, V10, P5845, DOI 10.1158/1078-0432.CCR-03-0590; Kang Shan, 2004, Zhonghua Fu Chan Ke Za Zhi, V39, P754; Kawaguchi H, 2000, CANCER RES, V60, P2753; Keshava C, 2002, CANCER EPIDEM BIOMAR, V11, P127; Khaliq S, 2000, GENET TEST, V4, P23, DOI 10.1089/109065700316435; Khrunin AV, 2005, MOL GENET GENOMICS, V272, P666, DOI 10.1007/s00438-004-1091-8; Kibel AS, 2003, CANCER RES, V63, P2033; Klug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009; Konishi R, 2000, J DERMATOL SCI, V24, P177, DOI 10.1016/S0923-1811(00)00096-7; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Koushik A, 2004, CANCER EPIDEM BIOMAR, V13, P11, DOI 10.1158/1055-9965.EPI-083-3; Kuroda Y, 2003, CANCER LETT, V189, P77, DOI 10.1016/S0304-3835(02)00518-9; Langerod A, 2002, CANCER EPIDEM BIOMAR, V11, P1684; LAW JC, 1995, HUM GENET, V95, P459; Lehman TA, 2000, CANCER RES, V60, P1062; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; LI YJ, 1995, ONCOGENE, V10, P599; Lukas J, 1997, AM J PATHOL, V150, P167; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Makni H, 2000, INT J CANCER, V87, P528, DOI 10.1002/1097-0215(20000815)87:4&lt;528::AID-IJC11&gt;3.0.CO;2-O; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; McKenzie KE, 1997, CLIN CANCER RES, V3, P1669; Milner BJ, 1996, EUR J CANCER, V32A, P2360, DOI 10.1016/S0959-8049(96)00306-1; Mitra S, 2005, J CLIN PATHOL, V58, P26, DOI 10.1136/jcp.2004.019315; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Nelson HH, 2005, CARCINOGENESIS, V26, P1770, DOI 10.1093/carcin/bgi125; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohayon T, 2005, BRIT J CANCER, V92, P1144, DOI 10.1038/sj.bjc.6602451; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pegoraro RJ, 2002, INT J GYNECOL CANCER, V12, P383, DOI 10.1046/j.1525-1438.2002.01109.x; Phelps M, 2003, CANCER RES, V63, P2616; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Powell BL, 2002, CARCINOGENESIS, V23, P311, DOI 10.1093/carcin/23.2.311; Ralhan R, 2000, CLIN CANCER RES, V6, P2440; RODRIGUES FC, CANC GENET CYTOGENET, V142, P92; Roh JW, 2004, GYNECOL ONCOL, V93, P499, DOI 10.1016/j.ygyno.2004.02.005; Roh JW, 2001, CANCER LETT, V165, P59, DOI 10.1016/S0304-3835(01)00401-3; RUNNEBAUM IB, 1995, LANCET, V345, P994, DOI 10.1016/S0140-6736(95)90745-9; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Shen HB, 2004, ONCOL REP, V11, P1115; Shen HB, 2003, J INVEST DERMATOL, V121, P1510, DOI 10.1046/j.1523-1747.2003.12648.x; Shen HB, 2002, CANCER LETT, V183, P123, DOI 10.1016/S0304-3835(02)00117-9; Shi Y, 1996, BRIT J CANCER, V74, P1336, DOI 10.1038/bjc.1996.546; Shih CM, 2000, JPN J CANCER RES, V91, P9, DOI 10.1111/j.1349-7006.2000.tb00854.x; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Sjalander A, 1996, HUM HERED, V46, P221, DOI 10.1159/000154357; SJALANDER A, 1995, HUM HERED, V45, P144, DOI 10.1159/000154275; Soulitzis N, 2002, CANCER LETT, V179, P175, DOI 10.1016/S0304-3835(01)00867-9; Sourvinos G, 2001, ORAL ONCOL, V37, P572, DOI 10.1016/S1368-8375(00)00139-1; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Su L, 2003, LUNG CANCER-J IASLC, V40, P259, DOI 10.1016/S0169-5002(03)00081-3; Su L, 2003, CANCER EPIDEM BIOMAR, V12, P174; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; SUN Y, 1995, CANCER EPIDEM BIOMAR, V4, P261; Suzuki K, 2003, J BIOMED SCI, V10, P430, DOI 10.1159/000071162; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Terry LA, 1996, MOL CARCINOGEN, V16, P221, DOI 10.1002/(SICI)1098-2744(199608)16:4<221::AID-MC6>3.0.CO;2-I; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Tiwawech D, 2003, CANCER LETT, V198, P69, DOI 10.1016/S0304-3835(03)00283-0; Tommiska J, 2005, CLIN CANCER RES, V11, P5098, DOI 10.1158/1078-0432.CCR-05-0173; Tsai MH, 2002, J CLIN LAB ANAL, V16, P146, DOI 10.1002/jcla.10032; Tsai MH, 2002, LARYNGOSCOPE, V112, P116, DOI 10.1097/00005537-200201000-00020; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wan M, 1996, BRIT J CANCER, V73, P1398, DOI 10.1038/bjc.1996.265; Wang YC, 1999, CLIN CANCER RES, V5, P129; Wang-Gohrke S, 1999, BRIT J CANCER, V81, P179, DOI 10.1038/sj.bjc.6690669; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Wu MT, 2004, CANCER LETT, V205, P61, DOI 10.1016/j.canlet.2003.11.026; Wu MT, 2003, CANCER LETT, V201, P175, DOI 10.1016/S0304-3835(03)00469-5; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681; Xi YG, 2004, CARCINOGENESIS, V25, P2201, DOI 10.1093/carcin/bgh229; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 2005, CLIN CANCER RES, V11, P7328, DOI 10.1158/1078-0432.CCR-05-0507; Zhang Jian-hui, 2003, Zhonghua Zhongliu Zazhi, V25, P365	134	185	190	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1602	1611		10.1038/sj.onc.1209367	http://dx.doi.org/10.1038/sj.onc.1209367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550160				2022-12-17	WOS:000235904700002
J	Launay, S; Hermine, O; Fontenay, M; Kroemer, G; Solary, E; Garrido, C				Launay, S; Hermine, O; Fontenay, M; Kroemer, G; Solary, E; Garrido, C			Vital functions for lethal caspases	ONCOGENE			English	Review						caspase; differentiation; programmed cell death; immune system; cell cycle	TUMOR-NECROSIS-FACTOR; T-CELL PROLIFERATION; HUMAN EPIDERMAL-KERATINOCYTES; LENS FIBER DIFFERENTIATION; FAS-MEDIATED APOPTOSIS; CYTOCHROME-C RELEASE; BONE-MARROW-CELLS; NF-KAPPA-B; TERMINAL DIFFERENTIATION; MYELODYSPLASTIC SYNDROMES	Caspases are a family of cysteine proteases expressed as inactive zymogens in virtually all animal cells. These enzymes play a central role in most cell death pathways leading to apoptosis but growing evidences implicate caspases also in nonapoptotic functions. Several of these enzymes, activated in molecular platforms referred to as inflammasomes, play a role in innate immune response by processing some of the cytokines involved in inflammatory response. Caspases are requested for terminal differentiation of specific cell types, whether this differentiation process leads to enucleation or not. These enzymes play also a role in T and B lymphocyte proliferation and, in some circumstances, appear to be cytoprotective rather than cytotoxic. These pleiotropic functions implicate caspases in the control of life and death but the. ne regulation of their dual effect remains poorly understood. The nonapoptotic functions of caspases implicate that cells can restrict the proteolytic activity of these enzymes to selected substrates. Deregulation of the pathways in which caspases exert these nonapoptotic functions is suspected to play a role in the pathophysiology of several human diseases.	INSERM, U 517, IFR100, Fac Med, F-21033 Dijon, France; Hop Necker Enfants Malad, Dept Adult Hematol, F-75743 Paris, France; INSERM, Inst Cochin, Dept Hematol, U 567, F-75679 Paris, France; Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Garrido, C (corresponding author), INSERM, U 517, IFR100, Fac Med, 7 Blvd Jeanne Arc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Hermine, Olivier/Q-7072-2018; Garrido, carmen/G-1633-2018; KROEMER, Guido/B-4263-2013; Garrido, Carolina/GWM-5557-2022; Kroemer, Guido/AAY-9859-2020	Garrido, carmen/0000-0003-1368-1493; KROEMER, Guido/0000-0002-9334-4405; Solary, Eric/0000-0002-8629-1341; Hermine, Olivier/0000-0003-2574-3874; Fontenay, Michaela/0000-0002-5492-6349				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Ahn EY, 2002, INT J CANCER, V100, P445, DOI 10.1002/ijc.10516; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Allombert-Blaise C, 2003, CELL DEATH DIFFER, V10, P850, DOI 10.1038/sj.cdd.4401245; Antonopoulos H, 2001, J IMMUNOL, V166, P3672, DOI 10.4049/jimmunol.166.6.3672; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Barnoy S, 2003, FEBS LETT, V546, P213, DOI 10.1016/S0014-5793(03)00573-8; Beisner DR, 2003, J IMMUNOL, V171, P247, DOI 10.4049/jimmunol.171.1.247; Boissonnas A, 2002, EUR J IMMUNOL, V32, P3007, DOI 10.1002/1521-4141(2002010)32:10<3007::AID-IMMU3007>3.0.CO;2-9; Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654; Cai JY, 2004, ARCH BIOCHEM BIOPHYS, V424, P119, DOI 10.1016/j.abb.2004.02.012; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chien AJ, 2002, BIOCHEM BIOPH RES CO, V296, P911, DOI 10.1016/S0006-291X(02)02015-6; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Claessens YE, 2002, BLOOD, V99, P1594, DOI 10.1182/blood.V99.5.1594; CLAESSENS YE, 2005, IN PRESS BLOOD; Cohen Z, 2004, THROMB RES, V113, P387, DOI 10.1016/j.thromres.2004.03.020; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; DeChant AK, 2002, ONCOGENE, V21, P5268, DOI 10.1038/sj.onc.1205648; Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj/cdd/4400930; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Foley JD, 2004, J BIOL CHEM, V279, P32142, DOI 10.1074/jbc.M313683200; Franchi L, 2003, BLOOD, V102, P2910, DOI 10.1182/blood-2003-03-0967; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gersuk GM, 1996, BLOOD, V88, P1122, DOI 10.1182/blood.V88.3.1122b.bloodjournal8831122b; Goss S J, 1978, Int Rev Cytol Suppl, VSuppl 8, P127; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Hawkins PN, 2004, ARTHRITIS RHEUM-US, V50, P607, DOI 10.1002/art.20033; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Krieser RJ, 2002, CELL DEATH DIFFER, V9, P956, DOI 10.1038/sj.cdd.4401056; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lamkanfi M, 2004, J BIOL CHEM, V279, P24785, DOI 10.1074/jbc.M400985200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Reilly LA, 2004, CELL DEATH DIFFER, V11, P724, DOI 10.1038/sj.cdd.4401408; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Oomman S, 2004, J COMP NEUROL, V476, P154, DOI 10.1002/cne.20223; Peller S, 2003, ONCOGENE, V22, P4648, DOI 10.1038/sj.onc.1206541; Plenchette S, 2004, BLOOD, V104, P2035, DOI 10.1182/blood-2004-01-0065; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Rieux-Laucat F, 2003, CURR OPIN IMMUNOL, V15, P325, DOI 10.1016/S0952-7915(03)00042-6; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Sanders EJ, 2002, J ANAT, V201, P121, DOI 10.1046/j.1469-7580.2002.00081.x; Schmidt-Mende J, 2001, LEUKEMIA, V15, P742, DOI 10.1038/sj.leu.2402110; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Sun SS, 2000, J CELL BIOCHEM, V76, P44; Tai TS, 2004, CELL DEATH DIFFER, V11, P69, DOI 10.1038/sj.cdd.4401316; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; Testa U, 2004, LEUKEMIA, V18, P1176, DOI 10.1038/sj.leu.2403383; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vischioni B, 2004, EXP CELL RES, V298, P535, DOI 10.1016/j.yexcr.2004.04.040; Vonarbourg C, 2002, EUR J IMMUNOL, V32, P2376, DOI 10.1002/1521-4141(200208)32:8<2376::AID-IMMU2376>3.0.CO;2-V; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Watanabe Y, 1999, J CELL PHYSIOL, V179, P45, DOI 10.1002/(SICI)1097-4652(199904)179:1<45::AID-JCP6>3.0.CO;2-H; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Yang JY, 2004, MOL CELL BIOL, V24, P10425, DOI 10.1128/MCB.24.23.10425-10436.2004; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yang XL, 2002, CANCER BIOL THER, V1, P407, DOI 10.4161/cbt.1.4.16; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zeuner A, 2003, CELL DEATH DIFFER, V10, P905, DOI 10.1038/sj.cdd.4401255; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603; 2004, SCIENCE, V303, P1138	129	185	196	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5137	5148		10.1038/sj.onc.1208524	http://dx.doi.org/10.1038/sj.onc.1208524			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	16079910				2022-12-17	WOS:000230964600001
J	Chen, DS; Washbrook, E; Sarwar, N; Bates, GJ; Pace, PE; Thirunuvakkarasu, V; Taylor, J; Epstein, RJ; Fuller-Pace, FV; Egly, JM; Coombes, RC; Ali, S				Chen, DS; Washbrook, E; Sarwar, N; Bates, GJ; Pace, PE; Thirunuvakkarasu, V; Taylor, J; Epstein, RJ; Fuller-Pace, FV; Egly, JM; Coombes, RC; Ali, S			Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera	ONCOGENE			English	Article						estrogen receptor alpha; phosphorylation; MAP kinase; TFIIH; breast cancer	ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; ESTRADIOL-INDUCED PHOSPHORYLATION; STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; MAP KINASE; BINDING-PROPERTIES; DNA-BINDING; BILE-ACIDS	Estrogen receptor alpha (ERalpha) is a transcription factor that regulates expression of target genes in a ligand-dependent manner. Activation of gene expression is mediated by two transcription activation functions AF-1 and AF-2, which act in a promoter- and cell-specific manner. Whilst AF-2 activity is regulated by estrogen (E2) binding, the activity of AF-1 is additionally modulated by phosphorylation at several sites. One of these phosphorylation sites, serine 118 (SI 18) is of particular interest as its mutation significantly reduces ERalpha activity. Previous studies have shown that S118 can be phosphorylated by the ERK1/2 mitogen activated protein kinases (MAPK) and by the cyclin-dependent protein kinase Cdk7. In this study we use antisera that specifically recognize ERa phosphorylated at S118 to demonstrate that MAPK phosphorylates S118 in a ligand-independent manner, whereas Cdk7 mediates E2-induced phosphorylation of S118. E2 stimulation of S118 phosphorylation was observed within 10 min of its addition and was maximal at 10(-7) m E2. S 118 phosphorylation was maximal at 30 min but then declined, such that by 180 min following E2 addition little S118 phosphorylation was evident. S118 phosphorylation was also induced by the partial estrogen antagonist 4-hydroxytamoxifen, but not by the complete antagonist ICI 182, 780. S118 phosphorylation upon addition of the MAPK inducers EGF or PMA followed the expected time courses. Finally, we show that ERalpha is phosphorylated at S118 in vivo using immunoblotting of extracts prepared from a series of ERalpha-positive breast tumours.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Imperial College London; University of Dundee; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.		Pace, Paul E/A-3104-2012; Ali, Simak/M-6912-2018	Pace, Paul E/0000-0003-1855-5760; Ali, Simak/0000-0002-1320-0816; Coombes, Raoul Charles/0000-0002-4811-1100				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Coutts AS, 1998, CANCER RES, V58, P4071; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Glass CK, 2000, GENE DEV, V14, P121; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; HORWITZ KB, 1994, J STEROID BIOCHEM, V49, P295, DOI 10.1016/0960-0760(94)90271-2; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922	56	185	195	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4921	4931		10.1038/sj.onc.1205420	http://dx.doi.org/10.1038/sj.onc.1205420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118371				2022-12-17	WOS:000176874800007
J	Alevizos, I; Mahadevappa, M; Zhang, X; Ohyama, H; Kohno, Y; Posner, M; Gallagher, GT; Varvares, M; Cohen, D; Kim, D; Kent, R; Donoff, RB; Todd, R; Yung, CM; Warrington, JA; Wong, DTW				Alevizos, I; Mahadevappa, M; Zhang, X; Ohyama, H; Kohno, Y; Posner, M; Gallagher, GT; Varvares, M; Cohen, D; Kim, D; Kent, R; Donoff, RB; Todd, R; Yung, CM; Warrington, JA; Wong, DTW			Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis	ONCOGENE			English	Article						oral cancer; gene expression; laser capture microdissection; microarrays	SQUAMOUS-CELL CARCINOMA; NEUROMEDIN U; PROGNOSTIC-SIGNIFICANCE; METABOLIZING-ENZYMES; HUMAN HEAD; IDENTIFICATION; TISSUE; TUMOR; OVEREXPRESSION; POLYMORPHISMS	Large scale gene expression profiling was carried out on laser capture microdissected (LCM) tumor and normal oral epithelial cells and analysed on high-density oligonucleotide microarrays. About 600 genes were found to be oral cancer associated. These oral cancer associated genes include oncogenes, tumor suppressors, transcription factors, xenobiotic enzymes, metastatic proteins, differentiation markers, and genes that have not been implicated in oral cancer. The database created provides a verifiable global profile of gene expression during oral carcinogenesis, revealing the potential role of known genes as well as genes that have not been previously implicated in oral cancer.	Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Biol, Boston, MA 02115 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; China Med Univ, Dept Biol, Shenyang 110001, Peoples R China; Dana Farber Canc Inst, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02115 USA; Univ Nebraska, Coll Dent, Ctr Med, Lincoln, NE 68583 USA; Forsyth Inst, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA; Chung Shan Med & Dent Coll, Taichung, Taiwan	Harvard University; Harvard School of Dental Medicine; Affymetrix; China Medical University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Eye & Ear Infirmary; University of Nebraska System; University of Nebraska Lincoln; Harvard University; Forsyth Institute; Harvard University; Massachusetts General Hospital; Chung Shan Medical University	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Med & Diagnost Sci, Div Oral Biol, 188 Longwood Ave, Boston, MA 02115 USA.	dwong@warren.med.harvard.edu	Todd, Robert/GWM-4486-2022		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467, R29DE011983, P30DE011814] Funding Source: NIH RePORTER; NIDCR NIH HHS [P30 DE11814, R29 DE11983, P01 DE12467] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JANOT F, 1993, CARCINOGENESIS, V14, P1279, DOI 10.1093/carcin/14.7.1279; Jourenkova-Mironova N, 1999, INT J CANCER, V81, P44, DOI 10.1002/(SICI)1097-0215(19990331)81:1<44::AID-IJC9>3.0.CO;2-A; JUNIEN C, 1983, AM J HUM GENET, V35, P584; Katoh T, 1999, INT J CANCER, V83, P606, DOI 10.1002/(SICI)1097-0215(19991126)83:5<606::AID-IJC6>3.3.CO;2-G; Kawamata H, 1997, INT J CANCER, V70, P120, DOI 10.1002/(SICI)1097-0215(19970106)70:1<120::AID-IJC18>3.0.CO;2-P; Kimura Y, 2000, CANCER LETT, V155, P163, DOI 10.1016/S0304-3835(00)00423-7; Kurokawa Hideo, 1998, Fukuoka Acta Medica, V89, P321; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; LIN LM, 1991, J ORAL PATHOL MED, V20, P479, DOI 10.1111/j.1600-0714.1991.tb00408.x; Liu CM, 1999, BRIT J CANCER, V79, P360, DOI 10.1038/sj.bjc.6690057; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lotan R, 1997, ENVIRON HEALTH PERSP, V105, P985, DOI 10.2307/3433315; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Magary SP, 2000, OTOLARYNG HEAD NECK, V122, P712, DOI 10.1016/S0194-5998(00)70202-6; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mighell AJ, 1997, ORAL ONCOL, V33, P155, DOI 10.1016/S0964-1955(96)00074-7; MURAMATSU H, 1995, CANCER RES, V55, P6210; MURRAY GI, 1994, GUT, V35, P599, DOI 10.1136/gut.35.5.599; Ohyama H, 2000, BIOTECHNIQUES, V29, P530, DOI 10.2144/00293st05; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Park JY, 1997, CANCER EPIDEM BIOMAR, V6, P791; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Porte H, 1998, CLIN CANCER RES, V4, P1375; Raddatz R, 2000, J BIOL CHEM, V275, P32452, DOI 10.1074/jbc.M004613200; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Sato M, 1999, CARCINOGENESIS, V20, P1927, DOI 10.1093/carcin/20.10.1927; Sgroi DC, 1999, CANCER RES, V59, P5656; Shillitoe EJ, 2000, ORAL ONCOL, V36, P8, DOI 10.1016/S1368-8375(99)00071-8; SHIN DM, 1994, CANCER EPIDEM BIOMAR, V3, P697; SHINTANI S, 1995, CANCER LETT, V95, P79, DOI 10.1016/0304-3835(95)03866-U; Strojan P, 2000, CLIN CANCER RES, V6, P1052; SUO Z, 1993, HISTOPATHOLOGY, V23, P45, DOI 10.1111/j.1365-2559.1993.tb01182.x; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; VIAENE AI, 1995, HISTOCHEM J, V27, P69, DOI 10.1007/BF00164174; vonBiberstein SE, 1996, ARCH OTOLARYNGOL, V122, P751; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Warrington JA, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P119; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L	47	185	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6196	6204		10.1038/sj.onc.1204685	http://dx.doi.org/10.1038/sj.onc.1204685			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593428				2022-12-17	WOS:000171206300011
J	Giannakakou, P; Robey, R; Fojo, T; Blagosklonny, MV				Giannakakou, P; Robey, R; Fojo, T; Blagosklonny, MV			Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity	ONCOGENE			English	Article						paclitaxel; G1 arrest; mitosis; p53; p21; Bcl-2	HUMAN CANCER-CELLS; INHIBITOR-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; SV40-TRANSFORMED CELLS; ANTICANCER AGENTS; G(1) ARREST; G2/M ARREST; HUMAN HEAD; TAXOL; OVARIAN	Paclitaxel (PTX), a microtubule-active agent, blocks cell proliferation by inhibiting mitotic progression leading to mitotic and postmitotic arrest and cell death. Here we demonstrate for the first time that very low concentrations of PTX (3-6 nM) can completely inhibit cell proliferation without arresting cells at mitosis, At these low concentrations that are insufficient to inhibit mitotic progression, PTX induced both p53 and p21 causing CI and G2 arrest in A549. In contrast, low PTX concentrations failed to induce G1 and G2 arrest in A549/E6 cells, that do not express p53, Furthermore, we observed that the levels of p53 and p21 induced by adriamycin and by low concentrations of PTX in A549 cells were comparable. This observation led us to conclude that tow concentrations of PTX can induce p53 and p21 sufficiently to cause G1 and G2, Many other cell lines, including HCT116 cells, do not readily upregulate p53 in response to PTX, and therefore undergo exclusively mitotic and postmitotic arrest after PTX treatment. At low concentrations that do not cause mitotic arrest, PTX did not significantly inhibit proliferation of these cells. In HCT116 cells, loss of p53 (HCT/p53(-/-)) or p21 (HCT/p21(-/-)) affects both Bax and Bcl-2 expression. In cells lacking p53, levels of Bax and p21 were decreased. In cells lacking p21, levels of wt p53 were highly increased to compensate for the loss of p21, This in turn results in upregulation of Bax and downregulation of Bcl-2 resulting in an increase of the apoptotic Bax/Bcl2 ratio consistent with increased sensitivity of these cells to apoptotic stimuli, High levels of p53 and Bax/Bcl-2 ratio can also explain why loss of p21 is rarely found in human cancer.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; Emory Univ, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University	Blagosklonny, MV (corresponding author), NCI, Med Branch, NIH, Bldg 10,R 12N226, Bethesda, MD 20892 USA.			Giannakakou, Paraskevi/0000-0001-7378-262X; Robey, Rob/0000-0002-0857-3650				An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; De Feudis P, 2000, NEOPLASIA, V2, P202, DOI 10.1038/sj.neo.7900086; Debernardis D, 1997, CANCER RES, V57, P870; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gan YB, 1996, CANCER RES, V56, P2086; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Khan SH, 1998, CANCER RES, V58, P396; Koutcher JA, 2000, CLIN CANCER RES, V6, P1498; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LONG BH, 1994, CANCER RES, V54, P4355; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maurer BJ, 1999, MOL PHARMACOL, V55, P938; MIYASHITA T, 1995, CELL, V80, P293; Motwani M, 2000, CLIN CANCER RES, V6, P924; Nielsen LL, 1998, CLIN CANCER RES, V4, P835; OConnor PM, 1997, CANCER RES, V57, P4285; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Safran H, 1996, CANCER, V78, P1203, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1203::AID-CNCR6>3.0.CO;2-A; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart ZA, 1999, CANCER RES, V59, P3831; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Torres K, 1998, CANCER RES, V58, P3620; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WALDMAN T, 1995, CANCER RES, V55, P5187; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zaffaroni N, 1998, BRIT J CANCER, V77, P1378, DOI 10.1038/bjc.1998.230; Zeng S, 2000, CLIN CANCER RES, V6, P3766; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	56	185	203	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3806	3813		10.1038/sj.onc.1204487	http://dx.doi.org/10.1038/sj.onc.1204487			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439344				2022-12-17	WOS:000169494700006
J	Fulda, S; Meyer, E; Friesen, C; Susin, SA; Kroemer, G; Debatin, KM				Fulda, S; Meyer, E; Friesen, C; Susin, SA; Kroemer, G; Debatin, KM			Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis	ONCOGENE			English	Article						apoptosis; drugs; mitochondria; CD95; caspases	CYTOCHROME-C RELEASE; RADIATION-INDUCED APOPTOSIS; CD95 APO-1/FAS SYSTEM; SIGNALING COMPLEX; ANTICANCER DRUGS; ACTIVATION; LIGAND; FAS; INDUCTION; BCL-2	Apoptosis in response to cellular stress such as treatment with cytotoxic drugs is mediated by effector caspases (caspase-3) which can be activated by different initiator pathways, Here, we report on a cell type specific triggering of death receptor and/or mitochondrial pathways upon drug treatment. In type I cells (BJAB), both the receptor and the mitochondrial pathway were activated upon drug treatment, since blockade of either the receptor pathway by overexpression of dominant negative FADD (FADD-DN) or of the mitochondrial pathway by overexpression of Bcl-X-L only partially inhibited apoptosis, Drug treatment induced formation of a FADD- and caspase-8-containing CD95 death-inducing signaling complex (DISC) in type I cells resulting in activation of caspase-8 as the most apical caspase. Tn contrast, in type II cells (Jurkat), apoptosis was predominantly controlled by mitochondria, since overexpression of Bcl-2 completely blocked drug-induced apoptosis, while overexpression of FADD-DN had no protective effect. In these cells, caspases including caspase-8 were activated by mitochondria-driven signaling events and no DISC was detected despite expression levels of CD95, FADD and caspase-8 proteins comparable to type I cells. Likewise, drug-induced CD95 aggregation was predominantly found in type I cells. Bid was cleaved prior to mitochondrial alterations in type I cells providing a molecular link between caspase-8 activation and mitochondrial perturbations, whereas in type. TT cells, Bid was cleaved downstream of mitochondria, Our findings of a cell type specific response to cytotoxic drugs have implications for the identification of molecular parameters for chemosensitivity or resistance in different tumor cells.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France	Ulm University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.		Kroemer, Guido/AAY-9859-2020; Debatin, Klaus-Michael/J-9704-2014; KROEMER, Guido/B-4263-2013; Fulda, Simone/D-5864-2011; Susin, Santos A/Q-6754-2017	Debatin, Klaus-Michael/0000-0002-8397-1886; KROEMER, Guido/0000-0002-9334-4405; Susin, Santos A/0000-0002-3366-1628; Fulda, Simone/0000-0002-0459-6417				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Caricchio R, 1998, J IMMUNOL, V161, P241; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1999, CELL DEATH DIFFER, V6, P471, DOI 10.1038/sj.cdd.4400512; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ibrado AM, 1996, CANCER RES, V56, P4743; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McGahon AJ, 1998, BRIT J HAEMATOL, V101, P539, DOI 10.1046/j.1365-2141.1998.00745.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	64	185	194	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1063	1075		10.1038/sj.onc.1204141	http://dx.doi.org/10.1038/sj.onc.1204141			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314043				2022-12-17	WOS:000167232100006
J	Larcher, F; Murillas, R; Bolontrade, M; Conti, CJ; Jorcano, JL				Larcher, F; Murillas, R; Bolontrade, M; Conti, CJ; Jorcano, JL			VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development	ONCOGENE			English	Article						angiogenesis; skin carcinogenesis; epidermis; transgenic mice	ENDOTHELIAL GROWTH-FACTOR; V-HA-RAS; RECEPTOR TYROSINE KINASE; MOUSE SKIN; PERMEABILITY FACTOR; MALIGNANT PROGRESSION; EPIDERMAL-KERATINOCYTES; ALPHA-6-BETA-4 INTEGRIN; FACTOR EXPRESSION; CARCINOGENESIS	Upregulation of keratinocyte-derived VEGF-A expression has recently been established in non-neoplastic processes of skin such as wound healing, blistering diseases and psoriasis, as well as in skin neoplasia, To further characterize the effects of VEGF-A in skin in vivo, we have developed transgenic mice expressing the mouse VEGF(120) under the control of a 2,4 kb 5' fragment of keratin K6 gene regulatory sequences that confers transgene inducibility upon hyperproliferative stimuli. As expected from the inducible nature of the transgene, two of the three founder mice obtained (V27 and V208), showed no apparent phenotype, However, one founder (V2), mosaic for transgene integration, developed scattered red spots throughout the skin at birth, The transgenic offspring derived from this founder developed a striking phenotype characterized by swelling and erythema, resulting in early postnatal lethality. Histological examination of the skin of these transgenics demonstrated highly increased vascularization and edema leading to disruption of skin architecture. Expression of the transgene was silent in adult animals of lines derived from founders V27 and V208, Phorbol ester-induced hyperplasia resulted in transgene induction and increased cutaneous vascularization in adult transgenic mice of these lines. Skin carcinogenesis experiments performed on hemizygous crosses of V208 mice with activated H-ras-carrying transgenic mice (TG.AC) resulted in accelerated papilloma development and increased tumor burden. Previous results from our laboratory showed that VEGF upregulation is a major angiogenic stimulus in mouse epidermal carcinogenesis. By overexpressing VEGF in the skin of transgenic mice we now move a step further toward showing that VEGF mediated angiogenesis is a rate-limiting step in the genesis of premalignant lesions, such as mouse skin papilloma, Our transgenic mice constitute an interesting :model system for in vivo study of the cutaneous angiogenic process and its relevance in tumorigenesis and other skin diseases.	Ctr Invest Energet Mediamnientales & Tecnol, Dept Cell & Mol Biol, Madrid 28040, Spain; Univ Texas, Md Anderson Canc Ctr, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Jorcano, JL (corresponding author), Ctr Invest Energet Mediamnientales & Tecnol, Dept Cell & Mol Biol, Madrid 28040, Spain.		Larcher, Fernando/J-1527-2016; MURILLAS, RODOLFO/H-8121-2017	Larcher, Fernando/0000-0002-6771-3561; MURILLAS, RODOLFO/0000-0001-9813-1006; Bolontrade, Marcela/0000-0002-8664-5541	NCI NIH HHS [CA 76540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; ALDAZ CM, 1988, CANCER RES, V48, P3253; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; Cano A, 1996, INT J CANCER, V65, P254; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; FERRARA N, 1996, EUR J CANCER, V32, P2143; FERRARA N, 1996, NATURE, V380, P389; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FOWLIS D, 1996, CELL GROWTH DIFFER, V3, P81; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOMEZ M, 1992, EXP CELL RES, V201, P250, DOI 10.1016/0014-4827(92)90272-A; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HANNAHAN D, 1996, CELL, V86, P353; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; Hogan B., 1986, MANIPULATING MOUSE E; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Larcher F, 1996, CANCER RES, V56, P5391; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MALHOTRA R, 1989, LAB INVEST, V61, P162; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MORBIDELLI L, 1998, IN PRESS ANGIOGENEIS, V1; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; RAK J, 1995, CANCER RES, V55, P4575; Ramirez A, 1998, DNA CELL BIOL, V17, P177, DOI 10.1089/dna.1998.17.177; RAMIREZ A, 1995, P NATL ACAD SCI USA, V92, P4783, DOI 10.1073/pnas.92.11.4783; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schweizer Juergen, 1993, P33; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; TENNENBAUM T, 1993, CANCER RES, V53, P4803; WANG XJ, 1995, ONCOGENE, V10, P279; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YUSPA SH, 1994, CANCER RES, V54, P1178	58	185	199	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					303	311		10.1038/sj.onc.1201928	http://dx.doi.org/10.1038/sj.onc.1201928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690512				2022-12-17	WOS:000074947500005
J	PELICCI, G; GIORDANO, S; ZHEN, Z; SALCINI, AE; LANFRANCONE, L; BARDELLI, A; PANAYOTOU, G; WATERFIELD, MD; PONZETTO, C; PELICCI, PG; COMOGLIO, PM				PELICCI, G; GIORDANO, S; ZHEN, Z; SALCINI, AE; LANFRANCONE, L; BARDELLI, A; PANAYOTOU, G; WATERFIELD, MD; PONZETTO, C; PELICCI, PG; COMOGLIO, PM			THE MOTOGENIC AND MITOGENIC RESPONSES TO HGF ARE AMPLIFIED BY THE SHC ADAPTER PROTEIN	ONCOGENE			English	Article						MET ONCOGENE; HEPATOCYTE GROWTH FACTOR; SCATTER FACTOR; SHC; CELL MOTILITY	HEPATOCYTE GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SCATTER FACTOR-RECEPTOR; C-MET PROTOONCOGENE; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; RAS PROTEINS; GRB2	The receptor of Hepatocyte Growth Factor-Scatter Factor (HGF) is a tyrosine kinase which regulates cell motility and growth. After ligand-induced tyrosine phosphorylation, the HGF receptor associates with the Shc adaptor, via the SH2 domain. Site-directed mutagenesis of the HGF receptor indicates that phosphotyrosines y(1349)VHV and (YVNV)-V-1356 can work as docking sites for Shc. The K-d of this interaction, measured in real time using synthetic phosphopeptides and recombinant She on a BIAcore biosensor, is 150 nm for both sites. After stimulation of the HGF receptor, Shc is phosphorylated on (YVNV)-V-317, generating an high affinity binding site for Gr62 (K-d = 15 nM). This duplicates the high affinity binding site for Grb2 present on the HGF receptor ((YVNV)-V-1356). Thus HGF stimulation can trigger the Ras pathway by recruiting Gr62 both directly through the receptor, and indirectly, through Site. Overexpression of wild-type She, but not of the Y-317 --> F mutant, enhances cell migration and growth in response to HGF. These data show that Shc is a relevant substrate of the HGF receptor, and works as an 'amplifier' of the motogenic as well as of the mitogenic response.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,TURIN,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Turin; University of Perugia; Ludwig Institute for Cancer Research			Salcini, Anna Elisabetta/G-4472-2017; Pelicci, Giuliana/AAA-8921-2022; Giordano, Silvia/J-9858-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; BARDELLI, Alberto/J-9721-2018	Pelicci, Giuliana/0000-0003-0986-8255; Giordano, Silvia/0000-0003-1854-1086; Lanfrancone, Luisa/0000-0002-4523-3815; Salcini, Anna Elisabetta/0000-0001-5828-2512; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328				ALBINI A, 1987, CANCER RES, V47, P3239; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHERARDI E, 1991, CANCER CELLS, V31, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU C, 1992, ONCOGENE, V7, P181; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MORUZZI EV, 1993, J BIOL CHEM, V268, P18176; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; OBERMEIER A, 1993, J BIOL CHEM, V267, P22963; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1993, CELL, V71, P1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097	55	185	196	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1631	1638						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731718				2022-12-17	WOS:A1995QU68100020
J	Dankner, M; Rose, AAN; Rajkumar, S; Siegel, PM; Watson, IR				Dankner, Matthew; Rose, April A. N.; Rajkumar, Shivshankari; Siegel, Peter M.; Watson, Ian R.			Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations	ONCOGENE			English	Review							MEK INHIBITOR TRAMETINIB; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; DABRAFENIB PLUS TRAMETINIB; WILD-TYPE; OPEN-LABEL; B-RAF; MAPK PATHWAY; MUTANT MELANOMA; DOSE-ESCALATION	The RAS-RAF-MEK-ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase. FDA-approved combination therapies of BRAF and MEK inhibitors are available that provide survival benefits to patients with a BRAF V600 mutation. Non-V600 BRAF mutants are found in many cancers, and are more prevalent than V600 mutations in certain tumor types. For example, between 50-80% of BRAF mutations in non-small cell lung cancer and 22-30% in colorectal cancer encode for non-V600 mutants. As next generation sequencing becomes increasingly used in clinical practice, oncologists are frequently identifying non-V600 BRAF mutations in their patient's tumors, but are uncertain of viable therapeutic options that could be employed for optimal treatment. From recent studies, a new classification system is emerging for BRAF mutations based on biochemical and signaling mechanisms associated with these mutants. Class I BRAF mutations affect amino acid V600 and signal as RAS-independent active monomers, class II mutations function as RAS-independent activated dimers, and class III mutations are kinase impaired but increase signaling through the MAPK pathway due to enhanced RAS binding and subsequent CRAF activation. These distinct classes of BRAF mutations predict response to targeted therapies and have important implications for future drug development. Herein, we discuss pre-clinical and clinical findings that may lead to improved treatments for all classes of BRAF mutant cancers.	[Dankner, Matthew; Rajkumar, Shivshankari; Siegel, Peter M.; Watson, Ian R.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Dankner, Matthew; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Rose, April A. N.] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada; [Rajkumar, Shivshankari; Watson, Ian R.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	McGill University; McGill University; University of Toronto; McGill University	Watson, IR (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada.; Watson, IR (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	ian.watson2@mcgill.ca	ravegnini, gloria/K-1330-2016; Rose, April/AAR-8222-2020	ravegnini, gloria/0000-0002-7774-402X; Rose, April/0000-0002-9845-4603; Watson, Ian/0000-0002-6025-3080; Dankner, Matthew/0000-0003-4869-5895	Canadian Institutes of Health Research (CIHR); Brain Tumor Foundation of Canada; David Cornfield Melanoma Fund Award; US Department of Defense (US DOD) [CA140389]; Melanoma Research Alliance (MRA) [412429]; V Foundation [V2016-023]; Canadian Institute of Health Research (CIHR) [PJT-152975]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Brain Tumor Foundation of Canada; David Cornfield Melanoma Fund Award; US Department of Defense (US DOD)(United States Department of Defense); Melanoma Research Alliance (MRA); V Foundation; Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	MD acknowledges MD/PhD training support from the Canadian Institutes of Health Research (CIHR) and the Brain Tumor Foundation of Canada. AANR acknowledges receipt of a David Cornfield Melanoma Fund Award. PMS acknowledges research support from the US Department of Defense (US DOD - CA140389), IRW is funded by grants from the Melanoma Research Alliance (MRA - Grant #412429), the V Foundation (Grant #V2016-023), and the Canadian Institute of Health Research (CIHR - Grant # PJT-152975). PMS is a William Dawson Scholar of McGill University and IRW is a Canada Research Chair.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Andreadi C, 2012, GENE DEV, V26, P1945, DOI 10.1101/gad.193458.112; [Anonymous], 2018, CANCER DISCOV, V8, P4, DOI [10.1158/2159-8290.CD-NB2017-163, DOI 10.1158/2159-8290.CD-NB2017-163]; [Anonymous], 2016, SOC MEL RES 13 INT C; Bahadoran P, 2013, J CLIN ONCOL, V31, pE324, DOI 10.1200/JCO.2012.46.1061; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Bendell JC, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3502; Berghoff AS, 2014, CURR OPIN NEUROL, V27, P689, DOI 10.1097/WCO.0000000000000146; Bowyer SE, 2014, MELANOMA RES, V24, P504, DOI 10.1097/CMR.0000000000000099; Brastianos PK, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv310; Brastianos PK, 2014, NAT GENET, V46, P161, DOI 10.1038/ng.2868; Brose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8; Burger MC, 2017, ONCOL REP, V38, P3291, DOI 10.3892/or.2017.6013; Cardarella S, 2013, CLIN CANCER RES, V19, P4532, DOI 10.1158/1078-0432.CCR-13-0657; Carrera C, 2015, JAMA DERMATOL, V151, P544, DOI 10.1001/jamadermatol.2014.4115; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dahlman KB, 2012, CANCER DISCOV, V2, P791, DOI 10.1158/2159-8290.CD-12-0097; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Falchook GS, 2015, THYROID, V25, P71, DOI 10.1089/thy.2014.0123; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, CANCER-AM CANCER SOC, V116, P4902, DOI 10.1002/cncr.25261; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Gallo S, 2018, MELANOMA RES, V28, P143, DOI 10.1097/CMR.0000000000000417; Gardini AC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2463-2; Garman B, 2017, CELL REP, V21, P1936, DOI 10.1016/j.celrep.2017.10.052; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Gautschi O, 2015, J THORAC ONCOL, V10, P1451, DOI 10.1097/JTO.0000000000000625; Gautschi O, 2013, LUNG CANCER, V82, P365, DOI 10.1016/j.lungcan.2013.08.012; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Grilley-Olson JE, 2016, INVEST NEW DRUG, V34, P740, DOI 10.1007/s10637-016-0377-0; Haase O, 2016, HAUTARZT, V67, P648, DOI 10.1007/s00105-016-3785-3; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hallmeyer S, 2017, MELANOMA RES, V27, P585, DOI 10.1097/CMR.0000000000000398; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6; Hsu HC, 2016, ONCOTARGET, V7, P22257, DOI 10.18632/oncotarget.8076; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Huijberts S, 2017, ANN ONCOL          S, V28, pv158, DOI [10.1093/annonc/mdx393, DOI 10.1093/ANNONC/MDX393]; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Johnson DB, 2018, PIGM CELL MELANOMA R, V31, P432, DOI 10.1111/pcmr.12674; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394; Joshi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118210; Karoulia Z, 2016, CANCER CELL, V30, P485, DOI 10.1016/j.ccell.2016.06.024; Kim DW, 2016, CANCER, V123, P1372; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966; Kopetz S., 2010, J CLIN ONCOL S15S, V28; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Krepler C, 2017, CELL REP, V21, P1953, DOI 10.1016/j.celrep.2017.10.021; Kulkarni A, 2017, CLIN CANCER RES, V23, P5631, DOI 10.1158/1078-0432.CCR-16-0758; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Lavoie H, 2013, NAT CHEM BIOL, V9, P428, DOI [10.1038/nchembio.1257, 10.1038/NCHEMBIO.1257]; Le K, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12092; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Litvak AM, 2014, J THORAC ONCOL, V9, P1669, DOI 10.1097/JTO.0000000000000344; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Marconcini R, 2017, EXP HEMATOL ONCOL, V6, DOI 10.1186/s40164-017-0067-4; Menzies AM, 2015, PIGM CELL MELANOMA R, V28, P607, DOI 10.1111/pcmr.12388; Miller WH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3057; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; Noeparast A, 2017, ONCOTARGET, V8, P60094, DOI 10.18632/oncotarget.11635; Nowroozi S, 2013, J CLIN ONCOL, V31; Okimoto RA, 2016, P NATL ACAD SCI USA, V113, P13456, DOI 10.1073/pnas.1610456113; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Preusser M, 2016, EXPERT OPIN INV DRUG, V25, P7, DOI 10.1517/13543784.2016.1110143; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Rasco DW, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14102; Reddy SM, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0531-z; Richtig G, 2016, CASE REP ONCOL, V9, P543, DOI 10.1159/000449125; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Rose AANDM, 2017, AACR NCI EORTC INT C; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2016, CLIN CANCER RES, V22, P6088, DOI 10.1158/1078-0432.CCR-16-1192; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Sakamoto N, 2017, ELIFE, V6, DOI 10.7554/eLife.20331; Santarpia L, 2009, HUM PATHOL, V40, P827, DOI 10.1016/j.humpath.2008.11.003; Sereno M, 2015, ANTI-CANCER DRUG, V26, P1004, DOI 10.1097/CAD.0000000000000277; Shinozaki E, 2017, BRIT J CANCER, V117, P1450, DOI 10.1038/bjc.2017.308; Siroy AE, 2015, J INVEST DERMATOL, V135, P508, DOI 10.1038/jid.2014.366; Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Sun Y, 2017, NEURO-ONCOLOGY, V19, P774, DOI 10.1093/neuonc/now261; Tejpar S, 2010, ONCOLOGIST, V15, P390, DOI 10.1634/theoncologist.2009-0233; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982; Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y	144	184	188	8	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3183	3199		10.1038/s41388-018-0171-x	http://dx.doi.org/10.1038/s41388-018-0171-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29540830				2022-12-17	WOS:000435526600001
J	Madan, B; Ke, Z; Harmston, N; Ho, SY; Frois, AO; Alam, J; Jeyaraj, DA; Pendharkar, V; Ghosh, K; Virshup, IH; Manoharan, V; Ong, EHQ; Sangthongpitag, K; Hill, J; Petretto, E; Keller, TH; Lee, MA; Matter, A; Virshup, DM				Madan, B.; Ke, Z.; Harmston, N.; Ho, S. Y.; Frois, A. O.; Alam, J.; Jeyaraj, D. A.; Pendharkar, V.; Ghosh, K.; Virshup, I. H.; Manoharan, V.; Ong, E. H. Q.; Sangthongpitag, K.; Hill, J.; Petretto, E.; Keller, T. H.; Lee, M. A.; Matter, A.; Virshup, D. M.			Wnt addiction of genetically defined cancers reversed by PORCN inhibition	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; COLON-CANCER; STEM-CELLS; EXPRESSION; PORCUPINE; PATHWAY; GROWTH; RNF43; TRANSCRIPTION; GENE	Enhanced sensitivity to Wnts is an emerging hallmark of a subset of cancers, defined in part by mutations regulating the abundance of their receptors. Whether these mutations identify a clinical opportunity is an important question. Inhibition of Wnt secretion by blocking an essential post-translational modification, palmitoleation, provides a useful therapeutic intervention. We developed a novel potent, orally available PORCN inhibitor, ETC-1922159 (henceforth called ETC-159) that blocks the secretion and activity of all Wnts. ETC-159 is remarkably effective in treating RSPO-translocation bearing colorectal cancer (CRC) patient-derived xenografts. This is the first example of effective targeted therapy for this subset of CRC. Consistent with a central role of Wnt signaling in regulation of gene expression, inhibition of PORCN in RSPO3-translocated cancers causes a marked remodeling of the transcriptome, with loss of cell cycle, stem cell and proliferation genes, and an increase in differentiation markers. Inhibition of Wnt signaling by PORCN inhibition holds promise as differentiation therapy in genetically defined human cancers.	[Madan, B.; Frois, A. O.; Ghosh, K.; Virshup, I. H.; Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Ke, Z.; Ho, S. Y.; Alam, J.; Jeyaraj, D. A.; Pendharkar, V.; Manoharan, V.; Ong, E. H. Q.; Sangthongpitag, K.; Hill, J.; Keller, T. H.; Lee, M. A.; Matter, A.] ASTAR, Ctr Expt Therapeut, Biopolis, Singapore, Singapore; [Harmston, N.; Petretto, E.] Duke NUS Grad Med Sch, Program Cardiovasc & Metab Dis, Singapore, Singapore; [Virshup, D. M.] Duke Univ, Dept Pediat, Durham, NC 27706 USA	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Experimental Drug Development Centre (EDDC); Experimental Therapeutics Centre; National University of Singapore; Duke University	Madan, B; Virshup, DM (corresponding author), Duke NUS, Grad Sch Med, Program Canc & Stem Cell Biol, 07-20,8 Coll Rd, Singapore 169857, Singapore.	Babita.Madan@duke-nus.edu.sg; David.Virshup@duke-nus.edu.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Madan, Babita/0000-0003-1065-8589; Ho, Soo Yei/0000-0001-8535-389X; Keller, Thomas/0000-0002-7553-6235; Petretto, Enrico/0000-0003-2163-5921; HARMSTON, NATHAN/0000-0002-8589-2938	National Research Foundation Singapore; Agency for Science, Technology and Research (A*STAR), Singapore; MRC Clinical Sciences Centre, Imperial College, London; Medical Research Council [MC_U120097112] Funding Source: researchfish; MRC [MC_U120097112] Funding Source: UKRI	National Research Foundation Singapore(National Research Foundation, Singapore); Agency for Science, Technology and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR)); MRC Clinical Sciences Centre, Imperial College, London(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We acknowledge the assistance of members of the Virshup lab including Jamal Aliyev, Naushad Moti and Edison and members of Experimental Therapeutics Centre including Shermaine Q Y Lim, Sifang Wang, Yu Wang, Vivien Wei Wen Cheong, and Grace Ruiting Lin. We acknowledge Ivana Mihalek for help with the alignment of PORCN sequences and Ralph Bunte, DVM, for his expert advice with histological analysis. We also acknowledge the assistance of the vivarium staff including Hock Lee. This research is supported in part by the National Research Foundation Singapore and administered by the Singapore Ministry of Health's National Medical Research Council under the STAR Award Program to DMV. The research in Experimental Therapeutics Centre is supported by the Agency for Science, Technology and Research (A*STAR), Singapore. EP and NH acknowledge the support of the MRC Clinical Sciences Centre, Imperial College, London.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Cardona GM, 2014, P 105 ANN M AM ASS C; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236; Coombs GS, 2012, ONCOGENE, V31, P213, DOI 10.1038/onc.2011.228; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Fu J, 2009, P NATL ACAD SCI USA, V106, P18598, DOI 10.1073/pnas.0904894106; Gao XX, 2011, FEBS LETT, V585, P2501, DOI 10.1016/j.febslet.2011.06.033; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Gibaldi M., 1982, PHARMACOKINETICS, V2nd ed., P409; Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109; Gurtner A, 2010, CANCER RES, V70, P9711, DOI 10.1158/0008-5472.CAN-10-0721; Hannoush RN, 2009, ACS CHEM BIOL, V4, P581, DOI 10.1021/cb900085z; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee SB, 2013, BIOCHEM BIOPH RES CO, V431, P746, DOI 10.1016/j.bbrc.2013.01.038; Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Lum L, 2012, SCIENCE, V337, P922, DOI 10.1126/science.1228179; Madan B, 2015, MOL CANCER THER, V14, P1087, DOI 10.1158/1535-7163.MCT-14-1038; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008-5472.CAN-12-2258; Rios-Esteves J, 2013, CELL REP, V4, P1072, DOI 10.1016/j.celrep.2013.08.027; Ryland GL, 2013, J PATHOL, V229, P469, DOI 10.1002/path.4134; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wang XL, 2013, J MED CHEM, V56, P2700, DOI 10.1021/jm400159c; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yu J, 2014, BIOSCIENCE REP, V34, P593, DOI 10.1042/BSR20140119	49	184	196	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2197	2207		10.1038/onc.2015.280	http://dx.doi.org/10.1038/onc.2015.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26257057	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000374986000006
J	Guedj, M; Marisa, L; de Reynies, A; Orsetti, B; Schiappa, R; Bibeau, F; MacGrogan, G; Lerebours, F; Finetti, P; Longy, M; Bertheau, P; Bertrand, F; Bonnet, F; Martin, AL; Feugeas, JP; Bieche, I; Lehmann-Che, J; Lidereau, R; Birnbaum, D; Bertucci, F; de The, H; Theillet, C				Guedj, M.; Marisa, L.; de Reynies, A.; Orsetti, B.; Schiappa, R.; Bibeau, F.; MacGrogan, G.; Lerebours, F.; Finetti, P.; Longy, M.; Bertheau, P.; Bertrand, F.; Bonnet, F.; Martin, A. L.; Feugeas, J. P.; Bieche, I.; Lehmann-Che, J.; Lidereau, R.; Birnbaum, D.; Bertucci, F.; de The, H.; Theillet, C.			A refined molecular taxonomy of breast cancer	ONCOGENE			English	Article						breast cancer; molecular classification; taxonomy; transcriptome; CGH-array, outcome	ANDROGEN RECEPTOR; SUBTYPES; TUMORS; METASTASIS; PROGENITORS; PREDICTORS; GRADE	The current histoclinical breast cancer classification is simple but imprecise. Several molecular classifications of breast cancers based on expression profiling have been proposed as alternatives. However, their reliability and clinical utility have been repeatedly questioned, notably because most of them were derived from relatively small initial patient populations. We analyzed the transcriptomes of 537 breast tumors using three unsupervised classification methods. A core subset of 355 tumors was assigned to six clusters by all three methods. These six subgroups overlapped with previously defined molecular classes of breast cancer, but also showed important differences, notably the absence of an ERBB2 subgroup and the division of the large luminal ER+ group into four subgroups, two of them being highly proliferative. Of the six subgroups, four were ER+/PR+/AR+, one was ER-PR-/AR+ and one was triple negative (AR-/ER-/PR-). ERBB2-amplified tumors were split between the ER-/PR-/AR+ subgroup and the highly proliferative ER+ LumC subgroup. Importantly, each of these six molecular subgroups showed specific copy-number alterations. Gene expression changes were correlated to specific signaling pathways. Each of these six subgroups showed very significant differences in tumor grade, metastatic sites, relapse-free survival or response to chemotherapy. All these findings were validated on large external datasets including more than 3000 tumors. Our data thus indicate that these six molecular subgroups represent well-defined clinico-biological entities of breast cancer. Their identification should facilitate the detection of novel prognostic factors or therapeutical targets in breast cancer. Oncogene (2012) 31, 1196-1206; doi:10.1038/onc.2011.301; published online 25 July 2011	[Theillet, C.] CRLC Val dAurelle Paul Lamarque, Inst Rech Canc Montpellier, INSERM, U896, F-34298 Montpellier 5, France; [Guedj, M.; Marisa, L.; de Reynies, A.; Schiappa, R.] Ligue Natl Canc, Cartes Identite Tumeurs Program, Paris, France; [Bibeau, F.] CRLC Val dAurelle Paul Lamarque, Dept Pathol, F-34298 Montpellier 5, France; [MacGrogan, G.; Longy, M.; Bonnet, F.] Univ Bordeaux 2, EA 3669, F-33076 Bordeaux, France; [MacGrogan, G.; Longy, M.; Bonnet, F.] Inst Bergonie, Dept Pathol, Bordeaux, France; [Lerebours, F.; Bertrand, F.; Bieche, I.; Lidereau, R.] Inst Curie Hop Ctr Rene Huguenin, Oncogenet Lab, INSERM, U735, St Cloud, France; [Finetti, P.; Birnbaum, D.; Bertucci, F.] Inst J Paoli I Calmettes, Dept Mol Oncol, CRCM, Ctr Rech Canc Marseille, F-13009 Marseille, France; [Bertheau, P.] Univ Paris, Hop St Louis, APHP, Dept Pathol, F-75252 Paris, France; [Martin, A. L.] Federat Natl Ctr Lutte Canc, Paris, France; [Feugeas, J. P.; Lehmann-Che, J.; de The, H.] Hop St Louis, APHP, Dept Biochem, Paris, France; [Feugeas, J. P.; Lehmann-Che, J.; de The, H.] CNRS, INSERM, UMR 944 7212, Paris, France; [Feugeas, J. P.; Lehmann-Che, J.; de The, H.] Univ Paris 07, Univ Hematol Inst, Paris, France; [Theillet, C.] Univ Montpellier 1, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Theillet, C (corresponding author), CRLC Val dAurelle Paul Lamarque, Inst Rech Canc Montpellier, INSERM, U896, F-34298 Montpellier 5, France.	charles.theillet@inserm.fr	Bièche, Ivan/O-7399-2017; SCHIAPPA, Renaud/K-8192-2019; Feillet, Francois/A-3648-2017; Theillet, Charles/O-7634-2018; de Reyniès, Aurélien/Q-8640-2017; Finetti, Pascal/O-8669-2017	Bièche, Ivan/0000-0002-2430-5429; Feillet, Francois/0000-0002-8717-469X; de Reyniès, Aurélien/0000-0002-1328-5290; Theillet, Charles/0000-0001-5555-2759; MacGrogan, Gaetan/0000-0002-3483-9758; Finetti, Pascal/0000-0002-2674-3123; SCHIAPPA, Renaud/0000-0001-5104-9507; Lehmann-Che, jacqueline/0000-0001-6685-3354	Ligue Nationale Contre le Cancer	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	This work was supported by the Carte d'Identite des Tumeurs Program from the Ligue Nationale Contre le Cancer. We thank Pr Jacqueline Godet and Dr Jacqueline Metral for their constant support during the course of this work. The expertize of the personnel serving the RNA extraction and qualification (Saint-Louis Hospital, Paris), Affymetrix expression array (IGBMC, Strasbourg), CIT database and array-CGH (IRCM, Montpellier) CIT platforms is gratefully acknowledged. We further thank Dr Stan du Manoir for critical reading of the manuscript, Vessela N Kristensen and Peter Van Loo for making their data available to us.	Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; Bertucci F, 2008, ONCOGENE, V27, P5359, DOI 10.1038/onc.2008.158; Bertucci F, 2006, OMICS, V10, P429, DOI 10.1089/omi.2006.10.429; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; ISOLA JJ, 1993, J PATHOL, V170, P31, DOI 10.1002/path.1711700106; Jonsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596; Kapp AV, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-231; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Naderi A, 2008, NEOPLASIA, V10, P542, DOI 10.1593/neo.08274; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Weigelt B, 2010, LANCET ONCOL, V11, P339, DOI 10.1016/S1470-2045(10)70008-5; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	35	184	193	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1196	1206		10.1038/onc.2011.301	http://dx.doi.org/10.1038/onc.2011.301			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21785460	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000300945900013
J	Wu, WKK; Coffelt, SB; Cho, CH; Wang, XJ; Lee, CW; Chan, FKL; Yu, J; Sung, JJY				Wu, W. K. K.; Coffelt, S. B.; Cho, C. H.; Wang, X. J.; Lee, C. W.; Chan, F. K. L.; Yu, J.; Sung, J. J. Y.			The autophagic paradox in cancer therapy	ONCOGENE			English	Review						autophagy; cell survival; cell death	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; CELL-DEATH; TUMOR-SUPPRESSOR; MAMMALIAN TARGET; PROSTATE-CANCER; BECLIN 1; REGULATES AUTOPHAGY; CYTOPROTECTIVE AUTOPHAGY; DEPENDENT INDUCTION	Autophagy, hallmarked by the formation of double-membrane bound organelles known as autophagosomes, is a lysosome-dependent pathway for protein degradation. The role of autophagy in carcinogenesis is context dependent. As a tumor-suppressing mechanism in early-stage carcinogenesis, autophagy inhibits inflammation and promotes genomic stability. Moreover, disruption of autophagy-related genes accelerates tumorigenesis in animals. However, autophagy may also act as a pro-survival mechanism to protect cancer cells from various forms of cellular stress. In cancer therapy, adaptive autophagy in cancer cells sustains tumor growth and survival in face of the toxicity of cancer therapy. To this end, inhibition of autophagy may sensitize cancer cells to chemotherapeutic agents and ionizing radiation. Nevertheless, in certain circumstances, autophagy mediates the therapeutic effects of some anticancer agents. Data from recent studies are beginning to unveil the apparently paradoxical nature of autophagy as a cell-fate decision machinery. Taken together, modulation of autophagy is a novel approach for enhancing the efficacy of existing cancer therapy, but its Janus-faced nature may complicate the clinical development of autophagy modulators as anticancer therapeutics. Oncogene (2012) 31, 939-953; doi:10.1038/onc.2011.295; published online 18 July 2011	[Wu, W. K. K.; Cho, C. H.; Wang, X. J.; Lee, C. W.; Chan, F. K. L.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, LKS Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Wu, W. K. K.; Cho, C. H.; Wang, X. J.; Lee, C. W.; Chan, F. K. L.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Coffelt, S. B.] Univ Sheffield, Sch Med, Acad Unit Inflammat & Tumour Targeting, Dept Infect & Immun, Sheffield, S Yorkshire, England; [Cho, C. H.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Sheffield; Chinese University of Hong Kong	Wu, WKK (corresponding author), Prince Wales Hosp, 7-F,LKS Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	wukakei@cuhk.edu.hk; junyu@cuhk.edu.hk; joesung@cuhk.edu.hk	Cho, Chi Hin/C-6543-2014; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015; Wu, William K.K./A-3277-2009; Coffelt, Seth/O-9929-2019; Chan, Francis K. L./F-4851-2010	Cho, Chi Hin/0000-0002-7658-3260; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153; Wu, William K.K./0000-0002-5662-5240; Coffelt, Seth/0000-0003-2257-2862; Chan, Francis K. L./0000-0001-7388-2436	CUHK [3110043]	CUHK(Chinese University of Hong Kong)	This work was supported by research grant from the CUHK Group Research Scheme (3110043) and CUHK Focused Investments Scheme-Scheme C.	Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069; Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x; Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Altman BJ, 2011, ONCOGENE, V30, P1855, DOI 10.1038/onc.2010.561; Altman BJ, 2009, MOL BIOL CELL, V20, P1180, DOI 10.1091/mbc.E08-08-0829; Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Bhoopathi P, 2010, CELL DEATH DIFFER, V17, P1529, DOI 10.1038/cdd.2010.28; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802; Castino R, 2008, J NEUROENDOCRINOL, V20, P1165, DOI 10.1111/j.1365-2826.2008.01769.x; Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509; Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; CLIBY W, 1993, CANCER RES, V53, P2393; Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; de Haan CAM, 2010, AUTOPHAGY, V6, P994, DOI 10.4161/auto.6.7.13309; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Ding Y, 2010, J BIOL CHEM, V285, P37909, DOI 10.1074/jbc.M109.093724; Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915; Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95; ECCLES DM, 1992, ONCOGENE, V7, P2069; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Fu L, 2009, CANCER RES, V69, P8967, DOI 10.1158/0008-5472.CAN-09-2190; Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x; Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; FUTREAL PA, 1992, CANCER RES, V52, P2624; Gajewska M, 2005, J Physiol Pharmacol, V56 Suppl 3, P143; Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33; GAO X, 1995, CANCER RES, V55, P1002; Ghavami S, 2008, J CELL MOL MED, V12, P1005, DOI 10.1111/j.1582-4934.2008.00129.x; Gu YP, 2004, FEBS LETT, V577, P357, DOI 10.1016/j.febslet.2004.10.040; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8; Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240; Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666; Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124; Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051; Hwang J, 2010, J NEUROIMMUNOL, V226, P66, DOI 10.1016/j.jneuroim.2010.05.037; Indelicato M, 2010, J CELL PHYSIOL, V223, P359, DOI 10.1002/jcp.22041; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Jiang H, 2010, AUTOPHAGY, V6, P1216, DOI 10.4161/auto.6.8.13695; Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kamitsuji Y, 2008, CELL DEATH DIFFER, V15, P1712, DOI 10.1038/cdd.2008.107; Kandouz M, 2010, CELL CYCLE, V9, P398, DOI 10.4161/cc.9.2.10505; Kang C, 2007, GENE DEV, V21, P2161, DOI 10.1101/gad.1573107; Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509; Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831; Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X; Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058; Kim KW, 2009, CLIN CANCER RES, V15, P6096, DOI 10.1158/1078-0432.CCR-09-0589; Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013; Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Koesters R, 2010, AM J PATHOL, V177, P632, DOI 10.2353/ajpath.2010.091012; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904; Kuo HP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000590; Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46; Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600-0560.2009.01359.x; Lazova R, 2009, EXP DERMATOL, V18, P934, DOI 10.1111/j.1600-0625.2009.00933.x; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491; Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157; Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98; Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu D, 2011, CANCER-AM CANCER SOC, V117, P3763, DOI 10.1002/cncr.25959; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537; Lorin S, 2009, CANCER RES, V69, P6924, DOI 10.1158/0008-5472.CAN-09-1270; Lovas A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-606; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma X, 2011, CLIN CANCER RES, V17, P1; Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathieu V, 2007, J INVEST DERMATOL, V127, P2399, DOI 10.1038/sj.jid.5700869; McPhee CK, 2010, NATURE, V465, P1093, DOI 10.1038/nature09127; Meschini S, 2008, AUTOPHAGY, V4, P1020, DOI 10.4161/auto.6952; Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257; Miracco C, 2007, INT J ONCOL, V30, P429; Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Narita M, 2009, AUTOPHAGY, V5, P1046, DOI 10.4161/auto.5.7.9444; Negri T, 2010, GENE CHROMOSOME CANC, V49, P901, DOI 10.1002/gcc.20798; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Nivon M, 2009, AUTOPHAGY, V5, P766, DOI 10.4161/auto.8788; Noble CG, 2008, J BIOL CHEM, V283, P26274, DOI 10.1074/jbc.M804723200; Nomura H, 2009, HUM PATHOL, V40, P83, DOI 10.1016/j.humpath.2008.06.018; O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066; Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774; Othman EQG, 2009, J CLIN LAB ANAL, V23, P249, DOI 10.1002/jcla.20309; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Pankiv S, 2010, AUTOPHAGY, V6, P550, DOI 10.4161/auto.6.4.11670; Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015; Park MA, 2008, MOL PHARMACOL, V73, P1168, DOI 10.1124/mol.107.042697; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117; Portillo JAC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014472; Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4; Reef S, 2007, ONCOGENE, V26, P6677, DOI 10.1038/sj.onc.1210485; Reef S, 2008, AUTOPHAGY, V4, P866, DOI 10.4161/auto.6691; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAITO H, 1993, CANCER RES, V53, P3382; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51; Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049; Steffan JJ, 2010, J CELL SCI, V123, P1151, DOI 10.1242/jcs.063644; Steffan JJ, 2010, TRAFFIC, V11, P274, DOI 10.1111/j.1600-0854.2009.01012.x; Stenmark H, 2010, FEBS J, V277, P4837, DOI 10.1111/j.1742-4658.2010.07900.x; Suzuki HI, 2010, AUTOPHAGY, V6, P645, DOI 10.4161/auto.6.5.12046; Tangir J, 1996, ONCOGENE, V12, P735; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004; Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Ueno T, 2008, AUTOPHAGY, V4, P692, DOI 10.4161/auto.6085; Voss V, 2010, MOL CANCER RES, V8, P1002, DOI 10.1158/1541-7786.MCR-09-0562; Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; Wild P, 2010, NAT CELL BIOL, V12, P104, DOI 10.1038/ncb0210-104; Wu WKK, 2010, DRUG RESIST UPDATE, V13, P87, DOI 10.1016/j.drup.2010.04.003; Wu WKK, 2010, CANCER LETT, V293, P15, DOI 10.1016/j.canlet.2009.12.002; Wu WKK, 2010, AUTOPHAGY, V6, P228, DOI 10.4161/auto.6.2.11042; Xu DZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-536; Yacoub A, 2010, CANCER RES, V70, P1120, DOI 10.1158/0008-5472.CAN-09-4043; Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yaswen P, 2007, CELL, V128, P233, DOI 10.1016/j.cell.2007.01.005; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng XH, 2008, CANCER RES, V68, P2384, DOI 10.1158/0008-5472.CAN-07-6163; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104; Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9; Zhang ZC, 2009, J HUAZHONG U SCI-MED, V29, P737, DOI 10.1007/s11596-009-0613-3; Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x	180	184	198	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					939	953		10.1038/onc.2011.295	http://dx.doi.org/10.1038/onc.2011.295			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765470				2022-12-17	WOS:000300709700001
J	Danial, NN				Danial, N. N.			BAD: undertaker by night, candyman by day	ONCOGENE			English	Review						BAD; apoptosis; metabolism; survival signaling	BCL-X-L; DEPENDENT PROTEIN-KINASE; HUMAN PANCREATIC-ISLETS; PROMOTES CELL-SURVIVAL; CYTOCHROME-C RELEASE; DEATH AGONIST BAD; GROWTH-FACTOR-II; BH3 DOMAIN; PROAPOPTOTIC BAD; FAMILY-MEMBERS	The BH3-only pro-apoptotic proteins are upstream sensors of cellular damage that selectively respond to specific, proximal death and survival signals. Genetic models and biochemical studies indicate that these molecules are latent killers until activated through transcriptional or post-translational mechanisms in a tissue-restricted and signal-specific manner. The large number of BH3-only proteins, their unique subcellular localization, protein-interaction network and diverse modes of activation suggest specialization of their damage-sensing function, ensuring that the core apoptotic machinery is poised to receive input from a wide range of cellular stress signals. The apoptotic response initiated by the activation of BH3-only proteins ultimately culminates in allosteric activation of pro-apoptotic BAX and BAK, the gateway proteins to the mitochondrial pathway of apoptosis. From activation of BH3-only proteins to oligomerization of BAX and BAK and mitochondrial outer membrane permeabilization, an intricate network of interactions between the pro-and anti-apoptotic members of the BCL-2 family orchestrates the decision to undergo apoptosis. Beyond regulation of apoptosis, multiple BCL-2 proteins have recently emerged as active components of select homeostatic pathways carrying other cellular functions. This review focuses on BAD, which was the first BH3-only protein linked to proximal survival signals through phosphorylation by survival kinases. In addition to findings that delineated the physiological role of BAD in apoptosis and its dynamic regulation by phosphorylation, studies pointing to new roles for this protein in other physiological pathways, such as glucose metabolism, are highlighted. By executing its 'day' and 'night' jobs in metabolism and apoptosis, respectively, BAD helps coordinate mitochondrial fuel metabolism and the apoptotic machinery. Oncogene (2009) 27, S53-S70; doi: 10.1038/onc.2009.44	[Danial, N. N.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Danial, N. N.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Danial, NN (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 3 Blackfan Circle,CLSB 11-143, Boston, MA 02115 USA.	nika_danial@dfci.harvard.edu			National Cancer Institute (NCI, Rockville, MD, USA) [5 K01 CA106596-02]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA) [R01 DK078081-01]; Iacocca Foundation ( Boston, MA, USA); Juvenile Diabetes Research Foundation (JDRF, London, UK); Novartis (Basel, Switzerland); DFCI/Novartis Drug Discovery Program; NATIONAL CANCER INSTITUTE [K01CA106596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078081] Funding Source: NIH RePORTER	National Cancer Institute (NCI, Rockville, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Iacocca Foundation ( Boston, MA, USA); Juvenile Diabetes Research Foundation (JDRF, London, UK)(Juvenile Diabetes Research Foundation); Novartis (Basel, Switzerland); DFCI/Novartis Drug Discovery Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	NN Danial iscurrent ly receiving grant support from the National Cancer Institute (NCI, Rockville, MD, USA) (5 K01 CA106596-02), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA) (R01 DK078081-01), the Iacocca Foundation ( Boston, MA, USA) and the Juvenile Diabetes Research Foundation (JDRF, London, UK). The author is also in receipt of a grant from Novartis ( Basel, Switzerland) as part of the DFCI/Novartis Drug Discovery Program and has a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund (Durham, NC, USA). NN Danial is a consultant/an advisor for the Novartis Institute for Biomedical Research (NIBR, Cambridge, MA, USA).	Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arden C, 2006, FEBS LETT, V580, P2065, DOI 10.1016/j.febslet.2006.03.009; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Balasubramanian R, 2007, PLANT PHYSIOL, V145, P1423, DOI 10.1104/pp.107.108704; Beene DL, 2007, CURR OPIN CELL BIOL, V19, P192, DOI 10.1016/j.ceb.2007.02.011; Berquin IM, 2007, J CLIN INVEST, V117, P1866, DOI 10.1172/JCI31494; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bose AK, 2005, DIABETES, V54, P146, DOI 10.2337/diabetes.54.1.146; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Rasmo D, 2008, CELL SIGNAL, V20, P989, DOI 10.1016/j.cellsig.2008.01.017; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; delPeso L, 1997, SCIENCE, V278, P687; Deng HB, 2008, J BIOL CHEM, V283, P20754, DOI 10.1074/jbc.M800024200; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Djouder N, 2007, MOL CELL, V28, P28, DOI 10.1016/j.molcel.2007.08.010; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Freilinger A, 2006, ONCOGENE, V25, P6467, DOI 10.1038/sj.onc.1209660; FREINKEL N, 1984, DIABETES, V33, P1028, DOI 10.2337/diabetes.33.11.1028; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Giege P, 2003, PLANT CELL, V15, P2140, DOI 10.1105/tpc.012500; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hekman M, 2006, J BIOL CHEM, V281, P17321, DOI 10.1074/jbc.M600292200; Hettiarachchi KD, 2008, EXP TOXICOL PATHOL, V60, P295, DOI 10.1016/j.etp.2008.02.009; Hickman JA, 2008, J NEUROPHYSIOL, V99, P1515, DOI 10.1152/jn.00598.2007; Hill DJ, 2000, ENDOCRINOLOGY, V141, P1151, DOI 10.1210/en.141.3.1151; HOGG J, 1994, J MOL ENDOCRINOL, V13, P49, DOI 10.1677/jme.0.0130049; Houslay M.D., 2006, SCI STKE, V2006, ppe32; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jetton TL, 2005, DIABETES, V54, P2294, DOI 10.2337/diabetes.54.8.2294; Jonas EA, 2003, J NEUROSCI, V23, P8423; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Khor TO, 2004, CANCER LETT, V210, P139, DOI 10.1016/j.canlet.2004.01.017; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim MR, 2007, DIGEST DIS SCI, V52, P2751, DOI 10.1007/s10620-007-9799-z; Kim WH, 2005, DIABETES, V54, P2602, DOI 10.2337/diabetes.54.9.2602; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li H, 2008, P NATL ACAD SCI USA, V105, P2169, DOI 10.1073/pnas.0711647105; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li WQ, 2004, J BIOL CHEM, V279, P29160, DOI 10.1074/jbc.M401656200; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Liadis N, 2007, DIABETES, V56, P2302, DOI 10.2337/db06-1771; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu WL, 2002, ENDOCRINOLOGY, V143, P3802, DOI 10.1210/en.2002-220058; Livigni A, 2006, MOL BIOL CELL, V17, P263, DOI 10.1091/mbc.e05-09-0827; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Marshall Stephen, 2006, Sci STKE, V2006, pre7; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Matschinsky FM, 2006, DIABETES, V55, P1; Miyawaki T, 2008, P NATL ACAD SCI USA, V105, P4892, DOI 10.1073/pnas.0800628105; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Murata T, 1997, FEBS LETT, V406, P109, DOI 10.1016/S0014-5793(97)00253-6; Ness JM, 2006, BRAIN RES, V1099, P150, DOI 10.1016/j.brainres.2006.04.132; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Owusu-Ansah E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petrik J, 1999, ENDOCRINOLOGY, V140, P2353, DOI 10.1210/en.140.5.2353; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; PIPELEERS D, 1994, DIABETOLOGIA, V37, pS57, DOI 10.1007/BF00400827; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Salomoni P, 2000, BLOOD, V96, P676; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sastry KSR, 2007, J BIOL CHEM, V282, P14094, DOI 10.1074/jbc.M611370200; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Smith WE, 2007, MOL ENDOCRINOL, V21, P1478, DOI 10.1210/me.2006-0356; Soderling SH, 2007, J NEUROSCI, V27, P355, DOI 10.1523/JNEUROSCI.3209-06.2006; Sone H, 2005, DIABETOLOGIA, V48, P58, DOI 10.1007/s00125-004-1605-2; Sung JY, 2008, P NATL ACAD SCI USA, V105, P3112, DOI 10.1073/pnas.0712180105; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Uzgare AR, 2004, CANCER RES, V64, P6190, DOI 10.1158/0008-5472.CAN-04-0968; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Waingeh VF, 2006, BIOPHYS J, V90, P1371, DOI 10.1529/biophysj.105.070052; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Wiederkehr A, 2006, ENDOCRINOLOGY, V147, P2643, DOI 10.1210/en.2006-0057; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Wikstrom JD, 2007, DIABETES, V56, P2569, DOI 10.2337/db06-0757; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wu L, 2004, J BIOL CHEM, V279, P12126, DOI 10.1074/jbc.M307097200; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	176	184	187	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S53	S70		10.1038/onc.2009.44	http://dx.doi.org/10.1038/onc.2009.44			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641507				2022-12-17	WOS:000268566800005
J	Sun, C; Dobi, A; Mohamed, A; Li, H; Thangapazham, RL; Furusato, B; Shaheduzzaman, S; Tan, SH; Vaidyanathan, G; Whitman, E; Hawksworth, DJ; Chen, Y; Nau, M; Patel, V; Vahey, M; Gutkind, JS; Sreenath, T; Petrovics, G; Sesterhenn, IA; McLeod, DG; Srivastava, S				Sun, C.; Dobi, A.; Mohamed, A.; Li, H.; Thangapazham, R. L.; Furusato, B.; Shaheduzzaman, S.; Tan, S-H; Vaidyanathan, G.; Whitman, E.; Hawksworth, D. J.; Chen, Y.; Nau, M.; Patel, V.; Vahey, M.; Gutkind, J. S.; Sreenath, T.; Petrovics, G.; Sesterhenn, I. A.; McLeod, D. G.; Srivastava, S.			TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation	ONCOGENE			English	Article						ERG; prostate cancer; oncogene; C-MYC; PSA; TMPRSS2-ERG	ETS TRANSCRIPTION FACTOR; ANDROGEN RECEPTOR; EXPRESSION; REARRANGEMENTS; LEUKEMIA; TARGETS; ADULTS; GENES; ERG	The high prevalence of TMPRSS2-ERG rearrangements (similar to 60%) in prostate cancer (CaP) leads to androgenic induction of the ETS-related gene (ERG) expression. However, the biological functions of ERG overexpression in CaP remain to be understood. ERG knockdown in TMPRSS2-ERG expressing CaP cells induced striking morphological changes and inhibited cell growth both in cell culture and SCID mice. Evaluation of the transcriptome and specific gene promoters in ERG siRNA-treated cells and investigation of gene expression signatures of human prostate tumors revealed ERG-mediated activation of C-MYC oncogene and the repression of prostate epithelial differentiation genes (PSA and SLC45A3/Prostein). Taken together, these data combining cell culture and animal models and human prostate tumors reveal that ERG overexpression in prostate tumor cells may contribute to the neoplastic process by activating C-MYC and by abrogating prostate epithelial differentiation as indicated by prostate epithelial specific markers.	[Sun, C.; Dobi, A.; Mohamed, A.; Li, H.; Thangapazham, R. L.; Furusato, B.; Shaheduzzaman, S.; Tan, S-H; Vaidyanathan, G.; Whitman, E.; Hawksworth, D. J.; Chen, Y.; Sreenath, T.; Petrovics, G.; McLeod, D. G.; Srivastava, S.] Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA; [Furusato, B.; Sesterhenn, I. A.] Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; [Whitman, E.; Hawksworth, D. J.; McLeod, D. G.] Walter Reed Army Med Ctr, Urol Serv, Dept Surg, Washington, DC 20307 USA; [Nau, M.; Vahey, M.] Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD USA; [Patel, V.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, Natl Inst Hlth, Bethesda, MD USA; [Dobi, A.; Sesterhenn, I. A.; McLeod, D. G.; Srivastava, S.] US Mil Canc Inst, Washington, DC USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org	Gutkind, J. Silvio/A-1053-2009; Jackson, Benjamin L/C-4297-2012; Tan, Shyh-Han/I-7037-2013; Gutkind, J. Silvio/J-1201-2016	Tan, Shyh-Han/0000-0001-8250-7005; Gutkind, J. Silvio/0000-0002-5150-4482; Petrovics, Gyorgy/0000-0003-3732-284X; Furusato, Bungo/0000-0003-4614-9882	US Army Medical Research and Materiel Command; NIH Grants [RO1 DK065977, RO1 CA106653]; NATIONAL CANCER INSTITUTE [R01CA106653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065977] Funding Source: NIH RePORTER	US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); NIH Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Authors express sincere thanks to Ms Lakshmi Ravindranath, Ms Atekelt Y Tadese, Ms Suma Ravulapalli and Mr Christopher Cook for their superb technical support of this study. The prostate tissue specimens used in this study were obtained under an IRB-approved protocol at Walter Reed Army Medical Center. This work was funded by the CPDR through an ongoing grant from the US Army Medical Research and Materiel Command, NIH Grants RO1 DK065977 to S. S and G. P. and RO1 CA106653 to S. S. and A. D. The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or the US Government.	Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Demichelis F, 2007, J CLIN PATHOL, V60, P1185, DOI 10.1136/jcp.2007.046557; Furusato B, 2008, MODERN PATHOL, V21, P67, DOI 10.1038/modpathol.3800981; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Korenchuk S, 2001, IN VIVO, V15, P163; Lin BY, 1999, CANCER RES, V59, P4180; Marcucci G, 2005, CURR OPIN HEMATOL, V12, P68, DOI 10.1097/01.moh.0000149608.29685.d1; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Owczarek CM, 2004, GENE, V324, P65, DOI 10.1016/j.gene.2003.09.047; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Scherf M, 2005, BRIEF BIOINFORM, V6, P287, DOI 10.1093/bib/6.3.287; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; SHAHEDUZZAMAN S, 2007, CANCER BIOL THER, V6, P1; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Turner DP, 2008, EXPERT REV ANTICANC, V8, P33, DOI 10.1586/14737140.8.1.33; Witte JS, 2007, NAT GENET, V39, P579, DOI 10.1038/ng0507-579	22	184	197	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5348	5353		10.1038/onc.2008.183	http://dx.doi.org/10.1038/onc.2008.183			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18542058	Green Accepted			2022-12-17	WOS:000259096100007
J	Sokolov, MV; Smilenov, LB; Hall, EJ; Panyutin, IG; Bonner, WM; Sedelnikova, OA				Sokolov, MV; Smilenov, LB; Hall, EJ; Panyutin, IG; Bonner, WM; Sedelnikova, OA			Ionizing radiation induces DNA double-strand breaks in bystander primary human fibroblasts	ONCOGENE			English	Article						bystander effect; DNA double-strand break; gamma-H2AX	MEDIATED INTERCELLULAR COMMUNICATION; TARGETED CYTOPLASMIC IRRADIATION; HISTONE H2AX PHOSPHORYLATION; C3H 10T(1)/(2) CELLS; ALPHA-PARTICLES; GENOMIC INSTABILITY; MAMMALIAN-CELLS; NONIRRADIATED CELLS; DAMAGE; INDUCTION	That irradiated cells affect their unirradiated 'bystander' neighbors is evidenced by reports of increased clonogenic mortality, genomic instability, and expression of DNA-repair genes in the bystander cell populations. The mechanisms underlying the bystander effect are obscure, but genomic instability suggests DNA double-strand breaks (DSBs) may be involved. Formation of DSBs induces the phosphorylation of the tumor suppressor protein, histone H2AX and this phosphorylated form, named gamma-H2AX, forms foci at DSB sites. Here we report that irradiation of target cells induces gamma-H2AX focus formation in bystander cell populations. The effect is manifested by increases in the fraction of cells in a population that contains multiple gamma-H2AX foci. After 18 h coculture with cells irradiated with 20 alpha-particles, the fraction of bystander cells with multiple foci increased 3.7-fold. Similar changes occurred in bystander populations mixed and grown with cells irradiated with gamma-rays, and in cultures containing media conditioned on gamma-irradiated cells. DNA DSB repair proteins accumulated at gamma-H2AX foci, indicating that they are sites of DNA DSB repair. Lindane, which blocks gap-junctions, prevented the bystander effect in mixing but not in media transfer protocols, while c-PTIO and aminoguanidine, which lower nitric oxide levels, prevented the bystander effect in both protocols. Thus, multiple mechanisms may be involved in transmitting bystander effects. These studies show that H2AX phosphorylation is an early step in the bystander effect and that the DNA DSBs underlying gamma-H2AX focus formation may be responsible for its downstream manifestations.	NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD 20892 USA; Inst Cell Biol & Genet Engn, Dept Radiat Biol & Biophys, UA-03143 Kiev, Ukraine; Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Academy of Sciences Ukraine; Institute of Cell Biology & Genetic Engineering of the National Academy of Sciences of Ukraine; Columbia University	Bonner, WM (corresponding author), NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH, Bldg 37 Room 5050,9000 Rockville Pike, Bethesda, MD 20892 USA.	bonnerw@mail.nih.gov; sedelnio@mail.nih.gov		Martin (nee Sedelnikova), Olga/0000-0003-3470-2935	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002033] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41-EB002033] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Azzam EI, 2004, CURR CANCER DRUG TAR, V4, P53, DOI 10.2174/1568009043481641; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bonner WM, 2004, MUTAT RES-FUND MOL M, V568, P33, DOI 10.1016/j.mrfmmm.2004.06.044; Brenner DJ, 2001, RADIAT RES, V155, P402, DOI 10.1667/0033-7587(2001)155[0402:TBEIRO]2.0.CO;2; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Hall EJ, 2003, ONCOGENE, V22, P7034, DOI 10.1038/sj.onc.1206900; Highfield D P, 1975, Methods Cell Biol, V9, P85, DOI 10.1016/S0091-679X(08)60070-9; Hill MA, 2005, RADIAT RES, V163, P36, DOI 10.1667/RR3282; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; MacPhail SH, 2003, RADIAT RES, V159, P759, DOI 10.1667/RR3003; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Marples B, 2003, RADIAT RES, V160, P38, DOI 10.1667/RR3013; Mitchell SA, 2004, INT J RADIAT BIOL, V80, P465, DOI 10.1080/09553000410001725116; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT RES, V157, P526, DOI 10.1667/0033-7587(2002)157[0526:RBRILD]2.0.CO;2; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; NAGASAWA H, 1992, CANCER RES, V52, P6394; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Ponnaiya B, 2004, RADIAT RES, V162, P426, DOI 10.1667/RR3236; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedelnikova OA, 2004, INT J RADIAT BIOL, V80, P927, DOI 10.1080/09553000400017648; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao C, 2003, CANCER RES, V63, P8437; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Suzuki M, 2004, RADIAT RES, V162, P264, DOI 10.1667/RR3226; Ward JF, 2000, COLD SPRING HARB SYM, V65, P377, DOI 10.1101/sqb.2000.65.377; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	46	184	191	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7257	7265		10.1038/sj.onc.1208886	http://dx.doi.org/10.1038/sj.onc.1208886			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16170376				2022-12-17	WOS:000233142100001
J	Pucci, S; Bonanno, E; Pichiorri, F; Angeloni, C; Spagnoli, LG				Pucci, S; Bonanno, E; Pichiorri, F; Angeloni, C; Spagnoli, LG			Modulation of different clusterin isoforms in human colon tumorigenesis	ONCOGENE			English	Article						clusterin/ApoJ; colon carcinoma; progression marker; tumor progression; clusterin isoforms	PROGRAMMED CELL-DEATH; EXPRESSION; PROTEIN; GENE; APOPTOSIS; PROSTATE; BREAST; RAT; OVEREXPRESSION; CARCINOMA	Clusterin is a ubiquitous secretory heterodimeric disulfide-linked glycoprotein, which is implicated in several physiological processes, including immune regulation, cell adhesion and morphological transformation, lipid transportation, tissue remodelling, membrane recycling and cell-cell interactions. A large number of studies have focused their interest on clusterin gene products as mediators of cell cycle progression and cell death induction, although data on the different isoforms and their role in the different cell processes are still obscure. Recently, an increased clusterin expression in breast cancer has been reported. In order to elucidate the role of clusterin in tumor progression and whether one of its isoforms is preferentially expressed in tumorigenesis, we examined its presence throughout the different steps of human colon carcinoma, one of the best-characterized models of human tumor progression. The immunohistochemical observation of 30 bioptic and surgical colon specimens demonstrated a cell compartment clusterin translocation from the nucleus to the cytoplasm directly related to tumor progression. In fact, a nuclear localization found in healthy colonic mucosa is consistent with the involvement of the proapoptotic nuclear form in the regulation of cell cycle progression and in cell death induction. The progression towards high-grade and metastatic carcinoma leads to cytoplasmic clusterin distribution. Protein extracts from freshly isolated cells of the same patients confirm in high-grade carcinomas with metastatic nodes the complete loss of the proapoptotic nuclear form and a cytoplasmic overexpression of the highly glycosylated form. Data obtained from in vitro experiments confirm that this form is released in the extracellular space and corresponded to the fully glycosylated one. These data suggest that the controversial data on clusterin function in tumors may be related to the pattern shift of its isoform production. As the secreted form of clusterin is correlated to cell matrix formation, cell membrane remodeling and cell-cell adhesion, the overexpression of this form in highly aggressive tumors and metastatic nodes could be a potential new prognostic and predictive marker for colon carcinoma aggressiveness.	Univ Roma Tor Vergata, Dept Biopathol, I-00133 Rome, Italy	University of Rome Tor Vergata	Pucci, S (corresponding author), Univ Roma Tor Vergata, Dept Biopathol, Via Montpellier 1, I-00133 Rome, Italy.	Sabina.Pucci@uniroma2.it; spagnoli@uniroma2.it		Spagnoli, Luigi Giusto/0000-0002-0684-5501; bonanno, elena/0000-0002-0222-0141; Pucci, Sabina/0000-0002-2418-6482				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; BANDYK MG, 1990, J UROLOGY, V143, P407, DOI 10.1016/S0022-5347(17)39975-5; Bettuzzi S, 2002, ONCOGENE, V21, P4328, DOI 10.1038/sj.onc.1205594; BURKEY BF, 1991, J LIPID RES, V32, P1039; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fratelli M, 1996, BBA-MOL CELL RES, V1311, P71, DOI 10.1016/0167-4889(95)00192-1; FRENCH LE, 1992, J CLIN INVEST, V90, P1919, DOI 10.1172/JCI116069; Ho SM, 1998, AM J PATHOL, V153, P131, DOI 10.1016/S0002-9440(10)65553-8; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Miyake H, 2001, CLIN CANCER RES, V7, P4245; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; O'Sullivan J, 2003, CELL DEATH DIFFER, V10, P914, DOI 10.1038/sj.cdd.4401254; Pucci S, 2001, ONCOGENE, V20, P739, DOI 10.1038/sj.onc.1204148; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Rigas B, 2001, CANCER RES, V61, P8381; WONG P, 1993, J BIOL CHEM, V268, P5021; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zellweger T, 2001, NEOPLASIA, V3, P360, DOI 10.1038/sj.neo.7900174; Zhou W, 2002, LIFE SCI, V72, P11, DOI 10.1016/S0024-3205(02)02183-5	25	184	196	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2298	2304		10.1038/sj.onc.1207404	http://dx.doi.org/10.1038/sj.onc.1207404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14755245	Green Published			2022-12-17	WOS:000220427700003
J	Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE			EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma	ONCOGENE			English	Article						EphA2; RNAi; siRNA; pancreatic adenocarcinoma; cancer; in vivo; anoikis; invasion; metastasis	FOCAL-ADHESION-KINASE; RECEPTOR TYROSINE KINASE; RNA INTERFERENCE; EPITHELIAL-CELLS; DIFFERENTIAL REGULATION; GROWTH-FACTOR; CANCER; OVEREXPRESSION; EXPRESSION; INVASION	The EphA2 receptor tyrosine kinase is overexpressed in a variety of human cancers. We sought to characterize the role of EphA2 in pancreatic adenocarcinoma and, using RNA interference (RNAi) mediated by small interfering RNA ( siRNA), we determined the effects of suppressing EphA2 expression in vitro and in vivo. EphA2 expression in PANC1, MIAPaCa2, BxPC3 and Capan2 cells was assessed by Northern and Western blot. We artificially overexpressed EphA2 by transient transfection and suppressed EphA2 expression using RNAi. Cellular invasiveness was quantified by modified Boyden chamber assay. Anoikis was induced by anchorage-independent polyHEMA culture and caspase 3 activity was quantified fluorometrically. Focal adhesion kinase (FAK) phosphorylation was assessed by immunoprecipitation. EphA2 siRNA treatment was assessed in a nude mouse xenograft model. Pancreatic adenocarcinoma cells differentially express EphA2. Inherent and induced EphA2 overexpression is associated with increased cellular invasiveness and anoikis resistance. EphA2 siRNA suppresses EphA2 expression, cellular invasiveness, anoikis resistance and FAK phosphorylation in vitro and retards tumor growth and inhibits metastasis in vivo. EphA2 is both a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.	Harvard Univ, Brigham & Womens Hosp, Dept Surg, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Surg, Sch Med, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						Balis FM, 2002, J NATL CANCER I, V94, P78, DOI 10.1093/jnci/94.2.78; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Braasch DA, 2002, BIOCHEMISTRY-US, V41, P4503, DOI 10.1021/bi0122112; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; EASTY DJ, 1995, CANCER RES, V55, P2528; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Farrell TJ, 1997, ANN SURG, V226, P66, DOI 10.1097/00000658-199707000-00009; Filleur S, 2003, CANCER RES, V63, P3919; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fujiwara H, 2002, J CLIN ENDOCR METAB, V87, P5801, DOI 10.1210/jc.2002-020508; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GORELIK E, 1991, CANCER RES, V51, P5212; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Holder N, 1999, DEVELOPMENT, V126, P2033; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kim HRC, 1999, CANCER RES, V59, P4148; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Lu M, 2003, CANCER RES, V63, P3425; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; Miyazaki T, 2003, BRIT J CANCER, V89, P140, DOI 10.1038/sj.bjc.6601050; OWENS LV, 1995, CANCER RES, V55, P2752; RAZ A, 1983, SCIENCE, V221, P1307, DOI 10.1126/science.6612347; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Schneider GB, 2002, CANCER, V95, P2508, DOI 10.1002/cncr.10992; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Sun FX, 2003, CANCER RES, V63, P80; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Weckbecker G, 1997, YALE J BIOL MED, V70, P549; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301	53	184	202	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1448	1456		10.1038/sj.onc.1207247	http://dx.doi.org/10.1038/sj.onc.1207247			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973554				2022-12-17	WOS:000189035800012
J	Richardson, C; Stark, JM; Ommundsen, M; Jasin, M				Richardson, C; Stark, JM; Ommundsen, M; Jasin, M			Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability	ONCOGENE			English	Article						translocation; DNA double-strand break; homologous recombination; crossover; genome instability; aneuploidy; Rad51	INDUCED DNA-REPLICATION; ACUTE MYELOID-LEUKEMIA; MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; GENE CONVERSION; CHROMOSOMAL TRANSLOCATIONS; ATP HYDROLYSIS; ES CELLS; C-MYC; PROTEIN	Genomic instability is characteristic of tumor cells, and a strong correlation exists between abnormal karyotype and tumorigenicity. Increased expression of the homologous recombination and DNA repair protein Rad51 has been reported in immortalized and tumor cells, which could alter recombination pathways to contribute to the chromosomal rearrangements found in these cells. We used a genetic system to examine the potential for multiple double-strand breaks to lead to genome rearrangements in the presence of increased Rad51 expression. Analysis of repair revealed a novel class of products consistent with crossing over, involving gene conversion associated with an exchange of flanking markers leading to chromosomal translocations. Increased Rad51 also promoted aneuploidy and multiple chromosomal rearrangements. These data provide a link between elevated Rad51 protein levels, genome instability, and tumor progression.	Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Columbia University; Cornell University; Memorial Sloan Kettering Cancer Center	Richardson, C (corresponding author), Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.	car10@columbia.edu			NCI NIH HHS [P30 CA13696] Funding Source: Medline; NCRR NIH HHS [S10 RR13701, S10 RR10506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013701, S10RR010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGUILERA A, 1989, GENETICS, V123, P683; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; ANTONARAKIS SE, 2002, GENETIC BASIS HUMAN, P7; Arnaudeau C, 1999, J MOL BIOL, V289, P1231, DOI 10.1006/jmbi.1999.2856; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bosco G, 1998, GENETICS, V150, P1037; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Cory S, 1999, CANCER RES, V59, p1685S; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Gibson L, 1996, ONCOGENE, V13, P665; Gloor GB, 1998, TRENDS GENET, V14, P43, DOI 10.1016/S0168-9525(97)01365-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morrison C, 1999, MOL CELL BIOL, V19, P6891; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; Raderschall E, 2002, J CELL SCI, V115, P153; Raderschall E, 2002, CANCER RES, V62, P219; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUPER HJG, 1993, BLOOD, V82, P3705; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tremblay A, 2000, MOL CELL BIOL, V20, P54, DOI 10.1128/MCB.20.1.54-60.2000; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yanez RJ, 1999, GENE THER, V6, P1282, DOI 10.1038/sj.gt.3300945	63	184	193	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					546	553		10.1038/sj.onc.1207098	http://dx.doi.org/10.1038/sj.onc.1207098			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724582				2022-12-17	WOS:000188098300025
J	Tucker, MA; Goldstein, AM				Tucker, MA; Goldstein, AM			Melanoma etiology: where are we?	ONCOGENE			English	Review						melanoma; epidemiology; nevi; genetic epidemiology	CUTANEOUS MALIGNANT-MELANOMA; DYSPLASTIC NEVUS SYNDROME; SUN-PROTECTION BEHAVIORS; MULTICENTER CASE-CONTROL; CDK4 GERMLINE MUTATIONS; DANISH CASE-CONTROL; MELANOCYTIC NEVI; RISK-FACTORS; CDKN2A MUTATIONS; PRONE FAMILIES	Melanoma incidence rates are rising rapidly, particularly in older men. Older men are also more likely to have thick melanomas, which confer high mortality and morbidity. The reasons for the rate of increase are not known; increasing sun and UV exposure, however, is the major hypothesized explanation. In the past several years, two major susceptibility genes for melanoma, CDKN2A and CDK4, have been identified, but the two genes together account for a minority of familial melanoma. Other high-risk susceptibility genes are being sought actively. Genetic epidemiologic studies suggest that penetrance of each of the two identified genes is altered by other factors, either genetic or environmental. Epidemiologic studies have also identified other major host factors important in the development of melanoma. In European, North American, and Australian populations, the presence of clinically identified dysplastic nevi confers greatly increased risk of melanoma. A new measure of sun exposure, based on individual residential history, confers substantially increased risk of melanoma. Recent surveys of sun behavior in the US reveal extensive sunburning and use of tanning beds in adolescents and adults. Sun protective behaviors are not as prevalent as in Australia, where population rates of melanoma are stabilizing.	NCI, DCEG, Genet Epidemiol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tucker, MA (corresponding author), NCI, DCEG, Genet Epidemiol Branch, Execut Plaza S 7122,6120 Execut Blvd, Bethesda, MD 20892 USA.	tuckerp@mail.nih.gov	Tucker, Margaret A/B-4297-2015					Aitken J, 1999, JNCI-J NATL CANCER I, V91, P446, DOI 10.1093/jnci/91.5.446; AITKEN JF, 1994, AM J EPIDEMIOL, V140, P961, DOI 10.1093/oxfordjournals.aje.a117203; Ang CG, 1998, MELANOMA RES, V8, P459, DOI 10.1097/00008390-199810000-00011; [Anonymous], 2003, SURVEILLANCE EPIDEMI; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; AUGUSTSSON A, 1991, ACTA DERM-VENEREOL, V71, P518; Auroy S, 2001, GENE CHROMOSOME CANC, V32, P195, DOI 10.1002/gcc.1183; BALE SJ, 1986, AM J HUM GENET, V38, P188; BARNHILL RL, 1992, DERMATOLOGY, V184, P2, DOI 10.1159/000247489; Bastuji-Garin S, 2002, BRIT J DERMATOL, V146, P24, DOI 10.1046/j.1365-2133.146.s61.9.x; Bataille V, 2000, JNCI-J NATL CANCER I, V92, P457, DOI 10.1093/jnci/92.6.457; Bataille V, 1998, BRIT J CANCER, V77, P505, DOI 10.1038/bjc.1998.81; BERAL V, 1977, BRIT J CANCER, V50, P681; Bergenmar M, 2001, CANCER NURS, V24, P341, DOI 10.1097/00002820-200110000-00002; BERGMAN W, 1992, CYTOGENET CELL GENET, V59, P161, DOI 10.1159/000133232; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; BISHOP JAN, 1994, MELANOMA RES, V4, P199, DOI 10.1097/00008390-199408000-00001; BLISS JM, 1995, INT J CANCER, V62, P367, DOI 10.1002/ijc.2910620402; Borg A, 2000, J NATL CANCER I, V92, P1260, DOI 10.1093/jnci/92.15.1260; Borg A, 1996, CANCER RES, V56, P2497; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Breitbart M, 1997, ACTA DERM-VENEREOL, V77, P374; Brenner AV, 2002, AM J EPIDEMIOL, V156, P353, DOI 10.1093/aje/kwf045; Buller DB, 2002, ARCH DERMATOL, V138, P771, DOI 10.1001/archderm.138.6.771; Bulliard JL, 2000, INT J EPIDEMIOL, V29, P416, DOI 10.1093/ije/29.3.416; CHAUDRA V, 2001, MELANOMA RES, V11, pS143; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; Clark WH, 1998, HUM PATHOL, V29, P8, DOI 10.1016/S0046-8177(98)90384-7; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLEMENTE C, 1991, HUM PATHOL, V22, P313, DOI 10.1016/0046-8177(91)90078-4; Cokkinides VE, 2002, PEDIATRICS, V109, P1124, DOI 10.1542/peds.109.6.1124; Darlington S, 2002, J AM ACAD DERMATOL, V46, P715, DOI 10.1067/mjd.2002.120931; Davis KJ, 2002, PEDIATRICS, V110, P27, DOI 10.1542/peds.110.1.27; Dwyer T, 2000, MELANOMA RES, V10, P387, DOI 10.1097/00008390-200008000-00011; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; English DR, 1998, CANCER EPIDEM BIOMAR, V7, P857; Fears TR, 2002, CANCER RES, V62, P3992; FORD D, 1995, INT J CANCER, V62, P377, DOI 10.1002/ijc.2910620403; Gallagher RDP, 2000, JAMA-J AM MED ASSOC, V283, P2955, DOI 10.1001/jama.283.22.2955; GARBE C, 1994, J INVEST DERMATOL, V102, P700, DOI 10.1111/1523-1747.ep12374298; GARBE C, 1994, J INVEST DERMATOL, V102, P695, DOI 10.1111/1523-1747.ep12374280; Geller AC, 2002, PEDIATRICS, V109, P1009, DOI 10.1542/peds.109.6.1009; Ghiorzo P, 1999, INT J CANCER, V83, P441, DOI 10.1002/(SICI)1097-0215(19991112)83:4<441::AID-IJC2>3.0.CO;2-R; Giles GG, 1996, BMJ-BRIT MED J, V312, P1121; Goldstein AM, 2000, CANCER EPIDEM BIOMAR, V9, P889; Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Goldstein AM, 2002, MELANOMA RES, V12, P51, DOI 10.1097/00008390-200202000-00008; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; Goldstein AM, 2001, BRIT J CANCER, V85, P527, DOI 10.1054/bjoc.2001.1944; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; HALPERN AC, 1993, J INVEST DERMATOL, V100, pS346, DOI 10.1038/jid.1993.61; HALPERN AC, 1993, J AM ACAD DERMATOL, V29, P51, DOI 10.1016/0190-9622(93)70151-I; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HARRISON SL, 1994, LANCET, V344, P1529, DOI 10.1016/S0140-6736(94)90348-4; Harrison SL, 1999, ARCH DERMATOL, V135, P47, DOI 10.1001/archderm.135.1.47; HARTGE P, 1995, CANCER EPIDEM BIOMAR, V4, P37; Hashemi J, 1999, MELANOMA RES, V9, P21, DOI 10.1097/00008390-199902000-00004; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; HOLLY EA, 1983, JNCI-J NATL CANCER I, V70, P827; Huncharek M, 2002, AM J PUBLIC HEALTH, V92, P1173, DOI 10.2105/AJPH.92.7.1173; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jemal A, 2000, JNCI-J NATL CANCER I, V92, P811, DOI 10.1093/jnci/92.10.811; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KAMB A, 1994, GENET, P22; Kanetsky PA, 2001, CANCER EPIDEM BIOMAR, V10, P509; Karagas MR, 2002, BRIT J CANCER, V86, P1085, DOI 10.1038/sj.bjc.6600196; Karlsson P, 2000, ACTA DERM-VENEREOL, V80, P335; KEFFORD R, 2002, ONCOLOGY, V3, P653; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; Kelly JW, 1997, MED J AUSTRALIA, V167, P191, DOI 10.5694/j.1326-5377.1997.tb138843.x; KELLY JW, 1994, J AM ACAD DERMATOL, V30, P40, DOI 10.1016/S0190-9622(94)70005-2; KOPF AW, 1986, JAMA-J AM MED ASSOC, V256, P1915; Kwan  T Y, 2000, J Cutan Med Surg, V4, P58; Lamberg L, 2002, JAMA-J AM MED ASSOC, V287, P2201, DOI 10.1001/jama.287.17.2201; Landi MT, 2002, JNCI-J NATL CANCER I, V94, P94, DOI 10.1093/jnci/94.2.94; Landi MT, 1999, ARCH DERMATOL, V135, P1554, DOI 10.1001/archderm.135.12.1554; Landi MT, 2001, BRIT J CANCER, V85, P1304, DOI 10.1054/bjoc.2001.2029; LEE JS, 1998, P 1998 ASCO ANN M LO, V17, pA514; Lucci A, 2001, J SURG RES, V97, P179, DOI 10.1006/jsre.2001.6146; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; MACKIE RM, 1989, LANCET, V2, P487; MACKIE RM, 1982, BRIT J DERMATOL, V107, P621, DOI 10.1111/j.1365-2133.1982.tb00519.x; MacKie RM, 2002, LANCET, V360, P587, DOI 10.1016/S0140-6736(02)09779-9; Mansson-Brahme E, 2002, ACTA ONCOL, V41, P138, DOI 10.1080/028418602753669508; Mantelli M, 2002, AM J MED GENET, V107, P214, DOI 10.1002/ajmg.10137; Marks R, 2002, RECENT RESULTS CANC, V160, P113; Marrett LD, 2001, INT J CANCER, V92, P457, DOI 10.1002/ijc.1203; McGregor B, 1999, GENET EPIDEMIOL, V16, P40, DOI 10.1002/(SICI)1098-2272(1999)16:1<40::AID-GEPI4>3.3.CO;2-T; Milne E, 2002, AM J EPIDEMIOL, V155, P739, DOI 10.1093/aje/155.8.739; Newton Bishop Julia A., 2000, Journal of Investigative Dermatology, V114, P28; NORDLUND JJ, 1985, CANCER RES, V45, P1855; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; OSTERLIND A, 1988, INT J CANCER, V42, P821, DOI 10.1002/ijc.2910420603; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Pfahlberg A, 2001, BRIT J DERMATOL, V144, P471, DOI 10.1046/j.1365-2133.2001.04070.x; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Puig S, 1997, HUM GENET, V101, P359, DOI 10.1007/s004390050642; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruiz A, 1999, J MED GENET, V36, P490; Saraiya M, 2002, AM J PREV MED, V23, P91, DOI 10.1016/S0749-3797(02)00461-0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stierner U, 1992, Melanoma Res, V1, P367; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; Tucker MA, 2002, CANCER, V94, P3192, DOI 10.1002/cncr.10605; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; Vasen HFA, 2000, INT J CANCER, V87, P809, DOI 10.1002/1097-0215(20000915)87:6<809::AID-IJC8>3.3.CO;2-L; Wachsmuth RC, 2001, J INVEST DERMATOL, V117, P348, DOI 10.1046/j.0022-202x.2001.01415.x; Weinstock MA, 1997, ARCH DERMATOL, V133, P953, DOI 10.1001/archderm.133.8.953; Weinstock MA, 2000, ANN BEHAV MED, V22, P286, DOI 10.1007/BF02895664; WHITE E, 1994, AM J EPIDEMIOL, V139, P857, DOI 10.1093/oxfordjournals.aje.a117092; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Youl P, 2002, INT J CANCER, V98, P92, DOI 10.1002/ijc.10117; Zanetti R, 2001, MELANOMA RES, V11, P551, DOI 10.1097/00008390-200112000-00001; Zhu G, 1999, AM J HUM GENET, V65, P483, DOI 10.1086/302494; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	122	184	192	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3042	3052		10.1038/sj.onc.1206444	http://dx.doi.org/10.1038/sj.onc.1206444			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789279				2022-12-17	WOS:000183096600004
J	Benezra, R; Rafii, S; Lyden, D				Benezra, R; Rafii, S; Lyden, D			The Id proteins and angiogenesis	ONCOGENE			English	Article						Id; angiogenesis; endothelial; precursor	ENDOTHELIAL GROWTH-FACTOR; LOOP-HELIX PROTEIN; RECEPTOR TYROSINE KINASE; FACTOR VEGF; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTORS; HEMATOPOIETIC-CELLS; EXPRESSION PATTERN; DNA-BINDING; GENE	Since the identification of the Id proteins over a decade ago, a great many cell cycle and cell fate decisions have been shown to be under the control of these proteins as described in other sections of this review issue. Perhaps the most unsuspected activity of this class of proteins has been their essential role in angiogenesis, both in the forebrain during development and during the growth and metastasis of tumors in adults. This section of the review issue will focus on the key observations which have led to these conclusions, speculations about potential mechanisms and the outlook for potential therapeutic interventions.	Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Hematol Oncol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.	r-benezra@ski.mskcc.org						Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Caprioli A, 1998, P NATL ACAD SCI USA, V95, P1641, DOI 10.1073/pnas.95.4.1641; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ELLMEIER W, 1995, DEV DYNAM, V203, P163, DOI 10.1002/aja.1002030205; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLAMME I, 1995, DEV BIOL, V169, P699, DOI 10.1006/dbio.1995.1180; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gill M, 2001, CIRC RES, V88, P167; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; KAGEYAMA R, 1995, CRIT REV NEUROBIOL, V9, P177; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ortega N, 1997, AM J PATHOL, V151, P1215; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; PERLMAN JM, 1986, AM J DIS CHILD, V140, P1122, DOI 10.1001/archpedi.1986.02140250048034; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Rafii S, 1995, ANN THORAC SURG, V60, P1627, DOI 10.1016/0003-4975(95)00807-1; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; RIECHMANN V, 1995, CELL GROWTH DIFFER, V6, P837; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robert B, 1996, AM J PHYSIOL-RENAL, V271, pF744, DOI 10.1152/ajprenal.1996.271.3.F744; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	75	184	199	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8334	8341		10.1038/sj.onc.1205160	http://dx.doi.org/10.1038/sj.onc.1205160			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840326				2022-12-17	WOS:000173319500007
J	Sirchia, SM; Ferguson, AT; Sironi, E; Subramanyan, S; Orlandi, R; Sukumar, S; Sacchi, N				Sirchia, SM; Ferguson, AT; Sironi, E; Subramanyan, S; Orlandi, R; Sukumar, S; Sacchi, N			Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta 2 promoter in breast cancer cells	ONCOGENE			English	Article						breast cancer; DNA methylation; chromatin remodeling; retinoic acid receptor (RAR)beta	ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE COMPLEX; EMBRYONAL CARCINOMA-CELLS; PLZF-RAR-ALPHA; DNA METHYLATION; EXPRESSION; GENE; TRANSCRIPTION; ACETYLATION; ACTIVATION	Retinoic acid (RA)-resistance in breast cancer cells has been associated with irreversible loss of retinoic acid receptor beta, RAR beta, gene expression. Search of the causes affecting RAR beta gene activity has been oriented at identifying possible differences either at the level of one of the RAR beta promoters, RAR beta 2, or at regulatory factors. We hypothesized that loss of RAR beta 2 activity occurs as a result of multiple factors, including epigenetic modifications, which can pattern RAR beta 2 chromatin state. Using methylation-specific PCR, we found hypermethylation at RAR beta 2 in a significant proportion of both breast cancer cell lines and primary breast tumors. Treatment of cells with a methylated RAR beta 2 promoter, by means of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), led to demethylation within RAR beta 2 and expression of RAR beta indicating that DNA methylation is at least one factor, contributing to RAR beta inactivity. However, identically methylated promoters can differentially respond to RA, suggesting that RAR beta 2 activity may be associated to different repressive chromatin states. This supposition is supported by the finding that the more stable repressive RAR beta 2 state in the RA-resistant MDA-MB-231 cell line can be alleviated by the HDAC inhibitor, trichostatin A (TSA), with restoration of RA-induced RAR beta transcription. Thus, chromatin-remodeling drugs might provide a strategy to restore RAR beta activity, and help to overcome the hurdle of RA-resistance In breast cancer.	Univ Milan, Dept Biol, I-20133 Milan, Italy; Univ Milan, Hosp San Paolo, Lab Human Genet, Milan, Italy; Johns Hopkins Univ, Ctr Oncol, Breast Canc Program, Baltimore, MD 21205 USA; Inst Nazl Studio & Cura Tumori, Milan, Italy	University of Milan; University of Milan; Johns Hopkins University; Johns Hopkins Medicine; Fondazione IRCCS Istituto Nazionale Tumori Milan	Sacchi, N (corresponding author), Univ Milan, Dept Biol, Via Celoria 26, I-20133 Milan, Italy.		Sirchia, Silvia/AAB-2620-2019; Orlandi, Rosaria/C-1182-2017	Orlandi, Rosaria/0000-0002-0533-9041; Sirchia, Silvia/0000-0002-6106-3721				Baust C, 1996, INT J CANCER, V67, P409, DOI 10.1002/(SICI)1097-0215(19960729)67:3<409::AID-IJC16>3.0.CO;2-2; Bhattacharyya N, 1997, MOL CELL BIOL, V17, P6481, DOI 10.1128/MCB.17.11.6481; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Cote S, 1997, ANTI-CANCER DRUG, V8, P56; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Formantici C, 1999, J PATHOL, V187, P424, DOI 10.1002/(SICI)1096-9896(199903)187:4<424::AID-PATH259>3.0.CO;2-0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gudas Lorraine J., 1994, P443; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Minna JD, 1997, J NATL CANCER I, V89, P602, DOI 10.1093/jnci/89.9.602; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROMAN SD, 1992, CANCER RES, V52, P2236; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SHAO ZM, 1994, INT J ONCOL, V4, P849; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TOULOUSE A, 1997, BBA, V1309, P1; Tsou HC, 1998, EXP CELL RES, V245, P221, DOI 10.1006/excr.1998.4268; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDERLEEDE BM, 1992, BIOCHEM BIOPH RES CO, V188, P695, DOI 10.1016/0006-291X(92)91112-4; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WIESCHWENDTNER M, 1997, CANCER RES, V17, P4158; Xu XC, 1997, CANCER RES, V57, P4992; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	46	184	193	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1556	1563		10.1038/sj.onc.1203456	http://dx.doi.org/10.1038/sj.onc.1203456			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734315				2022-12-17	WOS:000086108100008
J	Jordan, P; Brazao, R; Boavida, MG; Gespach, C; Chastre, E				Jordan, P; Brazao, R; Boavida, MG; Gespach, C; Chastre, E			Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors	ONCOGENE			English	Article						Rac1; Ras; GTPase; colorectal cancer; alternative splicing	CELL-CELL ADHESION; SMALL GTPASES; CRYSTAL-STRUCTURE; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SIGNALING PATHWAY; GTP ANALOG; RHO; CDC42; PROTEINS	Rac1 is a member of the Ras superfamily of small GTPases involved in signal transduction pathways that induce the formation of lamellipodia, stimulate cell proliferation and activate the JNK/SAPK protein kinase cascade, Here we describe that amplification by RT-PCR of the entire Rac1 coding sequence from a series of human adult and fetal tissues revealed beside the expected Rac1 cDNA, a variant product which contained additional 57 nucleotides between codons 75 and 76. This variant resulted in an in-frame insertion of 19 new amino acids immediately behind the switch II region, including two potential threonine phosphorylation sites for casein kinase II and protein kinase C, Primers designed within and downstream of the inserted nucleotide sequence allowed isolation of a genomic clone with intronic consensus sequences demonstrating that the insertion corresponds to a novel, yet undescribed exon 3b, This Rac1 splice variant, designated Rac1b, was predominantly identified in skin and epithelial tissues from the intestinal tract. Most notably, the expression of rac1b versus rad was found to be elevated in colorectal tumors at various stages of neoplastic progression, as compared to their respective adjacent tissues. We suggest that the 19 amino acid-insertion following the switch II region may create a novel effector binding site in rac1b, and thus participate in signaling pathways related to the normal or neoplastic growth of the intestinal mucosa.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Lab Oncobiol, P-1649 Lisbon, Portugal; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Instituto Nacional de Saude Dr. Ricardo Jorge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Lab Oncobiol, Ave Padre Cruz, P-1649 Lisbon, Portugal.		Jordan, Peter/G-9335-2012; CHASTRE, Eric/L-8446-2018	Jordan, Peter/0000-0002-1425-9211; CHASTRE, Eric/0000-0002-8993-1228				Allen WE, 1997, J CELL SCI, V110, P707; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Courjal F, 1997, GENOMICS, V44, P242, DOI 10.1006/geno.1997.4871; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schneider TD, 1997, NUCLEIC ACIDS RES, V25, P4408, DOI 10.1093/nar/25.21.4408; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Vider BZ, 1996, ONCOGENE, V12, P153; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	184	188	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6835	6839		10.1038/sj.onc.1203233	http://dx.doi.org/10.1038/sj.onc.1203233			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597294				2022-12-17	WOS:000083792000028
J	HAGUE, A; MOORGHEN, M; HICKS, D; CHAPMAN, M; PARASKEVA, C				HAGUE, A; MOORGHEN, M; HICKS, D; CHAPMAN, M; PARASKEVA, C			BCL-2 EXPRESSION IN HUMAN COLORECTAL ADENOMAS AND CARCINOMAS	ONCOGENE			English	Note							PROGRAMMED CELL-DEATH; DNA FRAGMENTATION; APOPTOSIS; PROTEIN; LINES; CANCER; NEUROBLASTOMA; PROTOONCOGENE; RESISTANCE; PROSTATE	As BCL-2 oncoprotein has been implicated as a survival factor in a number of tissues, we examined colorectal tumour specimens and cell lines for BCL-2 expression. BCL-2 protein was expressed in 19/22 adenocarcinomas and 12/13 adenomas. 6/9 carcinoma cell lines and 7/8 adenoma cell lines were also BCL-2 positive. BCL-2 expression was retained in metastases to the regional lymph nodes (3/3 specimens) and in the cell line SW620, derived from a lymph node metastasis. These studies suggest a role for BCL-2 in promoting cell survival of benign and malignant colorectal tumours and that BCL-2 deregulation may be a relatively early event in colorectal carcinogenesis. The retention of BCL-2 expression in the carcinomas and lymph node metastases may explain the resistance of colorectal tumours to chemotherapeutic treatment.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol								COLOMBEL M, 1993, AM J PATHOL, V143, P390; FEARON ER, 1990, SCIENCE, V247, P47; FISHER TC, 1993, CANCER RES, V53, P3321; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HANADA M, 1993, CANCER RES, V53, P4978; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IKEGAKI N, 1994, CANCER RES, V54, P6; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1992, CANCER RES, V52, P5407; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; RAMANI P, 1994, J PATHOL, V172, P273, DOI 10.1002/path.1711720308; REED JC, 1991, CANCER RES, V51, P6529; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519	25	184	185	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3367	3370						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936663				2022-12-17	WOS:A1994PM65800032
J	Matsuoka, M; Jeang, KT				Matsuoka, M.; Jeang, K-T			Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy	ONCOGENE			English	Review						human T-cell leukemia virus type 1 (HTLV-1); adult T-cell leukemia (ATL); Tax; HTLV-1 bZIP factor (HBZ); aneuploidy	NF-KAPPA-B; DNA-DAMAGE RESPONSE; TROPICAL SPASTIC PARAPARESIS; SPINDLE ASSEMBLY CHECKPOINT; PROTEASOME INHIBITOR PS-341; 1ST HUMAN RETROVIRUS; I TAX; TRANSCRIPTIONAL ACTIVITY; MONOCLONAL-ANTIBODY; CYCLE PROGRESSION	The human T-cell leukemia virus type 1 (HTLV-1) was the first retrovirus discovered to be causative of a human cancer, adult T-cell leukemia. The transforming entity of HTLV-1 has been attributed to the virally-encoded oncoprotein, Tax. Unlike the v-onc proteins encoded by other oncogenic animal retroviruses that transform cells, Tax does not originate from a c-onc counterpart. In this article, we review progress in our understanding of HTLV-1 infectivity, cellular transformation, anti-sense transcription and therapy, 30 years after the original discovery of this virus. Oncogene (2011) 30, 1379-1389; doi:10.1038/onc.2010.537; published online 29 November 2010	[Jeang, K-T] NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; [Matsuoka, M.] Kyoto Univ, Inst Virus Res, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kyoto University	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008	Matsuoka, Masao/0000-0002-0473-754X	NIAID; Ministry of Education, Science, Sports and Culture of Japan; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, ZIAAI001023] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Work in KTJ's laboratory is supported in part by NIAID intramural funds, and work in MM's laboratory is supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan. We thank Lauren Lee for preparation of manuscript and figures, and Junichiro Yasunaga and Linda Zane for discussions.	Akagi T, 1996, ONCOGENE, V12, P1645; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; Banerjee P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-8; Banerjee P, 2008, STEM CELLS, V26, P3047, DOI 10.1634/stemcells.2008-0353; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Bazarbachi A, 2010, J CLIN ONCOL, V28, P4177, DOI 10.1200/JCO.2010.28.0669; Belgnaoui SM, 2010, J BIOL CHEM, V285, P32897, DOI 10.1074/jbc.M110.146373; Bellon M, 2009, BLOOD, V113, P4914, DOI 10.1182/blood-2008-11-189845; Bernal-Mizrachi L, 2006, P NATL ACAD SCI USA, V103, P9220, DOI 10.1073/pnas.0507809103; Boschi-Pinto C, 2000, J INFECT DIS, V181, P35, DOI 10.1086/315177; Bouzar AB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-101; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Cavanagh MH, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-15; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Chandhasin C, 2008, J VIROL, V82, P6952, DOI 10.1128/JVI.02331-07; Chi YH, 2007, J CELL BIOCHEM, V102, P531, DOI 10.1002/jcb.21484; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128/JVI.77.9.5286-5294.2003; Durkin SS, 2006, J BIOL CHEM, V281, P31705, DOI 10.1074/jbc.M607011200; Durkin SS, 2008, J BIOL CHEM, V283, P36311, DOI 10.1074/jbc.M804931200; Etoh K, 1997, CANCER RES, V57, P4862; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fraedrich K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-54; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1985, LANCET, V2, P407; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Gotuzzo E, 1999, AM J TROP MED HYG, V60, P146, DOI 10.4269/ajtmh.1999.60.146; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Gupta SK, 2007, J BIOL CHEM, V282, P29431, DOI 10.1074/jbc.M704110200; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Haller K, 2006, ONCOGENE, V25, P2137, DOI 10.1038/sj.onc.1209259; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Harashima N, 2004, CANCER RES, V64, P391, DOI 10.1158/0008-5472.CAN-03-1452; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hein J, 2009, J VIROL, V83, P117, DOI 10.1128/JVI.01515-08; Higuchi M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-117; Hivin P, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-14; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; Iha H, 2008, EMBO J, V27, P629, DOI 10.1038/emboj.2008.5; Ishii T, 2010, CLIN CANCER RES, V16, P1520, DOI 10.1158/1078-0432.CCR-09-2697; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2008, VIROLOGY, V370, P264, DOI 10.1016/j.virol.2007.09.003; Jeong SJ, 2009, BIOCHEM BIOPH RES CO, V381, P294, DOI 10.1016/j.bbrc.2009.02.024; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Jones KS, 2008, NAT MED, V14, P429, DOI 10.1038/nm1745; Jones KS, 2006, J VIROL, V80, P8291, DOI 10.1128/JVI.00389-06; Jones KS, 2005, J VIROL, V79, P12692, DOI 10.1128/JVI.79.20.12692-12702.2005; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kinjo T, 2010, J VIROL, V84, P5431, DOI 10.1128/JVI.02460-09; KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451; Kuhlmann AS, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-92; Lambert S, 2009, BLOOD, V113, P5176, DOI 10.1182/blood-2008-04-150342; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lemasson I, 2007, J VIROL, V81, P1543, DOI 10.1128/JVI.00480-06; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; Lezin A, 2007, BLOOD, V110, P3722, DOI 10.1182/blood-2007-04-085076; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Lodewick J, 2009, VIROLOGY, V386, P68, DOI 10.1016/j.virol.2008.12.043; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Majorovits E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002251; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-71; Mazurov D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000788; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood-2003-11-3967; Miyazato A, 2005, J VIROL, V79, P9346, DOI 10.1128/JVI.79.14.9346-9350.2005; Mori N, 1996, BLOOD, V88, P1035; Morimoto H, 2005, AM J HEMATOL, V78, P100, DOI 10.1002/ajh.20259; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; Nejmeddine M, 2009, BLOOD, V114, P1016, DOI 10.1182/blood-2008-03-136770; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Ohsugi T, 2007, NAT MED, V13, P527, DOI 10.1038/nm0507-527; Okamura J, 2007, INT J HEMATOL, V86, P118, DOI 10.1532/IJH97.07070; OSAME M, 1989, JPN J MED, V28, P412, DOI 10.2169/internalmedicine1962.28.412; Pais-Correia AM, 2010, NAT MED, V16, P83, DOI 10.1038/nm.2065; Pan SH, 2009, CARCINOGENESIS, V30, P366, DOI 10.1093/carcin/bgn291; Park HU, 2006, ONCOGENE, V25, P438, DOI 10.1038/sj.onc.1209059; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Patel D, 2010, J VIROL, V84, P10956, DOI 10.1128/JVI.00259-10; Peloponese JM, 2006, IMMUNOL RES, V34, P1, DOI 10.1385/IR:34:1:1; Peloponese JM, 2009, J VIROL, V83, P3238, DOI 10.1128/JVI.01824-08; Peloponese JM, 2006, J BIOL CHEM, V281, P8927, DOI 10.1074/jbc.M510598200; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Phillips KE, 2000, CANCER RES, V60, P6977; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Ramadan E, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-92; Rauch D, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-116; REID RL, 1993, ONCOGENE, V8, P3029; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Ruggero K, 2010, MOL ASPECTS MED, V31, P367, DOI 10.1016/j.mam.2010.05.001; Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-19; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Shembade N, 2007, EMBO J, V26, P3910, DOI 10.1038/sj.emboj.7601823; Shoji T, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-83; Sibon D, 2006, J CLIN INVEST, V116, P974, DOI 10.1172/JCI27198; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Swaims AY, 2010, BLOOD, V116, P2994, DOI 10.1182/blood-2009-07-231050; Tabakin-Fix Y, 2006, CARCINOGENESIS, V27, P673, DOI 10.1093/carcin/bgi274; Takasaki Y, 2010, BLOOD, V115, P4337, DOI 10.1182/blood-2009-09-242347; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Tamiya S, 1998, BLOOD, V91, P3935; Tan C, 2002, CANCER RES, V62, P1083; Tanosaki R, 2008, BIOL BLOOD MARROW TR, V14, P702, DOI 10.1016/j.bbmt.2008.03.010; Taylor GP, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-63; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Toulza F, 2008, BLOOD, V111, P5047, DOI 10.1182/blood-2007-10-118539; Toulza F, 2010, J IMMUNOL, V185, P183, DOI 10.4049/jimmunol.0903846; Tsukasaki K, 2007, J CLIN ONCOL, V25, P5458, DOI 10.1200/JCO.2007.11.9958; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; Watanabe M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646; Watashi K, 2010, J BIOL CHEM, V285, P24707, DOI 10.1074/jbc.M109.062976; WELLES SL, 1994, INT J CANCER, V56, P337, DOI 10.1002/ijc.2910560307; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto K, 2010, J CLIN ONCOL, V28, P1591, DOI 10.1200/JCO.2009.25.3575; Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; Yasunaga JI, 2007, REV MED VIROL, V17, P301, DOI 10.1002/rmv.548; Yasunaga J, 2009, ENVIRON MOL MUTAGEN, V50, P733, DOI 10.1002/em.20480; Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2008, J VIROL, V82, P9359, DOI 10.1128/JVI.00242-08; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; Zane L, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-17; Zhang Z, 2003, CANCER RES, V63, P6453; Zhang Z, 2003, BLOOD, V102, P284, DOI 10.1182/blood-2002-11-3601; Zhao T, 2009, BLOOD, V113, P2755, DOI 10.1182/blood-2008-06-161729	164	183	189	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1379	1389		10.1038/onc.2010.537	http://dx.doi.org/10.1038/onc.2010.537			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21119600	Green Accepted			2022-12-17	WOS:000288743800001
J	Wesolowska, A; Kwiatkowska, A; Slomnicki, L; Dembinski, M; Master, A; Sliwa, M; Franciszkiewicz, K; Chouaib, S; Kaminska, B				Wesolowska, A.; Kwiatkowska, A.; Slomnicki, L.; Dembinski, M.; Master, A.; Sliwa, M.; Franciszkiewicz, K.; Chouaib, S.; Kaminska, B.			Microglia-derived TGF-beta as an important regulator of glioblastoma invasion - an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor	ONCOGENE			English	Article						gliomas; TGF-beta signaling; RNA interference; invasion/cell motility; tumor-host interactions; microglia	GROWTH-FACTOR-BETA; HUMAN GLIOMA-CELLS; RNA INTERFERENCE; MESSENGER-RNA; IN-VIVO; TARGETED DISRUPTION; INDUCIBLE ELEMENTS; TUMOR PROGRESSION; MAMMALIAN-CELLS; CYCLOSPORINE-A	The invasion of tumor cells into brain tissue is a pathologic hallmark of malignant gliomas and contributes to treatment failures. Diffuse glioblastomas contain numerous microglial cells, which enhance the progression of gliomas; however, factors responsible for invasion-promoting role of microglia are unknown. Transforming growth factor-beta (TGF-beta) can enhance tumor growth, invasion, angiogenesis and immunosuppression. Antagonizing TGF-beta activity has been shown to inhibit tumor invasion in vitro and tumorigenicity, but a systemic inhibition or lack of TGF-beta signaling results in acute inflammation and disruption of immune system homeostasis. We developed plasmid-transcribed small hairpin RNAs (shRNAs) to downregulate the TGF-beta type II receptor (T beta IIR) expression, which effectively inhibited cytokine-induced signaling pathways and transcriptional responses in transiently transfected human glioblastoma cells. Silencing of T beta IIR abolished TGF-beta-induced glioblastoma invasiveness and migratory responses in vitro. Moreover, tumorigenicity of glioblastoma cells stably expressing T beta IIR shRNAs in nude mice was reduced by 50%. Microglia strongly enhanced glioma invasiveness in the co-culture system, but this invasion-promoting activity was lost in glioma cells stably expressing shT beta RII, indicating a crucial role of microglia-derived TGF-beta in tumor-host interactions. Our results demonstrate a successful targeting of TGF-beta-dependent invasiveness and tumorigenicity of glioblastoma cells by RNAi-mediated gene silencing.	[Wesolowska, A.; Kwiatkowska, A.; Slomnicki, L.; Dembinski, M.; Master, A.; Sliwa, M.; Kaminska, B.] M Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, PL-002093 Warsaw, Poland; [Franciszkiewicz, K.; Chouaib, S.] Inst Gustave Roussy, Human Tumor Cytokines Lab, Villejuif, France	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; UNICANCER; Gustave Roussy	Kaminska, B (corresponding author), M Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, 3 Pasteur St, PL-002093 Warsaw, Poland.	bozenakk@nencki.gov.pl	Chouaib, Salem/F-7939-2016; Kaminska, Bozena/H-4592-2011; Kaminska, Bozena/B-2915-2014	Kaminska, Bozena/0000-0002-2642-4616; Master, Adam/0000-0001-9391-8846				ALBINI A, 1987, CANCER RES, V47, P3239; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Badie B, 2001, MICROSC RES TECHNIQ, V54, P106, DOI 10.1002/jemt.1125; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964; Jazag A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni130; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIEFER R, 1994, NEUROSCI LETT, V166, P161, DOI 10.1016/0304-3940(94)90475-8; Kjellman C, 2000, INT J CANCER, V89, P251, DOI 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ogorelkova M, 2006, OLIGONUCLEOTIDES, V16, P2, DOI 10.1089/oli.2006.16.2; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Pardridge WM, 2004, EXPERT OPIN BIOL TH, V4, P1103, DOI 10.1517/14712598.4.7.1103; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Platten M, 2001, MICROSC RES TECHNIQ, V52, P401, DOI 10.1002/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Praus M, 1999, GENE THER, V6, P227, DOI 10.1038/sj.gt.3300802; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Schlingensiepen KH, 2006, CYTOKINE GROWTH F R, V17, P129, DOI 10.1016/j.cytogfr.2005.09.002; Shah AH, 2002, CANCER RES, V62, P7135; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sliwa M, 2007, BRAIN, V130, P476, DOI 10.1093/brain/awl263; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Teicher BA, 2001, CANCER METAST REV, V20, P133, DOI 10.1023/A:1013177011767; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Won JW, 1999, CANCER RES, V59, P1273; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405; YAMAMOTO M, 1994, CANCER RES, V54, P3329; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Ye L, 2006, INT J ONCOL, V29, P1149; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zawadzka M, 2005, GLIA, V49, P36, DOI 10.1002/glia.20092; Zupanska A, 2005, NEUROCHEM INT, V47, P430, DOI 10.1016/j.neuint.2005.05.010	61	183	188	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					918	930		10.1038/sj.onc.1210683	http://dx.doi.org/10.1038/sj.onc.1210683			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17684491				2022-12-17	WOS:000252946300004
J	Jeggo, P; Lobrich, M				Jeggo, P. A.; Loebrich, M.			DNA double-strand breaks: their cellular and clinical impact? Introduction	ONCOGENE			English	Editorial Material							REPAIR; RECOMBINATION; MUTATIONS; ARTEMIS; PATHWAY; COMPLEX; ATM		Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Tech Univ Darmstadt, Darmstadt, Germany	University of Sussex; Technical University of Darmstadt	Jeggo, P (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	p.a.jeggo@sussex.ac.uk; lobrich@bio.tu-darmstadt.de			Medical Research Council [G0500897] Funding Source: Medline; MRC [G0500897] Funding Source: UKRI; Medical Research Council [G0300662B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Lobrich M, 2005, P NATL ACAD SCI USA, V102, P8984, DOI 10.1073/pnas.0501895102; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451	13	183	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7717	7719		10.1038/sj.onc.1210868	http://dx.doi.org/10.1038/sj.onc.1210868			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066083				2022-12-17	WOS:000251537900001
J	Martin, M; Kettmann, R; Dequiedt, F				Martin, M.; Kettmann, R.; Dequiedt, F.			Class IIa histone deacetylases: regulating the regulators	ONCOGENE			English	Review						14-3-3; acetylation; chromatin; phosphatase; shuttling	MYOCYTE ENHANCER FACTOR-2; MEF2 TRANSCRIPTION FACTOR; CONTROLS CHONDROCYTE HYPERTROPHY; ORPHAN STEROID-RECEPTOR; NUCLEAR EXPORT; GENE-EXPRESSION; CRYSTAL-STRUCTURE; 14-3-3 PROTEINS; CO-REPRESSOR; CLASS-I	In the last decade, the identification of enzymes that regulate acetylation of histones and nonhistone proteins has revealed the key role of dynamic acetylation and deacetylation in various cellular processes. Mammalian histone deacetylases ( HDACs), which catalyse the removal of acetyl groups from lysine residues, are grouped into three classes, on the basis of similarity to yeast counterparts. An abundance of experimental evidence has established class IIa HDACs as crucial transcriptional regulators of various developmental and differentiation processes. In the past 5 years, a tremendous effort has been dedicated to characterizing the regulation of these enzymes. In this review, we summarize the latest discoveries in the field and discuss the molecular and structural determinants of class IIa HDACs regulation. Finally, we emphasize that comprehension of the mechanisms underlying class IIa HDAC functions is essential for potential therapeutic applications.	FUSAGx, Cellular & Mol Biol Unit, B-5030 Gembloux, Belgium	University of Liege	Dequiedt, F (corresponding author), FUSAGx, Cellular & Mol Biol Unit, B-5030 Gembloux, Belgium.	dequiedt.f@fsagx.ac.be		Dequiedt, Franck/0000-0003-1234-7477; Martin, Maud/0000-0003-0048-6437				Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f; Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Bakin RE, 2004, J BIOL CHEM, V279, P51218, DOI 10.1074/jbc.M409271200; Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Berger I, 2003, J BIOL CHEM, V278, P17625, DOI 10.1074/jbc.M301646200; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bolger TA, 2005, J NEUROSCI, V25, P9544, DOI 10.1523/JNEUROSCI.1826-05.2005; Borghi S, 2001, J CELL SCI, V114, P4477; Bryant H, 2002, J VIROL, V76, P10290, DOI 10.1128/JVI.76.20.10290-10298.2002; Camins A, 2006, DRUG NEWS PERSPECT, V19, P453, DOI 10.1358/dnp.2006.19.8.1043961; Castet A, 2004, NUCLEIC ACIDS RES, V32, P1957, DOI 10.1093/nar/gkh524; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; Czubryt MP, 2004, RECENT PROG HORM RES, V59, P105, DOI 10.1210/rp.59.1.105; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Deng XB, 2005, J BIOL CHEM, V280, P4894, DOI 10.1074/jbc.M411894200; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Dequiedt F, 2006, MOL CELL BIOL, V26, P7086, DOI 10.1128/MCB.00231-06; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Ellis JJ, 2003, MOL CELL BIOCHEM, V242, P153, DOI 10.1023/A:1021158216582; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischler W, 2001, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2001/07/003; Franco PJ, 2003, MOL CELL ENDOCRINOL, V206, P1, DOI 10.1016/S0303-7207(03)00254-5; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gao CZ, 2006, FEBS LETT, V580, P5096, DOI 10.1016/j.febslet.2006.08.038; Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022; Glaser KB, 2003, MOL CANCER THER, V2, P151; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Guo L, 2007, P NATL ACAD SCI USA, V104, P4297, DOI 10.1073/pnas.0608041104; Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Halkidou K, 2004, EUR UROL, V45, P382, DOI 10.1016/j.eururo.2003.10.005; Han AD, 2005, J MOL BIOL, V345, P91, DOI 10.1016/j.jmb.2004.10.033; Harrison BC, 2004, MOL CELL BIOL, V24, P10636, DOI 10.1128/MCB.24.24.10636-10649.2004; Harrison BC, 2006, MOL CELL BIOL, V26, P3875, DOI 10.1128/MCB.26.10.3875-3888.2006; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Huynh KD, 2000, GENE DEV, V14, P1810; Huynh QK, 2006, ARCH BIOCHEM BIOPHYS, V450, P141, DOI 10.1016/j.abb.2006.02.014; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200; Jeong BC, 2004, MOL ENDOCRINOL, V18, P13, DOI 10.1210/me.2003-0065; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kadoglou NP, 2004, CURR MED RES OPIN, V20, P419, DOI 10.1185/030079904125003143; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; Karvonen U, 2006, EXP CELL RES, V312, P3165, DOI 10.1016/j.yexcr.2006.06.018; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurtev V, 2004, J BIOL CHEM, V279, P24834, DOI 10.1074/jbc.M312300200; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Lin Q, 1998, DEVELOPMENT, V125, P4565; Linseman DA, 2003, J BIOL CHEM, V278, P41472, DOI 10.1074/jbc.M307245200; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Liu YW, 2005, J CELL BIOL, V168, P887, DOI 10.1083/jcb.200408128; Lomonte P, 2004, J VIROL, V78, P6744, DOI 10.1128/JVI.78.13.6744-6757.2004; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Marmorstein R, 2004, BIOCHEM SOC T, V32, P904, DOI 10.1042/BST0320904; MARTIN M, IN PRESS PROTEIN PHO; Matthews SA, 2006, MOL CELL BIOL, V26, P1569, DOI 10.1128/MCB.26.4.1569-1577.2006; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2006, MOL BIOL CELL, V17, P438, DOI 10.1091/mbc.E05-07-0612; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; McKinsey TA, 2007, CARDIOVASC RES, V73, P667, DOI 10.1016/j.cardiores.2006.11.036; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakagawa Y, 2006, J MOL CELL CARDIOL, V41, P1010, DOI 10.1016/j.yjmcc.2006.08.010; Nielsen TK, 2005, J MOL BIOL, V354, P107, DOI 10.1016/j.jmb.2005.09.065; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; NUSINZON I, 2005, SCI STKE; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pagan JK, 2007, J BIOL CHEM, V282, P15248, DOI 10.1074/jbc.M700246200; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Parra M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Portal D, 2006, P NATL ACAD SCI USA, V103, P19278, DOI 10.1073/pnas.0609320103; Prima V, 2005, LEUKEMIA, V19, P806, DOI 10.1038/sj.leu.2403684; Puig-Kroger A, 2006, J CELL BIOCHEM, V98, P744, DOI 10.1002/jcb.20813; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Ranieri G., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P241, DOI 10.2174/1568008013341073; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sarvetnick N, 2003, CURR OPIN IMMUNOL, V15, P647, DOI 10.1016/j.coi.2003.09.019; Schneider A, 2004, J NEUROCHEM, V88, P1114, DOI 10.1046/j.1471-4159.2003.02228.x; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Shenoy G, 2003, STRUCT CHEM, V14, P3, DOI 10.1023/A:1021656723964; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Siggs OM, 2006, CURR OPIN IMMUNOL, V18, P175, DOI 10.1016/j.coi.2006.01.001; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Song K, 2006, CELL, V125, P453, DOI 10.1016/j.cell.2006.02.048; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Verdin E, 2004, METHOD ENZYMOL, V377, P180; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Verma S, 2004, CAN J CARDIOL, V20, P1335; Visvikis-Siest S, 2006, CURR OPIN LIPIDOL, V17, P139, DOI 10.1097/01.mol.0000217895.67444.de; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang H E, 2000, Prehosp Emerg Care, V4, P14, DOI 10.1080/10903120090941560; Wang JW, 2007, J NEUROSCI, V27, P574, DOI 10.1523/JNEUROSCI.5094-06.2007; Wang Qing, 2005, Curr Atheroscler Rep, V7, P235, DOI 10.1007/s11883-005-0012-6; Watabiki Y, 2003, J HIGH ENERGY PHYS; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Xing WB, 2006, CIRC RES, V98, P1089, DOI 10.1161/01.RES.0000218781.23144.3e; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x; Zhang AH, 2004, J BIOL CHEM, V279, P33799, DOI 10.1074/jbc.M403997200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	182	183	188	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5450	5467		10.1038/sj.onc.1210613	http://dx.doi.org/10.1038/sj.onc.1210613			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694086				2022-12-17	WOS:000248674300013
J	Lou, H; Dean, M				Lou, H.; Dean, M.			Targeted therapy for cancer stem cells: the patched pathway and ABC transporters	ONCOGENE			English	Review						cancer stem cell; hedgehog/patched pathway; smoothened; ABC transporters; ABCG2; cyclopamine	HUMAN HOMOLOG; TERATOCARCINOMA CELLS; MULTIDRUG-RESISTANCE; CARCINOMA SYNDROME; SIDE-POPULATION; HEDGEHOG; DROSOPHILA; INHIBITION; MUTATIONS; GENE	Data from certain leukemias as well as brain and breast cancer indicate that there is a small population of tumor cells with 'stem cell' characteristics and the capacity for self-renewal. The self-renewing cells have many of the properties of normal stem cells and have been termed 'cancer stem cells'. These cancer stem cells make up as few as 1% of the cells in a tumor, making them difficult to detect and study. Like normal stem cells, cancer stem cells have a number of properties permitting them to survive traditional cancer chemotherapy and radiation therapy. These cells express high levels of ATP-binding cassette (ABC) drug transporters, providing for a level of resistance; are relatively quiescent; have higher levels of DNA repair and a lowered ability to enter apoptosis. Combined cancer therapy approaches targeting the cancer stem cells and the non-stem cells may be developed with increased efficacy. Efforts to target the Hedgehog/Patched pathway, critical to embryonic growth and differentiation, and the ABCG2 drug efflux transporter will be presented.	NCI, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dean, M (corresponding author), NCI, Frederick, MD 21702 USA.	dean@ncifcrf.gov	Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; 	NATIONAL CANCER INSTITUTE [Z01BC005652, ZIABC005652, Z01BC005725, ZIABC005725] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008-5472.CAN-04-1393; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; BRINSTER RL, 1976, CANCER RES, V36, P3412; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chidambaram A, 1996, CANCER RES, V56, P4599; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dean M, 2006, MOL INTERV, V6, P140, DOI 10.1124/mi.6.3.5; Dean M, 1997, BBA-REV CANCER, V1332, pM43, DOI 10.1016/S0304-419X(96)00043-1; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Henrich CJ, 2006, J BIOMOL SCREEN, V11, P176, DOI 10.1177/1087057105284576; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; James LF, 2004, J AGR FOOD CHEM, V52, P3211, DOI 10.1021/jf0308206; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kim M, 2002, CLIN CANCER RES, V8, P22; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Kruger JA, 2006, BLOOD, V108, P3906, DOI 10.1182/blood-2006-05-024687; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Nakachi K, 2004, CANCER SCI, V95, P921, DOI 10.1111/j.1349-7006.2004.tb03178.x; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Robey RW, 2004, CANCER RES, V64, P1242, DOI 10.1158/0008-5472.CAN-03-3298; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	37	183	206	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1357	1360		10.1038/sj.onc.1210200	http://dx.doi.org/10.1038/sj.onc.1210200			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322922	Bronze			2022-12-17	WOS:000244558700014
J	Yeh, HH; Lai, WW; Chen, HHW; Liu, HS; Su, WC				Yeh, H-H; Lai, W-W; Chen, H. H. W.; Liu, H-S; Su, W-C			Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion	ONCOGENE			English	Article						malignant pleural effusion; lung cancer; IL-6; Stat3; VEGF	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; CANCER CELL-LINES; TUMOR ANGIOGENESIS; MOLECULAR TARGETS; CARCINOMA CELLS; FACTOR RECEPTOR; INTERLEUKIN-6; EXPRESSION; CYTOKINES	Malignant pleural effusion (MPE) is a poor prognostic sign for patients with non-small-cell lung cancer (NSCLC). The generation of MPE is largely regulated by vascular endothelial growth factor (VEGF), and upregulation of VEGF by Stat3 has been observed in several types of tumor cells. In this study, we demonstrate constitutively activated Stat3 in several human lung cancer cell lines and in tumor cells infiltrated in the pleurae of patients with adenocarcinoma cell lung cancer (ADCLC) and MPE. The observations suggest that activated Stat3 plays a role in the pathogenesis of ADCLC. In PC14PE6/AS2 cells, a Stat3-positive human ADCLC cell line, autocrine IL-6 activated Stat3 via JAKs, not via Src kinase. PC14PE6/AS2 cells express higher VEGF mRNA and protein than do Stat3-negative PC14PE6/AS2/dnStat3 cells. In an animal model, PC14P6/AS2/dnStat3 cells produced no MPE and less lung metastasis than did PC14P6/AS2 cells. PC14PE6/AS2 cells also expressed higher VEGF protein, microvessel density , and vascular permeability in tumors than did PC14P6/AS2/dnStat3 cells. Therefore, we hypothesize that autocrine IL-6 activation of Stat3 in ADCLC may be involved in the formation of malignant pleural effusion by upregulating VEGF. Higher levels of IL-6 and VEGF were also found in the pleural fluids of patients with ADCLC than in patients with congestive heart failure. The autocrine IL-6/Stat3/VEGF signaling pathway may also be activated in patients with ADCLC and MPE. These findings provide novel targets for the management of MPE.	Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Hematol Oncol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan 704, Taiwan; Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Radiotherapy, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Su, WC (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Hematol Oncol, 138 Sheng Li Rd, Tainan 704, Taiwan.	sunnysu@mail.ncku.edu.tw	, 賴吾為/T-8615-2019	, 賴吾為/0000-0001-9174-8310; Liu, Hsiao-Sheng/0000-0003-0576-7203; Su, Wu-Chou/0000-0003-2953-4105				Alexandrakis MG, 2000, ONCOL REP, V7, P1327; ANDERSON CB, 1974, CANCER-AM CANCER SOC, V33, P916, DOI 10.1002/1097-0142(197404)33:4<916::AID-CNCR2820330405>3.0.CO;2-U; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hoheisel G, 1998, RESPIRATION, V65, P183, DOI 10.1159/000029256; Hung TL, 2003, CLIN CANCER RES, V9, P2605; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; MEMON A, 1981, Current Problems in Cancer, V5, P1, DOI 10.1016/S0147-0272(81)80012-8; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Naito T, 1997, ANTICANCER RES, V17, P4743; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okamoto M, 1997, CANCER RES, V57, P141; Seki Y, 2004, INT J ONCOL, V24, P931; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Sugiura S, 1997, CLIN CANCER RES, V3, P47; Takayama K, 2000, CANCER RES, V60, P2169; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yamaguchi T, 2000, JPN J CLIN ONCOL, V30, P53, DOI 10.1093/jjco/hyd014; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano S, 2000, CLIN CANCER RES, V6, P957; YOKOYAMA A, 1992, CHEST, V102, P1055, DOI 10.1378/chest.102.4.1055; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364	36	183	188	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4300	4309		10.1038/sj.onc.1209464	http://dx.doi.org/10.1038/sj.onc.1209464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518408				2022-12-17	WOS:000239240100005
J	Egler, RA; Fernandes, E; Rothermund, K; Sereika, S; de Souza-Pinto, N; Jaruga, P; Dizdaroglu, M; Prochownik, EV				Egler, RA; Fernandes, E; Rothermund, K; Sereika, S; de Souza-Pinto, N; Jaruga, P; Dizdaroglu, M; Prochownik, EV			Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1	ONCOGENE			English	Article						peroxiredoxin 1; c-Myc; c-Abl; reactive oxygen species; DNA damage; Ras; Omnibank (R)	CHROMATOGRAPHY-MASS SPECTROMETRY; REPRESSES TRANSCRIPTION; CELL-PROLIFERATION; HYDROGEN-PEROXIDE; TUMOR-SUPPRESSOR; REPAIR PATHWAY; GROWTH-FACTORS; TARGET GENE; LIFE-SPAN; EXPRESSION	Overexpression of c-Myc results in transformation and multiple other phenotypes, and is accompanied by the deregulation of a large number of target genes. We previously demonstrated that peroxiredoxin 1 (Prdx1), a scavenger of reactive oxygen species (ROS), interacts with a region of the c-Myc transcriptional regulatory domain that is essential for transformation. This results either in the suppression or enhancement of some c-Myc functions and in the altered expression of select target genes. Most notably, c-Myc-mediated transformation is inhibited, implying a tumor suppressor role for Prdx1. Consistent with this, prdx1 -/- mice develop age-dependent hemolytic anemias and/or malignancies. We now show that erythrocytes and embryonic fibroblasts from these animals contain higher levels of ROS, and that the latter cells show evidence of c-Myc activation, including the ability to be transformed by a ras oncogene alone. In contrast, other primary cells from prdx1 -/- mice do not have elevated ROS, but nonetheless show increased oxidative DNA damage. This apparent paradox can be explained by the fact that ROS localize primarily to the cytoplasm of prdx1 -/- cells, whereas in prdx1 -/- cells, much higher levels of nuclear ROS are seen. We suggest that increased DNA damage and tumor susceptibility in prdx1 -/- animals results from this shift in intracellular ROS. prdx1 -/- mice should be useful in studying the role of oxidative DNA damage in the causation of cancer and its prevention by antioxidants. They should also help in studying the relationship between oncogenes such as c-Myc and DNA damage.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA; NIH, Lab Mol Gerontol, Baltimore, MD 21224 USA; Univ Maryland, Dept Chem & Biochem Engn, Baltimore, MD 21250 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Dept Pediat, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu	Souza-Pinto, Nadja/T-3050-2019; Souza-Pinto, Nadja C./C-3462-2013; Jaruga, Pawel/M-4378-2015	Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; Jaruga, Pawel/0000-0001-9192-6084	NHLBI NIH HHS [HL33741] Funding Source: Medline; NICHD NIH HHS [T32 HD042987] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD042987] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000727, Z01AG000727] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barker N, 2000, ADV CANCER RES, V77, P1; Birincioglu M, 2003, J AM CHEM SOC, V125, P11607, DOI 10.1021/ja0352146; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Bubendorf L, 1999, CANCER RES, V59, P803; Bubendorf L, 1999, CANCER RES, V59, P1388; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Dizdaroglu M, 2001, FREE RADICAL BIO MED, V30, P774, DOI 10.1016/S0891-5849(01)00464-6; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisen JA, 2000, GENOME BIOL, V1; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hironaka K, 2003, LAB INVEST, V83, P643, DOI 10.1097/01.LAB.0000067483.89649.11; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Iritani BM, 2002, EMBO J, V21, P4820, DOI 10.1093/emboj/cdf492; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Jaruga P, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh087; Jaruga P, 2002, BIOCHEMISTRY-US, V41, P3703, DOI 10.1021/bi016004d; Jaruga PW, 2001, FREE RADICAL BIO MED, V31, P336, DOI 10.1016/S0891-5849(01)00594-9; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Kuraoka I, 2001, J BIOL CHEM, V276, P49283, DOI 10.1074/jbc.M107779200; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Marietta C, 2002, DNA REPAIR, V1, P967, DOI 10.1016/S1568-7864(02)00148-9; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Naidu R, 2002, INT J MOL MED, V9, P189; Nakahara H, 1998, FREE RADICAL BIO MED, V24, P85, DOI 10.1016/S0891-5849(97)00164-0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Obaya AJ, 2002, J BIOL CHEM, V277, P31263, DOI 10.1074/jbc.M202528200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PARADA LF, 1985, PROG MED VIROL, V32, P115; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PIETILAINEN T, 1995, ANTICANCER RES, V15, P959; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Senturker S, 1999, FREE RADICAL BIO MED, V27, P370, DOI 10.1016/S0891-5849(99)00069-6; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Smith DR, 1996, CLIN CANCER RES, V2, P1049; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thorgeirsson SS, 2000, TOXICOL LETT, V112, P553, DOI 10.1016/S0378-4274(99)00224-6; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; Trzeciak AR, 2004, CARCINOGENESIS, V25, P1359, DOI 10.1093/carcin/bgh144; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; YUAN L, 1993, EXP CELL RES, V209, P375, DOI 10.1006/excr.1993.1323	99	183	191	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8038	8050		10.1038/sj.onc.1208821	http://dx.doi.org/10.1038/sj.onc.1208821			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170382				2022-12-17	WOS:000233656600010
J	Bykov, VJN; Zache, N; Stridh, H; Westman, J; Bergman, J; Selivanova, G; Wiman, KG				Bykov, VJN; Zache, N; Stridh, H; Westman, J; Bergman, J; Selivanova, G; Wiman, KG			PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis	ONCOGENE			English	Article						p53 mutation; cancer therapy; chemotherapeutic drugs; PRIMA-1; synergy	MUTANT P53; BREAST-CANCER; RESTORATION; GROWTH; INFORMATION; CONFORMATION; THERAPY; PEPTIDE; RESCUE; DOMAIN	Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.	CCK, Dept Oncol Pathol, Stockholm, Sweden; Aprea AB, Stockholm, Sweden; Novum, Dept Biosci, Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), CCK, Dept Oncol Pathol, Stockholm, Sweden.	klas.wiman@cck.ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332; Nakade Bykov, Vladimir/0000-0002-7199-8942				BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Campling Barbara G, 2003, Methods Mol Med, V75, P53; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Keshelava N, 2001, CANCER RES, V61, P6185; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; OConnor PM, 1997, CANCER RES, V57, P4285; Ohnishi Ken, 2002, Mol Cancer, V1, P4, DOI 10.1186/1476-4598-1-4; Ohnishi T, 1999, INT J RADIAT BIOL, V75, P1095; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	24	183	184	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3484	3491		10.1038/sj.onc.1208419	http://dx.doi.org/10.1038/sj.onc.1208419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735745				2022-12-17	WOS:000229038800010
J	Ivanov, VN; Bhoumik, A; Ronai, Z				Ivanov, VN; Bhoumik, A; Ronai, Z			Death receptors and melanoma resistance to apoptosis	ONCOGENE			English	Review						melanoma; apoptosis; death receptors; Fas; TNFR-1; TRAIL	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; PROTEIN LIGASE ACTIVITY; FAS-LIGAND; SIGNAL-TRANSDUCTION; DOWN-REGULATION; TNF-ALPHA; C-JUN; TRANSCRIPTIONAL REGULATION	Impaired ability to undergo programmed cell death in response to a wide range of external stimuli acquires melanomas a selective advantage for progression and metastasis as well as their notorious resistance to therapy. Better understanding of mechanisms that govern apoptosis has enabled identification of diverse routes by which melanomas manage to escape stimuli of apoptosis. Changes at genomic, transcriptional and post-translational levels of G-proteins and protein kinases (Ras, B-Raf) and their transcription factor effectors (c-Jun, ATF2, Stat3 and NF-kappaB) affects TNF, Fas and TRAIL receptors, which play important roles in acquiring melanoma's resistance to apoptosis. Here, we summarize our current understanding of changes that alters the regulation of death receptors during melanoma development.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.	Zeev.ronai@mssm.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [S15CA055995] Funding Source: NIH RePORTER; NCI NIH HHS [CA559908, CA55995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Aoki K, 2000, MOL THER, V1, P555, DOI 10.1006/mthe.2000.0076; Aragane Y, 2000, J INVEST DERMATOL, V115, P1008, DOI 10.1046/j.1523-1747.2000.00164.x; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bhoumik A, 2002, J CLIN INVEST, V110, P643, DOI 10.1172/JCI200216081; Bhoumik A, 2001, CLIN CANCER RES, V7, P331; Bullani RR, 2002, MELANOMA RES, V12, P263, DOI 10.1097/00008390-200206000-00010; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Ekmekcioglu S, 1999, MELANOMA RES, V9, P261, DOI 10.1097/00008390-199906000-00008; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Griffith TS, 1998, J IMMUNOL, V161, P2833; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Herlyn M, 1996, AM J PATHOL, V149, P739; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Hug H, 1997, BIOL CHEM, V378, P1405; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2001, ONCOGENE, V20, P2243, DOI 10.1038/sj.onc.1204314; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KRASILNIKOV M, 2003, IN PRESS MOL CELL BI; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; Marsters SA, 1999, RECENT PROG HORM RES, V54, P225; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matsui K, 1998, J IMMUNOL, V161, P3469; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Murray PG, 2001, J PATHOL, V194, P158, DOI 10.1002/path.873; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Niu GL, 2001, CANCER RES, V61, P3276; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Pollack IF, 2001, CLIN CANCER RES, V7, P1362; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reichmann E, 2002, SEMIN CANCER BIOL, V12, P309, DOI 10.1016/S1044-579X(02)00017-2; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Santourlidis S, 2001, MOL CARCINOGEN, V32, P36, DOI 10.1002/mc.1062; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Soubrane C, 2000, BRIT J DERMATOL, V143, P307, DOI 10.1046/j.1365-2133.2000.03655.x; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thomas WD, 1998, J IMMUNOL, V161, P2195; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Worth LL, 2002, ONCOL REP, V9, P823; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao RB, 2000, GENE DEV, V14, P981; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	123	183	191	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3152	3161		10.1038/sj.onc.1206456	http://dx.doi.org/10.1038/sj.onc.1206456			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789291	Green Published			2022-12-17	WOS:000183096600017
J	Cheng, CW; Wu, PE; Yu, JC; Huang, CS; Yue, CT; Wu, CW; Shen, CY				Cheng, CW; Wu, PE; Yu, JC; Huang, CS; Yue, CT; Wu, CW; Shen, CY			Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene	ONCOGENE			English	Article						E-cadherin; breast cancer; two-hit hypothesis; loss of heterozygosity; hypermethylation; snail	TRANSCRIPTION FACTOR SNAIL; LOW-INCIDENCE AREA; HUMAN CANCER; PROMOTER HYPERMETHYLATION; SPORADIC BREAST; GASTRIC-CANCER; ALPHA-CATENIN; GAMMA-CATENIN; BETA-CATENIN; ALLELIC LOSS	Loss of heterozygosity (LOH) allows the expression of recessive mutation in tumor suppressor genes (TSG), Therefore, on the basis of Knudson's 'two-hit' hypothesis for TSG inactivation, the detection of a high LOH frequency in a chromosomal region is considered critical for TSG localization. One of these LOH regions in breast cancer is 16q22.1, which has been suggested to reflect the involvement of E-cadherin (E-cad), a cell-tell adhesion molecule, To confirm the tumorigenic role of Ecad, 81 sporadic invasive ductal carcinomas (IDCs) of the breast were tested for the 'two hits' required to inactivate this gene. A high frequency (37.3%) of LOH was detected in 67 informative tumors, but no mutation was found. To examine the possibility that transcriptional mechanisms serve as the second hit in tumors with LOH, specific pathways, including genetic variant and hypermethylation at the promoter region and abnormal expression of positive (WT1) and negative (Snail) transcription factors, were identified. Of these, promoter hypermethylation and increased expression of Snail were found to be common (> 35%), and to be strongly associated with reduced/negative E-cad expression (P <0.05), However, unexpectedly, a significantly negative association was found between the existence of LOH and promoter hypermethylation (P <0.05), which contradicts the 'two-hit' model, Instead, since they coexisted in a high frequency of tumors, hypermethylation may work in concert with increased Snail to inactivate E-cad expression, Given that Ecad is involved in diverse mechanisms, loss of which is beneficial for tumors to invade but may also trigger apoptosis, this study suggests that maintaining a reversible mechanism, either by controlling the gene at the transcriptional level or by retaining an intact allele subsequent to LOH, might be important for E-cad in IDC and may also be common in TSGs possessing diverse functions, These findings provide clues to explain why certain TSGs identified by LOH cannot fulfil the two-hit hypothesis.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Lib Sci Lib, Taipei 115, Taiwan; Natl Taiwan Univ, Sch Publ Hlth, Grad Inst Epidemiol, Taipei 100, Taiwan; Natl Hlth Res Inst, Taipei 115, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Pathol, Taipei 111, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Triserv Gen Hosp, Dept Surg, Taipei 11490, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Health Research Institutes - Taiwan; Shin Kong Wu Ho Su Memorial Hospital; National Taiwan University; National Taiwan University Hospital; Tri-Service General Hospital	Shen, CY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	bmcys@ccvax.sinica.edu.tw	Shen, CY/F-6271-2010	Huang, Chiun-Sheng/0000-0002-6557-211X				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bindels EMJ, 2000, CANCER RES, V60, P177; Brown MA, 1997, ADV GENET, V36, P45, DOI 10.1016/S0065-2660(08)60307-7; Bukholm IK, 2000, J PATHOL, V190, P15; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Davidson B, 2000, J PATHOL, V192, P460; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fabre A, 1999, HUM PATHOL, V30, P661, DOI 10.1016/S0046-8177(99)90091-6; Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Healey CS, 2000, NAT GENET, V26, P362, DOI 10.1038/81691; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Huang CS, 1999, CANCER RES, V59, P4870; Ilyas M, 2000, J PATHOL, V190, P3, DOI 10.1002/(SICI)1096-9896(200001)190:1<3::AID-PATH490>3.0.CO;2-5; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ku WH, 1997, INT J CANCER, V72, P270, DOI 10.1002/(SICI)1097-0215(19970717)72:2<270::AID-IJC12>3.0.CO;2-K; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788; Li LC, 2000, CANCER RES, V60, P873; LINDBLOM A, 1993, CANCER RES, V53, P3707; Lo YL, 1998, INT J CANCER, V79, P580, DOI 10.1002/(SICI)1097-0215(19981218)79:6<580::AID-IJC5>3.0.CO;2-M; Lou MA, 1997, BRIT J CANCER, V75, P746, DOI 10.1038/bjc.1997.132; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Nass SJ, 2000, CANCER RES, V60, P4346; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shen CY, 2000, CANCER RES, V60, P3884; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Tan DSP, 1999, J PATHOL, V189, P20, DOI 10.1002/(SICI)1096-9896(199909)189:1<20::AID-PATH394>3.0.CO;2-2; Tseng SL, 1997, GENE CHROMOSOME CANC, V20, P377; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang PS, 1997, BRIT J CANCER, V75, P752, DOI 10.1038/bjc.1997.133	60	183	191	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3814	3823		10.1038/sj.onc.1204505	http://dx.doi.org/10.1038/sj.onc.1204505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439345				2022-12-17	WOS:000169494700007
J	Epinat, JC; Gilmore, TD				Epinat, JC; Gilmore, TD			Diverse agents act at multiple levels to inhibit the Rel/NF-kappa B signal transduction pathway	ONCOGENE			English	Review						Rel; NF-kappa B; I kappa B signal transduction; NF-kappa B inhibition; IKK	NITRIC-OXIDE SYNTHASE; DNA-BINDING ACTIVITY; GLUCOCORTICOID-MEDIATED REPRESSION; ADHESION MOLECULE EXPRESSION; FACTOR-INDUCED APOPTOSIS; ACID PHENETHYL ESTER; CD4(+) T-LYMPHOCYTES; N-TERMINAL KINASE; ALPHA-LIPOIC ACID; TRANSCRIPTION FACTOR	Rel/NF-kappa B transcription factors regulate several important physiological processes, including developmental processes, inflammation and immune responses, cell growth, cancer, apoptosis, and the expression of certain viral genes. Therefore, they have also been sought-after molecular targets for pharmacological intervention. As details of the Rel/NF-kappa B signal transduction pathway are revealed, it is clear that modulators of this pathway can act at several levels. Inhibitors of the Rel/NF-kappa B pathway include a variety of natural and designed molecules, including anti-oxidants, proteasome inhibitors, peptides, small molecules, and dominant-negative or constitutively active polypeptides in the pathway. Several of these molecules act as general inhibitors of Rel/NF-kappa B induction, whereas others inhibit specific pathways of induction. Inhibitors of Rel/NF-kappa B are likely to gain stature as treatments for certain cancers and neurodegenerative and inflammatory diseases.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Epinat, JC (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.							Arbault S, 1997, BIOMED PHARMACOTHER, V51, P430, DOI 10.1016/S0753-3322(97)82321-9; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778; Bork PM, 1999, PLANTA MED, V65, P297, DOI 10.1055/s-1999-13989; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006-2952(97)00535-2; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Cho S, 1998, BIOCHEM BIOPH RES CO, V253, P104, DOI 10.1006/bbrc.1998.9697; Cominacini L, 1997, J HYPERTENS, V15, P1633, DOI 10.1097/00004872-199715120-00065; D'Acquisto F, 1998, FEBS LETT, V440, P76, DOI 10.1016/S0014-5793(98)01407-0; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Duffey DC, 1999, CANCER RES, V59, P3468; Egan L J, 1998, Gastroenterology, V115, P1295, DOI 10.1016/S0016-5085(98)70106-4; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Ehrlich LC, 1998, NEUROREPORT, V9, P1723, DOI 10.1097/00001756-199806010-00010; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fiedler MA, 1996, J VIROL, V70, P9079, DOI 10.1128/JVI.70.12.9079-9082.1996; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gehrt A, 1998, J ANTIBIOT, V51, P455, DOI 10.7164/antibiotics.51.455; Geng ZH, 1997, FREE RADICAL BIO MED, V23, P345, DOI 10.1016/S0891-5849(97)00006-3; Gerbes AL, 1998, HEPATOLOGY, V28, P1309, DOI 10.1002/hep.510280520; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; GRUNBERGER D, 1988, EXPERIENTIA, V44, P230, DOI 10.1007/BF01941717; Harant H, 1998, FEBS LETT, V436, P329, DOI 10.1016/S0014-5793(98)01153-3; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hernandez-Presa MA, 1998, AM J PATHOL, V153, P1825, DOI 10.1016/S0002-9440(10)65697-0; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirano F, 1998, IMMUNOPHARMACOLOGY, V39, P31, DOI 10.1016/S0162-3109(97)00095-7; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; IQBAL M, 1995, J MED CHEM, V38, P2276, DOI 10.1021/jm00013a002; Islam KN, 1998, CIRCULATION, V98, P2255, DOI 10.1161/01.CIR.98.21.2255; ISRAEL N, 1992, J IMMUNOL, V149, P3386; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; Janssen YMW, 1999, METHOD ENZYMOL, V300, P363; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Katsuyama K, 1998, ARTERIOSCL THROM VAS, V18, P1796, DOI 10.1161/01.ATV.18.11.1796; Kawashima S, 1998, J INTERF CYTOK RES, V18, P423, DOI 10.1089/jir.1998.18.423; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kim CH, 1999, BIOCHEM BIOPH RES CO, V259, P505, DOI 10.1006/bbrc.1999.0814; Kimura T, 1997, BIOCHEM BIOPH RES CO, V231, P557, DOI 10.1006/bbrc.1997.6135; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kotake Y, 1998, BBA-MOL CELL RES, V1448, P77, DOI 10.1016/S0167-4889(98)00126-8; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; KUNZ D, 1995, BIOCHEM BIOPH RES CO, V216, P438, DOI 10.1006/bbrc.1995.2642; Lauzurica P, 1999, EUR J IMMUNOL, V29, P1890, DOI 10.1002/(SICI)1521-4141(199906)29:06<1890::AID-IMMU1890>3.0.CO;2-F; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mahboubi K, 1998, J PHARMACOL EXP THER, V285, P862; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Manna SK, 1999, BIOCHEM PHARMACOL, V57, P763, DOI 10.1016/S0006-2952(98)00354-2; Manna SK, 1998, J IMMUNOL, V161, P2863; Manna SK, 1999, J IMMUNOL, V162, P2095; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; MANNA SK, 1998, J IMMUNOL, V161, P2773; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MCCAFFREY PG, 1994, NUCLEIC ACIDS RES, V22, P2134, DOI 10.1093/nar/22.11.2134; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Musonda CA, 1998, CARCINOGENESIS, V19, P1583, DOI 10.1093/carcin/19.9.1583; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Oyama T, 1998, J IMMUNOL, V160, P1224; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palayoor ST, 1998, CLIN CANCER RES, V4, P763; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pierce JW, 1996, J IMMUNOL, V156, P3961; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Pyatt DW, 1998, TOXICOL APPL PHARM, V149, P178, DOI 10.1006/taap.1998.8369; Pyatt DW, 1998, TOXICOLOGY, V128, P83, DOI 10.1016/S0300-483X(98)00047-X; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; RITCHIE DM, 1995, INT J IMMUNOPHARMACO, V17, P805, DOI 10.1016/0192-0561(95)00072-A; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Saliou C, 1998, FEBS LETT, V440, P8, DOI 10.1016/S0014-5793(98)01409-4; SAPPEY C, 1995, AIDS RES HUM RETROV, V11, P1049, DOI 10.1089/aid.1995.11.1049; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sen CK, 1998, BIOCHEM BIOPH RES CO, V247, P223, DOI 10.1006/bbrc.1998.8764; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SEN J, 1995, J IMMUNOL, V154, P3213; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; Shoji S, 1998, BIOCHEM BIOPH RES CO, V249, P745, DOI 10.1006/bbrc.1998.9221; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Simpson CS, 1999, J NEUROCHEM, V73, P353, DOI 10.1046/j.1471-4159.1999.0730353.x; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; Singh S, 1996, J IMMUNOL, V157, P4412; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Spiecker M, 1999, METHOD ENZYMOL, V300, P374; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; Sueoka E, 1998, BIOCHEM BIOPH RES CO, V252, P566, DOI 10.1006/bbrc.1998.9695; Sugano N, 1998, BIOCHEM BIOPH RES CO, V252, P25, DOI 10.1006/bbrc.1998.9599; Sun WH, 1998, BIOCHEM BIOPH RES CO, V244, P691, DOI 10.1006/bbrc.1998.8324; SUZUKI YJ, 1994, BIOCHEM MOL BIOL INT, V32, P299; Suzuki YJ, 1995, BIOCHEM MOL BIOL INT, V36, P241; SUZUKI YJ, 1993, BIOCHEM BIOPH RES CO, V193, P277, DOI 10.1006/bbrc.1993.1620; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1993, BIOCHEM MOL BIOL INT, V31, P693; TEPPER MA, 1995, J IMMUNOL, V155, P2427; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Trepicchio WL, 1998, ANN NY ACAD SCI, V856, P12, DOI 10.1111/j.1749-6632.1998.tb08308.x; Umansky V, 1996, INT IMMUNOL, V8, P491, DOI 10.1093/intimm/8.4.491; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Venkataraman L, 1996, J IMMUNOL, V157, P1149; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JY, 1998, LIVER, V18, P180; Wang WH, 1997, IMMUNITY, V6, P165, DOI 10.1016/S1074-7613(00)80423-9; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; WEISSMANN G, 1991, HOSP PRACT, V26, P60; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	187	183	205	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6896	6909		10.1038/sj.onc.1203218	http://dx.doi.org/10.1038/sj.onc.1203218			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602465				2022-12-17	WOS:000083896500007
J	Basu, S; Kolesnick, R				Basu, S; Kolesnick, R			Stress signals for apoptosis: ceramide and c-Jun kinase	ONCOGENE			English	Article						apoptosis; stress; JNK; ceramide	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; RADIATION-INDUCED APOPTOSIS; CELL-DEATH; MEDIATED ACTIVATION; GAMMA-RADIATION; BINDING PROTEIN; KAPPA-B; SPHINGOMYELINASE; PATHWAY	Mammalian systems respond to environmental stress by either adapting or undergoing programmed cell death. While there is general agreement that the caspase family of proteases serve as the effecters of the apoptotic death response, the signaling apparatus involved in the decision to activate the caspase system is less clear. In the past few years, the sphingomyelin and c-Jun Kinase (JNK)/Stress-activated Protein Kinase (SAPK) pathways have been linked to the death response in many cellular systems. These signaling systems are found throughout the animal kingdom, and ceramide signaling is conserved through yeast. Since yeast do not undergo apoptosis, the sphingomyelin pathway appears evolutionarily older than the caspase-mediated death programs. While recent reviews by several groups have broadly surveyed ceramide signaling in apoptosis, this paper examines the role of sphingomyelinases and the JNK/SAPK pathway in coordinate signaling of apoptosis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Signal Transduct, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA 42385] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Dobrowsky RT, 1998, ANN NY ACAD SCI, V845, P32, DOI 10.1111/j.1749-6632.1998.tb09660.x; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Garzotto M, 1998, CANCER RES, V58, P2260; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Goldkorn T, 1998, J CELL SCI, V111, P3209; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Laethem RM, 1998, BLOOD, V91, P4350, DOI 10.1182/blood.V91.11.4350.411k27_4350_4360; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Merrill AH, 1996, ADV EXP MED BIOL, V392, P297; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	75	183	192	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3277	3285		10.1038/sj.onc.1202570	http://dx.doi.org/10.1038/sj.onc.1202570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916990				2022-12-17	WOS:000078048200009
J	Sato, M; Morii, E; Komori, T; Kawahata, H; Sugimoto, M; Terai, K; Shimizu, H; Yasui, T; Ogihara, H; Yasui, N; Ochi, T; Kitamura, Y; Ito, Y; Nomura, S				Sato, M; Morii, E; Komori, T; Kawahata, H; Sugimoto, M; Terai, K; Shimizu, H; Yasui, T; Ogihara, H; Yasui, N; Ochi, T; Kitamura, Y; Ito, Y; Nomura, S			Transcriptional regulation of osteopontin gene in vivo by PEBP2 alpha A/CBFA1 and ETS1 in the skeletal tissues	ONCOGENE			English	Article						osteopontin; PEBP2 alpha A/CBFA1; ETS1; synergistic transactivation; osteogenesis	LEUKEMIA-VIRUS ENHANCERS; CORE-BINDING-FACTOR; GM-CSF PROMOTER; RUNT DOMAIN; MESSENGER-RNA; RESPONSE ELEMENT; RECEPTOR-DELTA; BONE-FORMATION; NUCLEAR FACTOR; IN-VIVO	Osteopontin (Opn) and polyoma enhancer-binding protein (PEBP) 2 alpha A/core binding factor (CBFA) 1 have been suggested to play important roles in ossification, The overlapping localization of opn and PEBP2 alpha A/CBFA1 mRNA, and the marked decrease of opn mRNA expression in PEBP2 alpha A knockout mice, indicated that the transcription of opn gene was controlled by PEBP2 alpha A. In the present study, we determined the direct regulation of PEBP2 alpha A on the opn promoter activity, Opn promoter activity was markedly enhanced by PEBP2 alpha A and ETS1 in a synergistic manner, The synergistic effect was diminished when either the PEBP2 alpha A or ETS1 binding site was mutated, or the spatial arrangement of these sites was mutated by a 4-nt insertion. The distance between these sites was important for transactivation but not protein-DNA binding. The direct interaction between PEBP2 alpha A and ETS1 was depended on protein-DNA binding. These results suggested that the specific spatial arrangement of both sites and direct interaction between PEBP2 alpha A and ETS1, were essential for promoter function. Furthermore, endogenous opn mRNA was decreased with the introduction of dominant negative PEBP2 alpha A to MC3T3/E1 cells expressing endogenous PEBP2 alpha A, ETS1 and opn, These findings suggest that PEBP2 alpha A and ETS1 cooperate iii vivo to regulate expression of the opn gene in the skeletal tissue, Cell type-specific regulation of Opn gene expression will also be discussed.	Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Orthopaed Surg, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 5650871, Japan; Nagoya City Univ, Sch Med, Dept Urol, Nagoya, Aichi 4678601, Japan; Kyoto Univ, Sch Med, Inst Virus Res, Dept Viral Oncol, Kyoto 6068397, Japan	Osaka University; Osaka University; Osaka University; Nagoya City University; Kyoto University	Nomura, S (corresponding author), Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan.		YASUI, Takahiro/E-6401-2018	YASUI, Takahiro/0000-0003-2197-2477				AUBIN JE, 1996, J BONE MINER RES, V11, pS102; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BROWN LF, 1994, AM J PATHOL, V145, P610; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; HIROTA S, 1995, LAB INVEST, V72, P64; HIROTA S, 1993, AM J PATHOL, V143, P1003; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KOHRI K, 1993, J BIOL CHEM, V268, P15180; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKASE T, 1994, BONE MINER, V26, P109, DOI 10.1016/S0169-6009(08)80056-6; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oates AJ, 1996, ONCOGENE, V13, P97; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PAGANO M, 1992, ONCOGENE, V7, P1681; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SATO M, IN PRESS J BONE MINE; SINGH RP, 1991, J EXP MED, V171, P1931; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKEMURA T, 1994, HEARING RES, V79, P99, DOI 10.1016/0378-5955(94)90131-7; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YAMADA T, 1995, EUR J IMMUNOL, V25, P2710, DOI 10.1002/eji.1830250947; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	57	183	185	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 24	1998	17	12					1517	1525		10.1038/sj.onc.1202064	http://dx.doi.org/10.1038/sj.onc.1202064			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794229				2022-12-17	WOS:000076089900004
J	Finkenzeller, G; Sparacio, A; Technau, A; Marme, D; Siemeister, G				Finkenzeller, G; Sparacio, A; Technau, A; Marme, D; Siemeister, G			Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression	ONCOGENE			English	Article						PDGF; promoter; Sp1; tumor angiogenesis; VEGF	SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; TRANSCRIPTIONAL ACTIVATION; TUMOR ANGIOGENESIS; PERMEABILITY FACTOR; MESSENGER-RNA; BINDING; INDUCTION; HYPOXIA; INVIVO	Stimulation of NIH3T3 cells with platelet-derived growth factor (PDGF)-BB enhances expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of tumor angiogenesis. Here, we identified cis-acting VEGF promoter elements and trans-acting factors which are involved in PDGF-stimulated VEGF expression. By 5'-deletion and transient transfection analysis, a G + C-rich region at -85 to -50 of the human VEGF promoter was shown to be necessary and sufficient for both PDGF inducible and basal expression. The region contains three potential recognition sites for Spl transcription factors, which overlap with two Egr-1 sites. Mutations that abolish the ability of Spl to interact with the VEGF promoter element also abrogate expression induced by PDGF. Mutations of the potential Egr-1 binding sites did not affect PDGF responsiveness. Gel shift and antibody supershift analyses showed that Spl and Sp3 interact constitutively with the VEGF promoter element. Our data strongly suggest that enhanced VEGF gene expression in PDGF-induced NIH3T3 cells is mediated by Spl and/or Sp3 transcription factors bound to the -85 to -50 promoter region of the VEGF gene.	TUMOR BIOL CTR, INST MOL MED, D-79106 FREIBURG, GERMANY					, Gerhard/0000-0002-4712-0531				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BASHEERUDDIN K, 1995, ARTERIOSCL THROM VAS, V15, P1248, DOI 10.1161/01.ATV.15.8.1248; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HECHT A, 1990, THESIS HEIDELBERG GE; HERMANSON M, 1992, CANCER RES, V52, P3213; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Janknecht R, 1996, ONCOGENE, V12, P1961; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Liang YX, 1996, ONCOGENE, V13, P863; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJELLO B, 1995, ONCOGENE, V10, P1841; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAK J, 1995, CANCER RES, V55, P4575; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1996, CANCER RES, V56, P2299; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WEINDEL K, 1994, NEUROSURGERY, V35, P439, DOI 10.1227/00006123-199409000-00012	55	183	185	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	1997	15	6					669	676		10.1038/sj.onc.1201219	http://dx.doi.org/10.1038/sj.onc.1201219			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264407				2022-12-17	WOS:A1997XP68300006
J	Merritt, AJ; Allen, TD; Potten, CS; Hickman, JA				Merritt, AJ; Allen, TD; Potten, CS; Hickman, JA			Apoptosis in small intestinal epithelia from p53-null mice: Evidence for a delayed, p53-indepdendent G2/M-associated cell death after gamma-irradiation	ONCOGENE			English	Article						p53; apoptosis; p53-independent apoptosis; radiation; small intestine; G2/M checkpoint	RADIATION-INDUCED APOPTOSIS; DNA-DAMAGE; GASTROINTESTINAL-TRACT; P53; CRYPTS; CYCLE; PROGRESSION; CHECKPOINT; TUMORS; CANCER	The death of small intestinal epithelial cells has been characterized and quantitated after irradiation of mice rendered homozygously null for the p53 gene, In wild-type animals homozygous for p53 a rapid (4.5 h) elevation of p53 protein was observed in the proliferative compartment of the crypts after 8 Gy of irradiation, Cells underwent cell death by apoptosis in this region, We had reported previously a total repression of apoptosis in small intestinal crypt epithelia 4.5 h after the gamma-irradiation (8 Gy) of p53 homozygously null animals, Thus, while 400 apoptotic cells mere observed in 200 half crypts taken from mild-type animals at 4.5 h, this fell to background levels (10-30) in the p53 null animals (Merritt et al., 1994) and did not increase by 12 h, However, we have nom found a delayed initiation of a p53-independent apoptosis after 8 Gy of gamma-radiation: at 24 h, approximately 100 apoptotic cells were observed in 200 half crypts, This late wave of apoptosis was not observed after 1 Gy of gamma-radiation. The morphological appearance of this p53-independent apoptosis suggested that death may have arisen as the result of aberrant mitosis, Analysis of the regeneration of crypts 3 days after irradiation of mice with between 11 and 17 Gy showed that there was no significant increase (P=0.135) in the potential of clonogenic cells from the p53 nub animals to repopulate the crypts, The data support the idea that a p53-independent apoptotic mechanism permits the engagement of apoptosis, probably by a mitotic catastrophe, after 8 Gy of gamma-irradiation in,live and that a loss of p53 does not make these epithelial cells radioresistant lit vivo to doses of 8 Gy and above, In contrast, irradiation with 1 GS failed to induce a p53-independent apoptosis in vivo, suggesting that the p53 'sensor' of damage was more sensitive than that engaging the p53-independent mechanism of cell death.	CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT EPITHELIAL BIOL, CANC RES CAMPAIGN, MANCHESTER M20 4BX, LANCS, ENGLAND; CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT ULTRASTRUCT, MANCHESTER M20 4BX, LANCS, ENGLAND; UNIV MANCHESTER, SCH BIOL SCI, MOL & CELLULAR PHARMACOL GRP, MANCHESTER M13 9PT, LANCS, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fishel R, 1996, J NATL CANCER I, V88, P1608, DOI 10.1093/jnci/88.22.1608; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARMON BV, 1992, CELL PROLIFERAT, V25, P523, DOI 10.1111/j.1365-2184.1992.tb01457.x; HENDRY JH, 1979, RADIAT RES, V78, P404, DOI 10.2307/3574968; Kahlenberg MS, 1996, J NATL CANCER I, V88, P1665, DOI 10.1093/jnci/88.22.1665; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LESHER S, 1969, NATL CANCER I MONOGR, P185; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; Potten C. S., 1995, P45; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; POTTEN CS, 1981, INT J RADIAT BIOL, V40, P321, DOI 10.1080/09553008114551251; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; ROBERTS SA, 1990, INT J RADIAT BIOL, V57, P1243, DOI 10.1080/09553009014551321; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	183	192	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2759	2766		10.1038/sj.onc.1201126	http://dx.doi.org/10.1038/sj.onc.1201126			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190891				2022-12-17	WOS:A1997XD64300003
J	MANNING, AM; WILLIAMS, AC; GAME, SM; PARASKEVA, C				MANNING, AM; WILLIAMS, AC; GAME, SM; PARASKEVA, C			DIFFERENTIAL SENSITIVITY OF HUMAN COLONIC ADENOMA AND CARCINOMA-CELLS TO TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) - CONVERSION OF AN ADENOMA CELL-LINE TO A TUMORIGENIC PHENOTYPE IS ACCOMPANIED BY A REDUCED RESPONSE TO THE INHIBITORY EFFECTS OF TGF-BETA	ONCOGENE			English	Article							POLYPOSIS COLI PATIENTS; LIVER EPITHELIAL-CELLS; PROLIFERATION; CANCER; CARCINOGENESIS; PROGRESSION; RESISTANCE; RECEPTORS; ONCOGENE; GENE	The growth of three non-tumorigenic human colonic adenoma cell lines, designated AA/C1, RG/C2 and RR/C1, was inhibited by low concentrations of transforming growth factor-beta (TGF-beta) (0.05-0.5 ng ml-1). However, the growth of five human colon cancer cell lines under identical conditions was resistant to high concentrations of TGF-beta (2-10 ng ml-1). This is the first report of well-characterized premalignant human colonic cells showing sensitivity to TGF-beta. The TGF-beta-sensitive adenoma cell line AA/C1 was derived from a relatively large adenoma with a K-ras gene mutation and represents a relatively late-stage adenoma, indicating that loss of response to TGF-beta occurs at a relatively late stage in colorectal carcinogenesis and that the presence of a ras gene mutation does not necessarily confer resistance to TGF-beta. Of further interest, the RG/CZ cell line has a p53 mutation showing that p53 mutations do not necessarily lead to TGF-B insensitivity. Furthermore, in this paper we show that the conversion of the AA/C1 adenoma cell line to a tumorigenic phenotype [Williams et al., (1990) Cancer Res., 50, 4724] is accompanied by a reduced response to the growth-inhibitory effects of TGF-beta up to 10 ng ml-1. Reduced responsiveness to the inhibitory effects of TGF-beta may be an important event in the loss of growth control in colorectal carcinogenesis.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BRISTOL,DENT SCH & HOSP,DEPT ORAL MED,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol; University of Bristol				Williams, Ann/0000-0002-6009-7137				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; BAKER SJ, 1990, CANCER RES, V50, P777; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; COFFEY RJ, 1988, CANCER RES, V48, P1596; COFFEY RJ, 1986, CANCER RES, V46, P1164; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAME SM, 1990, CARCINOGENESIS, V11, P965, DOI 10.1093/carcin/11.6.965; HADDOW S, 1991, ONCOGENE, V6, P1467; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOUCK KA, 1989, ONCOGENE, V4, P19; HUBBS AF, 1989, CARCINOGENESIS, V10, P1599, DOI 10.1093/carcin/10.9.1599; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAMPRECHT SA, 1989, ANTICANCER RES, V9, P1877; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1985, CANCER CELL, V3, P65; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1990, BRIT J CANCER, V61, P828, DOI 10.1038/bjc.1990.185; PARASKEVA C, 1989, CANCER RES, V49, P1282; PARKINSON K, 1990, CARCINOGENESIS, V11, P195, DOI 10.1093/carcin/11.2.195; PIGNATELLI M, 1989, INT J CANCER, V44, P518, DOI 10.1002/ijc.2910440324; Reddel R R, 1988, Oncogene Res, V3, P401; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROLLINS BJ, 1989, J CELL PHYSIOL, V139, P455, DOI 10.1002/jcp.1041390302; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SONG MKH, 1985, EXP CELL RES, V156, P271, DOI 10.1016/0014-4827(85)90281-2; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS AC, 1990, CANCER RES, V50, P4724	39	183	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1471	1476						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886718				2022-12-17	WOS:A1991GX27200026
J	Mei, YP; Liao, JP; Shen, J; Yu, L; Liu, BL; Liu, L; Li, RY; Ji, L; Dorsey, SG; Jiang, ZR; Katz, RL; Wang, JY; Jiang, F				Mei, Y-P; Liao, J-P; Shen, J.; Yu, L.; Liu, B-L; Liu, L.; Li, R-Y; Ji, L.; Dorsey, S. G.; Jiang, Z-R; Katz, R. L.; Wang, J-Y; Jiang, F.			Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis	ONCOGENE			English	Article						small nucleolar RNA; tumorigenesis; biomarkers; apoptosis; p53	NONCODING RNAS; CANCER; P53; ACTIVATION; EXPRESSION; MICRORNAS; APOPTOSIS; CLUSTER; ARRAY	Non-small cell lung cancer (NSCLC) is the leading cause of cancer death, reflecting the need for better understanding the oncogenesis, and developing new diagnostic and therapeutic targets for the malignancy. Emerging evidence suggests that small nucleolar RNAs (snoRNAs) have malfunctioning roles in tumorigenesis. Our recent study demonstrated that small nucleolar RNA 42 (SNORA42) was overexpressed in lung tumors. Here, we investigate the role of SNORA42 in tumorigenesis of NSCLC. We simultaneously assess genomic dosages and expression levels of SNORA42 and its host gene, KIAA0907, in 10 NSCLC cell lines and a human bronchial epithelial cell line. We then determine in vitro functional significance of SNORA42 in lung cancer cell lines through gain- and loss-of-function analyses. We also inoculate cancer cells with SNORA42-siRNA into mice through either tail vein or subcutaneous injection. We finally evaluate expression level of SNORA42 on frozen surgically resected lung tumor tissues of 64 patients with stage I NSCLC by using quantitative reverse transcriptase PCR assay. Genomic amplification and associated high expression of SNORA42 rather than KIAA0907 are frequently observed in lung cancer cells, suggesting that SNORA42 overexpression is activated by its genomic amplification. SNORA42 knockdown in NSCLC cells inhibits in vitro and in vivo tumorigenicity, whereas enforced SNORA42 expression in bronchial epitheliums increases cell growth and colony formation. Such pleiotropy of SNORA42 suppression could be achieved at least partially through increased apoptosis of NSCLC cells in a p53-dependent manner. SNORA42 expression in lung tumor tissue specimens is inversely correlated with survival of NSCLC patients. Therefore, SNORA42 activation could have an oncogenic role in lung tumorigenesis and provide potential diagnostic and therapeutic targets for the malignancy. Oncogene (2012) 31, 2794-2804; doi: 10.1038/onc.2011.449; published online 10 October 2011	[Mei, Y-P; Liao, J-P; Shen, J.; Yu, L.; Jiang, Z-R; Jiang, F.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Liu, B-L] Univ Colorado Denver, Sch Med, Dept Pathol, Aurora, CO USA; [Liu, L.; Li, R-Y; Wang, J-Y] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Ji, L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; [Dorsey, S. G.] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA; [Katz, R. L.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center	Jiang, F (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St,MSTF 7th Floor, Baltimore, MD 21201 USA.	fjiang@som.umaryland.edu	liao, Jipei/B-2758-2017	liao, Jipei/0000-0001-5073-2275; Liu, Bolin/0000-0003-0150-8650	National Cancer Institute (NCI) [CA-135382, CA-137742, CA-133956]; NCI-The Early Detection Research Network; American Cancer Society; Maryland Stem Cell Research Fund; NIH; Flight Attendant Medical Research Institute [1 P30 NR011396]; Wendy Will Case Cancer Award; NATIONAL CANCER INSTITUTE [R01CA161837, R03CA137742, R21CA135382, R03CA133956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [P30NR011396] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI-The Early Detection Research Network; American Cancer Society(American Cancer Society); Maryland Stem Cell Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute; Wendy Will Case Cancer Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This work was supported in part by the National Cancer Institute (NCI) Grants CA-135382, CA-137742 and CA-133956, the Wendy Will Case Cancer Award, Associate Member Award from the NCI-The Early Detection Research Network, the American Cancer Society Research Scholar Grant, an exploratory research grant from the Maryland Stem Cell Research Fund, the NIH-K12-Multidisciplinary Clinical Research Career Development Program, and an clinical innovator award from the Flight Attendant Medical Research Institute to FJ and 1 P30 NR011396 to SGD.	Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Chang LS, 2002, BIOCHEM BIOPH RES CO, V299, P196, DOI 10.1016/S0006-291X(02)02623-2; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4; Donsante A, 2007, SCIENCE, V317, P477, DOI 10.1126/science.1142658; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Feng J, 2004, NEOPLASIA, V6, P623, DOI 10.1593/neo.04142; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiang F, 2010, CANCER PREV RES, V3, P1571, DOI 10.1158/1940-6207.CAPR-10-0128; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Li RY, 2006, LAB INVEST, V86, P619, DOI 10.1038/labinvest.3700408; Liao JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-198; Malstrom SE, 2004, TOXICOL APPL PHARM, V200, P219, DOI 10.1016/j.taap.2004.04.021; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Pena JTG, 2009, NAT METHODS, V6, P139, DOI [10.1038/NMETH.1294, 10.1038/nmeth.1294]; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; PRESS MF, 1990, PROG CLIN BIOL RES, V354, P209; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Turner AMW, 2010, BIOTECHNIQUES, V48, pIX, DOI 10.2144/000113442; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5; Wang XW, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp864; Winnard PT, 2006, NEOPLASIA, V8, P796, DOI 10.1593/neo.06304; Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200	37	182	194	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2794	2804		10.1038/onc.2011.449	http://dx.doi.org/10.1038/onc.2011.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21986946	Green Accepted, hybrid			2022-12-17	WOS:000304769000009
J	Wang, B; Hasan, MK; Alvarado, E; Yuan, H; Wu, H; Chen, WY				Wang, B.; Hasan, M. K.; Alvarado, E.; Yuan, H.; Wu, H.; Chen, W. Y.			NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response	ONCOGENE			English	Article						prostate cancer; NAMPT; SIRT1; NAD; nicotinamide; Foxo3a	COLONY-ENHANCING FACTOR; TRANSCRIPTION FACTOR FOXO3A; LIFE-SPAN EXTENSION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; CALORIE RESTRICTION; COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; P53-DEFICIENT MICE; ANDROGEN RECEPTOR; NAD BIOSYNTHESIS	Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in regenerating nicotinamide adenine dinucleotide (NAD(+)) from nicotinamide in mammals. NAMPT has crucial roles for many cellular functions by regulating NAD(+)-dependent SIRT1 deacetylase. However, roles of NAMPT in cancer are poorly defined. In this study, we show that NAMPT is prominently over-expressed in human prostate cancer cells along with SIRT1. Elevation of NAMPT expression occurs early for the prostate neoplasia. Inhibition of NAMPT significantly suppresses cell growth in culture, soft agar colony formation, cell invasion and growth of xenografted prostate cancer cells in mice. NAMPT knockdown sensitizes prostate cancer cells to oxidative stress caused by H2O2 or chemotherapeutic treatment. Overexpression of NAMPT increases prostate cancer cell resistance to oxidative stress, which is partially blocked by SIRT1 knockdown. We demonstrate that in addition to modulating SIRT1 functions, the NAMPT inhibition reduces forkhead box, class 'O' (FOXO)3a protein expression and its downstream anti-oxidant genes catalase and manganese superoxide dismutase. Our results suggest important roles of concomitant upregulation of NAMPT and SIRT1 along with increased FOXO3a protein level for prostate carcinogenesis and their contribution to oxidative stress resistance of prostate cancer cells. These findings may have implications for exploring the NAMPT pathway for prostate cancer prevention and treatment. Oncogene (2011) 30, 907-921; doi:10.1038/onc.2010.468; published online 18 October 2010	[Chen, W. Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Alvarado, E.] Calif State Univ Long Beach, Dept Biol, Long Beach, CA 90840 USA; [Wu, H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; California State University System; California State University Long Beach; City of Hope; Beckman Research Institute of City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	wechen@coh.org	yuan, hongfeng/A-3633-2012; Chen, WenYong/D-6748-2012	Chen, WenYong/0000-0001-6913-5729	City of Hope; STOPCANCER foundation; American Cancer Society; California Institute of Regenerative Medicine	City of Hope; STOPCANCER foundation; American Cancer Society(American Cancer Society); California Institute of Regenerative Medicine(California Institute for Regenerative Medicine)	This study is supported by the start-up fund from City of Hope, career development award from STOPCANCER foundation and research scholar award from American Cancer Society (WYC). EA was supported by a training grant awarded to CSULB from California Institute of Regenerative Medicine.	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267; Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chu F, 2005, CANCER RES, V65, P10183, DOI 10.1158/0008-5472.CAN-05-2002; Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Drevs J, 2003, ANTICANCER RES, V23, P4853; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Garten A, 2009, TRENDS ENDOCRIN MET, V20, P130, DOI 10.1016/j.tem.2008.10.004; Gartner EM, 2010, CANCER J, V16, P83, DOI 10.1097/PPO.0b013e3181d78223; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hasmann M, 2003, CANCER RES, V63, P7436; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1; Hwang CS, 2010, SCIENCE, V327, P973, DOI 10.1126/science.1183147; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jang KY, 2009, PATHOLOGY, V41, P366, DOI 10.1080/00313020902884451; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Karger S, 2009, ENDOCR-RELAT CANCER, V16, P189, DOI 10.1677/ERC-07-0283; Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590; Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muruganandham M, 2005, CLIN CANCER RES, V11, P3503, DOI 10.1158/1078-0432.CCR-04-1399; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Ognjanovic S, 2001, J MOL ENDOCRINOL, V26, P107, DOI 10.1677/jme.0.0260107; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Revollo JR, 2007, CELL METAB, V6, P363, DOI 10.1016/j.cmet.2007.09.003; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Shukla S, 2009, INT J ONCOL, V34, P1613, DOI 10.3892/ijo_00000291; Skokowa J, 2009, NAT MED, V15, P151, DOI 10.1038/nm.1913; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Turkbey B, 2009, NAT REV UROL, V6, P191, DOI 10.1038/nrurol.2009.27; van Beijnum JR, 2002, INT J CANCER, V101, P118, DOI 10.1002/ijc.10584; van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Warburg O., 1931, METABOLISM TUMORS; Watson M, 2009, MOL CELL BIOL, V29, P5872, DOI 10.1128/MCB.00112-09; Williams AC, 2005, J CLIN NEUROSCI, V12, P6, DOI 10.1016/j.jocn.2004.10.002; Xiao D, 2006, CARCINOGENESIS, V27, P2223, DOI 10.1093/carcin/bgl087; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103	79	182	195	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					907	921		10.1038/onc.2010.468	http://dx.doi.org/10.1038/onc.2010.468			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20956937				2022-12-17	WOS:000287695900003
J	Endersby, R; Baker, SJ				Endersby, R.; Baker, S. J.			PTEN signaling in brain: neuropathology and tumorigenesis	ONCOGENE			English	Review						PTEN; PI3 kinase; tumor suppressor; brain; glioblastoma	LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE-B; GROWTH-FACTOR RECEPTOR; FORKHEAD TRANSCRIPTION FACTORS; RILEY-RUVALCABA-SYNDROME; HUMAN-MALIGNANT GLIOMAS; LOW-GRADE GLIOMAS; IN-VIVO; GLIOBLASTOMA-MULTIFORME	Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor that antagonizes the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway by functioning as a lipid phosphatase. This ubiquitous and evolutionarily conserved signaling cascade influences numerous functions including cell growth, survival, proliferation, migration and metabolism. Inherited mutations in PTEN cause pleiotropic effects including cancer predisposition as well as a range of neurological abnormalities revealing specialized roles for PTEN in nervous system development and maintenance. Somatic mutations in PTEN occur frequently as late events in sporadic brain tumors. Mouse models based on Pten deletion in the brain have provided insights into the normal functions of Pten in the nervous system as well as the initiation and progression of gliomas. Compromised PTEN function may contribute to gliomagenesis through disrupted regulation of proliferation, migration, invasion, angiogenesis, stem cell self-renewal and regulation of other tumor suppressor pathways such as p53. Clinical findings in high-grade glioma suggest that PTEN gene alterations are associated with poor prognosis and may influence response to specific therapies. Emerging research using specific pharmacological inhibitors of the PI3K pathway may provide novel therapeutic options for the treatment of PTEN-deficient tumors.	[Endersby, R.; Baker, S. J.] St Jude Childrens Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Baker, SJ (corresponding author), St Jude Childrens Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.baker@stjude.org	Endersby, Raelene/A-2969-2013; Baker, Suzanne J/N-8167-2018	Endersby, Raelene/0000-0003-3554-2769; 	National Institutes of Health; American Lebanese; Syrian Associated Charities of St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE [R01CA135554] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese; Syrian Associated Charities of St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Baker laboratory for helpful comments and discussions. SJB is supported by grants from the National Institutes of Health and by the American Lebanese and Syrian Associated Charities of St Jude Children's Research Hospital.	Abel TW, 2005, J NEUROPATH EXP NEUR, V64, P341, DOI 10.1093/jnen/64.4.341; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boland E, 2007, AM J HUM GENET, V81, P292, DOI 10.1086/519999; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646; Chakravarti A, 2001, CLIN CANCER RES, V7, P2387; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Ding H, 2001, CANCER RES, V61, P3826; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Fraser MM, 2008, NEUROSCIENCE, V151, P476, DOI 10.1016/j.neuroscience.2007.10.048; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Furnari FB, 1998, CANCER RES, V58, P5002; Goffin A, 2001, AM J MED GENET, V105, P521, DOI 10.1002/ajmg.1477; Gottschalk AR, 2001, CANCER RES, V61, P2105; Goudar RK, 2005, MOL CANCER THER, V4, P101; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gustafson S, 2007, SEMIN ONCOL, V34, P428, DOI 10.1053/j.seminoncol.2007.07.009; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hartmann C, 2005, ACTA NEUROPATHOL, V109, P639, DOI 10.1007/s00401-005-1000-1; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hartmann W, 2006, CLIN CANCER RES, V12, P3019, DOI 10.1158/1078-0432.CCR-05-2187; Hayes MP, 2006, CLIN CANCER RES, V12, P5932, DOI 10.1158/1078-0432.CCR-06-1375; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hoekman MFM, 2006, GENE EXPR PATTERNS, V6, P134, DOI 10.1016/j.modgep.2005.07.003; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Homma T, 2006, J NEUROPATH EXP NEUR, V65, P846, DOI 10.1097/01.jnen.0000235118.75182.94; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595; Hunter C, 2006, CANCER RES, V66, P3987, DOI 10.1158/0008-5472.CAN-06-0127; Iida S, 1998, INT J MOL MED, V1, P925; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jones G, 2001, CANCER RES, V61, P5688; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Kraus JA, 2000, J NEURO-ONCOL, V48, P89, DOI 10.1023/A:1006402614838; Kubiatowski T, 2001, J NEUROSURG, V95, P480, DOI 10.3171/jns.2001.95.3.0480; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Lachlan KL, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049981; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2002, MOL CELL NEUROSCI, V20, P21, DOI 10.1006/mcne.2002.1115; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lin H, 1998, CLIN CANCER RES, V4, P2447; Louis DN, 2007, WHO CLASSIFICATION T; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Maity A, 2000, CANCER RES, V60, P5879; Marino S, 2002, DEVELOPMENT, V129, P3513; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nakayama K, 2006, CANCER BIOL THER, V5, P779, DOI 10.4161/cbt.5.7.2751; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Prados MD, 2006, NEURO-ONCOLOGY, V8, P67, DOI 10.1215/S1522851705000451; Pu PY, 2006, J NEURO-ONCOL, V76, P1, DOI 10.1007/s11060-005-3029-3; Raffel C, 1999, CLIN CANCER RES, V5, P4085; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Rasheed BKA, 1997, CANCER RES, V57, P4187; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Rickert CH, 2004, J NEUROPATH EXP NEUR, V63, P399, DOI 10.1093/jnen/63.5.399; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sano T, 1999, CANCER RES, V59, P1820; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Shannon P, 2005, AM J PATHOL, V167, P859, DOI 10.1016/S0002-9440(10)62057-3; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tada K, 2001, J NEUROSURG, V95, P651, DOI 10.3171/jns.2001.95.4.0651; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Uhlmann EJ, 2004, GLIA, V47, P180, DOI 10.1002/glia.20036; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Van Diepen MT, 2008, DEV NEUROSCI-BASEL, V30, P59, DOI 10.1159/000109852; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Wei QX, 2006, CANCER RES, V66, P7429, DOI 10.1158/0008-5472.CAN-06-0712; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003; Xiao A, 2005, CANCER RES, V65, P5172, DOI 10.1158/0008-5472.CAN-04-3902; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3; Yue Q, 2005, DEVELOPMENT, V132, P3281, DOI 10.1242/dev.01891; Zeng LH, 2007, NEUROBIOL DIS, V28, P184, DOI 10.1016/j.nbd.2007.07.015; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866; Zori RT, 1998, AM J MED GENET, V80, P399, DOI 10.1002/(SICI)1096-8628(19981204)80:4<399::AID-AJMG18>3.0.CO;2-O; Zundel W, 2000, GENE DEV, V14, P391	151	182	199	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 15	2008	27	41					5416	5430		10.1038/onc.2008.239	http://dx.doi.org/10.1038/onc.2008.239			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794877				2022-12-17	WOS:000259280700004
J	Williams, C; Edvardsson, K; Lewandowski, SA; Strom, A; Gustafsson, JA				Williams, C.; Edvardsson, K.; Lewandowski, S. A.; Stroem, A.; Gustafsson, J-A			A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; microarray; breast cancer; gene regulation	GENE-EXPRESSION; DOWN-REGULATION; IN-VITRO; ER-BETA; TARGET; PROLIFERATION; INTERLEUKIN-20; TRANSCRIPTION; ANGIOGENESIS; ESTRADIOL	Transcriptional effects of estrogen result from its activation of two estrogen receptor (ER) isoforms; ER alpha that drives proliferation and ER beta that is antiproliferative. Expression of ERb in xenograft tumors from the T47D breast cancer cell line reduces tumor growth and angiogenesis. If ERb can halt tumor growth, its introduction into cancers may be a novel therapeutic approach to the treatment of estrogen-responsive cancers. To assess the complete impact of ER beta on transcription, we have made a full transcriptome analysis of ER alpha- and ER beta-mediated gene regulation in T47D cell line with Tet-Off regulated ERb expression. Of the 35 000 genes and transcripts analysed, 4.1% (1434) were altered by ERa activation. Tet withdrawal and subsequent ER beta expression inhibited the ERa regulation of 998 genes and, in addition, altered expression of 152 non-ER alpha-regulated genes. ER alpha-induced and ER beta-repressed genes were involved in proliferation, steroid/xenobiotic metabolism and ion transport. The ER beta repressive effect was further confirmed by proliferation assays, where ER beta was shown to completely oppose the ER alpha-E2 induced proliferation. Additional analysis of ER beta with a mutated DNA-binding domain revealed that this mutant, at least for a quantity of genes, antagonizes ER alpha even more strongly than ER beta wt. From an examination of the genes regulated by ER alpha and ER beta, we suggest that introduction of ER beta may be an alternative therapeutic approach to the treatment of certain cancers.	[Williams, C.; Edvardsson, K.; Lewandowski, S. A.; Stroem, A.; Gustafsson, J-A] Karolinska Inst, Novum, Dept Biosci & Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet	Williams, C (corresponding author), Karolinska Inst, Novum, Dept Biosci & Nutr, Halsovagen 7-9, S-14157 Huddinge, Sweden.	cecilia.williams@biosci.ki.se	Williams, Cecilia/A-6677-2009; Lewandowski, Sebastian A./K-2492-2019	Williams, Cecilia/0000-0002-0602-2062; Lewandowski, Sebastian A./0000-0002-5935-0211				Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI [10.1093/carcin/bci339, 10.1093/carcin/bgi339]; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Chen WY, 2006, ARTERIOSCL THROM VAS, V26, P2090, DOI 10.1161/01.ATV.0000232502.88144.6f; Esslimani-Sahla M, 2005, CLIN CANCER RES, V11, P3170, DOI 10.1158/1078-0432.CCR-04-2298; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gougelet A, 2007, J STEROID BIOCHEM, V104, P110, DOI 10.1016/j.jsbmb.2007.03.002; Gustafsson JA, 2006, CLIMACTERIC, V9, P156, DOI 10.1080/14689360600734328; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hartman J, 2006, CANCER RES, V66, P11207, DOI 10.1158/0008-5472.CAN-06-0017; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hsieh MY, 2006, GENES IMMUN, V7, P234, DOI 10.1038/sj.gene.6364291; Hsu YH, 2006, ARTHRITIS RHEUM-US, V54, P2722, DOI 10.1002/art.22039; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Lo YL, 2005, INT J CANCER, V115, P276, DOI 10.1002/ijc.20855; Marshburn PB, 2004, AM J OBSTET GYNECOL, V191, P626, DOI 10.1016/j.ajog.2004.05.082; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Murphy LC, 2005, J MOL ENDOCRINOL, V34, P553, DOI 10.1677/jme.1.01688; Nikolova Z, 1998, J CELL SCI, V111, P2741; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Poola I, 2001, J STEROID BIOCHEM, V78, P459, DOI 10.1016/S0960-0760(01)00118-2; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Ricci MS, 1999, J BIOL CHEM, V274, P3430, DOI 10.1074/jbc.274.6.3430; Richter K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-75; ROBERTS M, 1988, BIOCHEM BIOPH RES CO, V151, P306, DOI 10.1016/0006-291X(88)90594-3; Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; Tomasini R, 2005, ONCOGENE, V24, P8093, DOI 10.1038/sj.onc.1208951; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Wang F, 2006, J INVEST DERMATOL, V126, P1590, DOI 10.1038/sj.jid.5700310; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975	49	182	187	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					1019	1032		10.1038/sj.onc.1210712	http://dx.doi.org/10.1038/sj.onc.1210712			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700529				2022-12-17	WOS:000252946300014
J	Nojima, M; Suzuki, H; Toyota, M; Watanabe, Y; Maruyama, R; Sasaki, S; Sasaki, Y; Mita, H; Nishikawa, N; Yamaguchi, K; Hirata, K; Itoh, F; Tokino, T; Mori, M; Imai, K; Shinomura, Y				Nojima, M.; Suzuki, H.; Toyota, M.; Watanabe, Y.; Maruyama, R.; Sasaki, S.; Sasaki, Y.; Mita, H.; Nishikawa, N.; Yamaguchi, K.; Hirata, K.; Itoh, F.; Tokino, T.; Mori, M.; Imai, K.; Shinomura, Y.			Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer	ONCOGENE			English	Article						SFRP; methylation; gastric cancer; Wnt signaling; apoptosis	BETA-CATENIN GENE; MATRIX METALLOPROTEINASE-7; ABERRANT METHYLATION; ANTAGONIST SFRP1; CYCLIN D1; EXPRESSION; APOPTOSIS; FAMILY; GROWTH; HYPERMETHYLATION	Activation of Wnt signaling has been implicated in gastric tumorigenesis, although mutations in APC (adenomatous polyposis coli), CTNNB1 (beta-catenin) and AXIN are seen much less frequently in gastric cancer (GC) than in colorectal cancer. In the present study, we investigated the relationship between activation of Wnt signaling and changes in the expression of secreted frizzled-related protein (SFRP) family genes in GC. We frequently observed nuclear beta-catenin accumulation (13/15; 87%) and detected the active form of beta-catenin in most (12/16; 75%) GC cell lines. CpG methylation-dependent silencing of SFRP1, SFRP2 and SFRP5 was frequently seen among GC cell lines (SFRP1, 16/16, 100%; SFRP2, 16/16, 100%; SFRP5, 13/16, 81%) and primary GC specimens (SFRP1, 42/46, 91%; SFRP2, 44/46, 96%; SFRP5, 30/46, 65%),and treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine rapidly restored SFRP expression. Ectopic expression of SFRPs downregulated T-cell factor/lymphocyte enhancer factor transcriptional activity, suppressed cell growth and induced apoptosis in GC cells. Analysis of global expression revealed that overexpression of SFRP2 repressed Wnt target genes and induced changes in the expression of numerous genes related to proliferation, growth and apoptosis in GC cells. It thus appears that aberrant SFRP methylation is one of the major mechanisms by which Wnt signaling is activated in GC.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Dept Publ Hlth, Sapporo, Hokkaido, Japan; Sapporo Med Univ, Dept Mol Biol, Inst Canc Res, Sapporo, Hokkaido, Japan; PRESTO JST, Kawaguchi, Japan; St Marianna Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Kawasaki, Kanagawa, Japan; Sapporo Med Univ, Dept Surg 1, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST); Saint Marianna University; Sapporo Medical University	Suzuki, H (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, S1,W16, Sapporo, Hokkaido 0608543, Japan.	hsuzuki@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; 				Arber N, 1999, HUM PATHOL, V30, P1087, DOI 10.1016/S0046-8177(99)90227-7; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Clements WM, 2002, CANCER RES, V62, P3503; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He B, 2005, CANCER RES, V65, P743; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; HORII A, 1992, CANCER RES, V52, P3231; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Ii M, 2006, EXP BIOL MED, V231, P20; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; KOPPERT LB, 2000, BRIT J CANCER, V90, P892; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Murai M, 2005, CLIN CANCER RES, V11, P1021; Naishiro Y, 2001, CANCER RES, V61, P2751; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Saikawa Y, 2001, JPN J CANCER RES, V92, P1102, DOI 10.1111/j.1349-7006.2001.tb01065.x; Sasaki Y, 2001, TUMOR BIOL, V22, P123, DOI 10.1159/000050606; Satoh A, 2003, CANCER RES, V63, P8606; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Suriano G, 2005, GENE CHROMOSOME CANC, V42, P238, DOI 10.1002/gcc.20135; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141	41	182	199	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4699	4713		10.1038/sj.onc.1210259	http://dx.doi.org/10.1038/sj.onc.1210259			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297461				2022-12-17	WOS:000248037900010
J	Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Okabe, S; Ohyashiki, JH; Ohyashiki, K				Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Okabe, S.; Ohyashiki, J. H.; Ohyashiki, K.			Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia	ONCOGENE			English	Article						telomerase inhibition; p38 MAP kinase; MKK3/6; apoptosis; in vivo study	TYROSINE KINASE INHIBITOR; DNA; SENESCENCE; TARGET; CELLS; INVOLVEMENT; ARREST; PARP-2	The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADPribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomer-ase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DN-hTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity in vivo.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan	Tokyo Medical University; University of Tokyo; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp; kshin@iam.u-tokyo.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blackburn EH, 1995, TELOMERES; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2003, CANCER RES, V63, P6149; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Gowan SM, 2001, MOL PHARMACOL, V60, P981, DOI 10.1124/mol.60.5.981; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; IZBICKA E, 1999, CANCER RES, V59, P369; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; Tauchi T, 2002, CLIN CANCER RES, V8, P3341; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	32	182	189	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5719	5725		10.1038/sj.onc.1209577	http://dx.doi.org/10.1038/sj.onc.1209577			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652154				2022-12-17	WOS:000240765800003
J	Sun, SC; Yamaoka, S				Sun, SC; Yamaoka, S			Activation of NF-kappa B by HTLV-I and implications for cell transformation	ONCOGENE			English	Review						adult T-cell leukemia; HTLV-I; tax; NF-kappa B	VIRUS TYPE-I; RECEPTOR GENE-EXPRESSION; CYTOTOXIC T-LYMPHOCYTES; TYPE-1 TAX INDUCTION; ALPHA IKK-ALPHA; WILD-TYPE P53; LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATOR; C-REL; CONSTITUTIVE ACTIVATION	T-cell transformation by the human T-cell leukemia virus type I ( HTLV-I) involves deregulation of cellular transcription factors, including members of the NF-kappa B family. In normal T cells, NF-kappa B activation occurs transiently in response to immune stimuli, which is required for antigen-stimulated T-cell proliferation and survival. However, HTLV-I induces persistent activation of NF-kappa B, causing deregulated expression of a large array of cellular genes, which in turn contributes to the induction of T-cell transformation. The HTLV-I transforming protein Tax functions as an intracellular stimulator of I kappa B kinase (IKK), a cellular kinase mediating NF-kappa B activation by diverse stimuli. Tax physically interacts with IKK and renders this inducible kinase constitutively active. By assembling different Tax/IKK complexes, Tax targets the persistent activation of both canonical and noncanonical NF-kappa B signaling pathways. Whereas Tax plays a primary role in HTLV-I-mediated NF-kappa B activation, recent studies reveal that the IKK/NF-kappa B signaling pathway is also activated in freshly isolated adult T-cell leukemia (ATL) cells that often lack detectable Tax expression. The mechanism underlying this Tax-independent pathway of NF-kappa B activation remains poorly understood. Clarifying the precise nature and consequences of the constitutive NF-kappa B activation in ATL cells is important for developing rational therapeutic strategies for this T-cell malignancy.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Tokyo Med & Dent Univ, Dept Mol Virol, Grad Sch Med, Bunkyo Ku, Tokyo 1138510, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Tokyo Medical & Dental University (TMDU)	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu; shojmmb@tmd.ac.jp			NCI NIH HHS [CA094922, CA68471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922, R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Al-Shamkhani A, 2004, CURR OPIN PHARMACOL, V4, P355, DOI 10.1016/j.coph.2004.02.007; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arima N, 1999, EXP HEMATOL, V27, P1168, DOI 10.1016/S0301-472X(99)00053-3; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Azran I, 2004, RETROVIROLOGY, V1, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BINDHU M, 2005, FRONT BIOSCI, V10, P17; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Burmeister T, 2001, REV MED VIROL, V11, P369, DOI 10.1002/rmv.331; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CESARMAN E, 1992, BLOOD, V80, P3205; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; De la Fuente C, 2000, AIDS RES HUM RETROV, V16, P1695, DOI 10.1089/08892220050193164; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 2005, VIROLOGY, V333, P145, DOI 10.1016/j.virol.2004.12.008; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HARNETT MM, 2004, SCI STKE, pPE25; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Higashimura N, 1996, JPN J CANCER RES, V87, P227, DOI 10.1111/j.1349-7006.1996.tb00210.x; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1992, ONCOGENE, V7, P1737; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Horie R, 2003, INT J HEMATOL, V77, P37, DOI 10.1007/BF02982601; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; IMADA K, 1995, BLOOD, V86, P2350, DOI 10.1182/blood.V86.6.2350.bloodjournal8662350; Imura A, 1997, BLOOD, V89, P2951, DOI 10.1182/blood.V89.8.2951; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Inoue M, 1998, JPN J CANCER RES, V89, P53, DOI 10.1111/j.1349-7006.1998.tb00479.x; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Jang IK, 2003, CURR OPIN IMMUNOL, V15, P315, DOI 10.1016/S0952-7915(03)00048-7; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; KANNAGI M, 1993, INT J CANCER, V54, P582, DOI 10.1002/ijc.2910540411; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kehn K, 2004, FRONT BIOSCI-LANDMRK, V9, P2347, DOI 10.2741/1401; Kim KE, 2000, ONCOGENE, V19, P1334, DOI 10.1038/sj.onc.1203432; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Koga H, 2004, CANCER SCI, V95, P411, DOI 10.1111/j.1349-7006.2004.tb03224.x; KOGA Y, 1989, J IMMUNOL, V142, P4493; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANOIX J, 1994, ONCOGENE, V9, P841; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Miura H, 2005, EXP CELL RES, V308, P29, DOI 10.1016/j.yexcr.2005.04.005; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Miyazato A, 2005, J VIROL, V79, P9346, DOI 10.1128/JVI.79.14.9346-9350.2005; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; Mori N, 1999, BLOOD, V93, P2360; Mori N, 2000, BLOOD, V95, P3915; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; Nonaka M, 2005, ONCOGENE, V24, P3976, DOI 10.1038/sj.onc.1208564; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Pankow R, 2000, J IMMUNOL, V165, P263, DOI 10.4049/jimmunol.165.1.263; Petropoulos L, 1998, VIROLOGY, V252, P189, DOI 10.1006/viro.1998.9430; Pise-Masison CA, 2005, FRONT BIOSCI-LANDMRK, V10, P919, DOI 10.2741/1586; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2002, CANCER RES, V62, P3562; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REID RL, 1993, ONCOGENE, V8, P3029; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Ruland J, 2003, IMMUNOL REV, V193, P93, DOI 10.1034/j.1600-065X.2003.00049.x; SAKASHITA A, 1992, BLOOD, V79, P477; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; Takemoto S, 2000, BLOOD, V95, P3939; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THAKUR S, 1994, ONCOGENE, V9, P2335; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Weil R, 1999, J VIROL, V73, P3709, DOI 10.1128/JVI.73.5.3709-3717.1999; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Younis I, 2005, FRONT BIOSCI-LANDMRK, V10, P431, DOI 10.2741/1539; YSSEL H, 1989, J IMMUNOL, V142, P2279; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	189	182	188	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5952	5964		10.1038/sj.onc.1208969	http://dx.doi.org/10.1038/sj.onc.1208969			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155602				2022-12-17	WOS:000231623400005
J	Nakagawa, H; Liyanarachchi, S; Davuluri, RV; Auer, H; Martin, EW; de la Chapelle, A; Frankel, WL				Nakagawa, H; Liyanarachchi, S; Davuluri, RV; Auer, H; Martin, EW; de la Chapelle, A; Frankel, WL			Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles	ONCOGENE			English	Article						colon cancer; cancer-associated stroma; cancer microenvironment; COX2	GROWTH-FACTOR; TUMOR-GROWTH; CELLS; TUMORIGENICITY; ACCELERATION; SUPPRESSION; INHIBITION; PROSTATE; MICE	The cancer microenvironment and interaction between cancer and stromal cells play critical roles in tumor development and progression. The molecular features of cancer stroma are less well understood than those of cancer cells. Cancer-associated stromal fibroblasts are the predominant component of stroma associated with colon cancer and its functions remain unclear. Fibroblast cell cultures were established from metastatic colon cancer in liver, liver away from the metastatic lesions, and skin from three patients with metastatic colorectal cancer. We generated expression profiles of cancer-associated fibroblasts using oligochip arrays and compared them to those of uninvolved fibroblasts. The conditioned media from the cancer-associated fibroblast cultures enhanced proliferation of colon cancer cell line HCT116 to a greater extent than cultures from uninvolved fibroblasts. In microarray expression analysis, cancer-associated fibroblasts clustered tightly into one group and skin fibroblasts into another. Approximately 170 of 22 000 genes were upregulated in cancer-associated fibroblasts ( fold change >2, P<0.05) as compared to skin fibroblasts, including many genes encoding cell adhesion molecules, growth factors, and COX2. By immunohistochemistry in-vivo, we confirmed COX2 and TGFB2 expression in cancer-associated fibroblasts in metastatic colon cancer. The distinct molecular expression profiles of cancer-associated fibroblasts in colon cancer metastasis support the notion that these fibroblasts form a favorable microenvironment for cancer cells.	Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Surg Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Frankel, WL (corresponding author), Ohio State Univ, Dept Pathol, 410 W 10th Ave,401 E Doan Hall, Columbus, OH 43210 USA.	frankel-1@medctr.osu.edu	Davuluri, Ramana/D-7348-2011; Thomson, Axel/A-7893-2013; Martin Jr, Edward/E-3604-2011	Frankel, Wendy/0000-0003-1658-1009	NCI NIH HHS [CA16058, CA67941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, U01CA067941, R01CA067941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bartholin L, 2002, ONCOGENE, V21, P2227, DOI 10.1038/sj.onc.1205294; BRATTAIN MG, 1982, J NATL CANCER I, V69, P767; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Conze D, 2001, CANCER RES, V61, P8851; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gho YS, 2001, CANCER RES, V61, P4253; GLEAVE M, 1991, CANCER RES, V51, P3753; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill DP, 2002, GENOME RES, V12, P1982, DOI 10.1101/gr.580102; Holen I, 2002, CANCER RES, V62, P1619; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Matrisian LM, 2001, CANCER RES, V61, P3844; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Paget S., 1889, 1889 CANC METASTASIS, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; PICARD O, 1986, CANCER RES, V46, P3290; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; Studeny M, 2002, CANCER RES, V62, P3603; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; WESTERMARK B, 1991, CANCER RES, V51, P5087; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	37	182	191	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7366	7377		10.1038/sj.onc.1208013	http://dx.doi.org/10.1038/sj.onc.1208013			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326482				2022-12-17	WOS:000224021400007
J	Russo, G; Zegar, C; Giordano, A				Russo, G; Zegar, C; Giordano, A			Advantages and limitations of microarray technology in human cancer	ONCOGENE			English	Review						microarray; proteomics; human cancer	GENE-EXPRESSION PROFILES; SQUAMOUS-CELL CARCINOMA; LASER-CAPTURE MICRODISSECTION; COMPLEMENTARY-DNA MICROARRAY; BENIGN PROSTATIC HYPERPLASIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; EPITHELIAL OVARIAN-CANCER; URINARY-BLADDER CANCER; CDNA MICROARRAY; BREAST-CANCER	Cancer is a highly variable disease with multiple heterogeneous genetic and epigenetic changes. Functional studies are essential to understanding the complexity and polymorphisms of cancer. The final deciphering of the complete human genome, together with the improvement of high throughput technologies, is causing a fundamental transformation in cancer research. Microarray is a new powerful tool for studying the molecular basis of interactions on a scale that is impossible using conventional analysis. This technique makes it possible to examine the expression of thousands of genes simultaneously. This technology promises to lead to improvements in developing rational approaches to therapy as well as to improvements in cancer diagnosis and prognosis, assuring its entry into clinical practice in specialist centers and hospitals within the next few years. Predicting who will develop cancer and how this disease will behave and respond to therapy after diagnosis will be one of the potential benefits of this technology within the next decade. In this review, we highlight some of the recent developments and results in microarray technology in cancer research, discuss potentially problematic areas associated with it, describe the eventual use of microarray technology for clinical applications and comment on future trends and issues.	Temple Univ, Dept Biotechnol, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Dept Biotechnol, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, 1900 N 12th St,Room 333, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Agrawal D, 2002, J NATL CANCER I, V94, P513; Ahr A, 2002, LANCET, V359, P131, DOI 10.1016/S0140-6736(02)07337-3; Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Barlund M, 2000, CANCER RES, V60, P5340; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; BATTIFORA H, 1986, LAB INVEST, V55, P244; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Belbin TJ, 2002, CANCER RES, V62, P1184; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Best C J, 2001, Expert Rev Mol Diagn, V1, P53, DOI 10.1586/14737159.1.1.53; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Brail LH, 1999, MUTAT RES-GENOMICS, V406, P45, DOI 10.1016/S1383-5726(98)00009-0; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Bubendorf L, 1999, CANCER RES, V59, P803; Bull JH, 2001, BRIT J CANCER, V84, P1512, DOI 10.1054/bjoc.2001.1816; Caldas C, 2002, NATURE, V415, P484, DOI 10.1038/415484a; Celis JE, 2000, FEBS LETT, V480, P2, DOI 10.1016/S0014-5793(00)01771-3; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheng Q, 2002, INT J CANCER, V98, P419, DOI 10.1002/ijc.10177; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Collins FS, 1999, NAT GENET, V21, P2, DOI 10.1038/4425; Devilard E, 2002, ONCOGENE, V21, P3095, DOI 10.1038/sj.onc.1205418; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Fejzo MS, 2001, AM J PATHOL, V159, P1645, DOI 10.1016/S0002-9440(10)63011-8; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gariboldi M, 2003, CANCER RES, V63, P1871; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gordon GJ, 2002, CANCER RES, V62, P4963; Granjeaud S, 1999, BIOESSAYS, V21, P781, DOI 10.1002/(SICI)1521-1878(199909)21:9<781::AID-BIES10>3.0.CO;2-2; Graves DJ, 1999, TRENDS BIOTECHNOL, V17, P127, DOI 10.1016/S0167-7799(98)01241-4; Han HY, 2002, CANCER RES, V62, P2890; Hanash S, 2003, NAT BIOTECHNOL, V21, P37, DOI 10.1038/nbt0103-37; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hedenfalk IA, 2002, ADV CANCER RES, V84, P1, DOI 10.1016/S0065-230X(02)84001-5; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hippo Y, 2002, CANCER RES, V62, P233; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Ismail RS, 2000, CANCER RES, V60, P6744; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Khan J, 1998, CANCER RES, V58, P5009; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6; Kodadek T, 2001, CHEM BIOL, V8, P105, DOI 10.1016/S1074-5521(00)90067-X; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kudoh K, 2000, CANCER RES, V60, P4161; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Leethanakul C, 2003, ORAL ONCOL, V39, P248, DOI 10.1016/S1368-8375(02)00107-0; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Luo J, 2001, CANCER RES, V61, P4683; Luo J, 2002, PROSTATE, V51, P189, DOI 10.1002/pros.10087; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Meldrum D, 2000, GENOME RES, V10, P1288, DOI 10.1101/gr.157400; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Niemeyer CM, 1999, ANGEW CHEM INT EDIT, V38, P2865, DOI 10.1002/(SICI)1521-3773(19991004)38:19<2865::AID-ANIE2865>3.0.CO;2-F; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Ono K, 2000, CANCER RES, V60, P5007; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; RUSSO G, 2003, IN PRESS ONCOGENE; Sallinen SL, 2000, CANCER RES, V60, P6617; Sawiris GP, 2002, CANCER RES, V62, P2923; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Senior K, 1999, MOL MED TODAY, V5, P326, DOI 10.1016/S1357-4310(99)01536-1; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shridhar V, 2001, CANCER RES, V61, P5895; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 2001, J NATL CANCER I, V93, P1141, DOI 10.1093/jnci/93.15.1141; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr433; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Stratowa C, 2001, INT J CANCER, V91, P474, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1078>3.0.CO;2-C; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2001, CANCER RES, V61, P7388; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Torhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; von Eggeling F, 2000, BIOTECHNIQUES, V29, P1066; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Xu JC, 2001, CANCER RES, V61, P1563; Zhou M, 2002, AM J SURG PATHOL, V26, P926, DOI 10.1097/00000478-200207000-00012	123	182	188	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 29	2003	22	42					6497	6507		10.1038/sj.onc.1206865	http://dx.doi.org/10.1038/sj.onc.1206865			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528274				2022-12-17	WOS:000185700700006
J	Inohara, N; Nunez, G				Inohara, N; Nunez, G			The NOD: a signaling module that regulates apoptosis and host defense against pathogens	ONCOGENE			English	Review						apoptosis; Apaf-1/Nod1/CED4 family; programmed cell death; ATPase/GTPases; NOD domain	CLASS-II TRANSACTIVATOR; PROGRAMMED CELL-DEATH; NF-KAPPA-B; SPINAL MUSCULAR-ATROPHY; INDUCED-PROXIMITY MODEL; BARE LYMPHOCYTE SYNDROME; BCL-2 FAMILY MEMBERS; CREB BINDING-PROTEIN; WD-40 REPEAT REGION; C-ELEGANS	Nods, a growing family of proteins containing a nucleotide-binding oligomerization domain (NOD), are involved in the regulation of programmed cell death (PCD) and immune responses. Members of the family include Apaf-1, Ced-4, Nod1, Nod2, and the cytosolic products of plant disease resistance genes. The NOD module is homologous to the ATP-binding cassette (ABC) found in a large number of proteins with diverse biological function. The centrally located NOD promotes activation of effector molecules through self-association and induced proximity of binding partners. The C-terminal domain of Nods serves as a sensor for intracellular ligands, whereas the N-terminal domain mediates binding to dowstream effector molecules and activation of diverse signaling pathways. Thus, Nods activate, through the NOD module, diverse signaling pathways involved in the elimination of cells via PCD and the host defense against pathogens.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [R01 CA64556-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bontron S, 1997, HUM GENET, V99, P541, DOI 10.1007/s004390050403; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; del Peso L, 2000, J BIOL CHEM, V275, P27205; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Diez E, 2000, J IMMUNOL, V164, P1470, DOI 10.4049/jimmunol.164.3.1470; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Fontes JD, 1999, MOL CELL BIOL, V19, P941; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Growney JD, 2000, GENOME RES, V10, P1158, DOI 10.1101/gr.10.8.1158; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holcik M, 2000, P NATL ACAD SCI USA, V97, P2286, DOI 10.1073/pnas.040469797; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jaroszewski L, 2000, PROTEINS, V39, P197, DOI 10.1002/(SICI)1097-0134(20000515)39:3<197::AID-PROT10>3.0.CO;2-V; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; Nickerson K, 2001, J BIOL CHEM, V276, P19089, DOI 10.1074/jbc.M101295200; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Parrish J, 2000, P NATL ACAD SCI USA, V97, P11916, DOI 10.1073/pnas.210391597; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scharf JM, 1996, GENOMICS, V38, P405, DOI 10.1006/geno.1996.0644; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Tong ZB, 2000, NAT GENET, V26, P267, DOI 10.1038/81547; Tong ZB, 1999, ENDOCRINOLOGY, V140, P3720, DOI 10.1210/en.140.8.3720; Tong ZB, 2000, MAMM GENOME, V11, P281, DOI 10.1007/s003350010053; TRENT C, 1983, GENETICS, V104, P619; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weinrauch Y, 1999, ANNU REV MICROBIOL, V53, P155, DOI 10.1146/annurev.micro.53.1.155; Wu DY, 1999, DEVELOPMENT, V126, P2021; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	133	182	194	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6473	6481		10.1038/sj.onc.1204787	http://dx.doi.org/10.1038/sj.onc.1204787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607846				2022-12-17	WOS:000171640600019
J	Wu, YL; Mehew, JW; Heckman, CA; Arcinas, M; Boxer, LM				Wu, YL; Mehew, JW; Heckman, CA; Arcinas, M; Boxer, LM			Negative regulation of bcl-2 expression by p53 in hematopoietic cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; p53	WILD-TYPE P53; TATA-BINDING PROTEIN; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR P53; FOLLICULAR LYMPHOMA; HISTONE DEACETYLASES; FUNCTIONAL DOMAIN; CREB PROTEINS; MDR1 GENE; BAX GENE	The p53 protein activates promoters containing p53 binding sites, and it represses other promoters. We examined the effect of p53 on bcl-2 expression in both the DHL-4 B cell line and the K562 erythroleukemia line. Transient transfection analyses revealed that wild-type p53 repressed the bcl-2 full-length promoter, The region of the bcl-2 promoter that was responsive to p53 was mapped to the bcl-2 P2 minimal promoter region, and we showed that p53 and the TATA binding protein bound to the bcl-2 TATA sequence. The TATA binding protein, p53, histone deacetylase-1 and mSin3a could be co-immunoprecipitated from K562 cell nuclear extract, The TATA binding protein and mSin3a could be recovered in a complex at the bcl-2 promoter TATA. sequence, however, the formation of this complex was not dependent on the presence of p53. Treatment of K562 cells,vith the histone deacetylase inhibitor, trichostatin ii, resulted in an increase in bcl-2 promoter activity whether p53 was present or not. Therefore, we demonstrated that p53 and the histone deacetylases repress the bcl-2 promoter independently. Similar results were obtained when endogenous bcl-2 mRNA or protein levels were measured in response to either p53 or trichostatin A, and p53 expression resulted in enhanced apoptosis, RNase protection assays demonstrated that transcription from the endogenous 3' bcl-2 promoter was decreased by p53. The regions of p53 that were required for repression of the bcl-2 promoter were defined. We conclude that the TATA sequence in the bcl-2 P2 minimal promoter is the target far repression by p53, and that the interaction between p53 and TBP is most likely responsible for the repression. Mutation of p53 may play a role in the up-regulation of bcl-2 expression in some B cell lymphomas.	Palo Alto Vet Affairs Med Ctr, Ctr Mol Biol Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Boxer, LM (corresponding author), Palo Alto Vet Affairs Med Ctr, Ctr Mol Biol Med, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARRANS S, 1995, BRIT J HAEMATOL, V90, P830, DOI 10.1111/j.1365-2141.1995.tb05203.x; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gotlieb T. M., 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Ilyas M, 1996, J PATHOL, V180, P249; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kramer MHH, 1996, J CLIN ONCOL, V14, P2131, DOI 10.1200/JCO.1996.14.7.2131; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEVINE AJ, 1997, CELL, V88, P232; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Miyazaki N., 1994, HDB MARINE MAMMALS, V5, P1; Moller MB, 1999, MODERN PATHOL, V12, P1010; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nguyen PL, 1996, AM J CLIN PATHOL, V105, P538; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SAID JW, 1992, AM J PATHOL, V141, P1343; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; SOINI Y, 1992, J CLIN PATHOL, V45, P1011, DOI 10.1136/jcp.45.11.1011; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Takano Y, 1997, PATHOL INT, V47, P90, DOI 10.1111/j.1440-1827.1997.tb03726.x; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VILLUENDAS R, 1992, J PATHOL, V166, P235, DOI 10.1002/path.1711660305; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang TTY, 1997, CANCER LETT, V116, P61, DOI 10.1016/S0304-3835(97)00175-4; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; YOSHIDA M, 1990, J BIOL CHEM, V265, P13062; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	59	182	186	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					240	251		10.1038/sj.onc.1204067	http://dx.doi.org/10.1038/sj.onc.1204067			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313951				2022-12-17	WOS:000166410900011
J	Hayashi, H; Ichihara, M; Iwashita, T; Murakami, H; Shimono, Y; Kawai, K; Kurokawa, K; Murakumo, Y; Imai, T; Funahashi, H; Nakao, A; Takahashi, M				Hayashi, H; Ichihara, M; Iwashita, T; Murakami, H; Shimono, Y; Kawai, K; Kurokawa, K; Murakumo, Y; Imai, T; Funahashi, H; Nakao, A; Takahashi, M			Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor	ONCOGENE			English	Article						RET; GDNF; SHC; CREB; NF-kappa B	MICE LACKING GDNF; ENTERIC NERVOUS-SYSTEM; DOCKING SITE; INDEPENDENT MECHANISMS; TRANSDUCTION PATHWAYS; SYMPATHETIC NEURONS; RECEPTOR COMPLEX; KINASE; NEURTURIN; SURVIVAL	Glial cell line derived neurotrophic factor (GDNF) signals through a multicomponent receptor complex consisting of RET receptor tyrosine kinase and a member of GDNF family receptor alpha (GPR alpha). Recently, it was shown that tyrosine 1062 in RET represents a binding site for SHC adaptor proteins and is crucial for both RAS/mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathways. In the present study, we characterized how these two pathways diverge from tyrosine 1062, using human neuroblastoma and primitive neuroectodermal tumor cell lines expressing RET at high levels. In response to GDNF stimulation, SHC bound to GAB1 and GRB2 adaptor proteins as well as RET, and SHC and GAB1 were highly phosphorylated on tyrosine. The complex formation consisting of SHC, GAB1 and GRB2 was almost abolished by replacement of tyrosine 1062 in RET with phenylalanine. Tyrosine-phosphorylated GAB1 was also associated with p85 subunit of PI3-K, resulting in PI3-K and AKT activation, whereas SHC-GRB2-SOS complex was responsible for the RAS/ERK signaling pathway. These results suggested that the RAS and PI3K pathways activated by GDNF bifurcate mainly through SHC bound to tyrosine 1062 in RET. Furthermore, using luciferase reporter-gene assays, we found that the RAS/ERK and PI3-K signaling pathways are important for activation of CREB and NF-kappa B in GDNF-treated cells, respectively.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; Kumi, Kawai/I-6275-2014	Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605; Shimono, Yohei/0000-0002-6256-4704				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Feng L, 1999, NEUROSCIENCE, V93, P265, DOI 10.1016/S0306-4522(99)00129-3; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Heuckeroth RO, 1999, NEURON, V22, P253, DOI 10.1016/S0896-6273(00)81087-9; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 1999, CANCER RES, V59, P1120; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Nishino J, 1999, NEURON, V23, P725, DOI 10.1016/S0896-6273(01)80031-3; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rossi J, 1999, NEURON, V22, P243, DOI 10.1016/S0896-6273(00)81086-7; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Soler RM, 1999, J NEUROSCI, V19, P9160; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909	48	182	188	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4469	4475		10.1038/sj.onc.1203799	http://dx.doi.org/10.1038/sj.onc.1203799			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002419				2022-12-17	WOS:000089236800003
J	FURUTA, Y; ILIC, D; KANAZAWA, S; TAKEDA, N; YAMAMOTO, T; AIZAWA, S				FURUTA, Y; ILIC, D; KANAZAWA, S; TAKEDA, N; YAMAMOTO, T; AIZAWA, S			MESODERMAL DEFECT IN LATE-PHASE OF GASTRULATION BY A TARGETED MUTATION OF FOCAL ADHESION KINASE, FAK	ONCOGENE			English	Article						MUTANT MOUSE; FAK; FOCAL ADHESION; CELL MOBILITY; MESODERM; CELL-EXTRACELLULAR MATRIX INTERACTION	PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; TUMOR-SUPPRESSOR; CELL-ADHESION; MOUSE EMBRYOS; GENE; EXPRESSION; FIBRONECTIN; BETA-1-INTEGRINS; PHOSPHORYLATION	FAK is a unique non-receptor protein tyrosine kinase that was found in cellular focal adhesions. An increasing number of in vitro observations has suggested that FAK mediates signaling through integrins brought about by interactions with extracellular matrix (ECM). It is highly tyrosine-phosphorylated in v-src-transformed cells and during embryogenesis. To clarify the function of FAK in cell-ECM interactions, embryonic phenotype of its mutant was analysed. FAK-deficient embryos could implant and initiate gastrulation normally, but showed abnormalities in. subsequent development. The abnormalities were characterized as a general deficiency in mesoderm, and the phenotype was quite similar to that caused by fibronectin-deficiency. The results suggest that FAK mediates fibronectin-integrin interactions uniquely at this stage of development, thereby playing an essential role in development of mesodermal cell lineages.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	Kumamoto University; University of Tokyo				ILIC, DUSKO/0000-0003-1647-0026				BARRY ST, 1994, J CELL SCI, V107, P2033; BOLEN JB, 1993, ONCOGENE, V8, P2025; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAMSKY C, 1993, FASEB J, V7, P1320, DOI 10.1096/fasebj.7.14.8224605; DRAKE CJ, 1992, DEV DYNAM, V193, P83, DOI 10.1002/aja.1001930111; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GLUKHOVA MA, 1993, SEMIN CANCER BIOL, V4, P241; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; ILIC D, 1995, IN PRESS NATURE; KADOWAKI T, 1994, CANCER RES, V54, P291; KANAZAWA S, 1995, IN PRESS BIOCH BIOPH; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOHMURA N, 1994, MOL CELL BIOL, V14, P6915, DOI 10.1128/MCB.14.10.6915; LINASK KK, 1988, DEV BIOL, V129, P315, DOI 10.1016/0012-1606(88)90378-8; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAKAMURA N, 1993, J CELL SCI, V106, P1057; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; YAGI T, 1994, ANAL BIOCHEM, V214, P70; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	40	182	187	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1989	1995						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478517				2022-12-17	WOS:A1995TF29700008
J	SHEIKH, MS; ROCHEFORT, H; GARCIA, M				SHEIKH, MS; ROCHEFORT, H; GARCIA, M			OVEREXPRESSION OF P21(WAF1/CIP1) INDUCES GROWTH ARREST, GIANT-CELL FORMATION AND APOPTOSIS IN HUMAN BREAST-CARCINOMA CELL-LINES	ONCOGENE			English	Note						TRANSFECTION; APOPTOSIS; GROWTH SUPPRESSION; BREAST CARCINOMA	SUPPRESSION; KINASES	The p21(WAF1/CIP1) protein was shown to be a critical downstream effector of p53 and a potent inhibitor of cyclin-dependent kinases. We investigated the effects of exogenous p21(WAF1/CIP1) in two different human breast carcinoma (HBC) cell lines MCF-7 and T47D, p21(WAF1/CIP1) transfected cells formed significantly reduced number of drug-resistant colonies than their mock-transfected counterparts, The majority of the p21(WAF1/CIP1) transfected MCF-7 cells acquired 50-100-fold increase in their sizes and persisted as single giant cells for several days without cell division, while the remainder underwent nuclear division (multiple nuclei) but were unable to complete cytokinesis, and finally all succumbed to apoptosis, Only few p21(WAF1/CIP1) transfected T47D cells displayed increase in their sizes while a number of them formed small sized drug-resistant colonies which diminished in size due to cell death, The cells in these shrinking colonies exhibited characteristic signs of apoptosis such as chromatin condensation and fragmented nuclei while their membrane integrity was preserved, Thus in HBC cell lines the growth suppression due to enforced overexpression of p21(WAF1/CIP1) is associated with giant cell formation and apoptosis.	UNIV MONTPELLIER 1, FAC MED, F-34090 MONTPELLIER, FRANCE	Universite de Montpellier	SHEIKH, MS (corresponding author), INSERM, U148, 60 RUE NAVACELLES, F-34090 MONTPELLIER, FRANCE.							CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CASEY G, 1991, ONCOGENE, V6, P1791; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Isaacs John T., 1994, Current Opinion in Oncology, V6, P82, DOI 10.1097/00001622-199401000-00012; MIYASHITA T, 1994, ONCOGENE, V9, P1799; REED SI, 1994, J CELL SCI, P69; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VOJTESEK B, 1993, J CELL SCI, V105, P607; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	18	182	187	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1899	1905						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478620				2022-12-17	WOS:A1995TD09400027
J	KEANE, MM; RIVEROLEZCANO, OM; MITCHELL, JA; ROBBINS, KC; LIPKOWITZ, S				KEANE, MM; RIVEROLEZCANO, OM; MITCHELL, JA; ROBBINS, KC; LIPKOWITZ, S			CLONING AND CHARACTERIZATION OF CBL-B - A SH3 BINDING-PROTEIN WITH HOMOLOGY TO THE C-CBL PROTOONCOGENE	ONCOGENE			English	Article						CBL-B; SK3 PROTEIN INTERACTIONS; MAMMARY CELLS; DIFFERENTIATION	ACUTE PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA; DNA-BINDING; ZINC FINGER; V-CBL; SACCHAROMYCES-CEREVISIAE; POINT MUTATIONS; RAR-ALPHA; GENE; SEQUENCE	We have cloned a new gene, cbl-b, with homology to the c-cbl proto-oncogene. A large protein is predicted (approx, MW 108 000) that has a proline rich domain, a nuclear localization signal, a C3HC4 zinc finger and a putative leucine zipper. There is striking nucleotide and amino acid homology to the c-cbl proto-oncogene most notably in the structural motifs described above. Cbl-b is expressed in normal and malignant mammary epithelial cells, in a variety of normal tissues, and in hematopoietic tissue and cell lines. Cbl-b expressions is up-regulated with macrophage/monocyte differentiation of the HL60 and U937 cell lines, There is direct association of the cbl-b protein with the Src Homology 3 domains of several proteins including signaling, cytoskeletal and adaptor proteins. Our data suggest that cbl-b encodes a protein which can interact with signal transduction proteins to regulate their function or to be regulated by them, Together, cbl-b and c-cbl are members of a novel family of proto-oncogenes involved in signal transduction.	USN HOSP,NCI,MED ONCOL BRANCH,BETHESDA,MD 20889; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Rivero-Lezcano, Octavio Miguel/J-9089-2015	Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Battey, 1986, BASIC METHODS MOL BI; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Langdon W Y, 1992, Curr Top Microbiol Immunol, V182, P467; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAWRENCE JB, 1988, CELL, V52, P51; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	43	182	189	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2367	2377						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784085				2022-12-17	WOS:A1995RE54300012
J	MOREAUGACHELIN, F; RAY, D; MATTEI, MG; TAMBOURIN, P; TAVITIAN, A				MOREAUGACHELIN, F; RAY, D; MATTEI, MG; TAMBOURIN, P; TAVITIAN, A			THE PUTATIVE ONCOGENE SPI-1 - MURINE CHROMOSOMAL LOCALIZATION AND TRANSCRIPTIONAL ACTIVATION IN MURINE ACUTE ERYTHROLEUKEMIAS	ONCOGENE			English	Article									HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE,FRANCE; HOP COCHIN,INSERM,U152,F-75674 PARIS 14,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	MOREAUGACHELIN, F (corresponding author), FAC MED LARIBOISIERE,INSERM,U248,10 AVE VERDUN,F-75010 PARIS,FRANCE.		Ray-Gallet, Dominique/A-9224-2019					BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BENOIST C, 1980, NUCLEIC ACIDS RES, V8, P127, DOI 10.1093/nar/8.1.127; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5298; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LINEMEYER DL, 1982, J VIROL, V43, P223, DOI 10.1128/JVI.43.1.223-233.1982; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MOREAUGACHELIN F, 1981, J NATL CANCER I, V66, P1121, DOI 10.1093/jnci/66.6.1121; MOREAUGACHELIN F, 1985, J VIROL, V53, P292, DOI 10.1128/JVI.53.1.292-295.1985; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; RAY D, 1987, MOL CELL BIOL, V7, P940, DOI 10.1128/MCB.7.2.940; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBERTLEZENES J, 1984, LEUKEMIA RES, V8, P975, DOI 10.1016/0145-2126(84)90051-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SPIRO C, 1988, J VIROL, V62, P4129, DOI 10.1128/JVI.62.11.4129-4135.1988; TAMBOURIN P, 1971, NATURE-NEW BIOL, V234, P230, DOI 10.1038/newbio234230a0; TAMBOURIN P, 1981, BLOOD CELLS, V7, P133; TROXLER DH, 1977, P NATL ACAD SCI USA, V74, P4671, DOI 10.1073/pnas.74.10.4671; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WOLFF L, 1986, VIROLOGY, V152, P272, DOI 10.1016/0042-6822(86)90393-4; YAMAMOTO Y, 1981, P NATL ACAD SCI-BIOL, V78, P6893, DOI 10.1073/pnas.78.11.6893	38	182	183	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1449	1456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2594367				2022-12-17	WOS:A1989CB65900005
J	Boll, K; Reiche, K; Kasack, K; Morbt, N; Kretzschmar, AK; Tomm, JM; Verhaegh, G; Schalken, J; von Bergen, M; Horn, F; Hackermuller, J				Boll, K.; Reiche, K.; Kasack, K.; Moerbt, N.; Kretzschmar, A. K.; Tomm, J. M.; Verhaegh, G.; Schalken, J.; von Bergen, M.; Horn, F.; Hackermueller, J.			MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma	ONCOGENE			English	Article						microRNAs; prostate carcinoma; androgen receptor signaling; MAPK pathway; microRNA targets	ANDROGEN RECEPTOR; MICRORNA EXPRESSION; TRANSCRIPTIONAL ACTIVITY; CANCER CELLS; GROWTH; IDENTIFICATION; PROLIFERATION; PROGRESSION; COACTIVATOR; INVASION	With similar to 30 000 deaths annually in the United States, prostate cancer (PCa) is a major oncologic disease. Here we show that the microRNAs miR-130a, miR-203 and miR-205 jointly interfere with the two major oncogenic pathways in prostate carcinoma and are downregulated in cancer tissue. Using transcriptomics we show that the microRNAs repress several gene products known to be overexpressed in this cancer. Argonaute 2 (AGO2) co-immunoprecipitation, reporter assays and western blot analysis demonstrate that the microRNAs directly target several components of the mitogen-activated protein kinase (MAPK) and androgen receptor (AR) signaling pathways, among those several AR coregulators and HRAS (Harvey rat sarcoma viral oncogene homolog), and repress signaling activity. Both pathways are central for the development of the primary tumor and in particular the progression to its incurable castration-resistant form. Reconstitution of the microRNAs in LNCaP PCa cells induce morphological changes, which resemble the effect of androgen deprivation, and jointly impair tumor cell growth by induction of apoptosis and cell cycle arrest. We therefore propose that these microRNAs jointly act as tumor suppressors in prostate carcinoma and might interfere with progression to castration resistance. Oncogene (2013) 32, 277-285; doi:10.1038/onc.2012.55; published online 5 March 2012	[Boll, K.; Reiche, K.; Kasack, K.; Kretzschmar, A. K.; Horn, F.; Hackermueller, J.] Fraunhofer IZI, RNom Grp, Leipzig, Germany; [Boll, K.; Kasack, K.; Horn, F.] Univ Leipzig, Inst Clin Immunol, D-04109 Leipzig, Germany; [Reiche, K.; Kasack, K.; Hackermueller, J.] UFZ Helmholtz Ctr Environm Res, Young Investigators Grp Bioinformat & Transcript, D-04318 Leipzig, Saxony, Germany; [Kasack, K.] Univ Leipzig, LIFE Leipzig Res Ctr Civilizat Dis, D-04109 Leipzig, Germany; [Moerbt, N.; Tomm, J. M.; von Bergen, M.; Hackermueller, J.] UFZ Helmholtz Ctr Environm Res, Dept Prote, D-04318 Leipzig, Saxony, Germany; [Verhaegh, G.; Schalken, J.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, NL-6525 ED Nijmegen, Netherlands; [von Bergen, M.] UFZ Helmholtz Ctr Environm Res, Dept Metabol, D-04318 Leipzig, Saxony, Germany; [Reiche, K.; Hackermueller, J.] Univ Leipzig, Dept Comp Sci, Bioinformat Grp, D-04109 Leipzig, Germany	Fraunhofer Gesellschaft; Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Radboud University Nijmegen; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University	Hackermuller, J (corresponding author), UFZ Helmholtz Ctr Environm Res, Young Investigators Grp Bioinformat & Transcript, Permoserstr 15, D-04318 Leipzig, Saxony, Germany.	joerg.hackermueller@ufz.de	Verhaegh, Gerald/L-4708-2015; Hackermüller, Jörg/F-2494-2016; Schalken, Jack A/B-1277-2014; von Bergen, Martin/D-7960-2011; Tomm, Janina M/F-8888-2014	Verhaegh, Gerald/0000-0003-0227-2280; Hackermüller, Jörg/0000-0003-4920-7072; Schalken, Jack A/0000-0001-8274-7797; von Bergen, Martin/0000-0003-2732-2977; Tomm, Janina M/0000-0001-8161-1812; Reiche, Kristin/0000-0002-4452-4872	Medical Faculty of the University of Leipzig through funding of the Interdisciplinary Center for Clinical Research; grant 'Sequence and functional analysis of non-coding RNA in prostate carcinoma' [formel.1]; European Framework Programme 6 Project SYNLET [043312]; Initiative and Networking Fund one of the Helmholtz Association [VH-NG-738]; LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig; European Social Fund; Free State of Saxony	Medical Faculty of the University of Leipzig through funding of the Interdisciplinary Center for Clinical Research; grant 'Sequence and functional analysis of non-coding RNA in prostate carcinoma'; European Framework Programme 6 Project SYNLET; Initiative and Networking Fund one of the Helmholtz Association; LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig; European Social Fund(European Social Fund (ESF)); Free State of Saxony	We thank Stephan Schreiber, Anne-Sophie Krakovic, Yvonne Kullnick, Sabina Christ, Kathrin Jager, Rudolf Ascherl and Christine Schumann for technical assistance and Catherine Davis for proof-reading. We thank Gunter Meister and colleagues for providing AGO2 antibodies. This work was supported in part by the Medical Faculty of the University of Leipzig through funding of the Interdisciplinary Center for Clinical Research and a formel.1 grant 'Sequence and functional analysis of non-coding RNA in prostate carcinoma', the European Framework Programme 6 Project SYNLET (EC contract number 043312), by the Initiative and Networking Fund one of the Helmholtz Association (VH-NG-738) and by LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig, which was funded by means of the European Social Fund and the Free State of Saxony.	Acevedo VD, 2009, CELL CYCLE, V8, P580, DOI 10.4161/cc.8.4.7657; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beitzinger M, 2007, RNA BIOL, V4, P76, DOI 10.4161/rna.4.2.4640; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Epis MR, 2009, J BIOL CHEM, V284, P24696, DOI 10.1074/jbc.M109.030098; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gandellini P, 2009, TRENDS MOL MED, V15, P381, DOI 10.1016/j.molmed.2009.07.004; Gavrielides MV, 2006, CANCER RES, V66, P11792, DOI 10.1158/0008-5472.CAN-06-1139; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Harada N, 2008, BIOCHEM BIOPH RES CO, V373, P373, DOI 10.1016/j.bbrc.2008.06.024; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Koochekpour S, 2005, ASIAN J ANDROL, V7, P147, DOI 10.1111/j.1745-7262.2005.00037.x; Koochekpour S, 2007, PROSTATE, V67, P178, DOI 10.1002/pros.20513; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee TJ, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-31; Majid S, 2010, CANCER-AM CANCER SOC, V116, P5637, DOI 10.1002/cncr.25488; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Mize GJ, 2008, MOL CANCER RES, V6, P1043, DOI 10.1158/1541-7786.MCR-08-0096; Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Papatsoris AG, 2007, MOL CANCER THER, V6, P811, DOI 10.1158/1535-7163.MCT-06-0610; Park JJ, 2000, CANCER RES, V60, P5946; Pitkanen-Arsiola T, 2006, PROSTATE, V66, P1177, DOI 10.1002/pros.20450; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Rajan P, 2008, J PATHOL, V215, P67, DOI 10.1002/path.2324; Saeed B, 1997, PROSTATE, V31, P145; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Satoh T, 2009, ENDOCRINOLOGY, V150, P3283, DOI 10.1210/en.2008-1122; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Sikand K, 2011, INT J CANCER, V129, P810, DOI 10.1002/ijc.25753; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Tillman JE, 2007, CANCER RES, V67, P4630, DOI 10.1158/0008-5472.CAN-06-4556; Truica CI, 2000, CANCER RES, V60, P4709; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Wang JG, 2006, FASEB J, V20, P2142, DOI 10.1096/fj.06-5900fje; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; Weber MJ, 2004, J CELL BIOCHEM, V91, P13, DOI 10.1002/jcb.10683; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	54	181	186	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					277	285		10.1038/onc.2012.55	http://dx.doi.org/10.1038/onc.2012.55			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391564				2022-12-17	WOS:000314736600002
J	Mizuno, T; Murakami, H; Fujii, M; Ishiguro, F; Tanaka, I; Kondo, Y; Akatsuka, S; Toyokuni, S; Yokoi, K; Osada, H; Sekido, Y				Mizuno, T.; Murakami, H.; Fujii, M.; Ishiguro, F.; Tanaka, I.; Kondo, Y.; Akatsuka, S.; Toyokuni, S.; Yokoi, K.; Osada, H.; Sekido, Y.			YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes	ONCOGENE			English	Article						malignant mesothelioma; Hippo pathway; YAP; CCND1; cell cycle	YES-ASSOCIATED PROTEIN; PATHWAY; DROSOPHILA; MUTATIONS; MERLIN; NF2; PROGRESSION; COMPONENTS; APOPTOSIS; MARKER	Malignant mesothelioma (MM) shows frequent inactivation of the neurofibromatosis type 2 (NF2) -tumor-suppressor gene. Recent studies have documented that the Hippo signaling pathway, a downstream cascade of Merlin (a product of NF2), has a key role in organ size control and carcinogenesis by regulating cell proliferation and apoptosis. We previously reported that MMs show overexpression of Yes-associated protein (YAP) transcriptional coactivator, the main downstream effector of the Hippo signaling pathway, which results from the inactivation of NF2, LATS2 and/or SAV1 genes (the latter two encoding core components of the mammalian Hippo pathway) or amplification of YAP itself. However, the detailed roles of YAP remain unclear, especially the target genes of YAP that enhance MM cell growth and survival. Here, we demonstrated that YAP-knockdown inhibited cell motility, invasion and anchorage-independent growth as well as cell proliferation of MM cells in vitro. We analyzed genes commonly regulated by YAP in three MM cell lines with constitutive YAP-activation, and found that the major subsets of YAP-upregulating genes encode cell cycle regulators. Among them, YAP directly induced the transcription of CCND1 and FOXM1, in cooperation with TEAD transcription factor. We also found that knockdown of CCND1 and FOXM1 suppressed MM cell proliferation, although the inhibitory effects were less evident than those of YAP knockdown. These results indicate that constitutive YAP activation in MM cells promotes cell cycle progression giving more aggressive phenotypes to MM cells. Oncogene (2012) 31, 5117-5122; doi:10.1038/onc.2012.5; published online 30 January 2012	[Sekido, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; [Mizuno, T.; Ishiguro, F.; Yokoi, K.] Nagoya Univ, Grad Sch Med, Dept Thorac Surg, Nagoya, Aichi 4648601, Japan; [Akatsuka, S.; Toyokuni, S.] Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Nagoya, Aichi 4648601, Japan; [Osada, H.; Sekido, Y.] Nagoya Univ, Grad Sch Med, Program Funct Construct Med, Dept Canc Genet, Nagoya, Aichi 4648601, Japan	Aichi Cancer Center; Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Kanokoden 1-1, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp	Sekido, Yoshitaka/P-9756-2015; Toyokuni, Shinya/ABE-7714-2021; Yokoi, Kohei/I-7261-2014; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Sekido, Yoshitaka/0000-0002-2428-3848	Special Coordination Fund for Promoting Science and Technology from Ministry of Education, Culture, Sports, Science and Technology of Japan [H18-1-3-3-1]; KAKENHI [18390245, 22300338]; Ministry of Health, Labor and Welfare of Japan; Takeda Science Foundation; Kobayashi Foundation for Cancer Research; Grants-in-Aid for Scientific Research [23501281] Funding Source: KAKEN	Special Coordination Fund for Promoting Science and Technology from Ministry of Education, Culture, Sports, Science and Technology of Japan; KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms Mika Yamamoto for her excellent technical assistance. This work was supported in part by a Special Coordination Fund for Promoting Science and Technology from the Ministry of Education, Culture, Sports, Science and Technology of Japan (H18-1-3-3-1), KAKENHI (18390245, 22300338), Grant-in-Aid for Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labor and Welfare of Japan, the Takeda Science Foundation and the Kobayashi Foundation for Cancer Research.	Anbanandam A, 2006, P NATL ACAD SCI USA, V103, P17225, DOI 10.1073/pnas.0607171103; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Cao XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Illei PB, 2003, CANCER CYTOPATHOL, V99, P51, DOI 10.1002/cncr.10923; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Nishioka N, 2009, DEV CELL, V16, P398, DOI 10.1016/j.devcel.2009.02.003; Pass HI, 2004, CURR PROB CANCER, V28, P85; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2011, PATHOL INT, V61, P331, DOI 10.1111/j.1440-1827.2011.02666.x; Sekido Y, 2010, CANCER SCI, V101, P1, DOI 10.1111/j.1349-7006.2009.01336.x; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	35	181	186	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5117	5122		10.1038/onc.2012.5	http://dx.doi.org/10.1038/onc.2012.5			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286761				2022-12-17	WOS:000312000900008
J	Lee, C; Longo, VD				Lee, C.; Longo, V. D.			Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients	ONCOGENE			English	Review						fasting; dietary restriction; chemotherapy; differential stress resistance; starvation	GROWTH-FACTOR-I; LIFE-SPAN EXTENSION; CALORIC RESTRICTION; STRESS RESISTANCE; OXIDATIVE STRESS; IGF-I; PROLONGED STARVATION; INSULIN SENSITIVITY; ENERGY RESTRICTION; PROTEIN-METABOLISM	The dietary recommendation for cancer patients receiving chemotherapy, as described by the American Cancer Society, is to increase calorie and protein intake. Yet, in simple organisms, mice, and humans, fasting-no calorie intake-induces a wide range of changes associated with cellular protection, which would be difficult to achieve even with a cocktail of potent drugs. In mammals, the protective effect of fasting is mediated, in part, by an over 50% reduction in glucose and insulin-like growth factor 1 (IGF-I) levels. Because proto-oncogenes function as key negative regulators of the protective changes induced by fasting, cells expressing oncogenes, and therefore the great majority of cancer cells, should not respond to the protective signals generated by fasting, promoting the differential protection (differential stress resistance) of normal and cancer cells. Preliminary reports indicate that fasting for up to 5 days followed by a normal diet, may also protect patients against chemotherapy without causing chronic weight loss. By contrast, the long-term 20 to 40% restriction in calorie intake (dietary restriction, DR), whose effects on cancer progression have been studied extensively for decades, requires weeks-months to be effective, causes much more modest changes in glucose and/or IGF-I levels, and promotes chronic weight loss in both rodents and humans. In this study, we review the basic as well as clinical studies on fasting, cellular protection and chemotherapy resistance, and compare them to those on DR and cancer treatment. Although additional pre-clinical and clinical studies are necessary, fasting has the potential to be translated into effective clinical interventions for the protection of patients and the improvement of therapeutic index. Oncogene (2011) 30, 3305-3316; doi:10.1038/onc.2011.91; published online 25 April 2011	[Longo, V. D.] Univ So Calif, Andrus Gerontol Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA; [Longo, V. D.] Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Longo, VD (corresponding author), Univ So Calif, Andrus Gerontol Ctr, Dept Biol Sci, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	vlongo@usc.edu						Al-Regaiey KA, 2007, J GERONTOL A-BIOL, V62, P18, DOI 10.1093/gerona/62.1.18; Alberts B., 2002, MOL BIOL CELL, V4th; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Bartke A, 2001, J ANTI-AGING MED, V4, P197, DOI 10.1089/109454501753249966; BLOOM WL, 1959, METABOLISM, V8, P214; Bonkowski MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004567; Bonorden MJL, 2009, NUTR CANCER, V61, P265, DOI 10.1080/01635580802419798; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; Brown-Borg HM, 2000, EXP GERONTOL, V35, P199, DOI 10.1016/S0531-5565(00)00079-6; Brown-Borg HM, 2002, EXP BIOL MED, V227, P94, DOI 10.1177/153537020222700203; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Buschemeyer WC, 2010, PROSTATE, V70, P1037, DOI 10.1002/pros.21136; Cahill G F Jr, 1970, N Engl J Med, V282, P668, DOI 10.1056/NEJM197003052821026; Cahill G J Jr, 1968, Adv Enzyme Regul, V6, P143, DOI 10.1016/0065-2571(68)90011-3; Cahill G Jr, 1970, Nord Med, V83, P89; Cahill GF, 2006, ANNU REV NUTR, V26, P1, DOI 10.1146/annurev.nutr.26.061505.111258; CAHILL GF, 1966, J CLIN INVEST, V45, P1751, DOI 10.1172/JCI105481; CAHILL GF, 1968, T AM CLIN CLIMAT ASS, V79, P13; Campisi J, 2009, J GERONTOL A-BIOL, V64, P175, DOI 10.1093/gerona/gln065; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chen Y, 2007, MOL INTERV, V7, P147, DOI 10.1124/mi.7.3.6; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; CUBBERLEY PT, 1965, NEW ENGL J MED, V272, P628, DOI 10.1056/NEJM196503252721208; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Doyle C, 2006, CA-CANCER J CLIN, V56, P323, DOI 10.3322/canjclin.56.6.323; DRENICK EJ, 1964, JAMA-J AM MED ASSOC, V187, P100; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Dunn SE, 1997, CANCER RES, V57, P4667; Escriva F, 2007, J ENDOCRINOL, V194, P131, DOI 10.1677/joe.1.07043; FABER M, 1995, BIOL TRACE ELEM RES, V47, P117, DOI 10.1007/BF02790108; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2003, GENETICS, V163, P35; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fearon KCH, 2003, GUT, V52, P1479, DOI 10.1136/gut.52.10.1479; Felgines C, 1999, JPEN-PARENTER ENTER, V23, P32, DOI 10.1177/014860719902300132; FILAIRE E, 2004, J EXERC PHYSIOLOGYON, V7, P8; Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x; Fontana L, 2006, AM J CLIN NUTR, V84, P1456, DOI 10.1093/ajcn/84.6.1456; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Fox KM, 2009, J ONCOL, V2009, DOI 10.1155/2009/693458; Frystyk J, 1999, AM J PHYSIOL-ENDOC M, V277, pE245, DOI 10.1152/ajpendo.1999.277.2.E245; GARNETT ES, 1969, LANCET, V1, P914; Giannakou ME, 2007, TRENDS BIOCHEM SCI, V32, P180, DOI 10.1016/j.tibs.2007.02.007; GO KG, 1988, METAB BRAIN DIS, V3, P257, DOI 10.1007/BF00999535; Goldhamer A, 2001, J MANIP PHYSIOL THER, V24, P335, DOI 10.1067/mmt.2001.115263; Goldhamer AC, 2002, J ALTERN COMPLEM MED, V8, P696, DOI 10.1089/10755530260511694; GOODRICK CL, 1983, J GERONTOL, V38, P36, DOI 10.1093/geronj/38.1.36; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heijboer AC, 2005, J LIPID RES, V46, P582, DOI 10.1194/jlr.M400440-JLR200; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Henis-Korenblit S, 2010, P NATL ACAD SCI USA, V107, P9730, DOI 10.1073/pnas.1002575107; HOLEHAN AM, 1985, MECH AGEING DEV, V33, P19, DOI 10.1016/0047-6374(85)90106-X; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honjoh S, 2009, NATURE, V457, P726, DOI 10.1038/nature07583; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; ISLEY WL, 1983, J CLIN INVEST, V71, P175, DOI 10.1172/JCI110757; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Johnstone AM, 2007, OBES REV, V8, P211, DOI 10.1111/j.1467-789X.2006.00266.x; Jones RA, 2010, ONCOGENE, V29, P4779, DOI 10.1038/onc.2010.231; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kalm LM, 2005, J NUTR, V135, P1347, DOI 10.1093/jn/135.6.1347; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KERNDT PR, 1982, WESTERN J MED, V137, P379; Kim SK, 1996, HEMATOL ONCOL CLIN N, V10, P377, DOI 10.1016/S0889-8588(05)70344-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOIZUMI A, 1992, J NUTR, V122, P1446, DOI 10.1093/jn/122.7.1446; Kristan DM, 2008, AGE, V30, P147, DOI 10.1007/s11357-008-9056-1; Kritchevsky D, 2001, J NUTR SCI VITAMINOL, V47, P13, DOI 10.3177/jnsv.47.13; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008-5472.CAN-09-3228; Lee SJ, 2009, CELL METAB, V10, P379, DOI 10.1016/j.cmet.2009.10.003; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Links M, 1999, DRUGS, V57, P293, DOI 10.2165/00003495-199957030-00003; Locher C, 2010, ANN NY ACAD SCI, V1209, P99, DOI 10.1111/j.1749-6632.2010.05763.x; Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Longo VD, 1999, NEUROBIOL AGING, V20, P479, DOI 10.1016/S0197-4580(99)00089-5; LOOK MP, 1994, CHEMOTHERAPY, V40, P8, DOI 10.1159/000239163; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma YT, 2010, SEMIN IMMUNOL, V22, P113, DOI 10.1016/j.smim.2010.03.001; Maccario M, 2001, INT J OBESITY, V25, P1233, DOI 10.1038/sj.ijo.0801671; Madia F, 2008, J CELL BIOL, V180, P67, DOI 10.1083/jcb.200707154; Madia F, 2009, J CELL BIOL, V186, P509, DOI 10.1083/jcb.200906011; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; Marino G, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3124pe19; MCCLURE TJ, 1959, J PHYSIOL-LONDON, V147, P221, DOI 10.1113/jphysiol.1959.sp006237; McColl G, 2010, CELL METAB, V12, P260, DOI 10.1016/j.cmet.2010.08.004; McDougald D, 2002, ANTON LEEUW INT J G, V81, P3, DOI 10.1023/A:1020540503200; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MENAHAN LA, 1983, COMP BIOCHEM PHYS B, V74, P859, DOI 10.1016/0305-0491(83)90157-8; MERIMEE TJ, 1982, J CLIN ENDOCR METAB, V55, P999, DOI 10.1210/jcem-55-5-999; MERIMEE TJ, 1974, J CLIN ENDOCR METAB, V39, P385, DOI 10.1210/jcem-39-2-385; Michalsen A, 2005, J ALTERN COMPLEM MED, V11, P601, DOI 10.1089/acm.2005.11.601; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Moller N, 2009, ENDOCR REV, V30, P152, DOI 10.1210/er.2008-0027; Moreschi C., 1909, ZIMMUNITATSFORSCH, V2, P651; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Morselli E, 2009, AGING-US, V1, P961, DOI 10.18632/aging.100110; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; Muller EE, 1999, PHYSIOL REV, V79, P511, DOI 10.1152/physrev.1999.79.2.511; Murakami S, 2006, EXP GERONTOL, V41, P1014, DOI 10.1016/j.exger.2006.06.061; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; Norrelund H, 2005, GROWTH HORM IGF RES, V15, P95, DOI 10.1016/j.ghir.2005.02.005; PALMBLAD J, 1977, ACTA MED SCAND, V201, P15; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Racette SB, 2006, J GERONTOL A-BIOL, V61, P943, DOI 10.1093/gerona/61.9.943; Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105; Reed MJ, 1996, MECH AGEING DEV, V89, P21, DOI 10.1016/0047-6374(96)01737-X; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; Ruckenstuhl C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004592; RUNCIE J, 1970, BRIT MED J, V3, P432, DOI 10.1136/bmj.3.5720.432; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; Safdie FM, 2009, AGING-US, V1, P988, DOI 10.18632/aging.100114; Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004; SANGEETHA P, 1990, PROSTAG LEUKOTR ESS, V39, P27, DOI 10.1016/0952-3278(90)90167-J; Sans MD, 2004, AM J PHYSIOL-GASTR L, V287, pG667, DOI 10.1152/ajpgi.00505.2003; SAUDEK CD, 1976, AM J MED, V60, P117, DOI 10.1016/0002-9343(76)90540-4; SCRIMSHAW NS, 1987, ANNU REV NUTR, V7, P1, DOI 10.1146/annurev.nu.07.070187.000245; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; Sharma HS, 2000, AMINO ACIDS, V19, P351, DOI 10.1007/s007260070066; Shelton LM, 2010, ASN NEURO, V2, DOI 10.1042/AN20100002; Shen JW, 2009, CELL IMMUNOL, V259, P66, DOI 10.1016/j.cellimm.2009.05.015; Shimokawa I, 2003, FASEB J, V17, P1108, DOI 10.1096/fj.02-0819fje; SPENCER IOB, 1968, LANCET, V2, P679; SPINDLER SR, 1990, J NUTR, V120, P1412, DOI 10.1093/jn/120.11.1412; Takenaka A, 2000, J NUTR, V130, P2910, DOI 10.1093/jn/130.12.2910; TANNENBAUM A, 1945, CANCER RES, V5, P616; TANNENBAUM GS, 1979, ENDOCRINOLOGY, V104, P1733, DOI 10.1210/endo-104-6-1733; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thissen JP, 1999, NUTR REV, V57, P167, DOI 10.1111/j.1753-4887.1999.tb06939.x; THOMSON TJ, 1966, LANCET, V2, P992; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; UNGER RH, 1963, J CLIN INVEST, V42, P1031, DOI 10.1172/JCI104788; van Ginhoven TM, 2009, LIVER TRANSPLANT, V15, P1183, DOI 10.1002/lt.21871; vandenBerghe G, 1996, J INHERIT METAB DIS, V19, P470, DOI 10.1007/BF01799108; Varady KA, 2007, AM J CLIN NUTR, V86, P7, DOI 10.1093/ajcn/86.1.7; Vaughn AE, 2008, NAT CELL BIOL, V10, P1477, DOI 10.1038/ncb1807; Vigne P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005422; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang T, 2006, ANNU REV PHYSIOL, V68, P223, DOI 10.1146/annurev.physiol.68.040104.105739; Wedding U, 2007, J CANCER RES CLIN, V133, P945, DOI 10.1007/s00432-007-0233-x; Wei M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040013; Wei M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000467; WEINDRUCH R, 1982, P NATL ACAD SCI-BIOL, V79, P898, DOI 10.1073/pnas.79.3.898; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Weinkove D, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-1; Xie LL, 2007, J BIOL CHEM, V282, P28025, DOI 10.1074/jbc.M604857200; Yan L, 2007, CELL, V130, P247, DOI 10.1016/j.cell.2007.05.038; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; ZAPF J, 1995, EUR J ENDOCRINOL, V132, P645, DOI 10.1530/eje.0.1320645; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107	175	181	195	1	64	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3305	3316		10.1038/onc.2011.91	http://dx.doi.org/10.1038/onc.2011.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21516129				2022-12-17	WOS:000293215700001
J	Zhao, YH; Zhou, M; Liu, H; Ding, Y; Khong, HT; Yu, D; Fodstad, O; Tan, M				Zhao, Y. H.; Zhou, M.; Liu, H.; Ding, Y.; Khong, H. T.; Yu, D.; Fodstad, O.; Tan, M.			Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth	ONCOGENE			English	Article						ErbB2; HSF1; LDH-A; glycolysis; Warburg effect; breast cancer	DNA-BINDING; FACTOR-I; ACTIVATION; METABOLISM; EXPRESSION; TRANSCRIPTION; WARBURG; HYPOXIA; OVEREXPRESSION; DEREGULATION	ErbB2 has been shown to activate signaling molecules that may regulate glucose metabolism. However, there is no evidence reported to directly link ErbB2 to glycolysis, and the mechanism underlying ErbB2-enhanced glycolysis is poorly understood. In this study, we investigated the role and mechanism of ErbB2 in regulating glycolysis. We found that ErbB2-overexpressing cells possessed a significantly higher level of glycolysis when compared to the ErbB2-low-expressing cells, and the downregulation of ErbB2 markedly decreased glycolysis. Overexpression of ErbB2 increased the expression of glycolysis-regulating molecules lactate dehydrogenase A (LDH-A) and heat shock factor 1 (HSF1). ErbB2 activated HSF1, indicated by the increased HSF1 trimer formation, and promoted HSF1 protein synthesis. HSF1 bound to LDH-A promoter and the downregulation of HSF1 reduced the expression of LDH-A and subsequently decreased cancer cell glycolysis and growth. Moreover, the glycolysis inhibitors, 2-deoxyglucose and oxamate, selectively inhibited the growth of ErbB2-overexpressing cells. Taken together, this study shows that in human breast cancer cells, ErbB2 promotes glycolysis at least partially through the HSF1-mediated upregulation of LDH-A. This pathway may have a major role in regulating glucose metabolism in breast cancer cells. These novel findings have important implications for the design of new approaches to target ErbB2-overexpressing breast cancers. Oncogene (2009) 28, 3689-3701; doi: 10.1038/onc.2009.229; published online 10 August 2009	[Tan, M.] Univ S Alabama, Mitchell Canc Inst, Ctr Basic & Translat Canc Res, Mobile, AL 36604 USA; [Zhao, Y. H.] Sichuan Univ, W China Med Ctr, Dept Biochem & Mol Biol, Chengdu 610064, Peoples R China; [Yu, D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Fodstad, O.] Univ Oslo, Norwegian Radium Hosp, Inst Canc Res, Oslo, Norway; [Tan, M.] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36604 USA	University of South Alabama; Sichuan University; University of Texas System; UTMD Anderson Cancer Center; University of Oslo; University of South Alabama	Tan, M (corresponding author), Univ S Alabama, Mitchell Canc Inst, Ctr Basic & Translat Canc Res, 1660 Spring Hill Ave, Mobile, AL 36604 USA.	mtan@usouthal.edu	Tan, Ming/ABD-5847-2021; Zhao, Yuhua/H-3210-2013	Tan, Ming/0000-0003-2007-9898; Zhao, Yuhua/0000-0002-4060-631X; Yu, Dihua/0000-0001-6231-9381	Jr. Cancer Research Foundation (M Tan) [334003]	Jr. Cancer Research Foundation (M Tan)	We thank Dr Ivor Benjamin for the HSF1 MEFs; Dr Jianrong Lu, Dr Adam Riker and Dr Laurie Owen for reading the article; Ms Amy Brown for editorial assistance; Dr June Ayling, Dr Robert Laush and Ms Judy Miller for assistance with equipments. We are grateful for the support from The Vincent F Kilborn, Jr. Cancer Research Foundation (M Tan) and from the Radiumhospitalets Legater Award Project 334003 (M Tan and O Fodstad).	BALINSKY D, 1983, CANCER RES, V43, P5895; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Gatenby RA, 2007, INT J BIOCHEM CELL B, V39, P1358, DOI 10.1016/j.biocel.2007.03.021; Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li YM, 2005, CANCER RES, V65, P3257, DOI 10.1158/0008-5472.CAN-04-1284; Liu HY, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-111; Lu J, 2009, CLIN CANCER RES, V15, P1326, DOI 10.1158/1078-0432.CCR-08-0954; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Nguyen T, 2008, J BIOL CHEM, V283, P29831, DOI 10.1074/jbc.M801642200; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361; Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan M, 1997, CANCER RES, V57, P1199; Wadekar SA, 2004, MOL ENDOCRINOL, V18, P500, DOI 10.1210/me.2003-0215; WARBURG O, 1956, SCIENCE, V124, P269; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	39	181	194	5	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3689	3701		10.1038/onc.2009.229	http://dx.doi.org/10.1038/onc.2009.229			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668225				2022-12-17	WOS:000271023200002
J	Katsuno, Y; Hanyu, A; Kanda, H; Ishikawa, Y; Akiyama, F; Iwase, T; Ogata, E; Ehata, S; Miyazono, K; Imamura, T				Katsuno, Y.; Hanyu, A.; Kanda, H.; Ishikawa, Y.; Akiyama, F.; Iwase, T.; Ogata, E.; Ehata, S.; Miyazono, K.; Imamura, T.			Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway	ONCOGENE			English	Article						TGF-beta; BMP; breast cancer; metastasis; invasion	TUMOR-SUPPRESSOR; BETA; GROWTH; EXPRESSION; OVEREXPRESSION; PROGRESSION; TRANSITION; MEMBRANE; MELANOMA; SKI	Transforming growth factor (TGF)-beta is known to promote tumor invasion and metastasis. Although bone morphogenetic proteins ( BMPs), members of the TGF-beta family, are expressed in a variety of human carcinoma cell lines, their roles in tumor progression have not been fully clarified. In this study, we sought to determine the roles of BMPs in the progression of breast cancer bone metastasis using human breast cancer samples and a mouse xenograft model. Immunohistochemical analysis of samples from breast cancer patients as well as a mouse xenograft model of MDA-231-D, highly metastatic human breast cancer cells, revealed phospho-Smad2 and phospho-Smad1/5/8 staining in the nuclei of cancer cells in primary tumor and/or bone metastasis. Using a functional in vivo bioluminescence imaging system, we showed that TGF-beta- and BMP-induced transcriptional pathways are active in bone metastatic lesions in vivo. In addition, both TGF-beta 3 and BMP-2 promoted the motility and invasiveness of the MDA-231-D cells in vitro. Moreover, expression of dominant-negative receptors for TGF-beta and/or BMPs in the MDA-231-D cells inhibited invasiveness in vitro and bone metastasis in the xenograft model. These results suggest that BMPs as well as TGF-beta promote invasion and bone metastasis of breast cancer.	[Katsuno, Y.; Hanyu, A.; Miyazono, K.; Imamura, T.] Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Koto Ku, Tokyo 1358550, Japan; [Katsuno, Y.; Ehata, S.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo, Japan; [Kanda, H.; Ishikawa, Y.; Akiyama, F.] Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Koto Ku, Tokyo 1358550, Japan; [Iwase, T.] Canc Inst Hosp, Dept Breast Oncol, Koto Ku, Tokyo, Japan; [Ogata, E.] Japanese Fdn Canc Res, Canc Inst Hosp, Koto Ku, Tokyo 1358550, Japan	Japanese Foundation for Cancer Research; University of Tokyo; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Imamura, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	timamura-ind@umin.ac.jp		Ehata, Shogo/0000-0002-6740-9391	Ministry of Education, Culture, Sports, Science and Technology of Japan; KAKENHI	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr H Miyoshi (RIKEN, Tsukuba) for the lentivirus system, and K Nomura, E Kobayashi, N Kaneniwa and Y Yuuki (The Cancer Institute) for technical assistance. This research was supported by KAKENHI (Grants-in-Aid for Scientific Research) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. TI was supported by the Naito Foundation.	Arwert E, 2007, CANCER RES, V67, P7335, DOI 10.1158/0008-5472.CAN-07-0077; Azuma H, 2005, JNCI-J NATL CANCER I, V97, P1734, DOI 10.1093/jnci/dji399; Bailey JM, 2007, J CELL BIOCHEM, V102, P829, DOI 10.1002/jcb.21509; Bleuming SA, 2007, CANCER RES, V67, P8149, DOI 10.1158/0008-5472.CAN-06-4659; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706; Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; HATAKEYAMA S, 1993, BIOCHEM BIOPH RES CO, V190, P695, DOI 10.1006/bbrc.1993.1105; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helms MW, 2005, J PATHOL, V206, P366, DOI 10.1002/path.1785; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008-5472.CAN-06-3950; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katagiri Takenobu, 2008, P121; Kim IY, 2000, CANCER RES, V60, P2840; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Rothhammer T, 2005, CANCER RES, V65, P448; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008-5472.CAN-05-0289; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54	42	181	193	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	49					6322	6333		10.1038/onc.2008.232	http://dx.doi.org/10.1038/onc.2008.232			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663362				2022-12-17	WOS:000260263400002
J	Inoue, T; Hiratsuka, M; Osaki, M; Yamada, H; Kishimoto, I; Yamaguchi, S; Nakano, S; Katoh, M; Ito, H; Oshimura, M				Inoue, T.; Hiratsuka, M.; Osaki, M.; Yamada, H.; Kishimoto, I.; Yamaguchi, S.; Nakano, S.; Katoh, M.; Ito, H.; Oshimura, M.			SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress	ONCOGENE			English	Article						SIRT2; mitotic checkpoint; endoreduplication; epigenetic modi. cation; subcellular localization	DIFFERENTIALLY-EXPRESSED GENES; NUCLEAR EXPORT SIGNALS; GLIOMA-CELL-LINES; POLO-LIKE KINASES; PROMOTER HYPERMETHYLATION; SPINDLE CHECKPOINT; DOWN-REGULATION; CHFR; CYCLE; CANCERS	We previously identified SIRT2, an nicotinamide adenine dinucleotide (NAD)-dependent tubulin deacetylase, as a protein downregulated in gliomas and glioma cell lines, which are characterized by aneuploidy. Other studies reported SIRT2 to be involved in mitotic progression in the normal cell cycle. We herein investigated whether SIRT2 functions in the mitotic checkpoint in response to mitotic stress caused by microtubule poisons. By monitoring chromosome condensation, the exogenously expressed SIRT2 was found to block the entry to chromosome condensation and subsequent hyperploid cell formation in glioma cell lines with a persistence of the cyclin B/cdc2 activity in response to mitotic stress. SIRT2 is thus a novel mitotic checkpoint protein that functions in the early metaphase to prevent chromosomal instability (CIN), characteristics previously reported for the CHFR protein. We further found that histone deacetylation, but not the aberrant DNA methylation of SIRT2 5'untranslated region is involved in the downregulation of SIRT2. Although SIRT2 is normally exclusively located in the cytoplasm, the rapid accumulation of SIRT2 in the nucleus was observed after treatment with a nuclear export inhibitor, leptomycin B and ionizing radiation in normal human. fibroblasts, suggesting that nucleo-cytoplasmic shuttling regulates the SIRT2 function. Collectively, our results suggest that the further study of SIRT2 may thus provide new insights into the relationships among CIN, epigenetic regulation and tumorigenesis.	Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, Yonago, Tottori 6838503, Japan; Tottori Univ, Grad Sch Med Sci, Dept Human Genome Sci, Yonago, Tottori 6838503, Japan; Tottori Univ, Fac Med, Dept Pathol & Microbiol, Div Organ Pathol, Yonago, Tottori 683, Japan	Tottori University; Tottori University; Tottori University	Oshimura, M (corresponding author), Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, 86 Nichi Cho, Yonago, Tottori 6838503, Japan.	oshimura@grape.med.tottori-u.ac.jp						Alonso M, 2003, MOL CANCER THER, V2, P139; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Bertholon J, 2003, ONCOGENE, V22, P8956, DOI 10.1038/sj.onc.1207078; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058; Chu YW, 1999, CYTOMETRY, V36, P333, DOI 10.1002/(SICI)1097-0320(19990801)36:4<333::AID-CYTO8>3.0.CO;2-F; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cortez D, 2000, NATURE, V406, P354, DOI 10.1038/35019227; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Honda T, 2004, BRIT J CANCER, V90, P2013, DOI 10.1038/sj.bjc.6601849; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nishigaki R, 2005, PROTEOMICS, V5, P3205, DOI 10.1002/pmic.200401307; Nitta M, 2002, GENES CELLS, V7, P151, DOI 10.1046/j.1356-9597.2001.00509.x; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Qian K, 2005, MOL HUM REPROD, V11, P245, DOI 10.1093/molehr/gah147; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Takahashi T, 2004, CLIN CANCER RES, V10, P6126, DOI 10.1158/1078-0432.CCR-04-0579; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	43	181	193	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					945	957		10.1038/sj.onc.1209857	http://dx.doi.org/10.1038/sj.onc.1209857			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909107				2022-12-17	WOS:000244245400001
J	De Virgilio, C; Loewith, R				De Virgilio, C.; Loewith, R.			Cell growth control: little eukaryotes make big contributions	ONCOGENE			English	Review						target of rapamycin (TOR); TOR complexes (TORC1, TORC2); anabolism; catabolism; longevity; cell polarity	DEPENDENT PROTEIN-KINASE; AMINO-ACID PERMEASE; REGULATES GENE-EXPRESSION; CHRONOLOGICAL LIFE-SPAN; TOR SIGNALING NETWORK; P70 S6 KINASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; TRANSLATION INITIATION; ACTIN CYTOSKELETON	The story of rapamycin is a pharmaceutical fairytale. Discovered as an antifungal activity in a soil sample collected on Easter Island, this macrocyclic lactone and its derivatives are now billion dollar drugs, used in, and being evaluated for, a number of clinical applications. Taking advantage of its antifungal property, the molecular Target Of Rapamycin, TOR, was.rst described in the budding yeast Saccharomyces cerevisiae. TORs encode large, Ser/Thr protein kinases that reside in two distinct, structurally and functionally conserved, multi-protein complexes. In yeast, these complexes coordinate many different aspects of cell growth. TOR complex 1, TORC1, promotes protein synthesis and other anabolic processes, while inhibiting macroautophagy and other catabolic and stress response processes. TORC2 primarily regulates cell polarity, although additional readouts of this complex are beginning to be characterized. TORC1 appears to be activated by nutrient cues and inhibited by stresses and rapamycin; however, detailed mechanisms are not known. In contrast, TORC2 is insensitive to rapamycin and physiological regulators of this complex have yet to be defined. Given the unsurpassed resources available to yeast researchers, this simple eukaryote continues to contribute to our understanding of eukaryotic cell growth in general and TOR function in particular.	Univ Geneva, CMU, Dept Microbiol & Med Mol, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Biol Mol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Loewith, R (corresponding author), Univ Geneva, CMU, Dept Microbiol & Med Mol, CH-1211 Geneva, Switzerland.	Claudio.DeVirgilio@medecine.unige.ch; Robbie.Loewith@molbio.unige.ch	Loewith, Robbie J/S-6289-2016; De Virgilio, Claudio/B-4707-2012	Loewith, Robbie J/0000-0002-2482-603X; De Virgilio, Claudio/0000-0001-8826-4323				Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Ai WD, 2002, MOL CELL, V10, P1295, DOI 10.1016/S1097-2765(02)00695-0; Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Albig AR, 2001, MOL BIOL CELL, V12, P3428, DOI 10.1091/mbc.12.11.3428; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Araki T, 2005, GENES GENET SYST, V80, P325, DOI 10.1266/ggs.80.325; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Ayscough KR, 2005, PROTOPLASMA, V226, P81, DOI 10.1007/s00709-005-0107-5; Bachmann RA, 2006, J BIOL CHEM, V281, P7357, DOI 10.1074/jbc.M512218200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barbe E., 1996, MEDITERR POLIT, V1, P25; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Beck T, 2001, Results Probl Cell Differ, V32, P231; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Budovskaya YV, 2004, J BIOL CHEM, V279, P20663, DOI 10.1074/jbc.M400272200; Bultynck G, 2006, MOL CELL BIOL, V26, P4729, DOI 10.1128/MCB.01973-05; Butcher RA, 2006, NAT CHEM BIOL, V2, P103, DOI 10.1038/nchembio762; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cameroni E, 2004, CELL CYCLE, V3, P462; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; Carvalho J, 2003, J BIOL CHEM, V278, P16878, DOI 10.1074/jbc.M300429200; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Chen EJ, 2002, P NATL ACAD SCI USA, V99, P14837, DOI 10.1073/pnas.232591899; Chen JCY, 2006, CURR GENET, V49, P281, DOI 10.1007/s00294-005-0055-9; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Colomina N, 2003, MOL CELL BIOL, V23, P7415, DOI 10.1128/MCB.23.20.7415-7424.2003; Cosentino GP, 2000, MOL CELL BIOL, V20, P4604, DOI 10.1128/MCB.20.13.4604-4613.2000; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Damelin M, 2002, MOL CELL, V9, P563, DOI 10.1016/S1097-2765(02)00475-6; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Danaie P, 1999, BIOCHEM J, V340, P135, DOI 10.1042/0264-6021:3400135; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; De Virgilio C, 2006, INT J BIOCHEM CELL B, V38, P1476, DOI 10.1016/j.biocel.2006.02.013; De Wever V, 2005, EMBO J, V24, P4115, DOI 10.1038/sj.emboj.7600871; DEAN RT, 1977, BIOCHEM J, V168, P603, DOI 10.1042/bj1680603; deHart AKA, 2003, MOL BIOL CELL, V14, P4676, DOI 10.1091/mbc.E03-05-0323; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Dilova I, 2004, J BIOL CHEM, V279, P46527, DOI 10.1074/jbc.M409012200; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Dubouloz F, 2005, MOL CELL, V19, P15, DOI 10.1016/j.molcel.2005.05.020; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; DUVEL K, 2004, TOR TARGET RAPAMYCIN, P20; Edinger AL, 2005, BIOCHEM SOC T, V33, P225, DOI 10.1042/BST0330225; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Gatherar IM, 2004, FUNGAL GENET BIOL, V41, P463, DOI 10.1016/j.fgb.2003.12.004; Gelperin D, 2002, GENETICS, V161, P1453; Giannattasio S, 2005, J BIOL CHEM, V280, P42528, DOI 10.1074/jbc.M509187200; Ginalski K, 2004, TRENDS BIOCHEM SCI, V29, P522, DOI 10.1016/j.tibs.2004.08.006; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Griffioen G, 2000, J BIOL CHEM, V275, P1449, DOI 10.1074/jbc.275.2.1449; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hall DB, 2006, MOL CELL BIOL, V26, P3672, DOI 10.1128/MCB.26.9.3672-3679.2006; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Harris Thurl E, 2003, Sci STKE, V2003, pre15; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; Hilti N, 1999, CURR GENET, V35, P585, DOI 10.1007/s002940050456; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Ho HL, 2005, CURR GENET, V47, P273, DOI 10.1007/s00294-005-0570-8; Holst B, 2000, MOL MICROBIOL, V37, P108, DOI 10.1046/j.1365-2958.2000.01968.x; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Huang J, 2004, P NATL ACAD SCI USA, V101, P16594, DOI 10.1073/pnas.0407117101; Humphrey EL, 2004, CHEM BIOL, V11, P295, DOI 10.1016/j.chembiol.2004.03.001; Iiboshi Y, 1999, BIOCHEM BIOPH RES CO, V260, P534, DOI 10.1006/bbrc.1999.0920; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kennedy BK, 2005, CELL, V123, P548, DOI 10.1016/j.cell.2005.11.002; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Krause SA, 2002, CURR BIOL, V12, P588, DOI 10.1016/S0960-9822(02)00760-1; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Kunz JB, 2004, J BIOL CHEM, V279, P9987, DOI 10.1074/jbc.M307905200; Kuruvilla FG, 2001, P NATL ACAD SCI USA, V98, P7283, DOI 10.1073/pnas.121186898; Leao AN, 2003, FEMS YEAST RES, V4, P131, DOI 10.1016/S1567-1356(03)00070-9; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Liu ZC, 2003, MOL CELL, V12, P401, DOI 10.1016/S1097-2765(03)00285-5; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Loewith Robbie, 2004, VVolume 42, P139; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Mach KE, 2000, GENETICS, V155, P611; MacLean M, 2001, YEAST, V18, P499, DOI 10.1002/yea.701; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Martin DE, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-148; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Matsuo T, 2003, EMBO J, V22, P3073, DOI 10.1093/emboj/cdg298; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Nakaji T, 1999, CANCER LETT, V147, P139, DOI 10.1016/S0304-3835(99)00285-2; Nakase Y, 2006, GENETICS, V173, P569, DOI 10.1534/genetics.106.056895; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Oakes ML, 2006, MOL CELL BIOL, V26, P3889, DOI 10.1128/MCB.26.10.3889-3901.2006; Okazaki N, 2000, MOL BRAIN RES, V85, P1, DOI 10.1016/S0169-328X(00)00218-7; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Pichler H, 2004, BBA-BIOMEMBRANES, V1666, P51, DOI 10.1016/j.bbamem.2004.05.011; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; Pruyne D, 2004, ANNU REV CELL DEV BI, V20, P559, DOI 10.1146/annurev.cellbio.20.010403.103108; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reinders A, 1998, GENE DEV, V12, P2943, DOI 10.1101/gad.12.18.2943; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Rempola B, 2000, MOL GEN GENET, V262, P1081, DOI 10.1007/PL00008651; Robaglia C, 2004, BIOCHEM SOC T, V32, P581, DOI 10.1042/BST0320581; Roberg KJ, 1997, GENETICS, V147, P1569; Roberts P, 2003, MOL BIOL CELL, V14, P129, DOI 10.1091/mbc.E02-08-0483; Roelants FM, 2004, MICROBIOL-SGM, V150, P3289, DOI 10.1099/mic.0.27286-0; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Rohde JR, 2003, MOL CELL BIOL, V23, P629, DOI 10.1128/MCB.23.2.629-635.2003; Roosen J, 2005, MOL MICROBIOL, V55, P862, DOI 10.1111/j.1365-2958.2004.04429.x; Rubio-Texeira M, 2006, MOL BIOL CELL, V17, P3031, DOI 10.1091/mbc.E05-07-0669; Rudra D, 2005, EMBO J, V24, P533, DOI 10.1038/sj.emboj.7600553; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Santhanam A, 2004, EUKARYOT CELL, V3, P1261, DOI 10.1128/EC.3.5.1261-1271.2004; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sattler T, 2000, J CELL BIOL, V151, P529, DOI 10.1083/jcb.151.3.529; Schawalder SB, 2004, NATURE, V432, P1058, DOI 10.1038/nature03200; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Schroder W, 2005, CELL SIGNAL, V17, P761, DOI 10.1016/j.cellsig.2004.10.015; Schroder W, 2004, GENE, V339, P17, DOI 10.1016/j.gene.2004.07.001; Scott C, 2000, BIOPHARM-APPL T BIO, V13, P8; Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2; Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Shitamukai A, 2004, J BIOL CHEM, V279, P3651, DOI 10.1074/jbc.M306098200; STAN R, 1994, J BIOL CHEM, V269, P32027; Swinnen E, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-3; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tabuchi M, 2006, MOL CELL BIOL, V26, P5861, DOI 10.1128/MCB.02403-05; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; TODA T, 1988, GENE DEV, V2, P517, DOI 10.1101/gad.2.5.517; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Uesono Y, 1997, J BIOL CHEM, V272, P16103, DOI 10.1074/jbc.272.26.16103; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Van Belle D, 2001, CURR OPIN CELL BIOL, V13, P389, DOI 10.1016/S0955-0674(00)00226-X; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wade JT, 2004, NATURE, V432, P1054, DOI 10.1038/nature03175; Wang LH, 2003, P NATL ACAD SCI USA, V100, P11249, DOI 10.1073/pnas.1534805100; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001; Wanke V, 2005, EMBO J, V24, P4271, DOI 10.1038/sj.emboj.7600889; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Weindruch R., 1988, RETARDATION AGING DI; Weisman R, 2003, CURR TOP MICROBIOL, V279, P85; Wilkinson MG, 1999, EMBO J, V18, P4210, DOI 10.1093/emboj/18.15.4210; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Xie MW, 2005, P NATL ACAD SCI USA, V102, P7215, DOI 10.1073/pnas.0500297102; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Yan GH, 2006, EMBO J, V25, P3546, DOI 10.1038/sj.emboj.7601239; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Zheng Y, 2005, MOL BIOL CELL, V16, P2119, DOI 10.1091/mbc.e04-09-0797; Zurita-Martinez SA, 2005, EUKARYOT CELL, V4, P63, DOI 10.1128/EC.4.1.63-71.2005	239	181	184	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6392	6415		10.1038/sj.onc.1209884	http://dx.doi.org/10.1038/sj.onc.1209884			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041625	Green Published			2022-12-17	WOS:000241380700006
J	Arroyo, JD; Hahn, WC				Arroyo, JD; Hahn, WC			Involvement of PP2A in viral and cellular transformation	ONCOGENE			English	Review						protein phosphatase 2A; SV40ST; transformation	PROTEIN PHOSPHATASE 2A; SMALL-T-ANTIGEN; SMALL TUMOR-ANTIGEN; SV40 LARGE-T; SIMIAN-VIRUS-40 LARGE-T; ANCHORAGE-INDEPENDENT GROWTH; PPP2R1B GENE ALTERATIONS; REGULATORY-A-SUBUNIT; MAP KINASE PATHWAY; VIRUS 40 GENE	Although the small DNA tumor virus SV40 ( simian virus 40) fails to replicate in human cells, understanding how SV40 transforms human and murine cells has and continues to provide important insights into cancer initiation and maintenance. The early region of SV40 encodes two oncoproteins: the large T ( LT) and small t ( ST) antigens. SV40 LT contributes to murine and human cell transformation in part by inactivating the p53 and retinoblastoma protein tumor suppressor proteins. SV40 ST inhibits the activity of the protein phosphatase 2A ( PP2A) family of serine-threonine phosphatases, and this interaction is required for SV40-mediated transformation of human cells. PP2A regulates multiple signaling pathways, suggesting many possible targets important for viral replication and cell transformation. Genetic manipulation of particular PP2A subunits has confirmed a role for specific complexes in transformation, and recent work implicates the perturbation of the phosphatidylinositol 3-kinase/Akt pathway and c-Myc stability in transformation by ST and PP2A. Mutations in PP2A subunits occur at low frequency in human tumors, suggesting that alterations of PP2A signaling play a role in both experimentally induced and spontaneously arising cancers. Unraveling the complexity of PP2A signaling will not only provide further insights into cancer development but may identify novel targets with promise for therapeutic manipulation.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Harvard Univ, Broad Inst, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Dana 710C, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu		Arroyo, Jason/0000-0002-5674-6739	NCI NIH HHS [P01 CA50661, K01 CA94223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050661, K01CA094223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIKEL I, 1986, MOL CELL BIOL, V6, P1172, DOI 10.1128/MCB.6.4.1172; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CHANG LS, 1985, VIROLOGY, V146, P246, DOI 10.1016/0042-6822(85)90008-X; CHANG LS, 1984, VIROLOGY, V133, P341, DOI 10.1016/0042-6822(84)90400-8; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cole CN, 1996, FIELDS VIROLOGY, P1997; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; CRAWFORD LV, 1978, P NATL ACAD SCI USA, V75, P117, DOI 10.1073/pnas.75.1.117; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Deichmann M, 2001, MELANOMA RES, V11, P577, DOI 10.1097/00008390-200112000-00004; DERONDE A, 1989, VIROLOGY, V171, P260, DOI 10.1016/0042-6822(89)90534-5; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; Francia G, 1999, INT J CANCER, V82, P709, DOI 10.1002/(SICI)1097-0215(19990827)82:5<709::AID-IJC14>3.3.CO;2-I; GLUZMAN Y, 1982, VIROLOGY, V123, P78, DOI 10.1016/0042-6822(82)90296-3; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gotz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925-4773(00)00267-7; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; Martens E, 2004, J MOL BIOL, V336, P971, DOI 10.1016/j.jmb.2003.12.047; MARTIN RG, 1975, J VIROL, V15, P599, DOI 10.1128/JVI.15.3.599-612.1975; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Moreno CS, 2004, CANCER RES, V64, P6978, DOI 10.1158/0008-5472.CAN-04-1150; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PAUCHA E, 1978, P NATL ACAD SCI USA, V75, P2165, DOI 10.1073/pnas.75.5.2165; Porras A, 1996, J VIROL, V70, P6902; PRIVES C, 1977, P NATL ACAD SCI USA, V74, P457, DOI 10.1073/pnas.74.2.457; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; RUBIN H, 1982, CELL, V30, P469, DOI 10.1016/0092-8674(82)90244-6; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; RUNDELL K, 1982, J VIROL, V42, P1135, DOI 10.1128/JVI.42.3.1135-1137.1982; RUNDELL K, 1981, J VIROL, V37, P1090, DOI 10.1128/JVI.37.3.1090-1093.1981; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SEGAWA K, 1993, ONCOGENE, V8, P543; SHENK TE, 1976, J VIROL, V18, P664, DOI 10.1128/JVI.18.2.664-671.1976; SILVA OBDC, 1987, FEBS LETT, V226, P176; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Simizu S, 2004, CANCER SCI, V95, P266, DOI 10.1111/j.1349-7006.2004.tb02214.x; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stevens I, 2003, EUR J BIOCHEM, V270, P376, DOI 10.1046/j.1432-1033.2003.03398.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Suzuki K, 2003, INT J ONCOL, V23, P1263; Suzuki K, 2005, J CELL PHYSIOL, V203, P487, DOI 10.1002/jcp.20249; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tamaki M, 2004, ONCOL REP, V11, P655; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; USUI H, 1988, J BIOL CHEM, V263, P3752; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1988, J VIROL, V62, P4760, DOI 10.1128/JVI.62.12.4760-4762.1988; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YANG YC, 1979, J VIROL, V32, P147, DOI 10.1128/JVI.32.1.147-154.1979; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zhou J, 2003, BIOCHEM J, V369, P387, DOI 10.1042/BJ20021244; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	143	181	191	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7746	7755		10.1038/sj.onc.1209038	http://dx.doi.org/10.1038/sj.onc.1209038			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299534				2022-12-17	WOS:000233372600010
J	Broemer, M; Krappmann, D; Scheidereit, C				Broemer, M; Krappmann, D; Scheidereit, C			Requirement of Hsp90 activity for I kappa B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappa B activation	ONCOGENE			English	Article						ubiquitin; chaperones; proteasome; ribosome; Reed-Sternberg cells; tumor cell pharmacology	DEATH DOMAIN KINASE; RIP; INHIBITION; ALPHA; LYMPHOTOXIN; RECRUITMENT; RECEPTOR; EXPRESSION; ARSENITE; CELLS	The molecular chaperone Hsp90 affects the function and fate of a number of signaling molecules. We have investigated the Hsp90 requirement for constitutive and inducible activity of the IkappaB kinase (IKK) complex and of NF-kappaB. Inhibition by the Hsp90 ATPase inhibitors, geldanamycin (GA) and radicicol ( RC), revealed that Hsp90 controls IKKs at two levels, inducibility of enzymatic activity and biogenesis, which can be discriminated by short- and long-time GA incubation, respectively. Short-time inhibition of Hsp90 resulted in impaired IKK kinase activation by TNFalpha, IL-1beta or phorbolester PMA. Furthermore, GA inhibited constitutive activation of IKK and NF-kappaB in Hodgkin's lymphoma cells. Hsp90 function was also required for trans- and autophosphorylation of transfected IKKbeta. GA exposure for several hours resulted in a downmodulation of IKK complex alpha, beta and gamma subunits to various extent. Proteasome inhibition interfered with GA mediated IKK depletion and Hsp90 inhibition induced polyubiquitination of IKKalpha and beta during protein synthesis. In fact, GA blocked biogenesis of IKKalpha and IKKbeta but did not interfere with post-translational turnover. Together, these results define a dual requirement for Hsp90 as a regulator of NF-kappaB signaling by its general involvement in IKK activation and by its role in IKK homeostasis.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Free Univ Berlin, Fac Biol Chem & Pharm, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	scheidereit@mdc-berlin.de	Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234				BASSO AD, 2002, J BIOL CHEM, V9, P9; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chakravortty D, 2001, J IMMUNOL, V166, P2011, DOI 10.4049/jimmunol.166.3.2011; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Fisher DL, 2000, EMBO J, V19, P1516, DOI 10.1093/emboj/19.7.1516; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sugita T, 1999, BIOCHEM MOL BIOL INT, V47, P587; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yorgin PD, 2000, J IMMUNOL, V164, P2915, DOI 10.4049/jimmunol.164.6.2915; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	38	181	187	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5378	5386		10.1038/sj.onc.1207705	http://dx.doi.org/10.1038/sj.onc.1207705			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077173				2022-12-17	WOS:000222491600013
J	Komarova, EA; Kondratov, RV; Wang, KH; Christov, K; Golovkina, TV; Goldblum, JR; Gudkov, AV				Komarova, EA; Kondratov, RV; Wang, KH; Christov, K; Golovkina, TV; Goldblum, JR; Gudkov, AV			Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice	ONCOGENE			English	Article						p53; radiation; hematopoietic syndrome; gastro-intestinal syndrome; apoptosis; growth arrest	SMALL-INTESTINE; INDUCED APOPTOSIS; P53-DEFICIENT MICE; IONIZING-RADIATION; CANCER-THERAPY; SUPPRESSION; IRRADIATION; INHIBITOR; NEURONS; CELLS	Ionizing radiation (IR) induces p53-dependent apoptosis in radiosensitive tissues, suggesting that p53 is a determinant of radiation syndromes. In fact, p53-deficient mice survive doses of IR that cause lethal hematopoietic syndrome in wild-type animals. Surprisingly, p53 deficiency results in sensitization of mice to higher doses of IR, causing lethal gastro-intestinal (GI) syndrome. While cells in the crypts of p53-wild-type epithelium undergo prolonged growth arrest after irradiation, continuous cell proliferation ongoing in p53-deficient epithelium correlates with accelerated death of damaged cells followed by rapid destruction of villi and accelerated lethality. p21-deficient mice are also characterized by increased sensitivity to GI syndrome-inducing doses of IR. We conclude that p53/p21-mediated growth arrest plays a protective role in the epithelium of small intestine after severe doses of IR. Pharmacological inhibition of p53 by a small molecule that can rescue from lethal hematopoietic syndrome has no effect on the lethality from gastro-intestinal syndrome, presumably because of a temporary and reversible nature of its action.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Quark Biotech Inc, Cleveland, OH 44195 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Jackson Laboratory; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@uic.edu		Kondratov, Roman/0000-0003-3449-745X; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Booth C, 2002, NAT MED, V8, P1360, DOI 10.1038/nm1202-1360; Botchkarev VA, 2000, CANCER RES, V60, P5002; Cai WB, 1997, INT J RADIAT BIOL, V71, P145, DOI 10.1080/095530097144265; Cui Y. F., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P159; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; Ohkusu-Tsukada K, 1999, J IMMUNOL, V163, P1966; Ookawa K, 2002, J BIOL CHEM, V277, P48270, DOI 10.1074/jbc.M207986200; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Somosy Z, 2002, MICRON, V33, P167, DOI 10.1016/S0968-4328(01)00013-0; Watson AJM, 2000, AM J PHYSIOL-GASTR L, V278, pG1, DOI 10.1152/ajpgi.2000.278.1.G1; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	27	181	197	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3265	3271		10.1038/sj.onc.1207494	http://dx.doi.org/10.1038/sj.onc.1207494			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064735				2022-12-17	WOS:000220975000001
J	Woo, JH; Lim, JH; Kim, YH; Suh, SI; Min, DS; Chang, JS; Lee, YH; Park, JW; Kwon, TK				Woo, JH; Lim, JH; Kim, YH; Suh, SI; Min, DS; Chang, JS; Lee, YH; Park, JW; Kwon, TK			Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction	ONCOGENE			English	Article						resveratrol; matrix metalloproteinase-9; NF-kappa B; PMA; PKC; JNK	ACTIVATED PROTEIN-KINASE; IV COLLAGENASE GENE; MECHANISM; METALLOPROTEINASES; PHOSPHORYLATION; SURFACE; ERK	Proteolytic degradation of the extracellular matrix and tumor metastasis correlate with the expression of endopeptidases known as matrix metalloproteinases (MMPs). The expression of MMPs is regulated by cytokines and signal transduction pathways, including those activated by phorbol myristate acetate (PMA). We found that resveratrol, a phytoalexin present in grapes, significantly inhibits the PMA-induced increase in MMP-9 expression and activity. These effects of resveratrol are dose dependent and correlate with the suppression of MMP-9 mRNA expression levels. PMA caused about a 23-fold increase in MMP-9 promoter activity, which was suppressed by resveratrol. Transient transfection utilizing MMP-9 constructs, in which specific transcriptional factors were mutagenized, indicated that the effects of PMA and resveratrol were mediated via an activator protein-1 and nuclear factor-kappaB response element. Resveratrol inhibited PMA-mediated activation of c-Jun N-terminal kinase (JNK) and protein kinase C (PKC)-delta activation. Therefore, we conclude that the MMP-9 inhibition activity of resveratrol and its inhibition of JNK and PKC-delta may have a therapeutic potential, given that a novel means of controlling growth and invasiveness of tumors.	Keimyung Univ, Sch Med, Dept Immunol, Taegu, South Korea; Keimyung Univ, Sch Med, Dept Microbiol, Taegu 700712, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Daejin Univ, Dept Life Sci, Pochon Gun, Kyeonggido, South Korea; Yeungnam Univ, Coll Med, Dept Biochem, Taegu, South Korea	Keimyung University; Keimyung University; Catholic University of Korea; Daejin University; Yeungnam University	Kwon, TK (corresponding author), Keimyung Univ, Sch Med, Dept Immunol, 194 DongSan Dong, Taegu, South Korea.	kwontk@dsmc.or.kr						Baek WK, 2002, GENE, V295, P117, DOI 10.1016/S0378-1119(02)00827-2; Banerjee S, 2002, CANCER RES, V62, P4945; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Godichaud S, 2000, HEPATOLOGY, V31, P922, DOI 10.1053/he.2000.5848; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; JANG M, 1999, CANC CHEMOTHER PHA S, V43, pS42; Lee PPH, 2000, ENDOCRINOLOGY, V141, P3764, DOI 10.1210/en.141.10.3764; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OHagan RC, 1996, ONCOGENE, V13, P1323; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; Simon C, 1998, CANCER RES, V58, P1135; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Waas ET, 2002, BRIT J CANCER, V86, P1876, DOI 10.1038/sj.bjc.6600366; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; ZUCKER S, 1993, CANCER RES, V53, P140	30	181	187	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1845	1853		10.1038/sj.onc.1207307	http://dx.doi.org/10.1038/sj.onc.1207307			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14661062				2022-12-17	WOS:000220129500006
